{
  "documents": [
    {
      "id": "18887130-DS-10:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \nNo Known Allergies / Adverse Drug Reactions\n \nAttending: ___\n \n___ Complaint:\nScheduled admit for cycle 2 of ICE\n \nMajor Surgical or Invasive Procedure:\nNone",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-10",
        "chart_time": "103284",
        "section": "General",
        "position": 0,
        "tokenCount": 84,
        "note_metadata": {
          "note_id": "18887130-DS-10",
          "subject_id": 18887130,
          "hadm_id": 20858810,
          "note_type": "DS",
          "note_seq": 10,
          "charttime": 103284,
          "storetime": 103284.775,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nScheduled admit for cycle 2 of ICE\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with a history of follicular \r\n\r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy. Per report, she has \r\nsignificant  neck and upper thoracic involvement, as well as \r\nmesenteric  involvement.  She underwent her first cycle of ICE \r\nwithout complications ___ and since then has been getting \r\nrituxan and neupogen. \r\n\r\nOn arrival to the floor, patient is feeling well.  Her only \r\ncomplaint from her previous session of chemo was mild stomach \r\nupset.  She denies any fevers/chills, headache, vision changes, \r\nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.\r\n\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n---------------\r\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \r\nMCH-31.3 MCHC-34.7 RDW-14.4\r\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \r\nBASOS-0.5\r\n___ 10:00AM   PLT COUNT-232#\r\n___ 10:00AM   ___ PTT-29.3 ___\r\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \r\nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\r\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \r\nPHOS-108* TOT BILI-0.2\r\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \r\nMAGNESIUM-2.1\r\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \r\nLEUK-NEG\r\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___\r\n\r\nDISCHARGE LABS:\r\n---------------\r\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \r\nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\r\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \r\nEos-0.1 Baso-0.4\r\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \r\nK-4.1 Cl-107 HCO3-26 AnGap-13\r\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \r\nTotBili-0.1\r\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old female with a history of follicular \r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy\r\n\r\n# DLBCL: Here for c2 of R-ICE.  c1 R-ICE started ___ and \r\ncompleted without complications. She will need Neupogen D5-12 to \r\nsupport ___.  Will continue bactrim, acyclovir and allopurinol \r\nfor ppx.  Plan for PET-CT after ___ cycle to assess disease \r\nresponse to therapy.  \r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#H/o LLE edema and cellulitis: the pt reports chronic b/l lower \r\nextremity edema s/p L TKR in ___ U/S was negative for DVT \r\non her most recent admission. She also has chronioc venous \r\nstasis and a h/o of MRSA infections (boils, abdominal and \r\nlabial) and on her most recent admission was treated empirically \r\nwith amoxicillin and bactrim. Currently without signs of \r\ninfections and ___ edema at her baseline.\r\n\r\n# Migraines: Takes coffee + indomethacin at home. She received 1 \r\ndose of fioricet for headache during her hospitalization with \r\nrelief of her symptoms.  \r\n\r\n# h/o SVC syndrome s/p thrombectomy. Currently no clinical \r\nevidence SVC thrombus.  She received heparin SC as her platelets \r\nremained >50 during her hospitalization.\r\n\r\n# HLD: continued home statin.\r\n\r\n# Mood: continued home venlafaxine. \r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 8 mg PO Q8H:PRN nausea \r\n2. Gabapentin 900 mg PO BID \r\n3. Allopurinol ___ mg PO DAILY \r\n4. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n5. Pravastatin 10 mg PO DAILY \r\n6. Furosemide 20 mg PO DAILY \r\n7. Acyclovir 400 mg PO Q8H \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Omeprazole 20 mg PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Aspirin 81 mg PO DAILY \r\n13. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO BID \r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron 8 mg PO Q8H:PRN nausea \r\n9. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n10. Pravastatin 10 mg PO DAILY \r\n11. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiffuse Large B cell lymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\n                             ___ MD ___\r\n \r\nCompleted by: ___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-10:1",
      "text": "History of Present Illness:\nMs. ___ is a ___ year old female with a history of follicular lymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \nthen rituximab x 6 in ___, now with transformed DLBCL who \npresents with for cycle 2 of ICE therapy. Per report, she has \nsignificant  neck and upper thoracic involvement, as well as \nmesenteric  involvement. She underwent her first cycle of ICE \nwithout complications ___ and since then has been getting \nrituxan and neupogen. On arrival to the floor, patient is feeling well. Her only \ncomplaint from her previous session of chemo was mild stomach \nupset. She denies any fevers/chills, headache, vision changes, \nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-10",
        "chart_time": "103284",
        "section": "General",
        "position": 1,
        "tokenCount": 182,
        "note_metadata": {
          "note_id": "18887130-DS-10",
          "subject_id": 18887130,
          "hadm_id": 20858810,
          "note_type": "DS",
          "note_seq": 10,
          "charttime": 103284,
          "storetime": 103284.775,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nScheduled admit for cycle 2 of ICE\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with a history of follicular \r\n\r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy. Per report, she has \r\nsignificant  neck and upper thoracic involvement, as well as \r\nmesenteric  involvement.  She underwent her first cycle of ICE \r\nwithout complications ___ and since then has been getting \r\nrituxan and neupogen. \r\n\r\nOn arrival to the floor, patient is feeling well.  Her only \r\ncomplaint from her previous session of chemo was mild stomach \r\nupset.  She denies any fevers/chills, headache, vision changes, \r\nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.\r\n\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n---------------\r\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \r\nMCH-31.3 MCHC-34.7 RDW-14.4\r\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \r\nBASOS-0.5\r\n___ 10:00AM   PLT COUNT-232#\r\n___ 10:00AM   ___ PTT-29.3 ___\r\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \r\nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\r\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \r\nPHOS-108* TOT BILI-0.2\r\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \r\nMAGNESIUM-2.1\r\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \r\nLEUK-NEG\r\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___\r\n\r\nDISCHARGE LABS:\r\n---------------\r\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \r\nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\r\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \r\nEos-0.1 Baso-0.4\r\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \r\nK-4.1 Cl-107 HCO3-26 AnGap-13\r\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \r\nTotBili-0.1\r\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old female with a history of follicular \r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy\r\n\r\n# DLBCL: Here for c2 of R-ICE.  c1 R-ICE started ___ and \r\ncompleted without complications. She will need Neupogen D5-12 to \r\nsupport ___.  Will continue bactrim, acyclovir and allopurinol \r\nfor ppx.  Plan for PET-CT after ___ cycle to assess disease \r\nresponse to therapy.  \r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#H/o LLE edema and cellulitis: the pt reports chronic b/l lower \r\nextremity edema s/p L TKR in ___ U/S was negative for DVT \r\non her most recent admission. She also has chronioc venous \r\nstasis and a h/o of MRSA infections (boils, abdominal and \r\nlabial) and on her most recent admission was treated empirically \r\nwith amoxicillin and bactrim. Currently without signs of \r\ninfections and ___ edema at her baseline.\r\n\r\n# Migraines: Takes coffee + indomethacin at home. She received 1 \r\ndose of fioricet for headache during her hospitalization with \r\nrelief of her symptoms.  \r\n\r\n# h/o SVC syndrome s/p thrombectomy. Currently no clinical \r\nevidence SVC thrombus.  She received heparin SC as her platelets \r\nremained >50 during her hospitalization.\r\n\r\n# HLD: continued home statin.\r\n\r\n# Mood: continued home venlafaxine. \r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 8 mg PO Q8H:PRN nausea \r\n2. Gabapentin 900 mg PO BID \r\n3. Allopurinol ___ mg PO DAILY \r\n4. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n5. Pravastatin 10 mg PO DAILY \r\n6. Furosemide 20 mg PO DAILY \r\n7. Acyclovir 400 mg PO Q8H \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Omeprazole 20 mg PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Aspirin 81 mg PO DAILY \r\n13. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO BID \r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron 8 mg PO Q8H:PRN nausea \r\n9. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n10. Pravastatin 10 mg PO DAILY \r\n11. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiffuse Large B cell lymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\n                             ___ MD ___\r\n \r\nCompleted by: ___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-10:2",
      "text": "Past Medical History:\nFollicular lymphoma stage IIA with disease recurrence\n- ___ developed worsening musculoskeletal back pain, early \nsatiety, hypoalbuminemia and found to have mesenteric mass\n- ?___ ex lap with 15 cm lobulated mass involving the \nduodenum, retroperitoneum and celiac access. Biopsies showed \nFollicular lymphomas grade II/III. Reportedly negative staging \nGallium scan. CD10+ BCL2+\n- ___ completed 6 cycles CHOP, complications included \nSVC/innominate thrombus (tPA)\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\nmarrow at completion was negative for lymphomatous involvement. - ___ PET-CT with very slight amount of increased tracer\nactivity within the posterior left supraclavicular region. No\nother areas of FDG avid disease were noted \n- ___ through ___ per records she was treated with CVP\nfollowed by course of single agent Rituxan\n- ___ through ___ surveillance imaging with no evidence of\nrecurrent disease, stable mesenteric mass. - ___ abdominal pain led to CT with no change in mass size,\nincreased conspicuity of nodular borders\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\nstable mesenteric mass with low level SUV 2.2 stable since \nprior. - ___ CT torso showed persistent mesenteric and left hilar\nlymphadenopathy. Stable right middle lobe small focus of ground\nglass opacity and adjacent subpleural fat hypertrophy, \nsuggestive\nof inflammatory process. Stable right adnexal cyst. - ___ Presented to PCP ___ ___iscomfort. Exam\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\nnormal differential, PLT 452. - ___ PET CT revealed, \"Large left cervical,\nsupraclavicular, mediastinal lymphadenopathy, and \nretroperitoneal lymphadenopathy, and small mesenteric \nlymphadenopathy, all of which is markedly FDG-avid and \nconcerning for\nlymphoma.\" SUVmax 35.5. - ___iopsy revealed diffuse large B cell\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \nare pending\n- ___ C1D1 ICE PAST MEDICAL/SURGICAL HISTORY:  \nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \n(*Known slight CN VI palsy & mild proptosis of R eye)\nHypogammaglobulinemia, \nMild GERD\nOA / LBP\nSmall Intestinal Bacterial Overgrowth\nTrochanteric Bursitis\ns/p Excisional Bx L Cervical Lymph Node\ns/p L total knee replacement ___\ns/p I&D Labial Abscess\ns/p Excision Cyst R ___ Digit of Hand Social History:\n___ Family History:\nNC",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-10",
        "chart_time": "103284",
        "section": "General",
        "position": 2,
        "tokenCount": 595,
        "note_metadata": {
          "note_id": "18887130-DS-10",
          "subject_id": 18887130,
          "hadm_id": 20858810,
          "note_type": "DS",
          "note_seq": 10,
          "charttime": 103284,
          "storetime": 103284.775,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nScheduled admit for cycle 2 of ICE\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with a history of follicular \r\n\r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy. Per report, she has \r\nsignificant  neck and upper thoracic involvement, as well as \r\nmesenteric  involvement.  She underwent her first cycle of ICE \r\nwithout complications ___ and since then has been getting \r\nrituxan and neupogen. \r\n\r\nOn arrival to the floor, patient is feeling well.  Her only \r\ncomplaint from her previous session of chemo was mild stomach \r\nupset.  She denies any fevers/chills, headache, vision changes, \r\nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.\r\n\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n---------------\r\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \r\nMCH-31.3 MCHC-34.7 RDW-14.4\r\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \r\nBASOS-0.5\r\n___ 10:00AM   PLT COUNT-232#\r\n___ 10:00AM   ___ PTT-29.3 ___\r\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \r\nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\r\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \r\nPHOS-108* TOT BILI-0.2\r\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \r\nMAGNESIUM-2.1\r\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \r\nLEUK-NEG\r\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___\r\n\r\nDISCHARGE LABS:\r\n---------------\r\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \r\nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\r\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \r\nEos-0.1 Baso-0.4\r\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \r\nK-4.1 Cl-107 HCO3-26 AnGap-13\r\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \r\nTotBili-0.1\r\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old female with a history of follicular \r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy\r\n\r\n# DLBCL: Here for c2 of R-ICE.  c1 R-ICE started ___ and \r\ncompleted without complications. She will need Neupogen D5-12 to \r\nsupport ___.  Will continue bactrim, acyclovir and allopurinol \r\nfor ppx.  Plan for PET-CT after ___ cycle to assess disease \r\nresponse to therapy.  \r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#H/o LLE edema and cellulitis: the pt reports chronic b/l lower \r\nextremity edema s/p L TKR in ___ U/S was negative for DVT \r\non her most recent admission. She also has chronioc venous \r\nstasis and a h/o of MRSA infections (boils, abdominal and \r\nlabial) and on her most recent admission was treated empirically \r\nwith amoxicillin and bactrim. Currently without signs of \r\ninfections and ___ edema at her baseline.\r\n\r\n# Migraines: Takes coffee + indomethacin at home. She received 1 \r\ndose of fioricet for headache during her hospitalization with \r\nrelief of her symptoms.  \r\n\r\n# h/o SVC syndrome s/p thrombectomy. Currently no clinical \r\nevidence SVC thrombus.  She received heparin SC as her platelets \r\nremained >50 during her hospitalization.\r\n\r\n# HLD: continued home statin.\r\n\r\n# Mood: continued home venlafaxine. \r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 8 mg PO Q8H:PRN nausea \r\n2. Gabapentin 900 mg PO BID \r\n3. Allopurinol ___ mg PO DAILY \r\n4. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n5. Pravastatin 10 mg PO DAILY \r\n6. Furosemide 20 mg PO DAILY \r\n7. Acyclovir 400 mg PO Q8H \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Omeprazole 20 mg PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Aspirin 81 mg PO DAILY \r\n13. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO BID \r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron 8 mg PO Q8H:PRN nausea \r\n9. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n10. Pravastatin 10 mg PO DAILY \r\n11. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiffuse Large B cell lymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\n                             ___ MD ___\r\n \r\nCompleted by: ___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-10:3",
      "text": "Physical Exam:\nADMISSION PHYSICAL EXAM:\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \nsoft palate(chronic per patient), otherwise OP is clear\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \nCV: RRR, no r/g/m \nLungs: CTA b/l\nAbdomen: Soft, NT, ND, +BS\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \non b/l shins    \nNeuro: Notable for R CN VI palsy & diminished sensation in CN \nV-1, also sluggish R CN III response to direct & indirect \nillumination, otherwise CN's grossly intact, intact muscle \nstrength all extremities, intact light sensation b/l ___\nSkin: R pheresis line c/d/i DISCHARGE PHYSICAL EXAM:\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \nsoft palate(chronic per patient), otherwise OP is clear\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \nCV: RRR, no r/g/m \nLungs: CTA b/l\nAbdomen: Soft, NT, ND, +BS\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \non b/l shins    \nNeuro: Notable for R CN VI palsy & diminished sensation in CN \nV-1, also sluggish R CN III response to direct & indirect \nillumination, otherwise CN's grossly intact, intact muscle \nstrength all extremities, intact light sensation b/l ___\nSkin: R pheresis line c/d/i Pertinent Results:\nADMISSION LABS:\n---------------\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \nMCH-31.3 MCHC-34.7 RDW-14.4\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \nBASOS-0.5\n___ 10:00AM   PLT COUNT-232#\n___ 10:00AM   ___ PTT-29.3 ___\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \nPHOS-108* TOT BILI-0.2\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \nMAGNESIUM-2.1\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \nLEUK-NEG\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___ DISCHARGE LABS:\n---------------\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \nEos-0.1 Baso-0.4\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \nK-4.1 Cl-107 HCO3-26 AnGap-13\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \nTotBili-0.1\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-10",
        "chart_time": "103284",
        "section": "General",
        "position": 3,
        "tokenCount": 637,
        "note_metadata": {
          "note_id": "18887130-DS-10",
          "subject_id": 18887130,
          "hadm_id": 20858810,
          "note_type": "DS",
          "note_seq": 10,
          "charttime": 103284,
          "storetime": 103284.775,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nScheduled admit for cycle 2 of ICE\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with a history of follicular \r\n\r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy. Per report, she has \r\nsignificant  neck and upper thoracic involvement, as well as \r\nmesenteric  involvement.  She underwent her first cycle of ICE \r\nwithout complications ___ and since then has been getting \r\nrituxan and neupogen. \r\n\r\nOn arrival to the floor, patient is feeling well.  Her only \r\ncomplaint from her previous session of chemo was mild stomach \r\nupset.  She denies any fevers/chills, headache, vision changes, \r\nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.\r\n\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n---------------\r\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \r\nMCH-31.3 MCHC-34.7 RDW-14.4\r\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \r\nBASOS-0.5\r\n___ 10:00AM   PLT COUNT-232#\r\n___ 10:00AM   ___ PTT-29.3 ___\r\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \r\nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\r\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \r\nPHOS-108* TOT BILI-0.2\r\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \r\nMAGNESIUM-2.1\r\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \r\nLEUK-NEG\r\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___\r\n\r\nDISCHARGE LABS:\r\n---------------\r\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \r\nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\r\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \r\nEos-0.1 Baso-0.4\r\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \r\nK-4.1 Cl-107 HCO3-26 AnGap-13\r\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \r\nTotBili-0.1\r\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old female with a history of follicular \r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy\r\n\r\n# DLBCL: Here for c2 of R-ICE.  c1 R-ICE started ___ and \r\ncompleted without complications. She will need Neupogen D5-12 to \r\nsupport ___.  Will continue bactrim, acyclovir and allopurinol \r\nfor ppx.  Plan for PET-CT after ___ cycle to assess disease \r\nresponse to therapy.  \r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#H/o LLE edema and cellulitis: the pt reports chronic b/l lower \r\nextremity edema s/p L TKR in ___ U/S was negative for DVT \r\non her most recent admission. She also has chronioc venous \r\nstasis and a h/o of MRSA infections (boils, abdominal and \r\nlabial) and on her most recent admission was treated empirically \r\nwith amoxicillin and bactrim. Currently without signs of \r\ninfections and ___ edema at her baseline.\r\n\r\n# Migraines: Takes coffee + indomethacin at home. She received 1 \r\ndose of fioricet for headache during her hospitalization with \r\nrelief of her symptoms.  \r\n\r\n# h/o SVC syndrome s/p thrombectomy. Currently no clinical \r\nevidence SVC thrombus.  She received heparin SC as her platelets \r\nremained >50 during her hospitalization.\r\n\r\n# HLD: continued home statin.\r\n\r\n# Mood: continued home venlafaxine. \r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 8 mg PO Q8H:PRN nausea \r\n2. Gabapentin 900 mg PO BID \r\n3. Allopurinol ___ mg PO DAILY \r\n4. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n5. Pravastatin 10 mg PO DAILY \r\n6. Furosemide 20 mg PO DAILY \r\n7. Acyclovir 400 mg PO Q8H \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Omeprazole 20 mg PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Aspirin 81 mg PO DAILY \r\n13. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO BID \r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron 8 mg PO Q8H:PRN nausea \r\n9. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n10. Pravastatin 10 mg PO DAILY \r\n11. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiffuse Large B cell lymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\n                             ___ MD ___\r\n \r\nCompleted by: ___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-10:4",
      "text": "Brief Hospital Course:\nMs. ___ is a ___ year old female with a history of follicular \nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \nthen rituximab x 6 in ___, now with transformed DLBCL who \npresents with for cycle 2 of ICE therapy # DLBCL: Here for c2 of R-ICE. c1 R-ICE started ___ and \ncompleted without complications. She will need Neupogen D5-12 to \nsupport ___. Will continue bactrim, acyclovir and allopurinol \nfor ppx. Plan for PET-CT after ___ cycle to assess disease \nresponse to therapy.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-10",
        "chart_time": "103284",
        "section": "General",
        "position": 4,
        "tokenCount": 129,
        "note_metadata": {
          "note_id": "18887130-DS-10",
          "subject_id": 18887130,
          "hadm_id": 20858810,
          "note_type": "DS",
          "note_seq": 10,
          "charttime": 103284,
          "storetime": 103284.775,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nScheduled admit for cycle 2 of ICE\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with a history of follicular \r\n\r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy. Per report, she has \r\nsignificant  neck and upper thoracic involvement, as well as \r\nmesenteric  involvement.  She underwent her first cycle of ICE \r\nwithout complications ___ and since then has been getting \r\nrituxan and neupogen. \r\n\r\nOn arrival to the floor, patient is feeling well.  Her only \r\ncomplaint from her previous session of chemo was mild stomach \r\nupset.  She denies any fevers/chills, headache, vision changes, \r\nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.\r\n\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n---------------\r\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \r\nMCH-31.3 MCHC-34.7 RDW-14.4\r\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \r\nBASOS-0.5\r\n___ 10:00AM   PLT COUNT-232#\r\n___ 10:00AM   ___ PTT-29.3 ___\r\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \r\nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\r\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \r\nPHOS-108* TOT BILI-0.2\r\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \r\nMAGNESIUM-2.1\r\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \r\nLEUK-NEG\r\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___\r\n\r\nDISCHARGE LABS:\r\n---------------\r\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \r\nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\r\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \r\nEos-0.1 Baso-0.4\r\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \r\nK-4.1 Cl-107 HCO3-26 AnGap-13\r\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \r\nTotBili-0.1\r\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old female with a history of follicular \r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy\r\n\r\n# DLBCL: Here for c2 of R-ICE.  c1 R-ICE started ___ and \r\ncompleted without complications. She will need Neupogen D5-12 to \r\nsupport ___.  Will continue bactrim, acyclovir and allopurinol \r\nfor ppx.  Plan for PET-CT after ___ cycle to assess disease \r\nresponse to therapy.  \r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#H/o LLE edema and cellulitis: the pt reports chronic b/l lower \r\nextremity edema s/p L TKR in ___ U/S was negative for DVT \r\non her most recent admission. She also has chronioc venous \r\nstasis and a h/o of MRSA infections (boils, abdominal and \r\nlabial) and on her most recent admission was treated empirically \r\nwith amoxicillin and bactrim. Currently without signs of \r\ninfections and ___ edema at her baseline.\r\n\r\n# Migraines: Takes coffee + indomethacin at home. She received 1 \r\ndose of fioricet for headache during her hospitalization with \r\nrelief of her symptoms.  \r\n\r\n# h/o SVC syndrome s/p thrombectomy. Currently no clinical \r\nevidence SVC thrombus.  She received heparin SC as her platelets \r\nremained >50 during her hospitalization.\r\n\r\n# HLD: continued home statin.\r\n\r\n# Mood: continued home venlafaxine. \r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 8 mg PO Q8H:PRN nausea \r\n2. Gabapentin 900 mg PO BID \r\n3. Allopurinol ___ mg PO DAILY \r\n4. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n5. Pravastatin 10 mg PO DAILY \r\n6. Furosemide 20 mg PO DAILY \r\n7. Acyclovir 400 mg PO Q8H \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Omeprazole 20 mg PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Aspirin 81 mg PO DAILY \r\n13. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO BID \r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron 8 mg PO Q8H:PRN nausea \r\n9. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n10. Pravastatin 10 mg PO DAILY \r\n11. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiffuse Large B cell lymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\n                             ___ MD ___\r\n \r\nCompleted by: ___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-10:5",
      "text": "CHRONIC ISSUES:\n===============\n#H/o LLE edema and cellulitis: the pt reports chronic b/l lower \nextremity edema s/p L TKR in ___ U/S was negative for DVT \non her most recent admission. She also has chronioc venous \nstasis and a h/o of MRSA infections (boils, abdominal and \nlabial) and on her most recent admission was treated empirically \nwith amoxicillin and bactrim. Currently without signs of \ninfections and ___ edema at her baseline. # Migraines: Takes coffee + indomethacin at home. She received 1 \ndose of fioricet for headache during her hospitalization with \nrelief of her symptoms. # h/o SVC syndrome s/p thrombectomy. Currently no clinical \nevidence SVC thrombus. She received heparin SC as her platelets \nremained >50 during her hospitalization. # HLD: continued home statin. # Mood: continued home venlafaxine. Medications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Ondansetron 8 mg PO Q8H:PRN nausea \n2. Gabapentin 900 mg PO BID \n3. Allopurinol ___ mg PO DAILY \n4. Prochlorperazine 10 mg PO Q6H:PRN nausea \n5. Pravastatin 10 mg PO DAILY \n6. Furosemide 20 mg PO DAILY \n7. Acyclovir 400 mg PO Q8H \n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \n9. Omeprazole 20 mg PO DAILY \n10. Venlafaxine 25 mg PO BID \n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \n12. Aspirin 81 mg PO DAILY \n13. Multivitamins 1 TAB PO DAILY",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-10",
        "chart_time": "103284",
        "section": "General",
        "position": 5,
        "tokenCount": 342,
        "note_metadata": {
          "note_id": "18887130-DS-10",
          "subject_id": 18887130,
          "hadm_id": 20858810,
          "note_type": "DS",
          "note_seq": 10,
          "charttime": 103284,
          "storetime": 103284.775,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nScheduled admit for cycle 2 of ICE\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with a history of follicular \r\n\r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy. Per report, she has \r\nsignificant  neck and upper thoracic involvement, as well as \r\nmesenteric  involvement.  She underwent her first cycle of ICE \r\nwithout complications ___ and since then has been getting \r\nrituxan and neupogen. \r\n\r\nOn arrival to the floor, patient is feeling well.  Her only \r\ncomplaint from her previous session of chemo was mild stomach \r\nupset.  She denies any fevers/chills, headache, vision changes, \r\nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.\r\n\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n---------------\r\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \r\nMCH-31.3 MCHC-34.7 RDW-14.4\r\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \r\nBASOS-0.5\r\n___ 10:00AM   PLT COUNT-232#\r\n___ 10:00AM   ___ PTT-29.3 ___\r\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \r\nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\r\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \r\nPHOS-108* TOT BILI-0.2\r\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \r\nMAGNESIUM-2.1\r\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \r\nLEUK-NEG\r\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___\r\n\r\nDISCHARGE LABS:\r\n---------------\r\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \r\nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\r\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \r\nEos-0.1 Baso-0.4\r\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \r\nK-4.1 Cl-107 HCO3-26 AnGap-13\r\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \r\nTotBili-0.1\r\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old female with a history of follicular \r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy\r\n\r\n# DLBCL: Here for c2 of R-ICE.  c1 R-ICE started ___ and \r\ncompleted without complications. She will need Neupogen D5-12 to \r\nsupport ___.  Will continue bactrim, acyclovir and allopurinol \r\nfor ppx.  Plan for PET-CT after ___ cycle to assess disease \r\nresponse to therapy.  \r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#H/o LLE edema and cellulitis: the pt reports chronic b/l lower \r\nextremity edema s/p L TKR in ___ U/S was negative for DVT \r\non her most recent admission. She also has chronioc venous \r\nstasis and a h/o of MRSA infections (boils, abdominal and \r\nlabial) and on her most recent admission was treated empirically \r\nwith amoxicillin and bactrim. Currently without signs of \r\ninfections and ___ edema at her baseline.\r\n\r\n# Migraines: Takes coffee + indomethacin at home. She received 1 \r\ndose of fioricet for headache during her hospitalization with \r\nrelief of her symptoms.  \r\n\r\n# h/o SVC syndrome s/p thrombectomy. Currently no clinical \r\nevidence SVC thrombus.  She received heparin SC as her platelets \r\nremained >50 during her hospitalization.\r\n\r\n# HLD: continued home statin.\r\n\r\n# Mood: continued home venlafaxine. \r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 8 mg PO Q8H:PRN nausea \r\n2. Gabapentin 900 mg PO BID \r\n3. Allopurinol ___ mg PO DAILY \r\n4. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n5. Pravastatin 10 mg PO DAILY \r\n6. Furosemide 20 mg PO DAILY \r\n7. Acyclovir 400 mg PO Q8H \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Omeprazole 20 mg PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Aspirin 81 mg PO DAILY \r\n13. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO BID \r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron 8 mg PO Q8H:PRN nausea \r\n9. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n10. Pravastatin 10 mg PO DAILY \r\n11. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiffuse Large B cell lymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\n                             ___ MD ___\r\n \r\nCompleted by: ___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-10:6",
      "text": "Discharge Medications:\n1. Acyclovir 400 mg PO Q8H \n2. Allopurinol ___ mg PO DAILY \n3. Aspirin 81 mg PO DAILY \n4. Furosemide 20 mg PO DAILY \n5. Gabapentin 900 mg PO BID \n6. Multivitamins 1 TAB PO DAILY \n7. Omeprazole 20 mg PO DAILY \n8. Ondansetron 8 mg PO Q8H:PRN nausea \n9. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \n10. Pravastatin 10 mg PO DAILY \n11. Prochlorperazine 10 mg PO Q6H:PRN nausea \n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \n13. Venlafaxine 25 mg PO BID Discharge Disposition:\nHome Discharge Diagnosis:\nDiffuse Large B cell lymphoma Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent. ___ MD ___\n \nCompleted by: ___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-10",
        "chart_time": "103284",
        "section": "General",
        "position": 6,
        "tokenCount": 184,
        "note_metadata": {
          "note_id": "18887130-DS-10",
          "subject_id": 18887130,
          "hadm_id": 20858810,
          "note_type": "DS",
          "note_seq": 10,
          "charttime": 103284,
          "storetime": 103284.775,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nScheduled admit for cycle 2 of ICE\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with a history of follicular \r\n\r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy. Per report, she has \r\nsignificant  neck and upper thoracic involvement, as well as \r\nmesenteric  involvement.  She underwent her first cycle of ICE \r\nwithout complications ___ and since then has been getting \r\nrituxan and neupogen. \r\n\r\nOn arrival to the floor, patient is feeling well.  Her only \r\ncomplaint from her previous session of chemo was mild stomach \r\nupset.  She denies any fevers/chills, headache, vision changes, \r\nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.\r\n\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n---------------\r\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \r\nMCH-31.3 MCHC-34.7 RDW-14.4\r\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \r\nBASOS-0.5\r\n___ 10:00AM   PLT COUNT-232#\r\n___ 10:00AM   ___ PTT-29.3 ___\r\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \r\nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\r\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \r\nPHOS-108* TOT BILI-0.2\r\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \r\nMAGNESIUM-2.1\r\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \r\nLEUK-NEG\r\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___\r\n\r\nDISCHARGE LABS:\r\n---------------\r\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \r\nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\r\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \r\nEos-0.1 Baso-0.4\r\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \r\nK-4.1 Cl-107 HCO3-26 AnGap-13\r\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \r\nTotBili-0.1\r\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old female with a history of follicular \r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy\r\n\r\n# DLBCL: Here for c2 of R-ICE.  c1 R-ICE started ___ and \r\ncompleted without complications. She will need Neupogen D5-12 to \r\nsupport ___.  Will continue bactrim, acyclovir and allopurinol \r\nfor ppx.  Plan for PET-CT after ___ cycle to assess disease \r\nresponse to therapy.  \r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#H/o LLE edema and cellulitis: the pt reports chronic b/l lower \r\nextremity edema s/p L TKR in ___ U/S was negative for DVT \r\non her most recent admission. She also has chronioc venous \r\nstasis and a h/o of MRSA infections (boils, abdominal and \r\nlabial) and on her most recent admission was treated empirically \r\nwith amoxicillin and bactrim. Currently without signs of \r\ninfections and ___ edema at her baseline.\r\n\r\n# Migraines: Takes coffee + indomethacin at home. She received 1 \r\ndose of fioricet for headache during her hospitalization with \r\nrelief of her symptoms.  \r\n\r\n# h/o SVC syndrome s/p thrombectomy. Currently no clinical \r\nevidence SVC thrombus.  She received heparin SC as her platelets \r\nremained >50 during her hospitalization.\r\n\r\n# HLD: continued home statin.\r\n\r\n# Mood: continued home venlafaxine. \r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 8 mg PO Q8H:PRN nausea \r\n2. Gabapentin 900 mg PO BID \r\n3. Allopurinol ___ mg PO DAILY \r\n4. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n5. Pravastatin 10 mg PO DAILY \r\n6. Furosemide 20 mg PO DAILY \r\n7. Acyclovir 400 mg PO Q8H \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Omeprazole 20 mg PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Aspirin 81 mg PO DAILY \r\n13. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO BID \r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron 8 mg PO Q8H:PRN nausea \r\n9. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n10. Pravastatin 10 mg PO DAILY \r\n11. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiffuse Large B cell lymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\n                             ___ MD ___\r\n \r\nCompleted by: ___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-11:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \nNo Known Allergies / Adverse Drug Reactions\n \nAttending: ___ Chief Complaint:\nChemotherapy\n \nMajor Surgical or Invasive Procedure:\nNone",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-11",
        "chart_time": "103315",
        "section": "General",
        "position": 0,
        "tokenCount": 78,
        "note_metadata": {
          "note_id": "18887130-DS-11",
          "subject_id": 18887130,
          "hadm_id": 26950422,
          "note_type": "DS",
          "note_seq": 11,
          "charttime": 103315,
          "storetime": 103315.57152777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nChemotherapy\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ female with transformed diffuse large B cell lymphoma \r\npresents today for cycle 3 of R-ICE.  She was initially \r\ndiagnosed with follicular lymphoma in ___, and relapsed in ___ \r\nwith a transformation to DLBCL. She will collect her stem cells \r\nfor autologous transplant after this cycle. Her workup is \r\ncomplete. The plan is for XRT after auto, as she has a residual \r\navid area in her abdominal mass. Today, she reports improving \r\nneck pain, for which she has been using occasional valium, soft \r\ncollar, and warmth. It started last week. Otherwise, no HA, \r\nneuro changes, n/v/d, fevers chills.\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nGeneral: WDWN female, NAD, A&Ox4. Ptosis noted R, ansicoria L>R\r\n(known).\r\nHEENT: oropharynx no lesions\r\nNeck: neck limited extention, rotation to R. No meningsmus. No\r\nadenopathy throughout   \r\nCV:  RRR no m/r/g\r\nLungs: CTA\r\nAbdomen: soft NT -HSM\r\nExt:  no edema \r\nNeuro: as above\r\nAccess: R chest IJ c/d/i\r\n\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD WBC-2.7* RBC-2.47* Hgb-7.8* Hct-23.9* \r\nMCV-96 MCH-31.4 MCHC-32.5 RDW-20.6* Plt ___\r\n___ 12:35AM BLOOD WBC-4.0 RBC-2.45* Hgb-7.9* Hct-23.5* \r\nMCV-96 MCH-32.1* MCHC-33.6 RDW-20.1* Plt ___\r\n___ 12:10AM BLOOD WBC-5.4 RBC-2.80* Hgb-8.6* Hct-27.4* \r\nMCV-98 MCH-30.6 MCHC-31.4 RDW-20.7* Plt ___\r\n___ 12:00AM BLOOD Neuts-90.3* Lymphs-4.5* Monos-4.8 Eos-0.4 \r\nBaso-0\r\n___ 12:35AM BLOOD Neuts-95.3* Lymphs-2.9* Monos-1.4* \r\nEos-0.3 Baso-0\r\n___ 12:10AM BLOOD Neuts-94.4* Lymphs-3.6* Monos-1.6* \r\nEos-0.5 Baso-0\r\n___ 12:00AM BLOOD Glucose-132* UreaN-13 Creat-0.6 Na-141 \r\nK-3.6 Cl-105 HCO3-24 AnGap-16\r\n___ 12:35AM BLOOD Glucose-156* UreaN-14 Creat-0.7 Na-140 \r\nK-4.1 Cl-106 HCO3-24 AnGap-14\r\n___ 12:10AM BLOOD Glucose-184* UreaN-14 Creat-0.7 Na-139 \r\nK-4.3 Cl-104 HCO3-25 AnGap-14\r\n___ 12:00AM BLOOD ALT-12 AST-14 LD(LDH)-189 AlkPhos-71 \r\nTotBili-0.2\r\n___ 12:35AM BLOOD ALT-11 AST-12 LD(___)-206 AlkPhos-77 \r\nTotBili-0.2\r\n___ 12:10AM BLOOD ALT-14 AST-18 LD(___)-256* AlkPhos-100 \r\nTotBili-0.___LBCL transformed from follicular lymphoma: Ms. ___ was \r\nadmitted for cycle 3 of R-ICE with goal of collection with this \r\ncycle, for which she has a right chest tunnelled line. Tolerated \r\nthe chemo, except for some nausea and poor appetite, which were \r\ntreated with anti-emetics. She will start her G-CSF upon \r\ndischarge. She was started on Ciprofloxacin prophylaxis in \r\nanticipation of HSCT. She remains on Bactrim for PJP \r\nprophylaxis. She will f/u in ___ clinic regarding \r\ncollection of her cells and schedule her transplant.\r\n.\r\n# history of coiled aneuyrsm and TIA: Her Aspirin was continued, \r\nbut she was advised to stop on ___ since her platelets are \r\nexpected to drop later this week. Her statin was held during \r\nchemo, which was resumed upon discharge.\r\n.\r\n# Torticolis, neck pain: Continued home regimen with Valium PRN, \r\nheat, and soft collar. She denied neck pain/stiffness at the \r\ntime of discharge.\r\n.\r\n# Migraine: She had migrainous headaches during admission, which \r\nresolved on their own.\r\n.\r\n# Volume overload: She experienced mild volume overload and \r\nweight gain during her chemo course, which responded to a Lasix \r\nbolus x1. Her discharge weight was 245.0 lbs. She was advised to \r\ntake oral Lasix PRN at home or to call clinic, if she notices \r\nincreased swelling.\r\n.\r\n# Access: Right chest double-lumen tunneled line. There were \r\nintermittently problems with drawing blood and flushes, which \r\nappeared to be positional in nature. This was successfully \r\nmanaged with tPA. Pheresis team evaluated abilty to use line, \r\nand felt it should be adequate for collection despite positional \r\nnature. Patient was advised to call clinic if she has any \r\nfurther issues with the line.\r\n.\r\nAll other chronic issues stable.\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Multivitamins 1 TAB PO DAILY \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 8 mg PO Q8H:PRN nausea \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Pravastatin 10 mg PO DAILY \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Venlafaxine 25 mg PO BID \r\n13. Furosemide 20 mg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY - through ___\r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ondansetron 8 mg PO Q8H:PRN nausea \r\n11. Furosemide 20 mg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n13. Pravastatin 10 mg PO DAILY \r\n14. Ciprofloxacin HCl 500 mg PO Q12H \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nLymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n.\r\nIt was a pleasure to meet you at the ___ \r\n___. You were admitted to receive chemotherapy both \r\nto treat your lymphoma and to mobilize your stem cells, which \r\nyou sucessfully completed while with us. \r\n.\r\nYou will inject yourself with neupogen, following the calendar \r\nthat ___ gives you. These injections may cause bone pain, \r\ntake oxycodone should you experience this.  As prior, do not \r\ndrive.\r\n.\r\nContinue all of your home medications as prior. We have added \r\ncipro to prevent infection while you collect. You should stop \r\ntaking Aspirin on ___ because we expect your \r\nplatelets to start dropping later this week.\r\n.\r\nThank you again for allowing us to participate in your care!\r\n.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-11:1",
      "text": "History of Present Illness:\n___ female with transformed diffuse large B cell lymphoma \npresents today for cycle 3 of R-ICE. She was initially \ndiagnosed with follicular lymphoma in ___, and relapsed in ___ \nwith a transformation to DLBCL. She will collect her stem cells \nfor autologous transplant after this cycle. Her workup is \ncomplete. The plan is for XRT after auto, as she has a residual \navid area in her abdominal mass. Today, she reports improving \nneck pain, for which she has been using occasional valium, soft \ncollar, and warmth. It started last week. Otherwise, no HA, \nneuro changes, n/v/d, fevers chills.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-11",
        "chart_time": "103315",
        "section": "General",
        "position": 1,
        "tokenCount": 156,
        "note_metadata": {
          "note_id": "18887130-DS-11",
          "subject_id": 18887130,
          "hadm_id": 26950422,
          "note_type": "DS",
          "note_seq": 11,
          "charttime": 103315,
          "storetime": 103315.57152777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nChemotherapy\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ female with transformed diffuse large B cell lymphoma \r\npresents today for cycle 3 of R-ICE.  She was initially \r\ndiagnosed with follicular lymphoma in ___, and relapsed in ___ \r\nwith a transformation to DLBCL. She will collect her stem cells \r\nfor autologous transplant after this cycle. Her workup is \r\ncomplete. The plan is for XRT after auto, as she has a residual \r\navid area in her abdominal mass. Today, she reports improving \r\nneck pain, for which she has been using occasional valium, soft \r\ncollar, and warmth. It started last week. Otherwise, no HA, \r\nneuro changes, n/v/d, fevers chills.\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nGeneral: WDWN female, NAD, A&Ox4. Ptosis noted R, ansicoria L>R\r\n(known).\r\nHEENT: oropharynx no lesions\r\nNeck: neck limited extention, rotation to R. No meningsmus. No\r\nadenopathy throughout   \r\nCV:  RRR no m/r/g\r\nLungs: CTA\r\nAbdomen: soft NT -HSM\r\nExt:  no edema \r\nNeuro: as above\r\nAccess: R chest IJ c/d/i\r\n\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD WBC-2.7* RBC-2.47* Hgb-7.8* Hct-23.9* \r\nMCV-96 MCH-31.4 MCHC-32.5 RDW-20.6* Plt ___\r\n___ 12:35AM BLOOD WBC-4.0 RBC-2.45* Hgb-7.9* Hct-23.5* \r\nMCV-96 MCH-32.1* MCHC-33.6 RDW-20.1* Plt ___\r\n___ 12:10AM BLOOD WBC-5.4 RBC-2.80* Hgb-8.6* Hct-27.4* \r\nMCV-98 MCH-30.6 MCHC-31.4 RDW-20.7* Plt ___\r\n___ 12:00AM BLOOD Neuts-90.3* Lymphs-4.5* Monos-4.8 Eos-0.4 \r\nBaso-0\r\n___ 12:35AM BLOOD Neuts-95.3* Lymphs-2.9* Monos-1.4* \r\nEos-0.3 Baso-0\r\n___ 12:10AM BLOOD Neuts-94.4* Lymphs-3.6* Monos-1.6* \r\nEos-0.5 Baso-0\r\n___ 12:00AM BLOOD Glucose-132* UreaN-13 Creat-0.6 Na-141 \r\nK-3.6 Cl-105 HCO3-24 AnGap-16\r\n___ 12:35AM BLOOD Glucose-156* UreaN-14 Creat-0.7 Na-140 \r\nK-4.1 Cl-106 HCO3-24 AnGap-14\r\n___ 12:10AM BLOOD Glucose-184* UreaN-14 Creat-0.7 Na-139 \r\nK-4.3 Cl-104 HCO3-25 AnGap-14\r\n___ 12:00AM BLOOD ALT-12 AST-14 LD(LDH)-189 AlkPhos-71 \r\nTotBili-0.2\r\n___ 12:35AM BLOOD ALT-11 AST-12 LD(___)-206 AlkPhos-77 \r\nTotBili-0.2\r\n___ 12:10AM BLOOD ALT-14 AST-18 LD(___)-256* AlkPhos-100 \r\nTotBili-0.___LBCL transformed from follicular lymphoma: Ms. ___ was \r\nadmitted for cycle 3 of R-ICE with goal of collection with this \r\ncycle, for which she has a right chest tunnelled line. Tolerated \r\nthe chemo, except for some nausea and poor appetite, which were \r\ntreated with anti-emetics. She will start her G-CSF upon \r\ndischarge. She was started on Ciprofloxacin prophylaxis in \r\nanticipation of HSCT. She remains on Bactrim for PJP \r\nprophylaxis. She will f/u in ___ clinic regarding \r\ncollection of her cells and schedule her transplant.\r\n.\r\n# history of coiled aneuyrsm and TIA: Her Aspirin was continued, \r\nbut she was advised to stop on ___ since her platelets are \r\nexpected to drop later this week. Her statin was held during \r\nchemo, which was resumed upon discharge.\r\n.\r\n# Torticolis, neck pain: Continued home regimen with Valium PRN, \r\nheat, and soft collar. She denied neck pain/stiffness at the \r\ntime of discharge.\r\n.\r\n# Migraine: She had migrainous headaches during admission, which \r\nresolved on their own.\r\n.\r\n# Volume overload: She experienced mild volume overload and \r\nweight gain during her chemo course, which responded to a Lasix \r\nbolus x1. Her discharge weight was 245.0 lbs. She was advised to \r\ntake oral Lasix PRN at home or to call clinic, if she notices \r\nincreased swelling.\r\n.\r\n# Access: Right chest double-lumen tunneled line. There were \r\nintermittently problems with drawing blood and flushes, which \r\nappeared to be positional in nature. This was successfully \r\nmanaged with tPA. Pheresis team evaluated abilty to use line, \r\nand felt it should be adequate for collection despite positional \r\nnature. Patient was advised to call clinic if she has any \r\nfurther issues with the line.\r\n.\r\nAll other chronic issues stable.\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Multivitamins 1 TAB PO DAILY \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 8 mg PO Q8H:PRN nausea \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Pravastatin 10 mg PO DAILY \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Venlafaxine 25 mg PO BID \r\n13. Furosemide 20 mg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY - through ___\r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ondansetron 8 mg PO Q8H:PRN nausea \r\n11. Furosemide 20 mg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n13. Pravastatin 10 mg PO DAILY \r\n14. Ciprofloxacin HCl 500 mg PO Q12H \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nLymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n.\r\nIt was a pleasure to meet you at the ___ \r\n___. You were admitted to receive chemotherapy both \r\nto treat your lymphoma and to mobilize your stem cells, which \r\nyou sucessfully completed while with us. \r\n.\r\nYou will inject yourself with neupogen, following the calendar \r\nthat ___ gives you. These injections may cause bone pain, \r\ntake oxycodone should you experience this.  As prior, do not \r\ndrive.\r\n.\r\nContinue all of your home medications as prior. We have added \r\ncipro to prevent infection while you collect. You should stop \r\ntaking Aspirin on ___ because we expect your \r\nplatelets to start dropping later this week.\r\n.\r\nThank you again for allowing us to participate in your care!\r\n.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-11:2",
      "text": "Past Medical History:\nFollicular lymphoma stage IIA with disease recurrence\n- ___ developed worsening musculoskeletal back pain, early \nsatiety, hypoalbuminemia and found to have mesenteric mass\n- ?___ ex lap with 15 cm lobulated mass involving the \nduodenum, retroperitoneum and celiac access. Biopsies showed \nFollicular lymphomas grade II/III. Reportedly negative staging \nGallium scan. CD10+ BCL2+\n- ___ completed 6 cycles CHOP, complications included \nSVC/innominate thrombus (tPA)\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\nmarrow at completion was negative for lymphomatous involvement. - ___ PET-CT with very slight amount of increased tracer\nactivity within the posterior left supraclavicular region. No\nother areas of FDG avid disease were noted \n- ___ through ___ per records she was treated with CVP\nfollowed by course of single agent Rituxan\n- ___ through ___ surveillance imaging with no evidence of\nrecurrent disease, stable mesenteric mass. - ___ abdominal pain led to CT with no change in mass size,\nincreased conspicuity of nodular borders\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\nstable mesenteric mass with low level SUV 2.2 stable since \nprior. - ___ CT torso showed persistent mesenteric and left hilar\nlymphadenopathy. Stable right middle lobe small focus of ground\nglass opacity and adjacent subpleural fat hypertrophy, \nsuggestive\nof inflammatory process. Stable right adnexal cyst. - ___ Presented to PCP ___ ___iscomfort. Exam\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\nnormal differential, PLT 452. - ___ PET CT revealed, \"Large left cervical,\nsupraclavicular, mediastinal lymphadenopathy, and \nretroperitoneal lymphadenopathy, and small mesenteric \nlymphadenopathy, all of which is markedly FDG-avid and \nconcerning for\nlymphoma.\" SUVmax 35.5. - ___iopsy revealed diffuse large B cell\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \nare pending\n- ___ C1D1 ICE PAST MEDICAL/SURGICAL HISTORY:  \nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \n(*Known slight CN VI palsy & mild proptosis of R eye)\nHypogammaglobulinemia, \nMild GERD\nOA / LBP\nSmall Intestinal Bacterial Overgrowth\nTrochanteric Bursitis\ns/p Excisional Bx L Cervical Lymph Node\ns/p L total knee replacement ___\ns/p I&D Labial Abscess\ns/p Excision Cyst R ___ Digit of Hand Social History:\n___ Family History:\nNC",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-11",
        "chart_time": "103315",
        "section": "General",
        "position": 2,
        "tokenCount": 595,
        "note_metadata": {
          "note_id": "18887130-DS-11",
          "subject_id": 18887130,
          "hadm_id": 26950422,
          "note_type": "DS",
          "note_seq": 11,
          "charttime": 103315,
          "storetime": 103315.57152777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nChemotherapy\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ female with transformed diffuse large B cell lymphoma \r\npresents today for cycle 3 of R-ICE.  She was initially \r\ndiagnosed with follicular lymphoma in ___, and relapsed in ___ \r\nwith a transformation to DLBCL. She will collect her stem cells \r\nfor autologous transplant after this cycle. Her workup is \r\ncomplete. The plan is for XRT after auto, as she has a residual \r\navid area in her abdominal mass. Today, she reports improving \r\nneck pain, for which she has been using occasional valium, soft \r\ncollar, and warmth. It started last week. Otherwise, no HA, \r\nneuro changes, n/v/d, fevers chills.\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nGeneral: WDWN female, NAD, A&Ox4. Ptosis noted R, ansicoria L>R\r\n(known).\r\nHEENT: oropharynx no lesions\r\nNeck: neck limited extention, rotation to R. No meningsmus. No\r\nadenopathy throughout   \r\nCV:  RRR no m/r/g\r\nLungs: CTA\r\nAbdomen: soft NT -HSM\r\nExt:  no edema \r\nNeuro: as above\r\nAccess: R chest IJ c/d/i\r\n\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD WBC-2.7* RBC-2.47* Hgb-7.8* Hct-23.9* \r\nMCV-96 MCH-31.4 MCHC-32.5 RDW-20.6* Plt ___\r\n___ 12:35AM BLOOD WBC-4.0 RBC-2.45* Hgb-7.9* Hct-23.5* \r\nMCV-96 MCH-32.1* MCHC-33.6 RDW-20.1* Plt ___\r\n___ 12:10AM BLOOD WBC-5.4 RBC-2.80* Hgb-8.6* Hct-27.4* \r\nMCV-98 MCH-30.6 MCHC-31.4 RDW-20.7* Plt ___\r\n___ 12:00AM BLOOD Neuts-90.3* Lymphs-4.5* Monos-4.8 Eos-0.4 \r\nBaso-0\r\n___ 12:35AM BLOOD Neuts-95.3* Lymphs-2.9* Monos-1.4* \r\nEos-0.3 Baso-0\r\n___ 12:10AM BLOOD Neuts-94.4* Lymphs-3.6* Monos-1.6* \r\nEos-0.5 Baso-0\r\n___ 12:00AM BLOOD Glucose-132* UreaN-13 Creat-0.6 Na-141 \r\nK-3.6 Cl-105 HCO3-24 AnGap-16\r\n___ 12:35AM BLOOD Glucose-156* UreaN-14 Creat-0.7 Na-140 \r\nK-4.1 Cl-106 HCO3-24 AnGap-14\r\n___ 12:10AM BLOOD Glucose-184* UreaN-14 Creat-0.7 Na-139 \r\nK-4.3 Cl-104 HCO3-25 AnGap-14\r\n___ 12:00AM BLOOD ALT-12 AST-14 LD(LDH)-189 AlkPhos-71 \r\nTotBili-0.2\r\n___ 12:35AM BLOOD ALT-11 AST-12 LD(___)-206 AlkPhos-77 \r\nTotBili-0.2\r\n___ 12:10AM BLOOD ALT-14 AST-18 LD(___)-256* AlkPhos-100 \r\nTotBili-0.___LBCL transformed from follicular lymphoma: Ms. ___ was \r\nadmitted for cycle 3 of R-ICE with goal of collection with this \r\ncycle, for which she has a right chest tunnelled line. Tolerated \r\nthe chemo, except for some nausea and poor appetite, which were \r\ntreated with anti-emetics. She will start her G-CSF upon \r\ndischarge. She was started on Ciprofloxacin prophylaxis in \r\nanticipation of HSCT. She remains on Bactrim for PJP \r\nprophylaxis. She will f/u in ___ clinic regarding \r\ncollection of her cells and schedule her transplant.\r\n.\r\n# history of coiled aneuyrsm and TIA: Her Aspirin was continued, \r\nbut she was advised to stop on ___ since her platelets are \r\nexpected to drop later this week. Her statin was held during \r\nchemo, which was resumed upon discharge.\r\n.\r\n# Torticolis, neck pain: Continued home regimen with Valium PRN, \r\nheat, and soft collar. She denied neck pain/stiffness at the \r\ntime of discharge.\r\n.\r\n# Migraine: She had migrainous headaches during admission, which \r\nresolved on their own.\r\n.\r\n# Volume overload: She experienced mild volume overload and \r\nweight gain during her chemo course, which responded to a Lasix \r\nbolus x1. Her discharge weight was 245.0 lbs. She was advised to \r\ntake oral Lasix PRN at home or to call clinic, if she notices \r\nincreased swelling.\r\n.\r\n# Access: Right chest double-lumen tunneled line. There were \r\nintermittently problems with drawing blood and flushes, which \r\nappeared to be positional in nature. This was successfully \r\nmanaged with tPA. Pheresis team evaluated abilty to use line, \r\nand felt it should be adequate for collection despite positional \r\nnature. Patient was advised to call clinic if she has any \r\nfurther issues with the line.\r\n.\r\nAll other chronic issues stable.\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Multivitamins 1 TAB PO DAILY \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 8 mg PO Q8H:PRN nausea \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Pravastatin 10 mg PO DAILY \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Venlafaxine 25 mg PO BID \r\n13. Furosemide 20 mg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY - through ___\r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ondansetron 8 mg PO Q8H:PRN nausea \r\n11. Furosemide 20 mg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n13. Pravastatin 10 mg PO DAILY \r\n14. Ciprofloxacin HCl 500 mg PO Q12H \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nLymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n.\r\nIt was a pleasure to meet you at the ___ \r\n___. You were admitted to receive chemotherapy both \r\nto treat your lymphoma and to mobilize your stem cells, which \r\nyou sucessfully completed while with us. \r\n.\r\nYou will inject yourself with neupogen, following the calendar \r\nthat ___ gives you. These injections may cause bone pain, \r\ntake oxycodone should you experience this.  As prior, do not \r\ndrive.\r\n.\r\nContinue all of your home medications as prior. We have added \r\ncipro to prevent infection while you collect. You should stop \r\ntaking Aspirin on ___ because we expect your \r\nplatelets to start dropping later this week.\r\n.\r\nThank you again for allowing us to participate in your care!\r\n.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-11:3",
      "text": "Physical Exam:\nGeneral: WDWN female, NAD, A&Ox4. Ptosis noted R, ansicoria L>R\n(known). HEENT: oropharynx no lesions\nNeck: neck limited extention, rotation to R. No meningsmus. No\nadenopathy throughout   \nCV:  RRR no m/r/g\nLungs: CTA\nAbdomen: soft NT -HSM\nExt:  no edema \nNeuro: as above\nAccess: R chest IJ c/d/i Pertinent Results:\n___ 12:00AM BLOOD WBC-2.7* RBC-2.47* Hgb-7.8* Hct-23.9* \nMCV-96 MCH-31.4 MCHC-32.5 RDW-20.6* Plt ___\n___ 12:35AM BLOOD WBC-4.0 RBC-2.45* Hgb-7.9* Hct-23.5* \nMCV-96 MCH-32.1* MCHC-33.6 RDW-20.1* Plt ___\n___ 12:10AM BLOOD WBC-5.4 RBC-2.80* Hgb-8.6* Hct-27.4* \nMCV-98 MCH-30.6 MCHC-31.4 RDW-20.7* Plt ___\n___ 12:00AM BLOOD Neuts-90.3* Lymphs-4.5* Monos-4.8 Eos-0.4 \nBaso-0\n___ 12:35AM BLOOD Neuts-95.3* Lymphs-2.9* Monos-1.4* \nEos-0.3 Baso-0\n___ 12:10AM BLOOD Neuts-94.4* Lymphs-3.6* Monos-1.6* \nEos-0.5 Baso-0\n___ 12:00AM BLOOD Glucose-132* UreaN-13 Creat-0.6 Na-141 \nK-3.6 Cl-105 HCO3-24 AnGap-16\n___ 12:35AM BLOOD Glucose-156* UreaN-14 Creat-0.7 Na-140 \nK-4.1 Cl-106 HCO3-24 AnGap-14\n___ 12:10AM BLOOD Glucose-184* UreaN-14 Creat-0.7 Na-139 \nK-4.3 Cl-104 HCO3-25 AnGap-14\n___ 12:00AM BLOOD ALT-12 AST-14 LD(LDH)-189 AlkPhos-71 \nTotBili-0.2\n___ 12:35AM BLOOD ALT-11 AST-12 LD(___)-206 AlkPhos-77 \nTotBili-0.2\n___ 12:10AM BLOOD ALT-14 AST-18 LD(___)-256* AlkPhos-100 \nTotBili-0.___LBCL transformed from follicular lymphoma: Ms. ___ was \nadmitted for cycle 3 of R-ICE with goal of collection with this \ncycle, for which she has a right chest tunnelled line. Tolerated \nthe chemo, except for some nausea and poor appetite, which were \ntreated with anti-emetics. She will start her G-CSF upon \ndischarge. She was started on Ciprofloxacin prophylaxis in \nanticipation of HSCT. She remains on Bactrim for PJP \nprophylaxis. She will f/u in ___ clinic regarding \ncollection of her cells and schedule her transplant. . # history of coiled aneuyrsm and TIA: Her Aspirin was continued, \nbut she was advised to stop on ___ since her platelets are \nexpected to drop later this week. Her statin was held during \nchemo, which was resumed upon discharge. . # Torticolis, neck pain: Continued home regimen with Valium PRN, \nheat, and soft collar. She denied neck pain/stiffness at the \ntime of discharge. . # Migraine: She had migrainous headaches during admission, which \nresolved on their own. . # Volume overload: She experienced mild volume overload and \nweight gain during her chemo course, which responded to a Lasix \nbolus x1. Her discharge weight was 245.0 lbs. She was advised to \ntake oral Lasix PRN at home or to call clinic, if she notices \nincreased swelling. . # Access: Right chest double-lumen tunneled line. There were \nintermittently problems with drawing blood and flushes, which \nappeared to be positional in nature.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-11",
        "chart_time": "103315",
        "section": "General",
        "position": 3,
        "tokenCount": 688,
        "note_metadata": {
          "note_id": "18887130-DS-11",
          "subject_id": 18887130,
          "hadm_id": 26950422,
          "note_type": "DS",
          "note_seq": 11,
          "charttime": 103315,
          "storetime": 103315.57152777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nChemotherapy\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ female with transformed diffuse large B cell lymphoma \r\npresents today for cycle 3 of R-ICE.  She was initially \r\ndiagnosed with follicular lymphoma in ___, and relapsed in ___ \r\nwith a transformation to DLBCL. She will collect her stem cells \r\nfor autologous transplant after this cycle. Her workup is \r\ncomplete. The plan is for XRT after auto, as she has a residual \r\navid area in her abdominal mass. Today, she reports improving \r\nneck pain, for which she has been using occasional valium, soft \r\ncollar, and warmth. It started last week. Otherwise, no HA, \r\nneuro changes, n/v/d, fevers chills.\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nGeneral: WDWN female, NAD, A&Ox4. Ptosis noted R, ansicoria L>R\r\n(known).\r\nHEENT: oropharynx no lesions\r\nNeck: neck limited extention, rotation to R. No meningsmus. No\r\nadenopathy throughout   \r\nCV:  RRR no m/r/g\r\nLungs: CTA\r\nAbdomen: soft NT -HSM\r\nExt:  no edema \r\nNeuro: as above\r\nAccess: R chest IJ c/d/i\r\n\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD WBC-2.7* RBC-2.47* Hgb-7.8* Hct-23.9* \r\nMCV-96 MCH-31.4 MCHC-32.5 RDW-20.6* Plt ___\r\n___ 12:35AM BLOOD WBC-4.0 RBC-2.45* Hgb-7.9* Hct-23.5* \r\nMCV-96 MCH-32.1* MCHC-33.6 RDW-20.1* Plt ___\r\n___ 12:10AM BLOOD WBC-5.4 RBC-2.80* Hgb-8.6* Hct-27.4* \r\nMCV-98 MCH-30.6 MCHC-31.4 RDW-20.7* Plt ___\r\n___ 12:00AM BLOOD Neuts-90.3* Lymphs-4.5* Monos-4.8 Eos-0.4 \r\nBaso-0\r\n___ 12:35AM BLOOD Neuts-95.3* Lymphs-2.9* Monos-1.4* \r\nEos-0.3 Baso-0\r\n___ 12:10AM BLOOD Neuts-94.4* Lymphs-3.6* Monos-1.6* \r\nEos-0.5 Baso-0\r\n___ 12:00AM BLOOD Glucose-132* UreaN-13 Creat-0.6 Na-141 \r\nK-3.6 Cl-105 HCO3-24 AnGap-16\r\n___ 12:35AM BLOOD Glucose-156* UreaN-14 Creat-0.7 Na-140 \r\nK-4.1 Cl-106 HCO3-24 AnGap-14\r\n___ 12:10AM BLOOD Glucose-184* UreaN-14 Creat-0.7 Na-139 \r\nK-4.3 Cl-104 HCO3-25 AnGap-14\r\n___ 12:00AM BLOOD ALT-12 AST-14 LD(LDH)-189 AlkPhos-71 \r\nTotBili-0.2\r\n___ 12:35AM BLOOD ALT-11 AST-12 LD(___)-206 AlkPhos-77 \r\nTotBili-0.2\r\n___ 12:10AM BLOOD ALT-14 AST-18 LD(___)-256* AlkPhos-100 \r\nTotBili-0.___LBCL transformed from follicular lymphoma: Ms. ___ was \r\nadmitted for cycle 3 of R-ICE with goal of collection with this \r\ncycle, for which she has a right chest tunnelled line. Tolerated \r\nthe chemo, except for some nausea and poor appetite, which were \r\ntreated with anti-emetics. She will start her G-CSF upon \r\ndischarge. She was started on Ciprofloxacin prophylaxis in \r\nanticipation of HSCT. She remains on Bactrim for PJP \r\nprophylaxis. She will f/u in ___ clinic regarding \r\ncollection of her cells and schedule her transplant.\r\n.\r\n# history of coiled aneuyrsm and TIA: Her Aspirin was continued, \r\nbut she was advised to stop on ___ since her platelets are \r\nexpected to drop later this week. Her statin was held during \r\nchemo, which was resumed upon discharge.\r\n.\r\n# Torticolis, neck pain: Continued home regimen with Valium PRN, \r\nheat, and soft collar. She denied neck pain/stiffness at the \r\ntime of discharge.\r\n.\r\n# Migraine: She had migrainous headaches during admission, which \r\nresolved on their own.\r\n.\r\n# Volume overload: She experienced mild volume overload and \r\nweight gain during her chemo course, which responded to a Lasix \r\nbolus x1. Her discharge weight was 245.0 lbs. She was advised to \r\ntake oral Lasix PRN at home or to call clinic, if she notices \r\nincreased swelling.\r\n.\r\n# Access: Right chest double-lumen tunneled line. There were \r\nintermittently problems with drawing blood and flushes, which \r\nappeared to be positional in nature. This was successfully \r\nmanaged with tPA. Pheresis team evaluated abilty to use line, \r\nand felt it should be adequate for collection despite positional \r\nnature. Patient was advised to call clinic if she has any \r\nfurther issues with the line.\r\n.\r\nAll other chronic issues stable.\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Multivitamins 1 TAB PO DAILY \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 8 mg PO Q8H:PRN nausea \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Pravastatin 10 mg PO DAILY \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Venlafaxine 25 mg PO BID \r\n13. Furosemide 20 mg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY - through ___\r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ondansetron 8 mg PO Q8H:PRN nausea \r\n11. Furosemide 20 mg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n13. Pravastatin 10 mg PO DAILY \r\n14. Ciprofloxacin HCl 500 mg PO Q12H \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nLymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n.\r\nIt was a pleasure to meet you at the ___ \r\n___. You were admitted to receive chemotherapy both \r\nto treat your lymphoma and to mobilize your stem cells, which \r\nyou sucessfully completed while with us. \r\n.\r\nYou will inject yourself with neupogen, following the calendar \r\nthat ___ gives you. These injections may cause bone pain, \r\ntake oxycodone should you experience this.  As prior, do not \r\ndrive.\r\n.\r\nContinue all of your home medications as prior. We have added \r\ncipro to prevent infection while you collect. You should stop \r\ntaking Aspirin on ___ because we expect your \r\nplatelets to start dropping later this week.\r\n.\r\nThank you again for allowing us to participate in your care!\r\n.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-11:4",
      "text": "She denied neck pain/stiffness at the \ntime of discharge. . # Migraine: She had migrainous headaches during admission, which \nresolved on their own. . # Volume overload: She experienced mild volume overload and \nweight gain during her chemo course, which responded to a Lasix \nbolus x1. Her discharge weight was 245.0 lbs. She was advised to \ntake oral Lasix PRN at home or to call clinic, if she notices \nincreased swelling. . # Access: Right chest double-lumen tunneled line. There were \nintermittently problems with drawing blood and flushes, which \nappeared to be positional in nature. This was successfully \nmanaged with tPA. Pheresis team evaluated abilty to use line, \nand felt it should be adequate for collection despite positional \nnature. Patient was advised to call clinic if she has any \nfurther issues with the line. . All other chronic issues stable. Medications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Acyclovir 400 mg PO Q8H \n2. Allopurinol ___ mg PO DAILY \n3. Aspirin 81 mg PO DAILY \n4. Gabapentin 900 mg PO BID \n5. Multivitamins 1 TAB PO DAILY \n6. Omeprazole 20 mg PO DAILY \n7. Ondansetron 8 mg PO Q8H:PRN nausea \n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \n9. Pravastatin 10 mg PO DAILY \n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \n12. Venlafaxine 25 mg PO BID \n13. Furosemide 20 mg PO DAILY",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-11",
        "chart_time": "103315",
        "section": "General",
        "position": 4,
        "tokenCount": 352,
        "note_metadata": {
          "note_id": "18887130-DS-11",
          "subject_id": 18887130,
          "hadm_id": 26950422,
          "note_type": "DS",
          "note_seq": 11,
          "charttime": 103315,
          "storetime": 103315.57152777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nChemotherapy\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ female with transformed diffuse large B cell lymphoma \r\npresents today for cycle 3 of R-ICE.  She was initially \r\ndiagnosed with follicular lymphoma in ___, and relapsed in ___ \r\nwith a transformation to DLBCL. She will collect her stem cells \r\nfor autologous transplant after this cycle. Her workup is \r\ncomplete. The plan is for XRT after auto, as she has a residual \r\navid area in her abdominal mass. Today, she reports improving \r\nneck pain, for which she has been using occasional valium, soft \r\ncollar, and warmth. It started last week. Otherwise, no HA, \r\nneuro changes, n/v/d, fevers chills.\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nGeneral: WDWN female, NAD, A&Ox4. Ptosis noted R, ansicoria L>R\r\n(known).\r\nHEENT: oropharynx no lesions\r\nNeck: neck limited extention, rotation to R. No meningsmus. No\r\nadenopathy throughout   \r\nCV:  RRR no m/r/g\r\nLungs: CTA\r\nAbdomen: soft NT -HSM\r\nExt:  no edema \r\nNeuro: as above\r\nAccess: R chest IJ c/d/i\r\n\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD WBC-2.7* RBC-2.47* Hgb-7.8* Hct-23.9* \r\nMCV-96 MCH-31.4 MCHC-32.5 RDW-20.6* Plt ___\r\n___ 12:35AM BLOOD WBC-4.0 RBC-2.45* Hgb-7.9* Hct-23.5* \r\nMCV-96 MCH-32.1* MCHC-33.6 RDW-20.1* Plt ___\r\n___ 12:10AM BLOOD WBC-5.4 RBC-2.80* Hgb-8.6* Hct-27.4* \r\nMCV-98 MCH-30.6 MCHC-31.4 RDW-20.7* Plt ___\r\n___ 12:00AM BLOOD Neuts-90.3* Lymphs-4.5* Monos-4.8 Eos-0.4 \r\nBaso-0\r\n___ 12:35AM BLOOD Neuts-95.3* Lymphs-2.9* Monos-1.4* \r\nEos-0.3 Baso-0\r\n___ 12:10AM BLOOD Neuts-94.4* Lymphs-3.6* Monos-1.6* \r\nEos-0.5 Baso-0\r\n___ 12:00AM BLOOD Glucose-132* UreaN-13 Creat-0.6 Na-141 \r\nK-3.6 Cl-105 HCO3-24 AnGap-16\r\n___ 12:35AM BLOOD Glucose-156* UreaN-14 Creat-0.7 Na-140 \r\nK-4.1 Cl-106 HCO3-24 AnGap-14\r\n___ 12:10AM BLOOD Glucose-184* UreaN-14 Creat-0.7 Na-139 \r\nK-4.3 Cl-104 HCO3-25 AnGap-14\r\n___ 12:00AM BLOOD ALT-12 AST-14 LD(LDH)-189 AlkPhos-71 \r\nTotBili-0.2\r\n___ 12:35AM BLOOD ALT-11 AST-12 LD(___)-206 AlkPhos-77 \r\nTotBili-0.2\r\n___ 12:10AM BLOOD ALT-14 AST-18 LD(___)-256* AlkPhos-100 \r\nTotBili-0.___LBCL transformed from follicular lymphoma: Ms. ___ was \r\nadmitted for cycle 3 of R-ICE with goal of collection with this \r\ncycle, for which she has a right chest tunnelled line. Tolerated \r\nthe chemo, except for some nausea and poor appetite, which were \r\ntreated with anti-emetics. She will start her G-CSF upon \r\ndischarge. She was started on Ciprofloxacin prophylaxis in \r\nanticipation of HSCT. She remains on Bactrim for PJP \r\nprophylaxis. She will f/u in ___ clinic regarding \r\ncollection of her cells and schedule her transplant.\r\n.\r\n# history of coiled aneuyrsm and TIA: Her Aspirin was continued, \r\nbut she was advised to stop on ___ since her platelets are \r\nexpected to drop later this week. Her statin was held during \r\nchemo, which was resumed upon discharge.\r\n.\r\n# Torticolis, neck pain: Continued home regimen with Valium PRN, \r\nheat, and soft collar. She denied neck pain/stiffness at the \r\ntime of discharge.\r\n.\r\n# Migraine: She had migrainous headaches during admission, which \r\nresolved on their own.\r\n.\r\n# Volume overload: She experienced mild volume overload and \r\nweight gain during her chemo course, which responded to a Lasix \r\nbolus x1. Her discharge weight was 245.0 lbs. She was advised to \r\ntake oral Lasix PRN at home or to call clinic, if she notices \r\nincreased swelling.\r\n.\r\n# Access: Right chest double-lumen tunneled line. There were \r\nintermittently problems with drawing blood and flushes, which \r\nappeared to be positional in nature. This was successfully \r\nmanaged with tPA. Pheresis team evaluated abilty to use line, \r\nand felt it should be adequate for collection despite positional \r\nnature. Patient was advised to call clinic if she has any \r\nfurther issues with the line.\r\n.\r\nAll other chronic issues stable.\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Multivitamins 1 TAB PO DAILY \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 8 mg PO Q8H:PRN nausea \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Pravastatin 10 mg PO DAILY \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Venlafaxine 25 mg PO BID \r\n13. Furosemide 20 mg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY - through ___\r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ondansetron 8 mg PO Q8H:PRN nausea \r\n11. Furosemide 20 mg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n13. Pravastatin 10 mg PO DAILY \r\n14. Ciprofloxacin HCl 500 mg PO Q12H \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nLymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n.\r\nIt was a pleasure to meet you at the ___ \r\n___. You were admitted to receive chemotherapy both \r\nto treat your lymphoma and to mobilize your stem cells, which \r\nyou sucessfully completed while with us. \r\n.\r\nYou will inject yourself with neupogen, following the calendar \r\nthat ___ gives you. These injections may cause bone pain, \r\ntake oxycodone should you experience this.  As prior, do not \r\ndrive.\r\n.\r\nContinue all of your home medications as prior. We have added \r\ncipro to prevent infection while you collect. You should stop \r\ntaking Aspirin on ___ because we expect your \r\nplatelets to start dropping later this week.\r\n.\r\nThank you again for allowing us to participate in your care!\r\n.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-11:5",
      "text": "Discharge Medications:\n1. Acyclovir 400 mg PO Q8H \n2. Allopurinol ___ mg PO DAILY \n3. Aspirin 81 mg PO DAILY - through ___\n4. Gabapentin 900 mg PO BID \n5. Omeprazole 20 mg PO DAILY \n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \n9. Venlafaxine 25 mg PO BID \n10. Ondansetron 8 mg PO Q8H:PRN nausea \n11. Furosemide 20 mg PO DAILY \n12. Multivitamins 1 TAB PO DAILY \n13. Pravastatin 10 mg PO DAILY \n14. Ciprofloxacin HCl 500 mg PO Q12H Discharge Disposition:\nHome Discharge Diagnosis:\nLymphoma Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-11",
        "chart_time": "103315",
        "section": "General",
        "position": 5,
        "tokenCount": 180,
        "note_metadata": {
          "note_id": "18887130-DS-11",
          "subject_id": 18887130,
          "hadm_id": 26950422,
          "note_type": "DS",
          "note_seq": 11,
          "charttime": 103315,
          "storetime": 103315.57152777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nChemotherapy\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ female with transformed diffuse large B cell lymphoma \r\npresents today for cycle 3 of R-ICE.  She was initially \r\ndiagnosed with follicular lymphoma in ___, and relapsed in ___ \r\nwith a transformation to DLBCL. She will collect her stem cells \r\nfor autologous transplant after this cycle. Her workup is \r\ncomplete. The plan is for XRT after auto, as she has a residual \r\navid area in her abdominal mass. Today, she reports improving \r\nneck pain, for which she has been using occasional valium, soft \r\ncollar, and warmth. It started last week. Otherwise, no HA, \r\nneuro changes, n/v/d, fevers chills.\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nGeneral: WDWN female, NAD, A&Ox4. Ptosis noted R, ansicoria L>R\r\n(known).\r\nHEENT: oropharynx no lesions\r\nNeck: neck limited extention, rotation to R. No meningsmus. No\r\nadenopathy throughout   \r\nCV:  RRR no m/r/g\r\nLungs: CTA\r\nAbdomen: soft NT -HSM\r\nExt:  no edema \r\nNeuro: as above\r\nAccess: R chest IJ c/d/i\r\n\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD WBC-2.7* RBC-2.47* Hgb-7.8* Hct-23.9* \r\nMCV-96 MCH-31.4 MCHC-32.5 RDW-20.6* Plt ___\r\n___ 12:35AM BLOOD WBC-4.0 RBC-2.45* Hgb-7.9* Hct-23.5* \r\nMCV-96 MCH-32.1* MCHC-33.6 RDW-20.1* Plt ___\r\n___ 12:10AM BLOOD WBC-5.4 RBC-2.80* Hgb-8.6* Hct-27.4* \r\nMCV-98 MCH-30.6 MCHC-31.4 RDW-20.7* Plt ___\r\n___ 12:00AM BLOOD Neuts-90.3* Lymphs-4.5* Monos-4.8 Eos-0.4 \r\nBaso-0\r\n___ 12:35AM BLOOD Neuts-95.3* Lymphs-2.9* Monos-1.4* \r\nEos-0.3 Baso-0\r\n___ 12:10AM BLOOD Neuts-94.4* Lymphs-3.6* Monos-1.6* \r\nEos-0.5 Baso-0\r\n___ 12:00AM BLOOD Glucose-132* UreaN-13 Creat-0.6 Na-141 \r\nK-3.6 Cl-105 HCO3-24 AnGap-16\r\n___ 12:35AM BLOOD Glucose-156* UreaN-14 Creat-0.7 Na-140 \r\nK-4.1 Cl-106 HCO3-24 AnGap-14\r\n___ 12:10AM BLOOD Glucose-184* UreaN-14 Creat-0.7 Na-139 \r\nK-4.3 Cl-104 HCO3-25 AnGap-14\r\n___ 12:00AM BLOOD ALT-12 AST-14 LD(LDH)-189 AlkPhos-71 \r\nTotBili-0.2\r\n___ 12:35AM BLOOD ALT-11 AST-12 LD(___)-206 AlkPhos-77 \r\nTotBili-0.2\r\n___ 12:10AM BLOOD ALT-14 AST-18 LD(___)-256* AlkPhos-100 \r\nTotBili-0.___LBCL transformed from follicular lymphoma: Ms. ___ was \r\nadmitted for cycle 3 of R-ICE with goal of collection with this \r\ncycle, for which she has a right chest tunnelled line. Tolerated \r\nthe chemo, except for some nausea and poor appetite, which were \r\ntreated with anti-emetics. She will start her G-CSF upon \r\ndischarge. She was started on Ciprofloxacin prophylaxis in \r\nanticipation of HSCT. She remains on Bactrim for PJP \r\nprophylaxis. She will f/u in ___ clinic regarding \r\ncollection of her cells and schedule her transplant.\r\n.\r\n# history of coiled aneuyrsm and TIA: Her Aspirin was continued, \r\nbut she was advised to stop on ___ since her platelets are \r\nexpected to drop later this week. Her statin was held during \r\nchemo, which was resumed upon discharge.\r\n.\r\n# Torticolis, neck pain: Continued home regimen with Valium PRN, \r\nheat, and soft collar. She denied neck pain/stiffness at the \r\ntime of discharge.\r\n.\r\n# Migraine: She had migrainous headaches during admission, which \r\nresolved on their own.\r\n.\r\n# Volume overload: She experienced mild volume overload and \r\nweight gain during her chemo course, which responded to a Lasix \r\nbolus x1. Her discharge weight was 245.0 lbs. She was advised to \r\ntake oral Lasix PRN at home or to call clinic, if she notices \r\nincreased swelling.\r\n.\r\n# Access: Right chest double-lumen tunneled line. There were \r\nintermittently problems with drawing blood and flushes, which \r\nappeared to be positional in nature. This was successfully \r\nmanaged with tPA. Pheresis team evaluated abilty to use line, \r\nand felt it should be adequate for collection despite positional \r\nnature. Patient was advised to call clinic if she has any \r\nfurther issues with the line.\r\n.\r\nAll other chronic issues stable.\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Multivitamins 1 TAB PO DAILY \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 8 mg PO Q8H:PRN nausea \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Pravastatin 10 mg PO DAILY \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Venlafaxine 25 mg PO BID \r\n13. Furosemide 20 mg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY - through ___\r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ondansetron 8 mg PO Q8H:PRN nausea \r\n11. Furosemide 20 mg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n13. Pravastatin 10 mg PO DAILY \r\n14. Ciprofloxacin HCl 500 mg PO Q12H \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nLymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n.\r\nIt was a pleasure to meet you at the ___ \r\n___. You were admitted to receive chemotherapy both \r\nto treat your lymphoma and to mobilize your stem cells, which \r\nyou sucessfully completed while with us. \r\n.\r\nYou will inject yourself with neupogen, following the calendar \r\nthat ___ gives you. These injections may cause bone pain, \r\ntake oxycodone should you experience this.  As prior, do not \r\ndrive.\r\n.\r\nContinue all of your home medications as prior. We have added \r\ncipro to prevent infection while you collect. You should stop \r\ntaking Aspirin on ___ because we expect your \r\nplatelets to start dropping later this week.\r\n.\r\nThank you again for allowing us to participate in your care!\r\n.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-11:6",
      "text": "Discharge Instructions:\nDear Ms. ___,\n. It was a pleasure to meet you at the ___ \n___. You were admitted to receive chemotherapy both \nto treat your lymphoma and to mobilize your stem cells, which \nyou sucessfully completed while with us. . You will inject yourself with neupogen, following the calendar \nthat ___ gives you. These injections may cause bone pain, \ntake oxycodone should you experience this. As prior, do not \ndrive. . Continue all of your home medications as prior. We have added \ncipro to prevent infection while you collect. You should stop \ntaking Aspirin on ___ because we expect your \nplatelets to start dropping later this week. . Thank you again for allowing us to participate in your care! . Followup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-11",
        "chart_time": "103315",
        "section": "General",
        "position": 6,
        "tokenCount": 186,
        "note_metadata": {
          "note_id": "18887130-DS-11",
          "subject_id": 18887130,
          "hadm_id": 26950422,
          "note_type": "DS",
          "note_seq": 11,
          "charttime": 103315,
          "storetime": 103315.57152777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nChemotherapy\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ female with transformed diffuse large B cell lymphoma \r\npresents today for cycle 3 of R-ICE.  She was initially \r\ndiagnosed with follicular lymphoma in ___, and relapsed in ___ \r\nwith a transformation to DLBCL. She will collect her stem cells \r\nfor autologous transplant after this cycle. Her workup is \r\ncomplete. The plan is for XRT after auto, as she has a residual \r\navid area in her abdominal mass. Today, she reports improving \r\nneck pain, for which she has been using occasional valium, soft \r\ncollar, and warmth. It started last week. Otherwise, no HA, \r\nneuro changes, n/v/d, fevers chills.\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nGeneral: WDWN female, NAD, A&Ox4. Ptosis noted R, ansicoria L>R\r\n(known).\r\nHEENT: oropharynx no lesions\r\nNeck: neck limited extention, rotation to R. No meningsmus. No\r\nadenopathy throughout   \r\nCV:  RRR no m/r/g\r\nLungs: CTA\r\nAbdomen: soft NT -HSM\r\nExt:  no edema \r\nNeuro: as above\r\nAccess: R chest IJ c/d/i\r\n\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD WBC-2.7* RBC-2.47* Hgb-7.8* Hct-23.9* \r\nMCV-96 MCH-31.4 MCHC-32.5 RDW-20.6* Plt ___\r\n___ 12:35AM BLOOD WBC-4.0 RBC-2.45* Hgb-7.9* Hct-23.5* \r\nMCV-96 MCH-32.1* MCHC-33.6 RDW-20.1* Plt ___\r\n___ 12:10AM BLOOD WBC-5.4 RBC-2.80* Hgb-8.6* Hct-27.4* \r\nMCV-98 MCH-30.6 MCHC-31.4 RDW-20.7* Plt ___\r\n___ 12:00AM BLOOD Neuts-90.3* Lymphs-4.5* Monos-4.8 Eos-0.4 \r\nBaso-0\r\n___ 12:35AM BLOOD Neuts-95.3* Lymphs-2.9* Monos-1.4* \r\nEos-0.3 Baso-0\r\n___ 12:10AM BLOOD Neuts-94.4* Lymphs-3.6* Monos-1.6* \r\nEos-0.5 Baso-0\r\n___ 12:00AM BLOOD Glucose-132* UreaN-13 Creat-0.6 Na-141 \r\nK-3.6 Cl-105 HCO3-24 AnGap-16\r\n___ 12:35AM BLOOD Glucose-156* UreaN-14 Creat-0.7 Na-140 \r\nK-4.1 Cl-106 HCO3-24 AnGap-14\r\n___ 12:10AM BLOOD Glucose-184* UreaN-14 Creat-0.7 Na-139 \r\nK-4.3 Cl-104 HCO3-25 AnGap-14\r\n___ 12:00AM BLOOD ALT-12 AST-14 LD(LDH)-189 AlkPhos-71 \r\nTotBili-0.2\r\n___ 12:35AM BLOOD ALT-11 AST-12 LD(___)-206 AlkPhos-77 \r\nTotBili-0.2\r\n___ 12:10AM BLOOD ALT-14 AST-18 LD(___)-256* AlkPhos-100 \r\nTotBili-0.___LBCL transformed from follicular lymphoma: Ms. ___ was \r\nadmitted for cycle 3 of R-ICE with goal of collection with this \r\ncycle, for which she has a right chest tunnelled line. Tolerated \r\nthe chemo, except for some nausea and poor appetite, which were \r\ntreated with anti-emetics. She will start her G-CSF upon \r\ndischarge. She was started on Ciprofloxacin prophylaxis in \r\nanticipation of HSCT. She remains on Bactrim for PJP \r\nprophylaxis. She will f/u in ___ clinic regarding \r\ncollection of her cells and schedule her transplant.\r\n.\r\n# history of coiled aneuyrsm and TIA: Her Aspirin was continued, \r\nbut she was advised to stop on ___ since her platelets are \r\nexpected to drop later this week. Her statin was held during \r\nchemo, which was resumed upon discharge.\r\n.\r\n# Torticolis, neck pain: Continued home regimen with Valium PRN, \r\nheat, and soft collar. She denied neck pain/stiffness at the \r\ntime of discharge.\r\n.\r\n# Migraine: She had migrainous headaches during admission, which \r\nresolved on their own.\r\n.\r\n# Volume overload: She experienced mild volume overload and \r\nweight gain during her chemo course, which responded to a Lasix \r\nbolus x1. Her discharge weight was 245.0 lbs. She was advised to \r\ntake oral Lasix PRN at home or to call clinic, if she notices \r\nincreased swelling.\r\n.\r\n# Access: Right chest double-lumen tunneled line. There were \r\nintermittently problems with drawing blood and flushes, which \r\nappeared to be positional in nature. This was successfully \r\nmanaged with tPA. Pheresis team evaluated abilty to use line, \r\nand felt it should be adequate for collection despite positional \r\nnature. Patient was advised to call clinic if she has any \r\nfurther issues with the line.\r\n.\r\nAll other chronic issues stable.\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Multivitamins 1 TAB PO DAILY \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 8 mg PO Q8H:PRN nausea \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Pravastatin 10 mg PO DAILY \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Venlafaxine 25 mg PO BID \r\n13. Furosemide 20 mg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY - through ___\r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ondansetron 8 mg PO Q8H:PRN nausea \r\n11. Furosemide 20 mg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n13. Pravastatin 10 mg PO DAILY \r\n14. Ciprofloxacin HCl 500 mg PO Q12H \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nLymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n.\r\nIt was a pleasure to meet you at the ___ \r\n___. You were admitted to receive chemotherapy both \r\nto treat your lymphoma and to mobilize your stem cells, which \r\nyou sucessfully completed while with us. \r\n.\r\nYou will inject yourself with neupogen, following the calendar \r\nthat ___ gives you. These injections may cause bone pain, \r\ntake oxycodone should you experience this.  As prior, do not \r\ndrive.\r\n.\r\nContinue all of your home medications as prior. We have added \r\ncipro to prevent infection while you collect. You should stop \r\ntaking Aspirin on ___ because we expect your \r\nplatelets to start dropping later this week.\r\n.\r\nThank you again for allowing us to participate in your care!\r\n.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-12:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \nNo Known Allergies / Adverse Drug Reactions\n \nAttending: ___\n \n___ Complaint:\nscheduled autologous transplant with BEAM conditioning\n \nMajor Surgical or Invasive Procedure:\n___: IVC filter placed\n___: auto-stem cell transplant",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-12",
        "chart_time": "103369",
        "section": "General",
        "position": 0,
        "tokenCount": 101,
        "note_metadata": {
          "note_id": "18887130-DS-12",
          "subject_id": 18887130,
          "hadm_id": 28224744,
          "note_type": "DS",
          "note_seq": 12,
          "charttime": 103369,
          "storetime": 103369.65416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nscheduled autologous transplant with BEAM conditioning\r\n \r\nMajor Surgical or Invasive Procedure:\r\n___: IVC filter placed\r\n___: auto-stem cell transplant\r\n\r\n \r\nHistory of Present Illness:\r\n___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. She was also reporting an \r\narea of right medial thigh erythema, tenderness and induration \r\nto the transplant nurse over the phone on ___. She had a \r\nscheduled outpatient appointment for pre-transplant lab work. \r\nShe had ___ at the outpatient heme/onc office which showed an \r\nacute right popliteal/ femoral DVT. \r\n\r\nStem cell collection period prolonged as counts slower to \r\nrecover than in the past.  Required addition of Mozibil with \r\nmuch improved stem cells collections with total yield of over 5 \r\nx 10(e)6 CD 3 cells/kg.  Her last PET CT showed almost a \r\ncomplete response with residual focus of avidity in the bed of \r\nthe abdominal mass.  She was evaluated by radiation oncology \r\nwith the plan for consolidative radiation therapy to be done \r\nfollowing her autologous transplant.  Echocardiogram on \r\n___ showed normal left ventricular wall thickness and \r\ncavity size with mildly depressed global systolic function with \r\nLVEF of 45%.  PFT's from ___ showed FVC of 66%, FEV1 of \r\n73%, TLC of 73% and DLCO of 93%.  Bone marrow aspirate and \r\nbiopsy on ___ showed no evidence for lymphoma but was \r\nnoted for a small mature lymphocyte clone that is a separate \r\nmalignancy of\r\nthe CLL phenotype.  She has no indication of this in her blood. \r\nAs her transformed lymphoma needs to be treated and is more life\r\nthreatening if left untreated, the decision was made to proceed\r\nwith the autologous transplant as planned.\r\n \r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access. Biopsies showed\r\nFollicular lymphomas grade II/III. Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new \r\nadenopathy. Labs notable for LDH 341, WBC 10.1, normal \r\ndifferential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal\r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric\r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ \r\nCD10+ lambda restricted. MIB and cytogenetics are pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clincally improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a \r\nresidual focus of avidity in the bed of the former abdominal \r\nmass, SUV ___ C4 Rituximab\r\n- PLANNED ___ C4 ICE followed by stem cell mobilization and \r\ncollection\r\n\r\n \r\nPast Medical History:\r\n--Transformed DLBCL with history of follicular lymphoma as noted\r\nabove. \r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia \r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM: \r\n.\r\nVITALS -  98.4, 126/62, 75, 18, 98% RA   weight: 238.2\r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, OP \r\nclear\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. Tender, erythematous corded vein on right medial \r\nmid-thigh. No cyanosis, clubbing or edema. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. Gait not assessed.\r\n.\r\nDISCHARGE EXAM: \r\n.\r\nVITALS -  97.5 118/78 104 18 99% RA  \r\nI/O yesterday (24hr): 1.4/0.9 (no BMs) \r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, no \r\nlesions\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley; healed skin tears in inguinal region; pink, no \r\npurulence, no surrounding errythema, IMPROVED \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. 2+ pitting edema ___ at ankles, L>R. No cyanosis or \r\nclubbing. L hip TTP, no masses, errhtyema, warmth. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. normal gait\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS: \r\n---------------\r\n___ 10:45AM   UREA N-11 CREAT-0.8 SODIUM-137 POTASSIUM-4.3 \r\nCHLORIDE-101 TOTAL CO2-26 ANION GAP-14\r\n___ 10:45AM   estGFR-Using this\r\n___ 10:45AM   ALT(SGPT)-12 AST(SGOT)-20 LD(LDH)-341* ALK \r\nPHOS-153* TOT BILI-0.2\r\n___ 10:45AM   TOT PROT-6.2* ALBUMIN-4.0 GLOBULIN-2.2 \r\nCALCIUM-8.6 PHOSPHATE-3.5 MAGNESIUM-2.1 URIC ACID-3.9\r\n___ 10:45AM   WBC-8.6# RBC-2.61* HGB-8.2* HCT-25.5* MCV-98 \r\nMCH-31.3 MCHC-32.0 RDW-24.1*\r\n___ 10:45AM   NEUTS-83.2* LYMPHS-7.0* MONOS-9.5 EOS-0.1 \r\nBASOS-0.2\r\n___ 10:45AM   PLT COUNT-281#\r\n___ 10:45AM   ___ PTT-29.1 ___\r\n.\r\nIMAGING: \r\n----------\r\n___ ___ Dopplers IMPRESSION:   \r\n1.  Acute deep venous thrombosis of the right femoral and \r\npopliteal veins.   2.  No evidence of deep vein thrombosis in \r\nthe left lower extremity.\r\n. \r\n___ CTA Chest: 1.  No pulmonary embolus demonstrated.  \r\n2.  Enlargement of the main pulmonary artery as seen on the \r\nprior examination ___.  This may reflect pulmonary \r\narterial hypertension.   \r\n.\r\n___ ___ Dopplers IMPRESSION: \r\n1.  No evidence of DVT in the left lower extremity.  Assessment \r\nof left calf veins is limited.   2.  Similar distribution of \r\nthrombus in the right lower extremity involving the right mid \r\nand distal femoral vein and popliteal vein.\r\n.   \r\nDISCHARGE LABS: \r\n---------------\r\n___ 12:04AM BLOOD WBC-4.2 RBC-2.62* Hgb-8.1* Hct-25.7* \r\nMCV-98 MCH-30.8 MCHC-31.4 RDW-20.3* Plt ___\r\n___ 12:04AM BLOOD Neuts-59 Bands-0 Lymphs-12* Monos-26* \r\nEos-0 Baso-0 Atyps-2* ___ Myelos-1*\r\n___ 12:04AM BLOOD Hypochr-1+ Anisocy-2+ Poiklo-1+ \r\nMacrocy-3+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-1+\r\n___ 12:04AM BLOOD Plt Smr-LOW Plt ___\r\n___ 12:04AM BLOOD Glucose-103* UreaN-9 Creat-0.7 Na-138 \r\nK-3.7 Cl-103 HCO3-26 AnGap-13\r\n___ 12:04AM BLOOD ALT-15 AST-20 LD(LDH)-219 AlkPhos-81 \r\nTotBili-0.3\r\n___ 12:04AM BLOOD Albumin-3.5 Calcium-8.2* Phos-3.5 Mg-1.___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. \r\n.\r\nACUTE ISSUES: \r\n.\r\n#Diffuse Large B-Cell Lymphoma (DLBCL): transformed from \r\nfollicular lyphoma. Underwent BEAM conditioning followed by \r\nscheduled autoSCT on ___. Post-transplant course complicated by \r\nfebrile neutropenia, for which she was on cefepime, vancomycin \r\nand micafungin (to cover inguinal skin wounds). Recieved 5U \r\nPRBCs and 5U platelets to maintain hct > 21 and plts > 10. She \r\nwas on PCA for a period of time for mucositis. Neutropenia \r\nresolved on ___, at which point antibiotics and G-CSF were \r\ndiscontinued. Patient was able to advance diet slowly as \r\nmucositis resolved; by discharge she was taking excellent PO \r\nhydration and continuing to advance her diet. Sent home on \r\nacyclovir for fungal ppx, to start Bactrim SS for PCP ppx on \r\n___.  \r\n.\r\n#DVT: New, provoked. ___ in outpatient heme/onc office showed \r\nacute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis. Secondary to malignancy. Given lovenox in the \r\nclinic. Pt reported to be tachycardic and dyspneic in clinic, \r\nc/f PE was high. CTA chest negative for PE. IVC filter placed on \r\n___ by ___. Heparin drip discontinued ___ given falling \r\nplatelet count. Left lower extemity noted to be swollen more \r\nsignificantly than the right on ___, but dopplers showed only \r\nstable right leg clot. Thrombocytopenia resolved on ___, and \r\nshe was started on warfarin as well as lovenox sc at \r\nprophylactic dose. On ___ she was switched to lovenox sc at \r\ntreatment dose (100mg BID); will start on warfarin as outpatient \r\nat a later date, once diet and medications have stabilized.  \r\n.\r\n#Bilateral groin skin tears: skin tears in inguinal region \r\nbeneath panus c/b intertrigo/fungal infection. Developed prior \r\nto onset of neutropneia, started on vancomycin and micafungin + \r\ntopical fungal cream. Healed well with proper wound care. \r\nMicafungin and vancomycin discontinued once neutropenia \r\nresolved. \r\n.\r\nCHRONIC ISSUES: \r\n.\r\n# Back and L hip pain: has h/o L hip bursistis; no h/o sciatica. \r\nDescription of pain c/w musculoskeletal source, no concerning \r\nphysical exam findings. Symptoms fluctuated through course of \r\nstay based on patient positioning/activity level. \r\n.\r\n#Migranes: Patient reporting unilateral (right sided) headache \r\nwith photosensitivity and nausea on ___. Resolved on ___ \r\nafter receiving fioracet and ativan for nausea. \r\n.\r\n#Neuropathy: Stable, likely secondary to old sensory stroke. \r\nAlso has new numbness on fingertips bilaterally likely secondary \r\nto etoposide. Continued home gabapentin.\r\n.\r\n#H/o cerebral aneurysm: Stable. Discovered ___ years ago on MRA \r\nhead in right ICA cavernous sinus. S/p coiling ___ years ago. Has \r\nstable dysconjugate gaze/pupil asymmetry from the aneurysm.   \r\n.\r\n#Depression: Stable, continued on home venlafaxine.\r\n.\r\nTRANSTIONAL ISSUES: \r\n.\r\n# ANTICOAGULATION: discharged on lovenox; will continue for at \r\nleast 2 weeks while diet increases/she starts on bactrim, and \r\nthen be transitioned to warfarin as outpatient. \r\n.\r\n# PCP ___: to start ___ sent home w/script\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Furosemide 20 mg PO DAILY \r\n3. Gabapentin 900 mg PO BID \r\n4. Omeprazole 20 mg PO DAILY \r\n5. Ondansetron 8 mg PO Q8H:PRN nausea \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Gabapentin 900 mg PO BID \r\n3. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n4. Venlafaxine 25 mg PO BID \r\n5. Miconazole 2% Cream 1 Appl TP BID \r\nRX *miconazole nitrate [Antifungal Cream] 2 % apply to groin for \r\nrash three times a day Disp #*1 Tube Refills:*0\r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Furosemide 20 mg PO DAILY \r\n9. Ondansetron 8 mg PO Q8H:PRN nausea \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0\r\n12. Enoxaparin Sodium 100 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\nRX *enoxaparin 100 mg/mL 100 mg sc twice a day Disp #*14 Syringe \r\nRefills:*0\r\n13. OLANZapine (Disintegrating Tablet) 2.5 mg PO BID nausea \r\nRX *olanzapine 2.5 mg 1 tablet(s) by mouth twice a day Disp #*14 \r\nTablet Refills:*0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n# Primary: Diffuse Large B-Cell Lymphoma (DLBCL) \r\n\r\n# Secondary: Febrile Neutropenia, Deep Venous Thrombosis, \r\nDepression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear ___, \r\n\r\n___ was a pleasure taking care of you at the ___ \r\n___. You came in for an auto-stem cell \r\ntransplant (autSCT) for your Diffuse Large B-Cell Lymphoma \r\n(DLBCL). Just prior to admission you were found to have a deep \r\nvein thrombosis (DVT), for which you were started on lovenox and \r\nhad an inferior vena cava (IVC) filter placed on ___. You \r\nrecieved your autoSCT on ___. \r\n\r\nYour post-transplant course was complicated by fever, requiring \r\nantibiotics. These were discontinued without incident when your \r\nwhite blood cell counts had recovered. Lovenox was held when \r\nyour platelet count fell during chemotherapy. Anticoagulation \r\nwith lovenox was restarted on ___ when your platelet count had \r\nrecovered. \r\n\r\nYou will remain on viral prophylaxis with acyclovir for now, and \r\nstart PCP prophylaxis with ___ on ___.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-12:1",
      "text": "History of Present Illness:\n___ with transformed DLBCL and h/o follicular lymphoma \npresenting for a scheduled autoSCT. She was also reporting an \narea of right medial thigh erythema, tenderness and induration \nto the transplant nurse over the phone on ___. She had a \nscheduled outpatient appointment for pre-transplant lab work. She had ___ at the outpatient heme/onc office which showed an \nacute right popliteal/ femoral DVT. Stem cell collection period prolonged as counts slower to \nrecover than in the past. Required addition of Mozibil with \nmuch improved stem cells collections with total yield of over 5 \nx 10(e)6 CD 3 cells/kg. Her last PET CT showed almost a \ncomplete response with residual focus of avidity in the bed of \nthe abdominal mass. She was evaluated by radiation oncology \nwith the plan for consolidative radiation therapy to be done \nfollowing her autologous transplant. Echocardiogram on \n___ showed normal left ventricular wall thickness and \ncavity size with mildly depressed global systolic function with \nLVEF of 45%. PFT's from ___ showed FVC of 66%, FEV1 of \n73%, TLC of 73% and DLCO of 93%. Bone marrow aspirate and \nbiopsy on ___ showed no evidence for lymphoma but was \nnoted for a small mature lymphocyte clone that is a separate \nmalignancy of\nthe CLL phenotype. She has no indication of this in her blood. As her transformed lymphoma needs to be treated and is more life\nthreatening if left untreated, the decision was made to proceed\nwith the autologous transplant as planned. PAST ONCOLOGIC HISTORY:  \nTransformed DLBCL with a history of follicular lymphoma stage \nIIA \n- ___ developed worsening musculoskeletal back pain, early\nsatiety, hypoalbuminemia and found to have mesenteric mass\n- ?___ ex lap with 15 cm lobulated mass involving the\nduodenum, retroperitoneum and celiac access. Biopsies showed\nFollicular lymphomas grade II/III. Reportedly negative staging\nGallium scan. CD10+ BCL2+\n- ___ completed 6 cycles CHOP, complications included\nSVC/innominate thrombus (tPA)\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\nmarrow at completion was negative for lymphomatous involvement. - ___ PET-CT with very slight amount of increased tracer\nactivity within the posterior left supraclavicular region. No\nother areas of FDG avid disease were noted \n- ___ through ___ per records she was treated with CVP\nfollowed by course of single agent Rituxan\n- ___ through ___ surveillance imaging with no evidence of\nrecurrent disease, stable mesenteric mass. - ___ abdominal pain led to CT with no change in mass size,\nincreased conspicuity of nodular borders\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\nstable mesenteric mass with low level SUV 2.2 stable since \nprior.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-12",
        "chart_time": "103369",
        "section": "General",
        "position": 1,
        "tokenCount": 683,
        "note_metadata": {
          "note_id": "18887130-DS-12",
          "subject_id": 18887130,
          "hadm_id": 28224744,
          "note_type": "DS",
          "note_seq": 12,
          "charttime": 103369,
          "storetime": 103369.65416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nscheduled autologous transplant with BEAM conditioning\r\n \r\nMajor Surgical or Invasive Procedure:\r\n___: IVC filter placed\r\n___: auto-stem cell transplant\r\n\r\n \r\nHistory of Present Illness:\r\n___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. She was also reporting an \r\narea of right medial thigh erythema, tenderness and induration \r\nto the transplant nurse over the phone on ___. She had a \r\nscheduled outpatient appointment for pre-transplant lab work. \r\nShe had ___ at the outpatient heme/onc office which showed an \r\nacute right popliteal/ femoral DVT. \r\n\r\nStem cell collection period prolonged as counts slower to \r\nrecover than in the past.  Required addition of Mozibil with \r\nmuch improved stem cells collections with total yield of over 5 \r\nx 10(e)6 CD 3 cells/kg.  Her last PET CT showed almost a \r\ncomplete response with residual focus of avidity in the bed of \r\nthe abdominal mass.  She was evaluated by radiation oncology \r\nwith the plan for consolidative radiation therapy to be done \r\nfollowing her autologous transplant.  Echocardiogram on \r\n___ showed normal left ventricular wall thickness and \r\ncavity size with mildly depressed global systolic function with \r\nLVEF of 45%.  PFT's from ___ showed FVC of 66%, FEV1 of \r\n73%, TLC of 73% and DLCO of 93%.  Bone marrow aspirate and \r\nbiopsy on ___ showed no evidence for lymphoma but was \r\nnoted for a small mature lymphocyte clone that is a separate \r\nmalignancy of\r\nthe CLL phenotype.  She has no indication of this in her blood. \r\nAs her transformed lymphoma needs to be treated and is more life\r\nthreatening if left untreated, the decision was made to proceed\r\nwith the autologous transplant as planned.\r\n \r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access. Biopsies showed\r\nFollicular lymphomas grade II/III. Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new \r\nadenopathy. Labs notable for LDH 341, WBC 10.1, normal \r\ndifferential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal\r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric\r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ \r\nCD10+ lambda restricted. MIB and cytogenetics are pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clincally improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a \r\nresidual focus of avidity in the bed of the former abdominal \r\nmass, SUV ___ C4 Rituximab\r\n- PLANNED ___ C4 ICE followed by stem cell mobilization and \r\ncollection\r\n\r\n \r\nPast Medical History:\r\n--Transformed DLBCL with history of follicular lymphoma as noted\r\nabove. \r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia \r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM: \r\n.\r\nVITALS -  98.4, 126/62, 75, 18, 98% RA   weight: 238.2\r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, OP \r\nclear\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. Tender, erythematous corded vein on right medial \r\nmid-thigh. No cyanosis, clubbing or edema. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. Gait not assessed.\r\n.\r\nDISCHARGE EXAM: \r\n.\r\nVITALS -  97.5 118/78 104 18 99% RA  \r\nI/O yesterday (24hr): 1.4/0.9 (no BMs) \r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, no \r\nlesions\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley; healed skin tears in inguinal region; pink, no \r\npurulence, no surrounding errythema, IMPROVED \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. 2+ pitting edema ___ at ankles, L>R. No cyanosis or \r\nclubbing. L hip TTP, no masses, errhtyema, warmth. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. normal gait\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS: \r\n---------------\r\n___ 10:45AM   UREA N-11 CREAT-0.8 SODIUM-137 POTASSIUM-4.3 \r\nCHLORIDE-101 TOTAL CO2-26 ANION GAP-14\r\n___ 10:45AM   estGFR-Using this\r\n___ 10:45AM   ALT(SGPT)-12 AST(SGOT)-20 LD(LDH)-341* ALK \r\nPHOS-153* TOT BILI-0.2\r\n___ 10:45AM   TOT PROT-6.2* ALBUMIN-4.0 GLOBULIN-2.2 \r\nCALCIUM-8.6 PHOSPHATE-3.5 MAGNESIUM-2.1 URIC ACID-3.9\r\n___ 10:45AM   WBC-8.6# RBC-2.61* HGB-8.2* HCT-25.5* MCV-98 \r\nMCH-31.3 MCHC-32.0 RDW-24.1*\r\n___ 10:45AM   NEUTS-83.2* LYMPHS-7.0* MONOS-9.5 EOS-0.1 \r\nBASOS-0.2\r\n___ 10:45AM   PLT COUNT-281#\r\n___ 10:45AM   ___ PTT-29.1 ___\r\n.\r\nIMAGING: \r\n----------\r\n___ ___ Dopplers IMPRESSION:   \r\n1.  Acute deep venous thrombosis of the right femoral and \r\npopliteal veins.   2.  No evidence of deep vein thrombosis in \r\nthe left lower extremity.\r\n. \r\n___ CTA Chest: 1.  No pulmonary embolus demonstrated.  \r\n2.  Enlargement of the main pulmonary artery as seen on the \r\nprior examination ___.  This may reflect pulmonary \r\narterial hypertension.   \r\n.\r\n___ ___ Dopplers IMPRESSION: \r\n1.  No evidence of DVT in the left lower extremity.  Assessment \r\nof left calf veins is limited.   2.  Similar distribution of \r\nthrombus in the right lower extremity involving the right mid \r\nand distal femoral vein and popliteal vein.\r\n.   \r\nDISCHARGE LABS: \r\n---------------\r\n___ 12:04AM BLOOD WBC-4.2 RBC-2.62* Hgb-8.1* Hct-25.7* \r\nMCV-98 MCH-30.8 MCHC-31.4 RDW-20.3* Plt ___\r\n___ 12:04AM BLOOD Neuts-59 Bands-0 Lymphs-12* Monos-26* \r\nEos-0 Baso-0 Atyps-2* ___ Myelos-1*\r\n___ 12:04AM BLOOD Hypochr-1+ Anisocy-2+ Poiklo-1+ \r\nMacrocy-3+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-1+\r\n___ 12:04AM BLOOD Plt Smr-LOW Plt ___\r\n___ 12:04AM BLOOD Glucose-103* UreaN-9 Creat-0.7 Na-138 \r\nK-3.7 Cl-103 HCO3-26 AnGap-13\r\n___ 12:04AM BLOOD ALT-15 AST-20 LD(LDH)-219 AlkPhos-81 \r\nTotBili-0.3\r\n___ 12:04AM BLOOD Albumin-3.5 Calcium-8.2* Phos-3.5 Mg-1.___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. \r\n.\r\nACUTE ISSUES: \r\n.\r\n#Diffuse Large B-Cell Lymphoma (DLBCL): transformed from \r\nfollicular lyphoma. Underwent BEAM conditioning followed by \r\nscheduled autoSCT on ___. Post-transplant course complicated by \r\nfebrile neutropenia, for which she was on cefepime, vancomycin \r\nand micafungin (to cover inguinal skin wounds). Recieved 5U \r\nPRBCs and 5U platelets to maintain hct > 21 and plts > 10. She \r\nwas on PCA for a period of time for mucositis. Neutropenia \r\nresolved on ___, at which point antibiotics and G-CSF were \r\ndiscontinued. Patient was able to advance diet slowly as \r\nmucositis resolved; by discharge she was taking excellent PO \r\nhydration and continuing to advance her diet. Sent home on \r\nacyclovir for fungal ppx, to start Bactrim SS for PCP ppx on \r\n___.  \r\n.\r\n#DVT: New, provoked. ___ in outpatient heme/onc office showed \r\nacute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis. Secondary to malignancy. Given lovenox in the \r\nclinic. Pt reported to be tachycardic and dyspneic in clinic, \r\nc/f PE was high. CTA chest negative for PE. IVC filter placed on \r\n___ by ___. Heparin drip discontinued ___ given falling \r\nplatelet count. Left lower extemity noted to be swollen more \r\nsignificantly than the right on ___, but dopplers showed only \r\nstable right leg clot. Thrombocytopenia resolved on ___, and \r\nshe was started on warfarin as well as lovenox sc at \r\nprophylactic dose. On ___ she was switched to lovenox sc at \r\ntreatment dose (100mg BID); will start on warfarin as outpatient \r\nat a later date, once diet and medications have stabilized.  \r\n.\r\n#Bilateral groin skin tears: skin tears in inguinal region \r\nbeneath panus c/b intertrigo/fungal infection. Developed prior \r\nto onset of neutropneia, started on vancomycin and micafungin + \r\ntopical fungal cream. Healed well with proper wound care. \r\nMicafungin and vancomycin discontinued once neutropenia \r\nresolved. \r\n.\r\nCHRONIC ISSUES: \r\n.\r\n# Back and L hip pain: has h/o L hip bursistis; no h/o sciatica. \r\nDescription of pain c/w musculoskeletal source, no concerning \r\nphysical exam findings. Symptoms fluctuated through course of \r\nstay based on patient positioning/activity level. \r\n.\r\n#Migranes: Patient reporting unilateral (right sided) headache \r\nwith photosensitivity and nausea on ___. Resolved on ___ \r\nafter receiving fioracet and ativan for nausea. \r\n.\r\n#Neuropathy: Stable, likely secondary to old sensory stroke. \r\nAlso has new numbness on fingertips bilaterally likely secondary \r\nto etoposide. Continued home gabapentin.\r\n.\r\n#H/o cerebral aneurysm: Stable. Discovered ___ years ago on MRA \r\nhead in right ICA cavernous sinus. S/p coiling ___ years ago. Has \r\nstable dysconjugate gaze/pupil asymmetry from the aneurysm.   \r\n.\r\n#Depression: Stable, continued on home venlafaxine.\r\n.\r\nTRANSTIONAL ISSUES: \r\n.\r\n# ANTICOAGULATION: discharged on lovenox; will continue for at \r\nleast 2 weeks while diet increases/she starts on bactrim, and \r\nthen be transitioned to warfarin as outpatient. \r\n.\r\n# PCP ___: to start ___ sent home w/script\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Furosemide 20 mg PO DAILY \r\n3. Gabapentin 900 mg PO BID \r\n4. Omeprazole 20 mg PO DAILY \r\n5. Ondansetron 8 mg PO Q8H:PRN nausea \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Gabapentin 900 mg PO BID \r\n3. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n4. Venlafaxine 25 mg PO BID \r\n5. Miconazole 2% Cream 1 Appl TP BID \r\nRX *miconazole nitrate [Antifungal Cream] 2 % apply to groin for \r\nrash three times a day Disp #*1 Tube Refills:*0\r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Furosemide 20 mg PO DAILY \r\n9. Ondansetron 8 mg PO Q8H:PRN nausea \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0\r\n12. Enoxaparin Sodium 100 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\nRX *enoxaparin 100 mg/mL 100 mg sc twice a day Disp #*14 Syringe \r\nRefills:*0\r\n13. OLANZapine (Disintegrating Tablet) 2.5 mg PO BID nausea \r\nRX *olanzapine 2.5 mg 1 tablet(s) by mouth twice a day Disp #*14 \r\nTablet Refills:*0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n# Primary: Diffuse Large B-Cell Lymphoma (DLBCL) \r\n\r\n# Secondary: Febrile Neutropenia, Deep Venous Thrombosis, \r\nDepression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear ___, \r\n\r\n___ was a pleasure taking care of you at the ___ \r\n___. You came in for an auto-stem cell \r\ntransplant (autSCT) for your Diffuse Large B-Cell Lymphoma \r\n(DLBCL). Just prior to admission you were found to have a deep \r\nvein thrombosis (DVT), for which you were started on lovenox and \r\nhad an inferior vena cava (IVC) filter placed on ___. You \r\nrecieved your autoSCT on ___. \r\n\r\nYour post-transplant course was complicated by fever, requiring \r\nantibiotics. These were discontinued without incident when your \r\nwhite blood cell counts had recovered. Lovenox was held when \r\nyour platelet count fell during chemotherapy. Anticoagulation \r\nwith lovenox was restarted on ___ when your platelet count had \r\nrecovered. \r\n\r\nYou will remain on viral prophylaxis with acyclovir for now, and \r\nstart PCP prophylaxis with ___ on ___.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-12:2",
      "text": "- ___ PET-CT with very slight amount of increased tracer\nactivity within the posterior left supraclavicular region. No\nother areas of FDG avid disease were noted \n- ___ through ___ per records she was treated with CVP\nfollowed by course of single agent Rituxan\n- ___ through ___ surveillance imaging with no evidence of\nrecurrent disease, stable mesenteric mass. - ___ abdominal pain led to CT with no change in mass size,\nincreased conspicuity of nodular borders\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\nstable mesenteric mass with low level SUV 2.2 stable since \nprior. - ___ CT torso showed persistent mesenteric and left hilar\nlymphadenopathy. Stable right middle lobe small focus of ground\nglass opacity and adjacent subpleural fat hypertrophy, \nsuggestive\nof inflammatory process. Stable right adnexal cyst. - ___ Presented to PCP ___ ___iscomfort. Exam revealed new \nadenopathy. Labs notable for LDH 341, WBC 10.1, normal \ndifferential, PLT 452. - ___ PET CT revealed, \"Large left cervical, \nsupraclavicular, mediastinal\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \nmesenteric\nlymphadenopathy, all of which is markedly FDG-avid and \nconcerning for\nlymphoma.\" SUVmax 35.5. - ___iopsy revealed diffuse large B cell \nlymphoma, CD20+ \nCD10+ lambda restricted. MIB and cytogenetics are pending\n- ___ C1D1 ICE\n- ___ C1 Rituximab, clincally improved adenopathy\n- ___ C2 Rituximab, WBC 6.5, PLT 43\n- ___ Admit for C2D1 ICE\n- ___ C3 Rituximab\n- ___ PET CT showed almost complete resolution of FDG avid \ndisease with a \nresidual focus of avidity in the bed of the former abdominal \nmass, SUV ___ C4 Rituximab\n- PLANNED ___ C4 ICE followed by stem cell mobilization and \ncollection",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-12",
        "chart_time": "103369",
        "section": "General",
        "position": 2,
        "tokenCount": 430,
        "note_metadata": {
          "note_id": "18887130-DS-12",
          "subject_id": 18887130,
          "hadm_id": 28224744,
          "note_type": "DS",
          "note_seq": 12,
          "charttime": 103369,
          "storetime": 103369.65416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nscheduled autologous transplant with BEAM conditioning\r\n \r\nMajor Surgical or Invasive Procedure:\r\n___: IVC filter placed\r\n___: auto-stem cell transplant\r\n\r\n \r\nHistory of Present Illness:\r\n___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. She was also reporting an \r\narea of right medial thigh erythema, tenderness and induration \r\nto the transplant nurse over the phone on ___. She had a \r\nscheduled outpatient appointment for pre-transplant lab work. \r\nShe had ___ at the outpatient heme/onc office which showed an \r\nacute right popliteal/ femoral DVT. \r\n\r\nStem cell collection period prolonged as counts slower to \r\nrecover than in the past.  Required addition of Mozibil with \r\nmuch improved stem cells collections with total yield of over 5 \r\nx 10(e)6 CD 3 cells/kg.  Her last PET CT showed almost a \r\ncomplete response with residual focus of avidity in the bed of \r\nthe abdominal mass.  She was evaluated by radiation oncology \r\nwith the plan for consolidative radiation therapy to be done \r\nfollowing her autologous transplant.  Echocardiogram on \r\n___ showed normal left ventricular wall thickness and \r\ncavity size with mildly depressed global systolic function with \r\nLVEF of 45%.  PFT's from ___ showed FVC of 66%, FEV1 of \r\n73%, TLC of 73% and DLCO of 93%.  Bone marrow aspirate and \r\nbiopsy on ___ showed no evidence for lymphoma but was \r\nnoted for a small mature lymphocyte clone that is a separate \r\nmalignancy of\r\nthe CLL phenotype.  She has no indication of this in her blood. \r\nAs her transformed lymphoma needs to be treated and is more life\r\nthreatening if left untreated, the decision was made to proceed\r\nwith the autologous transplant as planned.\r\n \r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access. Biopsies showed\r\nFollicular lymphomas grade II/III. Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new \r\nadenopathy. Labs notable for LDH 341, WBC 10.1, normal \r\ndifferential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal\r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric\r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ \r\nCD10+ lambda restricted. MIB and cytogenetics are pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clincally improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a \r\nresidual focus of avidity in the bed of the former abdominal \r\nmass, SUV ___ C4 Rituximab\r\n- PLANNED ___ C4 ICE followed by stem cell mobilization and \r\ncollection\r\n\r\n \r\nPast Medical History:\r\n--Transformed DLBCL with history of follicular lymphoma as noted\r\nabove. \r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia \r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM: \r\n.\r\nVITALS -  98.4, 126/62, 75, 18, 98% RA   weight: 238.2\r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, OP \r\nclear\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. Tender, erythematous corded vein on right medial \r\nmid-thigh. No cyanosis, clubbing or edema. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. Gait not assessed.\r\n.\r\nDISCHARGE EXAM: \r\n.\r\nVITALS -  97.5 118/78 104 18 99% RA  \r\nI/O yesterday (24hr): 1.4/0.9 (no BMs) \r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, no \r\nlesions\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley; healed skin tears in inguinal region; pink, no \r\npurulence, no surrounding errythema, IMPROVED \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. 2+ pitting edema ___ at ankles, L>R. No cyanosis or \r\nclubbing. L hip TTP, no masses, errhtyema, warmth. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. normal gait\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS: \r\n---------------\r\n___ 10:45AM   UREA N-11 CREAT-0.8 SODIUM-137 POTASSIUM-4.3 \r\nCHLORIDE-101 TOTAL CO2-26 ANION GAP-14\r\n___ 10:45AM   estGFR-Using this\r\n___ 10:45AM   ALT(SGPT)-12 AST(SGOT)-20 LD(LDH)-341* ALK \r\nPHOS-153* TOT BILI-0.2\r\n___ 10:45AM   TOT PROT-6.2* ALBUMIN-4.0 GLOBULIN-2.2 \r\nCALCIUM-8.6 PHOSPHATE-3.5 MAGNESIUM-2.1 URIC ACID-3.9\r\n___ 10:45AM   WBC-8.6# RBC-2.61* HGB-8.2* HCT-25.5* MCV-98 \r\nMCH-31.3 MCHC-32.0 RDW-24.1*\r\n___ 10:45AM   NEUTS-83.2* LYMPHS-7.0* MONOS-9.5 EOS-0.1 \r\nBASOS-0.2\r\n___ 10:45AM   PLT COUNT-281#\r\n___ 10:45AM   ___ PTT-29.1 ___\r\n.\r\nIMAGING: \r\n----------\r\n___ ___ Dopplers IMPRESSION:   \r\n1.  Acute deep venous thrombosis of the right femoral and \r\npopliteal veins.   2.  No evidence of deep vein thrombosis in \r\nthe left lower extremity.\r\n. \r\n___ CTA Chest: 1.  No pulmonary embolus demonstrated.  \r\n2.  Enlargement of the main pulmonary artery as seen on the \r\nprior examination ___.  This may reflect pulmonary \r\narterial hypertension.   \r\n.\r\n___ ___ Dopplers IMPRESSION: \r\n1.  No evidence of DVT in the left lower extremity.  Assessment \r\nof left calf veins is limited.   2.  Similar distribution of \r\nthrombus in the right lower extremity involving the right mid \r\nand distal femoral vein and popliteal vein.\r\n.   \r\nDISCHARGE LABS: \r\n---------------\r\n___ 12:04AM BLOOD WBC-4.2 RBC-2.62* Hgb-8.1* Hct-25.7* \r\nMCV-98 MCH-30.8 MCHC-31.4 RDW-20.3* Plt ___\r\n___ 12:04AM BLOOD Neuts-59 Bands-0 Lymphs-12* Monos-26* \r\nEos-0 Baso-0 Atyps-2* ___ Myelos-1*\r\n___ 12:04AM BLOOD Hypochr-1+ Anisocy-2+ Poiklo-1+ \r\nMacrocy-3+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-1+\r\n___ 12:04AM BLOOD Plt Smr-LOW Plt ___\r\n___ 12:04AM BLOOD Glucose-103* UreaN-9 Creat-0.7 Na-138 \r\nK-3.7 Cl-103 HCO3-26 AnGap-13\r\n___ 12:04AM BLOOD ALT-15 AST-20 LD(LDH)-219 AlkPhos-81 \r\nTotBili-0.3\r\n___ 12:04AM BLOOD Albumin-3.5 Calcium-8.2* Phos-3.5 Mg-1.___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. \r\n.\r\nACUTE ISSUES: \r\n.\r\n#Diffuse Large B-Cell Lymphoma (DLBCL): transformed from \r\nfollicular lyphoma. Underwent BEAM conditioning followed by \r\nscheduled autoSCT on ___. Post-transplant course complicated by \r\nfebrile neutropenia, for which she was on cefepime, vancomycin \r\nand micafungin (to cover inguinal skin wounds). Recieved 5U \r\nPRBCs and 5U platelets to maintain hct > 21 and plts > 10. She \r\nwas on PCA for a period of time for mucositis. Neutropenia \r\nresolved on ___, at which point antibiotics and G-CSF were \r\ndiscontinued. Patient was able to advance diet slowly as \r\nmucositis resolved; by discharge she was taking excellent PO \r\nhydration and continuing to advance her diet. Sent home on \r\nacyclovir for fungal ppx, to start Bactrim SS for PCP ppx on \r\n___.  \r\n.\r\n#DVT: New, provoked. ___ in outpatient heme/onc office showed \r\nacute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis. Secondary to malignancy. Given lovenox in the \r\nclinic. Pt reported to be tachycardic and dyspneic in clinic, \r\nc/f PE was high. CTA chest negative for PE. IVC filter placed on \r\n___ by ___. Heparin drip discontinued ___ given falling \r\nplatelet count. Left lower extemity noted to be swollen more \r\nsignificantly than the right on ___, but dopplers showed only \r\nstable right leg clot. Thrombocytopenia resolved on ___, and \r\nshe was started on warfarin as well as lovenox sc at \r\nprophylactic dose. On ___ she was switched to lovenox sc at \r\ntreatment dose (100mg BID); will start on warfarin as outpatient \r\nat a later date, once diet and medications have stabilized.  \r\n.\r\n#Bilateral groin skin tears: skin tears in inguinal region \r\nbeneath panus c/b intertrigo/fungal infection. Developed prior \r\nto onset of neutropneia, started on vancomycin and micafungin + \r\ntopical fungal cream. Healed well with proper wound care. \r\nMicafungin and vancomycin discontinued once neutropenia \r\nresolved. \r\n.\r\nCHRONIC ISSUES: \r\n.\r\n# Back and L hip pain: has h/o L hip bursistis; no h/o sciatica. \r\nDescription of pain c/w musculoskeletal source, no concerning \r\nphysical exam findings. Symptoms fluctuated through course of \r\nstay based on patient positioning/activity level. \r\n.\r\n#Migranes: Patient reporting unilateral (right sided) headache \r\nwith photosensitivity and nausea on ___. Resolved on ___ \r\nafter receiving fioracet and ativan for nausea. \r\n.\r\n#Neuropathy: Stable, likely secondary to old sensory stroke. \r\nAlso has new numbness on fingertips bilaterally likely secondary \r\nto etoposide. Continued home gabapentin.\r\n.\r\n#H/o cerebral aneurysm: Stable. Discovered ___ years ago on MRA \r\nhead in right ICA cavernous sinus. S/p coiling ___ years ago. Has \r\nstable dysconjugate gaze/pupil asymmetry from the aneurysm.   \r\n.\r\n#Depression: Stable, continued on home venlafaxine.\r\n.\r\nTRANSTIONAL ISSUES: \r\n.\r\n# ANTICOAGULATION: discharged on lovenox; will continue for at \r\nleast 2 weeks while diet increases/she starts on bactrim, and \r\nthen be transitioned to warfarin as outpatient. \r\n.\r\n# PCP ___: to start ___ sent home w/script\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Furosemide 20 mg PO DAILY \r\n3. Gabapentin 900 mg PO BID \r\n4. Omeprazole 20 mg PO DAILY \r\n5. Ondansetron 8 mg PO Q8H:PRN nausea \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Gabapentin 900 mg PO BID \r\n3. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n4. Venlafaxine 25 mg PO BID \r\n5. Miconazole 2% Cream 1 Appl TP BID \r\nRX *miconazole nitrate [Antifungal Cream] 2 % apply to groin for \r\nrash three times a day Disp #*1 Tube Refills:*0\r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Furosemide 20 mg PO DAILY \r\n9. Ondansetron 8 mg PO Q8H:PRN nausea \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0\r\n12. Enoxaparin Sodium 100 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\nRX *enoxaparin 100 mg/mL 100 mg sc twice a day Disp #*14 Syringe \r\nRefills:*0\r\n13. OLANZapine (Disintegrating Tablet) 2.5 mg PO BID nausea \r\nRX *olanzapine 2.5 mg 1 tablet(s) by mouth twice a day Disp #*14 \r\nTablet Refills:*0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n# Primary: Diffuse Large B-Cell Lymphoma (DLBCL) \r\n\r\n# Secondary: Febrile Neutropenia, Deep Venous Thrombosis, \r\nDepression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear ___, \r\n\r\n___ was a pleasure taking care of you at the ___ \r\n___. You came in for an auto-stem cell \r\ntransplant (autSCT) for your Diffuse Large B-Cell Lymphoma \r\n(DLBCL). Just prior to admission you were found to have a deep \r\nvein thrombosis (DVT), for which you were started on lovenox and \r\nhad an inferior vena cava (IVC) filter placed on ___. You \r\nrecieved your autoSCT on ___. \r\n\r\nYour post-transplant course was complicated by fever, requiring \r\nantibiotics. These were discontinued without incident when your \r\nwhite blood cell counts had recovered. Lovenox was held when \r\nyour platelet count fell during chemotherapy. Anticoagulation \r\nwith lovenox was restarted on ___ when your platelet count had \r\nrecovered. \r\n\r\nYou will remain on viral prophylaxis with acyclovir for now, and \r\nstart PCP prophylaxis with ___ on ___.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-12:3",
      "text": "Past Medical History:\n--Transformed DLBCL with history of follicular lymphoma as noted\nabove. --CLL, noted on BM biopsy on ___. --Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \n(*Known slight CN VI palsy & mild proptosis of R eye)\n--Hypogammaglobulinemia \n--Mild GERD\n--OA / LBP\n--Small Intestinal Bacterial Overgrowth\n--Trochanteric Bursitis\n--s/p Excisional Bx L Cervical Lymph Node\n--s/p L total knee replacement ___, walks with cane\n--s/p I&D Labial Abscess\n--s/p Excision Cyst R ___ Digit of Hand Social History:\n___ Family History:\nBrother: lymphoma.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-12",
        "chart_time": "103369",
        "section": "General",
        "position": 3,
        "tokenCount": 142,
        "note_metadata": {
          "note_id": "18887130-DS-12",
          "subject_id": 18887130,
          "hadm_id": 28224744,
          "note_type": "DS",
          "note_seq": 12,
          "charttime": 103369,
          "storetime": 103369.65416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nscheduled autologous transplant with BEAM conditioning\r\n \r\nMajor Surgical or Invasive Procedure:\r\n___: IVC filter placed\r\n___: auto-stem cell transplant\r\n\r\n \r\nHistory of Present Illness:\r\n___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. She was also reporting an \r\narea of right medial thigh erythema, tenderness and induration \r\nto the transplant nurse over the phone on ___. She had a \r\nscheduled outpatient appointment for pre-transplant lab work. \r\nShe had ___ at the outpatient heme/onc office which showed an \r\nacute right popliteal/ femoral DVT. \r\n\r\nStem cell collection period prolonged as counts slower to \r\nrecover than in the past.  Required addition of Mozibil with \r\nmuch improved stem cells collections with total yield of over 5 \r\nx 10(e)6 CD 3 cells/kg.  Her last PET CT showed almost a \r\ncomplete response with residual focus of avidity in the bed of \r\nthe abdominal mass.  She was evaluated by radiation oncology \r\nwith the plan for consolidative radiation therapy to be done \r\nfollowing her autologous transplant.  Echocardiogram on \r\n___ showed normal left ventricular wall thickness and \r\ncavity size with mildly depressed global systolic function with \r\nLVEF of 45%.  PFT's from ___ showed FVC of 66%, FEV1 of \r\n73%, TLC of 73% and DLCO of 93%.  Bone marrow aspirate and \r\nbiopsy on ___ showed no evidence for lymphoma but was \r\nnoted for a small mature lymphocyte clone that is a separate \r\nmalignancy of\r\nthe CLL phenotype.  She has no indication of this in her blood. \r\nAs her transformed lymphoma needs to be treated and is more life\r\nthreatening if left untreated, the decision was made to proceed\r\nwith the autologous transplant as planned.\r\n \r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access. Biopsies showed\r\nFollicular lymphomas grade II/III. Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new \r\nadenopathy. Labs notable for LDH 341, WBC 10.1, normal \r\ndifferential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal\r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric\r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ \r\nCD10+ lambda restricted. MIB and cytogenetics are pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clincally improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a \r\nresidual focus of avidity in the bed of the former abdominal \r\nmass, SUV ___ C4 Rituximab\r\n- PLANNED ___ C4 ICE followed by stem cell mobilization and \r\ncollection\r\n\r\n \r\nPast Medical History:\r\n--Transformed DLBCL with history of follicular lymphoma as noted\r\nabove. \r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia \r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM: \r\n.\r\nVITALS -  98.4, 126/62, 75, 18, 98% RA   weight: 238.2\r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, OP \r\nclear\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. Tender, erythematous corded vein on right medial \r\nmid-thigh. No cyanosis, clubbing or edema. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. Gait not assessed.\r\n.\r\nDISCHARGE EXAM: \r\n.\r\nVITALS -  97.5 118/78 104 18 99% RA  \r\nI/O yesterday (24hr): 1.4/0.9 (no BMs) \r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, no \r\nlesions\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley; healed skin tears in inguinal region; pink, no \r\npurulence, no surrounding errythema, IMPROVED \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. 2+ pitting edema ___ at ankles, L>R. No cyanosis or \r\nclubbing. L hip TTP, no masses, errhtyema, warmth. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. normal gait\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS: \r\n---------------\r\n___ 10:45AM   UREA N-11 CREAT-0.8 SODIUM-137 POTASSIUM-4.3 \r\nCHLORIDE-101 TOTAL CO2-26 ANION GAP-14\r\n___ 10:45AM   estGFR-Using this\r\n___ 10:45AM   ALT(SGPT)-12 AST(SGOT)-20 LD(LDH)-341* ALK \r\nPHOS-153* TOT BILI-0.2\r\n___ 10:45AM   TOT PROT-6.2* ALBUMIN-4.0 GLOBULIN-2.2 \r\nCALCIUM-8.6 PHOSPHATE-3.5 MAGNESIUM-2.1 URIC ACID-3.9\r\n___ 10:45AM   WBC-8.6# RBC-2.61* HGB-8.2* HCT-25.5* MCV-98 \r\nMCH-31.3 MCHC-32.0 RDW-24.1*\r\n___ 10:45AM   NEUTS-83.2* LYMPHS-7.0* MONOS-9.5 EOS-0.1 \r\nBASOS-0.2\r\n___ 10:45AM   PLT COUNT-281#\r\n___ 10:45AM   ___ PTT-29.1 ___\r\n.\r\nIMAGING: \r\n----------\r\n___ ___ Dopplers IMPRESSION:   \r\n1.  Acute deep venous thrombosis of the right femoral and \r\npopliteal veins.   2.  No evidence of deep vein thrombosis in \r\nthe left lower extremity.\r\n. \r\n___ CTA Chest: 1.  No pulmonary embolus demonstrated.  \r\n2.  Enlargement of the main pulmonary artery as seen on the \r\nprior examination ___.  This may reflect pulmonary \r\narterial hypertension.   \r\n.\r\n___ ___ Dopplers IMPRESSION: \r\n1.  No evidence of DVT in the left lower extremity.  Assessment \r\nof left calf veins is limited.   2.  Similar distribution of \r\nthrombus in the right lower extremity involving the right mid \r\nand distal femoral vein and popliteal vein.\r\n.   \r\nDISCHARGE LABS: \r\n---------------\r\n___ 12:04AM BLOOD WBC-4.2 RBC-2.62* Hgb-8.1* Hct-25.7* \r\nMCV-98 MCH-30.8 MCHC-31.4 RDW-20.3* Plt ___\r\n___ 12:04AM BLOOD Neuts-59 Bands-0 Lymphs-12* Monos-26* \r\nEos-0 Baso-0 Atyps-2* ___ Myelos-1*\r\n___ 12:04AM BLOOD Hypochr-1+ Anisocy-2+ Poiklo-1+ \r\nMacrocy-3+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-1+\r\n___ 12:04AM BLOOD Plt Smr-LOW Plt ___\r\n___ 12:04AM BLOOD Glucose-103* UreaN-9 Creat-0.7 Na-138 \r\nK-3.7 Cl-103 HCO3-26 AnGap-13\r\n___ 12:04AM BLOOD ALT-15 AST-20 LD(LDH)-219 AlkPhos-81 \r\nTotBili-0.3\r\n___ 12:04AM BLOOD Albumin-3.5 Calcium-8.2* Phos-3.5 Mg-1.___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. \r\n.\r\nACUTE ISSUES: \r\n.\r\n#Diffuse Large B-Cell Lymphoma (DLBCL): transformed from \r\nfollicular lyphoma. Underwent BEAM conditioning followed by \r\nscheduled autoSCT on ___. Post-transplant course complicated by \r\nfebrile neutropenia, for which she was on cefepime, vancomycin \r\nand micafungin (to cover inguinal skin wounds). Recieved 5U \r\nPRBCs and 5U platelets to maintain hct > 21 and plts > 10. She \r\nwas on PCA for a period of time for mucositis. Neutropenia \r\nresolved on ___, at which point antibiotics and G-CSF were \r\ndiscontinued. Patient was able to advance diet slowly as \r\nmucositis resolved; by discharge she was taking excellent PO \r\nhydration and continuing to advance her diet. Sent home on \r\nacyclovir for fungal ppx, to start Bactrim SS for PCP ppx on \r\n___.  \r\n.\r\n#DVT: New, provoked. ___ in outpatient heme/onc office showed \r\nacute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis. Secondary to malignancy. Given lovenox in the \r\nclinic. Pt reported to be tachycardic and dyspneic in clinic, \r\nc/f PE was high. CTA chest negative for PE. IVC filter placed on \r\n___ by ___. Heparin drip discontinued ___ given falling \r\nplatelet count. Left lower extemity noted to be swollen more \r\nsignificantly than the right on ___, but dopplers showed only \r\nstable right leg clot. Thrombocytopenia resolved on ___, and \r\nshe was started on warfarin as well as lovenox sc at \r\nprophylactic dose. On ___ she was switched to lovenox sc at \r\ntreatment dose (100mg BID); will start on warfarin as outpatient \r\nat a later date, once diet and medications have stabilized.  \r\n.\r\n#Bilateral groin skin tears: skin tears in inguinal region \r\nbeneath panus c/b intertrigo/fungal infection. Developed prior \r\nto onset of neutropneia, started on vancomycin and micafungin + \r\ntopical fungal cream. Healed well with proper wound care. \r\nMicafungin and vancomycin discontinued once neutropenia \r\nresolved. \r\n.\r\nCHRONIC ISSUES: \r\n.\r\n# Back and L hip pain: has h/o L hip bursistis; no h/o sciatica. \r\nDescription of pain c/w musculoskeletal source, no concerning \r\nphysical exam findings. Symptoms fluctuated through course of \r\nstay based on patient positioning/activity level. \r\n.\r\n#Migranes: Patient reporting unilateral (right sided) headache \r\nwith photosensitivity and nausea on ___. Resolved on ___ \r\nafter receiving fioracet and ativan for nausea. \r\n.\r\n#Neuropathy: Stable, likely secondary to old sensory stroke. \r\nAlso has new numbness on fingertips bilaterally likely secondary \r\nto etoposide. Continued home gabapentin.\r\n.\r\n#H/o cerebral aneurysm: Stable. Discovered ___ years ago on MRA \r\nhead in right ICA cavernous sinus. S/p coiling ___ years ago. Has \r\nstable dysconjugate gaze/pupil asymmetry from the aneurysm.   \r\n.\r\n#Depression: Stable, continued on home venlafaxine.\r\n.\r\nTRANSTIONAL ISSUES: \r\n.\r\n# ANTICOAGULATION: discharged on lovenox; will continue for at \r\nleast 2 weeks while diet increases/she starts on bactrim, and \r\nthen be transitioned to warfarin as outpatient. \r\n.\r\n# PCP ___: to start ___ sent home w/script\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Furosemide 20 mg PO DAILY \r\n3. Gabapentin 900 mg PO BID \r\n4. Omeprazole 20 mg PO DAILY \r\n5. Ondansetron 8 mg PO Q8H:PRN nausea \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Gabapentin 900 mg PO BID \r\n3. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n4. Venlafaxine 25 mg PO BID \r\n5. Miconazole 2% Cream 1 Appl TP BID \r\nRX *miconazole nitrate [Antifungal Cream] 2 % apply to groin for \r\nrash three times a day Disp #*1 Tube Refills:*0\r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Furosemide 20 mg PO DAILY \r\n9. Ondansetron 8 mg PO Q8H:PRN nausea \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0\r\n12. Enoxaparin Sodium 100 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\nRX *enoxaparin 100 mg/mL 100 mg sc twice a day Disp #*14 Syringe \r\nRefills:*0\r\n13. OLANZapine (Disintegrating Tablet) 2.5 mg PO BID nausea \r\nRX *olanzapine 2.5 mg 1 tablet(s) by mouth twice a day Disp #*14 \r\nTablet Refills:*0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n# Primary: Diffuse Large B-Cell Lymphoma (DLBCL) \r\n\r\n# Secondary: Febrile Neutropenia, Deep Venous Thrombosis, \r\nDepression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear ___, \r\n\r\n___ was a pleasure taking care of you at the ___ \r\n___. You came in for an auto-stem cell \r\ntransplant (autSCT) for your Diffuse Large B-Cell Lymphoma \r\n(DLBCL). Just prior to admission you were found to have a deep \r\nvein thrombosis (DVT), for which you were started on lovenox and \r\nhad an inferior vena cava (IVC) filter placed on ___. You \r\nrecieved your autoSCT on ___. \r\n\r\nYour post-transplant course was complicated by fever, requiring \r\nantibiotics. These were discontinued without incident when your \r\nwhite blood cell counts had recovered. Lovenox was held when \r\nyour platelet count fell during chemotherapy. Anticoagulation \r\nwith lovenox was restarted on ___ when your platelet count had \r\nrecovered. \r\n\r\nYou will remain on viral prophylaxis with acyclovir for now, and \r\nstart PCP prophylaxis with ___ on ___.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-12:4",
      "text": "Physical Exam:\nADMISSION EXAM: \n. VITALS -  98.4, 126/62, 75, 18, 98% RA   weight: 238.2\nGeneral: Alert, oriented x3, lying in bed in NAD\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, OP \nclear\nNeck: Supple, no ___, no thyromegaly\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \napex, no rubs or gallops\nLungs: CTAB, no W/R/R\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \nrebound or guarding. No masses or organomegaly. GU: no foley \nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \nlegs, R>L. Tender, erythematous corded vein on right medial \nmid-thigh. No cyanosis, clubbing or edema. Neuro: Exam nonfocal. CN ___ grossly intact. Gait not assessed. . DISCHARGE EXAM: \n. VITALS -  97.5 118/78 104 18 99% RA  \nI/O yesterday (24hr): 1.4/0.9 (no BMs) \nGeneral: Alert, oriented x3, lying in bed in NAD\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, no \nlesions\nNeck: Supple, no ___, no thyromegaly\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \napex, no rubs or gallops\nLungs: CTAB, no W/R/R\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \nrebound or guarding. No masses or organomegaly. GU: no foley; healed skin tears in inguinal region; pink, no \npurulence, no surrounding errythema, IMPROVED \nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \nlegs, R>L. 2+ pitting edema ___ at ankles, L>R. No cyanosis or \nclubbing. L hip TTP, no masses, errhtyema, warmth. Neuro: Exam nonfocal. CN ___ grossly intact. normal gait Pertinent Results:\nADMISSION LABS: \n---------------\n___ 10:45AM   UREA N-11 CREAT-0.8 SODIUM-137 POTASSIUM-4.3 \nCHLORIDE-101 TOTAL CO2-26 ANION GAP-14\n___ 10:45AM   estGFR-Using this\n___ 10:45AM   ALT(SGPT)-12 AST(SGOT)-20 LD(LDH)-341* ALK \nPHOS-153* TOT BILI-0.2\n___ 10:45AM   TOT PROT-6.2* ALBUMIN-4.0 GLOBULIN-2.2 \nCALCIUM-8.6 PHOSPHATE-3.5 MAGNESIUM-2.1 URIC ACID-3.9\n___ 10:45AM   WBC-8.6# RBC-2.61* HGB-8.2* HCT-25.5* MCV-98 \nMCH-31.3 MCHC-32.0 RDW-24.1*\n___ 10:45AM   NEUTS-83.2* LYMPHS-7.0* MONOS-9.5 EOS-0.1 \nBASOS-0.2\n___ 10:45AM   PLT COUNT-281#\n___ 10:45AM   ___ PTT-29.1 ___\n.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-12",
        "chart_time": "103369",
        "section": "General",
        "position": 4,
        "tokenCount": 533,
        "note_metadata": {
          "note_id": "18887130-DS-12",
          "subject_id": 18887130,
          "hadm_id": 28224744,
          "note_type": "DS",
          "note_seq": 12,
          "charttime": 103369,
          "storetime": 103369.65416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nscheduled autologous transplant with BEAM conditioning\r\n \r\nMajor Surgical or Invasive Procedure:\r\n___: IVC filter placed\r\n___: auto-stem cell transplant\r\n\r\n \r\nHistory of Present Illness:\r\n___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. She was also reporting an \r\narea of right medial thigh erythema, tenderness and induration \r\nto the transplant nurse over the phone on ___. She had a \r\nscheduled outpatient appointment for pre-transplant lab work. \r\nShe had ___ at the outpatient heme/onc office which showed an \r\nacute right popliteal/ femoral DVT. \r\n\r\nStem cell collection period prolonged as counts slower to \r\nrecover than in the past.  Required addition of Mozibil with \r\nmuch improved stem cells collections with total yield of over 5 \r\nx 10(e)6 CD 3 cells/kg.  Her last PET CT showed almost a \r\ncomplete response with residual focus of avidity in the bed of \r\nthe abdominal mass.  She was evaluated by radiation oncology \r\nwith the plan for consolidative radiation therapy to be done \r\nfollowing her autologous transplant.  Echocardiogram on \r\n___ showed normal left ventricular wall thickness and \r\ncavity size with mildly depressed global systolic function with \r\nLVEF of 45%.  PFT's from ___ showed FVC of 66%, FEV1 of \r\n73%, TLC of 73% and DLCO of 93%.  Bone marrow aspirate and \r\nbiopsy on ___ showed no evidence for lymphoma but was \r\nnoted for a small mature lymphocyte clone that is a separate \r\nmalignancy of\r\nthe CLL phenotype.  She has no indication of this in her blood. \r\nAs her transformed lymphoma needs to be treated and is more life\r\nthreatening if left untreated, the decision was made to proceed\r\nwith the autologous transplant as planned.\r\n \r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access. Biopsies showed\r\nFollicular lymphomas grade II/III. Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new \r\nadenopathy. Labs notable for LDH 341, WBC 10.1, normal \r\ndifferential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal\r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric\r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ \r\nCD10+ lambda restricted. MIB and cytogenetics are pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clincally improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a \r\nresidual focus of avidity in the bed of the former abdominal \r\nmass, SUV ___ C4 Rituximab\r\n- PLANNED ___ C4 ICE followed by stem cell mobilization and \r\ncollection\r\n\r\n \r\nPast Medical History:\r\n--Transformed DLBCL with history of follicular lymphoma as noted\r\nabove. \r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia \r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM: \r\n.\r\nVITALS -  98.4, 126/62, 75, 18, 98% RA   weight: 238.2\r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, OP \r\nclear\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. Tender, erythematous corded vein on right medial \r\nmid-thigh. No cyanosis, clubbing or edema. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. Gait not assessed.\r\n.\r\nDISCHARGE EXAM: \r\n.\r\nVITALS -  97.5 118/78 104 18 99% RA  \r\nI/O yesterday (24hr): 1.4/0.9 (no BMs) \r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, no \r\nlesions\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley; healed skin tears in inguinal region; pink, no \r\npurulence, no surrounding errythema, IMPROVED \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. 2+ pitting edema ___ at ankles, L>R. No cyanosis or \r\nclubbing. L hip TTP, no masses, errhtyema, warmth. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. normal gait\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS: \r\n---------------\r\n___ 10:45AM   UREA N-11 CREAT-0.8 SODIUM-137 POTASSIUM-4.3 \r\nCHLORIDE-101 TOTAL CO2-26 ANION GAP-14\r\n___ 10:45AM   estGFR-Using this\r\n___ 10:45AM   ALT(SGPT)-12 AST(SGOT)-20 LD(LDH)-341* ALK \r\nPHOS-153* TOT BILI-0.2\r\n___ 10:45AM   TOT PROT-6.2* ALBUMIN-4.0 GLOBULIN-2.2 \r\nCALCIUM-8.6 PHOSPHATE-3.5 MAGNESIUM-2.1 URIC ACID-3.9\r\n___ 10:45AM   WBC-8.6# RBC-2.61* HGB-8.2* HCT-25.5* MCV-98 \r\nMCH-31.3 MCHC-32.0 RDW-24.1*\r\n___ 10:45AM   NEUTS-83.2* LYMPHS-7.0* MONOS-9.5 EOS-0.1 \r\nBASOS-0.2\r\n___ 10:45AM   PLT COUNT-281#\r\n___ 10:45AM   ___ PTT-29.1 ___\r\n.\r\nIMAGING: \r\n----------\r\n___ ___ Dopplers IMPRESSION:   \r\n1.  Acute deep venous thrombosis of the right femoral and \r\npopliteal veins.   2.  No evidence of deep vein thrombosis in \r\nthe left lower extremity.\r\n. \r\n___ CTA Chest: 1.  No pulmonary embolus demonstrated.  \r\n2.  Enlargement of the main pulmonary artery as seen on the \r\nprior examination ___.  This may reflect pulmonary \r\narterial hypertension.   \r\n.\r\n___ ___ Dopplers IMPRESSION: \r\n1.  No evidence of DVT in the left lower extremity.  Assessment \r\nof left calf veins is limited.   2.  Similar distribution of \r\nthrombus in the right lower extremity involving the right mid \r\nand distal femoral vein and popliteal vein.\r\n.   \r\nDISCHARGE LABS: \r\n---------------\r\n___ 12:04AM BLOOD WBC-4.2 RBC-2.62* Hgb-8.1* Hct-25.7* \r\nMCV-98 MCH-30.8 MCHC-31.4 RDW-20.3* Plt ___\r\n___ 12:04AM BLOOD Neuts-59 Bands-0 Lymphs-12* Monos-26* \r\nEos-0 Baso-0 Atyps-2* ___ Myelos-1*\r\n___ 12:04AM BLOOD Hypochr-1+ Anisocy-2+ Poiklo-1+ \r\nMacrocy-3+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-1+\r\n___ 12:04AM BLOOD Plt Smr-LOW Plt ___\r\n___ 12:04AM BLOOD Glucose-103* UreaN-9 Creat-0.7 Na-138 \r\nK-3.7 Cl-103 HCO3-26 AnGap-13\r\n___ 12:04AM BLOOD ALT-15 AST-20 LD(LDH)-219 AlkPhos-81 \r\nTotBili-0.3\r\n___ 12:04AM BLOOD Albumin-3.5 Calcium-8.2* Phos-3.5 Mg-1.___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. \r\n.\r\nACUTE ISSUES: \r\n.\r\n#Diffuse Large B-Cell Lymphoma (DLBCL): transformed from \r\nfollicular lyphoma. Underwent BEAM conditioning followed by \r\nscheduled autoSCT on ___. Post-transplant course complicated by \r\nfebrile neutropenia, for which she was on cefepime, vancomycin \r\nand micafungin (to cover inguinal skin wounds). Recieved 5U \r\nPRBCs and 5U platelets to maintain hct > 21 and plts > 10. She \r\nwas on PCA for a period of time for mucositis. Neutropenia \r\nresolved on ___, at which point antibiotics and G-CSF were \r\ndiscontinued. Patient was able to advance diet slowly as \r\nmucositis resolved; by discharge she was taking excellent PO \r\nhydration and continuing to advance her diet. Sent home on \r\nacyclovir for fungal ppx, to start Bactrim SS for PCP ppx on \r\n___.  \r\n.\r\n#DVT: New, provoked. ___ in outpatient heme/onc office showed \r\nacute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis. Secondary to malignancy. Given lovenox in the \r\nclinic. Pt reported to be tachycardic and dyspneic in clinic, \r\nc/f PE was high. CTA chest negative for PE. IVC filter placed on \r\n___ by ___. Heparin drip discontinued ___ given falling \r\nplatelet count. Left lower extemity noted to be swollen more \r\nsignificantly than the right on ___, but dopplers showed only \r\nstable right leg clot. Thrombocytopenia resolved on ___, and \r\nshe was started on warfarin as well as lovenox sc at \r\nprophylactic dose. On ___ she was switched to lovenox sc at \r\ntreatment dose (100mg BID); will start on warfarin as outpatient \r\nat a later date, once diet and medications have stabilized.  \r\n.\r\n#Bilateral groin skin tears: skin tears in inguinal region \r\nbeneath panus c/b intertrigo/fungal infection. Developed prior \r\nto onset of neutropneia, started on vancomycin and micafungin + \r\ntopical fungal cream. Healed well with proper wound care. \r\nMicafungin and vancomycin discontinued once neutropenia \r\nresolved. \r\n.\r\nCHRONIC ISSUES: \r\n.\r\n# Back and L hip pain: has h/o L hip bursistis; no h/o sciatica. \r\nDescription of pain c/w musculoskeletal source, no concerning \r\nphysical exam findings. Symptoms fluctuated through course of \r\nstay based on patient positioning/activity level. \r\n.\r\n#Migranes: Patient reporting unilateral (right sided) headache \r\nwith photosensitivity and nausea on ___. Resolved on ___ \r\nafter receiving fioracet and ativan for nausea. \r\n.\r\n#Neuropathy: Stable, likely secondary to old sensory stroke. \r\nAlso has new numbness on fingertips bilaterally likely secondary \r\nto etoposide. Continued home gabapentin.\r\n.\r\n#H/o cerebral aneurysm: Stable. Discovered ___ years ago on MRA \r\nhead in right ICA cavernous sinus. S/p coiling ___ years ago. Has \r\nstable dysconjugate gaze/pupil asymmetry from the aneurysm.   \r\n.\r\n#Depression: Stable, continued on home venlafaxine.\r\n.\r\nTRANSTIONAL ISSUES: \r\n.\r\n# ANTICOAGULATION: discharged on lovenox; will continue for at \r\nleast 2 weeks while diet increases/she starts on bactrim, and \r\nthen be transitioned to warfarin as outpatient. \r\n.\r\n# PCP ___: to start ___ sent home w/script\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Furosemide 20 mg PO DAILY \r\n3. Gabapentin 900 mg PO BID \r\n4. Omeprazole 20 mg PO DAILY \r\n5. Ondansetron 8 mg PO Q8H:PRN nausea \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Gabapentin 900 mg PO BID \r\n3. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n4. Venlafaxine 25 mg PO BID \r\n5. Miconazole 2% Cream 1 Appl TP BID \r\nRX *miconazole nitrate [Antifungal Cream] 2 % apply to groin for \r\nrash three times a day Disp #*1 Tube Refills:*0\r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Furosemide 20 mg PO DAILY \r\n9. Ondansetron 8 mg PO Q8H:PRN nausea \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0\r\n12. Enoxaparin Sodium 100 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\nRX *enoxaparin 100 mg/mL 100 mg sc twice a day Disp #*14 Syringe \r\nRefills:*0\r\n13. OLANZapine (Disintegrating Tablet) 2.5 mg PO BID nausea \r\nRX *olanzapine 2.5 mg 1 tablet(s) by mouth twice a day Disp #*14 \r\nTablet Refills:*0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n# Primary: Diffuse Large B-Cell Lymphoma (DLBCL) \r\n\r\n# Secondary: Febrile Neutropenia, Deep Venous Thrombosis, \r\nDepression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear ___, \r\n\r\n___ was a pleasure taking care of you at the ___ \r\n___. You came in for an auto-stem cell \r\ntransplant (autSCT) for your Diffuse Large B-Cell Lymphoma \r\n(DLBCL). Just prior to admission you were found to have a deep \r\nvein thrombosis (DVT), for which you were started on lovenox and \r\nhad an inferior vena cava (IVC) filter placed on ___. You \r\nrecieved your autoSCT on ___. \r\n\r\nYour post-transplant course was complicated by fever, requiring \r\nantibiotics. These were discontinued without incident when your \r\nwhite blood cell counts had recovered. Lovenox was held when \r\nyour platelet count fell during chemotherapy. Anticoagulation \r\nwith lovenox was restarted on ___ when your platelet count had \r\nrecovered. \r\n\r\nYou will remain on viral prophylaxis with acyclovir for now, and \r\nstart PCP prophylaxis with ___ on ___.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-12:5",
      "text": "IMAGING: \n----------\n___ ___ Dopplers IMPRESSION:   \n1. Acute deep venous thrombosis of the right femoral and \npopliteal veins. 2. No evidence of deep vein thrombosis in \nthe left lower extremity. . ___ CTA Chest: 1. No pulmonary embolus demonstrated. 2. Enlargement of the main pulmonary artery as seen on the \nprior examination ___. This may reflect pulmonary \narterial hypertension. . ___ ___ Dopplers IMPRESSION: \n1. No evidence of DVT in the left lower extremity. Assessment \nof left calf veins is limited. 2. Similar distribution of \nthrombus in the right lower extremity involving the right mid \nand distal femoral vein and popliteal vein. . DISCHARGE LABS: \n---------------\n___ 12:04AM BLOOD WBC-4.2 RBC-2.62* Hgb-8.1* Hct-25.7* \nMCV-98 MCH-30.8 MCHC-31.4 RDW-20.3* Plt ___\n___ 12:04AM BLOOD Neuts-59 Bands-0 Lymphs-12* Monos-26* \nEos-0 Baso-0 Atyps-2* ___ Myelos-1*\n___ 12:04AM BLOOD Hypochr-1+ Anisocy-2+ Poiklo-1+ \nMacrocy-3+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-1+\n___ 12:04AM BLOOD Plt Smr-LOW Plt ___\n___ 12:04AM BLOOD Glucose-103* UreaN-9 Creat-0.7 Na-138 \nK-3.7 Cl-103 HCO3-26 AnGap-13\n___ 12:04AM BLOOD ALT-15 AST-20 LD(LDH)-219 AlkPhos-81 \nTotBili-0.3\n___ 12:04AM BLOOD Albumin-3.5 Calcium-8.2* Phos-3.5 Mg-1.___ with transformed DLBCL and h/o follicular lymphoma \npresenting for a scheduled autoSCT. .",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-12",
        "chart_time": "103369",
        "section": "General",
        "position": 5,
        "tokenCount": 331,
        "note_metadata": {
          "note_id": "18887130-DS-12",
          "subject_id": 18887130,
          "hadm_id": 28224744,
          "note_type": "DS",
          "note_seq": 12,
          "charttime": 103369,
          "storetime": 103369.65416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nscheduled autologous transplant with BEAM conditioning\r\n \r\nMajor Surgical or Invasive Procedure:\r\n___: IVC filter placed\r\n___: auto-stem cell transplant\r\n\r\n \r\nHistory of Present Illness:\r\n___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. She was also reporting an \r\narea of right medial thigh erythema, tenderness and induration \r\nto the transplant nurse over the phone on ___. She had a \r\nscheduled outpatient appointment for pre-transplant lab work. \r\nShe had ___ at the outpatient heme/onc office which showed an \r\nacute right popliteal/ femoral DVT. \r\n\r\nStem cell collection period prolonged as counts slower to \r\nrecover than in the past.  Required addition of Mozibil with \r\nmuch improved stem cells collections with total yield of over 5 \r\nx 10(e)6 CD 3 cells/kg.  Her last PET CT showed almost a \r\ncomplete response with residual focus of avidity in the bed of \r\nthe abdominal mass.  She was evaluated by radiation oncology \r\nwith the plan for consolidative radiation therapy to be done \r\nfollowing her autologous transplant.  Echocardiogram on \r\n___ showed normal left ventricular wall thickness and \r\ncavity size with mildly depressed global systolic function with \r\nLVEF of 45%.  PFT's from ___ showed FVC of 66%, FEV1 of \r\n73%, TLC of 73% and DLCO of 93%.  Bone marrow aspirate and \r\nbiopsy on ___ showed no evidence for lymphoma but was \r\nnoted for a small mature lymphocyte clone that is a separate \r\nmalignancy of\r\nthe CLL phenotype.  She has no indication of this in her blood. \r\nAs her transformed lymphoma needs to be treated and is more life\r\nthreatening if left untreated, the decision was made to proceed\r\nwith the autologous transplant as planned.\r\n \r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access. Biopsies showed\r\nFollicular lymphomas grade II/III. Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new \r\nadenopathy. Labs notable for LDH 341, WBC 10.1, normal \r\ndifferential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal\r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric\r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ \r\nCD10+ lambda restricted. MIB and cytogenetics are pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clincally improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a \r\nresidual focus of avidity in the bed of the former abdominal \r\nmass, SUV ___ C4 Rituximab\r\n- PLANNED ___ C4 ICE followed by stem cell mobilization and \r\ncollection\r\n\r\n \r\nPast Medical History:\r\n--Transformed DLBCL with history of follicular lymphoma as noted\r\nabove. \r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia \r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM: \r\n.\r\nVITALS -  98.4, 126/62, 75, 18, 98% RA   weight: 238.2\r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, OP \r\nclear\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. Tender, erythematous corded vein on right medial \r\nmid-thigh. No cyanosis, clubbing or edema. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. Gait not assessed.\r\n.\r\nDISCHARGE EXAM: \r\n.\r\nVITALS -  97.5 118/78 104 18 99% RA  \r\nI/O yesterday (24hr): 1.4/0.9 (no BMs) \r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, no \r\nlesions\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley; healed skin tears in inguinal region; pink, no \r\npurulence, no surrounding errythema, IMPROVED \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. 2+ pitting edema ___ at ankles, L>R. No cyanosis or \r\nclubbing. L hip TTP, no masses, errhtyema, warmth. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. normal gait\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS: \r\n---------------\r\n___ 10:45AM   UREA N-11 CREAT-0.8 SODIUM-137 POTASSIUM-4.3 \r\nCHLORIDE-101 TOTAL CO2-26 ANION GAP-14\r\n___ 10:45AM   estGFR-Using this\r\n___ 10:45AM   ALT(SGPT)-12 AST(SGOT)-20 LD(LDH)-341* ALK \r\nPHOS-153* TOT BILI-0.2\r\n___ 10:45AM   TOT PROT-6.2* ALBUMIN-4.0 GLOBULIN-2.2 \r\nCALCIUM-8.6 PHOSPHATE-3.5 MAGNESIUM-2.1 URIC ACID-3.9\r\n___ 10:45AM   WBC-8.6# RBC-2.61* HGB-8.2* HCT-25.5* MCV-98 \r\nMCH-31.3 MCHC-32.0 RDW-24.1*\r\n___ 10:45AM   NEUTS-83.2* LYMPHS-7.0* MONOS-9.5 EOS-0.1 \r\nBASOS-0.2\r\n___ 10:45AM   PLT COUNT-281#\r\n___ 10:45AM   ___ PTT-29.1 ___\r\n.\r\nIMAGING: \r\n----------\r\n___ ___ Dopplers IMPRESSION:   \r\n1.  Acute deep venous thrombosis of the right femoral and \r\npopliteal veins.   2.  No evidence of deep vein thrombosis in \r\nthe left lower extremity.\r\n. \r\n___ CTA Chest: 1.  No pulmonary embolus demonstrated.  \r\n2.  Enlargement of the main pulmonary artery as seen on the \r\nprior examination ___.  This may reflect pulmonary \r\narterial hypertension.   \r\n.\r\n___ ___ Dopplers IMPRESSION: \r\n1.  No evidence of DVT in the left lower extremity.  Assessment \r\nof left calf veins is limited.   2.  Similar distribution of \r\nthrombus in the right lower extremity involving the right mid \r\nand distal femoral vein and popliteal vein.\r\n.   \r\nDISCHARGE LABS: \r\n---------------\r\n___ 12:04AM BLOOD WBC-4.2 RBC-2.62* Hgb-8.1* Hct-25.7* \r\nMCV-98 MCH-30.8 MCHC-31.4 RDW-20.3* Plt ___\r\n___ 12:04AM BLOOD Neuts-59 Bands-0 Lymphs-12* Monos-26* \r\nEos-0 Baso-0 Atyps-2* ___ Myelos-1*\r\n___ 12:04AM BLOOD Hypochr-1+ Anisocy-2+ Poiklo-1+ \r\nMacrocy-3+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-1+\r\n___ 12:04AM BLOOD Plt Smr-LOW Plt ___\r\n___ 12:04AM BLOOD Glucose-103* UreaN-9 Creat-0.7 Na-138 \r\nK-3.7 Cl-103 HCO3-26 AnGap-13\r\n___ 12:04AM BLOOD ALT-15 AST-20 LD(LDH)-219 AlkPhos-81 \r\nTotBili-0.3\r\n___ 12:04AM BLOOD Albumin-3.5 Calcium-8.2* Phos-3.5 Mg-1.___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. \r\n.\r\nACUTE ISSUES: \r\n.\r\n#Diffuse Large B-Cell Lymphoma (DLBCL): transformed from \r\nfollicular lyphoma. Underwent BEAM conditioning followed by \r\nscheduled autoSCT on ___. Post-transplant course complicated by \r\nfebrile neutropenia, for which she was on cefepime, vancomycin \r\nand micafungin (to cover inguinal skin wounds). Recieved 5U \r\nPRBCs and 5U platelets to maintain hct > 21 and plts > 10. She \r\nwas on PCA for a period of time for mucositis. Neutropenia \r\nresolved on ___, at which point antibiotics and G-CSF were \r\ndiscontinued. Patient was able to advance diet slowly as \r\nmucositis resolved; by discharge she was taking excellent PO \r\nhydration and continuing to advance her diet. Sent home on \r\nacyclovir for fungal ppx, to start Bactrim SS for PCP ppx on \r\n___.  \r\n.\r\n#DVT: New, provoked. ___ in outpatient heme/onc office showed \r\nacute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis. Secondary to malignancy. Given lovenox in the \r\nclinic. Pt reported to be tachycardic and dyspneic in clinic, \r\nc/f PE was high. CTA chest negative for PE. IVC filter placed on \r\n___ by ___. Heparin drip discontinued ___ given falling \r\nplatelet count. Left lower extemity noted to be swollen more \r\nsignificantly than the right on ___, but dopplers showed only \r\nstable right leg clot. Thrombocytopenia resolved on ___, and \r\nshe was started on warfarin as well as lovenox sc at \r\nprophylactic dose. On ___ she was switched to lovenox sc at \r\ntreatment dose (100mg BID); will start on warfarin as outpatient \r\nat a later date, once diet and medications have stabilized.  \r\n.\r\n#Bilateral groin skin tears: skin tears in inguinal region \r\nbeneath panus c/b intertrigo/fungal infection. Developed prior \r\nto onset of neutropneia, started on vancomycin and micafungin + \r\ntopical fungal cream. Healed well with proper wound care. \r\nMicafungin and vancomycin discontinued once neutropenia \r\nresolved. \r\n.\r\nCHRONIC ISSUES: \r\n.\r\n# Back and L hip pain: has h/o L hip bursistis; no h/o sciatica. \r\nDescription of pain c/w musculoskeletal source, no concerning \r\nphysical exam findings. Symptoms fluctuated through course of \r\nstay based on patient positioning/activity level. \r\n.\r\n#Migranes: Patient reporting unilateral (right sided) headache \r\nwith photosensitivity and nausea on ___. Resolved on ___ \r\nafter receiving fioracet and ativan for nausea. \r\n.\r\n#Neuropathy: Stable, likely secondary to old sensory stroke. \r\nAlso has new numbness on fingertips bilaterally likely secondary \r\nto etoposide. Continued home gabapentin.\r\n.\r\n#H/o cerebral aneurysm: Stable. Discovered ___ years ago on MRA \r\nhead in right ICA cavernous sinus. S/p coiling ___ years ago. Has \r\nstable dysconjugate gaze/pupil asymmetry from the aneurysm.   \r\n.\r\n#Depression: Stable, continued on home venlafaxine.\r\n.\r\nTRANSTIONAL ISSUES: \r\n.\r\n# ANTICOAGULATION: discharged on lovenox; will continue for at \r\nleast 2 weeks while diet increases/she starts on bactrim, and \r\nthen be transitioned to warfarin as outpatient. \r\n.\r\n# PCP ___: to start ___ sent home w/script\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Furosemide 20 mg PO DAILY \r\n3. Gabapentin 900 mg PO BID \r\n4. Omeprazole 20 mg PO DAILY \r\n5. Ondansetron 8 mg PO Q8H:PRN nausea \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Gabapentin 900 mg PO BID \r\n3. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n4. Venlafaxine 25 mg PO BID \r\n5. Miconazole 2% Cream 1 Appl TP BID \r\nRX *miconazole nitrate [Antifungal Cream] 2 % apply to groin for \r\nrash three times a day Disp #*1 Tube Refills:*0\r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Furosemide 20 mg PO DAILY \r\n9. Ondansetron 8 mg PO Q8H:PRN nausea \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0\r\n12. Enoxaparin Sodium 100 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\nRX *enoxaparin 100 mg/mL 100 mg sc twice a day Disp #*14 Syringe \r\nRefills:*0\r\n13. OLANZapine (Disintegrating Tablet) 2.5 mg PO BID nausea \r\nRX *olanzapine 2.5 mg 1 tablet(s) by mouth twice a day Disp #*14 \r\nTablet Refills:*0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n# Primary: Diffuse Large B-Cell Lymphoma (DLBCL) \r\n\r\n# Secondary: Febrile Neutropenia, Deep Venous Thrombosis, \r\nDepression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear ___, \r\n\r\n___ was a pleasure taking care of you at the ___ \r\n___. You came in for an auto-stem cell \r\ntransplant (autSCT) for your Diffuse Large B-Cell Lymphoma \r\n(DLBCL). Just prior to admission you were found to have a deep \r\nvein thrombosis (DVT), for which you were started on lovenox and \r\nhad an inferior vena cava (IVC) filter placed on ___. You \r\nrecieved your autoSCT on ___. \r\n\r\nYour post-transplant course was complicated by fever, requiring \r\nantibiotics. These were discontinued without incident when your \r\nwhite blood cell counts had recovered. Lovenox was held when \r\nyour platelet count fell during chemotherapy. Anticoagulation \r\nwith lovenox was restarted on ___ when your platelet count had \r\nrecovered. \r\n\r\nYou will remain on viral prophylaxis with acyclovir for now, and \r\nstart PCP prophylaxis with ___ on ___.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-12:6",
      "text": "ACUTE ISSUES: \n. #Diffuse Large B-Cell Lymphoma (DLBCL): transformed from \nfollicular lyphoma. Underwent BEAM conditioning followed by \nscheduled autoSCT on ___. Post-transplant course complicated by \nfebrile neutropenia, for which she was on cefepime, vancomycin \nand micafungin (to cover inguinal skin wounds). Recieved 5U \nPRBCs and 5U platelets to maintain hct > 21 and plts > 10. She \nwas on PCA for a period of time for mucositis. Neutropenia \nresolved on ___, at which point antibiotics and G-CSF were \ndiscontinued. Patient was able to advance diet slowly as \nmucositis resolved; by discharge she was taking excellent PO \nhydration and continuing to advance her diet. Sent home on \nacyclovir for fungal ppx, to start Bactrim SS for PCP ppx on \n___. . #DVT: New, provoked. ___ in outpatient heme/onc office showed \nacute DVT in the right popliteal/femoral veins + superficial \nthrombosis. Secondary to malignancy. Given lovenox in the \nclinic. Pt reported to be tachycardic and dyspneic in clinic, \nc/f PE was high. CTA chest negative for PE. IVC filter placed on \n___ by ___. Heparin drip discontinued ___ given falling \nplatelet count. Left lower extemity noted to be swollen more \nsignificantly than the right on ___, but dopplers showed only \nstable right leg clot. Thrombocytopenia resolved on ___, and \nshe was started on warfarin as well as lovenox sc at \nprophylactic dose. On ___ she was switched to lovenox sc at \ntreatment dose (100mg BID); will start on warfarin as outpatient \nat a later date, once diet and medications have stabilized. . #Bilateral groin skin tears: skin tears in inguinal region \nbeneath panus c/b intertrigo/fungal infection. Developed prior \nto onset of neutropneia, started on vancomycin and micafungin + \ntopical fungal cream. Healed well with proper wound care. Micafungin and vancomycin discontinued once neutropenia \nresolved. .",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-12",
        "chart_time": "103369",
        "section": "General",
        "position": 6,
        "tokenCount": 469,
        "note_metadata": {
          "note_id": "18887130-DS-12",
          "subject_id": 18887130,
          "hadm_id": 28224744,
          "note_type": "DS",
          "note_seq": 12,
          "charttime": 103369,
          "storetime": 103369.65416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nscheduled autologous transplant with BEAM conditioning\r\n \r\nMajor Surgical or Invasive Procedure:\r\n___: IVC filter placed\r\n___: auto-stem cell transplant\r\n\r\n \r\nHistory of Present Illness:\r\n___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. She was also reporting an \r\narea of right medial thigh erythema, tenderness and induration \r\nto the transplant nurse over the phone on ___. She had a \r\nscheduled outpatient appointment for pre-transplant lab work. \r\nShe had ___ at the outpatient heme/onc office which showed an \r\nacute right popliteal/ femoral DVT. \r\n\r\nStem cell collection period prolonged as counts slower to \r\nrecover than in the past.  Required addition of Mozibil with \r\nmuch improved stem cells collections with total yield of over 5 \r\nx 10(e)6 CD 3 cells/kg.  Her last PET CT showed almost a \r\ncomplete response with residual focus of avidity in the bed of \r\nthe abdominal mass.  She was evaluated by radiation oncology \r\nwith the plan for consolidative radiation therapy to be done \r\nfollowing her autologous transplant.  Echocardiogram on \r\n___ showed normal left ventricular wall thickness and \r\ncavity size with mildly depressed global systolic function with \r\nLVEF of 45%.  PFT's from ___ showed FVC of 66%, FEV1 of \r\n73%, TLC of 73% and DLCO of 93%.  Bone marrow aspirate and \r\nbiopsy on ___ showed no evidence for lymphoma but was \r\nnoted for a small mature lymphocyte clone that is a separate \r\nmalignancy of\r\nthe CLL phenotype.  She has no indication of this in her blood. \r\nAs her transformed lymphoma needs to be treated and is more life\r\nthreatening if left untreated, the decision was made to proceed\r\nwith the autologous transplant as planned.\r\n \r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access. Biopsies showed\r\nFollicular lymphomas grade II/III. Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new \r\nadenopathy. Labs notable for LDH 341, WBC 10.1, normal \r\ndifferential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal\r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric\r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ \r\nCD10+ lambda restricted. MIB and cytogenetics are pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clincally improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a \r\nresidual focus of avidity in the bed of the former abdominal \r\nmass, SUV ___ C4 Rituximab\r\n- PLANNED ___ C4 ICE followed by stem cell mobilization and \r\ncollection\r\n\r\n \r\nPast Medical History:\r\n--Transformed DLBCL with history of follicular lymphoma as noted\r\nabove. \r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia \r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM: \r\n.\r\nVITALS -  98.4, 126/62, 75, 18, 98% RA   weight: 238.2\r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, OP \r\nclear\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. Tender, erythematous corded vein on right medial \r\nmid-thigh. No cyanosis, clubbing or edema. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. Gait not assessed.\r\n.\r\nDISCHARGE EXAM: \r\n.\r\nVITALS -  97.5 118/78 104 18 99% RA  \r\nI/O yesterday (24hr): 1.4/0.9 (no BMs) \r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, no \r\nlesions\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley; healed skin tears in inguinal region; pink, no \r\npurulence, no surrounding errythema, IMPROVED \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. 2+ pitting edema ___ at ankles, L>R. No cyanosis or \r\nclubbing. L hip TTP, no masses, errhtyema, warmth. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. normal gait\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS: \r\n---------------\r\n___ 10:45AM   UREA N-11 CREAT-0.8 SODIUM-137 POTASSIUM-4.3 \r\nCHLORIDE-101 TOTAL CO2-26 ANION GAP-14\r\n___ 10:45AM   estGFR-Using this\r\n___ 10:45AM   ALT(SGPT)-12 AST(SGOT)-20 LD(LDH)-341* ALK \r\nPHOS-153* TOT BILI-0.2\r\n___ 10:45AM   TOT PROT-6.2* ALBUMIN-4.0 GLOBULIN-2.2 \r\nCALCIUM-8.6 PHOSPHATE-3.5 MAGNESIUM-2.1 URIC ACID-3.9\r\n___ 10:45AM   WBC-8.6# RBC-2.61* HGB-8.2* HCT-25.5* MCV-98 \r\nMCH-31.3 MCHC-32.0 RDW-24.1*\r\n___ 10:45AM   NEUTS-83.2* LYMPHS-7.0* MONOS-9.5 EOS-0.1 \r\nBASOS-0.2\r\n___ 10:45AM   PLT COUNT-281#\r\n___ 10:45AM   ___ PTT-29.1 ___\r\n.\r\nIMAGING: \r\n----------\r\n___ ___ Dopplers IMPRESSION:   \r\n1.  Acute deep venous thrombosis of the right femoral and \r\npopliteal veins.   2.  No evidence of deep vein thrombosis in \r\nthe left lower extremity.\r\n. \r\n___ CTA Chest: 1.  No pulmonary embolus demonstrated.  \r\n2.  Enlargement of the main pulmonary artery as seen on the \r\nprior examination ___.  This may reflect pulmonary \r\narterial hypertension.   \r\n.\r\n___ ___ Dopplers IMPRESSION: \r\n1.  No evidence of DVT in the left lower extremity.  Assessment \r\nof left calf veins is limited.   2.  Similar distribution of \r\nthrombus in the right lower extremity involving the right mid \r\nand distal femoral vein and popliteal vein.\r\n.   \r\nDISCHARGE LABS: \r\n---------------\r\n___ 12:04AM BLOOD WBC-4.2 RBC-2.62* Hgb-8.1* Hct-25.7* \r\nMCV-98 MCH-30.8 MCHC-31.4 RDW-20.3* Plt ___\r\n___ 12:04AM BLOOD Neuts-59 Bands-0 Lymphs-12* Monos-26* \r\nEos-0 Baso-0 Atyps-2* ___ Myelos-1*\r\n___ 12:04AM BLOOD Hypochr-1+ Anisocy-2+ Poiklo-1+ \r\nMacrocy-3+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-1+\r\n___ 12:04AM BLOOD Plt Smr-LOW Plt ___\r\n___ 12:04AM BLOOD Glucose-103* UreaN-9 Creat-0.7 Na-138 \r\nK-3.7 Cl-103 HCO3-26 AnGap-13\r\n___ 12:04AM BLOOD ALT-15 AST-20 LD(LDH)-219 AlkPhos-81 \r\nTotBili-0.3\r\n___ 12:04AM BLOOD Albumin-3.5 Calcium-8.2* Phos-3.5 Mg-1.___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. \r\n.\r\nACUTE ISSUES: \r\n.\r\n#Diffuse Large B-Cell Lymphoma (DLBCL): transformed from \r\nfollicular lyphoma. Underwent BEAM conditioning followed by \r\nscheduled autoSCT on ___. Post-transplant course complicated by \r\nfebrile neutropenia, for which she was on cefepime, vancomycin \r\nand micafungin (to cover inguinal skin wounds). Recieved 5U \r\nPRBCs and 5U platelets to maintain hct > 21 and plts > 10. She \r\nwas on PCA for a period of time for mucositis. Neutropenia \r\nresolved on ___, at which point antibiotics and G-CSF were \r\ndiscontinued. Patient was able to advance diet slowly as \r\nmucositis resolved; by discharge she was taking excellent PO \r\nhydration and continuing to advance her diet. Sent home on \r\nacyclovir for fungal ppx, to start Bactrim SS for PCP ppx on \r\n___.  \r\n.\r\n#DVT: New, provoked. ___ in outpatient heme/onc office showed \r\nacute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis. Secondary to malignancy. Given lovenox in the \r\nclinic. Pt reported to be tachycardic and dyspneic in clinic, \r\nc/f PE was high. CTA chest negative for PE. IVC filter placed on \r\n___ by ___. Heparin drip discontinued ___ given falling \r\nplatelet count. Left lower extemity noted to be swollen more \r\nsignificantly than the right on ___, but dopplers showed only \r\nstable right leg clot. Thrombocytopenia resolved on ___, and \r\nshe was started on warfarin as well as lovenox sc at \r\nprophylactic dose. On ___ she was switched to lovenox sc at \r\ntreatment dose (100mg BID); will start on warfarin as outpatient \r\nat a later date, once diet and medications have stabilized.  \r\n.\r\n#Bilateral groin skin tears: skin tears in inguinal region \r\nbeneath panus c/b intertrigo/fungal infection. Developed prior \r\nto onset of neutropneia, started on vancomycin and micafungin + \r\ntopical fungal cream. Healed well with proper wound care. \r\nMicafungin and vancomycin discontinued once neutropenia \r\nresolved. \r\n.\r\nCHRONIC ISSUES: \r\n.\r\n# Back and L hip pain: has h/o L hip bursistis; no h/o sciatica. \r\nDescription of pain c/w musculoskeletal source, no concerning \r\nphysical exam findings. Symptoms fluctuated through course of \r\nstay based on patient positioning/activity level. \r\n.\r\n#Migranes: Patient reporting unilateral (right sided) headache \r\nwith photosensitivity and nausea on ___. Resolved on ___ \r\nafter receiving fioracet and ativan for nausea. \r\n.\r\n#Neuropathy: Stable, likely secondary to old sensory stroke. \r\nAlso has new numbness on fingertips bilaterally likely secondary \r\nto etoposide. Continued home gabapentin.\r\n.\r\n#H/o cerebral aneurysm: Stable. Discovered ___ years ago on MRA \r\nhead in right ICA cavernous sinus. S/p coiling ___ years ago. Has \r\nstable dysconjugate gaze/pupil asymmetry from the aneurysm.   \r\n.\r\n#Depression: Stable, continued on home venlafaxine.\r\n.\r\nTRANSTIONAL ISSUES: \r\n.\r\n# ANTICOAGULATION: discharged on lovenox; will continue for at \r\nleast 2 weeks while diet increases/she starts on bactrim, and \r\nthen be transitioned to warfarin as outpatient. \r\n.\r\n# PCP ___: to start ___ sent home w/script\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Furosemide 20 mg PO DAILY \r\n3. Gabapentin 900 mg PO BID \r\n4. Omeprazole 20 mg PO DAILY \r\n5. Ondansetron 8 mg PO Q8H:PRN nausea \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Gabapentin 900 mg PO BID \r\n3. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n4. Venlafaxine 25 mg PO BID \r\n5. Miconazole 2% Cream 1 Appl TP BID \r\nRX *miconazole nitrate [Antifungal Cream] 2 % apply to groin for \r\nrash three times a day Disp #*1 Tube Refills:*0\r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Furosemide 20 mg PO DAILY \r\n9. Ondansetron 8 mg PO Q8H:PRN nausea \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0\r\n12. Enoxaparin Sodium 100 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\nRX *enoxaparin 100 mg/mL 100 mg sc twice a day Disp #*14 Syringe \r\nRefills:*0\r\n13. OLANZapine (Disintegrating Tablet) 2.5 mg PO BID nausea \r\nRX *olanzapine 2.5 mg 1 tablet(s) by mouth twice a day Disp #*14 \r\nTablet Refills:*0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n# Primary: Diffuse Large B-Cell Lymphoma (DLBCL) \r\n\r\n# Secondary: Febrile Neutropenia, Deep Venous Thrombosis, \r\nDepression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear ___, \r\n\r\n___ was a pleasure taking care of you at the ___ \r\n___. You came in for an auto-stem cell \r\ntransplant (autSCT) for your Diffuse Large B-Cell Lymphoma \r\n(DLBCL). Just prior to admission you were found to have a deep \r\nvein thrombosis (DVT), for which you were started on lovenox and \r\nhad an inferior vena cava (IVC) filter placed on ___. You \r\nrecieved your autoSCT on ___. \r\n\r\nYour post-transplant course was complicated by fever, requiring \r\nantibiotics. These were discontinued without incident when your \r\nwhite blood cell counts had recovered. Lovenox was held when \r\nyour platelet count fell during chemotherapy. Anticoagulation \r\nwith lovenox was restarted on ___ when your platelet count had \r\nrecovered. \r\n\r\nYou will remain on viral prophylaxis with acyclovir for now, and \r\nstart PCP prophylaxis with ___ on ___.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-12:7",
      "text": "CHRONIC ISSUES: \n. # Back and L hip pain: has h/o L hip bursistis; no h/o sciatica. Description of pain c/w musculoskeletal source, no concerning \nphysical exam findings. Symptoms fluctuated through course of \nstay based on patient positioning/activity level. . #Migranes: Patient reporting unilateral (right sided) headache \nwith photosensitivity and nausea on ___. Resolved on ___ \nafter receiving fioracet and ativan for nausea. . #Neuropathy: Stable, likely secondary to old sensory stroke. Also has new numbness on fingertips bilaterally likely secondary \nto etoposide. Continued home gabapentin. . #H/o cerebral aneurysm: Stable. Discovered ___ years ago on MRA \nhead in right ICA cavernous sinus. S/p coiling ___ years ago. Has \nstable dysconjugate gaze/pupil asymmetry from the aneurysm. . #Depression: Stable, continued on home venlafaxine. . TRANSTIONAL ISSUES: \n. # ANTICOAGULATION: discharged on lovenox; will continue for at \nleast 2 weeks while diet increases/she starts on bactrim, and \nthen be transitioned to warfarin as outpatient. . # PCP ___: to start ___ sent home w/script\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Acyclovir 400 mg PO Q8H \n2. Furosemide 20 mg PO DAILY \n3. Gabapentin 900 mg PO BID \n4. Omeprazole 20 mg PO DAILY \n5. Ondansetron 8 mg PO Q8H:PRN nausea \n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \n9. Venlafaxine 25 mg PO BID \n10. Multivitamins 1 TAB PO DAILY",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-12",
        "chart_time": "103369",
        "section": "General",
        "position": 7,
        "tokenCount": 387,
        "note_metadata": {
          "note_id": "18887130-DS-12",
          "subject_id": 18887130,
          "hadm_id": 28224744,
          "note_type": "DS",
          "note_seq": 12,
          "charttime": 103369,
          "storetime": 103369.65416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nscheduled autologous transplant with BEAM conditioning\r\n \r\nMajor Surgical or Invasive Procedure:\r\n___: IVC filter placed\r\n___: auto-stem cell transplant\r\n\r\n \r\nHistory of Present Illness:\r\n___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. She was also reporting an \r\narea of right medial thigh erythema, tenderness and induration \r\nto the transplant nurse over the phone on ___. She had a \r\nscheduled outpatient appointment for pre-transplant lab work. \r\nShe had ___ at the outpatient heme/onc office which showed an \r\nacute right popliteal/ femoral DVT. \r\n\r\nStem cell collection period prolonged as counts slower to \r\nrecover than in the past.  Required addition of Mozibil with \r\nmuch improved stem cells collections with total yield of over 5 \r\nx 10(e)6 CD 3 cells/kg.  Her last PET CT showed almost a \r\ncomplete response with residual focus of avidity in the bed of \r\nthe abdominal mass.  She was evaluated by radiation oncology \r\nwith the plan for consolidative radiation therapy to be done \r\nfollowing her autologous transplant.  Echocardiogram on \r\n___ showed normal left ventricular wall thickness and \r\ncavity size with mildly depressed global systolic function with \r\nLVEF of 45%.  PFT's from ___ showed FVC of 66%, FEV1 of \r\n73%, TLC of 73% and DLCO of 93%.  Bone marrow aspirate and \r\nbiopsy on ___ showed no evidence for lymphoma but was \r\nnoted for a small mature lymphocyte clone that is a separate \r\nmalignancy of\r\nthe CLL phenotype.  She has no indication of this in her blood. \r\nAs her transformed lymphoma needs to be treated and is more life\r\nthreatening if left untreated, the decision was made to proceed\r\nwith the autologous transplant as planned.\r\n \r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access. Biopsies showed\r\nFollicular lymphomas grade II/III. Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new \r\nadenopathy. Labs notable for LDH 341, WBC 10.1, normal \r\ndifferential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal\r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric\r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ \r\nCD10+ lambda restricted. MIB and cytogenetics are pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clincally improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a \r\nresidual focus of avidity in the bed of the former abdominal \r\nmass, SUV ___ C4 Rituximab\r\n- PLANNED ___ C4 ICE followed by stem cell mobilization and \r\ncollection\r\n\r\n \r\nPast Medical History:\r\n--Transformed DLBCL with history of follicular lymphoma as noted\r\nabove. \r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia \r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM: \r\n.\r\nVITALS -  98.4, 126/62, 75, 18, 98% RA   weight: 238.2\r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, OP \r\nclear\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. Tender, erythematous corded vein on right medial \r\nmid-thigh. No cyanosis, clubbing or edema. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. Gait not assessed.\r\n.\r\nDISCHARGE EXAM: \r\n.\r\nVITALS -  97.5 118/78 104 18 99% RA  \r\nI/O yesterday (24hr): 1.4/0.9 (no BMs) \r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, no \r\nlesions\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley; healed skin tears in inguinal region; pink, no \r\npurulence, no surrounding errythema, IMPROVED \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. 2+ pitting edema ___ at ankles, L>R. No cyanosis or \r\nclubbing. L hip TTP, no masses, errhtyema, warmth. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. normal gait\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS: \r\n---------------\r\n___ 10:45AM   UREA N-11 CREAT-0.8 SODIUM-137 POTASSIUM-4.3 \r\nCHLORIDE-101 TOTAL CO2-26 ANION GAP-14\r\n___ 10:45AM   estGFR-Using this\r\n___ 10:45AM   ALT(SGPT)-12 AST(SGOT)-20 LD(LDH)-341* ALK \r\nPHOS-153* TOT BILI-0.2\r\n___ 10:45AM   TOT PROT-6.2* ALBUMIN-4.0 GLOBULIN-2.2 \r\nCALCIUM-8.6 PHOSPHATE-3.5 MAGNESIUM-2.1 URIC ACID-3.9\r\n___ 10:45AM   WBC-8.6# RBC-2.61* HGB-8.2* HCT-25.5* MCV-98 \r\nMCH-31.3 MCHC-32.0 RDW-24.1*\r\n___ 10:45AM   NEUTS-83.2* LYMPHS-7.0* MONOS-9.5 EOS-0.1 \r\nBASOS-0.2\r\n___ 10:45AM   PLT COUNT-281#\r\n___ 10:45AM   ___ PTT-29.1 ___\r\n.\r\nIMAGING: \r\n----------\r\n___ ___ Dopplers IMPRESSION:   \r\n1.  Acute deep venous thrombosis of the right femoral and \r\npopliteal veins.   2.  No evidence of deep vein thrombosis in \r\nthe left lower extremity.\r\n. \r\n___ CTA Chest: 1.  No pulmonary embolus demonstrated.  \r\n2.  Enlargement of the main pulmonary artery as seen on the \r\nprior examination ___.  This may reflect pulmonary \r\narterial hypertension.   \r\n.\r\n___ ___ Dopplers IMPRESSION: \r\n1.  No evidence of DVT in the left lower extremity.  Assessment \r\nof left calf veins is limited.   2.  Similar distribution of \r\nthrombus in the right lower extremity involving the right mid \r\nand distal femoral vein and popliteal vein.\r\n.   \r\nDISCHARGE LABS: \r\n---------------\r\n___ 12:04AM BLOOD WBC-4.2 RBC-2.62* Hgb-8.1* Hct-25.7* \r\nMCV-98 MCH-30.8 MCHC-31.4 RDW-20.3* Plt ___\r\n___ 12:04AM BLOOD Neuts-59 Bands-0 Lymphs-12* Monos-26* \r\nEos-0 Baso-0 Atyps-2* ___ Myelos-1*\r\n___ 12:04AM BLOOD Hypochr-1+ Anisocy-2+ Poiklo-1+ \r\nMacrocy-3+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-1+\r\n___ 12:04AM BLOOD Plt Smr-LOW Plt ___\r\n___ 12:04AM BLOOD Glucose-103* UreaN-9 Creat-0.7 Na-138 \r\nK-3.7 Cl-103 HCO3-26 AnGap-13\r\n___ 12:04AM BLOOD ALT-15 AST-20 LD(LDH)-219 AlkPhos-81 \r\nTotBili-0.3\r\n___ 12:04AM BLOOD Albumin-3.5 Calcium-8.2* Phos-3.5 Mg-1.___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. \r\n.\r\nACUTE ISSUES: \r\n.\r\n#Diffuse Large B-Cell Lymphoma (DLBCL): transformed from \r\nfollicular lyphoma. Underwent BEAM conditioning followed by \r\nscheduled autoSCT on ___. Post-transplant course complicated by \r\nfebrile neutropenia, for which she was on cefepime, vancomycin \r\nand micafungin (to cover inguinal skin wounds). Recieved 5U \r\nPRBCs and 5U platelets to maintain hct > 21 and plts > 10. She \r\nwas on PCA for a period of time for mucositis. Neutropenia \r\nresolved on ___, at which point antibiotics and G-CSF were \r\ndiscontinued. Patient was able to advance diet slowly as \r\nmucositis resolved; by discharge she was taking excellent PO \r\nhydration and continuing to advance her diet. Sent home on \r\nacyclovir for fungal ppx, to start Bactrim SS for PCP ppx on \r\n___.  \r\n.\r\n#DVT: New, provoked. ___ in outpatient heme/onc office showed \r\nacute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis. Secondary to malignancy. Given lovenox in the \r\nclinic. Pt reported to be tachycardic and dyspneic in clinic, \r\nc/f PE was high. CTA chest negative for PE. IVC filter placed on \r\n___ by ___. Heparin drip discontinued ___ given falling \r\nplatelet count. Left lower extemity noted to be swollen more \r\nsignificantly than the right on ___, but dopplers showed only \r\nstable right leg clot. Thrombocytopenia resolved on ___, and \r\nshe was started on warfarin as well as lovenox sc at \r\nprophylactic dose. On ___ she was switched to lovenox sc at \r\ntreatment dose (100mg BID); will start on warfarin as outpatient \r\nat a later date, once diet and medications have stabilized.  \r\n.\r\n#Bilateral groin skin tears: skin tears in inguinal region \r\nbeneath panus c/b intertrigo/fungal infection. Developed prior \r\nto onset of neutropneia, started on vancomycin and micafungin + \r\ntopical fungal cream. Healed well with proper wound care. \r\nMicafungin and vancomycin discontinued once neutropenia \r\nresolved. \r\n.\r\nCHRONIC ISSUES: \r\n.\r\n# Back and L hip pain: has h/o L hip bursistis; no h/o sciatica. \r\nDescription of pain c/w musculoskeletal source, no concerning \r\nphysical exam findings. Symptoms fluctuated through course of \r\nstay based on patient positioning/activity level. \r\n.\r\n#Migranes: Patient reporting unilateral (right sided) headache \r\nwith photosensitivity and nausea on ___. Resolved on ___ \r\nafter receiving fioracet and ativan for nausea. \r\n.\r\n#Neuropathy: Stable, likely secondary to old sensory stroke. \r\nAlso has new numbness on fingertips bilaterally likely secondary \r\nto etoposide. Continued home gabapentin.\r\n.\r\n#H/o cerebral aneurysm: Stable. Discovered ___ years ago on MRA \r\nhead in right ICA cavernous sinus. S/p coiling ___ years ago. Has \r\nstable dysconjugate gaze/pupil asymmetry from the aneurysm.   \r\n.\r\n#Depression: Stable, continued on home venlafaxine.\r\n.\r\nTRANSTIONAL ISSUES: \r\n.\r\n# ANTICOAGULATION: discharged on lovenox; will continue for at \r\nleast 2 weeks while diet increases/she starts on bactrim, and \r\nthen be transitioned to warfarin as outpatient. \r\n.\r\n# PCP ___: to start ___ sent home w/script\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Furosemide 20 mg PO DAILY \r\n3. Gabapentin 900 mg PO BID \r\n4. Omeprazole 20 mg PO DAILY \r\n5. Ondansetron 8 mg PO Q8H:PRN nausea \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Gabapentin 900 mg PO BID \r\n3. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n4. Venlafaxine 25 mg PO BID \r\n5. Miconazole 2% Cream 1 Appl TP BID \r\nRX *miconazole nitrate [Antifungal Cream] 2 % apply to groin for \r\nrash three times a day Disp #*1 Tube Refills:*0\r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Furosemide 20 mg PO DAILY \r\n9. Ondansetron 8 mg PO Q8H:PRN nausea \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0\r\n12. Enoxaparin Sodium 100 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\nRX *enoxaparin 100 mg/mL 100 mg sc twice a day Disp #*14 Syringe \r\nRefills:*0\r\n13. OLANZapine (Disintegrating Tablet) 2.5 mg PO BID nausea \r\nRX *olanzapine 2.5 mg 1 tablet(s) by mouth twice a day Disp #*14 \r\nTablet Refills:*0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n# Primary: Diffuse Large B-Cell Lymphoma (DLBCL) \r\n\r\n# Secondary: Febrile Neutropenia, Deep Venous Thrombosis, \r\nDepression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear ___, \r\n\r\n___ was a pleasure taking care of you at the ___ \r\n___. You came in for an auto-stem cell \r\ntransplant (autSCT) for your Diffuse Large B-Cell Lymphoma \r\n(DLBCL). Just prior to admission you were found to have a deep \r\nvein thrombosis (DVT), for which you were started on lovenox and \r\nhad an inferior vena cava (IVC) filter placed on ___. You \r\nrecieved your autoSCT on ___. \r\n\r\nYour post-transplant course was complicated by fever, requiring \r\nantibiotics. These were discontinued without incident when your \r\nwhite blood cell counts had recovered. Lovenox was held when \r\nyour platelet count fell during chemotherapy. Anticoagulation \r\nwith lovenox was restarted on ___ when your platelet count had \r\nrecovered. \r\n\r\nYou will remain on viral prophylaxis with acyclovir for now, and \r\nstart PCP prophylaxis with ___ on ___.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-12:8",
      "text": "Discharge Medications:\n1. Acyclovir 400 mg PO Q8H \n2. Gabapentin 900 mg PO BID \n3. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \n4. Venlafaxine 25 mg PO BID \n5. Miconazole 2% Cream 1 Appl TP BID \nRX *miconazole nitrate [Antifungal Cream] 2 % apply to groin for \nrash three times a day Disp #*1 Tube Refills:*0\n6. Multivitamins 1 TAB PO DAILY \n7. Omeprazole 20 mg PO DAILY \n8. Furosemide 20 mg PO DAILY \n9. Ondansetron 8 mg PO Q8H:PRN nausea \n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0\n12. Enoxaparin Sodium 100 mg SC Q12H \nStart: ___, First Dose: Next Routine Administration Time \nRX *enoxaparin 100 mg/mL 100 mg sc twice a day Disp #*14 Syringe \nRefills:*0\n13. OLANZapine (Disintegrating Tablet) 2.5 mg PO BID nausea \nRX *olanzapine 2.5 mg 1 tablet(s) by mouth twice a day Disp #*14 \nTablet Refills:*0 Discharge Disposition:\nHome With Service\n \nFacility:\n___ Discharge Diagnosis:\n# Primary: Diffuse Large B-Cell Lymphoma (DLBCL) # Secondary: Febrile Neutropenia, Deep Venous Thrombosis, \nDepression Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-12",
        "chart_time": "103369",
        "section": "General",
        "position": 8,
        "tokenCount": 329,
        "note_metadata": {
          "note_id": "18887130-DS-12",
          "subject_id": 18887130,
          "hadm_id": 28224744,
          "note_type": "DS",
          "note_seq": 12,
          "charttime": 103369,
          "storetime": 103369.65416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nscheduled autologous transplant with BEAM conditioning\r\n \r\nMajor Surgical or Invasive Procedure:\r\n___: IVC filter placed\r\n___: auto-stem cell transplant\r\n\r\n \r\nHistory of Present Illness:\r\n___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. She was also reporting an \r\narea of right medial thigh erythema, tenderness and induration \r\nto the transplant nurse over the phone on ___. She had a \r\nscheduled outpatient appointment for pre-transplant lab work. \r\nShe had ___ at the outpatient heme/onc office which showed an \r\nacute right popliteal/ femoral DVT. \r\n\r\nStem cell collection period prolonged as counts slower to \r\nrecover than in the past.  Required addition of Mozibil with \r\nmuch improved stem cells collections with total yield of over 5 \r\nx 10(e)6 CD 3 cells/kg.  Her last PET CT showed almost a \r\ncomplete response with residual focus of avidity in the bed of \r\nthe abdominal mass.  She was evaluated by radiation oncology \r\nwith the plan for consolidative radiation therapy to be done \r\nfollowing her autologous transplant.  Echocardiogram on \r\n___ showed normal left ventricular wall thickness and \r\ncavity size with mildly depressed global systolic function with \r\nLVEF of 45%.  PFT's from ___ showed FVC of 66%, FEV1 of \r\n73%, TLC of 73% and DLCO of 93%.  Bone marrow aspirate and \r\nbiopsy on ___ showed no evidence for lymphoma but was \r\nnoted for a small mature lymphocyte clone that is a separate \r\nmalignancy of\r\nthe CLL phenotype.  She has no indication of this in her blood. \r\nAs her transformed lymphoma needs to be treated and is more life\r\nthreatening if left untreated, the decision was made to proceed\r\nwith the autologous transplant as planned.\r\n \r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access. Biopsies showed\r\nFollicular lymphomas grade II/III. Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new \r\nadenopathy. Labs notable for LDH 341, WBC 10.1, normal \r\ndifferential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal\r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric\r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ \r\nCD10+ lambda restricted. MIB and cytogenetics are pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clincally improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a \r\nresidual focus of avidity in the bed of the former abdominal \r\nmass, SUV ___ C4 Rituximab\r\n- PLANNED ___ C4 ICE followed by stem cell mobilization and \r\ncollection\r\n\r\n \r\nPast Medical History:\r\n--Transformed DLBCL with history of follicular lymphoma as noted\r\nabove. \r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia \r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM: \r\n.\r\nVITALS -  98.4, 126/62, 75, 18, 98% RA   weight: 238.2\r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, OP \r\nclear\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. Tender, erythematous corded vein on right medial \r\nmid-thigh. No cyanosis, clubbing or edema. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. Gait not assessed.\r\n.\r\nDISCHARGE EXAM: \r\n.\r\nVITALS -  97.5 118/78 104 18 99% RA  \r\nI/O yesterday (24hr): 1.4/0.9 (no BMs) \r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, no \r\nlesions\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley; healed skin tears in inguinal region; pink, no \r\npurulence, no surrounding errythema, IMPROVED \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. 2+ pitting edema ___ at ankles, L>R. No cyanosis or \r\nclubbing. L hip TTP, no masses, errhtyema, warmth. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. normal gait\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS: \r\n---------------\r\n___ 10:45AM   UREA N-11 CREAT-0.8 SODIUM-137 POTASSIUM-4.3 \r\nCHLORIDE-101 TOTAL CO2-26 ANION GAP-14\r\n___ 10:45AM   estGFR-Using this\r\n___ 10:45AM   ALT(SGPT)-12 AST(SGOT)-20 LD(LDH)-341* ALK \r\nPHOS-153* TOT BILI-0.2\r\n___ 10:45AM   TOT PROT-6.2* ALBUMIN-4.0 GLOBULIN-2.2 \r\nCALCIUM-8.6 PHOSPHATE-3.5 MAGNESIUM-2.1 URIC ACID-3.9\r\n___ 10:45AM   WBC-8.6# RBC-2.61* HGB-8.2* HCT-25.5* MCV-98 \r\nMCH-31.3 MCHC-32.0 RDW-24.1*\r\n___ 10:45AM   NEUTS-83.2* LYMPHS-7.0* MONOS-9.5 EOS-0.1 \r\nBASOS-0.2\r\n___ 10:45AM   PLT COUNT-281#\r\n___ 10:45AM   ___ PTT-29.1 ___\r\n.\r\nIMAGING: \r\n----------\r\n___ ___ Dopplers IMPRESSION:   \r\n1.  Acute deep venous thrombosis of the right femoral and \r\npopliteal veins.   2.  No evidence of deep vein thrombosis in \r\nthe left lower extremity.\r\n. \r\n___ CTA Chest: 1.  No pulmonary embolus demonstrated.  \r\n2.  Enlargement of the main pulmonary artery as seen on the \r\nprior examination ___.  This may reflect pulmonary \r\narterial hypertension.   \r\n.\r\n___ ___ Dopplers IMPRESSION: \r\n1.  No evidence of DVT in the left lower extremity.  Assessment \r\nof left calf veins is limited.   2.  Similar distribution of \r\nthrombus in the right lower extremity involving the right mid \r\nand distal femoral vein and popliteal vein.\r\n.   \r\nDISCHARGE LABS: \r\n---------------\r\n___ 12:04AM BLOOD WBC-4.2 RBC-2.62* Hgb-8.1* Hct-25.7* \r\nMCV-98 MCH-30.8 MCHC-31.4 RDW-20.3* Plt ___\r\n___ 12:04AM BLOOD Neuts-59 Bands-0 Lymphs-12* Monos-26* \r\nEos-0 Baso-0 Atyps-2* ___ Myelos-1*\r\n___ 12:04AM BLOOD Hypochr-1+ Anisocy-2+ Poiklo-1+ \r\nMacrocy-3+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-1+\r\n___ 12:04AM BLOOD Plt Smr-LOW Plt ___\r\n___ 12:04AM BLOOD Glucose-103* UreaN-9 Creat-0.7 Na-138 \r\nK-3.7 Cl-103 HCO3-26 AnGap-13\r\n___ 12:04AM BLOOD ALT-15 AST-20 LD(LDH)-219 AlkPhos-81 \r\nTotBili-0.3\r\n___ 12:04AM BLOOD Albumin-3.5 Calcium-8.2* Phos-3.5 Mg-1.___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. \r\n.\r\nACUTE ISSUES: \r\n.\r\n#Diffuse Large B-Cell Lymphoma (DLBCL): transformed from \r\nfollicular lyphoma. Underwent BEAM conditioning followed by \r\nscheduled autoSCT on ___. Post-transplant course complicated by \r\nfebrile neutropenia, for which she was on cefepime, vancomycin \r\nand micafungin (to cover inguinal skin wounds). Recieved 5U \r\nPRBCs and 5U platelets to maintain hct > 21 and plts > 10. She \r\nwas on PCA for a period of time for mucositis. Neutropenia \r\nresolved on ___, at which point antibiotics and G-CSF were \r\ndiscontinued. Patient was able to advance diet slowly as \r\nmucositis resolved; by discharge she was taking excellent PO \r\nhydration and continuing to advance her diet. Sent home on \r\nacyclovir for fungal ppx, to start Bactrim SS for PCP ppx on \r\n___.  \r\n.\r\n#DVT: New, provoked. ___ in outpatient heme/onc office showed \r\nacute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis. Secondary to malignancy. Given lovenox in the \r\nclinic. Pt reported to be tachycardic and dyspneic in clinic, \r\nc/f PE was high. CTA chest negative for PE. IVC filter placed on \r\n___ by ___. Heparin drip discontinued ___ given falling \r\nplatelet count. Left lower extemity noted to be swollen more \r\nsignificantly than the right on ___, but dopplers showed only \r\nstable right leg clot. Thrombocytopenia resolved on ___, and \r\nshe was started on warfarin as well as lovenox sc at \r\nprophylactic dose. On ___ she was switched to lovenox sc at \r\ntreatment dose (100mg BID); will start on warfarin as outpatient \r\nat a later date, once diet and medications have stabilized.  \r\n.\r\n#Bilateral groin skin tears: skin tears in inguinal region \r\nbeneath panus c/b intertrigo/fungal infection. Developed prior \r\nto onset of neutropneia, started on vancomycin and micafungin + \r\ntopical fungal cream. Healed well with proper wound care. \r\nMicafungin and vancomycin discontinued once neutropenia \r\nresolved. \r\n.\r\nCHRONIC ISSUES: \r\n.\r\n# Back and L hip pain: has h/o L hip bursistis; no h/o sciatica. \r\nDescription of pain c/w musculoskeletal source, no concerning \r\nphysical exam findings. Symptoms fluctuated through course of \r\nstay based on patient positioning/activity level. \r\n.\r\n#Migranes: Patient reporting unilateral (right sided) headache \r\nwith photosensitivity and nausea on ___. Resolved on ___ \r\nafter receiving fioracet and ativan for nausea. \r\n.\r\n#Neuropathy: Stable, likely secondary to old sensory stroke. \r\nAlso has new numbness on fingertips bilaterally likely secondary \r\nto etoposide. Continued home gabapentin.\r\n.\r\n#H/o cerebral aneurysm: Stable. Discovered ___ years ago on MRA \r\nhead in right ICA cavernous sinus. S/p coiling ___ years ago. Has \r\nstable dysconjugate gaze/pupil asymmetry from the aneurysm.   \r\n.\r\n#Depression: Stable, continued on home venlafaxine.\r\n.\r\nTRANSTIONAL ISSUES: \r\n.\r\n# ANTICOAGULATION: discharged on lovenox; will continue for at \r\nleast 2 weeks while diet increases/she starts on bactrim, and \r\nthen be transitioned to warfarin as outpatient. \r\n.\r\n# PCP ___: to start ___ sent home w/script\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Furosemide 20 mg PO DAILY \r\n3. Gabapentin 900 mg PO BID \r\n4. Omeprazole 20 mg PO DAILY \r\n5. Ondansetron 8 mg PO Q8H:PRN nausea \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Gabapentin 900 mg PO BID \r\n3. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n4. Venlafaxine 25 mg PO BID \r\n5. Miconazole 2% Cream 1 Appl TP BID \r\nRX *miconazole nitrate [Antifungal Cream] 2 % apply to groin for \r\nrash three times a day Disp #*1 Tube Refills:*0\r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Furosemide 20 mg PO DAILY \r\n9. Ondansetron 8 mg PO Q8H:PRN nausea \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0\r\n12. Enoxaparin Sodium 100 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\nRX *enoxaparin 100 mg/mL 100 mg sc twice a day Disp #*14 Syringe \r\nRefills:*0\r\n13. OLANZapine (Disintegrating Tablet) 2.5 mg PO BID nausea \r\nRX *olanzapine 2.5 mg 1 tablet(s) by mouth twice a day Disp #*14 \r\nTablet Refills:*0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n# Primary: Diffuse Large B-Cell Lymphoma (DLBCL) \r\n\r\n# Secondary: Febrile Neutropenia, Deep Venous Thrombosis, \r\nDepression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear ___, \r\n\r\n___ was a pleasure taking care of you at the ___ \r\n___. You came in for an auto-stem cell \r\ntransplant (autSCT) for your Diffuse Large B-Cell Lymphoma \r\n(DLBCL). Just prior to admission you were found to have a deep \r\nvein thrombosis (DVT), for which you were started on lovenox and \r\nhad an inferior vena cava (IVC) filter placed on ___. You \r\nrecieved your autoSCT on ___. \r\n\r\nYour post-transplant course was complicated by fever, requiring \r\nantibiotics. These were discontinued without incident when your \r\nwhite blood cell counts had recovered. Lovenox was held when \r\nyour platelet count fell during chemotherapy. Anticoagulation \r\nwith lovenox was restarted on ___ when your platelet count had \r\nrecovered. \r\n\r\nYou will remain on viral prophylaxis with acyclovir for now, and \r\nstart PCP prophylaxis with ___ on ___.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-12:9",
      "text": "Discharge Instructions:\nDear ___, ___ was a pleasure taking care of you at the ___ \n___. You came in for an auto-stem cell \ntransplant (autSCT) for your Diffuse Large B-Cell Lymphoma \n(DLBCL). Just prior to admission you were found to have a deep \nvein thrombosis (DVT), for which you were started on lovenox and \nhad an inferior vena cava (IVC) filter placed on ___. You \nrecieved your autoSCT on ___. Your post-transplant course was complicated by fever, requiring \nantibiotics. These were discontinued without incident when your \nwhite blood cell counts had recovered. Lovenox was held when \nyour platelet count fell during chemotherapy. Anticoagulation \nwith lovenox was restarted on ___ when your platelet count had \nrecovered. You will remain on viral prophylaxis with acyclovir for now, and \nstart PCP prophylaxis with ___ on ___. Followup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-12",
        "chart_time": "103369",
        "section": "General",
        "position": 9,
        "tokenCount": 216,
        "note_metadata": {
          "note_id": "18887130-DS-12",
          "subject_id": 18887130,
          "hadm_id": 28224744,
          "note_type": "DS",
          "note_seq": 12,
          "charttime": 103369,
          "storetime": 103369.65416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nscheduled autologous transplant with BEAM conditioning\r\n \r\nMajor Surgical or Invasive Procedure:\r\n___: IVC filter placed\r\n___: auto-stem cell transplant\r\n\r\n \r\nHistory of Present Illness:\r\n___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. She was also reporting an \r\narea of right medial thigh erythema, tenderness and induration \r\nto the transplant nurse over the phone on ___. She had a \r\nscheduled outpatient appointment for pre-transplant lab work. \r\nShe had ___ at the outpatient heme/onc office which showed an \r\nacute right popliteal/ femoral DVT. \r\n\r\nStem cell collection period prolonged as counts slower to \r\nrecover than in the past.  Required addition of Mozibil with \r\nmuch improved stem cells collections with total yield of over 5 \r\nx 10(e)6 CD 3 cells/kg.  Her last PET CT showed almost a \r\ncomplete response with residual focus of avidity in the bed of \r\nthe abdominal mass.  She was evaluated by radiation oncology \r\nwith the plan for consolidative radiation therapy to be done \r\nfollowing her autologous transplant.  Echocardiogram on \r\n___ showed normal left ventricular wall thickness and \r\ncavity size with mildly depressed global systolic function with \r\nLVEF of 45%.  PFT's from ___ showed FVC of 66%, FEV1 of \r\n73%, TLC of 73% and DLCO of 93%.  Bone marrow aspirate and \r\nbiopsy on ___ showed no evidence for lymphoma but was \r\nnoted for a small mature lymphocyte clone that is a separate \r\nmalignancy of\r\nthe CLL phenotype.  She has no indication of this in her blood. \r\nAs her transformed lymphoma needs to be treated and is more life\r\nthreatening if left untreated, the decision was made to proceed\r\nwith the autologous transplant as planned.\r\n \r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access. Biopsies showed\r\nFollicular lymphomas grade II/III. Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new \r\nadenopathy. Labs notable for LDH 341, WBC 10.1, normal \r\ndifferential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal\r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric\r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ \r\nCD10+ lambda restricted. MIB and cytogenetics are pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clincally improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a \r\nresidual focus of avidity in the bed of the former abdominal \r\nmass, SUV ___ C4 Rituximab\r\n- PLANNED ___ C4 ICE followed by stem cell mobilization and \r\ncollection\r\n\r\n \r\nPast Medical History:\r\n--Transformed DLBCL with history of follicular lymphoma as noted\r\nabove. \r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia \r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM: \r\n.\r\nVITALS -  98.4, 126/62, 75, 18, 98% RA   weight: 238.2\r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, OP \r\nclear\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. Tender, erythematous corded vein on right medial \r\nmid-thigh. No cyanosis, clubbing or edema. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. Gait not assessed.\r\n.\r\nDISCHARGE EXAM: \r\n.\r\nVITALS -  97.5 118/78 104 18 99% RA  \r\nI/O yesterday (24hr): 1.4/0.9 (no BMs) \r\nGeneral: Alert, oriented x3, lying in bed in NAD\r\nHEENT: Normocephalic. Sclerae anicteric. PERRL, EOMI, MMM, no \r\nlesions\r\nNeck: Supple, no ___, no thyromegaly\r\nCV: RRR, normal S1/ S2, ___ systolic murmur heard best at the \r\napex, no rubs or gallops\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended. Normal bowel sounds. No \r\nrebound or guarding. No masses or organomegaly.\r\nGU: no foley; healed skin tears in inguinal region; pink, no \r\npurulence, no surrounding errythema, IMPROVED \r\nExt: WWP, pulses 2+. Chronic venous stasis changes on both lower \r\nlegs, R>L. 2+ pitting edema ___ at ankles, L>R. No cyanosis or \r\nclubbing. L hip TTP, no masses, errhtyema, warmth. \r\nNeuro: Exam nonfocal. CN ___ grossly intact. normal gait\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS: \r\n---------------\r\n___ 10:45AM   UREA N-11 CREAT-0.8 SODIUM-137 POTASSIUM-4.3 \r\nCHLORIDE-101 TOTAL CO2-26 ANION GAP-14\r\n___ 10:45AM   estGFR-Using this\r\n___ 10:45AM   ALT(SGPT)-12 AST(SGOT)-20 LD(LDH)-341* ALK \r\nPHOS-153* TOT BILI-0.2\r\n___ 10:45AM   TOT PROT-6.2* ALBUMIN-4.0 GLOBULIN-2.2 \r\nCALCIUM-8.6 PHOSPHATE-3.5 MAGNESIUM-2.1 URIC ACID-3.9\r\n___ 10:45AM   WBC-8.6# RBC-2.61* HGB-8.2* HCT-25.5* MCV-98 \r\nMCH-31.3 MCHC-32.0 RDW-24.1*\r\n___ 10:45AM   NEUTS-83.2* LYMPHS-7.0* MONOS-9.5 EOS-0.1 \r\nBASOS-0.2\r\n___ 10:45AM   PLT COUNT-281#\r\n___ 10:45AM   ___ PTT-29.1 ___\r\n.\r\nIMAGING: \r\n----------\r\n___ ___ Dopplers IMPRESSION:   \r\n1.  Acute deep venous thrombosis of the right femoral and \r\npopliteal veins.   2.  No evidence of deep vein thrombosis in \r\nthe left lower extremity.\r\n. \r\n___ CTA Chest: 1.  No pulmonary embolus demonstrated.  \r\n2.  Enlargement of the main pulmonary artery as seen on the \r\nprior examination ___.  This may reflect pulmonary \r\narterial hypertension.   \r\n.\r\n___ ___ Dopplers IMPRESSION: \r\n1.  No evidence of DVT in the left lower extremity.  Assessment \r\nof left calf veins is limited.   2.  Similar distribution of \r\nthrombus in the right lower extremity involving the right mid \r\nand distal femoral vein and popliteal vein.\r\n.   \r\nDISCHARGE LABS: \r\n---------------\r\n___ 12:04AM BLOOD WBC-4.2 RBC-2.62* Hgb-8.1* Hct-25.7* \r\nMCV-98 MCH-30.8 MCHC-31.4 RDW-20.3* Plt ___\r\n___ 12:04AM BLOOD Neuts-59 Bands-0 Lymphs-12* Monos-26* \r\nEos-0 Baso-0 Atyps-2* ___ Myelos-1*\r\n___ 12:04AM BLOOD Hypochr-1+ Anisocy-2+ Poiklo-1+ \r\nMacrocy-3+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-1+\r\n___ 12:04AM BLOOD Plt Smr-LOW Plt ___\r\n___ 12:04AM BLOOD Glucose-103* UreaN-9 Creat-0.7 Na-138 \r\nK-3.7 Cl-103 HCO3-26 AnGap-13\r\n___ 12:04AM BLOOD ALT-15 AST-20 LD(LDH)-219 AlkPhos-81 \r\nTotBili-0.3\r\n___ 12:04AM BLOOD Albumin-3.5 Calcium-8.2* Phos-3.5 Mg-1.___ with transformed DLBCL and h/o follicular lymphoma \r\npresenting for a scheduled autoSCT. \r\n.\r\nACUTE ISSUES: \r\n.\r\n#Diffuse Large B-Cell Lymphoma (DLBCL): transformed from \r\nfollicular lyphoma. Underwent BEAM conditioning followed by \r\nscheduled autoSCT on ___. Post-transplant course complicated by \r\nfebrile neutropenia, for which she was on cefepime, vancomycin \r\nand micafungin (to cover inguinal skin wounds). Recieved 5U \r\nPRBCs and 5U platelets to maintain hct > 21 and plts > 10. She \r\nwas on PCA for a period of time for mucositis. Neutropenia \r\nresolved on ___, at which point antibiotics and G-CSF were \r\ndiscontinued. Patient was able to advance diet slowly as \r\nmucositis resolved; by discharge she was taking excellent PO \r\nhydration and continuing to advance her diet. Sent home on \r\nacyclovir for fungal ppx, to start Bactrim SS for PCP ppx on \r\n___.  \r\n.\r\n#DVT: New, provoked. ___ in outpatient heme/onc office showed \r\nacute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis. Secondary to malignancy. Given lovenox in the \r\nclinic. Pt reported to be tachycardic and dyspneic in clinic, \r\nc/f PE was high. CTA chest negative for PE. IVC filter placed on \r\n___ by ___. Heparin drip discontinued ___ given falling \r\nplatelet count. Left lower extemity noted to be swollen more \r\nsignificantly than the right on ___, but dopplers showed only \r\nstable right leg clot. Thrombocytopenia resolved on ___, and \r\nshe was started on warfarin as well as lovenox sc at \r\nprophylactic dose. On ___ she was switched to lovenox sc at \r\ntreatment dose (100mg BID); will start on warfarin as outpatient \r\nat a later date, once diet and medications have stabilized.  \r\n.\r\n#Bilateral groin skin tears: skin tears in inguinal region \r\nbeneath panus c/b intertrigo/fungal infection. Developed prior \r\nto onset of neutropneia, started on vancomycin and micafungin + \r\ntopical fungal cream. Healed well with proper wound care. \r\nMicafungin and vancomycin discontinued once neutropenia \r\nresolved. \r\n.\r\nCHRONIC ISSUES: \r\n.\r\n# Back and L hip pain: has h/o L hip bursistis; no h/o sciatica. \r\nDescription of pain c/w musculoskeletal source, no concerning \r\nphysical exam findings. Symptoms fluctuated through course of \r\nstay based on patient positioning/activity level. \r\n.\r\n#Migranes: Patient reporting unilateral (right sided) headache \r\nwith photosensitivity and nausea on ___. Resolved on ___ \r\nafter receiving fioracet and ativan for nausea. \r\n.\r\n#Neuropathy: Stable, likely secondary to old sensory stroke. \r\nAlso has new numbness on fingertips bilaterally likely secondary \r\nto etoposide. Continued home gabapentin.\r\n.\r\n#H/o cerebral aneurysm: Stable. Discovered ___ years ago on MRA \r\nhead in right ICA cavernous sinus. S/p coiling ___ years ago. Has \r\nstable dysconjugate gaze/pupil asymmetry from the aneurysm.   \r\n.\r\n#Depression: Stable, continued on home venlafaxine.\r\n.\r\nTRANSTIONAL ISSUES: \r\n.\r\n# ANTICOAGULATION: discharged on lovenox; will continue for at \r\nleast 2 weeks while diet increases/she starts on bactrim, and \r\nthen be transitioned to warfarin as outpatient. \r\n.\r\n# PCP ___: to start ___ sent home w/script\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Furosemide 20 mg PO DAILY \r\n3. Gabapentin 900 mg PO BID \r\n4. Omeprazole 20 mg PO DAILY \r\n5. Ondansetron 8 mg PO Q8H:PRN nausea \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Gabapentin 900 mg PO BID \r\n3. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n4. Venlafaxine 25 mg PO BID \r\n5. Miconazole 2% Cream 1 Appl TP BID \r\nRX *miconazole nitrate [Antifungal Cream] 2 % apply to groin for \r\nrash three times a day Disp #*1 Tube Refills:*0\r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Furosemide 20 mg PO DAILY \r\n9. Ondansetron 8 mg PO Q8H:PRN nausea \r\n10. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0\r\n12. Enoxaparin Sodium 100 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\nRX *enoxaparin 100 mg/mL 100 mg sc twice a day Disp #*14 Syringe \r\nRefills:*0\r\n13. OLANZapine (Disintegrating Tablet) 2.5 mg PO BID nausea \r\nRX *olanzapine 2.5 mg 1 tablet(s) by mouth twice a day Disp #*14 \r\nTablet Refills:*0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n# Primary: Diffuse Large B-Cell Lymphoma (DLBCL) \r\n\r\n# Secondary: Febrile Neutropenia, Deep Venous Thrombosis, \r\nDepression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear ___, \r\n\r\n___ was a pleasure taking care of you at the ___ \r\n___. You came in for an auto-stem cell \r\ntransplant (autSCT) for your Diffuse Large B-Cell Lymphoma \r\n(DLBCL). Just prior to admission you were found to have a deep \r\nvein thrombosis (DVT), for which you were started on lovenox and \r\nhad an inferior vena cava (IVC) filter placed on ___. You \r\nrecieved your autoSCT on ___. \r\n\r\nYour post-transplant course was complicated by fever, requiring \r\nantibiotics. These were discontinued without incident when your \r\nwhite blood cell counts had recovered. Lovenox was held when \r\nyour platelet count fell during chemotherapy. Anticoagulation \r\nwith lovenox was restarted on ___ when your platelet count had \r\nrecovered. \r\n\r\nYou will remain on viral prophylaxis with acyclovir for now, and \r\nstart PCP prophylaxis with ___ on ___.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-13:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \nNo Known Allergies / Adverse Drug Reactions\n \nAttending: ___\n \n___ Complaint:\nFever\n \nMajor Surgical or Invasive Procedure:\nNone",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-13",
        "chart_time": "103398",
        "section": "General",
        "position": 0,
        "tokenCount": 77,
        "note_metadata": {
          "note_id": "18887130-DS-13",
          "subject_id": 18887130,
          "hadm_id": 28298007,
          "note_type": "DS",
          "note_seq": 13,
          "charttime": 103398,
          "storetime": 103398.76319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nFever\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with a history of transformed lymphoma s/p \r\nautoSCT 44 days ago as well as comorbid CVID and CLL, who \r\nreceived IVIg for immunodeficiency on the day prior to \r\nadmission. Today, she had a headache, rigors, and fever to \r\n100.5. She also reported general malaise. Patient has an \r\nindwelling catheter and IVC filter in place. She presented to \r\n___, where blood cultures x 2, urinalysis and urine \r\nculture were performed. She received empiric vancomycin and \r\ncefepime 2 grams IV as well as oseltamivir, flu swab pending. \r\nCXR at ___ showed no evidence of pneumonia. Urinalysis \r\nwas negative for evidence of infection. \r\n\r\nIn the ED, initial vitals were 102.4 ___ 18 94%. Labs at \r\n___ showed WBC count 8.8K with 89% neutrophils, \r\nhematocrit 28.2, platelets 104K. INR was 1.3. Anion gap was 13. \r\nCT head showed no acute intracranial abnormality. Patient \r\nreceived ondansetron 2 mg IV x 1, metoclopramide 5 mg IV x 1, \r\nand hydromorphone 2 mg IV x 1. Lumbar puncture was not attempted \r\ndue to patient being on rivaroxaban, and it was recommended he \r\nstart empiric IV acyclovir and he got one dose. Vitals on \r\ntransfer were 101.7 106 122/56 18 94% RA. \r\n\r\nOn the floor, patient notes diffuse headache with some neck \r\ndiscomfort and stiffness, as well as photophobia. This headache \r\nis different than migraines she has had in the past. She has \r\nalso been nauseous and vomited several times, non-bloody, \r\nnon-bilious. \r\n\r\nReview of sytems: \r\n(+) Per HPI \r\n(-) Denies recent weight loss or gain. Denies headache, sinus \r\ntenderness, rhinorrhea or congestion. Denies cough, shortness of \r\nbreath. Denies chest pain or tightness, palpitations. Denies \r\ndiarrhea, constipation or abdominal pain. No recent change in \r\nbowel or bladder habits. No dysuria. Denies arthralgias. Ten \r\npoint review of systems is otherwise negative. \r\n\r\n \r\nPast Medical History:\r\nONCOLOGIC HISTORY: \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n___: Transplant Date: 1 \r\n___: Day Post Transplant: 44 \r\n___: Graft: Auto \r\n___: Conditioning Intensity: Ablative \r\n___: Conditioning Regimen: BEAM \r\n\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass \r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access. Biopsies showed \r\nFollicular lymphomas grade II/III. Reportedly negative staging \r\nGallium scan. CD10+ BCL2+ \r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA) \r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone \r\nmarrow at completion was negative for lymphomatous involvement. \r\n- ___ PET-CT with very slight amount of increased tracer \r\nactivity within the posterior left supraclavicular region. No \r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP \r\nfollowed by course of single agent Rituxan \r\n- ___ through ___ surveillance imaging with no evidence of \r\nrecurrent disease, stable mesenteric mass. \r\n- ___ abdominal pain led to CT with no change in mass size, \r\nincreased conspicuity of nodular borders \r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise \r\n\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior. \r\n- ___ CT torso showed persistent mesenteric and left hilar \r\nlymphadenopathy. Stable right middle lobe small focus of ground \r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive \r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam \r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1, \r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal \r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning \r\nfor \r\nlymphoma.\" SUVmax 35.5. \r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare \r\npending \r\n- ___ C1D1 ICE \r\n- ___ C1 Rituximab, clincally improved adenopathy \r\n- ___ C2 Rituximab, WBC 6.5, PLT 43 \r\n- ___ Admit for C2D1 ICE \r\n- ___ C3 Rituximab \r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a residual focus of avidity in the bed of the \r\nformer \r\nabdominal mass, SUV 3 \r\n- ___ C4 Rituximab \r\n- ___ C4 ICE followed by stem cell mobilization and \r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive \r\nlymphoma \r\n- ___ Presented with large DVTs, SVC filter placed \r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis \r\n- ___ Switched to Rivaroxiban for AC \r\n- ___. Interval decrease in size of \r\nretroperitoneal lymphadenopathy, with persistent low-level FDG \r\nuptake. No new FDG-avid disease. 2. Resolution of cervical, \r\nsupraclavicular and mediastinal lymphadenopathy. 3. IVC filter \r\nin place, new since the prior PET-CT. 4. Stable non-FDG avid \r\nright adnexal hypodensity. PFTs with normal Hb adjusted DLCO \r\n- ___ IVIg 400 mg/kg \r\n\r\nPAST MEDICAL HISTORY: \r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\n\r\nabove. \r\n--CLL, noted on BM biopsy on ___. \r\n--Deep venous thrombosis \r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye) \r\n--Hypogammaglobulinemia \r\n--Mild GERD \r\n--OA / LBP \r\n--Small Intestinal Bacterial Overgrowth \r\n--Trochanteric Bursitis \r\n--s/p Excisional Bx L Cervical Lymph Node \r\n--s/p L total knee replacement ___, walks with cane \r\n--s/p I&D Labial Abscess \r\n--s/p Excision Cyst R ___ Digit of Hand \r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n--------------\r\nVitals: T: 101.8 BP: 130/84 P: 113 R: 18 O2: 94% on RA \r\nGEN: Alert, oriented to name, place and situation. Fatigued \r\nappearing but comfortable, no acute signs of distress. \r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MM dry. \r\nNeck: Supple, no JVD \r\nLymph nodes: No cervical, supraclavicular LAD. \r\nCV: S1S2, tachycardic but regular, no murmurs, rubs or gallops. \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing. \r\nABD: Soft, non-tender, non-distended, + bowel sounds. \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient. \r\nDERM: No active rash. Indwelling catheter in right chest, with \r\nmild erythema, no fluctuance, reportedly unchanged. \r\nNeuro: non-focal. \r\nPSYCH: Appropriate and calm. \r\n\r\nDISCHARGE EXAM\r\n--------------\r\nVitals:  98.___.4 125/62 88 18 97% RA\r\nGEN: Alert, oriented. NAD, looks well today\r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MMM.  \r\nNeck: Supple, no JVD  \r\nLymph nodes: No cervical, supraclavicular LAD.  \r\nCV: S1S2, RRR, no murmurs, rubs or gallops.  \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing.  \r\nABD: Soft, non-tender, non-distended, + bowel sounds.  \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient.  \r\nDERM: Indwelling catheter in right chest without acute signs of \r\ninfxn. \r\nNeuro: non-focal.  \r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n--------------\r\n___ 06:25AM BLOOD WBC-10.0# RBC-2.70* Hgb-8.9* Hct-28.6* \r\nMCV-106* MCH-32.9* MCHC-31.1 RDW-21.3* Plt ___\r\n___ 06:25AM BLOOD ___ PTT-33.1 ___\r\n___ 06:25AM BLOOD Glucose-118* UreaN-9 Creat-0.8 Na-137 \r\nK-3.5 Cl-103 HCO3-24 AnGap-14\r\n___ 06:25AM BLOOD ALT-13 AST-24 LD(LDH)-174 AlkPhos-72 \r\nTotBili-0.3\r\n___ 06:25AM BLOOD Calcium-8.5 Phos-2.7 Mg-1.7\r\n\r\nDISCHARGE LABS\r\n--------------\r\n___ 06:00AM BLOOD WBC-2.2* RBC-2.41* Hgb-8.1* Hct-25.9* \r\nMCV-107* MCH-33.6* MCHC-31.3 RDW-21.0* Plt Ct-78*\r\n___ 06:00AM BLOOD Glucose-91 UreaN-9 Creat-0.6 Na-140 K-4.0 \r\nCl-110* HCO3-25 AnGap-9\r\n___ 06:00AM BLOOD Calcium-8.2* Phos-2.5* Mg-2.1\r\n\r\nPENDING LABS\r\n--------------\r\n___ 11:57AM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-PND\r\n___ 11:57 am CMV Viral Load (Pending)\r\n \r\nBrief Hospital Course:\r\n___ with DVT s/p IVC filter and on rivaroxaban, CLL, CVID, and \r\ntransformed lymphoma s/p autoSCT 44 days ago, and IVIG ___, \r\nwho now presented with headache, fevers/rigors, and vomiting.\r\n\r\n# FEVER, HEADACHE, VOMITING: These symptoms occured within 12 \r\nhours of finishing her last infusion of IVIG. Etiology is most \r\nlikely aseptic meningitis as she also had neck stiffness and \r\nsome mild photophobia. Her symptoms improved with supportive IV \r\nfluids, anti-emetics, and NSAIDs. At first she was started \r\nempirically on IV Vanc, IV cefepime, IV acyclovir, and Tamiflu \r\nto treat possible bacterial or HSV meningitis or influenza. \r\nRapid flu screen was negative so Tamiflu was stopped. She had no \r\nencephalitis and was on ppx acyclovir prior to presentation, so \r\nsuspicion of HSV meningoencephalitis was very low so IV \r\nacyclovir was stopped. Once ___ blood cultures were \r\nnegative >24 hours, IV antibiotics were also stopped. The \r\npatient continued to improve and was afebrile > 24 hrs prior to \r\ndischarge. \r\n\r\n# LYMPHOMA: s/p auto-stem cell transplant 44 days prior to \r\nadmission. She was continued on ppx bactrim and acyclovir. She \r\nwill f/u with her outpatient providers.\r\n\r\n# H/o DVT: Rivaroxaban was held while inpatient since we were at \r\nfirst considering lumbar puncture. It was restarted on \r\ndischarge. \r\n\r\nTRANSITIONAL ISSUES:\r\n--------------------\r\n# F/u CMV and EBV viral loads\r\n# Code status: Full \r\n# Contact: husband ___, ___ \r\n\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Rivaroxaban 15 mg PO DAILY \r\n9. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Multivitamins 1 TAB PO DAILY \r\n4. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n5. Gabapentin 900 mg PO BID \r\n6. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n7. Venlafaxine 25 mg PO BID \r\n8. Metoclopramide 10 mg PO TID:PRN nausea \r\nRX *metoclopramide HCl 10 mg 1 tablet by mouth Up to three times \r\nper day Disp #*15 Tablet Refills:*0\r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n10. Furosemide 20 mg PO DAILY \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Potassium Chloride 10 mEq PO DAILY \r\n13. Rivaroxaban 15 mg PO DAILY \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS:\r\nIVIG Aseptic meningitis\r\n\r\nSECONDARY DIAGNOSIS:\r\ntransformed lymphoma s/p auto stem cell transplant\r\nCVID\r\nNeutropenia\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted to the hospital for high fevers, headache, and \r\nvomiting. We are not sure what caused your symptoms, but the \r\nmost likely cause is IVIG-associated aseptic meningitis. Another \r\ncause may be a viral infection. We felt it was very unlikely you \r\nhad a bacterial infection so we stopped your antibiotics. You \r\ncontinued to improve. Your fevers and headaches improved. Your \r\nvomiting was well-controlled on medications. And you were able \r\nto tolerate enough hydration by mouth and no longer needed IVs, \r\nso you were discharged home with plans to follow up with Dr. \r\n___ Dr. ___.\r\n\r\nIt was a pleasure to take care of you during your hospital stay,\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-13:1",
      "text": "transfer were 101.7 106 122/56 18 94% RA.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-13",
        "chart_time": "103398",
        "section": "Vital signs",
        "position": 1,
        "tokenCount": 11,
        "vitals": {
          "tempF": 101.7,
          "bpSys": 122,
          "bpDia": 56,
          "onRoomAir": true,
          "oxygenDevice": "Room air",
          "chunkIndex": 1,
          "section": "Vital signs",
          "sourceText": "transfer were 101.7 106 122/56 18 94% RA."
        },
        "note_metadata": {
          "note_id": "18887130-DS-13",
          "subject_id": 18887130,
          "hadm_id": 28298007,
          "note_type": "DS",
          "note_seq": 13,
          "charttime": 103398,
          "storetime": 103398.76319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nFever\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with a history of transformed lymphoma s/p \r\nautoSCT 44 days ago as well as comorbid CVID and CLL, who \r\nreceived IVIg for immunodeficiency on the day prior to \r\nadmission. Today, she had a headache, rigors, and fever to \r\n100.5. She also reported general malaise. Patient has an \r\nindwelling catheter and IVC filter in place. She presented to \r\n___, where blood cultures x 2, urinalysis and urine \r\nculture were performed. She received empiric vancomycin and \r\ncefepime 2 grams IV as well as oseltamivir, flu swab pending. \r\nCXR at ___ showed no evidence of pneumonia. Urinalysis \r\nwas negative for evidence of infection. \r\n\r\nIn the ED, initial vitals were 102.4 ___ 18 94%. Labs at \r\n___ showed WBC count 8.8K with 89% neutrophils, \r\nhematocrit 28.2, platelets 104K. INR was 1.3. Anion gap was 13. \r\nCT head showed no acute intracranial abnormality. Patient \r\nreceived ondansetron 2 mg IV x 1, metoclopramide 5 mg IV x 1, \r\nand hydromorphone 2 mg IV x 1. Lumbar puncture was not attempted \r\ndue to patient being on rivaroxaban, and it was recommended he \r\nstart empiric IV acyclovir and he got one dose. Vitals on \r\ntransfer were 101.7 106 122/56 18 94% RA. \r\n\r\nOn the floor, patient notes diffuse headache with some neck \r\ndiscomfort and stiffness, as well as photophobia. This headache \r\nis different than migraines she has had in the past. She has \r\nalso been nauseous and vomited several times, non-bloody, \r\nnon-bilious. \r\n\r\nReview of sytems: \r\n(+) Per HPI \r\n(-) Denies recent weight loss or gain. Denies headache, sinus \r\ntenderness, rhinorrhea or congestion. Denies cough, shortness of \r\nbreath. Denies chest pain or tightness, palpitations. Denies \r\ndiarrhea, constipation or abdominal pain. No recent change in \r\nbowel or bladder habits. No dysuria. Denies arthralgias. Ten \r\npoint review of systems is otherwise negative. \r\n\r\n \r\nPast Medical History:\r\nONCOLOGIC HISTORY: \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n___: Transplant Date: 1 \r\n___: Day Post Transplant: 44 \r\n___: Graft: Auto \r\n___: Conditioning Intensity: Ablative \r\n___: Conditioning Regimen: BEAM \r\n\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass \r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access. Biopsies showed \r\nFollicular lymphomas grade II/III. Reportedly negative staging \r\nGallium scan. CD10+ BCL2+ \r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA) \r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone \r\nmarrow at completion was negative for lymphomatous involvement. \r\n- ___ PET-CT with very slight amount of increased tracer \r\nactivity within the posterior left supraclavicular region. No \r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP \r\nfollowed by course of single agent Rituxan \r\n- ___ through ___ surveillance imaging with no evidence of \r\nrecurrent disease, stable mesenteric mass. \r\n- ___ abdominal pain led to CT with no change in mass size, \r\nincreased conspicuity of nodular borders \r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise \r\n\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior. \r\n- ___ CT torso showed persistent mesenteric and left hilar \r\nlymphadenopathy. Stable right middle lobe small focus of ground \r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive \r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam \r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1, \r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal \r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning \r\nfor \r\nlymphoma.\" SUVmax 35.5. \r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare \r\npending \r\n- ___ C1D1 ICE \r\n- ___ C1 Rituximab, clincally improved adenopathy \r\n- ___ C2 Rituximab, WBC 6.5, PLT 43 \r\n- ___ Admit for C2D1 ICE \r\n- ___ C3 Rituximab \r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a residual focus of avidity in the bed of the \r\nformer \r\nabdominal mass, SUV 3 \r\n- ___ C4 Rituximab \r\n- ___ C4 ICE followed by stem cell mobilization and \r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive \r\nlymphoma \r\n- ___ Presented with large DVTs, SVC filter placed \r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis \r\n- ___ Switched to Rivaroxiban for AC \r\n- ___. Interval decrease in size of \r\nretroperitoneal lymphadenopathy, with persistent low-level FDG \r\nuptake. No new FDG-avid disease. 2. Resolution of cervical, \r\nsupraclavicular and mediastinal lymphadenopathy. 3. IVC filter \r\nin place, new since the prior PET-CT. 4. Stable non-FDG avid \r\nright adnexal hypodensity. PFTs with normal Hb adjusted DLCO \r\n- ___ IVIg 400 mg/kg \r\n\r\nPAST MEDICAL HISTORY: \r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\n\r\nabove. \r\n--CLL, noted on BM biopsy on ___. \r\n--Deep venous thrombosis \r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye) \r\n--Hypogammaglobulinemia \r\n--Mild GERD \r\n--OA / LBP \r\n--Small Intestinal Bacterial Overgrowth \r\n--Trochanteric Bursitis \r\n--s/p Excisional Bx L Cervical Lymph Node \r\n--s/p L total knee replacement ___, walks with cane \r\n--s/p I&D Labial Abscess \r\n--s/p Excision Cyst R ___ Digit of Hand \r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n--------------\r\nVitals: T: 101.8 BP: 130/84 P: 113 R: 18 O2: 94% on RA \r\nGEN: Alert, oriented to name, place and situation. Fatigued \r\nappearing but comfortable, no acute signs of distress. \r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MM dry. \r\nNeck: Supple, no JVD \r\nLymph nodes: No cervical, supraclavicular LAD. \r\nCV: S1S2, tachycardic but regular, no murmurs, rubs or gallops. \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing. \r\nABD: Soft, non-tender, non-distended, + bowel sounds. \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient. \r\nDERM: No active rash. Indwelling catheter in right chest, with \r\nmild erythema, no fluctuance, reportedly unchanged. \r\nNeuro: non-focal. \r\nPSYCH: Appropriate and calm. \r\n\r\nDISCHARGE EXAM\r\n--------------\r\nVitals:  98.___.4 125/62 88 18 97% RA\r\nGEN: Alert, oriented. NAD, looks well today\r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MMM.  \r\nNeck: Supple, no JVD  \r\nLymph nodes: No cervical, supraclavicular LAD.  \r\nCV: S1S2, RRR, no murmurs, rubs or gallops.  \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing.  \r\nABD: Soft, non-tender, non-distended, + bowel sounds.  \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient.  \r\nDERM: Indwelling catheter in right chest without acute signs of \r\ninfxn. \r\nNeuro: non-focal.  \r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n--------------\r\n___ 06:25AM BLOOD WBC-10.0# RBC-2.70* Hgb-8.9* Hct-28.6* \r\nMCV-106* MCH-32.9* MCHC-31.1 RDW-21.3* Plt ___\r\n___ 06:25AM BLOOD ___ PTT-33.1 ___\r\n___ 06:25AM BLOOD Glucose-118* UreaN-9 Creat-0.8 Na-137 \r\nK-3.5 Cl-103 HCO3-24 AnGap-14\r\n___ 06:25AM BLOOD ALT-13 AST-24 LD(LDH)-174 AlkPhos-72 \r\nTotBili-0.3\r\n___ 06:25AM BLOOD Calcium-8.5 Phos-2.7 Mg-1.7\r\n\r\nDISCHARGE LABS\r\n--------------\r\n___ 06:00AM BLOOD WBC-2.2* RBC-2.41* Hgb-8.1* Hct-25.9* \r\nMCV-107* MCH-33.6* MCHC-31.3 RDW-21.0* Plt Ct-78*\r\n___ 06:00AM BLOOD Glucose-91 UreaN-9 Creat-0.6 Na-140 K-4.0 \r\nCl-110* HCO3-25 AnGap-9\r\n___ 06:00AM BLOOD Calcium-8.2* Phos-2.5* Mg-2.1\r\n\r\nPENDING LABS\r\n--------------\r\n___ 11:57AM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-PND\r\n___ 11:57 am CMV Viral Load (Pending)\r\n \r\nBrief Hospital Course:\r\n___ with DVT s/p IVC filter and on rivaroxaban, CLL, CVID, and \r\ntransformed lymphoma s/p autoSCT 44 days ago, and IVIG ___, \r\nwho now presented with headache, fevers/rigors, and vomiting.\r\n\r\n# FEVER, HEADACHE, VOMITING: These symptoms occured within 12 \r\nhours of finishing her last infusion of IVIG. Etiology is most \r\nlikely aseptic meningitis as she also had neck stiffness and \r\nsome mild photophobia. Her symptoms improved with supportive IV \r\nfluids, anti-emetics, and NSAIDs. At first she was started \r\nempirically on IV Vanc, IV cefepime, IV acyclovir, and Tamiflu \r\nto treat possible bacterial or HSV meningitis or influenza. \r\nRapid flu screen was negative so Tamiflu was stopped. She had no \r\nencephalitis and was on ppx acyclovir prior to presentation, so \r\nsuspicion of HSV meningoencephalitis was very low so IV \r\nacyclovir was stopped. Once ___ blood cultures were \r\nnegative >24 hours, IV antibiotics were also stopped. The \r\npatient continued to improve and was afebrile > 24 hrs prior to \r\ndischarge. \r\n\r\n# LYMPHOMA: s/p auto-stem cell transplant 44 days prior to \r\nadmission. She was continued on ppx bactrim and acyclovir. She \r\nwill f/u with her outpatient providers.\r\n\r\n# H/o DVT: Rivaroxaban was held while inpatient since we were at \r\nfirst considering lumbar puncture. It was restarted on \r\ndischarge. \r\n\r\nTRANSITIONAL ISSUES:\r\n--------------------\r\n# F/u CMV and EBV viral loads\r\n# Code status: Full \r\n# Contact: husband ___, ___ \r\n\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Rivaroxaban 15 mg PO DAILY \r\n9. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Multivitamins 1 TAB PO DAILY \r\n4. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n5. Gabapentin 900 mg PO BID \r\n6. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n7. Venlafaxine 25 mg PO BID \r\n8. Metoclopramide 10 mg PO TID:PRN nausea \r\nRX *metoclopramide HCl 10 mg 1 tablet by mouth Up to three times \r\nper day Disp #*15 Tablet Refills:*0\r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n10. Furosemide 20 mg PO DAILY \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Potassium Chloride 10 mEq PO DAILY \r\n13. Rivaroxaban 15 mg PO DAILY \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS:\r\nIVIG Aseptic meningitis\r\n\r\nSECONDARY DIAGNOSIS:\r\ntransformed lymphoma s/p auto stem cell transplant\r\nCVID\r\nNeutropenia\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted to the hospital for high fevers, headache, and \r\nvomiting. We are not sure what caused your symptoms, but the \r\nmost likely cause is IVIG-associated aseptic meningitis. Another \r\ncause may be a viral infection. We felt it was very unlikely you \r\nhad a bacterial infection so we stopped your antibiotics. You \r\ncontinued to improve. Your fevers and headaches improved. Your \r\nvomiting was well-controlled on medications. And you were able \r\nto tolerate enough hydration by mouth and no longer needed IVs, \r\nso you were discharged home with plans to follow up with Dr. \r\n___ Dr. ___.\r\n\r\nIt was a pleasure to take care of you during your hospital stay,\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-13:2",
      "text": "History of Present Illness:\n___ year old female with a history of transformed lymphoma s/p \nautoSCT 44 days ago as well as comorbid CVID and CLL, who \nreceived IVIg for immunodeficiency on the day prior to \nadmission. Today, she had a headache, rigors, and fever to \n100.5. She also reported general malaise. Patient has an \nindwelling catheter and IVC filter in place. She presented to \n___, where blood cultures x 2, urinalysis and urine \nculture were performed. She received empiric vancomycin and \ncefepime 2 grams IV as well as oseltamivir, flu swab pending. CXR at ___ showed no evidence of pneumonia. Urinalysis \nwas negative for evidence of infection. In the ED, initial vitals were 102.4 ___ 18 94%. Labs at \n___ showed WBC count 8.8K with 89% neutrophils, \nhematocrit 28.2, platelets 104K. INR was 1.3. Anion gap was 13. CT head showed no acute intracranial abnormality. Patient \nreceived ondansetron 2 mg IV x 1, metoclopramide 5 mg IV x 1, \nand hydromorphone 2 mg IV x 1. Lumbar puncture was not attempted \ndue to patient being on rivaroxaban, and it was recommended he \nstart empiric IV acyclovir and he got one dose. Vitals on On the floor, patient notes diffuse headache with some neck \ndiscomfort and stiffness, as well as photophobia. This headache \nis different than migraines she has had in the past. She has \nalso been nauseous and vomited several times, non-bloody, \nnon-bilious. Review of sytems: \n(+) Per HPI \n(-) Denies recent weight loss or gain. Denies headache, sinus \ntenderness, rhinorrhea or congestion. Denies cough, shortness of \nbreath. Denies chest pain or tightness, palpitations. Denies \ndiarrhea, constipation or abdominal pain. No recent change in \nbowel or bladder habits. No dysuria. Denies arthralgias. Ten \npoint review of systems is otherwise negative.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-13",
        "chart_time": "103398",
        "section": "General",
        "position": 2,
        "tokenCount": 449,
        "note_metadata": {
          "note_id": "18887130-DS-13",
          "subject_id": 18887130,
          "hadm_id": 28298007,
          "note_type": "DS",
          "note_seq": 13,
          "charttime": 103398,
          "storetime": 103398.76319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nFever\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with a history of transformed lymphoma s/p \r\nautoSCT 44 days ago as well as comorbid CVID and CLL, who \r\nreceived IVIg for immunodeficiency on the day prior to \r\nadmission. Today, she had a headache, rigors, and fever to \r\n100.5. She also reported general malaise. Patient has an \r\nindwelling catheter and IVC filter in place. She presented to \r\n___, where blood cultures x 2, urinalysis and urine \r\nculture were performed. She received empiric vancomycin and \r\ncefepime 2 grams IV as well as oseltamivir, flu swab pending. \r\nCXR at ___ showed no evidence of pneumonia. Urinalysis \r\nwas negative for evidence of infection. \r\n\r\nIn the ED, initial vitals were 102.4 ___ 18 94%. Labs at \r\n___ showed WBC count 8.8K with 89% neutrophils, \r\nhematocrit 28.2, platelets 104K. INR was 1.3. Anion gap was 13. \r\nCT head showed no acute intracranial abnormality. Patient \r\nreceived ondansetron 2 mg IV x 1, metoclopramide 5 mg IV x 1, \r\nand hydromorphone 2 mg IV x 1. Lumbar puncture was not attempted \r\ndue to patient being on rivaroxaban, and it was recommended he \r\nstart empiric IV acyclovir and he got one dose. Vitals on \r\ntransfer were 101.7 106 122/56 18 94% RA. \r\n\r\nOn the floor, patient notes diffuse headache with some neck \r\ndiscomfort and stiffness, as well as photophobia. This headache \r\nis different than migraines she has had in the past. She has \r\nalso been nauseous and vomited several times, non-bloody, \r\nnon-bilious. \r\n\r\nReview of sytems: \r\n(+) Per HPI \r\n(-) Denies recent weight loss or gain. Denies headache, sinus \r\ntenderness, rhinorrhea or congestion. Denies cough, shortness of \r\nbreath. Denies chest pain or tightness, palpitations. Denies \r\ndiarrhea, constipation or abdominal pain. No recent change in \r\nbowel or bladder habits. No dysuria. Denies arthralgias. Ten \r\npoint review of systems is otherwise negative. \r\n\r\n \r\nPast Medical History:\r\nONCOLOGIC HISTORY: \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n___: Transplant Date: 1 \r\n___: Day Post Transplant: 44 \r\n___: Graft: Auto \r\n___: Conditioning Intensity: Ablative \r\n___: Conditioning Regimen: BEAM \r\n\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass \r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access. Biopsies showed \r\nFollicular lymphomas grade II/III. Reportedly negative staging \r\nGallium scan. CD10+ BCL2+ \r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA) \r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone \r\nmarrow at completion was negative for lymphomatous involvement. \r\n- ___ PET-CT with very slight amount of increased tracer \r\nactivity within the posterior left supraclavicular region. No \r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP \r\nfollowed by course of single agent Rituxan \r\n- ___ through ___ surveillance imaging with no evidence of \r\nrecurrent disease, stable mesenteric mass. \r\n- ___ abdominal pain led to CT with no change in mass size, \r\nincreased conspicuity of nodular borders \r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise \r\n\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior. \r\n- ___ CT torso showed persistent mesenteric and left hilar \r\nlymphadenopathy. Stable right middle lobe small focus of ground \r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive \r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam \r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1, \r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal \r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning \r\nfor \r\nlymphoma.\" SUVmax 35.5. \r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare \r\npending \r\n- ___ C1D1 ICE \r\n- ___ C1 Rituximab, clincally improved adenopathy \r\n- ___ C2 Rituximab, WBC 6.5, PLT 43 \r\n- ___ Admit for C2D1 ICE \r\n- ___ C3 Rituximab \r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a residual focus of avidity in the bed of the \r\nformer \r\nabdominal mass, SUV 3 \r\n- ___ C4 Rituximab \r\n- ___ C4 ICE followed by stem cell mobilization and \r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive \r\nlymphoma \r\n- ___ Presented with large DVTs, SVC filter placed \r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis \r\n- ___ Switched to Rivaroxiban for AC \r\n- ___. Interval decrease in size of \r\nretroperitoneal lymphadenopathy, with persistent low-level FDG \r\nuptake. No new FDG-avid disease. 2. Resolution of cervical, \r\nsupraclavicular and mediastinal lymphadenopathy. 3. IVC filter \r\nin place, new since the prior PET-CT. 4. Stable non-FDG avid \r\nright adnexal hypodensity. PFTs with normal Hb adjusted DLCO \r\n- ___ IVIg 400 mg/kg \r\n\r\nPAST MEDICAL HISTORY: \r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\n\r\nabove. \r\n--CLL, noted on BM biopsy on ___. \r\n--Deep venous thrombosis \r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye) \r\n--Hypogammaglobulinemia \r\n--Mild GERD \r\n--OA / LBP \r\n--Small Intestinal Bacterial Overgrowth \r\n--Trochanteric Bursitis \r\n--s/p Excisional Bx L Cervical Lymph Node \r\n--s/p L total knee replacement ___, walks with cane \r\n--s/p I&D Labial Abscess \r\n--s/p Excision Cyst R ___ Digit of Hand \r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n--------------\r\nVitals: T: 101.8 BP: 130/84 P: 113 R: 18 O2: 94% on RA \r\nGEN: Alert, oriented to name, place and situation. Fatigued \r\nappearing but comfortable, no acute signs of distress. \r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MM dry. \r\nNeck: Supple, no JVD \r\nLymph nodes: No cervical, supraclavicular LAD. \r\nCV: S1S2, tachycardic but regular, no murmurs, rubs or gallops. \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing. \r\nABD: Soft, non-tender, non-distended, + bowel sounds. \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient. \r\nDERM: No active rash. Indwelling catheter in right chest, with \r\nmild erythema, no fluctuance, reportedly unchanged. \r\nNeuro: non-focal. \r\nPSYCH: Appropriate and calm. \r\n\r\nDISCHARGE EXAM\r\n--------------\r\nVitals:  98.___.4 125/62 88 18 97% RA\r\nGEN: Alert, oriented. NAD, looks well today\r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MMM.  \r\nNeck: Supple, no JVD  \r\nLymph nodes: No cervical, supraclavicular LAD.  \r\nCV: S1S2, RRR, no murmurs, rubs or gallops.  \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing.  \r\nABD: Soft, non-tender, non-distended, + bowel sounds.  \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient.  \r\nDERM: Indwelling catheter in right chest without acute signs of \r\ninfxn. \r\nNeuro: non-focal.  \r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n--------------\r\n___ 06:25AM BLOOD WBC-10.0# RBC-2.70* Hgb-8.9* Hct-28.6* \r\nMCV-106* MCH-32.9* MCHC-31.1 RDW-21.3* Plt ___\r\n___ 06:25AM BLOOD ___ PTT-33.1 ___\r\n___ 06:25AM BLOOD Glucose-118* UreaN-9 Creat-0.8 Na-137 \r\nK-3.5 Cl-103 HCO3-24 AnGap-14\r\n___ 06:25AM BLOOD ALT-13 AST-24 LD(LDH)-174 AlkPhos-72 \r\nTotBili-0.3\r\n___ 06:25AM BLOOD Calcium-8.5 Phos-2.7 Mg-1.7\r\n\r\nDISCHARGE LABS\r\n--------------\r\n___ 06:00AM BLOOD WBC-2.2* RBC-2.41* Hgb-8.1* Hct-25.9* \r\nMCV-107* MCH-33.6* MCHC-31.3 RDW-21.0* Plt Ct-78*\r\n___ 06:00AM BLOOD Glucose-91 UreaN-9 Creat-0.6 Na-140 K-4.0 \r\nCl-110* HCO3-25 AnGap-9\r\n___ 06:00AM BLOOD Calcium-8.2* Phos-2.5* Mg-2.1\r\n\r\nPENDING LABS\r\n--------------\r\n___ 11:57AM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-PND\r\n___ 11:57 am CMV Viral Load (Pending)\r\n \r\nBrief Hospital Course:\r\n___ with DVT s/p IVC filter and on rivaroxaban, CLL, CVID, and \r\ntransformed lymphoma s/p autoSCT 44 days ago, and IVIG ___, \r\nwho now presented with headache, fevers/rigors, and vomiting.\r\n\r\n# FEVER, HEADACHE, VOMITING: These symptoms occured within 12 \r\nhours of finishing her last infusion of IVIG. Etiology is most \r\nlikely aseptic meningitis as she also had neck stiffness and \r\nsome mild photophobia. Her symptoms improved with supportive IV \r\nfluids, anti-emetics, and NSAIDs. At first she was started \r\nempirically on IV Vanc, IV cefepime, IV acyclovir, and Tamiflu \r\nto treat possible bacterial or HSV meningitis or influenza. \r\nRapid flu screen was negative so Tamiflu was stopped. She had no \r\nencephalitis and was on ppx acyclovir prior to presentation, so \r\nsuspicion of HSV meningoencephalitis was very low so IV \r\nacyclovir was stopped. Once ___ blood cultures were \r\nnegative >24 hours, IV antibiotics were also stopped. The \r\npatient continued to improve and was afebrile > 24 hrs prior to \r\ndischarge. \r\n\r\n# LYMPHOMA: s/p auto-stem cell transplant 44 days prior to \r\nadmission. She was continued on ppx bactrim and acyclovir. She \r\nwill f/u with her outpatient providers.\r\n\r\n# H/o DVT: Rivaroxaban was held while inpatient since we were at \r\nfirst considering lumbar puncture. It was restarted on \r\ndischarge. \r\n\r\nTRANSITIONAL ISSUES:\r\n--------------------\r\n# F/u CMV and EBV viral loads\r\n# Code status: Full \r\n# Contact: husband ___, ___ \r\n\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Rivaroxaban 15 mg PO DAILY \r\n9. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Multivitamins 1 TAB PO DAILY \r\n4. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n5. Gabapentin 900 mg PO BID \r\n6. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n7. Venlafaxine 25 mg PO BID \r\n8. Metoclopramide 10 mg PO TID:PRN nausea \r\nRX *metoclopramide HCl 10 mg 1 tablet by mouth Up to three times \r\nper day Disp #*15 Tablet Refills:*0\r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n10. Furosemide 20 mg PO DAILY \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Potassium Chloride 10 mEq PO DAILY \r\n13. Rivaroxaban 15 mg PO DAILY \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS:\r\nIVIG Aseptic meningitis\r\n\r\nSECONDARY DIAGNOSIS:\r\ntransformed lymphoma s/p auto stem cell transplant\r\nCVID\r\nNeutropenia\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted to the hospital for high fevers, headache, and \r\nvomiting. We are not sure what caused your symptoms, but the \r\nmost likely cause is IVIG-associated aseptic meningitis. Another \r\ncause may be a viral infection. We felt it was very unlikely you \r\nhad a bacterial infection so we stopped your antibiotics. You \r\ncontinued to improve. Your fevers and headaches improved. Your \r\nvomiting was well-controlled on medications. And you were able \r\nto tolerate enough hydration by mouth and no longer needed IVs, \r\nso you were discharged home with plans to follow up with Dr. \r\n___ Dr. ___.\r\n\r\nIt was a pleasure to take care of you during your hospital stay,\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-13:3",
      "text": "Past Medical History:\nONCOLOGIC HISTORY: \nTransformed DLBCL with a history of follicular lymphoma stage \nIIA \n___: Transplant Date: 1 \n___: Day Post Transplant: 44 \n___: Graft: Auto \n___: Conditioning Intensity: Ablative \n___: Conditioning Regimen: BEAM - ___ developed worsening musculoskeletal back pain, early \nsatiety, hypoalbuminemia and found to have mesenteric mass \n- ?___ ex lap with 15 cm lobulated mass involving the \nduodenum, retroperitoneum and celiac access. Biopsies showed \nFollicular lymphomas grade II/III. Reportedly negative staging \nGallium scan. CD10+ BCL2+ \n- ___ completed 6 cycles CHOP, complications included \nSVC/innominate thrombus (tPA) \n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone \nmarrow at completion was negative for lymphomatous involvement. - ___ PET-CT with very slight amount of increased tracer \nactivity within the posterior left supraclavicular region. No \nother areas of FDG avid disease were noted \n- ___ through ___ per records she was treated with CVP \nfollowed by course of single agent Rituxan \n- ___ through ___ surveillance imaging with no evidence of \nrecurrent disease, stable mesenteric mass. - ___ abdominal pain led to CT with no change in mass size, \nincreased conspicuity of nodular borders \n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise stable mesenteric mass with low level SUV 2.2 stable since \nprior. - ___ CT torso showed persistent mesenteric and left hilar \nlymphadenopathy. Stable right middle lobe small focus of ground \nglass opacity and adjacent subpleural fat hypertrophy, \nsuggestive \nof inflammatory process. Stable right adnexal cyst. - ___ Presented to PCP ___ ___iscomfort. Exam \nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1, \nnormal differential, PLT 452. - ___ PET CT revealed, \"Large left cervical, \nsupraclavicular, mediastinal \nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \nmesenteric \nlymphadenopathy, all of which is markedly FDG-avid and \nconcerning \nfor \nlymphoma.\" SUVmax 35.5. - ___iopsy revealed diffuse large B cell \nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \nare \npending \n- ___ C1D1 ICE \n- ___ C1 Rituximab, clincally improved adenopathy \n- ___ C2 Rituximab, WBC 6.5, PLT 43 \n- ___ Admit for C2D1 ICE \n- ___ C3 Rituximab \n- ___ PET CT showed almost complete resolution of FDG avid \ndisease with a residual focus of avidity in the bed of the \nformer \nabdominal mass, SUV 3 \n- ___ C4 Rituximab \n- ___ C4 ICE followed by stem cell mobilization and \ncollection, BMBx showed a nest of CLL unrelated to her \naggressive \nlymphoma \n- ___ Presented with large DVTs, SVC filter placed \n- ___ D0 of a BEAM autoSCT, course notable for mucositis \n- ___ Switched to Rivaroxiban for AC \n- ___.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-13",
        "chart_time": "103398",
        "section": "General",
        "position": 3,
        "tokenCount": 688,
        "note_metadata": {
          "note_id": "18887130-DS-13",
          "subject_id": 18887130,
          "hadm_id": 28298007,
          "note_type": "DS",
          "note_seq": 13,
          "charttime": 103398,
          "storetime": 103398.76319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nFever\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with a history of transformed lymphoma s/p \r\nautoSCT 44 days ago as well as comorbid CVID and CLL, who \r\nreceived IVIg for immunodeficiency on the day prior to \r\nadmission. Today, she had a headache, rigors, and fever to \r\n100.5. She also reported general malaise. Patient has an \r\nindwelling catheter and IVC filter in place. She presented to \r\n___, where blood cultures x 2, urinalysis and urine \r\nculture were performed. She received empiric vancomycin and \r\ncefepime 2 grams IV as well as oseltamivir, flu swab pending. \r\nCXR at ___ showed no evidence of pneumonia. Urinalysis \r\nwas negative for evidence of infection. \r\n\r\nIn the ED, initial vitals were 102.4 ___ 18 94%. Labs at \r\n___ showed WBC count 8.8K with 89% neutrophils, \r\nhematocrit 28.2, platelets 104K. INR was 1.3. Anion gap was 13. \r\nCT head showed no acute intracranial abnormality. Patient \r\nreceived ondansetron 2 mg IV x 1, metoclopramide 5 mg IV x 1, \r\nand hydromorphone 2 mg IV x 1. Lumbar puncture was not attempted \r\ndue to patient being on rivaroxaban, and it was recommended he \r\nstart empiric IV acyclovir and he got one dose. Vitals on \r\ntransfer were 101.7 106 122/56 18 94% RA. \r\n\r\nOn the floor, patient notes diffuse headache with some neck \r\ndiscomfort and stiffness, as well as photophobia. This headache \r\nis different than migraines she has had in the past. She has \r\nalso been nauseous and vomited several times, non-bloody, \r\nnon-bilious. \r\n\r\nReview of sytems: \r\n(+) Per HPI \r\n(-) Denies recent weight loss or gain. Denies headache, sinus \r\ntenderness, rhinorrhea or congestion. Denies cough, shortness of \r\nbreath. Denies chest pain or tightness, palpitations. Denies \r\ndiarrhea, constipation or abdominal pain. No recent change in \r\nbowel or bladder habits. No dysuria. Denies arthralgias. Ten \r\npoint review of systems is otherwise negative. \r\n\r\n \r\nPast Medical History:\r\nONCOLOGIC HISTORY: \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n___: Transplant Date: 1 \r\n___: Day Post Transplant: 44 \r\n___: Graft: Auto \r\n___: Conditioning Intensity: Ablative \r\n___: Conditioning Regimen: BEAM \r\n\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass \r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access. Biopsies showed \r\nFollicular lymphomas grade II/III. Reportedly negative staging \r\nGallium scan. CD10+ BCL2+ \r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA) \r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone \r\nmarrow at completion was negative for lymphomatous involvement. \r\n- ___ PET-CT with very slight amount of increased tracer \r\nactivity within the posterior left supraclavicular region. No \r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP \r\nfollowed by course of single agent Rituxan \r\n- ___ through ___ surveillance imaging with no evidence of \r\nrecurrent disease, stable mesenteric mass. \r\n- ___ abdominal pain led to CT with no change in mass size, \r\nincreased conspicuity of nodular borders \r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise \r\n\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior. \r\n- ___ CT torso showed persistent mesenteric and left hilar \r\nlymphadenopathy. Stable right middle lobe small focus of ground \r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive \r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam \r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1, \r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal \r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning \r\nfor \r\nlymphoma.\" SUVmax 35.5. \r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare \r\npending \r\n- ___ C1D1 ICE \r\n- ___ C1 Rituximab, clincally improved adenopathy \r\n- ___ C2 Rituximab, WBC 6.5, PLT 43 \r\n- ___ Admit for C2D1 ICE \r\n- ___ C3 Rituximab \r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a residual focus of avidity in the bed of the \r\nformer \r\nabdominal mass, SUV 3 \r\n- ___ C4 Rituximab \r\n- ___ C4 ICE followed by stem cell mobilization and \r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive \r\nlymphoma \r\n- ___ Presented with large DVTs, SVC filter placed \r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis \r\n- ___ Switched to Rivaroxiban for AC \r\n- ___. Interval decrease in size of \r\nretroperitoneal lymphadenopathy, with persistent low-level FDG \r\nuptake. No new FDG-avid disease. 2. Resolution of cervical, \r\nsupraclavicular and mediastinal lymphadenopathy. 3. IVC filter \r\nin place, new since the prior PET-CT. 4. Stable non-FDG avid \r\nright adnexal hypodensity. PFTs with normal Hb adjusted DLCO \r\n- ___ IVIg 400 mg/kg \r\n\r\nPAST MEDICAL HISTORY: \r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\n\r\nabove. \r\n--CLL, noted on BM biopsy on ___. \r\n--Deep venous thrombosis \r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye) \r\n--Hypogammaglobulinemia \r\n--Mild GERD \r\n--OA / LBP \r\n--Small Intestinal Bacterial Overgrowth \r\n--Trochanteric Bursitis \r\n--s/p Excisional Bx L Cervical Lymph Node \r\n--s/p L total knee replacement ___, walks with cane \r\n--s/p I&D Labial Abscess \r\n--s/p Excision Cyst R ___ Digit of Hand \r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n--------------\r\nVitals: T: 101.8 BP: 130/84 P: 113 R: 18 O2: 94% on RA \r\nGEN: Alert, oriented to name, place and situation. Fatigued \r\nappearing but comfortable, no acute signs of distress. \r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MM dry. \r\nNeck: Supple, no JVD \r\nLymph nodes: No cervical, supraclavicular LAD. \r\nCV: S1S2, tachycardic but regular, no murmurs, rubs or gallops. \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing. \r\nABD: Soft, non-tender, non-distended, + bowel sounds. \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient. \r\nDERM: No active rash. Indwelling catheter in right chest, with \r\nmild erythema, no fluctuance, reportedly unchanged. \r\nNeuro: non-focal. \r\nPSYCH: Appropriate and calm. \r\n\r\nDISCHARGE EXAM\r\n--------------\r\nVitals:  98.___.4 125/62 88 18 97% RA\r\nGEN: Alert, oriented. NAD, looks well today\r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MMM.  \r\nNeck: Supple, no JVD  \r\nLymph nodes: No cervical, supraclavicular LAD.  \r\nCV: S1S2, RRR, no murmurs, rubs or gallops.  \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing.  \r\nABD: Soft, non-tender, non-distended, + bowel sounds.  \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient.  \r\nDERM: Indwelling catheter in right chest without acute signs of \r\ninfxn. \r\nNeuro: non-focal.  \r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n--------------\r\n___ 06:25AM BLOOD WBC-10.0# RBC-2.70* Hgb-8.9* Hct-28.6* \r\nMCV-106* MCH-32.9* MCHC-31.1 RDW-21.3* Plt ___\r\n___ 06:25AM BLOOD ___ PTT-33.1 ___\r\n___ 06:25AM BLOOD Glucose-118* UreaN-9 Creat-0.8 Na-137 \r\nK-3.5 Cl-103 HCO3-24 AnGap-14\r\n___ 06:25AM BLOOD ALT-13 AST-24 LD(LDH)-174 AlkPhos-72 \r\nTotBili-0.3\r\n___ 06:25AM BLOOD Calcium-8.5 Phos-2.7 Mg-1.7\r\n\r\nDISCHARGE LABS\r\n--------------\r\n___ 06:00AM BLOOD WBC-2.2* RBC-2.41* Hgb-8.1* Hct-25.9* \r\nMCV-107* MCH-33.6* MCHC-31.3 RDW-21.0* Plt Ct-78*\r\n___ 06:00AM BLOOD Glucose-91 UreaN-9 Creat-0.6 Na-140 K-4.0 \r\nCl-110* HCO3-25 AnGap-9\r\n___ 06:00AM BLOOD Calcium-8.2* Phos-2.5* Mg-2.1\r\n\r\nPENDING LABS\r\n--------------\r\n___ 11:57AM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-PND\r\n___ 11:57 am CMV Viral Load (Pending)\r\n \r\nBrief Hospital Course:\r\n___ with DVT s/p IVC filter and on rivaroxaban, CLL, CVID, and \r\ntransformed lymphoma s/p autoSCT 44 days ago, and IVIG ___, \r\nwho now presented with headache, fevers/rigors, and vomiting.\r\n\r\n# FEVER, HEADACHE, VOMITING: These symptoms occured within 12 \r\nhours of finishing her last infusion of IVIG. Etiology is most \r\nlikely aseptic meningitis as she also had neck stiffness and \r\nsome mild photophobia. Her symptoms improved with supportive IV \r\nfluids, anti-emetics, and NSAIDs. At first she was started \r\nempirically on IV Vanc, IV cefepime, IV acyclovir, and Tamiflu \r\nto treat possible bacterial or HSV meningitis or influenza. \r\nRapid flu screen was negative so Tamiflu was stopped. She had no \r\nencephalitis and was on ppx acyclovir prior to presentation, so \r\nsuspicion of HSV meningoencephalitis was very low so IV \r\nacyclovir was stopped. Once ___ blood cultures were \r\nnegative >24 hours, IV antibiotics were also stopped. The \r\npatient continued to improve and was afebrile > 24 hrs prior to \r\ndischarge. \r\n\r\n# LYMPHOMA: s/p auto-stem cell transplant 44 days prior to \r\nadmission. She was continued on ppx bactrim and acyclovir. She \r\nwill f/u with her outpatient providers.\r\n\r\n# H/o DVT: Rivaroxaban was held while inpatient since we were at \r\nfirst considering lumbar puncture. It was restarted on \r\ndischarge. \r\n\r\nTRANSITIONAL ISSUES:\r\n--------------------\r\n# F/u CMV and EBV viral loads\r\n# Code status: Full \r\n# Contact: husband ___, ___ \r\n\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Rivaroxaban 15 mg PO DAILY \r\n9. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Multivitamins 1 TAB PO DAILY \r\n4. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n5. Gabapentin 900 mg PO BID \r\n6. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n7. Venlafaxine 25 mg PO BID \r\n8. Metoclopramide 10 mg PO TID:PRN nausea \r\nRX *metoclopramide HCl 10 mg 1 tablet by mouth Up to three times \r\nper day Disp #*15 Tablet Refills:*0\r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n10. Furosemide 20 mg PO DAILY \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Potassium Chloride 10 mEq PO DAILY \r\n13. Rivaroxaban 15 mg PO DAILY \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS:\r\nIVIG Aseptic meningitis\r\n\r\nSECONDARY DIAGNOSIS:\r\ntransformed lymphoma s/p auto stem cell transplant\r\nCVID\r\nNeutropenia\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted to the hospital for high fevers, headache, and \r\nvomiting. We are not sure what caused your symptoms, but the \r\nmost likely cause is IVIG-associated aseptic meningitis. Another \r\ncause may be a viral infection. We felt it was very unlikely you \r\nhad a bacterial infection so we stopped your antibiotics. You \r\ncontinued to improve. Your fevers and headaches improved. Your \r\nvomiting was well-controlled on medications. And you were able \r\nto tolerate enough hydration by mouth and no longer needed IVs, \r\nso you were discharged home with plans to follow up with Dr. \r\n___ Dr. ___.\r\n\r\nIt was a pleasure to take care of you during your hospital stay,\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-13:4",
      "text": "MIB and cytogenetics \nare \npending \n- ___ C1D1 ICE \n- ___ C1 Rituximab, clincally improved adenopathy \n- ___ C2 Rituximab, WBC 6.5, PLT 43 \n- ___ Admit for C2D1 ICE \n- ___ C3 Rituximab \n- ___ PET CT showed almost complete resolution of FDG avid \ndisease with a residual focus of avidity in the bed of the \nformer \nabdominal mass, SUV 3 \n- ___ C4 Rituximab \n- ___ C4 ICE followed by stem cell mobilization and \ncollection, BMBx showed a nest of CLL unrelated to her \naggressive \nlymphoma \n- ___ Presented with large DVTs, SVC filter placed \n- ___ D0 of a BEAM autoSCT, course notable for mucositis \n- ___ Switched to Rivaroxiban for AC \n- ___. Interval decrease in size of \nretroperitoneal lymphadenopathy, with persistent low-level FDG \nuptake. No new FDG-avid disease. 2. Resolution of cervical, \nsupraclavicular and mediastinal lymphadenopathy. 3. IVC filter \nin place, new since the prior PET-CT. 4. Stable non-FDG avid \nright adnexal hypodensity. PFTs with normal Hb adjusted DLCO \n- ___ IVIg 400 mg/kg",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-13",
        "chart_time": "103398",
        "section": "General",
        "position": 4,
        "tokenCount": 252,
        "note_metadata": {
          "note_id": "18887130-DS-13",
          "subject_id": 18887130,
          "hadm_id": 28298007,
          "note_type": "DS",
          "note_seq": 13,
          "charttime": 103398,
          "storetime": 103398.76319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nFever\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with a history of transformed lymphoma s/p \r\nautoSCT 44 days ago as well as comorbid CVID and CLL, who \r\nreceived IVIg for immunodeficiency on the day prior to \r\nadmission. Today, she had a headache, rigors, and fever to \r\n100.5. She also reported general malaise. Patient has an \r\nindwelling catheter and IVC filter in place. She presented to \r\n___, where blood cultures x 2, urinalysis and urine \r\nculture were performed. She received empiric vancomycin and \r\ncefepime 2 grams IV as well as oseltamivir, flu swab pending. \r\nCXR at ___ showed no evidence of pneumonia. Urinalysis \r\nwas negative for evidence of infection. \r\n\r\nIn the ED, initial vitals were 102.4 ___ 18 94%. Labs at \r\n___ showed WBC count 8.8K with 89% neutrophils, \r\nhematocrit 28.2, platelets 104K. INR was 1.3. Anion gap was 13. \r\nCT head showed no acute intracranial abnormality. Patient \r\nreceived ondansetron 2 mg IV x 1, metoclopramide 5 mg IV x 1, \r\nand hydromorphone 2 mg IV x 1. Lumbar puncture was not attempted \r\ndue to patient being on rivaroxaban, and it was recommended he \r\nstart empiric IV acyclovir and he got one dose. Vitals on \r\ntransfer were 101.7 106 122/56 18 94% RA. \r\n\r\nOn the floor, patient notes diffuse headache with some neck \r\ndiscomfort and stiffness, as well as photophobia. This headache \r\nis different than migraines she has had in the past. She has \r\nalso been nauseous and vomited several times, non-bloody, \r\nnon-bilious. \r\n\r\nReview of sytems: \r\n(+) Per HPI \r\n(-) Denies recent weight loss or gain. Denies headache, sinus \r\ntenderness, rhinorrhea or congestion. Denies cough, shortness of \r\nbreath. Denies chest pain or tightness, palpitations. Denies \r\ndiarrhea, constipation or abdominal pain. No recent change in \r\nbowel or bladder habits. No dysuria. Denies arthralgias. Ten \r\npoint review of systems is otherwise negative. \r\n\r\n \r\nPast Medical History:\r\nONCOLOGIC HISTORY: \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n___: Transplant Date: 1 \r\n___: Day Post Transplant: 44 \r\n___: Graft: Auto \r\n___: Conditioning Intensity: Ablative \r\n___: Conditioning Regimen: BEAM \r\n\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass \r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access. Biopsies showed \r\nFollicular lymphomas grade II/III. Reportedly negative staging \r\nGallium scan. CD10+ BCL2+ \r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA) \r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone \r\nmarrow at completion was negative for lymphomatous involvement. \r\n- ___ PET-CT with very slight amount of increased tracer \r\nactivity within the posterior left supraclavicular region. No \r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP \r\nfollowed by course of single agent Rituxan \r\n- ___ through ___ surveillance imaging with no evidence of \r\nrecurrent disease, stable mesenteric mass. \r\n- ___ abdominal pain led to CT with no change in mass size, \r\nincreased conspicuity of nodular borders \r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise \r\n\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior. \r\n- ___ CT torso showed persistent mesenteric and left hilar \r\nlymphadenopathy. Stable right middle lobe small focus of ground \r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive \r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam \r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1, \r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal \r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning \r\nfor \r\nlymphoma.\" SUVmax 35.5. \r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare \r\npending \r\n- ___ C1D1 ICE \r\n- ___ C1 Rituximab, clincally improved adenopathy \r\n- ___ C2 Rituximab, WBC 6.5, PLT 43 \r\n- ___ Admit for C2D1 ICE \r\n- ___ C3 Rituximab \r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a residual focus of avidity in the bed of the \r\nformer \r\nabdominal mass, SUV 3 \r\n- ___ C4 Rituximab \r\n- ___ C4 ICE followed by stem cell mobilization and \r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive \r\nlymphoma \r\n- ___ Presented with large DVTs, SVC filter placed \r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis \r\n- ___ Switched to Rivaroxiban for AC \r\n- ___. Interval decrease in size of \r\nretroperitoneal lymphadenopathy, with persistent low-level FDG \r\nuptake. No new FDG-avid disease. 2. Resolution of cervical, \r\nsupraclavicular and mediastinal lymphadenopathy. 3. IVC filter \r\nin place, new since the prior PET-CT. 4. Stable non-FDG avid \r\nright adnexal hypodensity. PFTs with normal Hb adjusted DLCO \r\n- ___ IVIg 400 mg/kg \r\n\r\nPAST MEDICAL HISTORY: \r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\n\r\nabove. \r\n--CLL, noted on BM biopsy on ___. \r\n--Deep venous thrombosis \r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye) \r\n--Hypogammaglobulinemia \r\n--Mild GERD \r\n--OA / LBP \r\n--Small Intestinal Bacterial Overgrowth \r\n--Trochanteric Bursitis \r\n--s/p Excisional Bx L Cervical Lymph Node \r\n--s/p L total knee replacement ___, walks with cane \r\n--s/p I&D Labial Abscess \r\n--s/p Excision Cyst R ___ Digit of Hand \r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n--------------\r\nVitals: T: 101.8 BP: 130/84 P: 113 R: 18 O2: 94% on RA \r\nGEN: Alert, oriented to name, place and situation. Fatigued \r\nappearing but comfortable, no acute signs of distress. \r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MM dry. \r\nNeck: Supple, no JVD \r\nLymph nodes: No cervical, supraclavicular LAD. \r\nCV: S1S2, tachycardic but regular, no murmurs, rubs or gallops. \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing. \r\nABD: Soft, non-tender, non-distended, + bowel sounds. \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient. \r\nDERM: No active rash. Indwelling catheter in right chest, with \r\nmild erythema, no fluctuance, reportedly unchanged. \r\nNeuro: non-focal. \r\nPSYCH: Appropriate and calm. \r\n\r\nDISCHARGE EXAM\r\n--------------\r\nVitals:  98.___.4 125/62 88 18 97% RA\r\nGEN: Alert, oriented. NAD, looks well today\r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MMM.  \r\nNeck: Supple, no JVD  \r\nLymph nodes: No cervical, supraclavicular LAD.  \r\nCV: S1S2, RRR, no murmurs, rubs or gallops.  \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing.  \r\nABD: Soft, non-tender, non-distended, + bowel sounds.  \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient.  \r\nDERM: Indwelling catheter in right chest without acute signs of \r\ninfxn. \r\nNeuro: non-focal.  \r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n--------------\r\n___ 06:25AM BLOOD WBC-10.0# RBC-2.70* Hgb-8.9* Hct-28.6* \r\nMCV-106* MCH-32.9* MCHC-31.1 RDW-21.3* Plt ___\r\n___ 06:25AM BLOOD ___ PTT-33.1 ___\r\n___ 06:25AM BLOOD Glucose-118* UreaN-9 Creat-0.8 Na-137 \r\nK-3.5 Cl-103 HCO3-24 AnGap-14\r\n___ 06:25AM BLOOD ALT-13 AST-24 LD(LDH)-174 AlkPhos-72 \r\nTotBili-0.3\r\n___ 06:25AM BLOOD Calcium-8.5 Phos-2.7 Mg-1.7\r\n\r\nDISCHARGE LABS\r\n--------------\r\n___ 06:00AM BLOOD WBC-2.2* RBC-2.41* Hgb-8.1* Hct-25.9* \r\nMCV-107* MCH-33.6* MCHC-31.3 RDW-21.0* Plt Ct-78*\r\n___ 06:00AM BLOOD Glucose-91 UreaN-9 Creat-0.6 Na-140 K-4.0 \r\nCl-110* HCO3-25 AnGap-9\r\n___ 06:00AM BLOOD Calcium-8.2* Phos-2.5* Mg-2.1\r\n\r\nPENDING LABS\r\n--------------\r\n___ 11:57AM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-PND\r\n___ 11:57 am CMV Viral Load (Pending)\r\n \r\nBrief Hospital Course:\r\n___ with DVT s/p IVC filter and on rivaroxaban, CLL, CVID, and \r\ntransformed lymphoma s/p autoSCT 44 days ago, and IVIG ___, \r\nwho now presented with headache, fevers/rigors, and vomiting.\r\n\r\n# FEVER, HEADACHE, VOMITING: These symptoms occured within 12 \r\nhours of finishing her last infusion of IVIG. Etiology is most \r\nlikely aseptic meningitis as she also had neck stiffness and \r\nsome mild photophobia. Her symptoms improved with supportive IV \r\nfluids, anti-emetics, and NSAIDs. At first she was started \r\nempirically on IV Vanc, IV cefepime, IV acyclovir, and Tamiflu \r\nto treat possible bacterial or HSV meningitis or influenza. \r\nRapid flu screen was negative so Tamiflu was stopped. She had no \r\nencephalitis and was on ppx acyclovir prior to presentation, so \r\nsuspicion of HSV meningoencephalitis was very low so IV \r\nacyclovir was stopped. Once ___ blood cultures were \r\nnegative >24 hours, IV antibiotics were also stopped. The \r\npatient continued to improve and was afebrile > 24 hrs prior to \r\ndischarge. \r\n\r\n# LYMPHOMA: s/p auto-stem cell transplant 44 days prior to \r\nadmission. She was continued on ppx bactrim and acyclovir. She \r\nwill f/u with her outpatient providers.\r\n\r\n# H/o DVT: Rivaroxaban was held while inpatient since we were at \r\nfirst considering lumbar puncture. It was restarted on \r\ndischarge. \r\n\r\nTRANSITIONAL ISSUES:\r\n--------------------\r\n# F/u CMV and EBV viral loads\r\n# Code status: Full \r\n# Contact: husband ___, ___ \r\n\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Rivaroxaban 15 mg PO DAILY \r\n9. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Multivitamins 1 TAB PO DAILY \r\n4. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n5. Gabapentin 900 mg PO BID \r\n6. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n7. Venlafaxine 25 mg PO BID \r\n8. Metoclopramide 10 mg PO TID:PRN nausea \r\nRX *metoclopramide HCl 10 mg 1 tablet by mouth Up to three times \r\nper day Disp #*15 Tablet Refills:*0\r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n10. Furosemide 20 mg PO DAILY \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Potassium Chloride 10 mEq PO DAILY \r\n13. Rivaroxaban 15 mg PO DAILY \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS:\r\nIVIG Aseptic meningitis\r\n\r\nSECONDARY DIAGNOSIS:\r\ntransformed lymphoma s/p auto stem cell transplant\r\nCVID\r\nNeutropenia\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted to the hospital for high fevers, headache, and \r\nvomiting. We are not sure what caused your symptoms, but the \r\nmost likely cause is IVIG-associated aseptic meningitis. Another \r\ncause may be a viral infection. We felt it was very unlikely you \r\nhad a bacterial infection so we stopped your antibiotics. You \r\ncontinued to improve. Your fevers and headaches improved. Your \r\nvomiting was well-controlled on medications. And you were able \r\nto tolerate enough hydration by mouth and no longer needed IVs, \r\nso you were discharged home with plans to follow up with Dr. \r\n___ Dr. ___.\r\n\r\nIt was a pleasure to take care of you during your hospital stay,\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-13:5",
      "text": "PAST MEDICAL HISTORY: \n--Transformed DLBCL with history of follicular lymphoma as noted above. --CLL, noted on BM biopsy on ___. --Deep venous thrombosis \n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \n(*Known slight CN VI palsy & mild proptosis of R eye) \n--Hypogammaglobulinemia \n--Mild GERD \n--OA / LBP \n--Small Intestinal Bacterial Overgrowth \n--Trochanteric Bursitis \n--s/p Excisional Bx L Cervical Lymph Node \n--s/p L total knee replacement ___, walks with cane \n--s/p I&D Labial Abscess \n--s/p Excision Cyst R ___ Digit of Hand Social History:\n___ Family History:\nBrother: lymphoma.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-13",
        "chart_time": "103398",
        "section": "General",
        "position": 5,
        "tokenCount": 151,
        "note_metadata": {
          "note_id": "18887130-DS-13",
          "subject_id": 18887130,
          "hadm_id": 28298007,
          "note_type": "DS",
          "note_seq": 13,
          "charttime": 103398,
          "storetime": 103398.76319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nFever\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with a history of transformed lymphoma s/p \r\nautoSCT 44 days ago as well as comorbid CVID and CLL, who \r\nreceived IVIg for immunodeficiency on the day prior to \r\nadmission. Today, she had a headache, rigors, and fever to \r\n100.5. She also reported general malaise. Patient has an \r\nindwelling catheter and IVC filter in place. She presented to \r\n___, where blood cultures x 2, urinalysis and urine \r\nculture were performed. She received empiric vancomycin and \r\ncefepime 2 grams IV as well as oseltamivir, flu swab pending. \r\nCXR at ___ showed no evidence of pneumonia. Urinalysis \r\nwas negative for evidence of infection. \r\n\r\nIn the ED, initial vitals were 102.4 ___ 18 94%. Labs at \r\n___ showed WBC count 8.8K with 89% neutrophils, \r\nhematocrit 28.2, platelets 104K. INR was 1.3. Anion gap was 13. \r\nCT head showed no acute intracranial abnormality. Patient \r\nreceived ondansetron 2 mg IV x 1, metoclopramide 5 mg IV x 1, \r\nand hydromorphone 2 mg IV x 1. Lumbar puncture was not attempted \r\ndue to patient being on rivaroxaban, and it was recommended he \r\nstart empiric IV acyclovir and he got one dose. Vitals on \r\ntransfer were 101.7 106 122/56 18 94% RA. \r\n\r\nOn the floor, patient notes diffuse headache with some neck \r\ndiscomfort and stiffness, as well as photophobia. This headache \r\nis different than migraines she has had in the past. She has \r\nalso been nauseous and vomited several times, non-bloody, \r\nnon-bilious. \r\n\r\nReview of sytems: \r\n(+) Per HPI \r\n(-) Denies recent weight loss or gain. Denies headache, sinus \r\ntenderness, rhinorrhea or congestion. Denies cough, shortness of \r\nbreath. Denies chest pain or tightness, palpitations. Denies \r\ndiarrhea, constipation or abdominal pain. No recent change in \r\nbowel or bladder habits. No dysuria. Denies arthralgias. Ten \r\npoint review of systems is otherwise negative. \r\n\r\n \r\nPast Medical History:\r\nONCOLOGIC HISTORY: \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n___: Transplant Date: 1 \r\n___: Day Post Transplant: 44 \r\n___: Graft: Auto \r\n___: Conditioning Intensity: Ablative \r\n___: Conditioning Regimen: BEAM \r\n\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass \r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access. Biopsies showed \r\nFollicular lymphomas grade II/III. Reportedly negative staging \r\nGallium scan. CD10+ BCL2+ \r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA) \r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone \r\nmarrow at completion was negative for lymphomatous involvement. \r\n- ___ PET-CT with very slight amount of increased tracer \r\nactivity within the posterior left supraclavicular region. No \r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP \r\nfollowed by course of single agent Rituxan \r\n- ___ through ___ surveillance imaging with no evidence of \r\nrecurrent disease, stable mesenteric mass. \r\n- ___ abdominal pain led to CT with no change in mass size, \r\nincreased conspicuity of nodular borders \r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise \r\n\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior. \r\n- ___ CT torso showed persistent mesenteric and left hilar \r\nlymphadenopathy. Stable right middle lobe small focus of ground \r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive \r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam \r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1, \r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal \r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning \r\nfor \r\nlymphoma.\" SUVmax 35.5. \r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare \r\npending \r\n- ___ C1D1 ICE \r\n- ___ C1 Rituximab, clincally improved adenopathy \r\n- ___ C2 Rituximab, WBC 6.5, PLT 43 \r\n- ___ Admit for C2D1 ICE \r\n- ___ C3 Rituximab \r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a residual focus of avidity in the bed of the \r\nformer \r\nabdominal mass, SUV 3 \r\n- ___ C4 Rituximab \r\n- ___ C4 ICE followed by stem cell mobilization and \r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive \r\nlymphoma \r\n- ___ Presented with large DVTs, SVC filter placed \r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis \r\n- ___ Switched to Rivaroxiban for AC \r\n- ___. Interval decrease in size of \r\nretroperitoneal lymphadenopathy, with persistent low-level FDG \r\nuptake. No new FDG-avid disease. 2. Resolution of cervical, \r\nsupraclavicular and mediastinal lymphadenopathy. 3. IVC filter \r\nin place, new since the prior PET-CT. 4. Stable non-FDG avid \r\nright adnexal hypodensity. PFTs with normal Hb adjusted DLCO \r\n- ___ IVIg 400 mg/kg \r\n\r\nPAST MEDICAL HISTORY: \r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\n\r\nabove. \r\n--CLL, noted on BM biopsy on ___. \r\n--Deep venous thrombosis \r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye) \r\n--Hypogammaglobulinemia \r\n--Mild GERD \r\n--OA / LBP \r\n--Small Intestinal Bacterial Overgrowth \r\n--Trochanteric Bursitis \r\n--s/p Excisional Bx L Cervical Lymph Node \r\n--s/p L total knee replacement ___, walks with cane \r\n--s/p I&D Labial Abscess \r\n--s/p Excision Cyst R ___ Digit of Hand \r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n--------------\r\nVitals: T: 101.8 BP: 130/84 P: 113 R: 18 O2: 94% on RA \r\nGEN: Alert, oriented to name, place and situation. Fatigued \r\nappearing but comfortable, no acute signs of distress. \r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MM dry. \r\nNeck: Supple, no JVD \r\nLymph nodes: No cervical, supraclavicular LAD. \r\nCV: S1S2, tachycardic but regular, no murmurs, rubs or gallops. \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing. \r\nABD: Soft, non-tender, non-distended, + bowel sounds. \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient. \r\nDERM: No active rash. Indwelling catheter in right chest, with \r\nmild erythema, no fluctuance, reportedly unchanged. \r\nNeuro: non-focal. \r\nPSYCH: Appropriate and calm. \r\n\r\nDISCHARGE EXAM\r\n--------------\r\nVitals:  98.___.4 125/62 88 18 97% RA\r\nGEN: Alert, oriented. NAD, looks well today\r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MMM.  \r\nNeck: Supple, no JVD  \r\nLymph nodes: No cervical, supraclavicular LAD.  \r\nCV: S1S2, RRR, no murmurs, rubs or gallops.  \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing.  \r\nABD: Soft, non-tender, non-distended, + bowel sounds.  \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient.  \r\nDERM: Indwelling catheter in right chest without acute signs of \r\ninfxn. \r\nNeuro: non-focal.  \r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n--------------\r\n___ 06:25AM BLOOD WBC-10.0# RBC-2.70* Hgb-8.9* Hct-28.6* \r\nMCV-106* MCH-32.9* MCHC-31.1 RDW-21.3* Plt ___\r\n___ 06:25AM BLOOD ___ PTT-33.1 ___\r\n___ 06:25AM BLOOD Glucose-118* UreaN-9 Creat-0.8 Na-137 \r\nK-3.5 Cl-103 HCO3-24 AnGap-14\r\n___ 06:25AM BLOOD ALT-13 AST-24 LD(LDH)-174 AlkPhos-72 \r\nTotBili-0.3\r\n___ 06:25AM BLOOD Calcium-8.5 Phos-2.7 Mg-1.7\r\n\r\nDISCHARGE LABS\r\n--------------\r\n___ 06:00AM BLOOD WBC-2.2* RBC-2.41* Hgb-8.1* Hct-25.9* \r\nMCV-107* MCH-33.6* MCHC-31.3 RDW-21.0* Plt Ct-78*\r\n___ 06:00AM BLOOD Glucose-91 UreaN-9 Creat-0.6 Na-140 K-4.0 \r\nCl-110* HCO3-25 AnGap-9\r\n___ 06:00AM BLOOD Calcium-8.2* Phos-2.5* Mg-2.1\r\n\r\nPENDING LABS\r\n--------------\r\n___ 11:57AM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-PND\r\n___ 11:57 am CMV Viral Load (Pending)\r\n \r\nBrief Hospital Course:\r\n___ with DVT s/p IVC filter and on rivaroxaban, CLL, CVID, and \r\ntransformed lymphoma s/p autoSCT 44 days ago, and IVIG ___, \r\nwho now presented with headache, fevers/rigors, and vomiting.\r\n\r\n# FEVER, HEADACHE, VOMITING: These symptoms occured within 12 \r\nhours of finishing her last infusion of IVIG. Etiology is most \r\nlikely aseptic meningitis as she also had neck stiffness and \r\nsome mild photophobia. Her symptoms improved with supportive IV \r\nfluids, anti-emetics, and NSAIDs. At first she was started \r\nempirically on IV Vanc, IV cefepime, IV acyclovir, and Tamiflu \r\nto treat possible bacterial or HSV meningitis or influenza. \r\nRapid flu screen was negative so Tamiflu was stopped. She had no \r\nencephalitis and was on ppx acyclovir prior to presentation, so \r\nsuspicion of HSV meningoencephalitis was very low so IV \r\nacyclovir was stopped. Once ___ blood cultures were \r\nnegative >24 hours, IV antibiotics were also stopped. The \r\npatient continued to improve and was afebrile > 24 hrs prior to \r\ndischarge. \r\n\r\n# LYMPHOMA: s/p auto-stem cell transplant 44 days prior to \r\nadmission. She was continued on ppx bactrim and acyclovir. She \r\nwill f/u with her outpatient providers.\r\n\r\n# H/o DVT: Rivaroxaban was held while inpatient since we were at \r\nfirst considering lumbar puncture. It was restarted on \r\ndischarge. \r\n\r\nTRANSITIONAL ISSUES:\r\n--------------------\r\n# F/u CMV and EBV viral loads\r\n# Code status: Full \r\n# Contact: husband ___, ___ \r\n\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Rivaroxaban 15 mg PO DAILY \r\n9. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Multivitamins 1 TAB PO DAILY \r\n4. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n5. Gabapentin 900 mg PO BID \r\n6. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n7. Venlafaxine 25 mg PO BID \r\n8. Metoclopramide 10 mg PO TID:PRN nausea \r\nRX *metoclopramide HCl 10 mg 1 tablet by mouth Up to three times \r\nper day Disp #*15 Tablet Refills:*0\r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n10. Furosemide 20 mg PO DAILY \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Potassium Chloride 10 mEq PO DAILY \r\n13. Rivaroxaban 15 mg PO DAILY \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS:\r\nIVIG Aseptic meningitis\r\n\r\nSECONDARY DIAGNOSIS:\r\ntransformed lymphoma s/p auto stem cell transplant\r\nCVID\r\nNeutropenia\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted to the hospital for high fevers, headache, and \r\nvomiting. We are not sure what caused your symptoms, but the \r\nmost likely cause is IVIG-associated aseptic meningitis. Another \r\ncause may be a viral infection. We felt it was very unlikely you \r\nhad a bacterial infection so we stopped your antibiotics. You \r\ncontinued to improve. Your fevers and headaches improved. Your \r\nvomiting was well-controlled on medications. And you were able \r\nto tolerate enough hydration by mouth and no longer needed IVs, \r\nso you were discharged home with plans to follow up with Dr. \r\n___ Dr. ___.\r\n\r\nIt was a pleasure to take care of you during your hospital stay,\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-13:6",
      "text": "Physical Exam:\nADMISSION EXAM\n--------------\nVitals: T: 101.8 BP: 130/84 P: 113 R: 18 O2: 94% on RA \nGEN: Alert, oriented to name, place and situation. Fatigued \nappearing but comfortable, no acute signs of distress. HEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \nclear, MM dry. Neck: Supple, no JVD \nLymph nodes: No cervical, supraclavicular LAD. CV: S1S2, tachycardic but regular, no murmurs, rubs or gallops. RESP: Good air movement bilaterally, no rhonchi or wheezing. ABD: Soft, non-tender, non-distended, + bowel sounds. EXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \nchanges on lower legs consistent with known venous stasis, per \npatient. DERM: No active rash. Indwelling catheter in right chest, with \nmild erythema, no fluctuance, reportedly unchanged. Neuro: non-focal. PSYCH: Appropriate and calm. DISCHARGE EXAM\n--------------\nVitals:  98.___.4 125/62 88 18 97% RA\nGEN: Alert, oriented. NAD, looks well today\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \nclear, MMM. Neck: Supple, no JVD  \nLymph nodes: No cervical, supraclavicular LAD. CV: S1S2, RRR, no murmurs, rubs or gallops. RESP: Good air movement bilaterally, no rhonchi or wheezing. ABD: Soft, non-tender, non-distended, + bowel sounds. EXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \nchanges on lower legs consistent with known venous stasis, per \npatient. DERM: Indwelling catheter in right chest without acute signs of \ninfxn. Neuro: non-focal. Pertinent Results:\nADMISSION LABS\n--------------\n___ 06:25AM BLOOD WBC-10.0# RBC-2.70* Hgb-8.9* Hct-28.6* \nMCV-106* MCH-32.9* MCHC-31.1 RDW-21.3* Plt ___\n___ 06:25AM BLOOD ___ PTT-33.1 ___\n___ 06:25AM BLOOD Glucose-118* UreaN-9 Creat-0.8 Na-137 \nK-3.5 Cl-103 HCO3-24 AnGap-14\n___ 06:25AM BLOOD ALT-13 AST-24 LD(LDH)-174 AlkPhos-72 \nTotBili-0.3\n___ 06:25AM BLOOD Calcium-8.5 Phos-2.7 Mg-1.7 DISCHARGE LABS\n--------------\n___ 06:00AM BLOOD WBC-2.2* RBC-2.41* Hgb-8.1* Hct-25.9* \nMCV-107* MCH-33.6* MCHC-31.3 RDW-21.0* Plt Ct-78*\n___ 06:00AM BLOOD Glucose-91 UreaN-9 Creat-0.6 Na-140 K-4.0 \nCl-110* HCO3-25 AnGap-9\n___ 06:00AM BLOOD Calcium-8.2* Phos-2.5* Mg-2.1 PENDING LABS\n--------------\n___ 11:57AM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-PND\n___ 11:57 am CMV Viral Load (Pending)",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-13",
        "chart_time": "103398",
        "section": "General",
        "position": 6,
        "tokenCount": 568,
        "note_metadata": {
          "note_id": "18887130-DS-13",
          "subject_id": 18887130,
          "hadm_id": 28298007,
          "note_type": "DS",
          "note_seq": 13,
          "charttime": 103398,
          "storetime": 103398.76319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nFever\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with a history of transformed lymphoma s/p \r\nautoSCT 44 days ago as well as comorbid CVID and CLL, who \r\nreceived IVIg for immunodeficiency on the day prior to \r\nadmission. Today, she had a headache, rigors, and fever to \r\n100.5. She also reported general malaise. Patient has an \r\nindwelling catheter and IVC filter in place. She presented to \r\n___, where blood cultures x 2, urinalysis and urine \r\nculture were performed. She received empiric vancomycin and \r\ncefepime 2 grams IV as well as oseltamivir, flu swab pending. \r\nCXR at ___ showed no evidence of pneumonia. Urinalysis \r\nwas negative for evidence of infection. \r\n\r\nIn the ED, initial vitals were 102.4 ___ 18 94%. Labs at \r\n___ showed WBC count 8.8K with 89% neutrophils, \r\nhematocrit 28.2, platelets 104K. INR was 1.3. Anion gap was 13. \r\nCT head showed no acute intracranial abnormality. Patient \r\nreceived ondansetron 2 mg IV x 1, metoclopramide 5 mg IV x 1, \r\nand hydromorphone 2 mg IV x 1. Lumbar puncture was not attempted \r\ndue to patient being on rivaroxaban, and it was recommended he \r\nstart empiric IV acyclovir and he got one dose. Vitals on \r\ntransfer were 101.7 106 122/56 18 94% RA. \r\n\r\nOn the floor, patient notes diffuse headache with some neck \r\ndiscomfort and stiffness, as well as photophobia. This headache \r\nis different than migraines she has had in the past. She has \r\nalso been nauseous and vomited several times, non-bloody, \r\nnon-bilious. \r\n\r\nReview of sytems: \r\n(+) Per HPI \r\n(-) Denies recent weight loss or gain. Denies headache, sinus \r\ntenderness, rhinorrhea or congestion. Denies cough, shortness of \r\nbreath. Denies chest pain or tightness, palpitations. Denies \r\ndiarrhea, constipation or abdominal pain. No recent change in \r\nbowel or bladder habits. No dysuria. Denies arthralgias. Ten \r\npoint review of systems is otherwise negative. \r\n\r\n \r\nPast Medical History:\r\nONCOLOGIC HISTORY: \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n___: Transplant Date: 1 \r\n___: Day Post Transplant: 44 \r\n___: Graft: Auto \r\n___: Conditioning Intensity: Ablative \r\n___: Conditioning Regimen: BEAM \r\n\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass \r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access. Biopsies showed \r\nFollicular lymphomas grade II/III. Reportedly negative staging \r\nGallium scan. CD10+ BCL2+ \r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA) \r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone \r\nmarrow at completion was negative for lymphomatous involvement. \r\n- ___ PET-CT with very slight amount of increased tracer \r\nactivity within the posterior left supraclavicular region. No \r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP \r\nfollowed by course of single agent Rituxan \r\n- ___ through ___ surveillance imaging with no evidence of \r\nrecurrent disease, stable mesenteric mass. \r\n- ___ abdominal pain led to CT with no change in mass size, \r\nincreased conspicuity of nodular borders \r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise \r\n\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior. \r\n- ___ CT torso showed persistent mesenteric and left hilar \r\nlymphadenopathy. Stable right middle lobe small focus of ground \r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive \r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam \r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1, \r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal \r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning \r\nfor \r\nlymphoma.\" SUVmax 35.5. \r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare \r\npending \r\n- ___ C1D1 ICE \r\n- ___ C1 Rituximab, clincally improved adenopathy \r\n- ___ C2 Rituximab, WBC 6.5, PLT 43 \r\n- ___ Admit for C2D1 ICE \r\n- ___ C3 Rituximab \r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a residual focus of avidity in the bed of the \r\nformer \r\nabdominal mass, SUV 3 \r\n- ___ C4 Rituximab \r\n- ___ C4 ICE followed by stem cell mobilization and \r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive \r\nlymphoma \r\n- ___ Presented with large DVTs, SVC filter placed \r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis \r\n- ___ Switched to Rivaroxiban for AC \r\n- ___. Interval decrease in size of \r\nretroperitoneal lymphadenopathy, with persistent low-level FDG \r\nuptake. No new FDG-avid disease. 2. Resolution of cervical, \r\nsupraclavicular and mediastinal lymphadenopathy. 3. IVC filter \r\nin place, new since the prior PET-CT. 4. Stable non-FDG avid \r\nright adnexal hypodensity. PFTs with normal Hb adjusted DLCO \r\n- ___ IVIg 400 mg/kg \r\n\r\nPAST MEDICAL HISTORY: \r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\n\r\nabove. \r\n--CLL, noted on BM biopsy on ___. \r\n--Deep venous thrombosis \r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye) \r\n--Hypogammaglobulinemia \r\n--Mild GERD \r\n--OA / LBP \r\n--Small Intestinal Bacterial Overgrowth \r\n--Trochanteric Bursitis \r\n--s/p Excisional Bx L Cervical Lymph Node \r\n--s/p L total knee replacement ___, walks with cane \r\n--s/p I&D Labial Abscess \r\n--s/p Excision Cyst R ___ Digit of Hand \r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n--------------\r\nVitals: T: 101.8 BP: 130/84 P: 113 R: 18 O2: 94% on RA \r\nGEN: Alert, oriented to name, place and situation. Fatigued \r\nappearing but comfortable, no acute signs of distress. \r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MM dry. \r\nNeck: Supple, no JVD \r\nLymph nodes: No cervical, supraclavicular LAD. \r\nCV: S1S2, tachycardic but regular, no murmurs, rubs or gallops. \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing. \r\nABD: Soft, non-tender, non-distended, + bowel sounds. \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient. \r\nDERM: No active rash. Indwelling catheter in right chest, with \r\nmild erythema, no fluctuance, reportedly unchanged. \r\nNeuro: non-focal. \r\nPSYCH: Appropriate and calm. \r\n\r\nDISCHARGE EXAM\r\n--------------\r\nVitals:  98.___.4 125/62 88 18 97% RA\r\nGEN: Alert, oriented. NAD, looks well today\r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MMM.  \r\nNeck: Supple, no JVD  \r\nLymph nodes: No cervical, supraclavicular LAD.  \r\nCV: S1S2, RRR, no murmurs, rubs or gallops.  \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing.  \r\nABD: Soft, non-tender, non-distended, + bowel sounds.  \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient.  \r\nDERM: Indwelling catheter in right chest without acute signs of \r\ninfxn. \r\nNeuro: non-focal.  \r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n--------------\r\n___ 06:25AM BLOOD WBC-10.0# RBC-2.70* Hgb-8.9* Hct-28.6* \r\nMCV-106* MCH-32.9* MCHC-31.1 RDW-21.3* Plt ___\r\n___ 06:25AM BLOOD ___ PTT-33.1 ___\r\n___ 06:25AM BLOOD Glucose-118* UreaN-9 Creat-0.8 Na-137 \r\nK-3.5 Cl-103 HCO3-24 AnGap-14\r\n___ 06:25AM BLOOD ALT-13 AST-24 LD(LDH)-174 AlkPhos-72 \r\nTotBili-0.3\r\n___ 06:25AM BLOOD Calcium-8.5 Phos-2.7 Mg-1.7\r\n\r\nDISCHARGE LABS\r\n--------------\r\n___ 06:00AM BLOOD WBC-2.2* RBC-2.41* Hgb-8.1* Hct-25.9* \r\nMCV-107* MCH-33.6* MCHC-31.3 RDW-21.0* Plt Ct-78*\r\n___ 06:00AM BLOOD Glucose-91 UreaN-9 Creat-0.6 Na-140 K-4.0 \r\nCl-110* HCO3-25 AnGap-9\r\n___ 06:00AM BLOOD Calcium-8.2* Phos-2.5* Mg-2.1\r\n\r\nPENDING LABS\r\n--------------\r\n___ 11:57AM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-PND\r\n___ 11:57 am CMV Viral Load (Pending)\r\n \r\nBrief Hospital Course:\r\n___ with DVT s/p IVC filter and on rivaroxaban, CLL, CVID, and \r\ntransformed lymphoma s/p autoSCT 44 days ago, and IVIG ___, \r\nwho now presented with headache, fevers/rigors, and vomiting.\r\n\r\n# FEVER, HEADACHE, VOMITING: These symptoms occured within 12 \r\nhours of finishing her last infusion of IVIG. Etiology is most \r\nlikely aseptic meningitis as she also had neck stiffness and \r\nsome mild photophobia. Her symptoms improved with supportive IV \r\nfluids, anti-emetics, and NSAIDs. At first she was started \r\nempirically on IV Vanc, IV cefepime, IV acyclovir, and Tamiflu \r\nto treat possible bacterial or HSV meningitis or influenza. \r\nRapid flu screen was negative so Tamiflu was stopped. She had no \r\nencephalitis and was on ppx acyclovir prior to presentation, so \r\nsuspicion of HSV meningoencephalitis was very low so IV \r\nacyclovir was stopped. Once ___ blood cultures were \r\nnegative >24 hours, IV antibiotics were also stopped. The \r\npatient continued to improve and was afebrile > 24 hrs prior to \r\ndischarge. \r\n\r\n# LYMPHOMA: s/p auto-stem cell transplant 44 days prior to \r\nadmission. She was continued on ppx bactrim and acyclovir. She \r\nwill f/u with her outpatient providers.\r\n\r\n# H/o DVT: Rivaroxaban was held while inpatient since we were at \r\nfirst considering lumbar puncture. It was restarted on \r\ndischarge. \r\n\r\nTRANSITIONAL ISSUES:\r\n--------------------\r\n# F/u CMV and EBV viral loads\r\n# Code status: Full \r\n# Contact: husband ___, ___ \r\n\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Rivaroxaban 15 mg PO DAILY \r\n9. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Multivitamins 1 TAB PO DAILY \r\n4. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n5. Gabapentin 900 mg PO BID \r\n6. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n7. Venlafaxine 25 mg PO BID \r\n8. Metoclopramide 10 mg PO TID:PRN nausea \r\nRX *metoclopramide HCl 10 mg 1 tablet by mouth Up to three times \r\nper day Disp #*15 Tablet Refills:*0\r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n10. Furosemide 20 mg PO DAILY \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Potassium Chloride 10 mEq PO DAILY \r\n13. Rivaroxaban 15 mg PO DAILY \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS:\r\nIVIG Aseptic meningitis\r\n\r\nSECONDARY DIAGNOSIS:\r\ntransformed lymphoma s/p auto stem cell transplant\r\nCVID\r\nNeutropenia\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted to the hospital for high fevers, headache, and \r\nvomiting. We are not sure what caused your symptoms, but the \r\nmost likely cause is IVIG-associated aseptic meningitis. Another \r\ncause may be a viral infection. We felt it was very unlikely you \r\nhad a bacterial infection so we stopped your antibiotics. You \r\ncontinued to improve. Your fevers and headaches improved. Your \r\nvomiting was well-controlled on medications. And you were able \r\nto tolerate enough hydration by mouth and no longer needed IVs, \r\nso you were discharged home with plans to follow up with Dr. \r\n___ Dr. ___.\r\n\r\nIt was a pleasure to take care of you during your hospital stay,\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-13:7",
      "text": "Brief Hospital Course:\n___ with DVT s/p IVC filter and on rivaroxaban, CLL, CVID, and \ntransformed lymphoma s/p autoSCT 44 days ago, and IVIG ___, \nwho now presented with headache, fevers/rigors, and vomiting. # FEVER, HEADACHE, VOMITING: These symptoms occured within 12 \nhours of finishing her last infusion of IVIG. Etiology is most \nlikely aseptic meningitis as she also had neck stiffness and \nsome mild photophobia. Her symptoms improved with supportive IV \nfluids, anti-emetics, and NSAIDs. At first she was started \nempirically on IV Vanc, IV cefepime, IV acyclovir, and Tamiflu \nto treat possible bacterial or HSV meningitis or influenza. Rapid flu screen was negative so Tamiflu was stopped. She had no \nencephalitis and was on ppx acyclovir prior to presentation, so \nsuspicion of HSV meningoencephalitis was very low so IV \nacyclovir was stopped. Once ___ blood cultures were \nnegative >24 hours, IV antibiotics were also stopped. The \npatient continued to improve and was afebrile > 24 hrs prior to \ndischarge. # LYMPHOMA: s/p auto-stem cell transplant 44 days prior to \nadmission. She was continued on ppx bactrim and acyclovir. She \nwill f/u with her outpatient providers. # H/o DVT: Rivaroxaban was held while inpatient since we were at \nfirst considering lumbar puncture. It was restarted on \ndischarge. TRANSITIONAL ISSUES:\n--------------------\n# F/u CMV and EBV viral loads\n# Code status: Full \n# Contact: husband ___, ___ ___ on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Acyclovir 400 mg PO Q8H \n2. FoLIC Acid 1 mg PO DAILY \n3. Furosemide 20 mg PO DAILY \n4. Gabapentin 900 mg PO BID \n5. Omeprazole 20 mg PO DAILY \n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \n7. Potassium Chloride 10 mEq PO DAILY \n8. Rivaroxaban 15 mg PO DAILY \n9. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \n10. Venlafaxine 25 mg PO BID \n11. Cyanocobalamin 1000 mcg PO DAILY \n12. Multivitamins 1 TAB PO DAILY",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-13",
        "chart_time": "103398",
        "section": "General",
        "position": 7,
        "tokenCount": 484,
        "note_metadata": {
          "note_id": "18887130-DS-13",
          "subject_id": 18887130,
          "hadm_id": 28298007,
          "note_type": "DS",
          "note_seq": 13,
          "charttime": 103398,
          "storetime": 103398.76319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nFever\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with a history of transformed lymphoma s/p \r\nautoSCT 44 days ago as well as comorbid CVID and CLL, who \r\nreceived IVIg for immunodeficiency on the day prior to \r\nadmission. Today, she had a headache, rigors, and fever to \r\n100.5. She also reported general malaise. Patient has an \r\nindwelling catheter and IVC filter in place. She presented to \r\n___, where blood cultures x 2, urinalysis and urine \r\nculture were performed. She received empiric vancomycin and \r\ncefepime 2 grams IV as well as oseltamivir, flu swab pending. \r\nCXR at ___ showed no evidence of pneumonia. Urinalysis \r\nwas negative for evidence of infection. \r\n\r\nIn the ED, initial vitals were 102.4 ___ 18 94%. Labs at \r\n___ showed WBC count 8.8K with 89% neutrophils, \r\nhematocrit 28.2, platelets 104K. INR was 1.3. Anion gap was 13. \r\nCT head showed no acute intracranial abnormality. Patient \r\nreceived ondansetron 2 mg IV x 1, metoclopramide 5 mg IV x 1, \r\nand hydromorphone 2 mg IV x 1. Lumbar puncture was not attempted \r\ndue to patient being on rivaroxaban, and it was recommended he \r\nstart empiric IV acyclovir and he got one dose. Vitals on \r\ntransfer were 101.7 106 122/56 18 94% RA. \r\n\r\nOn the floor, patient notes diffuse headache with some neck \r\ndiscomfort and stiffness, as well as photophobia. This headache \r\nis different than migraines she has had in the past. She has \r\nalso been nauseous and vomited several times, non-bloody, \r\nnon-bilious. \r\n\r\nReview of sytems: \r\n(+) Per HPI \r\n(-) Denies recent weight loss or gain. Denies headache, sinus \r\ntenderness, rhinorrhea or congestion. Denies cough, shortness of \r\nbreath. Denies chest pain or tightness, palpitations. Denies \r\ndiarrhea, constipation or abdominal pain. No recent change in \r\nbowel or bladder habits. No dysuria. Denies arthralgias. Ten \r\npoint review of systems is otherwise negative. \r\n\r\n \r\nPast Medical History:\r\nONCOLOGIC HISTORY: \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n___: Transplant Date: 1 \r\n___: Day Post Transplant: 44 \r\n___: Graft: Auto \r\n___: Conditioning Intensity: Ablative \r\n___: Conditioning Regimen: BEAM \r\n\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass \r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access. Biopsies showed \r\nFollicular lymphomas grade II/III. Reportedly negative staging \r\nGallium scan. CD10+ BCL2+ \r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA) \r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone \r\nmarrow at completion was negative for lymphomatous involvement. \r\n- ___ PET-CT with very slight amount of increased tracer \r\nactivity within the posterior left supraclavicular region. No \r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP \r\nfollowed by course of single agent Rituxan \r\n- ___ through ___ surveillance imaging with no evidence of \r\nrecurrent disease, stable mesenteric mass. \r\n- ___ abdominal pain led to CT with no change in mass size, \r\nincreased conspicuity of nodular borders \r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise \r\n\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior. \r\n- ___ CT torso showed persistent mesenteric and left hilar \r\nlymphadenopathy. Stable right middle lobe small focus of ground \r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive \r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam \r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1, \r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal \r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning \r\nfor \r\nlymphoma.\" SUVmax 35.5. \r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare \r\npending \r\n- ___ C1D1 ICE \r\n- ___ C1 Rituximab, clincally improved adenopathy \r\n- ___ C2 Rituximab, WBC 6.5, PLT 43 \r\n- ___ Admit for C2D1 ICE \r\n- ___ C3 Rituximab \r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a residual focus of avidity in the bed of the \r\nformer \r\nabdominal mass, SUV 3 \r\n- ___ C4 Rituximab \r\n- ___ C4 ICE followed by stem cell mobilization and \r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive \r\nlymphoma \r\n- ___ Presented with large DVTs, SVC filter placed \r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis \r\n- ___ Switched to Rivaroxiban for AC \r\n- ___. Interval decrease in size of \r\nretroperitoneal lymphadenopathy, with persistent low-level FDG \r\nuptake. No new FDG-avid disease. 2. Resolution of cervical, \r\nsupraclavicular and mediastinal lymphadenopathy. 3. IVC filter \r\nin place, new since the prior PET-CT. 4. Stable non-FDG avid \r\nright adnexal hypodensity. PFTs with normal Hb adjusted DLCO \r\n- ___ IVIg 400 mg/kg \r\n\r\nPAST MEDICAL HISTORY: \r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\n\r\nabove. \r\n--CLL, noted on BM biopsy on ___. \r\n--Deep venous thrombosis \r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye) \r\n--Hypogammaglobulinemia \r\n--Mild GERD \r\n--OA / LBP \r\n--Small Intestinal Bacterial Overgrowth \r\n--Trochanteric Bursitis \r\n--s/p Excisional Bx L Cervical Lymph Node \r\n--s/p L total knee replacement ___, walks with cane \r\n--s/p I&D Labial Abscess \r\n--s/p Excision Cyst R ___ Digit of Hand \r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n--------------\r\nVitals: T: 101.8 BP: 130/84 P: 113 R: 18 O2: 94% on RA \r\nGEN: Alert, oriented to name, place and situation. Fatigued \r\nappearing but comfortable, no acute signs of distress. \r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MM dry. \r\nNeck: Supple, no JVD \r\nLymph nodes: No cervical, supraclavicular LAD. \r\nCV: S1S2, tachycardic but regular, no murmurs, rubs or gallops. \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing. \r\nABD: Soft, non-tender, non-distended, + bowel sounds. \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient. \r\nDERM: No active rash. Indwelling catheter in right chest, with \r\nmild erythema, no fluctuance, reportedly unchanged. \r\nNeuro: non-focal. \r\nPSYCH: Appropriate and calm. \r\n\r\nDISCHARGE EXAM\r\n--------------\r\nVitals:  98.___.4 125/62 88 18 97% RA\r\nGEN: Alert, oriented. NAD, looks well today\r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MMM.  \r\nNeck: Supple, no JVD  \r\nLymph nodes: No cervical, supraclavicular LAD.  \r\nCV: S1S2, RRR, no murmurs, rubs or gallops.  \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing.  \r\nABD: Soft, non-tender, non-distended, + bowel sounds.  \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient.  \r\nDERM: Indwelling catheter in right chest without acute signs of \r\ninfxn. \r\nNeuro: non-focal.  \r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n--------------\r\n___ 06:25AM BLOOD WBC-10.0# RBC-2.70* Hgb-8.9* Hct-28.6* \r\nMCV-106* MCH-32.9* MCHC-31.1 RDW-21.3* Plt ___\r\n___ 06:25AM BLOOD ___ PTT-33.1 ___\r\n___ 06:25AM BLOOD Glucose-118* UreaN-9 Creat-0.8 Na-137 \r\nK-3.5 Cl-103 HCO3-24 AnGap-14\r\n___ 06:25AM BLOOD ALT-13 AST-24 LD(LDH)-174 AlkPhos-72 \r\nTotBili-0.3\r\n___ 06:25AM BLOOD Calcium-8.5 Phos-2.7 Mg-1.7\r\n\r\nDISCHARGE LABS\r\n--------------\r\n___ 06:00AM BLOOD WBC-2.2* RBC-2.41* Hgb-8.1* Hct-25.9* \r\nMCV-107* MCH-33.6* MCHC-31.3 RDW-21.0* Plt Ct-78*\r\n___ 06:00AM BLOOD Glucose-91 UreaN-9 Creat-0.6 Na-140 K-4.0 \r\nCl-110* HCO3-25 AnGap-9\r\n___ 06:00AM BLOOD Calcium-8.2* Phos-2.5* Mg-2.1\r\n\r\nPENDING LABS\r\n--------------\r\n___ 11:57AM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-PND\r\n___ 11:57 am CMV Viral Load (Pending)\r\n \r\nBrief Hospital Course:\r\n___ with DVT s/p IVC filter and on rivaroxaban, CLL, CVID, and \r\ntransformed lymphoma s/p autoSCT 44 days ago, and IVIG ___, \r\nwho now presented with headache, fevers/rigors, and vomiting.\r\n\r\n# FEVER, HEADACHE, VOMITING: These symptoms occured within 12 \r\nhours of finishing her last infusion of IVIG. Etiology is most \r\nlikely aseptic meningitis as she also had neck stiffness and \r\nsome mild photophobia. Her symptoms improved with supportive IV \r\nfluids, anti-emetics, and NSAIDs. At first she was started \r\nempirically on IV Vanc, IV cefepime, IV acyclovir, and Tamiflu \r\nto treat possible bacterial or HSV meningitis or influenza. \r\nRapid flu screen was negative so Tamiflu was stopped. She had no \r\nencephalitis and was on ppx acyclovir prior to presentation, so \r\nsuspicion of HSV meningoencephalitis was very low so IV \r\nacyclovir was stopped. Once ___ blood cultures were \r\nnegative >24 hours, IV antibiotics were also stopped. The \r\npatient continued to improve and was afebrile > 24 hrs prior to \r\ndischarge. \r\n\r\n# LYMPHOMA: s/p auto-stem cell transplant 44 days prior to \r\nadmission. She was continued on ppx bactrim and acyclovir. She \r\nwill f/u with her outpatient providers.\r\n\r\n# H/o DVT: Rivaroxaban was held while inpatient since we were at \r\nfirst considering lumbar puncture. It was restarted on \r\ndischarge. \r\n\r\nTRANSITIONAL ISSUES:\r\n--------------------\r\n# F/u CMV and EBV viral loads\r\n# Code status: Full \r\n# Contact: husband ___, ___ \r\n\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Rivaroxaban 15 mg PO DAILY \r\n9. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Multivitamins 1 TAB PO DAILY \r\n4. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n5. Gabapentin 900 mg PO BID \r\n6. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n7. Venlafaxine 25 mg PO BID \r\n8. Metoclopramide 10 mg PO TID:PRN nausea \r\nRX *metoclopramide HCl 10 mg 1 tablet by mouth Up to three times \r\nper day Disp #*15 Tablet Refills:*0\r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n10. Furosemide 20 mg PO DAILY \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Potassium Chloride 10 mEq PO DAILY \r\n13. Rivaroxaban 15 mg PO DAILY \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS:\r\nIVIG Aseptic meningitis\r\n\r\nSECONDARY DIAGNOSIS:\r\ntransformed lymphoma s/p auto stem cell transplant\r\nCVID\r\nNeutropenia\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted to the hospital for high fevers, headache, and \r\nvomiting. We are not sure what caused your symptoms, but the \r\nmost likely cause is IVIG-associated aseptic meningitis. Another \r\ncause may be a viral infection. We felt it was very unlikely you \r\nhad a bacterial infection so we stopped your antibiotics. You \r\ncontinued to improve. Your fevers and headaches improved. Your \r\nvomiting was well-controlled on medications. And you were able \r\nto tolerate enough hydration by mouth and no longer needed IVs, \r\nso you were discharged home with plans to follow up with Dr. \r\n___ Dr. ___.\r\n\r\nIt was a pleasure to take care of you during your hospital stay,\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-13:8",
      "text": "Discharge Medications:\n1. Acyclovir 400 mg PO Q8H \n2. FoLIC Acid 1 mg PO DAILY \n3. Multivitamins 1 TAB PO DAILY \n4. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \n5. Gabapentin 900 mg PO BID \n6. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \n7. Venlafaxine 25 mg PO BID \n8. Metoclopramide 10 mg PO TID:PRN nausea \nRX *metoclopramide HCl 10 mg 1 tablet by mouth Up to three times \nper day Disp #*15 Tablet Refills:*0\n9. Cyanocobalamin 1000 mcg PO DAILY \n10. Furosemide 20 mg PO DAILY \n11. Omeprazole 20 mg PO DAILY \n12. Potassium Chloride 10 mEq PO DAILY \n13. Rivaroxaban 15 mg PO DAILY Discharge Disposition:\nHome Discharge Diagnosis:\nPRIMARY DIAGNOSIS:\nIVIG Aseptic meningitis SECONDARY DIAGNOSIS:\ntransformed lymphoma s/p auto stem cell transplant\nCVID\nNeutropenia Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-13",
        "chart_time": "103398",
        "section": "General",
        "position": 8,
        "tokenCount": 229,
        "note_metadata": {
          "note_id": "18887130-DS-13",
          "subject_id": 18887130,
          "hadm_id": 28298007,
          "note_type": "DS",
          "note_seq": 13,
          "charttime": 103398,
          "storetime": 103398.76319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nFever\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with a history of transformed lymphoma s/p \r\nautoSCT 44 days ago as well as comorbid CVID and CLL, who \r\nreceived IVIg for immunodeficiency on the day prior to \r\nadmission. Today, she had a headache, rigors, and fever to \r\n100.5. She also reported general malaise. Patient has an \r\nindwelling catheter and IVC filter in place. She presented to \r\n___, where blood cultures x 2, urinalysis and urine \r\nculture were performed. She received empiric vancomycin and \r\ncefepime 2 grams IV as well as oseltamivir, flu swab pending. \r\nCXR at ___ showed no evidence of pneumonia. Urinalysis \r\nwas negative for evidence of infection. \r\n\r\nIn the ED, initial vitals were 102.4 ___ 18 94%. Labs at \r\n___ showed WBC count 8.8K with 89% neutrophils, \r\nhematocrit 28.2, platelets 104K. INR was 1.3. Anion gap was 13. \r\nCT head showed no acute intracranial abnormality. Patient \r\nreceived ondansetron 2 mg IV x 1, metoclopramide 5 mg IV x 1, \r\nand hydromorphone 2 mg IV x 1. Lumbar puncture was not attempted \r\ndue to patient being on rivaroxaban, and it was recommended he \r\nstart empiric IV acyclovir and he got one dose. Vitals on \r\ntransfer were 101.7 106 122/56 18 94% RA. \r\n\r\nOn the floor, patient notes diffuse headache with some neck \r\ndiscomfort and stiffness, as well as photophobia. This headache \r\nis different than migraines she has had in the past. She has \r\nalso been nauseous and vomited several times, non-bloody, \r\nnon-bilious. \r\n\r\nReview of sytems: \r\n(+) Per HPI \r\n(-) Denies recent weight loss or gain. Denies headache, sinus \r\ntenderness, rhinorrhea or congestion. Denies cough, shortness of \r\nbreath. Denies chest pain or tightness, palpitations. Denies \r\ndiarrhea, constipation or abdominal pain. No recent change in \r\nbowel or bladder habits. No dysuria. Denies arthralgias. Ten \r\npoint review of systems is otherwise negative. \r\n\r\n \r\nPast Medical History:\r\nONCOLOGIC HISTORY: \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n___: Transplant Date: 1 \r\n___: Day Post Transplant: 44 \r\n___: Graft: Auto \r\n___: Conditioning Intensity: Ablative \r\n___: Conditioning Regimen: BEAM \r\n\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass \r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access. Biopsies showed \r\nFollicular lymphomas grade II/III. Reportedly negative staging \r\nGallium scan. CD10+ BCL2+ \r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA) \r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone \r\nmarrow at completion was negative for lymphomatous involvement. \r\n- ___ PET-CT with very slight amount of increased tracer \r\nactivity within the posterior left supraclavicular region. No \r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP \r\nfollowed by course of single agent Rituxan \r\n- ___ through ___ surveillance imaging with no evidence of \r\nrecurrent disease, stable mesenteric mass. \r\n- ___ abdominal pain led to CT with no change in mass size, \r\nincreased conspicuity of nodular borders \r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise \r\n\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior. \r\n- ___ CT torso showed persistent mesenteric and left hilar \r\nlymphadenopathy. Stable right middle lobe small focus of ground \r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive \r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam \r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1, \r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal \r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning \r\nfor \r\nlymphoma.\" SUVmax 35.5. \r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare \r\npending \r\n- ___ C1D1 ICE \r\n- ___ C1 Rituximab, clincally improved adenopathy \r\n- ___ C2 Rituximab, WBC 6.5, PLT 43 \r\n- ___ Admit for C2D1 ICE \r\n- ___ C3 Rituximab \r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a residual focus of avidity in the bed of the \r\nformer \r\nabdominal mass, SUV 3 \r\n- ___ C4 Rituximab \r\n- ___ C4 ICE followed by stem cell mobilization and \r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive \r\nlymphoma \r\n- ___ Presented with large DVTs, SVC filter placed \r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis \r\n- ___ Switched to Rivaroxiban for AC \r\n- ___. Interval decrease in size of \r\nretroperitoneal lymphadenopathy, with persistent low-level FDG \r\nuptake. No new FDG-avid disease. 2. Resolution of cervical, \r\nsupraclavicular and mediastinal lymphadenopathy. 3. IVC filter \r\nin place, new since the prior PET-CT. 4. Stable non-FDG avid \r\nright adnexal hypodensity. PFTs with normal Hb adjusted DLCO \r\n- ___ IVIg 400 mg/kg \r\n\r\nPAST MEDICAL HISTORY: \r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\n\r\nabove. \r\n--CLL, noted on BM biopsy on ___. \r\n--Deep venous thrombosis \r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye) \r\n--Hypogammaglobulinemia \r\n--Mild GERD \r\n--OA / LBP \r\n--Small Intestinal Bacterial Overgrowth \r\n--Trochanteric Bursitis \r\n--s/p Excisional Bx L Cervical Lymph Node \r\n--s/p L total knee replacement ___, walks with cane \r\n--s/p I&D Labial Abscess \r\n--s/p Excision Cyst R ___ Digit of Hand \r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n--------------\r\nVitals: T: 101.8 BP: 130/84 P: 113 R: 18 O2: 94% on RA \r\nGEN: Alert, oriented to name, place and situation. Fatigued \r\nappearing but comfortable, no acute signs of distress. \r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MM dry. \r\nNeck: Supple, no JVD \r\nLymph nodes: No cervical, supraclavicular LAD. \r\nCV: S1S2, tachycardic but regular, no murmurs, rubs or gallops. \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing. \r\nABD: Soft, non-tender, non-distended, + bowel sounds. \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient. \r\nDERM: No active rash. Indwelling catheter in right chest, with \r\nmild erythema, no fluctuance, reportedly unchanged. \r\nNeuro: non-focal. \r\nPSYCH: Appropriate and calm. \r\n\r\nDISCHARGE EXAM\r\n--------------\r\nVitals:  98.___.4 125/62 88 18 97% RA\r\nGEN: Alert, oriented. NAD, looks well today\r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MMM.  \r\nNeck: Supple, no JVD  \r\nLymph nodes: No cervical, supraclavicular LAD.  \r\nCV: S1S2, RRR, no murmurs, rubs or gallops.  \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing.  \r\nABD: Soft, non-tender, non-distended, + bowel sounds.  \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient.  \r\nDERM: Indwelling catheter in right chest without acute signs of \r\ninfxn. \r\nNeuro: non-focal.  \r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n--------------\r\n___ 06:25AM BLOOD WBC-10.0# RBC-2.70* Hgb-8.9* Hct-28.6* \r\nMCV-106* MCH-32.9* MCHC-31.1 RDW-21.3* Plt ___\r\n___ 06:25AM BLOOD ___ PTT-33.1 ___\r\n___ 06:25AM BLOOD Glucose-118* UreaN-9 Creat-0.8 Na-137 \r\nK-3.5 Cl-103 HCO3-24 AnGap-14\r\n___ 06:25AM BLOOD ALT-13 AST-24 LD(LDH)-174 AlkPhos-72 \r\nTotBili-0.3\r\n___ 06:25AM BLOOD Calcium-8.5 Phos-2.7 Mg-1.7\r\n\r\nDISCHARGE LABS\r\n--------------\r\n___ 06:00AM BLOOD WBC-2.2* RBC-2.41* Hgb-8.1* Hct-25.9* \r\nMCV-107* MCH-33.6* MCHC-31.3 RDW-21.0* Plt Ct-78*\r\n___ 06:00AM BLOOD Glucose-91 UreaN-9 Creat-0.6 Na-140 K-4.0 \r\nCl-110* HCO3-25 AnGap-9\r\n___ 06:00AM BLOOD Calcium-8.2* Phos-2.5* Mg-2.1\r\n\r\nPENDING LABS\r\n--------------\r\n___ 11:57AM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-PND\r\n___ 11:57 am CMV Viral Load (Pending)\r\n \r\nBrief Hospital Course:\r\n___ with DVT s/p IVC filter and on rivaroxaban, CLL, CVID, and \r\ntransformed lymphoma s/p autoSCT 44 days ago, and IVIG ___, \r\nwho now presented with headache, fevers/rigors, and vomiting.\r\n\r\n# FEVER, HEADACHE, VOMITING: These symptoms occured within 12 \r\nhours of finishing her last infusion of IVIG. Etiology is most \r\nlikely aseptic meningitis as she also had neck stiffness and \r\nsome mild photophobia. Her symptoms improved with supportive IV \r\nfluids, anti-emetics, and NSAIDs. At first she was started \r\nempirically on IV Vanc, IV cefepime, IV acyclovir, and Tamiflu \r\nto treat possible bacterial or HSV meningitis or influenza. \r\nRapid flu screen was negative so Tamiflu was stopped. She had no \r\nencephalitis and was on ppx acyclovir prior to presentation, so \r\nsuspicion of HSV meningoencephalitis was very low so IV \r\nacyclovir was stopped. Once ___ blood cultures were \r\nnegative >24 hours, IV antibiotics were also stopped. The \r\npatient continued to improve and was afebrile > 24 hrs prior to \r\ndischarge. \r\n\r\n# LYMPHOMA: s/p auto-stem cell transplant 44 days prior to \r\nadmission. She was continued on ppx bactrim and acyclovir. She \r\nwill f/u with her outpatient providers.\r\n\r\n# H/o DVT: Rivaroxaban was held while inpatient since we were at \r\nfirst considering lumbar puncture. It was restarted on \r\ndischarge. \r\n\r\nTRANSITIONAL ISSUES:\r\n--------------------\r\n# F/u CMV and EBV viral loads\r\n# Code status: Full \r\n# Contact: husband ___, ___ \r\n\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Rivaroxaban 15 mg PO DAILY \r\n9. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Multivitamins 1 TAB PO DAILY \r\n4. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n5. Gabapentin 900 mg PO BID \r\n6. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n7. Venlafaxine 25 mg PO BID \r\n8. Metoclopramide 10 mg PO TID:PRN nausea \r\nRX *metoclopramide HCl 10 mg 1 tablet by mouth Up to three times \r\nper day Disp #*15 Tablet Refills:*0\r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n10. Furosemide 20 mg PO DAILY \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Potassium Chloride 10 mEq PO DAILY \r\n13. Rivaroxaban 15 mg PO DAILY \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS:\r\nIVIG Aseptic meningitis\r\n\r\nSECONDARY DIAGNOSIS:\r\ntransformed lymphoma s/p auto stem cell transplant\r\nCVID\r\nNeutropenia\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted to the hospital for high fevers, headache, and \r\nvomiting. We are not sure what caused your symptoms, but the \r\nmost likely cause is IVIG-associated aseptic meningitis. Another \r\ncause may be a viral infection. We felt it was very unlikely you \r\nhad a bacterial infection so we stopped your antibiotics. You \r\ncontinued to improve. Your fevers and headaches improved. Your \r\nvomiting was well-controlled on medications. And you were able \r\nto tolerate enough hydration by mouth and no longer needed IVs, \r\nso you were discharged home with plans to follow up with Dr. \r\n___ Dr. ___.\r\n\r\nIt was a pleasure to take care of you during your hospital stay,\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-13:9",
      "text": "Discharge Instructions:\nDear Ms. ___, You were admitted to the hospital for high fevers, headache, and \nvomiting. We are not sure what caused your symptoms, but the \nmost likely cause is IVIG-associated aseptic meningitis. Another \ncause may be a viral infection. We felt it was very unlikely you \nhad a bacterial infection so we stopped your antibiotics. You \ncontinued to improve. Your fevers and headaches improved. Your \nvomiting was well-controlled on medications. And you were able \nto tolerate enough hydration by mouth and no longer needed IVs, \nso you were discharged home with plans to follow up with Dr. ___ Dr. ___. It was a pleasure to take care of you during your hospital stay,\nYour ___ Team \n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-13",
        "chart_time": "103398",
        "section": "General",
        "position": 9,
        "tokenCount": 184,
        "note_metadata": {
          "note_id": "18887130-DS-13",
          "subject_id": 18887130,
          "hadm_id": 28298007,
          "note_type": "DS",
          "note_seq": 13,
          "charttime": 103398,
          "storetime": 103398.76319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nFever\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with a history of transformed lymphoma s/p \r\nautoSCT 44 days ago as well as comorbid CVID and CLL, who \r\nreceived IVIg for immunodeficiency on the day prior to \r\nadmission. Today, she had a headache, rigors, and fever to \r\n100.5. She also reported general malaise. Patient has an \r\nindwelling catheter and IVC filter in place. She presented to \r\n___, where blood cultures x 2, urinalysis and urine \r\nculture were performed. She received empiric vancomycin and \r\ncefepime 2 grams IV as well as oseltamivir, flu swab pending. \r\nCXR at ___ showed no evidence of pneumonia. Urinalysis \r\nwas negative for evidence of infection. \r\n\r\nIn the ED, initial vitals were 102.4 ___ 18 94%. Labs at \r\n___ showed WBC count 8.8K with 89% neutrophils, \r\nhematocrit 28.2, platelets 104K. INR was 1.3. Anion gap was 13. \r\nCT head showed no acute intracranial abnormality. Patient \r\nreceived ondansetron 2 mg IV x 1, metoclopramide 5 mg IV x 1, \r\nand hydromorphone 2 mg IV x 1. Lumbar puncture was not attempted \r\ndue to patient being on rivaroxaban, and it was recommended he \r\nstart empiric IV acyclovir and he got one dose. Vitals on \r\ntransfer were 101.7 106 122/56 18 94% RA. \r\n\r\nOn the floor, patient notes diffuse headache with some neck \r\ndiscomfort and stiffness, as well as photophobia. This headache \r\nis different than migraines she has had in the past. She has \r\nalso been nauseous and vomited several times, non-bloody, \r\nnon-bilious. \r\n\r\nReview of sytems: \r\n(+) Per HPI \r\n(-) Denies recent weight loss or gain. Denies headache, sinus \r\ntenderness, rhinorrhea or congestion. Denies cough, shortness of \r\nbreath. Denies chest pain or tightness, palpitations. Denies \r\ndiarrhea, constipation or abdominal pain. No recent change in \r\nbowel or bladder habits. No dysuria. Denies arthralgias. Ten \r\npoint review of systems is otherwise negative. \r\n\r\n \r\nPast Medical History:\r\nONCOLOGIC HISTORY: \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA \r\n___: Transplant Date: 1 \r\n___: Day Post Transplant: 44 \r\n___: Graft: Auto \r\n___: Conditioning Intensity: Ablative \r\n___: Conditioning Regimen: BEAM \r\n\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass \r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access. Biopsies showed \r\nFollicular lymphomas grade II/III. Reportedly negative staging \r\nGallium scan. CD10+ BCL2+ \r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA) \r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone \r\nmarrow at completion was negative for lymphomatous involvement. \r\n- ___ PET-CT with very slight amount of increased tracer \r\nactivity within the posterior left supraclavicular region. No \r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP \r\nfollowed by course of single agent Rituxan \r\n- ___ through ___ surveillance imaging with no evidence of \r\nrecurrent disease, stable mesenteric mass. \r\n- ___ abdominal pain led to CT with no change in mass size, \r\nincreased conspicuity of nodular borders \r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise \r\n\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior. \r\n- ___ CT torso showed persistent mesenteric and left hilar \r\nlymphadenopathy. Stable right middle lobe small focus of ground \r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive \r\nof inflammatory process. Stable right adnexal cyst. \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam \r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1, \r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal \r\nlymphadenopathy, and retroperitoneal lymphadenopathy, and small \r\nmesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning \r\nfor \r\nlymphoma.\" SUVmax 35.5. \r\n- ___iopsy revealed diffuse large B cell \r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare \r\npending \r\n- ___ C1D1 ICE \r\n- ___ C1 Rituximab, clincally improved adenopathy \r\n- ___ C2 Rituximab, WBC 6.5, PLT 43 \r\n- ___ Admit for C2D1 ICE \r\n- ___ C3 Rituximab \r\n- ___ PET CT showed almost complete resolution of FDG avid \r\ndisease with a residual focus of avidity in the bed of the \r\nformer \r\nabdominal mass, SUV 3 \r\n- ___ C4 Rituximab \r\n- ___ C4 ICE followed by stem cell mobilization and \r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive \r\nlymphoma \r\n- ___ Presented with large DVTs, SVC filter placed \r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis \r\n- ___ Switched to Rivaroxiban for AC \r\n- ___. Interval decrease in size of \r\nretroperitoneal lymphadenopathy, with persistent low-level FDG \r\nuptake. No new FDG-avid disease. 2. Resolution of cervical, \r\nsupraclavicular and mediastinal lymphadenopathy. 3. IVC filter \r\nin place, new since the prior PET-CT. 4. Stable non-FDG avid \r\nright adnexal hypodensity. PFTs with normal Hb adjusted DLCO \r\n- ___ IVIg 400 mg/kg \r\n\r\nPAST MEDICAL HISTORY: \r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\n\r\nabove. \r\n--CLL, noted on BM biopsy on ___. \r\n--Deep venous thrombosis \r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye) \r\n--Hypogammaglobulinemia \r\n--Mild GERD \r\n--OA / LBP \r\n--Small Intestinal Bacterial Overgrowth \r\n--Trochanteric Bursitis \r\n--s/p Excisional Bx L Cervical Lymph Node \r\n--s/p L total knee replacement ___, walks with cane \r\n--s/p I&D Labial Abscess \r\n--s/p Excision Cyst R ___ Digit of Hand \r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother: lymphoma. \r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n--------------\r\nVitals: T: 101.8 BP: 130/84 P: 113 R: 18 O2: 94% on RA \r\nGEN: Alert, oriented to name, place and situation. Fatigued \r\nappearing but comfortable, no acute signs of distress. \r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MM dry. \r\nNeck: Supple, no JVD \r\nLymph nodes: No cervical, supraclavicular LAD. \r\nCV: S1S2, tachycardic but regular, no murmurs, rubs or gallops. \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing. \r\nABD: Soft, non-tender, non-distended, + bowel sounds. \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient. \r\nDERM: No active rash. Indwelling catheter in right chest, with \r\nmild erythema, no fluctuance, reportedly unchanged. \r\nNeuro: non-focal. \r\nPSYCH: Appropriate and calm. \r\n\r\nDISCHARGE EXAM\r\n--------------\r\nVitals:  98.___.4 125/62 88 18 97% RA\r\nGEN: Alert, oriented. NAD, looks well today\r\nHEENT: NCAT, Pupils equal and reactive, sclerae anicteric, OP \r\nclear, MMM.  \r\nNeck: Supple, no JVD  \r\nLymph nodes: No cervical, supraclavicular LAD.  \r\nCV: S1S2, RRR, no murmurs, rubs or gallops.  \r\nRESP: Good air movement bilaterally, no rhonchi or wheezing.  \r\nABD: Soft, non-tender, non-distended, + bowel sounds.  \r\nEXTR: No lower leg edema, no clubbing or cyanosis. Erythematous \r\nchanges on lower legs consistent with known venous stasis, per \r\npatient.  \r\nDERM: Indwelling catheter in right chest without acute signs of \r\ninfxn. \r\nNeuro: non-focal.  \r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n--------------\r\n___ 06:25AM BLOOD WBC-10.0# RBC-2.70* Hgb-8.9* Hct-28.6* \r\nMCV-106* MCH-32.9* MCHC-31.1 RDW-21.3* Plt ___\r\n___ 06:25AM BLOOD ___ PTT-33.1 ___\r\n___ 06:25AM BLOOD Glucose-118* UreaN-9 Creat-0.8 Na-137 \r\nK-3.5 Cl-103 HCO3-24 AnGap-14\r\n___ 06:25AM BLOOD ALT-13 AST-24 LD(LDH)-174 AlkPhos-72 \r\nTotBili-0.3\r\n___ 06:25AM BLOOD Calcium-8.5 Phos-2.7 Mg-1.7\r\n\r\nDISCHARGE LABS\r\n--------------\r\n___ 06:00AM BLOOD WBC-2.2* RBC-2.41* Hgb-8.1* Hct-25.9* \r\nMCV-107* MCH-33.6* MCHC-31.3 RDW-21.0* Plt Ct-78*\r\n___ 06:00AM BLOOD Glucose-91 UreaN-9 Creat-0.6 Na-140 K-4.0 \r\nCl-110* HCO3-25 AnGap-9\r\n___ 06:00AM BLOOD Calcium-8.2* Phos-2.5* Mg-2.1\r\n\r\nPENDING LABS\r\n--------------\r\n___ 11:57AM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-PND\r\n___ 11:57 am CMV Viral Load (Pending)\r\n \r\nBrief Hospital Course:\r\n___ with DVT s/p IVC filter and on rivaroxaban, CLL, CVID, and \r\ntransformed lymphoma s/p autoSCT 44 days ago, and IVIG ___, \r\nwho now presented with headache, fevers/rigors, and vomiting.\r\n\r\n# FEVER, HEADACHE, VOMITING: These symptoms occured within 12 \r\nhours of finishing her last infusion of IVIG. Etiology is most \r\nlikely aseptic meningitis as she also had neck stiffness and \r\nsome mild photophobia. Her symptoms improved with supportive IV \r\nfluids, anti-emetics, and NSAIDs. At first she was started \r\nempirically on IV Vanc, IV cefepime, IV acyclovir, and Tamiflu \r\nto treat possible bacterial or HSV meningitis or influenza. \r\nRapid flu screen was negative so Tamiflu was stopped. She had no \r\nencephalitis and was on ppx acyclovir prior to presentation, so \r\nsuspicion of HSV meningoencephalitis was very low so IV \r\nacyclovir was stopped. Once ___ blood cultures were \r\nnegative >24 hours, IV antibiotics were also stopped. The \r\npatient continued to improve and was afebrile > 24 hrs prior to \r\ndischarge. \r\n\r\n# LYMPHOMA: s/p auto-stem cell transplant 44 days prior to \r\nadmission. She was continued on ppx bactrim and acyclovir. She \r\nwill f/u with her outpatient providers.\r\n\r\n# H/o DVT: Rivaroxaban was held while inpatient since we were at \r\nfirst considering lumbar puncture. It was restarted on \r\ndischarge. \r\n\r\nTRANSITIONAL ISSUES:\r\n--------------------\r\n# F/u CMV and EBV viral loads\r\n# Code status: Full \r\n# Contact: husband ___, ___ \r\n\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Rivaroxaban 15 mg PO DAILY \r\n9. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 1 mg PO DAILY \r\n3. Multivitamins 1 TAB PO DAILY \r\n4. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n5. Gabapentin 900 mg PO BID \r\n6. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n7. Venlafaxine 25 mg PO BID \r\n8. Metoclopramide 10 mg PO TID:PRN nausea \r\nRX *metoclopramide HCl 10 mg 1 tablet by mouth Up to three times \r\nper day Disp #*15 Tablet Refills:*0\r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n10. Furosemide 20 mg PO DAILY \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Potassium Chloride 10 mEq PO DAILY \r\n13. Rivaroxaban 15 mg PO DAILY \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS:\r\nIVIG Aseptic meningitis\r\n\r\nSECONDARY DIAGNOSIS:\r\ntransformed lymphoma s/p auto stem cell transplant\r\nCVID\r\nNeutropenia\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted to the hospital for high fevers, headache, and \r\nvomiting. We are not sure what caused your symptoms, but the \r\nmost likely cause is IVIG-associated aseptic meningitis. Another \r\ncause may be a viral infection. We felt it was very unlikely you \r\nhad a bacterial infection so we stopped your antibiotics. You \r\ncontinued to improve. Your fevers and headaches improved. Your \r\nvomiting was well-controlled on medications. And you were able \r\nto tolerate enough hydration by mouth and no longer needed IVs, \r\nso you were discharged home with plans to follow up with Dr. \r\n___ Dr. ___.\r\n\r\nIt was a pleasure to take care of you during your hospital stay,\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-14:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \ndapsone\n \nAttending: ___\n \n___ Complaint:\ndiarrhea, abdominal discomfort Major Surgical or Invasive Procedure:\nNone",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-14",
        "chart_time": "103483",
        "section": "General",
        "position": 0,
        "tokenCount": 73,
        "note_metadata": {
          "note_id": "18887130-DS-14",
          "subject_id": 18887130,
          "hadm_id": 29581683,
          "note_type": "DS",
          "note_seq": 14,
          "charttime": 103483,
          "storetime": 103483.69791666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\ndiarrhea, abdominal discomfort\r\n\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\n___ year old female with transformed DLBCL stage IIIB s/p autoSCT \r\nwith BEAM conditioning course complicated by BCNU pneumonitis \r\nwho presents today on D+129 for evaluation of diarrhea.\r\n\r\nPatient reports feeling well, in her usual state of health about \r\n5 days ago.  On ___ evening, she noticed some mild epigastric \r\ndiscomfort.  Earlier in the day, both she and her husband had \r\nreheated ___ and vegetables.  She woke on ___ morning \r\nwith intermittent crampiness with sudden onset emesis and \r\ndiarrhea.  The emesis looked like undigested food, without blood \r\nor bile.  The diarrhea was non-bloody.  The symtoms persisted \r\nthroughout the day.  She tried to stay up with hydration.  The \r\npain, still intermittent, became more severe yesterday.  She \r\nthen was directed to ___.  In the ED, she received IVF, \r\na CT abdomen/pelvis was obtained (see below), she received some \r\nmorphine for pain control, and was discharged home after \r\nsymptoms improved.  After returning home, she had ongoing \r\ndiarrhea this morning, and presented to ___ clinic for routine \r\nfollow up, and has been admitted to the floor for further \r\nevaluation.\r\n\r\nUpon arrival to the floor, she notes intermittent epigastric \r\ndiscomfort, mild, without radiation.  She had an episode of \r\ndiarrhea in the clinic.  No emesis for about 48 hours.  She is \r\nnot hungry.  She denies any fevers or chills.  Her husband does \r\nnot have any GI symptoms, she has had no sick contact or recent \r\ntravel.  She denies any rashes.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission physical:\r\n\r\nPHYSICAL EXAM: \r\nVITALS -  98.8  116/78  HR ___  RR 16  96% RA\r\nGeneral: pleasant, no distress, appears stated age\r\nHEENT: anicteric sclerae, clear oropharynx without lesions\r\nNeck: no adenopathy\r\nCV: RRR, normal S1, S2, no murmurs or rubs\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions, active BS, soft, mildly \r\ntender in epigastrium, no rebound or guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: CNs ___ intact, strength and sensation grossly intact, \r\nambulatory without assistance\r\nSkin: no petechiae  \r\n\r\nDischarge physical:\r\n\r\nVITALS -  Tm 99.1, Tc 98, BP 100/62, HR 84, RR 18, SpO2 97 ra\r\nI/O: (-/400 over past 8 hours) (1600/750 over past 24)\r\nGeneral: pleasant, lying in bed in no acute distress\r\nHEENT: normalocephalic/atraumatic, anicteric sclerae \r\nNeck: supple\r\nCV: RRR, ___ holosystolic murmur noted loudest at ___ ___ \r\nintercostal space (patient confirmed history of flow murmur)\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions with some tissue \r\ndeformity, + BS, soft, mildly tender in epigastrium, no rebound \r\nor guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: Alert and conversing appropriately, moving all \r\nextremities\r\nSkin: no rashes or lesions \r\n\r\n \r\nPertinent Results:\r\nAdmission labs:\r\n\r\n___ 03:15PM BLOOD WBC-4.8 RBC-2.35* Hgb-9.8* Hct-31.4* \r\nMCV-134* MCH-41.8* MCHC-31.3 RDW-16.9* Plt Ct-69*\r\n___ 11:52PM BLOOD WBC-3.2* RBC-2.13* Hgb-8.8* Hct-28.3* \r\nMCV-133* MCH-41.3* MCHC-31.1 RDW-16.9* Plt Ct-68*\r\n___ 03:15PM BLOOD Neuts-93.3* Lymphs-4.6* Monos-1.7* \r\nEos-0.4 Baso-0.2\r\n___ 03:15PM BLOOD Plt Ct-69*\r\n___ 11:52PM BLOOD ___ PTT-32.1 ___\r\n___ 11:52PM BLOOD Plt Ct-68*\r\n___ 11:52PM BLOOD Ret Aut-4.6*\r\n___ 03:15PM BLOOD UreaN-16 Creat-0.7 Na-140 K-3.7 Cl-104 \r\nHCO3-26 AnGap-14\r\n___ 11:52PM BLOOD UreaN-14 Creat-0.7 Na-141 K-3.4 Cl-108 \r\nHCO3-26 AnGap-10\r\n___ 03:15PM BLOOD Albumin-3.7 Calcium-8.5 Phos-3.0 Mg-1.8\r\n___ 11:52PM BLOOD Calcium-8.1* Phos-3.0 Mg-1.8\r\n___ 03:15PM BLOOD ALT-19 AST-27 LD(LDH)-266* AlkPhos-69 \r\nTotBili-0.3\r\n\r\nMicro:\r\n\r\nStool cultures:\r\n\r\n___ 10:36 pm STOOL     CONSISTENCY: WATERY      Source: \r\nStool. \r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Illumigene DNA\r\n      amplification assay. \r\n           (Reference Range-Negative). \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   VIRAL CULTURE (Pending): \r\n\r\nImaging:\r\n\r\n___:  lipase 12, urinalysis normal  \r\n\r\nIMAGING at ___ ___:\r\n\r\nChest PA and lateral:\r\nThe lungs remains clear.  The heart and mediastinal structures \r\nare unremarkable for technique, and appear stable.  The bony \r\nthorax is grossly intact.  A double-lumen right internal jugular \r\ncatheter remains in place.\r\n\r\nCT abdomen/pelvis with oral contrast, without IV contrast \r\n(comparison made to PET CT from ___:\r\nREDEMONSTRATION OF RETROPERITONEAL OR MESENTERIC \r\nLYMPHADENOPATHY, WHICH, ALLOWING FOR DIFFERENCES IN TECHNIQUE, \r\nAPPEARS STABLE. ILL DEFINED INCREASED DENSITY WITHIN THE \r\nMESENTERY IS SLIGHTLY MORE PRONOUNCED THAN BEFORE.  IT IS \r\nPOSSIBLE THAT SUBTLE CHANGES ARE DUE TO ACTIVE LYMPHOMA AND, IF \r\nCLINICALLY INDICATED, FURTHER EVALUATION BY PET/CT IS \r\nRECOMMENDED.\r\n      \r\n3.5 CM-THICK LESION IN THE RIGHT PELVIS THAT PROBABLY REPRESENTS \r\nAN OVARIAN CYST, UNCHANGED.  THIS COULD BE FURTHER EVALUATED BY \r\nSONOGRAPHY, IF CLINICALLY INDICATED.\r\n\r\nDischarge labs:\r\n\r\n___ 12:00AM BLOOD WBC-3.5* RBC-2.16* Hgb-9.1* Hct-29.0* \r\nMCV-135* MCH-42.2* MCHC-31.3 RDW-16.5* Plt Ct-62*\r\n___ 12:00AM BLOOD Neuts-74.2* Lymphs-16.3* Monos-8.6 \r\nEos-0.7 Baso-0.1\r\n___ 12:00AM BLOOD Plt Ct-62*\r\n___ 12:00AM BLOOD Glucose-74 UreaN-11 Creat-0.7 Na-137 \r\nK-4.0 Cl-104 HCO3-26 AnGap-11\r\n___ 12:00AM BLOOD Calcium-8.6 Phos-2.9 Mg-1.9\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old woman with transformed DLBCL stage \r\nIIIB s/p autoSCT with BEAM conditioning course complicated by \r\n___ pneumonitis who presents today on D+131 (as of ___ for \r\nevaluation of diarrhea and abdominal pain, likely \r\ngastroenteritis.\r\n\r\n# Emesis/diarrhea- history most consistent with viral \r\ngastroenteritis, with norovirus on differential. On the day \r\nafter admission, she reported that her husband had fallen ill \r\nthat day with similar symptoms. CT did not demonstrate colitis, \r\nbut was performed without IV contrast. Ischemic colitis is \r\nunlikely given no cardiovascular risk factors. Other ddx include \r\ngastritis, pancreatitis, and hepatitis, but given her clinical \r\npresentation, these are less likely. Received 1L maintenance \r\nfluids overnight on ___. She still had some diarrhea and \r\nabdominal pain on ___ but her symptoms had greatly improved by \r\n___ and she was tolerating po's well. She was maintained on a \r\nlow residue diet and her home furosemide was temporarily held. \r\nC. diff returned negative and other stool cultures/pcr were \r\npending at the time of discharge. She was scheduled for clinic \r\nfollow-up on ___.\r\n\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by ___ pneumonitis. LDH 266. She has a restaging \r\nPET/CT scheduled for next week. She received pentamidine for PJP \r\nppx on ___. She was maintained on acyclovir ppx as an \r\ninpatient. Although patient's symptoms are most likely from \r\ngastroenteritis and are currently improving, disease progression \r\nshould be considered. She will obtain her outpatient PET/CT \r\nafter discharge.\r\n \r\n#Hypogammaglobulinemia: Patient's last IgG was 340 on ___. \r\nReceived an infusion on ___. Plan was to check an IgG \r\nlevel/consider IVIG infusion if symptoms worsened, but the \r\npatient improved with IV/po fluids. \r\n\r\n# History of BCNU pneumonitis- Patient receives weekly DLCO with \r\nprednisone taper (5 mg weekly). She was continued on prednisone \r\n25 mg daily with plans to continue taper after discharge. Her \r\nnext set of PFT's are already scheduled.\r\n\r\n# Right ___ DVT- continued rivaroxaban.  Has IVC filter in place.\r\n\r\n# Pancytopenia- Possibly viral suppression of bone \r\nmarrow/dilution effect from IVF. Reticulocyte count 4.6. WBC \r\nimproving on ___ but platelets continuing to downtrend. She \r\nwill need to f/u in clinic after discharge to ensure that her \r\ncounts and platelets are recovering.\r\n\r\n# Hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm. Continued home gabapentin.\r\n\r\n# GERD- continued home omeprazole\r\n\r\n# Depression- continued home venlafaxine\r\n\r\n# CODE: Full\r\n# EMERGENCY CONTACT: \r\nName of health care proxy: ___ \r\nRelationship: husband \r\nPhone number: ___\r\n\r\n___ issues:\r\n-Will need to f/u CBC in clinic to ensure recovery of her counts\r\n-Will need to continue her steroid taper as an outpatient: on 25 \r\nmg at discharge.\r\n-Ms. ___ did not require any prescriptions at discharge as \r\nshe stated she already has the medications she needs. She cares \r\nfor her triple lumen catheter herself.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ascorbic Acid ___ mg PO DAILY \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n4. Ascorbic Acid ___ mg PO DAILY \r\n5. Cyanocobalamin 1000 mcg PO DAILY \r\n6. Gabapentin 900 mg PO BID \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n11. Furosemide 20 mg PO DAILY \r\n12. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary diagnosis:\r\n# Emesis/diarrhea\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by BCNU pneumonitis. \r\n#Hypogammaglobulinemia\r\n# History of BCNU pneumonitis\r\n\r\nSecondary diagnoses\r\n# Right ___ DVT\r\n# Pancytopenia\r\n# Hyperthesia of R V1/V2\r\n# GERD\r\n# Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___. You were admitted \r\nafter experiencing nausea, diarrhea, and abdominal pain. Your \r\nsymptoms are likely from a viral illness and improved during \r\nyour hospital stay with fluids and pain medication. You were \r\neventually able to eat and drink adequately and were discharged \r\nhome. If you experience worsening diarrhea, nausea, or abdominal \r\npain or develop fever/chills after your discharge, please call \r\nclinic or return to the Emergency Department as soon as \r\npossible. You have follow-up appointments scheduled on ___ with \r\nheme-onc.\r\n\r\nTake care, and we wish you the best.\r\n\r\nSincerely,\r\nYour BMT team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-14:1",
      "text": "History of Present Illness:\n___ year old female with transformed DLBCL stage IIIB s/p autoSCT \nwith BEAM conditioning course complicated by BCNU pneumonitis \nwho presents today on D+129 for evaluation of diarrhea. Patient reports feeling well, in her usual state of health about \n5 days ago. On ___ evening, she noticed some mild epigastric \ndiscomfort. Earlier in the day, both she and her husband had \nreheated ___ and vegetables. She woke on ___ morning \nwith intermittent crampiness with sudden onset emesis and \ndiarrhea. The emesis looked like undigested food, without blood \nor bile. The diarrhea was non-bloody. The symtoms persisted \nthroughout the day. She tried to stay up with hydration. The \npain, still intermittent, became more severe yesterday. She \nthen was directed to ___. In the ED, she received IVF, \na CT abdomen/pelvis was obtained (see below), she received some \nmorphine for pain control, and was discharged home after \nsymptoms improved. After returning home, she had ongoing \ndiarrhea this morning, and presented to ___ clinic for routine \nfollow up, and has been admitted to the floor for further \nevaluation. Upon arrival to the floor, she notes intermittent epigastric \ndiscomfort, mild, without radiation. She had an episode of \ndiarrhea in the clinic. No emesis for about 48 hours. She is \nnot hungry. She denies any fevers or chills. Her husband does \nnot have any GI symptoms, she has had no sick contact or recent \ntravel. She denies any rashes.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-14",
        "chart_time": "103483",
        "section": "General",
        "position": 1,
        "tokenCount": 370,
        "note_metadata": {
          "note_id": "18887130-DS-14",
          "subject_id": 18887130,
          "hadm_id": 29581683,
          "note_type": "DS",
          "note_seq": 14,
          "charttime": 103483,
          "storetime": 103483.69791666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\ndiarrhea, abdominal discomfort\r\n\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\n___ year old female with transformed DLBCL stage IIIB s/p autoSCT \r\nwith BEAM conditioning course complicated by BCNU pneumonitis \r\nwho presents today on D+129 for evaluation of diarrhea.\r\n\r\nPatient reports feeling well, in her usual state of health about \r\n5 days ago.  On ___ evening, she noticed some mild epigastric \r\ndiscomfort.  Earlier in the day, both she and her husband had \r\nreheated ___ and vegetables.  She woke on ___ morning \r\nwith intermittent crampiness with sudden onset emesis and \r\ndiarrhea.  The emesis looked like undigested food, without blood \r\nor bile.  The diarrhea was non-bloody.  The symtoms persisted \r\nthroughout the day.  She tried to stay up with hydration.  The \r\npain, still intermittent, became more severe yesterday.  She \r\nthen was directed to ___.  In the ED, she received IVF, \r\na CT abdomen/pelvis was obtained (see below), she received some \r\nmorphine for pain control, and was discharged home after \r\nsymptoms improved.  After returning home, she had ongoing \r\ndiarrhea this morning, and presented to ___ clinic for routine \r\nfollow up, and has been admitted to the floor for further \r\nevaluation.\r\n\r\nUpon arrival to the floor, she notes intermittent epigastric \r\ndiscomfort, mild, without radiation.  She had an episode of \r\ndiarrhea in the clinic.  No emesis for about 48 hours.  She is \r\nnot hungry.  She denies any fevers or chills.  Her husband does \r\nnot have any GI symptoms, she has had no sick contact or recent \r\ntravel.  She denies any rashes.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission physical:\r\n\r\nPHYSICAL EXAM: \r\nVITALS -  98.8  116/78  HR ___  RR 16  96% RA\r\nGeneral: pleasant, no distress, appears stated age\r\nHEENT: anicteric sclerae, clear oropharynx without lesions\r\nNeck: no adenopathy\r\nCV: RRR, normal S1, S2, no murmurs or rubs\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions, active BS, soft, mildly \r\ntender in epigastrium, no rebound or guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: CNs ___ intact, strength and sensation grossly intact, \r\nambulatory without assistance\r\nSkin: no petechiae  \r\n\r\nDischarge physical:\r\n\r\nVITALS -  Tm 99.1, Tc 98, BP 100/62, HR 84, RR 18, SpO2 97 ra\r\nI/O: (-/400 over past 8 hours) (1600/750 over past 24)\r\nGeneral: pleasant, lying in bed in no acute distress\r\nHEENT: normalocephalic/atraumatic, anicteric sclerae \r\nNeck: supple\r\nCV: RRR, ___ holosystolic murmur noted loudest at ___ ___ \r\nintercostal space (patient confirmed history of flow murmur)\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions with some tissue \r\ndeformity, + BS, soft, mildly tender in epigastrium, no rebound \r\nor guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: Alert and conversing appropriately, moving all \r\nextremities\r\nSkin: no rashes or lesions \r\n\r\n \r\nPertinent Results:\r\nAdmission labs:\r\n\r\n___ 03:15PM BLOOD WBC-4.8 RBC-2.35* Hgb-9.8* Hct-31.4* \r\nMCV-134* MCH-41.8* MCHC-31.3 RDW-16.9* Plt Ct-69*\r\n___ 11:52PM BLOOD WBC-3.2* RBC-2.13* Hgb-8.8* Hct-28.3* \r\nMCV-133* MCH-41.3* MCHC-31.1 RDW-16.9* Plt Ct-68*\r\n___ 03:15PM BLOOD Neuts-93.3* Lymphs-4.6* Monos-1.7* \r\nEos-0.4 Baso-0.2\r\n___ 03:15PM BLOOD Plt Ct-69*\r\n___ 11:52PM BLOOD ___ PTT-32.1 ___\r\n___ 11:52PM BLOOD Plt Ct-68*\r\n___ 11:52PM BLOOD Ret Aut-4.6*\r\n___ 03:15PM BLOOD UreaN-16 Creat-0.7 Na-140 K-3.7 Cl-104 \r\nHCO3-26 AnGap-14\r\n___ 11:52PM BLOOD UreaN-14 Creat-0.7 Na-141 K-3.4 Cl-108 \r\nHCO3-26 AnGap-10\r\n___ 03:15PM BLOOD Albumin-3.7 Calcium-8.5 Phos-3.0 Mg-1.8\r\n___ 11:52PM BLOOD Calcium-8.1* Phos-3.0 Mg-1.8\r\n___ 03:15PM BLOOD ALT-19 AST-27 LD(LDH)-266* AlkPhos-69 \r\nTotBili-0.3\r\n\r\nMicro:\r\n\r\nStool cultures:\r\n\r\n___ 10:36 pm STOOL     CONSISTENCY: WATERY      Source: \r\nStool. \r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Illumigene DNA\r\n      amplification assay. \r\n           (Reference Range-Negative). \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   VIRAL CULTURE (Pending): \r\n\r\nImaging:\r\n\r\n___:  lipase 12, urinalysis normal  \r\n\r\nIMAGING at ___ ___:\r\n\r\nChest PA and lateral:\r\nThe lungs remains clear.  The heart and mediastinal structures \r\nare unremarkable for technique, and appear stable.  The bony \r\nthorax is grossly intact.  A double-lumen right internal jugular \r\ncatheter remains in place.\r\n\r\nCT abdomen/pelvis with oral contrast, without IV contrast \r\n(comparison made to PET CT from ___:\r\nREDEMONSTRATION OF RETROPERITONEAL OR MESENTERIC \r\nLYMPHADENOPATHY, WHICH, ALLOWING FOR DIFFERENCES IN TECHNIQUE, \r\nAPPEARS STABLE. ILL DEFINED INCREASED DENSITY WITHIN THE \r\nMESENTERY IS SLIGHTLY MORE PRONOUNCED THAN BEFORE.  IT IS \r\nPOSSIBLE THAT SUBTLE CHANGES ARE DUE TO ACTIVE LYMPHOMA AND, IF \r\nCLINICALLY INDICATED, FURTHER EVALUATION BY PET/CT IS \r\nRECOMMENDED.\r\n      \r\n3.5 CM-THICK LESION IN THE RIGHT PELVIS THAT PROBABLY REPRESENTS \r\nAN OVARIAN CYST, UNCHANGED.  THIS COULD BE FURTHER EVALUATED BY \r\nSONOGRAPHY, IF CLINICALLY INDICATED.\r\n\r\nDischarge labs:\r\n\r\n___ 12:00AM BLOOD WBC-3.5* RBC-2.16* Hgb-9.1* Hct-29.0* \r\nMCV-135* MCH-42.2* MCHC-31.3 RDW-16.5* Plt Ct-62*\r\n___ 12:00AM BLOOD Neuts-74.2* Lymphs-16.3* Monos-8.6 \r\nEos-0.7 Baso-0.1\r\n___ 12:00AM BLOOD Plt Ct-62*\r\n___ 12:00AM BLOOD Glucose-74 UreaN-11 Creat-0.7 Na-137 \r\nK-4.0 Cl-104 HCO3-26 AnGap-11\r\n___ 12:00AM BLOOD Calcium-8.6 Phos-2.9 Mg-1.9\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old woman with transformed DLBCL stage \r\nIIIB s/p autoSCT with BEAM conditioning course complicated by \r\n___ pneumonitis who presents today on D+131 (as of ___ for \r\nevaluation of diarrhea and abdominal pain, likely \r\ngastroenteritis.\r\n\r\n# Emesis/diarrhea- history most consistent with viral \r\ngastroenteritis, with norovirus on differential. On the day \r\nafter admission, she reported that her husband had fallen ill \r\nthat day with similar symptoms. CT did not demonstrate colitis, \r\nbut was performed without IV contrast. Ischemic colitis is \r\nunlikely given no cardiovascular risk factors. Other ddx include \r\ngastritis, pancreatitis, and hepatitis, but given her clinical \r\npresentation, these are less likely. Received 1L maintenance \r\nfluids overnight on ___. She still had some diarrhea and \r\nabdominal pain on ___ but her symptoms had greatly improved by \r\n___ and she was tolerating po's well. She was maintained on a \r\nlow residue diet and her home furosemide was temporarily held. \r\nC. diff returned negative and other stool cultures/pcr were \r\npending at the time of discharge. She was scheduled for clinic \r\nfollow-up on ___.\r\n\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by ___ pneumonitis. LDH 266. She has a restaging \r\nPET/CT scheduled for next week. She received pentamidine for PJP \r\nppx on ___. She was maintained on acyclovir ppx as an \r\ninpatient. Although patient's symptoms are most likely from \r\ngastroenteritis and are currently improving, disease progression \r\nshould be considered. She will obtain her outpatient PET/CT \r\nafter discharge.\r\n \r\n#Hypogammaglobulinemia: Patient's last IgG was 340 on ___. \r\nReceived an infusion on ___. Plan was to check an IgG \r\nlevel/consider IVIG infusion if symptoms worsened, but the \r\npatient improved with IV/po fluids. \r\n\r\n# History of BCNU pneumonitis- Patient receives weekly DLCO with \r\nprednisone taper (5 mg weekly). She was continued on prednisone \r\n25 mg daily with plans to continue taper after discharge. Her \r\nnext set of PFT's are already scheduled.\r\n\r\n# Right ___ DVT- continued rivaroxaban.  Has IVC filter in place.\r\n\r\n# Pancytopenia- Possibly viral suppression of bone \r\nmarrow/dilution effect from IVF. Reticulocyte count 4.6. WBC \r\nimproving on ___ but platelets continuing to downtrend. She \r\nwill need to f/u in clinic after discharge to ensure that her \r\ncounts and platelets are recovering.\r\n\r\n# Hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm. Continued home gabapentin.\r\n\r\n# GERD- continued home omeprazole\r\n\r\n# Depression- continued home venlafaxine\r\n\r\n# CODE: Full\r\n# EMERGENCY CONTACT: \r\nName of health care proxy: ___ \r\nRelationship: husband \r\nPhone number: ___\r\n\r\n___ issues:\r\n-Will need to f/u CBC in clinic to ensure recovery of her counts\r\n-Will need to continue her steroid taper as an outpatient: on 25 \r\nmg at discharge.\r\n-Ms. ___ did not require any prescriptions at discharge as \r\nshe stated she already has the medications she needs. She cares \r\nfor her triple lumen catheter herself.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ascorbic Acid ___ mg PO DAILY \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n4. Ascorbic Acid ___ mg PO DAILY \r\n5. Cyanocobalamin 1000 mcg PO DAILY \r\n6. Gabapentin 900 mg PO BID \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n11. Furosemide 20 mg PO DAILY \r\n12. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary diagnosis:\r\n# Emesis/diarrhea\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by BCNU pneumonitis. \r\n#Hypogammaglobulinemia\r\n# History of BCNU pneumonitis\r\n\r\nSecondary diagnoses\r\n# Right ___ DVT\r\n# Pancytopenia\r\n# Hyperthesia of R V1/V2\r\n# GERD\r\n# Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___. You were admitted \r\nafter experiencing nausea, diarrhea, and abdominal pain. Your \r\nsymptoms are likely from a viral illness and improved during \r\nyour hospital stay with fluids and pain medication. You were \r\neventually able to eat and drink adequately and were discharged \r\nhome. If you experience worsening diarrhea, nausea, or abdominal \r\npain or develop fever/chills after your discharge, please call \r\nclinic or return to the Emergency Department as soon as \r\npossible. You have follow-up appointments scheduled on ___ with \r\nheme-onc.\r\n\r\nTake care, and we wish you the best.\r\n\r\nSincerely,\r\nYour BMT team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-14:2",
      "text": "Past Medical History:\nOncologic history: In brief, history of follicular lymphoma \nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \nrituximab in ___ for residual disease. ___: RICE \nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \nlocal disease. She has a hx of hypogammaglobulinemia. obesity\nAcute DVT in the right popliteal/femoral veins + superficial \nthrombosis\n--Transformed DLBCL with history of follicular lymphoma as noted \nabove\n--CLL, noted on BM biopsy on ___. --Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \n(*Known slight CN VI palsy & mild proptosis of R eye)\n--Hypogammaglobulinemia, receives IVIG PRN\n--R leg DVT. IVC filter in place, on rivaroxaban\n--BCNU pneumonitis, on prednisone\n--Mild GERD\n--OA / LBP\n--Small Intestinal Bacterial Overgrowth\n--Trochanteric Bursitis\n--s/p Excisional Bx L Cervical Lymph Node\n--s/p L total knee replacement ___, walks with cane\n--s/p I&D Labial Abscess\n--s/p Excision Cyst R ___ Digit of Hand Social History:\n___ Family History:\nbrother- lymphoma Physical ___:\nAdmission physical:",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-14",
        "chart_time": "103483",
        "section": "General",
        "position": 2,
        "tokenCount": 266,
        "note_metadata": {
          "note_id": "18887130-DS-14",
          "subject_id": 18887130,
          "hadm_id": 29581683,
          "note_type": "DS",
          "note_seq": 14,
          "charttime": 103483,
          "storetime": 103483.69791666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\ndiarrhea, abdominal discomfort\r\n\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\n___ year old female with transformed DLBCL stage IIIB s/p autoSCT \r\nwith BEAM conditioning course complicated by BCNU pneumonitis \r\nwho presents today on D+129 for evaluation of diarrhea.\r\n\r\nPatient reports feeling well, in her usual state of health about \r\n5 days ago.  On ___ evening, she noticed some mild epigastric \r\ndiscomfort.  Earlier in the day, both she and her husband had \r\nreheated ___ and vegetables.  She woke on ___ morning \r\nwith intermittent crampiness with sudden onset emesis and \r\ndiarrhea.  The emesis looked like undigested food, without blood \r\nor bile.  The diarrhea was non-bloody.  The symtoms persisted \r\nthroughout the day.  She tried to stay up with hydration.  The \r\npain, still intermittent, became more severe yesterday.  She \r\nthen was directed to ___.  In the ED, she received IVF, \r\na CT abdomen/pelvis was obtained (see below), she received some \r\nmorphine for pain control, and was discharged home after \r\nsymptoms improved.  After returning home, she had ongoing \r\ndiarrhea this morning, and presented to ___ clinic for routine \r\nfollow up, and has been admitted to the floor for further \r\nevaluation.\r\n\r\nUpon arrival to the floor, she notes intermittent epigastric \r\ndiscomfort, mild, without radiation.  She had an episode of \r\ndiarrhea in the clinic.  No emesis for about 48 hours.  She is \r\nnot hungry.  She denies any fevers or chills.  Her husband does \r\nnot have any GI symptoms, she has had no sick contact or recent \r\ntravel.  She denies any rashes.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission physical:\r\n\r\nPHYSICAL EXAM: \r\nVITALS -  98.8  116/78  HR ___  RR 16  96% RA\r\nGeneral: pleasant, no distress, appears stated age\r\nHEENT: anicteric sclerae, clear oropharynx without lesions\r\nNeck: no adenopathy\r\nCV: RRR, normal S1, S2, no murmurs or rubs\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions, active BS, soft, mildly \r\ntender in epigastrium, no rebound or guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: CNs ___ intact, strength and sensation grossly intact, \r\nambulatory without assistance\r\nSkin: no petechiae  \r\n\r\nDischarge physical:\r\n\r\nVITALS -  Tm 99.1, Tc 98, BP 100/62, HR 84, RR 18, SpO2 97 ra\r\nI/O: (-/400 over past 8 hours) (1600/750 over past 24)\r\nGeneral: pleasant, lying in bed in no acute distress\r\nHEENT: normalocephalic/atraumatic, anicteric sclerae \r\nNeck: supple\r\nCV: RRR, ___ holosystolic murmur noted loudest at ___ ___ \r\nintercostal space (patient confirmed history of flow murmur)\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions with some tissue \r\ndeformity, + BS, soft, mildly tender in epigastrium, no rebound \r\nor guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: Alert and conversing appropriately, moving all \r\nextremities\r\nSkin: no rashes or lesions \r\n\r\n \r\nPertinent Results:\r\nAdmission labs:\r\n\r\n___ 03:15PM BLOOD WBC-4.8 RBC-2.35* Hgb-9.8* Hct-31.4* \r\nMCV-134* MCH-41.8* MCHC-31.3 RDW-16.9* Plt Ct-69*\r\n___ 11:52PM BLOOD WBC-3.2* RBC-2.13* Hgb-8.8* Hct-28.3* \r\nMCV-133* MCH-41.3* MCHC-31.1 RDW-16.9* Plt Ct-68*\r\n___ 03:15PM BLOOD Neuts-93.3* Lymphs-4.6* Monos-1.7* \r\nEos-0.4 Baso-0.2\r\n___ 03:15PM BLOOD Plt Ct-69*\r\n___ 11:52PM BLOOD ___ PTT-32.1 ___\r\n___ 11:52PM BLOOD Plt Ct-68*\r\n___ 11:52PM BLOOD Ret Aut-4.6*\r\n___ 03:15PM BLOOD UreaN-16 Creat-0.7 Na-140 K-3.7 Cl-104 \r\nHCO3-26 AnGap-14\r\n___ 11:52PM BLOOD UreaN-14 Creat-0.7 Na-141 K-3.4 Cl-108 \r\nHCO3-26 AnGap-10\r\n___ 03:15PM BLOOD Albumin-3.7 Calcium-8.5 Phos-3.0 Mg-1.8\r\n___ 11:52PM BLOOD Calcium-8.1* Phos-3.0 Mg-1.8\r\n___ 03:15PM BLOOD ALT-19 AST-27 LD(LDH)-266* AlkPhos-69 \r\nTotBili-0.3\r\n\r\nMicro:\r\n\r\nStool cultures:\r\n\r\n___ 10:36 pm STOOL     CONSISTENCY: WATERY      Source: \r\nStool. \r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Illumigene DNA\r\n      amplification assay. \r\n           (Reference Range-Negative). \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   VIRAL CULTURE (Pending): \r\n\r\nImaging:\r\n\r\n___:  lipase 12, urinalysis normal  \r\n\r\nIMAGING at ___ ___:\r\n\r\nChest PA and lateral:\r\nThe lungs remains clear.  The heart and mediastinal structures \r\nare unremarkable for technique, and appear stable.  The bony \r\nthorax is grossly intact.  A double-lumen right internal jugular \r\ncatheter remains in place.\r\n\r\nCT abdomen/pelvis with oral contrast, without IV contrast \r\n(comparison made to PET CT from ___:\r\nREDEMONSTRATION OF RETROPERITONEAL OR MESENTERIC \r\nLYMPHADENOPATHY, WHICH, ALLOWING FOR DIFFERENCES IN TECHNIQUE, \r\nAPPEARS STABLE. ILL DEFINED INCREASED DENSITY WITHIN THE \r\nMESENTERY IS SLIGHTLY MORE PRONOUNCED THAN BEFORE.  IT IS \r\nPOSSIBLE THAT SUBTLE CHANGES ARE DUE TO ACTIVE LYMPHOMA AND, IF \r\nCLINICALLY INDICATED, FURTHER EVALUATION BY PET/CT IS \r\nRECOMMENDED.\r\n      \r\n3.5 CM-THICK LESION IN THE RIGHT PELVIS THAT PROBABLY REPRESENTS \r\nAN OVARIAN CYST, UNCHANGED.  THIS COULD BE FURTHER EVALUATED BY \r\nSONOGRAPHY, IF CLINICALLY INDICATED.\r\n\r\nDischarge labs:\r\n\r\n___ 12:00AM BLOOD WBC-3.5* RBC-2.16* Hgb-9.1* Hct-29.0* \r\nMCV-135* MCH-42.2* MCHC-31.3 RDW-16.5* Plt Ct-62*\r\n___ 12:00AM BLOOD Neuts-74.2* Lymphs-16.3* Monos-8.6 \r\nEos-0.7 Baso-0.1\r\n___ 12:00AM BLOOD Plt Ct-62*\r\n___ 12:00AM BLOOD Glucose-74 UreaN-11 Creat-0.7 Na-137 \r\nK-4.0 Cl-104 HCO3-26 AnGap-11\r\n___ 12:00AM BLOOD Calcium-8.6 Phos-2.9 Mg-1.9\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old woman with transformed DLBCL stage \r\nIIIB s/p autoSCT with BEAM conditioning course complicated by \r\n___ pneumonitis who presents today on D+131 (as of ___ for \r\nevaluation of diarrhea and abdominal pain, likely \r\ngastroenteritis.\r\n\r\n# Emesis/diarrhea- history most consistent with viral \r\ngastroenteritis, with norovirus on differential. On the day \r\nafter admission, she reported that her husband had fallen ill \r\nthat day with similar symptoms. CT did not demonstrate colitis, \r\nbut was performed without IV contrast. Ischemic colitis is \r\nunlikely given no cardiovascular risk factors. Other ddx include \r\ngastritis, pancreatitis, and hepatitis, but given her clinical \r\npresentation, these are less likely. Received 1L maintenance \r\nfluids overnight on ___. She still had some diarrhea and \r\nabdominal pain on ___ but her symptoms had greatly improved by \r\n___ and she was tolerating po's well. She was maintained on a \r\nlow residue diet and her home furosemide was temporarily held. \r\nC. diff returned negative and other stool cultures/pcr were \r\npending at the time of discharge. She was scheduled for clinic \r\nfollow-up on ___.\r\n\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by ___ pneumonitis. LDH 266. She has a restaging \r\nPET/CT scheduled for next week. She received pentamidine for PJP \r\nppx on ___. She was maintained on acyclovir ppx as an \r\ninpatient. Although patient's symptoms are most likely from \r\ngastroenteritis and are currently improving, disease progression \r\nshould be considered. She will obtain her outpatient PET/CT \r\nafter discharge.\r\n \r\n#Hypogammaglobulinemia: Patient's last IgG was 340 on ___. \r\nReceived an infusion on ___. Plan was to check an IgG \r\nlevel/consider IVIG infusion if symptoms worsened, but the \r\npatient improved with IV/po fluids. \r\n\r\n# History of BCNU pneumonitis- Patient receives weekly DLCO with \r\nprednisone taper (5 mg weekly). She was continued on prednisone \r\n25 mg daily with plans to continue taper after discharge. Her \r\nnext set of PFT's are already scheduled.\r\n\r\n# Right ___ DVT- continued rivaroxaban.  Has IVC filter in place.\r\n\r\n# Pancytopenia- Possibly viral suppression of bone \r\nmarrow/dilution effect from IVF. Reticulocyte count 4.6. WBC \r\nimproving on ___ but platelets continuing to downtrend. She \r\nwill need to f/u in clinic after discharge to ensure that her \r\ncounts and platelets are recovering.\r\n\r\n# Hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm. Continued home gabapentin.\r\n\r\n# GERD- continued home omeprazole\r\n\r\n# Depression- continued home venlafaxine\r\n\r\n# CODE: Full\r\n# EMERGENCY CONTACT: \r\nName of health care proxy: ___ \r\nRelationship: husband \r\nPhone number: ___\r\n\r\n___ issues:\r\n-Will need to f/u CBC in clinic to ensure recovery of her counts\r\n-Will need to continue her steroid taper as an outpatient: on 25 \r\nmg at discharge.\r\n-Ms. ___ did not require any prescriptions at discharge as \r\nshe stated she already has the medications she needs. She cares \r\nfor her triple lumen catheter herself.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ascorbic Acid ___ mg PO DAILY \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n4. Ascorbic Acid ___ mg PO DAILY \r\n5. Cyanocobalamin 1000 mcg PO DAILY \r\n6. Gabapentin 900 mg PO BID \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n11. Furosemide 20 mg PO DAILY \r\n12. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary diagnosis:\r\n# Emesis/diarrhea\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by BCNU pneumonitis. \r\n#Hypogammaglobulinemia\r\n# History of BCNU pneumonitis\r\n\r\nSecondary diagnoses\r\n# Right ___ DVT\r\n# Pancytopenia\r\n# Hyperthesia of R V1/V2\r\n# GERD\r\n# Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___. You were admitted \r\nafter experiencing nausea, diarrhea, and abdominal pain. Your \r\nsymptoms are likely from a viral illness and improved during \r\nyour hospital stay with fluids and pain medication. You were \r\neventually able to eat and drink adequately and were discharged \r\nhome. If you experience worsening diarrhea, nausea, or abdominal \r\npain or develop fever/chills after your discharge, please call \r\nclinic or return to the Emergency Department as soon as \r\npossible. You have follow-up appointments scheduled on ___ with \r\nheme-onc.\r\n\r\nTake care, and we wish you the best.\r\n\r\nSincerely,\r\nYour BMT team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-14:3",
      "text": "PHYSICAL EXAM: \nVITALS -  98.8  116/78  HR ___  RR 16  96% RA\nGeneral: pleasant, no distress, appears stated age\nHEENT: anicteric sclerae, clear oropharynx without lesions\nNeck: no adenopathy\nCV: RRR, normal S1, S2, no murmurs or rubs\nLungs:  clear bilaterally, good air movement\nAbdomen: well-healed surgical incisions, active BS, soft, mildly \ntender in epigastrium, no rebound or guarding, no organomegaly\nExt:   2+ radial and DP pulses, no edema\nNeuro: CNs ___ intact, strength and sensation grossly intact, \nambulatory without assistance\nSkin: no petechiae Discharge physical: VITALS -  Tm 99.1, Tc 98, BP 100/62, HR 84, RR 18, SpO2 97 ra\nI/O: (-/400 over past 8 hours) (1600/750 over past 24)\nGeneral: pleasant, lying in bed in no acute distress\nHEENT: normalocephalic/atraumatic, anicteric sclerae \nNeck: supple\nCV: RRR, ___ holosystolic murmur noted loudest at ___ ___ \nintercostal space (patient confirmed history of flow murmur)\nLungs:  clear bilaterally, good air movement\nAbdomen: well-healed surgical incisions with some tissue \ndeformity, + BS, soft, mildly tender in epigastrium, no rebound \nor guarding, no organomegaly\nExt:   2+ radial and DP pulses, no edema\nNeuro: Alert and conversing appropriately, moving all \nextremities\nSkin: no rashes or lesions Pertinent Results:\nAdmission labs: ___ 03:15PM BLOOD WBC-4.8 RBC-2.35* Hgb-9.8* Hct-31.4* \nMCV-134* MCH-41.8* MCHC-31.3 RDW-16.9* Plt Ct-69*\n___ 11:52PM BLOOD WBC-3.2* RBC-2.13* Hgb-8.8* Hct-28.3* \nMCV-133* MCH-41.3* MCHC-31.1 RDW-16.9* Plt Ct-68*\n___ 03:15PM BLOOD Neuts-93.3* Lymphs-4.6* Monos-1.7* \nEos-0.4 Baso-0.2\n___ 03:15PM BLOOD Plt Ct-69*\n___ 11:52PM BLOOD ___ PTT-32.1 ___\n___ 11:52PM BLOOD Plt Ct-68*\n___ 11:52PM BLOOD Ret Aut-4.6*\n___ 03:15PM BLOOD UreaN-16 Creat-0.7 Na-140 K-3.7 Cl-104 \nHCO3-26 AnGap-14\n___ 11:52PM BLOOD UreaN-14 Creat-0.7 Na-141 K-3.4 Cl-108 \nHCO3-26 AnGap-10\n___ 03:15PM BLOOD Albumin-3.7 Calcium-8.5 Phos-3.0 Mg-1.8\n___ 11:52PM BLOOD Calcium-8.1* Phos-3.0 Mg-1.8\n___ 03:15PM BLOOD ALT-19 AST-27 LD(LDH)-266* AlkPhos-69 \nTotBili-0.3 Micro: Stool cultures: ___ 10:36 pm STOOL     CONSISTENCY: WATERY      Source: \nStool. C. difficile DNA amplification assay (Final ___: \n      Negative for toxigenic C. difficile by the Illumigene DNA\n      amplification assay. (Reference Range-Negative). FECAL CULTURE (Pending): CAMPYLOBACTER CULTURE (Pending): OVA + PARASITES (Final ___: \n      NO OVA AND PARASITES SEEN. This test does not reliably detect Cryptosporidium, \nCyclospora or\n      Microsporidium. While most cases of Giardia are detected \nby routine\n      O+P, the Giardia antigen test may enhance detection when \norganisms\n      are rare. VIRAL CULTURE (Pending):",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-14",
        "chart_time": "103483",
        "section": "General",
        "position": 3,
        "tokenCount": 668,
        "note_metadata": {
          "note_id": "18887130-DS-14",
          "subject_id": 18887130,
          "hadm_id": 29581683,
          "note_type": "DS",
          "note_seq": 14,
          "charttime": 103483,
          "storetime": 103483.69791666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\ndiarrhea, abdominal discomfort\r\n\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\n___ year old female with transformed DLBCL stage IIIB s/p autoSCT \r\nwith BEAM conditioning course complicated by BCNU pneumonitis \r\nwho presents today on D+129 for evaluation of diarrhea.\r\n\r\nPatient reports feeling well, in her usual state of health about \r\n5 days ago.  On ___ evening, she noticed some mild epigastric \r\ndiscomfort.  Earlier in the day, both she and her husband had \r\nreheated ___ and vegetables.  She woke on ___ morning \r\nwith intermittent crampiness with sudden onset emesis and \r\ndiarrhea.  The emesis looked like undigested food, without blood \r\nor bile.  The diarrhea was non-bloody.  The symtoms persisted \r\nthroughout the day.  She tried to stay up with hydration.  The \r\npain, still intermittent, became more severe yesterday.  She \r\nthen was directed to ___.  In the ED, she received IVF, \r\na CT abdomen/pelvis was obtained (see below), she received some \r\nmorphine for pain control, and was discharged home after \r\nsymptoms improved.  After returning home, she had ongoing \r\ndiarrhea this morning, and presented to ___ clinic for routine \r\nfollow up, and has been admitted to the floor for further \r\nevaluation.\r\n\r\nUpon arrival to the floor, she notes intermittent epigastric \r\ndiscomfort, mild, without radiation.  She had an episode of \r\ndiarrhea in the clinic.  No emesis for about 48 hours.  She is \r\nnot hungry.  She denies any fevers or chills.  Her husband does \r\nnot have any GI symptoms, she has had no sick contact or recent \r\ntravel.  She denies any rashes.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission physical:\r\n\r\nPHYSICAL EXAM: \r\nVITALS -  98.8  116/78  HR ___  RR 16  96% RA\r\nGeneral: pleasant, no distress, appears stated age\r\nHEENT: anicteric sclerae, clear oropharynx without lesions\r\nNeck: no adenopathy\r\nCV: RRR, normal S1, S2, no murmurs or rubs\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions, active BS, soft, mildly \r\ntender in epigastrium, no rebound or guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: CNs ___ intact, strength and sensation grossly intact, \r\nambulatory without assistance\r\nSkin: no petechiae  \r\n\r\nDischarge physical:\r\n\r\nVITALS -  Tm 99.1, Tc 98, BP 100/62, HR 84, RR 18, SpO2 97 ra\r\nI/O: (-/400 over past 8 hours) (1600/750 over past 24)\r\nGeneral: pleasant, lying in bed in no acute distress\r\nHEENT: normalocephalic/atraumatic, anicteric sclerae \r\nNeck: supple\r\nCV: RRR, ___ holosystolic murmur noted loudest at ___ ___ \r\nintercostal space (patient confirmed history of flow murmur)\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions with some tissue \r\ndeformity, + BS, soft, mildly tender in epigastrium, no rebound \r\nor guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: Alert and conversing appropriately, moving all \r\nextremities\r\nSkin: no rashes or lesions \r\n\r\n \r\nPertinent Results:\r\nAdmission labs:\r\n\r\n___ 03:15PM BLOOD WBC-4.8 RBC-2.35* Hgb-9.8* Hct-31.4* \r\nMCV-134* MCH-41.8* MCHC-31.3 RDW-16.9* Plt Ct-69*\r\n___ 11:52PM BLOOD WBC-3.2* RBC-2.13* Hgb-8.8* Hct-28.3* \r\nMCV-133* MCH-41.3* MCHC-31.1 RDW-16.9* Plt Ct-68*\r\n___ 03:15PM BLOOD Neuts-93.3* Lymphs-4.6* Monos-1.7* \r\nEos-0.4 Baso-0.2\r\n___ 03:15PM BLOOD Plt Ct-69*\r\n___ 11:52PM BLOOD ___ PTT-32.1 ___\r\n___ 11:52PM BLOOD Plt Ct-68*\r\n___ 11:52PM BLOOD Ret Aut-4.6*\r\n___ 03:15PM BLOOD UreaN-16 Creat-0.7 Na-140 K-3.7 Cl-104 \r\nHCO3-26 AnGap-14\r\n___ 11:52PM BLOOD UreaN-14 Creat-0.7 Na-141 K-3.4 Cl-108 \r\nHCO3-26 AnGap-10\r\n___ 03:15PM BLOOD Albumin-3.7 Calcium-8.5 Phos-3.0 Mg-1.8\r\n___ 11:52PM BLOOD Calcium-8.1* Phos-3.0 Mg-1.8\r\n___ 03:15PM BLOOD ALT-19 AST-27 LD(LDH)-266* AlkPhos-69 \r\nTotBili-0.3\r\n\r\nMicro:\r\n\r\nStool cultures:\r\n\r\n___ 10:36 pm STOOL     CONSISTENCY: WATERY      Source: \r\nStool. \r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Illumigene DNA\r\n      amplification assay. \r\n           (Reference Range-Negative). \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   VIRAL CULTURE (Pending): \r\n\r\nImaging:\r\n\r\n___:  lipase 12, urinalysis normal  \r\n\r\nIMAGING at ___ ___:\r\n\r\nChest PA and lateral:\r\nThe lungs remains clear.  The heart and mediastinal structures \r\nare unremarkable for technique, and appear stable.  The bony \r\nthorax is grossly intact.  A double-lumen right internal jugular \r\ncatheter remains in place.\r\n\r\nCT abdomen/pelvis with oral contrast, without IV contrast \r\n(comparison made to PET CT from ___:\r\nREDEMONSTRATION OF RETROPERITONEAL OR MESENTERIC \r\nLYMPHADENOPATHY, WHICH, ALLOWING FOR DIFFERENCES IN TECHNIQUE, \r\nAPPEARS STABLE. ILL DEFINED INCREASED DENSITY WITHIN THE \r\nMESENTERY IS SLIGHTLY MORE PRONOUNCED THAN BEFORE.  IT IS \r\nPOSSIBLE THAT SUBTLE CHANGES ARE DUE TO ACTIVE LYMPHOMA AND, IF \r\nCLINICALLY INDICATED, FURTHER EVALUATION BY PET/CT IS \r\nRECOMMENDED.\r\n      \r\n3.5 CM-THICK LESION IN THE RIGHT PELVIS THAT PROBABLY REPRESENTS \r\nAN OVARIAN CYST, UNCHANGED.  THIS COULD BE FURTHER EVALUATED BY \r\nSONOGRAPHY, IF CLINICALLY INDICATED.\r\n\r\nDischarge labs:\r\n\r\n___ 12:00AM BLOOD WBC-3.5* RBC-2.16* Hgb-9.1* Hct-29.0* \r\nMCV-135* MCH-42.2* MCHC-31.3 RDW-16.5* Plt Ct-62*\r\n___ 12:00AM BLOOD Neuts-74.2* Lymphs-16.3* Monos-8.6 \r\nEos-0.7 Baso-0.1\r\n___ 12:00AM BLOOD Plt Ct-62*\r\n___ 12:00AM BLOOD Glucose-74 UreaN-11 Creat-0.7 Na-137 \r\nK-4.0 Cl-104 HCO3-26 AnGap-11\r\n___ 12:00AM BLOOD Calcium-8.6 Phos-2.9 Mg-1.9\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old woman with transformed DLBCL stage \r\nIIIB s/p autoSCT with BEAM conditioning course complicated by \r\n___ pneumonitis who presents today on D+131 (as of ___ for \r\nevaluation of diarrhea and abdominal pain, likely \r\ngastroenteritis.\r\n\r\n# Emesis/diarrhea- history most consistent with viral \r\ngastroenteritis, with norovirus on differential. On the day \r\nafter admission, she reported that her husband had fallen ill \r\nthat day with similar symptoms. CT did not demonstrate colitis, \r\nbut was performed without IV contrast. Ischemic colitis is \r\nunlikely given no cardiovascular risk factors. Other ddx include \r\ngastritis, pancreatitis, and hepatitis, but given her clinical \r\npresentation, these are less likely. Received 1L maintenance \r\nfluids overnight on ___. She still had some diarrhea and \r\nabdominal pain on ___ but her symptoms had greatly improved by \r\n___ and she was tolerating po's well. She was maintained on a \r\nlow residue diet and her home furosemide was temporarily held. \r\nC. diff returned negative and other stool cultures/pcr were \r\npending at the time of discharge. She was scheduled for clinic \r\nfollow-up on ___.\r\n\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by ___ pneumonitis. LDH 266. She has a restaging \r\nPET/CT scheduled for next week. She received pentamidine for PJP \r\nppx on ___. She was maintained on acyclovir ppx as an \r\ninpatient. Although patient's symptoms are most likely from \r\ngastroenteritis and are currently improving, disease progression \r\nshould be considered. She will obtain her outpatient PET/CT \r\nafter discharge.\r\n \r\n#Hypogammaglobulinemia: Patient's last IgG was 340 on ___. \r\nReceived an infusion on ___. Plan was to check an IgG \r\nlevel/consider IVIG infusion if symptoms worsened, but the \r\npatient improved with IV/po fluids. \r\n\r\n# History of BCNU pneumonitis- Patient receives weekly DLCO with \r\nprednisone taper (5 mg weekly). She was continued on prednisone \r\n25 mg daily with plans to continue taper after discharge. Her \r\nnext set of PFT's are already scheduled.\r\n\r\n# Right ___ DVT- continued rivaroxaban.  Has IVC filter in place.\r\n\r\n# Pancytopenia- Possibly viral suppression of bone \r\nmarrow/dilution effect from IVF. Reticulocyte count 4.6. WBC \r\nimproving on ___ but platelets continuing to downtrend. She \r\nwill need to f/u in clinic after discharge to ensure that her \r\ncounts and platelets are recovering.\r\n\r\n# Hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm. Continued home gabapentin.\r\n\r\n# GERD- continued home omeprazole\r\n\r\n# Depression- continued home venlafaxine\r\n\r\n# CODE: Full\r\n# EMERGENCY CONTACT: \r\nName of health care proxy: ___ \r\nRelationship: husband \r\nPhone number: ___\r\n\r\n___ issues:\r\n-Will need to f/u CBC in clinic to ensure recovery of her counts\r\n-Will need to continue her steroid taper as an outpatient: on 25 \r\nmg at discharge.\r\n-Ms. ___ did not require any prescriptions at discharge as \r\nshe stated she already has the medications she needs. She cares \r\nfor her triple lumen catheter herself.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ascorbic Acid ___ mg PO DAILY \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n4. Ascorbic Acid ___ mg PO DAILY \r\n5. Cyanocobalamin 1000 mcg PO DAILY \r\n6. Gabapentin 900 mg PO BID \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n11. Furosemide 20 mg PO DAILY \r\n12. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary diagnosis:\r\n# Emesis/diarrhea\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by BCNU pneumonitis. \r\n#Hypogammaglobulinemia\r\n# History of BCNU pneumonitis\r\n\r\nSecondary diagnoses\r\n# Right ___ DVT\r\n# Pancytopenia\r\n# Hyperthesia of R V1/V2\r\n# GERD\r\n# Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___. You were admitted \r\nafter experiencing nausea, diarrhea, and abdominal pain. Your \r\nsymptoms are likely from a viral illness and improved during \r\nyour hospital stay with fluids and pain medication. You were \r\neventually able to eat and drink adequately and were discharged \r\nhome. If you experience worsening diarrhea, nausea, or abdominal \r\npain or develop fever/chills after your discharge, please call \r\nclinic or return to the Emergency Department as soon as \r\npossible. You have follow-up appointments scheduled on ___ with \r\nheme-onc.\r\n\r\nTake care, and we wish you the best.\r\n\r\nSincerely,\r\nYour BMT team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-14:4",
      "text": "Imaging: ___:  lipase 12, urinalysis normal IMAGING at ___ ___: Chest PA and lateral:\nThe lungs remains clear. The heart and mediastinal structures \nare unremarkable for technique, and appear stable. The bony \nthorax is grossly intact. A double-lumen right internal jugular \ncatheter remains in place. CT abdomen/pelvis with oral contrast, without IV contrast \n(comparison made to PET CT from ___:\nREDEMONSTRATION OF RETROPERITONEAL OR MESENTERIC \nLYMPHADENOPATHY, WHICH, ALLOWING FOR DIFFERENCES IN TECHNIQUE, \nAPPEARS STABLE. ILL DEFINED INCREASED DENSITY WITHIN THE \nMESENTERY IS SLIGHTLY MORE PRONOUNCED THAN BEFORE. IT IS \nPOSSIBLE THAT SUBTLE CHANGES ARE DUE TO ACTIVE LYMPHOMA AND, IF \nCLINICALLY INDICATED, FURTHER EVALUATION BY PET/CT IS \nRECOMMENDED. 3.5 CM-THICK LESION IN THE RIGHT PELVIS THAT PROBABLY REPRESENTS \nAN OVARIAN CYST, UNCHANGED. THIS COULD BE FURTHER EVALUATED BY \nSONOGRAPHY, IF CLINICALLY INDICATED. Discharge labs: ___ 12:00AM BLOOD WBC-3.5* RBC-2.16* Hgb-9.1* Hct-29.0* \nMCV-135* MCH-42.2* MCHC-31.3 RDW-16.5* Plt Ct-62*\n___ 12:00AM BLOOD Neuts-74.2* Lymphs-16.3* Monos-8.6 \nEos-0.7 Baso-0.1\n___ 12:00AM BLOOD Plt Ct-62*\n___ 12:00AM BLOOD Glucose-74 UreaN-11 Creat-0.7 Na-137 \nK-4.0 Cl-104 HCO3-26 AnGap-11\n___ 12:00AM BLOOD Calcium-8.6 Phos-2.9 Mg-1.9",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-14",
        "chart_time": "103483",
        "section": "General",
        "position": 4,
        "tokenCount": 321,
        "note_metadata": {
          "note_id": "18887130-DS-14",
          "subject_id": 18887130,
          "hadm_id": 29581683,
          "note_type": "DS",
          "note_seq": 14,
          "charttime": 103483,
          "storetime": 103483.69791666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\ndiarrhea, abdominal discomfort\r\n\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\n___ year old female with transformed DLBCL stage IIIB s/p autoSCT \r\nwith BEAM conditioning course complicated by BCNU pneumonitis \r\nwho presents today on D+129 for evaluation of diarrhea.\r\n\r\nPatient reports feeling well, in her usual state of health about \r\n5 days ago.  On ___ evening, she noticed some mild epigastric \r\ndiscomfort.  Earlier in the day, both she and her husband had \r\nreheated ___ and vegetables.  She woke on ___ morning \r\nwith intermittent crampiness with sudden onset emesis and \r\ndiarrhea.  The emesis looked like undigested food, without blood \r\nor bile.  The diarrhea was non-bloody.  The symtoms persisted \r\nthroughout the day.  She tried to stay up with hydration.  The \r\npain, still intermittent, became more severe yesterday.  She \r\nthen was directed to ___.  In the ED, she received IVF, \r\na CT abdomen/pelvis was obtained (see below), she received some \r\nmorphine for pain control, and was discharged home after \r\nsymptoms improved.  After returning home, she had ongoing \r\ndiarrhea this morning, and presented to ___ clinic for routine \r\nfollow up, and has been admitted to the floor for further \r\nevaluation.\r\n\r\nUpon arrival to the floor, she notes intermittent epigastric \r\ndiscomfort, mild, without radiation.  She had an episode of \r\ndiarrhea in the clinic.  No emesis for about 48 hours.  She is \r\nnot hungry.  She denies any fevers or chills.  Her husband does \r\nnot have any GI symptoms, she has had no sick contact or recent \r\ntravel.  She denies any rashes.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission physical:\r\n\r\nPHYSICAL EXAM: \r\nVITALS -  98.8  116/78  HR ___  RR 16  96% RA\r\nGeneral: pleasant, no distress, appears stated age\r\nHEENT: anicteric sclerae, clear oropharynx without lesions\r\nNeck: no adenopathy\r\nCV: RRR, normal S1, S2, no murmurs or rubs\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions, active BS, soft, mildly \r\ntender in epigastrium, no rebound or guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: CNs ___ intact, strength and sensation grossly intact, \r\nambulatory without assistance\r\nSkin: no petechiae  \r\n\r\nDischarge physical:\r\n\r\nVITALS -  Tm 99.1, Tc 98, BP 100/62, HR 84, RR 18, SpO2 97 ra\r\nI/O: (-/400 over past 8 hours) (1600/750 over past 24)\r\nGeneral: pleasant, lying in bed in no acute distress\r\nHEENT: normalocephalic/atraumatic, anicteric sclerae \r\nNeck: supple\r\nCV: RRR, ___ holosystolic murmur noted loudest at ___ ___ \r\nintercostal space (patient confirmed history of flow murmur)\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions with some tissue \r\ndeformity, + BS, soft, mildly tender in epigastrium, no rebound \r\nor guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: Alert and conversing appropriately, moving all \r\nextremities\r\nSkin: no rashes or lesions \r\n\r\n \r\nPertinent Results:\r\nAdmission labs:\r\n\r\n___ 03:15PM BLOOD WBC-4.8 RBC-2.35* Hgb-9.8* Hct-31.4* \r\nMCV-134* MCH-41.8* MCHC-31.3 RDW-16.9* Plt Ct-69*\r\n___ 11:52PM BLOOD WBC-3.2* RBC-2.13* Hgb-8.8* Hct-28.3* \r\nMCV-133* MCH-41.3* MCHC-31.1 RDW-16.9* Plt Ct-68*\r\n___ 03:15PM BLOOD Neuts-93.3* Lymphs-4.6* Monos-1.7* \r\nEos-0.4 Baso-0.2\r\n___ 03:15PM BLOOD Plt Ct-69*\r\n___ 11:52PM BLOOD ___ PTT-32.1 ___\r\n___ 11:52PM BLOOD Plt Ct-68*\r\n___ 11:52PM BLOOD Ret Aut-4.6*\r\n___ 03:15PM BLOOD UreaN-16 Creat-0.7 Na-140 K-3.7 Cl-104 \r\nHCO3-26 AnGap-14\r\n___ 11:52PM BLOOD UreaN-14 Creat-0.7 Na-141 K-3.4 Cl-108 \r\nHCO3-26 AnGap-10\r\n___ 03:15PM BLOOD Albumin-3.7 Calcium-8.5 Phos-3.0 Mg-1.8\r\n___ 11:52PM BLOOD Calcium-8.1* Phos-3.0 Mg-1.8\r\n___ 03:15PM BLOOD ALT-19 AST-27 LD(LDH)-266* AlkPhos-69 \r\nTotBili-0.3\r\n\r\nMicro:\r\n\r\nStool cultures:\r\n\r\n___ 10:36 pm STOOL     CONSISTENCY: WATERY      Source: \r\nStool. \r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Illumigene DNA\r\n      amplification assay. \r\n           (Reference Range-Negative). \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   VIRAL CULTURE (Pending): \r\n\r\nImaging:\r\n\r\n___:  lipase 12, urinalysis normal  \r\n\r\nIMAGING at ___ ___:\r\n\r\nChest PA and lateral:\r\nThe lungs remains clear.  The heart and mediastinal structures \r\nare unremarkable for technique, and appear stable.  The bony \r\nthorax is grossly intact.  A double-lumen right internal jugular \r\ncatheter remains in place.\r\n\r\nCT abdomen/pelvis with oral contrast, without IV contrast \r\n(comparison made to PET CT from ___:\r\nREDEMONSTRATION OF RETROPERITONEAL OR MESENTERIC \r\nLYMPHADENOPATHY, WHICH, ALLOWING FOR DIFFERENCES IN TECHNIQUE, \r\nAPPEARS STABLE. ILL DEFINED INCREASED DENSITY WITHIN THE \r\nMESENTERY IS SLIGHTLY MORE PRONOUNCED THAN BEFORE.  IT IS \r\nPOSSIBLE THAT SUBTLE CHANGES ARE DUE TO ACTIVE LYMPHOMA AND, IF \r\nCLINICALLY INDICATED, FURTHER EVALUATION BY PET/CT IS \r\nRECOMMENDED.\r\n      \r\n3.5 CM-THICK LESION IN THE RIGHT PELVIS THAT PROBABLY REPRESENTS \r\nAN OVARIAN CYST, UNCHANGED.  THIS COULD BE FURTHER EVALUATED BY \r\nSONOGRAPHY, IF CLINICALLY INDICATED.\r\n\r\nDischarge labs:\r\n\r\n___ 12:00AM BLOOD WBC-3.5* RBC-2.16* Hgb-9.1* Hct-29.0* \r\nMCV-135* MCH-42.2* MCHC-31.3 RDW-16.5* Plt Ct-62*\r\n___ 12:00AM BLOOD Neuts-74.2* Lymphs-16.3* Monos-8.6 \r\nEos-0.7 Baso-0.1\r\n___ 12:00AM BLOOD Plt Ct-62*\r\n___ 12:00AM BLOOD Glucose-74 UreaN-11 Creat-0.7 Na-137 \r\nK-4.0 Cl-104 HCO3-26 AnGap-11\r\n___ 12:00AM BLOOD Calcium-8.6 Phos-2.9 Mg-1.9\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old woman with transformed DLBCL stage \r\nIIIB s/p autoSCT with BEAM conditioning course complicated by \r\n___ pneumonitis who presents today on D+131 (as of ___ for \r\nevaluation of diarrhea and abdominal pain, likely \r\ngastroenteritis.\r\n\r\n# Emesis/diarrhea- history most consistent with viral \r\ngastroenteritis, with norovirus on differential. On the day \r\nafter admission, she reported that her husband had fallen ill \r\nthat day with similar symptoms. CT did not demonstrate colitis, \r\nbut was performed without IV contrast. Ischemic colitis is \r\nunlikely given no cardiovascular risk factors. Other ddx include \r\ngastritis, pancreatitis, and hepatitis, but given her clinical \r\npresentation, these are less likely. Received 1L maintenance \r\nfluids overnight on ___. She still had some diarrhea and \r\nabdominal pain on ___ but her symptoms had greatly improved by \r\n___ and she was tolerating po's well. She was maintained on a \r\nlow residue diet and her home furosemide was temporarily held. \r\nC. diff returned negative and other stool cultures/pcr were \r\npending at the time of discharge. She was scheduled for clinic \r\nfollow-up on ___.\r\n\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by ___ pneumonitis. LDH 266. She has a restaging \r\nPET/CT scheduled for next week. She received pentamidine for PJP \r\nppx on ___. She was maintained on acyclovir ppx as an \r\ninpatient. Although patient's symptoms are most likely from \r\ngastroenteritis and are currently improving, disease progression \r\nshould be considered. She will obtain her outpatient PET/CT \r\nafter discharge.\r\n \r\n#Hypogammaglobulinemia: Patient's last IgG was 340 on ___. \r\nReceived an infusion on ___. Plan was to check an IgG \r\nlevel/consider IVIG infusion if symptoms worsened, but the \r\npatient improved with IV/po fluids. \r\n\r\n# History of BCNU pneumonitis- Patient receives weekly DLCO with \r\nprednisone taper (5 mg weekly). She was continued on prednisone \r\n25 mg daily with plans to continue taper after discharge. Her \r\nnext set of PFT's are already scheduled.\r\n\r\n# Right ___ DVT- continued rivaroxaban.  Has IVC filter in place.\r\n\r\n# Pancytopenia- Possibly viral suppression of bone \r\nmarrow/dilution effect from IVF. Reticulocyte count 4.6. WBC \r\nimproving on ___ but platelets continuing to downtrend. She \r\nwill need to f/u in clinic after discharge to ensure that her \r\ncounts and platelets are recovering.\r\n\r\n# Hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm. Continued home gabapentin.\r\n\r\n# GERD- continued home omeprazole\r\n\r\n# Depression- continued home venlafaxine\r\n\r\n# CODE: Full\r\n# EMERGENCY CONTACT: \r\nName of health care proxy: ___ \r\nRelationship: husband \r\nPhone number: ___\r\n\r\n___ issues:\r\n-Will need to f/u CBC in clinic to ensure recovery of her counts\r\n-Will need to continue her steroid taper as an outpatient: on 25 \r\nmg at discharge.\r\n-Ms. ___ did not require any prescriptions at discharge as \r\nshe stated she already has the medications she needs. She cares \r\nfor her triple lumen catheter herself.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ascorbic Acid ___ mg PO DAILY \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n4. Ascorbic Acid ___ mg PO DAILY \r\n5. Cyanocobalamin 1000 mcg PO DAILY \r\n6. Gabapentin 900 mg PO BID \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n11. Furosemide 20 mg PO DAILY \r\n12. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary diagnosis:\r\n# Emesis/diarrhea\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by BCNU pneumonitis. \r\n#Hypogammaglobulinemia\r\n# History of BCNU pneumonitis\r\n\r\nSecondary diagnoses\r\n# Right ___ DVT\r\n# Pancytopenia\r\n# Hyperthesia of R V1/V2\r\n# GERD\r\n# Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___. You were admitted \r\nafter experiencing nausea, diarrhea, and abdominal pain. Your \r\nsymptoms are likely from a viral illness and improved during \r\nyour hospital stay with fluids and pain medication. You were \r\neventually able to eat and drink adequately and were discharged \r\nhome. If you experience worsening diarrhea, nausea, or abdominal \r\npain or develop fever/chills after your discharge, please call \r\nclinic or return to the Emergency Department as soon as \r\npossible. You have follow-up appointments scheduled on ___ with \r\nheme-onc.\r\n\r\nTake care, and we wish you the best.\r\n\r\nSincerely,\r\nYour BMT team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-14:5",
      "text": "Brief Hospital Course:\nMs. ___ is a ___ year old woman with transformed DLBCL stage \nIIIB s/p autoSCT with BEAM conditioning course complicated by \n___ pneumonitis who presents today on D+131 (as of ___ for \nevaluation of diarrhea and abdominal pain, likely \ngastroenteritis. # Emesis/diarrhea- history most consistent with viral \ngastroenteritis, with norovirus on differential. On the day \nafter admission, she reported that her husband had fallen ill \nthat day with similar symptoms. CT did not demonstrate colitis, \nbut was performed without IV contrast. Ischemic colitis is \nunlikely given no cardiovascular risk factors. Other ddx include \ngastritis, pancreatitis, and hepatitis, but given her clinical \npresentation, these are less likely. Received 1L maintenance \nfluids overnight on ___. She still had some diarrhea and \nabdominal pain on ___ but her symptoms had greatly improved by \n___ and she was tolerating po's well. She was maintained on a \nlow residue diet and her home furosemide was temporarily held. C. diff returned negative and other stool cultures/pcr were \npending at the time of discharge. She was scheduled for clinic \nfollow-up on ___. # DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \ncomplicated by ___ pneumonitis. LDH 266. She has a restaging \nPET/CT scheduled for next week. She received pentamidine for PJP \nppx on ___. She was maintained on acyclovir ppx as an \ninpatient. Although patient's symptoms are most likely from \ngastroenteritis and are currently improving, disease progression \nshould be considered. She will obtain her outpatient PET/CT \nafter discharge. #Hypogammaglobulinemia: Patient's last IgG was 340 on ___. Received an infusion on ___. Plan was to check an IgG \nlevel/consider IVIG infusion if symptoms worsened, but the \npatient improved with IV/po fluids. # History of BCNU pneumonitis- Patient receives weekly DLCO with \nprednisone taper (5 mg weekly). She was continued on prednisone \n25 mg daily with plans to continue taper after discharge. Her \nnext set of PFT's are already scheduled. # Right ___ DVT- continued rivaroxaban. Has IVC filter in place. # Pancytopenia- Possibly viral suppression of bone \nmarrow/dilution effect from IVF. Reticulocyte count 4.6. WBC \nimproving on ___ but platelets continuing to downtrend. She \nwill need to f/u in clinic after discharge to ensure that her \ncounts and platelets are recovering. # Hyperthesia of R V1/V2- chronic, occurred after coiling \nprocedure for cerebral aneurysm. Continued home gabapentin. # GERD- continued home omeprazole # Depression- continued home venlafaxine # CODE: Full\n# EMERGENCY CONTACT: \nName of health care proxy: ___ \nRelationship: husband \nPhone number: ___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-14",
        "chart_time": "103483",
        "section": "General",
        "position": 5,
        "tokenCount": 674,
        "note_metadata": {
          "note_id": "18887130-DS-14",
          "subject_id": 18887130,
          "hadm_id": 29581683,
          "note_type": "DS",
          "note_seq": 14,
          "charttime": 103483,
          "storetime": 103483.69791666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\ndiarrhea, abdominal discomfort\r\n\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\n___ year old female with transformed DLBCL stage IIIB s/p autoSCT \r\nwith BEAM conditioning course complicated by BCNU pneumonitis \r\nwho presents today on D+129 for evaluation of diarrhea.\r\n\r\nPatient reports feeling well, in her usual state of health about \r\n5 days ago.  On ___ evening, she noticed some mild epigastric \r\ndiscomfort.  Earlier in the day, both she and her husband had \r\nreheated ___ and vegetables.  She woke on ___ morning \r\nwith intermittent crampiness with sudden onset emesis and \r\ndiarrhea.  The emesis looked like undigested food, without blood \r\nor bile.  The diarrhea was non-bloody.  The symtoms persisted \r\nthroughout the day.  She tried to stay up with hydration.  The \r\npain, still intermittent, became more severe yesterday.  She \r\nthen was directed to ___.  In the ED, she received IVF, \r\na CT abdomen/pelvis was obtained (see below), she received some \r\nmorphine for pain control, and was discharged home after \r\nsymptoms improved.  After returning home, she had ongoing \r\ndiarrhea this morning, and presented to ___ clinic for routine \r\nfollow up, and has been admitted to the floor for further \r\nevaluation.\r\n\r\nUpon arrival to the floor, she notes intermittent epigastric \r\ndiscomfort, mild, without radiation.  She had an episode of \r\ndiarrhea in the clinic.  No emesis for about 48 hours.  She is \r\nnot hungry.  She denies any fevers or chills.  Her husband does \r\nnot have any GI symptoms, she has had no sick contact or recent \r\ntravel.  She denies any rashes.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission physical:\r\n\r\nPHYSICAL EXAM: \r\nVITALS -  98.8  116/78  HR ___  RR 16  96% RA\r\nGeneral: pleasant, no distress, appears stated age\r\nHEENT: anicteric sclerae, clear oropharynx without lesions\r\nNeck: no adenopathy\r\nCV: RRR, normal S1, S2, no murmurs or rubs\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions, active BS, soft, mildly \r\ntender in epigastrium, no rebound or guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: CNs ___ intact, strength and sensation grossly intact, \r\nambulatory without assistance\r\nSkin: no petechiae  \r\n\r\nDischarge physical:\r\n\r\nVITALS -  Tm 99.1, Tc 98, BP 100/62, HR 84, RR 18, SpO2 97 ra\r\nI/O: (-/400 over past 8 hours) (1600/750 over past 24)\r\nGeneral: pleasant, lying in bed in no acute distress\r\nHEENT: normalocephalic/atraumatic, anicteric sclerae \r\nNeck: supple\r\nCV: RRR, ___ holosystolic murmur noted loudest at ___ ___ \r\nintercostal space (patient confirmed history of flow murmur)\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions with some tissue \r\ndeformity, + BS, soft, mildly tender in epigastrium, no rebound \r\nor guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: Alert and conversing appropriately, moving all \r\nextremities\r\nSkin: no rashes or lesions \r\n\r\n \r\nPertinent Results:\r\nAdmission labs:\r\n\r\n___ 03:15PM BLOOD WBC-4.8 RBC-2.35* Hgb-9.8* Hct-31.4* \r\nMCV-134* MCH-41.8* MCHC-31.3 RDW-16.9* Plt Ct-69*\r\n___ 11:52PM BLOOD WBC-3.2* RBC-2.13* Hgb-8.8* Hct-28.3* \r\nMCV-133* MCH-41.3* MCHC-31.1 RDW-16.9* Plt Ct-68*\r\n___ 03:15PM BLOOD Neuts-93.3* Lymphs-4.6* Monos-1.7* \r\nEos-0.4 Baso-0.2\r\n___ 03:15PM BLOOD Plt Ct-69*\r\n___ 11:52PM BLOOD ___ PTT-32.1 ___\r\n___ 11:52PM BLOOD Plt Ct-68*\r\n___ 11:52PM BLOOD Ret Aut-4.6*\r\n___ 03:15PM BLOOD UreaN-16 Creat-0.7 Na-140 K-3.7 Cl-104 \r\nHCO3-26 AnGap-14\r\n___ 11:52PM BLOOD UreaN-14 Creat-0.7 Na-141 K-3.4 Cl-108 \r\nHCO3-26 AnGap-10\r\n___ 03:15PM BLOOD Albumin-3.7 Calcium-8.5 Phos-3.0 Mg-1.8\r\n___ 11:52PM BLOOD Calcium-8.1* Phos-3.0 Mg-1.8\r\n___ 03:15PM BLOOD ALT-19 AST-27 LD(LDH)-266* AlkPhos-69 \r\nTotBili-0.3\r\n\r\nMicro:\r\n\r\nStool cultures:\r\n\r\n___ 10:36 pm STOOL     CONSISTENCY: WATERY      Source: \r\nStool. \r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Illumigene DNA\r\n      amplification assay. \r\n           (Reference Range-Negative). \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   VIRAL CULTURE (Pending): \r\n\r\nImaging:\r\n\r\n___:  lipase 12, urinalysis normal  \r\n\r\nIMAGING at ___ ___:\r\n\r\nChest PA and lateral:\r\nThe lungs remains clear.  The heart and mediastinal structures \r\nare unremarkable for technique, and appear stable.  The bony \r\nthorax is grossly intact.  A double-lumen right internal jugular \r\ncatheter remains in place.\r\n\r\nCT abdomen/pelvis with oral contrast, without IV contrast \r\n(comparison made to PET CT from ___:\r\nREDEMONSTRATION OF RETROPERITONEAL OR MESENTERIC \r\nLYMPHADENOPATHY, WHICH, ALLOWING FOR DIFFERENCES IN TECHNIQUE, \r\nAPPEARS STABLE. ILL DEFINED INCREASED DENSITY WITHIN THE \r\nMESENTERY IS SLIGHTLY MORE PRONOUNCED THAN BEFORE.  IT IS \r\nPOSSIBLE THAT SUBTLE CHANGES ARE DUE TO ACTIVE LYMPHOMA AND, IF \r\nCLINICALLY INDICATED, FURTHER EVALUATION BY PET/CT IS \r\nRECOMMENDED.\r\n      \r\n3.5 CM-THICK LESION IN THE RIGHT PELVIS THAT PROBABLY REPRESENTS \r\nAN OVARIAN CYST, UNCHANGED.  THIS COULD BE FURTHER EVALUATED BY \r\nSONOGRAPHY, IF CLINICALLY INDICATED.\r\n\r\nDischarge labs:\r\n\r\n___ 12:00AM BLOOD WBC-3.5* RBC-2.16* Hgb-9.1* Hct-29.0* \r\nMCV-135* MCH-42.2* MCHC-31.3 RDW-16.5* Plt Ct-62*\r\n___ 12:00AM BLOOD Neuts-74.2* Lymphs-16.3* Monos-8.6 \r\nEos-0.7 Baso-0.1\r\n___ 12:00AM BLOOD Plt Ct-62*\r\n___ 12:00AM BLOOD Glucose-74 UreaN-11 Creat-0.7 Na-137 \r\nK-4.0 Cl-104 HCO3-26 AnGap-11\r\n___ 12:00AM BLOOD Calcium-8.6 Phos-2.9 Mg-1.9\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old woman with transformed DLBCL stage \r\nIIIB s/p autoSCT with BEAM conditioning course complicated by \r\n___ pneumonitis who presents today on D+131 (as of ___ for \r\nevaluation of diarrhea and abdominal pain, likely \r\ngastroenteritis.\r\n\r\n# Emesis/diarrhea- history most consistent with viral \r\ngastroenteritis, with norovirus on differential. On the day \r\nafter admission, she reported that her husband had fallen ill \r\nthat day with similar symptoms. CT did not demonstrate colitis, \r\nbut was performed without IV contrast. Ischemic colitis is \r\nunlikely given no cardiovascular risk factors. Other ddx include \r\ngastritis, pancreatitis, and hepatitis, but given her clinical \r\npresentation, these are less likely. Received 1L maintenance \r\nfluids overnight on ___. She still had some diarrhea and \r\nabdominal pain on ___ but her symptoms had greatly improved by \r\n___ and she was tolerating po's well. She was maintained on a \r\nlow residue diet and her home furosemide was temporarily held. \r\nC. diff returned negative and other stool cultures/pcr were \r\npending at the time of discharge. She was scheduled for clinic \r\nfollow-up on ___.\r\n\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by ___ pneumonitis. LDH 266. She has a restaging \r\nPET/CT scheduled for next week. She received pentamidine for PJP \r\nppx on ___. She was maintained on acyclovir ppx as an \r\ninpatient. Although patient's symptoms are most likely from \r\ngastroenteritis and are currently improving, disease progression \r\nshould be considered. She will obtain her outpatient PET/CT \r\nafter discharge.\r\n \r\n#Hypogammaglobulinemia: Patient's last IgG was 340 on ___. \r\nReceived an infusion on ___. Plan was to check an IgG \r\nlevel/consider IVIG infusion if symptoms worsened, but the \r\npatient improved with IV/po fluids. \r\n\r\n# History of BCNU pneumonitis- Patient receives weekly DLCO with \r\nprednisone taper (5 mg weekly). She was continued on prednisone \r\n25 mg daily with plans to continue taper after discharge. Her \r\nnext set of PFT's are already scheduled.\r\n\r\n# Right ___ DVT- continued rivaroxaban.  Has IVC filter in place.\r\n\r\n# Pancytopenia- Possibly viral suppression of bone \r\nmarrow/dilution effect from IVF. Reticulocyte count 4.6. WBC \r\nimproving on ___ but platelets continuing to downtrend. She \r\nwill need to f/u in clinic after discharge to ensure that her \r\ncounts and platelets are recovering.\r\n\r\n# Hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm. Continued home gabapentin.\r\n\r\n# GERD- continued home omeprazole\r\n\r\n# Depression- continued home venlafaxine\r\n\r\n# CODE: Full\r\n# EMERGENCY CONTACT: \r\nName of health care proxy: ___ \r\nRelationship: husband \r\nPhone number: ___\r\n\r\n___ issues:\r\n-Will need to f/u CBC in clinic to ensure recovery of her counts\r\n-Will need to continue her steroid taper as an outpatient: on 25 \r\nmg at discharge.\r\n-Ms. ___ did not require any prescriptions at discharge as \r\nshe stated she already has the medications she needs. She cares \r\nfor her triple lumen catheter herself.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ascorbic Acid ___ mg PO DAILY \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n4. Ascorbic Acid ___ mg PO DAILY \r\n5. Cyanocobalamin 1000 mcg PO DAILY \r\n6. Gabapentin 900 mg PO BID \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n11. Furosemide 20 mg PO DAILY \r\n12. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary diagnosis:\r\n# Emesis/diarrhea\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by BCNU pneumonitis. \r\n#Hypogammaglobulinemia\r\n# History of BCNU pneumonitis\r\n\r\nSecondary diagnoses\r\n# Right ___ DVT\r\n# Pancytopenia\r\n# Hyperthesia of R V1/V2\r\n# GERD\r\n# Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___. You were admitted \r\nafter experiencing nausea, diarrhea, and abdominal pain. Your \r\nsymptoms are likely from a viral illness and improved during \r\nyour hospital stay with fluids and pain medication. You were \r\neventually able to eat and drink adequately and were discharged \r\nhome. If you experience worsening diarrhea, nausea, or abdominal \r\npain or develop fever/chills after your discharge, please call \r\nclinic or return to the Emergency Department as soon as \r\npossible. You have follow-up appointments scheduled on ___ with \r\nheme-onc.\r\n\r\nTake care, and we wish you the best.\r\n\r\nSincerely,\r\nYour BMT team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-14:6",
      "text": "Has IVC filter in place. # Pancytopenia- Possibly viral suppression of bone \nmarrow/dilution effect from IVF. Reticulocyte count 4.6. WBC \nimproving on ___ but platelets continuing to downtrend. She \nwill need to f/u in clinic after discharge to ensure that her \ncounts and platelets are recovering. # Hyperthesia of R V1/V2- chronic, occurred after coiling \nprocedure for cerebral aneurysm. Continued home gabapentin. # GERD- continued home omeprazole # Depression- continued home venlafaxine # CODE: Full\n# EMERGENCY CONTACT: \nName of health care proxy: ___ \nRelationship: husband \nPhone number: ___ ___ issues:\n-Will need to f/u CBC in clinic to ensure recovery of her counts\n-Will need to continue her steroid taper as an outpatient: on 25 \nmg at discharge. -Ms. ___ did not require any prescriptions at discharge as \nshe stated she already has the medications she needs. She cares \nfor her triple lumen catheter herself. Medications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Acyclovir 400 mg PO Q8H \n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \n3. Furosemide 20 mg PO DAILY \n4. Gabapentin 900 mg PO BID \n5. Omeprazole 20 mg PO DAILY \n6. Klor-Con 10 (potassium chloride) 10 mEq oral daily \n7. PredniSONE 25 mg PO DAILY \n8. Rivaroxaban 20 mg PO DAILY \n9. Venlafaxine 25 mg PO BID \n10. Ascorbic Acid ___ mg PO DAILY \n11. Cyanocobalamin 1000 mcg PO DAILY \n12. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \n600 mg(1,500mg) -400 unit oral daily",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-14",
        "chart_time": "103483",
        "section": "General",
        "position": 6,
        "tokenCount": 374,
        "note_metadata": {
          "note_id": "18887130-DS-14",
          "subject_id": 18887130,
          "hadm_id": 29581683,
          "note_type": "DS",
          "note_seq": 14,
          "charttime": 103483,
          "storetime": 103483.69791666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\ndiarrhea, abdominal discomfort\r\n\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\n___ year old female with transformed DLBCL stage IIIB s/p autoSCT \r\nwith BEAM conditioning course complicated by BCNU pneumonitis \r\nwho presents today on D+129 for evaluation of diarrhea.\r\n\r\nPatient reports feeling well, in her usual state of health about \r\n5 days ago.  On ___ evening, she noticed some mild epigastric \r\ndiscomfort.  Earlier in the day, both she and her husband had \r\nreheated ___ and vegetables.  She woke on ___ morning \r\nwith intermittent crampiness with sudden onset emesis and \r\ndiarrhea.  The emesis looked like undigested food, without blood \r\nor bile.  The diarrhea was non-bloody.  The symtoms persisted \r\nthroughout the day.  She tried to stay up with hydration.  The \r\npain, still intermittent, became more severe yesterday.  She \r\nthen was directed to ___.  In the ED, she received IVF, \r\na CT abdomen/pelvis was obtained (see below), she received some \r\nmorphine for pain control, and was discharged home after \r\nsymptoms improved.  After returning home, she had ongoing \r\ndiarrhea this morning, and presented to ___ clinic for routine \r\nfollow up, and has been admitted to the floor for further \r\nevaluation.\r\n\r\nUpon arrival to the floor, she notes intermittent epigastric \r\ndiscomfort, mild, without radiation.  She had an episode of \r\ndiarrhea in the clinic.  No emesis for about 48 hours.  She is \r\nnot hungry.  She denies any fevers or chills.  Her husband does \r\nnot have any GI symptoms, she has had no sick contact or recent \r\ntravel.  She denies any rashes.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission physical:\r\n\r\nPHYSICAL EXAM: \r\nVITALS -  98.8  116/78  HR ___  RR 16  96% RA\r\nGeneral: pleasant, no distress, appears stated age\r\nHEENT: anicteric sclerae, clear oropharynx without lesions\r\nNeck: no adenopathy\r\nCV: RRR, normal S1, S2, no murmurs or rubs\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions, active BS, soft, mildly \r\ntender in epigastrium, no rebound or guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: CNs ___ intact, strength and sensation grossly intact, \r\nambulatory without assistance\r\nSkin: no petechiae  \r\n\r\nDischarge physical:\r\n\r\nVITALS -  Tm 99.1, Tc 98, BP 100/62, HR 84, RR 18, SpO2 97 ra\r\nI/O: (-/400 over past 8 hours) (1600/750 over past 24)\r\nGeneral: pleasant, lying in bed in no acute distress\r\nHEENT: normalocephalic/atraumatic, anicteric sclerae \r\nNeck: supple\r\nCV: RRR, ___ holosystolic murmur noted loudest at ___ ___ \r\nintercostal space (patient confirmed history of flow murmur)\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions with some tissue \r\ndeformity, + BS, soft, mildly tender in epigastrium, no rebound \r\nor guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: Alert and conversing appropriately, moving all \r\nextremities\r\nSkin: no rashes or lesions \r\n\r\n \r\nPertinent Results:\r\nAdmission labs:\r\n\r\n___ 03:15PM BLOOD WBC-4.8 RBC-2.35* Hgb-9.8* Hct-31.4* \r\nMCV-134* MCH-41.8* MCHC-31.3 RDW-16.9* Plt Ct-69*\r\n___ 11:52PM BLOOD WBC-3.2* RBC-2.13* Hgb-8.8* Hct-28.3* \r\nMCV-133* MCH-41.3* MCHC-31.1 RDW-16.9* Plt Ct-68*\r\n___ 03:15PM BLOOD Neuts-93.3* Lymphs-4.6* Monos-1.7* \r\nEos-0.4 Baso-0.2\r\n___ 03:15PM BLOOD Plt Ct-69*\r\n___ 11:52PM BLOOD ___ PTT-32.1 ___\r\n___ 11:52PM BLOOD Plt Ct-68*\r\n___ 11:52PM BLOOD Ret Aut-4.6*\r\n___ 03:15PM BLOOD UreaN-16 Creat-0.7 Na-140 K-3.7 Cl-104 \r\nHCO3-26 AnGap-14\r\n___ 11:52PM BLOOD UreaN-14 Creat-0.7 Na-141 K-3.4 Cl-108 \r\nHCO3-26 AnGap-10\r\n___ 03:15PM BLOOD Albumin-3.7 Calcium-8.5 Phos-3.0 Mg-1.8\r\n___ 11:52PM BLOOD Calcium-8.1* Phos-3.0 Mg-1.8\r\n___ 03:15PM BLOOD ALT-19 AST-27 LD(LDH)-266* AlkPhos-69 \r\nTotBili-0.3\r\n\r\nMicro:\r\n\r\nStool cultures:\r\n\r\n___ 10:36 pm STOOL     CONSISTENCY: WATERY      Source: \r\nStool. \r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Illumigene DNA\r\n      amplification assay. \r\n           (Reference Range-Negative). \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   VIRAL CULTURE (Pending): \r\n\r\nImaging:\r\n\r\n___:  lipase 12, urinalysis normal  \r\n\r\nIMAGING at ___ ___:\r\n\r\nChest PA and lateral:\r\nThe lungs remains clear.  The heart and mediastinal structures \r\nare unremarkable for technique, and appear stable.  The bony \r\nthorax is grossly intact.  A double-lumen right internal jugular \r\ncatheter remains in place.\r\n\r\nCT abdomen/pelvis with oral contrast, without IV contrast \r\n(comparison made to PET CT from ___:\r\nREDEMONSTRATION OF RETROPERITONEAL OR MESENTERIC \r\nLYMPHADENOPATHY, WHICH, ALLOWING FOR DIFFERENCES IN TECHNIQUE, \r\nAPPEARS STABLE. ILL DEFINED INCREASED DENSITY WITHIN THE \r\nMESENTERY IS SLIGHTLY MORE PRONOUNCED THAN BEFORE.  IT IS \r\nPOSSIBLE THAT SUBTLE CHANGES ARE DUE TO ACTIVE LYMPHOMA AND, IF \r\nCLINICALLY INDICATED, FURTHER EVALUATION BY PET/CT IS \r\nRECOMMENDED.\r\n      \r\n3.5 CM-THICK LESION IN THE RIGHT PELVIS THAT PROBABLY REPRESENTS \r\nAN OVARIAN CYST, UNCHANGED.  THIS COULD BE FURTHER EVALUATED BY \r\nSONOGRAPHY, IF CLINICALLY INDICATED.\r\n\r\nDischarge labs:\r\n\r\n___ 12:00AM BLOOD WBC-3.5* RBC-2.16* Hgb-9.1* Hct-29.0* \r\nMCV-135* MCH-42.2* MCHC-31.3 RDW-16.5* Plt Ct-62*\r\n___ 12:00AM BLOOD Neuts-74.2* Lymphs-16.3* Monos-8.6 \r\nEos-0.7 Baso-0.1\r\n___ 12:00AM BLOOD Plt Ct-62*\r\n___ 12:00AM BLOOD Glucose-74 UreaN-11 Creat-0.7 Na-137 \r\nK-4.0 Cl-104 HCO3-26 AnGap-11\r\n___ 12:00AM BLOOD Calcium-8.6 Phos-2.9 Mg-1.9\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old woman with transformed DLBCL stage \r\nIIIB s/p autoSCT with BEAM conditioning course complicated by \r\n___ pneumonitis who presents today on D+131 (as of ___ for \r\nevaluation of diarrhea and abdominal pain, likely \r\ngastroenteritis.\r\n\r\n# Emesis/diarrhea- history most consistent with viral \r\ngastroenteritis, with norovirus on differential. On the day \r\nafter admission, she reported that her husband had fallen ill \r\nthat day with similar symptoms. CT did not demonstrate colitis, \r\nbut was performed without IV contrast. Ischemic colitis is \r\nunlikely given no cardiovascular risk factors. Other ddx include \r\ngastritis, pancreatitis, and hepatitis, but given her clinical \r\npresentation, these are less likely. Received 1L maintenance \r\nfluids overnight on ___. She still had some diarrhea and \r\nabdominal pain on ___ but her symptoms had greatly improved by \r\n___ and she was tolerating po's well. She was maintained on a \r\nlow residue diet and her home furosemide was temporarily held. \r\nC. diff returned negative and other stool cultures/pcr were \r\npending at the time of discharge. She was scheduled for clinic \r\nfollow-up on ___.\r\n\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by ___ pneumonitis. LDH 266. She has a restaging \r\nPET/CT scheduled for next week. She received pentamidine for PJP \r\nppx on ___. She was maintained on acyclovir ppx as an \r\ninpatient. Although patient's symptoms are most likely from \r\ngastroenteritis and are currently improving, disease progression \r\nshould be considered. She will obtain her outpatient PET/CT \r\nafter discharge.\r\n \r\n#Hypogammaglobulinemia: Patient's last IgG was 340 on ___. \r\nReceived an infusion on ___. Plan was to check an IgG \r\nlevel/consider IVIG infusion if symptoms worsened, but the \r\npatient improved with IV/po fluids. \r\n\r\n# History of BCNU pneumonitis- Patient receives weekly DLCO with \r\nprednisone taper (5 mg weekly). She was continued on prednisone \r\n25 mg daily with plans to continue taper after discharge. Her \r\nnext set of PFT's are already scheduled.\r\n\r\n# Right ___ DVT- continued rivaroxaban.  Has IVC filter in place.\r\n\r\n# Pancytopenia- Possibly viral suppression of bone \r\nmarrow/dilution effect from IVF. Reticulocyte count 4.6. WBC \r\nimproving on ___ but platelets continuing to downtrend. She \r\nwill need to f/u in clinic after discharge to ensure that her \r\ncounts and platelets are recovering.\r\n\r\n# Hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm. Continued home gabapentin.\r\n\r\n# GERD- continued home omeprazole\r\n\r\n# Depression- continued home venlafaxine\r\n\r\n# CODE: Full\r\n# EMERGENCY CONTACT: \r\nName of health care proxy: ___ \r\nRelationship: husband \r\nPhone number: ___\r\n\r\n___ issues:\r\n-Will need to f/u CBC in clinic to ensure recovery of her counts\r\n-Will need to continue her steroid taper as an outpatient: on 25 \r\nmg at discharge.\r\n-Ms. ___ did not require any prescriptions at discharge as \r\nshe stated she already has the medications she needs. She cares \r\nfor her triple lumen catheter herself.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ascorbic Acid ___ mg PO DAILY \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n4. Ascorbic Acid ___ mg PO DAILY \r\n5. Cyanocobalamin 1000 mcg PO DAILY \r\n6. Gabapentin 900 mg PO BID \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n11. Furosemide 20 mg PO DAILY \r\n12. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary diagnosis:\r\n# Emesis/diarrhea\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by BCNU pneumonitis. \r\n#Hypogammaglobulinemia\r\n# History of BCNU pneumonitis\r\n\r\nSecondary diagnoses\r\n# Right ___ DVT\r\n# Pancytopenia\r\n# Hyperthesia of R V1/V2\r\n# GERD\r\n# Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___. You were admitted \r\nafter experiencing nausea, diarrhea, and abdominal pain. Your \r\nsymptoms are likely from a viral illness and improved during \r\nyour hospital stay with fluids and pain medication. You were \r\neventually able to eat and drink adequately and were discharged \r\nhome. If you experience worsening diarrhea, nausea, or abdominal \r\npain or develop fever/chills after your discharge, please call \r\nclinic or return to the Emergency Department as soon as \r\npossible. You have follow-up appointments scheduled on ___ with \r\nheme-onc.\r\n\r\nTake care, and we wish you the best.\r\n\r\nSincerely,\r\nYour BMT team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-14:7",
      "text": "Discharge Medications:\n1. Acyclovir 400 mg PO Q8H \n2. Omeprazole 20 mg PO DAILY \n3. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \n4. Ascorbic Acid ___ mg PO DAILY \n5. Cyanocobalamin 1000 mcg PO DAILY \n6. Gabapentin 900 mg PO BID \n7. PredniSONE 25 mg PO DAILY \n8. Rivaroxaban 20 mg PO DAILY \n9. Venlafaxine 25 mg PO BID \n10. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \n600 mg(1,500mg) -400 unit oral daily \n11. Furosemide 20 mg PO DAILY \n12. Klor-Con 10 (potassium chloride) 10 mEq oral daily Discharge Disposition:\nHome Discharge Diagnosis:\nPrimary diagnosis:\n# Emesis/diarrhea\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \ncomplicated by BCNU pneumonitis. #Hypogammaglobulinemia\n# History of BCNU pneumonitis Secondary diagnoses\n# Right ___ DVT\n# Pancytopenia\n# Hyperthesia of R V1/V2\n# GERD\n# Depression Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-14",
        "chart_time": "103483",
        "section": "General",
        "position": 7,
        "tokenCount": 245,
        "note_metadata": {
          "note_id": "18887130-DS-14",
          "subject_id": 18887130,
          "hadm_id": 29581683,
          "note_type": "DS",
          "note_seq": 14,
          "charttime": 103483,
          "storetime": 103483.69791666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\ndiarrhea, abdominal discomfort\r\n\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\n___ year old female with transformed DLBCL stage IIIB s/p autoSCT \r\nwith BEAM conditioning course complicated by BCNU pneumonitis \r\nwho presents today on D+129 for evaluation of diarrhea.\r\n\r\nPatient reports feeling well, in her usual state of health about \r\n5 days ago.  On ___ evening, she noticed some mild epigastric \r\ndiscomfort.  Earlier in the day, both she and her husband had \r\nreheated ___ and vegetables.  She woke on ___ morning \r\nwith intermittent crampiness with sudden onset emesis and \r\ndiarrhea.  The emesis looked like undigested food, without blood \r\nor bile.  The diarrhea was non-bloody.  The symtoms persisted \r\nthroughout the day.  She tried to stay up with hydration.  The \r\npain, still intermittent, became more severe yesterday.  She \r\nthen was directed to ___.  In the ED, she received IVF, \r\na CT abdomen/pelvis was obtained (see below), she received some \r\nmorphine for pain control, and was discharged home after \r\nsymptoms improved.  After returning home, she had ongoing \r\ndiarrhea this morning, and presented to ___ clinic for routine \r\nfollow up, and has been admitted to the floor for further \r\nevaluation.\r\n\r\nUpon arrival to the floor, she notes intermittent epigastric \r\ndiscomfort, mild, without radiation.  She had an episode of \r\ndiarrhea in the clinic.  No emesis for about 48 hours.  She is \r\nnot hungry.  She denies any fevers or chills.  Her husband does \r\nnot have any GI symptoms, she has had no sick contact or recent \r\ntravel.  She denies any rashes.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission physical:\r\n\r\nPHYSICAL EXAM: \r\nVITALS -  98.8  116/78  HR ___  RR 16  96% RA\r\nGeneral: pleasant, no distress, appears stated age\r\nHEENT: anicteric sclerae, clear oropharynx without lesions\r\nNeck: no adenopathy\r\nCV: RRR, normal S1, S2, no murmurs or rubs\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions, active BS, soft, mildly \r\ntender in epigastrium, no rebound or guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: CNs ___ intact, strength and sensation grossly intact, \r\nambulatory without assistance\r\nSkin: no petechiae  \r\n\r\nDischarge physical:\r\n\r\nVITALS -  Tm 99.1, Tc 98, BP 100/62, HR 84, RR 18, SpO2 97 ra\r\nI/O: (-/400 over past 8 hours) (1600/750 over past 24)\r\nGeneral: pleasant, lying in bed in no acute distress\r\nHEENT: normalocephalic/atraumatic, anicteric sclerae \r\nNeck: supple\r\nCV: RRR, ___ holosystolic murmur noted loudest at ___ ___ \r\nintercostal space (patient confirmed history of flow murmur)\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions with some tissue \r\ndeformity, + BS, soft, mildly tender in epigastrium, no rebound \r\nor guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: Alert and conversing appropriately, moving all \r\nextremities\r\nSkin: no rashes or lesions \r\n\r\n \r\nPertinent Results:\r\nAdmission labs:\r\n\r\n___ 03:15PM BLOOD WBC-4.8 RBC-2.35* Hgb-9.8* Hct-31.4* \r\nMCV-134* MCH-41.8* MCHC-31.3 RDW-16.9* Plt Ct-69*\r\n___ 11:52PM BLOOD WBC-3.2* RBC-2.13* Hgb-8.8* Hct-28.3* \r\nMCV-133* MCH-41.3* MCHC-31.1 RDW-16.9* Plt Ct-68*\r\n___ 03:15PM BLOOD Neuts-93.3* Lymphs-4.6* Monos-1.7* \r\nEos-0.4 Baso-0.2\r\n___ 03:15PM BLOOD Plt Ct-69*\r\n___ 11:52PM BLOOD ___ PTT-32.1 ___\r\n___ 11:52PM BLOOD Plt Ct-68*\r\n___ 11:52PM BLOOD Ret Aut-4.6*\r\n___ 03:15PM BLOOD UreaN-16 Creat-0.7 Na-140 K-3.7 Cl-104 \r\nHCO3-26 AnGap-14\r\n___ 11:52PM BLOOD UreaN-14 Creat-0.7 Na-141 K-3.4 Cl-108 \r\nHCO3-26 AnGap-10\r\n___ 03:15PM BLOOD Albumin-3.7 Calcium-8.5 Phos-3.0 Mg-1.8\r\n___ 11:52PM BLOOD Calcium-8.1* Phos-3.0 Mg-1.8\r\n___ 03:15PM BLOOD ALT-19 AST-27 LD(LDH)-266* AlkPhos-69 \r\nTotBili-0.3\r\n\r\nMicro:\r\n\r\nStool cultures:\r\n\r\n___ 10:36 pm STOOL     CONSISTENCY: WATERY      Source: \r\nStool. \r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Illumigene DNA\r\n      amplification assay. \r\n           (Reference Range-Negative). \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   VIRAL CULTURE (Pending): \r\n\r\nImaging:\r\n\r\n___:  lipase 12, urinalysis normal  \r\n\r\nIMAGING at ___ ___:\r\n\r\nChest PA and lateral:\r\nThe lungs remains clear.  The heart and mediastinal structures \r\nare unremarkable for technique, and appear stable.  The bony \r\nthorax is grossly intact.  A double-lumen right internal jugular \r\ncatheter remains in place.\r\n\r\nCT abdomen/pelvis with oral contrast, without IV contrast \r\n(comparison made to PET CT from ___:\r\nREDEMONSTRATION OF RETROPERITONEAL OR MESENTERIC \r\nLYMPHADENOPATHY, WHICH, ALLOWING FOR DIFFERENCES IN TECHNIQUE, \r\nAPPEARS STABLE. ILL DEFINED INCREASED DENSITY WITHIN THE \r\nMESENTERY IS SLIGHTLY MORE PRONOUNCED THAN BEFORE.  IT IS \r\nPOSSIBLE THAT SUBTLE CHANGES ARE DUE TO ACTIVE LYMPHOMA AND, IF \r\nCLINICALLY INDICATED, FURTHER EVALUATION BY PET/CT IS \r\nRECOMMENDED.\r\n      \r\n3.5 CM-THICK LESION IN THE RIGHT PELVIS THAT PROBABLY REPRESENTS \r\nAN OVARIAN CYST, UNCHANGED.  THIS COULD BE FURTHER EVALUATED BY \r\nSONOGRAPHY, IF CLINICALLY INDICATED.\r\n\r\nDischarge labs:\r\n\r\n___ 12:00AM BLOOD WBC-3.5* RBC-2.16* Hgb-9.1* Hct-29.0* \r\nMCV-135* MCH-42.2* MCHC-31.3 RDW-16.5* Plt Ct-62*\r\n___ 12:00AM BLOOD Neuts-74.2* Lymphs-16.3* Monos-8.6 \r\nEos-0.7 Baso-0.1\r\n___ 12:00AM BLOOD Plt Ct-62*\r\n___ 12:00AM BLOOD Glucose-74 UreaN-11 Creat-0.7 Na-137 \r\nK-4.0 Cl-104 HCO3-26 AnGap-11\r\n___ 12:00AM BLOOD Calcium-8.6 Phos-2.9 Mg-1.9\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old woman with transformed DLBCL stage \r\nIIIB s/p autoSCT with BEAM conditioning course complicated by \r\n___ pneumonitis who presents today on D+131 (as of ___ for \r\nevaluation of diarrhea and abdominal pain, likely \r\ngastroenteritis.\r\n\r\n# Emesis/diarrhea- history most consistent with viral \r\ngastroenteritis, with norovirus on differential. On the day \r\nafter admission, she reported that her husband had fallen ill \r\nthat day with similar symptoms. CT did not demonstrate colitis, \r\nbut was performed without IV contrast. Ischemic colitis is \r\nunlikely given no cardiovascular risk factors. Other ddx include \r\ngastritis, pancreatitis, and hepatitis, but given her clinical \r\npresentation, these are less likely. Received 1L maintenance \r\nfluids overnight on ___. She still had some diarrhea and \r\nabdominal pain on ___ but her symptoms had greatly improved by \r\n___ and she was tolerating po's well. She was maintained on a \r\nlow residue diet and her home furosemide was temporarily held. \r\nC. diff returned negative and other stool cultures/pcr were \r\npending at the time of discharge. She was scheduled for clinic \r\nfollow-up on ___.\r\n\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by ___ pneumonitis. LDH 266. She has a restaging \r\nPET/CT scheduled for next week. She received pentamidine for PJP \r\nppx on ___. She was maintained on acyclovir ppx as an \r\ninpatient. Although patient's symptoms are most likely from \r\ngastroenteritis and are currently improving, disease progression \r\nshould be considered. She will obtain her outpatient PET/CT \r\nafter discharge.\r\n \r\n#Hypogammaglobulinemia: Patient's last IgG was 340 on ___. \r\nReceived an infusion on ___. Plan was to check an IgG \r\nlevel/consider IVIG infusion if symptoms worsened, but the \r\npatient improved with IV/po fluids. \r\n\r\n# History of BCNU pneumonitis- Patient receives weekly DLCO with \r\nprednisone taper (5 mg weekly). She was continued on prednisone \r\n25 mg daily with plans to continue taper after discharge. Her \r\nnext set of PFT's are already scheduled.\r\n\r\n# Right ___ DVT- continued rivaroxaban.  Has IVC filter in place.\r\n\r\n# Pancytopenia- Possibly viral suppression of bone \r\nmarrow/dilution effect from IVF. Reticulocyte count 4.6. WBC \r\nimproving on ___ but platelets continuing to downtrend. She \r\nwill need to f/u in clinic after discharge to ensure that her \r\ncounts and platelets are recovering.\r\n\r\n# Hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm. Continued home gabapentin.\r\n\r\n# GERD- continued home omeprazole\r\n\r\n# Depression- continued home venlafaxine\r\n\r\n# CODE: Full\r\n# EMERGENCY CONTACT: \r\nName of health care proxy: ___ \r\nRelationship: husband \r\nPhone number: ___\r\n\r\n___ issues:\r\n-Will need to f/u CBC in clinic to ensure recovery of her counts\r\n-Will need to continue her steroid taper as an outpatient: on 25 \r\nmg at discharge.\r\n-Ms. ___ did not require any prescriptions at discharge as \r\nshe stated she already has the medications she needs. She cares \r\nfor her triple lumen catheter herself.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ascorbic Acid ___ mg PO DAILY \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n4. Ascorbic Acid ___ mg PO DAILY \r\n5. Cyanocobalamin 1000 mcg PO DAILY \r\n6. Gabapentin 900 mg PO BID \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n11. Furosemide 20 mg PO DAILY \r\n12. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary diagnosis:\r\n# Emesis/diarrhea\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by BCNU pneumonitis. \r\n#Hypogammaglobulinemia\r\n# History of BCNU pneumonitis\r\n\r\nSecondary diagnoses\r\n# Right ___ DVT\r\n# Pancytopenia\r\n# Hyperthesia of R V1/V2\r\n# GERD\r\n# Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___. You were admitted \r\nafter experiencing nausea, diarrhea, and abdominal pain. Your \r\nsymptoms are likely from a viral illness and improved during \r\nyour hospital stay with fluids and pain medication. You were \r\neventually able to eat and drink adequately and were discharged \r\nhome. If you experience worsening diarrhea, nausea, or abdominal \r\npain or develop fever/chills after your discharge, please call \r\nclinic or return to the Emergency Department as soon as \r\npossible. You have follow-up appointments scheduled on ___ with \r\nheme-onc.\r\n\r\nTake care, and we wish you the best.\r\n\r\nSincerely,\r\nYour BMT team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-14:8",
      "text": "Discharge Instructions:\nDear Ms. ___, It was a pleasure caring for you at ___. You were admitted \nafter experiencing nausea, diarrhea, and abdominal pain. Your \nsymptoms are likely from a viral illness and improved during \nyour hospital stay with fluids and pain medication. You were \neventually able to eat and drink adequately and were discharged \nhome. If you experience worsening diarrhea, nausea, or abdominal \npain or develop fever/chills after your discharge, please call \nclinic or return to the Emergency Department as soon as \npossible. You have follow-up appointments scheduled on ___ with \nheme-onc. Take care, and we wish you the best. Sincerely,\nYour BMT team\n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-14",
        "chart_time": "103483",
        "section": "General",
        "position": 8,
        "tokenCount": 176,
        "note_metadata": {
          "note_id": "18887130-DS-14",
          "subject_id": 18887130,
          "hadm_id": 29581683,
          "note_type": "DS",
          "note_seq": 14,
          "charttime": 103483,
          "storetime": 103483.69791666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\ndiarrhea, abdominal discomfort\r\n\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\n___ year old female with transformed DLBCL stage IIIB s/p autoSCT \r\nwith BEAM conditioning course complicated by BCNU pneumonitis \r\nwho presents today on D+129 for evaluation of diarrhea.\r\n\r\nPatient reports feeling well, in her usual state of health about \r\n5 days ago.  On ___ evening, she noticed some mild epigastric \r\ndiscomfort.  Earlier in the day, both she and her husband had \r\nreheated ___ and vegetables.  She woke on ___ morning \r\nwith intermittent crampiness with sudden onset emesis and \r\ndiarrhea.  The emesis looked like undigested food, without blood \r\nor bile.  The diarrhea was non-bloody.  The symtoms persisted \r\nthroughout the day.  She tried to stay up with hydration.  The \r\npain, still intermittent, became more severe yesterday.  She \r\nthen was directed to ___.  In the ED, she received IVF, \r\na CT abdomen/pelvis was obtained (see below), she received some \r\nmorphine for pain control, and was discharged home after \r\nsymptoms improved.  After returning home, she had ongoing \r\ndiarrhea this morning, and presented to ___ clinic for routine \r\nfollow up, and has been admitted to the floor for further \r\nevaluation.\r\n\r\nUpon arrival to the floor, she notes intermittent epigastric \r\ndiscomfort, mild, without radiation.  She had an episode of \r\ndiarrhea in the clinic.  No emesis for about 48 hours.  She is \r\nnot hungry.  She denies any fevers or chills.  Her husband does \r\nnot have any GI symptoms, she has had no sick contact or recent \r\ntravel.  She denies any rashes.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission physical:\r\n\r\nPHYSICAL EXAM: \r\nVITALS -  98.8  116/78  HR ___  RR 16  96% RA\r\nGeneral: pleasant, no distress, appears stated age\r\nHEENT: anicteric sclerae, clear oropharynx without lesions\r\nNeck: no adenopathy\r\nCV: RRR, normal S1, S2, no murmurs or rubs\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions, active BS, soft, mildly \r\ntender in epigastrium, no rebound or guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: CNs ___ intact, strength and sensation grossly intact, \r\nambulatory without assistance\r\nSkin: no petechiae  \r\n\r\nDischarge physical:\r\n\r\nVITALS -  Tm 99.1, Tc 98, BP 100/62, HR 84, RR 18, SpO2 97 ra\r\nI/O: (-/400 over past 8 hours) (1600/750 over past 24)\r\nGeneral: pleasant, lying in bed in no acute distress\r\nHEENT: normalocephalic/atraumatic, anicteric sclerae \r\nNeck: supple\r\nCV: RRR, ___ holosystolic murmur noted loudest at ___ ___ \r\nintercostal space (patient confirmed history of flow murmur)\r\nLungs:  clear bilaterally, good air movement\r\nAbdomen: well-healed surgical incisions with some tissue \r\ndeformity, + BS, soft, mildly tender in epigastrium, no rebound \r\nor guarding, no organomegaly\r\nExt:   2+ radial and DP pulses, no edema\r\nNeuro: Alert and conversing appropriately, moving all \r\nextremities\r\nSkin: no rashes or lesions \r\n\r\n \r\nPertinent Results:\r\nAdmission labs:\r\n\r\n___ 03:15PM BLOOD WBC-4.8 RBC-2.35* Hgb-9.8* Hct-31.4* \r\nMCV-134* MCH-41.8* MCHC-31.3 RDW-16.9* Plt Ct-69*\r\n___ 11:52PM BLOOD WBC-3.2* RBC-2.13* Hgb-8.8* Hct-28.3* \r\nMCV-133* MCH-41.3* MCHC-31.1 RDW-16.9* Plt Ct-68*\r\n___ 03:15PM BLOOD Neuts-93.3* Lymphs-4.6* Monos-1.7* \r\nEos-0.4 Baso-0.2\r\n___ 03:15PM BLOOD Plt Ct-69*\r\n___ 11:52PM BLOOD ___ PTT-32.1 ___\r\n___ 11:52PM BLOOD Plt Ct-68*\r\n___ 11:52PM BLOOD Ret Aut-4.6*\r\n___ 03:15PM BLOOD UreaN-16 Creat-0.7 Na-140 K-3.7 Cl-104 \r\nHCO3-26 AnGap-14\r\n___ 11:52PM BLOOD UreaN-14 Creat-0.7 Na-141 K-3.4 Cl-108 \r\nHCO3-26 AnGap-10\r\n___ 03:15PM BLOOD Albumin-3.7 Calcium-8.5 Phos-3.0 Mg-1.8\r\n___ 11:52PM BLOOD Calcium-8.1* Phos-3.0 Mg-1.8\r\n___ 03:15PM BLOOD ALT-19 AST-27 LD(LDH)-266* AlkPhos-69 \r\nTotBili-0.3\r\n\r\nMicro:\r\n\r\nStool cultures:\r\n\r\n___ 10:36 pm STOOL     CONSISTENCY: WATERY      Source: \r\nStool. \r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Illumigene DNA\r\n      amplification assay. \r\n           (Reference Range-Negative). \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   VIRAL CULTURE (Pending): \r\n\r\nImaging:\r\n\r\n___:  lipase 12, urinalysis normal  \r\n\r\nIMAGING at ___ ___:\r\n\r\nChest PA and lateral:\r\nThe lungs remains clear.  The heart and mediastinal structures \r\nare unremarkable for technique, and appear stable.  The bony \r\nthorax is grossly intact.  A double-lumen right internal jugular \r\ncatheter remains in place.\r\n\r\nCT abdomen/pelvis with oral contrast, without IV contrast \r\n(comparison made to PET CT from ___:\r\nREDEMONSTRATION OF RETROPERITONEAL OR MESENTERIC \r\nLYMPHADENOPATHY, WHICH, ALLOWING FOR DIFFERENCES IN TECHNIQUE, \r\nAPPEARS STABLE. ILL DEFINED INCREASED DENSITY WITHIN THE \r\nMESENTERY IS SLIGHTLY MORE PRONOUNCED THAN BEFORE.  IT IS \r\nPOSSIBLE THAT SUBTLE CHANGES ARE DUE TO ACTIVE LYMPHOMA AND, IF \r\nCLINICALLY INDICATED, FURTHER EVALUATION BY PET/CT IS \r\nRECOMMENDED.\r\n      \r\n3.5 CM-THICK LESION IN THE RIGHT PELVIS THAT PROBABLY REPRESENTS \r\nAN OVARIAN CYST, UNCHANGED.  THIS COULD BE FURTHER EVALUATED BY \r\nSONOGRAPHY, IF CLINICALLY INDICATED.\r\n\r\nDischarge labs:\r\n\r\n___ 12:00AM BLOOD WBC-3.5* RBC-2.16* Hgb-9.1* Hct-29.0* \r\nMCV-135* MCH-42.2* MCHC-31.3 RDW-16.5* Plt Ct-62*\r\n___ 12:00AM BLOOD Neuts-74.2* Lymphs-16.3* Monos-8.6 \r\nEos-0.7 Baso-0.1\r\n___ 12:00AM BLOOD Plt Ct-62*\r\n___ 12:00AM BLOOD Glucose-74 UreaN-11 Creat-0.7 Na-137 \r\nK-4.0 Cl-104 HCO3-26 AnGap-11\r\n___ 12:00AM BLOOD Calcium-8.6 Phos-2.9 Mg-1.9\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old woman with transformed DLBCL stage \r\nIIIB s/p autoSCT with BEAM conditioning course complicated by \r\n___ pneumonitis who presents today on D+131 (as of ___ for \r\nevaluation of diarrhea and abdominal pain, likely \r\ngastroenteritis.\r\n\r\n# Emesis/diarrhea- history most consistent with viral \r\ngastroenteritis, with norovirus on differential. On the day \r\nafter admission, she reported that her husband had fallen ill \r\nthat day with similar symptoms. CT did not demonstrate colitis, \r\nbut was performed without IV contrast. Ischemic colitis is \r\nunlikely given no cardiovascular risk factors. Other ddx include \r\ngastritis, pancreatitis, and hepatitis, but given her clinical \r\npresentation, these are less likely. Received 1L maintenance \r\nfluids overnight on ___. She still had some diarrhea and \r\nabdominal pain on ___ but her symptoms had greatly improved by \r\n___ and she was tolerating po's well. She was maintained on a \r\nlow residue diet and her home furosemide was temporarily held. \r\nC. diff returned negative and other stool cultures/pcr were \r\npending at the time of discharge. She was scheduled for clinic \r\nfollow-up on ___.\r\n\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by ___ pneumonitis. LDH 266. She has a restaging \r\nPET/CT scheduled for next week. She received pentamidine for PJP \r\nppx on ___. She was maintained on acyclovir ppx as an \r\ninpatient. Although patient's symptoms are most likely from \r\ngastroenteritis and are currently improving, disease progression \r\nshould be considered. She will obtain her outpatient PET/CT \r\nafter discharge.\r\n \r\n#Hypogammaglobulinemia: Patient's last IgG was 340 on ___. \r\nReceived an infusion on ___. Plan was to check an IgG \r\nlevel/consider IVIG infusion if symptoms worsened, but the \r\npatient improved with IV/po fluids. \r\n\r\n# History of BCNU pneumonitis- Patient receives weekly DLCO with \r\nprednisone taper (5 mg weekly). She was continued on prednisone \r\n25 mg daily with plans to continue taper after discharge. Her \r\nnext set of PFT's are already scheduled.\r\n\r\n# Right ___ DVT- continued rivaroxaban.  Has IVC filter in place.\r\n\r\n# Pancytopenia- Possibly viral suppression of bone \r\nmarrow/dilution effect from IVF. Reticulocyte count 4.6. WBC \r\nimproving on ___ but platelets continuing to downtrend. She \r\nwill need to f/u in clinic after discharge to ensure that her \r\ncounts and platelets are recovering.\r\n\r\n# Hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm. Continued home gabapentin.\r\n\r\n# GERD- continued home omeprazole\r\n\r\n# Depression- continued home venlafaxine\r\n\r\n# CODE: Full\r\n# EMERGENCY CONTACT: \r\nName of health care proxy: ___ \r\nRelationship: husband \r\nPhone number: ___\r\n\r\n___ issues:\r\n-Will need to f/u CBC in clinic to ensure recovery of her counts\r\n-Will need to continue her steroid taper as an outpatient: on 25 \r\nmg at discharge.\r\n-Ms. ___ did not require any prescriptions at discharge as \r\nshe stated she already has the medications she needs. She cares \r\nfor her triple lumen catheter herself.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 900 mg PO BID \r\n5. Omeprazole 20 mg PO DAILY \r\n6. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Ascorbic Acid ___ mg PO DAILY \r\n11. Cyanocobalamin 1000 mcg PO DAILY \r\n12. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Albuterol Inhaler ___ PUFF IH Q4H:PRN dyspnea \r\n4. Ascorbic Acid ___ mg PO DAILY \r\n5. Cyanocobalamin 1000 mcg PO DAILY \r\n6. Gabapentin 900 mg PO BID \r\n7. PredniSONE 25 mg PO DAILY \r\n8. Rivaroxaban 20 mg PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. Calcium 600 with Vitamin D3 (calcium carbonate-vitamin D3) \r\n600 mg(1,500mg) -400 unit oral daily \r\n11. Furosemide 20 mg PO DAILY \r\n12. Klor-Con 10 (potassium chloride) 10 mEq oral daily \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary diagnosis:\r\n# Emesis/diarrhea\r\n# DLBCL- stage IIIb s/p autoSCT with BEAM conditioning, \r\ncomplicated by BCNU pneumonitis. \r\n#Hypogammaglobulinemia\r\n# History of BCNU pneumonitis\r\n\r\nSecondary diagnoses\r\n# Right ___ DVT\r\n# Pancytopenia\r\n# Hyperthesia of R V1/V2\r\n# GERD\r\n# Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___. You were admitted \r\nafter experiencing nausea, diarrhea, and abdominal pain. Your \r\nsymptoms are likely from a viral illness and improved during \r\nyour hospital stay with fluids and pain medication. You were \r\neventually able to eat and drink adequately and were discharged \r\nhome. If you experience worsening diarrhea, nausea, or abdominal \r\npain or develop fever/chills after your discharge, please call \r\nclinic or return to the Emergency Department as soon as \r\npossible. You have follow-up appointments scheduled on ___ with \r\nheme-onc.\r\n\r\nTake care, and we wish you the best.\r\n\r\nSincerely,\r\nYour BMT team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-15:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: ORTHOPAEDICS Allergies: \ndapsone\n \nAttending: ___\n \n___ Complaint:\nR knee OA \n \nMajor Surgical or Invasive Procedure:\nR TKR History of Present Illness:\n___ with right knee osteoarthritis refractory to conservative \nmanagement now presenting for definitive treatment.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-15",
        "chart_time": "103691",
        "section": "General",
        "position": 0,
        "tokenCount": 106,
        "note_metadata": {
          "note_id": "18887130-DS-15",
          "subject_id": 18887130,
          "hadm_id": 21937304,
          "note_type": "DS",
          "note_seq": 15,
          "charttime": 103691,
          "storetime": 103691.45625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: ORTHOPAEDICS\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nR knee OA \r\n \r\nMajor Surgical or Invasive Procedure:\r\nR TKR \r\n\r\n \r\nHistory of Present Illness:\r\n___ with right knee osteoarthritis refractory to conservative \r\nmanagement now presenting for definitive treatment. \r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nWell appearing in no acute distress  \r\nAfebrile with stable vital signs  \r\nPain well-controlled  \r\nRespiratory: CTAB  \r\nCardiovascular: RRR  \r\nGastrointestinal: NT/ND  \r\nGenitourinary: Voiding independently  \r\nNeurologic: Intact with no focal deficits  \r\nPsychiatric: Pleasant, A&O x3  \r\nMusculoskeletal Lower Extremity:  \r\n* Incision healing well with staples  -Covered w/ Silverlon \r\n* Scant serosanguinous drainage  \r\n* Thigh full but soft  \r\n* No calf tenderness  \r\n* ___ strength FHL/G, ___ strength ___  \r\n* Sensation diminished in the DP and SP distribution otherwise \r\nSILT \r\n* Toes warm\r\n\r\n \r\nPertinent Results:\r\n___ 06:45AM BLOOD WBC-4.0 RBC-2.17* Hgb-8.0* Hct-24.0* \r\nMCV-111* MCH-36.7* MCHC-33.1 RDW-17.2* Plt Ct-63*\r\n___ 06:25AM BLOOD WBC-4.3 RBC-2.31* Hgb-8.7* Hct-25.9* \r\nMCV-112* MCH-37.4* MCHC-33.4 RDW-17.4* Plt Ct-71*\r\n___ 06:25AM BLOOD WBC-3.5* RBC-2.55* Hgb-9.1* Hct-28.2* \r\nMCV-111* MCH-35.9* MCHC-32.4 RDW-16.6* Plt Ct-82*\r\n___ 06:45AM BLOOD Glucose-87 UreaN-12 Creat-0.9 Na-140 \r\nK-3.8 Cl-102 HCO3-30 AnGap-12\r\n___ 06:25AM BLOOD Glucose-97 UreaN-10 Creat-0.7 Na-137 \r\nK-3.5 Cl-102 HCO3-29 AnGap-10\r\n___ 06:25AM BLOOD Glucose-125* UreaN-11 Creat-0.7 Na-137 \r\nK-4.1 Cl-104 HCO3-28 AnGap-9\r\n \r\nBrief Hospital Course:\r\nThe patient was admitted to the orthopedic surgery service and \r\nwas taken to the operating room for above described procedure. \r\nPlease see separately dictated operative report for details. The \r\nsurgery was uncomplicated and the patient tolerated the \r\nprocedure well. Patient received perioperative IV antibiotics.\r\n\r\nOtherwise, pain was initially controlled with a PCA followed by \r\na transition to oral pain medications on POD#1.  The patient \r\nreceived xarelto for DVT prophylaxis starting on the morning of \r\nPOD#1 (started at 10 mg uptitrated to her home dose of 20 mg \r\ndaily).  The foley was removed on POD2 and the patient was \r\nvoiding independently thereafter. The overlying surgical \r\ndressing was changed on POD#2 and the Silverlon dressing was \r\nfound to be clean and intact without erythema or abnormal \r\ndrainage. The patient was seen daily by physical therapy. Labs \r\nwere checked throughout the hospital course and repleted \r\naccordingly. At the time of discharge the patient was tolerating \r\na regular diet and feeling well.  The patient was afebrile with \r\nstable vital signs.  The patient's hematocrit was acceptable and \r\npain was adequately controlled on an oral regimen. The operative \r\nextremity was neurovascularly intact and the wound was benign. \r\n\r\nThe patient's weight-bearing status is weight bearing as \r\ntolerated on the operative extremity. \r\n \r\nMs. ___ is discharged to home with services in stable \r\ncondition.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 4 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 600 mg PO QID \r\n5. Rivaroxaban 20 mg PO DAILY \r\n6. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n7. Venlafaxine 25 mg PO BID \r\n8. Ascorbic Acid ___ mg PO DAILY \r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Ascorbic Acid ___ mg PO DAILY \r\n3. Cyanocobalamin 1000 mcg PO DAILY \r\n4. FoLIC Acid 4 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 600 mg PO QID \r\n7. Rivaroxaban 20 mg PO DAILY \r\n8. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n9. Venlafaxine 25 mg PO BID \r\n10. Acetaminophen 650 mg PO Q6H \r\n11. Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium 100 mg 1 capsule(s) by mouth twice a day \r\nDisp #*30 Capsule Refills:*1\r\n12. OxycoDONE (Immediate Release)  ___ mg PO Q4H:PRN Pain \r\nRX *oxycodone 5 mg ___ tablet(s) by mouth Q3-6hrs Disp #*120 \r\nTablet Refills:*0\r\n13. Senna 8.6 mg PO BID \r\nRX *sennosides [senna] 8.6 mg 1 tablet by mouth twice a day Disp \r\n#*30 Capsule Refills:*1\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nR knee osteoarthritis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\n1. Please return to the emergency department or notify your \r\nphysician if you experience any of the following: severe pain \r\nnot relieved by medication, increased swelling, decreased \r\nsensation, difficulty with movement, fevers greater than 101.5, \r\nshaking chills, increasing redness or drainage from the incision \r\nsite, chest pain, shortness of breath or any other concerns.\r\n \r\n2. Please follow up with your primary physician regarding this \r\nadmission and any new medications and refills. \r\n \r\n3. Resume your home medications unless otherwise instructed.\r\n \r\n4. You have been given medications for pain control. Please do \r\nnot drive, operate heavy machinery, or drink alcohol while \r\ntaking these medications. As your pain decreases, take fewer \r\ntablets and increase the time between doses. This medication can \r\ncause constipation, so you should drink plenty of water daily \r\nand take a stool softener (such as Colace) as needed to prevent \r\nthis side effect.  Call your surgeons office 3 days before you \r\nare out of medication so that it can be refilled.  These \r\nmedications cannot be called into your pharmacy and must be \r\npicked up in the clinic or mailed to your house.  Please allow \r\nan extra 2 days if you would like your medication mailed to your \r\nhome.\r\n \r\n5. You may not drive a car until cleared to do so by your \r\nsurgeon.\r\n \r\n6. Please call your surgeon's office to schedule or confirm your \r\nfollow-up appointment in three (3) weeks.\r\n \r\n7. SWELLING: Ice the operative joint 20 minutes at a time, \r\nespecially after activity or physical therapy. Do not place ice \r\ndirectly on the skin. You may wrap the knee with an ace bandage \r\nfor added compression. Please DO NOT take any non-steroidal \r\nanti-inflammatory medications (NSAIDs such as Celebrex, \r\nibuprofen, Advil, Aleve, Motrin, naproxen etc).\r\n \r\n8. ANTICOAGULATION: Please continue your Xarelto 20 mg daily to \r\nhelp prevent deep vein thrombosis (blood clots).  If you were \r\ntaking aspirin prior to your surgery, it is OK to continue at \r\nyour previous dose while taking this medication.  Wear ___ \r\nstockings for 6 weeks. \r\n \r\n9. WOUND CARE: Please keep your Silverlon dressing clean and \r\ndry. REMOVE on ___. It is okay to shower five days after \r\nsurgery but no tub baths, swimming, or submerging your incision \r\nuntil after your four (4) week checkup. You may place a dry \r\nsterile dressing on the wound after the Silverlon dressing is \r\nremoved, otherwise leave it open to air. Check wound regularly \r\nfor signs of infection such as redness or thick yellow drainage. \r\nStaples will be removed by at your follow-up visit in 3 weeks.\r\n \r\n10. ___ (once at home): Home ___, dressing changes as \r\ninstructed, and wound checks.\r\n \r\n11. ACTIVITY: Weight bearing as tolerated on the operative \r\nextremity. Mobilize. CPM/ROM as tolerated. No strenuous exercise \r\nor heavy lifting until follow up appointment.\r\n \r\n\r\nPhysical Therapy:\r\nWBAT RLE\r\nMobilize frequently \r\nTreatments Frequency:\r\ndaily dressing changes as needed for drainage\r\nwound checks daily\r\nice\r\nTEDs\r\nstaple removal and replace with steri-strips POD17 (___) \r\nremove silverlon on ___ (POD7) \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-15:1",
      "text": "Past Medical History:\nOncologic history: In brief, history of follicular lymphoma \nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \nrituximab in ___ for residual disease. ___: RICE \nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \nlocal disease. She has a hx of hypogammaglobulinemia. obesity\nAcute DVT in the right popliteal/femoral veins + superficial \nthrombosis\n--Transformed DLBCL with history of follicular lymphoma as noted \nabove\n--CLL, noted on BM biopsy on ___. --Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \n(*Known slight CN VI palsy & mild proptosis of R eye)\n--Hypogammaglobulinemia, receives IVIG PRN\n--R leg DVT. IVC filter in place, on rivaroxaban\n--BCNU pneumonitis, on prednisone\n--Mild GERD\n--OA / LBP\n--Small Intestinal Bacterial Overgrowth\n--Trochanteric Bursitis\n--s/p Excisional Bx L Cervical Lymph Node\n--s/p L total knee replacement ___, walks with cane\n--s/p I&D Labial Abscess\n--s/p Excision Cyst R ___ Digit of Hand Social History:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-15",
        "chart_time": "103691",
        "section": "General",
        "position": 1,
        "tokenCount": 249,
        "note_metadata": {
          "note_id": "18887130-DS-15",
          "subject_id": 18887130,
          "hadm_id": 21937304,
          "note_type": "DS",
          "note_seq": 15,
          "charttime": 103691,
          "storetime": 103691.45625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: ORTHOPAEDICS\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nR knee OA \r\n \r\nMajor Surgical or Invasive Procedure:\r\nR TKR \r\n\r\n \r\nHistory of Present Illness:\r\n___ with right knee osteoarthritis refractory to conservative \r\nmanagement now presenting for definitive treatment. \r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nWell appearing in no acute distress  \r\nAfebrile with stable vital signs  \r\nPain well-controlled  \r\nRespiratory: CTAB  \r\nCardiovascular: RRR  \r\nGastrointestinal: NT/ND  \r\nGenitourinary: Voiding independently  \r\nNeurologic: Intact with no focal deficits  \r\nPsychiatric: Pleasant, A&O x3  \r\nMusculoskeletal Lower Extremity:  \r\n* Incision healing well with staples  -Covered w/ Silverlon \r\n* Scant serosanguinous drainage  \r\n* Thigh full but soft  \r\n* No calf tenderness  \r\n* ___ strength FHL/G, ___ strength ___  \r\n* Sensation diminished in the DP and SP distribution otherwise \r\nSILT \r\n* Toes warm\r\n\r\n \r\nPertinent Results:\r\n___ 06:45AM BLOOD WBC-4.0 RBC-2.17* Hgb-8.0* Hct-24.0* \r\nMCV-111* MCH-36.7* MCHC-33.1 RDW-17.2* Plt Ct-63*\r\n___ 06:25AM BLOOD WBC-4.3 RBC-2.31* Hgb-8.7* Hct-25.9* \r\nMCV-112* MCH-37.4* MCHC-33.4 RDW-17.4* Plt Ct-71*\r\n___ 06:25AM BLOOD WBC-3.5* RBC-2.55* Hgb-9.1* Hct-28.2* \r\nMCV-111* MCH-35.9* MCHC-32.4 RDW-16.6* Plt Ct-82*\r\n___ 06:45AM BLOOD Glucose-87 UreaN-12 Creat-0.9 Na-140 \r\nK-3.8 Cl-102 HCO3-30 AnGap-12\r\n___ 06:25AM BLOOD Glucose-97 UreaN-10 Creat-0.7 Na-137 \r\nK-3.5 Cl-102 HCO3-29 AnGap-10\r\n___ 06:25AM BLOOD Glucose-125* UreaN-11 Creat-0.7 Na-137 \r\nK-4.1 Cl-104 HCO3-28 AnGap-9\r\n \r\nBrief Hospital Course:\r\nThe patient was admitted to the orthopedic surgery service and \r\nwas taken to the operating room for above described procedure. \r\nPlease see separately dictated operative report for details. The \r\nsurgery was uncomplicated and the patient tolerated the \r\nprocedure well. Patient received perioperative IV antibiotics.\r\n\r\nOtherwise, pain was initially controlled with a PCA followed by \r\na transition to oral pain medications on POD#1.  The patient \r\nreceived xarelto for DVT prophylaxis starting on the morning of \r\nPOD#1 (started at 10 mg uptitrated to her home dose of 20 mg \r\ndaily).  The foley was removed on POD2 and the patient was \r\nvoiding independently thereafter. The overlying surgical \r\ndressing was changed on POD#2 and the Silverlon dressing was \r\nfound to be clean and intact without erythema or abnormal \r\ndrainage. The patient was seen daily by physical therapy. Labs \r\nwere checked throughout the hospital course and repleted \r\naccordingly. At the time of discharge the patient was tolerating \r\na regular diet and feeling well.  The patient was afebrile with \r\nstable vital signs.  The patient's hematocrit was acceptable and \r\npain was adequately controlled on an oral regimen. The operative \r\nextremity was neurovascularly intact and the wound was benign. \r\n\r\nThe patient's weight-bearing status is weight bearing as \r\ntolerated on the operative extremity. \r\n \r\nMs. ___ is discharged to home with services in stable \r\ncondition.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 4 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 600 mg PO QID \r\n5. Rivaroxaban 20 mg PO DAILY \r\n6. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n7. Venlafaxine 25 mg PO BID \r\n8. Ascorbic Acid ___ mg PO DAILY \r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Ascorbic Acid ___ mg PO DAILY \r\n3. Cyanocobalamin 1000 mcg PO DAILY \r\n4. FoLIC Acid 4 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 600 mg PO QID \r\n7. Rivaroxaban 20 mg PO DAILY \r\n8. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n9. Venlafaxine 25 mg PO BID \r\n10. Acetaminophen 650 mg PO Q6H \r\n11. Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium 100 mg 1 capsule(s) by mouth twice a day \r\nDisp #*30 Capsule Refills:*1\r\n12. OxycoDONE (Immediate Release)  ___ mg PO Q4H:PRN Pain \r\nRX *oxycodone 5 mg ___ tablet(s) by mouth Q3-6hrs Disp #*120 \r\nTablet Refills:*0\r\n13. Senna 8.6 mg PO BID \r\nRX *sennosides [senna] 8.6 mg 1 tablet by mouth twice a day Disp \r\n#*30 Capsule Refills:*1\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nR knee osteoarthritis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\n1. Please return to the emergency department or notify your \r\nphysician if you experience any of the following: severe pain \r\nnot relieved by medication, increased swelling, decreased \r\nsensation, difficulty with movement, fevers greater than 101.5, \r\nshaking chills, increasing redness or drainage from the incision \r\nsite, chest pain, shortness of breath or any other concerns.\r\n \r\n2. Please follow up with your primary physician regarding this \r\nadmission and any new medications and refills. \r\n \r\n3. Resume your home medications unless otherwise instructed.\r\n \r\n4. You have been given medications for pain control. Please do \r\nnot drive, operate heavy machinery, or drink alcohol while \r\ntaking these medications. As your pain decreases, take fewer \r\ntablets and increase the time between doses. This medication can \r\ncause constipation, so you should drink plenty of water daily \r\nand take a stool softener (such as Colace) as needed to prevent \r\nthis side effect.  Call your surgeons office 3 days before you \r\nare out of medication so that it can be refilled.  These \r\nmedications cannot be called into your pharmacy and must be \r\npicked up in the clinic or mailed to your house.  Please allow \r\nan extra 2 days if you would like your medication mailed to your \r\nhome.\r\n \r\n5. You may not drive a car until cleared to do so by your \r\nsurgeon.\r\n \r\n6. Please call your surgeon's office to schedule or confirm your \r\nfollow-up appointment in three (3) weeks.\r\n \r\n7. SWELLING: Ice the operative joint 20 minutes at a time, \r\nespecially after activity or physical therapy. Do not place ice \r\ndirectly on the skin. You may wrap the knee with an ace bandage \r\nfor added compression. Please DO NOT take any non-steroidal \r\nanti-inflammatory medications (NSAIDs such as Celebrex, \r\nibuprofen, Advil, Aleve, Motrin, naproxen etc).\r\n \r\n8. ANTICOAGULATION: Please continue your Xarelto 20 mg daily to \r\nhelp prevent deep vein thrombosis (blood clots).  If you were \r\ntaking aspirin prior to your surgery, it is OK to continue at \r\nyour previous dose while taking this medication.  Wear ___ \r\nstockings for 6 weeks. \r\n \r\n9. WOUND CARE: Please keep your Silverlon dressing clean and \r\ndry. REMOVE on ___. It is okay to shower five days after \r\nsurgery but no tub baths, swimming, or submerging your incision \r\nuntil after your four (4) week checkup. You may place a dry \r\nsterile dressing on the wound after the Silverlon dressing is \r\nremoved, otherwise leave it open to air. Check wound regularly \r\nfor signs of infection such as redness or thick yellow drainage. \r\nStaples will be removed by at your follow-up visit in 3 weeks.\r\n \r\n10. ___ (once at home): Home ___, dressing changes as \r\ninstructed, and wound checks.\r\n \r\n11. ACTIVITY: Weight bearing as tolerated on the operative \r\nextremity. Mobilize. CPM/ROM as tolerated. No strenuous exercise \r\nor heavy lifting until follow up appointment.\r\n \r\n\r\nPhysical Therapy:\r\nWBAT RLE\r\nMobilize frequently \r\nTreatments Frequency:\r\ndaily dressing changes as needed for drainage\r\nwound checks daily\r\nice\r\nTEDs\r\nstaple removal and replace with steri-strips POD17 (___) \r\nremove silverlon on ___ (POD7) \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-15:2",
      "text": "Family History:\nbrother- lymphoma Physical ___:\nWell appearing in no acute distress  \nAfebrile with stable vital signs  \nPain well-controlled  \nRespiratory: CTAB  \nCardiovascular: RRR  \nGastrointestinal: NT/ND  \nGenitourinary: Voiding independently  \nNeurologic: Intact with no focal deficits  \nPsychiatric: Pleasant, A&O x3  \nMusculoskeletal Lower Extremity:  \n* Incision healing well with staples  -Covered w/ Silverlon \n* Scant serosanguinous drainage  \n* Thigh full but soft  \n* No calf tenderness  \n* ___ strength FHL/G, ___ strength ___  \n* Sensation diminished in the DP and SP distribution otherwise \nSILT \n* Toes warm Pertinent Results:\n___ 06:45AM BLOOD WBC-4.0 RBC-2.17* Hgb-8.0* Hct-24.0* \nMCV-111* MCH-36.7* MCHC-33.1 RDW-17.2* Plt Ct-63*\n___ 06:25AM BLOOD WBC-4.3 RBC-2.31* Hgb-8.7* Hct-25.9* \nMCV-112* MCH-37.4* MCHC-33.4 RDW-17.4* Plt Ct-71*\n___ 06:25AM BLOOD WBC-3.5* RBC-2.55* Hgb-9.1* Hct-28.2* \nMCV-111* MCH-35.9* MCHC-32.4 RDW-16.6* Plt Ct-82*\n___ 06:45AM BLOOD Glucose-87 UreaN-12 Creat-0.9 Na-140 \nK-3.8 Cl-102 HCO3-30 AnGap-12\n___ 06:25AM BLOOD Glucose-97 UreaN-10 Creat-0.7 Na-137 \nK-3.5 Cl-102 HCO3-29 AnGap-10\n___ 06:25AM BLOOD Glucose-125* UreaN-11 Creat-0.7 Na-137 \nK-4.1 Cl-104 HCO3-28 AnGap-9",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-15",
        "chart_time": "103691",
        "section": "General",
        "position": 2,
        "tokenCount": 306,
        "note_metadata": {
          "note_id": "18887130-DS-15",
          "subject_id": 18887130,
          "hadm_id": 21937304,
          "note_type": "DS",
          "note_seq": 15,
          "charttime": 103691,
          "storetime": 103691.45625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: ORTHOPAEDICS\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nR knee OA \r\n \r\nMajor Surgical or Invasive Procedure:\r\nR TKR \r\n\r\n \r\nHistory of Present Illness:\r\n___ with right knee osteoarthritis refractory to conservative \r\nmanagement now presenting for definitive treatment. \r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nWell appearing in no acute distress  \r\nAfebrile with stable vital signs  \r\nPain well-controlled  \r\nRespiratory: CTAB  \r\nCardiovascular: RRR  \r\nGastrointestinal: NT/ND  \r\nGenitourinary: Voiding independently  \r\nNeurologic: Intact with no focal deficits  \r\nPsychiatric: Pleasant, A&O x3  \r\nMusculoskeletal Lower Extremity:  \r\n* Incision healing well with staples  -Covered w/ Silverlon \r\n* Scant serosanguinous drainage  \r\n* Thigh full but soft  \r\n* No calf tenderness  \r\n* ___ strength FHL/G, ___ strength ___  \r\n* Sensation diminished in the DP and SP distribution otherwise \r\nSILT \r\n* Toes warm\r\n\r\n \r\nPertinent Results:\r\n___ 06:45AM BLOOD WBC-4.0 RBC-2.17* Hgb-8.0* Hct-24.0* \r\nMCV-111* MCH-36.7* MCHC-33.1 RDW-17.2* Plt Ct-63*\r\n___ 06:25AM BLOOD WBC-4.3 RBC-2.31* Hgb-8.7* Hct-25.9* \r\nMCV-112* MCH-37.4* MCHC-33.4 RDW-17.4* Plt Ct-71*\r\n___ 06:25AM BLOOD WBC-3.5* RBC-2.55* Hgb-9.1* Hct-28.2* \r\nMCV-111* MCH-35.9* MCHC-32.4 RDW-16.6* Plt Ct-82*\r\n___ 06:45AM BLOOD Glucose-87 UreaN-12 Creat-0.9 Na-140 \r\nK-3.8 Cl-102 HCO3-30 AnGap-12\r\n___ 06:25AM BLOOD Glucose-97 UreaN-10 Creat-0.7 Na-137 \r\nK-3.5 Cl-102 HCO3-29 AnGap-10\r\n___ 06:25AM BLOOD Glucose-125* UreaN-11 Creat-0.7 Na-137 \r\nK-4.1 Cl-104 HCO3-28 AnGap-9\r\n \r\nBrief Hospital Course:\r\nThe patient was admitted to the orthopedic surgery service and \r\nwas taken to the operating room for above described procedure. \r\nPlease see separately dictated operative report for details. The \r\nsurgery was uncomplicated and the patient tolerated the \r\nprocedure well. Patient received perioperative IV antibiotics.\r\n\r\nOtherwise, pain was initially controlled with a PCA followed by \r\na transition to oral pain medications on POD#1.  The patient \r\nreceived xarelto for DVT prophylaxis starting on the morning of \r\nPOD#1 (started at 10 mg uptitrated to her home dose of 20 mg \r\ndaily).  The foley was removed on POD2 and the patient was \r\nvoiding independently thereafter. The overlying surgical \r\ndressing was changed on POD#2 and the Silverlon dressing was \r\nfound to be clean and intact without erythema or abnormal \r\ndrainage. The patient was seen daily by physical therapy. Labs \r\nwere checked throughout the hospital course and repleted \r\naccordingly. At the time of discharge the patient was tolerating \r\na regular diet and feeling well.  The patient was afebrile with \r\nstable vital signs.  The patient's hematocrit was acceptable and \r\npain was adequately controlled on an oral regimen. The operative \r\nextremity was neurovascularly intact and the wound was benign. \r\n\r\nThe patient's weight-bearing status is weight bearing as \r\ntolerated on the operative extremity. \r\n \r\nMs. ___ is discharged to home with services in stable \r\ncondition.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 4 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 600 mg PO QID \r\n5. Rivaroxaban 20 mg PO DAILY \r\n6. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n7. Venlafaxine 25 mg PO BID \r\n8. Ascorbic Acid ___ mg PO DAILY \r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Ascorbic Acid ___ mg PO DAILY \r\n3. Cyanocobalamin 1000 mcg PO DAILY \r\n4. FoLIC Acid 4 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 600 mg PO QID \r\n7. Rivaroxaban 20 mg PO DAILY \r\n8. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n9. Venlafaxine 25 mg PO BID \r\n10. Acetaminophen 650 mg PO Q6H \r\n11. Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium 100 mg 1 capsule(s) by mouth twice a day \r\nDisp #*30 Capsule Refills:*1\r\n12. OxycoDONE (Immediate Release)  ___ mg PO Q4H:PRN Pain \r\nRX *oxycodone 5 mg ___ tablet(s) by mouth Q3-6hrs Disp #*120 \r\nTablet Refills:*0\r\n13. Senna 8.6 mg PO BID \r\nRX *sennosides [senna] 8.6 mg 1 tablet by mouth twice a day Disp \r\n#*30 Capsule Refills:*1\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nR knee osteoarthritis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\n1. Please return to the emergency department or notify your \r\nphysician if you experience any of the following: severe pain \r\nnot relieved by medication, increased swelling, decreased \r\nsensation, difficulty with movement, fevers greater than 101.5, \r\nshaking chills, increasing redness or drainage from the incision \r\nsite, chest pain, shortness of breath or any other concerns.\r\n \r\n2. Please follow up with your primary physician regarding this \r\nadmission and any new medications and refills. \r\n \r\n3. Resume your home medications unless otherwise instructed.\r\n \r\n4. You have been given medications for pain control. Please do \r\nnot drive, operate heavy machinery, or drink alcohol while \r\ntaking these medications. As your pain decreases, take fewer \r\ntablets and increase the time between doses. This medication can \r\ncause constipation, so you should drink plenty of water daily \r\nand take a stool softener (such as Colace) as needed to prevent \r\nthis side effect.  Call your surgeons office 3 days before you \r\nare out of medication so that it can be refilled.  These \r\nmedications cannot be called into your pharmacy and must be \r\npicked up in the clinic or mailed to your house.  Please allow \r\nan extra 2 days if you would like your medication mailed to your \r\nhome.\r\n \r\n5. You may not drive a car until cleared to do so by your \r\nsurgeon.\r\n \r\n6. Please call your surgeon's office to schedule or confirm your \r\nfollow-up appointment in three (3) weeks.\r\n \r\n7. SWELLING: Ice the operative joint 20 minutes at a time, \r\nespecially after activity or physical therapy. Do not place ice \r\ndirectly on the skin. You may wrap the knee with an ace bandage \r\nfor added compression. Please DO NOT take any non-steroidal \r\nanti-inflammatory medications (NSAIDs such as Celebrex, \r\nibuprofen, Advil, Aleve, Motrin, naproxen etc).\r\n \r\n8. ANTICOAGULATION: Please continue your Xarelto 20 mg daily to \r\nhelp prevent deep vein thrombosis (blood clots).  If you were \r\ntaking aspirin prior to your surgery, it is OK to continue at \r\nyour previous dose while taking this medication.  Wear ___ \r\nstockings for 6 weeks. \r\n \r\n9. WOUND CARE: Please keep your Silverlon dressing clean and \r\ndry. REMOVE on ___. It is okay to shower five days after \r\nsurgery but no tub baths, swimming, or submerging your incision \r\nuntil after your four (4) week checkup. You may place a dry \r\nsterile dressing on the wound after the Silverlon dressing is \r\nremoved, otherwise leave it open to air. Check wound regularly \r\nfor signs of infection such as redness or thick yellow drainage. \r\nStaples will be removed by at your follow-up visit in 3 weeks.\r\n \r\n10. ___ (once at home): Home ___, dressing changes as \r\ninstructed, and wound checks.\r\n \r\n11. ACTIVITY: Weight bearing as tolerated on the operative \r\nextremity. Mobilize. CPM/ROM as tolerated. No strenuous exercise \r\nor heavy lifting until follow up appointment.\r\n \r\n\r\nPhysical Therapy:\r\nWBAT RLE\r\nMobilize frequently \r\nTreatments Frequency:\r\ndaily dressing changes as needed for drainage\r\nwound checks daily\r\nice\r\nTEDs\r\nstaple removal and replace with steri-strips POD17 (___) \r\nremove silverlon on ___ (POD7) \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-15:3",
      "text": "Brief Hospital Course:\nThe patient was admitted to the orthopedic surgery service and \nwas taken to the operating room for above described procedure. Please see separately dictated operative report for details. The \nsurgery was uncomplicated and the patient tolerated the \nprocedure well. Patient received perioperative IV antibiotics. Otherwise, pain was initially controlled with a PCA followed by \na transition to oral pain medications on POD#1. The patient \nreceived xarelto for DVT prophylaxis starting on the morning of \nPOD#1 (started at 10 mg uptitrated to her home dose of 20 mg \ndaily). The foley was removed on POD2 and the patient was \nvoiding independently thereafter. The overlying surgical \ndressing was changed on POD#2 and the Silverlon dressing was \nfound to be clean and intact without erythema or abnormal \ndrainage. The patient was seen daily by physical therapy. Labs \nwere checked throughout the hospital course and repleted \naccordingly. At the time of discharge the patient was tolerating \na regular diet and feeling well. The patient was afebrile with \nstable vital signs. The patient's hematocrit was acceptable and \npain was adequately controlled on an oral regimen. The operative \nextremity was neurovascularly intact and the wound was benign. The patient's weight-bearing status is weight bearing as \ntolerated on the operative extremity. Ms. ___ is discharged to home with services in stable \ncondition. Medications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Acyclovir 400 mg PO Q8H \n2. FoLIC Acid 4 mg PO DAILY \n3. Furosemide 20 mg PO DAILY \n4. Gabapentin 600 mg PO QID \n5. Rivaroxaban 20 mg PO DAILY \n6. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \n7. Venlafaxine 25 mg PO BID \n8. Ascorbic Acid ___ mg PO DAILY \n9. Cyanocobalamin 1000 mcg PO DAILY",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-15",
        "chart_time": "103691",
        "section": "General",
        "position": 3,
        "tokenCount": 455,
        "note_metadata": {
          "note_id": "18887130-DS-15",
          "subject_id": 18887130,
          "hadm_id": 21937304,
          "note_type": "DS",
          "note_seq": 15,
          "charttime": 103691,
          "storetime": 103691.45625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: ORTHOPAEDICS\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nR knee OA \r\n \r\nMajor Surgical or Invasive Procedure:\r\nR TKR \r\n\r\n \r\nHistory of Present Illness:\r\n___ with right knee osteoarthritis refractory to conservative \r\nmanagement now presenting for definitive treatment. \r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nWell appearing in no acute distress  \r\nAfebrile with stable vital signs  \r\nPain well-controlled  \r\nRespiratory: CTAB  \r\nCardiovascular: RRR  \r\nGastrointestinal: NT/ND  \r\nGenitourinary: Voiding independently  \r\nNeurologic: Intact with no focal deficits  \r\nPsychiatric: Pleasant, A&O x3  \r\nMusculoskeletal Lower Extremity:  \r\n* Incision healing well with staples  -Covered w/ Silverlon \r\n* Scant serosanguinous drainage  \r\n* Thigh full but soft  \r\n* No calf tenderness  \r\n* ___ strength FHL/G, ___ strength ___  \r\n* Sensation diminished in the DP and SP distribution otherwise \r\nSILT \r\n* Toes warm\r\n\r\n \r\nPertinent Results:\r\n___ 06:45AM BLOOD WBC-4.0 RBC-2.17* Hgb-8.0* Hct-24.0* \r\nMCV-111* MCH-36.7* MCHC-33.1 RDW-17.2* Plt Ct-63*\r\n___ 06:25AM BLOOD WBC-4.3 RBC-2.31* Hgb-8.7* Hct-25.9* \r\nMCV-112* MCH-37.4* MCHC-33.4 RDW-17.4* Plt Ct-71*\r\n___ 06:25AM BLOOD WBC-3.5* RBC-2.55* Hgb-9.1* Hct-28.2* \r\nMCV-111* MCH-35.9* MCHC-32.4 RDW-16.6* Plt Ct-82*\r\n___ 06:45AM BLOOD Glucose-87 UreaN-12 Creat-0.9 Na-140 \r\nK-3.8 Cl-102 HCO3-30 AnGap-12\r\n___ 06:25AM BLOOD Glucose-97 UreaN-10 Creat-0.7 Na-137 \r\nK-3.5 Cl-102 HCO3-29 AnGap-10\r\n___ 06:25AM BLOOD Glucose-125* UreaN-11 Creat-0.7 Na-137 \r\nK-4.1 Cl-104 HCO3-28 AnGap-9\r\n \r\nBrief Hospital Course:\r\nThe patient was admitted to the orthopedic surgery service and \r\nwas taken to the operating room for above described procedure. \r\nPlease see separately dictated operative report for details. The \r\nsurgery was uncomplicated and the patient tolerated the \r\nprocedure well. Patient received perioperative IV antibiotics.\r\n\r\nOtherwise, pain was initially controlled with a PCA followed by \r\na transition to oral pain medications on POD#1.  The patient \r\nreceived xarelto for DVT prophylaxis starting on the morning of \r\nPOD#1 (started at 10 mg uptitrated to her home dose of 20 mg \r\ndaily).  The foley was removed on POD2 and the patient was \r\nvoiding independently thereafter. The overlying surgical \r\ndressing was changed on POD#2 and the Silverlon dressing was \r\nfound to be clean and intact without erythema or abnormal \r\ndrainage. The patient was seen daily by physical therapy. Labs \r\nwere checked throughout the hospital course and repleted \r\naccordingly. At the time of discharge the patient was tolerating \r\na regular diet and feeling well.  The patient was afebrile with \r\nstable vital signs.  The patient's hematocrit was acceptable and \r\npain was adequately controlled on an oral regimen. The operative \r\nextremity was neurovascularly intact and the wound was benign. \r\n\r\nThe patient's weight-bearing status is weight bearing as \r\ntolerated on the operative extremity. \r\n \r\nMs. ___ is discharged to home with services in stable \r\ncondition.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 4 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 600 mg PO QID \r\n5. Rivaroxaban 20 mg PO DAILY \r\n6. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n7. Venlafaxine 25 mg PO BID \r\n8. Ascorbic Acid ___ mg PO DAILY \r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Ascorbic Acid ___ mg PO DAILY \r\n3. Cyanocobalamin 1000 mcg PO DAILY \r\n4. FoLIC Acid 4 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 600 mg PO QID \r\n7. Rivaroxaban 20 mg PO DAILY \r\n8. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n9. Venlafaxine 25 mg PO BID \r\n10. Acetaminophen 650 mg PO Q6H \r\n11. Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium 100 mg 1 capsule(s) by mouth twice a day \r\nDisp #*30 Capsule Refills:*1\r\n12. OxycoDONE (Immediate Release)  ___ mg PO Q4H:PRN Pain \r\nRX *oxycodone 5 mg ___ tablet(s) by mouth Q3-6hrs Disp #*120 \r\nTablet Refills:*0\r\n13. Senna 8.6 mg PO BID \r\nRX *sennosides [senna] 8.6 mg 1 tablet by mouth twice a day Disp \r\n#*30 Capsule Refills:*1\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nR knee osteoarthritis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\n1. Please return to the emergency department or notify your \r\nphysician if you experience any of the following: severe pain \r\nnot relieved by medication, increased swelling, decreased \r\nsensation, difficulty with movement, fevers greater than 101.5, \r\nshaking chills, increasing redness or drainage from the incision \r\nsite, chest pain, shortness of breath or any other concerns.\r\n \r\n2. Please follow up with your primary physician regarding this \r\nadmission and any new medications and refills. \r\n \r\n3. Resume your home medications unless otherwise instructed.\r\n \r\n4. You have been given medications for pain control. Please do \r\nnot drive, operate heavy machinery, or drink alcohol while \r\ntaking these medications. As your pain decreases, take fewer \r\ntablets and increase the time between doses. This medication can \r\ncause constipation, so you should drink plenty of water daily \r\nand take a stool softener (such as Colace) as needed to prevent \r\nthis side effect.  Call your surgeons office 3 days before you \r\nare out of medication so that it can be refilled.  These \r\nmedications cannot be called into your pharmacy and must be \r\npicked up in the clinic or mailed to your house.  Please allow \r\nan extra 2 days if you would like your medication mailed to your \r\nhome.\r\n \r\n5. You may not drive a car until cleared to do so by your \r\nsurgeon.\r\n \r\n6. Please call your surgeon's office to schedule or confirm your \r\nfollow-up appointment in three (3) weeks.\r\n \r\n7. SWELLING: Ice the operative joint 20 minutes at a time, \r\nespecially after activity or physical therapy. Do not place ice \r\ndirectly on the skin. You may wrap the knee with an ace bandage \r\nfor added compression. Please DO NOT take any non-steroidal \r\nanti-inflammatory medications (NSAIDs such as Celebrex, \r\nibuprofen, Advil, Aleve, Motrin, naproxen etc).\r\n \r\n8. ANTICOAGULATION: Please continue your Xarelto 20 mg daily to \r\nhelp prevent deep vein thrombosis (blood clots).  If you were \r\ntaking aspirin prior to your surgery, it is OK to continue at \r\nyour previous dose while taking this medication.  Wear ___ \r\nstockings for 6 weeks. \r\n \r\n9. WOUND CARE: Please keep your Silverlon dressing clean and \r\ndry. REMOVE on ___. It is okay to shower five days after \r\nsurgery but no tub baths, swimming, or submerging your incision \r\nuntil after your four (4) week checkup. You may place a dry \r\nsterile dressing on the wound after the Silverlon dressing is \r\nremoved, otherwise leave it open to air. Check wound regularly \r\nfor signs of infection such as redness or thick yellow drainage. \r\nStaples will be removed by at your follow-up visit in 3 weeks.\r\n \r\n10. ___ (once at home): Home ___, dressing changes as \r\ninstructed, and wound checks.\r\n \r\n11. ACTIVITY: Weight bearing as tolerated on the operative \r\nextremity. Mobilize. CPM/ROM as tolerated. No strenuous exercise \r\nor heavy lifting until follow up appointment.\r\n \r\n\r\nPhysical Therapy:\r\nWBAT RLE\r\nMobilize frequently \r\nTreatments Frequency:\r\ndaily dressing changes as needed for drainage\r\nwound checks daily\r\nice\r\nTEDs\r\nstaple removal and replace with steri-strips POD17 (___) \r\nremove silverlon on ___ (POD7) \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-15:4",
      "text": "Discharge Medications:\n1. Acyclovir 400 mg PO Q8H \n2. Ascorbic Acid ___ mg PO DAILY \n3. Cyanocobalamin 1000 mcg PO DAILY \n4. FoLIC Acid 4 mg PO DAILY \n5. Furosemide 20 mg PO DAILY \n6. Gabapentin 600 mg PO QID \n7. Rivaroxaban 20 mg PO DAILY \n8. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \n9. Venlafaxine 25 mg PO BID \n10. Acetaminophen 650 mg PO Q6H \n11. Docusate Sodium 100 mg PO BID \nRX *docusate sodium 100 mg 1 capsule(s) by mouth twice a day \nDisp #*30 Capsule Refills:*1\n12. OxycoDONE (Immediate Release)  ___ mg PO Q4H:PRN Pain \nRX *oxycodone 5 mg ___ tablet(s) by mouth Q3-6hrs Disp #*120 \nTablet Refills:*0\n13. Senna 8.6 mg PO BID \nRX *sennosides [senna] 8.6 mg 1 tablet by mouth twice a day Disp \n#*30 Capsule Refills:*1 Discharge Disposition:\nHome With Service\n \nFacility:\n___ Discharge Diagnosis:\nR knee osteoarthritis Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - requires assistance or aid (walker \nor cane).",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-15",
        "chart_time": "103691",
        "section": "General",
        "position": 4,
        "tokenCount": 254,
        "note_metadata": {
          "note_id": "18887130-DS-15",
          "subject_id": 18887130,
          "hadm_id": 21937304,
          "note_type": "DS",
          "note_seq": 15,
          "charttime": 103691,
          "storetime": 103691.45625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: ORTHOPAEDICS\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nR knee OA \r\n \r\nMajor Surgical or Invasive Procedure:\r\nR TKR \r\n\r\n \r\nHistory of Present Illness:\r\n___ with right knee osteoarthritis refractory to conservative \r\nmanagement now presenting for definitive treatment. \r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nWell appearing in no acute distress  \r\nAfebrile with stable vital signs  \r\nPain well-controlled  \r\nRespiratory: CTAB  \r\nCardiovascular: RRR  \r\nGastrointestinal: NT/ND  \r\nGenitourinary: Voiding independently  \r\nNeurologic: Intact with no focal deficits  \r\nPsychiatric: Pleasant, A&O x3  \r\nMusculoskeletal Lower Extremity:  \r\n* Incision healing well with staples  -Covered w/ Silverlon \r\n* Scant serosanguinous drainage  \r\n* Thigh full but soft  \r\n* No calf tenderness  \r\n* ___ strength FHL/G, ___ strength ___  \r\n* Sensation diminished in the DP and SP distribution otherwise \r\nSILT \r\n* Toes warm\r\n\r\n \r\nPertinent Results:\r\n___ 06:45AM BLOOD WBC-4.0 RBC-2.17* Hgb-8.0* Hct-24.0* \r\nMCV-111* MCH-36.7* MCHC-33.1 RDW-17.2* Plt Ct-63*\r\n___ 06:25AM BLOOD WBC-4.3 RBC-2.31* Hgb-8.7* Hct-25.9* \r\nMCV-112* MCH-37.4* MCHC-33.4 RDW-17.4* Plt Ct-71*\r\n___ 06:25AM BLOOD WBC-3.5* RBC-2.55* Hgb-9.1* Hct-28.2* \r\nMCV-111* MCH-35.9* MCHC-32.4 RDW-16.6* Plt Ct-82*\r\n___ 06:45AM BLOOD Glucose-87 UreaN-12 Creat-0.9 Na-140 \r\nK-3.8 Cl-102 HCO3-30 AnGap-12\r\n___ 06:25AM BLOOD Glucose-97 UreaN-10 Creat-0.7 Na-137 \r\nK-3.5 Cl-102 HCO3-29 AnGap-10\r\n___ 06:25AM BLOOD Glucose-125* UreaN-11 Creat-0.7 Na-137 \r\nK-4.1 Cl-104 HCO3-28 AnGap-9\r\n \r\nBrief Hospital Course:\r\nThe patient was admitted to the orthopedic surgery service and \r\nwas taken to the operating room for above described procedure. \r\nPlease see separately dictated operative report for details. The \r\nsurgery was uncomplicated and the patient tolerated the \r\nprocedure well. Patient received perioperative IV antibiotics.\r\n\r\nOtherwise, pain was initially controlled with a PCA followed by \r\na transition to oral pain medications on POD#1.  The patient \r\nreceived xarelto for DVT prophylaxis starting on the morning of \r\nPOD#1 (started at 10 mg uptitrated to her home dose of 20 mg \r\ndaily).  The foley was removed on POD2 and the patient was \r\nvoiding independently thereafter. The overlying surgical \r\ndressing was changed on POD#2 and the Silverlon dressing was \r\nfound to be clean and intact without erythema or abnormal \r\ndrainage. The patient was seen daily by physical therapy. Labs \r\nwere checked throughout the hospital course and repleted \r\naccordingly. At the time of discharge the patient was tolerating \r\na regular diet and feeling well.  The patient was afebrile with \r\nstable vital signs.  The patient's hematocrit was acceptable and \r\npain was adequately controlled on an oral regimen. The operative \r\nextremity was neurovascularly intact and the wound was benign. \r\n\r\nThe patient's weight-bearing status is weight bearing as \r\ntolerated on the operative extremity. \r\n \r\nMs. ___ is discharged to home with services in stable \r\ncondition.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 4 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 600 mg PO QID \r\n5. Rivaroxaban 20 mg PO DAILY \r\n6. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n7. Venlafaxine 25 mg PO BID \r\n8. Ascorbic Acid ___ mg PO DAILY \r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Ascorbic Acid ___ mg PO DAILY \r\n3. Cyanocobalamin 1000 mcg PO DAILY \r\n4. FoLIC Acid 4 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 600 mg PO QID \r\n7. Rivaroxaban 20 mg PO DAILY \r\n8. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n9. Venlafaxine 25 mg PO BID \r\n10. Acetaminophen 650 mg PO Q6H \r\n11. Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium 100 mg 1 capsule(s) by mouth twice a day \r\nDisp #*30 Capsule Refills:*1\r\n12. OxycoDONE (Immediate Release)  ___ mg PO Q4H:PRN Pain \r\nRX *oxycodone 5 mg ___ tablet(s) by mouth Q3-6hrs Disp #*120 \r\nTablet Refills:*0\r\n13. Senna 8.6 mg PO BID \r\nRX *sennosides [senna] 8.6 mg 1 tablet by mouth twice a day Disp \r\n#*30 Capsule Refills:*1\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nR knee osteoarthritis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\n1. Please return to the emergency department or notify your \r\nphysician if you experience any of the following: severe pain \r\nnot relieved by medication, increased swelling, decreased \r\nsensation, difficulty with movement, fevers greater than 101.5, \r\nshaking chills, increasing redness or drainage from the incision \r\nsite, chest pain, shortness of breath or any other concerns.\r\n \r\n2. Please follow up with your primary physician regarding this \r\nadmission and any new medications and refills. \r\n \r\n3. Resume your home medications unless otherwise instructed.\r\n \r\n4. You have been given medications for pain control. Please do \r\nnot drive, operate heavy machinery, or drink alcohol while \r\ntaking these medications. As your pain decreases, take fewer \r\ntablets and increase the time between doses. This medication can \r\ncause constipation, so you should drink plenty of water daily \r\nand take a stool softener (such as Colace) as needed to prevent \r\nthis side effect.  Call your surgeons office 3 days before you \r\nare out of medication so that it can be refilled.  These \r\nmedications cannot be called into your pharmacy and must be \r\npicked up in the clinic or mailed to your house.  Please allow \r\nan extra 2 days if you would like your medication mailed to your \r\nhome.\r\n \r\n5. You may not drive a car until cleared to do so by your \r\nsurgeon.\r\n \r\n6. Please call your surgeon's office to schedule or confirm your \r\nfollow-up appointment in three (3) weeks.\r\n \r\n7. SWELLING: Ice the operative joint 20 minutes at a time, \r\nespecially after activity or physical therapy. Do not place ice \r\ndirectly on the skin. You may wrap the knee with an ace bandage \r\nfor added compression. Please DO NOT take any non-steroidal \r\nanti-inflammatory medications (NSAIDs such as Celebrex, \r\nibuprofen, Advil, Aleve, Motrin, naproxen etc).\r\n \r\n8. ANTICOAGULATION: Please continue your Xarelto 20 mg daily to \r\nhelp prevent deep vein thrombosis (blood clots).  If you were \r\ntaking aspirin prior to your surgery, it is OK to continue at \r\nyour previous dose while taking this medication.  Wear ___ \r\nstockings for 6 weeks. \r\n \r\n9. WOUND CARE: Please keep your Silverlon dressing clean and \r\ndry. REMOVE on ___. It is okay to shower five days after \r\nsurgery but no tub baths, swimming, or submerging your incision \r\nuntil after your four (4) week checkup. You may place a dry \r\nsterile dressing on the wound after the Silverlon dressing is \r\nremoved, otherwise leave it open to air. Check wound regularly \r\nfor signs of infection such as redness or thick yellow drainage. \r\nStaples will be removed by at your follow-up visit in 3 weeks.\r\n \r\n10. ___ (once at home): Home ___, dressing changes as \r\ninstructed, and wound checks.\r\n \r\n11. ACTIVITY: Weight bearing as tolerated on the operative \r\nextremity. Mobilize. CPM/ROM as tolerated. No strenuous exercise \r\nor heavy lifting until follow up appointment.\r\n \r\n\r\nPhysical Therapy:\r\nWBAT RLE\r\nMobilize frequently \r\nTreatments Frequency:\r\ndaily dressing changes as needed for drainage\r\nwound checks daily\r\nice\r\nTEDs\r\nstaple removal and replace with steri-strips POD17 (___) \r\nremove silverlon on ___ (POD7) \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-15:5",
      "text": "Discharge Instructions:\n1. Please return to the emergency department or notify your \nphysician if you experience any of the following: severe pain \nnot relieved by medication, increased swelling, decreased \nsensation, difficulty with movement, fevers greater than 101.5, \nshaking chills, increasing redness or drainage from the incision \nsite, chest pain, shortness of breath or any other concerns. 2. Please follow up with your primary physician regarding this \nadmission and any new medications and refills. 3. Resume your home medications unless otherwise instructed. 4. You have been given medications for pain control. Please do \nnot drive, operate heavy machinery, or drink alcohol while \ntaking these medications. As your pain decreases, take fewer \ntablets and increase the time between doses. This medication can \ncause constipation, so you should drink plenty of water daily \nand take a stool softener (such as Colace) as needed to prevent \nthis side effect. Call your surgeons office 3 days before you \nare out of medication so that it can be refilled. These \nmedications cannot be called into your pharmacy and must be \npicked up in the clinic or mailed to your house. Please allow \nan extra 2 days if you would like your medication mailed to your \nhome. 5. You may not drive a car until cleared to do so by your \nsurgeon. 6. Please call your surgeon's office to schedule or confirm your \nfollow-up appointment in three (3) weeks. 7. SWELLING: Ice the operative joint 20 minutes at a time, \nespecially after activity or physical therapy. Do not place ice \ndirectly on the skin. You may wrap the knee with an ace bandage \nfor added compression. Please DO NOT take any non-steroidal \nanti-inflammatory medications (NSAIDs such as Celebrex, \nibuprofen, Advil, Aleve, Motrin, naproxen etc). 8. ANTICOAGULATION: Please continue your Xarelto 20 mg daily to \nhelp prevent deep vein thrombosis (blood clots). If you were \ntaking aspirin prior to your surgery, it is OK to continue at \nyour previous dose while taking this medication. Wear ___ \nstockings for 6 weeks. 9. WOUND CARE: Please keep your Silverlon dressing clean and \ndry. REMOVE on ___. It is okay to shower five days after \nsurgery but no tub baths, swimming, or submerging your incision \nuntil after your four (4) week checkup. You may place a dry \nsterile dressing on the wound after the Silverlon dressing is \nremoved, otherwise leave it open to air. Check wound regularly \nfor signs of infection such as redness or thick yellow drainage. Staples will be removed by at your follow-up visit in 3 weeks. 10. ___ (once at home): Home ___, dressing changes as \ninstructed, and wound checks. 11. ACTIVITY: Weight bearing as tolerated on the operative \nextremity. Mobilize. CPM/ROM as tolerated.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-15",
        "chart_time": "103691",
        "section": "General",
        "position": 5,
        "tokenCount": 690,
        "note_metadata": {
          "note_id": "18887130-DS-15",
          "subject_id": 18887130,
          "hadm_id": 21937304,
          "note_type": "DS",
          "note_seq": 15,
          "charttime": 103691,
          "storetime": 103691.45625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: ORTHOPAEDICS\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nR knee OA \r\n \r\nMajor Surgical or Invasive Procedure:\r\nR TKR \r\n\r\n \r\nHistory of Present Illness:\r\n___ with right knee osteoarthritis refractory to conservative \r\nmanagement now presenting for definitive treatment. \r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nWell appearing in no acute distress  \r\nAfebrile with stable vital signs  \r\nPain well-controlled  \r\nRespiratory: CTAB  \r\nCardiovascular: RRR  \r\nGastrointestinal: NT/ND  \r\nGenitourinary: Voiding independently  \r\nNeurologic: Intact with no focal deficits  \r\nPsychiatric: Pleasant, A&O x3  \r\nMusculoskeletal Lower Extremity:  \r\n* Incision healing well with staples  -Covered w/ Silverlon \r\n* Scant serosanguinous drainage  \r\n* Thigh full but soft  \r\n* No calf tenderness  \r\n* ___ strength FHL/G, ___ strength ___  \r\n* Sensation diminished in the DP and SP distribution otherwise \r\nSILT \r\n* Toes warm\r\n\r\n \r\nPertinent Results:\r\n___ 06:45AM BLOOD WBC-4.0 RBC-2.17* Hgb-8.0* Hct-24.0* \r\nMCV-111* MCH-36.7* MCHC-33.1 RDW-17.2* Plt Ct-63*\r\n___ 06:25AM BLOOD WBC-4.3 RBC-2.31* Hgb-8.7* Hct-25.9* \r\nMCV-112* MCH-37.4* MCHC-33.4 RDW-17.4* Plt Ct-71*\r\n___ 06:25AM BLOOD WBC-3.5* RBC-2.55* Hgb-9.1* Hct-28.2* \r\nMCV-111* MCH-35.9* MCHC-32.4 RDW-16.6* Plt Ct-82*\r\n___ 06:45AM BLOOD Glucose-87 UreaN-12 Creat-0.9 Na-140 \r\nK-3.8 Cl-102 HCO3-30 AnGap-12\r\n___ 06:25AM BLOOD Glucose-97 UreaN-10 Creat-0.7 Na-137 \r\nK-3.5 Cl-102 HCO3-29 AnGap-10\r\n___ 06:25AM BLOOD Glucose-125* UreaN-11 Creat-0.7 Na-137 \r\nK-4.1 Cl-104 HCO3-28 AnGap-9\r\n \r\nBrief Hospital Course:\r\nThe patient was admitted to the orthopedic surgery service and \r\nwas taken to the operating room for above described procedure. \r\nPlease see separately dictated operative report for details. The \r\nsurgery was uncomplicated and the patient tolerated the \r\nprocedure well. Patient received perioperative IV antibiotics.\r\n\r\nOtherwise, pain was initially controlled with a PCA followed by \r\na transition to oral pain medications on POD#1.  The patient \r\nreceived xarelto for DVT prophylaxis starting on the morning of \r\nPOD#1 (started at 10 mg uptitrated to her home dose of 20 mg \r\ndaily).  The foley was removed on POD2 and the patient was \r\nvoiding independently thereafter. The overlying surgical \r\ndressing was changed on POD#2 and the Silverlon dressing was \r\nfound to be clean and intact without erythema or abnormal \r\ndrainage. The patient was seen daily by physical therapy. Labs \r\nwere checked throughout the hospital course and repleted \r\naccordingly. At the time of discharge the patient was tolerating \r\na regular diet and feeling well.  The patient was afebrile with \r\nstable vital signs.  The patient's hematocrit was acceptable and \r\npain was adequately controlled on an oral regimen. The operative \r\nextremity was neurovascularly intact and the wound was benign. \r\n\r\nThe patient's weight-bearing status is weight bearing as \r\ntolerated on the operative extremity. \r\n \r\nMs. ___ is discharged to home with services in stable \r\ncondition.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 4 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 600 mg PO QID \r\n5. Rivaroxaban 20 mg PO DAILY \r\n6. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n7. Venlafaxine 25 mg PO BID \r\n8. Ascorbic Acid ___ mg PO DAILY \r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Ascorbic Acid ___ mg PO DAILY \r\n3. Cyanocobalamin 1000 mcg PO DAILY \r\n4. FoLIC Acid 4 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 600 mg PO QID \r\n7. Rivaroxaban 20 mg PO DAILY \r\n8. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n9. Venlafaxine 25 mg PO BID \r\n10. Acetaminophen 650 mg PO Q6H \r\n11. Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium 100 mg 1 capsule(s) by mouth twice a day \r\nDisp #*30 Capsule Refills:*1\r\n12. OxycoDONE (Immediate Release)  ___ mg PO Q4H:PRN Pain \r\nRX *oxycodone 5 mg ___ tablet(s) by mouth Q3-6hrs Disp #*120 \r\nTablet Refills:*0\r\n13. Senna 8.6 mg PO BID \r\nRX *sennosides [senna] 8.6 mg 1 tablet by mouth twice a day Disp \r\n#*30 Capsule Refills:*1\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nR knee osteoarthritis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\n1. Please return to the emergency department or notify your \r\nphysician if you experience any of the following: severe pain \r\nnot relieved by medication, increased swelling, decreased \r\nsensation, difficulty with movement, fevers greater than 101.5, \r\nshaking chills, increasing redness or drainage from the incision \r\nsite, chest pain, shortness of breath or any other concerns.\r\n \r\n2. Please follow up with your primary physician regarding this \r\nadmission and any new medications and refills. \r\n \r\n3. Resume your home medications unless otherwise instructed.\r\n \r\n4. You have been given medications for pain control. Please do \r\nnot drive, operate heavy machinery, or drink alcohol while \r\ntaking these medications. As your pain decreases, take fewer \r\ntablets and increase the time between doses. This medication can \r\ncause constipation, so you should drink plenty of water daily \r\nand take a stool softener (such as Colace) as needed to prevent \r\nthis side effect.  Call your surgeons office 3 days before you \r\nare out of medication so that it can be refilled.  These \r\nmedications cannot be called into your pharmacy and must be \r\npicked up in the clinic or mailed to your house.  Please allow \r\nan extra 2 days if you would like your medication mailed to your \r\nhome.\r\n \r\n5. You may not drive a car until cleared to do so by your \r\nsurgeon.\r\n \r\n6. Please call your surgeon's office to schedule or confirm your \r\nfollow-up appointment in three (3) weeks.\r\n \r\n7. SWELLING: Ice the operative joint 20 minutes at a time, \r\nespecially after activity or physical therapy. Do not place ice \r\ndirectly on the skin. You may wrap the knee with an ace bandage \r\nfor added compression. Please DO NOT take any non-steroidal \r\nanti-inflammatory medications (NSAIDs such as Celebrex, \r\nibuprofen, Advil, Aleve, Motrin, naproxen etc).\r\n \r\n8. ANTICOAGULATION: Please continue your Xarelto 20 mg daily to \r\nhelp prevent deep vein thrombosis (blood clots).  If you were \r\ntaking aspirin prior to your surgery, it is OK to continue at \r\nyour previous dose while taking this medication.  Wear ___ \r\nstockings for 6 weeks. \r\n \r\n9. WOUND CARE: Please keep your Silverlon dressing clean and \r\ndry. REMOVE on ___. It is okay to shower five days after \r\nsurgery but no tub baths, swimming, or submerging your incision \r\nuntil after your four (4) week checkup. You may place a dry \r\nsterile dressing on the wound after the Silverlon dressing is \r\nremoved, otherwise leave it open to air. Check wound regularly \r\nfor signs of infection such as redness or thick yellow drainage. \r\nStaples will be removed by at your follow-up visit in 3 weeks.\r\n \r\n10. ___ (once at home): Home ___, dressing changes as \r\ninstructed, and wound checks.\r\n \r\n11. ACTIVITY: Weight bearing as tolerated on the operative \r\nextremity. Mobilize. CPM/ROM as tolerated. No strenuous exercise \r\nor heavy lifting until follow up appointment.\r\n \r\n\r\nPhysical Therapy:\r\nWBAT RLE\r\nMobilize frequently \r\nTreatments Frequency:\r\ndaily dressing changes as needed for drainage\r\nwound checks daily\r\nice\r\nTEDs\r\nstaple removal and replace with steri-strips POD17 (___) \r\nremove silverlon on ___ (POD7) \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-15:6",
      "text": "You may place a dry \nsterile dressing on the wound after the Silverlon dressing is \nremoved, otherwise leave it open to air. Check wound regularly \nfor signs of infection such as redness or thick yellow drainage. Staples will be removed by at your follow-up visit in 3 weeks. 10. ___ (once at home): Home ___, dressing changes as \ninstructed, and wound checks. 11. ACTIVITY: Weight bearing as tolerated on the operative \nextremity. Mobilize. CPM/ROM as tolerated. No strenuous exercise \nor heavy lifting until follow up appointment. Physical Therapy:\nWBAT RLE\nMobilize frequently \nTreatments Frequency:\ndaily dressing changes as needed for drainage\nwound checks daily\nice\nTEDs\nstaple removal and replace with steri-strips POD17 (___) \nremove silverlon on ___ (POD7) \n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-15",
        "chart_time": "103691",
        "section": "General",
        "position": 6,
        "tokenCount": 199,
        "note_metadata": {
          "note_id": "18887130-DS-15",
          "subject_id": 18887130,
          "hadm_id": 21937304,
          "note_type": "DS",
          "note_seq": 15,
          "charttime": 103691,
          "storetime": 103691.45625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: ORTHOPAEDICS\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nR knee OA \r\n \r\nMajor Surgical or Invasive Procedure:\r\nR TKR \r\n\r\n \r\nHistory of Present Illness:\r\n___ with right knee osteoarthritis refractory to conservative \r\nmanagement now presenting for definitive treatment. \r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM).  ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nWell appearing in no acute distress  \r\nAfebrile with stable vital signs  \r\nPain well-controlled  \r\nRespiratory: CTAB  \r\nCardiovascular: RRR  \r\nGastrointestinal: NT/ND  \r\nGenitourinary: Voiding independently  \r\nNeurologic: Intact with no focal deficits  \r\nPsychiatric: Pleasant, A&O x3  \r\nMusculoskeletal Lower Extremity:  \r\n* Incision healing well with staples  -Covered w/ Silverlon \r\n* Scant serosanguinous drainage  \r\n* Thigh full but soft  \r\n* No calf tenderness  \r\n* ___ strength FHL/G, ___ strength ___  \r\n* Sensation diminished in the DP and SP distribution otherwise \r\nSILT \r\n* Toes warm\r\n\r\n \r\nPertinent Results:\r\n___ 06:45AM BLOOD WBC-4.0 RBC-2.17* Hgb-8.0* Hct-24.0* \r\nMCV-111* MCH-36.7* MCHC-33.1 RDW-17.2* Plt Ct-63*\r\n___ 06:25AM BLOOD WBC-4.3 RBC-2.31* Hgb-8.7* Hct-25.9* \r\nMCV-112* MCH-37.4* MCHC-33.4 RDW-17.4* Plt Ct-71*\r\n___ 06:25AM BLOOD WBC-3.5* RBC-2.55* Hgb-9.1* Hct-28.2* \r\nMCV-111* MCH-35.9* MCHC-32.4 RDW-16.6* Plt Ct-82*\r\n___ 06:45AM BLOOD Glucose-87 UreaN-12 Creat-0.9 Na-140 \r\nK-3.8 Cl-102 HCO3-30 AnGap-12\r\n___ 06:25AM BLOOD Glucose-97 UreaN-10 Creat-0.7 Na-137 \r\nK-3.5 Cl-102 HCO3-29 AnGap-10\r\n___ 06:25AM BLOOD Glucose-125* UreaN-11 Creat-0.7 Na-137 \r\nK-4.1 Cl-104 HCO3-28 AnGap-9\r\n \r\nBrief Hospital Course:\r\nThe patient was admitted to the orthopedic surgery service and \r\nwas taken to the operating room for above described procedure. \r\nPlease see separately dictated operative report for details. The \r\nsurgery was uncomplicated and the patient tolerated the \r\nprocedure well. Patient received perioperative IV antibiotics.\r\n\r\nOtherwise, pain was initially controlled with a PCA followed by \r\na transition to oral pain medications on POD#1.  The patient \r\nreceived xarelto for DVT prophylaxis starting on the morning of \r\nPOD#1 (started at 10 mg uptitrated to her home dose of 20 mg \r\ndaily).  The foley was removed on POD2 and the patient was \r\nvoiding independently thereafter. The overlying surgical \r\ndressing was changed on POD#2 and the Silverlon dressing was \r\nfound to be clean and intact without erythema or abnormal \r\ndrainage. The patient was seen daily by physical therapy. Labs \r\nwere checked throughout the hospital course and repleted \r\naccordingly. At the time of discharge the patient was tolerating \r\na regular diet and feeling well.  The patient was afebrile with \r\nstable vital signs.  The patient's hematocrit was acceptable and \r\npain was adequately controlled on an oral regimen. The operative \r\nextremity was neurovascularly intact and the wound was benign. \r\n\r\nThe patient's weight-bearing status is weight bearing as \r\ntolerated on the operative extremity. \r\n \r\nMs. ___ is discharged to home with services in stable \r\ncondition.\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. FoLIC Acid 4 mg PO DAILY \r\n3. Furosemide 20 mg PO DAILY \r\n4. Gabapentin 600 mg PO QID \r\n5. Rivaroxaban 20 mg PO DAILY \r\n6. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n7. Venlafaxine 25 mg PO BID \r\n8. Ascorbic Acid ___ mg PO DAILY \r\n9. Cyanocobalamin 1000 mcg PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Ascorbic Acid ___ mg PO DAILY \r\n3. Cyanocobalamin 1000 mcg PO DAILY \r\n4. FoLIC Acid 4 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 600 mg PO QID \r\n7. Rivaroxaban 20 mg PO DAILY \r\n8. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) \r\n9. Venlafaxine 25 mg PO BID \r\n10. Acetaminophen 650 mg PO Q6H \r\n11. Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium 100 mg 1 capsule(s) by mouth twice a day \r\nDisp #*30 Capsule Refills:*1\r\n12. OxycoDONE (Immediate Release)  ___ mg PO Q4H:PRN Pain \r\nRX *oxycodone 5 mg ___ tablet(s) by mouth Q3-6hrs Disp #*120 \r\nTablet Refills:*0\r\n13. Senna 8.6 mg PO BID \r\nRX *sennosides [senna] 8.6 mg 1 tablet by mouth twice a day Disp \r\n#*30 Capsule Refills:*1\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nR knee osteoarthritis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\n1. Please return to the emergency department or notify your \r\nphysician if you experience any of the following: severe pain \r\nnot relieved by medication, increased swelling, decreased \r\nsensation, difficulty with movement, fevers greater than 101.5, \r\nshaking chills, increasing redness or drainage from the incision \r\nsite, chest pain, shortness of breath or any other concerns.\r\n \r\n2. Please follow up with your primary physician regarding this \r\nadmission and any new medications and refills. \r\n \r\n3. Resume your home medications unless otherwise instructed.\r\n \r\n4. You have been given medications for pain control. Please do \r\nnot drive, operate heavy machinery, or drink alcohol while \r\ntaking these medications. As your pain decreases, take fewer \r\ntablets and increase the time between doses. This medication can \r\ncause constipation, so you should drink plenty of water daily \r\nand take a stool softener (such as Colace) as needed to prevent \r\nthis side effect.  Call your surgeons office 3 days before you \r\nare out of medication so that it can be refilled.  These \r\nmedications cannot be called into your pharmacy and must be \r\npicked up in the clinic or mailed to your house.  Please allow \r\nan extra 2 days if you would like your medication mailed to your \r\nhome.\r\n \r\n5. You may not drive a car until cleared to do so by your \r\nsurgeon.\r\n \r\n6. Please call your surgeon's office to schedule or confirm your \r\nfollow-up appointment in three (3) weeks.\r\n \r\n7. SWELLING: Ice the operative joint 20 minutes at a time, \r\nespecially after activity or physical therapy. Do not place ice \r\ndirectly on the skin. You may wrap the knee with an ace bandage \r\nfor added compression. Please DO NOT take any non-steroidal \r\nanti-inflammatory medications (NSAIDs such as Celebrex, \r\nibuprofen, Advil, Aleve, Motrin, naproxen etc).\r\n \r\n8. ANTICOAGULATION: Please continue your Xarelto 20 mg daily to \r\nhelp prevent deep vein thrombosis (blood clots).  If you were \r\ntaking aspirin prior to your surgery, it is OK to continue at \r\nyour previous dose while taking this medication.  Wear ___ \r\nstockings for 6 weeks. \r\n \r\n9. WOUND CARE: Please keep your Silverlon dressing clean and \r\ndry. REMOVE on ___. It is okay to shower five days after \r\nsurgery but no tub baths, swimming, or submerging your incision \r\nuntil after your four (4) week checkup. You may place a dry \r\nsterile dressing on the wound after the Silverlon dressing is \r\nremoved, otherwise leave it open to air. Check wound regularly \r\nfor signs of infection such as redness or thick yellow drainage. \r\nStaples will be removed by at your follow-up visit in 3 weeks.\r\n \r\n10. ___ (once at home): Home ___, dressing changes as \r\ninstructed, and wound checks.\r\n \r\n11. ACTIVITY: Weight bearing as tolerated on the operative \r\nextremity. Mobilize. CPM/ROM as tolerated. No strenuous exercise \r\nor heavy lifting until follow up appointment.\r\n \r\n\r\nPhysical Therapy:\r\nWBAT RLE\r\nMobilize frequently \r\nTreatments Frequency:\r\ndaily dressing changes as needed for drainage\r\nwound checks daily\r\nice\r\nTEDs\r\nstaple removal and replace with steri-strips POD17 (___) \r\nremove silverlon on ___ (POD7) \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-16:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \ndapsone\n \nAttending: ___. Chief Complaint:\nBack pain, nose bleed and pancytopenia\n \nMajor Surgical or Invasive Procedure:\nBone marrow biopsy by interventional radiology (___)",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-16",
        "chart_time": "104467",
        "section": "General",
        "position": 0,
        "tokenCount": 88,
        "note_metadata": {
          "note_id": "18887130-DS-16",
          "subject_id": 18887130,
          "hadm_id": 26068131,
          "note_type": "DS",
          "note_seq": 16,
          "charttime": 104467,
          "storetime": 104467.76458333334,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, nose bleed and pancytopenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy by interventional radiology (___)\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed follicular \r\nlymphoma s/p multiple past regimens as noted below, and \r\nultimately an autoSCT with BEAM conditioning in ___.  She \r\nhas comorbid CVID and receives IVIG monthly.  Her\r\npost transplant course was complicated by ___ pneumonitis.  She \r\nunderwent a total right knee replacement on ___.  Her \r\npostoperative course was complicated by foot drop likely due to \r\nirritation of her peroneal nerve from the CPM machine as well as \r\na cellulitis of the right leg following her surgery which was \r\ntreated with a course of Keflex.  This is the same leg as her \r\nprevious DVT and her circulation is poor.  She has had ongoing \r\nissues with sciatica with hip and left lower back pain, and has \r\nhad steroid injections.\r\n\r\nAt the end of ___ of ___, Ms. ___ noted \r\nincreasing swelling of her right leg with shortness of breath.  \r\nShe had been on Xarelto for prior DVT and has an IVC filter in \r\nplace.  Her dose of Xarelto had been decreased to 10 mg daily \r\ngiven her age and chronic history of DVT; she also had a lower \r\nplatelet count for a period of time.  She was seen and admitted \r\nat ___ with ultrasound showing DVT of the right leg \r\nonce again.  Chest CT with no PE or other adenopathy.  Abdomen \r\nand Pelvic CT without adenopathy or concern for lymphoma \r\nrecurrence.  Xarelto was increased back to 20 mg daily. \r\n\r\nINTERVAL HISTORY:  Over the past 1 - 2 months, Ms. ___ was \r\nnoted for a drop in her white count with neutropenia as well as \r\na drop in her platelet count.  This had been noticed in the past \r\nwith the plan to repeat a bone marrow biopsy but her counts \r\nreturned to baseline so bone marrow biopsy was deferred.  She \r\nwas also noted for a nonhealing wound on her left leg after hit \r\non the shin several weeks ago.  She was treated with a course of \r\nKeflex with still poor healing.  Given 2 doses of Neupogen to \r\nsupport counts.  She was seen by the wound care clinic at ___ \r\n___ yesterday and the area was debrided and dressing \r\napplied.\r\n\r\nAt her visit today, Ms. ___ is noted for further drop in \r\nblood counts(platelet count is low but more her baseline).  She \r\nreports not feeling well towards the middle of last week and on \r\n___ morning, she developed increasing left lower back pain, \r\nradiating to the buttock area.  She feels this is related to her \r\nsciatica but is different pain pattern; no radiating pain down \r\nthe leg as she usually has.  Pain increases with changing \r\npositions and with initial ambulation.  She walks with a cane.  \r\nIn addition, she developed increasing nasal congestion on \r\n___ night which seemed to come on suddenly.  No fevers, \r\nchills, night sweats, sore throat.  When blowing her nose, she \r\nnoted increased blood with clots although no frank epistaxis.  \r\n\r\nBecause of the more acute drop in counts, Ms. ___ is being \r\nadmitted for further evaluation for possible bleed given on \r\nanticoagulation vs evolving MDS-->Leukemia.  \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PHYSICAL:\r\n===================\r\nVITALS - 17:27 ___ 98.9 PO ___ 18 97 RA \r\nGeneral: pleasant, no distress, sitting at edge of bed \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: clear bilaterally, good air movement \r\nAbdomen: well-healed surgical incisions, active BS, soft, no\r\nrebound or guarding, no organomegaly \r\nExt: Bilateral ___ swelling, R > L. L shin wound is wrapped and\r\nc/d/I. 2+ radial and DP pulses, 3+ pitting edema bilaterally \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\n  \r\nDISCHARGE PHYSICAL:\r\n===================\r\nVS: TC 98.8 PO 130/80 93 18 98%RA \r\nWeight: 258.7 lbs (___) -> 254.4 lbs (___) \r\nGeneral: pleasant, sitting in chair with tiara on, no distress \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: CTAB, no wheezes, rales or rhonchi \r\nAbdomen: Active BS, soft, no rebound or guarding, no\r\norganomegaly \r\nBack: No tenderness over spinous processes or L iliac crest \r\nExt: Bilateral ___ swelling, R > L. R leg with TEDS stocking on.\r\nL shin wound is stable. 2+ radial and DP pulses \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\nSkin: Erythematous venous stasis changes in bilateral lower\r\nextremities from mid-tibia to medial malleolus \r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n===============\r\n___ 10:45AM BLOOD WBC-2.3* RBC-2.46* Hgb-8.0* Hct-24.4* \r\nMCV-99* MCH-32.5* MCHC-32.8 RDW-21.4* RDWSD-76.8* Plt Ct-93*\r\n___ 10:45AM BLOOD Neuts-29* Bands-0 ___ Monos-26* \r\nEos-0 Baso-0 ___ Metas-2* Myelos-0 Blasts-1* NRBC-4* \r\nAbsNeut-0.67* AbsLymp-0.97* AbsMono-0.60 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 10:45AM BLOOD Hypochr-1+ Anisocy-1+ Poiklo-1+ \r\nMacrocy-1+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-OCCASIONAL \r\nTear Dr-1+\r\n___ 10:45AM BLOOD ___ PTT-39.0* ___\r\n___ 10:45AM BLOOD Ret Aut-1.2 Abs Ret-0.03\r\n___ 10:45AM BLOOD UreaN-15 Creat-0.9 Na-139 K-4.1 Cl-102 \r\nHCO3-26 AnGap-15\r\n___ 10:45AM BLOOD ALT-12 AST-16 LD(LDH)-232 AlkPhos-96 \r\nTotBili-0.3\r\n___ 10:45AM BLOOD Albumin-3.5 Calcium-8.1* Mg-2.2 Iron-49\r\n___ 10:45AM BLOOD ___ Folate->20 Hapto-254* \r\nFerritn-389*\r\n___ 10:45AM BLOOD TSH-1.9\r\n___ 10:45AM BLOOD IgG-728\r\n \r\nOTHER PERTINENT LABS:\r\n=====================\r\n___ 12:32PM URINE RBC-1 WBC-7* Bacteri-FEW Yeast-NONE \r\nEpi-<1 TransE-<1\r\n___ 12:32PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.5 Leuks-TR\r\n___ 12:32PM URINE Color-Straw Appear-Clear Sp ___\r\n \r\nMICROBIOLOGY:\r\n=============\r\n___ 12:32 pm URINE      Source: ___. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   URINE CULTURE (Final ___:    NO GROWTH. \r\n\r\n___ 11:30PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n___ 10:00AM OTHER BODY FLUID STANDARD LEUKEMIA/LYMPHOMA \r\nPANEL (24 MARKERS)-TEST      \r\n___ 10:00AM BONE MARROW IPT-DONE\r\n___ 10:00AM BONE MARROW CEBPA MUTATION ANALYSIS-PND\r\n___ 10:00AM BONE MARROW RAPID HEME PANEL-PND\r\n \r\nIMAGING:\r\n========\r\n___ 3:___BD & PELVIS W/O CONTRAST\r\nIMPRESSION:\r\n1. No evidence of retroperitoneal hematoma or lymphadenopathy.\r\n2. Stable 3.2 cm right adnexal cyst.  Continued attention is \r\nadvised on futurefollow up.\r\n3. Severe degenerative changes of lumbar spine are similar to \r\nbefore.\r\n\r\n___ 3:___HEST W/O CONTRAST\r\nIMPRESSION: \r\nNo evidence of acute intrathoracic abnormality.\r\nNo evidence of intrathoracic lymphoma.\r\nDilated main pulmonary artery, concerning for pulmonary \r\nhypertension, unchanged since ___.\r\n\r\n___ 3:38 ___\r\nCT HEAD W/O CONTRAST\r\nIMPRESSION: \r\n1. Of note, significant streak artifact from the right \r\nsupraclinoid vascular embolization coil limits evaluation of \r\nadjacent structures.  Given these limitations, there is no \r\nevidence of acute major territorial infarction, hemorrhage, or \r\nfracture.\r\n2. Paranasal sinus disease, as described above.\r\n\r\n___ 3:28 ___\r\nCT SINUS/MANDIBLE/MAXILLOFACIA\r\nIMPRESSION: \r\nMild mucosal thickening in both maxillary sinuses and ethmoid \r\nair cells, similar to recent CT head.  No evidence of bony \r\nerosion.\r\n \r\nPATHOLOGY: RESULT PENDING AT DISCHARGE\r\n==========\r\n\r\nDISCHARGE LABS:\r\n===============\r\n___ 12:00AM BLOOD WBC-2.5* RBC-2.29* Hgb-7.2* Hct-22.7* \r\nMCV-99* MCH-31.4 MCHC-31.7* RDW-20.6* RDWSD-75.0* Plt Ct-85*\r\n___ 12:00AM BLOOD Neuts-11* Bands-0 Lymphs-55* Monos-26* \r\nEos-0 Baso-0 ___ Metas-1* Myelos-4* Promyel-2* Blasts-1* \r\nNRBC-6* AbsNeut-0.28* AbsLymp-1.38 AbsMono-0.65 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-2+ Poiklo-1+ \r\nMacrocy-2+ Microcy-1+ Polychr-NORMAL Ovalocy-1+ \r\nSchisto-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 12:00AM BLOOD Plt Smr-LOW Plt Ct-85*\r\n___ 12:00AM BLOOD Glucose-110* UreaN-18 Creat-0.8 Na-142 \r\nK-3.6 Cl-101 HCO3-23 AnGap-22*\r\n___ 12:00AM BLOOD ALT-9 AST-11 LD(LDH)-238 AlkPhos-89 \r\nTotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.5 Mg-2.2\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\nDLBCL s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, concerning for RP bleed and \r\ndisease progression.  \r\n\r\nACUTE ISSUES:\r\n=============\r\n#Pancytopenia/Lymphoma disease status: Pancytopenic on \r\nadmission. Counts remained stable while in house. BM Bx \r\nperformed under fluoroscopy on ___ showed was concerning for \r\nMDS, final results are pending at discharge. Treatment plan \r\ndeveloped with Dr. ___ likely involve administration \r\nof dacogen but this will be further delineated outpatient. \r\nHemoglobin 7.1 on admission and patient received 1U prbcs prior \r\nto discharge.  \r\n\r\n#Infection/URI: Presented w/ congestion and recent blood nasal \r\nexudates. On ___, was febrile. Respiratory viral, Blood, and \r\nUrine cx were obtained; CXR and CT sinus were evaluated. Vanc \r\nand cefepime were started. No infectious pathogen was identified \r\nand the patient had no further fevers. On ___, vancomycin was \r\ndiscontinued. On ___, cefepime was discontinued. She received \r\nsymptomatic treatment with nasal saline and oxymetazoline. She \r\nwas discharged with levaquin 500mg q24hrs (to complete a 7D \r\ncourse on ___ \r\n\r\n#LLE Wound: Wearing Unna boot on presentation which had been \r\nplaced 5d PTA. Seen by wound c/s service. Daily dressing changes \r\nwhile in house. Lesion stable. Rash of chronic venous stasis, \r\nstable. Discharged with instructions to follow-up for usual care \r\nat ___.\r\n\r\n#Anti-coagulation/DVT: Concern for RP Bleed on admission, ruled \r\nout by CT. Rivaroxaban held and patient treated with enoxaparin. \r\nThe dose was held or modified at different times because of \r\nplanned procedures. The patient did not have any acute bleeding \r\nevents apart from bloody nasal exudate with nose blowing. On \r\ndischarge, patient was restarted on home dose of Rivaroxaban \r\n(20mg PO daily). Platelets 85K at discharge \r\n\r\n#Back Pain: Improved with rest and oxycodone while patient was \r\nin hospital. Otherwise, continued gabapentin 900mg TID at \r\ndischarge. No acute pain episodes prior to leaving.\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Pulm HTN\r\n#History of BCNU pneumonitis- Followed by Dr. ___. No active \r\nsymptoms. PRN inhalers ordered\r\n\r\n#H/o Migraine: R-sided pain, usually early morning onset, \r\nassociated with photophobia. Typically reaches peak intensity \r\nafter 4 hours and resolves with one or two episodes of vomiting. \r\nWould take indomethacin at home for this, but it is not \r\nappropriate given thrombocytopenia. No acute episodes prior to \r\ndischarge, continue to monitor closely outpatient \r\n\r\n#hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm, cont gabapentin  \r\n\r\n#GERD- PPI  \r\n\r\n#Depression- venlafaxine \r\n\r\nDISPO: patient discharged on ___. RTC on ___ on ___ with \r\nDr. ___\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Gabapentin 900 mg PO TID \r\n2. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n3. Rivaroxaban 20 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO BID \r\n8. Venlafaxine 25 mg PO BID \r\n9. albuterol sulfate 90 mcg/actuation inhalation Q4H:PRN \r\n10. Cyanocobalamin 1000 mcg PO QHS \r\n11. FoLIC Acid 3.2 mg PO DAILY \r\n12. Ascorbic Acid ___ mg PO BID \r\n13. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n\r\n \r\nDischarge Medications:\r\n1.  Levofloxacin 500 mg PO Q24H Duration: 6 Days \r\nTake daily from ___ to ___.  Potassium Chloride 10 mEq PO DAILY  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  Ascorbic Acid ___ mg PO BID  \r\n6.  Cyanocobalamin 1000 mcg PO QHS  \r\n7.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n8.  FoLIC Acid 3.2 mg PO DAILY  \r\n9.  Furosemide 20 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Rivaroxaban 20 mg PO DAILY  \r\n14.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\n==================\r\nMyelodisplastic Syndrome\r\nDiffuse large B cell lymphoma\r\nFebrile neutropenia\r\nRhinosinusitis\r\n\r\nSecondary Diagnoses:\r\n====================\r\nHistory of deep venous thromboembolism (DVT) on anticoagulation\r\nCommon variable immunodeficiency (CVID)\r\nMigraine\r\nChronic non-healing wound\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ came to ___ because ___ had \r\nback pain and low blood counts.\r\n\r\nWhat was done for me in the hospital?\r\n- CT scans of your torso and sinuses looking for bleeding and \r\ninfection. Neither infection nor bleeding was found.\r\n- Bone marrow biopsy to assess cancer disease status was \r\nconcerning for Myelodisplastic syndrome\r\n- Antibiotics for a fever.\r\n- Supportive care for your congestion.\r\n\r\nWhat should I do now that I am leaving the hospital?\r\n- Attend your scheduled follow-up appointments, listed below.\r\n- Take your medications as prescribed.\r\n- Return the to hospital if ___ have any concerning symptoms \r\n(some key symptoms are listed below).\r\n\r\nIt was a pleasure participating in your care. Wishing ___ all \r\nthe best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-16:1",
      "text": "History of Present Illness:\nA ___ year old female with a history of transformed follicular \nlymphoma s/p multiple past regimens as noted below, and \nultimately an autoSCT with BEAM conditioning in ___. She \nhas comorbid CVID and receives IVIG monthly. Her\npost transplant course was complicated by ___ pneumonitis. She \nunderwent a total right knee replacement on ___. Her \npostoperative course was complicated by foot drop likely due to \nirritation of her peroneal nerve from the CPM machine as well as \na cellulitis of the right leg following her surgery which was \ntreated with a course of Keflex. This is the same leg as her \nprevious DVT and her circulation is poor. She has had ongoing \nissues with sciatica with hip and left lower back pain, and has \nhad steroid injections. At the end of ___ of ___, Ms. ___ noted \nincreasing swelling of her right leg with shortness of breath. She had been on Xarelto for prior DVT and has an IVC filter in \nplace. Her dose of Xarelto had been decreased to 10 mg daily \ngiven her age and chronic history of DVT; she also had a lower \nplatelet count for a period of time. She was seen and admitted \nat ___ with ultrasound showing DVT of the right leg \nonce again. Chest CT with no PE or other adenopathy. Abdomen \nand Pelvic CT without adenopathy or concern for lymphoma \nrecurrence. Xarelto was increased back to 20 mg daily. INTERVAL HISTORY:  Over the past 1 - 2 months, Ms. ___ was \nnoted for a drop in her white count with neutropenia as well as \na drop in her platelet count. This had been noticed in the past \nwith the plan to repeat a bone marrow biopsy but her counts \nreturned to baseline so bone marrow biopsy was deferred. She \nwas also noted for a nonhealing wound on her left leg after hit \non the shin several weeks ago. She was treated with a course of \nKeflex with still poor healing. Given 2 doses of Neupogen to \nsupport counts. She was seen by the wound care clinic at ___ \n___ yesterday and the area was debrided and dressing \napplied. At her visit today, Ms. ___ is noted for further drop in \nblood counts(platelet count is low but more her baseline). She \nreports not feeling well towards the middle of last week and on \n___ morning, she developed increasing left lower back pain, \nradiating to the buttock area. She feels this is related to her \nsciatica but is different pain pattern; no radiating pain down \nthe leg as she usually has. Pain increases with changing \npositions and with initial ambulation. She walks with a cane. In addition, she developed increasing nasal congestion on \n___ night which seemed to come on suddenly. No fevers, \nchills, night sweats, sore throat. When blowing her nose, she \nnoted increased blood with clots although no frank epistaxis.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-16",
        "chart_time": "104467",
        "section": "General",
        "position": 1,
        "tokenCount": 684,
        "note_metadata": {
          "note_id": "18887130-DS-16",
          "subject_id": 18887130,
          "hadm_id": 26068131,
          "note_type": "DS",
          "note_seq": 16,
          "charttime": 104467,
          "storetime": 104467.76458333334,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, nose bleed and pancytopenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy by interventional radiology (___)\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed follicular \r\nlymphoma s/p multiple past regimens as noted below, and \r\nultimately an autoSCT with BEAM conditioning in ___.  She \r\nhas comorbid CVID and receives IVIG monthly.  Her\r\npost transplant course was complicated by ___ pneumonitis.  She \r\nunderwent a total right knee replacement on ___.  Her \r\npostoperative course was complicated by foot drop likely due to \r\nirritation of her peroneal nerve from the CPM machine as well as \r\na cellulitis of the right leg following her surgery which was \r\ntreated with a course of Keflex.  This is the same leg as her \r\nprevious DVT and her circulation is poor.  She has had ongoing \r\nissues with sciatica with hip and left lower back pain, and has \r\nhad steroid injections.\r\n\r\nAt the end of ___ of ___, Ms. ___ noted \r\nincreasing swelling of her right leg with shortness of breath.  \r\nShe had been on Xarelto for prior DVT and has an IVC filter in \r\nplace.  Her dose of Xarelto had been decreased to 10 mg daily \r\ngiven her age and chronic history of DVT; she also had a lower \r\nplatelet count for a period of time.  She was seen and admitted \r\nat ___ with ultrasound showing DVT of the right leg \r\nonce again.  Chest CT with no PE or other adenopathy.  Abdomen \r\nand Pelvic CT without adenopathy or concern for lymphoma \r\nrecurrence.  Xarelto was increased back to 20 mg daily. \r\n\r\nINTERVAL HISTORY:  Over the past 1 - 2 months, Ms. ___ was \r\nnoted for a drop in her white count with neutropenia as well as \r\na drop in her platelet count.  This had been noticed in the past \r\nwith the plan to repeat a bone marrow biopsy but her counts \r\nreturned to baseline so bone marrow biopsy was deferred.  She \r\nwas also noted for a nonhealing wound on her left leg after hit \r\non the shin several weeks ago.  She was treated with a course of \r\nKeflex with still poor healing.  Given 2 doses of Neupogen to \r\nsupport counts.  She was seen by the wound care clinic at ___ \r\n___ yesterday and the area was debrided and dressing \r\napplied.\r\n\r\nAt her visit today, Ms. ___ is noted for further drop in \r\nblood counts(platelet count is low but more her baseline).  She \r\nreports not feeling well towards the middle of last week and on \r\n___ morning, she developed increasing left lower back pain, \r\nradiating to the buttock area.  She feels this is related to her \r\nsciatica but is different pain pattern; no radiating pain down \r\nthe leg as she usually has.  Pain increases with changing \r\npositions and with initial ambulation.  She walks with a cane.  \r\nIn addition, she developed increasing nasal congestion on \r\n___ night which seemed to come on suddenly.  No fevers, \r\nchills, night sweats, sore throat.  When blowing her nose, she \r\nnoted increased blood with clots although no frank epistaxis.  \r\n\r\nBecause of the more acute drop in counts, Ms. ___ is being \r\nadmitted for further evaluation for possible bleed given on \r\nanticoagulation vs evolving MDS-->Leukemia.  \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PHYSICAL:\r\n===================\r\nVITALS - 17:27 ___ 98.9 PO ___ 18 97 RA \r\nGeneral: pleasant, no distress, sitting at edge of bed \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: clear bilaterally, good air movement \r\nAbdomen: well-healed surgical incisions, active BS, soft, no\r\nrebound or guarding, no organomegaly \r\nExt: Bilateral ___ swelling, R > L. L shin wound is wrapped and\r\nc/d/I. 2+ radial and DP pulses, 3+ pitting edema bilaterally \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\n  \r\nDISCHARGE PHYSICAL:\r\n===================\r\nVS: TC 98.8 PO 130/80 93 18 98%RA \r\nWeight: 258.7 lbs (___) -> 254.4 lbs (___) \r\nGeneral: pleasant, sitting in chair with tiara on, no distress \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: CTAB, no wheezes, rales or rhonchi \r\nAbdomen: Active BS, soft, no rebound or guarding, no\r\norganomegaly \r\nBack: No tenderness over spinous processes or L iliac crest \r\nExt: Bilateral ___ swelling, R > L. R leg with TEDS stocking on.\r\nL shin wound is stable. 2+ radial and DP pulses \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\nSkin: Erythematous venous stasis changes in bilateral lower\r\nextremities from mid-tibia to medial malleolus \r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n===============\r\n___ 10:45AM BLOOD WBC-2.3* RBC-2.46* Hgb-8.0* Hct-24.4* \r\nMCV-99* MCH-32.5* MCHC-32.8 RDW-21.4* RDWSD-76.8* Plt Ct-93*\r\n___ 10:45AM BLOOD Neuts-29* Bands-0 ___ Monos-26* \r\nEos-0 Baso-0 ___ Metas-2* Myelos-0 Blasts-1* NRBC-4* \r\nAbsNeut-0.67* AbsLymp-0.97* AbsMono-0.60 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 10:45AM BLOOD Hypochr-1+ Anisocy-1+ Poiklo-1+ \r\nMacrocy-1+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-OCCASIONAL \r\nTear Dr-1+\r\n___ 10:45AM BLOOD ___ PTT-39.0* ___\r\n___ 10:45AM BLOOD Ret Aut-1.2 Abs Ret-0.03\r\n___ 10:45AM BLOOD UreaN-15 Creat-0.9 Na-139 K-4.1 Cl-102 \r\nHCO3-26 AnGap-15\r\n___ 10:45AM BLOOD ALT-12 AST-16 LD(LDH)-232 AlkPhos-96 \r\nTotBili-0.3\r\n___ 10:45AM BLOOD Albumin-3.5 Calcium-8.1* Mg-2.2 Iron-49\r\n___ 10:45AM BLOOD ___ Folate->20 Hapto-254* \r\nFerritn-389*\r\n___ 10:45AM BLOOD TSH-1.9\r\n___ 10:45AM BLOOD IgG-728\r\n \r\nOTHER PERTINENT LABS:\r\n=====================\r\n___ 12:32PM URINE RBC-1 WBC-7* Bacteri-FEW Yeast-NONE \r\nEpi-<1 TransE-<1\r\n___ 12:32PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.5 Leuks-TR\r\n___ 12:32PM URINE Color-Straw Appear-Clear Sp ___\r\n \r\nMICROBIOLOGY:\r\n=============\r\n___ 12:32 pm URINE      Source: ___. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   URINE CULTURE (Final ___:    NO GROWTH. \r\n\r\n___ 11:30PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n___ 10:00AM OTHER BODY FLUID STANDARD LEUKEMIA/LYMPHOMA \r\nPANEL (24 MARKERS)-TEST      \r\n___ 10:00AM BONE MARROW IPT-DONE\r\n___ 10:00AM BONE MARROW CEBPA MUTATION ANALYSIS-PND\r\n___ 10:00AM BONE MARROW RAPID HEME PANEL-PND\r\n \r\nIMAGING:\r\n========\r\n___ 3:___BD & PELVIS W/O CONTRAST\r\nIMPRESSION:\r\n1. No evidence of retroperitoneal hematoma or lymphadenopathy.\r\n2. Stable 3.2 cm right adnexal cyst.  Continued attention is \r\nadvised on futurefollow up.\r\n3. Severe degenerative changes of lumbar spine are similar to \r\nbefore.\r\n\r\n___ 3:___HEST W/O CONTRAST\r\nIMPRESSION: \r\nNo evidence of acute intrathoracic abnormality.\r\nNo evidence of intrathoracic lymphoma.\r\nDilated main pulmonary artery, concerning for pulmonary \r\nhypertension, unchanged since ___.\r\n\r\n___ 3:38 ___\r\nCT HEAD W/O CONTRAST\r\nIMPRESSION: \r\n1. Of note, significant streak artifact from the right \r\nsupraclinoid vascular embolization coil limits evaluation of \r\nadjacent structures.  Given these limitations, there is no \r\nevidence of acute major territorial infarction, hemorrhage, or \r\nfracture.\r\n2. Paranasal sinus disease, as described above.\r\n\r\n___ 3:28 ___\r\nCT SINUS/MANDIBLE/MAXILLOFACIA\r\nIMPRESSION: \r\nMild mucosal thickening in both maxillary sinuses and ethmoid \r\nair cells, similar to recent CT head.  No evidence of bony \r\nerosion.\r\n \r\nPATHOLOGY: RESULT PENDING AT DISCHARGE\r\n==========\r\n\r\nDISCHARGE LABS:\r\n===============\r\n___ 12:00AM BLOOD WBC-2.5* RBC-2.29* Hgb-7.2* Hct-22.7* \r\nMCV-99* MCH-31.4 MCHC-31.7* RDW-20.6* RDWSD-75.0* Plt Ct-85*\r\n___ 12:00AM BLOOD Neuts-11* Bands-0 Lymphs-55* Monos-26* \r\nEos-0 Baso-0 ___ Metas-1* Myelos-4* Promyel-2* Blasts-1* \r\nNRBC-6* AbsNeut-0.28* AbsLymp-1.38 AbsMono-0.65 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-2+ Poiklo-1+ \r\nMacrocy-2+ Microcy-1+ Polychr-NORMAL Ovalocy-1+ \r\nSchisto-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 12:00AM BLOOD Plt Smr-LOW Plt Ct-85*\r\n___ 12:00AM BLOOD Glucose-110* UreaN-18 Creat-0.8 Na-142 \r\nK-3.6 Cl-101 HCO3-23 AnGap-22*\r\n___ 12:00AM BLOOD ALT-9 AST-11 LD(LDH)-238 AlkPhos-89 \r\nTotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.5 Mg-2.2\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\nDLBCL s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, concerning for RP bleed and \r\ndisease progression.  \r\n\r\nACUTE ISSUES:\r\n=============\r\n#Pancytopenia/Lymphoma disease status: Pancytopenic on \r\nadmission. Counts remained stable while in house. BM Bx \r\nperformed under fluoroscopy on ___ showed was concerning for \r\nMDS, final results are pending at discharge. Treatment plan \r\ndeveloped with Dr. ___ likely involve administration \r\nof dacogen but this will be further delineated outpatient. \r\nHemoglobin 7.1 on admission and patient received 1U prbcs prior \r\nto discharge.  \r\n\r\n#Infection/URI: Presented w/ congestion and recent blood nasal \r\nexudates. On ___, was febrile. Respiratory viral, Blood, and \r\nUrine cx were obtained; CXR and CT sinus were evaluated. Vanc \r\nand cefepime were started. No infectious pathogen was identified \r\nand the patient had no further fevers. On ___, vancomycin was \r\ndiscontinued. On ___, cefepime was discontinued. She received \r\nsymptomatic treatment with nasal saline and oxymetazoline. She \r\nwas discharged with levaquin 500mg q24hrs (to complete a 7D \r\ncourse on ___ \r\n\r\n#LLE Wound: Wearing Unna boot on presentation which had been \r\nplaced 5d PTA. Seen by wound c/s service. Daily dressing changes \r\nwhile in house. Lesion stable. Rash of chronic venous stasis, \r\nstable. Discharged with instructions to follow-up for usual care \r\nat ___.\r\n\r\n#Anti-coagulation/DVT: Concern for RP Bleed on admission, ruled \r\nout by CT. Rivaroxaban held and patient treated with enoxaparin. \r\nThe dose was held or modified at different times because of \r\nplanned procedures. The patient did not have any acute bleeding \r\nevents apart from bloody nasal exudate with nose blowing. On \r\ndischarge, patient was restarted on home dose of Rivaroxaban \r\n(20mg PO daily). Platelets 85K at discharge \r\n\r\n#Back Pain: Improved with rest and oxycodone while patient was \r\nin hospital. Otherwise, continued gabapentin 900mg TID at \r\ndischarge. No acute pain episodes prior to leaving.\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Pulm HTN\r\n#History of BCNU pneumonitis- Followed by Dr. ___. No active \r\nsymptoms. PRN inhalers ordered\r\n\r\n#H/o Migraine: R-sided pain, usually early morning onset, \r\nassociated with photophobia. Typically reaches peak intensity \r\nafter 4 hours and resolves with one or two episodes of vomiting. \r\nWould take indomethacin at home for this, but it is not \r\nappropriate given thrombocytopenia. No acute episodes prior to \r\ndischarge, continue to monitor closely outpatient \r\n\r\n#hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm, cont gabapentin  \r\n\r\n#GERD- PPI  \r\n\r\n#Depression- venlafaxine \r\n\r\nDISPO: patient discharged on ___. RTC on ___ on ___ with \r\nDr. ___\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Gabapentin 900 mg PO TID \r\n2. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n3. Rivaroxaban 20 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO BID \r\n8. Venlafaxine 25 mg PO BID \r\n9. albuterol sulfate 90 mcg/actuation inhalation Q4H:PRN \r\n10. Cyanocobalamin 1000 mcg PO QHS \r\n11. FoLIC Acid 3.2 mg PO DAILY \r\n12. Ascorbic Acid ___ mg PO BID \r\n13. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n\r\n \r\nDischarge Medications:\r\n1.  Levofloxacin 500 mg PO Q24H Duration: 6 Days \r\nTake daily from ___ to ___.  Potassium Chloride 10 mEq PO DAILY  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  Ascorbic Acid ___ mg PO BID  \r\n6.  Cyanocobalamin 1000 mcg PO QHS  \r\n7.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n8.  FoLIC Acid 3.2 mg PO DAILY  \r\n9.  Furosemide 20 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Rivaroxaban 20 mg PO DAILY  \r\n14.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\n==================\r\nMyelodisplastic Syndrome\r\nDiffuse large B cell lymphoma\r\nFebrile neutropenia\r\nRhinosinusitis\r\n\r\nSecondary Diagnoses:\r\n====================\r\nHistory of deep venous thromboembolism (DVT) on anticoagulation\r\nCommon variable immunodeficiency (CVID)\r\nMigraine\r\nChronic non-healing wound\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ came to ___ because ___ had \r\nback pain and low blood counts.\r\n\r\nWhat was done for me in the hospital?\r\n- CT scans of your torso and sinuses looking for bleeding and \r\ninfection. Neither infection nor bleeding was found.\r\n- Bone marrow biopsy to assess cancer disease status was \r\nconcerning for Myelodisplastic syndrome\r\n- Antibiotics for a fever.\r\n- Supportive care for your congestion.\r\n\r\nWhat should I do now that I am leaving the hospital?\r\n- Attend your scheduled follow-up appointments, listed below.\r\n- Take your medications as prescribed.\r\n- Return the to hospital if ___ have any concerning symptoms \r\n(some key symptoms are listed below).\r\n\r\nIt was a pleasure participating in your care. Wishing ___ all \r\nthe best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-16:2",
      "text": "She feels this is related to her \nsciatica but is different pain pattern; no radiating pain down \nthe leg as she usually has. Pain increases with changing \npositions and with initial ambulation. She walks with a cane. In addition, she developed increasing nasal congestion on \n___ night which seemed to come on suddenly. No fevers, \nchills, night sweats, sore throat. When blowing her nose, she \nnoted increased blood with clots although no frank epistaxis. Because of the more acute drop in counts, Ms. ___ is being \nadmitted for further evaluation for possible bleed given on \nanticoagulation vs evolving MDS-->Leukemia.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-16",
        "chart_time": "104467",
        "section": "General",
        "position": 2,
        "tokenCount": 156,
        "note_metadata": {
          "note_id": "18887130-DS-16",
          "subject_id": 18887130,
          "hadm_id": 26068131,
          "note_type": "DS",
          "note_seq": 16,
          "charttime": 104467,
          "storetime": 104467.76458333334,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, nose bleed and pancytopenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy by interventional radiology (___)\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed follicular \r\nlymphoma s/p multiple past regimens as noted below, and \r\nultimately an autoSCT with BEAM conditioning in ___.  She \r\nhas comorbid CVID and receives IVIG monthly.  Her\r\npost transplant course was complicated by ___ pneumonitis.  She \r\nunderwent a total right knee replacement on ___.  Her \r\npostoperative course was complicated by foot drop likely due to \r\nirritation of her peroneal nerve from the CPM machine as well as \r\na cellulitis of the right leg following her surgery which was \r\ntreated with a course of Keflex.  This is the same leg as her \r\nprevious DVT and her circulation is poor.  She has had ongoing \r\nissues with sciatica with hip and left lower back pain, and has \r\nhad steroid injections.\r\n\r\nAt the end of ___ of ___, Ms. ___ noted \r\nincreasing swelling of her right leg with shortness of breath.  \r\nShe had been on Xarelto for prior DVT and has an IVC filter in \r\nplace.  Her dose of Xarelto had been decreased to 10 mg daily \r\ngiven her age and chronic history of DVT; she also had a lower \r\nplatelet count for a period of time.  She was seen and admitted \r\nat ___ with ultrasound showing DVT of the right leg \r\nonce again.  Chest CT with no PE or other adenopathy.  Abdomen \r\nand Pelvic CT without adenopathy or concern for lymphoma \r\nrecurrence.  Xarelto was increased back to 20 mg daily. \r\n\r\nINTERVAL HISTORY:  Over the past 1 - 2 months, Ms. ___ was \r\nnoted for a drop in her white count with neutropenia as well as \r\na drop in her platelet count.  This had been noticed in the past \r\nwith the plan to repeat a bone marrow biopsy but her counts \r\nreturned to baseline so bone marrow biopsy was deferred.  She \r\nwas also noted for a nonhealing wound on her left leg after hit \r\non the shin several weeks ago.  She was treated with a course of \r\nKeflex with still poor healing.  Given 2 doses of Neupogen to \r\nsupport counts.  She was seen by the wound care clinic at ___ \r\n___ yesterday and the area was debrided and dressing \r\napplied.\r\n\r\nAt her visit today, Ms. ___ is noted for further drop in \r\nblood counts(platelet count is low but more her baseline).  She \r\nreports not feeling well towards the middle of last week and on \r\n___ morning, she developed increasing left lower back pain, \r\nradiating to the buttock area.  She feels this is related to her \r\nsciatica but is different pain pattern; no radiating pain down \r\nthe leg as she usually has.  Pain increases with changing \r\npositions and with initial ambulation.  She walks with a cane.  \r\nIn addition, she developed increasing nasal congestion on \r\n___ night which seemed to come on suddenly.  No fevers, \r\nchills, night sweats, sore throat.  When blowing her nose, she \r\nnoted increased blood with clots although no frank epistaxis.  \r\n\r\nBecause of the more acute drop in counts, Ms. ___ is being \r\nadmitted for further evaluation for possible bleed given on \r\nanticoagulation vs evolving MDS-->Leukemia.  \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PHYSICAL:\r\n===================\r\nVITALS - 17:27 ___ 98.9 PO ___ 18 97 RA \r\nGeneral: pleasant, no distress, sitting at edge of bed \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: clear bilaterally, good air movement \r\nAbdomen: well-healed surgical incisions, active BS, soft, no\r\nrebound or guarding, no organomegaly \r\nExt: Bilateral ___ swelling, R > L. L shin wound is wrapped and\r\nc/d/I. 2+ radial and DP pulses, 3+ pitting edema bilaterally \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\n  \r\nDISCHARGE PHYSICAL:\r\n===================\r\nVS: TC 98.8 PO 130/80 93 18 98%RA \r\nWeight: 258.7 lbs (___) -> 254.4 lbs (___) \r\nGeneral: pleasant, sitting in chair with tiara on, no distress \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: CTAB, no wheezes, rales or rhonchi \r\nAbdomen: Active BS, soft, no rebound or guarding, no\r\norganomegaly \r\nBack: No tenderness over spinous processes or L iliac crest \r\nExt: Bilateral ___ swelling, R > L. R leg with TEDS stocking on.\r\nL shin wound is stable. 2+ radial and DP pulses \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\nSkin: Erythematous venous stasis changes in bilateral lower\r\nextremities from mid-tibia to medial malleolus \r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n===============\r\n___ 10:45AM BLOOD WBC-2.3* RBC-2.46* Hgb-8.0* Hct-24.4* \r\nMCV-99* MCH-32.5* MCHC-32.8 RDW-21.4* RDWSD-76.8* Plt Ct-93*\r\n___ 10:45AM BLOOD Neuts-29* Bands-0 ___ Monos-26* \r\nEos-0 Baso-0 ___ Metas-2* Myelos-0 Blasts-1* NRBC-4* \r\nAbsNeut-0.67* AbsLymp-0.97* AbsMono-0.60 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 10:45AM BLOOD Hypochr-1+ Anisocy-1+ Poiklo-1+ \r\nMacrocy-1+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-OCCASIONAL \r\nTear Dr-1+\r\n___ 10:45AM BLOOD ___ PTT-39.0* ___\r\n___ 10:45AM BLOOD Ret Aut-1.2 Abs Ret-0.03\r\n___ 10:45AM BLOOD UreaN-15 Creat-0.9 Na-139 K-4.1 Cl-102 \r\nHCO3-26 AnGap-15\r\n___ 10:45AM BLOOD ALT-12 AST-16 LD(LDH)-232 AlkPhos-96 \r\nTotBili-0.3\r\n___ 10:45AM BLOOD Albumin-3.5 Calcium-8.1* Mg-2.2 Iron-49\r\n___ 10:45AM BLOOD ___ Folate->20 Hapto-254* \r\nFerritn-389*\r\n___ 10:45AM BLOOD TSH-1.9\r\n___ 10:45AM BLOOD IgG-728\r\n \r\nOTHER PERTINENT LABS:\r\n=====================\r\n___ 12:32PM URINE RBC-1 WBC-7* Bacteri-FEW Yeast-NONE \r\nEpi-<1 TransE-<1\r\n___ 12:32PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.5 Leuks-TR\r\n___ 12:32PM URINE Color-Straw Appear-Clear Sp ___\r\n \r\nMICROBIOLOGY:\r\n=============\r\n___ 12:32 pm URINE      Source: ___. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   URINE CULTURE (Final ___:    NO GROWTH. \r\n\r\n___ 11:30PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n___ 10:00AM OTHER BODY FLUID STANDARD LEUKEMIA/LYMPHOMA \r\nPANEL (24 MARKERS)-TEST      \r\n___ 10:00AM BONE MARROW IPT-DONE\r\n___ 10:00AM BONE MARROW CEBPA MUTATION ANALYSIS-PND\r\n___ 10:00AM BONE MARROW RAPID HEME PANEL-PND\r\n \r\nIMAGING:\r\n========\r\n___ 3:___BD & PELVIS W/O CONTRAST\r\nIMPRESSION:\r\n1. No evidence of retroperitoneal hematoma or lymphadenopathy.\r\n2. Stable 3.2 cm right adnexal cyst.  Continued attention is \r\nadvised on futurefollow up.\r\n3. Severe degenerative changes of lumbar spine are similar to \r\nbefore.\r\n\r\n___ 3:___HEST W/O CONTRAST\r\nIMPRESSION: \r\nNo evidence of acute intrathoracic abnormality.\r\nNo evidence of intrathoracic lymphoma.\r\nDilated main pulmonary artery, concerning for pulmonary \r\nhypertension, unchanged since ___.\r\n\r\n___ 3:38 ___\r\nCT HEAD W/O CONTRAST\r\nIMPRESSION: \r\n1. Of note, significant streak artifact from the right \r\nsupraclinoid vascular embolization coil limits evaluation of \r\nadjacent structures.  Given these limitations, there is no \r\nevidence of acute major territorial infarction, hemorrhage, or \r\nfracture.\r\n2. Paranasal sinus disease, as described above.\r\n\r\n___ 3:28 ___\r\nCT SINUS/MANDIBLE/MAXILLOFACIA\r\nIMPRESSION: \r\nMild mucosal thickening in both maxillary sinuses and ethmoid \r\nair cells, similar to recent CT head.  No evidence of bony \r\nerosion.\r\n \r\nPATHOLOGY: RESULT PENDING AT DISCHARGE\r\n==========\r\n\r\nDISCHARGE LABS:\r\n===============\r\n___ 12:00AM BLOOD WBC-2.5* RBC-2.29* Hgb-7.2* Hct-22.7* \r\nMCV-99* MCH-31.4 MCHC-31.7* RDW-20.6* RDWSD-75.0* Plt Ct-85*\r\n___ 12:00AM BLOOD Neuts-11* Bands-0 Lymphs-55* Monos-26* \r\nEos-0 Baso-0 ___ Metas-1* Myelos-4* Promyel-2* Blasts-1* \r\nNRBC-6* AbsNeut-0.28* AbsLymp-1.38 AbsMono-0.65 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-2+ Poiklo-1+ \r\nMacrocy-2+ Microcy-1+ Polychr-NORMAL Ovalocy-1+ \r\nSchisto-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 12:00AM BLOOD Plt Smr-LOW Plt Ct-85*\r\n___ 12:00AM BLOOD Glucose-110* UreaN-18 Creat-0.8 Na-142 \r\nK-3.6 Cl-101 HCO3-23 AnGap-22*\r\n___ 12:00AM BLOOD ALT-9 AST-11 LD(LDH)-238 AlkPhos-89 \r\nTotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.5 Mg-2.2\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\nDLBCL s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, concerning for RP bleed and \r\ndisease progression.  \r\n\r\nACUTE ISSUES:\r\n=============\r\n#Pancytopenia/Lymphoma disease status: Pancytopenic on \r\nadmission. Counts remained stable while in house. BM Bx \r\nperformed under fluoroscopy on ___ showed was concerning for \r\nMDS, final results are pending at discharge. Treatment plan \r\ndeveloped with Dr. ___ likely involve administration \r\nof dacogen but this will be further delineated outpatient. \r\nHemoglobin 7.1 on admission and patient received 1U prbcs prior \r\nto discharge.  \r\n\r\n#Infection/URI: Presented w/ congestion and recent blood nasal \r\nexudates. On ___, was febrile. Respiratory viral, Blood, and \r\nUrine cx were obtained; CXR and CT sinus were evaluated. Vanc \r\nand cefepime were started. No infectious pathogen was identified \r\nand the patient had no further fevers. On ___, vancomycin was \r\ndiscontinued. On ___, cefepime was discontinued. She received \r\nsymptomatic treatment with nasal saline and oxymetazoline. She \r\nwas discharged with levaquin 500mg q24hrs (to complete a 7D \r\ncourse on ___ \r\n\r\n#LLE Wound: Wearing Unna boot on presentation which had been \r\nplaced 5d PTA. Seen by wound c/s service. Daily dressing changes \r\nwhile in house. Lesion stable. Rash of chronic venous stasis, \r\nstable. Discharged with instructions to follow-up for usual care \r\nat ___.\r\n\r\n#Anti-coagulation/DVT: Concern for RP Bleed on admission, ruled \r\nout by CT. Rivaroxaban held and patient treated with enoxaparin. \r\nThe dose was held or modified at different times because of \r\nplanned procedures. The patient did not have any acute bleeding \r\nevents apart from bloody nasal exudate with nose blowing. On \r\ndischarge, patient was restarted on home dose of Rivaroxaban \r\n(20mg PO daily). Platelets 85K at discharge \r\n\r\n#Back Pain: Improved with rest and oxycodone while patient was \r\nin hospital. Otherwise, continued gabapentin 900mg TID at \r\ndischarge. No acute pain episodes prior to leaving.\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Pulm HTN\r\n#History of BCNU pneumonitis- Followed by Dr. ___. No active \r\nsymptoms. PRN inhalers ordered\r\n\r\n#H/o Migraine: R-sided pain, usually early morning onset, \r\nassociated with photophobia. Typically reaches peak intensity \r\nafter 4 hours and resolves with one or two episodes of vomiting. \r\nWould take indomethacin at home for this, but it is not \r\nappropriate given thrombocytopenia. No acute episodes prior to \r\ndischarge, continue to monitor closely outpatient \r\n\r\n#hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm, cont gabapentin  \r\n\r\n#GERD- PPI  \r\n\r\n#Depression- venlafaxine \r\n\r\nDISPO: patient discharged on ___. RTC on ___ on ___ with \r\nDr. ___\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Gabapentin 900 mg PO TID \r\n2. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n3. Rivaroxaban 20 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO BID \r\n8. Venlafaxine 25 mg PO BID \r\n9. albuterol sulfate 90 mcg/actuation inhalation Q4H:PRN \r\n10. Cyanocobalamin 1000 mcg PO QHS \r\n11. FoLIC Acid 3.2 mg PO DAILY \r\n12. Ascorbic Acid ___ mg PO BID \r\n13. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n\r\n \r\nDischarge Medications:\r\n1.  Levofloxacin 500 mg PO Q24H Duration: 6 Days \r\nTake daily from ___ to ___.  Potassium Chloride 10 mEq PO DAILY  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  Ascorbic Acid ___ mg PO BID  \r\n6.  Cyanocobalamin 1000 mcg PO QHS  \r\n7.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n8.  FoLIC Acid 3.2 mg PO DAILY  \r\n9.  Furosemide 20 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Rivaroxaban 20 mg PO DAILY  \r\n14.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\n==================\r\nMyelodisplastic Syndrome\r\nDiffuse large B cell lymphoma\r\nFebrile neutropenia\r\nRhinosinusitis\r\n\r\nSecondary Diagnoses:\r\n====================\r\nHistory of deep venous thromboembolism (DVT) on anticoagulation\r\nCommon variable immunodeficiency (CVID)\r\nMigraine\r\nChronic non-healing wound\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ came to ___ because ___ had \r\nback pain and low blood counts.\r\n\r\nWhat was done for me in the hospital?\r\n- CT scans of your torso and sinuses looking for bleeding and \r\ninfection. Neither infection nor bleeding was found.\r\n- Bone marrow biopsy to assess cancer disease status was \r\nconcerning for Myelodisplastic syndrome\r\n- Antibiotics for a fever.\r\n- Supportive care for your congestion.\r\n\r\nWhat should I do now that I am leaving the hospital?\r\n- Attend your scheduled follow-up appointments, listed below.\r\n- Take your medications as prescribed.\r\n- Return the to hospital if ___ have any concerning symptoms \r\n(some key symptoms are listed below).\r\n\r\nIt was a pleasure participating in your care. Wishing ___ all \r\nthe best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-16:3",
      "text": "Past Medical History:\nOncologic history: In brief, history of follicular lymphoma \nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \nrituximab in ___ for residual disease. ___: RICE \nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \nlocal disease. She has a hx of hypogammaglobulinemia. Other PMH:\nobesity\nAcute DVT in the right popliteal/femoral veins + superficial \nthrombosis\n--Transformed DLBCL with history of follicular lymphoma as noted \nabove\n--CLL, noted on BM biopsy on ___. --Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \n(*Known slight CN VI palsy & mild proptosis of R eye)\n--Hypogammaglobulinemia, receives IVIG PRN\n--R leg DVT. IVC filter in place, on rivaroxaban\n--BCNU pneumonitis, on prednisone\n--Mild GERD\n--OA / LBP\n--Small Intestinal Bacterial Overgrowth\n--Trochanteric Bursitis\n--s/p Excisional Bx L Cervical Lymph Node\n--s/p L total knee replacement ___, walks with cane\n--s/p I&D Labial Abscess\n--s/p Excision Cyst R ___ Digit of Hand Social History:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-16",
        "chart_time": "104467",
        "section": "General",
        "position": 3,
        "tokenCount": 252,
        "note_metadata": {
          "note_id": "18887130-DS-16",
          "subject_id": 18887130,
          "hadm_id": 26068131,
          "note_type": "DS",
          "note_seq": 16,
          "charttime": 104467,
          "storetime": 104467.76458333334,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, nose bleed and pancytopenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy by interventional radiology (___)\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed follicular \r\nlymphoma s/p multiple past regimens as noted below, and \r\nultimately an autoSCT with BEAM conditioning in ___.  She \r\nhas comorbid CVID and receives IVIG monthly.  Her\r\npost transplant course was complicated by ___ pneumonitis.  She \r\nunderwent a total right knee replacement on ___.  Her \r\npostoperative course was complicated by foot drop likely due to \r\nirritation of her peroneal nerve from the CPM machine as well as \r\na cellulitis of the right leg following her surgery which was \r\ntreated with a course of Keflex.  This is the same leg as her \r\nprevious DVT and her circulation is poor.  She has had ongoing \r\nissues with sciatica with hip and left lower back pain, and has \r\nhad steroid injections.\r\n\r\nAt the end of ___ of ___, Ms. ___ noted \r\nincreasing swelling of her right leg with shortness of breath.  \r\nShe had been on Xarelto for prior DVT and has an IVC filter in \r\nplace.  Her dose of Xarelto had been decreased to 10 mg daily \r\ngiven her age and chronic history of DVT; she also had a lower \r\nplatelet count for a period of time.  She was seen and admitted \r\nat ___ with ultrasound showing DVT of the right leg \r\nonce again.  Chest CT with no PE or other adenopathy.  Abdomen \r\nand Pelvic CT without adenopathy or concern for lymphoma \r\nrecurrence.  Xarelto was increased back to 20 mg daily. \r\n\r\nINTERVAL HISTORY:  Over the past 1 - 2 months, Ms. ___ was \r\nnoted for a drop in her white count with neutropenia as well as \r\na drop in her platelet count.  This had been noticed in the past \r\nwith the plan to repeat a bone marrow biopsy but her counts \r\nreturned to baseline so bone marrow biopsy was deferred.  She \r\nwas also noted for a nonhealing wound on her left leg after hit \r\non the shin several weeks ago.  She was treated with a course of \r\nKeflex with still poor healing.  Given 2 doses of Neupogen to \r\nsupport counts.  She was seen by the wound care clinic at ___ \r\n___ yesterday and the area was debrided and dressing \r\napplied.\r\n\r\nAt her visit today, Ms. ___ is noted for further drop in \r\nblood counts(platelet count is low but more her baseline).  She \r\nreports not feeling well towards the middle of last week and on \r\n___ morning, she developed increasing left lower back pain, \r\nradiating to the buttock area.  She feels this is related to her \r\nsciatica but is different pain pattern; no radiating pain down \r\nthe leg as she usually has.  Pain increases with changing \r\npositions and with initial ambulation.  She walks with a cane.  \r\nIn addition, she developed increasing nasal congestion on \r\n___ night which seemed to come on suddenly.  No fevers, \r\nchills, night sweats, sore throat.  When blowing her nose, she \r\nnoted increased blood with clots although no frank epistaxis.  \r\n\r\nBecause of the more acute drop in counts, Ms. ___ is being \r\nadmitted for further evaluation for possible bleed given on \r\nanticoagulation vs evolving MDS-->Leukemia.  \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PHYSICAL:\r\n===================\r\nVITALS - 17:27 ___ 98.9 PO ___ 18 97 RA \r\nGeneral: pleasant, no distress, sitting at edge of bed \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: clear bilaterally, good air movement \r\nAbdomen: well-healed surgical incisions, active BS, soft, no\r\nrebound or guarding, no organomegaly \r\nExt: Bilateral ___ swelling, R > L. L shin wound is wrapped and\r\nc/d/I. 2+ radial and DP pulses, 3+ pitting edema bilaterally \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\n  \r\nDISCHARGE PHYSICAL:\r\n===================\r\nVS: TC 98.8 PO 130/80 93 18 98%RA \r\nWeight: 258.7 lbs (___) -> 254.4 lbs (___) \r\nGeneral: pleasant, sitting in chair with tiara on, no distress \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: CTAB, no wheezes, rales or rhonchi \r\nAbdomen: Active BS, soft, no rebound or guarding, no\r\norganomegaly \r\nBack: No tenderness over spinous processes or L iliac crest \r\nExt: Bilateral ___ swelling, R > L. R leg with TEDS stocking on.\r\nL shin wound is stable. 2+ radial and DP pulses \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\nSkin: Erythematous venous stasis changes in bilateral lower\r\nextremities from mid-tibia to medial malleolus \r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n===============\r\n___ 10:45AM BLOOD WBC-2.3* RBC-2.46* Hgb-8.0* Hct-24.4* \r\nMCV-99* MCH-32.5* MCHC-32.8 RDW-21.4* RDWSD-76.8* Plt Ct-93*\r\n___ 10:45AM BLOOD Neuts-29* Bands-0 ___ Monos-26* \r\nEos-0 Baso-0 ___ Metas-2* Myelos-0 Blasts-1* NRBC-4* \r\nAbsNeut-0.67* AbsLymp-0.97* AbsMono-0.60 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 10:45AM BLOOD Hypochr-1+ Anisocy-1+ Poiklo-1+ \r\nMacrocy-1+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-OCCASIONAL \r\nTear Dr-1+\r\n___ 10:45AM BLOOD ___ PTT-39.0* ___\r\n___ 10:45AM BLOOD Ret Aut-1.2 Abs Ret-0.03\r\n___ 10:45AM BLOOD UreaN-15 Creat-0.9 Na-139 K-4.1 Cl-102 \r\nHCO3-26 AnGap-15\r\n___ 10:45AM BLOOD ALT-12 AST-16 LD(LDH)-232 AlkPhos-96 \r\nTotBili-0.3\r\n___ 10:45AM BLOOD Albumin-3.5 Calcium-8.1* Mg-2.2 Iron-49\r\n___ 10:45AM BLOOD ___ Folate->20 Hapto-254* \r\nFerritn-389*\r\n___ 10:45AM BLOOD TSH-1.9\r\n___ 10:45AM BLOOD IgG-728\r\n \r\nOTHER PERTINENT LABS:\r\n=====================\r\n___ 12:32PM URINE RBC-1 WBC-7* Bacteri-FEW Yeast-NONE \r\nEpi-<1 TransE-<1\r\n___ 12:32PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.5 Leuks-TR\r\n___ 12:32PM URINE Color-Straw Appear-Clear Sp ___\r\n \r\nMICROBIOLOGY:\r\n=============\r\n___ 12:32 pm URINE      Source: ___. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   URINE CULTURE (Final ___:    NO GROWTH. \r\n\r\n___ 11:30PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n___ 10:00AM OTHER BODY FLUID STANDARD LEUKEMIA/LYMPHOMA \r\nPANEL (24 MARKERS)-TEST      \r\n___ 10:00AM BONE MARROW IPT-DONE\r\n___ 10:00AM BONE MARROW CEBPA MUTATION ANALYSIS-PND\r\n___ 10:00AM BONE MARROW RAPID HEME PANEL-PND\r\n \r\nIMAGING:\r\n========\r\n___ 3:___BD & PELVIS W/O CONTRAST\r\nIMPRESSION:\r\n1. No evidence of retroperitoneal hematoma or lymphadenopathy.\r\n2. Stable 3.2 cm right adnexal cyst.  Continued attention is \r\nadvised on futurefollow up.\r\n3. Severe degenerative changes of lumbar spine are similar to \r\nbefore.\r\n\r\n___ 3:___HEST W/O CONTRAST\r\nIMPRESSION: \r\nNo evidence of acute intrathoracic abnormality.\r\nNo evidence of intrathoracic lymphoma.\r\nDilated main pulmonary artery, concerning for pulmonary \r\nhypertension, unchanged since ___.\r\n\r\n___ 3:38 ___\r\nCT HEAD W/O CONTRAST\r\nIMPRESSION: \r\n1. Of note, significant streak artifact from the right \r\nsupraclinoid vascular embolization coil limits evaluation of \r\nadjacent structures.  Given these limitations, there is no \r\nevidence of acute major territorial infarction, hemorrhage, or \r\nfracture.\r\n2. Paranasal sinus disease, as described above.\r\n\r\n___ 3:28 ___\r\nCT SINUS/MANDIBLE/MAXILLOFACIA\r\nIMPRESSION: \r\nMild mucosal thickening in both maxillary sinuses and ethmoid \r\nair cells, similar to recent CT head.  No evidence of bony \r\nerosion.\r\n \r\nPATHOLOGY: RESULT PENDING AT DISCHARGE\r\n==========\r\n\r\nDISCHARGE LABS:\r\n===============\r\n___ 12:00AM BLOOD WBC-2.5* RBC-2.29* Hgb-7.2* Hct-22.7* \r\nMCV-99* MCH-31.4 MCHC-31.7* RDW-20.6* RDWSD-75.0* Plt Ct-85*\r\n___ 12:00AM BLOOD Neuts-11* Bands-0 Lymphs-55* Monos-26* \r\nEos-0 Baso-0 ___ Metas-1* Myelos-4* Promyel-2* Blasts-1* \r\nNRBC-6* AbsNeut-0.28* AbsLymp-1.38 AbsMono-0.65 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-2+ Poiklo-1+ \r\nMacrocy-2+ Microcy-1+ Polychr-NORMAL Ovalocy-1+ \r\nSchisto-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 12:00AM BLOOD Plt Smr-LOW Plt Ct-85*\r\n___ 12:00AM BLOOD Glucose-110* UreaN-18 Creat-0.8 Na-142 \r\nK-3.6 Cl-101 HCO3-23 AnGap-22*\r\n___ 12:00AM BLOOD ALT-9 AST-11 LD(LDH)-238 AlkPhos-89 \r\nTotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.5 Mg-2.2\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\nDLBCL s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, concerning for RP bleed and \r\ndisease progression.  \r\n\r\nACUTE ISSUES:\r\n=============\r\n#Pancytopenia/Lymphoma disease status: Pancytopenic on \r\nadmission. Counts remained stable while in house. BM Bx \r\nperformed under fluoroscopy on ___ showed was concerning for \r\nMDS, final results are pending at discharge. Treatment plan \r\ndeveloped with Dr. ___ likely involve administration \r\nof dacogen but this will be further delineated outpatient. \r\nHemoglobin 7.1 on admission and patient received 1U prbcs prior \r\nto discharge.  \r\n\r\n#Infection/URI: Presented w/ congestion and recent blood nasal \r\nexudates. On ___, was febrile. Respiratory viral, Blood, and \r\nUrine cx were obtained; CXR and CT sinus were evaluated. Vanc \r\nand cefepime were started. No infectious pathogen was identified \r\nand the patient had no further fevers. On ___, vancomycin was \r\ndiscontinued. On ___, cefepime was discontinued. She received \r\nsymptomatic treatment with nasal saline and oxymetazoline. She \r\nwas discharged with levaquin 500mg q24hrs (to complete a 7D \r\ncourse on ___ \r\n\r\n#LLE Wound: Wearing Unna boot on presentation which had been \r\nplaced 5d PTA. Seen by wound c/s service. Daily dressing changes \r\nwhile in house. Lesion stable. Rash of chronic venous stasis, \r\nstable. Discharged with instructions to follow-up for usual care \r\nat ___.\r\n\r\n#Anti-coagulation/DVT: Concern for RP Bleed on admission, ruled \r\nout by CT. Rivaroxaban held and patient treated with enoxaparin. \r\nThe dose was held or modified at different times because of \r\nplanned procedures. The patient did not have any acute bleeding \r\nevents apart from bloody nasal exudate with nose blowing. On \r\ndischarge, patient was restarted on home dose of Rivaroxaban \r\n(20mg PO daily). Platelets 85K at discharge \r\n\r\n#Back Pain: Improved with rest and oxycodone while patient was \r\nin hospital. Otherwise, continued gabapentin 900mg TID at \r\ndischarge. No acute pain episodes prior to leaving.\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Pulm HTN\r\n#History of BCNU pneumonitis- Followed by Dr. ___. No active \r\nsymptoms. PRN inhalers ordered\r\n\r\n#H/o Migraine: R-sided pain, usually early morning onset, \r\nassociated with photophobia. Typically reaches peak intensity \r\nafter 4 hours and resolves with one or two episodes of vomiting. \r\nWould take indomethacin at home for this, but it is not \r\nappropriate given thrombocytopenia. No acute episodes prior to \r\ndischarge, continue to monitor closely outpatient \r\n\r\n#hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm, cont gabapentin  \r\n\r\n#GERD- PPI  \r\n\r\n#Depression- venlafaxine \r\n\r\nDISPO: patient discharged on ___. RTC on ___ on ___ with \r\nDr. ___\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Gabapentin 900 mg PO TID \r\n2. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n3. Rivaroxaban 20 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO BID \r\n8. Venlafaxine 25 mg PO BID \r\n9. albuterol sulfate 90 mcg/actuation inhalation Q4H:PRN \r\n10. Cyanocobalamin 1000 mcg PO QHS \r\n11. FoLIC Acid 3.2 mg PO DAILY \r\n12. Ascorbic Acid ___ mg PO BID \r\n13. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n\r\n \r\nDischarge Medications:\r\n1.  Levofloxacin 500 mg PO Q24H Duration: 6 Days \r\nTake daily from ___ to ___.  Potassium Chloride 10 mEq PO DAILY  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  Ascorbic Acid ___ mg PO BID  \r\n6.  Cyanocobalamin 1000 mcg PO QHS  \r\n7.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n8.  FoLIC Acid 3.2 mg PO DAILY  \r\n9.  Furosemide 20 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Rivaroxaban 20 mg PO DAILY  \r\n14.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\n==================\r\nMyelodisplastic Syndrome\r\nDiffuse large B cell lymphoma\r\nFebrile neutropenia\r\nRhinosinusitis\r\n\r\nSecondary Diagnoses:\r\n====================\r\nHistory of deep venous thromboembolism (DVT) on anticoagulation\r\nCommon variable immunodeficiency (CVID)\r\nMigraine\r\nChronic non-healing wound\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ came to ___ because ___ had \r\nback pain and low blood counts.\r\n\r\nWhat was done for me in the hospital?\r\n- CT scans of your torso and sinuses looking for bleeding and \r\ninfection. Neither infection nor bleeding was found.\r\n- Bone marrow biopsy to assess cancer disease status was \r\nconcerning for Myelodisplastic syndrome\r\n- Antibiotics for a fever.\r\n- Supportive care for your congestion.\r\n\r\nWhat should I do now that I am leaving the hospital?\r\n- Attend your scheduled follow-up appointments, listed below.\r\n- Take your medications as prescribed.\r\n- Return the to hospital if ___ have any concerning symptoms \r\n(some key symptoms are listed below).\r\n\r\nIt was a pleasure participating in your care. Wishing ___ all \r\nthe best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-16:4",
      "text": "Family History:\nbrother- lymphoma Physical ___:\nADMISSION PHYSICAL:\n===================\nVITALS - 17:27 ___ 98.9 PO ___ 18 97 RA \nGeneral: pleasant, no distress, sitting at edge of bed \nHEENT: anicteric sclerae, clear oropharynx without lesions \nNeck: no adenopathy \nCV: RRR, normal S1, S2, no murmurs or rubs \nLungs: clear bilaterally, good air movement \nAbdomen: well-healed surgical incisions, active BS, soft, no\nrebound or guarding, no organomegaly \nExt: Bilateral ___ swelling, R > L. L shin wound is wrapped and\nc/d/I. 2+ radial and DP pulses, 3+ pitting edema bilaterally \nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\npupil, strength and sensation grossly intact, ambulates with \ncane\n  \nDISCHARGE PHYSICAL:\n===================\nVS: TC 98.8 PO 130/80 93 18 98%RA \nWeight: 258.7 lbs (___) -> 254.4 lbs (___) \nGeneral: pleasant, sitting in chair with tiara on, no distress \nHEENT: anicteric sclerae, clear oropharynx without lesions \nNeck: no adenopathy \nCV: RRR, normal S1, S2, no murmurs or rubs \nLungs: CTAB, no wheezes, rales or rhonchi \nAbdomen: Active BS, soft, no rebound or guarding, no\norganomegaly \nBack: No tenderness over spinous processes or L iliac crest \nExt: Bilateral ___ swelling, R > L. R leg with TEDS stocking on. L shin wound is stable. 2+ radial and DP pulses \nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\npupil, strength and sensation grossly intact, ambulates with \ncane\nSkin: Erythematous venous stasis changes in bilateral lower\nextremities from mid-tibia to medial malleolus \n \nPertinent Results:\nADMISSION LABS:\n===============\n___ 10:45AM BLOOD WBC-2.3* RBC-2.46* Hgb-8.0* Hct-24.4* \nMCV-99* MCH-32.5* MCHC-32.8 RDW-21.4* RDWSD-76.8* Plt Ct-93*\n___ 10:45AM BLOOD Neuts-29* Bands-0 ___ Monos-26* \nEos-0 Baso-0 ___ Metas-2* Myelos-0 Blasts-1* NRBC-4* \nAbsNeut-0.67* AbsLymp-0.97* AbsMono-0.60 AbsEos-0.00* \nAbsBaso-0.00*\n___ 10:45AM BLOOD Hypochr-1+ Anisocy-1+ Poiklo-1+ \nMacrocy-1+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-OCCASIONAL \nTear Dr-1+\n___ 10:45AM BLOOD ___ PTT-39.0* ___\n___ 10:45AM BLOOD Ret Aut-1.2 Abs Ret-0.03\n___ 10:45AM BLOOD UreaN-15 Creat-0.9 Na-139 K-4.1 Cl-102 \nHCO3-26 AnGap-15\n___ 10:45AM BLOOD ALT-12 AST-16 LD(LDH)-232 AlkPhos-96 \nTotBili-0.3\n___ 10:45AM BLOOD Albumin-3.5 Calcium-8.1* Mg-2.2 Iron-49\n___ 10:45AM BLOOD ___ Folate->20 Hapto-254* \nFerritn-389*\n___ 10:45AM BLOOD TSH-1.9\n___ 10:45AM BLOOD IgG-728\n \nOTHER PERTINENT LABS:\n=====================\n___ 12:32PM URINE RBC-1 WBC-7* Bacteri-FEW Yeast-NONE \nEpi-<1 TransE-<1\n___ 12:32PM URINE Blood-NEG Nitrite-NEG Protein-30 \nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.5 Leuks-TR\n___ 12:32PM URINE Color-Straw Appear-Clear Sp ___\n \nMICROBIOLOGY:\n=============\n___ 12:32 pm URINE      Source: ___. **FINAL REPORT ___ **FINAL REPORT ___ URINE CULTURE (Final ___:    NO GROWTH. ___ 11:30PM OTHER BODY FLUID FluAPCR-NEGATIVE \nFluBPCR-NEGATIVE\n___ 10:00AM OTHER BODY FLUID STANDARD LEUKEMIA/LYMPHOMA \nPANEL (24 MARKERS)-TEST      \n___ 10:00AM BONE MARROW IPT-DONE\n___ 10:00AM BONE MARROW CEBPA MUTATION ANALYSIS-PND\n___ 10:00AM BONE MARROW RAPID HEME PANEL-PND IMAGING:\n========\n___ 3:___BD & PELVIS W/O CONTRAST IMPRESSION:\n1. No evidence of retroperitoneal hematoma or lymphadenopathy. 2. Stable 3.2 cm right adnexal cyst. Continued attention is \nadvised on futurefollow up. 3. Severe degenerative changes of lumbar spine are similar to \nbefore. ___ 3:___HEST W/O CONTRAST IMPRESSION: \nNo evidence of acute intrathoracic abnormality. No evidence of intrathoracic lymphoma. Dilated main pulmonary artery, concerning for pulmonary \nhypertension, unchanged since ___. ___ 3:38 ___\nCT HEAD W/O CONTRAST IMPRESSION: \n1. Of note, significant streak artifact from the right \nsupraclinoid vascular embolization coil limits evaluation of \nadjacent structures. Given these limitations, there is no \nevidence of acute major territorial infarction, hemorrhage, or \nfracture. 2. Paranasal sinus disease, as described above. ___ 3:28 ___\nCT SINUS/MANDIBLE/MAXILLOFACIA",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-16",
        "chart_time": "104467",
        "section": "General",
        "position": 4,
        "tokenCount": 1002,
        "note_metadata": {
          "note_id": "18887130-DS-16",
          "subject_id": 18887130,
          "hadm_id": 26068131,
          "note_type": "DS",
          "note_seq": 16,
          "charttime": 104467,
          "storetime": 104467.76458333334,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, nose bleed and pancytopenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy by interventional radiology (___)\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed follicular \r\nlymphoma s/p multiple past regimens as noted below, and \r\nultimately an autoSCT with BEAM conditioning in ___.  She \r\nhas comorbid CVID and receives IVIG monthly.  Her\r\npost transplant course was complicated by ___ pneumonitis.  She \r\nunderwent a total right knee replacement on ___.  Her \r\npostoperative course was complicated by foot drop likely due to \r\nirritation of her peroneal nerve from the CPM machine as well as \r\na cellulitis of the right leg following her surgery which was \r\ntreated with a course of Keflex.  This is the same leg as her \r\nprevious DVT and her circulation is poor.  She has had ongoing \r\nissues with sciatica with hip and left lower back pain, and has \r\nhad steroid injections.\r\n\r\nAt the end of ___ of ___, Ms. ___ noted \r\nincreasing swelling of her right leg with shortness of breath.  \r\nShe had been on Xarelto for prior DVT and has an IVC filter in \r\nplace.  Her dose of Xarelto had been decreased to 10 mg daily \r\ngiven her age and chronic history of DVT; she also had a lower \r\nplatelet count for a period of time.  She was seen and admitted \r\nat ___ with ultrasound showing DVT of the right leg \r\nonce again.  Chest CT with no PE or other adenopathy.  Abdomen \r\nand Pelvic CT without adenopathy or concern for lymphoma \r\nrecurrence.  Xarelto was increased back to 20 mg daily. \r\n\r\nINTERVAL HISTORY:  Over the past 1 - 2 months, Ms. ___ was \r\nnoted for a drop in her white count with neutropenia as well as \r\na drop in her platelet count.  This had been noticed in the past \r\nwith the plan to repeat a bone marrow biopsy but her counts \r\nreturned to baseline so bone marrow biopsy was deferred.  She \r\nwas also noted for a nonhealing wound on her left leg after hit \r\non the shin several weeks ago.  She was treated with a course of \r\nKeflex with still poor healing.  Given 2 doses of Neupogen to \r\nsupport counts.  She was seen by the wound care clinic at ___ \r\n___ yesterday and the area was debrided and dressing \r\napplied.\r\n\r\nAt her visit today, Ms. ___ is noted for further drop in \r\nblood counts(platelet count is low but more her baseline).  She \r\nreports not feeling well towards the middle of last week and on \r\n___ morning, she developed increasing left lower back pain, \r\nradiating to the buttock area.  She feels this is related to her \r\nsciatica but is different pain pattern; no radiating pain down \r\nthe leg as she usually has.  Pain increases with changing \r\npositions and with initial ambulation.  She walks with a cane.  \r\nIn addition, she developed increasing nasal congestion on \r\n___ night which seemed to come on suddenly.  No fevers, \r\nchills, night sweats, sore throat.  When blowing her nose, she \r\nnoted increased blood with clots although no frank epistaxis.  \r\n\r\nBecause of the more acute drop in counts, Ms. ___ is being \r\nadmitted for further evaluation for possible bleed given on \r\nanticoagulation vs evolving MDS-->Leukemia.  \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PHYSICAL:\r\n===================\r\nVITALS - 17:27 ___ 98.9 PO ___ 18 97 RA \r\nGeneral: pleasant, no distress, sitting at edge of bed \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: clear bilaterally, good air movement \r\nAbdomen: well-healed surgical incisions, active BS, soft, no\r\nrebound or guarding, no organomegaly \r\nExt: Bilateral ___ swelling, R > L. L shin wound is wrapped and\r\nc/d/I. 2+ radial and DP pulses, 3+ pitting edema bilaterally \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\n  \r\nDISCHARGE PHYSICAL:\r\n===================\r\nVS: TC 98.8 PO 130/80 93 18 98%RA \r\nWeight: 258.7 lbs (___) -> 254.4 lbs (___) \r\nGeneral: pleasant, sitting in chair with tiara on, no distress \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: CTAB, no wheezes, rales or rhonchi \r\nAbdomen: Active BS, soft, no rebound or guarding, no\r\norganomegaly \r\nBack: No tenderness over spinous processes or L iliac crest \r\nExt: Bilateral ___ swelling, R > L. R leg with TEDS stocking on.\r\nL shin wound is stable. 2+ radial and DP pulses \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\nSkin: Erythematous venous stasis changes in bilateral lower\r\nextremities from mid-tibia to medial malleolus \r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n===============\r\n___ 10:45AM BLOOD WBC-2.3* RBC-2.46* Hgb-8.0* Hct-24.4* \r\nMCV-99* MCH-32.5* MCHC-32.8 RDW-21.4* RDWSD-76.8* Plt Ct-93*\r\n___ 10:45AM BLOOD Neuts-29* Bands-0 ___ Monos-26* \r\nEos-0 Baso-0 ___ Metas-2* Myelos-0 Blasts-1* NRBC-4* \r\nAbsNeut-0.67* AbsLymp-0.97* AbsMono-0.60 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 10:45AM BLOOD Hypochr-1+ Anisocy-1+ Poiklo-1+ \r\nMacrocy-1+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-OCCASIONAL \r\nTear Dr-1+\r\n___ 10:45AM BLOOD ___ PTT-39.0* ___\r\n___ 10:45AM BLOOD Ret Aut-1.2 Abs Ret-0.03\r\n___ 10:45AM BLOOD UreaN-15 Creat-0.9 Na-139 K-4.1 Cl-102 \r\nHCO3-26 AnGap-15\r\n___ 10:45AM BLOOD ALT-12 AST-16 LD(LDH)-232 AlkPhos-96 \r\nTotBili-0.3\r\n___ 10:45AM BLOOD Albumin-3.5 Calcium-8.1* Mg-2.2 Iron-49\r\n___ 10:45AM BLOOD ___ Folate->20 Hapto-254* \r\nFerritn-389*\r\n___ 10:45AM BLOOD TSH-1.9\r\n___ 10:45AM BLOOD IgG-728\r\n \r\nOTHER PERTINENT LABS:\r\n=====================\r\n___ 12:32PM URINE RBC-1 WBC-7* Bacteri-FEW Yeast-NONE \r\nEpi-<1 TransE-<1\r\n___ 12:32PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.5 Leuks-TR\r\n___ 12:32PM URINE Color-Straw Appear-Clear Sp ___\r\n \r\nMICROBIOLOGY:\r\n=============\r\n___ 12:32 pm URINE      Source: ___. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   URINE CULTURE (Final ___:    NO GROWTH. \r\n\r\n___ 11:30PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n___ 10:00AM OTHER BODY FLUID STANDARD LEUKEMIA/LYMPHOMA \r\nPANEL (24 MARKERS)-TEST      \r\n___ 10:00AM BONE MARROW IPT-DONE\r\n___ 10:00AM BONE MARROW CEBPA MUTATION ANALYSIS-PND\r\n___ 10:00AM BONE MARROW RAPID HEME PANEL-PND\r\n \r\nIMAGING:\r\n========\r\n___ 3:___BD & PELVIS W/O CONTRAST\r\nIMPRESSION:\r\n1. No evidence of retroperitoneal hematoma or lymphadenopathy.\r\n2. Stable 3.2 cm right adnexal cyst.  Continued attention is \r\nadvised on futurefollow up.\r\n3. Severe degenerative changes of lumbar spine are similar to \r\nbefore.\r\n\r\n___ 3:___HEST W/O CONTRAST\r\nIMPRESSION: \r\nNo evidence of acute intrathoracic abnormality.\r\nNo evidence of intrathoracic lymphoma.\r\nDilated main pulmonary artery, concerning for pulmonary \r\nhypertension, unchanged since ___.\r\n\r\n___ 3:38 ___\r\nCT HEAD W/O CONTRAST\r\nIMPRESSION: \r\n1. Of note, significant streak artifact from the right \r\nsupraclinoid vascular embolization coil limits evaluation of \r\nadjacent structures.  Given these limitations, there is no \r\nevidence of acute major territorial infarction, hemorrhage, or \r\nfracture.\r\n2. Paranasal sinus disease, as described above.\r\n\r\n___ 3:28 ___\r\nCT SINUS/MANDIBLE/MAXILLOFACIA\r\nIMPRESSION: \r\nMild mucosal thickening in both maxillary sinuses and ethmoid \r\nair cells, similar to recent CT head.  No evidence of bony \r\nerosion.\r\n \r\nPATHOLOGY: RESULT PENDING AT DISCHARGE\r\n==========\r\n\r\nDISCHARGE LABS:\r\n===============\r\n___ 12:00AM BLOOD WBC-2.5* RBC-2.29* Hgb-7.2* Hct-22.7* \r\nMCV-99* MCH-31.4 MCHC-31.7* RDW-20.6* RDWSD-75.0* Plt Ct-85*\r\n___ 12:00AM BLOOD Neuts-11* Bands-0 Lymphs-55* Monos-26* \r\nEos-0 Baso-0 ___ Metas-1* Myelos-4* Promyel-2* Blasts-1* \r\nNRBC-6* AbsNeut-0.28* AbsLymp-1.38 AbsMono-0.65 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-2+ Poiklo-1+ \r\nMacrocy-2+ Microcy-1+ Polychr-NORMAL Ovalocy-1+ \r\nSchisto-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 12:00AM BLOOD Plt Smr-LOW Plt Ct-85*\r\n___ 12:00AM BLOOD Glucose-110* UreaN-18 Creat-0.8 Na-142 \r\nK-3.6 Cl-101 HCO3-23 AnGap-22*\r\n___ 12:00AM BLOOD ALT-9 AST-11 LD(LDH)-238 AlkPhos-89 \r\nTotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.5 Mg-2.2\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\nDLBCL s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, concerning for RP bleed and \r\ndisease progression.  \r\n\r\nACUTE ISSUES:\r\n=============\r\n#Pancytopenia/Lymphoma disease status: Pancytopenic on \r\nadmission. Counts remained stable while in house. BM Bx \r\nperformed under fluoroscopy on ___ showed was concerning for \r\nMDS, final results are pending at discharge. Treatment plan \r\ndeveloped with Dr. ___ likely involve administration \r\nof dacogen but this will be further delineated outpatient. \r\nHemoglobin 7.1 on admission and patient received 1U prbcs prior \r\nto discharge.  \r\n\r\n#Infection/URI: Presented w/ congestion and recent blood nasal \r\nexudates. On ___, was febrile. Respiratory viral, Blood, and \r\nUrine cx were obtained; CXR and CT sinus were evaluated. Vanc \r\nand cefepime were started. No infectious pathogen was identified \r\nand the patient had no further fevers. On ___, vancomycin was \r\ndiscontinued. On ___, cefepime was discontinued. She received \r\nsymptomatic treatment with nasal saline and oxymetazoline. She \r\nwas discharged with levaquin 500mg q24hrs (to complete a 7D \r\ncourse on ___ \r\n\r\n#LLE Wound: Wearing Unna boot on presentation which had been \r\nplaced 5d PTA. Seen by wound c/s service. Daily dressing changes \r\nwhile in house. Lesion stable. Rash of chronic venous stasis, \r\nstable. Discharged with instructions to follow-up for usual care \r\nat ___.\r\n\r\n#Anti-coagulation/DVT: Concern for RP Bleed on admission, ruled \r\nout by CT. Rivaroxaban held and patient treated with enoxaparin. \r\nThe dose was held or modified at different times because of \r\nplanned procedures. The patient did not have any acute bleeding \r\nevents apart from bloody nasal exudate with nose blowing. On \r\ndischarge, patient was restarted on home dose of Rivaroxaban \r\n(20mg PO daily). Platelets 85K at discharge \r\n\r\n#Back Pain: Improved with rest and oxycodone while patient was \r\nin hospital. Otherwise, continued gabapentin 900mg TID at \r\ndischarge. No acute pain episodes prior to leaving.\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Pulm HTN\r\n#History of BCNU pneumonitis- Followed by Dr. ___. No active \r\nsymptoms. PRN inhalers ordered\r\n\r\n#H/o Migraine: R-sided pain, usually early morning onset, \r\nassociated with photophobia. Typically reaches peak intensity \r\nafter 4 hours and resolves with one or two episodes of vomiting. \r\nWould take indomethacin at home for this, but it is not \r\nappropriate given thrombocytopenia. No acute episodes prior to \r\ndischarge, continue to monitor closely outpatient \r\n\r\n#hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm, cont gabapentin  \r\n\r\n#GERD- PPI  \r\n\r\n#Depression- venlafaxine \r\n\r\nDISPO: patient discharged on ___. RTC on ___ on ___ with \r\nDr. ___\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Gabapentin 900 mg PO TID \r\n2. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n3. Rivaroxaban 20 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO BID \r\n8. Venlafaxine 25 mg PO BID \r\n9. albuterol sulfate 90 mcg/actuation inhalation Q4H:PRN \r\n10. Cyanocobalamin 1000 mcg PO QHS \r\n11. FoLIC Acid 3.2 mg PO DAILY \r\n12. Ascorbic Acid ___ mg PO BID \r\n13. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n\r\n \r\nDischarge Medications:\r\n1.  Levofloxacin 500 mg PO Q24H Duration: 6 Days \r\nTake daily from ___ to ___.  Potassium Chloride 10 mEq PO DAILY  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  Ascorbic Acid ___ mg PO BID  \r\n6.  Cyanocobalamin 1000 mcg PO QHS  \r\n7.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n8.  FoLIC Acid 3.2 mg PO DAILY  \r\n9.  Furosemide 20 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Rivaroxaban 20 mg PO DAILY  \r\n14.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\n==================\r\nMyelodisplastic Syndrome\r\nDiffuse large B cell lymphoma\r\nFebrile neutropenia\r\nRhinosinusitis\r\n\r\nSecondary Diagnoses:\r\n====================\r\nHistory of deep venous thromboembolism (DVT) on anticoagulation\r\nCommon variable immunodeficiency (CVID)\r\nMigraine\r\nChronic non-healing wound\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ came to ___ because ___ had \r\nback pain and low blood counts.\r\n\r\nWhat was done for me in the hospital?\r\n- CT scans of your torso and sinuses looking for bleeding and \r\ninfection. Neither infection nor bleeding was found.\r\n- Bone marrow biopsy to assess cancer disease status was \r\nconcerning for Myelodisplastic syndrome\r\n- Antibiotics for a fever.\r\n- Supportive care for your congestion.\r\n\r\nWhat should I do now that I am leaving the hospital?\r\n- Attend your scheduled follow-up appointments, listed below.\r\n- Take your medications as prescribed.\r\n- Return the to hospital if ___ have any concerning symptoms \r\n(some key symptoms are listed below).\r\n\r\nIt was a pleasure participating in your care. Wishing ___ all \r\nthe best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-16:5",
      "text": "IMPRESSION: \nMild mucosal thickening in both maxillary sinuses and ethmoid \nair cells, similar to recent CT head. No evidence of bony \nerosion. PATHOLOGY: RESULT PENDING AT DISCHARGE\n========== DISCHARGE LABS:\n===============\n___ 12:00AM BLOOD WBC-2.5* RBC-2.29* Hgb-7.2* Hct-22.7* \nMCV-99* MCH-31.4 MCHC-31.7* RDW-20.6* RDWSD-75.0* Plt Ct-85*\n___ 12:00AM BLOOD Neuts-11* Bands-0 Lymphs-55* Monos-26* \nEos-0 Baso-0 ___ Metas-1* Myelos-4* Promyel-2* Blasts-1* \nNRBC-6* AbsNeut-0.28* AbsLymp-1.38 AbsMono-0.65 AbsEos-0.00* \nAbsBaso-0.00*\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-2+ Poiklo-1+ \nMacrocy-2+ Microcy-1+ Polychr-NORMAL Ovalocy-1+ \nSchisto-OCCASIONAL Tear Dr-OCCASIONAL\n___ 12:00AM BLOOD Plt Smr-LOW Plt Ct-85*\n___ 12:00AM BLOOD Glucose-110* UreaN-18 Creat-0.8 Na-142 \nK-3.6 Cl-101 HCO3-23 AnGap-22*\n___ 12:00AM BLOOD ALT-9 AST-11 LD(LDH)-238 AlkPhos-89 \nTotBili-0.2\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.5 Mg-2.2 Brief Hospital Course:\nMrs. ___ is a ___ year old female with history of transformed \nDLBCL s/p a curative attempt with an autoSCT with BEAM \nconditioning in ___ ___s IFRT with course complicated \nby BCNU pneumonitis as well as persistent norovirus p/w acute \nLBP, epistaxis, pancytopenia, concerning for RP bleed and \ndisease progression.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-16",
        "chart_time": "104467",
        "section": "General",
        "position": 5,
        "tokenCount": 319,
        "note_metadata": {
          "note_id": "18887130-DS-16",
          "subject_id": 18887130,
          "hadm_id": 26068131,
          "note_type": "DS",
          "note_seq": 16,
          "charttime": 104467,
          "storetime": 104467.76458333334,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, nose bleed and pancytopenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy by interventional radiology (___)\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed follicular \r\nlymphoma s/p multiple past regimens as noted below, and \r\nultimately an autoSCT with BEAM conditioning in ___.  She \r\nhas comorbid CVID and receives IVIG monthly.  Her\r\npost transplant course was complicated by ___ pneumonitis.  She \r\nunderwent a total right knee replacement on ___.  Her \r\npostoperative course was complicated by foot drop likely due to \r\nirritation of her peroneal nerve from the CPM machine as well as \r\na cellulitis of the right leg following her surgery which was \r\ntreated with a course of Keflex.  This is the same leg as her \r\nprevious DVT and her circulation is poor.  She has had ongoing \r\nissues with sciatica with hip and left lower back pain, and has \r\nhad steroid injections.\r\n\r\nAt the end of ___ of ___, Ms. ___ noted \r\nincreasing swelling of her right leg with shortness of breath.  \r\nShe had been on Xarelto for prior DVT and has an IVC filter in \r\nplace.  Her dose of Xarelto had been decreased to 10 mg daily \r\ngiven her age and chronic history of DVT; she also had a lower \r\nplatelet count for a period of time.  She was seen and admitted \r\nat ___ with ultrasound showing DVT of the right leg \r\nonce again.  Chest CT with no PE or other adenopathy.  Abdomen \r\nand Pelvic CT without adenopathy or concern for lymphoma \r\nrecurrence.  Xarelto was increased back to 20 mg daily. \r\n\r\nINTERVAL HISTORY:  Over the past 1 - 2 months, Ms. ___ was \r\nnoted for a drop in her white count with neutropenia as well as \r\na drop in her platelet count.  This had been noticed in the past \r\nwith the plan to repeat a bone marrow biopsy but her counts \r\nreturned to baseline so bone marrow biopsy was deferred.  She \r\nwas also noted for a nonhealing wound on her left leg after hit \r\non the shin several weeks ago.  She was treated with a course of \r\nKeflex with still poor healing.  Given 2 doses of Neupogen to \r\nsupport counts.  She was seen by the wound care clinic at ___ \r\n___ yesterday and the area was debrided and dressing \r\napplied.\r\n\r\nAt her visit today, Ms. ___ is noted for further drop in \r\nblood counts(platelet count is low but more her baseline).  She \r\nreports not feeling well towards the middle of last week and on \r\n___ morning, she developed increasing left lower back pain, \r\nradiating to the buttock area.  She feels this is related to her \r\nsciatica but is different pain pattern; no radiating pain down \r\nthe leg as she usually has.  Pain increases with changing \r\npositions and with initial ambulation.  She walks with a cane.  \r\nIn addition, she developed increasing nasal congestion on \r\n___ night which seemed to come on suddenly.  No fevers, \r\nchills, night sweats, sore throat.  When blowing her nose, she \r\nnoted increased blood with clots although no frank epistaxis.  \r\n\r\nBecause of the more acute drop in counts, Ms. ___ is being \r\nadmitted for further evaluation for possible bleed given on \r\nanticoagulation vs evolving MDS-->Leukemia.  \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PHYSICAL:\r\n===================\r\nVITALS - 17:27 ___ 98.9 PO ___ 18 97 RA \r\nGeneral: pleasant, no distress, sitting at edge of bed \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: clear bilaterally, good air movement \r\nAbdomen: well-healed surgical incisions, active BS, soft, no\r\nrebound or guarding, no organomegaly \r\nExt: Bilateral ___ swelling, R > L. L shin wound is wrapped and\r\nc/d/I. 2+ radial and DP pulses, 3+ pitting edema bilaterally \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\n  \r\nDISCHARGE PHYSICAL:\r\n===================\r\nVS: TC 98.8 PO 130/80 93 18 98%RA \r\nWeight: 258.7 lbs (___) -> 254.4 lbs (___) \r\nGeneral: pleasant, sitting in chair with tiara on, no distress \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: CTAB, no wheezes, rales or rhonchi \r\nAbdomen: Active BS, soft, no rebound or guarding, no\r\norganomegaly \r\nBack: No tenderness over spinous processes or L iliac crest \r\nExt: Bilateral ___ swelling, R > L. R leg with TEDS stocking on.\r\nL shin wound is stable. 2+ radial and DP pulses \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\nSkin: Erythematous venous stasis changes in bilateral lower\r\nextremities from mid-tibia to medial malleolus \r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n===============\r\n___ 10:45AM BLOOD WBC-2.3* RBC-2.46* Hgb-8.0* Hct-24.4* \r\nMCV-99* MCH-32.5* MCHC-32.8 RDW-21.4* RDWSD-76.8* Plt Ct-93*\r\n___ 10:45AM BLOOD Neuts-29* Bands-0 ___ Monos-26* \r\nEos-0 Baso-0 ___ Metas-2* Myelos-0 Blasts-1* NRBC-4* \r\nAbsNeut-0.67* AbsLymp-0.97* AbsMono-0.60 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 10:45AM BLOOD Hypochr-1+ Anisocy-1+ Poiklo-1+ \r\nMacrocy-1+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-OCCASIONAL \r\nTear Dr-1+\r\n___ 10:45AM BLOOD ___ PTT-39.0* ___\r\n___ 10:45AM BLOOD Ret Aut-1.2 Abs Ret-0.03\r\n___ 10:45AM BLOOD UreaN-15 Creat-0.9 Na-139 K-4.1 Cl-102 \r\nHCO3-26 AnGap-15\r\n___ 10:45AM BLOOD ALT-12 AST-16 LD(LDH)-232 AlkPhos-96 \r\nTotBili-0.3\r\n___ 10:45AM BLOOD Albumin-3.5 Calcium-8.1* Mg-2.2 Iron-49\r\n___ 10:45AM BLOOD ___ Folate->20 Hapto-254* \r\nFerritn-389*\r\n___ 10:45AM BLOOD TSH-1.9\r\n___ 10:45AM BLOOD IgG-728\r\n \r\nOTHER PERTINENT LABS:\r\n=====================\r\n___ 12:32PM URINE RBC-1 WBC-7* Bacteri-FEW Yeast-NONE \r\nEpi-<1 TransE-<1\r\n___ 12:32PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.5 Leuks-TR\r\n___ 12:32PM URINE Color-Straw Appear-Clear Sp ___\r\n \r\nMICROBIOLOGY:\r\n=============\r\n___ 12:32 pm URINE      Source: ___. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   URINE CULTURE (Final ___:    NO GROWTH. \r\n\r\n___ 11:30PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n___ 10:00AM OTHER BODY FLUID STANDARD LEUKEMIA/LYMPHOMA \r\nPANEL (24 MARKERS)-TEST      \r\n___ 10:00AM BONE MARROW IPT-DONE\r\n___ 10:00AM BONE MARROW CEBPA MUTATION ANALYSIS-PND\r\n___ 10:00AM BONE MARROW RAPID HEME PANEL-PND\r\n \r\nIMAGING:\r\n========\r\n___ 3:___BD & PELVIS W/O CONTRAST\r\nIMPRESSION:\r\n1. No evidence of retroperitoneal hematoma or lymphadenopathy.\r\n2. Stable 3.2 cm right adnexal cyst.  Continued attention is \r\nadvised on futurefollow up.\r\n3. Severe degenerative changes of lumbar spine are similar to \r\nbefore.\r\n\r\n___ 3:___HEST W/O CONTRAST\r\nIMPRESSION: \r\nNo evidence of acute intrathoracic abnormality.\r\nNo evidence of intrathoracic lymphoma.\r\nDilated main pulmonary artery, concerning for pulmonary \r\nhypertension, unchanged since ___.\r\n\r\n___ 3:38 ___\r\nCT HEAD W/O CONTRAST\r\nIMPRESSION: \r\n1. Of note, significant streak artifact from the right \r\nsupraclinoid vascular embolization coil limits evaluation of \r\nadjacent structures.  Given these limitations, there is no \r\nevidence of acute major territorial infarction, hemorrhage, or \r\nfracture.\r\n2. Paranasal sinus disease, as described above.\r\n\r\n___ 3:28 ___\r\nCT SINUS/MANDIBLE/MAXILLOFACIA\r\nIMPRESSION: \r\nMild mucosal thickening in both maxillary sinuses and ethmoid \r\nair cells, similar to recent CT head.  No evidence of bony \r\nerosion.\r\n \r\nPATHOLOGY: RESULT PENDING AT DISCHARGE\r\n==========\r\n\r\nDISCHARGE LABS:\r\n===============\r\n___ 12:00AM BLOOD WBC-2.5* RBC-2.29* Hgb-7.2* Hct-22.7* \r\nMCV-99* MCH-31.4 MCHC-31.7* RDW-20.6* RDWSD-75.0* Plt Ct-85*\r\n___ 12:00AM BLOOD Neuts-11* Bands-0 Lymphs-55* Monos-26* \r\nEos-0 Baso-0 ___ Metas-1* Myelos-4* Promyel-2* Blasts-1* \r\nNRBC-6* AbsNeut-0.28* AbsLymp-1.38 AbsMono-0.65 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-2+ Poiklo-1+ \r\nMacrocy-2+ Microcy-1+ Polychr-NORMAL Ovalocy-1+ \r\nSchisto-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 12:00AM BLOOD Plt Smr-LOW Plt Ct-85*\r\n___ 12:00AM BLOOD Glucose-110* UreaN-18 Creat-0.8 Na-142 \r\nK-3.6 Cl-101 HCO3-23 AnGap-22*\r\n___ 12:00AM BLOOD ALT-9 AST-11 LD(LDH)-238 AlkPhos-89 \r\nTotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.5 Mg-2.2\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\nDLBCL s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, concerning for RP bleed and \r\ndisease progression.  \r\n\r\nACUTE ISSUES:\r\n=============\r\n#Pancytopenia/Lymphoma disease status: Pancytopenic on \r\nadmission. Counts remained stable while in house. BM Bx \r\nperformed under fluoroscopy on ___ showed was concerning for \r\nMDS, final results are pending at discharge. Treatment plan \r\ndeveloped with Dr. ___ likely involve administration \r\nof dacogen but this will be further delineated outpatient. \r\nHemoglobin 7.1 on admission and patient received 1U prbcs prior \r\nto discharge.  \r\n\r\n#Infection/URI: Presented w/ congestion and recent blood nasal \r\nexudates. On ___, was febrile. Respiratory viral, Blood, and \r\nUrine cx were obtained; CXR and CT sinus were evaluated. Vanc \r\nand cefepime were started. No infectious pathogen was identified \r\nand the patient had no further fevers. On ___, vancomycin was \r\ndiscontinued. On ___, cefepime was discontinued. She received \r\nsymptomatic treatment with nasal saline and oxymetazoline. She \r\nwas discharged with levaquin 500mg q24hrs (to complete a 7D \r\ncourse on ___ \r\n\r\n#LLE Wound: Wearing Unna boot on presentation which had been \r\nplaced 5d PTA. Seen by wound c/s service. Daily dressing changes \r\nwhile in house. Lesion stable. Rash of chronic venous stasis, \r\nstable. Discharged with instructions to follow-up for usual care \r\nat ___.\r\n\r\n#Anti-coagulation/DVT: Concern for RP Bleed on admission, ruled \r\nout by CT. Rivaroxaban held and patient treated with enoxaparin. \r\nThe dose was held or modified at different times because of \r\nplanned procedures. The patient did not have any acute bleeding \r\nevents apart from bloody nasal exudate with nose blowing. On \r\ndischarge, patient was restarted on home dose of Rivaroxaban \r\n(20mg PO daily). Platelets 85K at discharge \r\n\r\n#Back Pain: Improved with rest and oxycodone while patient was \r\nin hospital. Otherwise, continued gabapentin 900mg TID at \r\ndischarge. No acute pain episodes prior to leaving.\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Pulm HTN\r\n#History of BCNU pneumonitis- Followed by Dr. ___. No active \r\nsymptoms. PRN inhalers ordered\r\n\r\n#H/o Migraine: R-sided pain, usually early morning onset, \r\nassociated with photophobia. Typically reaches peak intensity \r\nafter 4 hours and resolves with one or two episodes of vomiting. \r\nWould take indomethacin at home for this, but it is not \r\nappropriate given thrombocytopenia. No acute episodes prior to \r\ndischarge, continue to monitor closely outpatient \r\n\r\n#hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm, cont gabapentin  \r\n\r\n#GERD- PPI  \r\n\r\n#Depression- venlafaxine \r\n\r\nDISPO: patient discharged on ___. RTC on ___ on ___ with \r\nDr. ___\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Gabapentin 900 mg PO TID \r\n2. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n3. Rivaroxaban 20 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO BID \r\n8. Venlafaxine 25 mg PO BID \r\n9. albuterol sulfate 90 mcg/actuation inhalation Q4H:PRN \r\n10. Cyanocobalamin 1000 mcg PO QHS \r\n11. FoLIC Acid 3.2 mg PO DAILY \r\n12. Ascorbic Acid ___ mg PO BID \r\n13. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n\r\n \r\nDischarge Medications:\r\n1.  Levofloxacin 500 mg PO Q24H Duration: 6 Days \r\nTake daily from ___ to ___.  Potassium Chloride 10 mEq PO DAILY  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  Ascorbic Acid ___ mg PO BID  \r\n6.  Cyanocobalamin 1000 mcg PO QHS  \r\n7.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n8.  FoLIC Acid 3.2 mg PO DAILY  \r\n9.  Furosemide 20 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Rivaroxaban 20 mg PO DAILY  \r\n14.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\n==================\r\nMyelodisplastic Syndrome\r\nDiffuse large B cell lymphoma\r\nFebrile neutropenia\r\nRhinosinusitis\r\n\r\nSecondary Diagnoses:\r\n====================\r\nHistory of deep venous thromboembolism (DVT) on anticoagulation\r\nCommon variable immunodeficiency (CVID)\r\nMigraine\r\nChronic non-healing wound\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ came to ___ because ___ had \r\nback pain and low blood counts.\r\n\r\nWhat was done for me in the hospital?\r\n- CT scans of your torso and sinuses looking for bleeding and \r\ninfection. Neither infection nor bleeding was found.\r\n- Bone marrow biopsy to assess cancer disease status was \r\nconcerning for Myelodisplastic syndrome\r\n- Antibiotics for a fever.\r\n- Supportive care for your congestion.\r\n\r\nWhat should I do now that I am leaving the hospital?\r\n- Attend your scheduled follow-up appointments, listed below.\r\n- Take your medications as prescribed.\r\n- Return the to hospital if ___ have any concerning symptoms \r\n(some key symptoms are listed below).\r\n\r\nIt was a pleasure participating in your care. Wishing ___ all \r\nthe best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-16:6",
      "text": "ACUTE ISSUES:\n=============\n#Pancytopenia/Lymphoma disease status: Pancytopenic on \nadmission. Counts remained stable while in house. BM Bx \nperformed under fluoroscopy on ___ showed was concerning for \nMDS, final results are pending at discharge. Treatment plan \ndeveloped with Dr. ___ likely involve administration \nof dacogen but this will be further delineated outpatient. Hemoglobin 7.1 on admission and patient received 1U prbcs prior \nto discharge. #Infection/URI: Presented w/ congestion and recent blood nasal \nexudates. On ___, was febrile. Respiratory viral, Blood, and \nUrine cx were obtained; CXR and CT sinus were evaluated. Vanc \nand cefepime were started. No infectious pathogen was identified \nand the patient had no further fevers. On ___, vancomycin was \ndiscontinued. On ___, cefepime was discontinued. She received \nsymptomatic treatment with nasal saline and oxymetazoline. She \nwas discharged with levaquin 500mg q24hrs (to complete a 7D \ncourse on ___ #LLE Wound: Wearing Unna boot on presentation which had been \nplaced 5d PTA. Seen by wound c/s service. Daily dressing changes \nwhile in house. Lesion stable. Rash of chronic venous stasis, \nstable. Discharged with instructions to follow-up for usual care \nat ___. #Anti-coagulation/DVT: Concern for RP Bleed on admission, ruled \nout by CT. Rivaroxaban held and patient treated with enoxaparin. The dose was held or modified at different times because of \nplanned procedures. The patient did not have any acute bleeding \nevents apart from bloody nasal exudate with nose blowing. On \ndischarge, patient was restarted on home dose of Rivaroxaban \n(20mg PO daily). Platelets 85K at discharge #Back Pain: Improved with rest and oxycodone while patient was \nin hospital. Otherwise, continued gabapentin 900mg TID at \ndischarge. No acute pain episodes prior to leaving.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-16",
        "chart_time": "104467",
        "section": "General",
        "position": 6,
        "tokenCount": 460,
        "note_metadata": {
          "note_id": "18887130-DS-16",
          "subject_id": 18887130,
          "hadm_id": 26068131,
          "note_type": "DS",
          "note_seq": 16,
          "charttime": 104467,
          "storetime": 104467.76458333334,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, nose bleed and pancytopenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy by interventional radiology (___)\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed follicular \r\nlymphoma s/p multiple past regimens as noted below, and \r\nultimately an autoSCT with BEAM conditioning in ___.  She \r\nhas comorbid CVID and receives IVIG monthly.  Her\r\npost transplant course was complicated by ___ pneumonitis.  She \r\nunderwent a total right knee replacement on ___.  Her \r\npostoperative course was complicated by foot drop likely due to \r\nirritation of her peroneal nerve from the CPM machine as well as \r\na cellulitis of the right leg following her surgery which was \r\ntreated with a course of Keflex.  This is the same leg as her \r\nprevious DVT and her circulation is poor.  She has had ongoing \r\nissues with sciatica with hip and left lower back pain, and has \r\nhad steroid injections.\r\n\r\nAt the end of ___ of ___, Ms. ___ noted \r\nincreasing swelling of her right leg with shortness of breath.  \r\nShe had been on Xarelto for prior DVT and has an IVC filter in \r\nplace.  Her dose of Xarelto had been decreased to 10 mg daily \r\ngiven her age and chronic history of DVT; she also had a lower \r\nplatelet count for a period of time.  She was seen and admitted \r\nat ___ with ultrasound showing DVT of the right leg \r\nonce again.  Chest CT with no PE or other adenopathy.  Abdomen \r\nand Pelvic CT without adenopathy or concern for lymphoma \r\nrecurrence.  Xarelto was increased back to 20 mg daily. \r\n\r\nINTERVAL HISTORY:  Over the past 1 - 2 months, Ms. ___ was \r\nnoted for a drop in her white count with neutropenia as well as \r\na drop in her platelet count.  This had been noticed in the past \r\nwith the plan to repeat a bone marrow biopsy but her counts \r\nreturned to baseline so bone marrow biopsy was deferred.  She \r\nwas also noted for a nonhealing wound on her left leg after hit \r\non the shin several weeks ago.  She was treated with a course of \r\nKeflex with still poor healing.  Given 2 doses of Neupogen to \r\nsupport counts.  She was seen by the wound care clinic at ___ \r\n___ yesterday and the area was debrided and dressing \r\napplied.\r\n\r\nAt her visit today, Ms. ___ is noted for further drop in \r\nblood counts(platelet count is low but more her baseline).  She \r\nreports not feeling well towards the middle of last week and on \r\n___ morning, she developed increasing left lower back pain, \r\nradiating to the buttock area.  She feels this is related to her \r\nsciatica but is different pain pattern; no radiating pain down \r\nthe leg as she usually has.  Pain increases with changing \r\npositions and with initial ambulation.  She walks with a cane.  \r\nIn addition, she developed increasing nasal congestion on \r\n___ night which seemed to come on suddenly.  No fevers, \r\nchills, night sweats, sore throat.  When blowing her nose, she \r\nnoted increased blood with clots although no frank epistaxis.  \r\n\r\nBecause of the more acute drop in counts, Ms. ___ is being \r\nadmitted for further evaluation for possible bleed given on \r\nanticoagulation vs evolving MDS-->Leukemia.  \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PHYSICAL:\r\n===================\r\nVITALS - 17:27 ___ 98.9 PO ___ 18 97 RA \r\nGeneral: pleasant, no distress, sitting at edge of bed \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: clear bilaterally, good air movement \r\nAbdomen: well-healed surgical incisions, active BS, soft, no\r\nrebound or guarding, no organomegaly \r\nExt: Bilateral ___ swelling, R > L. L shin wound is wrapped and\r\nc/d/I. 2+ radial and DP pulses, 3+ pitting edema bilaterally \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\n  \r\nDISCHARGE PHYSICAL:\r\n===================\r\nVS: TC 98.8 PO 130/80 93 18 98%RA \r\nWeight: 258.7 lbs (___) -> 254.4 lbs (___) \r\nGeneral: pleasant, sitting in chair with tiara on, no distress \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: CTAB, no wheezes, rales or rhonchi \r\nAbdomen: Active BS, soft, no rebound or guarding, no\r\norganomegaly \r\nBack: No tenderness over spinous processes or L iliac crest \r\nExt: Bilateral ___ swelling, R > L. R leg with TEDS stocking on.\r\nL shin wound is stable. 2+ radial and DP pulses \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\nSkin: Erythematous venous stasis changes in bilateral lower\r\nextremities from mid-tibia to medial malleolus \r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n===============\r\n___ 10:45AM BLOOD WBC-2.3* RBC-2.46* Hgb-8.0* Hct-24.4* \r\nMCV-99* MCH-32.5* MCHC-32.8 RDW-21.4* RDWSD-76.8* Plt Ct-93*\r\n___ 10:45AM BLOOD Neuts-29* Bands-0 ___ Monos-26* \r\nEos-0 Baso-0 ___ Metas-2* Myelos-0 Blasts-1* NRBC-4* \r\nAbsNeut-0.67* AbsLymp-0.97* AbsMono-0.60 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 10:45AM BLOOD Hypochr-1+ Anisocy-1+ Poiklo-1+ \r\nMacrocy-1+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-OCCASIONAL \r\nTear Dr-1+\r\n___ 10:45AM BLOOD ___ PTT-39.0* ___\r\n___ 10:45AM BLOOD Ret Aut-1.2 Abs Ret-0.03\r\n___ 10:45AM BLOOD UreaN-15 Creat-0.9 Na-139 K-4.1 Cl-102 \r\nHCO3-26 AnGap-15\r\n___ 10:45AM BLOOD ALT-12 AST-16 LD(LDH)-232 AlkPhos-96 \r\nTotBili-0.3\r\n___ 10:45AM BLOOD Albumin-3.5 Calcium-8.1* Mg-2.2 Iron-49\r\n___ 10:45AM BLOOD ___ Folate->20 Hapto-254* \r\nFerritn-389*\r\n___ 10:45AM BLOOD TSH-1.9\r\n___ 10:45AM BLOOD IgG-728\r\n \r\nOTHER PERTINENT LABS:\r\n=====================\r\n___ 12:32PM URINE RBC-1 WBC-7* Bacteri-FEW Yeast-NONE \r\nEpi-<1 TransE-<1\r\n___ 12:32PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.5 Leuks-TR\r\n___ 12:32PM URINE Color-Straw Appear-Clear Sp ___\r\n \r\nMICROBIOLOGY:\r\n=============\r\n___ 12:32 pm URINE      Source: ___. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   URINE CULTURE (Final ___:    NO GROWTH. \r\n\r\n___ 11:30PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n___ 10:00AM OTHER BODY FLUID STANDARD LEUKEMIA/LYMPHOMA \r\nPANEL (24 MARKERS)-TEST      \r\n___ 10:00AM BONE MARROW IPT-DONE\r\n___ 10:00AM BONE MARROW CEBPA MUTATION ANALYSIS-PND\r\n___ 10:00AM BONE MARROW RAPID HEME PANEL-PND\r\n \r\nIMAGING:\r\n========\r\n___ 3:___BD & PELVIS W/O CONTRAST\r\nIMPRESSION:\r\n1. No evidence of retroperitoneal hematoma or lymphadenopathy.\r\n2. Stable 3.2 cm right adnexal cyst.  Continued attention is \r\nadvised on futurefollow up.\r\n3. Severe degenerative changes of lumbar spine are similar to \r\nbefore.\r\n\r\n___ 3:___HEST W/O CONTRAST\r\nIMPRESSION: \r\nNo evidence of acute intrathoracic abnormality.\r\nNo evidence of intrathoracic lymphoma.\r\nDilated main pulmonary artery, concerning for pulmonary \r\nhypertension, unchanged since ___.\r\n\r\n___ 3:38 ___\r\nCT HEAD W/O CONTRAST\r\nIMPRESSION: \r\n1. Of note, significant streak artifact from the right \r\nsupraclinoid vascular embolization coil limits evaluation of \r\nadjacent structures.  Given these limitations, there is no \r\nevidence of acute major territorial infarction, hemorrhage, or \r\nfracture.\r\n2. Paranasal sinus disease, as described above.\r\n\r\n___ 3:28 ___\r\nCT SINUS/MANDIBLE/MAXILLOFACIA\r\nIMPRESSION: \r\nMild mucosal thickening in both maxillary sinuses and ethmoid \r\nair cells, similar to recent CT head.  No evidence of bony \r\nerosion.\r\n \r\nPATHOLOGY: RESULT PENDING AT DISCHARGE\r\n==========\r\n\r\nDISCHARGE LABS:\r\n===============\r\n___ 12:00AM BLOOD WBC-2.5* RBC-2.29* Hgb-7.2* Hct-22.7* \r\nMCV-99* MCH-31.4 MCHC-31.7* RDW-20.6* RDWSD-75.0* Plt Ct-85*\r\n___ 12:00AM BLOOD Neuts-11* Bands-0 Lymphs-55* Monos-26* \r\nEos-0 Baso-0 ___ Metas-1* Myelos-4* Promyel-2* Blasts-1* \r\nNRBC-6* AbsNeut-0.28* AbsLymp-1.38 AbsMono-0.65 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-2+ Poiklo-1+ \r\nMacrocy-2+ Microcy-1+ Polychr-NORMAL Ovalocy-1+ \r\nSchisto-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 12:00AM BLOOD Plt Smr-LOW Plt Ct-85*\r\n___ 12:00AM BLOOD Glucose-110* UreaN-18 Creat-0.8 Na-142 \r\nK-3.6 Cl-101 HCO3-23 AnGap-22*\r\n___ 12:00AM BLOOD ALT-9 AST-11 LD(LDH)-238 AlkPhos-89 \r\nTotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.5 Mg-2.2\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\nDLBCL s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, concerning for RP bleed and \r\ndisease progression.  \r\n\r\nACUTE ISSUES:\r\n=============\r\n#Pancytopenia/Lymphoma disease status: Pancytopenic on \r\nadmission. Counts remained stable while in house. BM Bx \r\nperformed under fluoroscopy on ___ showed was concerning for \r\nMDS, final results are pending at discharge. Treatment plan \r\ndeveloped with Dr. ___ likely involve administration \r\nof dacogen but this will be further delineated outpatient. \r\nHemoglobin 7.1 on admission and patient received 1U prbcs prior \r\nto discharge.  \r\n\r\n#Infection/URI: Presented w/ congestion and recent blood nasal \r\nexudates. On ___, was febrile. Respiratory viral, Blood, and \r\nUrine cx were obtained; CXR and CT sinus were evaluated. Vanc \r\nand cefepime were started. No infectious pathogen was identified \r\nand the patient had no further fevers. On ___, vancomycin was \r\ndiscontinued. On ___, cefepime was discontinued. She received \r\nsymptomatic treatment with nasal saline and oxymetazoline. She \r\nwas discharged with levaquin 500mg q24hrs (to complete a 7D \r\ncourse on ___ \r\n\r\n#LLE Wound: Wearing Unna boot on presentation which had been \r\nplaced 5d PTA. Seen by wound c/s service. Daily dressing changes \r\nwhile in house. Lesion stable. Rash of chronic venous stasis, \r\nstable. Discharged with instructions to follow-up for usual care \r\nat ___.\r\n\r\n#Anti-coagulation/DVT: Concern for RP Bleed on admission, ruled \r\nout by CT. Rivaroxaban held and patient treated with enoxaparin. \r\nThe dose was held or modified at different times because of \r\nplanned procedures. The patient did not have any acute bleeding \r\nevents apart from bloody nasal exudate with nose blowing. On \r\ndischarge, patient was restarted on home dose of Rivaroxaban \r\n(20mg PO daily). Platelets 85K at discharge \r\n\r\n#Back Pain: Improved with rest and oxycodone while patient was \r\nin hospital. Otherwise, continued gabapentin 900mg TID at \r\ndischarge. No acute pain episodes prior to leaving.\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Pulm HTN\r\n#History of BCNU pneumonitis- Followed by Dr. ___. No active \r\nsymptoms. PRN inhalers ordered\r\n\r\n#H/o Migraine: R-sided pain, usually early morning onset, \r\nassociated with photophobia. Typically reaches peak intensity \r\nafter 4 hours and resolves with one or two episodes of vomiting. \r\nWould take indomethacin at home for this, but it is not \r\nappropriate given thrombocytopenia. No acute episodes prior to \r\ndischarge, continue to monitor closely outpatient \r\n\r\n#hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm, cont gabapentin  \r\n\r\n#GERD- PPI  \r\n\r\n#Depression- venlafaxine \r\n\r\nDISPO: patient discharged on ___. RTC on ___ on ___ with \r\nDr. ___\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Gabapentin 900 mg PO TID \r\n2. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n3. Rivaroxaban 20 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO BID \r\n8. Venlafaxine 25 mg PO BID \r\n9. albuterol sulfate 90 mcg/actuation inhalation Q4H:PRN \r\n10. Cyanocobalamin 1000 mcg PO QHS \r\n11. FoLIC Acid 3.2 mg PO DAILY \r\n12. Ascorbic Acid ___ mg PO BID \r\n13. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n\r\n \r\nDischarge Medications:\r\n1.  Levofloxacin 500 mg PO Q24H Duration: 6 Days \r\nTake daily from ___ to ___.  Potassium Chloride 10 mEq PO DAILY  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  Ascorbic Acid ___ mg PO BID  \r\n6.  Cyanocobalamin 1000 mcg PO QHS  \r\n7.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n8.  FoLIC Acid 3.2 mg PO DAILY  \r\n9.  Furosemide 20 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Rivaroxaban 20 mg PO DAILY  \r\n14.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\n==================\r\nMyelodisplastic Syndrome\r\nDiffuse large B cell lymphoma\r\nFebrile neutropenia\r\nRhinosinusitis\r\n\r\nSecondary Diagnoses:\r\n====================\r\nHistory of deep venous thromboembolism (DVT) on anticoagulation\r\nCommon variable immunodeficiency (CVID)\r\nMigraine\r\nChronic non-healing wound\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ came to ___ because ___ had \r\nback pain and low blood counts.\r\n\r\nWhat was done for me in the hospital?\r\n- CT scans of your torso and sinuses looking for bleeding and \r\ninfection. Neither infection nor bleeding was found.\r\n- Bone marrow biopsy to assess cancer disease status was \r\nconcerning for Myelodisplastic syndrome\r\n- Antibiotics for a fever.\r\n- Supportive care for your congestion.\r\n\r\nWhat should I do now that I am leaving the hospital?\r\n- Attend your scheduled follow-up appointments, listed below.\r\n- Take your medications as prescribed.\r\n- Return the to hospital if ___ have any concerning symptoms \r\n(some key symptoms are listed below).\r\n\r\nIt was a pleasure participating in your care. Wishing ___ all \r\nthe best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-16:7",
      "text": "CHRONIC ISSUES:\n===============\n#Pulm HTN\n#History of BCNU pneumonitis- Followed by Dr. ___. No active \nsymptoms. PRN inhalers ordered #H/o Migraine: R-sided pain, usually early morning onset, \nassociated with photophobia. Typically reaches peak intensity \nafter 4 hours and resolves with one or two episodes of vomiting. Would take indomethacin at home for this, but it is not \nappropriate given thrombocytopenia. No acute episodes prior to \ndischarge, continue to monitor closely outpatient #hyperthesia of R V1/V2- chronic, occurred after coiling \nprocedure for cerebral aneurysm, cont gabapentin #GERD- PPI #Depression- venlafaxine DISPO: patient discharged on ___. RTC on ___ on ___ with \nDr. ___\n \n___ on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Gabapentin 900 mg PO TID \n2. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \n3. Rivaroxaban 20 mg PO DAILY \n4. Furosemide 20 mg PO DAILY \n5. Fluticasone Propionate 110mcg 2 PUFF IH BID \n6. Omeprazole 20 mg PO DAILY \n7. Potassium Chloride 10 mEq PO BID \n8. Venlafaxine 25 mg PO BID \n9. albuterol sulfate 90 mcg/actuation inhalation Q4H:PRN \n10. Cyanocobalamin 1000 mcg PO QHS \n11. FoLIC Acid 3.2 mg PO DAILY \n12. Ascorbic Acid ___ mg PO BID \n13. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-16",
        "chart_time": "104467",
        "section": "General",
        "position": 7,
        "tokenCount": 322,
        "note_metadata": {
          "note_id": "18887130-DS-16",
          "subject_id": 18887130,
          "hadm_id": 26068131,
          "note_type": "DS",
          "note_seq": 16,
          "charttime": 104467,
          "storetime": 104467.76458333334,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, nose bleed and pancytopenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy by interventional radiology (___)\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed follicular \r\nlymphoma s/p multiple past regimens as noted below, and \r\nultimately an autoSCT with BEAM conditioning in ___.  She \r\nhas comorbid CVID and receives IVIG monthly.  Her\r\npost transplant course was complicated by ___ pneumonitis.  She \r\nunderwent a total right knee replacement on ___.  Her \r\npostoperative course was complicated by foot drop likely due to \r\nirritation of her peroneal nerve from the CPM machine as well as \r\na cellulitis of the right leg following her surgery which was \r\ntreated with a course of Keflex.  This is the same leg as her \r\nprevious DVT and her circulation is poor.  She has had ongoing \r\nissues with sciatica with hip and left lower back pain, and has \r\nhad steroid injections.\r\n\r\nAt the end of ___ of ___, Ms. ___ noted \r\nincreasing swelling of her right leg with shortness of breath.  \r\nShe had been on Xarelto for prior DVT and has an IVC filter in \r\nplace.  Her dose of Xarelto had been decreased to 10 mg daily \r\ngiven her age and chronic history of DVT; she also had a lower \r\nplatelet count for a period of time.  She was seen and admitted \r\nat ___ with ultrasound showing DVT of the right leg \r\nonce again.  Chest CT with no PE or other adenopathy.  Abdomen \r\nand Pelvic CT without adenopathy or concern for lymphoma \r\nrecurrence.  Xarelto was increased back to 20 mg daily. \r\n\r\nINTERVAL HISTORY:  Over the past 1 - 2 months, Ms. ___ was \r\nnoted for a drop in her white count with neutropenia as well as \r\na drop in her platelet count.  This had been noticed in the past \r\nwith the plan to repeat a bone marrow biopsy but her counts \r\nreturned to baseline so bone marrow biopsy was deferred.  She \r\nwas also noted for a nonhealing wound on her left leg after hit \r\non the shin several weeks ago.  She was treated with a course of \r\nKeflex with still poor healing.  Given 2 doses of Neupogen to \r\nsupport counts.  She was seen by the wound care clinic at ___ \r\n___ yesterday and the area was debrided and dressing \r\napplied.\r\n\r\nAt her visit today, Ms. ___ is noted for further drop in \r\nblood counts(platelet count is low but more her baseline).  She \r\nreports not feeling well towards the middle of last week and on \r\n___ morning, she developed increasing left lower back pain, \r\nradiating to the buttock area.  She feels this is related to her \r\nsciatica but is different pain pattern; no radiating pain down \r\nthe leg as she usually has.  Pain increases with changing \r\npositions and with initial ambulation.  She walks with a cane.  \r\nIn addition, she developed increasing nasal congestion on \r\n___ night which seemed to come on suddenly.  No fevers, \r\nchills, night sweats, sore throat.  When blowing her nose, she \r\nnoted increased blood with clots although no frank epistaxis.  \r\n\r\nBecause of the more acute drop in counts, Ms. ___ is being \r\nadmitted for further evaluation for possible bleed given on \r\nanticoagulation vs evolving MDS-->Leukemia.  \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PHYSICAL:\r\n===================\r\nVITALS - 17:27 ___ 98.9 PO ___ 18 97 RA \r\nGeneral: pleasant, no distress, sitting at edge of bed \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: clear bilaterally, good air movement \r\nAbdomen: well-healed surgical incisions, active BS, soft, no\r\nrebound or guarding, no organomegaly \r\nExt: Bilateral ___ swelling, R > L. L shin wound is wrapped and\r\nc/d/I. 2+ radial and DP pulses, 3+ pitting edema bilaterally \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\n  \r\nDISCHARGE PHYSICAL:\r\n===================\r\nVS: TC 98.8 PO 130/80 93 18 98%RA \r\nWeight: 258.7 lbs (___) -> 254.4 lbs (___) \r\nGeneral: pleasant, sitting in chair with tiara on, no distress \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: CTAB, no wheezes, rales or rhonchi \r\nAbdomen: Active BS, soft, no rebound or guarding, no\r\norganomegaly \r\nBack: No tenderness over spinous processes or L iliac crest \r\nExt: Bilateral ___ swelling, R > L. R leg with TEDS stocking on.\r\nL shin wound is stable. 2+ radial and DP pulses \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\nSkin: Erythematous venous stasis changes in bilateral lower\r\nextremities from mid-tibia to medial malleolus \r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n===============\r\n___ 10:45AM BLOOD WBC-2.3* RBC-2.46* Hgb-8.0* Hct-24.4* \r\nMCV-99* MCH-32.5* MCHC-32.8 RDW-21.4* RDWSD-76.8* Plt Ct-93*\r\n___ 10:45AM BLOOD Neuts-29* Bands-0 ___ Monos-26* \r\nEos-0 Baso-0 ___ Metas-2* Myelos-0 Blasts-1* NRBC-4* \r\nAbsNeut-0.67* AbsLymp-0.97* AbsMono-0.60 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 10:45AM BLOOD Hypochr-1+ Anisocy-1+ Poiklo-1+ \r\nMacrocy-1+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-OCCASIONAL \r\nTear Dr-1+\r\n___ 10:45AM BLOOD ___ PTT-39.0* ___\r\n___ 10:45AM BLOOD Ret Aut-1.2 Abs Ret-0.03\r\n___ 10:45AM BLOOD UreaN-15 Creat-0.9 Na-139 K-4.1 Cl-102 \r\nHCO3-26 AnGap-15\r\n___ 10:45AM BLOOD ALT-12 AST-16 LD(LDH)-232 AlkPhos-96 \r\nTotBili-0.3\r\n___ 10:45AM BLOOD Albumin-3.5 Calcium-8.1* Mg-2.2 Iron-49\r\n___ 10:45AM BLOOD ___ Folate->20 Hapto-254* \r\nFerritn-389*\r\n___ 10:45AM BLOOD TSH-1.9\r\n___ 10:45AM BLOOD IgG-728\r\n \r\nOTHER PERTINENT LABS:\r\n=====================\r\n___ 12:32PM URINE RBC-1 WBC-7* Bacteri-FEW Yeast-NONE \r\nEpi-<1 TransE-<1\r\n___ 12:32PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.5 Leuks-TR\r\n___ 12:32PM URINE Color-Straw Appear-Clear Sp ___\r\n \r\nMICROBIOLOGY:\r\n=============\r\n___ 12:32 pm URINE      Source: ___. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   URINE CULTURE (Final ___:    NO GROWTH. \r\n\r\n___ 11:30PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n___ 10:00AM OTHER BODY FLUID STANDARD LEUKEMIA/LYMPHOMA \r\nPANEL (24 MARKERS)-TEST      \r\n___ 10:00AM BONE MARROW IPT-DONE\r\n___ 10:00AM BONE MARROW CEBPA MUTATION ANALYSIS-PND\r\n___ 10:00AM BONE MARROW RAPID HEME PANEL-PND\r\n \r\nIMAGING:\r\n========\r\n___ 3:___BD & PELVIS W/O CONTRAST\r\nIMPRESSION:\r\n1. No evidence of retroperitoneal hematoma or lymphadenopathy.\r\n2. Stable 3.2 cm right adnexal cyst.  Continued attention is \r\nadvised on futurefollow up.\r\n3. Severe degenerative changes of lumbar spine are similar to \r\nbefore.\r\n\r\n___ 3:___HEST W/O CONTRAST\r\nIMPRESSION: \r\nNo evidence of acute intrathoracic abnormality.\r\nNo evidence of intrathoracic lymphoma.\r\nDilated main pulmonary artery, concerning for pulmonary \r\nhypertension, unchanged since ___.\r\n\r\n___ 3:38 ___\r\nCT HEAD W/O CONTRAST\r\nIMPRESSION: \r\n1. Of note, significant streak artifact from the right \r\nsupraclinoid vascular embolization coil limits evaluation of \r\nadjacent structures.  Given these limitations, there is no \r\nevidence of acute major territorial infarction, hemorrhage, or \r\nfracture.\r\n2. Paranasal sinus disease, as described above.\r\n\r\n___ 3:28 ___\r\nCT SINUS/MANDIBLE/MAXILLOFACIA\r\nIMPRESSION: \r\nMild mucosal thickening in both maxillary sinuses and ethmoid \r\nair cells, similar to recent CT head.  No evidence of bony \r\nerosion.\r\n \r\nPATHOLOGY: RESULT PENDING AT DISCHARGE\r\n==========\r\n\r\nDISCHARGE LABS:\r\n===============\r\n___ 12:00AM BLOOD WBC-2.5* RBC-2.29* Hgb-7.2* Hct-22.7* \r\nMCV-99* MCH-31.4 MCHC-31.7* RDW-20.6* RDWSD-75.0* Plt Ct-85*\r\n___ 12:00AM BLOOD Neuts-11* Bands-0 Lymphs-55* Monos-26* \r\nEos-0 Baso-0 ___ Metas-1* Myelos-4* Promyel-2* Blasts-1* \r\nNRBC-6* AbsNeut-0.28* AbsLymp-1.38 AbsMono-0.65 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-2+ Poiklo-1+ \r\nMacrocy-2+ Microcy-1+ Polychr-NORMAL Ovalocy-1+ \r\nSchisto-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 12:00AM BLOOD Plt Smr-LOW Plt Ct-85*\r\n___ 12:00AM BLOOD Glucose-110* UreaN-18 Creat-0.8 Na-142 \r\nK-3.6 Cl-101 HCO3-23 AnGap-22*\r\n___ 12:00AM BLOOD ALT-9 AST-11 LD(LDH)-238 AlkPhos-89 \r\nTotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.5 Mg-2.2\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\nDLBCL s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, concerning for RP bleed and \r\ndisease progression.  \r\n\r\nACUTE ISSUES:\r\n=============\r\n#Pancytopenia/Lymphoma disease status: Pancytopenic on \r\nadmission. Counts remained stable while in house. BM Bx \r\nperformed under fluoroscopy on ___ showed was concerning for \r\nMDS, final results are pending at discharge. Treatment plan \r\ndeveloped with Dr. ___ likely involve administration \r\nof dacogen but this will be further delineated outpatient. \r\nHemoglobin 7.1 on admission and patient received 1U prbcs prior \r\nto discharge.  \r\n\r\n#Infection/URI: Presented w/ congestion and recent blood nasal \r\nexudates. On ___, was febrile. Respiratory viral, Blood, and \r\nUrine cx were obtained; CXR and CT sinus were evaluated. Vanc \r\nand cefepime were started. No infectious pathogen was identified \r\nand the patient had no further fevers. On ___, vancomycin was \r\ndiscontinued. On ___, cefepime was discontinued. She received \r\nsymptomatic treatment with nasal saline and oxymetazoline. She \r\nwas discharged with levaquin 500mg q24hrs (to complete a 7D \r\ncourse on ___ \r\n\r\n#LLE Wound: Wearing Unna boot on presentation which had been \r\nplaced 5d PTA. Seen by wound c/s service. Daily dressing changes \r\nwhile in house. Lesion stable. Rash of chronic venous stasis, \r\nstable. Discharged with instructions to follow-up for usual care \r\nat ___.\r\n\r\n#Anti-coagulation/DVT: Concern for RP Bleed on admission, ruled \r\nout by CT. Rivaroxaban held and patient treated with enoxaparin. \r\nThe dose was held or modified at different times because of \r\nplanned procedures. The patient did not have any acute bleeding \r\nevents apart from bloody nasal exudate with nose blowing. On \r\ndischarge, patient was restarted on home dose of Rivaroxaban \r\n(20mg PO daily). Platelets 85K at discharge \r\n\r\n#Back Pain: Improved with rest and oxycodone while patient was \r\nin hospital. Otherwise, continued gabapentin 900mg TID at \r\ndischarge. No acute pain episodes prior to leaving.\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Pulm HTN\r\n#History of BCNU pneumonitis- Followed by Dr. ___. No active \r\nsymptoms. PRN inhalers ordered\r\n\r\n#H/o Migraine: R-sided pain, usually early morning onset, \r\nassociated with photophobia. Typically reaches peak intensity \r\nafter 4 hours and resolves with one or two episodes of vomiting. \r\nWould take indomethacin at home for this, but it is not \r\nappropriate given thrombocytopenia. No acute episodes prior to \r\ndischarge, continue to monitor closely outpatient \r\n\r\n#hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm, cont gabapentin  \r\n\r\n#GERD- PPI  \r\n\r\n#Depression- venlafaxine \r\n\r\nDISPO: patient discharged on ___. RTC on ___ on ___ with \r\nDr. ___\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Gabapentin 900 mg PO TID \r\n2. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n3. Rivaroxaban 20 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO BID \r\n8. Venlafaxine 25 mg PO BID \r\n9. albuterol sulfate 90 mcg/actuation inhalation Q4H:PRN \r\n10. Cyanocobalamin 1000 mcg PO QHS \r\n11. FoLIC Acid 3.2 mg PO DAILY \r\n12. Ascorbic Acid ___ mg PO BID \r\n13. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n\r\n \r\nDischarge Medications:\r\n1.  Levofloxacin 500 mg PO Q24H Duration: 6 Days \r\nTake daily from ___ to ___.  Potassium Chloride 10 mEq PO DAILY  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  Ascorbic Acid ___ mg PO BID  \r\n6.  Cyanocobalamin 1000 mcg PO QHS  \r\n7.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n8.  FoLIC Acid 3.2 mg PO DAILY  \r\n9.  Furosemide 20 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Rivaroxaban 20 mg PO DAILY  \r\n14.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\n==================\r\nMyelodisplastic Syndrome\r\nDiffuse large B cell lymphoma\r\nFebrile neutropenia\r\nRhinosinusitis\r\n\r\nSecondary Diagnoses:\r\n====================\r\nHistory of deep venous thromboembolism (DVT) on anticoagulation\r\nCommon variable immunodeficiency (CVID)\r\nMigraine\r\nChronic non-healing wound\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ came to ___ because ___ had \r\nback pain and low blood counts.\r\n\r\nWhat was done for me in the hospital?\r\n- CT scans of your torso and sinuses looking for bleeding and \r\ninfection. Neither infection nor bleeding was found.\r\n- Bone marrow biopsy to assess cancer disease status was \r\nconcerning for Myelodisplastic syndrome\r\n- Antibiotics for a fever.\r\n- Supportive care for your congestion.\r\n\r\nWhat should I do now that I am leaving the hospital?\r\n- Attend your scheduled follow-up appointments, listed below.\r\n- Take your medications as prescribed.\r\n- Return the to hospital if ___ have any concerning symptoms \r\n(some key symptoms are listed below).\r\n\r\nIt was a pleasure participating in your care. Wishing ___ all \r\nthe best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-16:8",
      "text": "Discharge Medications:\n1. Levofloxacin 500 mg PO Q24H Duration: 6 Days \nTake daily from ___ to ___. Potassium Chloride 10 mEq PO DAILY  \n3. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \n4. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \n5. Ascorbic Acid ___ mg PO BID  \n6. Cyanocobalamin 1000 mcg PO QHS  \n7. Fluticasone Propionate 110mcg 2 PUFF IH BID  \n8. FoLIC Acid 3.2 mg PO DAILY  \n9. Furosemide 20 mg PO DAILY  \n10. Gabapentin 900 mg PO TID  \n11. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \n12. Omeprazole 20 mg PO DAILY  \n13. Rivaroxaban 20 mg PO DAILY  \n14. Venlafaxine 25 mg PO BID Discharge Disposition:\nHome Discharge Diagnosis:\nPrimary Diagnoses:\n==================\nMyelodisplastic Syndrome\nDiffuse large B cell lymphoma\nFebrile neutropenia\nRhinosinusitis Secondary Diagnoses:\n====================\nHistory of deep venous thromboembolism (DVT) on anticoagulation\nCommon variable immunodeficiency (CVID)\nMigraine\nChronic non-healing wound Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - requires assistance or aid (walker \nor cane).",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-16",
        "chart_time": "104467",
        "section": "General",
        "position": 8,
        "tokenCount": 290,
        "note_metadata": {
          "note_id": "18887130-DS-16",
          "subject_id": 18887130,
          "hadm_id": 26068131,
          "note_type": "DS",
          "note_seq": 16,
          "charttime": 104467,
          "storetime": 104467.76458333334,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, nose bleed and pancytopenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy by interventional radiology (___)\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed follicular \r\nlymphoma s/p multiple past regimens as noted below, and \r\nultimately an autoSCT with BEAM conditioning in ___.  She \r\nhas comorbid CVID and receives IVIG monthly.  Her\r\npost transplant course was complicated by ___ pneumonitis.  She \r\nunderwent a total right knee replacement on ___.  Her \r\npostoperative course was complicated by foot drop likely due to \r\nirritation of her peroneal nerve from the CPM machine as well as \r\na cellulitis of the right leg following her surgery which was \r\ntreated with a course of Keflex.  This is the same leg as her \r\nprevious DVT and her circulation is poor.  She has had ongoing \r\nissues with sciatica with hip and left lower back pain, and has \r\nhad steroid injections.\r\n\r\nAt the end of ___ of ___, Ms. ___ noted \r\nincreasing swelling of her right leg with shortness of breath.  \r\nShe had been on Xarelto for prior DVT and has an IVC filter in \r\nplace.  Her dose of Xarelto had been decreased to 10 mg daily \r\ngiven her age and chronic history of DVT; she also had a lower \r\nplatelet count for a period of time.  She was seen and admitted \r\nat ___ with ultrasound showing DVT of the right leg \r\nonce again.  Chest CT with no PE or other adenopathy.  Abdomen \r\nand Pelvic CT without adenopathy or concern for lymphoma \r\nrecurrence.  Xarelto was increased back to 20 mg daily. \r\n\r\nINTERVAL HISTORY:  Over the past 1 - 2 months, Ms. ___ was \r\nnoted for a drop in her white count with neutropenia as well as \r\na drop in her platelet count.  This had been noticed in the past \r\nwith the plan to repeat a bone marrow biopsy but her counts \r\nreturned to baseline so bone marrow biopsy was deferred.  She \r\nwas also noted for a nonhealing wound on her left leg after hit \r\non the shin several weeks ago.  She was treated with a course of \r\nKeflex with still poor healing.  Given 2 doses of Neupogen to \r\nsupport counts.  She was seen by the wound care clinic at ___ \r\n___ yesterday and the area was debrided and dressing \r\napplied.\r\n\r\nAt her visit today, Ms. ___ is noted for further drop in \r\nblood counts(platelet count is low but more her baseline).  She \r\nreports not feeling well towards the middle of last week and on \r\n___ morning, she developed increasing left lower back pain, \r\nradiating to the buttock area.  She feels this is related to her \r\nsciatica but is different pain pattern; no radiating pain down \r\nthe leg as she usually has.  Pain increases with changing \r\npositions and with initial ambulation.  She walks with a cane.  \r\nIn addition, she developed increasing nasal congestion on \r\n___ night which seemed to come on suddenly.  No fevers, \r\nchills, night sweats, sore throat.  When blowing her nose, she \r\nnoted increased blood with clots although no frank epistaxis.  \r\n\r\nBecause of the more acute drop in counts, Ms. ___ is being \r\nadmitted for further evaluation for possible bleed given on \r\nanticoagulation vs evolving MDS-->Leukemia.  \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PHYSICAL:\r\n===================\r\nVITALS - 17:27 ___ 98.9 PO ___ 18 97 RA \r\nGeneral: pleasant, no distress, sitting at edge of bed \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: clear bilaterally, good air movement \r\nAbdomen: well-healed surgical incisions, active BS, soft, no\r\nrebound or guarding, no organomegaly \r\nExt: Bilateral ___ swelling, R > L. L shin wound is wrapped and\r\nc/d/I. 2+ radial and DP pulses, 3+ pitting edema bilaterally \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\n  \r\nDISCHARGE PHYSICAL:\r\n===================\r\nVS: TC 98.8 PO 130/80 93 18 98%RA \r\nWeight: 258.7 lbs (___) -> 254.4 lbs (___) \r\nGeneral: pleasant, sitting in chair with tiara on, no distress \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: CTAB, no wheezes, rales or rhonchi \r\nAbdomen: Active BS, soft, no rebound or guarding, no\r\norganomegaly \r\nBack: No tenderness over spinous processes or L iliac crest \r\nExt: Bilateral ___ swelling, R > L. R leg with TEDS stocking on.\r\nL shin wound is stable. 2+ radial and DP pulses \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\nSkin: Erythematous venous stasis changes in bilateral lower\r\nextremities from mid-tibia to medial malleolus \r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n===============\r\n___ 10:45AM BLOOD WBC-2.3* RBC-2.46* Hgb-8.0* Hct-24.4* \r\nMCV-99* MCH-32.5* MCHC-32.8 RDW-21.4* RDWSD-76.8* Plt Ct-93*\r\n___ 10:45AM BLOOD Neuts-29* Bands-0 ___ Monos-26* \r\nEos-0 Baso-0 ___ Metas-2* Myelos-0 Blasts-1* NRBC-4* \r\nAbsNeut-0.67* AbsLymp-0.97* AbsMono-0.60 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 10:45AM BLOOD Hypochr-1+ Anisocy-1+ Poiklo-1+ \r\nMacrocy-1+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-OCCASIONAL \r\nTear Dr-1+\r\n___ 10:45AM BLOOD ___ PTT-39.0* ___\r\n___ 10:45AM BLOOD Ret Aut-1.2 Abs Ret-0.03\r\n___ 10:45AM BLOOD UreaN-15 Creat-0.9 Na-139 K-4.1 Cl-102 \r\nHCO3-26 AnGap-15\r\n___ 10:45AM BLOOD ALT-12 AST-16 LD(LDH)-232 AlkPhos-96 \r\nTotBili-0.3\r\n___ 10:45AM BLOOD Albumin-3.5 Calcium-8.1* Mg-2.2 Iron-49\r\n___ 10:45AM BLOOD ___ Folate->20 Hapto-254* \r\nFerritn-389*\r\n___ 10:45AM BLOOD TSH-1.9\r\n___ 10:45AM BLOOD IgG-728\r\n \r\nOTHER PERTINENT LABS:\r\n=====================\r\n___ 12:32PM URINE RBC-1 WBC-7* Bacteri-FEW Yeast-NONE \r\nEpi-<1 TransE-<1\r\n___ 12:32PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.5 Leuks-TR\r\n___ 12:32PM URINE Color-Straw Appear-Clear Sp ___\r\n \r\nMICROBIOLOGY:\r\n=============\r\n___ 12:32 pm URINE      Source: ___. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   URINE CULTURE (Final ___:    NO GROWTH. \r\n\r\n___ 11:30PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n___ 10:00AM OTHER BODY FLUID STANDARD LEUKEMIA/LYMPHOMA \r\nPANEL (24 MARKERS)-TEST      \r\n___ 10:00AM BONE MARROW IPT-DONE\r\n___ 10:00AM BONE MARROW CEBPA MUTATION ANALYSIS-PND\r\n___ 10:00AM BONE MARROW RAPID HEME PANEL-PND\r\n \r\nIMAGING:\r\n========\r\n___ 3:___BD & PELVIS W/O CONTRAST\r\nIMPRESSION:\r\n1. No evidence of retroperitoneal hematoma or lymphadenopathy.\r\n2. Stable 3.2 cm right adnexal cyst.  Continued attention is \r\nadvised on futurefollow up.\r\n3. Severe degenerative changes of lumbar spine are similar to \r\nbefore.\r\n\r\n___ 3:___HEST W/O CONTRAST\r\nIMPRESSION: \r\nNo evidence of acute intrathoracic abnormality.\r\nNo evidence of intrathoracic lymphoma.\r\nDilated main pulmonary artery, concerning for pulmonary \r\nhypertension, unchanged since ___.\r\n\r\n___ 3:38 ___\r\nCT HEAD W/O CONTRAST\r\nIMPRESSION: \r\n1. Of note, significant streak artifact from the right \r\nsupraclinoid vascular embolization coil limits evaluation of \r\nadjacent structures.  Given these limitations, there is no \r\nevidence of acute major territorial infarction, hemorrhage, or \r\nfracture.\r\n2. Paranasal sinus disease, as described above.\r\n\r\n___ 3:28 ___\r\nCT SINUS/MANDIBLE/MAXILLOFACIA\r\nIMPRESSION: \r\nMild mucosal thickening in both maxillary sinuses and ethmoid \r\nair cells, similar to recent CT head.  No evidence of bony \r\nerosion.\r\n \r\nPATHOLOGY: RESULT PENDING AT DISCHARGE\r\n==========\r\n\r\nDISCHARGE LABS:\r\n===============\r\n___ 12:00AM BLOOD WBC-2.5* RBC-2.29* Hgb-7.2* Hct-22.7* \r\nMCV-99* MCH-31.4 MCHC-31.7* RDW-20.6* RDWSD-75.0* Plt Ct-85*\r\n___ 12:00AM BLOOD Neuts-11* Bands-0 Lymphs-55* Monos-26* \r\nEos-0 Baso-0 ___ Metas-1* Myelos-4* Promyel-2* Blasts-1* \r\nNRBC-6* AbsNeut-0.28* AbsLymp-1.38 AbsMono-0.65 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-2+ Poiklo-1+ \r\nMacrocy-2+ Microcy-1+ Polychr-NORMAL Ovalocy-1+ \r\nSchisto-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 12:00AM BLOOD Plt Smr-LOW Plt Ct-85*\r\n___ 12:00AM BLOOD Glucose-110* UreaN-18 Creat-0.8 Na-142 \r\nK-3.6 Cl-101 HCO3-23 AnGap-22*\r\n___ 12:00AM BLOOD ALT-9 AST-11 LD(LDH)-238 AlkPhos-89 \r\nTotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.5 Mg-2.2\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\nDLBCL s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, concerning for RP bleed and \r\ndisease progression.  \r\n\r\nACUTE ISSUES:\r\n=============\r\n#Pancytopenia/Lymphoma disease status: Pancytopenic on \r\nadmission. Counts remained stable while in house. BM Bx \r\nperformed under fluoroscopy on ___ showed was concerning for \r\nMDS, final results are pending at discharge. Treatment plan \r\ndeveloped with Dr. ___ likely involve administration \r\nof dacogen but this will be further delineated outpatient. \r\nHemoglobin 7.1 on admission and patient received 1U prbcs prior \r\nto discharge.  \r\n\r\n#Infection/URI: Presented w/ congestion and recent blood nasal \r\nexudates. On ___, was febrile. Respiratory viral, Blood, and \r\nUrine cx were obtained; CXR and CT sinus were evaluated. Vanc \r\nand cefepime were started. No infectious pathogen was identified \r\nand the patient had no further fevers. On ___, vancomycin was \r\ndiscontinued. On ___, cefepime was discontinued. She received \r\nsymptomatic treatment with nasal saline and oxymetazoline. She \r\nwas discharged with levaquin 500mg q24hrs (to complete a 7D \r\ncourse on ___ \r\n\r\n#LLE Wound: Wearing Unna boot on presentation which had been \r\nplaced 5d PTA. Seen by wound c/s service. Daily dressing changes \r\nwhile in house. Lesion stable. Rash of chronic venous stasis, \r\nstable. Discharged with instructions to follow-up for usual care \r\nat ___.\r\n\r\n#Anti-coagulation/DVT: Concern for RP Bleed on admission, ruled \r\nout by CT. Rivaroxaban held and patient treated with enoxaparin. \r\nThe dose was held or modified at different times because of \r\nplanned procedures. The patient did not have any acute bleeding \r\nevents apart from bloody nasal exudate with nose blowing. On \r\ndischarge, patient was restarted on home dose of Rivaroxaban \r\n(20mg PO daily). Platelets 85K at discharge \r\n\r\n#Back Pain: Improved with rest and oxycodone while patient was \r\nin hospital. Otherwise, continued gabapentin 900mg TID at \r\ndischarge. No acute pain episodes prior to leaving.\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Pulm HTN\r\n#History of BCNU pneumonitis- Followed by Dr. ___. No active \r\nsymptoms. PRN inhalers ordered\r\n\r\n#H/o Migraine: R-sided pain, usually early morning onset, \r\nassociated with photophobia. Typically reaches peak intensity \r\nafter 4 hours and resolves with one or two episodes of vomiting. \r\nWould take indomethacin at home for this, but it is not \r\nappropriate given thrombocytopenia. No acute episodes prior to \r\ndischarge, continue to monitor closely outpatient \r\n\r\n#hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm, cont gabapentin  \r\n\r\n#GERD- PPI  \r\n\r\n#Depression- venlafaxine \r\n\r\nDISPO: patient discharged on ___. RTC on ___ on ___ with \r\nDr. ___\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Gabapentin 900 mg PO TID \r\n2. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n3. Rivaroxaban 20 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO BID \r\n8. Venlafaxine 25 mg PO BID \r\n9. albuterol sulfate 90 mcg/actuation inhalation Q4H:PRN \r\n10. Cyanocobalamin 1000 mcg PO QHS \r\n11. FoLIC Acid 3.2 mg PO DAILY \r\n12. Ascorbic Acid ___ mg PO BID \r\n13. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n\r\n \r\nDischarge Medications:\r\n1.  Levofloxacin 500 mg PO Q24H Duration: 6 Days \r\nTake daily from ___ to ___.  Potassium Chloride 10 mEq PO DAILY  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  Ascorbic Acid ___ mg PO BID  \r\n6.  Cyanocobalamin 1000 mcg PO QHS  \r\n7.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n8.  FoLIC Acid 3.2 mg PO DAILY  \r\n9.  Furosemide 20 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Rivaroxaban 20 mg PO DAILY  \r\n14.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\n==================\r\nMyelodisplastic Syndrome\r\nDiffuse large B cell lymphoma\r\nFebrile neutropenia\r\nRhinosinusitis\r\n\r\nSecondary Diagnoses:\r\n====================\r\nHistory of deep venous thromboembolism (DVT) on anticoagulation\r\nCommon variable immunodeficiency (CVID)\r\nMigraine\r\nChronic non-healing wound\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ came to ___ because ___ had \r\nback pain and low blood counts.\r\n\r\nWhat was done for me in the hospital?\r\n- CT scans of your torso and sinuses looking for bleeding and \r\ninfection. Neither infection nor bleeding was found.\r\n- Bone marrow biopsy to assess cancer disease status was \r\nconcerning for Myelodisplastic syndrome\r\n- Antibiotics for a fever.\r\n- Supportive care for your congestion.\r\n\r\nWhat should I do now that I am leaving the hospital?\r\n- Attend your scheduled follow-up appointments, listed below.\r\n- Take your medications as prescribed.\r\n- Return the to hospital if ___ have any concerning symptoms \r\n(some key symptoms are listed below).\r\n\r\nIt was a pleasure participating in your care. Wishing ___ all \r\nthe best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-16:9",
      "text": "Discharge Instructions:\nDear ___, ___ came to ___ because ___ had \nback pain and low blood counts. What was done for me in the hospital? - CT scans of your torso and sinuses looking for bleeding and \ninfection. Neither infection nor bleeding was found. - Bone marrow biopsy to assess cancer disease status was \nconcerning for Myelodisplastic syndrome\n- Antibiotics for a fever. - Supportive care for your congestion. What should I do now that I am leaving the hospital? - Attend your scheduled follow-up appointments, listed below. - Take your medications as prescribed. - Return the to hospital if ___ have any concerning symptoms \n(some key symptoms are listed below). It was a pleasure participating in your care. Wishing ___ all \nthe best! Sincerely,\nYour ___ Team\n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-16",
        "chart_time": "104467",
        "section": "General",
        "position": 9,
        "tokenCount": 200,
        "note_metadata": {
          "note_id": "18887130-DS-16",
          "subject_id": 18887130,
          "hadm_id": 26068131,
          "note_type": "DS",
          "note_seq": 16,
          "charttime": 104467,
          "storetime": 104467.76458333334,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, nose bleed and pancytopenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy by interventional radiology (___)\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed follicular \r\nlymphoma s/p multiple past regimens as noted below, and \r\nultimately an autoSCT with BEAM conditioning in ___.  She \r\nhas comorbid CVID and receives IVIG monthly.  Her\r\npost transplant course was complicated by ___ pneumonitis.  She \r\nunderwent a total right knee replacement on ___.  Her \r\npostoperative course was complicated by foot drop likely due to \r\nirritation of her peroneal nerve from the CPM machine as well as \r\na cellulitis of the right leg following her surgery which was \r\ntreated with a course of Keflex.  This is the same leg as her \r\nprevious DVT and her circulation is poor.  She has had ongoing \r\nissues with sciatica with hip and left lower back pain, and has \r\nhad steroid injections.\r\n\r\nAt the end of ___ of ___, Ms. ___ noted \r\nincreasing swelling of her right leg with shortness of breath.  \r\nShe had been on Xarelto for prior DVT and has an IVC filter in \r\nplace.  Her dose of Xarelto had been decreased to 10 mg daily \r\ngiven her age and chronic history of DVT; she also had a lower \r\nplatelet count for a period of time.  She was seen and admitted \r\nat ___ with ultrasound showing DVT of the right leg \r\nonce again.  Chest CT with no PE or other adenopathy.  Abdomen \r\nand Pelvic CT without adenopathy or concern for lymphoma \r\nrecurrence.  Xarelto was increased back to 20 mg daily. \r\n\r\nINTERVAL HISTORY:  Over the past 1 - 2 months, Ms. ___ was \r\nnoted for a drop in her white count with neutropenia as well as \r\na drop in her platelet count.  This had been noticed in the past \r\nwith the plan to repeat a bone marrow biopsy but her counts \r\nreturned to baseline so bone marrow biopsy was deferred.  She \r\nwas also noted for a nonhealing wound on her left leg after hit \r\non the shin several weeks ago.  She was treated with a course of \r\nKeflex with still poor healing.  Given 2 doses of Neupogen to \r\nsupport counts.  She was seen by the wound care clinic at ___ \r\n___ yesterday and the area was debrided and dressing \r\napplied.\r\n\r\nAt her visit today, Ms. ___ is noted for further drop in \r\nblood counts(platelet count is low but more her baseline).  She \r\nreports not feeling well towards the middle of last week and on \r\n___ morning, she developed increasing left lower back pain, \r\nradiating to the buttock area.  She feels this is related to her \r\nsciatica but is different pain pattern; no radiating pain down \r\nthe leg as she usually has.  Pain increases with changing \r\npositions and with initial ambulation.  She walks with a cane.  \r\nIn addition, she developed increasing nasal congestion on \r\n___ night which seemed to come on suddenly.  No fevers, \r\nchills, night sweats, sore throat.  When blowing her nose, she \r\nnoted increased blood with clots although no frank epistaxis.  \r\n\r\nBecause of the more acute drop in counts, Ms. ___ is being \r\nadmitted for further evaluation for possible bleed given on \r\nanticoagulation vs evolving MDS-->Leukemia.  \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother- lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PHYSICAL:\r\n===================\r\nVITALS - 17:27 ___ 98.9 PO ___ 18 97 RA \r\nGeneral: pleasant, no distress, sitting at edge of bed \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: clear bilaterally, good air movement \r\nAbdomen: well-healed surgical incisions, active BS, soft, no\r\nrebound or guarding, no organomegaly \r\nExt: Bilateral ___ swelling, R > L. L shin wound is wrapped and\r\nc/d/I. 2+ radial and DP pulses, 3+ pitting edema bilaterally \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\n  \r\nDISCHARGE PHYSICAL:\r\n===================\r\nVS: TC 98.8 PO 130/80 93 18 98%RA \r\nWeight: 258.7 lbs (___) -> 254.4 lbs (___) \r\nGeneral: pleasant, sitting in chair with tiara on, no distress \r\nHEENT: anicteric sclerae, clear oropharynx without lesions \r\nNeck: no adenopathy \r\nCV: RRR, normal S1, S2, no murmurs or rubs \r\nLungs: CTAB, no wheezes, rales or rhonchi \r\nAbdomen: Active BS, soft, no rebound or guarding, no\r\norganomegaly \r\nBack: No tenderness over spinous processes or L iliac crest \r\nExt: Bilateral ___ swelling, R > L. R leg with TEDS stocking on.\r\nL shin wound is stable. 2+ radial and DP pulses \r\nNeuro: CNs ___ intact, noted dysmetria of R eye and sluggish\r\npupil, strength and sensation grossly intact, ambulates with \r\ncane\r\nSkin: Erythematous venous stasis changes in bilateral lower\r\nextremities from mid-tibia to medial malleolus \r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n===============\r\n___ 10:45AM BLOOD WBC-2.3* RBC-2.46* Hgb-8.0* Hct-24.4* \r\nMCV-99* MCH-32.5* MCHC-32.8 RDW-21.4* RDWSD-76.8* Plt Ct-93*\r\n___ 10:45AM BLOOD Neuts-29* Bands-0 ___ Monos-26* \r\nEos-0 Baso-0 ___ Metas-2* Myelos-0 Blasts-1* NRBC-4* \r\nAbsNeut-0.67* AbsLymp-0.97* AbsMono-0.60 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 10:45AM BLOOD Hypochr-1+ Anisocy-1+ Poiklo-1+ \r\nMacrocy-1+ Microcy-1+ Polychr-1+ Ovalocy-1+ Schisto-OCCASIONAL \r\nTear Dr-1+\r\n___ 10:45AM BLOOD ___ PTT-39.0* ___\r\n___ 10:45AM BLOOD Ret Aut-1.2 Abs Ret-0.03\r\n___ 10:45AM BLOOD UreaN-15 Creat-0.9 Na-139 K-4.1 Cl-102 \r\nHCO3-26 AnGap-15\r\n___ 10:45AM BLOOD ALT-12 AST-16 LD(LDH)-232 AlkPhos-96 \r\nTotBili-0.3\r\n___ 10:45AM BLOOD Albumin-3.5 Calcium-8.1* Mg-2.2 Iron-49\r\n___ 10:45AM BLOOD ___ Folate->20 Hapto-254* \r\nFerritn-389*\r\n___ 10:45AM BLOOD TSH-1.9\r\n___ 10:45AM BLOOD IgG-728\r\n \r\nOTHER PERTINENT LABS:\r\n=====================\r\n___ 12:32PM URINE RBC-1 WBC-7* Bacteri-FEW Yeast-NONE \r\nEpi-<1 TransE-<1\r\n___ 12:32PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.5 Leuks-TR\r\n___ 12:32PM URINE Color-Straw Appear-Clear Sp ___\r\n \r\nMICROBIOLOGY:\r\n=============\r\n___ 12:32 pm URINE      Source: ___. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   URINE CULTURE (Final ___:    NO GROWTH. \r\n\r\n___ 11:30PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n___ 10:00AM OTHER BODY FLUID STANDARD LEUKEMIA/LYMPHOMA \r\nPANEL (24 MARKERS)-TEST      \r\n___ 10:00AM BONE MARROW IPT-DONE\r\n___ 10:00AM BONE MARROW CEBPA MUTATION ANALYSIS-PND\r\n___ 10:00AM BONE MARROW RAPID HEME PANEL-PND\r\n \r\nIMAGING:\r\n========\r\n___ 3:___BD & PELVIS W/O CONTRAST\r\nIMPRESSION:\r\n1. No evidence of retroperitoneal hematoma or lymphadenopathy.\r\n2. Stable 3.2 cm right adnexal cyst.  Continued attention is \r\nadvised on futurefollow up.\r\n3. Severe degenerative changes of lumbar spine are similar to \r\nbefore.\r\n\r\n___ 3:___HEST W/O CONTRAST\r\nIMPRESSION: \r\nNo evidence of acute intrathoracic abnormality.\r\nNo evidence of intrathoracic lymphoma.\r\nDilated main pulmonary artery, concerning for pulmonary \r\nhypertension, unchanged since ___.\r\n\r\n___ 3:38 ___\r\nCT HEAD W/O CONTRAST\r\nIMPRESSION: \r\n1. Of note, significant streak artifact from the right \r\nsupraclinoid vascular embolization coil limits evaluation of \r\nadjacent structures.  Given these limitations, there is no \r\nevidence of acute major territorial infarction, hemorrhage, or \r\nfracture.\r\n2. Paranasal sinus disease, as described above.\r\n\r\n___ 3:28 ___\r\nCT SINUS/MANDIBLE/MAXILLOFACIA\r\nIMPRESSION: \r\nMild mucosal thickening in both maxillary sinuses and ethmoid \r\nair cells, similar to recent CT head.  No evidence of bony \r\nerosion.\r\n \r\nPATHOLOGY: RESULT PENDING AT DISCHARGE\r\n==========\r\n\r\nDISCHARGE LABS:\r\n===============\r\n___ 12:00AM BLOOD WBC-2.5* RBC-2.29* Hgb-7.2* Hct-22.7* \r\nMCV-99* MCH-31.4 MCHC-31.7* RDW-20.6* RDWSD-75.0* Plt Ct-85*\r\n___ 12:00AM BLOOD Neuts-11* Bands-0 Lymphs-55* Monos-26* \r\nEos-0 Baso-0 ___ Metas-1* Myelos-4* Promyel-2* Blasts-1* \r\nNRBC-6* AbsNeut-0.28* AbsLymp-1.38 AbsMono-0.65 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-2+ Poiklo-1+ \r\nMacrocy-2+ Microcy-1+ Polychr-NORMAL Ovalocy-1+ \r\nSchisto-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 12:00AM BLOOD Plt Smr-LOW Plt Ct-85*\r\n___ 12:00AM BLOOD Glucose-110* UreaN-18 Creat-0.8 Na-142 \r\nK-3.6 Cl-101 HCO3-23 AnGap-22*\r\n___ 12:00AM BLOOD ALT-9 AST-11 LD(LDH)-238 AlkPhos-89 \r\nTotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.5 Mg-2.2\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\nDLBCL s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, concerning for RP bleed and \r\ndisease progression.  \r\n\r\nACUTE ISSUES:\r\n=============\r\n#Pancytopenia/Lymphoma disease status: Pancytopenic on \r\nadmission. Counts remained stable while in house. BM Bx \r\nperformed under fluoroscopy on ___ showed was concerning for \r\nMDS, final results are pending at discharge. Treatment plan \r\ndeveloped with Dr. ___ likely involve administration \r\nof dacogen but this will be further delineated outpatient. \r\nHemoglobin 7.1 on admission and patient received 1U prbcs prior \r\nto discharge.  \r\n\r\n#Infection/URI: Presented w/ congestion and recent blood nasal \r\nexudates. On ___, was febrile. Respiratory viral, Blood, and \r\nUrine cx were obtained; CXR and CT sinus were evaluated. Vanc \r\nand cefepime were started. No infectious pathogen was identified \r\nand the patient had no further fevers. On ___, vancomycin was \r\ndiscontinued. On ___, cefepime was discontinued. She received \r\nsymptomatic treatment with nasal saline and oxymetazoline. She \r\nwas discharged with levaquin 500mg q24hrs (to complete a 7D \r\ncourse on ___ \r\n\r\n#LLE Wound: Wearing Unna boot on presentation which had been \r\nplaced 5d PTA. Seen by wound c/s service. Daily dressing changes \r\nwhile in house. Lesion stable. Rash of chronic venous stasis, \r\nstable. Discharged with instructions to follow-up for usual care \r\nat ___.\r\n\r\n#Anti-coagulation/DVT: Concern for RP Bleed on admission, ruled \r\nout by CT. Rivaroxaban held and patient treated with enoxaparin. \r\nThe dose was held or modified at different times because of \r\nplanned procedures. The patient did not have any acute bleeding \r\nevents apart from bloody nasal exudate with nose blowing. On \r\ndischarge, patient was restarted on home dose of Rivaroxaban \r\n(20mg PO daily). Platelets 85K at discharge \r\n\r\n#Back Pain: Improved with rest and oxycodone while patient was \r\nin hospital. Otherwise, continued gabapentin 900mg TID at \r\ndischarge. No acute pain episodes prior to leaving.\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Pulm HTN\r\n#History of BCNU pneumonitis- Followed by Dr. ___. No active \r\nsymptoms. PRN inhalers ordered\r\n\r\n#H/o Migraine: R-sided pain, usually early morning onset, \r\nassociated with photophobia. Typically reaches peak intensity \r\nafter 4 hours and resolves with one or two episodes of vomiting. \r\nWould take indomethacin at home for this, but it is not \r\nappropriate given thrombocytopenia. No acute episodes prior to \r\ndischarge, continue to monitor closely outpatient \r\n\r\n#hyperthesia of R V1/V2- chronic, occurred after coiling \r\nprocedure for cerebral aneurysm, cont gabapentin  \r\n\r\n#GERD- PPI  \r\n\r\n#Depression- venlafaxine \r\n\r\nDISPO: patient discharged on ___. RTC on ___ on ___ with \r\nDr. ___\r\n \r\n___ on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Gabapentin 900 mg PO TID \r\n2. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n3. Rivaroxaban 20 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO BID \r\n8. Venlafaxine 25 mg PO BID \r\n9. albuterol sulfate 90 mcg/actuation inhalation Q4H:PRN \r\n10. Cyanocobalamin 1000 mcg PO QHS \r\n11. FoLIC Acid 3.2 mg PO DAILY \r\n12. Ascorbic Acid ___ mg PO BID \r\n13. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n\r\n \r\nDischarge Medications:\r\n1.  Levofloxacin 500 mg PO Q24H Duration: 6 Days \r\nTake daily from ___ to ___.  Potassium Chloride 10 mEq PO DAILY  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  Ascorbic Acid ___ mg PO BID  \r\n6.  Cyanocobalamin 1000 mcg PO QHS  \r\n7.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n8.  FoLIC Acid 3.2 mg PO DAILY  \r\n9.  Furosemide 20 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Rivaroxaban 20 mg PO DAILY  \r\n14.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\n==================\r\nMyelodisplastic Syndrome\r\nDiffuse large B cell lymphoma\r\nFebrile neutropenia\r\nRhinosinusitis\r\n\r\nSecondary Diagnoses:\r\n====================\r\nHistory of deep venous thromboembolism (DVT) on anticoagulation\r\nCommon variable immunodeficiency (CVID)\r\nMigraine\r\nChronic non-healing wound\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ came to ___ because ___ had \r\nback pain and low blood counts.\r\n\r\nWhat was done for me in the hospital?\r\n- CT scans of your torso and sinuses looking for bleeding and \r\ninfection. Neither infection nor bleeding was found.\r\n- Bone marrow biopsy to assess cancer disease status was \r\nconcerning for Myelodisplastic syndrome\r\n- Antibiotics for a fever.\r\n- Supportive care for your congestion.\r\n\r\nWhat should I do now that I am leaving the hospital?\r\n- Attend your scheduled follow-up appointments, listed below.\r\n- Take your medications as prescribed.\r\n- Return the to hospital if ___ have any concerning symptoms \r\n(some key symptoms are listed below).\r\n\r\nIt was a pleasure participating in your care. Wishing ___ all \r\nthe best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-17:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \ndapsone\n \nAttending: ___. Chief Complaint:\nBack pain, fever + neutropenia\n \nMajor Surgical or Invasive Procedure:\nL psoas and prespinal biopsy\nLLE skin biopsy",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-17",
        "chart_time": "104487",
        "section": "General",
        "position": 0,
        "tokenCount": 84,
        "note_metadata": {
          "note_id": "18887130-DS-17",
          "subject_id": 18887130,
          "hadm_id": 27240020,
          "note_type": "DS",
          "note_seq": 17,
          "charttime": 104487,
          "storetime": 104488.35277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, fever + neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nL psoas and prespinal biopsy\r\nLLE skin biopsy\r\n\r\n \r\nHistory of Present Illness:\r\n___ F with CVID, h/o transformed follicular lymphoma and h/o CLL \r\ns/p auto SCT (BEAM prep) in ___ in remission from lymphoma \r\nstandpoint but developed worsening pancytopenia and bleeding \r\nissues this month found to have treatment related MDS, now C1D3 \r\ndacogen presenting with borderline neutropenia and temp today of \r\n100.4.\r\n\r\nOther v/s in clinic: Vital Signs: BP: 111/53. Heart Rate:\r\n98. O2 Saturation%: 100.  Weight: 256.6. Height: 61.25. BMI:\r\n48.1. Temperature: 100.4. Resp. Rate: 18. Pain Score: 5 (back). \r\n\r\nGiven functional neutropenia, admitted for treatment of febrile \r\nneutropenia. Got vanc/cefepime in clinic. Blood cultures sent in \r\nclinic. She reported having some chills at the time and general \r\nfatigue but denied any other specific symptoms. Temp came back \r\ndown on it's own and she was 98.9 before leaving clinic. Hgb \r\n7.1,\r\nclinic orderd 1u blood which she will receive here. Regarding \r\nher other PMH: she is on xarelto for thrombosis history (DVT, \r\nalso has IVCF which was placed), and has h/o bleo toxicity \r\npneumonitis (off steroids now but cont with inhalers), and also \r\nhas intermittent LBP and left sciatica due to degenerative \r\ndisease,\r\non gabapentin, and she has chronic right pupil dilation and \r\ndysmetria.\r\n\r\nNote she was recently admitted and discharged ___. SHe had BM \r\nbx ___ which showed MDS as above. She also reported nasal \r\ncongestion and had fever ___, initially covered broadly but \r\nwith negative cultures, ultimately discharged to complete 7d \r\ncourse of levaquin on ___. Pt states she stopped taking the \r\nlevoquin ___ days ago. Last night took her temp and it was 100.1 \r\n(was\r\ninstructed to monitor temps, she had no symptoms that prompted \r\nthis check). This morning driving in to clinic appointment felt \r\na bit chilled but not shaking and not sick in any other way. In \r\nclinic found to have temp of 100.4. Also notes that she \r\ntypically has left sided sciatica but that in the past week sinc \r\nethe bone marrow biopsy has developed right lower back pain \r\nwhich has required ___ doses of vicodin daily and is a new pain \r\nworsening over time, present constantly, but worse with movement \r\nor deep palpation. Denies loss of strength or sensation though \r\nhas chronic right foot drop and dysesthesias at baseline after \r\nknee replacement on that side in the past. No incontinence or \r\ndysuria.\r\n\r\nFinally, her history is significant for a \"blood blister\" she \r\nnoted on the left foreleg per pt about ___ weeks ago which was \r\nultimately debrided in the past, and poor wound healing \r\nattributed to venous stasis. THis has been healing well she \r\nstates, though there is still an open wound surrounded by \r\nerythema but she is confident it continues to improve \r\ndramatically and no recent drainage. She is covering it with \r\nxeroform dressing daily.\r\n\r\nfurther nose bleeds or other bleeding.  She is also noted for a \r\nnonhealing wound on her left leg after hitting her shin several \r\nweeks ago.  She is using xerofrom dressing to the area and \r\nchanging it daily with slow healing. All other 10 point ROS neg.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM:\r\nGeneral: NAD  \r\nT 99.6 BP 100/58  HR 95  20  96%RA\r\nHEENT: Right pupil slower to react to light which is baseline.  \r\nMMM, no OP lesions or thrush.  \r\nCV: RR, NL S1S2 no MRG  \r\nPULM: CTAB no wheezing or crackles  \r\nABD: BS+, soft, NTND  \r\nSKIN/limbs: left anterior foreleg with 1cm open circular wound \r\nwithout drainage, covered w/xeroform, with 4-5 cm diameter \r\nsurrounding erythema, not warm to touch, lower extr are equal in \r\ngirth, no pitting edema\r\nBack: pt is tender to palpation around the left SI joint, has \r\nresolving hematoma over the medial aspect of right sacrum, but \r\nno tenderness over the hematoma which appears superficial, no \r\nswelling\r\n\r\nDISCHARGE EXAM:\r\nVS: 98.1 ___ 22 97RA\r\nGEN: NAD, seated in chair, conversational\r\nHEENT: AT/NC; R pupil mildly larger, slower to react than L \r\n(baseline per records); MMM\r\nCV: RRR, no M/R/G, +S1/S2\r\nPULM: CTAB\r\nABD: obese, soft, nontender to palpation, referred pain from \r\nback in band/belt distribution in low abdomen; +BS\r\nSKIN: unroofed vesicle with mild bleeding covered with xeroform\r\nEXT: chronic venous stasis changes in B/L ___ over shins\r\nNEURO: A/Ox3; CNII-XII assessed and grossly intact except for \r\nR>L pupillary dilataion and sluggish reactivity\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n___ 11:30AM BLOOD WBC-2.3* RBC-2.28* Hgb-7.1* Hct-22.1* \r\nMCV-97 MCH-31.1 MCHC-32.1 RDW-21.8* RDWSD-77.3* Plt ___\r\n___ 11:30AM BLOOD Neuts-37 Bands-6* ___ Monos-11 \r\nEos-0 Baso-0 Atyps-2* Metas-3* Myelos-1* Blasts-2* NRBC-3* \r\nAbsNeut-0.99* AbsLymp-0.92* AbsMono-0.25 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD ___ PTT-39.0* ___\r\n___ 11:30AM BLOOD UreaN-15 Creat-0.9 Na-137 K-3.8 Cl-102 \r\nHCO3-25 AnGap-14\r\n___ 11:30AM BLOOD ALT-8 AST-10 LD(LDH)-260* AlkPhos-81 \r\nTotBili-0.3\r\n___ 11:30AM BLOOD Albumin-3.4* Calcium-8.1* Mg-2.2\r\n\r\nINTERVAL LABS:\r\n___ 12:00AM BLOOD CRP-108.7*\r\n___ 12:00AM BLOOD IgG-805\r\n___ 04:00PM BLOOD HIV Ab-Negative\r\n___ 04:00PM BLOOD CMV VL-NOT DETECT\r\n___ 02:20PM BLOOD SED RATE-Test      \r\n___ 04:00PM BLOOD HERPES 6 DNA PCR, QUANTITATIVE-Test      \r\n___ 04:00PM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-Test   \r\n   \r\n___ 07:45PM BLOOD B-GLUCAN-Test      \r\n___ 07:45PM BLOOD ASPERGILLUS GALACTOMANNAN ANTIGEN-Test\r\n\r\nMICRO:\r\n___ Skin biopsy: All cx. negative\r\n___ RPR: negative\r\n___ Myco/lytic cx: no growth\r\n___ Psoas tissue cx: negative\r\nAll other blood and urine cultures final/negative\r\n\r\nSTUDIES:\r\nConclusions\r\nThe left atrium is mildly dilated. The left atrial volume index \r\nis mildly increased. The estimated right atrial pressure is ___ \r\nmmHg. Left ventricular wall thickness, cavity size and \r\nregional/global systolic function are normal (LVEF >55%). The \r\nestimated cardiac index is normal (>=2.5L/min/m2). Tissue \r\nDoppler imaging suggests an increased left ventricular filling \r\npressure (PCWP>18mmHg). Right ventricular chamber size and free \r\nwall motion are normal. The aortic valve leaflets (3) are mildly \r\nthickened but aortic stenosis is not present. No masses or \r\nvegetations are seen on the aortic valve. No aortic valve \r\nabscess is seen. No aortic regurgitation is seen. The mitral \r\nvalve leaflets are mildly thickened. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. There is moderate \r\npulmonary artery systolic hypertension. No vegetation/mass is \r\nseen on the pulmonic valve. There is an anterior space which \r\nmost likely represents a prominent fat pad. \r\n\r\nIMPRESSION: No echocardiographic evidence of endocarditis. \r\nNormal biventricular cavity sizes with preserved global and \r\nregional biventricular systolic function. Suggestion of elevated \r\nLV filling pressure. Mild mitral and tricuspid regurgitation. \r\nModerate pulmonary hypertension.\r\n\r\nCompared with the prior study (images reviewed) of ___, \r\nthe degrees of mitral and tricuspid regurgitation are slightly \r\ngreater and the estimated pulmonary arterial pressure is higher.\r\n\r\nIMAGING:\r\n___ L gluteal U/S:\r\nIMPRESSION:\r\nInflammation or edema of the superficial soft tissues without \r\nfocal fluid\r\ncollection.\r\n\r\n___ MR ___:\r\nIMPRESSION:\r\n1. Severe multilevel degenerative changes as described above \r\nhave slightly\r\nprogressed since the prior examination of ___.\r\n2. Scoliosis of lumbar spine with  signal changes and edema \r\nedema in the\r\nendplates, mild adjacent soft tissue signal and enhancement and \r\nenhancement in the left psoas muscle at L4-5 level without \r\nepidural phlegmon or paraspinal fluid collection are \r\nnonspecific.  Both advanced degenerative changes or early \r\ndiscitis osteomyelitis could give similar appearances.  The \r\nappearance on the prior CT abdomen of ___ or more was \r\nmore consistent with degenerative change. However, Correlation \r\nwith laboratory findings is essential to exclude early discitis \r\nosteomyelitis.\r\n\r\nDISCHARGE LABS:\r\n___ 01:18AM BLOOD WBC-0.4* RBC-2.58* Hgb-7.6* Hct-23.6* \r\nMCV-92 MCH-29.5 MCHC-32.2 RDW-18.6* RDWSD-62.0* Plt Ct-15*\r\n___ 01:18AM BLOOD Neuts-12* Bands-0 Lymphs-78* Monos-7 \r\nEos-1 Baso-0 Atyps-1* ___ Myelos-1* AbsNeut-0.05* \r\nAbsLymp-0.32* AbsMono-0.03* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:18AM BLOOD ___ PTT-34.5 ___\r\n___ 01:18AM BLOOD Glucose-147* UreaN-14 Creat-0.9 Na-136 \r\nK-3.7 Cl-99 HCO3-27 AnGap-14\r\n___ 12:00AM BLOOD ALT-14 AST-14 LD(LDH)-247 AlkPhos-90 \r\nTotBili-0.5\r\n___ 01:18AM BLOOD Calcium-8.1* Phos-2.7 Mg-2.3\r\n___ 06:25AM BLOOD Vanco-19.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, diagnosed with treatment related \r\nMDS. ___ was started on decitabine as an outpatient and \r\nre-presented with fevers and neutropenia. She had an exhaustive \r\nworkup of her fevers, including skin and psoas biopsies, and \r\ntissue uPCR was sent, but there was no culture positivity or \r\npositive findings in her infectious workup. However, after \r\nconsultation with ID, it was decided to treat empirically for \r\npresumptive osteomyelitis/discitis with 6 weeks of vancomycin \r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO \r\nq24h). Micafungin was chosen instead of posaconazole due to \r\n___ differences; but she did receive posaconazole while \r\ninpatient. Simultaneously, the patient was having significantly \r\nworsened back pain after her MDS diagnosing bone marrow biopsy. \r\nShe was started on opioid pain control, which was uptitrated and \r\naugmented with Valium to good effect. She went home with BID \r\noxycontin, PRN oxycodone, and QHS Valium. She will follow-up as \r\noutpatient with Dr. ___.\r\n\r\n# Fever + neutropenia: The patient received 2 doses of \r\ndecitabine as outpatient prior to experiencing first fever of \r\n101 at home, then 100.4 in clinic during third dose decitabine \r\nadministration. She was admitted for fever in setting of \r\ncytoreduction, and she eventually became truly neutropenic. An \r\nexhaustive workup was performed, centering on MRI findings of \r\npotential osteomyelitis/discitis with potential L psoas \r\ninvovlvement. This tissue was biopsied, negative by culture, and \r\nuPCR pending at the time of discharge. The patient will be given \r\nempiric therapy of vancomycin/cefepime/micafungin for a total of \r\n6 weeks (___) and instructed to have 1 month follow-up \r\nspinal imaging. A LLE wound was also biopsied and grew nothing. \r\nBy exclusion, decitabine is thought to be the likely culprit of \r\nthe fever.\r\n\r\n# left gluteal furuncle: Formed at the marked site of the ___ L \r\npsoas biopsy. By ultrasound found to only have subcutaneous \r\nedema without fluid collection. This will be followed by patient \r\nand outpatient team as potential new nidus of infection if \r\nappearing worse or causing pain.\r\n\r\n# low back pain: Acute on chronic in this patient, who has \r\nbaseline degenerative changes. She also had R iliac crest bone \r\nmarrow biopsy prior to this admission which may have caused \r\nhematoma, inflammatory, or direct nerve injury which contributed \r\nto her severe pain. She was uptitrated to a pain regimen \r\nincluding standing Oxycontin BID, oxycodone PRN, and Valium QHS, \r\nwhich she was able to tolerate with good effect. She worked with \r\n___ and was deemed fit for discharge home with services.\r\n\r\n# treatment related MDS: Secondary to autoSCT with BEAM \r\nconditioning for DLBCL. Patient had bone marrow biopsy which \r\ndiagnosed new-onset treatment related MDS, but may have also \r\ncaused severe acute-on-chronic back pain for which she is \r\nreceiving opioids and benzodiazapines. Will receive Bactrim for \r\nPCP prophylaxis starting at discharge.\r\n\r\n# history of DVT: History of LLE DVTs, on Rivaroxaban at home \r\nand IVC filter in place. Rivaroxaban was held once Plt<75k in \r\nsetting of multi-line decline from decitabine.\r\n\r\n# common variable immunodeficiency: Patient had multiple IgG \r\nchecks for known CVID and did not require IVIG as inpatient.\r\n\r\nTRANSITIONAL ISSUES:\r\n- complete 6 week antibiotics: vancomycin, cefepime, \r\nmicafungin(d1 = ___, end ___, follow-up with OPAT\r\n- weekly labs: CBC with differential, BUN, Cr, Vancomycin\r\ntrough, AST, ALT (fax to ATTN: ___ CLINIC - FAX: \r\n___\r\n- repeat MR ___ 1 month after discharge\r\n- PCP prophylaxis with ___ SS daily\r\n- plan future decitabine with Dr. ___ team\r\n- plan for curative transplant with Dr. ___ team\r\n- continue to monitor L gluteal furuncle\r\n- consider restarting rivaroxaban when deemed appropriate \r\n(stopped inpatient due to thrombocytopenia)\r\n- Code: Full\r\n- Contact: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. FoLIC Acid 3.2 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Venlafaxine 25 mg PO BID \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n12. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n13. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n14. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q6H:PRN \r\nPain - Mild \r\n\r\n \r\nDischarge Medications:\r\n1.  CefePIME 2 g IV Q12H \r\nRX *cefepime [Maxipime] 2 gram 2 g IV every twelve (12) hours \r\nDisp #*60 Vial Refills:*0 \r\n2.  Diazepam 5 mg PO QHS \r\nRX *diazepam 5 mg 1 tab by mouth at bedtime Disp #*7 Tablet \r\nRefills:*0 \r\n3.  Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium [Colace] 100 mg 1 capsule(s) by mouth twice \r\na day Disp #*60 Capsule Refills:*0 \r\n4.  Micafungin 100 mg IV Q24H \r\nRX *micafungin [Mycamine] 100 mg 100 mg IV q24h Disp #*30 Vial \r\nRefills:*0 \r\n5.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\nRX *oxycodone 10 mg 1 tablet(s) by mouth every six (6) hours \r\nDisp #*24 Tablet Refills:*0 \r\n6.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\nRX *oxycodone 20 mg 1 tablet(s) by mouth every twelve (12) hours \r\nDisp #*14 Tablet Refills:*0 \r\n7.  Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\nRX *polyethylene glycol 3350 [Miralax] 17 gram 1 powder(s) by \r\nmouth daily Disp #*30 Packet Refills:*0 \r\n8.  Senna 8.6 mg PO BID:PRN constipation \r\nRX *sennosides [senna] 8.6 mg 1 tab by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n9.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n10.  Vancomycin 750 mg IV Q 12H \r\nRX *vancomycin 750 mg 750 mg IV every twelve (12) hours Disp \r\n#*60 Vial Refills:*0 \r\n11.  Potassium Chloride 10 mEq PO DAILY  \r\n12.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n13.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n14.  Ascorbic Acid ___ mg PO BID  \r\n15.  Cyanocobalamin 1000 mcg PO QHS  \r\n16.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n17.  FoLIC Acid 3.2 mg PO DAILY  \r\n18.  Furosemide 20 mg PO DAILY  \r\n19.  Gabapentin 900 mg PO TID  \r\n20.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n21.  Omeprazole 20 mg PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until insructed to by your outpatient \r\ndoctor\r\n24.Outpatient Lab Work\r\nTo be drawn weekly: CBC with differential, BUN, Cr, Vancomycin \r\ntrough, AST, ALT\r\nSend results to: ___ CLINIC - FAX: ___\r\nICD 10: ___.0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n- fever and neutropenia\r\n- low back pain\r\n- treatment related MDS\r\n- history of DVT\r\n- common variable immunodeficiency\r\n- left gluteal furuncle\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ was a pleasure caring for you while you were at ___. You \r\ncame to the hospital with a fever in the setting of your \r\ndecitabine therapy and had significantly worse back pain after \r\nyour bone marrow biopsy several weeks back. Despite a thorough \r\nworkup including multiple sets of blood cultures, urine \r\ncultures, and imaging including MRIs there was no infectious \r\nsource found as the culprit for your fevers. You were started on \r\nIV antibiotics to treat a presumptive infection, which you will \r\ncontinue for six weeks. You will follow-up with the infectious \r\ndisease physicians as an outpatient. You were started on several \r\nopioid pain medications and Valium which helped you be more \r\nactive and have good pain control. \r\n\r\nIt was a pleasure to participate in your care. We wish you all \r\nthe best.\r\n\r\nSincerely,\r\nYour ___ care team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-17:1",
      "text": "History of Present Illness:\n___ F with CVID, h/o transformed follicular lymphoma and h/o CLL \ns/p auto SCT (BEAM prep) in ___ in remission from lymphoma \nstandpoint but developed worsening pancytopenia and bleeding \nissues this month found to have treatment related MDS, now C1D3 \ndacogen presenting with borderline neutropenia and temp today of \n100.4. Other v/s in clinic: Vital Signs: BP: 111/53. Heart Rate:\n98. O2 Saturation%: 100. Weight: 256.6. Height: 61.25. BMI:\n48.1. Temperature: 100.4. Resp. Rate: 18. Pain Score: 5 (back). Given functional neutropenia, admitted for treatment of febrile \nneutropenia. Got vanc/cefepime in clinic. Blood cultures sent in \nclinic. She reported having some chills at the time and general \nfatigue but denied any other specific symptoms. Temp came back \ndown on it's own and she was 98.9 before leaving clinic. Hgb \n7.1,\nclinic orderd 1u blood which she will receive here. Regarding \nher other PMH: she is on xarelto for thrombosis history (DVT, \nalso has IVCF which was placed), and has h/o bleo toxicity \npneumonitis (off steroids now but cont with inhalers), and also \nhas intermittent LBP and left sciatica due to degenerative \ndisease,\non gabapentin, and she has chronic right pupil dilation and \ndysmetria. Note she was recently admitted and discharged ___. SHe had BM \nbx ___ which showed MDS as above. She also reported nasal \ncongestion and had fever ___, initially covered broadly but \nwith negative cultures, ultimately discharged to complete 7d \ncourse of levaquin on ___. Pt states she stopped taking the \nlevoquin ___ days ago. Last night took her temp and it was 100.1 \n(was\ninstructed to monitor temps, she had no symptoms that prompted \nthis check). This morning driving in to clinic appointment felt \na bit chilled but not shaking and not sick in any other way. In \nclinic found to have temp of 100.4. Also notes that she \ntypically has left sided sciatica but that in the past week sinc \nethe bone marrow biopsy has developed right lower back pain \nwhich has required ___ doses of vicodin daily and is a new pain \nworsening over time, present constantly, but worse with movement \nor deep palpation. Denies loss of strength or sensation though \nhas chronic right foot drop and dysesthesias at baseline after \nknee replacement on that side in the past. No incontinence or \ndysuria. Finally, her history is significant for a \"blood blister\" she \nnoted on the left foreleg per pt about ___ weeks ago which was \nultimately debrided in the past, and poor wound healing \nattributed to venous stasis. THis has been healing well she \nstates, though there is still an open wound surrounded by \nerythema but she is confident it continues to improve \ndramatically and no recent drainage.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-17",
        "chart_time": "104487",
        "section": "General",
        "position": 1,
        "tokenCount": 684,
        "note_metadata": {
          "note_id": "18887130-DS-17",
          "subject_id": 18887130,
          "hadm_id": 27240020,
          "note_type": "DS",
          "note_seq": 17,
          "charttime": 104487,
          "storetime": 104488.35277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, fever + neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nL psoas and prespinal biopsy\r\nLLE skin biopsy\r\n\r\n \r\nHistory of Present Illness:\r\n___ F with CVID, h/o transformed follicular lymphoma and h/o CLL \r\ns/p auto SCT (BEAM prep) in ___ in remission from lymphoma \r\nstandpoint but developed worsening pancytopenia and bleeding \r\nissues this month found to have treatment related MDS, now C1D3 \r\ndacogen presenting with borderline neutropenia and temp today of \r\n100.4.\r\n\r\nOther v/s in clinic: Vital Signs: BP: 111/53. Heart Rate:\r\n98. O2 Saturation%: 100.  Weight: 256.6. Height: 61.25. BMI:\r\n48.1. Temperature: 100.4. Resp. Rate: 18. Pain Score: 5 (back). \r\n\r\nGiven functional neutropenia, admitted for treatment of febrile \r\nneutropenia. Got vanc/cefepime in clinic. Blood cultures sent in \r\nclinic. She reported having some chills at the time and general \r\nfatigue but denied any other specific symptoms. Temp came back \r\ndown on it's own and she was 98.9 before leaving clinic. Hgb \r\n7.1,\r\nclinic orderd 1u blood which she will receive here. Regarding \r\nher other PMH: she is on xarelto for thrombosis history (DVT, \r\nalso has IVCF which was placed), and has h/o bleo toxicity \r\npneumonitis (off steroids now but cont with inhalers), and also \r\nhas intermittent LBP and left sciatica due to degenerative \r\ndisease,\r\non gabapentin, and she has chronic right pupil dilation and \r\ndysmetria.\r\n\r\nNote she was recently admitted and discharged ___. SHe had BM \r\nbx ___ which showed MDS as above. She also reported nasal \r\ncongestion and had fever ___, initially covered broadly but \r\nwith negative cultures, ultimately discharged to complete 7d \r\ncourse of levaquin on ___. Pt states she stopped taking the \r\nlevoquin ___ days ago. Last night took her temp and it was 100.1 \r\n(was\r\ninstructed to monitor temps, she had no symptoms that prompted \r\nthis check). This morning driving in to clinic appointment felt \r\na bit chilled but not shaking and not sick in any other way. In \r\nclinic found to have temp of 100.4. Also notes that she \r\ntypically has left sided sciatica but that in the past week sinc \r\nethe bone marrow biopsy has developed right lower back pain \r\nwhich has required ___ doses of vicodin daily and is a new pain \r\nworsening over time, present constantly, but worse with movement \r\nor deep palpation. Denies loss of strength or sensation though \r\nhas chronic right foot drop and dysesthesias at baseline after \r\nknee replacement on that side in the past. No incontinence or \r\ndysuria.\r\n\r\nFinally, her history is significant for a \"blood blister\" she \r\nnoted on the left foreleg per pt about ___ weeks ago which was \r\nultimately debrided in the past, and poor wound healing \r\nattributed to venous stasis. THis has been healing well she \r\nstates, though there is still an open wound surrounded by \r\nerythema but she is confident it continues to improve \r\ndramatically and no recent drainage. She is covering it with \r\nxeroform dressing daily.\r\n\r\nfurther nose bleeds or other bleeding.  She is also noted for a \r\nnonhealing wound on her left leg after hitting her shin several \r\nweeks ago.  She is using xerofrom dressing to the area and \r\nchanging it daily with slow healing. All other 10 point ROS neg.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM:\r\nGeneral: NAD  \r\nT 99.6 BP 100/58  HR 95  20  96%RA\r\nHEENT: Right pupil slower to react to light which is baseline.  \r\nMMM, no OP lesions or thrush.  \r\nCV: RR, NL S1S2 no MRG  \r\nPULM: CTAB no wheezing or crackles  \r\nABD: BS+, soft, NTND  \r\nSKIN/limbs: left anterior foreleg with 1cm open circular wound \r\nwithout drainage, covered w/xeroform, with 4-5 cm diameter \r\nsurrounding erythema, not warm to touch, lower extr are equal in \r\ngirth, no pitting edema\r\nBack: pt is tender to palpation around the left SI joint, has \r\nresolving hematoma over the medial aspect of right sacrum, but \r\nno tenderness over the hematoma which appears superficial, no \r\nswelling\r\n\r\nDISCHARGE EXAM:\r\nVS: 98.1 ___ 22 97RA\r\nGEN: NAD, seated in chair, conversational\r\nHEENT: AT/NC; R pupil mildly larger, slower to react than L \r\n(baseline per records); MMM\r\nCV: RRR, no M/R/G, +S1/S2\r\nPULM: CTAB\r\nABD: obese, soft, nontender to palpation, referred pain from \r\nback in band/belt distribution in low abdomen; +BS\r\nSKIN: unroofed vesicle with mild bleeding covered with xeroform\r\nEXT: chronic venous stasis changes in B/L ___ over shins\r\nNEURO: A/Ox3; CNII-XII assessed and grossly intact except for \r\nR>L pupillary dilataion and sluggish reactivity\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n___ 11:30AM BLOOD WBC-2.3* RBC-2.28* Hgb-7.1* Hct-22.1* \r\nMCV-97 MCH-31.1 MCHC-32.1 RDW-21.8* RDWSD-77.3* Plt ___\r\n___ 11:30AM BLOOD Neuts-37 Bands-6* ___ Monos-11 \r\nEos-0 Baso-0 Atyps-2* Metas-3* Myelos-1* Blasts-2* NRBC-3* \r\nAbsNeut-0.99* AbsLymp-0.92* AbsMono-0.25 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD ___ PTT-39.0* ___\r\n___ 11:30AM BLOOD UreaN-15 Creat-0.9 Na-137 K-3.8 Cl-102 \r\nHCO3-25 AnGap-14\r\n___ 11:30AM BLOOD ALT-8 AST-10 LD(LDH)-260* AlkPhos-81 \r\nTotBili-0.3\r\n___ 11:30AM BLOOD Albumin-3.4* Calcium-8.1* Mg-2.2\r\n\r\nINTERVAL LABS:\r\n___ 12:00AM BLOOD CRP-108.7*\r\n___ 12:00AM BLOOD IgG-805\r\n___ 04:00PM BLOOD HIV Ab-Negative\r\n___ 04:00PM BLOOD CMV VL-NOT DETECT\r\n___ 02:20PM BLOOD SED RATE-Test      \r\n___ 04:00PM BLOOD HERPES 6 DNA PCR, QUANTITATIVE-Test      \r\n___ 04:00PM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-Test   \r\n   \r\n___ 07:45PM BLOOD B-GLUCAN-Test      \r\n___ 07:45PM BLOOD ASPERGILLUS GALACTOMANNAN ANTIGEN-Test\r\n\r\nMICRO:\r\n___ Skin biopsy: All cx. negative\r\n___ RPR: negative\r\n___ Myco/lytic cx: no growth\r\n___ Psoas tissue cx: negative\r\nAll other blood and urine cultures final/negative\r\n\r\nSTUDIES:\r\nConclusions\r\nThe left atrium is mildly dilated. The left atrial volume index \r\nis mildly increased. The estimated right atrial pressure is ___ \r\nmmHg. Left ventricular wall thickness, cavity size and \r\nregional/global systolic function are normal (LVEF >55%). The \r\nestimated cardiac index is normal (>=2.5L/min/m2). Tissue \r\nDoppler imaging suggests an increased left ventricular filling \r\npressure (PCWP>18mmHg). Right ventricular chamber size and free \r\nwall motion are normal. The aortic valve leaflets (3) are mildly \r\nthickened but aortic stenosis is not present. No masses or \r\nvegetations are seen on the aortic valve. No aortic valve \r\nabscess is seen. No aortic regurgitation is seen. The mitral \r\nvalve leaflets are mildly thickened. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. There is moderate \r\npulmonary artery systolic hypertension. No vegetation/mass is \r\nseen on the pulmonic valve. There is an anterior space which \r\nmost likely represents a prominent fat pad. \r\n\r\nIMPRESSION: No echocardiographic evidence of endocarditis. \r\nNormal biventricular cavity sizes with preserved global and \r\nregional biventricular systolic function. Suggestion of elevated \r\nLV filling pressure. Mild mitral and tricuspid regurgitation. \r\nModerate pulmonary hypertension.\r\n\r\nCompared with the prior study (images reviewed) of ___, \r\nthe degrees of mitral and tricuspid regurgitation are slightly \r\ngreater and the estimated pulmonary arterial pressure is higher.\r\n\r\nIMAGING:\r\n___ L gluteal U/S:\r\nIMPRESSION:\r\nInflammation or edema of the superficial soft tissues without \r\nfocal fluid\r\ncollection.\r\n\r\n___ MR ___:\r\nIMPRESSION:\r\n1. Severe multilevel degenerative changes as described above \r\nhave slightly\r\nprogressed since the prior examination of ___.\r\n2. Scoliosis of lumbar spine with  signal changes and edema \r\nedema in the\r\nendplates, mild adjacent soft tissue signal and enhancement and \r\nenhancement in the left psoas muscle at L4-5 level without \r\nepidural phlegmon or paraspinal fluid collection are \r\nnonspecific.  Both advanced degenerative changes or early \r\ndiscitis osteomyelitis could give similar appearances.  The \r\nappearance on the prior CT abdomen of ___ or more was \r\nmore consistent with degenerative change. However, Correlation \r\nwith laboratory findings is essential to exclude early discitis \r\nosteomyelitis.\r\n\r\nDISCHARGE LABS:\r\n___ 01:18AM BLOOD WBC-0.4* RBC-2.58* Hgb-7.6* Hct-23.6* \r\nMCV-92 MCH-29.5 MCHC-32.2 RDW-18.6* RDWSD-62.0* Plt Ct-15*\r\n___ 01:18AM BLOOD Neuts-12* Bands-0 Lymphs-78* Monos-7 \r\nEos-1 Baso-0 Atyps-1* ___ Myelos-1* AbsNeut-0.05* \r\nAbsLymp-0.32* AbsMono-0.03* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:18AM BLOOD ___ PTT-34.5 ___\r\n___ 01:18AM BLOOD Glucose-147* UreaN-14 Creat-0.9 Na-136 \r\nK-3.7 Cl-99 HCO3-27 AnGap-14\r\n___ 12:00AM BLOOD ALT-14 AST-14 LD(LDH)-247 AlkPhos-90 \r\nTotBili-0.5\r\n___ 01:18AM BLOOD Calcium-8.1* Phos-2.7 Mg-2.3\r\n___ 06:25AM BLOOD Vanco-19.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, diagnosed with treatment related \r\nMDS. ___ was started on decitabine as an outpatient and \r\nre-presented with fevers and neutropenia. She had an exhaustive \r\nworkup of her fevers, including skin and psoas biopsies, and \r\ntissue uPCR was sent, but there was no culture positivity or \r\npositive findings in her infectious workup. However, after \r\nconsultation with ID, it was decided to treat empirically for \r\npresumptive osteomyelitis/discitis with 6 weeks of vancomycin \r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO \r\nq24h). Micafungin was chosen instead of posaconazole due to \r\n___ differences; but she did receive posaconazole while \r\ninpatient. Simultaneously, the patient was having significantly \r\nworsened back pain after her MDS diagnosing bone marrow biopsy. \r\nShe was started on opioid pain control, which was uptitrated and \r\naugmented with Valium to good effect. She went home with BID \r\noxycontin, PRN oxycodone, and QHS Valium. She will follow-up as \r\noutpatient with Dr. ___.\r\n\r\n# Fever + neutropenia: The patient received 2 doses of \r\ndecitabine as outpatient prior to experiencing first fever of \r\n101 at home, then 100.4 in clinic during third dose decitabine \r\nadministration. She was admitted for fever in setting of \r\ncytoreduction, and she eventually became truly neutropenic. An \r\nexhaustive workup was performed, centering on MRI findings of \r\npotential osteomyelitis/discitis with potential L psoas \r\ninvovlvement. This tissue was biopsied, negative by culture, and \r\nuPCR pending at the time of discharge. The patient will be given \r\nempiric therapy of vancomycin/cefepime/micafungin for a total of \r\n6 weeks (___) and instructed to have 1 month follow-up \r\nspinal imaging. A LLE wound was also biopsied and grew nothing. \r\nBy exclusion, decitabine is thought to be the likely culprit of \r\nthe fever.\r\n\r\n# left gluteal furuncle: Formed at the marked site of the ___ L \r\npsoas biopsy. By ultrasound found to only have subcutaneous \r\nedema without fluid collection. This will be followed by patient \r\nand outpatient team as potential new nidus of infection if \r\nappearing worse or causing pain.\r\n\r\n# low back pain: Acute on chronic in this patient, who has \r\nbaseline degenerative changes. She also had R iliac crest bone \r\nmarrow biopsy prior to this admission which may have caused \r\nhematoma, inflammatory, or direct nerve injury which contributed \r\nto her severe pain. She was uptitrated to a pain regimen \r\nincluding standing Oxycontin BID, oxycodone PRN, and Valium QHS, \r\nwhich she was able to tolerate with good effect. She worked with \r\n___ and was deemed fit for discharge home with services.\r\n\r\n# treatment related MDS: Secondary to autoSCT with BEAM \r\nconditioning for DLBCL. Patient had bone marrow biopsy which \r\ndiagnosed new-onset treatment related MDS, but may have also \r\ncaused severe acute-on-chronic back pain for which she is \r\nreceiving opioids and benzodiazapines. Will receive Bactrim for \r\nPCP prophylaxis starting at discharge.\r\n\r\n# history of DVT: History of LLE DVTs, on Rivaroxaban at home \r\nand IVC filter in place. Rivaroxaban was held once Plt<75k in \r\nsetting of multi-line decline from decitabine.\r\n\r\n# common variable immunodeficiency: Patient had multiple IgG \r\nchecks for known CVID and did not require IVIG as inpatient.\r\n\r\nTRANSITIONAL ISSUES:\r\n- complete 6 week antibiotics: vancomycin, cefepime, \r\nmicafungin(d1 = ___, end ___, follow-up with OPAT\r\n- weekly labs: CBC with differential, BUN, Cr, Vancomycin\r\ntrough, AST, ALT (fax to ATTN: ___ CLINIC - FAX: \r\n___\r\n- repeat MR ___ 1 month after discharge\r\n- PCP prophylaxis with ___ SS daily\r\n- plan future decitabine with Dr. ___ team\r\n- plan for curative transplant with Dr. ___ team\r\n- continue to monitor L gluteal furuncle\r\n- consider restarting rivaroxaban when deemed appropriate \r\n(stopped inpatient due to thrombocytopenia)\r\n- Code: Full\r\n- Contact: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. FoLIC Acid 3.2 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Venlafaxine 25 mg PO BID \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n12. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n13. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n14. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q6H:PRN \r\nPain - Mild \r\n\r\n \r\nDischarge Medications:\r\n1.  CefePIME 2 g IV Q12H \r\nRX *cefepime [Maxipime] 2 gram 2 g IV every twelve (12) hours \r\nDisp #*60 Vial Refills:*0 \r\n2.  Diazepam 5 mg PO QHS \r\nRX *diazepam 5 mg 1 tab by mouth at bedtime Disp #*7 Tablet \r\nRefills:*0 \r\n3.  Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium [Colace] 100 mg 1 capsule(s) by mouth twice \r\na day Disp #*60 Capsule Refills:*0 \r\n4.  Micafungin 100 mg IV Q24H \r\nRX *micafungin [Mycamine] 100 mg 100 mg IV q24h Disp #*30 Vial \r\nRefills:*0 \r\n5.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\nRX *oxycodone 10 mg 1 tablet(s) by mouth every six (6) hours \r\nDisp #*24 Tablet Refills:*0 \r\n6.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\nRX *oxycodone 20 mg 1 tablet(s) by mouth every twelve (12) hours \r\nDisp #*14 Tablet Refills:*0 \r\n7.  Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\nRX *polyethylene glycol 3350 [Miralax] 17 gram 1 powder(s) by \r\nmouth daily Disp #*30 Packet Refills:*0 \r\n8.  Senna 8.6 mg PO BID:PRN constipation \r\nRX *sennosides [senna] 8.6 mg 1 tab by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n9.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n10.  Vancomycin 750 mg IV Q 12H \r\nRX *vancomycin 750 mg 750 mg IV every twelve (12) hours Disp \r\n#*60 Vial Refills:*0 \r\n11.  Potassium Chloride 10 mEq PO DAILY  \r\n12.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n13.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n14.  Ascorbic Acid ___ mg PO BID  \r\n15.  Cyanocobalamin 1000 mcg PO QHS  \r\n16.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n17.  FoLIC Acid 3.2 mg PO DAILY  \r\n18.  Furosemide 20 mg PO DAILY  \r\n19.  Gabapentin 900 mg PO TID  \r\n20.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n21.  Omeprazole 20 mg PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until insructed to by your outpatient \r\ndoctor\r\n24.Outpatient Lab Work\r\nTo be drawn weekly: CBC with differential, BUN, Cr, Vancomycin \r\ntrough, AST, ALT\r\nSend results to: ___ CLINIC - FAX: ___\r\nICD 10: ___.0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n- fever and neutropenia\r\n- low back pain\r\n- treatment related MDS\r\n- history of DVT\r\n- common variable immunodeficiency\r\n- left gluteal furuncle\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ was a pleasure caring for you while you were at ___. You \r\ncame to the hospital with a fever in the setting of your \r\ndecitabine therapy and had significantly worse back pain after \r\nyour bone marrow biopsy several weeks back. Despite a thorough \r\nworkup including multiple sets of blood cultures, urine \r\ncultures, and imaging including MRIs there was no infectious \r\nsource found as the culprit for your fevers. You were started on \r\nIV antibiotics to treat a presumptive infection, which you will \r\ncontinue for six weeks. You will follow-up with the infectious \r\ndisease physicians as an outpatient. You were started on several \r\nopioid pain medications and Valium which helped you be more \r\nactive and have good pain control. \r\n\r\nIt was a pleasure to participate in your care. We wish you all \r\nthe best.\r\n\r\nSincerely,\r\nYour ___ care team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-17:2",
      "text": "Denies loss of strength or sensation though \nhas chronic right foot drop and dysesthesias at baseline after \nknee replacement on that side in the past. No incontinence or \ndysuria. Finally, her history is significant for a \"blood blister\" she \nnoted on the left foreleg per pt about ___ weeks ago which was \nultimately debrided in the past, and poor wound healing \nattributed to venous stasis. THis has been healing well she \nstates, though there is still an open wound surrounded by \nerythema but she is confident it continues to improve \ndramatically and no recent drainage. She is covering it with \nxeroform dressing daily. further nose bleeds or other bleeding. She is also noted for a \nnonhealing wound on her left leg after hitting her shin several \nweeks ago. She is using xerofrom dressing to the area and \nchanging it daily with slow healing. All other 10 point ROS neg.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-17",
        "chart_time": "104487",
        "section": "General",
        "position": 2,
        "tokenCount": 220,
        "note_metadata": {
          "note_id": "18887130-DS-17",
          "subject_id": 18887130,
          "hadm_id": 27240020,
          "note_type": "DS",
          "note_seq": 17,
          "charttime": 104487,
          "storetime": 104488.35277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, fever + neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nL psoas and prespinal biopsy\r\nLLE skin biopsy\r\n\r\n \r\nHistory of Present Illness:\r\n___ F with CVID, h/o transformed follicular lymphoma and h/o CLL \r\ns/p auto SCT (BEAM prep) in ___ in remission from lymphoma \r\nstandpoint but developed worsening pancytopenia and bleeding \r\nissues this month found to have treatment related MDS, now C1D3 \r\ndacogen presenting with borderline neutropenia and temp today of \r\n100.4.\r\n\r\nOther v/s in clinic: Vital Signs: BP: 111/53. Heart Rate:\r\n98. O2 Saturation%: 100.  Weight: 256.6. Height: 61.25. BMI:\r\n48.1. Temperature: 100.4. Resp. Rate: 18. Pain Score: 5 (back). \r\n\r\nGiven functional neutropenia, admitted for treatment of febrile \r\nneutropenia. Got vanc/cefepime in clinic. Blood cultures sent in \r\nclinic. She reported having some chills at the time and general \r\nfatigue but denied any other specific symptoms. Temp came back \r\ndown on it's own and she was 98.9 before leaving clinic. Hgb \r\n7.1,\r\nclinic orderd 1u blood which she will receive here. Regarding \r\nher other PMH: she is on xarelto for thrombosis history (DVT, \r\nalso has IVCF which was placed), and has h/o bleo toxicity \r\npneumonitis (off steroids now but cont with inhalers), and also \r\nhas intermittent LBP and left sciatica due to degenerative \r\ndisease,\r\non gabapentin, and she has chronic right pupil dilation and \r\ndysmetria.\r\n\r\nNote she was recently admitted and discharged ___. SHe had BM \r\nbx ___ which showed MDS as above. She also reported nasal \r\ncongestion and had fever ___, initially covered broadly but \r\nwith negative cultures, ultimately discharged to complete 7d \r\ncourse of levaquin on ___. Pt states she stopped taking the \r\nlevoquin ___ days ago. Last night took her temp and it was 100.1 \r\n(was\r\ninstructed to monitor temps, she had no symptoms that prompted \r\nthis check). This morning driving in to clinic appointment felt \r\na bit chilled but not shaking and not sick in any other way. In \r\nclinic found to have temp of 100.4. Also notes that she \r\ntypically has left sided sciatica but that in the past week sinc \r\nethe bone marrow biopsy has developed right lower back pain \r\nwhich has required ___ doses of vicodin daily and is a new pain \r\nworsening over time, present constantly, but worse with movement \r\nor deep palpation. Denies loss of strength or sensation though \r\nhas chronic right foot drop and dysesthesias at baseline after \r\nknee replacement on that side in the past. No incontinence or \r\ndysuria.\r\n\r\nFinally, her history is significant for a \"blood blister\" she \r\nnoted on the left foreleg per pt about ___ weeks ago which was \r\nultimately debrided in the past, and poor wound healing \r\nattributed to venous stasis. THis has been healing well she \r\nstates, though there is still an open wound surrounded by \r\nerythema but she is confident it continues to improve \r\ndramatically and no recent drainage. She is covering it with \r\nxeroform dressing daily.\r\n\r\nfurther nose bleeds or other bleeding.  She is also noted for a \r\nnonhealing wound on her left leg after hitting her shin several \r\nweeks ago.  She is using xerofrom dressing to the area and \r\nchanging it daily with slow healing. All other 10 point ROS neg.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM:\r\nGeneral: NAD  \r\nT 99.6 BP 100/58  HR 95  20  96%RA\r\nHEENT: Right pupil slower to react to light which is baseline.  \r\nMMM, no OP lesions or thrush.  \r\nCV: RR, NL S1S2 no MRG  \r\nPULM: CTAB no wheezing or crackles  \r\nABD: BS+, soft, NTND  \r\nSKIN/limbs: left anterior foreleg with 1cm open circular wound \r\nwithout drainage, covered w/xeroform, with 4-5 cm diameter \r\nsurrounding erythema, not warm to touch, lower extr are equal in \r\ngirth, no pitting edema\r\nBack: pt is tender to palpation around the left SI joint, has \r\nresolving hematoma over the medial aspect of right sacrum, but \r\nno tenderness over the hematoma which appears superficial, no \r\nswelling\r\n\r\nDISCHARGE EXAM:\r\nVS: 98.1 ___ 22 97RA\r\nGEN: NAD, seated in chair, conversational\r\nHEENT: AT/NC; R pupil mildly larger, slower to react than L \r\n(baseline per records); MMM\r\nCV: RRR, no M/R/G, +S1/S2\r\nPULM: CTAB\r\nABD: obese, soft, nontender to palpation, referred pain from \r\nback in band/belt distribution in low abdomen; +BS\r\nSKIN: unroofed vesicle with mild bleeding covered with xeroform\r\nEXT: chronic venous stasis changes in B/L ___ over shins\r\nNEURO: A/Ox3; CNII-XII assessed and grossly intact except for \r\nR>L pupillary dilataion and sluggish reactivity\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n___ 11:30AM BLOOD WBC-2.3* RBC-2.28* Hgb-7.1* Hct-22.1* \r\nMCV-97 MCH-31.1 MCHC-32.1 RDW-21.8* RDWSD-77.3* Plt ___\r\n___ 11:30AM BLOOD Neuts-37 Bands-6* ___ Monos-11 \r\nEos-0 Baso-0 Atyps-2* Metas-3* Myelos-1* Blasts-2* NRBC-3* \r\nAbsNeut-0.99* AbsLymp-0.92* AbsMono-0.25 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD ___ PTT-39.0* ___\r\n___ 11:30AM BLOOD UreaN-15 Creat-0.9 Na-137 K-3.8 Cl-102 \r\nHCO3-25 AnGap-14\r\n___ 11:30AM BLOOD ALT-8 AST-10 LD(LDH)-260* AlkPhos-81 \r\nTotBili-0.3\r\n___ 11:30AM BLOOD Albumin-3.4* Calcium-8.1* Mg-2.2\r\n\r\nINTERVAL LABS:\r\n___ 12:00AM BLOOD CRP-108.7*\r\n___ 12:00AM BLOOD IgG-805\r\n___ 04:00PM BLOOD HIV Ab-Negative\r\n___ 04:00PM BLOOD CMV VL-NOT DETECT\r\n___ 02:20PM BLOOD SED RATE-Test      \r\n___ 04:00PM BLOOD HERPES 6 DNA PCR, QUANTITATIVE-Test      \r\n___ 04:00PM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-Test   \r\n   \r\n___ 07:45PM BLOOD B-GLUCAN-Test      \r\n___ 07:45PM BLOOD ASPERGILLUS GALACTOMANNAN ANTIGEN-Test\r\n\r\nMICRO:\r\n___ Skin biopsy: All cx. negative\r\n___ RPR: negative\r\n___ Myco/lytic cx: no growth\r\n___ Psoas tissue cx: negative\r\nAll other blood and urine cultures final/negative\r\n\r\nSTUDIES:\r\nConclusions\r\nThe left atrium is mildly dilated. The left atrial volume index \r\nis mildly increased. The estimated right atrial pressure is ___ \r\nmmHg. Left ventricular wall thickness, cavity size and \r\nregional/global systolic function are normal (LVEF >55%). The \r\nestimated cardiac index is normal (>=2.5L/min/m2). Tissue \r\nDoppler imaging suggests an increased left ventricular filling \r\npressure (PCWP>18mmHg). Right ventricular chamber size and free \r\nwall motion are normal. The aortic valve leaflets (3) are mildly \r\nthickened but aortic stenosis is not present. No masses or \r\nvegetations are seen on the aortic valve. No aortic valve \r\nabscess is seen. No aortic regurgitation is seen. The mitral \r\nvalve leaflets are mildly thickened. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. There is moderate \r\npulmonary artery systolic hypertension. No vegetation/mass is \r\nseen on the pulmonic valve. There is an anterior space which \r\nmost likely represents a prominent fat pad. \r\n\r\nIMPRESSION: No echocardiographic evidence of endocarditis. \r\nNormal biventricular cavity sizes with preserved global and \r\nregional biventricular systolic function. Suggestion of elevated \r\nLV filling pressure. Mild mitral and tricuspid regurgitation. \r\nModerate pulmonary hypertension.\r\n\r\nCompared with the prior study (images reviewed) of ___, \r\nthe degrees of mitral and tricuspid regurgitation are slightly \r\ngreater and the estimated pulmonary arterial pressure is higher.\r\n\r\nIMAGING:\r\n___ L gluteal U/S:\r\nIMPRESSION:\r\nInflammation or edema of the superficial soft tissues without \r\nfocal fluid\r\ncollection.\r\n\r\n___ MR ___:\r\nIMPRESSION:\r\n1. Severe multilevel degenerative changes as described above \r\nhave slightly\r\nprogressed since the prior examination of ___.\r\n2. Scoliosis of lumbar spine with  signal changes and edema \r\nedema in the\r\nendplates, mild adjacent soft tissue signal and enhancement and \r\nenhancement in the left psoas muscle at L4-5 level without \r\nepidural phlegmon or paraspinal fluid collection are \r\nnonspecific.  Both advanced degenerative changes or early \r\ndiscitis osteomyelitis could give similar appearances.  The \r\nappearance on the prior CT abdomen of ___ or more was \r\nmore consistent with degenerative change. However, Correlation \r\nwith laboratory findings is essential to exclude early discitis \r\nosteomyelitis.\r\n\r\nDISCHARGE LABS:\r\n___ 01:18AM BLOOD WBC-0.4* RBC-2.58* Hgb-7.6* Hct-23.6* \r\nMCV-92 MCH-29.5 MCHC-32.2 RDW-18.6* RDWSD-62.0* Plt Ct-15*\r\n___ 01:18AM BLOOD Neuts-12* Bands-0 Lymphs-78* Monos-7 \r\nEos-1 Baso-0 Atyps-1* ___ Myelos-1* AbsNeut-0.05* \r\nAbsLymp-0.32* AbsMono-0.03* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:18AM BLOOD ___ PTT-34.5 ___\r\n___ 01:18AM BLOOD Glucose-147* UreaN-14 Creat-0.9 Na-136 \r\nK-3.7 Cl-99 HCO3-27 AnGap-14\r\n___ 12:00AM BLOOD ALT-14 AST-14 LD(LDH)-247 AlkPhos-90 \r\nTotBili-0.5\r\n___ 01:18AM BLOOD Calcium-8.1* Phos-2.7 Mg-2.3\r\n___ 06:25AM BLOOD Vanco-19.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, diagnosed with treatment related \r\nMDS. ___ was started on decitabine as an outpatient and \r\nre-presented with fevers and neutropenia. She had an exhaustive \r\nworkup of her fevers, including skin and psoas biopsies, and \r\ntissue uPCR was sent, but there was no culture positivity or \r\npositive findings in her infectious workup. However, after \r\nconsultation with ID, it was decided to treat empirically for \r\npresumptive osteomyelitis/discitis with 6 weeks of vancomycin \r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO \r\nq24h). Micafungin was chosen instead of posaconazole due to \r\n___ differences; but she did receive posaconazole while \r\ninpatient. Simultaneously, the patient was having significantly \r\nworsened back pain after her MDS diagnosing bone marrow biopsy. \r\nShe was started on opioid pain control, which was uptitrated and \r\naugmented with Valium to good effect. She went home with BID \r\noxycontin, PRN oxycodone, and QHS Valium. She will follow-up as \r\noutpatient with Dr. ___.\r\n\r\n# Fever + neutropenia: The patient received 2 doses of \r\ndecitabine as outpatient prior to experiencing first fever of \r\n101 at home, then 100.4 in clinic during third dose decitabine \r\nadministration. She was admitted for fever in setting of \r\ncytoreduction, and she eventually became truly neutropenic. An \r\nexhaustive workup was performed, centering on MRI findings of \r\npotential osteomyelitis/discitis with potential L psoas \r\ninvovlvement. This tissue was biopsied, negative by culture, and \r\nuPCR pending at the time of discharge. The patient will be given \r\nempiric therapy of vancomycin/cefepime/micafungin for a total of \r\n6 weeks (___) and instructed to have 1 month follow-up \r\nspinal imaging. A LLE wound was also biopsied and grew nothing. \r\nBy exclusion, decitabine is thought to be the likely culprit of \r\nthe fever.\r\n\r\n# left gluteal furuncle: Formed at the marked site of the ___ L \r\npsoas biopsy. By ultrasound found to only have subcutaneous \r\nedema without fluid collection. This will be followed by patient \r\nand outpatient team as potential new nidus of infection if \r\nappearing worse or causing pain.\r\n\r\n# low back pain: Acute on chronic in this patient, who has \r\nbaseline degenerative changes. She also had R iliac crest bone \r\nmarrow biopsy prior to this admission which may have caused \r\nhematoma, inflammatory, or direct nerve injury which contributed \r\nto her severe pain. She was uptitrated to a pain regimen \r\nincluding standing Oxycontin BID, oxycodone PRN, and Valium QHS, \r\nwhich she was able to tolerate with good effect. She worked with \r\n___ and was deemed fit for discharge home with services.\r\n\r\n# treatment related MDS: Secondary to autoSCT with BEAM \r\nconditioning for DLBCL. Patient had bone marrow biopsy which \r\ndiagnosed new-onset treatment related MDS, but may have also \r\ncaused severe acute-on-chronic back pain for which she is \r\nreceiving opioids and benzodiazapines. Will receive Bactrim for \r\nPCP prophylaxis starting at discharge.\r\n\r\n# history of DVT: History of LLE DVTs, on Rivaroxaban at home \r\nand IVC filter in place. Rivaroxaban was held once Plt<75k in \r\nsetting of multi-line decline from decitabine.\r\n\r\n# common variable immunodeficiency: Patient had multiple IgG \r\nchecks for known CVID and did not require IVIG as inpatient.\r\n\r\nTRANSITIONAL ISSUES:\r\n- complete 6 week antibiotics: vancomycin, cefepime, \r\nmicafungin(d1 = ___, end ___, follow-up with OPAT\r\n- weekly labs: CBC with differential, BUN, Cr, Vancomycin\r\ntrough, AST, ALT (fax to ATTN: ___ CLINIC - FAX: \r\n___\r\n- repeat MR ___ 1 month after discharge\r\n- PCP prophylaxis with ___ SS daily\r\n- plan future decitabine with Dr. ___ team\r\n- plan for curative transplant with Dr. ___ team\r\n- continue to monitor L gluteal furuncle\r\n- consider restarting rivaroxaban when deemed appropriate \r\n(stopped inpatient due to thrombocytopenia)\r\n- Code: Full\r\n- Contact: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. FoLIC Acid 3.2 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Venlafaxine 25 mg PO BID \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n12. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n13. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n14. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q6H:PRN \r\nPain - Mild \r\n\r\n \r\nDischarge Medications:\r\n1.  CefePIME 2 g IV Q12H \r\nRX *cefepime [Maxipime] 2 gram 2 g IV every twelve (12) hours \r\nDisp #*60 Vial Refills:*0 \r\n2.  Diazepam 5 mg PO QHS \r\nRX *diazepam 5 mg 1 tab by mouth at bedtime Disp #*7 Tablet \r\nRefills:*0 \r\n3.  Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium [Colace] 100 mg 1 capsule(s) by mouth twice \r\na day Disp #*60 Capsule Refills:*0 \r\n4.  Micafungin 100 mg IV Q24H \r\nRX *micafungin [Mycamine] 100 mg 100 mg IV q24h Disp #*30 Vial \r\nRefills:*0 \r\n5.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\nRX *oxycodone 10 mg 1 tablet(s) by mouth every six (6) hours \r\nDisp #*24 Tablet Refills:*0 \r\n6.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\nRX *oxycodone 20 mg 1 tablet(s) by mouth every twelve (12) hours \r\nDisp #*14 Tablet Refills:*0 \r\n7.  Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\nRX *polyethylene glycol 3350 [Miralax] 17 gram 1 powder(s) by \r\nmouth daily Disp #*30 Packet Refills:*0 \r\n8.  Senna 8.6 mg PO BID:PRN constipation \r\nRX *sennosides [senna] 8.6 mg 1 tab by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n9.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n10.  Vancomycin 750 mg IV Q 12H \r\nRX *vancomycin 750 mg 750 mg IV every twelve (12) hours Disp \r\n#*60 Vial Refills:*0 \r\n11.  Potassium Chloride 10 mEq PO DAILY  \r\n12.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n13.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n14.  Ascorbic Acid ___ mg PO BID  \r\n15.  Cyanocobalamin 1000 mcg PO QHS  \r\n16.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n17.  FoLIC Acid 3.2 mg PO DAILY  \r\n18.  Furosemide 20 mg PO DAILY  \r\n19.  Gabapentin 900 mg PO TID  \r\n20.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n21.  Omeprazole 20 mg PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until insructed to by your outpatient \r\ndoctor\r\n24.Outpatient Lab Work\r\nTo be drawn weekly: CBC with differential, BUN, Cr, Vancomycin \r\ntrough, AST, ALT\r\nSend results to: ___ CLINIC - FAX: ___\r\nICD 10: ___.0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n- fever and neutropenia\r\n- low back pain\r\n- treatment related MDS\r\n- history of DVT\r\n- common variable immunodeficiency\r\n- left gluteal furuncle\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ was a pleasure caring for you while you were at ___. You \r\ncame to the hospital with a fever in the setting of your \r\ndecitabine therapy and had significantly worse back pain after \r\nyour bone marrow biopsy several weeks back. Despite a thorough \r\nworkup including multiple sets of blood cultures, urine \r\ncultures, and imaging including MRIs there was no infectious \r\nsource found as the culprit for your fevers. You were started on \r\nIV antibiotics to treat a presumptive infection, which you will \r\ncontinue for six weeks. You will follow-up with the infectious \r\ndisease physicians as an outpatient. You were started on several \r\nopioid pain medications and Valium which helped you be more \r\nactive and have good pain control. \r\n\r\nIt was a pleasure to participate in your care. We wish you all \r\nthe best.\r\n\r\nSincerely,\r\nYour ___ care team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-17:3",
      "text": "Past Medical History:\nOncologic history: In brief, history of follicular lymphoma \nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \nrituximab in ___ for residual disease. ___: RICE \nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \nlocal disease. She has a hx of hypogammaglobulinemia. Other PMH:\nobesity\nAcute DVT in the right popliteal/femoral veins + superficial \nthrombosis\n--Transformed DLBCL with history of follicular lymphoma as noted \nabove\n--CLL, noted on BM biopsy on ___. --Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \n(*Known slight CN VI palsy & mild proptosis of R eye)\n--Hypogammaglobulinemia, receives IVIG PRN\n--R leg DVT. IVC filter in place, on rivaroxaban\n--BCNU pneumonitis, on prednisone\n--Mild GERD\n--OA / LBP\n--Small Intestinal Bacterial Overgrowth\n--Trochanteric Bursitis\n--s/p Excisional Bx L Cervical Lymph Node\n--s/p L total knee replacement ___, walks with cane\n--s/p I&D Labial Abscess\n--s/p Excision Cyst R ___ Digit of Hand Social History:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-17",
        "chart_time": "104487",
        "section": "General",
        "position": 3,
        "tokenCount": 252,
        "note_metadata": {
          "note_id": "18887130-DS-17",
          "subject_id": 18887130,
          "hadm_id": 27240020,
          "note_type": "DS",
          "note_seq": 17,
          "charttime": 104487,
          "storetime": 104488.35277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, fever + neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nL psoas and prespinal biopsy\r\nLLE skin biopsy\r\n\r\n \r\nHistory of Present Illness:\r\n___ F with CVID, h/o transformed follicular lymphoma and h/o CLL \r\ns/p auto SCT (BEAM prep) in ___ in remission from lymphoma \r\nstandpoint but developed worsening pancytopenia and bleeding \r\nissues this month found to have treatment related MDS, now C1D3 \r\ndacogen presenting with borderline neutropenia and temp today of \r\n100.4.\r\n\r\nOther v/s in clinic: Vital Signs: BP: 111/53. Heart Rate:\r\n98. O2 Saturation%: 100.  Weight: 256.6. Height: 61.25. BMI:\r\n48.1. Temperature: 100.4. Resp. Rate: 18. Pain Score: 5 (back). \r\n\r\nGiven functional neutropenia, admitted for treatment of febrile \r\nneutropenia. Got vanc/cefepime in clinic. Blood cultures sent in \r\nclinic. She reported having some chills at the time and general \r\nfatigue but denied any other specific symptoms. Temp came back \r\ndown on it's own and she was 98.9 before leaving clinic. Hgb \r\n7.1,\r\nclinic orderd 1u blood which she will receive here. Regarding \r\nher other PMH: she is on xarelto for thrombosis history (DVT, \r\nalso has IVCF which was placed), and has h/o bleo toxicity \r\npneumonitis (off steroids now but cont with inhalers), and also \r\nhas intermittent LBP and left sciatica due to degenerative \r\ndisease,\r\non gabapentin, and she has chronic right pupil dilation and \r\ndysmetria.\r\n\r\nNote she was recently admitted and discharged ___. SHe had BM \r\nbx ___ which showed MDS as above. She also reported nasal \r\ncongestion and had fever ___, initially covered broadly but \r\nwith negative cultures, ultimately discharged to complete 7d \r\ncourse of levaquin on ___. Pt states she stopped taking the \r\nlevoquin ___ days ago. Last night took her temp and it was 100.1 \r\n(was\r\ninstructed to monitor temps, she had no symptoms that prompted \r\nthis check). This morning driving in to clinic appointment felt \r\na bit chilled but not shaking and not sick in any other way. In \r\nclinic found to have temp of 100.4. Also notes that she \r\ntypically has left sided sciatica but that in the past week sinc \r\nethe bone marrow biopsy has developed right lower back pain \r\nwhich has required ___ doses of vicodin daily and is a new pain \r\nworsening over time, present constantly, but worse with movement \r\nor deep palpation. Denies loss of strength or sensation though \r\nhas chronic right foot drop and dysesthesias at baseline after \r\nknee replacement on that side in the past. No incontinence or \r\ndysuria.\r\n\r\nFinally, her history is significant for a \"blood blister\" she \r\nnoted on the left foreleg per pt about ___ weeks ago which was \r\nultimately debrided in the past, and poor wound healing \r\nattributed to venous stasis. THis has been healing well she \r\nstates, though there is still an open wound surrounded by \r\nerythema but she is confident it continues to improve \r\ndramatically and no recent drainage. She is covering it with \r\nxeroform dressing daily.\r\n\r\nfurther nose bleeds or other bleeding.  She is also noted for a \r\nnonhealing wound on her left leg after hitting her shin several \r\nweeks ago.  She is using xerofrom dressing to the area and \r\nchanging it daily with slow healing. All other 10 point ROS neg.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM:\r\nGeneral: NAD  \r\nT 99.6 BP 100/58  HR 95  20  96%RA\r\nHEENT: Right pupil slower to react to light which is baseline.  \r\nMMM, no OP lesions or thrush.  \r\nCV: RR, NL S1S2 no MRG  \r\nPULM: CTAB no wheezing or crackles  \r\nABD: BS+, soft, NTND  \r\nSKIN/limbs: left anterior foreleg with 1cm open circular wound \r\nwithout drainage, covered w/xeroform, with 4-5 cm diameter \r\nsurrounding erythema, not warm to touch, lower extr are equal in \r\ngirth, no pitting edema\r\nBack: pt is tender to palpation around the left SI joint, has \r\nresolving hematoma over the medial aspect of right sacrum, but \r\nno tenderness over the hematoma which appears superficial, no \r\nswelling\r\n\r\nDISCHARGE EXAM:\r\nVS: 98.1 ___ 22 97RA\r\nGEN: NAD, seated in chair, conversational\r\nHEENT: AT/NC; R pupil mildly larger, slower to react than L \r\n(baseline per records); MMM\r\nCV: RRR, no M/R/G, +S1/S2\r\nPULM: CTAB\r\nABD: obese, soft, nontender to palpation, referred pain from \r\nback in band/belt distribution in low abdomen; +BS\r\nSKIN: unroofed vesicle with mild bleeding covered with xeroform\r\nEXT: chronic venous stasis changes in B/L ___ over shins\r\nNEURO: A/Ox3; CNII-XII assessed and grossly intact except for \r\nR>L pupillary dilataion and sluggish reactivity\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n___ 11:30AM BLOOD WBC-2.3* RBC-2.28* Hgb-7.1* Hct-22.1* \r\nMCV-97 MCH-31.1 MCHC-32.1 RDW-21.8* RDWSD-77.3* Plt ___\r\n___ 11:30AM BLOOD Neuts-37 Bands-6* ___ Monos-11 \r\nEos-0 Baso-0 Atyps-2* Metas-3* Myelos-1* Blasts-2* NRBC-3* \r\nAbsNeut-0.99* AbsLymp-0.92* AbsMono-0.25 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD ___ PTT-39.0* ___\r\n___ 11:30AM BLOOD UreaN-15 Creat-0.9 Na-137 K-3.8 Cl-102 \r\nHCO3-25 AnGap-14\r\n___ 11:30AM BLOOD ALT-8 AST-10 LD(LDH)-260* AlkPhos-81 \r\nTotBili-0.3\r\n___ 11:30AM BLOOD Albumin-3.4* Calcium-8.1* Mg-2.2\r\n\r\nINTERVAL LABS:\r\n___ 12:00AM BLOOD CRP-108.7*\r\n___ 12:00AM BLOOD IgG-805\r\n___ 04:00PM BLOOD HIV Ab-Negative\r\n___ 04:00PM BLOOD CMV VL-NOT DETECT\r\n___ 02:20PM BLOOD SED RATE-Test      \r\n___ 04:00PM BLOOD HERPES 6 DNA PCR, QUANTITATIVE-Test      \r\n___ 04:00PM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-Test   \r\n   \r\n___ 07:45PM BLOOD B-GLUCAN-Test      \r\n___ 07:45PM BLOOD ASPERGILLUS GALACTOMANNAN ANTIGEN-Test\r\n\r\nMICRO:\r\n___ Skin biopsy: All cx. negative\r\n___ RPR: negative\r\n___ Myco/lytic cx: no growth\r\n___ Psoas tissue cx: negative\r\nAll other blood and urine cultures final/negative\r\n\r\nSTUDIES:\r\nConclusions\r\nThe left atrium is mildly dilated. The left atrial volume index \r\nis mildly increased. The estimated right atrial pressure is ___ \r\nmmHg. Left ventricular wall thickness, cavity size and \r\nregional/global systolic function are normal (LVEF >55%). The \r\nestimated cardiac index is normal (>=2.5L/min/m2). Tissue \r\nDoppler imaging suggests an increased left ventricular filling \r\npressure (PCWP>18mmHg). Right ventricular chamber size and free \r\nwall motion are normal. The aortic valve leaflets (3) are mildly \r\nthickened but aortic stenosis is not present. No masses or \r\nvegetations are seen on the aortic valve. No aortic valve \r\nabscess is seen. No aortic regurgitation is seen. The mitral \r\nvalve leaflets are mildly thickened. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. There is moderate \r\npulmonary artery systolic hypertension. No vegetation/mass is \r\nseen on the pulmonic valve. There is an anterior space which \r\nmost likely represents a prominent fat pad. \r\n\r\nIMPRESSION: No echocardiographic evidence of endocarditis. \r\nNormal biventricular cavity sizes with preserved global and \r\nregional biventricular systolic function. Suggestion of elevated \r\nLV filling pressure. Mild mitral and tricuspid regurgitation. \r\nModerate pulmonary hypertension.\r\n\r\nCompared with the prior study (images reviewed) of ___, \r\nthe degrees of mitral and tricuspid regurgitation are slightly \r\ngreater and the estimated pulmonary arterial pressure is higher.\r\n\r\nIMAGING:\r\n___ L gluteal U/S:\r\nIMPRESSION:\r\nInflammation or edema of the superficial soft tissues without \r\nfocal fluid\r\ncollection.\r\n\r\n___ MR ___:\r\nIMPRESSION:\r\n1. Severe multilevel degenerative changes as described above \r\nhave slightly\r\nprogressed since the prior examination of ___.\r\n2. Scoliosis of lumbar spine with  signal changes and edema \r\nedema in the\r\nendplates, mild adjacent soft tissue signal and enhancement and \r\nenhancement in the left psoas muscle at L4-5 level without \r\nepidural phlegmon or paraspinal fluid collection are \r\nnonspecific.  Both advanced degenerative changes or early \r\ndiscitis osteomyelitis could give similar appearances.  The \r\nappearance on the prior CT abdomen of ___ or more was \r\nmore consistent with degenerative change. However, Correlation \r\nwith laboratory findings is essential to exclude early discitis \r\nosteomyelitis.\r\n\r\nDISCHARGE LABS:\r\n___ 01:18AM BLOOD WBC-0.4* RBC-2.58* Hgb-7.6* Hct-23.6* \r\nMCV-92 MCH-29.5 MCHC-32.2 RDW-18.6* RDWSD-62.0* Plt Ct-15*\r\n___ 01:18AM BLOOD Neuts-12* Bands-0 Lymphs-78* Monos-7 \r\nEos-1 Baso-0 Atyps-1* ___ Myelos-1* AbsNeut-0.05* \r\nAbsLymp-0.32* AbsMono-0.03* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:18AM BLOOD ___ PTT-34.5 ___\r\n___ 01:18AM BLOOD Glucose-147* UreaN-14 Creat-0.9 Na-136 \r\nK-3.7 Cl-99 HCO3-27 AnGap-14\r\n___ 12:00AM BLOOD ALT-14 AST-14 LD(LDH)-247 AlkPhos-90 \r\nTotBili-0.5\r\n___ 01:18AM BLOOD Calcium-8.1* Phos-2.7 Mg-2.3\r\n___ 06:25AM BLOOD Vanco-19.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, diagnosed with treatment related \r\nMDS. ___ was started on decitabine as an outpatient and \r\nre-presented with fevers and neutropenia. She had an exhaustive \r\nworkup of her fevers, including skin and psoas biopsies, and \r\ntissue uPCR was sent, but there was no culture positivity or \r\npositive findings in her infectious workup. However, after \r\nconsultation with ID, it was decided to treat empirically for \r\npresumptive osteomyelitis/discitis with 6 weeks of vancomycin \r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO \r\nq24h). Micafungin was chosen instead of posaconazole due to \r\n___ differences; but she did receive posaconazole while \r\ninpatient. Simultaneously, the patient was having significantly \r\nworsened back pain after her MDS diagnosing bone marrow biopsy. \r\nShe was started on opioid pain control, which was uptitrated and \r\naugmented with Valium to good effect. She went home with BID \r\noxycontin, PRN oxycodone, and QHS Valium. She will follow-up as \r\noutpatient with Dr. ___.\r\n\r\n# Fever + neutropenia: The patient received 2 doses of \r\ndecitabine as outpatient prior to experiencing first fever of \r\n101 at home, then 100.4 in clinic during third dose decitabine \r\nadministration. She was admitted for fever in setting of \r\ncytoreduction, and she eventually became truly neutropenic. An \r\nexhaustive workup was performed, centering on MRI findings of \r\npotential osteomyelitis/discitis with potential L psoas \r\ninvovlvement. This tissue was biopsied, negative by culture, and \r\nuPCR pending at the time of discharge. The patient will be given \r\nempiric therapy of vancomycin/cefepime/micafungin for a total of \r\n6 weeks (___) and instructed to have 1 month follow-up \r\nspinal imaging. A LLE wound was also biopsied and grew nothing. \r\nBy exclusion, decitabine is thought to be the likely culprit of \r\nthe fever.\r\n\r\n# left gluteal furuncle: Formed at the marked site of the ___ L \r\npsoas biopsy. By ultrasound found to only have subcutaneous \r\nedema without fluid collection. This will be followed by patient \r\nand outpatient team as potential new nidus of infection if \r\nappearing worse or causing pain.\r\n\r\n# low back pain: Acute on chronic in this patient, who has \r\nbaseline degenerative changes. She also had R iliac crest bone \r\nmarrow biopsy prior to this admission which may have caused \r\nhematoma, inflammatory, or direct nerve injury which contributed \r\nto her severe pain. She was uptitrated to a pain regimen \r\nincluding standing Oxycontin BID, oxycodone PRN, and Valium QHS, \r\nwhich she was able to tolerate with good effect. She worked with \r\n___ and was deemed fit for discharge home with services.\r\n\r\n# treatment related MDS: Secondary to autoSCT with BEAM \r\nconditioning for DLBCL. Patient had bone marrow biopsy which \r\ndiagnosed new-onset treatment related MDS, but may have also \r\ncaused severe acute-on-chronic back pain for which she is \r\nreceiving opioids and benzodiazapines. Will receive Bactrim for \r\nPCP prophylaxis starting at discharge.\r\n\r\n# history of DVT: History of LLE DVTs, on Rivaroxaban at home \r\nand IVC filter in place. Rivaroxaban was held once Plt<75k in \r\nsetting of multi-line decline from decitabine.\r\n\r\n# common variable immunodeficiency: Patient had multiple IgG \r\nchecks for known CVID and did not require IVIG as inpatient.\r\n\r\nTRANSITIONAL ISSUES:\r\n- complete 6 week antibiotics: vancomycin, cefepime, \r\nmicafungin(d1 = ___, end ___, follow-up with OPAT\r\n- weekly labs: CBC with differential, BUN, Cr, Vancomycin\r\ntrough, AST, ALT (fax to ATTN: ___ CLINIC - FAX: \r\n___\r\n- repeat MR ___ 1 month after discharge\r\n- PCP prophylaxis with ___ SS daily\r\n- plan future decitabine with Dr. ___ team\r\n- plan for curative transplant with Dr. ___ team\r\n- continue to monitor L gluteal furuncle\r\n- consider restarting rivaroxaban when deemed appropriate \r\n(stopped inpatient due to thrombocytopenia)\r\n- Code: Full\r\n- Contact: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. FoLIC Acid 3.2 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Venlafaxine 25 mg PO BID \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n12. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n13. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n14. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q6H:PRN \r\nPain - Mild \r\n\r\n \r\nDischarge Medications:\r\n1.  CefePIME 2 g IV Q12H \r\nRX *cefepime [Maxipime] 2 gram 2 g IV every twelve (12) hours \r\nDisp #*60 Vial Refills:*0 \r\n2.  Diazepam 5 mg PO QHS \r\nRX *diazepam 5 mg 1 tab by mouth at bedtime Disp #*7 Tablet \r\nRefills:*0 \r\n3.  Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium [Colace] 100 mg 1 capsule(s) by mouth twice \r\na day Disp #*60 Capsule Refills:*0 \r\n4.  Micafungin 100 mg IV Q24H \r\nRX *micafungin [Mycamine] 100 mg 100 mg IV q24h Disp #*30 Vial \r\nRefills:*0 \r\n5.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\nRX *oxycodone 10 mg 1 tablet(s) by mouth every six (6) hours \r\nDisp #*24 Tablet Refills:*0 \r\n6.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\nRX *oxycodone 20 mg 1 tablet(s) by mouth every twelve (12) hours \r\nDisp #*14 Tablet Refills:*0 \r\n7.  Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\nRX *polyethylene glycol 3350 [Miralax] 17 gram 1 powder(s) by \r\nmouth daily Disp #*30 Packet Refills:*0 \r\n8.  Senna 8.6 mg PO BID:PRN constipation \r\nRX *sennosides [senna] 8.6 mg 1 tab by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n9.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n10.  Vancomycin 750 mg IV Q 12H \r\nRX *vancomycin 750 mg 750 mg IV every twelve (12) hours Disp \r\n#*60 Vial Refills:*0 \r\n11.  Potassium Chloride 10 mEq PO DAILY  \r\n12.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n13.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n14.  Ascorbic Acid ___ mg PO BID  \r\n15.  Cyanocobalamin 1000 mcg PO QHS  \r\n16.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n17.  FoLIC Acid 3.2 mg PO DAILY  \r\n18.  Furosemide 20 mg PO DAILY  \r\n19.  Gabapentin 900 mg PO TID  \r\n20.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n21.  Omeprazole 20 mg PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until insructed to by your outpatient \r\ndoctor\r\n24.Outpatient Lab Work\r\nTo be drawn weekly: CBC with differential, BUN, Cr, Vancomycin \r\ntrough, AST, ALT\r\nSend results to: ___ CLINIC - FAX: ___\r\nICD 10: ___.0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n- fever and neutropenia\r\n- low back pain\r\n- treatment related MDS\r\n- history of DVT\r\n- common variable immunodeficiency\r\n- left gluteal furuncle\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ was a pleasure caring for you while you were at ___. You \r\ncame to the hospital with a fever in the setting of your \r\ndecitabine therapy and had significantly worse back pain after \r\nyour bone marrow biopsy several weeks back. Despite a thorough \r\nworkup including multiple sets of blood cultures, urine \r\ncultures, and imaging including MRIs there was no infectious \r\nsource found as the culprit for your fevers. You were started on \r\nIV antibiotics to treat a presumptive infection, which you will \r\ncontinue for six weeks. You will follow-up with the infectious \r\ndisease physicians as an outpatient. You were started on several \r\nopioid pain medications and Valium which helped you be more \r\nactive and have good pain control. \r\n\r\nIt was a pleasure to participate in your care. We wish you all \r\nthe best.\r\n\r\nSincerely,\r\nYour ___ care team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-17:4",
      "text": "Family History:\nbrother - lymphoma Physical ___:\nADMISSION EXAM:\nGeneral: NAD  \nT 99.6 BP 100/58  HR 95  20  96%RA\nHEENT: Right pupil slower to react to light which is baseline. MMM, no OP lesions or thrush. CV: RR, NL S1S2 no MRG  \nPULM: CTAB no wheezing or crackles  \nABD: BS+, soft, NTND  \nSKIN/limbs: left anterior foreleg with 1cm open circular wound \nwithout drainage, covered w/xeroform, with 4-5 cm diameter \nsurrounding erythema, not warm to touch, lower extr are equal in \ngirth, no pitting edema\nBack: pt is tender to palpation around the left SI joint, has \nresolving hematoma over the medial aspect of right sacrum, but \nno tenderness over the hematoma which appears superficial, no \nswelling DISCHARGE EXAM:\nVS: 98.1 ___ 22 97RA\nGEN: NAD, seated in chair, conversational\nHEENT: AT/NC; R pupil mildly larger, slower to react than L \n(baseline per records); MMM\nCV: RRR, no M/R/G, +S1/S2\nPULM: CTAB\nABD: obese, soft, nontender to palpation, referred pain from \nback in band/belt distribution in low abdomen; +BS\nSKIN: unroofed vesicle with mild bleeding covered with xeroform\nEXT: chronic venous stasis changes in B/L ___ over shins\nNEURO: A/Ox3; CNII-XII assessed and grossly intact except for \nR>L pupillary dilataion and sluggish reactivity\n \nPertinent Results:\nADMISSION LABS:\n___ 11:30AM BLOOD WBC-2.3* RBC-2.28* Hgb-7.1* Hct-22.1* \nMCV-97 MCH-31.1 MCHC-32.1 RDW-21.8* RDWSD-77.3* Plt ___\n___ 11:30AM BLOOD Neuts-37 Bands-6* ___ Monos-11 \nEos-0 Baso-0 Atyps-2* Metas-3* Myelos-1* Blasts-2* NRBC-3* \nAbsNeut-0.99* AbsLymp-0.92* AbsMono-0.25 AbsEos-0.00* \nAbsBaso-0.00*\n___ 12:00AM BLOOD ___ PTT-39.0* ___\n___ 11:30AM BLOOD UreaN-15 Creat-0.9 Na-137 K-3.8 Cl-102 \nHCO3-25 AnGap-14\n___ 11:30AM BLOOD ALT-8 AST-10 LD(LDH)-260* AlkPhos-81 \nTotBili-0.3\n___ 11:30AM BLOOD Albumin-3.4* Calcium-8.1* Mg-2.2 INTERVAL LABS:\n___ 12:00AM BLOOD CRP-108.7*\n___ 12:00AM BLOOD IgG-805\n___ 04:00PM BLOOD HIV Ab-Negative\n___ 04:00PM BLOOD CMV VL-NOT DETECT\n___ 02:20PM BLOOD SED RATE-Test      \n___ 04:00PM BLOOD HERPES 6 DNA PCR, QUANTITATIVE-Test      \n___ 04:00PM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-Test   \n   \n___ 07:45PM BLOOD B-GLUCAN-Test      \n___ 07:45PM BLOOD ASPERGILLUS GALACTOMANNAN ANTIGEN-Test MICRO:\n___ Skin biopsy: All cx. negative\n___ RPR: negative\n___ Myco/lytic cx: no growth\n___ Psoas tissue cx: negative\nAll other blood and urine cultures final/negative STUDIES:\nConclusions\nThe left atrium is mildly dilated. The left atrial volume index \nis mildly increased. The estimated right atrial pressure is ___ \nmmHg. Left ventricular wall thickness, cavity size and \nregional/global systolic function are normal (LVEF >55%). The \nestimated cardiac index is normal (>=2.5L/min/m2).",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-17",
        "chart_time": "104487",
        "section": "General",
        "position": 4,
        "tokenCount": 676,
        "note_metadata": {
          "note_id": "18887130-DS-17",
          "subject_id": 18887130,
          "hadm_id": 27240020,
          "note_type": "DS",
          "note_seq": 17,
          "charttime": 104487,
          "storetime": 104488.35277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, fever + neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nL psoas and prespinal biopsy\r\nLLE skin biopsy\r\n\r\n \r\nHistory of Present Illness:\r\n___ F with CVID, h/o transformed follicular lymphoma and h/o CLL \r\ns/p auto SCT (BEAM prep) in ___ in remission from lymphoma \r\nstandpoint but developed worsening pancytopenia and bleeding \r\nissues this month found to have treatment related MDS, now C1D3 \r\ndacogen presenting with borderline neutropenia and temp today of \r\n100.4.\r\n\r\nOther v/s in clinic: Vital Signs: BP: 111/53. Heart Rate:\r\n98. O2 Saturation%: 100.  Weight: 256.6. Height: 61.25. BMI:\r\n48.1. Temperature: 100.4. Resp. Rate: 18. Pain Score: 5 (back). \r\n\r\nGiven functional neutropenia, admitted for treatment of febrile \r\nneutropenia. Got vanc/cefepime in clinic. Blood cultures sent in \r\nclinic. She reported having some chills at the time and general \r\nfatigue but denied any other specific symptoms. Temp came back \r\ndown on it's own and she was 98.9 before leaving clinic. Hgb \r\n7.1,\r\nclinic orderd 1u blood which she will receive here. Regarding \r\nher other PMH: she is on xarelto for thrombosis history (DVT, \r\nalso has IVCF which was placed), and has h/o bleo toxicity \r\npneumonitis (off steroids now but cont with inhalers), and also \r\nhas intermittent LBP and left sciatica due to degenerative \r\ndisease,\r\non gabapentin, and she has chronic right pupil dilation and \r\ndysmetria.\r\n\r\nNote she was recently admitted and discharged ___. SHe had BM \r\nbx ___ which showed MDS as above. She also reported nasal \r\ncongestion and had fever ___, initially covered broadly but \r\nwith negative cultures, ultimately discharged to complete 7d \r\ncourse of levaquin on ___. Pt states she stopped taking the \r\nlevoquin ___ days ago. Last night took her temp and it was 100.1 \r\n(was\r\ninstructed to monitor temps, she had no symptoms that prompted \r\nthis check). This morning driving in to clinic appointment felt \r\na bit chilled but not shaking and not sick in any other way. In \r\nclinic found to have temp of 100.4. Also notes that she \r\ntypically has left sided sciatica but that in the past week sinc \r\nethe bone marrow biopsy has developed right lower back pain \r\nwhich has required ___ doses of vicodin daily and is a new pain \r\nworsening over time, present constantly, but worse with movement \r\nor deep palpation. Denies loss of strength or sensation though \r\nhas chronic right foot drop and dysesthesias at baseline after \r\nknee replacement on that side in the past. No incontinence or \r\ndysuria.\r\n\r\nFinally, her history is significant for a \"blood blister\" she \r\nnoted on the left foreleg per pt about ___ weeks ago which was \r\nultimately debrided in the past, and poor wound healing \r\nattributed to venous stasis. THis has been healing well she \r\nstates, though there is still an open wound surrounded by \r\nerythema but she is confident it continues to improve \r\ndramatically and no recent drainage. She is covering it with \r\nxeroform dressing daily.\r\n\r\nfurther nose bleeds or other bleeding.  She is also noted for a \r\nnonhealing wound on her left leg after hitting her shin several \r\nweeks ago.  She is using xerofrom dressing to the area and \r\nchanging it daily with slow healing. All other 10 point ROS neg.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM:\r\nGeneral: NAD  \r\nT 99.6 BP 100/58  HR 95  20  96%RA\r\nHEENT: Right pupil slower to react to light which is baseline.  \r\nMMM, no OP lesions or thrush.  \r\nCV: RR, NL S1S2 no MRG  \r\nPULM: CTAB no wheezing or crackles  \r\nABD: BS+, soft, NTND  \r\nSKIN/limbs: left anterior foreleg with 1cm open circular wound \r\nwithout drainage, covered w/xeroform, with 4-5 cm diameter \r\nsurrounding erythema, not warm to touch, lower extr are equal in \r\ngirth, no pitting edema\r\nBack: pt is tender to palpation around the left SI joint, has \r\nresolving hematoma over the medial aspect of right sacrum, but \r\nno tenderness over the hematoma which appears superficial, no \r\nswelling\r\n\r\nDISCHARGE EXAM:\r\nVS: 98.1 ___ 22 97RA\r\nGEN: NAD, seated in chair, conversational\r\nHEENT: AT/NC; R pupil mildly larger, slower to react than L \r\n(baseline per records); MMM\r\nCV: RRR, no M/R/G, +S1/S2\r\nPULM: CTAB\r\nABD: obese, soft, nontender to palpation, referred pain from \r\nback in band/belt distribution in low abdomen; +BS\r\nSKIN: unroofed vesicle with mild bleeding covered with xeroform\r\nEXT: chronic venous stasis changes in B/L ___ over shins\r\nNEURO: A/Ox3; CNII-XII assessed and grossly intact except for \r\nR>L pupillary dilataion and sluggish reactivity\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n___ 11:30AM BLOOD WBC-2.3* RBC-2.28* Hgb-7.1* Hct-22.1* \r\nMCV-97 MCH-31.1 MCHC-32.1 RDW-21.8* RDWSD-77.3* Plt ___\r\n___ 11:30AM BLOOD Neuts-37 Bands-6* ___ Monos-11 \r\nEos-0 Baso-0 Atyps-2* Metas-3* Myelos-1* Blasts-2* NRBC-3* \r\nAbsNeut-0.99* AbsLymp-0.92* AbsMono-0.25 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD ___ PTT-39.0* ___\r\n___ 11:30AM BLOOD UreaN-15 Creat-0.9 Na-137 K-3.8 Cl-102 \r\nHCO3-25 AnGap-14\r\n___ 11:30AM BLOOD ALT-8 AST-10 LD(LDH)-260* AlkPhos-81 \r\nTotBili-0.3\r\n___ 11:30AM BLOOD Albumin-3.4* Calcium-8.1* Mg-2.2\r\n\r\nINTERVAL LABS:\r\n___ 12:00AM BLOOD CRP-108.7*\r\n___ 12:00AM BLOOD IgG-805\r\n___ 04:00PM BLOOD HIV Ab-Negative\r\n___ 04:00PM BLOOD CMV VL-NOT DETECT\r\n___ 02:20PM BLOOD SED RATE-Test      \r\n___ 04:00PM BLOOD HERPES 6 DNA PCR, QUANTITATIVE-Test      \r\n___ 04:00PM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-Test   \r\n   \r\n___ 07:45PM BLOOD B-GLUCAN-Test      \r\n___ 07:45PM BLOOD ASPERGILLUS GALACTOMANNAN ANTIGEN-Test\r\n\r\nMICRO:\r\n___ Skin biopsy: All cx. negative\r\n___ RPR: negative\r\n___ Myco/lytic cx: no growth\r\n___ Psoas tissue cx: negative\r\nAll other blood and urine cultures final/negative\r\n\r\nSTUDIES:\r\nConclusions\r\nThe left atrium is mildly dilated. The left atrial volume index \r\nis mildly increased. The estimated right atrial pressure is ___ \r\nmmHg. Left ventricular wall thickness, cavity size and \r\nregional/global systolic function are normal (LVEF >55%). The \r\nestimated cardiac index is normal (>=2.5L/min/m2). Tissue \r\nDoppler imaging suggests an increased left ventricular filling \r\npressure (PCWP>18mmHg). Right ventricular chamber size and free \r\nwall motion are normal. The aortic valve leaflets (3) are mildly \r\nthickened but aortic stenosis is not present. No masses or \r\nvegetations are seen on the aortic valve. No aortic valve \r\nabscess is seen. No aortic regurgitation is seen. The mitral \r\nvalve leaflets are mildly thickened. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. There is moderate \r\npulmonary artery systolic hypertension. No vegetation/mass is \r\nseen on the pulmonic valve. There is an anterior space which \r\nmost likely represents a prominent fat pad. \r\n\r\nIMPRESSION: No echocardiographic evidence of endocarditis. \r\nNormal biventricular cavity sizes with preserved global and \r\nregional biventricular systolic function. Suggestion of elevated \r\nLV filling pressure. Mild mitral and tricuspid regurgitation. \r\nModerate pulmonary hypertension.\r\n\r\nCompared with the prior study (images reviewed) of ___, \r\nthe degrees of mitral and tricuspid regurgitation are slightly \r\ngreater and the estimated pulmonary arterial pressure is higher.\r\n\r\nIMAGING:\r\n___ L gluteal U/S:\r\nIMPRESSION:\r\nInflammation or edema of the superficial soft tissues without \r\nfocal fluid\r\ncollection.\r\n\r\n___ MR ___:\r\nIMPRESSION:\r\n1. Severe multilevel degenerative changes as described above \r\nhave slightly\r\nprogressed since the prior examination of ___.\r\n2. Scoliosis of lumbar spine with  signal changes and edema \r\nedema in the\r\nendplates, mild adjacent soft tissue signal and enhancement and \r\nenhancement in the left psoas muscle at L4-5 level without \r\nepidural phlegmon or paraspinal fluid collection are \r\nnonspecific.  Both advanced degenerative changes or early \r\ndiscitis osteomyelitis could give similar appearances.  The \r\nappearance on the prior CT abdomen of ___ or more was \r\nmore consistent with degenerative change. However, Correlation \r\nwith laboratory findings is essential to exclude early discitis \r\nosteomyelitis.\r\n\r\nDISCHARGE LABS:\r\n___ 01:18AM BLOOD WBC-0.4* RBC-2.58* Hgb-7.6* Hct-23.6* \r\nMCV-92 MCH-29.5 MCHC-32.2 RDW-18.6* RDWSD-62.0* Plt Ct-15*\r\n___ 01:18AM BLOOD Neuts-12* Bands-0 Lymphs-78* Monos-7 \r\nEos-1 Baso-0 Atyps-1* ___ Myelos-1* AbsNeut-0.05* \r\nAbsLymp-0.32* AbsMono-0.03* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:18AM BLOOD ___ PTT-34.5 ___\r\n___ 01:18AM BLOOD Glucose-147* UreaN-14 Creat-0.9 Na-136 \r\nK-3.7 Cl-99 HCO3-27 AnGap-14\r\n___ 12:00AM BLOOD ALT-14 AST-14 LD(LDH)-247 AlkPhos-90 \r\nTotBili-0.5\r\n___ 01:18AM BLOOD Calcium-8.1* Phos-2.7 Mg-2.3\r\n___ 06:25AM BLOOD Vanco-19.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, diagnosed with treatment related \r\nMDS. ___ was started on decitabine as an outpatient and \r\nre-presented with fevers and neutropenia. She had an exhaustive \r\nworkup of her fevers, including skin and psoas biopsies, and \r\ntissue uPCR was sent, but there was no culture positivity or \r\npositive findings in her infectious workup. However, after \r\nconsultation with ID, it was decided to treat empirically for \r\npresumptive osteomyelitis/discitis with 6 weeks of vancomycin \r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO \r\nq24h). Micafungin was chosen instead of posaconazole due to \r\n___ differences; but she did receive posaconazole while \r\ninpatient. Simultaneously, the patient was having significantly \r\nworsened back pain after her MDS diagnosing bone marrow biopsy. \r\nShe was started on opioid pain control, which was uptitrated and \r\naugmented with Valium to good effect. She went home with BID \r\noxycontin, PRN oxycodone, and QHS Valium. She will follow-up as \r\noutpatient with Dr. ___.\r\n\r\n# Fever + neutropenia: The patient received 2 doses of \r\ndecitabine as outpatient prior to experiencing first fever of \r\n101 at home, then 100.4 in clinic during third dose decitabine \r\nadministration. She was admitted for fever in setting of \r\ncytoreduction, and she eventually became truly neutropenic. An \r\nexhaustive workup was performed, centering on MRI findings of \r\npotential osteomyelitis/discitis with potential L psoas \r\ninvovlvement. This tissue was biopsied, negative by culture, and \r\nuPCR pending at the time of discharge. The patient will be given \r\nempiric therapy of vancomycin/cefepime/micafungin for a total of \r\n6 weeks (___) and instructed to have 1 month follow-up \r\nspinal imaging. A LLE wound was also biopsied and grew nothing. \r\nBy exclusion, decitabine is thought to be the likely culprit of \r\nthe fever.\r\n\r\n# left gluteal furuncle: Formed at the marked site of the ___ L \r\npsoas biopsy. By ultrasound found to only have subcutaneous \r\nedema without fluid collection. This will be followed by patient \r\nand outpatient team as potential new nidus of infection if \r\nappearing worse or causing pain.\r\n\r\n# low back pain: Acute on chronic in this patient, who has \r\nbaseline degenerative changes. She also had R iliac crest bone \r\nmarrow biopsy prior to this admission which may have caused \r\nhematoma, inflammatory, or direct nerve injury which contributed \r\nto her severe pain. She was uptitrated to a pain regimen \r\nincluding standing Oxycontin BID, oxycodone PRN, and Valium QHS, \r\nwhich she was able to tolerate with good effect. She worked with \r\n___ and was deemed fit for discharge home with services.\r\n\r\n# treatment related MDS: Secondary to autoSCT with BEAM \r\nconditioning for DLBCL. Patient had bone marrow biopsy which \r\ndiagnosed new-onset treatment related MDS, but may have also \r\ncaused severe acute-on-chronic back pain for which she is \r\nreceiving opioids and benzodiazapines. Will receive Bactrim for \r\nPCP prophylaxis starting at discharge.\r\n\r\n# history of DVT: History of LLE DVTs, on Rivaroxaban at home \r\nand IVC filter in place. Rivaroxaban was held once Plt<75k in \r\nsetting of multi-line decline from decitabine.\r\n\r\n# common variable immunodeficiency: Patient had multiple IgG \r\nchecks for known CVID and did not require IVIG as inpatient.\r\n\r\nTRANSITIONAL ISSUES:\r\n- complete 6 week antibiotics: vancomycin, cefepime, \r\nmicafungin(d1 = ___, end ___, follow-up with OPAT\r\n- weekly labs: CBC with differential, BUN, Cr, Vancomycin\r\ntrough, AST, ALT (fax to ATTN: ___ CLINIC - FAX: \r\n___\r\n- repeat MR ___ 1 month after discharge\r\n- PCP prophylaxis with ___ SS daily\r\n- plan future decitabine with Dr. ___ team\r\n- plan for curative transplant with Dr. ___ team\r\n- continue to monitor L gluteal furuncle\r\n- consider restarting rivaroxaban when deemed appropriate \r\n(stopped inpatient due to thrombocytopenia)\r\n- Code: Full\r\n- Contact: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. FoLIC Acid 3.2 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Venlafaxine 25 mg PO BID \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n12. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n13. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n14. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q6H:PRN \r\nPain - Mild \r\n\r\n \r\nDischarge Medications:\r\n1.  CefePIME 2 g IV Q12H \r\nRX *cefepime [Maxipime] 2 gram 2 g IV every twelve (12) hours \r\nDisp #*60 Vial Refills:*0 \r\n2.  Diazepam 5 mg PO QHS \r\nRX *diazepam 5 mg 1 tab by mouth at bedtime Disp #*7 Tablet \r\nRefills:*0 \r\n3.  Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium [Colace] 100 mg 1 capsule(s) by mouth twice \r\na day Disp #*60 Capsule Refills:*0 \r\n4.  Micafungin 100 mg IV Q24H \r\nRX *micafungin [Mycamine] 100 mg 100 mg IV q24h Disp #*30 Vial \r\nRefills:*0 \r\n5.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\nRX *oxycodone 10 mg 1 tablet(s) by mouth every six (6) hours \r\nDisp #*24 Tablet Refills:*0 \r\n6.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\nRX *oxycodone 20 mg 1 tablet(s) by mouth every twelve (12) hours \r\nDisp #*14 Tablet Refills:*0 \r\n7.  Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\nRX *polyethylene glycol 3350 [Miralax] 17 gram 1 powder(s) by \r\nmouth daily Disp #*30 Packet Refills:*0 \r\n8.  Senna 8.6 mg PO BID:PRN constipation \r\nRX *sennosides [senna] 8.6 mg 1 tab by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n9.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n10.  Vancomycin 750 mg IV Q 12H \r\nRX *vancomycin 750 mg 750 mg IV every twelve (12) hours Disp \r\n#*60 Vial Refills:*0 \r\n11.  Potassium Chloride 10 mEq PO DAILY  \r\n12.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n13.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n14.  Ascorbic Acid ___ mg PO BID  \r\n15.  Cyanocobalamin 1000 mcg PO QHS  \r\n16.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n17.  FoLIC Acid 3.2 mg PO DAILY  \r\n18.  Furosemide 20 mg PO DAILY  \r\n19.  Gabapentin 900 mg PO TID  \r\n20.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n21.  Omeprazole 20 mg PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until insructed to by your outpatient \r\ndoctor\r\n24.Outpatient Lab Work\r\nTo be drawn weekly: CBC with differential, BUN, Cr, Vancomycin \r\ntrough, AST, ALT\r\nSend results to: ___ CLINIC - FAX: ___\r\nICD 10: ___.0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n- fever and neutropenia\r\n- low back pain\r\n- treatment related MDS\r\n- history of DVT\r\n- common variable immunodeficiency\r\n- left gluteal furuncle\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ was a pleasure caring for you while you were at ___. You \r\ncame to the hospital with a fever in the setting of your \r\ndecitabine therapy and had significantly worse back pain after \r\nyour bone marrow biopsy several weeks back. Despite a thorough \r\nworkup including multiple sets of blood cultures, urine \r\ncultures, and imaging including MRIs there was no infectious \r\nsource found as the culprit for your fevers. You were started on \r\nIV antibiotics to treat a presumptive infection, which you will \r\ncontinue for six weeks. You will follow-up with the infectious \r\ndisease physicians as an outpatient. You were started on several \r\nopioid pain medications and Valium which helped you be more \r\nactive and have good pain control. \r\n\r\nIt was a pleasure to participate in your care. We wish you all \r\nthe best.\r\n\r\nSincerely,\r\nYour ___ care team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-17:5",
      "text": "MICRO:\n___ Skin biopsy: All cx. negative\n___ RPR: negative\n___ Myco/lytic cx: no growth\n___ Psoas tissue cx: negative\nAll other blood and urine cultures final/negative STUDIES:\nConclusions\nThe left atrium is mildly dilated. The left atrial volume index \nis mildly increased. The estimated right atrial pressure is ___ \nmmHg. Left ventricular wall thickness, cavity size and \nregional/global systolic function are normal (LVEF >55%). The \nestimated cardiac index is normal (>=2.5L/min/m2). Tissue \nDoppler imaging suggests an increased left ventricular filling \npressure (PCWP>18mmHg). Right ventricular chamber size and free \nwall motion are normal. The aortic valve leaflets (3) are mildly \nthickened but aortic stenosis is not present. No masses or \nvegetations are seen on the aortic valve. No aortic valve \nabscess is seen. No aortic regurgitation is seen. The mitral \nvalve leaflets are mildly thickened. There is no mitral valve \nprolapse. No mass or vegetation is seen on the mitral valve. Mild (1+) mitral regurgitation is seen. There is moderate \npulmonary artery systolic hypertension. No vegetation/mass is \nseen on the pulmonic valve. There is an anterior space which \nmost likely represents a prominent fat pad. IMPRESSION: No echocardiographic evidence of endocarditis. Normal biventricular cavity sizes with preserved global and \nregional biventricular systolic function. Suggestion of elevated \nLV filling pressure. Mild mitral and tricuspid regurgitation. Moderate pulmonary hypertension. Compared with the prior study (images reviewed) of ___, \nthe degrees of mitral and tricuspid regurgitation are slightly \ngreater and the estimated pulmonary arterial pressure is higher. IMAGING:\n___ L gluteal U/S: IMPRESSION:\nInflammation or edema of the superficial soft tissues without \nfocal fluid\ncollection. ___ MR ___:",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-17",
        "chart_time": "104487",
        "section": "General",
        "position": 5,
        "tokenCount": 458,
        "note_metadata": {
          "note_id": "18887130-DS-17",
          "subject_id": 18887130,
          "hadm_id": 27240020,
          "note_type": "DS",
          "note_seq": 17,
          "charttime": 104487,
          "storetime": 104488.35277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, fever + neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nL psoas and prespinal biopsy\r\nLLE skin biopsy\r\n\r\n \r\nHistory of Present Illness:\r\n___ F with CVID, h/o transformed follicular lymphoma and h/o CLL \r\ns/p auto SCT (BEAM prep) in ___ in remission from lymphoma \r\nstandpoint but developed worsening pancytopenia and bleeding \r\nissues this month found to have treatment related MDS, now C1D3 \r\ndacogen presenting with borderline neutropenia and temp today of \r\n100.4.\r\n\r\nOther v/s in clinic: Vital Signs: BP: 111/53. Heart Rate:\r\n98. O2 Saturation%: 100.  Weight: 256.6. Height: 61.25. BMI:\r\n48.1. Temperature: 100.4. Resp. Rate: 18. Pain Score: 5 (back). \r\n\r\nGiven functional neutropenia, admitted for treatment of febrile \r\nneutropenia. Got vanc/cefepime in clinic. Blood cultures sent in \r\nclinic. She reported having some chills at the time and general \r\nfatigue but denied any other specific symptoms. Temp came back \r\ndown on it's own and she was 98.9 before leaving clinic. Hgb \r\n7.1,\r\nclinic orderd 1u blood which she will receive here. Regarding \r\nher other PMH: she is on xarelto for thrombosis history (DVT, \r\nalso has IVCF which was placed), and has h/o bleo toxicity \r\npneumonitis (off steroids now but cont with inhalers), and also \r\nhas intermittent LBP and left sciatica due to degenerative \r\ndisease,\r\non gabapentin, and she has chronic right pupil dilation and \r\ndysmetria.\r\n\r\nNote she was recently admitted and discharged ___. SHe had BM \r\nbx ___ which showed MDS as above. She also reported nasal \r\ncongestion and had fever ___, initially covered broadly but \r\nwith negative cultures, ultimately discharged to complete 7d \r\ncourse of levaquin on ___. Pt states she stopped taking the \r\nlevoquin ___ days ago. Last night took her temp and it was 100.1 \r\n(was\r\ninstructed to monitor temps, she had no symptoms that prompted \r\nthis check). This morning driving in to clinic appointment felt \r\na bit chilled but not shaking and not sick in any other way. In \r\nclinic found to have temp of 100.4. Also notes that she \r\ntypically has left sided sciatica but that in the past week sinc \r\nethe bone marrow biopsy has developed right lower back pain \r\nwhich has required ___ doses of vicodin daily and is a new pain \r\nworsening over time, present constantly, but worse with movement \r\nor deep palpation. Denies loss of strength or sensation though \r\nhas chronic right foot drop and dysesthesias at baseline after \r\nknee replacement on that side in the past. No incontinence or \r\ndysuria.\r\n\r\nFinally, her history is significant for a \"blood blister\" she \r\nnoted on the left foreleg per pt about ___ weeks ago which was \r\nultimately debrided in the past, and poor wound healing \r\nattributed to venous stasis. THis has been healing well she \r\nstates, though there is still an open wound surrounded by \r\nerythema but she is confident it continues to improve \r\ndramatically and no recent drainage. She is covering it with \r\nxeroform dressing daily.\r\n\r\nfurther nose bleeds or other bleeding.  She is also noted for a \r\nnonhealing wound on her left leg after hitting her shin several \r\nweeks ago.  She is using xerofrom dressing to the area and \r\nchanging it daily with slow healing. All other 10 point ROS neg.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM:\r\nGeneral: NAD  \r\nT 99.6 BP 100/58  HR 95  20  96%RA\r\nHEENT: Right pupil slower to react to light which is baseline.  \r\nMMM, no OP lesions or thrush.  \r\nCV: RR, NL S1S2 no MRG  \r\nPULM: CTAB no wheezing or crackles  \r\nABD: BS+, soft, NTND  \r\nSKIN/limbs: left anterior foreleg with 1cm open circular wound \r\nwithout drainage, covered w/xeroform, with 4-5 cm diameter \r\nsurrounding erythema, not warm to touch, lower extr are equal in \r\ngirth, no pitting edema\r\nBack: pt is tender to palpation around the left SI joint, has \r\nresolving hematoma over the medial aspect of right sacrum, but \r\nno tenderness over the hematoma which appears superficial, no \r\nswelling\r\n\r\nDISCHARGE EXAM:\r\nVS: 98.1 ___ 22 97RA\r\nGEN: NAD, seated in chair, conversational\r\nHEENT: AT/NC; R pupil mildly larger, slower to react than L \r\n(baseline per records); MMM\r\nCV: RRR, no M/R/G, +S1/S2\r\nPULM: CTAB\r\nABD: obese, soft, nontender to palpation, referred pain from \r\nback in band/belt distribution in low abdomen; +BS\r\nSKIN: unroofed vesicle with mild bleeding covered with xeroform\r\nEXT: chronic venous stasis changes in B/L ___ over shins\r\nNEURO: A/Ox3; CNII-XII assessed and grossly intact except for \r\nR>L pupillary dilataion and sluggish reactivity\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n___ 11:30AM BLOOD WBC-2.3* RBC-2.28* Hgb-7.1* Hct-22.1* \r\nMCV-97 MCH-31.1 MCHC-32.1 RDW-21.8* RDWSD-77.3* Plt ___\r\n___ 11:30AM BLOOD Neuts-37 Bands-6* ___ Monos-11 \r\nEos-0 Baso-0 Atyps-2* Metas-3* Myelos-1* Blasts-2* NRBC-3* \r\nAbsNeut-0.99* AbsLymp-0.92* AbsMono-0.25 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD ___ PTT-39.0* ___\r\n___ 11:30AM BLOOD UreaN-15 Creat-0.9 Na-137 K-3.8 Cl-102 \r\nHCO3-25 AnGap-14\r\n___ 11:30AM BLOOD ALT-8 AST-10 LD(LDH)-260* AlkPhos-81 \r\nTotBili-0.3\r\n___ 11:30AM BLOOD Albumin-3.4* Calcium-8.1* Mg-2.2\r\n\r\nINTERVAL LABS:\r\n___ 12:00AM BLOOD CRP-108.7*\r\n___ 12:00AM BLOOD IgG-805\r\n___ 04:00PM BLOOD HIV Ab-Negative\r\n___ 04:00PM BLOOD CMV VL-NOT DETECT\r\n___ 02:20PM BLOOD SED RATE-Test      \r\n___ 04:00PM BLOOD HERPES 6 DNA PCR, QUANTITATIVE-Test      \r\n___ 04:00PM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-Test   \r\n   \r\n___ 07:45PM BLOOD B-GLUCAN-Test      \r\n___ 07:45PM BLOOD ASPERGILLUS GALACTOMANNAN ANTIGEN-Test\r\n\r\nMICRO:\r\n___ Skin biopsy: All cx. negative\r\n___ RPR: negative\r\n___ Myco/lytic cx: no growth\r\n___ Psoas tissue cx: negative\r\nAll other blood and urine cultures final/negative\r\n\r\nSTUDIES:\r\nConclusions\r\nThe left atrium is mildly dilated. The left atrial volume index \r\nis mildly increased. The estimated right atrial pressure is ___ \r\nmmHg. Left ventricular wall thickness, cavity size and \r\nregional/global systolic function are normal (LVEF >55%). The \r\nestimated cardiac index is normal (>=2.5L/min/m2). Tissue \r\nDoppler imaging suggests an increased left ventricular filling \r\npressure (PCWP>18mmHg). Right ventricular chamber size and free \r\nwall motion are normal. The aortic valve leaflets (3) are mildly \r\nthickened but aortic stenosis is not present. No masses or \r\nvegetations are seen on the aortic valve. No aortic valve \r\nabscess is seen. No aortic regurgitation is seen. The mitral \r\nvalve leaflets are mildly thickened. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. There is moderate \r\npulmonary artery systolic hypertension. No vegetation/mass is \r\nseen on the pulmonic valve. There is an anterior space which \r\nmost likely represents a prominent fat pad. \r\n\r\nIMPRESSION: No echocardiographic evidence of endocarditis. \r\nNormal biventricular cavity sizes with preserved global and \r\nregional biventricular systolic function. Suggestion of elevated \r\nLV filling pressure. Mild mitral and tricuspid regurgitation. \r\nModerate pulmonary hypertension.\r\n\r\nCompared with the prior study (images reviewed) of ___, \r\nthe degrees of mitral and tricuspid regurgitation are slightly \r\ngreater and the estimated pulmonary arterial pressure is higher.\r\n\r\nIMAGING:\r\n___ L gluteal U/S:\r\nIMPRESSION:\r\nInflammation or edema of the superficial soft tissues without \r\nfocal fluid\r\ncollection.\r\n\r\n___ MR ___:\r\nIMPRESSION:\r\n1. Severe multilevel degenerative changes as described above \r\nhave slightly\r\nprogressed since the prior examination of ___.\r\n2. Scoliosis of lumbar spine with  signal changes and edema \r\nedema in the\r\nendplates, mild adjacent soft tissue signal and enhancement and \r\nenhancement in the left psoas muscle at L4-5 level without \r\nepidural phlegmon or paraspinal fluid collection are \r\nnonspecific.  Both advanced degenerative changes or early \r\ndiscitis osteomyelitis could give similar appearances.  The \r\nappearance on the prior CT abdomen of ___ or more was \r\nmore consistent with degenerative change. However, Correlation \r\nwith laboratory findings is essential to exclude early discitis \r\nosteomyelitis.\r\n\r\nDISCHARGE LABS:\r\n___ 01:18AM BLOOD WBC-0.4* RBC-2.58* Hgb-7.6* Hct-23.6* \r\nMCV-92 MCH-29.5 MCHC-32.2 RDW-18.6* RDWSD-62.0* Plt Ct-15*\r\n___ 01:18AM BLOOD Neuts-12* Bands-0 Lymphs-78* Monos-7 \r\nEos-1 Baso-0 Atyps-1* ___ Myelos-1* AbsNeut-0.05* \r\nAbsLymp-0.32* AbsMono-0.03* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:18AM BLOOD ___ PTT-34.5 ___\r\n___ 01:18AM BLOOD Glucose-147* UreaN-14 Creat-0.9 Na-136 \r\nK-3.7 Cl-99 HCO3-27 AnGap-14\r\n___ 12:00AM BLOOD ALT-14 AST-14 LD(LDH)-247 AlkPhos-90 \r\nTotBili-0.5\r\n___ 01:18AM BLOOD Calcium-8.1* Phos-2.7 Mg-2.3\r\n___ 06:25AM BLOOD Vanco-19.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, diagnosed with treatment related \r\nMDS. ___ was started on decitabine as an outpatient and \r\nre-presented with fevers and neutropenia. She had an exhaustive \r\nworkup of her fevers, including skin and psoas biopsies, and \r\ntissue uPCR was sent, but there was no culture positivity or \r\npositive findings in her infectious workup. However, after \r\nconsultation with ID, it was decided to treat empirically for \r\npresumptive osteomyelitis/discitis with 6 weeks of vancomycin \r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO \r\nq24h). Micafungin was chosen instead of posaconazole due to \r\n___ differences; but she did receive posaconazole while \r\ninpatient. Simultaneously, the patient was having significantly \r\nworsened back pain after her MDS diagnosing bone marrow biopsy. \r\nShe was started on opioid pain control, which was uptitrated and \r\naugmented with Valium to good effect. She went home with BID \r\noxycontin, PRN oxycodone, and QHS Valium. She will follow-up as \r\noutpatient with Dr. ___.\r\n\r\n# Fever + neutropenia: The patient received 2 doses of \r\ndecitabine as outpatient prior to experiencing first fever of \r\n101 at home, then 100.4 in clinic during third dose decitabine \r\nadministration. She was admitted for fever in setting of \r\ncytoreduction, and she eventually became truly neutropenic. An \r\nexhaustive workup was performed, centering on MRI findings of \r\npotential osteomyelitis/discitis with potential L psoas \r\ninvovlvement. This tissue was biopsied, negative by culture, and \r\nuPCR pending at the time of discharge. The patient will be given \r\nempiric therapy of vancomycin/cefepime/micafungin for a total of \r\n6 weeks (___) and instructed to have 1 month follow-up \r\nspinal imaging. A LLE wound was also biopsied and grew nothing. \r\nBy exclusion, decitabine is thought to be the likely culprit of \r\nthe fever.\r\n\r\n# left gluteal furuncle: Formed at the marked site of the ___ L \r\npsoas biopsy. By ultrasound found to only have subcutaneous \r\nedema without fluid collection. This will be followed by patient \r\nand outpatient team as potential new nidus of infection if \r\nappearing worse or causing pain.\r\n\r\n# low back pain: Acute on chronic in this patient, who has \r\nbaseline degenerative changes. She also had R iliac crest bone \r\nmarrow biopsy prior to this admission which may have caused \r\nhematoma, inflammatory, or direct nerve injury which contributed \r\nto her severe pain. She was uptitrated to a pain regimen \r\nincluding standing Oxycontin BID, oxycodone PRN, and Valium QHS, \r\nwhich she was able to tolerate with good effect. She worked with \r\n___ and was deemed fit for discharge home with services.\r\n\r\n# treatment related MDS: Secondary to autoSCT with BEAM \r\nconditioning for DLBCL. Patient had bone marrow biopsy which \r\ndiagnosed new-onset treatment related MDS, but may have also \r\ncaused severe acute-on-chronic back pain for which she is \r\nreceiving opioids and benzodiazapines. Will receive Bactrim for \r\nPCP prophylaxis starting at discharge.\r\n\r\n# history of DVT: History of LLE DVTs, on Rivaroxaban at home \r\nand IVC filter in place. Rivaroxaban was held once Plt<75k in \r\nsetting of multi-line decline from decitabine.\r\n\r\n# common variable immunodeficiency: Patient had multiple IgG \r\nchecks for known CVID and did not require IVIG as inpatient.\r\n\r\nTRANSITIONAL ISSUES:\r\n- complete 6 week antibiotics: vancomycin, cefepime, \r\nmicafungin(d1 = ___, end ___, follow-up with OPAT\r\n- weekly labs: CBC with differential, BUN, Cr, Vancomycin\r\ntrough, AST, ALT (fax to ATTN: ___ CLINIC - FAX: \r\n___\r\n- repeat MR ___ 1 month after discharge\r\n- PCP prophylaxis with ___ SS daily\r\n- plan future decitabine with Dr. ___ team\r\n- plan for curative transplant with Dr. ___ team\r\n- continue to monitor L gluteal furuncle\r\n- consider restarting rivaroxaban when deemed appropriate \r\n(stopped inpatient due to thrombocytopenia)\r\n- Code: Full\r\n- Contact: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. FoLIC Acid 3.2 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Venlafaxine 25 mg PO BID \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n12. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n13. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n14. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q6H:PRN \r\nPain - Mild \r\n\r\n \r\nDischarge Medications:\r\n1.  CefePIME 2 g IV Q12H \r\nRX *cefepime [Maxipime] 2 gram 2 g IV every twelve (12) hours \r\nDisp #*60 Vial Refills:*0 \r\n2.  Diazepam 5 mg PO QHS \r\nRX *diazepam 5 mg 1 tab by mouth at bedtime Disp #*7 Tablet \r\nRefills:*0 \r\n3.  Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium [Colace] 100 mg 1 capsule(s) by mouth twice \r\na day Disp #*60 Capsule Refills:*0 \r\n4.  Micafungin 100 mg IV Q24H \r\nRX *micafungin [Mycamine] 100 mg 100 mg IV q24h Disp #*30 Vial \r\nRefills:*0 \r\n5.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\nRX *oxycodone 10 mg 1 tablet(s) by mouth every six (6) hours \r\nDisp #*24 Tablet Refills:*0 \r\n6.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\nRX *oxycodone 20 mg 1 tablet(s) by mouth every twelve (12) hours \r\nDisp #*14 Tablet Refills:*0 \r\n7.  Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\nRX *polyethylene glycol 3350 [Miralax] 17 gram 1 powder(s) by \r\nmouth daily Disp #*30 Packet Refills:*0 \r\n8.  Senna 8.6 mg PO BID:PRN constipation \r\nRX *sennosides [senna] 8.6 mg 1 tab by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n9.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n10.  Vancomycin 750 mg IV Q 12H \r\nRX *vancomycin 750 mg 750 mg IV every twelve (12) hours Disp \r\n#*60 Vial Refills:*0 \r\n11.  Potassium Chloride 10 mEq PO DAILY  \r\n12.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n13.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n14.  Ascorbic Acid ___ mg PO BID  \r\n15.  Cyanocobalamin 1000 mcg PO QHS  \r\n16.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n17.  FoLIC Acid 3.2 mg PO DAILY  \r\n18.  Furosemide 20 mg PO DAILY  \r\n19.  Gabapentin 900 mg PO TID  \r\n20.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n21.  Omeprazole 20 mg PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until insructed to by your outpatient \r\ndoctor\r\n24.Outpatient Lab Work\r\nTo be drawn weekly: CBC with differential, BUN, Cr, Vancomycin \r\ntrough, AST, ALT\r\nSend results to: ___ CLINIC - FAX: ___\r\nICD 10: ___.0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n- fever and neutropenia\r\n- low back pain\r\n- treatment related MDS\r\n- history of DVT\r\n- common variable immunodeficiency\r\n- left gluteal furuncle\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ was a pleasure caring for you while you were at ___. You \r\ncame to the hospital with a fever in the setting of your \r\ndecitabine therapy and had significantly worse back pain after \r\nyour bone marrow biopsy several weeks back. Despite a thorough \r\nworkup including multiple sets of blood cultures, urine \r\ncultures, and imaging including MRIs there was no infectious \r\nsource found as the culprit for your fevers. You were started on \r\nIV antibiotics to treat a presumptive infection, which you will \r\ncontinue for six weeks. You will follow-up with the infectious \r\ndisease physicians as an outpatient. You were started on several \r\nopioid pain medications and Valium which helped you be more \r\nactive and have good pain control. \r\n\r\nIt was a pleasure to participate in your care. We wish you all \r\nthe best.\r\n\r\nSincerely,\r\nYour ___ care team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-17:6",
      "text": "IMPRESSION:\n1. Severe multilevel degenerative changes as described above \nhave slightly\nprogressed since the prior examination of ___. 2. Scoliosis of lumbar spine with  signal changes and edema \nedema in the\nendplates, mild adjacent soft tissue signal and enhancement and \nenhancement in the left psoas muscle at L4-5 level without \nepidural phlegmon or paraspinal fluid collection are \nnonspecific. Both advanced degenerative changes or early \ndiscitis osteomyelitis could give similar appearances. The \nappearance on the prior CT abdomen of ___ or more was \nmore consistent with degenerative change. However, Correlation \nwith laboratory findings is essential to exclude early discitis \nosteomyelitis. DISCHARGE LABS:\n___ 01:18AM BLOOD WBC-0.4* RBC-2.58* Hgb-7.6* Hct-23.6* \nMCV-92 MCH-29.5 MCHC-32.2 RDW-18.6* RDWSD-62.0* Plt Ct-15*\n___ 01:18AM BLOOD Neuts-12* Bands-0 Lymphs-78* Monos-7 \nEos-1 Baso-0 Atyps-1* ___ Myelos-1* AbsNeut-0.05* \nAbsLymp-0.32* AbsMono-0.03* AbsEos-0.00* AbsBaso-0.00*\n___ 01:18AM BLOOD ___ PTT-34.5 ___\n___ 01:18AM BLOOD Glucose-147* UreaN-14 Creat-0.9 Na-136 \nK-3.7 Cl-99 HCO3-27 AnGap-14\n___ 12:00AM BLOOD ALT-14 AST-14 LD(LDH)-247 AlkPhos-90 \nTotBili-0.5\n___ 01:18AM BLOOD Calcium-8.1* Phos-2.7 Mg-2.3\n___ 06:25AM BLOOD Vanco-19.___ year old female with history of transformed diffuse large B \ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \nconditioning in ___ ___s IFRT with course complicated \nby BCNU pneumonitis as well as persistent norovirus p/w acute \nLBP, epistaxis, pancytopenia, diagnosed with treatment related \nMDS. ___ was started on decitabine as an outpatient and \nre-presented with fevers and neutropenia. She had an exhaustive \nworkup of her fevers, including skin and psoas biopsies, and \ntissue uPCR was sent, but there was no culture positivity or \npositive findings in her infectious workup. However, after \nconsultation with ID, it was decided to treat empirically for \npresumptive osteomyelitis/discitis with 6 weeks of vancomycin \n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO \nq24h). Micafungin was chosen instead of posaconazole due to \n___ differences; but she did receive posaconazole while \ninpatient. Simultaneously, the patient was having significantly \nworsened back pain after her MDS diagnosing bone marrow biopsy. She was started on opioid pain control, which was uptitrated and \naugmented with Valium to good effect. She went home with BID \noxycontin, PRN oxycodone, and QHS Valium. She will follow-up as \noutpatient with Dr. ___. # Fever + neutropenia: The patient received 2 doses of \ndecitabine as outpatient prior to experiencing first fever of \n101 at home, then 100.4 in clinic during third dose decitabine \nadministration.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-17",
        "chart_time": "104487",
        "section": "General",
        "position": 6,
        "tokenCount": 683,
        "note_metadata": {
          "note_id": "18887130-DS-17",
          "subject_id": 18887130,
          "hadm_id": 27240020,
          "note_type": "DS",
          "note_seq": 17,
          "charttime": 104487,
          "storetime": 104488.35277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, fever + neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nL psoas and prespinal biopsy\r\nLLE skin biopsy\r\n\r\n \r\nHistory of Present Illness:\r\n___ F with CVID, h/o transformed follicular lymphoma and h/o CLL \r\ns/p auto SCT (BEAM prep) in ___ in remission from lymphoma \r\nstandpoint but developed worsening pancytopenia and bleeding \r\nissues this month found to have treatment related MDS, now C1D3 \r\ndacogen presenting with borderline neutropenia and temp today of \r\n100.4.\r\n\r\nOther v/s in clinic: Vital Signs: BP: 111/53. Heart Rate:\r\n98. O2 Saturation%: 100.  Weight: 256.6. Height: 61.25. BMI:\r\n48.1. Temperature: 100.4. Resp. Rate: 18. Pain Score: 5 (back). \r\n\r\nGiven functional neutropenia, admitted for treatment of febrile \r\nneutropenia. Got vanc/cefepime in clinic. Blood cultures sent in \r\nclinic. She reported having some chills at the time and general \r\nfatigue but denied any other specific symptoms. Temp came back \r\ndown on it's own and she was 98.9 before leaving clinic. Hgb \r\n7.1,\r\nclinic orderd 1u blood which she will receive here. Regarding \r\nher other PMH: she is on xarelto for thrombosis history (DVT, \r\nalso has IVCF which was placed), and has h/o bleo toxicity \r\npneumonitis (off steroids now but cont with inhalers), and also \r\nhas intermittent LBP and left sciatica due to degenerative \r\ndisease,\r\non gabapentin, and she has chronic right pupil dilation and \r\ndysmetria.\r\n\r\nNote she was recently admitted and discharged ___. SHe had BM \r\nbx ___ which showed MDS as above. She also reported nasal \r\ncongestion and had fever ___, initially covered broadly but \r\nwith negative cultures, ultimately discharged to complete 7d \r\ncourse of levaquin on ___. Pt states she stopped taking the \r\nlevoquin ___ days ago. Last night took her temp and it was 100.1 \r\n(was\r\ninstructed to monitor temps, she had no symptoms that prompted \r\nthis check). This morning driving in to clinic appointment felt \r\na bit chilled but not shaking and not sick in any other way. In \r\nclinic found to have temp of 100.4. Also notes that she \r\ntypically has left sided sciatica but that in the past week sinc \r\nethe bone marrow biopsy has developed right lower back pain \r\nwhich has required ___ doses of vicodin daily and is a new pain \r\nworsening over time, present constantly, but worse with movement \r\nor deep palpation. Denies loss of strength or sensation though \r\nhas chronic right foot drop and dysesthesias at baseline after \r\nknee replacement on that side in the past. No incontinence or \r\ndysuria.\r\n\r\nFinally, her history is significant for a \"blood blister\" she \r\nnoted on the left foreleg per pt about ___ weeks ago which was \r\nultimately debrided in the past, and poor wound healing \r\nattributed to venous stasis. THis has been healing well she \r\nstates, though there is still an open wound surrounded by \r\nerythema but she is confident it continues to improve \r\ndramatically and no recent drainage. She is covering it with \r\nxeroform dressing daily.\r\n\r\nfurther nose bleeds or other bleeding.  She is also noted for a \r\nnonhealing wound on her left leg after hitting her shin several \r\nweeks ago.  She is using xerofrom dressing to the area and \r\nchanging it daily with slow healing. All other 10 point ROS neg.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM:\r\nGeneral: NAD  \r\nT 99.6 BP 100/58  HR 95  20  96%RA\r\nHEENT: Right pupil slower to react to light which is baseline.  \r\nMMM, no OP lesions or thrush.  \r\nCV: RR, NL S1S2 no MRG  \r\nPULM: CTAB no wheezing or crackles  \r\nABD: BS+, soft, NTND  \r\nSKIN/limbs: left anterior foreleg with 1cm open circular wound \r\nwithout drainage, covered w/xeroform, with 4-5 cm diameter \r\nsurrounding erythema, not warm to touch, lower extr are equal in \r\ngirth, no pitting edema\r\nBack: pt is tender to palpation around the left SI joint, has \r\nresolving hematoma over the medial aspect of right sacrum, but \r\nno tenderness over the hematoma which appears superficial, no \r\nswelling\r\n\r\nDISCHARGE EXAM:\r\nVS: 98.1 ___ 22 97RA\r\nGEN: NAD, seated in chair, conversational\r\nHEENT: AT/NC; R pupil mildly larger, slower to react than L \r\n(baseline per records); MMM\r\nCV: RRR, no M/R/G, +S1/S2\r\nPULM: CTAB\r\nABD: obese, soft, nontender to palpation, referred pain from \r\nback in band/belt distribution in low abdomen; +BS\r\nSKIN: unroofed vesicle with mild bleeding covered with xeroform\r\nEXT: chronic venous stasis changes in B/L ___ over shins\r\nNEURO: A/Ox3; CNII-XII assessed and grossly intact except for \r\nR>L pupillary dilataion and sluggish reactivity\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n___ 11:30AM BLOOD WBC-2.3* RBC-2.28* Hgb-7.1* Hct-22.1* \r\nMCV-97 MCH-31.1 MCHC-32.1 RDW-21.8* RDWSD-77.3* Plt ___\r\n___ 11:30AM BLOOD Neuts-37 Bands-6* ___ Monos-11 \r\nEos-0 Baso-0 Atyps-2* Metas-3* Myelos-1* Blasts-2* NRBC-3* \r\nAbsNeut-0.99* AbsLymp-0.92* AbsMono-0.25 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD ___ PTT-39.0* ___\r\n___ 11:30AM BLOOD UreaN-15 Creat-0.9 Na-137 K-3.8 Cl-102 \r\nHCO3-25 AnGap-14\r\n___ 11:30AM BLOOD ALT-8 AST-10 LD(LDH)-260* AlkPhos-81 \r\nTotBili-0.3\r\n___ 11:30AM BLOOD Albumin-3.4* Calcium-8.1* Mg-2.2\r\n\r\nINTERVAL LABS:\r\n___ 12:00AM BLOOD CRP-108.7*\r\n___ 12:00AM BLOOD IgG-805\r\n___ 04:00PM BLOOD HIV Ab-Negative\r\n___ 04:00PM BLOOD CMV VL-NOT DETECT\r\n___ 02:20PM BLOOD SED RATE-Test      \r\n___ 04:00PM BLOOD HERPES 6 DNA PCR, QUANTITATIVE-Test      \r\n___ 04:00PM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-Test   \r\n   \r\n___ 07:45PM BLOOD B-GLUCAN-Test      \r\n___ 07:45PM BLOOD ASPERGILLUS GALACTOMANNAN ANTIGEN-Test\r\n\r\nMICRO:\r\n___ Skin biopsy: All cx. negative\r\n___ RPR: negative\r\n___ Myco/lytic cx: no growth\r\n___ Psoas tissue cx: negative\r\nAll other blood and urine cultures final/negative\r\n\r\nSTUDIES:\r\nConclusions\r\nThe left atrium is mildly dilated. The left atrial volume index \r\nis mildly increased. The estimated right atrial pressure is ___ \r\nmmHg. Left ventricular wall thickness, cavity size and \r\nregional/global systolic function are normal (LVEF >55%). The \r\nestimated cardiac index is normal (>=2.5L/min/m2). Tissue \r\nDoppler imaging suggests an increased left ventricular filling \r\npressure (PCWP>18mmHg). Right ventricular chamber size and free \r\nwall motion are normal. The aortic valve leaflets (3) are mildly \r\nthickened but aortic stenosis is not present. No masses or \r\nvegetations are seen on the aortic valve. No aortic valve \r\nabscess is seen. No aortic regurgitation is seen. The mitral \r\nvalve leaflets are mildly thickened. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. There is moderate \r\npulmonary artery systolic hypertension. No vegetation/mass is \r\nseen on the pulmonic valve. There is an anterior space which \r\nmost likely represents a prominent fat pad. \r\n\r\nIMPRESSION: No echocardiographic evidence of endocarditis. \r\nNormal biventricular cavity sizes with preserved global and \r\nregional biventricular systolic function. Suggestion of elevated \r\nLV filling pressure. Mild mitral and tricuspid regurgitation. \r\nModerate pulmonary hypertension.\r\n\r\nCompared with the prior study (images reviewed) of ___, \r\nthe degrees of mitral and tricuspid regurgitation are slightly \r\ngreater and the estimated pulmonary arterial pressure is higher.\r\n\r\nIMAGING:\r\n___ L gluteal U/S:\r\nIMPRESSION:\r\nInflammation or edema of the superficial soft tissues without \r\nfocal fluid\r\ncollection.\r\n\r\n___ MR ___:\r\nIMPRESSION:\r\n1. Severe multilevel degenerative changes as described above \r\nhave slightly\r\nprogressed since the prior examination of ___.\r\n2. Scoliosis of lumbar spine with  signal changes and edema \r\nedema in the\r\nendplates, mild adjacent soft tissue signal and enhancement and \r\nenhancement in the left psoas muscle at L4-5 level without \r\nepidural phlegmon or paraspinal fluid collection are \r\nnonspecific.  Both advanced degenerative changes or early \r\ndiscitis osteomyelitis could give similar appearances.  The \r\nappearance on the prior CT abdomen of ___ or more was \r\nmore consistent with degenerative change. However, Correlation \r\nwith laboratory findings is essential to exclude early discitis \r\nosteomyelitis.\r\n\r\nDISCHARGE LABS:\r\n___ 01:18AM BLOOD WBC-0.4* RBC-2.58* Hgb-7.6* Hct-23.6* \r\nMCV-92 MCH-29.5 MCHC-32.2 RDW-18.6* RDWSD-62.0* Plt Ct-15*\r\n___ 01:18AM BLOOD Neuts-12* Bands-0 Lymphs-78* Monos-7 \r\nEos-1 Baso-0 Atyps-1* ___ Myelos-1* AbsNeut-0.05* \r\nAbsLymp-0.32* AbsMono-0.03* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:18AM BLOOD ___ PTT-34.5 ___\r\n___ 01:18AM BLOOD Glucose-147* UreaN-14 Creat-0.9 Na-136 \r\nK-3.7 Cl-99 HCO3-27 AnGap-14\r\n___ 12:00AM BLOOD ALT-14 AST-14 LD(LDH)-247 AlkPhos-90 \r\nTotBili-0.5\r\n___ 01:18AM BLOOD Calcium-8.1* Phos-2.7 Mg-2.3\r\n___ 06:25AM BLOOD Vanco-19.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, diagnosed with treatment related \r\nMDS. ___ was started on decitabine as an outpatient and \r\nre-presented with fevers and neutropenia. She had an exhaustive \r\nworkup of her fevers, including skin and psoas biopsies, and \r\ntissue uPCR was sent, but there was no culture positivity or \r\npositive findings in her infectious workup. However, after \r\nconsultation with ID, it was decided to treat empirically for \r\npresumptive osteomyelitis/discitis with 6 weeks of vancomycin \r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO \r\nq24h). Micafungin was chosen instead of posaconazole due to \r\n___ differences; but she did receive posaconazole while \r\ninpatient. Simultaneously, the patient was having significantly \r\nworsened back pain after her MDS diagnosing bone marrow biopsy. \r\nShe was started on opioid pain control, which was uptitrated and \r\naugmented with Valium to good effect. She went home with BID \r\noxycontin, PRN oxycodone, and QHS Valium. She will follow-up as \r\noutpatient with Dr. ___.\r\n\r\n# Fever + neutropenia: The patient received 2 doses of \r\ndecitabine as outpatient prior to experiencing first fever of \r\n101 at home, then 100.4 in clinic during third dose decitabine \r\nadministration. She was admitted for fever in setting of \r\ncytoreduction, and she eventually became truly neutropenic. An \r\nexhaustive workup was performed, centering on MRI findings of \r\npotential osteomyelitis/discitis with potential L psoas \r\ninvovlvement. This tissue was biopsied, negative by culture, and \r\nuPCR pending at the time of discharge. The patient will be given \r\nempiric therapy of vancomycin/cefepime/micafungin for a total of \r\n6 weeks (___) and instructed to have 1 month follow-up \r\nspinal imaging. A LLE wound was also biopsied and grew nothing. \r\nBy exclusion, decitabine is thought to be the likely culprit of \r\nthe fever.\r\n\r\n# left gluteal furuncle: Formed at the marked site of the ___ L \r\npsoas biopsy. By ultrasound found to only have subcutaneous \r\nedema without fluid collection. This will be followed by patient \r\nand outpatient team as potential new nidus of infection if \r\nappearing worse or causing pain.\r\n\r\n# low back pain: Acute on chronic in this patient, who has \r\nbaseline degenerative changes. She also had R iliac crest bone \r\nmarrow biopsy prior to this admission which may have caused \r\nhematoma, inflammatory, or direct nerve injury which contributed \r\nto her severe pain. She was uptitrated to a pain regimen \r\nincluding standing Oxycontin BID, oxycodone PRN, and Valium QHS, \r\nwhich she was able to tolerate with good effect. She worked with \r\n___ and was deemed fit for discharge home with services.\r\n\r\n# treatment related MDS: Secondary to autoSCT with BEAM \r\nconditioning for DLBCL. Patient had bone marrow biopsy which \r\ndiagnosed new-onset treatment related MDS, but may have also \r\ncaused severe acute-on-chronic back pain for which she is \r\nreceiving opioids and benzodiazapines. Will receive Bactrim for \r\nPCP prophylaxis starting at discharge.\r\n\r\n# history of DVT: History of LLE DVTs, on Rivaroxaban at home \r\nand IVC filter in place. Rivaroxaban was held once Plt<75k in \r\nsetting of multi-line decline from decitabine.\r\n\r\n# common variable immunodeficiency: Patient had multiple IgG \r\nchecks for known CVID and did not require IVIG as inpatient.\r\n\r\nTRANSITIONAL ISSUES:\r\n- complete 6 week antibiotics: vancomycin, cefepime, \r\nmicafungin(d1 = ___, end ___, follow-up with OPAT\r\n- weekly labs: CBC with differential, BUN, Cr, Vancomycin\r\ntrough, AST, ALT (fax to ATTN: ___ CLINIC - FAX: \r\n___\r\n- repeat MR ___ 1 month after discharge\r\n- PCP prophylaxis with ___ SS daily\r\n- plan future decitabine with Dr. ___ team\r\n- plan for curative transplant with Dr. ___ team\r\n- continue to monitor L gluteal furuncle\r\n- consider restarting rivaroxaban when deemed appropriate \r\n(stopped inpatient due to thrombocytopenia)\r\n- Code: Full\r\n- Contact: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. FoLIC Acid 3.2 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Venlafaxine 25 mg PO BID \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n12. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n13. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n14. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q6H:PRN \r\nPain - Mild \r\n\r\n \r\nDischarge Medications:\r\n1.  CefePIME 2 g IV Q12H \r\nRX *cefepime [Maxipime] 2 gram 2 g IV every twelve (12) hours \r\nDisp #*60 Vial Refills:*0 \r\n2.  Diazepam 5 mg PO QHS \r\nRX *diazepam 5 mg 1 tab by mouth at bedtime Disp #*7 Tablet \r\nRefills:*0 \r\n3.  Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium [Colace] 100 mg 1 capsule(s) by mouth twice \r\na day Disp #*60 Capsule Refills:*0 \r\n4.  Micafungin 100 mg IV Q24H \r\nRX *micafungin [Mycamine] 100 mg 100 mg IV q24h Disp #*30 Vial \r\nRefills:*0 \r\n5.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\nRX *oxycodone 10 mg 1 tablet(s) by mouth every six (6) hours \r\nDisp #*24 Tablet Refills:*0 \r\n6.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\nRX *oxycodone 20 mg 1 tablet(s) by mouth every twelve (12) hours \r\nDisp #*14 Tablet Refills:*0 \r\n7.  Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\nRX *polyethylene glycol 3350 [Miralax] 17 gram 1 powder(s) by \r\nmouth daily Disp #*30 Packet Refills:*0 \r\n8.  Senna 8.6 mg PO BID:PRN constipation \r\nRX *sennosides [senna] 8.6 mg 1 tab by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n9.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n10.  Vancomycin 750 mg IV Q 12H \r\nRX *vancomycin 750 mg 750 mg IV every twelve (12) hours Disp \r\n#*60 Vial Refills:*0 \r\n11.  Potassium Chloride 10 mEq PO DAILY  \r\n12.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n13.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n14.  Ascorbic Acid ___ mg PO BID  \r\n15.  Cyanocobalamin 1000 mcg PO QHS  \r\n16.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n17.  FoLIC Acid 3.2 mg PO DAILY  \r\n18.  Furosemide 20 mg PO DAILY  \r\n19.  Gabapentin 900 mg PO TID  \r\n20.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n21.  Omeprazole 20 mg PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until insructed to by your outpatient \r\ndoctor\r\n24.Outpatient Lab Work\r\nTo be drawn weekly: CBC with differential, BUN, Cr, Vancomycin \r\ntrough, AST, ALT\r\nSend results to: ___ CLINIC - FAX: ___\r\nICD 10: ___.0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n- fever and neutropenia\r\n- low back pain\r\n- treatment related MDS\r\n- history of DVT\r\n- common variable immunodeficiency\r\n- left gluteal furuncle\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ was a pleasure caring for you while you were at ___. You \r\ncame to the hospital with a fever in the setting of your \r\ndecitabine therapy and had significantly worse back pain after \r\nyour bone marrow biopsy several weeks back. Despite a thorough \r\nworkup including multiple sets of blood cultures, urine \r\ncultures, and imaging including MRIs there was no infectious \r\nsource found as the culprit for your fevers. You were started on \r\nIV antibiotics to treat a presumptive infection, which you will \r\ncontinue for six weeks. You will follow-up with the infectious \r\ndisease physicians as an outpatient. You were started on several \r\nopioid pain medications and Valium which helped you be more \r\nactive and have good pain control. \r\n\r\nIt was a pleasure to participate in your care. We wish you all \r\nthe best.\r\n\r\nSincerely,\r\nYour ___ care team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-17:7",
      "text": "Simultaneously, the patient was having significantly \nworsened back pain after her MDS diagnosing bone marrow biopsy. She was started on opioid pain control, which was uptitrated and \naugmented with Valium to good effect. She went home with BID \noxycontin, PRN oxycodone, and QHS Valium. She will follow-up as \noutpatient with Dr. ___. # Fever + neutropenia: The patient received 2 doses of \ndecitabine as outpatient prior to experiencing first fever of \n101 at home, then 100.4 in clinic during third dose decitabine \nadministration. She was admitted for fever in setting of \ncytoreduction, and she eventually became truly neutropenic. An \nexhaustive workup was performed, centering on MRI findings of \npotential osteomyelitis/discitis with potential L psoas \ninvovlvement. This tissue was biopsied, negative by culture, and \nuPCR pending at the time of discharge. The patient will be given \nempiric therapy of vancomycin/cefepime/micafungin for a total of \n6 weeks (___) and instructed to have 1 month follow-up \nspinal imaging. A LLE wound was also biopsied and grew nothing. By exclusion, decitabine is thought to be the likely culprit of \nthe fever. # left gluteal furuncle: Formed at the marked site of the ___ L \npsoas biopsy. By ultrasound found to only have subcutaneous \nedema without fluid collection. This will be followed by patient \nand outpatient team as potential new nidus of infection if \nappearing worse or causing pain. # low back pain: Acute on chronic in this patient, who has \nbaseline degenerative changes. She also had R iliac crest bone \nmarrow biopsy prior to this admission which may have caused \nhematoma, inflammatory, or direct nerve injury which contributed \nto her severe pain. She was uptitrated to a pain regimen \nincluding standing Oxycontin BID, oxycodone PRN, and Valium QHS, \nwhich she was able to tolerate with good effect. She worked with \n___ and was deemed fit for discharge home with services. # treatment related MDS: Secondary to autoSCT with BEAM \nconditioning for DLBCL. Patient had bone marrow biopsy which \ndiagnosed new-onset treatment related MDS, but may have also \ncaused severe acute-on-chronic back pain for which she is \nreceiving opioids and benzodiazapines. Will receive Bactrim for \nPCP prophylaxis starting at discharge. # history of DVT: History of LLE DVTs, on Rivaroxaban at home \nand IVC filter in place. Rivaroxaban was held once Plt<75k in \nsetting of multi-line decline from decitabine. # common variable immunodeficiency: Patient had multiple IgG \nchecks for known CVID and did not require IVIG as inpatient.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-17",
        "chart_time": "104487",
        "section": "General",
        "position": 7,
        "tokenCount": 645,
        "note_metadata": {
          "note_id": "18887130-DS-17",
          "subject_id": 18887130,
          "hadm_id": 27240020,
          "note_type": "DS",
          "note_seq": 17,
          "charttime": 104487,
          "storetime": 104488.35277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, fever + neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nL psoas and prespinal biopsy\r\nLLE skin biopsy\r\n\r\n \r\nHistory of Present Illness:\r\n___ F with CVID, h/o transformed follicular lymphoma and h/o CLL \r\ns/p auto SCT (BEAM prep) in ___ in remission from lymphoma \r\nstandpoint but developed worsening pancytopenia and bleeding \r\nissues this month found to have treatment related MDS, now C1D3 \r\ndacogen presenting with borderline neutropenia and temp today of \r\n100.4.\r\n\r\nOther v/s in clinic: Vital Signs: BP: 111/53. Heart Rate:\r\n98. O2 Saturation%: 100.  Weight: 256.6. Height: 61.25. BMI:\r\n48.1. Temperature: 100.4. Resp. Rate: 18. Pain Score: 5 (back). \r\n\r\nGiven functional neutropenia, admitted for treatment of febrile \r\nneutropenia. Got vanc/cefepime in clinic. Blood cultures sent in \r\nclinic. She reported having some chills at the time and general \r\nfatigue but denied any other specific symptoms. Temp came back \r\ndown on it's own and she was 98.9 before leaving clinic. Hgb \r\n7.1,\r\nclinic orderd 1u blood which she will receive here. Regarding \r\nher other PMH: she is on xarelto for thrombosis history (DVT, \r\nalso has IVCF which was placed), and has h/o bleo toxicity \r\npneumonitis (off steroids now but cont with inhalers), and also \r\nhas intermittent LBP and left sciatica due to degenerative \r\ndisease,\r\non gabapentin, and she has chronic right pupil dilation and \r\ndysmetria.\r\n\r\nNote she was recently admitted and discharged ___. SHe had BM \r\nbx ___ which showed MDS as above. She also reported nasal \r\ncongestion and had fever ___, initially covered broadly but \r\nwith negative cultures, ultimately discharged to complete 7d \r\ncourse of levaquin on ___. Pt states she stopped taking the \r\nlevoquin ___ days ago. Last night took her temp and it was 100.1 \r\n(was\r\ninstructed to monitor temps, she had no symptoms that prompted \r\nthis check). This morning driving in to clinic appointment felt \r\na bit chilled but not shaking and not sick in any other way. In \r\nclinic found to have temp of 100.4. Also notes that she \r\ntypically has left sided sciatica but that in the past week sinc \r\nethe bone marrow biopsy has developed right lower back pain \r\nwhich has required ___ doses of vicodin daily and is a new pain \r\nworsening over time, present constantly, but worse with movement \r\nor deep palpation. Denies loss of strength or sensation though \r\nhas chronic right foot drop and dysesthesias at baseline after \r\nknee replacement on that side in the past. No incontinence or \r\ndysuria.\r\n\r\nFinally, her history is significant for a \"blood blister\" she \r\nnoted on the left foreleg per pt about ___ weeks ago which was \r\nultimately debrided in the past, and poor wound healing \r\nattributed to venous stasis. THis has been healing well she \r\nstates, though there is still an open wound surrounded by \r\nerythema but she is confident it continues to improve \r\ndramatically and no recent drainage. She is covering it with \r\nxeroform dressing daily.\r\n\r\nfurther nose bleeds or other bleeding.  She is also noted for a \r\nnonhealing wound on her left leg after hitting her shin several \r\nweeks ago.  She is using xerofrom dressing to the area and \r\nchanging it daily with slow healing. All other 10 point ROS neg.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM:\r\nGeneral: NAD  \r\nT 99.6 BP 100/58  HR 95  20  96%RA\r\nHEENT: Right pupil slower to react to light which is baseline.  \r\nMMM, no OP lesions or thrush.  \r\nCV: RR, NL S1S2 no MRG  \r\nPULM: CTAB no wheezing or crackles  \r\nABD: BS+, soft, NTND  \r\nSKIN/limbs: left anterior foreleg with 1cm open circular wound \r\nwithout drainage, covered w/xeroform, with 4-5 cm diameter \r\nsurrounding erythema, not warm to touch, lower extr are equal in \r\ngirth, no pitting edema\r\nBack: pt is tender to palpation around the left SI joint, has \r\nresolving hematoma over the medial aspect of right sacrum, but \r\nno tenderness over the hematoma which appears superficial, no \r\nswelling\r\n\r\nDISCHARGE EXAM:\r\nVS: 98.1 ___ 22 97RA\r\nGEN: NAD, seated in chair, conversational\r\nHEENT: AT/NC; R pupil mildly larger, slower to react than L \r\n(baseline per records); MMM\r\nCV: RRR, no M/R/G, +S1/S2\r\nPULM: CTAB\r\nABD: obese, soft, nontender to palpation, referred pain from \r\nback in band/belt distribution in low abdomen; +BS\r\nSKIN: unroofed vesicle with mild bleeding covered with xeroform\r\nEXT: chronic venous stasis changes in B/L ___ over shins\r\nNEURO: A/Ox3; CNII-XII assessed and grossly intact except for \r\nR>L pupillary dilataion and sluggish reactivity\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n___ 11:30AM BLOOD WBC-2.3* RBC-2.28* Hgb-7.1* Hct-22.1* \r\nMCV-97 MCH-31.1 MCHC-32.1 RDW-21.8* RDWSD-77.3* Plt ___\r\n___ 11:30AM BLOOD Neuts-37 Bands-6* ___ Monos-11 \r\nEos-0 Baso-0 Atyps-2* Metas-3* Myelos-1* Blasts-2* NRBC-3* \r\nAbsNeut-0.99* AbsLymp-0.92* AbsMono-0.25 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD ___ PTT-39.0* ___\r\n___ 11:30AM BLOOD UreaN-15 Creat-0.9 Na-137 K-3.8 Cl-102 \r\nHCO3-25 AnGap-14\r\n___ 11:30AM BLOOD ALT-8 AST-10 LD(LDH)-260* AlkPhos-81 \r\nTotBili-0.3\r\n___ 11:30AM BLOOD Albumin-3.4* Calcium-8.1* Mg-2.2\r\n\r\nINTERVAL LABS:\r\n___ 12:00AM BLOOD CRP-108.7*\r\n___ 12:00AM BLOOD IgG-805\r\n___ 04:00PM BLOOD HIV Ab-Negative\r\n___ 04:00PM BLOOD CMV VL-NOT DETECT\r\n___ 02:20PM BLOOD SED RATE-Test      \r\n___ 04:00PM BLOOD HERPES 6 DNA PCR, QUANTITATIVE-Test      \r\n___ 04:00PM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-Test   \r\n   \r\n___ 07:45PM BLOOD B-GLUCAN-Test      \r\n___ 07:45PM BLOOD ASPERGILLUS GALACTOMANNAN ANTIGEN-Test\r\n\r\nMICRO:\r\n___ Skin biopsy: All cx. negative\r\n___ RPR: negative\r\n___ Myco/lytic cx: no growth\r\n___ Psoas tissue cx: negative\r\nAll other blood and urine cultures final/negative\r\n\r\nSTUDIES:\r\nConclusions\r\nThe left atrium is mildly dilated. The left atrial volume index \r\nis mildly increased. The estimated right atrial pressure is ___ \r\nmmHg. Left ventricular wall thickness, cavity size and \r\nregional/global systolic function are normal (LVEF >55%). The \r\nestimated cardiac index is normal (>=2.5L/min/m2). Tissue \r\nDoppler imaging suggests an increased left ventricular filling \r\npressure (PCWP>18mmHg). Right ventricular chamber size and free \r\nwall motion are normal. The aortic valve leaflets (3) are mildly \r\nthickened but aortic stenosis is not present. No masses or \r\nvegetations are seen on the aortic valve. No aortic valve \r\nabscess is seen. No aortic regurgitation is seen. The mitral \r\nvalve leaflets are mildly thickened. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. There is moderate \r\npulmonary artery systolic hypertension. No vegetation/mass is \r\nseen on the pulmonic valve. There is an anterior space which \r\nmost likely represents a prominent fat pad. \r\n\r\nIMPRESSION: No echocardiographic evidence of endocarditis. \r\nNormal biventricular cavity sizes with preserved global and \r\nregional biventricular systolic function. Suggestion of elevated \r\nLV filling pressure. Mild mitral and tricuspid regurgitation. \r\nModerate pulmonary hypertension.\r\n\r\nCompared with the prior study (images reviewed) of ___, \r\nthe degrees of mitral and tricuspid regurgitation are slightly \r\ngreater and the estimated pulmonary arterial pressure is higher.\r\n\r\nIMAGING:\r\n___ L gluteal U/S:\r\nIMPRESSION:\r\nInflammation or edema of the superficial soft tissues without \r\nfocal fluid\r\ncollection.\r\n\r\n___ MR ___:\r\nIMPRESSION:\r\n1. Severe multilevel degenerative changes as described above \r\nhave slightly\r\nprogressed since the prior examination of ___.\r\n2. Scoliosis of lumbar spine with  signal changes and edema \r\nedema in the\r\nendplates, mild adjacent soft tissue signal and enhancement and \r\nenhancement in the left psoas muscle at L4-5 level without \r\nepidural phlegmon or paraspinal fluid collection are \r\nnonspecific.  Both advanced degenerative changes or early \r\ndiscitis osteomyelitis could give similar appearances.  The \r\nappearance on the prior CT abdomen of ___ or more was \r\nmore consistent with degenerative change. However, Correlation \r\nwith laboratory findings is essential to exclude early discitis \r\nosteomyelitis.\r\n\r\nDISCHARGE LABS:\r\n___ 01:18AM BLOOD WBC-0.4* RBC-2.58* Hgb-7.6* Hct-23.6* \r\nMCV-92 MCH-29.5 MCHC-32.2 RDW-18.6* RDWSD-62.0* Plt Ct-15*\r\n___ 01:18AM BLOOD Neuts-12* Bands-0 Lymphs-78* Monos-7 \r\nEos-1 Baso-0 Atyps-1* ___ Myelos-1* AbsNeut-0.05* \r\nAbsLymp-0.32* AbsMono-0.03* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:18AM BLOOD ___ PTT-34.5 ___\r\n___ 01:18AM BLOOD Glucose-147* UreaN-14 Creat-0.9 Na-136 \r\nK-3.7 Cl-99 HCO3-27 AnGap-14\r\n___ 12:00AM BLOOD ALT-14 AST-14 LD(LDH)-247 AlkPhos-90 \r\nTotBili-0.5\r\n___ 01:18AM BLOOD Calcium-8.1* Phos-2.7 Mg-2.3\r\n___ 06:25AM BLOOD Vanco-19.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, diagnosed with treatment related \r\nMDS. ___ was started on decitabine as an outpatient and \r\nre-presented with fevers and neutropenia. She had an exhaustive \r\nworkup of her fevers, including skin and psoas biopsies, and \r\ntissue uPCR was sent, but there was no culture positivity or \r\npositive findings in her infectious workup. However, after \r\nconsultation with ID, it was decided to treat empirically for \r\npresumptive osteomyelitis/discitis with 6 weeks of vancomycin \r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO \r\nq24h). Micafungin was chosen instead of posaconazole due to \r\n___ differences; but she did receive posaconazole while \r\ninpatient. Simultaneously, the patient was having significantly \r\nworsened back pain after her MDS diagnosing bone marrow biopsy. \r\nShe was started on opioid pain control, which was uptitrated and \r\naugmented with Valium to good effect. She went home with BID \r\noxycontin, PRN oxycodone, and QHS Valium. She will follow-up as \r\noutpatient with Dr. ___.\r\n\r\n# Fever + neutropenia: The patient received 2 doses of \r\ndecitabine as outpatient prior to experiencing first fever of \r\n101 at home, then 100.4 in clinic during third dose decitabine \r\nadministration. She was admitted for fever in setting of \r\ncytoreduction, and she eventually became truly neutropenic. An \r\nexhaustive workup was performed, centering on MRI findings of \r\npotential osteomyelitis/discitis with potential L psoas \r\ninvovlvement. This tissue was biopsied, negative by culture, and \r\nuPCR pending at the time of discharge. The patient will be given \r\nempiric therapy of vancomycin/cefepime/micafungin for a total of \r\n6 weeks (___) and instructed to have 1 month follow-up \r\nspinal imaging. A LLE wound was also biopsied and grew nothing. \r\nBy exclusion, decitabine is thought to be the likely culprit of \r\nthe fever.\r\n\r\n# left gluteal furuncle: Formed at the marked site of the ___ L \r\npsoas biopsy. By ultrasound found to only have subcutaneous \r\nedema without fluid collection. This will be followed by patient \r\nand outpatient team as potential new nidus of infection if \r\nappearing worse or causing pain.\r\n\r\n# low back pain: Acute on chronic in this patient, who has \r\nbaseline degenerative changes. She also had R iliac crest bone \r\nmarrow biopsy prior to this admission which may have caused \r\nhematoma, inflammatory, or direct nerve injury which contributed \r\nto her severe pain. She was uptitrated to a pain regimen \r\nincluding standing Oxycontin BID, oxycodone PRN, and Valium QHS, \r\nwhich she was able to tolerate with good effect. She worked with \r\n___ and was deemed fit for discharge home with services.\r\n\r\n# treatment related MDS: Secondary to autoSCT with BEAM \r\nconditioning for DLBCL. Patient had bone marrow biopsy which \r\ndiagnosed new-onset treatment related MDS, but may have also \r\ncaused severe acute-on-chronic back pain for which she is \r\nreceiving opioids and benzodiazapines. Will receive Bactrim for \r\nPCP prophylaxis starting at discharge.\r\n\r\n# history of DVT: History of LLE DVTs, on Rivaroxaban at home \r\nand IVC filter in place. Rivaroxaban was held once Plt<75k in \r\nsetting of multi-line decline from decitabine.\r\n\r\n# common variable immunodeficiency: Patient had multiple IgG \r\nchecks for known CVID and did not require IVIG as inpatient.\r\n\r\nTRANSITIONAL ISSUES:\r\n- complete 6 week antibiotics: vancomycin, cefepime, \r\nmicafungin(d1 = ___, end ___, follow-up with OPAT\r\n- weekly labs: CBC with differential, BUN, Cr, Vancomycin\r\ntrough, AST, ALT (fax to ATTN: ___ CLINIC - FAX: \r\n___\r\n- repeat MR ___ 1 month after discharge\r\n- PCP prophylaxis with ___ SS daily\r\n- plan future decitabine with Dr. ___ team\r\n- plan for curative transplant with Dr. ___ team\r\n- continue to monitor L gluteal furuncle\r\n- consider restarting rivaroxaban when deemed appropriate \r\n(stopped inpatient due to thrombocytopenia)\r\n- Code: Full\r\n- Contact: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. FoLIC Acid 3.2 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Venlafaxine 25 mg PO BID \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n12. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n13. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n14. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q6H:PRN \r\nPain - Mild \r\n\r\n \r\nDischarge Medications:\r\n1.  CefePIME 2 g IV Q12H \r\nRX *cefepime [Maxipime] 2 gram 2 g IV every twelve (12) hours \r\nDisp #*60 Vial Refills:*0 \r\n2.  Diazepam 5 mg PO QHS \r\nRX *diazepam 5 mg 1 tab by mouth at bedtime Disp #*7 Tablet \r\nRefills:*0 \r\n3.  Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium [Colace] 100 mg 1 capsule(s) by mouth twice \r\na day Disp #*60 Capsule Refills:*0 \r\n4.  Micafungin 100 mg IV Q24H \r\nRX *micafungin [Mycamine] 100 mg 100 mg IV q24h Disp #*30 Vial \r\nRefills:*0 \r\n5.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\nRX *oxycodone 10 mg 1 tablet(s) by mouth every six (6) hours \r\nDisp #*24 Tablet Refills:*0 \r\n6.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\nRX *oxycodone 20 mg 1 tablet(s) by mouth every twelve (12) hours \r\nDisp #*14 Tablet Refills:*0 \r\n7.  Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\nRX *polyethylene glycol 3350 [Miralax] 17 gram 1 powder(s) by \r\nmouth daily Disp #*30 Packet Refills:*0 \r\n8.  Senna 8.6 mg PO BID:PRN constipation \r\nRX *sennosides [senna] 8.6 mg 1 tab by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n9.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n10.  Vancomycin 750 mg IV Q 12H \r\nRX *vancomycin 750 mg 750 mg IV every twelve (12) hours Disp \r\n#*60 Vial Refills:*0 \r\n11.  Potassium Chloride 10 mEq PO DAILY  \r\n12.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n13.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n14.  Ascorbic Acid ___ mg PO BID  \r\n15.  Cyanocobalamin 1000 mcg PO QHS  \r\n16.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n17.  FoLIC Acid 3.2 mg PO DAILY  \r\n18.  Furosemide 20 mg PO DAILY  \r\n19.  Gabapentin 900 mg PO TID  \r\n20.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n21.  Omeprazole 20 mg PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until insructed to by your outpatient \r\ndoctor\r\n24.Outpatient Lab Work\r\nTo be drawn weekly: CBC with differential, BUN, Cr, Vancomycin \r\ntrough, AST, ALT\r\nSend results to: ___ CLINIC - FAX: ___\r\nICD 10: ___.0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n- fever and neutropenia\r\n- low back pain\r\n- treatment related MDS\r\n- history of DVT\r\n- common variable immunodeficiency\r\n- left gluteal furuncle\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ was a pleasure caring for you while you were at ___. You \r\ncame to the hospital with a fever in the setting of your \r\ndecitabine therapy and had significantly worse back pain after \r\nyour bone marrow biopsy several weeks back. Despite a thorough \r\nworkup including multiple sets of blood cultures, urine \r\ncultures, and imaging including MRIs there was no infectious \r\nsource found as the culprit for your fevers. You were started on \r\nIV antibiotics to treat a presumptive infection, which you will \r\ncontinue for six weeks. You will follow-up with the infectious \r\ndisease physicians as an outpatient. You were started on several \r\nopioid pain medications and Valium which helped you be more \r\nactive and have good pain control. \r\n\r\nIt was a pleasure to participate in your care. We wish you all \r\nthe best.\r\n\r\nSincerely,\r\nYour ___ care team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-17:8",
      "text": "Patient had bone marrow biopsy which \ndiagnosed new-onset treatment related MDS, but may have also \ncaused severe acute-on-chronic back pain for which she is \nreceiving opioids and benzodiazapines. Will receive Bactrim for \nPCP prophylaxis starting at discharge. # history of DVT: History of LLE DVTs, on Rivaroxaban at home \nand IVC filter in place. Rivaroxaban was held once Plt<75k in \nsetting of multi-line decline from decitabine. # common variable immunodeficiency: Patient had multiple IgG \nchecks for known CVID and did not require IVIG as inpatient. TRANSITIONAL ISSUES:\n- complete 6 week antibiotics: vancomycin, cefepime, \nmicafungin(d1 = ___, end ___, follow-up with OPAT\n- weekly labs: CBC with differential, BUN, Cr, Vancomycin\ntrough, AST, ALT (fax to ATTN: ___ CLINIC - FAX: \n___\n- repeat MR ___ 1 month after discharge\n- PCP prophylaxis with ___ SS daily\n- plan future decitabine with Dr. ___ team\n- plan for curative transplant with Dr. ___ team\n- continue to monitor L gluteal furuncle\n- consider restarting rivaroxaban when deemed appropriate \n(stopped inpatient due to thrombocytopenia)\n- Code: Full\n- Contact: ___ (husband) ___\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Ascorbic Acid ___ mg PO BID \n2. Cyanocobalamin 1000 mcg PO QHS \n3. FoLIC Acid 3.2 mg PO DAILY \n4. Furosemide 20 mg PO DAILY \n5. Gabapentin 900 mg PO TID \n6. Omeprazole 20 mg PO DAILY \n7. Potassium Chloride 10 mEq PO DAILY \n8. Venlafaxine 25 mg PO BID \n9. Rivaroxaban 20 mg PO DAILY \n10. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \ncongestion \n12. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \n13. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \n14. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q6H:PRN \nPain - Mild",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-17",
        "chart_time": "104487",
        "section": "General",
        "position": 8,
        "tokenCount": 462,
        "note_metadata": {
          "note_id": "18887130-DS-17",
          "subject_id": 18887130,
          "hadm_id": 27240020,
          "note_type": "DS",
          "note_seq": 17,
          "charttime": 104487,
          "storetime": 104488.35277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, fever + neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nL psoas and prespinal biopsy\r\nLLE skin biopsy\r\n\r\n \r\nHistory of Present Illness:\r\n___ F with CVID, h/o transformed follicular lymphoma and h/o CLL \r\ns/p auto SCT (BEAM prep) in ___ in remission from lymphoma \r\nstandpoint but developed worsening pancytopenia and bleeding \r\nissues this month found to have treatment related MDS, now C1D3 \r\ndacogen presenting with borderline neutropenia and temp today of \r\n100.4.\r\n\r\nOther v/s in clinic: Vital Signs: BP: 111/53. Heart Rate:\r\n98. O2 Saturation%: 100.  Weight: 256.6. Height: 61.25. BMI:\r\n48.1. Temperature: 100.4. Resp. Rate: 18. Pain Score: 5 (back). \r\n\r\nGiven functional neutropenia, admitted for treatment of febrile \r\nneutropenia. Got vanc/cefepime in clinic. Blood cultures sent in \r\nclinic. She reported having some chills at the time and general \r\nfatigue but denied any other specific symptoms. Temp came back \r\ndown on it's own and she was 98.9 before leaving clinic. Hgb \r\n7.1,\r\nclinic orderd 1u blood which she will receive here. Regarding \r\nher other PMH: she is on xarelto for thrombosis history (DVT, \r\nalso has IVCF which was placed), and has h/o bleo toxicity \r\npneumonitis (off steroids now but cont with inhalers), and also \r\nhas intermittent LBP and left sciatica due to degenerative \r\ndisease,\r\non gabapentin, and she has chronic right pupil dilation and \r\ndysmetria.\r\n\r\nNote she was recently admitted and discharged ___. SHe had BM \r\nbx ___ which showed MDS as above. She also reported nasal \r\ncongestion and had fever ___, initially covered broadly but \r\nwith negative cultures, ultimately discharged to complete 7d \r\ncourse of levaquin on ___. Pt states she stopped taking the \r\nlevoquin ___ days ago. Last night took her temp and it was 100.1 \r\n(was\r\ninstructed to monitor temps, she had no symptoms that prompted \r\nthis check). This morning driving in to clinic appointment felt \r\na bit chilled but not shaking and not sick in any other way. In \r\nclinic found to have temp of 100.4. Also notes that she \r\ntypically has left sided sciatica but that in the past week sinc \r\nethe bone marrow biopsy has developed right lower back pain \r\nwhich has required ___ doses of vicodin daily and is a new pain \r\nworsening over time, present constantly, but worse with movement \r\nor deep palpation. Denies loss of strength or sensation though \r\nhas chronic right foot drop and dysesthesias at baseline after \r\nknee replacement on that side in the past. No incontinence or \r\ndysuria.\r\n\r\nFinally, her history is significant for a \"blood blister\" she \r\nnoted on the left foreleg per pt about ___ weeks ago which was \r\nultimately debrided in the past, and poor wound healing \r\nattributed to venous stasis. THis has been healing well she \r\nstates, though there is still an open wound surrounded by \r\nerythema but she is confident it continues to improve \r\ndramatically and no recent drainage. She is covering it with \r\nxeroform dressing daily.\r\n\r\nfurther nose bleeds or other bleeding.  She is also noted for a \r\nnonhealing wound on her left leg after hitting her shin several \r\nweeks ago.  She is using xerofrom dressing to the area and \r\nchanging it daily with slow healing. All other 10 point ROS neg.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM:\r\nGeneral: NAD  \r\nT 99.6 BP 100/58  HR 95  20  96%RA\r\nHEENT: Right pupil slower to react to light which is baseline.  \r\nMMM, no OP lesions or thrush.  \r\nCV: RR, NL S1S2 no MRG  \r\nPULM: CTAB no wheezing or crackles  \r\nABD: BS+, soft, NTND  \r\nSKIN/limbs: left anterior foreleg with 1cm open circular wound \r\nwithout drainage, covered w/xeroform, with 4-5 cm diameter \r\nsurrounding erythema, not warm to touch, lower extr are equal in \r\ngirth, no pitting edema\r\nBack: pt is tender to palpation around the left SI joint, has \r\nresolving hematoma over the medial aspect of right sacrum, but \r\nno tenderness over the hematoma which appears superficial, no \r\nswelling\r\n\r\nDISCHARGE EXAM:\r\nVS: 98.1 ___ 22 97RA\r\nGEN: NAD, seated in chair, conversational\r\nHEENT: AT/NC; R pupil mildly larger, slower to react than L \r\n(baseline per records); MMM\r\nCV: RRR, no M/R/G, +S1/S2\r\nPULM: CTAB\r\nABD: obese, soft, nontender to palpation, referred pain from \r\nback in band/belt distribution in low abdomen; +BS\r\nSKIN: unroofed vesicle with mild bleeding covered with xeroform\r\nEXT: chronic venous stasis changes in B/L ___ over shins\r\nNEURO: A/Ox3; CNII-XII assessed and grossly intact except for \r\nR>L pupillary dilataion and sluggish reactivity\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n___ 11:30AM BLOOD WBC-2.3* RBC-2.28* Hgb-7.1* Hct-22.1* \r\nMCV-97 MCH-31.1 MCHC-32.1 RDW-21.8* RDWSD-77.3* Plt ___\r\n___ 11:30AM BLOOD Neuts-37 Bands-6* ___ Monos-11 \r\nEos-0 Baso-0 Atyps-2* Metas-3* Myelos-1* Blasts-2* NRBC-3* \r\nAbsNeut-0.99* AbsLymp-0.92* AbsMono-0.25 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD ___ PTT-39.0* ___\r\n___ 11:30AM BLOOD UreaN-15 Creat-0.9 Na-137 K-3.8 Cl-102 \r\nHCO3-25 AnGap-14\r\n___ 11:30AM BLOOD ALT-8 AST-10 LD(LDH)-260* AlkPhos-81 \r\nTotBili-0.3\r\n___ 11:30AM BLOOD Albumin-3.4* Calcium-8.1* Mg-2.2\r\n\r\nINTERVAL LABS:\r\n___ 12:00AM BLOOD CRP-108.7*\r\n___ 12:00AM BLOOD IgG-805\r\n___ 04:00PM BLOOD HIV Ab-Negative\r\n___ 04:00PM BLOOD CMV VL-NOT DETECT\r\n___ 02:20PM BLOOD SED RATE-Test      \r\n___ 04:00PM BLOOD HERPES 6 DNA PCR, QUANTITATIVE-Test      \r\n___ 04:00PM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-Test   \r\n   \r\n___ 07:45PM BLOOD B-GLUCAN-Test      \r\n___ 07:45PM BLOOD ASPERGILLUS GALACTOMANNAN ANTIGEN-Test\r\n\r\nMICRO:\r\n___ Skin biopsy: All cx. negative\r\n___ RPR: negative\r\n___ Myco/lytic cx: no growth\r\n___ Psoas tissue cx: negative\r\nAll other blood and urine cultures final/negative\r\n\r\nSTUDIES:\r\nConclusions\r\nThe left atrium is mildly dilated. The left atrial volume index \r\nis mildly increased. The estimated right atrial pressure is ___ \r\nmmHg. Left ventricular wall thickness, cavity size and \r\nregional/global systolic function are normal (LVEF >55%). The \r\nestimated cardiac index is normal (>=2.5L/min/m2). Tissue \r\nDoppler imaging suggests an increased left ventricular filling \r\npressure (PCWP>18mmHg). Right ventricular chamber size and free \r\nwall motion are normal. The aortic valve leaflets (3) are mildly \r\nthickened but aortic stenosis is not present. No masses or \r\nvegetations are seen on the aortic valve. No aortic valve \r\nabscess is seen. No aortic regurgitation is seen. The mitral \r\nvalve leaflets are mildly thickened. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. There is moderate \r\npulmonary artery systolic hypertension. No vegetation/mass is \r\nseen on the pulmonic valve. There is an anterior space which \r\nmost likely represents a prominent fat pad. \r\n\r\nIMPRESSION: No echocardiographic evidence of endocarditis. \r\nNormal biventricular cavity sizes with preserved global and \r\nregional biventricular systolic function. Suggestion of elevated \r\nLV filling pressure. Mild mitral and tricuspid regurgitation. \r\nModerate pulmonary hypertension.\r\n\r\nCompared with the prior study (images reviewed) of ___, \r\nthe degrees of mitral and tricuspid regurgitation are slightly \r\ngreater and the estimated pulmonary arterial pressure is higher.\r\n\r\nIMAGING:\r\n___ L gluteal U/S:\r\nIMPRESSION:\r\nInflammation or edema of the superficial soft tissues without \r\nfocal fluid\r\ncollection.\r\n\r\n___ MR ___:\r\nIMPRESSION:\r\n1. Severe multilevel degenerative changes as described above \r\nhave slightly\r\nprogressed since the prior examination of ___.\r\n2. Scoliosis of lumbar spine with  signal changes and edema \r\nedema in the\r\nendplates, mild adjacent soft tissue signal and enhancement and \r\nenhancement in the left psoas muscle at L4-5 level without \r\nepidural phlegmon or paraspinal fluid collection are \r\nnonspecific.  Both advanced degenerative changes or early \r\ndiscitis osteomyelitis could give similar appearances.  The \r\nappearance on the prior CT abdomen of ___ or more was \r\nmore consistent with degenerative change. However, Correlation \r\nwith laboratory findings is essential to exclude early discitis \r\nosteomyelitis.\r\n\r\nDISCHARGE LABS:\r\n___ 01:18AM BLOOD WBC-0.4* RBC-2.58* Hgb-7.6* Hct-23.6* \r\nMCV-92 MCH-29.5 MCHC-32.2 RDW-18.6* RDWSD-62.0* Plt Ct-15*\r\n___ 01:18AM BLOOD Neuts-12* Bands-0 Lymphs-78* Monos-7 \r\nEos-1 Baso-0 Atyps-1* ___ Myelos-1* AbsNeut-0.05* \r\nAbsLymp-0.32* AbsMono-0.03* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:18AM BLOOD ___ PTT-34.5 ___\r\n___ 01:18AM BLOOD Glucose-147* UreaN-14 Creat-0.9 Na-136 \r\nK-3.7 Cl-99 HCO3-27 AnGap-14\r\n___ 12:00AM BLOOD ALT-14 AST-14 LD(LDH)-247 AlkPhos-90 \r\nTotBili-0.5\r\n___ 01:18AM BLOOD Calcium-8.1* Phos-2.7 Mg-2.3\r\n___ 06:25AM BLOOD Vanco-19.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, diagnosed with treatment related \r\nMDS. ___ was started on decitabine as an outpatient and \r\nre-presented with fevers and neutropenia. She had an exhaustive \r\nworkup of her fevers, including skin and psoas biopsies, and \r\ntissue uPCR was sent, but there was no culture positivity or \r\npositive findings in her infectious workup. However, after \r\nconsultation with ID, it was decided to treat empirically for \r\npresumptive osteomyelitis/discitis with 6 weeks of vancomycin \r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO \r\nq24h). Micafungin was chosen instead of posaconazole due to \r\n___ differences; but she did receive posaconazole while \r\ninpatient. Simultaneously, the patient was having significantly \r\nworsened back pain after her MDS diagnosing bone marrow biopsy. \r\nShe was started on opioid pain control, which was uptitrated and \r\naugmented with Valium to good effect. She went home with BID \r\noxycontin, PRN oxycodone, and QHS Valium. She will follow-up as \r\noutpatient with Dr. ___.\r\n\r\n# Fever + neutropenia: The patient received 2 doses of \r\ndecitabine as outpatient prior to experiencing first fever of \r\n101 at home, then 100.4 in clinic during third dose decitabine \r\nadministration. She was admitted for fever in setting of \r\ncytoreduction, and she eventually became truly neutropenic. An \r\nexhaustive workup was performed, centering on MRI findings of \r\npotential osteomyelitis/discitis with potential L psoas \r\ninvovlvement. This tissue was biopsied, negative by culture, and \r\nuPCR pending at the time of discharge. The patient will be given \r\nempiric therapy of vancomycin/cefepime/micafungin for a total of \r\n6 weeks (___) and instructed to have 1 month follow-up \r\nspinal imaging. A LLE wound was also biopsied and grew nothing. \r\nBy exclusion, decitabine is thought to be the likely culprit of \r\nthe fever.\r\n\r\n# left gluteal furuncle: Formed at the marked site of the ___ L \r\npsoas biopsy. By ultrasound found to only have subcutaneous \r\nedema without fluid collection. This will be followed by patient \r\nand outpatient team as potential new nidus of infection if \r\nappearing worse or causing pain.\r\n\r\n# low back pain: Acute on chronic in this patient, who has \r\nbaseline degenerative changes. She also had R iliac crest bone \r\nmarrow biopsy prior to this admission which may have caused \r\nhematoma, inflammatory, or direct nerve injury which contributed \r\nto her severe pain. She was uptitrated to a pain regimen \r\nincluding standing Oxycontin BID, oxycodone PRN, and Valium QHS, \r\nwhich she was able to tolerate with good effect. She worked with \r\n___ and was deemed fit for discharge home with services.\r\n\r\n# treatment related MDS: Secondary to autoSCT with BEAM \r\nconditioning for DLBCL. Patient had bone marrow biopsy which \r\ndiagnosed new-onset treatment related MDS, but may have also \r\ncaused severe acute-on-chronic back pain for which she is \r\nreceiving opioids and benzodiazapines. Will receive Bactrim for \r\nPCP prophylaxis starting at discharge.\r\n\r\n# history of DVT: History of LLE DVTs, on Rivaroxaban at home \r\nand IVC filter in place. Rivaroxaban was held once Plt<75k in \r\nsetting of multi-line decline from decitabine.\r\n\r\n# common variable immunodeficiency: Patient had multiple IgG \r\nchecks for known CVID and did not require IVIG as inpatient.\r\n\r\nTRANSITIONAL ISSUES:\r\n- complete 6 week antibiotics: vancomycin, cefepime, \r\nmicafungin(d1 = ___, end ___, follow-up with OPAT\r\n- weekly labs: CBC with differential, BUN, Cr, Vancomycin\r\ntrough, AST, ALT (fax to ATTN: ___ CLINIC - FAX: \r\n___\r\n- repeat MR ___ 1 month after discharge\r\n- PCP prophylaxis with ___ SS daily\r\n- plan future decitabine with Dr. ___ team\r\n- plan for curative transplant with Dr. ___ team\r\n- continue to monitor L gluteal furuncle\r\n- consider restarting rivaroxaban when deemed appropriate \r\n(stopped inpatient due to thrombocytopenia)\r\n- Code: Full\r\n- Contact: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. FoLIC Acid 3.2 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Venlafaxine 25 mg PO BID \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n12. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n13. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n14. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q6H:PRN \r\nPain - Mild \r\n\r\n \r\nDischarge Medications:\r\n1.  CefePIME 2 g IV Q12H \r\nRX *cefepime [Maxipime] 2 gram 2 g IV every twelve (12) hours \r\nDisp #*60 Vial Refills:*0 \r\n2.  Diazepam 5 mg PO QHS \r\nRX *diazepam 5 mg 1 tab by mouth at bedtime Disp #*7 Tablet \r\nRefills:*0 \r\n3.  Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium [Colace] 100 mg 1 capsule(s) by mouth twice \r\na day Disp #*60 Capsule Refills:*0 \r\n4.  Micafungin 100 mg IV Q24H \r\nRX *micafungin [Mycamine] 100 mg 100 mg IV q24h Disp #*30 Vial \r\nRefills:*0 \r\n5.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\nRX *oxycodone 10 mg 1 tablet(s) by mouth every six (6) hours \r\nDisp #*24 Tablet Refills:*0 \r\n6.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\nRX *oxycodone 20 mg 1 tablet(s) by mouth every twelve (12) hours \r\nDisp #*14 Tablet Refills:*0 \r\n7.  Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\nRX *polyethylene glycol 3350 [Miralax] 17 gram 1 powder(s) by \r\nmouth daily Disp #*30 Packet Refills:*0 \r\n8.  Senna 8.6 mg PO BID:PRN constipation \r\nRX *sennosides [senna] 8.6 mg 1 tab by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n9.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n10.  Vancomycin 750 mg IV Q 12H \r\nRX *vancomycin 750 mg 750 mg IV every twelve (12) hours Disp \r\n#*60 Vial Refills:*0 \r\n11.  Potassium Chloride 10 mEq PO DAILY  \r\n12.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n13.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n14.  Ascorbic Acid ___ mg PO BID  \r\n15.  Cyanocobalamin 1000 mcg PO QHS  \r\n16.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n17.  FoLIC Acid 3.2 mg PO DAILY  \r\n18.  Furosemide 20 mg PO DAILY  \r\n19.  Gabapentin 900 mg PO TID  \r\n20.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n21.  Omeprazole 20 mg PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until insructed to by your outpatient \r\ndoctor\r\n24.Outpatient Lab Work\r\nTo be drawn weekly: CBC with differential, BUN, Cr, Vancomycin \r\ntrough, AST, ALT\r\nSend results to: ___ CLINIC - FAX: ___\r\nICD 10: ___.0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n- fever and neutropenia\r\n- low back pain\r\n- treatment related MDS\r\n- history of DVT\r\n- common variable immunodeficiency\r\n- left gluteal furuncle\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ was a pleasure caring for you while you were at ___. You \r\ncame to the hospital with a fever in the setting of your \r\ndecitabine therapy and had significantly worse back pain after \r\nyour bone marrow biopsy several weeks back. Despite a thorough \r\nworkup including multiple sets of blood cultures, urine \r\ncultures, and imaging including MRIs there was no infectious \r\nsource found as the culprit for your fevers. You were started on \r\nIV antibiotics to treat a presumptive infection, which you will \r\ncontinue for six weeks. You will follow-up with the infectious \r\ndisease physicians as an outpatient. You were started on several \r\nopioid pain medications and Valium which helped you be more \r\nactive and have good pain control. \r\n\r\nIt was a pleasure to participate in your care. We wish you all \r\nthe best.\r\n\r\nSincerely,\r\nYour ___ care team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-17:9",
      "text": "Discharge Medications:\n1. CefePIME 2 g IV Q12H \nRX *cefepime [Maxipime] 2 gram 2 g IV every twelve (12) hours \nDisp #*60 Vial Refills:*0 \n2. Diazepam 5 mg PO QHS \nRX *diazepam 5 mg 1 tab by mouth at bedtime Disp #*7 Tablet \nRefills:*0 \n3. Docusate Sodium 100 mg PO BID \nRX *docusate sodium [Colace] 100 mg 1 capsule(s) by mouth twice \na day Disp #*60 Capsule Refills:*0 \n4. Micafungin 100 mg IV Q24H \nRX *micafungin [Mycamine] 100 mg 100 mg IV q24h Disp #*30 Vial \nRefills:*0 \n5. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \nModerate \nRX *oxycodone 10 mg 1 tablet(s) by mouth every six (6) hours \nDisp #*24 Tablet Refills:*0 \n6. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \nRX *oxycodone 20 mg 1 tablet(s) by mouth every twelve (12) hours \nDisp #*14 Tablet Refills:*0 \n7. Polyethylene Glycol 17 g PO DAILY:PRN constipation \nRX *polyethylene glycol 3350 [Miralax] 17 gram 1 powder(s) by \nmouth daily Disp #*30 Packet Refills:*0 \n8. Senna 8.6 mg PO BID:PRN constipation \nRX *sennosides [senna] 8.6 mg 1 tab by mouth twice a day Disp \n#*60 Tablet Refills:*0 \n9. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \n10. Vancomycin 750 mg IV Q 12H \nRX *vancomycin 750 mg 750 mg IV every twelve (12) hours Disp \n#*60 Vial Refills:*0 \n11. Potassium Chloride 10 mEq PO DAILY  \n12. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \n13. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \n14. Ascorbic Acid ___ mg PO BID  \n15. Cyanocobalamin 1000 mcg PO QHS  \n16. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \ncongestion  \n17. FoLIC Acid 3.2 mg PO DAILY  \n18. Furosemide 20 mg PO DAILY  \n19. Gabapentin 900 mg PO TID  \n20. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \n21. Omeprazole 20 mg PO DAILY  \n22. Venlafaxine 25 mg PO BID  \n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. Do not restart Rivaroxaban until insructed to by your outpatient \ndoctor\n24.Outpatient Lab Work\nTo be drawn weekly: CBC with differential, BUN, Cr, Vancomycin \ntrough, AST, ALT\nSend results to: ___ CLINIC - FAX: ___\nICD 10: ___.0 Discharge Disposition:\nHome With Service\n \nFacility:\n___ Discharge Diagnosis:\n- fever and neutropenia\n- low back pain\n- treatment related MDS\n- history of DVT\n- common variable immunodeficiency\n- left gluteal furuncle Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - requires assistance or aid (walker \nor cane).",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-17",
        "chart_time": "104487",
        "section": "General",
        "position": 9,
        "tokenCount": 638,
        "note_metadata": {
          "note_id": "18887130-DS-17",
          "subject_id": 18887130,
          "hadm_id": 27240020,
          "note_type": "DS",
          "note_seq": 17,
          "charttime": 104487,
          "storetime": 104488.35277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, fever + neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nL psoas and prespinal biopsy\r\nLLE skin biopsy\r\n\r\n \r\nHistory of Present Illness:\r\n___ F with CVID, h/o transformed follicular lymphoma and h/o CLL \r\ns/p auto SCT (BEAM prep) in ___ in remission from lymphoma \r\nstandpoint but developed worsening pancytopenia and bleeding \r\nissues this month found to have treatment related MDS, now C1D3 \r\ndacogen presenting with borderline neutropenia and temp today of \r\n100.4.\r\n\r\nOther v/s in clinic: Vital Signs: BP: 111/53. Heart Rate:\r\n98. O2 Saturation%: 100.  Weight: 256.6. Height: 61.25. BMI:\r\n48.1. Temperature: 100.4. Resp. Rate: 18. Pain Score: 5 (back). \r\n\r\nGiven functional neutropenia, admitted for treatment of febrile \r\nneutropenia. Got vanc/cefepime in clinic. Blood cultures sent in \r\nclinic. She reported having some chills at the time and general \r\nfatigue but denied any other specific symptoms. Temp came back \r\ndown on it's own and she was 98.9 before leaving clinic. Hgb \r\n7.1,\r\nclinic orderd 1u blood which she will receive here. Regarding \r\nher other PMH: she is on xarelto for thrombosis history (DVT, \r\nalso has IVCF which was placed), and has h/o bleo toxicity \r\npneumonitis (off steroids now but cont with inhalers), and also \r\nhas intermittent LBP and left sciatica due to degenerative \r\ndisease,\r\non gabapentin, and she has chronic right pupil dilation and \r\ndysmetria.\r\n\r\nNote she was recently admitted and discharged ___. SHe had BM \r\nbx ___ which showed MDS as above. She also reported nasal \r\ncongestion and had fever ___, initially covered broadly but \r\nwith negative cultures, ultimately discharged to complete 7d \r\ncourse of levaquin on ___. Pt states she stopped taking the \r\nlevoquin ___ days ago. Last night took her temp and it was 100.1 \r\n(was\r\ninstructed to monitor temps, she had no symptoms that prompted \r\nthis check). This morning driving in to clinic appointment felt \r\na bit chilled but not shaking and not sick in any other way. In \r\nclinic found to have temp of 100.4. Also notes that she \r\ntypically has left sided sciatica but that in the past week sinc \r\nethe bone marrow biopsy has developed right lower back pain \r\nwhich has required ___ doses of vicodin daily and is a new pain \r\nworsening over time, present constantly, but worse with movement \r\nor deep palpation. Denies loss of strength or sensation though \r\nhas chronic right foot drop and dysesthesias at baseline after \r\nknee replacement on that side in the past. No incontinence or \r\ndysuria.\r\n\r\nFinally, her history is significant for a \"blood blister\" she \r\nnoted on the left foreleg per pt about ___ weeks ago which was \r\nultimately debrided in the past, and poor wound healing \r\nattributed to venous stasis. THis has been healing well she \r\nstates, though there is still an open wound surrounded by \r\nerythema but she is confident it continues to improve \r\ndramatically and no recent drainage. She is covering it with \r\nxeroform dressing daily.\r\n\r\nfurther nose bleeds or other bleeding.  She is also noted for a \r\nnonhealing wound on her left leg after hitting her shin several \r\nweeks ago.  She is using xerofrom dressing to the area and \r\nchanging it daily with slow healing. All other 10 point ROS neg.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM:\r\nGeneral: NAD  \r\nT 99.6 BP 100/58  HR 95  20  96%RA\r\nHEENT: Right pupil slower to react to light which is baseline.  \r\nMMM, no OP lesions or thrush.  \r\nCV: RR, NL S1S2 no MRG  \r\nPULM: CTAB no wheezing or crackles  \r\nABD: BS+, soft, NTND  \r\nSKIN/limbs: left anterior foreleg with 1cm open circular wound \r\nwithout drainage, covered w/xeroform, with 4-5 cm diameter \r\nsurrounding erythema, not warm to touch, lower extr are equal in \r\ngirth, no pitting edema\r\nBack: pt is tender to palpation around the left SI joint, has \r\nresolving hematoma over the medial aspect of right sacrum, but \r\nno tenderness over the hematoma which appears superficial, no \r\nswelling\r\n\r\nDISCHARGE EXAM:\r\nVS: 98.1 ___ 22 97RA\r\nGEN: NAD, seated in chair, conversational\r\nHEENT: AT/NC; R pupil mildly larger, slower to react than L \r\n(baseline per records); MMM\r\nCV: RRR, no M/R/G, +S1/S2\r\nPULM: CTAB\r\nABD: obese, soft, nontender to palpation, referred pain from \r\nback in band/belt distribution in low abdomen; +BS\r\nSKIN: unroofed vesicle with mild bleeding covered with xeroform\r\nEXT: chronic venous stasis changes in B/L ___ over shins\r\nNEURO: A/Ox3; CNII-XII assessed and grossly intact except for \r\nR>L pupillary dilataion and sluggish reactivity\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n___ 11:30AM BLOOD WBC-2.3* RBC-2.28* Hgb-7.1* Hct-22.1* \r\nMCV-97 MCH-31.1 MCHC-32.1 RDW-21.8* RDWSD-77.3* Plt ___\r\n___ 11:30AM BLOOD Neuts-37 Bands-6* ___ Monos-11 \r\nEos-0 Baso-0 Atyps-2* Metas-3* Myelos-1* Blasts-2* NRBC-3* \r\nAbsNeut-0.99* AbsLymp-0.92* AbsMono-0.25 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD ___ PTT-39.0* ___\r\n___ 11:30AM BLOOD UreaN-15 Creat-0.9 Na-137 K-3.8 Cl-102 \r\nHCO3-25 AnGap-14\r\n___ 11:30AM BLOOD ALT-8 AST-10 LD(LDH)-260* AlkPhos-81 \r\nTotBili-0.3\r\n___ 11:30AM BLOOD Albumin-3.4* Calcium-8.1* Mg-2.2\r\n\r\nINTERVAL LABS:\r\n___ 12:00AM BLOOD CRP-108.7*\r\n___ 12:00AM BLOOD IgG-805\r\n___ 04:00PM BLOOD HIV Ab-Negative\r\n___ 04:00PM BLOOD CMV VL-NOT DETECT\r\n___ 02:20PM BLOOD SED RATE-Test      \r\n___ 04:00PM BLOOD HERPES 6 DNA PCR, QUANTITATIVE-Test      \r\n___ 04:00PM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-Test   \r\n   \r\n___ 07:45PM BLOOD B-GLUCAN-Test      \r\n___ 07:45PM BLOOD ASPERGILLUS GALACTOMANNAN ANTIGEN-Test\r\n\r\nMICRO:\r\n___ Skin biopsy: All cx. negative\r\n___ RPR: negative\r\n___ Myco/lytic cx: no growth\r\n___ Psoas tissue cx: negative\r\nAll other blood and urine cultures final/negative\r\n\r\nSTUDIES:\r\nConclusions\r\nThe left atrium is mildly dilated. The left atrial volume index \r\nis mildly increased. The estimated right atrial pressure is ___ \r\nmmHg. Left ventricular wall thickness, cavity size and \r\nregional/global systolic function are normal (LVEF >55%). The \r\nestimated cardiac index is normal (>=2.5L/min/m2). Tissue \r\nDoppler imaging suggests an increased left ventricular filling \r\npressure (PCWP>18mmHg). Right ventricular chamber size and free \r\nwall motion are normal. The aortic valve leaflets (3) are mildly \r\nthickened but aortic stenosis is not present. No masses or \r\nvegetations are seen on the aortic valve. No aortic valve \r\nabscess is seen. No aortic regurgitation is seen. The mitral \r\nvalve leaflets are mildly thickened. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. There is moderate \r\npulmonary artery systolic hypertension. No vegetation/mass is \r\nseen on the pulmonic valve. There is an anterior space which \r\nmost likely represents a prominent fat pad. \r\n\r\nIMPRESSION: No echocardiographic evidence of endocarditis. \r\nNormal biventricular cavity sizes with preserved global and \r\nregional biventricular systolic function. Suggestion of elevated \r\nLV filling pressure. Mild mitral and tricuspid regurgitation. \r\nModerate pulmonary hypertension.\r\n\r\nCompared with the prior study (images reviewed) of ___, \r\nthe degrees of mitral and tricuspid regurgitation are slightly \r\ngreater and the estimated pulmonary arterial pressure is higher.\r\n\r\nIMAGING:\r\n___ L gluteal U/S:\r\nIMPRESSION:\r\nInflammation or edema of the superficial soft tissues without \r\nfocal fluid\r\ncollection.\r\n\r\n___ MR ___:\r\nIMPRESSION:\r\n1. Severe multilevel degenerative changes as described above \r\nhave slightly\r\nprogressed since the prior examination of ___.\r\n2. Scoliosis of lumbar spine with  signal changes and edema \r\nedema in the\r\nendplates, mild adjacent soft tissue signal and enhancement and \r\nenhancement in the left psoas muscle at L4-5 level without \r\nepidural phlegmon or paraspinal fluid collection are \r\nnonspecific.  Both advanced degenerative changes or early \r\ndiscitis osteomyelitis could give similar appearances.  The \r\nappearance on the prior CT abdomen of ___ or more was \r\nmore consistent with degenerative change. However, Correlation \r\nwith laboratory findings is essential to exclude early discitis \r\nosteomyelitis.\r\n\r\nDISCHARGE LABS:\r\n___ 01:18AM BLOOD WBC-0.4* RBC-2.58* Hgb-7.6* Hct-23.6* \r\nMCV-92 MCH-29.5 MCHC-32.2 RDW-18.6* RDWSD-62.0* Plt Ct-15*\r\n___ 01:18AM BLOOD Neuts-12* Bands-0 Lymphs-78* Monos-7 \r\nEos-1 Baso-0 Atyps-1* ___ Myelos-1* AbsNeut-0.05* \r\nAbsLymp-0.32* AbsMono-0.03* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:18AM BLOOD ___ PTT-34.5 ___\r\n___ 01:18AM BLOOD Glucose-147* UreaN-14 Creat-0.9 Na-136 \r\nK-3.7 Cl-99 HCO3-27 AnGap-14\r\n___ 12:00AM BLOOD ALT-14 AST-14 LD(LDH)-247 AlkPhos-90 \r\nTotBili-0.5\r\n___ 01:18AM BLOOD Calcium-8.1* Phos-2.7 Mg-2.3\r\n___ 06:25AM BLOOD Vanco-19.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, diagnosed with treatment related \r\nMDS. ___ was started on decitabine as an outpatient and \r\nre-presented with fevers and neutropenia. She had an exhaustive \r\nworkup of her fevers, including skin and psoas biopsies, and \r\ntissue uPCR was sent, but there was no culture positivity or \r\npositive findings in her infectious workup. However, after \r\nconsultation with ID, it was decided to treat empirically for \r\npresumptive osteomyelitis/discitis with 6 weeks of vancomycin \r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO \r\nq24h). Micafungin was chosen instead of posaconazole due to \r\n___ differences; but she did receive posaconazole while \r\ninpatient. Simultaneously, the patient was having significantly \r\nworsened back pain after her MDS diagnosing bone marrow biopsy. \r\nShe was started on opioid pain control, which was uptitrated and \r\naugmented with Valium to good effect. She went home with BID \r\noxycontin, PRN oxycodone, and QHS Valium. She will follow-up as \r\noutpatient with Dr. ___.\r\n\r\n# Fever + neutropenia: The patient received 2 doses of \r\ndecitabine as outpatient prior to experiencing first fever of \r\n101 at home, then 100.4 in clinic during third dose decitabine \r\nadministration. She was admitted for fever in setting of \r\ncytoreduction, and she eventually became truly neutropenic. An \r\nexhaustive workup was performed, centering on MRI findings of \r\npotential osteomyelitis/discitis with potential L psoas \r\ninvovlvement. This tissue was biopsied, negative by culture, and \r\nuPCR pending at the time of discharge. The patient will be given \r\nempiric therapy of vancomycin/cefepime/micafungin for a total of \r\n6 weeks (___) and instructed to have 1 month follow-up \r\nspinal imaging. A LLE wound was also biopsied and grew nothing. \r\nBy exclusion, decitabine is thought to be the likely culprit of \r\nthe fever.\r\n\r\n# left gluteal furuncle: Formed at the marked site of the ___ L \r\npsoas biopsy. By ultrasound found to only have subcutaneous \r\nedema without fluid collection. This will be followed by patient \r\nand outpatient team as potential new nidus of infection if \r\nappearing worse or causing pain.\r\n\r\n# low back pain: Acute on chronic in this patient, who has \r\nbaseline degenerative changes. She also had R iliac crest bone \r\nmarrow biopsy prior to this admission which may have caused \r\nhematoma, inflammatory, or direct nerve injury which contributed \r\nto her severe pain. She was uptitrated to a pain regimen \r\nincluding standing Oxycontin BID, oxycodone PRN, and Valium QHS, \r\nwhich she was able to tolerate with good effect. She worked with \r\n___ and was deemed fit for discharge home with services.\r\n\r\n# treatment related MDS: Secondary to autoSCT with BEAM \r\nconditioning for DLBCL. Patient had bone marrow biopsy which \r\ndiagnosed new-onset treatment related MDS, but may have also \r\ncaused severe acute-on-chronic back pain for which she is \r\nreceiving opioids and benzodiazapines. Will receive Bactrim for \r\nPCP prophylaxis starting at discharge.\r\n\r\n# history of DVT: History of LLE DVTs, on Rivaroxaban at home \r\nand IVC filter in place. Rivaroxaban was held once Plt<75k in \r\nsetting of multi-line decline from decitabine.\r\n\r\n# common variable immunodeficiency: Patient had multiple IgG \r\nchecks for known CVID and did not require IVIG as inpatient.\r\n\r\nTRANSITIONAL ISSUES:\r\n- complete 6 week antibiotics: vancomycin, cefepime, \r\nmicafungin(d1 = ___, end ___, follow-up with OPAT\r\n- weekly labs: CBC with differential, BUN, Cr, Vancomycin\r\ntrough, AST, ALT (fax to ATTN: ___ CLINIC - FAX: \r\n___\r\n- repeat MR ___ 1 month after discharge\r\n- PCP prophylaxis with ___ SS daily\r\n- plan future decitabine with Dr. ___ team\r\n- plan for curative transplant with Dr. ___ team\r\n- continue to monitor L gluteal furuncle\r\n- consider restarting rivaroxaban when deemed appropriate \r\n(stopped inpatient due to thrombocytopenia)\r\n- Code: Full\r\n- Contact: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. FoLIC Acid 3.2 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Venlafaxine 25 mg PO BID \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n12. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n13. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n14. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q6H:PRN \r\nPain - Mild \r\n\r\n \r\nDischarge Medications:\r\n1.  CefePIME 2 g IV Q12H \r\nRX *cefepime [Maxipime] 2 gram 2 g IV every twelve (12) hours \r\nDisp #*60 Vial Refills:*0 \r\n2.  Diazepam 5 mg PO QHS \r\nRX *diazepam 5 mg 1 tab by mouth at bedtime Disp #*7 Tablet \r\nRefills:*0 \r\n3.  Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium [Colace] 100 mg 1 capsule(s) by mouth twice \r\na day Disp #*60 Capsule Refills:*0 \r\n4.  Micafungin 100 mg IV Q24H \r\nRX *micafungin [Mycamine] 100 mg 100 mg IV q24h Disp #*30 Vial \r\nRefills:*0 \r\n5.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\nRX *oxycodone 10 mg 1 tablet(s) by mouth every six (6) hours \r\nDisp #*24 Tablet Refills:*0 \r\n6.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\nRX *oxycodone 20 mg 1 tablet(s) by mouth every twelve (12) hours \r\nDisp #*14 Tablet Refills:*0 \r\n7.  Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\nRX *polyethylene glycol 3350 [Miralax] 17 gram 1 powder(s) by \r\nmouth daily Disp #*30 Packet Refills:*0 \r\n8.  Senna 8.6 mg PO BID:PRN constipation \r\nRX *sennosides [senna] 8.6 mg 1 tab by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n9.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n10.  Vancomycin 750 mg IV Q 12H \r\nRX *vancomycin 750 mg 750 mg IV every twelve (12) hours Disp \r\n#*60 Vial Refills:*0 \r\n11.  Potassium Chloride 10 mEq PO DAILY  \r\n12.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n13.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n14.  Ascorbic Acid ___ mg PO BID  \r\n15.  Cyanocobalamin 1000 mcg PO QHS  \r\n16.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n17.  FoLIC Acid 3.2 mg PO DAILY  \r\n18.  Furosemide 20 mg PO DAILY  \r\n19.  Gabapentin 900 mg PO TID  \r\n20.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n21.  Omeprazole 20 mg PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until insructed to by your outpatient \r\ndoctor\r\n24.Outpatient Lab Work\r\nTo be drawn weekly: CBC with differential, BUN, Cr, Vancomycin \r\ntrough, AST, ALT\r\nSend results to: ___ CLINIC - FAX: ___\r\nICD 10: ___.0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n- fever and neutropenia\r\n- low back pain\r\n- treatment related MDS\r\n- history of DVT\r\n- common variable immunodeficiency\r\n- left gluteal furuncle\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ was a pleasure caring for you while you were at ___. You \r\ncame to the hospital with a fever in the setting of your \r\ndecitabine therapy and had significantly worse back pain after \r\nyour bone marrow biopsy several weeks back. Despite a thorough \r\nworkup including multiple sets of blood cultures, urine \r\ncultures, and imaging including MRIs there was no infectious \r\nsource found as the culprit for your fevers. You were started on \r\nIV antibiotics to treat a presumptive infection, which you will \r\ncontinue for six weeks. You will follow-up with the infectious \r\ndisease physicians as an outpatient. You were started on several \r\nopioid pain medications and Valium which helped you be more \r\nactive and have good pain control. \r\n\r\nIt was a pleasure to participate in your care. We wish you all \r\nthe best.\r\n\r\nSincerely,\r\nYour ___ care team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-17:10",
      "text": "Discharge Instructions:\nDear ___, ___ was a pleasure caring for you while you were at ___. You \ncame to the hospital with a fever in the setting of your \ndecitabine therapy and had significantly worse back pain after \nyour bone marrow biopsy several weeks back. Despite a thorough \nworkup including multiple sets of blood cultures, urine \ncultures, and imaging including MRIs there was no infectious \nsource found as the culprit for your fevers. You were started on \nIV antibiotics to treat a presumptive infection, which you will \ncontinue for six weeks. You will follow-up with the infectious \ndisease physicians as an outpatient. You were started on several \nopioid pain medications and Valium which helped you be more \nactive and have good pain control. It was a pleasure to participate in your care. We wish you all \nthe best. Sincerely,\nYour ___ care team\n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-17",
        "chart_time": "104487",
        "section": "General",
        "position": 10,
        "tokenCount": 223,
        "note_metadata": {
          "note_id": "18887130-DS-17",
          "subject_id": 18887130,
          "hadm_id": 27240020,
          "note_type": "DS",
          "note_seq": 17,
          "charttime": 104487,
          "storetime": 104488.35277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nBack pain, fever + neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nL psoas and prespinal biopsy\r\nLLE skin biopsy\r\n\r\n \r\nHistory of Present Illness:\r\n___ F with CVID, h/o transformed follicular lymphoma and h/o CLL \r\ns/p auto SCT (BEAM prep) in ___ in remission from lymphoma \r\nstandpoint but developed worsening pancytopenia and bleeding \r\nissues this month found to have treatment related MDS, now C1D3 \r\ndacogen presenting with borderline neutropenia and temp today of \r\n100.4.\r\n\r\nOther v/s in clinic: Vital Signs: BP: 111/53. Heart Rate:\r\n98. O2 Saturation%: 100.  Weight: 256.6. Height: 61.25. BMI:\r\n48.1. Temperature: 100.4. Resp. Rate: 18. Pain Score: 5 (back). \r\n\r\nGiven functional neutropenia, admitted for treatment of febrile \r\nneutropenia. Got vanc/cefepime in clinic. Blood cultures sent in \r\nclinic. She reported having some chills at the time and general \r\nfatigue but denied any other specific symptoms. Temp came back \r\ndown on it's own and she was 98.9 before leaving clinic. Hgb \r\n7.1,\r\nclinic orderd 1u blood which she will receive here. Regarding \r\nher other PMH: she is on xarelto for thrombosis history (DVT, \r\nalso has IVCF which was placed), and has h/o bleo toxicity \r\npneumonitis (off steroids now but cont with inhalers), and also \r\nhas intermittent LBP and left sciatica due to degenerative \r\ndisease,\r\non gabapentin, and she has chronic right pupil dilation and \r\ndysmetria.\r\n\r\nNote she was recently admitted and discharged ___. SHe had BM \r\nbx ___ which showed MDS as above. She also reported nasal \r\ncongestion and had fever ___, initially covered broadly but \r\nwith negative cultures, ultimately discharged to complete 7d \r\ncourse of levaquin on ___. Pt states she stopped taking the \r\nlevoquin ___ days ago. Last night took her temp and it was 100.1 \r\n(was\r\ninstructed to monitor temps, she had no symptoms that prompted \r\nthis check). This morning driving in to clinic appointment felt \r\na bit chilled but not shaking and not sick in any other way. In \r\nclinic found to have temp of 100.4. Also notes that she \r\ntypically has left sided sciatica but that in the past week sinc \r\nethe bone marrow biopsy has developed right lower back pain \r\nwhich has required ___ doses of vicodin daily and is a new pain \r\nworsening over time, present constantly, but worse with movement \r\nor deep palpation. Denies loss of strength or sensation though \r\nhas chronic right foot drop and dysesthesias at baseline after \r\nknee replacement on that side in the past. No incontinence or \r\ndysuria.\r\n\r\nFinally, her history is significant for a \"blood blister\" she \r\nnoted on the left foreleg per pt about ___ weeks ago which was \r\nultimately debrided in the past, and poor wound healing \r\nattributed to venous stasis. THis has been healing well she \r\nstates, though there is still an open wound surrounded by \r\nerythema but she is confident it continues to improve \r\ndramatically and no recent drainage. She is covering it with \r\nxeroform dressing daily.\r\n\r\nfurther nose bleeds or other bleeding.  She is also noted for a \r\nnonhealing wound on her left leg after hitting her shin several \r\nweeks ago.  She is using xerofrom dressing to the area and \r\nchanging it daily with slow healing. All other 10 point ROS neg.\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM:\r\nGeneral: NAD  \r\nT 99.6 BP 100/58  HR 95  20  96%RA\r\nHEENT: Right pupil slower to react to light which is baseline.  \r\nMMM, no OP lesions or thrush.  \r\nCV: RR, NL S1S2 no MRG  \r\nPULM: CTAB no wheezing or crackles  \r\nABD: BS+, soft, NTND  \r\nSKIN/limbs: left anterior foreleg with 1cm open circular wound \r\nwithout drainage, covered w/xeroform, with 4-5 cm diameter \r\nsurrounding erythema, not warm to touch, lower extr are equal in \r\ngirth, no pitting edema\r\nBack: pt is tender to palpation around the left SI joint, has \r\nresolving hematoma over the medial aspect of right sacrum, but \r\nno tenderness over the hematoma which appears superficial, no \r\nswelling\r\n\r\nDISCHARGE EXAM:\r\nVS: 98.1 ___ 22 97RA\r\nGEN: NAD, seated in chair, conversational\r\nHEENT: AT/NC; R pupil mildly larger, slower to react than L \r\n(baseline per records); MMM\r\nCV: RRR, no M/R/G, +S1/S2\r\nPULM: CTAB\r\nABD: obese, soft, nontender to palpation, referred pain from \r\nback in band/belt distribution in low abdomen; +BS\r\nSKIN: unroofed vesicle with mild bleeding covered with xeroform\r\nEXT: chronic venous stasis changes in B/L ___ over shins\r\nNEURO: A/Ox3; CNII-XII assessed and grossly intact except for \r\nR>L pupillary dilataion and sluggish reactivity\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n___ 11:30AM BLOOD WBC-2.3* RBC-2.28* Hgb-7.1* Hct-22.1* \r\nMCV-97 MCH-31.1 MCHC-32.1 RDW-21.8* RDWSD-77.3* Plt ___\r\n___ 11:30AM BLOOD Neuts-37 Bands-6* ___ Monos-11 \r\nEos-0 Baso-0 Atyps-2* Metas-3* Myelos-1* Blasts-2* NRBC-3* \r\nAbsNeut-0.99* AbsLymp-0.92* AbsMono-0.25 AbsEos-0.00* \r\nAbsBaso-0.00*\r\n___ 12:00AM BLOOD ___ PTT-39.0* ___\r\n___ 11:30AM BLOOD UreaN-15 Creat-0.9 Na-137 K-3.8 Cl-102 \r\nHCO3-25 AnGap-14\r\n___ 11:30AM BLOOD ALT-8 AST-10 LD(LDH)-260* AlkPhos-81 \r\nTotBili-0.3\r\n___ 11:30AM BLOOD Albumin-3.4* Calcium-8.1* Mg-2.2\r\n\r\nINTERVAL LABS:\r\n___ 12:00AM BLOOD CRP-108.7*\r\n___ 12:00AM BLOOD IgG-805\r\n___ 04:00PM BLOOD HIV Ab-Negative\r\n___ 04:00PM BLOOD CMV VL-NOT DETECT\r\n___ 02:20PM BLOOD SED RATE-Test      \r\n___ 04:00PM BLOOD HERPES 6 DNA PCR, QUANTITATIVE-Test      \r\n___ 04:00PM BLOOD EBV PCR, QUANTITATIVE, WHOLE BLOOD-Test   \r\n   \r\n___ 07:45PM BLOOD B-GLUCAN-Test      \r\n___ 07:45PM BLOOD ASPERGILLUS GALACTOMANNAN ANTIGEN-Test\r\n\r\nMICRO:\r\n___ Skin biopsy: All cx. negative\r\n___ RPR: negative\r\n___ Myco/lytic cx: no growth\r\n___ Psoas tissue cx: negative\r\nAll other blood and urine cultures final/negative\r\n\r\nSTUDIES:\r\nConclusions\r\nThe left atrium is mildly dilated. The left atrial volume index \r\nis mildly increased. The estimated right atrial pressure is ___ \r\nmmHg. Left ventricular wall thickness, cavity size and \r\nregional/global systolic function are normal (LVEF >55%). The \r\nestimated cardiac index is normal (>=2.5L/min/m2). Tissue \r\nDoppler imaging suggests an increased left ventricular filling \r\npressure (PCWP>18mmHg). Right ventricular chamber size and free \r\nwall motion are normal. The aortic valve leaflets (3) are mildly \r\nthickened but aortic stenosis is not present. No masses or \r\nvegetations are seen on the aortic valve. No aortic valve \r\nabscess is seen. No aortic regurgitation is seen. The mitral \r\nvalve leaflets are mildly thickened. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. There is moderate \r\npulmonary artery systolic hypertension. No vegetation/mass is \r\nseen on the pulmonic valve. There is an anterior space which \r\nmost likely represents a prominent fat pad. \r\n\r\nIMPRESSION: No echocardiographic evidence of endocarditis. \r\nNormal biventricular cavity sizes with preserved global and \r\nregional biventricular systolic function. Suggestion of elevated \r\nLV filling pressure. Mild mitral and tricuspid regurgitation. \r\nModerate pulmonary hypertension.\r\n\r\nCompared with the prior study (images reviewed) of ___, \r\nthe degrees of mitral and tricuspid regurgitation are slightly \r\ngreater and the estimated pulmonary arterial pressure is higher.\r\n\r\nIMAGING:\r\n___ L gluteal U/S:\r\nIMPRESSION:\r\nInflammation or edema of the superficial soft tissues without \r\nfocal fluid\r\ncollection.\r\n\r\n___ MR ___:\r\nIMPRESSION:\r\n1. Severe multilevel degenerative changes as described above \r\nhave slightly\r\nprogressed since the prior examination of ___.\r\n2. Scoliosis of lumbar spine with  signal changes and edema \r\nedema in the\r\nendplates, mild adjacent soft tissue signal and enhancement and \r\nenhancement in the left psoas muscle at L4-5 level without \r\nepidural phlegmon or paraspinal fluid collection are \r\nnonspecific.  Both advanced degenerative changes or early \r\ndiscitis osteomyelitis could give similar appearances.  The \r\nappearance on the prior CT abdomen of ___ or more was \r\nmore consistent with degenerative change. However, Correlation \r\nwith laboratory findings is essential to exclude early discitis \r\nosteomyelitis.\r\n\r\nDISCHARGE LABS:\r\n___ 01:18AM BLOOD WBC-0.4* RBC-2.58* Hgb-7.6* Hct-23.6* \r\nMCV-92 MCH-29.5 MCHC-32.2 RDW-18.6* RDWSD-62.0* Plt Ct-15*\r\n___ 01:18AM BLOOD Neuts-12* Bands-0 Lymphs-78* Monos-7 \r\nEos-1 Baso-0 Atyps-1* ___ Myelos-1* AbsNeut-0.05* \r\nAbsLymp-0.32* AbsMono-0.03* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:18AM BLOOD ___ PTT-34.5 ___\r\n___ 01:18AM BLOOD Glucose-147* UreaN-14 Creat-0.9 Na-136 \r\nK-3.7 Cl-99 HCO3-27 AnGap-14\r\n___ 12:00AM BLOOD ALT-14 AST-14 LD(LDH)-247 AlkPhos-90 \r\nTotBili-0.5\r\n___ 01:18AM BLOOD Calcium-8.1* Phos-2.7 Mg-2.3\r\n___ 06:25AM BLOOD Vanco-19.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis as well as persistent norovirus p/w acute \r\nLBP, epistaxis, pancytopenia, diagnosed with treatment related \r\nMDS. ___ was started on decitabine as an outpatient and \r\nre-presented with fevers and neutropenia. She had an exhaustive \r\nworkup of her fevers, including skin and psoas biopsies, and \r\ntissue uPCR was sent, but there was no culture positivity or \r\npositive findings in her infectious workup. However, after \r\nconsultation with ID, it was decided to treat empirically for \r\npresumptive osteomyelitis/discitis with 6 weeks of vancomycin \r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO \r\nq24h). Micafungin was chosen instead of posaconazole due to \r\n___ differences; but she did receive posaconazole while \r\ninpatient. Simultaneously, the patient was having significantly \r\nworsened back pain after her MDS diagnosing bone marrow biopsy. \r\nShe was started on opioid pain control, which was uptitrated and \r\naugmented with Valium to good effect. She went home with BID \r\noxycontin, PRN oxycodone, and QHS Valium. She will follow-up as \r\noutpatient with Dr. ___.\r\n\r\n# Fever + neutropenia: The patient received 2 doses of \r\ndecitabine as outpatient prior to experiencing first fever of \r\n101 at home, then 100.4 in clinic during third dose decitabine \r\nadministration. She was admitted for fever in setting of \r\ncytoreduction, and she eventually became truly neutropenic. An \r\nexhaustive workup was performed, centering on MRI findings of \r\npotential osteomyelitis/discitis with potential L psoas \r\ninvovlvement. This tissue was biopsied, negative by culture, and \r\nuPCR pending at the time of discharge. The patient will be given \r\nempiric therapy of vancomycin/cefepime/micafungin for a total of \r\n6 weeks (___) and instructed to have 1 month follow-up \r\nspinal imaging. A LLE wound was also biopsied and grew nothing. \r\nBy exclusion, decitabine is thought to be the likely culprit of \r\nthe fever.\r\n\r\n# left gluteal furuncle: Formed at the marked site of the ___ L \r\npsoas biopsy. By ultrasound found to only have subcutaneous \r\nedema without fluid collection. This will be followed by patient \r\nand outpatient team as potential new nidus of infection if \r\nappearing worse or causing pain.\r\n\r\n# low back pain: Acute on chronic in this patient, who has \r\nbaseline degenerative changes. She also had R iliac crest bone \r\nmarrow biopsy prior to this admission which may have caused \r\nhematoma, inflammatory, or direct nerve injury which contributed \r\nto her severe pain. She was uptitrated to a pain regimen \r\nincluding standing Oxycontin BID, oxycodone PRN, and Valium QHS, \r\nwhich she was able to tolerate with good effect. She worked with \r\n___ and was deemed fit for discharge home with services.\r\n\r\n# treatment related MDS: Secondary to autoSCT with BEAM \r\nconditioning for DLBCL. Patient had bone marrow biopsy which \r\ndiagnosed new-onset treatment related MDS, but may have also \r\ncaused severe acute-on-chronic back pain for which she is \r\nreceiving opioids and benzodiazapines. Will receive Bactrim for \r\nPCP prophylaxis starting at discharge.\r\n\r\n# history of DVT: History of LLE DVTs, on Rivaroxaban at home \r\nand IVC filter in place. Rivaroxaban was held once Plt<75k in \r\nsetting of multi-line decline from decitabine.\r\n\r\n# common variable immunodeficiency: Patient had multiple IgG \r\nchecks for known CVID and did not require IVIG as inpatient.\r\n\r\nTRANSITIONAL ISSUES:\r\n- complete 6 week antibiotics: vancomycin, cefepime, \r\nmicafungin(d1 = ___, end ___, follow-up with OPAT\r\n- weekly labs: CBC with differential, BUN, Cr, Vancomycin\r\ntrough, AST, ALT (fax to ATTN: ___ CLINIC - FAX: \r\n___\r\n- repeat MR ___ 1 month after discharge\r\n- PCP prophylaxis with ___ SS daily\r\n- plan future decitabine with Dr. ___ team\r\n- plan for curative transplant with Dr. ___ team\r\n- continue to monitor L gluteal furuncle\r\n- consider restarting rivaroxaban when deemed appropriate \r\n(stopped inpatient due to thrombocytopenia)\r\n- Code: Full\r\n- Contact: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. FoLIC Acid 3.2 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Potassium Chloride 10 mEq PO DAILY \r\n8. Venlafaxine 25 mg PO BID \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n12. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n13. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n14. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q6H:PRN \r\nPain - Mild \r\n\r\n \r\nDischarge Medications:\r\n1.  CefePIME 2 g IV Q12H \r\nRX *cefepime [Maxipime] 2 gram 2 g IV every twelve (12) hours \r\nDisp #*60 Vial Refills:*0 \r\n2.  Diazepam 5 mg PO QHS \r\nRX *diazepam 5 mg 1 tab by mouth at bedtime Disp #*7 Tablet \r\nRefills:*0 \r\n3.  Docusate Sodium 100 mg PO BID \r\nRX *docusate sodium [Colace] 100 mg 1 capsule(s) by mouth twice \r\na day Disp #*60 Capsule Refills:*0 \r\n4.  Micafungin 100 mg IV Q24H \r\nRX *micafungin [Mycamine] 100 mg 100 mg IV q24h Disp #*30 Vial \r\nRefills:*0 \r\n5.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\nRX *oxycodone 10 mg 1 tablet(s) by mouth every six (6) hours \r\nDisp #*24 Tablet Refills:*0 \r\n6.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\nRX *oxycodone 20 mg 1 tablet(s) by mouth every twelve (12) hours \r\nDisp #*14 Tablet Refills:*0 \r\n7.  Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\nRX *polyethylene glycol 3350 [Miralax] 17 gram 1 powder(s) by \r\nmouth daily Disp #*30 Packet Refills:*0 \r\n8.  Senna 8.6 mg PO BID:PRN constipation \r\nRX *sennosides [senna] 8.6 mg 1 tab by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n9.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n10.  Vancomycin 750 mg IV Q 12H \r\nRX *vancomycin 750 mg 750 mg IV every twelve (12) hours Disp \r\n#*60 Vial Refills:*0 \r\n11.  Potassium Chloride 10 mEq PO DAILY  \r\n12.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n13.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n14.  Ascorbic Acid ___ mg PO BID  \r\n15.  Cyanocobalamin 1000 mcg PO QHS  \r\n16.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n17.  FoLIC Acid 3.2 mg PO DAILY  \r\n18.  Furosemide 20 mg PO DAILY  \r\n19.  Gabapentin 900 mg PO TID  \r\n20.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n21.  Omeprazole 20 mg PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until insructed to by your outpatient \r\ndoctor\r\n24.Outpatient Lab Work\r\nTo be drawn weekly: CBC with differential, BUN, Cr, Vancomycin \r\ntrough, AST, ALT\r\nSend results to: ___ CLINIC - FAX: ___\r\nICD 10: ___.0\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\n- fever and neutropenia\r\n- low back pain\r\n- treatment related MDS\r\n- history of DVT\r\n- common variable immunodeficiency\r\n- left gluteal furuncle\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___,\r\n\r\n___ was a pleasure caring for you while you were at ___. You \r\ncame to the hospital with a fever in the setting of your \r\ndecitabine therapy and had significantly worse back pain after \r\nyour bone marrow biopsy several weeks back. Despite a thorough \r\nworkup including multiple sets of blood cultures, urine \r\ncultures, and imaging including MRIs there was no infectious \r\nsource found as the culprit for your fevers. You were started on \r\nIV antibiotics to treat a presumptive infection, which you will \r\ncontinue for six weeks. You will follow-up with the infectious \r\ndisease physicians as an outpatient. You were started on several \r\nopioid pain medications and Valium which helped you be more \r\nactive and have good pain control. \r\n\r\nIt was a pleasure to participate in your care. We wish you all \r\nthe best.\r\n\r\nSincerely,\r\nYour ___ care team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \ndapsone\n \nAttending: ___. Chief Complaint:\nAltered mental status, chills\n \nMajor Surgical or Invasive Procedure:\nNone",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 0,
        "tokenCount": 74,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:1",
      "text": "History of Present Illness:\n___ year old female with history of transformed diffuse large B \ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \nconditioning in ___ ___s IFRT with course complicated \nby BCNU pneumonitis, who was subsequently found to have\ntreatment-related MDS on BM biopsy performed on ___. She is\ncurrently on C2D12 of treatment with decitabine and presents \nwith\none day of confusion, round to have rigors in the ED. Of note, patient was recently admitted to ___ service from\n___ to ___ after starting her first cycle of decitabine for\npersistent neutropenic fever, with no clear source identified. She had negative cultures. Imaging with MRI revealed possible\nearly discitis and possible myositis of the psoas muscle. She\nunderwent psoas muscle biopsy and also had an ulcer on the L \nshin\nwhich was biopsied. Culture and infectious studies were all\nnegative. In addition, a universal PCR was sent which was\nnegative. Infectious Disease team consulted. She was treated\nultimately with 6week course of vancomycin/Cefepime/Micafungin\n(last day previously planned for ___ with empiric coverage\nfor osteomyelitis. She was seen yesterday in ___ clinic for\nfollow-up on ___ where she reported feeling well and was noted \nto\nbe _______alert and oriented. In ER, endorses vomiting, anxiety and confusion. Does not feel\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\nshowed no acute intracranial process. CXR showed moderate\ncardiomegaly (unchanged) and mild Pulm vasc congestion. She was treated with Vancomycin, cefepime and Micafungin and was\nadmitted to ___ service. On floor, patient seen in distress from headaches and nausea. Headache, \"not very severe, not ___ , more of a moderate pain\"\npresent on only R side of the head, unlike her previous migraine\nattacks. Denies neck stiffness, able to touch chin to chest\nwithout issues. No sick contacts. No fevers or rash suggestive \nof\nmeningococcal infection. She is nauseous and is seen moving\naround in be trying to find a comfortable position. She is able to provide good history but some slowing in her\nthought process seen, unsure if she is distracted from the pain\nand nausea but she stops sentences midway and needs prompting to\nfinish her sentences. She is AO-3. Clear thought content. Goal\ndirected behavior. Able to express herself well albeit above\nsymptoms. Temp yesterday per pt was 97 but she felt chills. No other\ndocumented high fevers. Review of Systems:  \n(+) Per HPI. Positive for fevers and chill. Positive for Nausea. Negative for\nneck stiffness, night sweats, headache, vision changes,\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\nBRBPR, melena, hematochezia, dysuria, hematuria.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 1,
        "tokenCount": 695,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:2",
      "text": "Past Medical History:\nOncologic history: In brief, history of follicular lymphoma \nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \nrituximab in ___ for residual disease. ___: RICE \nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \nlocal disease. She has a hx of hypogammaglobulinemia. Other PMH:\nobesity\nAcute DVT in the right popliteal/femoral veins + superficial \nthrombosis\n--Transformed DLBCL with history of follicular lymphoma as noted \nabove\n--CLL, noted on BM biopsy on ___. --Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \n(*Known slight CN VI palsy & mild proptosis of R eye)\n--Hypogammaglobulinemia, receives IVIG PRN\n--R leg DVT. IVC filter in place, on rivaroxaban\n--BCNU pneumonitis, on prednisone\n--Mild GERD\n--OA / LBP\n--Small Intestinal Bacterial Overgrowth\n--Trochanteric Bursitis\n--s/p Excisional Bx L Cervical Lymph Node\n--s/p L total knee replacement ___, walks with cane\n--s/p I&D Labial Abscess\n--s/p Excision Cyst R ___ Digit of Hand Social History:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 2,
        "tokenCount": 252,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:3",
      "text": "Family History:\nbrother - lymphoma Physical ___:\nADMISSION EXAM\n===============\nVitals: 98.6 PO 144 / 90 87 22 97 RA \nGen: appears in distress, nauseous, moving around in bed seeking\na comfortable position\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\nsluggishly responds to light. L eye brisk, this anomaly is a old\nissue per patient. NECK: No JVD. CV: Normocardic, regular. Normal S1,S2. No MRG. LUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi. ABD: NABS. Soft, NT, ND. obese,   \nEXT: WWP. No ___ edema. SKIN: No rashes/lesions, petechiae/purpura ecchymoses. NEURO: A&Ox3.Normal finger to nose testing. Normal strength and\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\nkernig's sign. LINES: L chest wall port. DISCHARGE EXAM\n==============\nVitals: 99.1 130 / 52 87 18 100 RA \nGeneral: Appears comfortable, upbeat, NAD\nHEENT: OP clear\nCV: RRR, no m/r/g\nPulm: CTAB, poor air movement in expiratory phase\nAbd: Obese, soft, NT, ND, NABS\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \nTTP on ___ medical shin without induration or warmth; tense ___ b/l \nstable from prior  \nNeuro: A&Ox3 without word finding difficulty. Pertinent Results:\nADMISSION: ___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \nHCO3-26 AnGap-13\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\n___ 12:00AM BLOOD TSH-2.3\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\n___ 12:49PM BLOOD Lactate-1.6 MICRO: URINE CULTURE (Final ___: \n      ENTEROCOCCUS FAECIUM. 10,000-100,000 CFU/mL. LINEZOLID sensitivity testing performed by ___. SENSITIVITIES: MIC expressed in \nMCG/ML\n                      \n_________________________________________________________\n                             ENTEROCOCCUS FAECIUM\n                             |   \nAMPICILLIN------------  =>32 R\nLINEZOLID-------------       S\nNITROFURANTOIN--------   128 R\nTETRACYCLINE----------  =>16 R\nVANCOMYCIN------------  =>32 R",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 3,
        "tokenCount": 526,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:4",
      "text": "IMAGING:\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \n  \nINDICATION:  ___ year old woman with transformed follicular \nlymphoma and h/o \nCLL s/p auto SCT in ___ in remission from lymphoma but now with \nMDS; h/o R \nDVT off anticoagulation; anterior medial leg swelling near site \nof former \ntrauma  // r/o DVT; r/o drainable collection \n  \nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \nwas performed \non the left lower extremity veins. COMPARISON:  Bilateral lower extremity venous duplex ultrasound \n___ FINDINGS:  \n  \nThere is normal compressibility, flow, and augmentation of the \nleft common \nfemoral, femoral, and popliteal veins. The posterior tibial and \nperoneal \nveins could not be visualized due to extensive soft tissue \nedema. There is normal respiratory variation in the common femoral \nveins bilaterally.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 4,
        "tokenCount": 208,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:5",
      "text": "IMPRESSION:  \n  \nNo evidence of deep venous thrombosis in the left common \nfemoral, femoral, and \npopliteal veins. The posterior tibial and peroneal veins could \nnot be \nvisualized due to extensive soft tissue edema. EXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \n  \nINDICATION:  ___ year old woman with transformed follicular \nlymphoma and h/o \nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \non \nantimicrobials. She has h/o DVT and now with \nswelling/tenderness/erythema of \nL anterior/medial leg  // r/o drainable collection \n  \nTECHNIQUE:  Grayscale ultrasound images were obtained of the \nsuperficial \ntissues of the left calf in the area of the scab. COMPARISON:  None FINDINGS:  \n  \nTransverse and sagittal images were obtained of the superficial \ntissues of the \nleft calf in the area of the scab. Extensive soft tissue edema \nis seen. There is a 0.___alcification in the subcutaneous fat in \nthis region. No other masses are seen. There is no abscess.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 5,
        "tokenCount": 246,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:6",
      "text": "IMPRESSION:  \n  \nExtensive soft tissue edema in the left calf in the area of the \nscab. No \ndrainable fluid collections are seen. There is a 0.8 cm \ncalcification in the \nsubcutaneous fat in this region which most likely represents a \nphlebolith. This could be confirmed with x-ray. EXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \n  \nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \nevaluate for mass \nor hemorrhage. TECHNIQUE:  Contiguous axial images of the brain were obtained \nwithout \ncontrast. Coronal and sagittal reformations as well as bone \nalgorithm \nreconstructions were provided and reviewed. DOSE:  Acquisition sequence: \n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \n(Head) DLP = \n802.7 mGy-cm. Total DLP (Head) = 803 mGy-cm. COMPARISON:  Prior head CT dated ___.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 6,
        "tokenCount": 203,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:7",
      "text": "FINDINGS:  \n  \nMetallic streak artifact related to prior right supraclinoid ICA \nembolization \nlimits evaluation of the skullbase. There is no evidence of \ninfarction, \nhemorrhage, edema, or mass. There is prominence of the \nventricles and sulci \nsuggestive of involutional changes. There is no evidence of fracture. The visualized portion of the \nparanasal \nsinuses, mastoid air cells, and middle ear cavities are clear. The visualized \nportion of the orbits are unremarkable. IMPRESSION: \n  \n  \n1. No evidence of acute intracranial process. 2. Age related involutional changes. 3. Mildly limited evaluation of the skullbase due to streak \nartifact from \nright supraclinoid ICA embolization. TECHNIQUE:  Chest PA and lateral \n  \nCOMPARISON:  Prior chest radiographs dated ___. FINDINGS:  \n  \nAn accessed left pectoral Port-A-Cath catheter tip terminates in \nthe mid SVC. Moderate cardiomegaly and mild pulmonary vascular congestion \nwithout frank \npulmonary edema is unchanged from the prior study. There is no \npleural \neffusion, pneumothorax, or focal consolidation. Irregularity of \nthe right \nupper chest wall is chronic and unchanged.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 7,
        "tokenCount": 285,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:8",
      "text": "IMPRESSION:  \n  \nUnchanged moderate cardiomegaly and mild pulmonary vascular \ncongestion without \nfrank edema. No consolidation. EXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \n  \nINDICATION:  ___ patient with myelodysplastic syndrome, \nlow platelets, \nright cerebellar aneurysm clipping in ___, presenting with \nheadaches and \nsepsis. Evaluate for hemorrhage. TECHNIQUE:  Sagittal and axial T1 weighted imaging were \nperformed. After \nadministration of 11 mL of Gadavist intravenous contrast, axial \nimaging was \nperformed with gradient echo, FLAIR, diffusion, and T1 \ntechnique. Sagittal \nMPRAGE imaging was performed and re-formatted in axial and \ncoronal \norientations. COMPARISON:  CT head ___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 8,
        "tokenCount": 177,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:9",
      "text": "FINDINGS:  \n  \nThere is no evidence of acute infarction, or intracranial \nhemorrhage. The \nventricles are normal in size without mass effect or midline \nshift. There is \nno abnormal enhancement, enhancing mass, or leptomeningeal \ndisease. There is \nminimal nonspecific scattered foci of hyperintense T2/FLAIR \nsignal changes \nwithin the subcortical and periventricular white matter, which \nis likely a \nsequela of chronic small vessel microangiopathy. The dural \nvenous sinuses \nappear patent on post-contrast MPRAGE images. The paranasal \nsinuses appear \nclear. The bilateral mastoid air cells appear unremarkable. The orbits and \nvisualized soft tissues appear unremarkable.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 9,
        "tokenCount": 169,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:10",
      "text": "IMPRESSION: \n  \n  \n1. No evidence of intracranial hemorrhage, acute infarction, \nedema, or \nabnormal enhancement. EXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \n  \nINDICATION:  ___ year old woman with transformed follicular \nlymphoma and h/o \nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \nbut developed \ntreatment related MDS, receiving Dacogen who developed \nneutropenic fevers and \nMRI on ___ showed ? early discitis and L psoas abnormality \nnow 5 weeks \ninto antibiotics. // Evaluate for the evolution of theL4-L5 \nprocess involving \nendplates and L psoas muscle  ___ year old woman with transformed \nfollicular \nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \nlymphoma \nstandpoint but developed treatment related MDS, receiving \nDacogen who \ndeveloped neutropenic fevers and MRI on ___ showed ? early \ndiscitis and L \npsoas abnormality now 5 weeks into antibiotics. // Evaluate for \nthe evolution \nof theL4-L5 process involving endplates and L psoas muscle   \nEvaluate for the \nevolution of theL4-L5 process involving endplates and L psoas \nmuscle \n  \nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \ntechnique, \nfollowed by axial T2 imaging. This was followed by sagittal and \naxial T1 \nimages obtained after the uneventful intravenous administration \nof 11 mL of \nGadavist  contrast agent. COMPARISON:  Lumbar spine MR examinations ___ and ___. CT abdomen and pelvis ___.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 10,
        "tokenCount": 357,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:11",
      "text": "FINDINGS:  \n  \nAgain seen is scoliosis convex to the left in the upper lumbar \nspine and to \nthe right in the lower lumbar spine. Again seen is anterior \nsubluxation of L5 \non S1. Again seen is ___ type 1 signal intensity change at \nL2-3. This \nincludes a low signal of the vertebral endplates on the T1 \nweighted images and \nhigh signal of these endplates on the STIR images. This finding \nhas not \nchanged since ___. New since ___ but unchanged since ___ are \nsimilar changes \nat the L4-5 interspace. There is low signal of the endplates on \nthe T1 \nweighted images and high signal on the STIR images. All of the \nlumbar discs \nare hypointense on the T2 weighted and STIR images as are the \ndiscs at the T9 \nthrough T12 level. These are further manifestations of \ndegenerative disc \ndisease. The endplates at L2-3 and at L4-5 enhance after \ncontrast \nadministration. This is typical ___ type 1 change. The \nintervertebral \ndiscs themselves do not enhance after contrast administration. Again seen are hypointensities in the intervertebral discs at \nmultiple levels. Correlation with the CT abdomen and pelvis of ___ \ndemonstrates \nthat at every level from L2 through S1 included a vacuum \nphenomenon in the \nintervertebral disc. There is no evidence of abnormal intraspinal \ncontrast-enhancement. The psoas and spinal erector muscles are asymmetric and \ndemonstrate fatty \natrophy bilaterally. These changes are likely a result of the \nscoliosis. Much \nof the hyperintensity seen on the pre and postcontrast axial T1 \nweighted \nimages through the medial portion of the left psoas muscle at \nthe lower L4 \nlevel is due to the fatty atrophy, rather than enhancement. It \nis unclear \nwhether there is any abnormal enhancement of the left psoas \nmuscle, if so, it \nis minimal. Hypointensity on the T1 weighted images with enhancement after \ncontrast \nadministration involves the left side of the superior portion of \nthe L5 \nvertebral body and extends through the pedicle into the facet \njoint. This \ncorrelates with mild hyperintensity in these regions on the STIR \nimages. There is slight induration of the adjacent fat between the \nvertebral body and \nthe psoas muscle, best seen on image 30 of series 7 with \nenhancement seen on \nimage 30 of series 9. These findings may represent further \ninflammatory \nchange due to degenerative disease, or a local focus of \ninfection. Note that \nthis appearance is quite similar to that of the ___ \nstudy. The CT \nscans through the left facet joint at this level consistently \ndemonstrated a \nvacuum phenomenon, arguing strongly against infection of the \njoint. There is \nno evidence of bone destruction on the CT scans, which would be \nhighly unusual \nif there were chronic osteomyelitis extending as far back as \n___.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 11,
        "tokenCount": 690,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:12",
      "text": "These findings may represent further \ninflammatory \nchange due to degenerative disease, or a local focus of \ninfection. Note that \nthis appearance is quite similar to that of the ___ \nstudy. The CT \nscans through the left facet joint at this level consistently \ndemonstrated a \nvacuum phenomenon, arguing strongly against infection of the \njoint. There is \nno evidence of bone destruction on the CT scans, which would be \nhighly unusual \nif there were chronic osteomyelitis extending as far back as \n___. There is similar mild enhancement posteriorly along the left \nlamina at this \nlevel. Overall, these findings again are more likely due to \ninflammatory \ndegenerative disease than infection. The combination of vacuum phenomenon, low signal of the disc on \nthe T2 \nweighted images, ___ type 1 signal intensity changes of the \nendplates and \nstability over time all argue in favor of degenerative disc \ndisease as the \ncause of these changes. This constellation of findings would be \nextremely \nunlikely in the setting of discitis. There is a mild bulge of the T11-12 disc with no encroachment on \nthe spinal \ncord or neural foramina. At T12-L1 there is no encroachment on the cord or foramina. Incidentally \nnoted is an apparent right renal cyst, better evaluated on the \nrecent CT scan. There is a small midline and right-sided protrusion of the \nintervertebral disc \nthat extends superiorly along the posterior margin of the L1 \nvertebral body. This does not contact the nerve roots. The neural foramina \nappear normal. At L1-2 there is a small midline and right-sided disc protrusion \nthat \nencroaches on the thecal sac but does not contact the nerve \nroots. This \nfragment extends superiorly along the posterior margin of the L1 \nbody. The \nneural foramina appear normal. At L2-3, bulging of the disc and facet osteophytes produce \nencroachment on the \ntraversing L3 nerve roots bilaterally. There is narrowing of \nthe right neural \nforamen due to facet osteophytes and intervertebral osteophytes. At L3-4, disc bulging and intervertebral osteophytes contact the \ntraversing \nright L4 nerve root. The neural foramina are moderately \nnarrowed bilaterally. At L4-5, there is disc bulging but no evidence of nerve root \ncompression \nwithin the spinal canal. There are prominent facet osteophytes \nbilaterally \nthe produce severe left and moderate right \n  \nAt L5-S1, there is elongation of the spinal canal due to the \nsubluxation of L5 \non S1. There are prominent facet osteophytes bilaterally. The \ncombination of \nthese factors and loss of height of the intervertebral disc as \nwell as disc \nbulging produces moderate -severe narrowing of the neural \nforamina \nbilaterally.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 12,
        "tokenCount": 670,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:13",
      "text": "IMPRESSION: \n  \n  \n1. As discussed above, the vertebral, intervertebral disc, facet \nand left \npsoas muscle findings are likely due to a combination of \nscoliosis and chronic \ndegenerative disc disease, likely with inflammation on this \nbasis. 2. The minimal change over time, vacuum phenomenon in the \nintervertebral discs \nand facet joints, absence of bone destruction and pattern of \nsignal intensity \nabnormalities argue against infection as the etiology. 3. Degenerative disc disease produces mild encroachment on \nseveral nerve roots \nand more severe narrowing of the neural foramina at several \nlevels. EXAMINATION:  TIB/FIB (AP AND LAT) LEFT \n  \nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \non US  // \nphlebolith seen on US? TECHNIQUE:  Left tibia, fibula two views \n  \nCOMPARISON:  Ultrasound lower extremity ___ FINDINGS:  \n  \nLeft knee arthroplasty. There are few benign rounded \ncalcifications in the \nanterior pretibial soft tissues, likely represent phleboliths. There is no \nsoft tissue swelling. Surgical clips in the soft tissues. Calcaneal Achilles \nbone spur. Degenerative changes in the midfoot. Radiopaque \ndensity projected \nover proximal leg, just below medial ___ be external to \nthe patient.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 13,
        "tokenCount": 309,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:14",
      "text": "IMPRESSION:  \n  \nFew rounded calcifications in pretibial soft tissues, likely \nrepresent \nphleboliths. DISCHARGE: ___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \nK-3.8 Cl-103 HCO3-22 AnGap-18\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \nTotBili-0.3\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \nconditioning in ___ ___s IFRT with course complicated \nby ___ pneumonitis, who was subsequently found to have\ntreatment-related MDS on BM biopsy performed on ___. She is\ncurrently on C2D12 of treatment with decitabine and presents \nwith\none day of confusion and chills. Neutropenic and afebrile with \nno infectious source identified, improved rapidly to baseline on \n___ and IV antibiotics were deescalated. #Altered mental status: Presented with word finding difficulty \nand generalized malaise with decreased PO intake, without true \nglobal sensorium deficit. 1 month prior during hospitalization \nhad been diagnosed with presumed osteomyelitis though imaging \nwas equivocal, and started on 1 month broad spectrum ABX course. On this admission, ___ c/f meningitis, cefepime was increased to \nmeningitis dosing and ampicillin was added. Her home vanc and \nmica were continued. On ___ ___ the patient rapidly improved and \nmental status and symptoms were back to her baseline. Urine \nculture drawn in the ED (taken in bed-pan, not sterile) grew \nEnteroccus faecium pan-resistant, including ampicillin and \nvancomycin. The organism was not sensitive to any of the \nantibiotics that she was on, thus the organism was not treated, \nhowever she improved to baseline as above. Thus the UTI was \nlikely not the source of her AMS. In this light, she was not \nsent out on further antibiotics, but was counseled to return to \nthe hospital if she developed urinary symptoms or more \nconfusion. The true etiology is unclear. It may have been a \nviral infection or possibly cerebral hypoperfusion in the \nsetting of vascular pathology (h/o aneurysms). #UTI: see above for urine culture growing Enterococcus faecium. #LLE edema: Had a history of DVTs and was previously on \nrivaroxaban but this had been held for some time ___ \nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \nwas not restarted ___ thrombocytopenia. Held on discharge.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 14,
        "tokenCount": 665,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:15",
      "text": "The true etiology is unclear. It may have been a \nviral infection or possibly cerebral hypoperfusion in the \nsetting of vascular pathology (h/o aneurysms). #UTI: see above for urine culture growing Enterococcus faecium. #LLE edema: Had a history of DVTs and was previously on \nrivaroxaban but this had been held for some time ___ \nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \nwas not restarted ___ thrombocytopenia. Held on discharge. #?Nocardia skin rash: Had area of tenderness at site chronic \nvenous stasis dermatitis, previously biopsied by not sent for \nAFB/nocardia. When patient had AMS, nocardia was thought to be \npossible explanation with skin finding and AMS. Biopsy was \ndeferred in-house since patient resolved to baseline. Consider \nbiopsy if symptoms return. #Neutropenia: Started on PO cipro and fluconazole once IV abx \nwere discharged as above. Discharged on cipro and fluc. qTC on \ndischarge was 431ms. TRANISTION ISSUES\n=================\n[]acyclovir not seen as a previous home med, was started on \nacyclovir for ppx on discharge \n[]discharged on PO fluconazole and cipro ongoing for ppx\n[]consider biopsy of L medial shin and sending for AFB/nocardia # CODE: Confirmed Full\n# EMERGENCY CONTACT: ___ (husband) ___\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Ascorbic Acid ___ mg PO BID \n2. Cyanocobalamin 1000 mcg PO QHS \n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \ncongestion \n4. FoLIC Acid 3.2 mg PO DAILY \n5. Gabapentin 900 mg PO TID \n6. Omeprazole 20 mg PO DAILY \n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \n8. Potassium Chloride 10 mEq PO DAILY \n9. Venlafaxine 25 mg PO BID \n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \n12. Furosemide 20 mg PO DAILY \n13. Diazepam 5 mg PO QHS \n14. CefePIME 2 g IV Q12H \n15. Docusate Sodium 100 mg PO BID \n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \n17. Senna 8.6 mg PO BID:PRN constipation \n18. Rivaroxaban 20 mg PO DAILY \n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \nModerate \n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \n21. Vancomycin 750 mg IV Q 12H \n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \n23. Micafungin 100 mg IV Q24H",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 15,
        "tokenCount": 571,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:16",
      "text": "Discharge Medications:\n1. Acyclovir 400 mg PO Q8H \nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \n#*90 Tablet Refills:*0 \n2. Ciprofloxacin HCl 500 mg PO Q12H \nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \nDisp #*60 Tablet Refills:*0 \n3. Fluconazole 400 mg PO Q24H \nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \nTablet Refills:*0 \n4. Potassium Chloride 10 mEq PO DAILY  \n5. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \n6. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \n7. Ascorbic Acid ___ mg PO BID  \n8. Cyanocobalamin 1000 mcg PO QHS  \n9. Diazepam 5 mg PO QHS  \n10. Docusate Sodium 100 mg PO BID  \n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \ncongestion  \n12. FoLIC Acid 3.2 mg PO DAILY  \n13. Furosemide 20 mg PO DAILY  \n14. Gabapentin 900 mg PO TID  \n15. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \n16. Omeprazole 20 mg PO DAILY  \n17. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \nModerate  \n18. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \n19. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \n20. Senna 8.6 mg PO BID:PRN constipation  \n21. Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \n22. Venlafaxine 25 mg PO BID  \n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. Do not restart Rivaroxaban until checking with your oncologist \nor PCP, as your platelets are too low to take this now Discharge Disposition:\nHome With Service\n \nFacility:\n___ Discharge Diagnosis:\nPrimary: \nDiffuse large B-cell lymphoma\nMDS\n___ encephalopathy \n___ Secondary:\nHistory of cerebrovascular accident\nChronic venous stasis Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 16,
        "tokenCount": 442,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-18:17",
      "text": "Discharge Instructions:\nDear Ms. ___, You came to the hospital because you were confused and we were \nconcerned for infection. What happened in the hospital:\n- You had scans of your brain that did not show bleeding or \ninfection\n- You had an MRI of your spine that did not show evidence of \nbone infection, also called osteomyelitis\n- We added an antibiotic in the hospital to your home regimen of \nIV antibiotics \n- Your confusion cleared and you returned to your baseline \n- We found a bacteria in your urine that was not treated by the \nantibiotics you were on. However, bacteria can normally be in \nthe urine and we do not think this was the cause of your \nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. After you leave the hospital: \n- Attend your follow-up appointments \n- Take your medications as prescribed \n- Take your new medications, ciprofloxacin, acyclovir, and \nfluconazole (to prevent infections), until otherwise instructed \nby your oncologist It was a pleasure taking care of you. Sincerely, Your ___ Team\n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-18",
        "chart_time": "104518",
        "section": "General",
        "position": 17,
        "tokenCount": 294,
        "note_metadata": {
          "note_id": "18887130-DS-18",
          "subject_id": 18887130,
          "hadm_id": 23600251,
          "note_type": "DS",
          "note_seq": 18,
          "charttime": 104518,
          "storetime": 104518.7625,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nAltered mental status, chills\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone \r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby BCNU pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion, round to have rigors in the ED. \r\n\r\nOf note, patient was recently admitted to ___ service from\r\n___ to ___ after starting her first cycle of decitabine for\r\npersistent neutropenic fever, with no clear source identified.\r\nShe had negative cultures. Imaging with MRI revealed possible\r\nearly discitis and possible myositis of the psoas muscle. She\r\nunderwent psoas muscle biopsy and also had an ulcer on the L \r\nshin\r\nwhich was biopsied. Culture and infectious studies were all\r\nnegative. In addition, a universal PCR was sent which was\r\nnegative. Infectious Disease team consulted. She was treated\r\nultimately with 6week course of vancomycin/Cefepime/Micafungin\r\n(last day previously planned for ___ with empiric coverage\r\nfor osteomyelitis. She was seen yesterday in ___ clinic for\r\nfollow-up on ___ where she reported feeling well and was noted \r\nto\r\nbe _______alert and oriented. \r\n\r\nIn ER, endorses vomiting, anxiety and confusion. Does not feel\r\nfeverish and denies CP, SOB. She was noted to be AO-3 in ER. CTH\r\nshowed no acute intracranial process. CXR showed moderate\r\ncardiomegaly (unchanged) and mild Pulm vasc congestion.\r\nShe was treated with Vancomycin, cefepime and Micafungin and was\r\nadmitted to ___ service.\r\n\r\n  On floor, patient seen in distress from headaches and nausea.\r\nHeadache, \"not very severe, not ___ , more of a moderate pain\"\r\npresent on only R side of the head, unlike her previous migraine\r\nattacks. Denies neck stiffness, able to touch chin to chest\r\nwithout issues. No sick contacts. No fevers or rash suggestive \r\nof\r\nmeningococcal infection. She is nauseous and is seen moving\r\naround in be trying to find a comfortable position. \r\n\r\n She is able to provide good history but some slowing in her\r\nthought process seen, unsure if she is distracted from the pain\r\nand nausea but she stops sentences midway and needs prompting to\r\nfinish her sentences. She is AO-3. Clear thought content. Goal\r\ndirected behavior. Able to express herself well albeit above\r\nsymptoms. \r\n\r\n Temp yesterday per pt was 97 but she felt chills. No other\r\ndocumented high fevers. \r\n\r\nReview of Systems:  \r\n(+) Per HPI.\r\nPositive for fevers and chill. Positive for Nausea. Negative for\r\nneck stiffness, night sweats, headache, vision changes,\r\nrhinorrhea, congestion, sore throat, cough, shortness of breath,\r\nchest pain, abdominal pain, vomiting, diarrhea, constipation,\r\nBRBPR, melena, hematochezia, dysuria, hematuria. \r\n\r\n \r\nPast Medical History:\r\nOncologic history: In brief, history of follicular lymphoma \r\nstage IIIA s/p CHOP x 6 cycles in ___ followed by CVP and \r\nrituximab in ___ for residual disease. ___: RICE \r\nchemotherapy x 3 cycles. ___ autoBMT (BEAM). ___ XRT to \r\nlocal disease. She has a hx of hypogammaglobulinemia.\r\n\r\nOther PMH:\r\nobesity\r\nAcute DVT in the right popliteal/femoral veins + superficial \r\nthrombosis\r\n--Transformed DLBCL with history of follicular lymphoma as noted \r\nabove\r\n--CLL, noted on BM biopsy on ___.\r\n--Cerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\n--Hypogammaglobulinemia, receives IVIG PRN\r\n--R leg DVT.  IVC filter in place, on rivaroxaban\r\n--BCNU pneumonitis, on prednisone\r\n--Mild GERD\r\n--OA / LBP\r\n--Small Intestinal Bacterial Overgrowth\r\n--Trochanteric Bursitis\r\n--s/p Excisional Bx L Cervical Lymph Node\r\n--s/p L total knee replacement ___, walks with cane\r\n--s/p I&D Labial Abscess\r\n--s/p Excision Cyst R ___ Digit of Hand\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION EXAM\r\n===============\r\nVitals: 98.6 PO 144 / 90 87 22 97 RA \r\nGen: appears in distress, nauseous, moving around in bed seeking\r\na comfortable position\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.R eye\r\nsluggishly responds to light. L eye brisk, this anomaly is a old\r\nissue per patient.   \r\nNECK: No JVD.  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND. obese,   \r\nEXT: WWP. No ___ edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3.Normal finger to nose testing. Normal strength and\r\nsensation in all 4 extremities. DTR 2+ in patella b/L. Negative\r\nkernig's sign. \r\nLINES: L chest wall port.\r\n\r\nDISCHARGE EXAM\r\n==============\r\nVitals: 99.1 130 / 52 87 18 100 RA \r\nGeneral: Appears comfortable, upbeat, NAD\r\nHEENT: OP clear\r\nCV: RRR, no m/r/g\r\nPulm: CTAB, poor air movement in expiratory phase\r\nAbd: Obese, soft, NT, ND, NABS\r\nEXT: Large violaceous confluent patch on shins b/l, exquisitely \r\nTTP on ___ medical shin without induration or warmth; tense ___ b/l \r\nstable from prior  \r\nNeuro: A&Ox3 without word finding difficulty. \r\n \r\nPertinent Results:\r\nADMISSION:\r\n\r\n___ 12:05PM BLOOD WBC-0.6* RBC-2.77* Hgb-7.9* Hct-24.5* \r\nMCV-88 MCH-28.5 MCHC-32.2 RDW-14.2 RDWSD-45.2 Plt Ct-18*#\r\n___ 12:05PM BLOOD UreaN-17 Creat-0.7 Na-140 K-4.1 Cl-105 \r\nHCO3-26 AnGap-13\r\n___ 12:00AM BLOOD ALT-9 AST-13 AlkPhos-138* TotBili-0.7\r\n___ 12:05PM BLOOD Albumin-3.9 Calcium-8.6 Phos-2.1* Mg-2.2\r\n___ 12:00AM BLOOD TSH-2.3\r\n___ 12:00AM BLOOD IgG-960 IgA-89 IgM-29*\r\n___ 12:49PM BLOOD Lactate-1.6\r\n\r\nMICRO:\r\n\r\n   URINE CULTURE (Final ___: \r\n      ENTEROCOCCUS FAECIUM.    10,000-100,000 CFU/mL. \r\n         LINEZOLID sensitivity testing performed by ___. \r\n\r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             ENTEROCOCCUS FAECIUM\r\n                             |   \r\nAMPICILLIN------------  =>32 R\r\nLINEZOLID-------------       S\r\nNITROFURANTOIN--------   128 R\r\nTETRACYCLINE----------  =>16 R\r\nVANCOMYCIN------------  =>32 R\r\n\r\nIMAGING:\r\nEXAMINATION:  UNILAT LOWER EXT VEINS LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma but now with \r\nMDS; h/o R \r\nDVT off anticoagulation; anterior medial leg swelling near site \r\nof former \r\ntrauma  // r/o DVT; r/o drainable collection \r\n  \r\nTECHNIQUE:  Grey scale, color, and spectral Doppler evaluation \r\nwas performed \r\non the left lower extremity veins. \r\n  \r\nCOMPARISON:  Bilateral lower extremity venous duplex ultrasound \r\n___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is normal compressibility, flow, and augmentation of the \r\nleft common \r\nfemoral, femoral, and popliteal veins.  The posterior tibial and \r\nperoneal \r\nveins could not be visualized due to extensive soft tissue \r\nedema. \r\n  \r\nThere is normal respiratory variation in the common femoral \r\nveins bilaterally. \r\n  \r\nIMPRESSION:  \r\n  \r\nNo evidence of deep venous thrombosis in the left common \r\nfemoral, femoral, and \r\npopliteal veins. The posterior tibial and peroneal veins could \r\nnot be \r\nvisualized due to extensive soft tissue edema. \r\n  \r\nEXAMINATION:  US LOWER EXTREMITY, SOFT TISSUE LEFT \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ now with treatment MDS and spinal osteo \r\non \r\nantimicrobials.  She has h/o DVT and now with \r\nswelling/tenderness/erythema of \r\nL anterior/medial leg  // r/o drainable collection \r\n  \r\nTECHNIQUE:  Grayscale ultrasound images were obtained of the \r\nsuperficial \r\ntissues of the left calf in the area of the scab. \r\n  \r\nCOMPARISON:  None \r\n  \r\nFINDINGS:  \r\n  \r\nTransverse and sagittal images were obtained of the superficial \r\ntissues of the \r\nleft calf in the area of the scab.  Extensive soft tissue edema \r\nis seen.  \r\nThere is a 0.___alcification in the subcutaneous fat in \r\nthis region.  \r\nNo other masses are seen.  There is no abscess. \r\n  \r\nIMPRESSION:  \r\n  \r\nExtensive soft tissue edema in the left calf in the area of the \r\nscab.  No \r\ndrainable fluid collections are seen.  There is a 0.8 cm \r\ncalcification in the \r\nsubcutaneous fat in this region which most likely represents a \r\nphlebolith.  \r\nThis could be confirmed with x-ray. \r\n\r\nEXAMINATION:  CT HEAD W/O CONTRAST Q111 CT HEAD \r\n  \r\nINDICATION:  ___ with neutropenia, DLBCL, acute confusion, \r\nevaluate for mass \r\nor hemorrhage. \r\n  \r\nTECHNIQUE:  Contiguous axial images of the brain were obtained \r\nwithout \r\ncontrast. Coronal and sagittal reformations as well as bone \r\nalgorithm \r\nreconstructions were provided and reviewed. \r\n  \r\nDOSE:  Acquisition sequence: \r\n   1) Sequenced Acquisition 16.0 s, 16.4 cm; CTDIvol = 48.9 mGy \r\n(Head) DLP = \r\n802.7 mGy-cm. \r\n Total DLP (Head) = 803 mGy-cm. \r\n  \r\nCOMPARISON:  Prior head CT dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nMetallic streak artifact related to prior right supraclinoid ICA \r\nembolization \r\nlimits evaluation of the skullbase.  There is no evidence of \r\ninfarction, \r\nhemorrhage, edema, or mass.  There is prominence of the \r\nventricles and sulci \r\nsuggestive of involutional changes. \r\n  \r\nThere is no evidence of fracture.  The visualized portion of the \r\nparanasal \r\nsinuses, mastoid air cells, and middle ear cavities are clear.  \r\nThe visualized \r\nportion of the orbits are unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of acute intracranial process. \r\n2. Age related involutional changes. \r\n3. Mildly limited evaluation of the skullbase due to streak \r\nartifact from \r\nright supraclinoid ICA embolization. \r\n\r\nTECHNIQUE:  Chest PA and lateral \r\n  \r\nCOMPARISON:  Prior chest radiographs dated ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAn accessed left pectoral Port-A-Cath catheter tip terminates in \r\nthe mid SVC.  \r\nModerate cardiomegaly and mild pulmonary vascular congestion \r\nwithout frank \r\npulmonary edema is unchanged from the prior study.  There is no \r\npleural \r\neffusion, pneumothorax, or focal consolidation.  Irregularity of \r\nthe right \r\nupper chest wall is chronic and unchanged. \r\n  \r\nIMPRESSION:  \r\n  \r\nUnchanged moderate cardiomegaly and mild pulmonary vascular \r\ncongestion without \r\nfrank edema.  No consolidation. \r\n\r\nEXAMINATION:  MR HEAD W AND W/O CONTRAST T9112 MR HEAD \r\n  \r\nINDICATION:  ___ patient with myelodysplastic syndrome, \r\nlow platelets, \r\nright cerebellar aneurysm clipping in ___, presenting with \r\nheadaches and \r\nsepsis.  Evaluate for hemorrhage. \r\n  \r\nTECHNIQUE:  Sagittal and axial T1 weighted imaging were \r\nperformed. After \r\nadministration of 11 mL of Gadavist intravenous contrast, axial \r\nimaging was \r\nperformed with gradient echo, FLAIR, diffusion, and T1 \r\ntechnique. Sagittal \r\nMPRAGE imaging was performed and re-formatted in axial and \r\ncoronal \r\norientations. \r\n  \r\nCOMPARISON:  CT head ___ \r\n  \r\nFINDINGS:  \r\n  \r\nThere is no evidence of acute infarction, or intracranial \r\nhemorrhage.  The \r\nventricles are normal in size without mass effect or midline \r\nshift.  There is \r\nno abnormal enhancement, enhancing mass, or leptomeningeal \r\ndisease.  There is \r\nminimal nonspecific scattered foci of hyperintense T2/FLAIR \r\nsignal changes \r\nwithin the subcortical and periventricular white matter, which \r\nis likely a \r\nsequela of chronic small vessel microangiopathy.  The dural \r\nvenous sinuses \r\nappear patent on post-contrast MPRAGE images.  The paranasal \r\nsinuses appear \r\nclear.  The bilateral mastoid air cells appear unremarkable.  \r\nThe orbits and \r\nvisualized soft tissues appear unremarkable. \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. No evidence of intracranial hemorrhage, acute infarction, \r\nedema, or \r\nabnormal enhancement. \r\n\r\nEXAMINATION:  MR ___ AND W/O CONTRAST ___ MR SPINE \r\n  \r\nINDICATION:  ___ year old woman with transformed follicular \r\nlymphoma and h/o \r\nCLL s/p auto SCT in ___ in remission from lymphoma standpoint \r\nbut developed \r\ntreatment related MDS, receiving Dacogen who developed \r\nneutropenic fevers and \r\nMRI on ___ showed ? early discitis and L psoas abnormality \r\nnow 5 weeks \r\ninto antibiotics.  // Evaluate for the evolution of theL4-L5 \r\nprocess involving \r\nendplates and L psoas muscle  ___ year old woman with transformed \r\nfollicular \r\nlymphoma and h/o CLL s/p auto SCT in ___ in remission from \r\nlymphoma \r\nstandpoint but developed treatment related MDS, receiving \r\nDacogen who \r\ndeveloped neutropenic fevers and MRI on ___ showed ? early \r\ndiscitis and L \r\npsoas abnormality now 5 weeks into antibiotics.  // Evaluate for \r\nthe evolution \r\nof theL4-L5 process involving endplates and L psoas muscle   \r\nEvaluate for the \r\nevolution of theL4-L5 process involving endplates and L psoas \r\nmuscle \r\n  \r\nTECHNIQUE:  Sagittal imaging was performed with T2, T1, and STIR \r\ntechnique, \r\nfollowed by axial T2 imaging. This was followed by sagittal and \r\naxial T1 \r\nimages obtained after the uneventful intravenous administration \r\nof 11 mL of \r\nGadavist  contrast agent. \r\n  \r\nCOMPARISON:  Lumbar spine MR examinations ___ and ___.  \r\nCT abdomen and pelvis ___. \r\n  \r\nFINDINGS:  \r\n  \r\nAgain seen is scoliosis convex to the left in the upper lumbar \r\nspine and to \r\nthe right in the lower lumbar spine.  Again seen is anterior \r\nsubluxation of L5 \r\non S1.  Again seen is ___ type 1 signal intensity change at \r\nL2-3.  This \r\nincludes a low signal of the vertebral endplates on the T1 \r\nweighted images and \r\nhigh signal of these endplates on the STIR images.  This finding \r\nhas not \r\nchanged since ___. \r\n  \r\nNew since ___ but unchanged since ___ are \r\nsimilar changes \r\nat the L4-5 interspace.  There is low signal of the endplates on \r\nthe T1 \r\nweighted images and high signal on the STIR images.  All of the \r\nlumbar discs \r\nare hypointense on the T2 weighted and STIR images as are the \r\ndiscs at the T9 \r\nthrough T12 level.  These are further manifestations of \r\ndegenerative disc \r\ndisease.  The endplates at L2-3 and at L4-5 enhance after \r\ncontrast \r\nadministration.  This is typical ___ type 1 change.  The \r\nintervertebral \r\ndiscs themselves do not enhance after contrast administration. \r\n  \r\nAgain seen are hypointensities in the intervertebral discs at \r\nmultiple levels. \r\nCorrelation with the CT abdomen and pelvis of ___ \r\ndemonstrates \r\nthat at every level from L2 through S1 included a vacuum \r\nphenomenon in the \r\nintervertebral disc. \r\n  \r\nThere is no evidence of abnormal intraspinal \r\ncontrast-enhancement. \r\n  \r\nThe psoas and spinal erector muscles are asymmetric and \r\ndemonstrate fatty \r\natrophy bilaterally. These changes are likely a result of the \r\nscoliosis.  Much \r\nof the hyperintensity seen on the pre and postcontrast axial T1 \r\nweighted \r\nimages through the medial portion of the left psoas muscle at \r\nthe lower L4 \r\nlevel is due to the fatty atrophy, rather than enhancement.  It \r\nis unclear \r\nwhether there is any abnormal enhancement of the left psoas \r\nmuscle, if so, it \r\nis minimal. \r\n  \r\nHypointensity on the T1 weighted images with enhancement after \r\ncontrast \r\nadministration involves the left side of the superior portion of \r\nthe L5 \r\nvertebral body and extends through the pedicle into the facet \r\njoint.  This \r\ncorrelates with mild hyperintensity in these regions on the STIR \r\nimages.  \r\nThere is slight induration of the adjacent fat between the \r\nvertebral body and \r\nthe psoas muscle, best seen on image 30 of series 7 with \r\nenhancement seen on \r\nimage 30 of series 9.  These findings may represent further \r\ninflammatory \r\nchange due to degenerative disease, or a local focus of \r\ninfection.  Note that \r\nthis appearance is quite similar to that of the ___ \r\nstudy.  The CT \r\nscans through the left facet joint at this level consistently \r\ndemonstrated a \r\nvacuum phenomenon, arguing strongly against infection of the \r\njoint.  There is \r\nno evidence of bone destruction on the CT scans, which would be \r\nhighly unusual \r\nif there were chronic osteomyelitis extending as far back as \r\n___.  \r\nThere is similar mild enhancement posteriorly along the left \r\nlamina at this \r\nlevel.  Overall, these findings again are more likely due to \r\ninflammatory \r\ndegenerative disease than infection. \r\n  \r\nThe combination of vacuum phenomenon, low signal of the disc on \r\nthe T2 \r\nweighted images, ___ type 1 signal intensity changes of the \r\nendplates and \r\nstability over time all argue in favor of degenerative disc \r\ndisease as the \r\ncause of these changes.  This constellation of findings would be \r\nextremely \r\nunlikely in the setting of discitis. \r\n  \r\nThere is a mild bulge of the T11-12 disc with no encroachment on \r\nthe spinal \r\ncord or neural foramina. \r\n  \r\nAt T12-L1 there is no encroachment on the cord or foramina.  \r\nIncidentally \r\nnoted is an apparent right renal cyst, better evaluated on the \r\nrecent CT scan. \r\nThere is a small midline and right-sided protrusion of the \r\nintervertebral disc \r\nthat extends superiorly along the posterior margin of the L1 \r\nvertebral body.  \r\nThis does not contact the nerve roots.  The neural foramina \r\nappear normal. \r\n  \r\nAt L1-2 there is a small midline and right-sided disc protrusion \r\nthat \r\nencroaches on the thecal sac but does not contact the nerve \r\nroots.  This \r\nfragment extends superiorly along the posterior margin of the L1 \r\nbody.  The \r\nneural foramina appear normal. \r\n  \r\nAt L2-3, bulging of the disc and facet osteophytes produce \r\nencroachment on the \r\ntraversing L3 nerve roots bilaterally.  There is narrowing of \r\nthe right neural \r\nforamen due to facet osteophytes and intervertebral osteophytes. \r\n\r\n  \r\nAt L3-4, disc bulging and intervertebral osteophytes contact the \r\ntraversing \r\nright L4 nerve root.  The neural foramina are moderately \r\nnarrowed bilaterally. \r\n  \r\nAt L4-5, there is disc bulging but no evidence of nerve root \r\ncompression \r\nwithin the spinal canal.  There are prominent facet osteophytes \r\nbilaterally \r\nthe produce severe left and moderate right \r\n  \r\nAt L5-S1, there is elongation of the spinal canal due to the \r\nsubluxation of L5 \r\non S1.  There are prominent facet osteophytes bilaterally.  The \r\ncombination of \r\nthese factors and loss of height of the intervertebral disc as \r\nwell as disc \r\nbulging produces moderate -severe narrowing of the neural \r\nforamina \r\nbilaterally. \r\n  \r\n  \r\nIMPRESSION: \r\n  \r\n  \r\n1. As discussed above, the vertebral, intervertebral disc, facet \r\nand left \r\npsoas muscle findings are likely due to a combination of \r\nscoliosis and chronic \r\ndegenerative disc disease, likely with inflammation on this \r\nbasis. \r\n2. The minimal change over time, vacuum phenomenon in the \r\nintervertebral discs \r\nand facet joints, absence of bone destruction and pattern of \r\nsignal intensity \r\nabnormalities argue against infection as the etiology. \r\n3. Degenerative disc disease produces mild encroachment on \r\nseveral nerve roots \r\nand more severe narrowing of the neural foramina at several \r\nlevels. \r\n\r\nEXAMINATION:  TIB/FIB (AP AND LAT) LEFT \r\n  \r\nINDICATION:  ___ year old woman with LLE edema, phlebolith seen \r\non US  // \r\nphlebolith seen on US? \r\n  \r\nTECHNIQUE:  Left tibia, fibula two views \r\n  \r\nCOMPARISON:  Ultrasound lower extremity ___ \r\n  \r\nFINDINGS:  \r\n  \r\nLeft knee arthroplasty.  There are few benign rounded \r\ncalcifications in the \r\nanterior pretibial soft tissues, likely represent phleboliths.  \r\nThere is no \r\nsoft tissue swelling.  Surgical clips in the soft tissues.  \r\nCalcaneal Achilles \r\nbone spur.  Degenerative changes in the midfoot.  Radiopaque \r\ndensity projected \r\nover proximal leg, just below medial ___ be external to \r\nthe patient. \r\n  \r\nIMPRESSION:  \r\n  \r\nFew rounded calcifications in pretibial soft tissues, likely \r\nrepresent \r\nphleboliths. \r\n\r\nDISCHARGE:\r\n\r\n___ 12:25AM BLOOD WBC-0.6* RBC-2.74* Hgb-7.8* Hct-24.4* \r\nMCV-89 MCH-28.5 MCHC-32.0 RDW-14.1 RDWSD-44.7 Plt Ct-13*\r\n___ 12:25AM BLOOD Neuts-5* Bands-0 Lymphs-94* Monos-0 Eos-0 \r\nBaso-1 ___ Myelos-0 AbsNeut-0.03* AbsLymp-0.56* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.01\r\n___ 12:25AM BLOOD Glucose-115* UreaN-12 Creat-0.9 Na-139 \r\nK-3.8 Cl-103 HCO3-22 AnGap-18\r\n___ 12:25AM BLOOD ALT-12 AST-15 LD(LDH)-169 AlkPhos-174* \r\nTotBili-0.3\r\n___ 12:25AM BLOOD Albumin-4.1 Calcium-8.4 Phos-2.9 Mg-2.___ year old female with history of transformed diffuse large B \r\ncell lymphoma s/p a curative attempt with an auto SCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS on BM biopsy performed on ___. She is\r\ncurrently on C2D12 of treatment with decitabine and presents \r\nwith\r\none day of confusion and chills. Neutropenic and afebrile with \r\nno infectious source identified, improved rapidly to baseline on \r\n___ and IV antibiotics were deescalated. \r\n\r\n#Altered mental status: Presented with word finding difficulty \r\nand generalized malaise with decreased PO intake, without true \r\nglobal sensorium deficit. 1 month prior during hospitalization \r\nhad been diagnosed with presumed osteomyelitis though imaging \r\nwas equivocal, and started on 1 month broad spectrum ABX course. \r\nOn this admission, ___ c/f meningitis, cefepime was increased to \r\nmeningitis dosing and ampicillin was added. Her home vanc and \r\nmica were continued. On ___ ___ the patient rapidly improved and \r\nmental status and symptoms were back to her baseline. Urine \r\nculture drawn in the ED (taken in bed-pan, not sterile) grew \r\nEnteroccus faecium pan-resistant, including ampicillin and \r\nvancomycin. The organism was not sensitive to any of the \r\nantibiotics that she was on, thus the organism was not treated, \r\nhowever she improved to baseline as above. Thus the UTI was \r\nlikely not the source of her AMS. In this light, she was not \r\nsent out on further antibiotics, but was counseled to return to \r\nthe hospital if she developed urinary symptoms or more \r\nconfusion. The true etiology is unclear. It may have been a \r\nviral infection or possibly cerebral hypoperfusion in the \r\nsetting of vascular pathology (h/o aneurysms). \r\n\r\n#UTI: see above for urine culture growing Enterococcus faecium. \r\n\r\n#LLE edema: Had a history of DVTs and was previously on \r\nrivaroxaban but this had been held for some time ___ \r\nthrombocytopenia. She has an IVC filter in place. Rivaroxaban \r\nwas not restarted ___ thrombocytopenia. Held on discharge. \r\n\r\n#?Nocardia skin rash: Had area of tenderness at site chronic \r\nvenous stasis dermatitis, previously biopsied by not sent for \r\nAFB/nocardia. When patient had AMS, nocardia was thought to be \r\npossible explanation with skin finding and AMS. Biopsy was \r\ndeferred in-house since patient resolved to baseline. Consider \r\nbiopsy if symptoms return. \r\n\r\n#Neutropenia: Started on PO cipro and fluconazole once IV abx \r\nwere discharged as above. Discharged on cipro and fluc. qTC on \r\ndischarge was 431ms. \r\n\r\nTRANISTION ISSUES\r\n=================\r\n[]acyclovir not seen as a previous home med, was started on \r\nacyclovir for ppx on discharge \r\n[]discharged on PO fluconazole and cipro ongoing for ppx\r\n[]consider biopsy of L medial shin and sending for AFB/nocardia \r\n\r\n# CODE: Confirmed Full\r\n# EMERGENCY CONTACT: ___ (husband) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 900 mg PO TID \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Potassium Chloride 10 mEq PO DAILY \r\n9. Venlafaxine 25 mg PO BID \r\n10. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Furosemide 20 mg PO DAILY \r\n13. Diazepam 5 mg PO QHS \r\n14. CefePIME 2 g IV Q12H \r\n15. Docusate Sodium 100 mg PO BID \r\n16. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n17. Senna 8.6 mg PO BID:PRN constipation \r\n18. Rivaroxaban 20 mg PO DAILY \r\n19. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n20. OxyCODONE SR (OxyconTIN) 20 mg PO Q12H \r\n21. Vancomycin 750 mg IV Q 12H \r\n22. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n23. Micafungin 100 mg IV Q24H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H \r\nRX *acyclovir 400 mg 1 tablet(s) by mouth three times a day Disp \r\n#*90 Tablet Refills:*0 \r\n2.  Ciprofloxacin HCl 500 mg PO Q12H \r\nRX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day \r\nDisp #*60 Tablet Refills:*0 \r\n3.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n4.  Potassium Chloride 10 mEq PO DAILY  \r\n5.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n6.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n7.  Ascorbic Acid ___ mg PO BID  \r\n8.  Cyanocobalamin 1000 mcg PO QHS  \r\n9.  Diazepam 5 mg PO QHS  \r\n10.  Docusate Sodium 100 mg PO BID  \r\n11.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n12.  FoLIC Acid 3.2 mg PO DAILY  \r\n13.  Furosemide 20 mg PO DAILY  \r\n14.  Gabapentin 900 mg PO TID  \r\n15.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate  \r\n18.  OxyCODONE SR (OxyconTIN) 20 mg PO Q12H  \r\n19.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n20.  Senna 8.6 mg PO BID:PRN constipation  \r\n21.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n22.  Venlafaxine 25 mg PO BID  \r\n23. HELD- Rivaroxaban 20 mg PO DAILY  This medication was held. \r\nDo not restart Rivaroxaban until checking with your oncologist \r\nor PCP, as your platelets are too low to take this now\r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nDiffuse large B-cell lymphoma\r\nMDS\r\n___ encephalopathy \r\n___ \r\n\r\nSecondary:\r\nHistory of cerebrovascular accident\r\nChronic venous stasis \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou came to the hospital because you were confused and we were \r\nconcerned for infection. \r\n\r\nWhat happened in the hospital:\r\n- You had scans of your brain that did not show bleeding or \r\ninfection\r\n- You had an MRI of your spine that did not show evidence of \r\nbone infection, also called osteomyelitis\r\n- We added an antibiotic in the hospital to your home regimen of \r\nIV antibiotics \r\n- Your confusion cleared and you returned to your baseline \r\n- We found a bacteria in your urine that was not treated by the \r\nantibiotics you were on. However, bacteria can normally be in \r\nthe urine and we do not think this was the cause of your \r\nconfusion or chills. IF YOU DO HAVE PAIN WITH URINATION OR \r\nINCREASED URINARY FREQUENCY, OR IF YOU BECOME CONFUSED AGAIN, \r\nCOME BACK TO THE HOSPITAL AND CALL YOUR DOCTOR. \r\n\r\nAfter you leave the hospital: \r\n- Attend your follow-up appointments \r\n- Take your medications as prescribed \r\n- Take your new medications, ciprofloxacin, acyclovir, and \r\nfluconazole (to prevent infections), until otherwise instructed \r\nby your oncologist\r\n\r\nIt was a pleasure taking care of you. \r\n\r\nSincerely,\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-19:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \ndapsone\n \nAttending: ___ Chief Complaint:\nfebrile neutropenia\n \nMajor Surgical or Invasive Procedure:\nLumbar puncture",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-19",
        "chart_time": "104548",
        "section": "General",
        "position": 0,
        "tokenCount": 74,
        "note_metadata": {
          "note_id": "18887130-DS-19",
          "subject_id": 18887130,
          "hadm_id": 28046425,
          "note_type": "DS",
          "note_seq": 19,
          "charttime": 104548,
          "storetime": 104566.79166666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nfebrile neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture \r\n \r\nHistory of Present Illness:\r\n___ year old female DLBLC,  history of transformed diffuse large \r\nB\r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS now on decitabine, with neutropenia and ~4\r\nweeks broad spectrum antibiotics for empiric L4-5\r\ndiscitis/osteomyelitis, readmitted mid ___ for acute history of\r\nword finding difficulty and nausea vomiting without apparent\r\nsource, now presenting with 2 days of nausea/vomiting, fever, \r\nand\r\nurinary incontinence.\r\n\r\nNote her recent admit ___ she was recently admitted with\r\nmental status changes and vague confusion/word finding \r\ndifficulty\r\nand nausea/vomiting. She had been seen by ID ___ with concern \r\nfor\r\ninfection vs DVT of LLE where she has a slow healing wound, but\r\nultrasound was reassuring, but on the way home from appointment\r\nshe vomited and had chills, but no fevers She did have\r\nenterococcus UTI on admission, which didn't seem to be true UTI\r\nor explain her focal neurologic deficits, especially as she had\r\nbeen on vancomycin, but given low risks she did complete 5d\r\ncourse of amp/amox. On discharge she was continued on ppx cipro\r\nand fluc.\r\n\r\nShe was next and last seen by ___ on ___ at which point she was\r\nC2D22 dacogen. plan for dacogen ___ next at ___.  Mental\r\nstatus had resolved. Her ANC was 0 at time of that visit. \r\n\r\nShe reports feeling fairly well until ___ night when she \r\nbegan\r\ndeveloping extreme fatigue and generalized weakness. Also had 1x\r\nepisode where she suddenly had to urinate and was incontinent of\r\nurine. This happened again yesterday. No dysuria. No back pain,\r\nno headaches, visual changes, and no one extremity has been\r\nparticularly weak compared to the rest of her body ( endorses \r\nleg\r\nweakness but in line with generalized body weakness). She also\r\nhas been vomiting when she tries to eat for the past 48 hrs and\r\nhas no appetite but denies any melena, diarrhea, abd pain, and\r\nhad regular formed BM today and continues passing gas. Is \r\nburping\r\nmore than usual however. NO chest pain, dyspnea, cough, sore\r\nthroat, runny nose, or rash. All other 10 point ROS neg.\r\n\r\nED COURSE:\r\nT 100.2 up to 101.4  HR 110 BP 148/58  RR 18  94% RA. Pt \r\nreceived\r\nlinezolid, zosyn, IV APAP, multiple liters of LR. Labs with\r\nlactate 1.1, \r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission Physical Exam\r\nVITAL SIGNS: 98.0  109/68  83  18  97%RA\r\nGeneral:  NAD but weak, seems to have some mild dyspnea but\r\nstates this is baseline and denies SOB\r\nHEENT:  MMM, no OP lesions, no cervical, supraclavicular, or\r\naxillary adenopathy, no thyromegaly\r\nCV:  RR, NL S1S2 no S3S4 MRG\r\nPULM:  CTAB\r\nGI:  protuberant abd but BS+, soft, NTND, no masses or\r\nhepatosplenomegaly\r\nLIMBSSKIN:  ___ with mild trace pitting edema up to knees, well\r\nhealing ulceration over anterior shins and no skin breakdown\r\notherwise no erythema/rashes. port without erythema/drainage\r\nNEURO: generally weak and fatigued but conversant, alert,\r\nOriented x3. Cranial nerves II-XII are within normal limits\r\nexcluding visual acuity which was not assessed, no nystagmus;\r\nstrength is ___ of the proximal and distal upper and lower\r\nextremities but symmetric on both sides. no tremor/ asterixis.\r\nNeck supple.\r\n\r\nDischarge Physical Exam\r\nVS: 98.0 119/75 87 18 97 RA  \r\nGeneral: sitting comfortably in recliner eating breakfast, NAD.\r\nHEENT: moist mucus membranes, no OP lesions. Right pupil fixed\r\nand right eye with gaze palsy \r\nCV: RRR, ___ systolic murmur at LLSB. \r\nPULM: CTAB, no crackles, wheeze, rhonchi \r\nGI: Soft, NT, ND, +BS. \r\nEXT: ___ with trace edema bilat, right leg slightly larger than\r\nleft with well healed ulceration over anterior right shin and no\r\nskin breakdown.  \r\nSKIN: No new rashes or lesions. Chronic venous stasis changes\r\nbilat c/w lipodermatosclerosis\r\nNEURO: A&Ox3. Chronic and stable R sided facial droop and \r\nptosis.\r\n\r\n \r\nPertinent Results:\r\nAdmission Labs\r\n___ 04:45PM BLOOD WBC-0.3* RBC-2.83* Hgb-8.4* Hct-26.0* \r\nMCV-92 MCH-29.7 MCHC-32.3 RDW-16.3* RDWSD-46.7* Plt Ct-74*\r\n___ 04:45PM BLOOD Neuts-8* Bands-0 Lymphs-86* Monos-6 Eos-0 \r\nBaso-0 ___ Myelos-0 AbsNeut-0.02* AbsLymp-0.26* \r\nAbsMono-0.02* AbsEos-0.00* AbsBaso-0.00*\r\n___ 04:45PM BLOOD Glucose-123* UreaN-14 Creat-0.9 Na-137 \r\nK-4.2 Cl-103 HCO3-21* AnGap-17\r\n___ 04:45PM BLOOD ALT-9 AST-14 AlkPhos-135* TotBili-0.3\r\n___ 04:45PM BLOOD Albumin-3.9\r\n___ 05:01PM BLOOD Lactate-1.1\r\n___ 05:37PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 05:37PM URINE Blood-SM  Nitrite-NEG Protein-600 \r\nGlucose-NEG Ketone-10 Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\r\n___ 05:37PM URINE RBC-3* WBC-1 Bacteri-FEW Yeast-NONE \r\nEpi-<1\r\n___ 05:37PM URINE Mucous-RARE\r\n___ 05:37PM URINE CastHy-3*\r\n___ 05:56PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nDischarge Labs\r\n___ 12:02AM BLOOD WBC-2.9* RBC-2.80* Hgb-8.4* Hct-26.6* \r\nMCV-95 MCH-30.0 MCHC-31.6* RDW-17.4* RDWSD-51.3* Plt Ct-83*\r\n___ 12:02AM BLOOD Neuts-58.2 ___ Monos-8.9 Eos-0.0* \r\nBaso-0.3 NRBC-1.0* Im ___ AbsNeut-1.70 AbsLymp-0.91* \r\nAbsMono-0.26 AbsEos-0.00* AbsBaso-0.01\r\n___ 12:02AM BLOOD ___ PTT-40.8* ___\r\n___ 12:02AM BLOOD  WBC-2.9* Lymph-31 Abs ___ CD3%-70 \r\nAbs CD3-627 CD4%-42 Abs CD4-382 CD8%-26 Abs CD8-236 CD4/CD8-1.62\r\n___ 12:02AM BLOOD Glucose-118* UreaN-12 Creat-0.9 Na-139 \r\nK-4.2 Cl-102 HCO3-23 AnGap-18\r\n___ 12:02AM BLOOD Albumin-3.5 Calcium-8.3* Phos-2.6* Mg-2.1\r\n\r\nMicrobiology: Extensive workup including numerous blood \r\ncultures, spinal tap,  negative except for corona virus on \r\nextended respiratory multiplex panel. Please see OMR for \r\ndetails.\r\n\r\nImaging: All imaging consistent with priors. No signs of \r\ninfection. Performed Ultrasounds BLE negative, Brain/Spine MRI, \r\nCXR, RUE ultrasound.\r\n\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\ndiffuse large B cell lymphoma s/p a curative attempt with an \r\nautoSCT with BEAM conditioning in ___ ___s IFRT with \r\ncourse complicated by ___ pneumonitis, who was subsequently \r\nfound to have treatment-related MDS now on decitabine, with \r\nneutropenia and 6 weeks broad spectrum antibiotics for empiric \r\nL4-5 discitis/osteomyelitis, readmitted mid ___ for acute \r\nhistory of word finding difficulty and nausea vomiting without \r\napparent source, presenting with 2 days of nausea/vomiting, \r\nfever, and\r\nurinary incontinence. Incredibly extensive infectious workup \r\nnegative and fevers now resolved after almost two weeks on broad \r\nspectrum antibiotics.\r\n\r\n# Pancytopenia/MDS - per outpt decision made to treat with \r\nDacogen with plan to move towards allogeneic transplant. Was due \r\nfor decitabine ___. Extensive infectious workup and ultimately \r\nstarted Decitabine ___ and completed cycle in the hospital \r\nwithout further incident.\r\n\r\n#Elevated liver enzyemes: Unclear cause, but may be related to \r\nposaconazole level of ___. Posaconazole held starting ___ \r\nenzymes trending down. Plan to restart as outpatient.\r\n\r\n#Neutropenic fever: Resolving after several weeks of workup with \r\nno clear correlation to particular treatment or any source \r\nidentified. Did have positive coronavirus on multiplex pcr. \r\n\r\n#Lower back pain: continued gabapentin\r\n\r\n#Hx of right leg DVT:  Was on Xarelto 20 mg daily but now on \r\nhold with low platelet count.  Has IVC filter in place.  Will \r\ncontinue to hold for platelet count < 75,000. No anticoagulation\r\n\r\n#Depression: Continue home venlafaxine\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Docusate Sodium 100 mg PO BID \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 900 mg PO TID \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Omeprazole 20 mg PO DAILY \r\n9. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n  Reason for PRN duplicate override: changing dose\r\n10. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n11. Potassium Chloride 10 mEq PO DAILY \r\n12. Senna 8.6 mg PO BID:PRN constipation \r\n13. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n14. Venlafaxine 25 mg PO BID \r\n15. Ciprofloxacin HCl 500 mg PO Q12H \r\n16. Fluconazole 400 mg PO Q24H \r\n17. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n18. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n19. Diazepam 5 mg PO QHS \r\n20. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n21. Rivaroxaban 20 mg PO DAILY \r\n22. Acyclovir 400 mg PO Q8H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  Ascorbic Acid ___ mg PO BID  \r\n5.  Cyanocobalamin 1000 mcg PO QHS  \r\n6.  Diazepam 5 mg PO QHS  \r\n7.  Docusate Sodium 100 mg PO BID  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n9.  FoLIC Acid 3.2 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14.  Rivaroxaban 20 mg PO DAILY  \r\n15.  Senna 8.6 mg PO BID:PRN constipation  \r\n16.  Venlafaxine 25 mg PO BID  \r\n17. HELD- Fluconazole 400 mg PO Q24H  This medication was held. \r\nDo not restart Fluconazole until you are directed to. \r\n18. HELD- Furosemide 20 mg PO DAILY  This medication was held. \r\nDo not restart Furosemide until you are directed to by your \r\noutpatient oncologist. \r\n19. HELD- Potassium Chloride 10 mEq PO DAILY  This medication \r\nwas held. Do not restart Potassium Chloride until you speak with \r\nyour doctor. \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nMyelodysplastic syndrome\r\nNeutropenic fever \r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted to ___ for fever, nausea, and vomiting. We \r\ndid several tests to identify the cause of these symptoms but \r\nwere unable to find a source of infection. You were treated with \r\na strong antibiotic and you improved. \r\n\r\nWe also gave you a cycle of chemotherapy, which you tolerated \r\nwell. \r\n\r\nThere have been some changes to your medications which are \r\noutlined below. \r\n\r\nYou will have follow-up with Dr. ___ week. You will be \r\ncontacted with the specific day and time. \r\n\r\nPlease contact Dr. ___ if you have any questions or \r\nconcerns. Someone is available to help at any time, day or \r\nnight. \r\n\r\nIt was a pleasure taking care of you and we wish you the best, \r\nThe ___ Care Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-19:1",
      "text": "History of Present Illness:\n___ year old female DLBLC,  history of transformed diffuse large \nB\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \nconditioning in ___ ___s IFRT with course complicated \nby ___ pneumonitis, who was subsequently found to have\ntreatment-related MDS now on decitabine, with neutropenia and ~4\nweeks broad spectrum antibiotics for empiric L4-5\ndiscitis/osteomyelitis, readmitted mid ___ for acute history of\nword finding difficulty and nausea vomiting without apparent\nsource, now presenting with 2 days of nausea/vomiting, fever, \nand\nurinary incontinence. Note her recent admit ___ she was recently admitted with\nmental status changes and vague confusion/word finding \ndifficulty\nand nausea/vomiting. She had been seen by ID ___ with concern \nfor\ninfection vs DVT of LLE where she has a slow healing wound, but\nultrasound was reassuring, but on the way home from appointment\nshe vomited and had chills, but no fevers She did have\nenterococcus UTI on admission, which didn't seem to be true UTI\nor explain her focal neurologic deficits, especially as she had\nbeen on vancomycin, but given low risks she did complete 5d\ncourse of amp/amox. On discharge she was continued on ppx cipro\nand fluc. She was next and last seen by ___ on ___ at which point she was\nC2D22 dacogen. plan for dacogen ___ next at ___. Mental\nstatus had resolved. Her ANC was 0 at time of that visit. She reports feeling fairly well until ___ night when she \nbegan\ndeveloping extreme fatigue and generalized weakness. Also had 1x\nepisode where she suddenly had to urinate and was incontinent of\nurine. This happened again yesterday. No dysuria. No back pain,\nno headaches, visual changes, and no one extremity has been\nparticularly weak compared to the rest of her body ( endorses \nleg\nweakness but in line with generalized body weakness). She also\nhas been vomiting when she tries to eat for the past 48 hrs and\nhas no appetite but denies any melena, diarrhea, abd pain, and\nhad regular formed BM today and continues passing gas. Is \nburping\nmore than usual however. NO chest pain, dyspnea, cough, sore\nthroat, runny nose, or rash. All other 10 point ROS neg. ED COURSE:\nT 100.2 up to 101.4  HR 110 BP 148/58  RR 18  94% RA. Pt \nreceived\nlinezolid, zosyn, IV APAP, multiple liters of LR. Labs with\nlactate 1.1,",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-19",
        "chart_time": "104548",
        "section": "General",
        "position": 1,
        "tokenCount": 581,
        "note_metadata": {
          "note_id": "18887130-DS-19",
          "subject_id": 18887130,
          "hadm_id": 28046425,
          "note_type": "DS",
          "note_seq": 19,
          "charttime": 104548,
          "storetime": 104566.79166666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nfebrile neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture \r\n \r\nHistory of Present Illness:\r\n___ year old female DLBLC,  history of transformed diffuse large \r\nB\r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS now on decitabine, with neutropenia and ~4\r\nweeks broad spectrum antibiotics for empiric L4-5\r\ndiscitis/osteomyelitis, readmitted mid ___ for acute history of\r\nword finding difficulty and nausea vomiting without apparent\r\nsource, now presenting with 2 days of nausea/vomiting, fever, \r\nand\r\nurinary incontinence.\r\n\r\nNote her recent admit ___ she was recently admitted with\r\nmental status changes and vague confusion/word finding \r\ndifficulty\r\nand nausea/vomiting. She had been seen by ID ___ with concern \r\nfor\r\ninfection vs DVT of LLE where she has a slow healing wound, but\r\nultrasound was reassuring, but on the way home from appointment\r\nshe vomited and had chills, but no fevers She did have\r\nenterococcus UTI on admission, which didn't seem to be true UTI\r\nor explain her focal neurologic deficits, especially as she had\r\nbeen on vancomycin, but given low risks she did complete 5d\r\ncourse of amp/amox. On discharge she was continued on ppx cipro\r\nand fluc.\r\n\r\nShe was next and last seen by ___ on ___ at which point she was\r\nC2D22 dacogen. plan for dacogen ___ next at ___.  Mental\r\nstatus had resolved. Her ANC was 0 at time of that visit. \r\n\r\nShe reports feeling fairly well until ___ night when she \r\nbegan\r\ndeveloping extreme fatigue and generalized weakness. Also had 1x\r\nepisode where she suddenly had to urinate and was incontinent of\r\nurine. This happened again yesterday. No dysuria. No back pain,\r\nno headaches, visual changes, and no one extremity has been\r\nparticularly weak compared to the rest of her body ( endorses \r\nleg\r\nweakness but in line with generalized body weakness). She also\r\nhas been vomiting when she tries to eat for the past 48 hrs and\r\nhas no appetite but denies any melena, diarrhea, abd pain, and\r\nhad regular formed BM today and continues passing gas. Is \r\nburping\r\nmore than usual however. NO chest pain, dyspnea, cough, sore\r\nthroat, runny nose, or rash. All other 10 point ROS neg.\r\n\r\nED COURSE:\r\nT 100.2 up to 101.4  HR 110 BP 148/58  RR 18  94% RA. Pt \r\nreceived\r\nlinezolid, zosyn, IV APAP, multiple liters of LR. Labs with\r\nlactate 1.1, \r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission Physical Exam\r\nVITAL SIGNS: 98.0  109/68  83  18  97%RA\r\nGeneral:  NAD but weak, seems to have some mild dyspnea but\r\nstates this is baseline and denies SOB\r\nHEENT:  MMM, no OP lesions, no cervical, supraclavicular, or\r\naxillary adenopathy, no thyromegaly\r\nCV:  RR, NL S1S2 no S3S4 MRG\r\nPULM:  CTAB\r\nGI:  protuberant abd but BS+, soft, NTND, no masses or\r\nhepatosplenomegaly\r\nLIMBSSKIN:  ___ with mild trace pitting edema up to knees, well\r\nhealing ulceration over anterior shins and no skin breakdown\r\notherwise no erythema/rashes. port without erythema/drainage\r\nNEURO: generally weak and fatigued but conversant, alert,\r\nOriented x3. Cranial nerves II-XII are within normal limits\r\nexcluding visual acuity which was not assessed, no nystagmus;\r\nstrength is ___ of the proximal and distal upper and lower\r\nextremities but symmetric on both sides. no tremor/ asterixis.\r\nNeck supple.\r\n\r\nDischarge Physical Exam\r\nVS: 98.0 119/75 87 18 97 RA  \r\nGeneral: sitting comfortably in recliner eating breakfast, NAD.\r\nHEENT: moist mucus membranes, no OP lesions. Right pupil fixed\r\nand right eye with gaze palsy \r\nCV: RRR, ___ systolic murmur at LLSB. \r\nPULM: CTAB, no crackles, wheeze, rhonchi \r\nGI: Soft, NT, ND, +BS. \r\nEXT: ___ with trace edema bilat, right leg slightly larger than\r\nleft with well healed ulceration over anterior right shin and no\r\nskin breakdown.  \r\nSKIN: No new rashes or lesions. Chronic venous stasis changes\r\nbilat c/w lipodermatosclerosis\r\nNEURO: A&Ox3. Chronic and stable R sided facial droop and \r\nptosis.\r\n\r\n \r\nPertinent Results:\r\nAdmission Labs\r\n___ 04:45PM BLOOD WBC-0.3* RBC-2.83* Hgb-8.4* Hct-26.0* \r\nMCV-92 MCH-29.7 MCHC-32.3 RDW-16.3* RDWSD-46.7* Plt Ct-74*\r\n___ 04:45PM BLOOD Neuts-8* Bands-0 Lymphs-86* Monos-6 Eos-0 \r\nBaso-0 ___ Myelos-0 AbsNeut-0.02* AbsLymp-0.26* \r\nAbsMono-0.02* AbsEos-0.00* AbsBaso-0.00*\r\n___ 04:45PM BLOOD Glucose-123* UreaN-14 Creat-0.9 Na-137 \r\nK-4.2 Cl-103 HCO3-21* AnGap-17\r\n___ 04:45PM BLOOD ALT-9 AST-14 AlkPhos-135* TotBili-0.3\r\n___ 04:45PM BLOOD Albumin-3.9\r\n___ 05:01PM BLOOD Lactate-1.1\r\n___ 05:37PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 05:37PM URINE Blood-SM  Nitrite-NEG Protein-600 \r\nGlucose-NEG Ketone-10 Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\r\n___ 05:37PM URINE RBC-3* WBC-1 Bacteri-FEW Yeast-NONE \r\nEpi-<1\r\n___ 05:37PM URINE Mucous-RARE\r\n___ 05:37PM URINE CastHy-3*\r\n___ 05:56PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nDischarge Labs\r\n___ 12:02AM BLOOD WBC-2.9* RBC-2.80* Hgb-8.4* Hct-26.6* \r\nMCV-95 MCH-30.0 MCHC-31.6* RDW-17.4* RDWSD-51.3* Plt Ct-83*\r\n___ 12:02AM BLOOD Neuts-58.2 ___ Monos-8.9 Eos-0.0* \r\nBaso-0.3 NRBC-1.0* Im ___ AbsNeut-1.70 AbsLymp-0.91* \r\nAbsMono-0.26 AbsEos-0.00* AbsBaso-0.01\r\n___ 12:02AM BLOOD ___ PTT-40.8* ___\r\n___ 12:02AM BLOOD  WBC-2.9* Lymph-31 Abs ___ CD3%-70 \r\nAbs CD3-627 CD4%-42 Abs CD4-382 CD8%-26 Abs CD8-236 CD4/CD8-1.62\r\n___ 12:02AM BLOOD Glucose-118* UreaN-12 Creat-0.9 Na-139 \r\nK-4.2 Cl-102 HCO3-23 AnGap-18\r\n___ 12:02AM BLOOD Albumin-3.5 Calcium-8.3* Phos-2.6* Mg-2.1\r\n\r\nMicrobiology: Extensive workup including numerous blood \r\ncultures, spinal tap,  negative except for corona virus on \r\nextended respiratory multiplex panel. Please see OMR for \r\ndetails.\r\n\r\nImaging: All imaging consistent with priors. No signs of \r\ninfection. Performed Ultrasounds BLE negative, Brain/Spine MRI, \r\nCXR, RUE ultrasound.\r\n\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\ndiffuse large B cell lymphoma s/p a curative attempt with an \r\nautoSCT with BEAM conditioning in ___ ___s IFRT with \r\ncourse complicated by ___ pneumonitis, who was subsequently \r\nfound to have treatment-related MDS now on decitabine, with \r\nneutropenia and 6 weeks broad spectrum antibiotics for empiric \r\nL4-5 discitis/osteomyelitis, readmitted mid ___ for acute \r\nhistory of word finding difficulty and nausea vomiting without \r\napparent source, presenting with 2 days of nausea/vomiting, \r\nfever, and\r\nurinary incontinence. Incredibly extensive infectious workup \r\nnegative and fevers now resolved after almost two weeks on broad \r\nspectrum antibiotics.\r\n\r\n# Pancytopenia/MDS - per outpt decision made to treat with \r\nDacogen with plan to move towards allogeneic transplant. Was due \r\nfor decitabine ___. Extensive infectious workup and ultimately \r\nstarted Decitabine ___ and completed cycle in the hospital \r\nwithout further incident.\r\n\r\n#Elevated liver enzyemes: Unclear cause, but may be related to \r\nposaconazole level of ___. Posaconazole held starting ___ \r\nenzymes trending down. Plan to restart as outpatient.\r\n\r\n#Neutropenic fever: Resolving after several weeks of workup with \r\nno clear correlation to particular treatment or any source \r\nidentified. Did have positive coronavirus on multiplex pcr. \r\n\r\n#Lower back pain: continued gabapentin\r\n\r\n#Hx of right leg DVT:  Was on Xarelto 20 mg daily but now on \r\nhold with low platelet count.  Has IVC filter in place.  Will \r\ncontinue to hold for platelet count < 75,000. No anticoagulation\r\n\r\n#Depression: Continue home venlafaxine\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Docusate Sodium 100 mg PO BID \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 900 mg PO TID \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Omeprazole 20 mg PO DAILY \r\n9. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n  Reason for PRN duplicate override: changing dose\r\n10. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n11. Potassium Chloride 10 mEq PO DAILY \r\n12. Senna 8.6 mg PO BID:PRN constipation \r\n13. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n14. Venlafaxine 25 mg PO BID \r\n15. Ciprofloxacin HCl 500 mg PO Q12H \r\n16. Fluconazole 400 mg PO Q24H \r\n17. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n18. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n19. Diazepam 5 mg PO QHS \r\n20. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n21. Rivaroxaban 20 mg PO DAILY \r\n22. Acyclovir 400 mg PO Q8H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  Ascorbic Acid ___ mg PO BID  \r\n5.  Cyanocobalamin 1000 mcg PO QHS  \r\n6.  Diazepam 5 mg PO QHS  \r\n7.  Docusate Sodium 100 mg PO BID  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n9.  FoLIC Acid 3.2 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14.  Rivaroxaban 20 mg PO DAILY  \r\n15.  Senna 8.6 mg PO BID:PRN constipation  \r\n16.  Venlafaxine 25 mg PO BID  \r\n17. HELD- Fluconazole 400 mg PO Q24H  This medication was held. \r\nDo not restart Fluconazole until you are directed to. \r\n18. HELD- Furosemide 20 mg PO DAILY  This medication was held. \r\nDo not restart Furosemide until you are directed to by your \r\noutpatient oncologist. \r\n19. HELD- Potassium Chloride 10 mEq PO DAILY  This medication \r\nwas held. Do not restart Potassium Chloride until you speak with \r\nyour doctor. \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nMyelodysplastic syndrome\r\nNeutropenic fever \r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted to ___ for fever, nausea, and vomiting. We \r\ndid several tests to identify the cause of these symptoms but \r\nwere unable to find a source of infection. You were treated with \r\na strong antibiotic and you improved. \r\n\r\nWe also gave you a cycle of chemotherapy, which you tolerated \r\nwell. \r\n\r\nThere have been some changes to your medications which are \r\noutlined below. \r\n\r\nYou will have follow-up with Dr. ___ week. You will be \r\ncontacted with the specific day and time. \r\n\r\nPlease contact Dr. ___ if you have any questions or \r\nconcerns. Someone is available to help at any time, day or \r\nnight. \r\n\r\nIt was a pleasure taking care of you and we wish you the best, \r\nThe ___ Care Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-19:2",
      "text": "Past Medical History:\nTRANSPLANT DATA:\n___: Transplant Date: 1\n          Graft: Auto\n          Conditioning Intensity: Ablative\n          Conditioning Regimen: BEAM PAST ONCOLOGIC HISTORY:\nTransformed DLBCL with a history of follicular lymphoma stage \nIIA\n- ___ developed worsening musculoskeletal back pain, early\nsatiety, hypoalbuminemia and found to have mesenteric mass\n- ?___ ex lap with 15 cm lobulated mass involving the\nduodenum, retroperitoneum and celiac access. Biopsies showed\nFollicular lymphomas grade II/III. Reportedly negative staging\nGallium scan. CD10+ BCL2+\n- ___ completed 6 cycles CHOP, complications included\nSVC/innominate thrombus (tPA)\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\nmarrow at completion was negative for lymphomatous involvement. - ___ PET-CT with very slight amount of increased tracer\nactivity within the posterior left supraclavicular region. No\nother areas of FDG avid disease were noted \n- ___ through ___ per records she was treated with CVP\nfollowed by course of single agent Rituxan\n- ___ through ___ surveillance imaging with no evidence of\nrecurrent disease, stable mesenteric mass. - ___ abdominal pain led to CT with no change in mass size,\nincreased conspicuity of nodular borders\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\nstable mesenteric mass with low level SUV 2.2 stable since \nprior. - ___ CT torso showed persistent mesenteric and left hilar\nlymphadenopathy. Stable right middle lobe small focus of ground\nglass opacity and adjacent subpleural fat hypertrophy, \nsuggestive\nof inflammatory process. Stable right adnexal cyst. - ___ Presented to PCP ___ ___iscomfort. Exam\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\nnormal differential, PLT 452. - ___ PET CT revealed, \"Large left cervical,\nsupraclavicular, mediastinal lymphadenopathy, and \nretroperitoneal\nlymphadenopathy, and small mesenteric\nlymphadenopathy, all markedly FDG-avid and concerning for\nlymphoma.\" SUVmax 35.5. - ___iopsy revealed diffuse large B cell\nlymphoma, CD20+ CD10+ lambda restricted.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-19",
        "chart_time": "104548",
        "section": "General",
        "position": 2,
        "tokenCount": 518,
        "note_metadata": {
          "note_id": "18887130-DS-19",
          "subject_id": 18887130,
          "hadm_id": 28046425,
          "note_type": "DS",
          "note_seq": 19,
          "charttime": 104548,
          "storetime": 104566.79166666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nfebrile neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture \r\n \r\nHistory of Present Illness:\r\n___ year old female DLBLC,  history of transformed diffuse large \r\nB\r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS now on decitabine, with neutropenia and ~4\r\nweeks broad spectrum antibiotics for empiric L4-5\r\ndiscitis/osteomyelitis, readmitted mid ___ for acute history of\r\nword finding difficulty and nausea vomiting without apparent\r\nsource, now presenting with 2 days of nausea/vomiting, fever, \r\nand\r\nurinary incontinence.\r\n\r\nNote her recent admit ___ she was recently admitted with\r\nmental status changes and vague confusion/word finding \r\ndifficulty\r\nand nausea/vomiting. She had been seen by ID ___ with concern \r\nfor\r\ninfection vs DVT of LLE where she has a slow healing wound, but\r\nultrasound was reassuring, but on the way home from appointment\r\nshe vomited and had chills, but no fevers She did have\r\nenterococcus UTI on admission, which didn't seem to be true UTI\r\nor explain her focal neurologic deficits, especially as she had\r\nbeen on vancomycin, but given low risks she did complete 5d\r\ncourse of amp/amox. On discharge she was continued on ppx cipro\r\nand fluc.\r\n\r\nShe was next and last seen by ___ on ___ at which point she was\r\nC2D22 dacogen. plan for dacogen ___ next at ___.  Mental\r\nstatus had resolved. Her ANC was 0 at time of that visit. \r\n\r\nShe reports feeling fairly well until ___ night when she \r\nbegan\r\ndeveloping extreme fatigue and generalized weakness. Also had 1x\r\nepisode where she suddenly had to urinate and was incontinent of\r\nurine. This happened again yesterday. No dysuria. No back pain,\r\nno headaches, visual changes, and no one extremity has been\r\nparticularly weak compared to the rest of her body ( endorses \r\nleg\r\nweakness but in line with generalized body weakness). She also\r\nhas been vomiting when she tries to eat for the past 48 hrs and\r\nhas no appetite but denies any melena, diarrhea, abd pain, and\r\nhad regular formed BM today and continues passing gas. Is \r\nburping\r\nmore than usual however. NO chest pain, dyspnea, cough, sore\r\nthroat, runny nose, or rash. All other 10 point ROS neg.\r\n\r\nED COURSE:\r\nT 100.2 up to 101.4  HR 110 BP 148/58  RR 18  94% RA. Pt \r\nreceived\r\nlinezolid, zosyn, IV APAP, multiple liters of LR. Labs with\r\nlactate 1.1, \r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission Physical Exam\r\nVITAL SIGNS: 98.0  109/68  83  18  97%RA\r\nGeneral:  NAD but weak, seems to have some mild dyspnea but\r\nstates this is baseline and denies SOB\r\nHEENT:  MMM, no OP lesions, no cervical, supraclavicular, or\r\naxillary adenopathy, no thyromegaly\r\nCV:  RR, NL S1S2 no S3S4 MRG\r\nPULM:  CTAB\r\nGI:  protuberant abd but BS+, soft, NTND, no masses or\r\nhepatosplenomegaly\r\nLIMBSSKIN:  ___ with mild trace pitting edema up to knees, well\r\nhealing ulceration over anterior shins and no skin breakdown\r\notherwise no erythema/rashes. port without erythema/drainage\r\nNEURO: generally weak and fatigued but conversant, alert,\r\nOriented x3. Cranial nerves II-XII are within normal limits\r\nexcluding visual acuity which was not assessed, no nystagmus;\r\nstrength is ___ of the proximal and distal upper and lower\r\nextremities but symmetric on both sides. no tremor/ asterixis.\r\nNeck supple.\r\n\r\nDischarge Physical Exam\r\nVS: 98.0 119/75 87 18 97 RA  \r\nGeneral: sitting comfortably in recliner eating breakfast, NAD.\r\nHEENT: moist mucus membranes, no OP lesions. Right pupil fixed\r\nand right eye with gaze palsy \r\nCV: RRR, ___ systolic murmur at LLSB. \r\nPULM: CTAB, no crackles, wheeze, rhonchi \r\nGI: Soft, NT, ND, +BS. \r\nEXT: ___ with trace edema bilat, right leg slightly larger than\r\nleft with well healed ulceration over anterior right shin and no\r\nskin breakdown.  \r\nSKIN: No new rashes or lesions. Chronic venous stasis changes\r\nbilat c/w lipodermatosclerosis\r\nNEURO: A&Ox3. Chronic and stable R sided facial droop and \r\nptosis.\r\n\r\n \r\nPertinent Results:\r\nAdmission Labs\r\n___ 04:45PM BLOOD WBC-0.3* RBC-2.83* Hgb-8.4* Hct-26.0* \r\nMCV-92 MCH-29.7 MCHC-32.3 RDW-16.3* RDWSD-46.7* Plt Ct-74*\r\n___ 04:45PM BLOOD Neuts-8* Bands-0 Lymphs-86* Monos-6 Eos-0 \r\nBaso-0 ___ Myelos-0 AbsNeut-0.02* AbsLymp-0.26* \r\nAbsMono-0.02* AbsEos-0.00* AbsBaso-0.00*\r\n___ 04:45PM BLOOD Glucose-123* UreaN-14 Creat-0.9 Na-137 \r\nK-4.2 Cl-103 HCO3-21* AnGap-17\r\n___ 04:45PM BLOOD ALT-9 AST-14 AlkPhos-135* TotBili-0.3\r\n___ 04:45PM BLOOD Albumin-3.9\r\n___ 05:01PM BLOOD Lactate-1.1\r\n___ 05:37PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 05:37PM URINE Blood-SM  Nitrite-NEG Protein-600 \r\nGlucose-NEG Ketone-10 Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\r\n___ 05:37PM URINE RBC-3* WBC-1 Bacteri-FEW Yeast-NONE \r\nEpi-<1\r\n___ 05:37PM URINE Mucous-RARE\r\n___ 05:37PM URINE CastHy-3*\r\n___ 05:56PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nDischarge Labs\r\n___ 12:02AM BLOOD WBC-2.9* RBC-2.80* Hgb-8.4* Hct-26.6* \r\nMCV-95 MCH-30.0 MCHC-31.6* RDW-17.4* RDWSD-51.3* Plt Ct-83*\r\n___ 12:02AM BLOOD Neuts-58.2 ___ Monos-8.9 Eos-0.0* \r\nBaso-0.3 NRBC-1.0* Im ___ AbsNeut-1.70 AbsLymp-0.91* \r\nAbsMono-0.26 AbsEos-0.00* AbsBaso-0.01\r\n___ 12:02AM BLOOD ___ PTT-40.8* ___\r\n___ 12:02AM BLOOD  WBC-2.9* Lymph-31 Abs ___ CD3%-70 \r\nAbs CD3-627 CD4%-42 Abs CD4-382 CD8%-26 Abs CD8-236 CD4/CD8-1.62\r\n___ 12:02AM BLOOD Glucose-118* UreaN-12 Creat-0.9 Na-139 \r\nK-4.2 Cl-102 HCO3-23 AnGap-18\r\n___ 12:02AM BLOOD Albumin-3.5 Calcium-8.3* Phos-2.6* Mg-2.1\r\n\r\nMicrobiology: Extensive workup including numerous blood \r\ncultures, spinal tap,  negative except for corona virus on \r\nextended respiratory multiplex panel. Please see OMR for \r\ndetails.\r\n\r\nImaging: All imaging consistent with priors. No signs of \r\ninfection. Performed Ultrasounds BLE negative, Brain/Spine MRI, \r\nCXR, RUE ultrasound.\r\n\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\ndiffuse large B cell lymphoma s/p a curative attempt with an \r\nautoSCT with BEAM conditioning in ___ ___s IFRT with \r\ncourse complicated by ___ pneumonitis, who was subsequently \r\nfound to have treatment-related MDS now on decitabine, with \r\nneutropenia and 6 weeks broad spectrum antibiotics for empiric \r\nL4-5 discitis/osteomyelitis, readmitted mid ___ for acute \r\nhistory of word finding difficulty and nausea vomiting without \r\napparent source, presenting with 2 days of nausea/vomiting, \r\nfever, and\r\nurinary incontinence. Incredibly extensive infectious workup \r\nnegative and fevers now resolved after almost two weeks on broad \r\nspectrum antibiotics.\r\n\r\n# Pancytopenia/MDS - per outpt decision made to treat with \r\nDacogen with plan to move towards allogeneic transplant. Was due \r\nfor decitabine ___. Extensive infectious workup and ultimately \r\nstarted Decitabine ___ and completed cycle in the hospital \r\nwithout further incident.\r\n\r\n#Elevated liver enzyemes: Unclear cause, but may be related to \r\nposaconazole level of ___. Posaconazole held starting ___ \r\nenzymes trending down. Plan to restart as outpatient.\r\n\r\n#Neutropenic fever: Resolving after several weeks of workup with \r\nno clear correlation to particular treatment or any source \r\nidentified. Did have positive coronavirus on multiplex pcr. \r\n\r\n#Lower back pain: continued gabapentin\r\n\r\n#Hx of right leg DVT:  Was on Xarelto 20 mg daily but now on \r\nhold with low platelet count.  Has IVC filter in place.  Will \r\ncontinue to hold for platelet count < 75,000. No anticoagulation\r\n\r\n#Depression: Continue home venlafaxine\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Docusate Sodium 100 mg PO BID \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 900 mg PO TID \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Omeprazole 20 mg PO DAILY \r\n9. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n  Reason for PRN duplicate override: changing dose\r\n10. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n11. Potassium Chloride 10 mEq PO DAILY \r\n12. Senna 8.6 mg PO BID:PRN constipation \r\n13. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n14. Venlafaxine 25 mg PO BID \r\n15. Ciprofloxacin HCl 500 mg PO Q12H \r\n16. Fluconazole 400 mg PO Q24H \r\n17. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n18. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n19. Diazepam 5 mg PO QHS \r\n20. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n21. Rivaroxaban 20 mg PO DAILY \r\n22. Acyclovir 400 mg PO Q8H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  Ascorbic Acid ___ mg PO BID  \r\n5.  Cyanocobalamin 1000 mcg PO QHS  \r\n6.  Diazepam 5 mg PO QHS  \r\n7.  Docusate Sodium 100 mg PO BID  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n9.  FoLIC Acid 3.2 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14.  Rivaroxaban 20 mg PO DAILY  \r\n15.  Senna 8.6 mg PO BID:PRN constipation  \r\n16.  Venlafaxine 25 mg PO BID  \r\n17. HELD- Fluconazole 400 mg PO Q24H  This medication was held. \r\nDo not restart Fluconazole until you are directed to. \r\n18. HELD- Furosemide 20 mg PO DAILY  This medication was held. \r\nDo not restart Furosemide until you are directed to by your \r\noutpatient oncologist. \r\n19. HELD- Potassium Chloride 10 mEq PO DAILY  This medication \r\nwas held. Do not restart Potassium Chloride until you speak with \r\nyour doctor. \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nMyelodysplastic syndrome\r\nNeutropenic fever \r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted to ___ for fever, nausea, and vomiting. We \r\ndid several tests to identify the cause of these symptoms but \r\nwere unable to find a source of infection. You were treated with \r\na strong antibiotic and you improved. \r\n\r\nWe also gave you a cycle of chemotherapy, which you tolerated \r\nwell. \r\n\r\nThere have been some changes to your medications which are \r\noutlined below. \r\n\r\nYou will have follow-up with Dr. ___ week. You will be \r\ncontacted with the specific day and time. \r\n\r\nPlease contact Dr. ___ if you have any questions or \r\nconcerns. Someone is available to help at any time, day or \r\nnight. \r\n\r\nIt was a pleasure taking care of you and we wish you the best, \r\nThe ___ Care Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-19:3",
      "text": "Stable right adnexal cyst. - ___ Presented to PCP ___ ___iscomfort. Exam\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\nnormal differential, PLT 452. - ___ PET CT revealed, \"Large left cervical,\nsupraclavicular, mediastinal lymphadenopathy, and \nretroperitoneal\nlymphadenopathy, and small mesenteric\nlymphadenopathy, all markedly FDG-avid and concerning for\nlymphoma.\" SUVmax 35.5. - ___iopsy revealed diffuse large B cell\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \nare\npending\n- ___ C1D1 ICE\n- ___ C1 Rituximab, clinically improved adenopathy\n- ___ C2 Rituximab, WBC 6.5, PLT 43\n- ___ Admit for C2D1 ICE\n- ___ C3 Rituximab\n- ___ PET CT showed almost complete resolution of FDG avid\ndisease with a residual focus of avidity in the bed of the \nformer\nabdominal mass, SUV 3\n- ___ C4 Rituximab\n- ___ C4 ICE followed by stem cell mobilization and\ncollection, BMBx showed a nest of CLL unrelated to her \naggressive\nlymphoma\n- ___ Presented with large DVTs, SVC filter placed\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\n- ___ Switched to Rivaroxiban for AC\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\ncytopenias\n- ___ Start XRT\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\nHb). Started prednisone 80 mg PO daily\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \nmg\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___. - Weekly monitoring of DLCO with taper of prednisone to 10 mg\ndaily as of ___ with DLCO 99%. Dapsone d/ced on ___\ndue to hemolysis. - ___ Decreased prednisone to 5 mg PO daily. Noro virus\npersistently positive. - ___ CT torso with no evidence of active disease. Unchanged mesenteric fullness. - ___ DLCO decrease (not reported) increase prednisone to \n10\nmg\n- ___ IVIg 400 mg/kg\n- ___ DLCO 121%, continue prednisone 10 mg\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia. - ___, tapered off prednisone. - ___, CT torso with no evidence of active disease. Stable\nappearance of a conglomeration of mesenteric lymph nodes. - ___, Right total knee replacement, primary, complicated\nby foot drop likely d/t irritation of peroneal nerve and\ncellulitis. - ___, CT Torso with no evidence of active disease. Stable appearance of conglomerate of mesenteric LN's. Increased\ndilatation of the main pulmonary artery suggests worsening\npulmonary arterial hypertension of indeterminate etiology. - ___, CT torso with no evidence of active disease. Increased\ndilation of pulmonary artery. Evaluated by Dr. ___\n- ___, increasing right leg swelling with noted DVT.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-19",
        "chart_time": "104548",
        "section": "General",
        "position": 3,
        "tokenCount": 678,
        "note_metadata": {
          "note_id": "18887130-DS-19",
          "subject_id": 18887130,
          "hadm_id": 28046425,
          "note_type": "DS",
          "note_seq": 19,
          "charttime": 104548,
          "storetime": 104566.79166666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nfebrile neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture \r\n \r\nHistory of Present Illness:\r\n___ year old female DLBLC,  history of transformed diffuse large \r\nB\r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS now on decitabine, with neutropenia and ~4\r\nweeks broad spectrum antibiotics for empiric L4-5\r\ndiscitis/osteomyelitis, readmitted mid ___ for acute history of\r\nword finding difficulty and nausea vomiting without apparent\r\nsource, now presenting with 2 days of nausea/vomiting, fever, \r\nand\r\nurinary incontinence.\r\n\r\nNote her recent admit ___ she was recently admitted with\r\nmental status changes and vague confusion/word finding \r\ndifficulty\r\nand nausea/vomiting. She had been seen by ID ___ with concern \r\nfor\r\ninfection vs DVT of LLE where she has a slow healing wound, but\r\nultrasound was reassuring, but on the way home from appointment\r\nshe vomited and had chills, but no fevers She did have\r\nenterococcus UTI on admission, which didn't seem to be true UTI\r\nor explain her focal neurologic deficits, especially as she had\r\nbeen on vancomycin, but given low risks she did complete 5d\r\ncourse of amp/amox. On discharge she was continued on ppx cipro\r\nand fluc.\r\n\r\nShe was next and last seen by ___ on ___ at which point she was\r\nC2D22 dacogen. plan for dacogen ___ next at ___.  Mental\r\nstatus had resolved. Her ANC was 0 at time of that visit. \r\n\r\nShe reports feeling fairly well until ___ night when she \r\nbegan\r\ndeveloping extreme fatigue and generalized weakness. Also had 1x\r\nepisode where she suddenly had to urinate and was incontinent of\r\nurine. This happened again yesterday. No dysuria. No back pain,\r\nno headaches, visual changes, and no one extremity has been\r\nparticularly weak compared to the rest of her body ( endorses \r\nleg\r\nweakness but in line with generalized body weakness). She also\r\nhas been vomiting when she tries to eat for the past 48 hrs and\r\nhas no appetite but denies any melena, diarrhea, abd pain, and\r\nhad regular formed BM today and continues passing gas. Is \r\nburping\r\nmore than usual however. NO chest pain, dyspnea, cough, sore\r\nthroat, runny nose, or rash. All other 10 point ROS neg.\r\n\r\nED COURSE:\r\nT 100.2 up to 101.4  HR 110 BP 148/58  RR 18  94% RA. Pt \r\nreceived\r\nlinezolid, zosyn, IV APAP, multiple liters of LR. Labs with\r\nlactate 1.1, \r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission Physical Exam\r\nVITAL SIGNS: 98.0  109/68  83  18  97%RA\r\nGeneral:  NAD but weak, seems to have some mild dyspnea but\r\nstates this is baseline and denies SOB\r\nHEENT:  MMM, no OP lesions, no cervical, supraclavicular, or\r\naxillary adenopathy, no thyromegaly\r\nCV:  RR, NL S1S2 no S3S4 MRG\r\nPULM:  CTAB\r\nGI:  protuberant abd but BS+, soft, NTND, no masses or\r\nhepatosplenomegaly\r\nLIMBSSKIN:  ___ with mild trace pitting edema up to knees, well\r\nhealing ulceration over anterior shins and no skin breakdown\r\notherwise no erythema/rashes. port without erythema/drainage\r\nNEURO: generally weak and fatigued but conversant, alert,\r\nOriented x3. Cranial nerves II-XII are within normal limits\r\nexcluding visual acuity which was not assessed, no nystagmus;\r\nstrength is ___ of the proximal and distal upper and lower\r\nextremities but symmetric on both sides. no tremor/ asterixis.\r\nNeck supple.\r\n\r\nDischarge Physical Exam\r\nVS: 98.0 119/75 87 18 97 RA  \r\nGeneral: sitting comfortably in recliner eating breakfast, NAD.\r\nHEENT: moist mucus membranes, no OP lesions. Right pupil fixed\r\nand right eye with gaze palsy \r\nCV: RRR, ___ systolic murmur at LLSB. \r\nPULM: CTAB, no crackles, wheeze, rhonchi \r\nGI: Soft, NT, ND, +BS. \r\nEXT: ___ with trace edema bilat, right leg slightly larger than\r\nleft with well healed ulceration over anterior right shin and no\r\nskin breakdown.  \r\nSKIN: No new rashes or lesions. Chronic venous stasis changes\r\nbilat c/w lipodermatosclerosis\r\nNEURO: A&Ox3. Chronic and stable R sided facial droop and \r\nptosis.\r\n\r\n \r\nPertinent Results:\r\nAdmission Labs\r\n___ 04:45PM BLOOD WBC-0.3* RBC-2.83* Hgb-8.4* Hct-26.0* \r\nMCV-92 MCH-29.7 MCHC-32.3 RDW-16.3* RDWSD-46.7* Plt Ct-74*\r\n___ 04:45PM BLOOD Neuts-8* Bands-0 Lymphs-86* Monos-6 Eos-0 \r\nBaso-0 ___ Myelos-0 AbsNeut-0.02* AbsLymp-0.26* \r\nAbsMono-0.02* AbsEos-0.00* AbsBaso-0.00*\r\n___ 04:45PM BLOOD Glucose-123* UreaN-14 Creat-0.9 Na-137 \r\nK-4.2 Cl-103 HCO3-21* AnGap-17\r\n___ 04:45PM BLOOD ALT-9 AST-14 AlkPhos-135* TotBili-0.3\r\n___ 04:45PM BLOOD Albumin-3.9\r\n___ 05:01PM BLOOD Lactate-1.1\r\n___ 05:37PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 05:37PM URINE Blood-SM  Nitrite-NEG Protein-600 \r\nGlucose-NEG Ketone-10 Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\r\n___ 05:37PM URINE RBC-3* WBC-1 Bacteri-FEW Yeast-NONE \r\nEpi-<1\r\n___ 05:37PM URINE Mucous-RARE\r\n___ 05:37PM URINE CastHy-3*\r\n___ 05:56PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nDischarge Labs\r\n___ 12:02AM BLOOD WBC-2.9* RBC-2.80* Hgb-8.4* Hct-26.6* \r\nMCV-95 MCH-30.0 MCHC-31.6* RDW-17.4* RDWSD-51.3* Plt Ct-83*\r\n___ 12:02AM BLOOD Neuts-58.2 ___ Monos-8.9 Eos-0.0* \r\nBaso-0.3 NRBC-1.0* Im ___ AbsNeut-1.70 AbsLymp-0.91* \r\nAbsMono-0.26 AbsEos-0.00* AbsBaso-0.01\r\n___ 12:02AM BLOOD ___ PTT-40.8* ___\r\n___ 12:02AM BLOOD  WBC-2.9* Lymph-31 Abs ___ CD3%-70 \r\nAbs CD3-627 CD4%-42 Abs CD4-382 CD8%-26 Abs CD8-236 CD4/CD8-1.62\r\n___ 12:02AM BLOOD Glucose-118* UreaN-12 Creat-0.9 Na-139 \r\nK-4.2 Cl-102 HCO3-23 AnGap-18\r\n___ 12:02AM BLOOD Albumin-3.5 Calcium-8.3* Phos-2.6* Mg-2.1\r\n\r\nMicrobiology: Extensive workup including numerous blood \r\ncultures, spinal tap,  negative except for corona virus on \r\nextended respiratory multiplex panel. Please see OMR for \r\ndetails.\r\n\r\nImaging: All imaging consistent with priors. No signs of \r\ninfection. Performed Ultrasounds BLE negative, Brain/Spine MRI, \r\nCXR, RUE ultrasound.\r\n\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\ndiffuse large B cell lymphoma s/p a curative attempt with an \r\nautoSCT with BEAM conditioning in ___ ___s IFRT with \r\ncourse complicated by ___ pneumonitis, who was subsequently \r\nfound to have treatment-related MDS now on decitabine, with \r\nneutropenia and 6 weeks broad spectrum antibiotics for empiric \r\nL4-5 discitis/osteomyelitis, readmitted mid ___ for acute \r\nhistory of word finding difficulty and nausea vomiting without \r\napparent source, presenting with 2 days of nausea/vomiting, \r\nfever, and\r\nurinary incontinence. Incredibly extensive infectious workup \r\nnegative and fevers now resolved after almost two weeks on broad \r\nspectrum antibiotics.\r\n\r\n# Pancytopenia/MDS - per outpt decision made to treat with \r\nDacogen with plan to move towards allogeneic transplant. Was due \r\nfor decitabine ___. Extensive infectious workup and ultimately \r\nstarted Decitabine ___ and completed cycle in the hospital \r\nwithout further incident.\r\n\r\n#Elevated liver enzyemes: Unclear cause, but may be related to \r\nposaconazole level of ___. Posaconazole held starting ___ \r\nenzymes trending down. Plan to restart as outpatient.\r\n\r\n#Neutropenic fever: Resolving after several weeks of workup with \r\nno clear correlation to particular treatment or any source \r\nidentified. Did have positive coronavirus on multiplex pcr. \r\n\r\n#Lower back pain: continued gabapentin\r\n\r\n#Hx of right leg DVT:  Was on Xarelto 20 mg daily but now on \r\nhold with low platelet count.  Has IVC filter in place.  Will \r\ncontinue to hold for platelet count < 75,000. No anticoagulation\r\n\r\n#Depression: Continue home venlafaxine\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Docusate Sodium 100 mg PO BID \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 900 mg PO TID \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Omeprazole 20 mg PO DAILY \r\n9. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n  Reason for PRN duplicate override: changing dose\r\n10. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n11. Potassium Chloride 10 mEq PO DAILY \r\n12. Senna 8.6 mg PO BID:PRN constipation \r\n13. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n14. Venlafaxine 25 mg PO BID \r\n15. Ciprofloxacin HCl 500 mg PO Q12H \r\n16. Fluconazole 400 mg PO Q24H \r\n17. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n18. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n19. Diazepam 5 mg PO QHS \r\n20. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n21. Rivaroxaban 20 mg PO DAILY \r\n22. Acyclovir 400 mg PO Q8H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  Ascorbic Acid ___ mg PO BID  \r\n5.  Cyanocobalamin 1000 mcg PO QHS  \r\n6.  Diazepam 5 mg PO QHS  \r\n7.  Docusate Sodium 100 mg PO BID  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n9.  FoLIC Acid 3.2 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14.  Rivaroxaban 20 mg PO DAILY  \r\n15.  Senna 8.6 mg PO BID:PRN constipation  \r\n16.  Venlafaxine 25 mg PO BID  \r\n17. HELD- Fluconazole 400 mg PO Q24H  This medication was held. \r\nDo not restart Fluconazole until you are directed to. \r\n18. HELD- Furosemide 20 mg PO DAILY  This medication was held. \r\nDo not restart Furosemide until you are directed to by your \r\noutpatient oncologist. \r\n19. HELD- Potassium Chloride 10 mEq PO DAILY  This medication \r\nwas held. Do not restart Potassium Chloride until you speak with \r\nyour doctor. \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nMyelodysplastic syndrome\r\nNeutropenic fever \r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted to ___ for fever, nausea, and vomiting. We \r\ndid several tests to identify the cause of these symptoms but \r\nwere unable to find a source of infection. You were treated with \r\na strong antibiotic and you improved. \r\n\r\nWe also gave you a cycle of chemotherapy, which you tolerated \r\nwell. \r\n\r\nThere have been some changes to your medications which are \r\noutlined below. \r\n\r\nYou will have follow-up with Dr. ___ week. You will be \r\ncontacted with the specific day and time. \r\n\r\nPlease contact Dr. ___ if you have any questions or \r\nconcerns. Someone is available to help at any time, day or \r\nnight. \r\n\r\nIt was a pleasure taking care of you and we wish you the best, \r\nThe ___ Care Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-19:4",
      "text": "Stable\nappearance of a conglomeration of mesenteric lymph nodes. - ___, Right total knee replacement, primary, complicated\nby foot drop likely d/t irritation of peroneal nerve and\ncellulitis. - ___, CT Torso with no evidence of active disease. Stable appearance of conglomerate of mesenteric LN's. Increased\ndilatation of the main pulmonary artery suggests worsening\npulmonary arterial hypertension of indeterminate etiology. - ___, CT torso with no evidence of active disease. Increased\ndilation of pulmonary artery. Evaluated by Dr. ___\n- ___, increasing right leg swelling with noted DVT. Xarelto\nincreased back to 20 mg daily(had been decreased given age and\nprior chronic DVT). No evidence for lymphoma on CT imaging. - ___, noted drop in blood counts. BM biopsy with evidence\nfor MDS. - ___, C1 Dacogen\n- ___, C2 Dacogen\n- ___, C3 Dacogen\n \nOTHER PAST MEDICAL HISTORY\n- CVID, received IVIG monthly. last given ___\n- GERD                                          \n- Osteoarthritis                                         \n- DVT, right lower extremity, IVC filter in place\n- Cervical radiculopathy\n- Sciatica\n- Obstructive sleep apnea, wears CPAP\n- H/O cerebral aneurism, noted on MRA with small R internal\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\nthe right eye, mild proptosis of the right eye, and hyperthesia\nof the right V1 distribution\n- Asthma\n- Obesity\n- Hypertension\n- Migraines Social History:\n___ Family History:\nbrother - lymphoma Physical ___:\nAdmission Physical Exam",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-19",
        "chart_time": "104548",
        "section": "General",
        "position": 4,
        "tokenCount": 391,
        "note_metadata": {
          "note_id": "18887130-DS-19",
          "subject_id": 18887130,
          "hadm_id": 28046425,
          "note_type": "DS",
          "note_seq": 19,
          "charttime": 104548,
          "storetime": 104566.79166666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nfebrile neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture \r\n \r\nHistory of Present Illness:\r\n___ year old female DLBLC,  history of transformed diffuse large \r\nB\r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS now on decitabine, with neutropenia and ~4\r\nweeks broad spectrum antibiotics for empiric L4-5\r\ndiscitis/osteomyelitis, readmitted mid ___ for acute history of\r\nword finding difficulty and nausea vomiting without apparent\r\nsource, now presenting with 2 days of nausea/vomiting, fever, \r\nand\r\nurinary incontinence.\r\n\r\nNote her recent admit ___ she was recently admitted with\r\nmental status changes and vague confusion/word finding \r\ndifficulty\r\nand nausea/vomiting. She had been seen by ID ___ with concern \r\nfor\r\ninfection vs DVT of LLE where she has a slow healing wound, but\r\nultrasound was reassuring, but on the way home from appointment\r\nshe vomited and had chills, but no fevers She did have\r\nenterococcus UTI on admission, which didn't seem to be true UTI\r\nor explain her focal neurologic deficits, especially as she had\r\nbeen on vancomycin, but given low risks she did complete 5d\r\ncourse of amp/amox. On discharge she was continued on ppx cipro\r\nand fluc.\r\n\r\nShe was next and last seen by ___ on ___ at which point she was\r\nC2D22 dacogen. plan for dacogen ___ next at ___.  Mental\r\nstatus had resolved. Her ANC was 0 at time of that visit. \r\n\r\nShe reports feeling fairly well until ___ night when she \r\nbegan\r\ndeveloping extreme fatigue and generalized weakness. Also had 1x\r\nepisode where she suddenly had to urinate and was incontinent of\r\nurine. This happened again yesterday. No dysuria. No back pain,\r\nno headaches, visual changes, and no one extremity has been\r\nparticularly weak compared to the rest of her body ( endorses \r\nleg\r\nweakness but in line with generalized body weakness). She also\r\nhas been vomiting when she tries to eat for the past 48 hrs and\r\nhas no appetite but denies any melena, diarrhea, abd pain, and\r\nhad regular formed BM today and continues passing gas. Is \r\nburping\r\nmore than usual however. NO chest pain, dyspnea, cough, sore\r\nthroat, runny nose, or rash. All other 10 point ROS neg.\r\n\r\nED COURSE:\r\nT 100.2 up to 101.4  HR 110 BP 148/58  RR 18  94% RA. Pt \r\nreceived\r\nlinezolid, zosyn, IV APAP, multiple liters of LR. Labs with\r\nlactate 1.1, \r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission Physical Exam\r\nVITAL SIGNS: 98.0  109/68  83  18  97%RA\r\nGeneral:  NAD but weak, seems to have some mild dyspnea but\r\nstates this is baseline and denies SOB\r\nHEENT:  MMM, no OP lesions, no cervical, supraclavicular, or\r\naxillary adenopathy, no thyromegaly\r\nCV:  RR, NL S1S2 no S3S4 MRG\r\nPULM:  CTAB\r\nGI:  protuberant abd but BS+, soft, NTND, no masses or\r\nhepatosplenomegaly\r\nLIMBSSKIN:  ___ with mild trace pitting edema up to knees, well\r\nhealing ulceration over anterior shins and no skin breakdown\r\notherwise no erythema/rashes. port without erythema/drainage\r\nNEURO: generally weak and fatigued but conversant, alert,\r\nOriented x3. Cranial nerves II-XII are within normal limits\r\nexcluding visual acuity which was not assessed, no nystagmus;\r\nstrength is ___ of the proximal and distal upper and lower\r\nextremities but symmetric on both sides. no tremor/ asterixis.\r\nNeck supple.\r\n\r\nDischarge Physical Exam\r\nVS: 98.0 119/75 87 18 97 RA  \r\nGeneral: sitting comfortably in recliner eating breakfast, NAD.\r\nHEENT: moist mucus membranes, no OP lesions. Right pupil fixed\r\nand right eye with gaze palsy \r\nCV: RRR, ___ systolic murmur at LLSB. \r\nPULM: CTAB, no crackles, wheeze, rhonchi \r\nGI: Soft, NT, ND, +BS. \r\nEXT: ___ with trace edema bilat, right leg slightly larger than\r\nleft with well healed ulceration over anterior right shin and no\r\nskin breakdown.  \r\nSKIN: No new rashes or lesions. Chronic venous stasis changes\r\nbilat c/w lipodermatosclerosis\r\nNEURO: A&Ox3. Chronic and stable R sided facial droop and \r\nptosis.\r\n\r\n \r\nPertinent Results:\r\nAdmission Labs\r\n___ 04:45PM BLOOD WBC-0.3* RBC-2.83* Hgb-8.4* Hct-26.0* \r\nMCV-92 MCH-29.7 MCHC-32.3 RDW-16.3* RDWSD-46.7* Plt Ct-74*\r\n___ 04:45PM BLOOD Neuts-8* Bands-0 Lymphs-86* Monos-6 Eos-0 \r\nBaso-0 ___ Myelos-0 AbsNeut-0.02* AbsLymp-0.26* \r\nAbsMono-0.02* AbsEos-0.00* AbsBaso-0.00*\r\n___ 04:45PM BLOOD Glucose-123* UreaN-14 Creat-0.9 Na-137 \r\nK-4.2 Cl-103 HCO3-21* AnGap-17\r\n___ 04:45PM BLOOD ALT-9 AST-14 AlkPhos-135* TotBili-0.3\r\n___ 04:45PM BLOOD Albumin-3.9\r\n___ 05:01PM BLOOD Lactate-1.1\r\n___ 05:37PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 05:37PM URINE Blood-SM  Nitrite-NEG Protein-600 \r\nGlucose-NEG Ketone-10 Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\r\n___ 05:37PM URINE RBC-3* WBC-1 Bacteri-FEW Yeast-NONE \r\nEpi-<1\r\n___ 05:37PM URINE Mucous-RARE\r\n___ 05:37PM URINE CastHy-3*\r\n___ 05:56PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nDischarge Labs\r\n___ 12:02AM BLOOD WBC-2.9* RBC-2.80* Hgb-8.4* Hct-26.6* \r\nMCV-95 MCH-30.0 MCHC-31.6* RDW-17.4* RDWSD-51.3* Plt Ct-83*\r\n___ 12:02AM BLOOD Neuts-58.2 ___ Monos-8.9 Eos-0.0* \r\nBaso-0.3 NRBC-1.0* Im ___ AbsNeut-1.70 AbsLymp-0.91* \r\nAbsMono-0.26 AbsEos-0.00* AbsBaso-0.01\r\n___ 12:02AM BLOOD ___ PTT-40.8* ___\r\n___ 12:02AM BLOOD  WBC-2.9* Lymph-31 Abs ___ CD3%-70 \r\nAbs CD3-627 CD4%-42 Abs CD4-382 CD8%-26 Abs CD8-236 CD4/CD8-1.62\r\n___ 12:02AM BLOOD Glucose-118* UreaN-12 Creat-0.9 Na-139 \r\nK-4.2 Cl-102 HCO3-23 AnGap-18\r\n___ 12:02AM BLOOD Albumin-3.5 Calcium-8.3* Phos-2.6* Mg-2.1\r\n\r\nMicrobiology: Extensive workup including numerous blood \r\ncultures, spinal tap,  negative except for corona virus on \r\nextended respiratory multiplex panel. Please see OMR for \r\ndetails.\r\n\r\nImaging: All imaging consistent with priors. No signs of \r\ninfection. Performed Ultrasounds BLE negative, Brain/Spine MRI, \r\nCXR, RUE ultrasound.\r\n\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\ndiffuse large B cell lymphoma s/p a curative attempt with an \r\nautoSCT with BEAM conditioning in ___ ___s IFRT with \r\ncourse complicated by ___ pneumonitis, who was subsequently \r\nfound to have treatment-related MDS now on decitabine, with \r\nneutropenia and 6 weeks broad spectrum antibiotics for empiric \r\nL4-5 discitis/osteomyelitis, readmitted mid ___ for acute \r\nhistory of word finding difficulty and nausea vomiting without \r\napparent source, presenting with 2 days of nausea/vomiting, \r\nfever, and\r\nurinary incontinence. Incredibly extensive infectious workup \r\nnegative and fevers now resolved after almost two weeks on broad \r\nspectrum antibiotics.\r\n\r\n# Pancytopenia/MDS - per outpt decision made to treat with \r\nDacogen with plan to move towards allogeneic transplant. Was due \r\nfor decitabine ___. Extensive infectious workup and ultimately \r\nstarted Decitabine ___ and completed cycle in the hospital \r\nwithout further incident.\r\n\r\n#Elevated liver enzyemes: Unclear cause, but may be related to \r\nposaconazole level of ___. Posaconazole held starting ___ \r\nenzymes trending down. Plan to restart as outpatient.\r\n\r\n#Neutropenic fever: Resolving after several weeks of workup with \r\nno clear correlation to particular treatment or any source \r\nidentified. Did have positive coronavirus on multiplex pcr. \r\n\r\n#Lower back pain: continued gabapentin\r\n\r\n#Hx of right leg DVT:  Was on Xarelto 20 mg daily but now on \r\nhold with low platelet count.  Has IVC filter in place.  Will \r\ncontinue to hold for platelet count < 75,000. No anticoagulation\r\n\r\n#Depression: Continue home venlafaxine\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Docusate Sodium 100 mg PO BID \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 900 mg PO TID \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Omeprazole 20 mg PO DAILY \r\n9. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n  Reason for PRN duplicate override: changing dose\r\n10. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n11. Potassium Chloride 10 mEq PO DAILY \r\n12. Senna 8.6 mg PO BID:PRN constipation \r\n13. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n14. Venlafaxine 25 mg PO BID \r\n15. Ciprofloxacin HCl 500 mg PO Q12H \r\n16. Fluconazole 400 mg PO Q24H \r\n17. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n18. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n19. Diazepam 5 mg PO QHS \r\n20. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n21. Rivaroxaban 20 mg PO DAILY \r\n22. Acyclovir 400 mg PO Q8H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  Ascorbic Acid ___ mg PO BID  \r\n5.  Cyanocobalamin 1000 mcg PO QHS  \r\n6.  Diazepam 5 mg PO QHS  \r\n7.  Docusate Sodium 100 mg PO BID  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n9.  FoLIC Acid 3.2 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14.  Rivaroxaban 20 mg PO DAILY  \r\n15.  Senna 8.6 mg PO BID:PRN constipation  \r\n16.  Venlafaxine 25 mg PO BID  \r\n17. HELD- Fluconazole 400 mg PO Q24H  This medication was held. \r\nDo not restart Fluconazole until you are directed to. \r\n18. HELD- Furosemide 20 mg PO DAILY  This medication was held. \r\nDo not restart Furosemide until you are directed to by your \r\noutpatient oncologist. \r\n19. HELD- Potassium Chloride 10 mEq PO DAILY  This medication \r\nwas held. Do not restart Potassium Chloride until you speak with \r\nyour doctor. \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nMyelodysplastic syndrome\r\nNeutropenic fever \r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted to ___ for fever, nausea, and vomiting. We \r\ndid several tests to identify the cause of these symptoms but \r\nwere unable to find a source of infection. You were treated with \r\na strong antibiotic and you improved. \r\n\r\nWe also gave you a cycle of chemotherapy, which you tolerated \r\nwell. \r\n\r\nThere have been some changes to your medications which are \r\noutlined below. \r\n\r\nYou will have follow-up with Dr. ___ week. You will be \r\ncontacted with the specific day and time. \r\n\r\nPlease contact Dr. ___ if you have any questions or \r\nconcerns. Someone is available to help at any time, day or \r\nnight. \r\n\r\nIt was a pleasure taking care of you and we wish you the best, \r\nThe ___ Care Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-19:5",
      "text": "VITAL SIGNS: 98.0  109/68  83  18  97%RA\nGeneral:  NAD but weak, seems to have some mild dyspnea but\nstates this is baseline and denies SOB\nHEENT:  MMM, no OP lesions, no cervical, supraclavicular, or\naxillary adenopathy, no thyromegaly\nCV:  RR, NL S1S2 no S3S4 MRG\nPULM:  CTAB\nGI:  protuberant abd but BS+, soft, NTND, no masses or\nhepatosplenomegaly\nLIMBSSKIN:  ___ with mild trace pitting edema up to knees, well\nhealing ulceration over anterior shins and no skin breakdown\notherwise no erythema/rashes. port without erythema/drainage\nNEURO: generally weak and fatigued but conversant, alert,\nOriented x3. Cranial nerves II-XII are within normal limits\nexcluding visual acuity which was not assessed, no nystagmus;\nstrength is ___ of the proximal and distal upper and lower\nextremities but symmetric on both sides. no tremor/ asterixis. Neck supple. Discharge Physical Exam\nVS: 98.0 119/75 87 18 97 RA  \nGeneral: sitting comfortably in recliner eating breakfast, NAD. HEENT: moist mucus membranes, no OP lesions. Right pupil fixed\nand right eye with gaze palsy \nCV: RRR, ___ systolic murmur at LLSB. PULM: CTAB, no crackles, wheeze, rhonchi \nGI: Soft, NT, ND, +BS. EXT: ___ with trace edema bilat, right leg slightly larger than\nleft with well healed ulceration over anterior right shin and no\nskin breakdown. SKIN: No new rashes or lesions. Chronic venous stasis changes\nbilat c/w lipodermatosclerosis\nNEURO: A&Ox3. Chronic and stable R sided facial droop and \nptosis. Pertinent Results:\nAdmission Labs\n___ 04:45PM BLOOD WBC-0.3* RBC-2.83* Hgb-8.4* Hct-26.0* \nMCV-92 MCH-29.7 MCHC-32.3 RDW-16.3* RDWSD-46.7* Plt Ct-74*\n___ 04:45PM BLOOD Neuts-8* Bands-0 Lymphs-86* Monos-6 Eos-0 \nBaso-0 ___ Myelos-0 AbsNeut-0.02* AbsLymp-0.26* \nAbsMono-0.02* AbsEos-0.00* AbsBaso-0.00*\n___ 04:45PM BLOOD Glucose-123* UreaN-14 Creat-0.9 Na-137 \nK-4.2 Cl-103 HCO3-21* AnGap-17\n___ 04:45PM BLOOD ALT-9 AST-14 AlkPhos-135* TotBili-0.3\n___ 04:45PM BLOOD Albumin-3.9\n___ 05:01PM BLOOD Lactate-1.1\n___ 05:37PM URINE Color-Yellow Appear-Clear Sp ___\n___ 05:37PM URINE Blood-SM  Nitrite-NEG Protein-600 \nGlucose-NEG Ketone-10 Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\n___ 05:37PM URINE RBC-3* WBC-1 Bacteri-FEW Yeast-NONE \nEpi-<1\n___ 05:37PM URINE Mucous-RARE\n___ 05:37PM URINE CastHy-3*\n___ 05:56PM OTHER BODY FLUID FluAPCR-NEGATIVE \nFluBPCR-NEGATIVE",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-19",
        "chart_time": "104548",
        "section": "General",
        "position": 5,
        "tokenCount": 583,
        "note_metadata": {
          "note_id": "18887130-DS-19",
          "subject_id": 18887130,
          "hadm_id": 28046425,
          "note_type": "DS",
          "note_seq": 19,
          "charttime": 104548,
          "storetime": 104566.79166666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nfebrile neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture \r\n \r\nHistory of Present Illness:\r\n___ year old female DLBLC,  history of transformed diffuse large \r\nB\r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS now on decitabine, with neutropenia and ~4\r\nweeks broad spectrum antibiotics for empiric L4-5\r\ndiscitis/osteomyelitis, readmitted mid ___ for acute history of\r\nword finding difficulty and nausea vomiting without apparent\r\nsource, now presenting with 2 days of nausea/vomiting, fever, \r\nand\r\nurinary incontinence.\r\n\r\nNote her recent admit ___ she was recently admitted with\r\nmental status changes and vague confusion/word finding \r\ndifficulty\r\nand nausea/vomiting. She had been seen by ID ___ with concern \r\nfor\r\ninfection vs DVT of LLE where she has a slow healing wound, but\r\nultrasound was reassuring, but on the way home from appointment\r\nshe vomited and had chills, but no fevers She did have\r\nenterococcus UTI on admission, which didn't seem to be true UTI\r\nor explain her focal neurologic deficits, especially as she had\r\nbeen on vancomycin, but given low risks she did complete 5d\r\ncourse of amp/amox. On discharge she was continued on ppx cipro\r\nand fluc.\r\n\r\nShe was next and last seen by ___ on ___ at which point she was\r\nC2D22 dacogen. plan for dacogen ___ next at ___.  Mental\r\nstatus had resolved. Her ANC was 0 at time of that visit. \r\n\r\nShe reports feeling fairly well until ___ night when she \r\nbegan\r\ndeveloping extreme fatigue and generalized weakness. Also had 1x\r\nepisode where she suddenly had to urinate and was incontinent of\r\nurine. This happened again yesterday. No dysuria. No back pain,\r\nno headaches, visual changes, and no one extremity has been\r\nparticularly weak compared to the rest of her body ( endorses \r\nleg\r\nweakness but in line with generalized body weakness). She also\r\nhas been vomiting when she tries to eat for the past 48 hrs and\r\nhas no appetite but denies any melena, diarrhea, abd pain, and\r\nhad regular formed BM today and continues passing gas. Is \r\nburping\r\nmore than usual however. NO chest pain, dyspnea, cough, sore\r\nthroat, runny nose, or rash. All other 10 point ROS neg.\r\n\r\nED COURSE:\r\nT 100.2 up to 101.4  HR 110 BP 148/58  RR 18  94% RA. Pt \r\nreceived\r\nlinezolid, zosyn, IV APAP, multiple liters of LR. Labs with\r\nlactate 1.1, \r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission Physical Exam\r\nVITAL SIGNS: 98.0  109/68  83  18  97%RA\r\nGeneral:  NAD but weak, seems to have some mild dyspnea but\r\nstates this is baseline and denies SOB\r\nHEENT:  MMM, no OP lesions, no cervical, supraclavicular, or\r\naxillary adenopathy, no thyromegaly\r\nCV:  RR, NL S1S2 no S3S4 MRG\r\nPULM:  CTAB\r\nGI:  protuberant abd but BS+, soft, NTND, no masses or\r\nhepatosplenomegaly\r\nLIMBSSKIN:  ___ with mild trace pitting edema up to knees, well\r\nhealing ulceration over anterior shins and no skin breakdown\r\notherwise no erythema/rashes. port without erythema/drainage\r\nNEURO: generally weak and fatigued but conversant, alert,\r\nOriented x3. Cranial nerves II-XII are within normal limits\r\nexcluding visual acuity which was not assessed, no nystagmus;\r\nstrength is ___ of the proximal and distal upper and lower\r\nextremities but symmetric on both sides. no tremor/ asterixis.\r\nNeck supple.\r\n\r\nDischarge Physical Exam\r\nVS: 98.0 119/75 87 18 97 RA  \r\nGeneral: sitting comfortably in recliner eating breakfast, NAD.\r\nHEENT: moist mucus membranes, no OP lesions. Right pupil fixed\r\nand right eye with gaze palsy \r\nCV: RRR, ___ systolic murmur at LLSB. \r\nPULM: CTAB, no crackles, wheeze, rhonchi \r\nGI: Soft, NT, ND, +BS. \r\nEXT: ___ with trace edema bilat, right leg slightly larger than\r\nleft with well healed ulceration over anterior right shin and no\r\nskin breakdown.  \r\nSKIN: No new rashes or lesions. Chronic venous stasis changes\r\nbilat c/w lipodermatosclerosis\r\nNEURO: A&Ox3. Chronic and stable R sided facial droop and \r\nptosis.\r\n\r\n \r\nPertinent Results:\r\nAdmission Labs\r\n___ 04:45PM BLOOD WBC-0.3* RBC-2.83* Hgb-8.4* Hct-26.0* \r\nMCV-92 MCH-29.7 MCHC-32.3 RDW-16.3* RDWSD-46.7* Plt Ct-74*\r\n___ 04:45PM BLOOD Neuts-8* Bands-0 Lymphs-86* Monos-6 Eos-0 \r\nBaso-0 ___ Myelos-0 AbsNeut-0.02* AbsLymp-0.26* \r\nAbsMono-0.02* AbsEos-0.00* AbsBaso-0.00*\r\n___ 04:45PM BLOOD Glucose-123* UreaN-14 Creat-0.9 Na-137 \r\nK-4.2 Cl-103 HCO3-21* AnGap-17\r\n___ 04:45PM BLOOD ALT-9 AST-14 AlkPhos-135* TotBili-0.3\r\n___ 04:45PM BLOOD Albumin-3.9\r\n___ 05:01PM BLOOD Lactate-1.1\r\n___ 05:37PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 05:37PM URINE Blood-SM  Nitrite-NEG Protein-600 \r\nGlucose-NEG Ketone-10 Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\r\n___ 05:37PM URINE RBC-3* WBC-1 Bacteri-FEW Yeast-NONE \r\nEpi-<1\r\n___ 05:37PM URINE Mucous-RARE\r\n___ 05:37PM URINE CastHy-3*\r\n___ 05:56PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nDischarge Labs\r\n___ 12:02AM BLOOD WBC-2.9* RBC-2.80* Hgb-8.4* Hct-26.6* \r\nMCV-95 MCH-30.0 MCHC-31.6* RDW-17.4* RDWSD-51.3* Plt Ct-83*\r\n___ 12:02AM BLOOD Neuts-58.2 ___ Monos-8.9 Eos-0.0* \r\nBaso-0.3 NRBC-1.0* Im ___ AbsNeut-1.70 AbsLymp-0.91* \r\nAbsMono-0.26 AbsEos-0.00* AbsBaso-0.01\r\n___ 12:02AM BLOOD ___ PTT-40.8* ___\r\n___ 12:02AM BLOOD  WBC-2.9* Lymph-31 Abs ___ CD3%-70 \r\nAbs CD3-627 CD4%-42 Abs CD4-382 CD8%-26 Abs CD8-236 CD4/CD8-1.62\r\n___ 12:02AM BLOOD Glucose-118* UreaN-12 Creat-0.9 Na-139 \r\nK-4.2 Cl-102 HCO3-23 AnGap-18\r\n___ 12:02AM BLOOD Albumin-3.5 Calcium-8.3* Phos-2.6* Mg-2.1\r\n\r\nMicrobiology: Extensive workup including numerous blood \r\ncultures, spinal tap,  negative except for corona virus on \r\nextended respiratory multiplex panel. Please see OMR for \r\ndetails.\r\n\r\nImaging: All imaging consistent with priors. No signs of \r\ninfection. Performed Ultrasounds BLE negative, Brain/Spine MRI, \r\nCXR, RUE ultrasound.\r\n\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\ndiffuse large B cell lymphoma s/p a curative attempt with an \r\nautoSCT with BEAM conditioning in ___ ___s IFRT with \r\ncourse complicated by ___ pneumonitis, who was subsequently \r\nfound to have treatment-related MDS now on decitabine, with \r\nneutropenia and 6 weeks broad spectrum antibiotics for empiric \r\nL4-5 discitis/osteomyelitis, readmitted mid ___ for acute \r\nhistory of word finding difficulty and nausea vomiting without \r\napparent source, presenting with 2 days of nausea/vomiting, \r\nfever, and\r\nurinary incontinence. Incredibly extensive infectious workup \r\nnegative and fevers now resolved after almost two weeks on broad \r\nspectrum antibiotics.\r\n\r\n# Pancytopenia/MDS - per outpt decision made to treat with \r\nDacogen with plan to move towards allogeneic transplant. Was due \r\nfor decitabine ___. Extensive infectious workup and ultimately \r\nstarted Decitabine ___ and completed cycle in the hospital \r\nwithout further incident.\r\n\r\n#Elevated liver enzyemes: Unclear cause, but may be related to \r\nposaconazole level of ___. Posaconazole held starting ___ \r\nenzymes trending down. Plan to restart as outpatient.\r\n\r\n#Neutropenic fever: Resolving after several weeks of workup with \r\nno clear correlation to particular treatment or any source \r\nidentified. Did have positive coronavirus on multiplex pcr. \r\n\r\n#Lower back pain: continued gabapentin\r\n\r\n#Hx of right leg DVT:  Was on Xarelto 20 mg daily but now on \r\nhold with low platelet count.  Has IVC filter in place.  Will \r\ncontinue to hold for platelet count < 75,000. No anticoagulation\r\n\r\n#Depression: Continue home venlafaxine\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Docusate Sodium 100 mg PO BID \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 900 mg PO TID \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Omeprazole 20 mg PO DAILY \r\n9. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n  Reason for PRN duplicate override: changing dose\r\n10. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n11. Potassium Chloride 10 mEq PO DAILY \r\n12. Senna 8.6 mg PO BID:PRN constipation \r\n13. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n14. Venlafaxine 25 mg PO BID \r\n15. Ciprofloxacin HCl 500 mg PO Q12H \r\n16. Fluconazole 400 mg PO Q24H \r\n17. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n18. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n19. Diazepam 5 mg PO QHS \r\n20. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n21. Rivaroxaban 20 mg PO DAILY \r\n22. Acyclovir 400 mg PO Q8H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  Ascorbic Acid ___ mg PO BID  \r\n5.  Cyanocobalamin 1000 mcg PO QHS  \r\n6.  Diazepam 5 mg PO QHS  \r\n7.  Docusate Sodium 100 mg PO BID  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n9.  FoLIC Acid 3.2 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14.  Rivaroxaban 20 mg PO DAILY  \r\n15.  Senna 8.6 mg PO BID:PRN constipation  \r\n16.  Venlafaxine 25 mg PO BID  \r\n17. HELD- Fluconazole 400 mg PO Q24H  This medication was held. \r\nDo not restart Fluconazole until you are directed to. \r\n18. HELD- Furosemide 20 mg PO DAILY  This medication was held. \r\nDo not restart Furosemide until you are directed to by your \r\noutpatient oncologist. \r\n19. HELD- Potassium Chloride 10 mEq PO DAILY  This medication \r\nwas held. Do not restart Potassium Chloride until you speak with \r\nyour doctor. \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nMyelodysplastic syndrome\r\nNeutropenic fever \r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted to ___ for fever, nausea, and vomiting. We \r\ndid several tests to identify the cause of these symptoms but \r\nwere unable to find a source of infection. You were treated with \r\na strong antibiotic and you improved. \r\n\r\nWe also gave you a cycle of chemotherapy, which you tolerated \r\nwell. \r\n\r\nThere have been some changes to your medications which are \r\noutlined below. \r\n\r\nYou will have follow-up with Dr. ___ week. You will be \r\ncontacted with the specific day and time. \r\n\r\nPlease contact Dr. ___ if you have any questions or \r\nconcerns. Someone is available to help at any time, day or \r\nnight. \r\n\r\nIt was a pleasure taking care of you and we wish you the best, \r\nThe ___ Care Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-19:6",
      "text": "Pertinent Results:\nAdmission Labs\n___ 04:45PM BLOOD WBC-0.3* RBC-2.83* Hgb-8.4* Hct-26.0* \nMCV-92 MCH-29.7 MCHC-32.3 RDW-16.3* RDWSD-46.7* Plt Ct-74*\n___ 04:45PM BLOOD Neuts-8* Bands-0 Lymphs-86* Monos-6 Eos-0 \nBaso-0 ___ Myelos-0 AbsNeut-0.02* AbsLymp-0.26* \nAbsMono-0.02* AbsEos-0.00* AbsBaso-0.00*\n___ 04:45PM BLOOD Glucose-123* UreaN-14 Creat-0.9 Na-137 \nK-4.2 Cl-103 HCO3-21* AnGap-17\n___ 04:45PM BLOOD ALT-9 AST-14 AlkPhos-135* TotBili-0.3\n___ 04:45PM BLOOD Albumin-3.9\n___ 05:01PM BLOOD Lactate-1.1\n___ 05:37PM URINE Color-Yellow Appear-Clear Sp ___\n___ 05:37PM URINE Blood-SM  Nitrite-NEG Protein-600 \nGlucose-NEG Ketone-10 Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\n___ 05:37PM URINE RBC-3* WBC-1 Bacteri-FEW Yeast-NONE \nEpi-<1\n___ 05:37PM URINE Mucous-RARE\n___ 05:37PM URINE CastHy-3*\n___ 05:56PM OTHER BODY FLUID FluAPCR-NEGATIVE \nFluBPCR-NEGATIVE Discharge Labs\n___ 12:02AM BLOOD WBC-2.9* RBC-2.80* Hgb-8.4* Hct-26.6* \nMCV-95 MCH-30.0 MCHC-31.6* RDW-17.4* RDWSD-51.3* Plt Ct-83*\n___ 12:02AM BLOOD Neuts-58.2 ___ Monos-8.9 Eos-0.0* \nBaso-0.3 NRBC-1.0* Im ___ AbsNeut-1.70 AbsLymp-0.91* \nAbsMono-0.26 AbsEos-0.00* AbsBaso-0.01\n___ 12:02AM BLOOD ___ PTT-40.8* ___\n___ 12:02AM BLOOD  WBC-2.9* Lymph-31 Abs ___ CD3%-70 \nAbs CD3-627 CD4%-42 Abs CD4-382 CD8%-26 Abs CD8-236 CD4/CD8-1.62\n___ 12:02AM BLOOD Glucose-118* UreaN-12 Creat-0.9 Na-139 \nK-4.2 Cl-102 HCO3-23 AnGap-18\n___ 12:02AM BLOOD Albumin-3.5 Calcium-8.3* Phos-2.6* Mg-2.1 Microbiology: Extensive workup including numerous blood \ncultures, spinal tap,  negative except for corona virus on \nextended respiratory multiplex panel. Please see OMR for \ndetails. Imaging: All imaging consistent with priors. No signs of \ninfection. Performed Ultrasounds BLE negative, Brain/Spine MRI, \nCXR, RUE ultrasound.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-19",
        "chart_time": "104548",
        "section": "General",
        "position": 6,
        "tokenCount": 442,
        "note_metadata": {
          "note_id": "18887130-DS-19",
          "subject_id": 18887130,
          "hadm_id": 28046425,
          "note_type": "DS",
          "note_seq": 19,
          "charttime": 104548,
          "storetime": 104566.79166666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nfebrile neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture \r\n \r\nHistory of Present Illness:\r\n___ year old female DLBLC,  history of transformed diffuse large \r\nB\r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS now on decitabine, with neutropenia and ~4\r\nweeks broad spectrum antibiotics for empiric L4-5\r\ndiscitis/osteomyelitis, readmitted mid ___ for acute history of\r\nword finding difficulty and nausea vomiting without apparent\r\nsource, now presenting with 2 days of nausea/vomiting, fever, \r\nand\r\nurinary incontinence.\r\n\r\nNote her recent admit ___ she was recently admitted with\r\nmental status changes and vague confusion/word finding \r\ndifficulty\r\nand nausea/vomiting. She had been seen by ID ___ with concern \r\nfor\r\ninfection vs DVT of LLE where she has a slow healing wound, but\r\nultrasound was reassuring, but on the way home from appointment\r\nshe vomited and had chills, but no fevers She did have\r\nenterococcus UTI on admission, which didn't seem to be true UTI\r\nor explain her focal neurologic deficits, especially as she had\r\nbeen on vancomycin, but given low risks she did complete 5d\r\ncourse of amp/amox. On discharge she was continued on ppx cipro\r\nand fluc.\r\n\r\nShe was next and last seen by ___ on ___ at which point she was\r\nC2D22 dacogen. plan for dacogen ___ next at ___.  Mental\r\nstatus had resolved. Her ANC was 0 at time of that visit. \r\n\r\nShe reports feeling fairly well until ___ night when she \r\nbegan\r\ndeveloping extreme fatigue and generalized weakness. Also had 1x\r\nepisode where she suddenly had to urinate and was incontinent of\r\nurine. This happened again yesterday. No dysuria. No back pain,\r\nno headaches, visual changes, and no one extremity has been\r\nparticularly weak compared to the rest of her body ( endorses \r\nleg\r\nweakness but in line with generalized body weakness). She also\r\nhas been vomiting when she tries to eat for the past 48 hrs and\r\nhas no appetite but denies any melena, diarrhea, abd pain, and\r\nhad regular formed BM today and continues passing gas. Is \r\nburping\r\nmore than usual however. NO chest pain, dyspnea, cough, sore\r\nthroat, runny nose, or rash. All other 10 point ROS neg.\r\n\r\nED COURSE:\r\nT 100.2 up to 101.4  HR 110 BP 148/58  RR 18  94% RA. Pt \r\nreceived\r\nlinezolid, zosyn, IV APAP, multiple liters of LR. Labs with\r\nlactate 1.1, \r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission Physical Exam\r\nVITAL SIGNS: 98.0  109/68  83  18  97%RA\r\nGeneral:  NAD but weak, seems to have some mild dyspnea but\r\nstates this is baseline and denies SOB\r\nHEENT:  MMM, no OP lesions, no cervical, supraclavicular, or\r\naxillary adenopathy, no thyromegaly\r\nCV:  RR, NL S1S2 no S3S4 MRG\r\nPULM:  CTAB\r\nGI:  protuberant abd but BS+, soft, NTND, no masses or\r\nhepatosplenomegaly\r\nLIMBSSKIN:  ___ with mild trace pitting edema up to knees, well\r\nhealing ulceration over anterior shins and no skin breakdown\r\notherwise no erythema/rashes. port without erythema/drainage\r\nNEURO: generally weak and fatigued but conversant, alert,\r\nOriented x3. Cranial nerves II-XII are within normal limits\r\nexcluding visual acuity which was not assessed, no nystagmus;\r\nstrength is ___ of the proximal and distal upper and lower\r\nextremities but symmetric on both sides. no tremor/ asterixis.\r\nNeck supple.\r\n\r\nDischarge Physical Exam\r\nVS: 98.0 119/75 87 18 97 RA  \r\nGeneral: sitting comfortably in recliner eating breakfast, NAD.\r\nHEENT: moist mucus membranes, no OP lesions. Right pupil fixed\r\nand right eye with gaze palsy \r\nCV: RRR, ___ systolic murmur at LLSB. \r\nPULM: CTAB, no crackles, wheeze, rhonchi \r\nGI: Soft, NT, ND, +BS. \r\nEXT: ___ with trace edema bilat, right leg slightly larger than\r\nleft with well healed ulceration over anterior right shin and no\r\nskin breakdown.  \r\nSKIN: No new rashes or lesions. Chronic venous stasis changes\r\nbilat c/w lipodermatosclerosis\r\nNEURO: A&Ox3. Chronic and stable R sided facial droop and \r\nptosis.\r\n\r\n \r\nPertinent Results:\r\nAdmission Labs\r\n___ 04:45PM BLOOD WBC-0.3* RBC-2.83* Hgb-8.4* Hct-26.0* \r\nMCV-92 MCH-29.7 MCHC-32.3 RDW-16.3* RDWSD-46.7* Plt Ct-74*\r\n___ 04:45PM BLOOD Neuts-8* Bands-0 Lymphs-86* Monos-6 Eos-0 \r\nBaso-0 ___ Myelos-0 AbsNeut-0.02* AbsLymp-0.26* \r\nAbsMono-0.02* AbsEos-0.00* AbsBaso-0.00*\r\n___ 04:45PM BLOOD Glucose-123* UreaN-14 Creat-0.9 Na-137 \r\nK-4.2 Cl-103 HCO3-21* AnGap-17\r\n___ 04:45PM BLOOD ALT-9 AST-14 AlkPhos-135* TotBili-0.3\r\n___ 04:45PM BLOOD Albumin-3.9\r\n___ 05:01PM BLOOD Lactate-1.1\r\n___ 05:37PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 05:37PM URINE Blood-SM  Nitrite-NEG Protein-600 \r\nGlucose-NEG Ketone-10 Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\r\n___ 05:37PM URINE RBC-3* WBC-1 Bacteri-FEW Yeast-NONE \r\nEpi-<1\r\n___ 05:37PM URINE Mucous-RARE\r\n___ 05:37PM URINE CastHy-3*\r\n___ 05:56PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nDischarge Labs\r\n___ 12:02AM BLOOD WBC-2.9* RBC-2.80* Hgb-8.4* Hct-26.6* \r\nMCV-95 MCH-30.0 MCHC-31.6* RDW-17.4* RDWSD-51.3* Plt Ct-83*\r\n___ 12:02AM BLOOD Neuts-58.2 ___ Monos-8.9 Eos-0.0* \r\nBaso-0.3 NRBC-1.0* Im ___ AbsNeut-1.70 AbsLymp-0.91* \r\nAbsMono-0.26 AbsEos-0.00* AbsBaso-0.01\r\n___ 12:02AM BLOOD ___ PTT-40.8* ___\r\n___ 12:02AM BLOOD  WBC-2.9* Lymph-31 Abs ___ CD3%-70 \r\nAbs CD3-627 CD4%-42 Abs CD4-382 CD8%-26 Abs CD8-236 CD4/CD8-1.62\r\n___ 12:02AM BLOOD Glucose-118* UreaN-12 Creat-0.9 Na-139 \r\nK-4.2 Cl-102 HCO3-23 AnGap-18\r\n___ 12:02AM BLOOD Albumin-3.5 Calcium-8.3* Phos-2.6* Mg-2.1\r\n\r\nMicrobiology: Extensive workup including numerous blood \r\ncultures, spinal tap,  negative except for corona virus on \r\nextended respiratory multiplex panel. Please see OMR for \r\ndetails.\r\n\r\nImaging: All imaging consistent with priors. No signs of \r\ninfection. Performed Ultrasounds BLE negative, Brain/Spine MRI, \r\nCXR, RUE ultrasound.\r\n\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\ndiffuse large B cell lymphoma s/p a curative attempt with an \r\nautoSCT with BEAM conditioning in ___ ___s IFRT with \r\ncourse complicated by ___ pneumonitis, who was subsequently \r\nfound to have treatment-related MDS now on decitabine, with \r\nneutropenia and 6 weeks broad spectrum antibiotics for empiric \r\nL4-5 discitis/osteomyelitis, readmitted mid ___ for acute \r\nhistory of word finding difficulty and nausea vomiting without \r\napparent source, presenting with 2 days of nausea/vomiting, \r\nfever, and\r\nurinary incontinence. Incredibly extensive infectious workup \r\nnegative and fevers now resolved after almost two weeks on broad \r\nspectrum antibiotics.\r\n\r\n# Pancytopenia/MDS - per outpt decision made to treat with \r\nDacogen with plan to move towards allogeneic transplant. Was due \r\nfor decitabine ___. Extensive infectious workup and ultimately \r\nstarted Decitabine ___ and completed cycle in the hospital \r\nwithout further incident.\r\n\r\n#Elevated liver enzyemes: Unclear cause, but may be related to \r\nposaconazole level of ___. Posaconazole held starting ___ \r\nenzymes trending down. Plan to restart as outpatient.\r\n\r\n#Neutropenic fever: Resolving after several weeks of workup with \r\nno clear correlation to particular treatment or any source \r\nidentified. Did have positive coronavirus on multiplex pcr. \r\n\r\n#Lower back pain: continued gabapentin\r\n\r\n#Hx of right leg DVT:  Was on Xarelto 20 mg daily but now on \r\nhold with low platelet count.  Has IVC filter in place.  Will \r\ncontinue to hold for platelet count < 75,000. No anticoagulation\r\n\r\n#Depression: Continue home venlafaxine\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Docusate Sodium 100 mg PO BID \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 900 mg PO TID \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Omeprazole 20 mg PO DAILY \r\n9. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n  Reason for PRN duplicate override: changing dose\r\n10. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n11. Potassium Chloride 10 mEq PO DAILY \r\n12. Senna 8.6 mg PO BID:PRN constipation \r\n13. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n14. Venlafaxine 25 mg PO BID \r\n15. Ciprofloxacin HCl 500 mg PO Q12H \r\n16. Fluconazole 400 mg PO Q24H \r\n17. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n18. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n19. Diazepam 5 mg PO QHS \r\n20. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n21. Rivaroxaban 20 mg PO DAILY \r\n22. Acyclovir 400 mg PO Q8H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  Ascorbic Acid ___ mg PO BID  \r\n5.  Cyanocobalamin 1000 mcg PO QHS  \r\n6.  Diazepam 5 mg PO QHS  \r\n7.  Docusate Sodium 100 mg PO BID  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n9.  FoLIC Acid 3.2 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14.  Rivaroxaban 20 mg PO DAILY  \r\n15.  Senna 8.6 mg PO BID:PRN constipation  \r\n16.  Venlafaxine 25 mg PO BID  \r\n17. HELD- Fluconazole 400 mg PO Q24H  This medication was held. \r\nDo not restart Fluconazole until you are directed to. \r\n18. HELD- Furosemide 20 mg PO DAILY  This medication was held. \r\nDo not restart Furosemide until you are directed to by your \r\noutpatient oncologist. \r\n19. HELD- Potassium Chloride 10 mEq PO DAILY  This medication \r\nwas held. Do not restart Potassium Chloride until you speak with \r\nyour doctor. \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nMyelodysplastic syndrome\r\nNeutropenic fever \r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted to ___ for fever, nausea, and vomiting. We \r\ndid several tests to identify the cause of these symptoms but \r\nwere unable to find a source of infection. You were treated with \r\na strong antibiotic and you improved. \r\n\r\nWe also gave you a cycle of chemotherapy, which you tolerated \r\nwell. \r\n\r\nThere have been some changes to your medications which are \r\noutlined below. \r\n\r\nYou will have follow-up with Dr. ___ week. You will be \r\ncontacted with the specific day and time. \r\n\r\nPlease contact Dr. ___ if you have any questions or \r\nconcerns. Someone is available to help at any time, day or \r\nnight. \r\n\r\nIt was a pleasure taking care of you and we wish you the best, \r\nThe ___ Care Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-19:7",
      "text": "Brief Hospital Course:\nMrs. ___ is a ___ year old female with history of transformed \ndiffuse large B cell lymphoma s/p a curative attempt with an \nautoSCT with BEAM conditioning in ___ ___s IFRT with \ncourse complicated by ___ pneumonitis, who was subsequently \nfound to have treatment-related MDS now on decitabine, with \nneutropenia and 6 weeks broad spectrum antibiotics for empiric \nL4-5 discitis/osteomyelitis, readmitted mid ___ for acute \nhistory of word finding difficulty and nausea vomiting without \napparent source, presenting with 2 days of nausea/vomiting, \nfever, and\nurinary incontinence. Incredibly extensive infectious workup \nnegative and fevers now resolved after almost two weeks on broad \nspectrum antibiotics. # Pancytopenia/MDS - per outpt decision made to treat with \nDacogen with plan to move towards allogeneic transplant. Was due \nfor decitabine ___. Extensive infectious workup and ultimately \nstarted Decitabine ___ and completed cycle in the hospital \nwithout further incident. #Elevated liver enzyemes: Unclear cause, but may be related to \nposaconazole level of ___. Posaconazole held starting ___ \nenzymes trending down. Plan to restart as outpatient. #Neutropenic fever: Resolving after several weeks of workup with \nno clear correlation to particular treatment or any source \nidentified. Did have positive coronavirus on multiplex pcr. #Lower back pain: continued gabapentin #Hx of right leg DVT:  Was on Xarelto 20 mg daily but now on \nhold with low platelet count. Has IVC filter in place. Will \ncontinue to hold for platelet count < 75,000. No anticoagulation #Depression: Continue home venlafaxine\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Ascorbic Acid ___ mg PO BID \n2. Cyanocobalamin 1000 mcg PO QHS \n3. Docusate Sodium 100 mg PO BID \n4. FoLIC Acid 3.2 mg PO DAILY \n5. Furosemide 20 mg PO DAILY \n6. Gabapentin 900 mg PO TID \n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \n8. Omeprazole 20 mg PO DAILY \n9. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \nModerate \n  Reason for PRN duplicate override: changing dose\n10. Polyethylene Glycol 17 g PO DAILY:PRN constipation \n11. Potassium Chloride 10 mEq PO DAILY \n12. Senna 8.6 mg PO BID:PRN constipation \n13. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \n14. Venlafaxine 25 mg PO BID \n15. Ciprofloxacin HCl 500 mg PO Q12H \n16. Fluconazole 400 mg PO Q24H \n17. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \n18. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \n19. Diazepam 5 mg PO QHS \n20. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \ncongestion \n21. Rivaroxaban 20 mg PO DAILY \n22. Acyclovir 400 mg PO Q8H",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-19",
        "chart_time": "104548",
        "section": "General",
        "position": 7,
        "tokenCount": 671,
        "note_metadata": {
          "note_id": "18887130-DS-19",
          "subject_id": 18887130,
          "hadm_id": 28046425,
          "note_type": "DS",
          "note_seq": 19,
          "charttime": 104548,
          "storetime": 104566.79166666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nfebrile neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture \r\n \r\nHistory of Present Illness:\r\n___ year old female DLBLC,  history of transformed diffuse large \r\nB\r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS now on decitabine, with neutropenia and ~4\r\nweeks broad spectrum antibiotics for empiric L4-5\r\ndiscitis/osteomyelitis, readmitted mid ___ for acute history of\r\nword finding difficulty and nausea vomiting without apparent\r\nsource, now presenting with 2 days of nausea/vomiting, fever, \r\nand\r\nurinary incontinence.\r\n\r\nNote her recent admit ___ she was recently admitted with\r\nmental status changes and vague confusion/word finding \r\ndifficulty\r\nand nausea/vomiting. She had been seen by ID ___ with concern \r\nfor\r\ninfection vs DVT of LLE where she has a slow healing wound, but\r\nultrasound was reassuring, but on the way home from appointment\r\nshe vomited and had chills, but no fevers She did have\r\nenterococcus UTI on admission, which didn't seem to be true UTI\r\nor explain her focal neurologic deficits, especially as she had\r\nbeen on vancomycin, but given low risks she did complete 5d\r\ncourse of amp/amox. On discharge she was continued on ppx cipro\r\nand fluc.\r\n\r\nShe was next and last seen by ___ on ___ at which point she was\r\nC2D22 dacogen. plan for dacogen ___ next at ___.  Mental\r\nstatus had resolved. Her ANC was 0 at time of that visit. \r\n\r\nShe reports feeling fairly well until ___ night when she \r\nbegan\r\ndeveloping extreme fatigue and generalized weakness. Also had 1x\r\nepisode where she suddenly had to urinate and was incontinent of\r\nurine. This happened again yesterday. No dysuria. No back pain,\r\nno headaches, visual changes, and no one extremity has been\r\nparticularly weak compared to the rest of her body ( endorses \r\nleg\r\nweakness but in line with generalized body weakness). She also\r\nhas been vomiting when she tries to eat for the past 48 hrs and\r\nhas no appetite but denies any melena, diarrhea, abd pain, and\r\nhad regular formed BM today and continues passing gas. Is \r\nburping\r\nmore than usual however. NO chest pain, dyspnea, cough, sore\r\nthroat, runny nose, or rash. All other 10 point ROS neg.\r\n\r\nED COURSE:\r\nT 100.2 up to 101.4  HR 110 BP 148/58  RR 18  94% RA. Pt \r\nreceived\r\nlinezolid, zosyn, IV APAP, multiple liters of LR. Labs with\r\nlactate 1.1, \r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission Physical Exam\r\nVITAL SIGNS: 98.0  109/68  83  18  97%RA\r\nGeneral:  NAD but weak, seems to have some mild dyspnea but\r\nstates this is baseline and denies SOB\r\nHEENT:  MMM, no OP lesions, no cervical, supraclavicular, or\r\naxillary adenopathy, no thyromegaly\r\nCV:  RR, NL S1S2 no S3S4 MRG\r\nPULM:  CTAB\r\nGI:  protuberant abd but BS+, soft, NTND, no masses or\r\nhepatosplenomegaly\r\nLIMBSSKIN:  ___ with mild trace pitting edema up to knees, well\r\nhealing ulceration over anterior shins and no skin breakdown\r\notherwise no erythema/rashes. port without erythema/drainage\r\nNEURO: generally weak and fatigued but conversant, alert,\r\nOriented x3. Cranial nerves II-XII are within normal limits\r\nexcluding visual acuity which was not assessed, no nystagmus;\r\nstrength is ___ of the proximal and distal upper and lower\r\nextremities but symmetric on both sides. no tremor/ asterixis.\r\nNeck supple.\r\n\r\nDischarge Physical Exam\r\nVS: 98.0 119/75 87 18 97 RA  \r\nGeneral: sitting comfortably in recliner eating breakfast, NAD.\r\nHEENT: moist mucus membranes, no OP lesions. Right pupil fixed\r\nand right eye with gaze palsy \r\nCV: RRR, ___ systolic murmur at LLSB. \r\nPULM: CTAB, no crackles, wheeze, rhonchi \r\nGI: Soft, NT, ND, +BS. \r\nEXT: ___ with trace edema bilat, right leg slightly larger than\r\nleft with well healed ulceration over anterior right shin and no\r\nskin breakdown.  \r\nSKIN: No new rashes or lesions. Chronic venous stasis changes\r\nbilat c/w lipodermatosclerosis\r\nNEURO: A&Ox3. Chronic and stable R sided facial droop and \r\nptosis.\r\n\r\n \r\nPertinent Results:\r\nAdmission Labs\r\n___ 04:45PM BLOOD WBC-0.3* RBC-2.83* Hgb-8.4* Hct-26.0* \r\nMCV-92 MCH-29.7 MCHC-32.3 RDW-16.3* RDWSD-46.7* Plt Ct-74*\r\n___ 04:45PM BLOOD Neuts-8* Bands-0 Lymphs-86* Monos-6 Eos-0 \r\nBaso-0 ___ Myelos-0 AbsNeut-0.02* AbsLymp-0.26* \r\nAbsMono-0.02* AbsEos-0.00* AbsBaso-0.00*\r\n___ 04:45PM BLOOD Glucose-123* UreaN-14 Creat-0.9 Na-137 \r\nK-4.2 Cl-103 HCO3-21* AnGap-17\r\n___ 04:45PM BLOOD ALT-9 AST-14 AlkPhos-135* TotBili-0.3\r\n___ 04:45PM BLOOD Albumin-3.9\r\n___ 05:01PM BLOOD Lactate-1.1\r\n___ 05:37PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 05:37PM URINE Blood-SM  Nitrite-NEG Protein-600 \r\nGlucose-NEG Ketone-10 Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\r\n___ 05:37PM URINE RBC-3* WBC-1 Bacteri-FEW Yeast-NONE \r\nEpi-<1\r\n___ 05:37PM URINE Mucous-RARE\r\n___ 05:37PM URINE CastHy-3*\r\n___ 05:56PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nDischarge Labs\r\n___ 12:02AM BLOOD WBC-2.9* RBC-2.80* Hgb-8.4* Hct-26.6* \r\nMCV-95 MCH-30.0 MCHC-31.6* RDW-17.4* RDWSD-51.3* Plt Ct-83*\r\n___ 12:02AM BLOOD Neuts-58.2 ___ Monos-8.9 Eos-0.0* \r\nBaso-0.3 NRBC-1.0* Im ___ AbsNeut-1.70 AbsLymp-0.91* \r\nAbsMono-0.26 AbsEos-0.00* AbsBaso-0.01\r\n___ 12:02AM BLOOD ___ PTT-40.8* ___\r\n___ 12:02AM BLOOD  WBC-2.9* Lymph-31 Abs ___ CD3%-70 \r\nAbs CD3-627 CD4%-42 Abs CD4-382 CD8%-26 Abs CD8-236 CD4/CD8-1.62\r\n___ 12:02AM BLOOD Glucose-118* UreaN-12 Creat-0.9 Na-139 \r\nK-4.2 Cl-102 HCO3-23 AnGap-18\r\n___ 12:02AM BLOOD Albumin-3.5 Calcium-8.3* Phos-2.6* Mg-2.1\r\n\r\nMicrobiology: Extensive workup including numerous blood \r\ncultures, spinal tap,  negative except for corona virus on \r\nextended respiratory multiplex panel. Please see OMR for \r\ndetails.\r\n\r\nImaging: All imaging consistent with priors. No signs of \r\ninfection. Performed Ultrasounds BLE negative, Brain/Spine MRI, \r\nCXR, RUE ultrasound.\r\n\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\ndiffuse large B cell lymphoma s/p a curative attempt with an \r\nautoSCT with BEAM conditioning in ___ ___s IFRT with \r\ncourse complicated by ___ pneumonitis, who was subsequently \r\nfound to have treatment-related MDS now on decitabine, with \r\nneutropenia and 6 weeks broad spectrum antibiotics for empiric \r\nL4-5 discitis/osteomyelitis, readmitted mid ___ for acute \r\nhistory of word finding difficulty and nausea vomiting without \r\napparent source, presenting with 2 days of nausea/vomiting, \r\nfever, and\r\nurinary incontinence. Incredibly extensive infectious workup \r\nnegative and fevers now resolved after almost two weeks on broad \r\nspectrum antibiotics.\r\n\r\n# Pancytopenia/MDS - per outpt decision made to treat with \r\nDacogen with plan to move towards allogeneic transplant. Was due \r\nfor decitabine ___. Extensive infectious workup and ultimately \r\nstarted Decitabine ___ and completed cycle in the hospital \r\nwithout further incident.\r\n\r\n#Elevated liver enzyemes: Unclear cause, but may be related to \r\nposaconazole level of ___. Posaconazole held starting ___ \r\nenzymes trending down. Plan to restart as outpatient.\r\n\r\n#Neutropenic fever: Resolving after several weeks of workup with \r\nno clear correlation to particular treatment or any source \r\nidentified. Did have positive coronavirus on multiplex pcr. \r\n\r\n#Lower back pain: continued gabapentin\r\n\r\n#Hx of right leg DVT:  Was on Xarelto 20 mg daily but now on \r\nhold with low platelet count.  Has IVC filter in place.  Will \r\ncontinue to hold for platelet count < 75,000. No anticoagulation\r\n\r\n#Depression: Continue home venlafaxine\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Docusate Sodium 100 mg PO BID \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 900 mg PO TID \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Omeprazole 20 mg PO DAILY \r\n9. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n  Reason for PRN duplicate override: changing dose\r\n10. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n11. Potassium Chloride 10 mEq PO DAILY \r\n12. Senna 8.6 mg PO BID:PRN constipation \r\n13. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n14. Venlafaxine 25 mg PO BID \r\n15. Ciprofloxacin HCl 500 mg PO Q12H \r\n16. Fluconazole 400 mg PO Q24H \r\n17. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n18. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n19. Diazepam 5 mg PO QHS \r\n20. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n21. Rivaroxaban 20 mg PO DAILY \r\n22. Acyclovir 400 mg PO Q8H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  Ascorbic Acid ___ mg PO BID  \r\n5.  Cyanocobalamin 1000 mcg PO QHS  \r\n6.  Diazepam 5 mg PO QHS  \r\n7.  Docusate Sodium 100 mg PO BID  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n9.  FoLIC Acid 3.2 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14.  Rivaroxaban 20 mg PO DAILY  \r\n15.  Senna 8.6 mg PO BID:PRN constipation  \r\n16.  Venlafaxine 25 mg PO BID  \r\n17. HELD- Fluconazole 400 mg PO Q24H  This medication was held. \r\nDo not restart Fluconazole until you are directed to. \r\n18. HELD- Furosemide 20 mg PO DAILY  This medication was held. \r\nDo not restart Furosemide until you are directed to by your \r\noutpatient oncologist. \r\n19. HELD- Potassium Chloride 10 mEq PO DAILY  This medication \r\nwas held. Do not restart Potassium Chloride until you speak with \r\nyour doctor. \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nMyelodysplastic syndrome\r\nNeutropenic fever \r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted to ___ for fever, nausea, and vomiting. We \r\ndid several tests to identify the cause of these symptoms but \r\nwere unable to find a source of infection. You were treated with \r\na strong antibiotic and you improved. \r\n\r\nWe also gave you a cycle of chemotherapy, which you tolerated \r\nwell. \r\n\r\nThere have been some changes to your medications which are \r\noutlined below. \r\n\r\nYou will have follow-up with Dr. ___ week. You will be \r\ncontacted with the specific day and time. \r\n\r\nPlease contact Dr. ___ if you have any questions or \r\nconcerns. Someone is available to help at any time, day or \r\nnight. \r\n\r\nIt was a pleasure taking care of you and we wish you the best, \r\nThe ___ Care Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-19:8",
      "text": "Discharge Medications:\n1. Acyclovir 400 mg PO Q8H  \n2. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \n3. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \n4. Ascorbic Acid ___ mg PO BID  \n5. Cyanocobalamin 1000 mcg PO QHS  \n6. Diazepam 5 mg PO QHS  \n7. Docusate Sodium 100 mg PO BID  \n8. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \ncongestion  \n9. FoLIC Acid 3.2 mg PO DAILY  \n10. Gabapentin 900 mg PO TID  \n11. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \n12. Omeprazole 20 mg PO DAILY  \n13. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \n14. Rivaroxaban 20 mg PO DAILY  \n15. Senna 8.6 mg PO BID:PRN constipation  \n16. Venlafaxine 25 mg PO BID  \n17. HELD- Fluconazole 400 mg PO Q24H  This medication was held. Do not restart Fluconazole until you are directed to. 18. HELD- Furosemide 20 mg PO DAILY  This medication was held. Do not restart Furosemide until you are directed to by your \noutpatient oncologist. 19. HELD- Potassium Chloride 10 mEq PO DAILY  This medication \nwas held. Do not restart Potassium Chloride until you speak with \nyour doctor. Discharge Disposition:\nHome With Service\n \nFacility:\n___ Discharge Diagnosis:\nMyelodysplastic syndrome\nNeutropenic fever Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - requires assistance or aid (walker \nor cane).",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-19",
        "chart_time": "104548",
        "section": "General",
        "position": 8,
        "tokenCount": 350,
        "note_metadata": {
          "note_id": "18887130-DS-19",
          "subject_id": 18887130,
          "hadm_id": 28046425,
          "note_type": "DS",
          "note_seq": 19,
          "charttime": 104548,
          "storetime": 104566.79166666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nfebrile neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture \r\n \r\nHistory of Present Illness:\r\n___ year old female DLBLC,  history of transformed diffuse large \r\nB\r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS now on decitabine, with neutropenia and ~4\r\nweeks broad spectrum antibiotics for empiric L4-5\r\ndiscitis/osteomyelitis, readmitted mid ___ for acute history of\r\nword finding difficulty and nausea vomiting without apparent\r\nsource, now presenting with 2 days of nausea/vomiting, fever, \r\nand\r\nurinary incontinence.\r\n\r\nNote her recent admit ___ she was recently admitted with\r\nmental status changes and vague confusion/word finding \r\ndifficulty\r\nand nausea/vomiting. She had been seen by ID ___ with concern \r\nfor\r\ninfection vs DVT of LLE where she has a slow healing wound, but\r\nultrasound was reassuring, but on the way home from appointment\r\nshe vomited and had chills, but no fevers She did have\r\nenterococcus UTI on admission, which didn't seem to be true UTI\r\nor explain her focal neurologic deficits, especially as she had\r\nbeen on vancomycin, but given low risks she did complete 5d\r\ncourse of amp/amox. On discharge she was continued on ppx cipro\r\nand fluc.\r\n\r\nShe was next and last seen by ___ on ___ at which point she was\r\nC2D22 dacogen. plan for dacogen ___ next at ___.  Mental\r\nstatus had resolved. Her ANC was 0 at time of that visit. \r\n\r\nShe reports feeling fairly well until ___ night when she \r\nbegan\r\ndeveloping extreme fatigue and generalized weakness. Also had 1x\r\nepisode where she suddenly had to urinate and was incontinent of\r\nurine. This happened again yesterday. No dysuria. No back pain,\r\nno headaches, visual changes, and no one extremity has been\r\nparticularly weak compared to the rest of her body ( endorses \r\nleg\r\nweakness but in line with generalized body weakness). She also\r\nhas been vomiting when she tries to eat for the past 48 hrs and\r\nhas no appetite but denies any melena, diarrhea, abd pain, and\r\nhad regular formed BM today and continues passing gas. Is \r\nburping\r\nmore than usual however. NO chest pain, dyspnea, cough, sore\r\nthroat, runny nose, or rash. All other 10 point ROS neg.\r\n\r\nED COURSE:\r\nT 100.2 up to 101.4  HR 110 BP 148/58  RR 18  94% RA. Pt \r\nreceived\r\nlinezolid, zosyn, IV APAP, multiple liters of LR. Labs with\r\nlactate 1.1, \r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission Physical Exam\r\nVITAL SIGNS: 98.0  109/68  83  18  97%RA\r\nGeneral:  NAD but weak, seems to have some mild dyspnea but\r\nstates this is baseline and denies SOB\r\nHEENT:  MMM, no OP lesions, no cervical, supraclavicular, or\r\naxillary adenopathy, no thyromegaly\r\nCV:  RR, NL S1S2 no S3S4 MRG\r\nPULM:  CTAB\r\nGI:  protuberant abd but BS+, soft, NTND, no masses or\r\nhepatosplenomegaly\r\nLIMBSSKIN:  ___ with mild trace pitting edema up to knees, well\r\nhealing ulceration over anterior shins and no skin breakdown\r\notherwise no erythema/rashes. port without erythema/drainage\r\nNEURO: generally weak and fatigued but conversant, alert,\r\nOriented x3. Cranial nerves II-XII are within normal limits\r\nexcluding visual acuity which was not assessed, no nystagmus;\r\nstrength is ___ of the proximal and distal upper and lower\r\nextremities but symmetric on both sides. no tremor/ asterixis.\r\nNeck supple.\r\n\r\nDischarge Physical Exam\r\nVS: 98.0 119/75 87 18 97 RA  \r\nGeneral: sitting comfortably in recliner eating breakfast, NAD.\r\nHEENT: moist mucus membranes, no OP lesions. Right pupil fixed\r\nand right eye with gaze palsy \r\nCV: RRR, ___ systolic murmur at LLSB. \r\nPULM: CTAB, no crackles, wheeze, rhonchi \r\nGI: Soft, NT, ND, +BS. \r\nEXT: ___ with trace edema bilat, right leg slightly larger than\r\nleft with well healed ulceration over anterior right shin and no\r\nskin breakdown.  \r\nSKIN: No new rashes or lesions. Chronic venous stasis changes\r\nbilat c/w lipodermatosclerosis\r\nNEURO: A&Ox3. Chronic and stable R sided facial droop and \r\nptosis.\r\n\r\n \r\nPertinent Results:\r\nAdmission Labs\r\n___ 04:45PM BLOOD WBC-0.3* RBC-2.83* Hgb-8.4* Hct-26.0* \r\nMCV-92 MCH-29.7 MCHC-32.3 RDW-16.3* RDWSD-46.7* Plt Ct-74*\r\n___ 04:45PM BLOOD Neuts-8* Bands-0 Lymphs-86* Monos-6 Eos-0 \r\nBaso-0 ___ Myelos-0 AbsNeut-0.02* AbsLymp-0.26* \r\nAbsMono-0.02* AbsEos-0.00* AbsBaso-0.00*\r\n___ 04:45PM BLOOD Glucose-123* UreaN-14 Creat-0.9 Na-137 \r\nK-4.2 Cl-103 HCO3-21* AnGap-17\r\n___ 04:45PM BLOOD ALT-9 AST-14 AlkPhos-135* TotBili-0.3\r\n___ 04:45PM BLOOD Albumin-3.9\r\n___ 05:01PM BLOOD Lactate-1.1\r\n___ 05:37PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 05:37PM URINE Blood-SM  Nitrite-NEG Protein-600 \r\nGlucose-NEG Ketone-10 Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\r\n___ 05:37PM URINE RBC-3* WBC-1 Bacteri-FEW Yeast-NONE \r\nEpi-<1\r\n___ 05:37PM URINE Mucous-RARE\r\n___ 05:37PM URINE CastHy-3*\r\n___ 05:56PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nDischarge Labs\r\n___ 12:02AM BLOOD WBC-2.9* RBC-2.80* Hgb-8.4* Hct-26.6* \r\nMCV-95 MCH-30.0 MCHC-31.6* RDW-17.4* RDWSD-51.3* Plt Ct-83*\r\n___ 12:02AM BLOOD Neuts-58.2 ___ Monos-8.9 Eos-0.0* \r\nBaso-0.3 NRBC-1.0* Im ___ AbsNeut-1.70 AbsLymp-0.91* \r\nAbsMono-0.26 AbsEos-0.00* AbsBaso-0.01\r\n___ 12:02AM BLOOD ___ PTT-40.8* ___\r\n___ 12:02AM BLOOD  WBC-2.9* Lymph-31 Abs ___ CD3%-70 \r\nAbs CD3-627 CD4%-42 Abs CD4-382 CD8%-26 Abs CD8-236 CD4/CD8-1.62\r\n___ 12:02AM BLOOD Glucose-118* UreaN-12 Creat-0.9 Na-139 \r\nK-4.2 Cl-102 HCO3-23 AnGap-18\r\n___ 12:02AM BLOOD Albumin-3.5 Calcium-8.3* Phos-2.6* Mg-2.1\r\n\r\nMicrobiology: Extensive workup including numerous blood \r\ncultures, spinal tap,  negative except for corona virus on \r\nextended respiratory multiplex panel. Please see OMR for \r\ndetails.\r\n\r\nImaging: All imaging consistent with priors. No signs of \r\ninfection. Performed Ultrasounds BLE negative, Brain/Spine MRI, \r\nCXR, RUE ultrasound.\r\n\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\ndiffuse large B cell lymphoma s/p a curative attempt with an \r\nautoSCT with BEAM conditioning in ___ ___s IFRT with \r\ncourse complicated by ___ pneumonitis, who was subsequently \r\nfound to have treatment-related MDS now on decitabine, with \r\nneutropenia and 6 weeks broad spectrum antibiotics for empiric \r\nL4-5 discitis/osteomyelitis, readmitted mid ___ for acute \r\nhistory of word finding difficulty and nausea vomiting without \r\napparent source, presenting with 2 days of nausea/vomiting, \r\nfever, and\r\nurinary incontinence. Incredibly extensive infectious workup \r\nnegative and fevers now resolved after almost two weeks on broad \r\nspectrum antibiotics.\r\n\r\n# Pancytopenia/MDS - per outpt decision made to treat with \r\nDacogen with plan to move towards allogeneic transplant. Was due \r\nfor decitabine ___. Extensive infectious workup and ultimately \r\nstarted Decitabine ___ and completed cycle in the hospital \r\nwithout further incident.\r\n\r\n#Elevated liver enzyemes: Unclear cause, but may be related to \r\nposaconazole level of ___. Posaconazole held starting ___ \r\nenzymes trending down. Plan to restart as outpatient.\r\n\r\n#Neutropenic fever: Resolving after several weeks of workup with \r\nno clear correlation to particular treatment or any source \r\nidentified. Did have positive coronavirus on multiplex pcr. \r\n\r\n#Lower back pain: continued gabapentin\r\n\r\n#Hx of right leg DVT:  Was on Xarelto 20 mg daily but now on \r\nhold with low platelet count.  Has IVC filter in place.  Will \r\ncontinue to hold for platelet count < 75,000. No anticoagulation\r\n\r\n#Depression: Continue home venlafaxine\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Docusate Sodium 100 mg PO BID \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 900 mg PO TID \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Omeprazole 20 mg PO DAILY \r\n9. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n  Reason for PRN duplicate override: changing dose\r\n10. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n11. Potassium Chloride 10 mEq PO DAILY \r\n12. Senna 8.6 mg PO BID:PRN constipation \r\n13. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n14. Venlafaxine 25 mg PO BID \r\n15. Ciprofloxacin HCl 500 mg PO Q12H \r\n16. Fluconazole 400 mg PO Q24H \r\n17. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n18. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n19. Diazepam 5 mg PO QHS \r\n20. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n21. Rivaroxaban 20 mg PO DAILY \r\n22. Acyclovir 400 mg PO Q8H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  Ascorbic Acid ___ mg PO BID  \r\n5.  Cyanocobalamin 1000 mcg PO QHS  \r\n6.  Diazepam 5 mg PO QHS  \r\n7.  Docusate Sodium 100 mg PO BID  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n9.  FoLIC Acid 3.2 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14.  Rivaroxaban 20 mg PO DAILY  \r\n15.  Senna 8.6 mg PO BID:PRN constipation  \r\n16.  Venlafaxine 25 mg PO BID  \r\n17. HELD- Fluconazole 400 mg PO Q24H  This medication was held. \r\nDo not restart Fluconazole until you are directed to. \r\n18. HELD- Furosemide 20 mg PO DAILY  This medication was held. \r\nDo not restart Furosemide until you are directed to by your \r\noutpatient oncologist. \r\n19. HELD- Potassium Chloride 10 mEq PO DAILY  This medication \r\nwas held. Do not restart Potassium Chloride until you speak with \r\nyour doctor. \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nMyelodysplastic syndrome\r\nNeutropenic fever \r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted to ___ for fever, nausea, and vomiting. We \r\ndid several tests to identify the cause of these symptoms but \r\nwere unable to find a source of infection. You were treated with \r\na strong antibiotic and you improved. \r\n\r\nWe also gave you a cycle of chemotherapy, which you tolerated \r\nwell. \r\n\r\nThere have been some changes to your medications which are \r\noutlined below. \r\n\r\nYou will have follow-up with Dr. ___ week. You will be \r\ncontacted with the specific day and time. \r\n\r\nPlease contact Dr. ___ if you have any questions or \r\nconcerns. Someone is available to help at any time, day or \r\nnight. \r\n\r\nIt was a pleasure taking care of you and we wish you the best, \r\nThe ___ Care Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-19:9",
      "text": "Discharge Instructions:\nDear Ms. ___, You were admitted to ___ for fever, nausea, and vomiting. We \ndid several tests to identify the cause of these symptoms but \nwere unable to find a source of infection. You were treated with \na strong antibiotic and you improved. We also gave you a cycle of chemotherapy, which you tolerated \nwell. There have been some changes to your medications which are \noutlined below. You will have follow-up with Dr. ___ week. You will be \ncontacted with the specific day and time. Please contact Dr. ___ if you have any questions or \nconcerns. Someone is available to help at any time, day or \nnight. It was a pleasure taking care of you and we wish you the best, \nThe ___ Care Team \n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-19",
        "chart_time": "104548",
        "section": "General",
        "position": 9,
        "tokenCount": 186,
        "note_metadata": {
          "note_id": "18887130-DS-19",
          "subject_id": 18887130,
          "hadm_id": 28046425,
          "note_type": "DS",
          "note_seq": 19,
          "charttime": 104548,
          "storetime": 104566.79166666667,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nfebrile neutropenia\r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture \r\n \r\nHistory of Present Illness:\r\n___ year old female DLBLC,  history of transformed diffuse large \r\nB\r\ncell lymphoma s/p a curative attempt with an autoSCT with BEAM \r\nconditioning in ___ ___s IFRT with course complicated \r\nby ___ pneumonitis, who was subsequently found to have\r\ntreatment-related MDS now on decitabine, with neutropenia and ~4\r\nweeks broad spectrum antibiotics for empiric L4-5\r\ndiscitis/osteomyelitis, readmitted mid ___ for acute history of\r\nword finding difficulty and nausea vomiting without apparent\r\nsource, now presenting with 2 days of nausea/vomiting, fever, \r\nand\r\nurinary incontinence.\r\n\r\nNote her recent admit ___ she was recently admitted with\r\nmental status changes and vague confusion/word finding \r\ndifficulty\r\nand nausea/vomiting. She had been seen by ID ___ with concern \r\nfor\r\ninfection vs DVT of LLE where she has a slow healing wound, but\r\nultrasound was reassuring, but on the way home from appointment\r\nshe vomited and had chills, but no fevers She did have\r\nenterococcus UTI on admission, which didn't seem to be true UTI\r\nor explain her focal neurologic deficits, especially as she had\r\nbeen on vancomycin, but given low risks she did complete 5d\r\ncourse of amp/amox. On discharge she was continued on ppx cipro\r\nand fluc.\r\n\r\nShe was next and last seen by ___ on ___ at which point she was\r\nC2D22 dacogen. plan for dacogen ___ next at ___.  Mental\r\nstatus had resolved. Her ANC was 0 at time of that visit. \r\n\r\nShe reports feeling fairly well until ___ night when she \r\nbegan\r\ndeveloping extreme fatigue and generalized weakness. Also had 1x\r\nepisode where she suddenly had to urinate and was incontinent of\r\nurine. This happened again yesterday. No dysuria. No back pain,\r\nno headaches, visual changes, and no one extremity has been\r\nparticularly weak compared to the rest of her body ( endorses \r\nleg\r\nweakness but in line with generalized body weakness). She also\r\nhas been vomiting when she tries to eat for the past 48 hrs and\r\nhas no appetite but denies any melena, diarrhea, abd pain, and\r\nhad regular formed BM today and continues passing gas. Is \r\nburping\r\nmore than usual however. NO chest pain, dyspnea, cough, sore\r\nthroat, runny nose, or rash. All other 10 point ROS neg.\r\n\r\nED COURSE:\r\nT 100.2 up to 101.4  HR 110 BP 148/58  RR 18  94% RA. Pt \r\nreceived\r\nlinezolid, zosyn, IV APAP, multiple liters of LR. Labs with\r\nlactate 1.1, \r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nAdmission Physical Exam\r\nVITAL SIGNS: 98.0  109/68  83  18  97%RA\r\nGeneral:  NAD but weak, seems to have some mild dyspnea but\r\nstates this is baseline and denies SOB\r\nHEENT:  MMM, no OP lesions, no cervical, supraclavicular, or\r\naxillary adenopathy, no thyromegaly\r\nCV:  RR, NL S1S2 no S3S4 MRG\r\nPULM:  CTAB\r\nGI:  protuberant abd but BS+, soft, NTND, no masses or\r\nhepatosplenomegaly\r\nLIMBSSKIN:  ___ with mild trace pitting edema up to knees, well\r\nhealing ulceration over anterior shins and no skin breakdown\r\notherwise no erythema/rashes. port without erythema/drainage\r\nNEURO: generally weak and fatigued but conversant, alert,\r\nOriented x3. Cranial nerves II-XII are within normal limits\r\nexcluding visual acuity which was not assessed, no nystagmus;\r\nstrength is ___ of the proximal and distal upper and lower\r\nextremities but symmetric on both sides. no tremor/ asterixis.\r\nNeck supple.\r\n\r\nDischarge Physical Exam\r\nVS: 98.0 119/75 87 18 97 RA  \r\nGeneral: sitting comfortably in recliner eating breakfast, NAD.\r\nHEENT: moist mucus membranes, no OP lesions. Right pupil fixed\r\nand right eye with gaze palsy \r\nCV: RRR, ___ systolic murmur at LLSB. \r\nPULM: CTAB, no crackles, wheeze, rhonchi \r\nGI: Soft, NT, ND, +BS. \r\nEXT: ___ with trace edema bilat, right leg slightly larger than\r\nleft with well healed ulceration over anterior right shin and no\r\nskin breakdown.  \r\nSKIN: No new rashes or lesions. Chronic venous stasis changes\r\nbilat c/w lipodermatosclerosis\r\nNEURO: A&Ox3. Chronic and stable R sided facial droop and \r\nptosis.\r\n\r\n \r\nPertinent Results:\r\nAdmission Labs\r\n___ 04:45PM BLOOD WBC-0.3* RBC-2.83* Hgb-8.4* Hct-26.0* \r\nMCV-92 MCH-29.7 MCHC-32.3 RDW-16.3* RDWSD-46.7* Plt Ct-74*\r\n___ 04:45PM BLOOD Neuts-8* Bands-0 Lymphs-86* Monos-6 Eos-0 \r\nBaso-0 ___ Myelos-0 AbsNeut-0.02* AbsLymp-0.26* \r\nAbsMono-0.02* AbsEos-0.00* AbsBaso-0.00*\r\n___ 04:45PM BLOOD Glucose-123* UreaN-14 Creat-0.9 Na-137 \r\nK-4.2 Cl-103 HCO3-21* AnGap-17\r\n___ 04:45PM BLOOD ALT-9 AST-14 AlkPhos-135* TotBili-0.3\r\n___ 04:45PM BLOOD Albumin-3.9\r\n___ 05:01PM BLOOD Lactate-1.1\r\n___ 05:37PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 05:37PM URINE Blood-SM  Nitrite-NEG Protein-600 \r\nGlucose-NEG Ketone-10 Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\r\n___ 05:37PM URINE RBC-3* WBC-1 Bacteri-FEW Yeast-NONE \r\nEpi-<1\r\n___ 05:37PM URINE Mucous-RARE\r\n___ 05:37PM URINE CastHy-3*\r\n___ 05:56PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nDischarge Labs\r\n___ 12:02AM BLOOD WBC-2.9* RBC-2.80* Hgb-8.4* Hct-26.6* \r\nMCV-95 MCH-30.0 MCHC-31.6* RDW-17.4* RDWSD-51.3* Plt Ct-83*\r\n___ 12:02AM BLOOD Neuts-58.2 ___ Monos-8.9 Eos-0.0* \r\nBaso-0.3 NRBC-1.0* Im ___ AbsNeut-1.70 AbsLymp-0.91* \r\nAbsMono-0.26 AbsEos-0.00* AbsBaso-0.01\r\n___ 12:02AM BLOOD ___ PTT-40.8* ___\r\n___ 12:02AM BLOOD  WBC-2.9* Lymph-31 Abs ___ CD3%-70 \r\nAbs CD3-627 CD4%-42 Abs CD4-382 CD8%-26 Abs CD8-236 CD4/CD8-1.62\r\n___ 12:02AM BLOOD Glucose-118* UreaN-12 Creat-0.9 Na-139 \r\nK-4.2 Cl-102 HCO3-23 AnGap-18\r\n___ 12:02AM BLOOD Albumin-3.5 Calcium-8.3* Phos-2.6* Mg-2.1\r\n\r\nMicrobiology: Extensive workup including numerous blood \r\ncultures, spinal tap,  negative except for corona virus on \r\nextended respiratory multiplex panel. Please see OMR for \r\ndetails.\r\n\r\nImaging: All imaging consistent with priors. No signs of \r\ninfection. Performed Ultrasounds BLE negative, Brain/Spine MRI, \r\nCXR, RUE ultrasound.\r\n\r\n \r\nBrief Hospital Course:\r\nMrs. ___ is a ___ year old female with history of transformed \r\ndiffuse large B cell lymphoma s/p a curative attempt with an \r\nautoSCT with BEAM conditioning in ___ ___s IFRT with \r\ncourse complicated by ___ pneumonitis, who was subsequently \r\nfound to have treatment-related MDS now on decitabine, with \r\nneutropenia and 6 weeks broad spectrum antibiotics for empiric \r\nL4-5 discitis/osteomyelitis, readmitted mid ___ for acute \r\nhistory of word finding difficulty and nausea vomiting without \r\napparent source, presenting with 2 days of nausea/vomiting, \r\nfever, and\r\nurinary incontinence. Incredibly extensive infectious workup \r\nnegative and fevers now resolved after almost two weeks on broad \r\nspectrum antibiotics.\r\n\r\n# Pancytopenia/MDS - per outpt decision made to treat with \r\nDacogen with plan to move towards allogeneic transplant. Was due \r\nfor decitabine ___. Extensive infectious workup and ultimately \r\nstarted Decitabine ___ and completed cycle in the hospital \r\nwithout further incident.\r\n\r\n#Elevated liver enzyemes: Unclear cause, but may be related to \r\nposaconazole level of ___. Posaconazole held starting ___ \r\nenzymes trending down. Plan to restart as outpatient.\r\n\r\n#Neutropenic fever: Resolving after several weeks of workup with \r\nno clear correlation to particular treatment or any source \r\nidentified. Did have positive coronavirus on multiplex pcr. \r\n\r\n#Lower back pain: continued gabapentin\r\n\r\n#Hx of right leg DVT:  Was on Xarelto 20 mg daily but now on \r\nhold with low platelet count.  Has IVC filter in place.  Will \r\ncontinue to hold for platelet count < 75,000. No anticoagulation\r\n\r\n#Depression: Continue home venlafaxine\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ascorbic Acid ___ mg PO BID \r\n2. Cyanocobalamin 1000 mcg PO QHS \r\n3. Docusate Sodium 100 mg PO BID \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Furosemide 20 mg PO DAILY \r\n6. Gabapentin 900 mg PO TID \r\n7. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze  \r\n8. Omeprazole 20 mg PO DAILY \r\n9. OxyCODONE (Immediate Release) ___ mg PO Q6H:PRN Pain - \r\nModerate \r\n  Reason for PRN duplicate override: changing dose\r\n10. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n11. Potassium Chloride 10 mEq PO DAILY \r\n12. Senna 8.6 mg PO BID:PRN constipation \r\n13. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n14. Venlafaxine 25 mg PO BID \r\n15. Ciprofloxacin HCl 500 mg PO Q12H \r\n16. Fluconazole 400 mg PO Q24H \r\n17. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H \r\n18. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n19. Diazepam 5 mg PO QHS \r\n20. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion \r\n21. Rivaroxaban 20 mg PO DAILY \r\n22. Acyclovir 400 mg PO Q8H \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H  \r\n4.  Ascorbic Acid ___ mg PO BID  \r\n5.  Cyanocobalamin 1000 mcg PO QHS  \r\n6.  Diazepam 5 mg PO QHS  \r\n7.  Docusate Sodium 100 mg PO BID  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN nasal \r\ncongestion  \r\n9.  FoLIC Acid 3.2 mg PO DAILY  \r\n10.  Gabapentin 900 mg PO TID  \r\n11.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheeze   \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14.  Rivaroxaban 20 mg PO DAILY  \r\n15.  Senna 8.6 mg PO BID:PRN constipation  \r\n16.  Venlafaxine 25 mg PO BID  \r\n17. HELD- Fluconazole 400 mg PO Q24H  This medication was held. \r\nDo not restart Fluconazole until you are directed to. \r\n18. HELD- Furosemide 20 mg PO DAILY  This medication was held. \r\nDo not restart Furosemide until you are directed to by your \r\noutpatient oncologist. \r\n19. HELD- Potassium Chloride 10 mEq PO DAILY  This medication \r\nwas held. Do not restart Potassium Chloride until you speak with \r\nyour doctor. \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nMyelodysplastic syndrome\r\nNeutropenic fever \r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted to ___ for fever, nausea, and vomiting. We \r\ndid several tests to identify the cause of these symptoms but \r\nwere unable to find a source of infection. You were treated with \r\na strong antibiotic and you improved. \r\n\r\nWe also gave you a cycle of chemotherapy, which you tolerated \r\nwell. \r\n\r\nThere have been some changes to your medications which are \r\noutlined below. \r\n\r\nYou will have follow-up with Dr. ___ week. You will be \r\ncontacted with the specific day and time. \r\n\r\nPlease contact Dr. ___ if you have any questions or \r\nconcerns. Someone is available to help at any time, day or \r\nnight. \r\n\r\nIt was a pleasure taking care of you and we wish you the best, \r\nThe ___ Care Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-20:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \ndapsone\n \nAttending: ___. Chief Complaint:\nfatigue, abdominal cramping, diarrhea and decreased appetite\n \nMajor Surgical or Invasive Procedure:\nNone History of Present Illness:\nA ___ year old female with a history of transformed diffuse large \nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \n conditioning in ___ ___s IFRT with course complicated \n by ___ pneumonitis, who was subsequently found to have \ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \npresenting with 2 days of poor oral intake, fatigue, diarrhea \nand abdominal cramping.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-20",
        "chart_time": "104566",
        "section": "General",
        "position": 0,
        "tokenCount": 187,
        "note_metadata": {
          "note_id": "18887130-DS-20",
          "subject_id": 18887130,
          "hadm_id": 27191597,
          "note_type": "DS",
          "note_seq": 20,
          "charttime": 104566,
          "storetime": 104566.725,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfatigue, abdominal cramping, diarrhea and decreased appetite\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed diffuse large \r\nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \r\n conditioning in ___ ___s IFRT with course complicated \r\n by ___ pneumonitis, who was subsequently found to have \r\ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \r\npresenting with 2 days of poor oral intake, fatigue, diarrhea \r\nand abdominal cramping.\r\n\r\nREVIEW OF SYSTEMS:\r\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. \r\nHEENT: No congestion, sore throat. No sores in the mouth,\r\npainful swallowing, sinus tenderness. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough; notes shortness of breath with exertion which\r\nhas increased somewhat; no shortness of breath at rest; no\r\nwheezing or hemoptysis. \r\nGI: GI upset with no specific nausea or vomiting with\r\ndecreased food intake; + diarrhea ___ night and ___ AM with\r\nepigatric pain. No constipation, hematochezia, or melena. \r\nGU: No dysuria or change in bladder habits. \r\nMSK: Right lower back pain much improved. No need for pain\r\nmedications. Occasional left lower back/sciatica pain which is\r\nchronic.  \r\nDERM: No new rashes or skin lesions. \r\nNEURO: Alert and oriented; no further issues with word finding;\r\nno confusion. + headache on ___ with history of migraines.\r\nNo visual changes. Slight lightheadedness. Usual numbness of\r\nright toes following prior surgery; no increased numbness. Has\r\nstarted tapering her Gabapentin but numbness of fingers has\r\nimproved.\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed ___ with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PE:\r\nGEN: More tired appearing in NAD\r\nWT: 101.6 lbs. \r\nVS: TC 98.5 PO 127/84 86 18 98%RA \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2 no MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg\r\nwith well healed area with no further surrounding erythema;\r\nhyperpigmented skin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n\r\nDISCHARGE PE:\r\nGEN: NAD. Fatigue improved\r\nWT: 101.6 lbs. \r\nVS: TC 97.7 108/54 80 20 96%RA  \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2. No MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg with well \r\nhealed area with no further surrounding erythema; hyperpigmented \r\nskin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n \r\nPertinent Results:\r\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \r\nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\r\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \r\nMAGNESIUM-2.0\r\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \r\nPHOS-131* TOT BILI-0.5\r\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \r\nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\r\n___ 10:45PM URINE  MUCOUS-RARE\r\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \r\nEPI-1\r\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \r\nLEUK-NEG\r\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\r\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\r\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \r\nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \r\nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\r\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \r\nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \r\nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\r\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \r\nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\r\n___ 12:00AM   IgG-762\r\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \r\nMAGNESIUM-2.0\r\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \r\nPHOS-127* TOT BILI-0.4\r\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \r\nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\r\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \r\nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\r\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \r\nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \r\nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\r\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \r\nCl-105 HCO3-22 AnGap-16\r\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \r\nTotBili-0.5\r\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\r\n___ 12:00AM BLOOD IgG-762\r\n\r\nMICRO:\r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Pending): \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Pending): \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n\r\nBLOOD CULTURE ___ AND ___ NTD\r\n \r\nBrief Hospital Course:\r\nASSESSMENT AND PLAN: ___ year old female with history of \r\ntransformed diffuse large B cell lymphoma ___ a curative attempt \r\nwith an AutoSCT with BEAM conditioning in ___ ___s \r\nIFRT with course complicated by BCNU pneumonitis as well as \r\npersistent norovirus with now noted treatment related MDS ___ \r\nC3 of Dacogen) presenting with poor oral intake, diarrhea and \r\nfatigue\r\n\r\n#Diarrhea, epigastric discomfort and poor oral intake: Improved \r\nsince admission. Poor intake in the past 2 days prior to \r\nadmission. No vomiting or nausea. Had ___ loose stools since \r\nadmission. No fevers at home and remained afebrile throughout \r\nhospital course. No other associated infectious symptoms \r\ncurrently.\r\n-Cdiff negative; other stool cultures PND at discharge \r\n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \r\nat discharge \r\n\r\n#Hypokalemia: Now normalized, was 3.0 prior to admission. Her \r\nhypokalemia was noted in the setting of decreased oral intake \r\nand GI loss (diarrhea). Received K+ repletions at home. \r\n\r\n#Shortness of breath on exertion and lightheadedness: Improved \r\nsince admission. Etiology likely related to profound anemia and \r\ndecreased oral intake. Received 1U\r\nprbcs at clinic prior to admission and received 1U in-house for \r\nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \r\nacute pulmonary process. Hemoglobin 9.4 at discharge. \r\n\r\n#MDS: Noted for rapid progression of pancytopenia, particularly \r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with \r\nnoted cytogenetic abnormalities concerning for treatment related \r\nMDS. ___ made to treat with Dacogen with\r\nplan to move towards allogeneic transplant. Neutrophils and \r\nplatelets recovered prior to starting ___ cycle. Counts now low \r\nfollowing treatment as expected although platelet appear to be \r\nrecovering. She is currently ___ ___ C3 of Dacogen. \r\n-transfuse for platelets < 20,000 (54 at discharge) and HGB < \r\n7.5 (9.4 at discharge).\r\n-C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \r\nforward with allogeneic transplant. Has unrelated donor. \r\n-Ciprofloxacin and Fluconazole have been on hold; restarted \r\nciprofloxacin on admission as ___ < 500. \r\n-Bactrim discontinued as CD4 count > 200\r\n-Will monitor IGG level; give IVIG for IGG less than 300 or \r\ninfections as IVIG can affect counts. Last IVIG ___ = 762\r\n\r\n#Lymphoma/CLL/Disease Status: Has been in remission with last CT \r\nscan in ___ without evidence of lymphoma/adenopathy. Has \r\nhistory of CLL as well; no evidence of this on BM biopsy by \r\nreport. \r\n\r\n#Lower back pain: None on admission. No longer using narcotics \r\nor oxycontin. Continues on Gabapentin taper \r\n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.\r\n\r\n#Headache: History of headaches; reported an episode on ___ \r\nbut has had extensive w/u in the past that were reassuring. \r\nDenies headache since ___. Will not pursue further evaluation \r\nor treatment unless acute worsening or focal deficits\r\n\r\n#Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \r\n75,000. Has IVC filter in place.\r\n\r\n#Depression: Continue home venlafaxine\r\n\r\nProphylaxes:\r\n# Access: L POC placed ___\r\n# FEN: neutropenic diet\r\n# Bowel regimen: holding given diarrhea\r\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\r\n# Contact: ___ (husband)Phone number: ___ \r\nCell phone: ___ ___ (daughter) ___ \r\n# Disposition: Discharged ___. RTC on ___ for follow up\r\n# Code Status: FULL \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing \r\n3. Docusate Sodium 100 mg PO BID:PRN constipation \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 800 mg PO QAFTERNOON \r\n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n9. Senna 8.6 mg PO BID:PRN constipation \r\n10. Venlafaxine 25 mg PO BID \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Gabapentin 700 mg PO QPM \r\n13. Gabapentin 900 mg PO QAM \r\n \r\nDischarge Medications:\r\n1.  Ciprofloxacin HCl 500 mg PO Q12H  \r\n2.  Acyclovir 400 mg PO Q8H  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  FoLIC Acid 3.2 mg PO DAILY  \r\n6.  Gabapentin 800 mg PO QAFTERNOON  \r\n7.  Gabapentin 700 mg PO QPM  \r\n8.  Gabapentin 900 mg PO QAM  \r\n9.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiarrhea\r\nMDS\r\n___ DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___:\r\n\r\nYou were admitted because you were having decreased appetite, \r\nfatigue and diarrhea for several days at home. You received red \r\nblood cell transfusion and intravenous fluids with improvements \r\nin your symptoms. We think that these symptoms are likely side \r\neffects of your chemotherapy as further workup did not show a \r\nsource of infection. Please continue to take all of your \r\nmedications as ordered. Refer below for your next clinic \r\nappointment.\r\n\r\nIt was a pleasure taking care of you!\r\n\r\nSincerely,\r\nYOUR ___ TEAM\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-20:1",
      "text": "REVIEW OF SYSTEMS:\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. HEENT: No congestion, sore throat. No sores in the mouth,\npainful swallowing, sinus tenderness. CARDS: No chest pain, chest pressure, exertional symptoms, or\npalpitations. PULM: No cough; notes shortness of breath with exertion which\nhas increased somewhat; no shortness of breath at rest; no\nwheezing or hemoptysis. GI: GI upset with no specific nausea or vomiting with\ndecreased food intake; + diarrhea ___ night and ___ AM with\nepigatric pain. No constipation, hematochezia, or melena. GU: No dysuria or change in bladder habits. MSK: Right lower back pain much improved. No need for pain\nmedications. Occasional left lower back/sciatica pain which is\nchronic. DERM: No new rashes or skin lesions. NEURO: Alert and oriented; no further issues with word finding;\nno confusion. + headache on ___ with history of migraines. No visual changes. Slight lightheadedness. Usual numbness of\nright toes following prior surgery; no increased numbness. Has\nstarted tapering her Gabapentin but numbness of fingers has\nimproved.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-20",
        "chart_time": "104566",
        "section": "General",
        "position": 1,
        "tokenCount": 275,
        "note_metadata": {
          "note_id": "18887130-DS-20",
          "subject_id": 18887130,
          "hadm_id": 27191597,
          "note_type": "DS",
          "note_seq": 20,
          "charttime": 104566,
          "storetime": 104566.725,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfatigue, abdominal cramping, diarrhea and decreased appetite\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed diffuse large \r\nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \r\n conditioning in ___ ___s IFRT with course complicated \r\n by ___ pneumonitis, who was subsequently found to have \r\ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \r\npresenting with 2 days of poor oral intake, fatigue, diarrhea \r\nand abdominal cramping.\r\n\r\nREVIEW OF SYSTEMS:\r\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. \r\nHEENT: No congestion, sore throat. No sores in the mouth,\r\npainful swallowing, sinus tenderness. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough; notes shortness of breath with exertion which\r\nhas increased somewhat; no shortness of breath at rest; no\r\nwheezing or hemoptysis. \r\nGI: GI upset with no specific nausea or vomiting with\r\ndecreased food intake; + diarrhea ___ night and ___ AM with\r\nepigatric pain. No constipation, hematochezia, or melena. \r\nGU: No dysuria or change in bladder habits. \r\nMSK: Right lower back pain much improved. No need for pain\r\nmedications. Occasional left lower back/sciatica pain which is\r\nchronic.  \r\nDERM: No new rashes or skin lesions. \r\nNEURO: Alert and oriented; no further issues with word finding;\r\nno confusion. + headache on ___ with history of migraines.\r\nNo visual changes. Slight lightheadedness. Usual numbness of\r\nright toes following prior surgery; no increased numbness. Has\r\nstarted tapering her Gabapentin but numbness of fingers has\r\nimproved.\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed ___ with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PE:\r\nGEN: More tired appearing in NAD\r\nWT: 101.6 lbs. \r\nVS: TC 98.5 PO 127/84 86 18 98%RA \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2 no MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg\r\nwith well healed area with no further surrounding erythema;\r\nhyperpigmented skin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n\r\nDISCHARGE PE:\r\nGEN: NAD. Fatigue improved\r\nWT: 101.6 lbs. \r\nVS: TC 97.7 108/54 80 20 96%RA  \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2. No MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg with well \r\nhealed area with no further surrounding erythema; hyperpigmented \r\nskin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n \r\nPertinent Results:\r\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \r\nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\r\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \r\nMAGNESIUM-2.0\r\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \r\nPHOS-131* TOT BILI-0.5\r\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \r\nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\r\n___ 10:45PM URINE  MUCOUS-RARE\r\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \r\nEPI-1\r\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \r\nLEUK-NEG\r\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\r\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\r\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \r\nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \r\nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\r\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \r\nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \r\nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\r\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \r\nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\r\n___ 12:00AM   IgG-762\r\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \r\nMAGNESIUM-2.0\r\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \r\nPHOS-127* TOT BILI-0.4\r\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \r\nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\r\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \r\nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\r\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \r\nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \r\nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\r\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \r\nCl-105 HCO3-22 AnGap-16\r\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \r\nTotBili-0.5\r\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\r\n___ 12:00AM BLOOD IgG-762\r\n\r\nMICRO:\r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Pending): \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Pending): \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n\r\nBLOOD CULTURE ___ AND ___ NTD\r\n \r\nBrief Hospital Course:\r\nASSESSMENT AND PLAN: ___ year old female with history of \r\ntransformed diffuse large B cell lymphoma ___ a curative attempt \r\nwith an AutoSCT with BEAM conditioning in ___ ___s \r\nIFRT with course complicated by BCNU pneumonitis as well as \r\npersistent norovirus with now noted treatment related MDS ___ \r\nC3 of Dacogen) presenting with poor oral intake, diarrhea and \r\nfatigue\r\n\r\n#Diarrhea, epigastric discomfort and poor oral intake: Improved \r\nsince admission. Poor intake in the past 2 days prior to \r\nadmission. No vomiting or nausea. Had ___ loose stools since \r\nadmission. No fevers at home and remained afebrile throughout \r\nhospital course. No other associated infectious symptoms \r\ncurrently.\r\n-Cdiff negative; other stool cultures PND at discharge \r\n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \r\nat discharge \r\n\r\n#Hypokalemia: Now normalized, was 3.0 prior to admission. Her \r\nhypokalemia was noted in the setting of decreased oral intake \r\nand GI loss (diarrhea). Received K+ repletions at home. \r\n\r\n#Shortness of breath on exertion and lightheadedness: Improved \r\nsince admission. Etiology likely related to profound anemia and \r\ndecreased oral intake. Received 1U\r\nprbcs at clinic prior to admission and received 1U in-house for \r\nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \r\nacute pulmonary process. Hemoglobin 9.4 at discharge. \r\n\r\n#MDS: Noted for rapid progression of pancytopenia, particularly \r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with \r\nnoted cytogenetic abnormalities concerning for treatment related \r\nMDS. ___ made to treat with Dacogen with\r\nplan to move towards allogeneic transplant. Neutrophils and \r\nplatelets recovered prior to starting ___ cycle. Counts now low \r\nfollowing treatment as expected although platelet appear to be \r\nrecovering. She is currently ___ ___ C3 of Dacogen. \r\n-transfuse for platelets < 20,000 (54 at discharge) and HGB < \r\n7.5 (9.4 at discharge).\r\n-C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \r\nforward with allogeneic transplant. Has unrelated donor. \r\n-Ciprofloxacin and Fluconazole have been on hold; restarted \r\nciprofloxacin on admission as ___ < 500. \r\n-Bactrim discontinued as CD4 count > 200\r\n-Will monitor IGG level; give IVIG for IGG less than 300 or \r\ninfections as IVIG can affect counts. Last IVIG ___ = 762\r\n\r\n#Lymphoma/CLL/Disease Status: Has been in remission with last CT \r\nscan in ___ without evidence of lymphoma/adenopathy. Has \r\nhistory of CLL as well; no evidence of this on BM biopsy by \r\nreport. \r\n\r\n#Lower back pain: None on admission. No longer using narcotics \r\nor oxycontin. Continues on Gabapentin taper \r\n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.\r\n\r\n#Headache: History of headaches; reported an episode on ___ \r\nbut has had extensive w/u in the past that were reassuring. \r\nDenies headache since ___. Will not pursue further evaluation \r\nor treatment unless acute worsening or focal deficits\r\n\r\n#Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \r\n75,000. Has IVC filter in place.\r\n\r\n#Depression: Continue home venlafaxine\r\n\r\nProphylaxes:\r\n# Access: L POC placed ___\r\n# FEN: neutropenic diet\r\n# Bowel regimen: holding given diarrhea\r\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\r\n# Contact: ___ (husband)Phone number: ___ \r\nCell phone: ___ ___ (daughter) ___ \r\n# Disposition: Discharged ___. RTC on ___ for follow up\r\n# Code Status: FULL \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing \r\n3. Docusate Sodium 100 mg PO BID:PRN constipation \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 800 mg PO QAFTERNOON \r\n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n9. Senna 8.6 mg PO BID:PRN constipation \r\n10. Venlafaxine 25 mg PO BID \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Gabapentin 700 mg PO QPM \r\n13. Gabapentin 900 mg PO QAM \r\n \r\nDischarge Medications:\r\n1.  Ciprofloxacin HCl 500 mg PO Q12H  \r\n2.  Acyclovir 400 mg PO Q8H  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  FoLIC Acid 3.2 mg PO DAILY  \r\n6.  Gabapentin 800 mg PO QAFTERNOON  \r\n7.  Gabapentin 700 mg PO QPM  \r\n8.  Gabapentin 900 mg PO QAM  \r\n9.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiarrhea\r\nMDS\r\n___ DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___:\r\n\r\nYou were admitted because you were having decreased appetite, \r\nfatigue and diarrhea for several days at home. You received red \r\nblood cell transfusion and intravenous fluids with improvements \r\nin your symptoms. We think that these symptoms are likely side \r\neffects of your chemotherapy as further workup did not show a \r\nsource of infection. Please continue to take all of your \r\nmedications as ordered. Refer below for your next clinic \r\nappointment.\r\n\r\nIt was a pleasure taking care of you!\r\n\r\nSincerely,\r\nYOUR ___ TEAM\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-20:2",
      "text": "Past Medical History:\nTRANSPLANT DATA:\n___: Transplant Date: 1\n          Graft: Auto\n          Conditioning Intensity: Ablative\n          Conditioning Regimen: BEAM PAST ONCOLOGIC HISTORY:\nTransformed ___ with a history of follicular lymphoma stage \nIIA\n- ___ developed worsening musculoskeletal back pain, early\nsatiety, hypoalbuminemia and found to have mesenteric mass\n- ?___ ex lap with 15 cm lobulated mass involving the\nduodenum, retroperitoneum and celiac access. Biopsies showed\nFollicular lymphomas grade II/III. Reportedly negative staging\nGallium scan. CD10+ BCL2+\n- ___ completed 6 cycles CHOP, complications included\nSVC/innominate thrombus (tPA)\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\nmarrow at completion was negative for lymphomatous involvement. - ___ PET-CT with very slight amount of increased tracer\nactivity within the posterior left supraclavicular region. No\nother areas of FDG avid disease were noted \n- ___ through ___ per records she was treated with CVP\nfollowed by course of single agent Rituxan\n- ___ through ___ surveillance imaging with no evidence of\nrecurrent disease, stable mesenteric mass. - ___ abdominal pain led to CT with no change in mass size,\nincreased conspicuity of nodular borders\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\nstable mesenteric mass with low level SUV 2.2 stable since \nprior. - ___ CT torso showed persistent mesenteric and left hilar\nlymphadenopathy. Stable right middle lobe small focus of ground\nglass opacity and adjacent subpleural fat hypertrophy, \nsuggestive\nof inflammatory process. Stable right adnexal cyst. - ___ Presented to PCP ___ ___iscomfort. Exam\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\nnormal differential, PLT 452. - ___ PET CT revealed, \"Large left cervical,\nsupraclavicular, mediastinal lymphadenopathy, and \nretroperitoneal\nlymphadenopathy, and small mesenteric\nlymphadenopathy, all markedly FDG-avid and concerning for\nlymphoma.\" SUVmax 35.5. - ___iopsy revealed diffuse large B cell\nlymphoma, CD20+ CD10+ lambda restricted.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-20",
        "chart_time": "104566",
        "section": "General",
        "position": 2,
        "tokenCount": 517,
        "note_metadata": {
          "note_id": "18887130-DS-20",
          "subject_id": 18887130,
          "hadm_id": 27191597,
          "note_type": "DS",
          "note_seq": 20,
          "charttime": 104566,
          "storetime": 104566.725,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfatigue, abdominal cramping, diarrhea and decreased appetite\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed diffuse large \r\nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \r\n conditioning in ___ ___s IFRT with course complicated \r\n by ___ pneumonitis, who was subsequently found to have \r\ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \r\npresenting with 2 days of poor oral intake, fatigue, diarrhea \r\nand abdominal cramping.\r\n\r\nREVIEW OF SYSTEMS:\r\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. \r\nHEENT: No congestion, sore throat. No sores in the mouth,\r\npainful swallowing, sinus tenderness. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough; notes shortness of breath with exertion which\r\nhas increased somewhat; no shortness of breath at rest; no\r\nwheezing or hemoptysis. \r\nGI: GI upset with no specific nausea or vomiting with\r\ndecreased food intake; + diarrhea ___ night and ___ AM with\r\nepigatric pain. No constipation, hematochezia, or melena. \r\nGU: No dysuria or change in bladder habits. \r\nMSK: Right lower back pain much improved. No need for pain\r\nmedications. Occasional left lower back/sciatica pain which is\r\nchronic.  \r\nDERM: No new rashes or skin lesions. \r\nNEURO: Alert and oriented; no further issues with word finding;\r\nno confusion. + headache on ___ with history of migraines.\r\nNo visual changes. Slight lightheadedness. Usual numbness of\r\nright toes following prior surgery; no increased numbness. Has\r\nstarted tapering her Gabapentin but numbness of fingers has\r\nimproved.\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed ___ with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PE:\r\nGEN: More tired appearing in NAD\r\nWT: 101.6 lbs. \r\nVS: TC 98.5 PO 127/84 86 18 98%RA \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2 no MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg\r\nwith well healed area with no further surrounding erythema;\r\nhyperpigmented skin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n\r\nDISCHARGE PE:\r\nGEN: NAD. Fatigue improved\r\nWT: 101.6 lbs. \r\nVS: TC 97.7 108/54 80 20 96%RA  \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2. No MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg with well \r\nhealed area with no further surrounding erythema; hyperpigmented \r\nskin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n \r\nPertinent Results:\r\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \r\nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\r\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \r\nMAGNESIUM-2.0\r\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \r\nPHOS-131* TOT BILI-0.5\r\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \r\nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\r\n___ 10:45PM URINE  MUCOUS-RARE\r\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \r\nEPI-1\r\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \r\nLEUK-NEG\r\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\r\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\r\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \r\nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \r\nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\r\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \r\nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \r\nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\r\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \r\nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\r\n___ 12:00AM   IgG-762\r\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \r\nMAGNESIUM-2.0\r\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \r\nPHOS-127* TOT BILI-0.4\r\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \r\nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\r\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \r\nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\r\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \r\nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \r\nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\r\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \r\nCl-105 HCO3-22 AnGap-16\r\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \r\nTotBili-0.5\r\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\r\n___ 12:00AM BLOOD IgG-762\r\n\r\nMICRO:\r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Pending): \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Pending): \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n\r\nBLOOD CULTURE ___ AND ___ NTD\r\n \r\nBrief Hospital Course:\r\nASSESSMENT AND PLAN: ___ year old female with history of \r\ntransformed diffuse large B cell lymphoma ___ a curative attempt \r\nwith an AutoSCT with BEAM conditioning in ___ ___s \r\nIFRT with course complicated by BCNU pneumonitis as well as \r\npersistent norovirus with now noted treatment related MDS ___ \r\nC3 of Dacogen) presenting with poor oral intake, diarrhea and \r\nfatigue\r\n\r\n#Diarrhea, epigastric discomfort and poor oral intake: Improved \r\nsince admission. Poor intake in the past 2 days prior to \r\nadmission. No vomiting or nausea. Had ___ loose stools since \r\nadmission. No fevers at home and remained afebrile throughout \r\nhospital course. No other associated infectious symptoms \r\ncurrently.\r\n-Cdiff negative; other stool cultures PND at discharge \r\n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \r\nat discharge \r\n\r\n#Hypokalemia: Now normalized, was 3.0 prior to admission. Her \r\nhypokalemia was noted in the setting of decreased oral intake \r\nand GI loss (diarrhea). Received K+ repletions at home. \r\n\r\n#Shortness of breath on exertion and lightheadedness: Improved \r\nsince admission. Etiology likely related to profound anemia and \r\ndecreased oral intake. Received 1U\r\nprbcs at clinic prior to admission and received 1U in-house for \r\nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \r\nacute pulmonary process. Hemoglobin 9.4 at discharge. \r\n\r\n#MDS: Noted for rapid progression of pancytopenia, particularly \r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with \r\nnoted cytogenetic abnormalities concerning for treatment related \r\nMDS. ___ made to treat with Dacogen with\r\nplan to move towards allogeneic transplant. Neutrophils and \r\nplatelets recovered prior to starting ___ cycle. Counts now low \r\nfollowing treatment as expected although platelet appear to be \r\nrecovering. She is currently ___ ___ C3 of Dacogen. \r\n-transfuse for platelets < 20,000 (54 at discharge) and HGB < \r\n7.5 (9.4 at discharge).\r\n-C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \r\nforward with allogeneic transplant. Has unrelated donor. \r\n-Ciprofloxacin and Fluconazole have been on hold; restarted \r\nciprofloxacin on admission as ___ < 500. \r\n-Bactrim discontinued as CD4 count > 200\r\n-Will monitor IGG level; give IVIG for IGG less than 300 or \r\ninfections as IVIG can affect counts. Last IVIG ___ = 762\r\n\r\n#Lymphoma/CLL/Disease Status: Has been in remission with last CT \r\nscan in ___ without evidence of lymphoma/adenopathy. Has \r\nhistory of CLL as well; no evidence of this on BM biopsy by \r\nreport. \r\n\r\n#Lower back pain: None on admission. No longer using narcotics \r\nor oxycontin. Continues on Gabapentin taper \r\n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.\r\n\r\n#Headache: History of headaches; reported an episode on ___ \r\nbut has had extensive w/u in the past that were reassuring. \r\nDenies headache since ___. Will not pursue further evaluation \r\nor treatment unless acute worsening or focal deficits\r\n\r\n#Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \r\n75,000. Has IVC filter in place.\r\n\r\n#Depression: Continue home venlafaxine\r\n\r\nProphylaxes:\r\n# Access: L POC placed ___\r\n# FEN: neutropenic diet\r\n# Bowel regimen: holding given diarrhea\r\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\r\n# Contact: ___ (husband)Phone number: ___ \r\nCell phone: ___ ___ (daughter) ___ \r\n# Disposition: Discharged ___. RTC on ___ for follow up\r\n# Code Status: FULL \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing \r\n3. Docusate Sodium 100 mg PO BID:PRN constipation \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 800 mg PO QAFTERNOON \r\n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n9. Senna 8.6 mg PO BID:PRN constipation \r\n10. Venlafaxine 25 mg PO BID \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Gabapentin 700 mg PO QPM \r\n13. Gabapentin 900 mg PO QAM \r\n \r\nDischarge Medications:\r\n1.  Ciprofloxacin HCl 500 mg PO Q12H  \r\n2.  Acyclovir 400 mg PO Q8H  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  FoLIC Acid 3.2 mg PO DAILY  \r\n6.  Gabapentin 800 mg PO QAFTERNOON  \r\n7.  Gabapentin 700 mg PO QPM  \r\n8.  Gabapentin 900 mg PO QAM  \r\n9.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiarrhea\r\nMDS\r\n___ DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___:\r\n\r\nYou were admitted because you were having decreased appetite, \r\nfatigue and diarrhea for several days at home. You received red \r\nblood cell transfusion and intravenous fluids with improvements \r\nin your symptoms. We think that these symptoms are likely side \r\neffects of your chemotherapy as further workup did not show a \r\nsource of infection. Please continue to take all of your \r\nmedications as ordered. Refer below for your next clinic \r\nappointment.\r\n\r\nIt was a pleasure taking care of you!\r\n\r\nSincerely,\r\nYOUR ___ TEAM\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-20:3",
      "text": "Stable right adnexal cyst. - ___ Presented to PCP ___ ___iscomfort. Exam\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\nnormal differential, PLT 452. - ___ PET CT revealed, \"Large left cervical,\nsupraclavicular, mediastinal lymphadenopathy, and \nretroperitoneal\nlymphadenopathy, and small mesenteric\nlymphadenopathy, all markedly FDG-avid and concerning for\nlymphoma.\" SUVmax 35.5. - ___iopsy revealed diffuse large B cell\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \nare\npending\n- ___ C1D1 ICE\n- ___ C1 Rituximab, clinically improved adenopathy\n- ___ C2 Rituximab, WBC 6.5, PLT 43\n- ___ Admit for C2D1 ICE\n- ___ C3 Rituximab\n- ___ PET CT showed almost complete resolution of FDG avid\ndisease with a residual focus of avidity in the bed of the \nformer\nabdominal mass, SUV ___\n- ___ C4 Rituximab\n- ___ C4 ICE followed by stem cell mobilization and\ncollection, BMBx showed a nest of CLL unrelated to her \naggressive\nlymphoma\n- ___ Presented with large DVTs, SVC filter placed\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\n- ___ Switched to Rivaroxiban for AC\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\ncytopenias\n- ___ Start XRT\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\nHb). Started prednisone 80 mg PO daily\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \nmg\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___. - Weekly monitoring of DLCO with taper of prednisone to 10 mg\ndaily as of ___ with DLCO 99%. Dapsone d/ced on ___\ndue to hemolysis. - ___ Decreased prednisone to 5 mg PO daily. Noro virus\npersistently positive. - ___ CT torso with no evidence of active disease. Unchanged mesenteric fullness. - ___ DLCO decrease (not reported) increase prednisone to \n10\nmg\n- ___ IVIg 400 mg/kg\n- ___ DLCO 121%, continue prednisone 10 mg\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia. - ___, tapered off prednisone. - ___, CT torso with no evidence of active disease. Stable\nappearance of a conglomeration of mesenteric lymph nodes. - ___, Right total knee replacement, primary, complicated\nby foot drop likely d/t irritation of peroneal nerve and\ncellulitis. - ___, CT Torso with no evidence of active disease. Stable appearance of conglomerate of mesenteric LN's. Increased\ndilatation of the main pulmonary artery suggests worsening\npulmonary arterial hypertension of indeterminate etiology. - ___, CT torso with no evidence of active disease. Increased\ndilation of pulmonary artery. Evaluated by Dr. ___\n- ___, increasing right leg swelling with noted DVT.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-20",
        "chart_time": "104566",
        "section": "General",
        "position": 3,
        "tokenCount": 679,
        "note_metadata": {
          "note_id": "18887130-DS-20",
          "subject_id": 18887130,
          "hadm_id": 27191597,
          "note_type": "DS",
          "note_seq": 20,
          "charttime": 104566,
          "storetime": 104566.725,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfatigue, abdominal cramping, diarrhea and decreased appetite\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed diffuse large \r\nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \r\n conditioning in ___ ___s IFRT with course complicated \r\n by ___ pneumonitis, who was subsequently found to have \r\ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \r\npresenting with 2 days of poor oral intake, fatigue, diarrhea \r\nand abdominal cramping.\r\n\r\nREVIEW OF SYSTEMS:\r\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. \r\nHEENT: No congestion, sore throat. No sores in the mouth,\r\npainful swallowing, sinus tenderness. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough; notes shortness of breath with exertion which\r\nhas increased somewhat; no shortness of breath at rest; no\r\nwheezing or hemoptysis. \r\nGI: GI upset with no specific nausea or vomiting with\r\ndecreased food intake; + diarrhea ___ night and ___ AM with\r\nepigatric pain. No constipation, hematochezia, or melena. \r\nGU: No dysuria or change in bladder habits. \r\nMSK: Right lower back pain much improved. No need for pain\r\nmedications. Occasional left lower back/sciatica pain which is\r\nchronic.  \r\nDERM: No new rashes or skin lesions. \r\nNEURO: Alert and oriented; no further issues with word finding;\r\nno confusion. + headache on ___ with history of migraines.\r\nNo visual changes. Slight lightheadedness. Usual numbness of\r\nright toes following prior surgery; no increased numbness. Has\r\nstarted tapering her Gabapentin but numbness of fingers has\r\nimproved.\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed ___ with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PE:\r\nGEN: More tired appearing in NAD\r\nWT: 101.6 lbs. \r\nVS: TC 98.5 PO 127/84 86 18 98%RA \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2 no MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg\r\nwith well healed area with no further surrounding erythema;\r\nhyperpigmented skin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n\r\nDISCHARGE PE:\r\nGEN: NAD. Fatigue improved\r\nWT: 101.6 lbs. \r\nVS: TC 97.7 108/54 80 20 96%RA  \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2. No MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg with well \r\nhealed area with no further surrounding erythema; hyperpigmented \r\nskin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n \r\nPertinent Results:\r\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \r\nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\r\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \r\nMAGNESIUM-2.0\r\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \r\nPHOS-131* TOT BILI-0.5\r\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \r\nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\r\n___ 10:45PM URINE  MUCOUS-RARE\r\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \r\nEPI-1\r\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \r\nLEUK-NEG\r\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\r\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\r\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \r\nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \r\nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\r\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \r\nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \r\nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\r\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \r\nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\r\n___ 12:00AM   IgG-762\r\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \r\nMAGNESIUM-2.0\r\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \r\nPHOS-127* TOT BILI-0.4\r\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \r\nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\r\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \r\nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\r\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \r\nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \r\nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\r\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \r\nCl-105 HCO3-22 AnGap-16\r\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \r\nTotBili-0.5\r\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\r\n___ 12:00AM BLOOD IgG-762\r\n\r\nMICRO:\r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Pending): \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Pending): \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n\r\nBLOOD CULTURE ___ AND ___ NTD\r\n \r\nBrief Hospital Course:\r\nASSESSMENT AND PLAN: ___ year old female with history of \r\ntransformed diffuse large B cell lymphoma ___ a curative attempt \r\nwith an AutoSCT with BEAM conditioning in ___ ___s \r\nIFRT with course complicated by BCNU pneumonitis as well as \r\npersistent norovirus with now noted treatment related MDS ___ \r\nC3 of Dacogen) presenting with poor oral intake, diarrhea and \r\nfatigue\r\n\r\n#Diarrhea, epigastric discomfort and poor oral intake: Improved \r\nsince admission. Poor intake in the past 2 days prior to \r\nadmission. No vomiting or nausea. Had ___ loose stools since \r\nadmission. No fevers at home and remained afebrile throughout \r\nhospital course. No other associated infectious symptoms \r\ncurrently.\r\n-Cdiff negative; other stool cultures PND at discharge \r\n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \r\nat discharge \r\n\r\n#Hypokalemia: Now normalized, was 3.0 prior to admission. Her \r\nhypokalemia was noted in the setting of decreased oral intake \r\nand GI loss (diarrhea). Received K+ repletions at home. \r\n\r\n#Shortness of breath on exertion and lightheadedness: Improved \r\nsince admission. Etiology likely related to profound anemia and \r\ndecreased oral intake. Received 1U\r\nprbcs at clinic prior to admission and received 1U in-house for \r\nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \r\nacute pulmonary process. Hemoglobin 9.4 at discharge. \r\n\r\n#MDS: Noted for rapid progression of pancytopenia, particularly \r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with \r\nnoted cytogenetic abnormalities concerning for treatment related \r\nMDS. ___ made to treat with Dacogen with\r\nplan to move towards allogeneic transplant. Neutrophils and \r\nplatelets recovered prior to starting ___ cycle. Counts now low \r\nfollowing treatment as expected although platelet appear to be \r\nrecovering. She is currently ___ ___ C3 of Dacogen. \r\n-transfuse for platelets < 20,000 (54 at discharge) and HGB < \r\n7.5 (9.4 at discharge).\r\n-C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \r\nforward with allogeneic transplant. Has unrelated donor. \r\n-Ciprofloxacin and Fluconazole have been on hold; restarted \r\nciprofloxacin on admission as ___ < 500. \r\n-Bactrim discontinued as CD4 count > 200\r\n-Will monitor IGG level; give IVIG for IGG less than 300 or \r\ninfections as IVIG can affect counts. Last IVIG ___ = 762\r\n\r\n#Lymphoma/CLL/Disease Status: Has been in remission with last CT \r\nscan in ___ without evidence of lymphoma/adenopathy. Has \r\nhistory of CLL as well; no evidence of this on BM biopsy by \r\nreport. \r\n\r\n#Lower back pain: None on admission. No longer using narcotics \r\nor oxycontin. Continues on Gabapentin taper \r\n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.\r\n\r\n#Headache: History of headaches; reported an episode on ___ \r\nbut has had extensive w/u in the past that were reassuring. \r\nDenies headache since ___. Will not pursue further evaluation \r\nor treatment unless acute worsening or focal deficits\r\n\r\n#Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \r\n75,000. Has IVC filter in place.\r\n\r\n#Depression: Continue home venlafaxine\r\n\r\nProphylaxes:\r\n# Access: L POC placed ___\r\n# FEN: neutropenic diet\r\n# Bowel regimen: holding given diarrhea\r\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\r\n# Contact: ___ (husband)Phone number: ___ \r\nCell phone: ___ ___ (daughter) ___ \r\n# Disposition: Discharged ___. RTC on ___ for follow up\r\n# Code Status: FULL \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing \r\n3. Docusate Sodium 100 mg PO BID:PRN constipation \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 800 mg PO QAFTERNOON \r\n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n9. Senna 8.6 mg PO BID:PRN constipation \r\n10. Venlafaxine 25 mg PO BID \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Gabapentin 700 mg PO QPM \r\n13. Gabapentin 900 mg PO QAM \r\n \r\nDischarge Medications:\r\n1.  Ciprofloxacin HCl 500 mg PO Q12H  \r\n2.  Acyclovir 400 mg PO Q8H  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  FoLIC Acid 3.2 mg PO DAILY  \r\n6.  Gabapentin 800 mg PO QAFTERNOON  \r\n7.  Gabapentin 700 mg PO QPM  \r\n8.  Gabapentin 900 mg PO QAM  \r\n9.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiarrhea\r\nMDS\r\n___ DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___:\r\n\r\nYou were admitted because you were having decreased appetite, \r\nfatigue and diarrhea for several days at home. You received red \r\nblood cell transfusion and intravenous fluids with improvements \r\nin your symptoms. We think that these symptoms are likely side \r\neffects of your chemotherapy as further workup did not show a \r\nsource of infection. Please continue to take all of your \r\nmedications as ordered. Refer below for your next clinic \r\nappointment.\r\n\r\nIt was a pleasure taking care of you!\r\n\r\nSincerely,\r\nYOUR ___ TEAM\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-20:4",
      "text": "Stable\nappearance of a conglomeration of mesenteric lymph nodes. - ___, Right total knee replacement, primary, complicated\nby foot drop likely d/t irritation of peroneal nerve and\ncellulitis. - ___, CT Torso with no evidence of active disease. Stable appearance of conglomerate of mesenteric LN's. Increased\ndilatation of the main pulmonary artery suggests worsening\npulmonary arterial hypertension of indeterminate etiology. - ___, CT torso with no evidence of active disease. Increased\ndilation of pulmonary artery. Evaluated by Dr. ___\n- ___, increasing right leg swelling with noted DVT. Xarelto\nincreased back to 20 mg daily(had been decreased given age and\nprior chronic DVT). No evidence for lymphoma on CT imaging. - ___, noted drop in blood counts. BM biopsy with evidence\nfor MDS. - ___, C1 Dacogen\n- ___, C2 Dacogen\n- ___, C3 Dacogen\n \nOTHER PAST MEDICAL HISTORY\n- CVID, received IVIG monthly. last given ___\n- GERD                                          \n- Osteoarthritis                                         \n- DVT, right lower extremity, IVC filter in place\n- Cervical radiculopathy\n- Sciatica\n- Obstructive sleep apnea, wears CPAP\n- H/O cerebral aneurism, noted on MRA with small R internal\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\nthe right eye, mild proptosis of the right eye, and hyperthesia\nof the right V1 distribution\n- Asthma\n- Obesity\n- Hypertension\n- Migraines Social History:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-20",
        "chart_time": "104566",
        "section": "General",
        "position": 4,
        "tokenCount": 373,
        "note_metadata": {
          "note_id": "18887130-DS-20",
          "subject_id": 18887130,
          "hadm_id": 27191597,
          "note_type": "DS",
          "note_seq": 20,
          "charttime": 104566,
          "storetime": 104566.725,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfatigue, abdominal cramping, diarrhea and decreased appetite\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed diffuse large \r\nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \r\n conditioning in ___ ___s IFRT with course complicated \r\n by ___ pneumonitis, who was subsequently found to have \r\ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \r\npresenting with 2 days of poor oral intake, fatigue, diarrhea \r\nand abdominal cramping.\r\n\r\nREVIEW OF SYSTEMS:\r\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. \r\nHEENT: No congestion, sore throat. No sores in the mouth,\r\npainful swallowing, sinus tenderness. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough; notes shortness of breath with exertion which\r\nhas increased somewhat; no shortness of breath at rest; no\r\nwheezing or hemoptysis. \r\nGI: GI upset with no specific nausea or vomiting with\r\ndecreased food intake; + diarrhea ___ night and ___ AM with\r\nepigatric pain. No constipation, hematochezia, or melena. \r\nGU: No dysuria or change in bladder habits. \r\nMSK: Right lower back pain much improved. No need for pain\r\nmedications. Occasional left lower back/sciatica pain which is\r\nchronic.  \r\nDERM: No new rashes or skin lesions. \r\nNEURO: Alert and oriented; no further issues with word finding;\r\nno confusion. + headache on ___ with history of migraines.\r\nNo visual changes. Slight lightheadedness. Usual numbness of\r\nright toes following prior surgery; no increased numbness. Has\r\nstarted tapering her Gabapentin but numbness of fingers has\r\nimproved.\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed ___ with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PE:\r\nGEN: More tired appearing in NAD\r\nWT: 101.6 lbs. \r\nVS: TC 98.5 PO 127/84 86 18 98%RA \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2 no MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg\r\nwith well healed area with no further surrounding erythema;\r\nhyperpigmented skin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n\r\nDISCHARGE PE:\r\nGEN: NAD. Fatigue improved\r\nWT: 101.6 lbs. \r\nVS: TC 97.7 108/54 80 20 96%RA  \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2. No MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg with well \r\nhealed area with no further surrounding erythema; hyperpigmented \r\nskin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n \r\nPertinent Results:\r\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \r\nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\r\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \r\nMAGNESIUM-2.0\r\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \r\nPHOS-131* TOT BILI-0.5\r\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \r\nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\r\n___ 10:45PM URINE  MUCOUS-RARE\r\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \r\nEPI-1\r\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \r\nLEUK-NEG\r\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\r\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\r\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \r\nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \r\nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\r\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \r\nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \r\nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\r\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \r\nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\r\n___ 12:00AM   IgG-762\r\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \r\nMAGNESIUM-2.0\r\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \r\nPHOS-127* TOT BILI-0.4\r\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \r\nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\r\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \r\nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\r\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \r\nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \r\nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\r\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \r\nCl-105 HCO3-22 AnGap-16\r\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \r\nTotBili-0.5\r\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\r\n___ 12:00AM BLOOD IgG-762\r\n\r\nMICRO:\r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Pending): \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Pending): \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n\r\nBLOOD CULTURE ___ AND ___ NTD\r\n \r\nBrief Hospital Course:\r\nASSESSMENT AND PLAN: ___ year old female with history of \r\ntransformed diffuse large B cell lymphoma ___ a curative attempt \r\nwith an AutoSCT with BEAM conditioning in ___ ___s \r\nIFRT with course complicated by BCNU pneumonitis as well as \r\npersistent norovirus with now noted treatment related MDS ___ \r\nC3 of Dacogen) presenting with poor oral intake, diarrhea and \r\nfatigue\r\n\r\n#Diarrhea, epigastric discomfort and poor oral intake: Improved \r\nsince admission. Poor intake in the past 2 days prior to \r\nadmission. No vomiting or nausea. Had ___ loose stools since \r\nadmission. No fevers at home and remained afebrile throughout \r\nhospital course. No other associated infectious symptoms \r\ncurrently.\r\n-Cdiff negative; other stool cultures PND at discharge \r\n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \r\nat discharge \r\n\r\n#Hypokalemia: Now normalized, was 3.0 prior to admission. Her \r\nhypokalemia was noted in the setting of decreased oral intake \r\nand GI loss (diarrhea). Received K+ repletions at home. \r\n\r\n#Shortness of breath on exertion and lightheadedness: Improved \r\nsince admission. Etiology likely related to profound anemia and \r\ndecreased oral intake. Received 1U\r\nprbcs at clinic prior to admission and received 1U in-house for \r\nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \r\nacute pulmonary process. Hemoglobin 9.4 at discharge. \r\n\r\n#MDS: Noted for rapid progression of pancytopenia, particularly \r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with \r\nnoted cytogenetic abnormalities concerning for treatment related \r\nMDS. ___ made to treat with Dacogen with\r\nplan to move towards allogeneic transplant. Neutrophils and \r\nplatelets recovered prior to starting ___ cycle. Counts now low \r\nfollowing treatment as expected although platelet appear to be \r\nrecovering. She is currently ___ ___ C3 of Dacogen. \r\n-transfuse for platelets < 20,000 (54 at discharge) and HGB < \r\n7.5 (9.4 at discharge).\r\n-C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \r\nforward with allogeneic transplant. Has unrelated donor. \r\n-Ciprofloxacin and Fluconazole have been on hold; restarted \r\nciprofloxacin on admission as ___ < 500. \r\n-Bactrim discontinued as CD4 count > 200\r\n-Will monitor IGG level; give IVIG for IGG less than 300 or \r\ninfections as IVIG can affect counts. Last IVIG ___ = 762\r\n\r\n#Lymphoma/CLL/Disease Status: Has been in remission with last CT \r\nscan in ___ without evidence of lymphoma/adenopathy. Has \r\nhistory of CLL as well; no evidence of this on BM biopsy by \r\nreport. \r\n\r\n#Lower back pain: None on admission. No longer using narcotics \r\nor oxycontin. Continues on Gabapentin taper \r\n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.\r\n\r\n#Headache: History of headaches; reported an episode on ___ \r\nbut has had extensive w/u in the past that were reassuring. \r\nDenies headache since ___. Will not pursue further evaluation \r\nor treatment unless acute worsening or focal deficits\r\n\r\n#Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \r\n75,000. Has IVC filter in place.\r\n\r\n#Depression: Continue home venlafaxine\r\n\r\nProphylaxes:\r\n# Access: L POC placed ___\r\n# FEN: neutropenic diet\r\n# Bowel regimen: holding given diarrhea\r\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\r\n# Contact: ___ (husband)Phone number: ___ \r\nCell phone: ___ ___ (daughter) ___ \r\n# Disposition: Discharged ___. RTC on ___ for follow up\r\n# Code Status: FULL \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing \r\n3. Docusate Sodium 100 mg PO BID:PRN constipation \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 800 mg PO QAFTERNOON \r\n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n9. Senna 8.6 mg PO BID:PRN constipation \r\n10. Venlafaxine 25 mg PO BID \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Gabapentin 700 mg PO QPM \r\n13. Gabapentin 900 mg PO QAM \r\n \r\nDischarge Medications:\r\n1.  Ciprofloxacin HCl 500 mg PO Q12H  \r\n2.  Acyclovir 400 mg PO Q8H  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  FoLIC Acid 3.2 mg PO DAILY  \r\n6.  Gabapentin 800 mg PO QAFTERNOON  \r\n7.  Gabapentin 700 mg PO QPM  \r\n8.  Gabapentin 900 mg PO QAM  \r\n9.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiarrhea\r\nMDS\r\n___ DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___:\r\n\r\nYou were admitted because you were having decreased appetite, \r\nfatigue and diarrhea for several days at home. You received red \r\nblood cell transfusion and intravenous fluids with improvements \r\nin your symptoms. We think that these symptoms are likely side \r\neffects of your chemotherapy as further workup did not show a \r\nsource of infection. Please continue to take all of your \r\nmedications as ordered. Refer below for your next clinic \r\nappointment.\r\n\r\nIt was a pleasure taking care of you!\r\n\r\nSincerely,\r\nYOUR ___ TEAM\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-20:5",
      "text": "Family History:\nbrother - lymphoma Physical ___:\nADMISSION PE:\nGEN: More tired appearing in NAD\nWT: 101.6 lbs. VS: TC 98.5 PO 127/84 86 18 98%RA \nHEENT: Right pupil slower to react to light which is baseline. MMM, no OP lesions or increased erythema. CV: RRR, NL S1/S2 no MRG\nPULM: CTAB with decreased breath sounds at bases; no rales or\nwheezing. Normal respiratory effort. ABD: Obese. BS+, soft, NT/ND. No HSM appreciated. LIMBS: Right leg with decreased edema; left lower leg\nwith well healed area with no further surrounding erythema;\nhyperpigmented skin changes on lower legs. Calves softer. SKIN: No rashes or new skin eruptions. ACCESS: L POC w/o erythema, edema or tenderness DISCHARGE PE:\nGEN: NAD. Fatigue improved\nWT: 101.6 lbs. VS: TC 97.7 108/54 80 20 96%RA  \nHEENT: Right pupil slower to react to light which is baseline. MMM, no OP lesions or increased erythema. CV: RRR, NL S1/S2. No MRG\nPULM: CTAB with decreased breath sounds at bases; no rales or\nwheezing. Normal respiratory effort. ABD: Obese. BS+, soft, NT/ND. No HSM appreciated. LIMBS: Right leg with decreased edema; left lower leg with well \nhealed area with no further surrounding erythema; hyperpigmented \nskin changes on lower legs. Calves softer. SKIN: No rashes or new skin eruptions.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-20",
        "chart_time": "104566",
        "section": "General",
        "position": 5,
        "tokenCount": 317,
        "note_metadata": {
          "note_id": "18887130-DS-20",
          "subject_id": 18887130,
          "hadm_id": 27191597,
          "note_type": "DS",
          "note_seq": 20,
          "charttime": 104566,
          "storetime": 104566.725,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfatigue, abdominal cramping, diarrhea and decreased appetite\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed diffuse large \r\nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \r\n conditioning in ___ ___s IFRT with course complicated \r\n by ___ pneumonitis, who was subsequently found to have \r\ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \r\npresenting with 2 days of poor oral intake, fatigue, diarrhea \r\nand abdominal cramping.\r\n\r\nREVIEW OF SYSTEMS:\r\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. \r\nHEENT: No congestion, sore throat. No sores in the mouth,\r\npainful swallowing, sinus tenderness. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough; notes shortness of breath with exertion which\r\nhas increased somewhat; no shortness of breath at rest; no\r\nwheezing or hemoptysis. \r\nGI: GI upset with no specific nausea or vomiting with\r\ndecreased food intake; + diarrhea ___ night and ___ AM with\r\nepigatric pain. No constipation, hematochezia, or melena. \r\nGU: No dysuria or change in bladder habits. \r\nMSK: Right lower back pain much improved. No need for pain\r\nmedications. Occasional left lower back/sciatica pain which is\r\nchronic.  \r\nDERM: No new rashes or skin lesions. \r\nNEURO: Alert and oriented; no further issues with word finding;\r\nno confusion. + headache on ___ with history of migraines.\r\nNo visual changes. Slight lightheadedness. Usual numbness of\r\nright toes following prior surgery; no increased numbness. Has\r\nstarted tapering her Gabapentin but numbness of fingers has\r\nimproved.\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed ___ with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PE:\r\nGEN: More tired appearing in NAD\r\nWT: 101.6 lbs. \r\nVS: TC 98.5 PO 127/84 86 18 98%RA \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2 no MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg\r\nwith well healed area with no further surrounding erythema;\r\nhyperpigmented skin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n\r\nDISCHARGE PE:\r\nGEN: NAD. Fatigue improved\r\nWT: 101.6 lbs. \r\nVS: TC 97.7 108/54 80 20 96%RA  \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2. No MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg with well \r\nhealed area with no further surrounding erythema; hyperpigmented \r\nskin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n \r\nPertinent Results:\r\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \r\nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\r\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \r\nMAGNESIUM-2.0\r\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \r\nPHOS-131* TOT BILI-0.5\r\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \r\nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\r\n___ 10:45PM URINE  MUCOUS-RARE\r\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \r\nEPI-1\r\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \r\nLEUK-NEG\r\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\r\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\r\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \r\nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \r\nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\r\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \r\nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \r\nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\r\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \r\nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\r\n___ 12:00AM   IgG-762\r\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \r\nMAGNESIUM-2.0\r\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \r\nPHOS-127* TOT BILI-0.4\r\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \r\nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\r\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \r\nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\r\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \r\nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \r\nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\r\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \r\nCl-105 HCO3-22 AnGap-16\r\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \r\nTotBili-0.5\r\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\r\n___ 12:00AM BLOOD IgG-762\r\n\r\nMICRO:\r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Pending): \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Pending): \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n\r\nBLOOD CULTURE ___ AND ___ NTD\r\n \r\nBrief Hospital Course:\r\nASSESSMENT AND PLAN: ___ year old female with history of \r\ntransformed diffuse large B cell lymphoma ___ a curative attempt \r\nwith an AutoSCT with BEAM conditioning in ___ ___s \r\nIFRT with course complicated by BCNU pneumonitis as well as \r\npersistent norovirus with now noted treatment related MDS ___ \r\nC3 of Dacogen) presenting with poor oral intake, diarrhea and \r\nfatigue\r\n\r\n#Diarrhea, epigastric discomfort and poor oral intake: Improved \r\nsince admission. Poor intake in the past 2 days prior to \r\nadmission. No vomiting or nausea. Had ___ loose stools since \r\nadmission. No fevers at home and remained afebrile throughout \r\nhospital course. No other associated infectious symptoms \r\ncurrently.\r\n-Cdiff negative; other stool cultures PND at discharge \r\n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \r\nat discharge \r\n\r\n#Hypokalemia: Now normalized, was 3.0 prior to admission. Her \r\nhypokalemia was noted in the setting of decreased oral intake \r\nand GI loss (diarrhea). Received K+ repletions at home. \r\n\r\n#Shortness of breath on exertion and lightheadedness: Improved \r\nsince admission. Etiology likely related to profound anemia and \r\ndecreased oral intake. Received 1U\r\nprbcs at clinic prior to admission and received 1U in-house for \r\nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \r\nacute pulmonary process. Hemoglobin 9.4 at discharge. \r\n\r\n#MDS: Noted for rapid progression of pancytopenia, particularly \r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with \r\nnoted cytogenetic abnormalities concerning for treatment related \r\nMDS. ___ made to treat with Dacogen with\r\nplan to move towards allogeneic transplant. Neutrophils and \r\nplatelets recovered prior to starting ___ cycle. Counts now low \r\nfollowing treatment as expected although platelet appear to be \r\nrecovering. She is currently ___ ___ C3 of Dacogen. \r\n-transfuse for platelets < 20,000 (54 at discharge) and HGB < \r\n7.5 (9.4 at discharge).\r\n-C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \r\nforward with allogeneic transplant. Has unrelated donor. \r\n-Ciprofloxacin and Fluconazole have been on hold; restarted \r\nciprofloxacin on admission as ___ < 500. \r\n-Bactrim discontinued as CD4 count > 200\r\n-Will monitor IGG level; give IVIG for IGG less than 300 or \r\ninfections as IVIG can affect counts. Last IVIG ___ = 762\r\n\r\n#Lymphoma/CLL/Disease Status: Has been in remission with last CT \r\nscan in ___ without evidence of lymphoma/adenopathy. Has \r\nhistory of CLL as well; no evidence of this on BM biopsy by \r\nreport. \r\n\r\n#Lower back pain: None on admission. No longer using narcotics \r\nor oxycontin. Continues on Gabapentin taper \r\n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.\r\n\r\n#Headache: History of headaches; reported an episode on ___ \r\nbut has had extensive w/u in the past that were reassuring. \r\nDenies headache since ___. Will not pursue further evaluation \r\nor treatment unless acute worsening or focal deficits\r\n\r\n#Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \r\n75,000. Has IVC filter in place.\r\n\r\n#Depression: Continue home venlafaxine\r\n\r\nProphylaxes:\r\n# Access: L POC placed ___\r\n# FEN: neutropenic diet\r\n# Bowel regimen: holding given diarrhea\r\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\r\n# Contact: ___ (husband)Phone number: ___ \r\nCell phone: ___ ___ (daughter) ___ \r\n# Disposition: Discharged ___. RTC on ___ for follow up\r\n# Code Status: FULL \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing \r\n3. Docusate Sodium 100 mg PO BID:PRN constipation \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 800 mg PO QAFTERNOON \r\n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n9. Senna 8.6 mg PO BID:PRN constipation \r\n10. Venlafaxine 25 mg PO BID \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Gabapentin 700 mg PO QPM \r\n13. Gabapentin 900 mg PO QAM \r\n \r\nDischarge Medications:\r\n1.  Ciprofloxacin HCl 500 mg PO Q12H  \r\n2.  Acyclovir 400 mg PO Q8H  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  FoLIC Acid 3.2 mg PO DAILY  \r\n6.  Gabapentin 800 mg PO QAFTERNOON  \r\n7.  Gabapentin 700 mg PO QPM  \r\n8.  Gabapentin 900 mg PO QAM  \r\n9.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiarrhea\r\nMDS\r\n___ DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___:\r\n\r\nYou were admitted because you were having decreased appetite, \r\nfatigue and diarrhea for several days at home. You received red \r\nblood cell transfusion and intravenous fluids with improvements \r\nin your symptoms. We think that these symptoms are likely side \r\neffects of your chemotherapy as further workup did not show a \r\nsource of infection. Please continue to take all of your \r\nmedications as ordered. Refer below for your next clinic \r\nappointment.\r\n\r\nIt was a pleasure taking care of you!\r\n\r\nSincerely,\r\nYOUR ___ TEAM\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-20:6",
      "text": "DISCHARGE PE:\nGEN: NAD. Fatigue improved\nWT: 101.6 lbs. VS: TC 97.7 108/54 80 20 96%RA  \nHEENT: Right pupil slower to react to light which is baseline. MMM, no OP lesions or increased erythema. CV: RRR, NL S1/S2. No MRG\nPULM: CTAB with decreased breath sounds at bases; no rales or\nwheezing. Normal respiratory effort. ABD: Obese. BS+, soft, NT/ND. No HSM appreciated. LIMBS: Right leg with decreased edema; left lower leg with well \nhealed area with no further surrounding erythema; hyperpigmented \nskin changes on lower legs. Calves softer. SKIN: No rashes or new skin eruptions. ACCESS: L POC w/o erythema, edema or tenderness\n \nPertinent Results:\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \nMAGNESIUM-2.0\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \nPHOS-131* TOT BILI-0.5\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\n___ 10:45PM URINE  MUCOUS-RARE\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \nEPI-1\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \nLEUK-NEG\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\n___ 12:00AM   IgG-762\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \nMAGNESIUM-2.0\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \nPHOS-127* TOT BILI-0.4\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \nCl-105 HCO3-22 AnGap-16\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \nTotBili-0.5\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\n___ 12:00AM BLOOD IgG-762",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-20",
        "chart_time": "104566",
        "section": "General",
        "position": 6,
        "tokenCount": 760,
        "note_metadata": {
          "note_id": "18887130-DS-20",
          "subject_id": 18887130,
          "hadm_id": 27191597,
          "note_type": "DS",
          "note_seq": 20,
          "charttime": 104566,
          "storetime": 104566.725,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfatigue, abdominal cramping, diarrhea and decreased appetite\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed diffuse large \r\nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \r\n conditioning in ___ ___s IFRT with course complicated \r\n by ___ pneumonitis, who was subsequently found to have \r\ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \r\npresenting with 2 days of poor oral intake, fatigue, diarrhea \r\nand abdominal cramping.\r\n\r\nREVIEW OF SYSTEMS:\r\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. \r\nHEENT: No congestion, sore throat. No sores in the mouth,\r\npainful swallowing, sinus tenderness. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough; notes shortness of breath with exertion which\r\nhas increased somewhat; no shortness of breath at rest; no\r\nwheezing or hemoptysis. \r\nGI: GI upset with no specific nausea or vomiting with\r\ndecreased food intake; + diarrhea ___ night and ___ AM with\r\nepigatric pain. No constipation, hematochezia, or melena. \r\nGU: No dysuria or change in bladder habits. \r\nMSK: Right lower back pain much improved. No need for pain\r\nmedications. Occasional left lower back/sciatica pain which is\r\nchronic.  \r\nDERM: No new rashes or skin lesions. \r\nNEURO: Alert and oriented; no further issues with word finding;\r\nno confusion. + headache on ___ with history of migraines.\r\nNo visual changes. Slight lightheadedness. Usual numbness of\r\nright toes following prior surgery; no increased numbness. Has\r\nstarted tapering her Gabapentin but numbness of fingers has\r\nimproved.\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed ___ with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PE:\r\nGEN: More tired appearing in NAD\r\nWT: 101.6 lbs. \r\nVS: TC 98.5 PO 127/84 86 18 98%RA \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2 no MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg\r\nwith well healed area with no further surrounding erythema;\r\nhyperpigmented skin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n\r\nDISCHARGE PE:\r\nGEN: NAD. Fatigue improved\r\nWT: 101.6 lbs. \r\nVS: TC 97.7 108/54 80 20 96%RA  \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2. No MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg with well \r\nhealed area with no further surrounding erythema; hyperpigmented \r\nskin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n \r\nPertinent Results:\r\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \r\nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\r\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \r\nMAGNESIUM-2.0\r\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \r\nPHOS-131* TOT BILI-0.5\r\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \r\nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\r\n___ 10:45PM URINE  MUCOUS-RARE\r\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \r\nEPI-1\r\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \r\nLEUK-NEG\r\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\r\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\r\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \r\nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \r\nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\r\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \r\nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \r\nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\r\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \r\nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\r\n___ 12:00AM   IgG-762\r\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \r\nMAGNESIUM-2.0\r\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \r\nPHOS-127* TOT BILI-0.4\r\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \r\nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\r\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \r\nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\r\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \r\nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \r\nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\r\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \r\nCl-105 HCO3-22 AnGap-16\r\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \r\nTotBili-0.5\r\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\r\n___ 12:00AM BLOOD IgG-762\r\n\r\nMICRO:\r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Pending): \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Pending): \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n\r\nBLOOD CULTURE ___ AND ___ NTD\r\n \r\nBrief Hospital Course:\r\nASSESSMENT AND PLAN: ___ year old female with history of \r\ntransformed diffuse large B cell lymphoma ___ a curative attempt \r\nwith an AutoSCT with BEAM conditioning in ___ ___s \r\nIFRT with course complicated by BCNU pneumonitis as well as \r\npersistent norovirus with now noted treatment related MDS ___ \r\nC3 of Dacogen) presenting with poor oral intake, diarrhea and \r\nfatigue\r\n\r\n#Diarrhea, epigastric discomfort and poor oral intake: Improved \r\nsince admission. Poor intake in the past 2 days prior to \r\nadmission. No vomiting or nausea. Had ___ loose stools since \r\nadmission. No fevers at home and remained afebrile throughout \r\nhospital course. No other associated infectious symptoms \r\ncurrently.\r\n-Cdiff negative; other stool cultures PND at discharge \r\n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \r\nat discharge \r\n\r\n#Hypokalemia: Now normalized, was 3.0 prior to admission. Her \r\nhypokalemia was noted in the setting of decreased oral intake \r\nand GI loss (diarrhea). Received K+ repletions at home. \r\n\r\n#Shortness of breath on exertion and lightheadedness: Improved \r\nsince admission. Etiology likely related to profound anemia and \r\ndecreased oral intake. Received 1U\r\nprbcs at clinic prior to admission and received 1U in-house for \r\nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \r\nacute pulmonary process. Hemoglobin 9.4 at discharge. \r\n\r\n#MDS: Noted for rapid progression of pancytopenia, particularly \r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with \r\nnoted cytogenetic abnormalities concerning for treatment related \r\nMDS. ___ made to treat with Dacogen with\r\nplan to move towards allogeneic transplant. Neutrophils and \r\nplatelets recovered prior to starting ___ cycle. Counts now low \r\nfollowing treatment as expected although platelet appear to be \r\nrecovering. She is currently ___ ___ C3 of Dacogen. \r\n-transfuse for platelets < 20,000 (54 at discharge) and HGB < \r\n7.5 (9.4 at discharge).\r\n-C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \r\nforward with allogeneic transplant. Has unrelated donor. \r\n-Ciprofloxacin and Fluconazole have been on hold; restarted \r\nciprofloxacin on admission as ___ < 500. \r\n-Bactrim discontinued as CD4 count > 200\r\n-Will monitor IGG level; give IVIG for IGG less than 300 or \r\ninfections as IVIG can affect counts. Last IVIG ___ = 762\r\n\r\n#Lymphoma/CLL/Disease Status: Has been in remission with last CT \r\nscan in ___ without evidence of lymphoma/adenopathy. Has \r\nhistory of CLL as well; no evidence of this on BM biopsy by \r\nreport. \r\n\r\n#Lower back pain: None on admission. No longer using narcotics \r\nor oxycontin. Continues on Gabapentin taper \r\n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.\r\n\r\n#Headache: History of headaches; reported an episode on ___ \r\nbut has had extensive w/u in the past that were reassuring. \r\nDenies headache since ___. Will not pursue further evaluation \r\nor treatment unless acute worsening or focal deficits\r\n\r\n#Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \r\n75,000. Has IVC filter in place.\r\n\r\n#Depression: Continue home venlafaxine\r\n\r\nProphylaxes:\r\n# Access: L POC placed ___\r\n# FEN: neutropenic diet\r\n# Bowel regimen: holding given diarrhea\r\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\r\n# Contact: ___ (husband)Phone number: ___ \r\nCell phone: ___ ___ (daughter) ___ \r\n# Disposition: Discharged ___. RTC on ___ for follow up\r\n# Code Status: FULL \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing \r\n3. Docusate Sodium 100 mg PO BID:PRN constipation \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 800 mg PO QAFTERNOON \r\n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n9. Senna 8.6 mg PO BID:PRN constipation \r\n10. Venlafaxine 25 mg PO BID \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Gabapentin 700 mg PO QPM \r\n13. Gabapentin 900 mg PO QAM \r\n \r\nDischarge Medications:\r\n1.  Ciprofloxacin HCl 500 mg PO Q12H  \r\n2.  Acyclovir 400 mg PO Q8H  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  FoLIC Acid 3.2 mg PO DAILY  \r\n6.  Gabapentin 800 mg PO QAFTERNOON  \r\n7.  Gabapentin 700 mg PO QPM  \r\n8.  Gabapentin 900 mg PO QAM  \r\n9.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiarrhea\r\nMDS\r\n___ DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___:\r\n\r\nYou were admitted because you were having decreased appetite, \r\nfatigue and diarrhea for several days at home. You received red \r\nblood cell transfusion and intravenous fluids with improvements \r\nin your symptoms. We think that these symptoms are likely side \r\neffects of your chemotherapy as further workup did not show a \r\nsource of infection. Please continue to take all of your \r\nmedications as ordered. Refer below for your next clinic \r\nappointment.\r\n\r\nIt was a pleasure taking care of you!\r\n\r\nSincerely,\r\nYOUR ___ TEAM\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-20:7",
      "text": "ACCESS: L POC w/o erythema, edema or tenderness\n \nPertinent Results:\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \nMAGNESIUM-2.0\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \nPHOS-131* TOT BILI-0.5\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\n___ 10:45PM URINE  MUCOUS-RARE\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \nEPI-1\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \nLEUK-NEG\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\n___ 12:00AM   IgG-762\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \nMAGNESIUM-2.0\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \nPHOS-127* TOT BILI-0.4\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \nCl-105 HCO3-22 AnGap-16\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \nTotBili-0.5\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\n___ 12:00AM BLOOD IgG-762 MICRO: ___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \nStool. **FINAL REPORT ___ C. difficile DNA amplification assay (Final ___: \n      Negative for toxigenic C. difficile by the Cepheid nucleic \nacid\n      amplification assay.. (Reference Range-Negative). ___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \nStool.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-20",
        "chart_time": "104566",
        "section": "General",
        "position": 7,
        "tokenCount": 697,
        "note_metadata": {
          "note_id": "18887130-DS-20",
          "subject_id": 18887130,
          "hadm_id": 27191597,
          "note_type": "DS",
          "note_seq": 20,
          "charttime": 104566,
          "storetime": 104566.725,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfatigue, abdominal cramping, diarrhea and decreased appetite\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed diffuse large \r\nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \r\n conditioning in ___ ___s IFRT with course complicated \r\n by ___ pneumonitis, who was subsequently found to have \r\ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \r\npresenting with 2 days of poor oral intake, fatigue, diarrhea \r\nand abdominal cramping.\r\n\r\nREVIEW OF SYSTEMS:\r\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. \r\nHEENT: No congestion, sore throat. No sores in the mouth,\r\npainful swallowing, sinus tenderness. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough; notes shortness of breath with exertion which\r\nhas increased somewhat; no shortness of breath at rest; no\r\nwheezing or hemoptysis. \r\nGI: GI upset with no specific nausea or vomiting with\r\ndecreased food intake; + diarrhea ___ night and ___ AM with\r\nepigatric pain. No constipation, hematochezia, or melena. \r\nGU: No dysuria or change in bladder habits. \r\nMSK: Right lower back pain much improved. No need for pain\r\nmedications. Occasional left lower back/sciatica pain which is\r\nchronic.  \r\nDERM: No new rashes or skin lesions. \r\nNEURO: Alert and oriented; no further issues with word finding;\r\nno confusion. + headache on ___ with history of migraines.\r\nNo visual changes. Slight lightheadedness. Usual numbness of\r\nright toes following prior surgery; no increased numbness. Has\r\nstarted tapering her Gabapentin but numbness of fingers has\r\nimproved.\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed ___ with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PE:\r\nGEN: More tired appearing in NAD\r\nWT: 101.6 lbs. \r\nVS: TC 98.5 PO 127/84 86 18 98%RA \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2 no MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg\r\nwith well healed area with no further surrounding erythema;\r\nhyperpigmented skin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n\r\nDISCHARGE PE:\r\nGEN: NAD. Fatigue improved\r\nWT: 101.6 lbs. \r\nVS: TC 97.7 108/54 80 20 96%RA  \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2. No MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg with well \r\nhealed area with no further surrounding erythema; hyperpigmented \r\nskin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n \r\nPertinent Results:\r\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \r\nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\r\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \r\nMAGNESIUM-2.0\r\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \r\nPHOS-131* TOT BILI-0.5\r\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \r\nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\r\n___ 10:45PM URINE  MUCOUS-RARE\r\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \r\nEPI-1\r\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \r\nLEUK-NEG\r\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\r\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\r\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \r\nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \r\nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\r\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \r\nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \r\nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\r\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \r\nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\r\n___ 12:00AM   IgG-762\r\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \r\nMAGNESIUM-2.0\r\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \r\nPHOS-127* TOT BILI-0.4\r\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \r\nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\r\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \r\nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\r\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \r\nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \r\nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\r\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \r\nCl-105 HCO3-22 AnGap-16\r\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \r\nTotBili-0.5\r\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\r\n___ 12:00AM BLOOD IgG-762\r\n\r\nMICRO:\r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Pending): \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Pending): \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n\r\nBLOOD CULTURE ___ AND ___ NTD\r\n \r\nBrief Hospital Course:\r\nASSESSMENT AND PLAN: ___ year old female with history of \r\ntransformed diffuse large B cell lymphoma ___ a curative attempt \r\nwith an AutoSCT with BEAM conditioning in ___ ___s \r\nIFRT with course complicated by BCNU pneumonitis as well as \r\npersistent norovirus with now noted treatment related MDS ___ \r\nC3 of Dacogen) presenting with poor oral intake, diarrhea and \r\nfatigue\r\n\r\n#Diarrhea, epigastric discomfort and poor oral intake: Improved \r\nsince admission. Poor intake in the past 2 days prior to \r\nadmission. No vomiting or nausea. Had ___ loose stools since \r\nadmission. No fevers at home and remained afebrile throughout \r\nhospital course. No other associated infectious symptoms \r\ncurrently.\r\n-Cdiff negative; other stool cultures PND at discharge \r\n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \r\nat discharge \r\n\r\n#Hypokalemia: Now normalized, was 3.0 prior to admission. Her \r\nhypokalemia was noted in the setting of decreased oral intake \r\nand GI loss (diarrhea). Received K+ repletions at home. \r\n\r\n#Shortness of breath on exertion and lightheadedness: Improved \r\nsince admission. Etiology likely related to profound anemia and \r\ndecreased oral intake. Received 1U\r\nprbcs at clinic prior to admission and received 1U in-house for \r\nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \r\nacute pulmonary process. Hemoglobin 9.4 at discharge. \r\n\r\n#MDS: Noted for rapid progression of pancytopenia, particularly \r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with \r\nnoted cytogenetic abnormalities concerning for treatment related \r\nMDS. ___ made to treat with Dacogen with\r\nplan to move towards allogeneic transplant. Neutrophils and \r\nplatelets recovered prior to starting ___ cycle. Counts now low \r\nfollowing treatment as expected although platelet appear to be \r\nrecovering. She is currently ___ ___ C3 of Dacogen. \r\n-transfuse for platelets < 20,000 (54 at discharge) and HGB < \r\n7.5 (9.4 at discharge).\r\n-C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \r\nforward with allogeneic transplant. Has unrelated donor. \r\n-Ciprofloxacin and Fluconazole have been on hold; restarted \r\nciprofloxacin on admission as ___ < 500. \r\n-Bactrim discontinued as CD4 count > 200\r\n-Will monitor IGG level; give IVIG for IGG less than 300 or \r\ninfections as IVIG can affect counts. Last IVIG ___ = 762\r\n\r\n#Lymphoma/CLL/Disease Status: Has been in remission with last CT \r\nscan in ___ without evidence of lymphoma/adenopathy. Has \r\nhistory of CLL as well; no evidence of this on BM biopsy by \r\nreport. \r\n\r\n#Lower back pain: None on admission. No longer using narcotics \r\nor oxycontin. Continues on Gabapentin taper \r\n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.\r\n\r\n#Headache: History of headaches; reported an episode on ___ \r\nbut has had extensive w/u in the past that were reassuring. \r\nDenies headache since ___. Will not pursue further evaluation \r\nor treatment unless acute worsening or focal deficits\r\n\r\n#Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \r\n75,000. Has IVC filter in place.\r\n\r\n#Depression: Continue home venlafaxine\r\n\r\nProphylaxes:\r\n# Access: L POC placed ___\r\n# FEN: neutropenic diet\r\n# Bowel regimen: holding given diarrhea\r\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\r\n# Contact: ___ (husband)Phone number: ___ \r\nCell phone: ___ ___ (daughter) ___ \r\n# Disposition: Discharged ___. RTC on ___ for follow up\r\n# Code Status: FULL \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing \r\n3. Docusate Sodium 100 mg PO BID:PRN constipation \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 800 mg PO QAFTERNOON \r\n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n9. Senna 8.6 mg PO BID:PRN constipation \r\n10. Venlafaxine 25 mg PO BID \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Gabapentin 700 mg PO QPM \r\n13. Gabapentin 900 mg PO QAM \r\n \r\nDischarge Medications:\r\n1.  Ciprofloxacin HCl 500 mg PO Q12H  \r\n2.  Acyclovir 400 mg PO Q8H  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  FoLIC Acid 3.2 mg PO DAILY  \r\n6.  Gabapentin 800 mg PO QAFTERNOON  \r\n7.  Gabapentin 700 mg PO QPM  \r\n8.  Gabapentin 900 mg PO QAM  \r\n9.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiarrhea\r\nMDS\r\n___ DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___:\r\n\r\nYou were admitted because you were having decreased appetite, \r\nfatigue and diarrhea for several days at home. You received red \r\nblood cell transfusion and intravenous fluids with improvements \r\nin your symptoms. We think that these symptoms are likely side \r\neffects of your chemotherapy as further workup did not show a \r\nsource of infection. Please continue to take all of your \r\nmedications as ordered. Refer below for your next clinic \r\nappointment.\r\n\r\nIt was a pleasure taking care of you!\r\n\r\nSincerely,\r\nYOUR ___ TEAM\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-20:8",
      "text": "MICRO: ___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \nStool. **FINAL REPORT ___ C. difficile DNA amplification assay (Final ___: \n      Negative for toxigenic C. difficile by the Cepheid nucleic \nacid\n      amplification assay.. (Reference Range-Negative). ___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \nStool. MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \nSEEN. CYCLOSPORA STAIN (Pending): FECAL CULTURE (Pending): CAMPYLOBACTER CULTURE (Pending): OVA + PARASITES (Pending): Cryptosporidium/Giardia (DFA) (Final ___: \n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. BLOOD CULTURE ___ AND ___ NTD Brief Hospital Course:",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-20",
        "chart_time": "104566",
        "section": "General",
        "position": 8,
        "tokenCount": 160,
        "note_metadata": {
          "note_id": "18887130-DS-20",
          "subject_id": 18887130,
          "hadm_id": 27191597,
          "note_type": "DS",
          "note_seq": 20,
          "charttime": 104566,
          "storetime": 104566.725,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfatigue, abdominal cramping, diarrhea and decreased appetite\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed diffuse large \r\nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \r\n conditioning in ___ ___s IFRT with course complicated \r\n by ___ pneumonitis, who was subsequently found to have \r\ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \r\npresenting with 2 days of poor oral intake, fatigue, diarrhea \r\nand abdominal cramping.\r\n\r\nREVIEW OF SYSTEMS:\r\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. \r\nHEENT: No congestion, sore throat. No sores in the mouth,\r\npainful swallowing, sinus tenderness. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough; notes shortness of breath with exertion which\r\nhas increased somewhat; no shortness of breath at rest; no\r\nwheezing or hemoptysis. \r\nGI: GI upset with no specific nausea or vomiting with\r\ndecreased food intake; + diarrhea ___ night and ___ AM with\r\nepigatric pain. No constipation, hematochezia, or melena. \r\nGU: No dysuria or change in bladder habits. \r\nMSK: Right lower back pain much improved. No need for pain\r\nmedications. Occasional left lower back/sciatica pain which is\r\nchronic.  \r\nDERM: No new rashes or skin lesions. \r\nNEURO: Alert and oriented; no further issues with word finding;\r\nno confusion. + headache on ___ with history of migraines.\r\nNo visual changes. Slight lightheadedness. Usual numbness of\r\nright toes following prior surgery; no increased numbness. Has\r\nstarted tapering her Gabapentin but numbness of fingers has\r\nimproved.\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed ___ with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PE:\r\nGEN: More tired appearing in NAD\r\nWT: 101.6 lbs. \r\nVS: TC 98.5 PO 127/84 86 18 98%RA \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2 no MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg\r\nwith well healed area with no further surrounding erythema;\r\nhyperpigmented skin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n\r\nDISCHARGE PE:\r\nGEN: NAD. Fatigue improved\r\nWT: 101.6 lbs. \r\nVS: TC 97.7 108/54 80 20 96%RA  \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2. No MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg with well \r\nhealed area with no further surrounding erythema; hyperpigmented \r\nskin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n \r\nPertinent Results:\r\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \r\nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\r\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \r\nMAGNESIUM-2.0\r\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \r\nPHOS-131* TOT BILI-0.5\r\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \r\nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\r\n___ 10:45PM URINE  MUCOUS-RARE\r\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \r\nEPI-1\r\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \r\nLEUK-NEG\r\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\r\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\r\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \r\nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \r\nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\r\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \r\nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \r\nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\r\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \r\nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\r\n___ 12:00AM   IgG-762\r\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \r\nMAGNESIUM-2.0\r\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \r\nPHOS-127* TOT BILI-0.4\r\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \r\nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\r\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \r\nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\r\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \r\nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \r\nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\r\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \r\nCl-105 HCO3-22 AnGap-16\r\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \r\nTotBili-0.5\r\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\r\n___ 12:00AM BLOOD IgG-762\r\n\r\nMICRO:\r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Pending): \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Pending): \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n\r\nBLOOD CULTURE ___ AND ___ NTD\r\n \r\nBrief Hospital Course:\r\nASSESSMENT AND PLAN: ___ year old female with history of \r\ntransformed diffuse large B cell lymphoma ___ a curative attempt \r\nwith an AutoSCT with BEAM conditioning in ___ ___s \r\nIFRT with course complicated by BCNU pneumonitis as well as \r\npersistent norovirus with now noted treatment related MDS ___ \r\nC3 of Dacogen) presenting with poor oral intake, diarrhea and \r\nfatigue\r\n\r\n#Diarrhea, epigastric discomfort and poor oral intake: Improved \r\nsince admission. Poor intake in the past 2 days prior to \r\nadmission. No vomiting or nausea. Had ___ loose stools since \r\nadmission. No fevers at home and remained afebrile throughout \r\nhospital course. No other associated infectious symptoms \r\ncurrently.\r\n-Cdiff negative; other stool cultures PND at discharge \r\n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \r\nat discharge \r\n\r\n#Hypokalemia: Now normalized, was 3.0 prior to admission. Her \r\nhypokalemia was noted in the setting of decreased oral intake \r\nand GI loss (diarrhea). Received K+ repletions at home. \r\n\r\n#Shortness of breath on exertion and lightheadedness: Improved \r\nsince admission. Etiology likely related to profound anemia and \r\ndecreased oral intake. Received 1U\r\nprbcs at clinic prior to admission and received 1U in-house for \r\nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \r\nacute pulmonary process. Hemoglobin 9.4 at discharge. \r\n\r\n#MDS: Noted for rapid progression of pancytopenia, particularly \r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with \r\nnoted cytogenetic abnormalities concerning for treatment related \r\nMDS. ___ made to treat with Dacogen with\r\nplan to move towards allogeneic transplant. Neutrophils and \r\nplatelets recovered prior to starting ___ cycle. Counts now low \r\nfollowing treatment as expected although platelet appear to be \r\nrecovering. She is currently ___ ___ C3 of Dacogen. \r\n-transfuse for platelets < 20,000 (54 at discharge) and HGB < \r\n7.5 (9.4 at discharge).\r\n-C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \r\nforward with allogeneic transplant. Has unrelated donor. \r\n-Ciprofloxacin and Fluconazole have been on hold; restarted \r\nciprofloxacin on admission as ___ < 500. \r\n-Bactrim discontinued as CD4 count > 200\r\n-Will monitor IGG level; give IVIG for IGG less than 300 or \r\ninfections as IVIG can affect counts. Last IVIG ___ = 762\r\n\r\n#Lymphoma/CLL/Disease Status: Has been in remission with last CT \r\nscan in ___ without evidence of lymphoma/adenopathy. Has \r\nhistory of CLL as well; no evidence of this on BM biopsy by \r\nreport. \r\n\r\n#Lower back pain: None on admission. No longer using narcotics \r\nor oxycontin. Continues on Gabapentin taper \r\n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.\r\n\r\n#Headache: History of headaches; reported an episode on ___ \r\nbut has had extensive w/u in the past that were reassuring. \r\nDenies headache since ___. Will not pursue further evaluation \r\nor treatment unless acute worsening or focal deficits\r\n\r\n#Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \r\n75,000. Has IVC filter in place.\r\n\r\n#Depression: Continue home venlafaxine\r\n\r\nProphylaxes:\r\n# Access: L POC placed ___\r\n# FEN: neutropenic diet\r\n# Bowel regimen: holding given diarrhea\r\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\r\n# Contact: ___ (husband)Phone number: ___ \r\nCell phone: ___ ___ (daughter) ___ \r\n# Disposition: Discharged ___. RTC on ___ for follow up\r\n# Code Status: FULL \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing \r\n3. Docusate Sodium 100 mg PO BID:PRN constipation \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 800 mg PO QAFTERNOON \r\n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n9. Senna 8.6 mg PO BID:PRN constipation \r\n10. Venlafaxine 25 mg PO BID \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Gabapentin 700 mg PO QPM \r\n13. Gabapentin 900 mg PO QAM \r\n \r\nDischarge Medications:\r\n1.  Ciprofloxacin HCl 500 mg PO Q12H  \r\n2.  Acyclovir 400 mg PO Q8H  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  FoLIC Acid 3.2 mg PO DAILY  \r\n6.  Gabapentin 800 mg PO QAFTERNOON  \r\n7.  Gabapentin 700 mg PO QPM  \r\n8.  Gabapentin 900 mg PO QAM  \r\n9.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiarrhea\r\nMDS\r\n___ DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___:\r\n\r\nYou were admitted because you were having decreased appetite, \r\nfatigue and diarrhea for several days at home. You received red \r\nblood cell transfusion and intravenous fluids with improvements \r\nin your symptoms. We think that these symptoms are likely side \r\neffects of your chemotherapy as further workup did not show a \r\nsource of infection. Please continue to take all of your \r\nmedications as ordered. Refer below for your next clinic \r\nappointment.\r\n\r\nIt was a pleasure taking care of you!\r\n\r\nSincerely,\r\nYOUR ___ TEAM\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-20:9",
      "text": "ASSESSMENT AND PLAN: ___ year old female with history of \ntransformed diffuse large B cell lymphoma ___ a curative attempt \nwith an AutoSCT with BEAM conditioning in ___ ___s \nIFRT with course complicated by BCNU pneumonitis as well as \npersistent norovirus with now noted treatment related MDS ___ \nC3 of Dacogen) presenting with poor oral intake, diarrhea and \nfatigue #Diarrhea, epigastric discomfort and poor oral intake: Improved \nsince admission. Poor intake in the past 2 days prior to \nadmission. No vomiting or nausea. Had ___ loose stools since \nadmission. No fevers at home and remained afebrile throughout \nhospital course. No other associated infectious symptoms \ncurrently. -Cdiff negative; other stool cultures PND at discharge \n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \nat discharge #Hypokalemia: Now normalized, was 3.0 prior to admission. Her \nhypokalemia was noted in the setting of decreased oral intake \nand GI loss (diarrhea). Received K+ repletions at home. #Shortness of breath on exertion and lightheadedness: Improved \nsince admission. Etiology likely related to profound anemia and \ndecreased oral intake. Received 1U\nprbcs at clinic prior to admission and received 1U in-house for \nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \nacute pulmonary process. Hemoglobin 9.4 at discharge. #MDS: Noted for rapid progression of pancytopenia, particularly \nanemia. Bone marrow biopsy with dysplasia of all cell lines with \nnoted cytogenetic abnormalities concerning for treatment related \nMDS. ___ made to treat with Dacogen with\nplan to move towards allogeneic transplant. Neutrophils and \nplatelets recovered prior to starting ___ cycle. Counts now low \nfollowing treatment as expected although platelet appear to be \nrecovering. She is currently ___ ___ C3 of Dacogen. -transfuse for platelets < 20,000 (54 at discharge) and HGB < \n7.5 (9.4 at discharge). -C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \nforward with allogeneic transplant. Has unrelated donor. -Ciprofloxacin and Fluconazole have been on hold; restarted \nciprofloxacin on admission as ___ < 500. -Bactrim discontinued as CD4 count > 200\n-Will monitor IGG level; give IVIG for IGG less than 300 or \ninfections as IVIG can affect counts. Last IVIG ___ = 762 #Lymphoma/CLL/Disease Status: Has been in remission with last CT \nscan in ___ without evidence of lymphoma/adenopathy. Has \nhistory of CLL as well; no evidence of this on BM biopsy by \nreport. #Lower back pain: None on admission. No longer using narcotics \nor oxycontin. Continues on Gabapentin taper \n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-20",
        "chart_time": "104566",
        "section": "General",
        "position": 9,
        "tokenCount": 676,
        "note_metadata": {
          "note_id": "18887130-DS-20",
          "subject_id": 18887130,
          "hadm_id": 27191597,
          "note_type": "DS",
          "note_seq": 20,
          "charttime": 104566,
          "storetime": 104566.725,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfatigue, abdominal cramping, diarrhea and decreased appetite\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed diffuse large \r\nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \r\n conditioning in ___ ___s IFRT with course complicated \r\n by ___ pneumonitis, who was subsequently found to have \r\ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \r\npresenting with 2 days of poor oral intake, fatigue, diarrhea \r\nand abdominal cramping.\r\n\r\nREVIEW OF SYSTEMS:\r\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. \r\nHEENT: No congestion, sore throat. No sores in the mouth,\r\npainful swallowing, sinus tenderness. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough; notes shortness of breath with exertion which\r\nhas increased somewhat; no shortness of breath at rest; no\r\nwheezing or hemoptysis. \r\nGI: GI upset with no specific nausea or vomiting with\r\ndecreased food intake; + diarrhea ___ night and ___ AM with\r\nepigatric pain. No constipation, hematochezia, or melena. \r\nGU: No dysuria or change in bladder habits. \r\nMSK: Right lower back pain much improved. No need for pain\r\nmedications. Occasional left lower back/sciatica pain which is\r\nchronic.  \r\nDERM: No new rashes or skin lesions. \r\nNEURO: Alert and oriented; no further issues with word finding;\r\nno confusion. + headache on ___ with history of migraines.\r\nNo visual changes. Slight lightheadedness. Usual numbness of\r\nright toes following prior surgery; no increased numbness. Has\r\nstarted tapering her Gabapentin but numbness of fingers has\r\nimproved.\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed ___ with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PE:\r\nGEN: More tired appearing in NAD\r\nWT: 101.6 lbs. \r\nVS: TC 98.5 PO 127/84 86 18 98%RA \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2 no MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg\r\nwith well healed area with no further surrounding erythema;\r\nhyperpigmented skin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n\r\nDISCHARGE PE:\r\nGEN: NAD. Fatigue improved\r\nWT: 101.6 lbs. \r\nVS: TC 97.7 108/54 80 20 96%RA  \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2. No MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg with well \r\nhealed area with no further surrounding erythema; hyperpigmented \r\nskin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n \r\nPertinent Results:\r\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \r\nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\r\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \r\nMAGNESIUM-2.0\r\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \r\nPHOS-131* TOT BILI-0.5\r\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \r\nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\r\n___ 10:45PM URINE  MUCOUS-RARE\r\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \r\nEPI-1\r\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \r\nLEUK-NEG\r\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\r\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\r\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \r\nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \r\nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\r\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \r\nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \r\nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\r\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \r\nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\r\n___ 12:00AM   IgG-762\r\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \r\nMAGNESIUM-2.0\r\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \r\nPHOS-127* TOT BILI-0.4\r\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \r\nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\r\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \r\nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\r\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \r\nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \r\nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\r\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \r\nCl-105 HCO3-22 AnGap-16\r\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \r\nTotBili-0.5\r\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\r\n___ 12:00AM BLOOD IgG-762\r\n\r\nMICRO:\r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Pending): \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Pending): \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n\r\nBLOOD CULTURE ___ AND ___ NTD\r\n \r\nBrief Hospital Course:\r\nASSESSMENT AND PLAN: ___ year old female with history of \r\ntransformed diffuse large B cell lymphoma ___ a curative attempt \r\nwith an AutoSCT with BEAM conditioning in ___ ___s \r\nIFRT with course complicated by BCNU pneumonitis as well as \r\npersistent norovirus with now noted treatment related MDS ___ \r\nC3 of Dacogen) presenting with poor oral intake, diarrhea and \r\nfatigue\r\n\r\n#Diarrhea, epigastric discomfort and poor oral intake: Improved \r\nsince admission. Poor intake in the past 2 days prior to \r\nadmission. No vomiting or nausea. Had ___ loose stools since \r\nadmission. No fevers at home and remained afebrile throughout \r\nhospital course. No other associated infectious symptoms \r\ncurrently.\r\n-Cdiff negative; other stool cultures PND at discharge \r\n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \r\nat discharge \r\n\r\n#Hypokalemia: Now normalized, was 3.0 prior to admission. Her \r\nhypokalemia was noted in the setting of decreased oral intake \r\nand GI loss (diarrhea). Received K+ repletions at home. \r\n\r\n#Shortness of breath on exertion and lightheadedness: Improved \r\nsince admission. Etiology likely related to profound anemia and \r\ndecreased oral intake. Received 1U\r\nprbcs at clinic prior to admission and received 1U in-house for \r\nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \r\nacute pulmonary process. Hemoglobin 9.4 at discharge. \r\n\r\n#MDS: Noted for rapid progression of pancytopenia, particularly \r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with \r\nnoted cytogenetic abnormalities concerning for treatment related \r\nMDS. ___ made to treat with Dacogen with\r\nplan to move towards allogeneic transplant. Neutrophils and \r\nplatelets recovered prior to starting ___ cycle. Counts now low \r\nfollowing treatment as expected although platelet appear to be \r\nrecovering. She is currently ___ ___ C3 of Dacogen. \r\n-transfuse for platelets < 20,000 (54 at discharge) and HGB < \r\n7.5 (9.4 at discharge).\r\n-C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \r\nforward with allogeneic transplant. Has unrelated donor. \r\n-Ciprofloxacin and Fluconazole have been on hold; restarted \r\nciprofloxacin on admission as ___ < 500. \r\n-Bactrim discontinued as CD4 count > 200\r\n-Will monitor IGG level; give IVIG for IGG less than 300 or \r\ninfections as IVIG can affect counts. Last IVIG ___ = 762\r\n\r\n#Lymphoma/CLL/Disease Status: Has been in remission with last CT \r\nscan in ___ without evidence of lymphoma/adenopathy. Has \r\nhistory of CLL as well; no evidence of this on BM biopsy by \r\nreport. \r\n\r\n#Lower back pain: None on admission. No longer using narcotics \r\nor oxycontin. Continues on Gabapentin taper \r\n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.\r\n\r\n#Headache: History of headaches; reported an episode on ___ \r\nbut has had extensive w/u in the past that were reassuring. \r\nDenies headache since ___. Will not pursue further evaluation \r\nor treatment unless acute worsening or focal deficits\r\n\r\n#Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \r\n75,000. Has IVC filter in place.\r\n\r\n#Depression: Continue home venlafaxine\r\n\r\nProphylaxes:\r\n# Access: L POC placed ___\r\n# FEN: neutropenic diet\r\n# Bowel regimen: holding given diarrhea\r\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\r\n# Contact: ___ (husband)Phone number: ___ \r\nCell phone: ___ ___ (daughter) ___ \r\n# Disposition: Discharged ___. RTC on ___ for follow up\r\n# Code Status: FULL \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing \r\n3. Docusate Sodium 100 mg PO BID:PRN constipation \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 800 mg PO QAFTERNOON \r\n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n9. Senna 8.6 mg PO BID:PRN constipation \r\n10. Venlafaxine 25 mg PO BID \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Gabapentin 700 mg PO QPM \r\n13. Gabapentin 900 mg PO QAM \r\n \r\nDischarge Medications:\r\n1.  Ciprofloxacin HCl 500 mg PO Q12H  \r\n2.  Acyclovir 400 mg PO Q8H  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  FoLIC Acid 3.2 mg PO DAILY  \r\n6.  Gabapentin 800 mg PO QAFTERNOON  \r\n7.  Gabapentin 700 mg PO QPM  \r\n8.  Gabapentin 900 mg PO QAM  \r\n9.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiarrhea\r\nMDS\r\n___ DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___:\r\n\r\nYou were admitted because you were having decreased appetite, \r\nfatigue and diarrhea for several days at home. You received red \r\nblood cell transfusion and intravenous fluids with improvements \r\nin your symptoms. We think that these symptoms are likely side \r\neffects of your chemotherapy as further workup did not show a \r\nsource of infection. Please continue to take all of your \r\nmedications as ordered. Refer below for your next clinic \r\nappointment.\r\n\r\nIt was a pleasure taking care of you!\r\n\r\nSincerely,\r\nYOUR ___ TEAM\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-20:10",
      "text": "-Bactrim discontinued as CD4 count > 200\n-Will monitor IGG level; give IVIG for IGG less than 300 or \ninfections as IVIG can affect counts. Last IVIG ___ = 762 #Lymphoma/CLL/Disease Status: Has been in remission with last CT \nscan in ___ without evidence of lymphoma/adenopathy. Has \nhistory of CLL as well; no evidence of this on BM biopsy by \nreport. #Lower back pain: None on admission. No longer using narcotics \nor oxycontin. Continues on Gabapentin taper \n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report. #Headache: History of headaches; reported an episode on ___ \nbut has had extensive w/u in the past that were reassuring. Denies headache since ___. Will not pursue further evaluation \nor treatment unless acute worsening or focal deficits #Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \n75,000. Has IVC filter in place. #Depression: Continue home venlafaxine Prophylaxes:\n# Access: L POC placed ___\n# FEN: neutropenic diet\n# Bowel regimen: holding given diarrhea\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\n# Contact: ___ (husband)Phone number: ___ \nCell phone: ___ ___ (daughter) ___ \n# Disposition: Discharged ___. RTC on ___ for follow up\n# Code Status: FULL \n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Acyclovir 400 mg PO Q8H \n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \nsob/wheezing \n3. Docusate Sodium 100 mg PO BID:PRN constipation \n4. FoLIC Acid 3.2 mg PO DAILY \n5. Gabapentin 800 mg PO QAFTERNOON \n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \n7. Omeprazole 20 mg PO DAILY \n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \n9. Senna 8.6 mg PO BID:PRN constipation \n10. Venlafaxine 25 mg PO BID \n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \n12. Gabapentin 700 mg PO QPM \n13. Gabapentin 900 mg PO QAM",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-20",
        "chart_time": "104566",
        "section": "General",
        "position": 10,
        "tokenCount": 465,
        "note_metadata": {
          "note_id": "18887130-DS-20",
          "subject_id": 18887130,
          "hadm_id": 27191597,
          "note_type": "DS",
          "note_seq": 20,
          "charttime": 104566,
          "storetime": 104566.725,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfatigue, abdominal cramping, diarrhea and decreased appetite\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed diffuse large \r\nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \r\n conditioning in ___ ___s IFRT with course complicated \r\n by ___ pneumonitis, who was subsequently found to have \r\ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \r\npresenting with 2 days of poor oral intake, fatigue, diarrhea \r\nand abdominal cramping.\r\n\r\nREVIEW OF SYSTEMS:\r\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. \r\nHEENT: No congestion, sore throat. No sores in the mouth,\r\npainful swallowing, sinus tenderness. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough; notes shortness of breath with exertion which\r\nhas increased somewhat; no shortness of breath at rest; no\r\nwheezing or hemoptysis. \r\nGI: GI upset with no specific nausea or vomiting with\r\ndecreased food intake; + diarrhea ___ night and ___ AM with\r\nepigatric pain. No constipation, hematochezia, or melena. \r\nGU: No dysuria or change in bladder habits. \r\nMSK: Right lower back pain much improved. No need for pain\r\nmedications. Occasional left lower back/sciatica pain which is\r\nchronic.  \r\nDERM: No new rashes or skin lesions. \r\nNEURO: Alert and oriented; no further issues with word finding;\r\nno confusion. + headache on ___ with history of migraines.\r\nNo visual changes. Slight lightheadedness. Usual numbness of\r\nright toes following prior surgery; no increased numbness. Has\r\nstarted tapering her Gabapentin but numbness of fingers has\r\nimproved.\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed ___ with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PE:\r\nGEN: More tired appearing in NAD\r\nWT: 101.6 lbs. \r\nVS: TC 98.5 PO 127/84 86 18 98%RA \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2 no MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg\r\nwith well healed area with no further surrounding erythema;\r\nhyperpigmented skin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n\r\nDISCHARGE PE:\r\nGEN: NAD. Fatigue improved\r\nWT: 101.6 lbs. \r\nVS: TC 97.7 108/54 80 20 96%RA  \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2. No MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg with well \r\nhealed area with no further surrounding erythema; hyperpigmented \r\nskin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n \r\nPertinent Results:\r\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \r\nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\r\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \r\nMAGNESIUM-2.0\r\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \r\nPHOS-131* TOT BILI-0.5\r\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \r\nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\r\n___ 10:45PM URINE  MUCOUS-RARE\r\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \r\nEPI-1\r\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \r\nLEUK-NEG\r\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\r\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\r\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \r\nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \r\nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\r\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \r\nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \r\nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\r\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \r\nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\r\n___ 12:00AM   IgG-762\r\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \r\nMAGNESIUM-2.0\r\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \r\nPHOS-127* TOT BILI-0.4\r\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \r\nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\r\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \r\nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\r\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \r\nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \r\nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\r\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \r\nCl-105 HCO3-22 AnGap-16\r\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \r\nTotBili-0.5\r\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\r\n___ 12:00AM BLOOD IgG-762\r\n\r\nMICRO:\r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Pending): \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Pending): \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n\r\nBLOOD CULTURE ___ AND ___ NTD\r\n \r\nBrief Hospital Course:\r\nASSESSMENT AND PLAN: ___ year old female with history of \r\ntransformed diffuse large B cell lymphoma ___ a curative attempt \r\nwith an AutoSCT with BEAM conditioning in ___ ___s \r\nIFRT with course complicated by BCNU pneumonitis as well as \r\npersistent norovirus with now noted treatment related MDS ___ \r\nC3 of Dacogen) presenting with poor oral intake, diarrhea and \r\nfatigue\r\n\r\n#Diarrhea, epigastric discomfort and poor oral intake: Improved \r\nsince admission. Poor intake in the past 2 days prior to \r\nadmission. No vomiting or nausea. Had ___ loose stools since \r\nadmission. No fevers at home and remained afebrile throughout \r\nhospital course. No other associated infectious symptoms \r\ncurrently.\r\n-Cdiff negative; other stool cultures PND at discharge \r\n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \r\nat discharge \r\n\r\n#Hypokalemia: Now normalized, was 3.0 prior to admission. Her \r\nhypokalemia was noted in the setting of decreased oral intake \r\nand GI loss (diarrhea). Received K+ repletions at home. \r\n\r\n#Shortness of breath on exertion and lightheadedness: Improved \r\nsince admission. Etiology likely related to profound anemia and \r\ndecreased oral intake. Received 1U\r\nprbcs at clinic prior to admission and received 1U in-house for \r\nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \r\nacute pulmonary process. Hemoglobin 9.4 at discharge. \r\n\r\n#MDS: Noted for rapid progression of pancytopenia, particularly \r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with \r\nnoted cytogenetic abnormalities concerning for treatment related \r\nMDS. ___ made to treat with Dacogen with\r\nplan to move towards allogeneic transplant. Neutrophils and \r\nplatelets recovered prior to starting ___ cycle. Counts now low \r\nfollowing treatment as expected although platelet appear to be \r\nrecovering. She is currently ___ ___ C3 of Dacogen. \r\n-transfuse for platelets < 20,000 (54 at discharge) and HGB < \r\n7.5 (9.4 at discharge).\r\n-C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \r\nforward with allogeneic transplant. Has unrelated donor. \r\n-Ciprofloxacin and Fluconazole have been on hold; restarted \r\nciprofloxacin on admission as ___ < 500. \r\n-Bactrim discontinued as CD4 count > 200\r\n-Will monitor IGG level; give IVIG for IGG less than 300 or \r\ninfections as IVIG can affect counts. Last IVIG ___ = 762\r\n\r\n#Lymphoma/CLL/Disease Status: Has been in remission with last CT \r\nscan in ___ without evidence of lymphoma/adenopathy. Has \r\nhistory of CLL as well; no evidence of this on BM biopsy by \r\nreport. \r\n\r\n#Lower back pain: None on admission. No longer using narcotics \r\nor oxycontin. Continues on Gabapentin taper \r\n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.\r\n\r\n#Headache: History of headaches; reported an episode on ___ \r\nbut has had extensive w/u in the past that were reassuring. \r\nDenies headache since ___. Will not pursue further evaluation \r\nor treatment unless acute worsening or focal deficits\r\n\r\n#Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \r\n75,000. Has IVC filter in place.\r\n\r\n#Depression: Continue home venlafaxine\r\n\r\nProphylaxes:\r\n# Access: L POC placed ___\r\n# FEN: neutropenic diet\r\n# Bowel regimen: holding given diarrhea\r\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\r\n# Contact: ___ (husband)Phone number: ___ \r\nCell phone: ___ ___ (daughter) ___ \r\n# Disposition: Discharged ___. RTC on ___ for follow up\r\n# Code Status: FULL \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing \r\n3. Docusate Sodium 100 mg PO BID:PRN constipation \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 800 mg PO QAFTERNOON \r\n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n9. Senna 8.6 mg PO BID:PRN constipation \r\n10. Venlafaxine 25 mg PO BID \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Gabapentin 700 mg PO QPM \r\n13. Gabapentin 900 mg PO QAM \r\n \r\nDischarge Medications:\r\n1.  Ciprofloxacin HCl 500 mg PO Q12H  \r\n2.  Acyclovir 400 mg PO Q8H  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  FoLIC Acid 3.2 mg PO DAILY  \r\n6.  Gabapentin 800 mg PO QAFTERNOON  \r\n7.  Gabapentin 700 mg PO QPM  \r\n8.  Gabapentin 900 mg PO QAM  \r\n9.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiarrhea\r\nMDS\r\n___ DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___:\r\n\r\nYou were admitted because you were having decreased appetite, \r\nfatigue and diarrhea for several days at home. You received red \r\nblood cell transfusion and intravenous fluids with improvements \r\nin your symptoms. We think that these symptoms are likely side \r\neffects of your chemotherapy as further workup did not show a \r\nsource of infection. Please continue to take all of your \r\nmedications as ordered. Refer below for your next clinic \r\nappointment.\r\n\r\nIt was a pleasure taking care of you!\r\n\r\nSincerely,\r\nYOUR ___ TEAM\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-20:11",
      "text": "Discharge Medications:\n1. Ciprofloxacin HCl 500 mg PO Q12H  \n2. Acyclovir 400 mg PO Q8H  \n3. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \nsob/wheezing  \n4. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \n5. FoLIC Acid 3.2 mg PO DAILY  \n6. Gabapentin 800 mg PO QAFTERNOON  \n7. Gabapentin 700 mg PO QPM  \n8. Gabapentin 900 mg PO QAM  \n9. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \n10. Omeprazole 20 mg PO DAILY  \n11. Venlafaxine 25 mg PO BID Discharge Disposition:\nHome Discharge Diagnosis:\nDiarrhea\nMDS\n___ DVT Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - requires assistance or aid (walker \nor cane).",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-20",
        "chart_time": "104566",
        "section": "General",
        "position": 11,
        "tokenCount": 183,
        "note_metadata": {
          "note_id": "18887130-DS-20",
          "subject_id": 18887130,
          "hadm_id": 27191597,
          "note_type": "DS",
          "note_seq": 20,
          "charttime": 104566,
          "storetime": 104566.725,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfatigue, abdominal cramping, diarrhea and decreased appetite\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed diffuse large \r\nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \r\n conditioning in ___ ___s IFRT with course complicated \r\n by ___ pneumonitis, who was subsequently found to have \r\ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \r\npresenting with 2 days of poor oral intake, fatigue, diarrhea \r\nand abdominal cramping.\r\n\r\nREVIEW OF SYSTEMS:\r\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. \r\nHEENT: No congestion, sore throat. No sores in the mouth,\r\npainful swallowing, sinus tenderness. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough; notes shortness of breath with exertion which\r\nhas increased somewhat; no shortness of breath at rest; no\r\nwheezing or hemoptysis. \r\nGI: GI upset with no specific nausea or vomiting with\r\ndecreased food intake; + diarrhea ___ night and ___ AM with\r\nepigatric pain. No constipation, hematochezia, or melena. \r\nGU: No dysuria or change in bladder habits. \r\nMSK: Right lower back pain much improved. No need for pain\r\nmedications. Occasional left lower back/sciatica pain which is\r\nchronic.  \r\nDERM: No new rashes or skin lesions. \r\nNEURO: Alert and oriented; no further issues with word finding;\r\nno confusion. + headache on ___ with history of migraines.\r\nNo visual changes. Slight lightheadedness. Usual numbness of\r\nright toes following prior surgery; no increased numbness. Has\r\nstarted tapering her Gabapentin but numbness of fingers has\r\nimproved.\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed ___ with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PE:\r\nGEN: More tired appearing in NAD\r\nWT: 101.6 lbs. \r\nVS: TC 98.5 PO 127/84 86 18 98%RA \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2 no MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg\r\nwith well healed area with no further surrounding erythema;\r\nhyperpigmented skin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n\r\nDISCHARGE PE:\r\nGEN: NAD. Fatigue improved\r\nWT: 101.6 lbs. \r\nVS: TC 97.7 108/54 80 20 96%RA  \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2. No MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg with well \r\nhealed area with no further surrounding erythema; hyperpigmented \r\nskin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n \r\nPertinent Results:\r\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \r\nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\r\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \r\nMAGNESIUM-2.0\r\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \r\nPHOS-131* TOT BILI-0.5\r\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \r\nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\r\n___ 10:45PM URINE  MUCOUS-RARE\r\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \r\nEPI-1\r\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \r\nLEUK-NEG\r\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\r\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\r\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \r\nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \r\nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\r\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \r\nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \r\nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\r\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \r\nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\r\n___ 12:00AM   IgG-762\r\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \r\nMAGNESIUM-2.0\r\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \r\nPHOS-127* TOT BILI-0.4\r\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \r\nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\r\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \r\nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\r\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \r\nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \r\nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\r\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \r\nCl-105 HCO3-22 AnGap-16\r\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \r\nTotBili-0.5\r\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\r\n___ 12:00AM BLOOD IgG-762\r\n\r\nMICRO:\r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Pending): \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Pending): \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n\r\nBLOOD CULTURE ___ AND ___ NTD\r\n \r\nBrief Hospital Course:\r\nASSESSMENT AND PLAN: ___ year old female with history of \r\ntransformed diffuse large B cell lymphoma ___ a curative attempt \r\nwith an AutoSCT with BEAM conditioning in ___ ___s \r\nIFRT with course complicated by BCNU pneumonitis as well as \r\npersistent norovirus with now noted treatment related MDS ___ \r\nC3 of Dacogen) presenting with poor oral intake, diarrhea and \r\nfatigue\r\n\r\n#Diarrhea, epigastric discomfort and poor oral intake: Improved \r\nsince admission. Poor intake in the past 2 days prior to \r\nadmission. No vomiting or nausea. Had ___ loose stools since \r\nadmission. No fevers at home and remained afebrile throughout \r\nhospital course. No other associated infectious symptoms \r\ncurrently.\r\n-Cdiff negative; other stool cultures PND at discharge \r\n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \r\nat discharge \r\n\r\n#Hypokalemia: Now normalized, was 3.0 prior to admission. Her \r\nhypokalemia was noted in the setting of decreased oral intake \r\nand GI loss (diarrhea). Received K+ repletions at home. \r\n\r\n#Shortness of breath on exertion and lightheadedness: Improved \r\nsince admission. Etiology likely related to profound anemia and \r\ndecreased oral intake. Received 1U\r\nprbcs at clinic prior to admission and received 1U in-house for \r\nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \r\nacute pulmonary process. Hemoglobin 9.4 at discharge. \r\n\r\n#MDS: Noted for rapid progression of pancytopenia, particularly \r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with \r\nnoted cytogenetic abnormalities concerning for treatment related \r\nMDS. ___ made to treat with Dacogen with\r\nplan to move towards allogeneic transplant. Neutrophils and \r\nplatelets recovered prior to starting ___ cycle. Counts now low \r\nfollowing treatment as expected although platelet appear to be \r\nrecovering. She is currently ___ ___ C3 of Dacogen. \r\n-transfuse for platelets < 20,000 (54 at discharge) and HGB < \r\n7.5 (9.4 at discharge).\r\n-C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \r\nforward with allogeneic transplant. Has unrelated donor. \r\n-Ciprofloxacin and Fluconazole have been on hold; restarted \r\nciprofloxacin on admission as ___ < 500. \r\n-Bactrim discontinued as CD4 count > 200\r\n-Will monitor IGG level; give IVIG for IGG less than 300 or \r\ninfections as IVIG can affect counts. Last IVIG ___ = 762\r\n\r\n#Lymphoma/CLL/Disease Status: Has been in remission with last CT \r\nscan in ___ without evidence of lymphoma/adenopathy. Has \r\nhistory of CLL as well; no evidence of this on BM biopsy by \r\nreport. \r\n\r\n#Lower back pain: None on admission. No longer using narcotics \r\nor oxycontin. Continues on Gabapentin taper \r\n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.\r\n\r\n#Headache: History of headaches; reported an episode on ___ \r\nbut has had extensive w/u in the past that were reassuring. \r\nDenies headache since ___. Will not pursue further evaluation \r\nor treatment unless acute worsening or focal deficits\r\n\r\n#Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \r\n75,000. Has IVC filter in place.\r\n\r\n#Depression: Continue home venlafaxine\r\n\r\nProphylaxes:\r\n# Access: L POC placed ___\r\n# FEN: neutropenic diet\r\n# Bowel regimen: holding given diarrhea\r\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\r\n# Contact: ___ (husband)Phone number: ___ \r\nCell phone: ___ ___ (daughter) ___ \r\n# Disposition: Discharged ___. RTC on ___ for follow up\r\n# Code Status: FULL \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing \r\n3. Docusate Sodium 100 mg PO BID:PRN constipation \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 800 mg PO QAFTERNOON \r\n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n9. Senna 8.6 mg PO BID:PRN constipation \r\n10. Venlafaxine 25 mg PO BID \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Gabapentin 700 mg PO QPM \r\n13. Gabapentin 900 mg PO QAM \r\n \r\nDischarge Medications:\r\n1.  Ciprofloxacin HCl 500 mg PO Q12H  \r\n2.  Acyclovir 400 mg PO Q8H  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  FoLIC Acid 3.2 mg PO DAILY  \r\n6.  Gabapentin 800 mg PO QAFTERNOON  \r\n7.  Gabapentin 700 mg PO QPM  \r\n8.  Gabapentin 900 mg PO QAM  \r\n9.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiarrhea\r\nMDS\r\n___ DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___:\r\n\r\nYou were admitted because you were having decreased appetite, \r\nfatigue and diarrhea for several days at home. You received red \r\nblood cell transfusion and intravenous fluids with improvements \r\nin your symptoms. We think that these symptoms are likely side \r\neffects of your chemotherapy as further workup did not show a \r\nsource of infection. Please continue to take all of your \r\nmedications as ordered. Refer below for your next clinic \r\nappointment.\r\n\r\nIt was a pleasure taking care of you!\r\n\r\nSincerely,\r\nYOUR ___ TEAM\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-20:12",
      "text": "Discharge Instructions:\nDear ___: You were admitted because you were having decreased appetite, \nfatigue and diarrhea for several days at home. You received red \nblood cell transfusion and intravenous fluids with improvements \nin your symptoms. We think that these symptoms are likely side \neffects of your chemotherapy as further workup did not show a \nsource of infection. Please continue to take all of your \nmedications as ordered. Refer below for your next clinic \nappointment. It was a pleasure taking care of you! Sincerely,\nYOUR ___ TEAM\n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-20",
        "chart_time": "104566",
        "section": "General",
        "position": 12,
        "tokenCount": 144,
        "note_metadata": {
          "note_id": "18887130-DS-20",
          "subject_id": 18887130,
          "hadm_id": 27191597,
          "note_type": "DS",
          "note_seq": 20,
          "charttime": 104566,
          "storetime": 104566.725,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfatigue, abdominal cramping, diarrhea and decreased appetite\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with a history of transformed diffuse large \r\nB cell lymphoma ___ a curative attempt with an AutoSCT with BEAM \r\n conditioning in ___ ___s IFRT with course complicated \r\n by ___ pneumonitis, who was subsequently found to have \r\ntreatment-related MDS now ___ cycle 3 of Decitabine (D22) \r\npresenting with 2 days of poor oral intake, fatigue, diarrhea \r\nand abdominal cramping.\r\n\r\nREVIEW OF SYSTEMS:\r\nGENERAL: Fatigue. No fever, chills, night sweats. No itching. \r\nHEENT: No congestion, sore throat. No sores in the mouth,\r\npainful swallowing, sinus tenderness. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough; notes shortness of breath with exertion which\r\nhas increased somewhat; no shortness of breath at rest; no\r\nwheezing or hemoptysis. \r\nGI: GI upset with no specific nausea or vomiting with\r\ndecreased food intake; + diarrhea ___ night and ___ AM with\r\nepigatric pain. No constipation, hematochezia, or melena. \r\nGU: No dysuria or change in bladder habits. \r\nMSK: Right lower back pain much improved. No need for pain\r\nmedications. Occasional left lower back/sciatica pain which is\r\nchronic.  \r\nDERM: No new rashes or skin lesions. \r\nNEURO: Alert and oriented; no further issues with word finding;\r\nno confusion. + headache on ___ with history of migraines.\r\nNo visual changes. Slight lightheadedness. Usual numbness of\r\nright toes following prior surgery; no increased numbness. Has\r\nstarted tapering her Gabapentin but numbness of fingers has\r\nimproved.\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA:\r\n___: Transplant Date: 1\r\n          Graft: Auto\r\n          Conditioning Intensity: Ablative\r\n          Conditioning Regimen: BEAM\r\n\r\nPAST ONCOLOGIC HISTORY:\r\nTransformed ___ with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg\r\nPO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10\r\nmg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continue prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobuonemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT).  No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n \r\nOTHER PAST MEDICAL HISTORY\r\n- CVID, received IVIG monthly. last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nbrother - lymphoma\r\n\r\n \r\nPhysical ___:\r\nADMISSION PE:\r\nGEN: More tired appearing in NAD\r\nWT: 101.6 lbs. \r\nVS: TC 98.5 PO 127/84 86 18 98%RA \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2 no MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg\r\nwith well healed area with no further surrounding erythema;\r\nhyperpigmented skin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n\r\nDISCHARGE PE:\r\nGEN: NAD. Fatigue improved\r\nWT: 101.6 lbs. \r\nVS: TC 97.7 108/54 80 20 96%RA  \r\nHEENT: Right pupil slower to react to light which is baseline. \r\nMMM, no OP lesions or increased erythema.\r\nCV: RRR, NL S1/S2. No MRG\r\nPULM: CTAB with decreased breath sounds at bases; no rales or\r\nwheezing. Normal respiratory effort.\r\nABD: Obese. BS+, soft, NT/ND. No HSM appreciated.\r\nLIMBS: Right leg with decreased edema; left lower leg with well \r\nhealed area with no further surrounding erythema; hyperpigmented \r\nskin changes on lower legs. Calves softer. \r\nSKIN: No rashes or new skin eruptions.\r\nACCESS: L POC w/o erythema, edema or tenderness\r\n \r\nPertinent Results:\r\n___ 01:35PM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   NEUTS-28* BANDS-0 LYMPHS-70* MONOS-1* EOS-1 \r\nBASOS-0 ___ MYELOS-0 AbsNeut-0.11* AbsLymp-0.28* \r\nAbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*\r\n___ 01:35PM   WBC-0.4*# RBC-2.28* HGB-7.0* HCT-21.7* MCV-95 \r\nMCH-30.7 MCHC-32.3 RDW-20.9* RDWSD-51.6*\r\n___ 01:35PM   ALBUMIN-3.6 CALCIUM-8.5 PHOSPHATE-2.2* \r\nMAGNESIUM-2.0\r\n___ 01:35PM   ALT(SGPT)-21 AST(SGOT)-24 LD(LDH)-188 ALK \r\nPHOS-131* TOT BILI-0.5\r\n___ 01:35PM   UREA N-9 CREAT-0.8 SODIUM-140 POTASSIUM-3.0* \r\nCHLORIDE-107 TOTAL CO2-24 ANION GAP-12\r\n___ 10:45PM URINE  MUCOUS-RARE\r\n___ 10:45PM URINE  RBC-1 WBC-6* BACTERIA-FEW YEAST-NONE \r\nEPI-1\r\n___ 10:45PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-30 \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.5 \r\nLEUK-NEG\r\n___ 10:45PM URINE  COLOR-Yellow APPEAR-Clear SP ___\r\n___ 10:45PM STOOL  NoroGI-NEGATIVE NoroGII-NEGATIVE\r\n___ 12:00AM   PLT SMR-VERY LOW PLT COUNT-42*\r\n___ 12:00AM   HYPOCHROM-1+ ANISOCYT-1+ POIKILOCY-1+ \r\nMACROCYT-1+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-1+ \r\nSCHISTOCY-OCCASIONAL TEARDROP-OCCASIONAL\r\n___ 12:00AM   NEUTS-19* BANDS-0 LYMPHS-79* MONOS-0 EOS-1 \r\nBASOS-0 ATYPS-1* ___ MYELOS-0 NUC RBCS-2* AbsNeut-0.11* \r\nAbsLymp-0.48* AbsMono-0.00* AbsEos-0.01* AbsBaso-0.00*\r\n___ 12:00AM   WBC-0.6* RBC-2.72* HGB-8.4* HCT-25.2* MCV-93 \r\nMCH-30.9 MCHC-33.3 RDW-19.2* RDWSD-48.3*\r\n___ 12:00AM   IgG-762\r\n___ 12:00AM   ALBUMIN-3.4* CALCIUM-8.0* PHOSPHATE-3.3 \r\nMAGNESIUM-2.0\r\n___ 12:00AM   ALT(SGPT)-21 AST(SGOT)-23 LD(LDH)-178 ALK \r\nPHOS-127* TOT BILI-0.4\r\n___ 12:00AM   GLUCOSE-87 UREA N-8 CREAT-0.8 SODIUM-143 \r\nPOTASSIUM-3.4 CHLORIDE-108 TOTAL CO2-22 ANION GAP-16\r\n___ 12:00AM BLOOD WBC-0.9* RBC-3.10* Hgb-9.4* Hct-29.0* \r\nMCV-94 MCH-30.3 MCHC-32.4 RDW-19.9* RDWSD-51.1* Plt Ct-53*\r\n___ 12:00AM BLOOD Neuts-15* Bands-0 Lymphs-84* Monos-1* \r\nEos-0 Baso-0 ___ Myelos-0 NRBC-1* AbsNeut-0.14* \r\nAbsLymp-0.76* AbsMono-0.01* AbsEos-0.00* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-NORMAL Ovalocy-1+\r\n___ 12:00AM BLOOD Glucose-92 UreaN-6 Creat-0.9 Na-139 K-3.5 \r\nCl-105 HCO3-22 AnGap-16\r\n___ 12:00AM BLOOD ALT-24 AST-27 LD(LDH)-223 AlkPhos-146* \r\nTotBili-0.5\r\n___ 12:00AM BLOOD Albumin-3.7 Calcium-8.3* Phos-3.4 Mg-2.4\r\n___ 12:00AM BLOOD IgG-762\r\n\r\nMICRO:\r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n\r\n___ 10:45 pm STOOL     CONSISTENCY: LOOSE      Source: \r\nStool. \r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Pending): \r\n\r\n   FECAL CULTURE (Pending): \r\n\r\n   CAMPYLOBACTER CULTURE (Pending): \r\n\r\n   OVA + PARASITES (Pending): \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n\r\nBLOOD CULTURE ___ AND ___ NTD\r\n \r\nBrief Hospital Course:\r\nASSESSMENT AND PLAN: ___ year old female with history of \r\ntransformed diffuse large B cell lymphoma ___ a curative attempt \r\nwith an AutoSCT with BEAM conditioning in ___ ___s \r\nIFRT with course complicated by BCNU pneumonitis as well as \r\npersistent norovirus with now noted treatment related MDS ___ \r\nC3 of Dacogen) presenting with poor oral intake, diarrhea and \r\nfatigue\r\n\r\n#Diarrhea, epigastric discomfort and poor oral intake: Improved \r\nsince admission. Poor intake in the past 2 days prior to \r\nadmission. No vomiting or nausea. Had ___ loose stools since \r\nadmission. No fevers at home and remained afebrile throughout \r\nhospital course. No other associated infectious symptoms \r\ncurrently.\r\n-Cdiff negative; other stool cultures PND at discharge \r\n-UA with 6WBC; urine culture < 10, 000; Repeat UA/Urine CX PND \r\nat discharge \r\n\r\n#Hypokalemia: Now normalized, was 3.0 prior to admission. Her \r\nhypokalemia was noted in the setting of decreased oral intake \r\nand GI loss (diarrhea). Received K+ repletions at home. \r\n\r\n#Shortness of breath on exertion and lightheadedness: Improved \r\nsince admission. Etiology likely related to profound anemia and \r\ndecreased oral intake. Received 1U\r\nprbcs at clinic prior to admission and received 1U in-house for \r\nhemoglobin of 7. No evidence of hypoxia or fever to suggest an \r\nacute pulmonary process. Hemoglobin 9.4 at discharge. \r\n\r\n#MDS: Noted for rapid progression of pancytopenia, particularly \r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with \r\nnoted cytogenetic abnormalities concerning for treatment related \r\nMDS. ___ made to treat with Dacogen with\r\nplan to move towards allogeneic transplant. Neutrophils and \r\nplatelets recovered prior to starting ___ cycle. Counts now low \r\nfollowing treatment as expected although platelet appear to be \r\nrecovering. She is currently ___ ___ C3 of Dacogen. \r\n-transfuse for platelets < 20,000 (54 at discharge) and HGB < \r\n7.5 (9.4 at discharge).\r\n-C4 Dacogen due on ___ has appointment with Dr. ___ bone marrow biopsy after 4 cycles and hopefully move \r\nforward with allogeneic transplant. Has unrelated donor. \r\n-Ciprofloxacin and Fluconazole have been on hold; restarted \r\nciprofloxacin on admission as ___ < 500. \r\n-Bactrim discontinued as CD4 count > 200\r\n-Will monitor IGG level; give IVIG for IGG less than 300 or \r\ninfections as IVIG can affect counts. Last IVIG ___ = 762\r\n\r\n#Lymphoma/CLL/Disease Status: Has been in remission with last CT \r\nscan in ___ without evidence of lymphoma/adenopathy. Has \r\nhistory of CLL as well; no evidence of this on BM biopsy by \r\nreport. \r\n\r\n#Lower back pain: None on admission. No longer using narcotics \r\nor oxycontin. Continues on Gabapentin taper \r\n(900mgQAM--800mgQAfternoon--700mgQPM) per patient report.\r\n\r\n#Headache: History of headaches; reported an episode on ___ \r\nbut has had extensive w/u in the past that were reassuring. \r\nDenies headache since ___. Will not pursue further evaluation \r\nor treatment unless acute worsening or focal deficits\r\n\r\n#Right leg DVT: Holding Xarelto 20 mg daily as platelet count < \r\n75,000. Has IVC filter in place.\r\n\r\n#Depression: Continue home venlafaxine\r\n\r\nProphylaxes:\r\n# Access: L POC placed ___\r\n# FEN: neutropenic diet\r\n# Bowel regimen: holding given diarrhea\r\n# DVT PPX: holding Xarelto for hx of ___ DVT as plts < 75K\r\n# Contact: ___ (husband)Phone number: ___ \r\nCell phone: ___ ___ (daughter) ___ \r\n# Disposition: Discharged ___. RTC on ___ for follow up\r\n# Code Status: FULL \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing \r\n3. Docusate Sodium 100 mg PO BID:PRN constipation \r\n4. FoLIC Acid 3.2 mg PO DAILY \r\n5. Gabapentin 800 mg PO QAFTERNOON \r\n6. Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Polyethylene Glycol 17 g PO DAILY:PRN constipation \r\n9. Senna 8.6 mg PO BID:PRN constipation \r\n10. Venlafaxine 25 mg PO BID \r\n11. albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing \r\n12. Gabapentin 700 mg PO QPM \r\n13. Gabapentin 900 mg PO QAM \r\n \r\nDischarge Medications:\r\n1.  Ciprofloxacin HCl 500 mg PO Q12H  \r\n2.  Acyclovir 400 mg PO Q8H  \r\n3.  albuterol sulfate 2.5 mg /3 mL (0.083 %) inhalation Q6H:PRN \r\nsob/wheezing  \r\n4.  albuterol sulfate 90 mcg inhalation Q4H:PRN sob/wheezing  \r\n5.  FoLIC Acid 3.2 mg PO DAILY  \r\n6.  Gabapentin 800 mg PO QAFTERNOON  \r\n7.  Gabapentin 700 mg PO QPM  \r\n8.  Gabapentin 900 mg PO QAM  \r\n9.  Ipratropium Bromide MDI 2 PUFF IH QID:PRN wheezing/sob  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiarrhea\r\nMDS\r\n___ DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - requires assistance or aid (walker \r\nor cane).\r\n\r\n \r\nDischarge Instructions:\r\nDear ___:\r\n\r\nYou were admitted because you were having decreased appetite, \r\nfatigue and diarrhea for several days at home. You received red \r\nblood cell transfusion and intravenous fluids with improvements \r\nin your symptoms. We think that these symptoms are likely side \r\neffects of your chemotherapy as further workup did not show a \r\nsource of infection. Please continue to take all of your \r\nmedications as ordered. Refer below for your next clinic \r\nappointment.\r\n\r\nIt was a pleasure taking care of you!\r\n\r\nSincerely,\r\nYOUR ___ TEAM\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-21:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \ndapsone\n \nAttending: ___. Chief Complaint:\nCough, wheezing\n \nMajor Surgical or Invasive Procedure:\nNone",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-21",
        "chart_time": "104607",
        "section": "General",
        "position": 0,
        "tokenCount": 70,
        "note_metadata": {
          "note_id": "18887130-DS-21",
          "subject_id": 18887130,
          "hadm_id": 22357254,
          "note_type": "DS",
          "note_seq": 21,
          "charttime": 104607,
          "storetime": 104608.70416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nCough, wheezing\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for transplant, who \r\npresents with cough and wheezing x2 days. She states that her \r\ncough is productive with clear sputum with no blood. She denies \r\nany fever or chills. She has no chest pain, shortness of breath, \r\nabdominal pain,  diarrhea, or difficulty/pain with urination. \r\nShe does endorse some nasal congestion and dry throat.  \r\n\r\nShe has had issues with bronchitis/pneumonias in the past. Given \r\nher profound neutropenia, she was referred to the ED for \r\npossible admission. \r\n\r\nIn the ED, labs were notable for WBC 0.8, ANC 170, H/H 8.0/24.6, \r\nPlt 27, lactate 1.0, coags wnl. \r\nChem 7: Na 140, K 3.8, Cl 107, CO2 21, BUN 16, Cr 0.8, Glucose \r\n72.\r\nUA, urine and blood cultures were ordered. \r\nCXR did not show evidence of pneumonia, however with patient's \r\nworsening cough and wheezes along with her neutropenia, she was \r\ntreated with empiric antibiotics, including cefepime, \r\nvancomycin, and azithromycin. \r\nShe also received albuterol and ipratropium nebs.\r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new adenopathy. Labs notable for LDH 341, WBC \r\n10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all markedly FDG-avid and concerning for \r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer abdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxaban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis, \r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg PO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10 mg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continued prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobulinemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LNs. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT). No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n- ___, C4 Dacogen\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\n- CVID, received IVIG monthly. Last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurysm, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___.\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.3, BP 128/58, P 88, RR 22, O2sat 100% on RA\r\nGen: Pleasant, calm, \r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear. No \r\npharyngeal erythema or exudates, no sinus tenderness, normal TM \r\nbilaterally, trachea midline  \r\nLYMPH: No cervical or supraclavicular LAD  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Bilateral end expiratory wheezes in \r\nupper lung fields b/l.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: No rashes/lesions, petechiae/purpura, or ecchymoses.  \r\nNEURO: A&Ox3.  \r\nLINES: Port\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.2-98.3, BP 117-122/76-80, P 85-91, RR ___, O2sat \r\n97-98% on RA/CPAP\r\nGen: Pleasant, calm, no acute distress, coughing occasionally\r\nHEENT: No conjunctival pallor. No icterus. MMM. \r\nCV: RRR. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Diffuse expiratory wheezes.\r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: Venous stasis changes in b/l ___, non-pitting ___ edema\r\nLINES: Port\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n====================\r\n___ 09:09AM BLOOD WBC-0.9* RBC-2.50* Hgb-8.1* Hct-24.9* \r\nMCV-100* MCH-32.4* MCHC-32.5 RDW-21.2* RDWSD-72.1* Plt Ct-17*\r\n___ 09:09AM BLOOD Neuts-31* Bands-0 Lymphs-64* Monos-4* \r\nEos-0 Baso-1 ___ Myelos-0 NRBC-3* AbsNeut-0.28* \r\nAbsLymp-0.58* AbsMono-0.04* AbsEos-0.00* AbsBaso-0.01\r\n___ 09:09AM BLOOD Hypochr-NORMAL Anisocy-1+ Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-1+ Ovalocy-OCCASIONAL\r\n\r\nOTHER RELEVANT LABS:\r\n======================\r\n___ 12:56PM BLOOD Lactate-1.0\r\n___ 12:00AM BLOOD IgG-774\r\n___ 04:10PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 04:10PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 04:10PM URINE RBC-<1 WBC-1 Bacteri-NONE Yeast-NONE \r\nEpi-<1\r\n___ 02:18PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nRespiratory Viral Antigen Screen (Final ___: \r\nPositive for Respiratory viral antigens. \r\nPOSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). \r\nViral antigen identified by immunofluorescence. \r\n\r\nDISCHARGE LABS:\r\n======================\r\n___ 12:00AM BLOOD WBC-0.6* RBC-2.73* Hgb-8.6* Hct-26.4* \r\nMCV-97 MCH-31.5 MCHC-32.6 RDW-21.7* RDWSD-72.9* Plt Ct-61*\r\n___ 12:00AM BLOOD Neuts-27* Bands-0 Lymphs-67* Monos-3* \r\nEos-3 Baso-0 ___ Myelos-0 AbsNeut-0.16* \r\nAbsLymp-0.40* AbsMono-0.02* AbsEos-0.02* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-NORMAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL\r\n___ 12:00AM BLOOD Glucose-92 UreaN-19 Creat-0.8 Na-140 \r\nK-4.2 Cl-104 HCO3-22 AnGap-18\r\n___ 12:00AM BLOOD Calcium-8.5 Phos-2.9 Mg-2.4\r\n\r\nIMAGING:\r\n=====================\r\nCXR- PA and LATERAL (___): No acute cardiopulmonary abnormality \r\n\r\n \r\nBrief Hospital Course:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for allo transplant, \r\nwho presented with cough/wheezing and was found to have RSV \r\nbronchiolitis.\r\n\r\n#RSV bronchiolitis\r\n#Cough and wheezing\r\nPatient is neutropenic and has CVID and presented with cough and \r\nwheezing. She was initially started on cefepime and azithromycin \r\nfor empiric coverage. Patient's respiratory viral screen was \r\npositive for RSV. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis. She was also \r\ntreated symptomatically with duonebs q6h, mucinex, benzonatate, \r\nand guaifenesin-codeine at night. Her symptoms improved \r\nsignificantly with these measures. She was able to maintain \r\nO2sat > 95% while ambulating. \r\n\r\n#Myelodysplastic syndrome- Patient is ___ 4 cycles of dacogen \r\nwith plans to move towards allogeneic transplant. She was \r\ncontinued on acyclovir for prophylaxis. Her bacterial \r\nprophylaxis was transitioned to levaquin on ___ as above. She \r\nwas also started on fluconazole during this admission for fungal \r\nprophylaxis. She was transfused for Hgb < 7 or Plt < 10. She \r\nreceived a total of 2U pRBCs and 1U platelets during this \r\nadmission.\r\n\r\n#Low back pain- Continued gabapentin 600 mg TID\r\n\r\nTRANSITIONAL ISSUES:\r\n======================\r\n- New medications: fluconazole, levofloxacin, guaifenesin with \r\ncodeine, benzonatate, duonebs\r\n- Patient started on fluconazole 200 mg daily during this \r\nadmission for fungal prophylaxis, can consider adjusting dose to \r\n400 mg daily based on patient's weight\r\n- Patient initially on cefepime for broad spectrum antibiotic \r\ncoverage given significant symptoms and neutropenia that was \r\ntransitioned to levofloxacin on ___. Can consider de-escalating \r\nto ciprofloxacin if patient continues to clinically improve.\r\n- Of note, patient's PFTs (originally scheduled for ___ were \r\nrescheduled for ___ due to her acute illness. Can reschedule as \r\nneeded.\r\n \r\nMedications on Admission:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol 0.083% Neb Soln 1 NEB IH Q6H:PRN wheezing/cough \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n4. Gabapentin 600 mg PO TID \r\n5. Ipratropium Bromide Neb 1 NEB IH Q6H:PRN shortness of breath \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 4 mg PO Q8H:PRN nausea \r\n8. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN cough \r\nRX *benzonatate 100 mg 1 capsule(s) by mouth three time a day \r\nDisp #*30 Capsule Refills:*0 \r\n2.  Fluconazole 200 mg PO Q24H \r\nRX *fluconazole 200 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n3.  FoLIC Acid 3 mg PO DAILY \r\nRX *folic acid 1 mg 3 tablet(s) by mouth daily Disp #*90 Tablet \r\nRefills:*0 \r\n4.  Guaifenesin-CODEINE Phosphate ___ mL PO HS:PRN cough \r\nRX *codeine-guaifenesin 10 mg-100 mg/5 mL 5 mL by mouth at night \r\nRefills:*0 \r\n5.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nIH every 6 hours Disp #*120 Ampule Refills:*0 \r\n6.  Levofloxacin 500 mg PO Q24H \r\nRX *levofloxacin 500 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n7.  Acyclovir 400 mg PO Q8H  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n9.  Gabapentin 600 mg PO TID  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n12.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nRespiratory syncytial virus bronchiolitis\r\nMyelodysplastic syndrome\r\n\r\nSecondary:\r\nLow back pain\r\nCombined variable immunodeficiency\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted because you were having a cough and wheezing. \r\nWe found you had a virus called RSV that we treated with \r\nmedications called palvilizumab and ribavirin. We also gave you \r\n4 doses of 10g IVIg. We also supported your breathing with \r\nnebulizer treatments and cough medications. By the time of your \r\ndischarge, you were feeling much better. \r\n\r\nPlease follow-up with Dr. ___ at the \r\nappointment that was set up for you. \r\n\r\nIt was a pleasure taking care of you, and we wish you the best. \r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-21:1",
      "text": "History of Present Illness:\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \nin ___ in remission from lymphoma then with treatment-related \nMDS ___ 4 cycles of decitabine and planning for transplant, who \npresents with cough and wheezing x2 days. She states that her \ncough is productive with clear sputum with no blood. She denies \nany fever or chills. She has no chest pain, shortness of breath, \nabdominal pain,  diarrhea, or difficulty/pain with urination. She does endorse some nasal congestion and dry throat. She has had issues with bronchitis/pneumonias in the past. Given \nher profound neutropenia, she was referred to the ED for \npossible admission. In the ED, labs were notable for WBC 0.8, ANC 170, H/H 8.0/24.6, \nPlt 27, lactate 1.0, coags wnl. Chem 7: Na 140, K 3.8, Cl 107, CO2 21, BUN 16, Cr 0.8, Glucose \n72. UA, urine and blood cultures were ordered. CXR did not show evidence of pneumonia, however with patient's \nworsening cough and wheezes along with her neutropenia, she was \ntreated with empiric antibiotics, including cefepime, \nvancomycin, and azithromycin. She also received albuterol and ipratropium nebs.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-21",
        "chart_time": "104607",
        "section": "General",
        "position": 1,
        "tokenCount": 288,
        "note_metadata": {
          "note_id": "18887130-DS-21",
          "subject_id": 18887130,
          "hadm_id": 22357254,
          "note_type": "DS",
          "note_seq": 21,
          "charttime": 104607,
          "storetime": 104608.70416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nCough, wheezing\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for transplant, who \r\npresents with cough and wheezing x2 days. She states that her \r\ncough is productive with clear sputum with no blood. She denies \r\nany fever or chills. She has no chest pain, shortness of breath, \r\nabdominal pain,  diarrhea, or difficulty/pain with urination. \r\nShe does endorse some nasal congestion and dry throat.  \r\n\r\nShe has had issues with bronchitis/pneumonias in the past. Given \r\nher profound neutropenia, she was referred to the ED for \r\npossible admission. \r\n\r\nIn the ED, labs were notable for WBC 0.8, ANC 170, H/H 8.0/24.6, \r\nPlt 27, lactate 1.0, coags wnl. \r\nChem 7: Na 140, K 3.8, Cl 107, CO2 21, BUN 16, Cr 0.8, Glucose \r\n72.\r\nUA, urine and blood cultures were ordered. \r\nCXR did not show evidence of pneumonia, however with patient's \r\nworsening cough and wheezes along with her neutropenia, she was \r\ntreated with empiric antibiotics, including cefepime, \r\nvancomycin, and azithromycin. \r\nShe also received albuterol and ipratropium nebs.\r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new adenopathy. Labs notable for LDH 341, WBC \r\n10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all markedly FDG-avid and concerning for \r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer abdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxaban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis, \r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg PO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10 mg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continued prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobulinemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LNs. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT). No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n- ___, C4 Dacogen\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\n- CVID, received IVIG monthly. Last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurysm, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___.\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.3, BP 128/58, P 88, RR 22, O2sat 100% on RA\r\nGen: Pleasant, calm, \r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear. No \r\npharyngeal erythema or exudates, no sinus tenderness, normal TM \r\nbilaterally, trachea midline  \r\nLYMPH: No cervical or supraclavicular LAD  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Bilateral end expiratory wheezes in \r\nupper lung fields b/l.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: No rashes/lesions, petechiae/purpura, or ecchymoses.  \r\nNEURO: A&Ox3.  \r\nLINES: Port\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.2-98.3, BP 117-122/76-80, P 85-91, RR ___, O2sat \r\n97-98% on RA/CPAP\r\nGen: Pleasant, calm, no acute distress, coughing occasionally\r\nHEENT: No conjunctival pallor. No icterus. MMM. \r\nCV: RRR. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Diffuse expiratory wheezes.\r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: Venous stasis changes in b/l ___, non-pitting ___ edema\r\nLINES: Port\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n====================\r\n___ 09:09AM BLOOD WBC-0.9* RBC-2.50* Hgb-8.1* Hct-24.9* \r\nMCV-100* MCH-32.4* MCHC-32.5 RDW-21.2* RDWSD-72.1* Plt Ct-17*\r\n___ 09:09AM BLOOD Neuts-31* Bands-0 Lymphs-64* Monos-4* \r\nEos-0 Baso-1 ___ Myelos-0 NRBC-3* AbsNeut-0.28* \r\nAbsLymp-0.58* AbsMono-0.04* AbsEos-0.00* AbsBaso-0.01\r\n___ 09:09AM BLOOD Hypochr-NORMAL Anisocy-1+ Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-1+ Ovalocy-OCCASIONAL\r\n\r\nOTHER RELEVANT LABS:\r\n======================\r\n___ 12:56PM BLOOD Lactate-1.0\r\n___ 12:00AM BLOOD IgG-774\r\n___ 04:10PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 04:10PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 04:10PM URINE RBC-<1 WBC-1 Bacteri-NONE Yeast-NONE \r\nEpi-<1\r\n___ 02:18PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nRespiratory Viral Antigen Screen (Final ___: \r\nPositive for Respiratory viral antigens. \r\nPOSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). \r\nViral antigen identified by immunofluorescence. \r\n\r\nDISCHARGE LABS:\r\n======================\r\n___ 12:00AM BLOOD WBC-0.6* RBC-2.73* Hgb-8.6* Hct-26.4* \r\nMCV-97 MCH-31.5 MCHC-32.6 RDW-21.7* RDWSD-72.9* Plt Ct-61*\r\n___ 12:00AM BLOOD Neuts-27* Bands-0 Lymphs-67* Monos-3* \r\nEos-3 Baso-0 ___ Myelos-0 AbsNeut-0.16* \r\nAbsLymp-0.40* AbsMono-0.02* AbsEos-0.02* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-NORMAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL\r\n___ 12:00AM BLOOD Glucose-92 UreaN-19 Creat-0.8 Na-140 \r\nK-4.2 Cl-104 HCO3-22 AnGap-18\r\n___ 12:00AM BLOOD Calcium-8.5 Phos-2.9 Mg-2.4\r\n\r\nIMAGING:\r\n=====================\r\nCXR- PA and LATERAL (___): No acute cardiopulmonary abnormality \r\n\r\n \r\nBrief Hospital Course:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for allo transplant, \r\nwho presented with cough/wheezing and was found to have RSV \r\nbronchiolitis.\r\n\r\n#RSV bronchiolitis\r\n#Cough and wheezing\r\nPatient is neutropenic and has CVID and presented with cough and \r\nwheezing. She was initially started on cefepime and azithromycin \r\nfor empiric coverage. Patient's respiratory viral screen was \r\npositive for RSV. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis. She was also \r\ntreated symptomatically with duonebs q6h, mucinex, benzonatate, \r\nand guaifenesin-codeine at night. Her symptoms improved \r\nsignificantly with these measures. She was able to maintain \r\nO2sat > 95% while ambulating. \r\n\r\n#Myelodysplastic syndrome- Patient is ___ 4 cycles of dacogen \r\nwith plans to move towards allogeneic transplant. She was \r\ncontinued on acyclovir for prophylaxis. Her bacterial \r\nprophylaxis was transitioned to levaquin on ___ as above. She \r\nwas also started on fluconazole during this admission for fungal \r\nprophylaxis. She was transfused for Hgb < 7 or Plt < 10. She \r\nreceived a total of 2U pRBCs and 1U platelets during this \r\nadmission.\r\n\r\n#Low back pain- Continued gabapentin 600 mg TID\r\n\r\nTRANSITIONAL ISSUES:\r\n======================\r\n- New medications: fluconazole, levofloxacin, guaifenesin with \r\ncodeine, benzonatate, duonebs\r\n- Patient started on fluconazole 200 mg daily during this \r\nadmission for fungal prophylaxis, can consider adjusting dose to \r\n400 mg daily based on patient's weight\r\n- Patient initially on cefepime for broad spectrum antibiotic \r\ncoverage given significant symptoms and neutropenia that was \r\ntransitioned to levofloxacin on ___. Can consider de-escalating \r\nto ciprofloxacin if patient continues to clinically improve.\r\n- Of note, patient's PFTs (originally scheduled for ___ were \r\nrescheduled for ___ due to her acute illness. Can reschedule as \r\nneeded.\r\n \r\nMedications on Admission:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol 0.083% Neb Soln 1 NEB IH Q6H:PRN wheezing/cough \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n4. Gabapentin 600 mg PO TID \r\n5. Ipratropium Bromide Neb 1 NEB IH Q6H:PRN shortness of breath \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 4 mg PO Q8H:PRN nausea \r\n8. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN cough \r\nRX *benzonatate 100 mg 1 capsule(s) by mouth three time a day \r\nDisp #*30 Capsule Refills:*0 \r\n2.  Fluconazole 200 mg PO Q24H \r\nRX *fluconazole 200 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n3.  FoLIC Acid 3 mg PO DAILY \r\nRX *folic acid 1 mg 3 tablet(s) by mouth daily Disp #*90 Tablet \r\nRefills:*0 \r\n4.  Guaifenesin-CODEINE Phosphate ___ mL PO HS:PRN cough \r\nRX *codeine-guaifenesin 10 mg-100 mg/5 mL 5 mL by mouth at night \r\nRefills:*0 \r\n5.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nIH every 6 hours Disp #*120 Ampule Refills:*0 \r\n6.  Levofloxacin 500 mg PO Q24H \r\nRX *levofloxacin 500 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n7.  Acyclovir 400 mg PO Q8H  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n9.  Gabapentin 600 mg PO TID  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n12.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nRespiratory syncytial virus bronchiolitis\r\nMyelodysplastic syndrome\r\n\r\nSecondary:\r\nLow back pain\r\nCombined variable immunodeficiency\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted because you were having a cough and wheezing. \r\nWe found you had a virus called RSV that we treated with \r\nmedications called palvilizumab and ribavirin. We also gave you \r\n4 doses of 10g IVIg. We also supported your breathing with \r\nnebulizer treatments and cough medications. By the time of your \r\ndischarge, you were feeling much better. \r\n\r\nPlease follow-up with Dr. ___ at the \r\nappointment that was set up for you. \r\n\r\nIt was a pleasure taking care of you, and we wish you the best. \r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-21:2",
      "text": "Past Medical History:\nPAST ONCOLOGIC HISTORY:  \nTransformed DLBCL with a history of follicular lymphoma stage \nIIA\n- ___ developed worsening musculoskeletal back pain, early\nsatiety, hypoalbuminemia and found to have mesenteric mass\n- ?___ ex lap with 15 cm lobulated mass involving the \nduodenum, retroperitoneum and celiac access. Biopsies showed \nFollicular lymphomas grade II/III. Reportedly negative staging \nGallium scan. CD10+ BCL2+\n- ___ completed 6 cycles CHOP, complications included\nSVC/innominate thrombus (tPA)\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\nmarrow at completion was negative for lymphomatous involvement. - ___ PET-CT with very slight amount of increased tracer\nactivity within the posterior left supraclavicular region. No\nother areas of FDG avid disease were noted \n- ___ through ___ per records she was treated with CVP\nfollowed by course of single agent Rituxan\n- ___ through ___ surveillance imaging with no evidence of\nrecurrent disease, stable mesenteric mass. - ___ abdominal pain led to CT with no change in mass size,\nincreased conspicuity of nodular borders\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\nstable mesenteric mass with low level SUV 2.2 stable since \nprior. - ___ CT torso showed persistent mesenteric and left hilar\nlymphadenopathy. Stable right middle lobe small focus of ground\nglass opacity and adjacent subpleural fat hypertrophy, \nsuggestive\nof inflammatory process. Stable right adnexal cyst. - ___ Presented to PCP ___ ___iscomfort. Exam revealed new adenopathy. Labs notable for LDH 341, WBC \n10.1,\nnormal differential, PLT 452. - ___ PET CT revealed, \"Large left cervical, \nsupraclavicular, mediastinal lymphadenopathy, and \nretroperitoneal lymphadenopathy, and small mesenteric \nlymphadenopathy, all markedly FDG-avid and concerning for \nlymphoma.\" SUVmax 35.5. - ___iopsy revealed diffuse large B cell\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \nare pending\n- ___ C1D1 ICE\n- ___ C1 Rituximab, clinically improved adenopathy\n- ___ C2 Rituximab, WBC 6.5, PLT 43\n- ___ Admit for C2D1 ICE\n- ___ C3 Rituximab\n- ___ PET CT showed almost complete resolution of FDG avid\ndisease with a residual focus of avidity in the bed of the \nformer abdominal mass, SUV ___ C4 Rituximab\n- ___ C4 ICE followed by stem cell mobilization and\ncollection, BMBx showed a nest of CLL unrelated to her \naggressive\nlymphoma\n- ___ Presented with large DVTs, SVC filter placed\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\n- ___ Switched to Rivaroxaban for AC\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis, \ncytopenias\n- ___ Start XRT\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\nHb).",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-21",
        "chart_time": "104607",
        "section": "General",
        "position": 2,
        "tokenCount": 688,
        "note_metadata": {
          "note_id": "18887130-DS-21",
          "subject_id": 18887130,
          "hadm_id": 22357254,
          "note_type": "DS",
          "note_seq": 21,
          "charttime": 104607,
          "storetime": 104608.70416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nCough, wheezing\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for transplant, who \r\npresents with cough and wheezing x2 days. She states that her \r\ncough is productive with clear sputum with no blood. She denies \r\nany fever or chills. She has no chest pain, shortness of breath, \r\nabdominal pain,  diarrhea, or difficulty/pain with urination. \r\nShe does endorse some nasal congestion and dry throat.  \r\n\r\nShe has had issues with bronchitis/pneumonias in the past. Given \r\nher profound neutropenia, she was referred to the ED for \r\npossible admission. \r\n\r\nIn the ED, labs were notable for WBC 0.8, ANC 170, H/H 8.0/24.6, \r\nPlt 27, lactate 1.0, coags wnl. \r\nChem 7: Na 140, K 3.8, Cl 107, CO2 21, BUN 16, Cr 0.8, Glucose \r\n72.\r\nUA, urine and blood cultures were ordered. \r\nCXR did not show evidence of pneumonia, however with patient's \r\nworsening cough and wheezes along with her neutropenia, she was \r\ntreated with empiric antibiotics, including cefepime, \r\nvancomycin, and azithromycin. \r\nShe also received albuterol and ipratropium nebs.\r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new adenopathy. Labs notable for LDH 341, WBC \r\n10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all markedly FDG-avid and concerning for \r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer abdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxaban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis, \r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg PO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10 mg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continued prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobulinemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LNs. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT). No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n- ___, C4 Dacogen\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\n- CVID, received IVIG monthly. Last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurysm, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___.\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.3, BP 128/58, P 88, RR 22, O2sat 100% on RA\r\nGen: Pleasant, calm, \r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear. No \r\npharyngeal erythema or exudates, no sinus tenderness, normal TM \r\nbilaterally, trachea midline  \r\nLYMPH: No cervical or supraclavicular LAD  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Bilateral end expiratory wheezes in \r\nupper lung fields b/l.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: No rashes/lesions, petechiae/purpura, or ecchymoses.  \r\nNEURO: A&Ox3.  \r\nLINES: Port\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.2-98.3, BP 117-122/76-80, P 85-91, RR ___, O2sat \r\n97-98% on RA/CPAP\r\nGen: Pleasant, calm, no acute distress, coughing occasionally\r\nHEENT: No conjunctival pallor. No icterus. MMM. \r\nCV: RRR. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Diffuse expiratory wheezes.\r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: Venous stasis changes in b/l ___, non-pitting ___ edema\r\nLINES: Port\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n====================\r\n___ 09:09AM BLOOD WBC-0.9* RBC-2.50* Hgb-8.1* Hct-24.9* \r\nMCV-100* MCH-32.4* MCHC-32.5 RDW-21.2* RDWSD-72.1* Plt Ct-17*\r\n___ 09:09AM BLOOD Neuts-31* Bands-0 Lymphs-64* Monos-4* \r\nEos-0 Baso-1 ___ Myelos-0 NRBC-3* AbsNeut-0.28* \r\nAbsLymp-0.58* AbsMono-0.04* AbsEos-0.00* AbsBaso-0.01\r\n___ 09:09AM BLOOD Hypochr-NORMAL Anisocy-1+ Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-1+ Ovalocy-OCCASIONAL\r\n\r\nOTHER RELEVANT LABS:\r\n======================\r\n___ 12:56PM BLOOD Lactate-1.0\r\n___ 12:00AM BLOOD IgG-774\r\n___ 04:10PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 04:10PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 04:10PM URINE RBC-<1 WBC-1 Bacteri-NONE Yeast-NONE \r\nEpi-<1\r\n___ 02:18PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nRespiratory Viral Antigen Screen (Final ___: \r\nPositive for Respiratory viral antigens. \r\nPOSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). \r\nViral antigen identified by immunofluorescence. \r\n\r\nDISCHARGE LABS:\r\n======================\r\n___ 12:00AM BLOOD WBC-0.6* RBC-2.73* Hgb-8.6* Hct-26.4* \r\nMCV-97 MCH-31.5 MCHC-32.6 RDW-21.7* RDWSD-72.9* Plt Ct-61*\r\n___ 12:00AM BLOOD Neuts-27* Bands-0 Lymphs-67* Monos-3* \r\nEos-3 Baso-0 ___ Myelos-0 AbsNeut-0.16* \r\nAbsLymp-0.40* AbsMono-0.02* AbsEos-0.02* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-NORMAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL\r\n___ 12:00AM BLOOD Glucose-92 UreaN-19 Creat-0.8 Na-140 \r\nK-4.2 Cl-104 HCO3-22 AnGap-18\r\n___ 12:00AM BLOOD Calcium-8.5 Phos-2.9 Mg-2.4\r\n\r\nIMAGING:\r\n=====================\r\nCXR- PA and LATERAL (___): No acute cardiopulmonary abnormality \r\n\r\n \r\nBrief Hospital Course:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for allo transplant, \r\nwho presented with cough/wheezing and was found to have RSV \r\nbronchiolitis.\r\n\r\n#RSV bronchiolitis\r\n#Cough and wheezing\r\nPatient is neutropenic and has CVID and presented with cough and \r\nwheezing. She was initially started on cefepime and azithromycin \r\nfor empiric coverage. Patient's respiratory viral screen was \r\npositive for RSV. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis. She was also \r\ntreated symptomatically with duonebs q6h, mucinex, benzonatate, \r\nand guaifenesin-codeine at night. Her symptoms improved \r\nsignificantly with these measures. She was able to maintain \r\nO2sat > 95% while ambulating. \r\n\r\n#Myelodysplastic syndrome- Patient is ___ 4 cycles of dacogen \r\nwith plans to move towards allogeneic transplant. She was \r\ncontinued on acyclovir for prophylaxis. Her bacterial \r\nprophylaxis was transitioned to levaquin on ___ as above. She \r\nwas also started on fluconazole during this admission for fungal \r\nprophylaxis. She was transfused for Hgb < 7 or Plt < 10. She \r\nreceived a total of 2U pRBCs and 1U platelets during this \r\nadmission.\r\n\r\n#Low back pain- Continued gabapentin 600 mg TID\r\n\r\nTRANSITIONAL ISSUES:\r\n======================\r\n- New medications: fluconazole, levofloxacin, guaifenesin with \r\ncodeine, benzonatate, duonebs\r\n- Patient started on fluconazole 200 mg daily during this \r\nadmission for fungal prophylaxis, can consider adjusting dose to \r\n400 mg daily based on patient's weight\r\n- Patient initially on cefepime for broad spectrum antibiotic \r\ncoverage given significant symptoms and neutropenia that was \r\ntransitioned to levofloxacin on ___. Can consider de-escalating \r\nto ciprofloxacin if patient continues to clinically improve.\r\n- Of note, patient's PFTs (originally scheduled for ___ were \r\nrescheduled for ___ due to her acute illness. Can reschedule as \r\nneeded.\r\n \r\nMedications on Admission:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol 0.083% Neb Soln 1 NEB IH Q6H:PRN wheezing/cough \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n4. Gabapentin 600 mg PO TID \r\n5. Ipratropium Bromide Neb 1 NEB IH Q6H:PRN shortness of breath \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 4 mg PO Q8H:PRN nausea \r\n8. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN cough \r\nRX *benzonatate 100 mg 1 capsule(s) by mouth three time a day \r\nDisp #*30 Capsule Refills:*0 \r\n2.  Fluconazole 200 mg PO Q24H \r\nRX *fluconazole 200 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n3.  FoLIC Acid 3 mg PO DAILY \r\nRX *folic acid 1 mg 3 tablet(s) by mouth daily Disp #*90 Tablet \r\nRefills:*0 \r\n4.  Guaifenesin-CODEINE Phosphate ___ mL PO HS:PRN cough \r\nRX *codeine-guaifenesin 10 mg-100 mg/5 mL 5 mL by mouth at night \r\nRefills:*0 \r\n5.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nIH every 6 hours Disp #*120 Ampule Refills:*0 \r\n6.  Levofloxacin 500 mg PO Q24H \r\nRX *levofloxacin 500 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n7.  Acyclovir 400 mg PO Q8H  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n9.  Gabapentin 600 mg PO TID  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n12.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nRespiratory syncytial virus bronchiolitis\r\nMyelodysplastic syndrome\r\n\r\nSecondary:\r\nLow back pain\r\nCombined variable immunodeficiency\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted because you were having a cough and wheezing. \r\nWe found you had a virus called RSV that we treated with \r\nmedications called palvilizumab and ribavirin. We also gave you \r\n4 doses of 10g IVIg. We also supported your breathing with \r\nnebulizer treatments and cough medications. By the time of your \r\ndischarge, you were feeling much better. \r\n\r\nPlease follow-up with Dr. ___ at the \r\nappointment that was set up for you. \r\n\r\nIt was a pleasure taking care of you, and we wish you the best. \r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-21:3",
      "text": "MIB and cytogenetics \nare pending\n- ___ C1D1 ICE\n- ___ C1 Rituximab, clinically improved adenopathy\n- ___ C2 Rituximab, WBC 6.5, PLT 43\n- ___ Admit for C2D1 ICE\n- ___ C3 Rituximab\n- ___ PET CT showed almost complete resolution of FDG avid\ndisease with a residual focus of avidity in the bed of the \nformer abdominal mass, SUV ___ C4 Rituximab\n- ___ C4 ICE followed by stem cell mobilization and\ncollection, BMBx showed a nest of CLL unrelated to her \naggressive\nlymphoma\n- ___ Presented with large DVTs, SVC filter placed\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\n- ___ Switched to Rivaroxaban for AC\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis, \ncytopenias\n- ___ Start XRT\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\nHb). Started prednisone 80 mg PO daily\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \nmg PO daily. PLT 81, Bactrim switched to Dapsone for PCP ___. - Weekly monitoring of DLCO with taper of prednisone to 10 mg\ndaily as of ___ with DLCO 99%. Dapsone d/ced on ___\ndue to hemolysis. - ___ Decreased prednisone to 5 mg PO daily. Noro virus\npersistently positive. - ___ CT torso with no evidence of active disease. Unchanged mesenteric fullness. - ___ DLCO decrease (not reported) increase prednisone to \n10 mg\n- ___ IVIg 400 mg/kg\n- ___ DLCO 121%, continued prednisone 10 mg\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobulinemia. - ___, tapered off prednisone. - ___, CT torso with no evidence of active disease. Stable\nappearance of a conglomeration of mesenteric lymph nodes. - ___, Right total knee replacement, primary, complicated\nby foot drop likely d/t irritation of peroneal nerve and\ncellulitis. - ___, CT Torso with no evidence of active disease. Stable appearance of conglomerate of mesenteric LNs. Increased\ndilatation of the main pulmonary artery suggests worsening\npulmonary arterial hypertension of indeterminate etiology. - ___, CT torso with no evidence of active disease. Increased\ndilation of pulmonary artery. Evaluated by Dr. ___\n- ___, increasing right leg swelling with noted DVT. Xarelto\nincreased back to 20 mg daily(had been decreased given age and\nprior chronic DVT). No evidence for lymphoma on CT imaging. - ___, noted drop in blood counts. BM biopsy with evidence\nfor MDS. - ___, C1 Dacogen\n- ___, C2 Dacogen\n- ___, C3 Dacogen\n- ___, C4 Dacogen PAST MEDICAL/SURGICAL HISTORY:  \n- CVID, received IVIG monthly.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-21",
        "chart_time": "104607",
        "section": "General",
        "position": 3,
        "tokenCount": 642,
        "note_metadata": {
          "note_id": "18887130-DS-21",
          "subject_id": 18887130,
          "hadm_id": 22357254,
          "note_type": "DS",
          "note_seq": 21,
          "charttime": 104607,
          "storetime": 104608.70416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nCough, wheezing\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for transplant, who \r\npresents with cough and wheezing x2 days. She states that her \r\ncough is productive with clear sputum with no blood. She denies \r\nany fever or chills. She has no chest pain, shortness of breath, \r\nabdominal pain,  diarrhea, or difficulty/pain with urination. \r\nShe does endorse some nasal congestion and dry throat.  \r\n\r\nShe has had issues with bronchitis/pneumonias in the past. Given \r\nher profound neutropenia, she was referred to the ED for \r\npossible admission. \r\n\r\nIn the ED, labs were notable for WBC 0.8, ANC 170, H/H 8.0/24.6, \r\nPlt 27, lactate 1.0, coags wnl. \r\nChem 7: Na 140, K 3.8, Cl 107, CO2 21, BUN 16, Cr 0.8, Glucose \r\n72.\r\nUA, urine and blood cultures were ordered. \r\nCXR did not show evidence of pneumonia, however with patient's \r\nworsening cough and wheezes along with her neutropenia, she was \r\ntreated with empiric antibiotics, including cefepime, \r\nvancomycin, and azithromycin. \r\nShe also received albuterol and ipratropium nebs.\r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new adenopathy. Labs notable for LDH 341, WBC \r\n10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all markedly FDG-avid and concerning for \r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer abdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxaban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis, \r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg PO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10 mg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continued prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobulinemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LNs. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT). No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n- ___, C4 Dacogen\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\n- CVID, received IVIG monthly. Last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurysm, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___.\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.3, BP 128/58, P 88, RR 22, O2sat 100% on RA\r\nGen: Pleasant, calm, \r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear. No \r\npharyngeal erythema or exudates, no sinus tenderness, normal TM \r\nbilaterally, trachea midline  \r\nLYMPH: No cervical or supraclavicular LAD  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Bilateral end expiratory wheezes in \r\nupper lung fields b/l.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: No rashes/lesions, petechiae/purpura, or ecchymoses.  \r\nNEURO: A&Ox3.  \r\nLINES: Port\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.2-98.3, BP 117-122/76-80, P 85-91, RR ___, O2sat \r\n97-98% on RA/CPAP\r\nGen: Pleasant, calm, no acute distress, coughing occasionally\r\nHEENT: No conjunctival pallor. No icterus. MMM. \r\nCV: RRR. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Diffuse expiratory wheezes.\r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: Venous stasis changes in b/l ___, non-pitting ___ edema\r\nLINES: Port\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n====================\r\n___ 09:09AM BLOOD WBC-0.9* RBC-2.50* Hgb-8.1* Hct-24.9* \r\nMCV-100* MCH-32.4* MCHC-32.5 RDW-21.2* RDWSD-72.1* Plt Ct-17*\r\n___ 09:09AM BLOOD Neuts-31* Bands-0 Lymphs-64* Monos-4* \r\nEos-0 Baso-1 ___ Myelos-0 NRBC-3* AbsNeut-0.28* \r\nAbsLymp-0.58* AbsMono-0.04* AbsEos-0.00* AbsBaso-0.01\r\n___ 09:09AM BLOOD Hypochr-NORMAL Anisocy-1+ Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-1+ Ovalocy-OCCASIONAL\r\n\r\nOTHER RELEVANT LABS:\r\n======================\r\n___ 12:56PM BLOOD Lactate-1.0\r\n___ 12:00AM BLOOD IgG-774\r\n___ 04:10PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 04:10PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 04:10PM URINE RBC-<1 WBC-1 Bacteri-NONE Yeast-NONE \r\nEpi-<1\r\n___ 02:18PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nRespiratory Viral Antigen Screen (Final ___: \r\nPositive for Respiratory viral antigens. \r\nPOSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). \r\nViral antigen identified by immunofluorescence. \r\n\r\nDISCHARGE LABS:\r\n======================\r\n___ 12:00AM BLOOD WBC-0.6* RBC-2.73* Hgb-8.6* Hct-26.4* \r\nMCV-97 MCH-31.5 MCHC-32.6 RDW-21.7* RDWSD-72.9* Plt Ct-61*\r\n___ 12:00AM BLOOD Neuts-27* Bands-0 Lymphs-67* Monos-3* \r\nEos-3 Baso-0 ___ Myelos-0 AbsNeut-0.16* \r\nAbsLymp-0.40* AbsMono-0.02* AbsEos-0.02* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-NORMAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL\r\n___ 12:00AM BLOOD Glucose-92 UreaN-19 Creat-0.8 Na-140 \r\nK-4.2 Cl-104 HCO3-22 AnGap-18\r\n___ 12:00AM BLOOD Calcium-8.5 Phos-2.9 Mg-2.4\r\n\r\nIMAGING:\r\n=====================\r\nCXR- PA and LATERAL (___): No acute cardiopulmonary abnormality \r\n\r\n \r\nBrief Hospital Course:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for allo transplant, \r\nwho presented with cough/wheezing and was found to have RSV \r\nbronchiolitis.\r\n\r\n#RSV bronchiolitis\r\n#Cough and wheezing\r\nPatient is neutropenic and has CVID and presented with cough and \r\nwheezing. She was initially started on cefepime and azithromycin \r\nfor empiric coverage. Patient's respiratory viral screen was \r\npositive for RSV. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis. She was also \r\ntreated symptomatically with duonebs q6h, mucinex, benzonatate, \r\nand guaifenesin-codeine at night. Her symptoms improved \r\nsignificantly with these measures. She was able to maintain \r\nO2sat > 95% while ambulating. \r\n\r\n#Myelodysplastic syndrome- Patient is ___ 4 cycles of dacogen \r\nwith plans to move towards allogeneic transplant. She was \r\ncontinued on acyclovir for prophylaxis. Her bacterial \r\nprophylaxis was transitioned to levaquin on ___ as above. She \r\nwas also started on fluconazole during this admission for fungal \r\nprophylaxis. She was transfused for Hgb < 7 or Plt < 10. She \r\nreceived a total of 2U pRBCs and 1U platelets during this \r\nadmission.\r\n\r\n#Low back pain- Continued gabapentin 600 mg TID\r\n\r\nTRANSITIONAL ISSUES:\r\n======================\r\n- New medications: fluconazole, levofloxacin, guaifenesin with \r\ncodeine, benzonatate, duonebs\r\n- Patient started on fluconazole 200 mg daily during this \r\nadmission for fungal prophylaxis, can consider adjusting dose to \r\n400 mg daily based on patient's weight\r\n- Patient initially on cefepime for broad spectrum antibiotic \r\ncoverage given significant symptoms and neutropenia that was \r\ntransitioned to levofloxacin on ___. Can consider de-escalating \r\nto ciprofloxacin if patient continues to clinically improve.\r\n- Of note, patient's PFTs (originally scheduled for ___ were \r\nrescheduled for ___ due to her acute illness. Can reschedule as \r\nneeded.\r\n \r\nMedications on Admission:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol 0.083% Neb Soln 1 NEB IH Q6H:PRN wheezing/cough \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n4. Gabapentin 600 mg PO TID \r\n5. Ipratropium Bromide Neb 1 NEB IH Q6H:PRN shortness of breath \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 4 mg PO Q8H:PRN nausea \r\n8. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN cough \r\nRX *benzonatate 100 mg 1 capsule(s) by mouth three time a day \r\nDisp #*30 Capsule Refills:*0 \r\n2.  Fluconazole 200 mg PO Q24H \r\nRX *fluconazole 200 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n3.  FoLIC Acid 3 mg PO DAILY \r\nRX *folic acid 1 mg 3 tablet(s) by mouth daily Disp #*90 Tablet \r\nRefills:*0 \r\n4.  Guaifenesin-CODEINE Phosphate ___ mL PO HS:PRN cough \r\nRX *codeine-guaifenesin 10 mg-100 mg/5 mL 5 mL by mouth at night \r\nRefills:*0 \r\n5.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nIH every 6 hours Disp #*120 Ampule Refills:*0 \r\n6.  Levofloxacin 500 mg PO Q24H \r\nRX *levofloxacin 500 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n7.  Acyclovir 400 mg PO Q8H  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n9.  Gabapentin 600 mg PO TID  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n12.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nRespiratory syncytial virus bronchiolitis\r\nMyelodysplastic syndrome\r\n\r\nSecondary:\r\nLow back pain\r\nCombined variable immunodeficiency\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted because you were having a cough and wheezing. \r\nWe found you had a virus called RSV that we treated with \r\nmedications called palvilizumab and ribavirin. We also gave you \r\n4 doses of 10g IVIg. We also supported your breathing with \r\nnebulizer treatments and cough medications. By the time of your \r\ndischarge, you were feeling much better. \r\n\r\nPlease follow-up with Dr. ___ at the \r\nappointment that was set up for you. \r\n\r\nIt was a pleasure taking care of you, and we wish you the best. \r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-21:4",
      "text": "- ___, CT torso with no evidence of active disease. Increased\ndilation of pulmonary artery. Evaluated by Dr. ___\n- ___, increasing right leg swelling with noted DVT. Xarelto\nincreased back to 20 mg daily(had been decreased given age and\nprior chronic DVT). No evidence for lymphoma on CT imaging. - ___, noted drop in blood counts. BM biopsy with evidence\nfor MDS. - ___, C1 Dacogen\n- ___, C2 Dacogen\n- ___, C3 Dacogen\n- ___, C4 Dacogen PAST MEDICAL/SURGICAL HISTORY:  \n- CVID, received IVIG monthly. Last given ___\n- GERD                                          \n- Osteoarthritis                                         \n- DVT, right lower extremity, IVC filter in place\n- Cervical radiculopathy\n- Sciatica\n- Obstructive sleep apnea, wears CPAP\n- H/O cerebral aneurysm, noted on MRA with small R internal\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\nthe right eye, mild proptosis of the right eye, and hyperthesia\nof the right V1 distribution\n- Asthma\n- Obesity\n- Hypertension\n- Migraines Social History:\n___ Family History:\nBrother with lymphoma, died at age ___.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-21",
        "chart_time": "104607",
        "section": "General",
        "position": 4,
        "tokenCount": 286,
        "note_metadata": {
          "note_id": "18887130-DS-21",
          "subject_id": 18887130,
          "hadm_id": 22357254,
          "note_type": "DS",
          "note_seq": 21,
          "charttime": 104607,
          "storetime": 104608.70416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nCough, wheezing\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for transplant, who \r\npresents with cough and wheezing x2 days. She states that her \r\ncough is productive with clear sputum with no blood. She denies \r\nany fever or chills. She has no chest pain, shortness of breath, \r\nabdominal pain,  diarrhea, or difficulty/pain with urination. \r\nShe does endorse some nasal congestion and dry throat.  \r\n\r\nShe has had issues with bronchitis/pneumonias in the past. Given \r\nher profound neutropenia, she was referred to the ED for \r\npossible admission. \r\n\r\nIn the ED, labs were notable for WBC 0.8, ANC 170, H/H 8.0/24.6, \r\nPlt 27, lactate 1.0, coags wnl. \r\nChem 7: Na 140, K 3.8, Cl 107, CO2 21, BUN 16, Cr 0.8, Glucose \r\n72.\r\nUA, urine and blood cultures were ordered. \r\nCXR did not show evidence of pneumonia, however with patient's \r\nworsening cough and wheezes along with her neutropenia, she was \r\ntreated with empiric antibiotics, including cefepime, \r\nvancomycin, and azithromycin. \r\nShe also received albuterol and ipratropium nebs.\r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new adenopathy. Labs notable for LDH 341, WBC \r\n10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all markedly FDG-avid and concerning for \r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer abdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxaban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis, \r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg PO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10 mg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continued prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobulinemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LNs. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT). No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n- ___, C4 Dacogen\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\n- CVID, received IVIG monthly. Last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurysm, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___.\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.3, BP 128/58, P 88, RR 22, O2sat 100% on RA\r\nGen: Pleasant, calm, \r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear. No \r\npharyngeal erythema or exudates, no sinus tenderness, normal TM \r\nbilaterally, trachea midline  \r\nLYMPH: No cervical or supraclavicular LAD  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Bilateral end expiratory wheezes in \r\nupper lung fields b/l.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: No rashes/lesions, petechiae/purpura, or ecchymoses.  \r\nNEURO: A&Ox3.  \r\nLINES: Port\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.2-98.3, BP 117-122/76-80, P 85-91, RR ___, O2sat \r\n97-98% on RA/CPAP\r\nGen: Pleasant, calm, no acute distress, coughing occasionally\r\nHEENT: No conjunctival pallor. No icterus. MMM. \r\nCV: RRR. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Diffuse expiratory wheezes.\r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: Venous stasis changes in b/l ___, non-pitting ___ edema\r\nLINES: Port\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n====================\r\n___ 09:09AM BLOOD WBC-0.9* RBC-2.50* Hgb-8.1* Hct-24.9* \r\nMCV-100* MCH-32.4* MCHC-32.5 RDW-21.2* RDWSD-72.1* Plt Ct-17*\r\n___ 09:09AM BLOOD Neuts-31* Bands-0 Lymphs-64* Monos-4* \r\nEos-0 Baso-1 ___ Myelos-0 NRBC-3* AbsNeut-0.28* \r\nAbsLymp-0.58* AbsMono-0.04* AbsEos-0.00* AbsBaso-0.01\r\n___ 09:09AM BLOOD Hypochr-NORMAL Anisocy-1+ Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-1+ Ovalocy-OCCASIONAL\r\n\r\nOTHER RELEVANT LABS:\r\n======================\r\n___ 12:56PM BLOOD Lactate-1.0\r\n___ 12:00AM BLOOD IgG-774\r\n___ 04:10PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 04:10PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 04:10PM URINE RBC-<1 WBC-1 Bacteri-NONE Yeast-NONE \r\nEpi-<1\r\n___ 02:18PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nRespiratory Viral Antigen Screen (Final ___: \r\nPositive for Respiratory viral antigens. \r\nPOSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). \r\nViral antigen identified by immunofluorescence. \r\n\r\nDISCHARGE LABS:\r\n======================\r\n___ 12:00AM BLOOD WBC-0.6* RBC-2.73* Hgb-8.6* Hct-26.4* \r\nMCV-97 MCH-31.5 MCHC-32.6 RDW-21.7* RDWSD-72.9* Plt Ct-61*\r\n___ 12:00AM BLOOD Neuts-27* Bands-0 Lymphs-67* Monos-3* \r\nEos-3 Baso-0 ___ Myelos-0 AbsNeut-0.16* \r\nAbsLymp-0.40* AbsMono-0.02* AbsEos-0.02* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-NORMAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL\r\n___ 12:00AM BLOOD Glucose-92 UreaN-19 Creat-0.8 Na-140 \r\nK-4.2 Cl-104 HCO3-22 AnGap-18\r\n___ 12:00AM BLOOD Calcium-8.5 Phos-2.9 Mg-2.4\r\n\r\nIMAGING:\r\n=====================\r\nCXR- PA and LATERAL (___): No acute cardiopulmonary abnormality \r\n\r\n \r\nBrief Hospital Course:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for allo transplant, \r\nwho presented with cough/wheezing and was found to have RSV \r\nbronchiolitis.\r\n\r\n#RSV bronchiolitis\r\n#Cough and wheezing\r\nPatient is neutropenic and has CVID and presented with cough and \r\nwheezing. She was initially started on cefepime and azithromycin \r\nfor empiric coverage. Patient's respiratory viral screen was \r\npositive for RSV. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis. She was also \r\ntreated symptomatically with duonebs q6h, mucinex, benzonatate, \r\nand guaifenesin-codeine at night. Her symptoms improved \r\nsignificantly with these measures. She was able to maintain \r\nO2sat > 95% while ambulating. \r\n\r\n#Myelodysplastic syndrome- Patient is ___ 4 cycles of dacogen \r\nwith plans to move towards allogeneic transplant. She was \r\ncontinued on acyclovir for prophylaxis. Her bacterial \r\nprophylaxis was transitioned to levaquin on ___ as above. She \r\nwas also started on fluconazole during this admission for fungal \r\nprophylaxis. She was transfused for Hgb < 7 or Plt < 10. She \r\nreceived a total of 2U pRBCs and 1U platelets during this \r\nadmission.\r\n\r\n#Low back pain- Continued gabapentin 600 mg TID\r\n\r\nTRANSITIONAL ISSUES:\r\n======================\r\n- New medications: fluconazole, levofloxacin, guaifenesin with \r\ncodeine, benzonatate, duonebs\r\n- Patient started on fluconazole 200 mg daily during this \r\nadmission for fungal prophylaxis, can consider adjusting dose to \r\n400 mg daily based on patient's weight\r\n- Patient initially on cefepime for broad spectrum antibiotic \r\ncoverage given significant symptoms and neutropenia that was \r\ntransitioned to levofloxacin on ___. Can consider de-escalating \r\nto ciprofloxacin if patient continues to clinically improve.\r\n- Of note, patient's PFTs (originally scheduled for ___ were \r\nrescheduled for ___ due to her acute illness. Can reschedule as \r\nneeded.\r\n \r\nMedications on Admission:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol 0.083% Neb Soln 1 NEB IH Q6H:PRN wheezing/cough \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n4. Gabapentin 600 mg PO TID \r\n5. Ipratropium Bromide Neb 1 NEB IH Q6H:PRN shortness of breath \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 4 mg PO Q8H:PRN nausea \r\n8. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN cough \r\nRX *benzonatate 100 mg 1 capsule(s) by mouth three time a day \r\nDisp #*30 Capsule Refills:*0 \r\n2.  Fluconazole 200 mg PO Q24H \r\nRX *fluconazole 200 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n3.  FoLIC Acid 3 mg PO DAILY \r\nRX *folic acid 1 mg 3 tablet(s) by mouth daily Disp #*90 Tablet \r\nRefills:*0 \r\n4.  Guaifenesin-CODEINE Phosphate ___ mL PO HS:PRN cough \r\nRX *codeine-guaifenesin 10 mg-100 mg/5 mL 5 mL by mouth at night \r\nRefills:*0 \r\n5.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nIH every 6 hours Disp #*120 Ampule Refills:*0 \r\n6.  Levofloxacin 500 mg PO Q24H \r\nRX *levofloxacin 500 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n7.  Acyclovir 400 mg PO Q8H  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n9.  Gabapentin 600 mg PO TID  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n12.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nRespiratory syncytial virus bronchiolitis\r\nMyelodysplastic syndrome\r\n\r\nSecondary:\r\nLow back pain\r\nCombined variable immunodeficiency\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted because you were having a cough and wheezing. \r\nWe found you had a virus called RSV that we treated with \r\nmedications called palvilizumab and ribavirin. We also gave you \r\n4 doses of 10g IVIg. We also supported your breathing with \r\nnebulizer treatments and cough medications. By the time of your \r\ndischarge, you were feeling much better. \r\n\r\nPlease follow-up with Dr. ___ at the \r\nappointment that was set up for you. \r\n\r\nIt was a pleasure taking care of you, and we wish you the best. \r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-21:5",
      "text": "Physical Exam:\nADMISSION PHYSICAL EXAM:\n=============================\nVitals: T 98.3, BP 128/58, P 88, RR 22, O2sat 100% on RA\nGen: Pleasant, calm, \nHEENT: No conjunctival pallor. No icterus. MMM. OP clear. No \npharyngeal erythema or exudates, no sinus tenderness, normal TM \nbilaterally, trachea midline  \nLYMPH: No cervical or supraclavicular LAD  \nCV: Normocardic, regular. Normal S1,S2. No MRG. LUNGS: No increased WOB. Bilateral end expiratory wheezes in \nupper lung fields b/l. ABD: NABS. Soft, NT, ND. EXT: WWP. No ___ edema. SKIN: No rashes/lesions, petechiae/purpura, or ecchymoses. NEURO: A&Ox3. LINES: Port DISCHARGE PHYSICAL EXAM:\n=============================\nVitals: T 98.2-98.3, BP 117-122/76-80, P 85-91, RR ___, O2sat \n97-98% on RA/CPAP\nGen: Pleasant, calm, no acute distress, coughing occasionally\nHEENT: No conjunctival pallor. No icterus. MMM. CV: RRR. Normal S1,S2. No MRG. LUNGS: No increased WOB. Diffuse expiratory wheezes. ABD: NABS. Soft, NT, ND. EXT: WWP. No ___ edema. SKIN: Venous stasis changes in b/l ___, non-pitting ___ edema\nLINES: Port Pertinent Results:\nADMISSION LABS:\n====================\n___ 09:09AM BLOOD WBC-0.9* RBC-2.50* Hgb-8.1* Hct-24.9* \nMCV-100* MCH-32.4* MCHC-32.5 RDW-21.2* RDWSD-72.1* Plt Ct-17*\n___ 09:09AM BLOOD Neuts-31* Bands-0 Lymphs-64* Monos-4* \nEos-0 Baso-1 ___ Myelos-0 NRBC-3* AbsNeut-0.28* \nAbsLymp-0.58* AbsMono-0.04* AbsEos-0.00* AbsBaso-0.01\n___ 09:09AM BLOOD Hypochr-NORMAL Anisocy-1+ Poiklo-1+ \nMacrocy-NORMAL Microcy-NORMAL Polychr-1+ Ovalocy-OCCASIONAL OTHER RELEVANT LABS:\n======================\n___ 12:56PM BLOOD Lactate-1.0\n___ 12:00AM BLOOD IgG-774\n___ 04:10PM URINE Color-Yellow Appear-Clear Sp ___\n___ 04:10PM URINE Blood-NEG Nitrite-NEG Protein-30 \nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\n___ 04:10PM URINE RBC-<1 WBC-1 Bacteri-NONE Yeast-NONE \nEpi-<1\n___ 02:18PM OTHER BODY FLUID FluAPCR-NEGATIVE \nFluBPCR-NEGATIVE Respiratory Viral Antigen Screen (Final ___: \nPositive for Respiratory viral antigens. POSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). Viral antigen identified by immunofluorescence. DISCHARGE LABS:\n======================\n___ 12:00AM BLOOD WBC-0.6* RBC-2.73* Hgb-8.6* Hct-26.4* \nMCV-97 MCH-31.5 MCHC-32.6 RDW-21.7* RDWSD-72.9* Plt Ct-61*\n___ 12:00AM BLOOD Neuts-27* Bands-0 Lymphs-67* Monos-3* \nEos-3 Baso-0 ___ Myelos-0 AbsNeut-0.16* \nAbsLymp-0.40* AbsMono-0.02* AbsEos-0.02* AbsBaso-0.00*\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL \nPoiklo-NORMAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL\n___ 12:00AM BLOOD Glucose-92 UreaN-19 Creat-0.8 Na-140 \nK-4.2 Cl-104 HCO3-22 AnGap-18\n___ 12:00AM BLOOD Calcium-8.5 Phos-2.9 Mg-2.4 IMAGING:\n=====================\nCXR- PA and LATERAL (___): No acute cardiopulmonary abnormality",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-21",
        "chart_time": "104607",
        "section": "General",
        "position": 5,
        "tokenCount": 685,
        "note_metadata": {
          "note_id": "18887130-DS-21",
          "subject_id": 18887130,
          "hadm_id": 22357254,
          "note_type": "DS",
          "note_seq": 21,
          "charttime": 104607,
          "storetime": 104608.70416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nCough, wheezing\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for transplant, who \r\npresents with cough and wheezing x2 days. She states that her \r\ncough is productive with clear sputum with no blood. She denies \r\nany fever or chills. She has no chest pain, shortness of breath, \r\nabdominal pain,  diarrhea, or difficulty/pain with urination. \r\nShe does endorse some nasal congestion and dry throat.  \r\n\r\nShe has had issues with bronchitis/pneumonias in the past. Given \r\nher profound neutropenia, she was referred to the ED for \r\npossible admission. \r\n\r\nIn the ED, labs were notable for WBC 0.8, ANC 170, H/H 8.0/24.6, \r\nPlt 27, lactate 1.0, coags wnl. \r\nChem 7: Na 140, K 3.8, Cl 107, CO2 21, BUN 16, Cr 0.8, Glucose \r\n72.\r\nUA, urine and blood cultures were ordered. \r\nCXR did not show evidence of pneumonia, however with patient's \r\nworsening cough and wheezes along with her neutropenia, she was \r\ntreated with empiric antibiotics, including cefepime, \r\nvancomycin, and azithromycin. \r\nShe also received albuterol and ipratropium nebs.\r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new adenopathy. Labs notable for LDH 341, WBC \r\n10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all markedly FDG-avid and concerning for \r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer abdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxaban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis, \r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg PO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10 mg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continued prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobulinemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LNs. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT). No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n- ___, C4 Dacogen\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\n- CVID, received IVIG monthly. Last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurysm, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___.\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.3, BP 128/58, P 88, RR 22, O2sat 100% on RA\r\nGen: Pleasant, calm, \r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear. No \r\npharyngeal erythema or exudates, no sinus tenderness, normal TM \r\nbilaterally, trachea midline  \r\nLYMPH: No cervical or supraclavicular LAD  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Bilateral end expiratory wheezes in \r\nupper lung fields b/l.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: No rashes/lesions, petechiae/purpura, or ecchymoses.  \r\nNEURO: A&Ox3.  \r\nLINES: Port\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.2-98.3, BP 117-122/76-80, P 85-91, RR ___, O2sat \r\n97-98% on RA/CPAP\r\nGen: Pleasant, calm, no acute distress, coughing occasionally\r\nHEENT: No conjunctival pallor. No icterus. MMM. \r\nCV: RRR. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Diffuse expiratory wheezes.\r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: Venous stasis changes in b/l ___, non-pitting ___ edema\r\nLINES: Port\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n====================\r\n___ 09:09AM BLOOD WBC-0.9* RBC-2.50* Hgb-8.1* Hct-24.9* \r\nMCV-100* MCH-32.4* MCHC-32.5 RDW-21.2* RDWSD-72.1* Plt Ct-17*\r\n___ 09:09AM BLOOD Neuts-31* Bands-0 Lymphs-64* Monos-4* \r\nEos-0 Baso-1 ___ Myelos-0 NRBC-3* AbsNeut-0.28* \r\nAbsLymp-0.58* AbsMono-0.04* AbsEos-0.00* AbsBaso-0.01\r\n___ 09:09AM BLOOD Hypochr-NORMAL Anisocy-1+ Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-1+ Ovalocy-OCCASIONAL\r\n\r\nOTHER RELEVANT LABS:\r\n======================\r\n___ 12:56PM BLOOD Lactate-1.0\r\n___ 12:00AM BLOOD IgG-774\r\n___ 04:10PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 04:10PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 04:10PM URINE RBC-<1 WBC-1 Bacteri-NONE Yeast-NONE \r\nEpi-<1\r\n___ 02:18PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nRespiratory Viral Antigen Screen (Final ___: \r\nPositive for Respiratory viral antigens. \r\nPOSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). \r\nViral antigen identified by immunofluorescence. \r\n\r\nDISCHARGE LABS:\r\n======================\r\n___ 12:00AM BLOOD WBC-0.6* RBC-2.73* Hgb-8.6* Hct-26.4* \r\nMCV-97 MCH-31.5 MCHC-32.6 RDW-21.7* RDWSD-72.9* Plt Ct-61*\r\n___ 12:00AM BLOOD Neuts-27* Bands-0 Lymphs-67* Monos-3* \r\nEos-3 Baso-0 ___ Myelos-0 AbsNeut-0.16* \r\nAbsLymp-0.40* AbsMono-0.02* AbsEos-0.02* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-NORMAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL\r\n___ 12:00AM BLOOD Glucose-92 UreaN-19 Creat-0.8 Na-140 \r\nK-4.2 Cl-104 HCO3-22 AnGap-18\r\n___ 12:00AM BLOOD Calcium-8.5 Phos-2.9 Mg-2.4\r\n\r\nIMAGING:\r\n=====================\r\nCXR- PA and LATERAL (___): No acute cardiopulmonary abnormality \r\n\r\n \r\nBrief Hospital Course:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for allo transplant, \r\nwho presented with cough/wheezing and was found to have RSV \r\nbronchiolitis.\r\n\r\n#RSV bronchiolitis\r\n#Cough and wheezing\r\nPatient is neutropenic and has CVID and presented with cough and \r\nwheezing. She was initially started on cefepime and azithromycin \r\nfor empiric coverage. Patient's respiratory viral screen was \r\npositive for RSV. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis. She was also \r\ntreated symptomatically with duonebs q6h, mucinex, benzonatate, \r\nand guaifenesin-codeine at night. Her symptoms improved \r\nsignificantly with these measures. She was able to maintain \r\nO2sat > 95% while ambulating. \r\n\r\n#Myelodysplastic syndrome- Patient is ___ 4 cycles of dacogen \r\nwith plans to move towards allogeneic transplant. She was \r\ncontinued on acyclovir for prophylaxis. Her bacterial \r\nprophylaxis was transitioned to levaquin on ___ as above. She \r\nwas also started on fluconazole during this admission for fungal \r\nprophylaxis. She was transfused for Hgb < 7 or Plt < 10. She \r\nreceived a total of 2U pRBCs and 1U platelets during this \r\nadmission.\r\n\r\n#Low back pain- Continued gabapentin 600 mg TID\r\n\r\nTRANSITIONAL ISSUES:\r\n======================\r\n- New medications: fluconazole, levofloxacin, guaifenesin with \r\ncodeine, benzonatate, duonebs\r\n- Patient started on fluconazole 200 mg daily during this \r\nadmission for fungal prophylaxis, can consider adjusting dose to \r\n400 mg daily based on patient's weight\r\n- Patient initially on cefepime for broad spectrum antibiotic \r\ncoverage given significant symptoms and neutropenia that was \r\ntransitioned to levofloxacin on ___. Can consider de-escalating \r\nto ciprofloxacin if patient continues to clinically improve.\r\n- Of note, patient's PFTs (originally scheduled for ___ were \r\nrescheduled for ___ due to her acute illness. Can reschedule as \r\nneeded.\r\n \r\nMedications on Admission:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol 0.083% Neb Soln 1 NEB IH Q6H:PRN wheezing/cough \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n4. Gabapentin 600 mg PO TID \r\n5. Ipratropium Bromide Neb 1 NEB IH Q6H:PRN shortness of breath \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 4 mg PO Q8H:PRN nausea \r\n8. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN cough \r\nRX *benzonatate 100 mg 1 capsule(s) by mouth three time a day \r\nDisp #*30 Capsule Refills:*0 \r\n2.  Fluconazole 200 mg PO Q24H \r\nRX *fluconazole 200 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n3.  FoLIC Acid 3 mg PO DAILY \r\nRX *folic acid 1 mg 3 tablet(s) by mouth daily Disp #*90 Tablet \r\nRefills:*0 \r\n4.  Guaifenesin-CODEINE Phosphate ___ mL PO HS:PRN cough \r\nRX *codeine-guaifenesin 10 mg-100 mg/5 mL 5 mL by mouth at night \r\nRefills:*0 \r\n5.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nIH every 6 hours Disp #*120 Ampule Refills:*0 \r\n6.  Levofloxacin 500 mg PO Q24H \r\nRX *levofloxacin 500 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n7.  Acyclovir 400 mg PO Q8H  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n9.  Gabapentin 600 mg PO TID  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n12.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nRespiratory syncytial virus bronchiolitis\r\nMyelodysplastic syndrome\r\n\r\nSecondary:\r\nLow back pain\r\nCombined variable immunodeficiency\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted because you were having a cough and wheezing. \r\nWe found you had a virus called RSV that we treated with \r\nmedications called palvilizumab and ribavirin. We also gave you \r\n4 doses of 10g IVIg. We also supported your breathing with \r\nnebulizer treatments and cough medications. By the time of your \r\ndischarge, you were feeling much better. \r\n\r\nPlease follow-up with Dr. ___ at the \r\nappointment that was set up for you. \r\n\r\nIt was a pleasure taking care of you, and we wish you the best. \r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-21:6",
      "text": "Brief Hospital Course:\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \nin ___ in remission from lymphoma then with treatment-related \nMDS ___ 4 cycles of decitabine and planning for allo transplant, \nwho presented with cough/wheezing and was found to have RSV \nbronchiolitis. #RSV bronchiolitis\n#Cough and wheezing\nPatient is neutropenic and has CVID and presented with cough and \nwheezing. She was initially started on cefepime and azithromycin \nfor empiric coverage. Patient's respiratory viral screen was \npositive for RSV. She was treated with palvilizumab on ___ and \nribavirin 600 mg q8h (___). Patient also was treated \nwith 4 days of 10 g IVIg (___). She received a 5 day \ncourse of azithromycin for anti-inflammatory effect. She was \nalso continued on cefepime (___), that was transitioned \nto levaquin on ___ for bacterial prophylaxis. She was also \ntreated symptomatically with duonebs q6h, mucinex, benzonatate, \nand guaifenesin-codeine at night. Her symptoms improved \nsignificantly with these measures. She was able to maintain \nO2sat > 95% while ambulating. #Myelodysplastic syndrome- Patient is ___ 4 cycles of dacogen \nwith plans to move towards allogeneic transplant. She was \ncontinued on acyclovir for prophylaxis. Her bacterial \nprophylaxis was transitioned to levaquin on ___ as above. She \nwas also started on fluconazole during this admission for fungal \nprophylaxis. She was transfused for Hgb < 7 or Plt < 10. She \nreceived a total of 2U pRBCs and 1U platelets during this \nadmission. #Low back pain- Continued gabapentin 600 mg TID TRANSITIONAL ISSUES:\n======================\n- New medications: fluconazole, levofloxacin, guaifenesin with \ncodeine, benzonatate, duonebs\n- Patient started on fluconazole 200 mg daily during this \nadmission for fungal prophylaxis, can consider adjusting dose to \n400 mg daily based on patient's weight\n- Patient initially on cefepime for broad spectrum antibiotic \ncoverage given significant symptoms and neutropenia that was \ntransitioned to levofloxacin on ___. Can consider de-escalating \nto ciprofloxacin if patient continues to clinically improve. - Of note, patient's PFTs (originally scheduled for ___ were \nrescheduled for ___ due to her acute illness. Can reschedule as \nneeded. Medications on Admission:\n1. Acyclovir 400 mg PO Q8H \n2. Albuterol 0.083% Neb Soln 1 NEB IH Q6H:PRN wheezing/cough \n3. Fluticasone Propionate 110mcg 2 PUFF IH BID \n4. Gabapentin 600 mg PO TID \n5. Ipratropium Bromide Neb 1 NEB IH Q6H:PRN shortness of breath \n6. Omeprazole 20 mg PO DAILY \n7. Ondansetron 4 mg PO Q8H:PRN nausea \n8. Venlafaxine 25 mg PO BID",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-21",
        "chart_time": "104607",
        "section": "General",
        "position": 6,
        "tokenCount": 655,
        "note_metadata": {
          "note_id": "18887130-DS-21",
          "subject_id": 18887130,
          "hadm_id": 22357254,
          "note_type": "DS",
          "note_seq": 21,
          "charttime": 104607,
          "storetime": 104608.70416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nCough, wheezing\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for transplant, who \r\npresents with cough and wheezing x2 days. She states that her \r\ncough is productive with clear sputum with no blood. She denies \r\nany fever or chills. She has no chest pain, shortness of breath, \r\nabdominal pain,  diarrhea, or difficulty/pain with urination. \r\nShe does endorse some nasal congestion and dry throat.  \r\n\r\nShe has had issues with bronchitis/pneumonias in the past. Given \r\nher profound neutropenia, she was referred to the ED for \r\npossible admission. \r\n\r\nIn the ED, labs were notable for WBC 0.8, ANC 170, H/H 8.0/24.6, \r\nPlt 27, lactate 1.0, coags wnl. \r\nChem 7: Na 140, K 3.8, Cl 107, CO2 21, BUN 16, Cr 0.8, Glucose \r\n72.\r\nUA, urine and blood cultures were ordered. \r\nCXR did not show evidence of pneumonia, however with patient's \r\nworsening cough and wheezes along with her neutropenia, she was \r\ntreated with empiric antibiotics, including cefepime, \r\nvancomycin, and azithromycin. \r\nShe also received albuterol and ipratropium nebs.\r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new adenopathy. Labs notable for LDH 341, WBC \r\n10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all markedly FDG-avid and concerning for \r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer abdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxaban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis, \r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg PO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10 mg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continued prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobulinemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LNs. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT). No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n- ___, C4 Dacogen\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\n- CVID, received IVIG monthly. Last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurysm, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___.\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.3, BP 128/58, P 88, RR 22, O2sat 100% on RA\r\nGen: Pleasant, calm, \r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear. No \r\npharyngeal erythema or exudates, no sinus tenderness, normal TM \r\nbilaterally, trachea midline  \r\nLYMPH: No cervical or supraclavicular LAD  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Bilateral end expiratory wheezes in \r\nupper lung fields b/l.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: No rashes/lesions, petechiae/purpura, or ecchymoses.  \r\nNEURO: A&Ox3.  \r\nLINES: Port\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.2-98.3, BP 117-122/76-80, P 85-91, RR ___, O2sat \r\n97-98% on RA/CPAP\r\nGen: Pleasant, calm, no acute distress, coughing occasionally\r\nHEENT: No conjunctival pallor. No icterus. MMM. \r\nCV: RRR. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Diffuse expiratory wheezes.\r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: Venous stasis changes in b/l ___, non-pitting ___ edema\r\nLINES: Port\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n====================\r\n___ 09:09AM BLOOD WBC-0.9* RBC-2.50* Hgb-8.1* Hct-24.9* \r\nMCV-100* MCH-32.4* MCHC-32.5 RDW-21.2* RDWSD-72.1* Plt Ct-17*\r\n___ 09:09AM BLOOD Neuts-31* Bands-0 Lymphs-64* Monos-4* \r\nEos-0 Baso-1 ___ Myelos-0 NRBC-3* AbsNeut-0.28* \r\nAbsLymp-0.58* AbsMono-0.04* AbsEos-0.00* AbsBaso-0.01\r\n___ 09:09AM BLOOD Hypochr-NORMAL Anisocy-1+ Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-1+ Ovalocy-OCCASIONAL\r\n\r\nOTHER RELEVANT LABS:\r\n======================\r\n___ 12:56PM BLOOD Lactate-1.0\r\n___ 12:00AM BLOOD IgG-774\r\n___ 04:10PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 04:10PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 04:10PM URINE RBC-<1 WBC-1 Bacteri-NONE Yeast-NONE \r\nEpi-<1\r\n___ 02:18PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nRespiratory Viral Antigen Screen (Final ___: \r\nPositive for Respiratory viral antigens. \r\nPOSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). \r\nViral antigen identified by immunofluorescence. \r\n\r\nDISCHARGE LABS:\r\n======================\r\n___ 12:00AM BLOOD WBC-0.6* RBC-2.73* Hgb-8.6* Hct-26.4* \r\nMCV-97 MCH-31.5 MCHC-32.6 RDW-21.7* RDWSD-72.9* Plt Ct-61*\r\n___ 12:00AM BLOOD Neuts-27* Bands-0 Lymphs-67* Monos-3* \r\nEos-3 Baso-0 ___ Myelos-0 AbsNeut-0.16* \r\nAbsLymp-0.40* AbsMono-0.02* AbsEos-0.02* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-NORMAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL\r\n___ 12:00AM BLOOD Glucose-92 UreaN-19 Creat-0.8 Na-140 \r\nK-4.2 Cl-104 HCO3-22 AnGap-18\r\n___ 12:00AM BLOOD Calcium-8.5 Phos-2.9 Mg-2.4\r\n\r\nIMAGING:\r\n=====================\r\nCXR- PA and LATERAL (___): No acute cardiopulmonary abnormality \r\n\r\n \r\nBrief Hospital Course:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for allo transplant, \r\nwho presented with cough/wheezing and was found to have RSV \r\nbronchiolitis.\r\n\r\n#RSV bronchiolitis\r\n#Cough and wheezing\r\nPatient is neutropenic and has CVID and presented with cough and \r\nwheezing. She was initially started on cefepime and azithromycin \r\nfor empiric coverage. Patient's respiratory viral screen was \r\npositive for RSV. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis. She was also \r\ntreated symptomatically with duonebs q6h, mucinex, benzonatate, \r\nand guaifenesin-codeine at night. Her symptoms improved \r\nsignificantly with these measures. She was able to maintain \r\nO2sat > 95% while ambulating. \r\n\r\n#Myelodysplastic syndrome- Patient is ___ 4 cycles of dacogen \r\nwith plans to move towards allogeneic transplant. She was \r\ncontinued on acyclovir for prophylaxis. Her bacterial \r\nprophylaxis was transitioned to levaquin on ___ as above. She \r\nwas also started on fluconazole during this admission for fungal \r\nprophylaxis. She was transfused for Hgb < 7 or Plt < 10. She \r\nreceived a total of 2U pRBCs and 1U platelets during this \r\nadmission.\r\n\r\n#Low back pain- Continued gabapentin 600 mg TID\r\n\r\nTRANSITIONAL ISSUES:\r\n======================\r\n- New medications: fluconazole, levofloxacin, guaifenesin with \r\ncodeine, benzonatate, duonebs\r\n- Patient started on fluconazole 200 mg daily during this \r\nadmission for fungal prophylaxis, can consider adjusting dose to \r\n400 mg daily based on patient's weight\r\n- Patient initially on cefepime for broad spectrum antibiotic \r\ncoverage given significant symptoms and neutropenia that was \r\ntransitioned to levofloxacin on ___. Can consider de-escalating \r\nto ciprofloxacin if patient continues to clinically improve.\r\n- Of note, patient's PFTs (originally scheduled for ___ were \r\nrescheduled for ___ due to her acute illness. Can reschedule as \r\nneeded.\r\n \r\nMedications on Admission:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol 0.083% Neb Soln 1 NEB IH Q6H:PRN wheezing/cough \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n4. Gabapentin 600 mg PO TID \r\n5. Ipratropium Bromide Neb 1 NEB IH Q6H:PRN shortness of breath \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 4 mg PO Q8H:PRN nausea \r\n8. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN cough \r\nRX *benzonatate 100 mg 1 capsule(s) by mouth three time a day \r\nDisp #*30 Capsule Refills:*0 \r\n2.  Fluconazole 200 mg PO Q24H \r\nRX *fluconazole 200 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n3.  FoLIC Acid 3 mg PO DAILY \r\nRX *folic acid 1 mg 3 tablet(s) by mouth daily Disp #*90 Tablet \r\nRefills:*0 \r\n4.  Guaifenesin-CODEINE Phosphate ___ mL PO HS:PRN cough \r\nRX *codeine-guaifenesin 10 mg-100 mg/5 mL 5 mL by mouth at night \r\nRefills:*0 \r\n5.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nIH every 6 hours Disp #*120 Ampule Refills:*0 \r\n6.  Levofloxacin 500 mg PO Q24H \r\nRX *levofloxacin 500 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n7.  Acyclovir 400 mg PO Q8H  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n9.  Gabapentin 600 mg PO TID  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n12.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nRespiratory syncytial virus bronchiolitis\r\nMyelodysplastic syndrome\r\n\r\nSecondary:\r\nLow back pain\r\nCombined variable immunodeficiency\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted because you were having a cough and wheezing. \r\nWe found you had a virus called RSV that we treated with \r\nmedications called palvilizumab and ribavirin. We also gave you \r\n4 doses of 10g IVIg. We also supported your breathing with \r\nnebulizer treatments and cough medications. By the time of your \r\ndischarge, you were feeling much better. \r\n\r\nPlease follow-up with Dr. ___ at the \r\nappointment that was set up for you. \r\n\r\nIt was a pleasure taking care of you, and we wish you the best. \r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-21:7",
      "text": "Discharge Medications:\n1. Benzonatate 100 mg PO TID:PRN cough \nRX *benzonatate 100 mg 1 capsule(s) by mouth three time a day \nDisp #*30 Capsule Refills:*0 \n2. Fluconazole 200 mg PO Q24H \nRX *fluconazole 200 mg 1 tablet(s) by mouth daily Disp #*30 \nTablet Refills:*0 \n3. FoLIC Acid 3 mg PO DAILY \nRX *folic acid 1 mg 3 tablet(s) by mouth daily Disp #*90 Tablet \nRefills:*0 \n4. Guaifenesin-CODEINE Phosphate ___ mL PO HS:PRN cough \nRX *codeine-guaifenesin 10 mg-100 mg/5 mL 5 mL by mouth at night \nRefills:*0 \n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H \nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \nIH every 6 hours Disp #*120 Ampule Refills:*0 \n6. Levofloxacin 500 mg PO Q24H \nRX *levofloxacin 500 mg 1 tablet(s) by mouth daily Disp #*30 \nTablet Refills:*0 \n7. Acyclovir 400 mg PO Q8H  \n8. Fluticasone Propionate 110mcg 2 PUFF IH BID  \n9. Gabapentin 600 mg PO TID  \n10. Omeprazole 20 mg PO DAILY  \n11. Ondansetron 4 mg PO Q8H:PRN nausea  \n12. Venlafaxine 25 mg PO BID Discharge Disposition:\nHome Discharge Diagnosis:\nPrimary: \nRespiratory syncytial virus bronchiolitis\nMyelodysplastic syndrome Secondary:\nLow back pain\nCombined variable immunodeficiency Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-21",
        "chart_time": "104607",
        "section": "General",
        "position": 7,
        "tokenCount": 330,
        "note_metadata": {
          "note_id": "18887130-DS-21",
          "subject_id": 18887130,
          "hadm_id": 22357254,
          "note_type": "DS",
          "note_seq": 21,
          "charttime": 104607,
          "storetime": 104608.70416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nCough, wheezing\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for transplant, who \r\npresents with cough and wheezing x2 days. She states that her \r\ncough is productive with clear sputum with no blood. She denies \r\nany fever or chills. She has no chest pain, shortness of breath, \r\nabdominal pain,  diarrhea, or difficulty/pain with urination. \r\nShe does endorse some nasal congestion and dry throat.  \r\n\r\nShe has had issues with bronchitis/pneumonias in the past. Given \r\nher profound neutropenia, she was referred to the ED for \r\npossible admission. \r\n\r\nIn the ED, labs were notable for WBC 0.8, ANC 170, H/H 8.0/24.6, \r\nPlt 27, lactate 1.0, coags wnl. \r\nChem 7: Na 140, K 3.8, Cl 107, CO2 21, BUN 16, Cr 0.8, Glucose \r\n72.\r\nUA, urine and blood cultures were ordered. \r\nCXR did not show evidence of pneumonia, however with patient's \r\nworsening cough and wheezes along with her neutropenia, she was \r\ntreated with empiric antibiotics, including cefepime, \r\nvancomycin, and azithromycin. \r\nShe also received albuterol and ipratropium nebs.\r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new adenopathy. Labs notable for LDH 341, WBC \r\n10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all markedly FDG-avid and concerning for \r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer abdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxaban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis, \r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg PO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10 mg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continued prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobulinemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LNs. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT). No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n- ___, C4 Dacogen\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\n- CVID, received IVIG monthly. Last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurysm, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___.\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.3, BP 128/58, P 88, RR 22, O2sat 100% on RA\r\nGen: Pleasant, calm, \r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear. No \r\npharyngeal erythema or exudates, no sinus tenderness, normal TM \r\nbilaterally, trachea midline  \r\nLYMPH: No cervical or supraclavicular LAD  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Bilateral end expiratory wheezes in \r\nupper lung fields b/l.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: No rashes/lesions, petechiae/purpura, or ecchymoses.  \r\nNEURO: A&Ox3.  \r\nLINES: Port\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.2-98.3, BP 117-122/76-80, P 85-91, RR ___, O2sat \r\n97-98% on RA/CPAP\r\nGen: Pleasant, calm, no acute distress, coughing occasionally\r\nHEENT: No conjunctival pallor. No icterus. MMM. \r\nCV: RRR. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Diffuse expiratory wheezes.\r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: Venous stasis changes in b/l ___, non-pitting ___ edema\r\nLINES: Port\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n====================\r\n___ 09:09AM BLOOD WBC-0.9* RBC-2.50* Hgb-8.1* Hct-24.9* \r\nMCV-100* MCH-32.4* MCHC-32.5 RDW-21.2* RDWSD-72.1* Plt Ct-17*\r\n___ 09:09AM BLOOD Neuts-31* Bands-0 Lymphs-64* Monos-4* \r\nEos-0 Baso-1 ___ Myelos-0 NRBC-3* AbsNeut-0.28* \r\nAbsLymp-0.58* AbsMono-0.04* AbsEos-0.00* AbsBaso-0.01\r\n___ 09:09AM BLOOD Hypochr-NORMAL Anisocy-1+ Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-1+ Ovalocy-OCCASIONAL\r\n\r\nOTHER RELEVANT LABS:\r\n======================\r\n___ 12:56PM BLOOD Lactate-1.0\r\n___ 12:00AM BLOOD IgG-774\r\n___ 04:10PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 04:10PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 04:10PM URINE RBC-<1 WBC-1 Bacteri-NONE Yeast-NONE \r\nEpi-<1\r\n___ 02:18PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nRespiratory Viral Antigen Screen (Final ___: \r\nPositive for Respiratory viral antigens. \r\nPOSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). \r\nViral antigen identified by immunofluorescence. \r\n\r\nDISCHARGE LABS:\r\n======================\r\n___ 12:00AM BLOOD WBC-0.6* RBC-2.73* Hgb-8.6* Hct-26.4* \r\nMCV-97 MCH-31.5 MCHC-32.6 RDW-21.7* RDWSD-72.9* Plt Ct-61*\r\n___ 12:00AM BLOOD Neuts-27* Bands-0 Lymphs-67* Monos-3* \r\nEos-3 Baso-0 ___ Myelos-0 AbsNeut-0.16* \r\nAbsLymp-0.40* AbsMono-0.02* AbsEos-0.02* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-NORMAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL\r\n___ 12:00AM BLOOD Glucose-92 UreaN-19 Creat-0.8 Na-140 \r\nK-4.2 Cl-104 HCO3-22 AnGap-18\r\n___ 12:00AM BLOOD Calcium-8.5 Phos-2.9 Mg-2.4\r\n\r\nIMAGING:\r\n=====================\r\nCXR- PA and LATERAL (___): No acute cardiopulmonary abnormality \r\n\r\n \r\nBrief Hospital Course:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for allo transplant, \r\nwho presented with cough/wheezing and was found to have RSV \r\nbronchiolitis.\r\n\r\n#RSV bronchiolitis\r\n#Cough and wheezing\r\nPatient is neutropenic and has CVID and presented with cough and \r\nwheezing. She was initially started on cefepime and azithromycin \r\nfor empiric coverage. Patient's respiratory viral screen was \r\npositive for RSV. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis. She was also \r\ntreated symptomatically with duonebs q6h, mucinex, benzonatate, \r\nand guaifenesin-codeine at night. Her symptoms improved \r\nsignificantly with these measures. She was able to maintain \r\nO2sat > 95% while ambulating. \r\n\r\n#Myelodysplastic syndrome- Patient is ___ 4 cycles of dacogen \r\nwith plans to move towards allogeneic transplant. She was \r\ncontinued on acyclovir for prophylaxis. Her bacterial \r\nprophylaxis was transitioned to levaquin on ___ as above. She \r\nwas also started on fluconazole during this admission for fungal \r\nprophylaxis. She was transfused for Hgb < 7 or Plt < 10. She \r\nreceived a total of 2U pRBCs and 1U platelets during this \r\nadmission.\r\n\r\n#Low back pain- Continued gabapentin 600 mg TID\r\n\r\nTRANSITIONAL ISSUES:\r\n======================\r\n- New medications: fluconazole, levofloxacin, guaifenesin with \r\ncodeine, benzonatate, duonebs\r\n- Patient started on fluconazole 200 mg daily during this \r\nadmission for fungal prophylaxis, can consider adjusting dose to \r\n400 mg daily based on patient's weight\r\n- Patient initially on cefepime for broad spectrum antibiotic \r\ncoverage given significant symptoms and neutropenia that was \r\ntransitioned to levofloxacin on ___. Can consider de-escalating \r\nto ciprofloxacin if patient continues to clinically improve.\r\n- Of note, patient's PFTs (originally scheduled for ___ were \r\nrescheduled for ___ due to her acute illness. Can reschedule as \r\nneeded.\r\n \r\nMedications on Admission:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol 0.083% Neb Soln 1 NEB IH Q6H:PRN wheezing/cough \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n4. Gabapentin 600 mg PO TID \r\n5. Ipratropium Bromide Neb 1 NEB IH Q6H:PRN shortness of breath \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 4 mg PO Q8H:PRN nausea \r\n8. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN cough \r\nRX *benzonatate 100 mg 1 capsule(s) by mouth three time a day \r\nDisp #*30 Capsule Refills:*0 \r\n2.  Fluconazole 200 mg PO Q24H \r\nRX *fluconazole 200 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n3.  FoLIC Acid 3 mg PO DAILY \r\nRX *folic acid 1 mg 3 tablet(s) by mouth daily Disp #*90 Tablet \r\nRefills:*0 \r\n4.  Guaifenesin-CODEINE Phosphate ___ mL PO HS:PRN cough \r\nRX *codeine-guaifenesin 10 mg-100 mg/5 mL 5 mL by mouth at night \r\nRefills:*0 \r\n5.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nIH every 6 hours Disp #*120 Ampule Refills:*0 \r\n6.  Levofloxacin 500 mg PO Q24H \r\nRX *levofloxacin 500 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n7.  Acyclovir 400 mg PO Q8H  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n9.  Gabapentin 600 mg PO TID  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n12.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nRespiratory syncytial virus bronchiolitis\r\nMyelodysplastic syndrome\r\n\r\nSecondary:\r\nLow back pain\r\nCombined variable immunodeficiency\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted because you were having a cough and wheezing. \r\nWe found you had a virus called RSV that we treated with \r\nmedications called palvilizumab and ribavirin. We also gave you \r\n4 doses of 10g IVIg. We also supported your breathing with \r\nnebulizer treatments and cough medications. By the time of your \r\ndischarge, you were feeling much better. \r\n\r\nPlease follow-up with Dr. ___ at the \r\nappointment that was set up for you. \r\n\r\nIt was a pleasure taking care of you, and we wish you the best. \r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-21:8",
      "text": "Discharge Instructions:\nDear Ms. ___, You were admitted because you were having a cough and wheezing. We found you had a virus called RSV that we treated with \nmedications called palvilizumab and ribavirin. We also gave you \n4 doses of 10g IVIg. We also supported your breathing with \nnebulizer treatments and cough medications. By the time of your \ndischarge, you were feeling much better. Please follow-up with Dr. ___ at the \nappointment that was set up for you. It was a pleasure taking care of you, and we wish you the best. Sincerely,\nYour ___ Team\n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-21",
        "chart_time": "104607",
        "section": "General",
        "position": 8,
        "tokenCount": 146,
        "note_metadata": {
          "note_id": "18887130-DS-21",
          "subject_id": 18887130,
          "hadm_id": 22357254,
          "note_type": "DS",
          "note_seq": 21,
          "charttime": 104607,
          "storetime": 104608.70416666666,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nCough, wheezing\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for transplant, who \r\npresents with cough and wheezing x2 days. She states that her \r\ncough is productive with clear sputum with no blood. She denies \r\nany fever or chills. She has no chest pain, shortness of breath, \r\nabdominal pain,  diarrhea, or difficulty/pain with urination. \r\nShe does endorse some nasal congestion and dry throat.  \r\n\r\nShe has had issues with bronchitis/pneumonias in the past. Given \r\nher profound neutropenia, she was referred to the ED for \r\npossible admission. \r\n\r\nIn the ED, labs were notable for WBC 0.8, ANC 170, H/H 8.0/24.6, \r\nPlt 27, lactate 1.0, coags wnl. \r\nChem 7: Na 140, K 3.8, Cl 107, CO2 21, BUN 16, Cr 0.8, Glucose \r\n72.\r\nUA, urine and blood cultures were ordered. \r\nCXR did not show evidence of pneumonia, however with patient's \r\nworsening cough and wheezes along with her neutropenia, she was \r\ntreated with empiric antibiotics, including cefepime, \r\nvancomycin, and azithromycin. \r\nShe also received albuterol and ipratropium nebs.\r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY:  \r\nTransformed DLBCL with a history of follicular lymphoma stage \r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam revealed new adenopathy. Labs notable for LDH 341, WBC \r\n10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical, \r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all markedly FDG-avid and concerning for \r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer abdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxaban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis, \r\ncytopenias\r\n- ___ Start XRT\r\n- ___ Presented w dyspnea, DLCO 79% predicted (adjusted for\r\nHb). Started prednisone 80 mg PO daily\r\n- ___ DLCO 96%, reduce prednisone to 50 mg PO daily\r\n- ___ DLCO 111%, reduce prednisone to 30 mg PO daily\r\n- ___ DLCO 84%, pulse steroids, increase prednisone to 50 \r\nmg PO daily. PLT 81, Bactrim switched to Dapsone for PCP ___.\r\n- Weekly monitoring of DLCO with taper of prednisone to 10 mg\r\ndaily as of ___ with DLCO 99%.  Dapsone d/ced on ___\r\ndue to hemolysis.\r\n- ___ Decreased prednisone to 5 mg PO daily. Noro virus\r\npersistently positive. \r\n- ___ CT torso with no evidence of active disease.\r\nUnchanged mesenteric fullness. \r\n- ___ DLCO decrease (not reported) increase prednisone to \r\n10 mg\r\n- ___ IVIg 400 mg/kg\r\n- ___ DLCO 121%, continued prednisone 10 mg\r\n- IVIg 400 mg/kg, continues monthly for Hypogammaglobulinemia.\r\n- ___, tapered off prednisone.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, primary, complicated\r\nby foot drop likely d/t irritation of peroneal nerve and\r\ncellulitis.\r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LNs. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, increasing right leg swelling with noted DVT.  Xarelto\r\nincreased back to 20 mg daily(had been decreased given age and\r\nprior chronic DVT). No evidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts.  BM biopsy with evidence\r\nfor MDS.\r\n- ___, C1 Dacogen\r\n- ___, C2 Dacogen\r\n- ___, C3 Dacogen\r\n- ___, C4 Dacogen\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\n- CVID, received IVIG monthly. Last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurysm, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___.\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.3, BP 128/58, P 88, RR 22, O2sat 100% on RA\r\nGen: Pleasant, calm, \r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear. No \r\npharyngeal erythema or exudates, no sinus tenderness, normal TM \r\nbilaterally, trachea midline  \r\nLYMPH: No cervical or supraclavicular LAD  \r\nCV: Normocardic, regular. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Bilateral end expiratory wheezes in \r\nupper lung fields b/l.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: No rashes/lesions, petechiae/purpura, or ecchymoses.  \r\nNEURO: A&Ox3.  \r\nLINES: Port\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n=============================\r\nVitals: T 98.2-98.3, BP 117-122/76-80, P 85-91, RR ___, O2sat \r\n97-98% on RA/CPAP\r\nGen: Pleasant, calm, no acute distress, coughing occasionally\r\nHEENT: No conjunctival pallor. No icterus. MMM. \r\nCV: RRR. Normal S1,S2. No MRG.  \r\nLUNGS: No increased WOB. Diffuse expiratory wheezes.\r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No ___ edema.\r\nSKIN: Venous stasis changes in b/l ___, non-pitting ___ edema\r\nLINES: Port\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n====================\r\n___ 09:09AM BLOOD WBC-0.9* RBC-2.50* Hgb-8.1* Hct-24.9* \r\nMCV-100* MCH-32.4* MCHC-32.5 RDW-21.2* RDWSD-72.1* Plt Ct-17*\r\n___ 09:09AM BLOOD Neuts-31* Bands-0 Lymphs-64* Monos-4* \r\nEos-0 Baso-1 ___ Myelos-0 NRBC-3* AbsNeut-0.28* \r\nAbsLymp-0.58* AbsMono-0.04* AbsEos-0.00* AbsBaso-0.01\r\n___ 09:09AM BLOOD Hypochr-NORMAL Anisocy-1+ Poiklo-1+ \r\nMacrocy-NORMAL Microcy-NORMAL Polychr-1+ Ovalocy-OCCASIONAL\r\n\r\nOTHER RELEVANT LABS:\r\n======================\r\n___ 12:56PM BLOOD Lactate-1.0\r\n___ 12:00AM BLOOD IgG-774\r\n___ 04:10PM URINE Color-Yellow Appear-Clear Sp ___\r\n___ 04:10PM URINE Blood-NEG Nitrite-NEG Protein-30 \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 04:10PM URINE RBC-<1 WBC-1 Bacteri-NONE Yeast-NONE \r\nEpi-<1\r\n___ 02:18PM OTHER BODY FLUID FluAPCR-NEGATIVE \r\nFluBPCR-NEGATIVE\r\n\r\nRespiratory Viral Antigen Screen (Final ___: \r\nPositive for Respiratory viral antigens. \r\nPOSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). \r\nViral antigen identified by immunofluorescence. \r\n\r\nDISCHARGE LABS:\r\n======================\r\n___ 12:00AM BLOOD WBC-0.6* RBC-2.73* Hgb-8.6* Hct-26.4* \r\nMCV-97 MCH-31.5 MCHC-32.6 RDW-21.7* RDWSD-72.9* Plt Ct-61*\r\n___ 12:00AM BLOOD Neuts-27* Bands-0 Lymphs-67* Monos-3* \r\nEos-3 Baso-0 ___ Myelos-0 AbsNeut-0.16* \r\nAbsLymp-0.40* AbsMono-0.02* AbsEos-0.02* AbsBaso-0.00*\r\n___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-NORMAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL\r\n___ 12:00AM BLOOD Glucose-92 UreaN-19 Creat-0.8 Na-140 \r\nK-4.2 Cl-104 HCO3-22 AnGap-18\r\n___ 12:00AM BLOOD Calcium-8.5 Phos-2.9 Mg-2.4\r\n\r\nIMAGING:\r\n=====================\r\nCXR- PA and LATERAL (___): No acute cardiopulmonary abnormality \r\n\r\n \r\nBrief Hospital Course:\r\n___ w/ CVID, h/o FL transformed to DLBCL ___ autoSCT (BEAM prep) \r\nin ___ in remission from lymphoma then with treatment-related \r\nMDS ___ 4 cycles of decitabine and planning for allo transplant, \r\nwho presented with cough/wheezing and was found to have RSV \r\nbronchiolitis.\r\n\r\n#RSV bronchiolitis\r\n#Cough and wheezing\r\nPatient is neutropenic and has CVID and presented with cough and \r\nwheezing. She was initially started on cefepime and azithromycin \r\nfor empiric coverage. Patient's respiratory viral screen was \r\npositive for RSV. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis. She was also \r\ntreated symptomatically with duonebs q6h, mucinex, benzonatate, \r\nand guaifenesin-codeine at night. Her symptoms improved \r\nsignificantly with these measures. She was able to maintain \r\nO2sat > 95% while ambulating. \r\n\r\n#Myelodysplastic syndrome- Patient is ___ 4 cycles of dacogen \r\nwith plans to move towards allogeneic transplant. She was \r\ncontinued on acyclovir for prophylaxis. Her bacterial \r\nprophylaxis was transitioned to levaquin on ___ as above. She \r\nwas also started on fluconazole during this admission for fungal \r\nprophylaxis. She was transfused for Hgb < 7 or Plt < 10. She \r\nreceived a total of 2U pRBCs and 1U platelets during this \r\nadmission.\r\n\r\n#Low back pain- Continued gabapentin 600 mg TID\r\n\r\nTRANSITIONAL ISSUES:\r\n======================\r\n- New medications: fluconazole, levofloxacin, guaifenesin with \r\ncodeine, benzonatate, duonebs\r\n- Patient started on fluconazole 200 mg daily during this \r\nadmission for fungal prophylaxis, can consider adjusting dose to \r\n400 mg daily based on patient's weight\r\n- Patient initially on cefepime for broad spectrum antibiotic \r\ncoverage given significant symptoms and neutropenia that was \r\ntransitioned to levofloxacin on ___. Can consider de-escalating \r\nto ciprofloxacin if patient continues to clinically improve.\r\n- Of note, patient's PFTs (originally scheduled for ___ were \r\nrescheduled for ___ due to her acute illness. Can reschedule as \r\nneeded.\r\n \r\nMedications on Admission:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Albuterol 0.083% Neb Soln 1 NEB IH Q6H:PRN wheezing/cough \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID \r\n4. Gabapentin 600 mg PO TID \r\n5. Ipratropium Bromide Neb 1 NEB IH Q6H:PRN shortness of breath \r\n6. Omeprazole 20 mg PO DAILY \r\n7. Ondansetron 4 mg PO Q8H:PRN nausea \r\n8. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN cough \r\nRX *benzonatate 100 mg 1 capsule(s) by mouth three time a day \r\nDisp #*30 Capsule Refills:*0 \r\n2.  Fluconazole 200 mg PO Q24H \r\nRX *fluconazole 200 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n3.  FoLIC Acid 3 mg PO DAILY \r\nRX *folic acid 1 mg 3 tablet(s) by mouth daily Disp #*90 Tablet \r\nRefills:*0 \r\n4.  Guaifenesin-CODEINE Phosphate ___ mL PO HS:PRN cough \r\nRX *codeine-guaifenesin 10 mg-100 mg/5 mL 5 mL by mouth at night \r\nRefills:*0 \r\n5.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nIH every 6 hours Disp #*120 Ampule Refills:*0 \r\n6.  Levofloxacin 500 mg PO Q24H \r\nRX *levofloxacin 500 mg 1 tablet(s) by mouth daily Disp #*30 \r\nTablet Refills:*0 \r\n7.  Acyclovir 400 mg PO Q8H  \r\n8.  Fluticasone Propionate 110mcg 2 PUFF IH BID  \r\n9.  Gabapentin 600 mg PO TID  \r\n10.  Omeprazole 20 mg PO DAILY  \r\n11.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n12.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary: \r\nRespiratory syncytial virus bronchiolitis\r\nMyelodysplastic syndrome\r\n\r\nSecondary:\r\nLow back pain\r\nCombined variable immunodeficiency\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nYou were admitted because you were having a cough and wheezing. \r\nWe found you had a virus called RSV that we treated with \r\nmedications called palvilizumab and ribavirin. We also gave you \r\n4 doses of 10g IVIg. We also supported your breathing with \r\nnebulizer treatments and cough medications. By the time of your \r\ndischarge, you were feeling much better. \r\n\r\nPlease follow-up with Dr. ___ at the \r\nappointment that was set up for you. \r\n\r\nIt was a pleasure taking care of you, and we wish you the best. \r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-22:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \ndapsone\n \nAttending: ___ Chief Complaint:\nAlloSCT Admission\n \nMajor Surgical or Invasive Procedure:\nTemporary CVL",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-22",
        "chart_time": "104681",
        "section": "General",
        "position": 0,
        "tokenCount": 73,
        "note_metadata": {
          "note_id": "18887130-DS-22",
          "subject_id": 18887130,
          "hadm_id": 20942569,
          "note_type": "DS",
          "note_seq": 22,
          "charttime": 104681,
          "storetime": 104682.30277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nAlloSCT Admission\r\n \r\nMajor Surgical or Invasive Procedure:\r\nTemporary CVL\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with CVID, history of follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ in remission from \r\nlymphoma, but noted for treatment-related MDS ___ 4 cycles of \r\nDecitabine(C4 D1 =\r\n___, now presents for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\nOf note, the patient was discharged ___ after admission for \r\nRSV Bronchiolitis. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis.\r\n\r\nShe also had a tooth extraction on the lower left side on \r\n___ due to persistent tooth pain and completed 1 week of \r\nAmoxicillin.\r\n\r\nOn arrival to the floor the patient is feeling quite well. \r\nMinimal discomfort from her tooth extraction. Otherwise denying \r\ncomplete review of systems. She is ready to go through with \r\ntransplant and hoping to get it over with.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n \r\nPhysical Exam:\r\nADMISSION: \r\nVitals: 98.3 142/77 89 16 99 RA\r\nGen: Pleasant, calm, A&Ox3\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.  \r\nNECK: Supple, No LAD\r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No pitting edema but changes consistent with venous \r\nstasis dermatitis and edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3. Known R CN6 palsy since aneurism repair and R \r\npupil with minimal response to light. Otherwise CN intact and \r\nstrength ___ all extremities.\r\nLINES: L port, R CVL\r\n \r\nPertinent Results:\r\nADMISSION: \r\n___ 11:15AM BLOOD WBC-5.0 RBC-2.49* Hgb-8.7* Hct-27.2* \r\nMCV-109* MCH-34.9* MCHC-32.0 RDW-UNABLE TO  RDWSD-UNABLE TO  Plt \r\nCt-67*\r\n___ 11:15AM BLOOD Neuts-74.9* Lymphs-16.9* Monos-6.2 \r\nEos-1.2 Baso-0.4 Im ___ AbsNeut-3.78 AbsLymp-0.85* \r\nAbsMono-0.31 AbsEos-0.06 AbsBaso-0.02\r\n___ 11:15AM BLOOD Hypochr-NORMAL Anisocy-3+ Poiklo-1+ \r\nMacrocy-3+ Microcy-NORMAL Polychr-1+ Ovalocy-1+ Tear \r\nDr-OCCASIONAL\r\n___ 11:15AM BLOOD ___ PTT-30.7 ___\r\n___ 05:15AM BLOOD ___\r\n___ 11:15AM BLOOD UreaN-15 Creat-0.9 Na-140 K-4.0 Cl-105 \r\nHCO3-22 AnGap-17\r\n___ 11:15AM BLOOD ALT-11 AST-16 LD(LDH)-260* AlkPhos-124* \r\nTotBili-0.2 DirBili-<0.2 IndBili-0.2\r\n___ 11:15AM BLOOD TotProt-6.7 Albumin-4.2 Globuln-2.5 \r\nCalcium-8.7 Phos-3.4 Mg-2.2 UricAcd-3.7\r\n\r\nIMAGING: \r\n\r\nCXR ___:\r\nIn comparison with the study of ___, the cardiac silhouette \r\nremains at the upper limits of normal or mildly enlarged.  Mild \r\nindistinctness of pulmonary vessels is consistent with mild \r\nelevation of pulmonary venous pressure.  However, no evidence of \r\nacute focal pneumonia or pleural effusion. There has been \r\ninterval placement of right IJ catheter that extends to the \r\nlower SVC. \r\n\r\nRUQUS ___:\r\n1. Patent hepatic vasculature. \r\n2. Echogenic liver consistent with steatosis. Other forms of \r\nliver disease \r\nincluding steatohepatitis, hepatic fibrosis, or cirrhosis cannot \r\nbe excluded on the basis of this examination. \r\n\r\n \r\nBrief Hospital Course:\r\n___ year old female with CVID, RLE DVT, OSA on CPAP, and hx \r\ncerebral aneurism ___ coil, who follows for follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ now with \r\ntreatment-related MDS ___ 4 cycles of Decitabine(C4 D1 \r\n___, admitted for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\n#Treatment-Related MDS:\r\nPatient with follicular lymphoma transformed to DLBCL ___ \r\nautoSCT in ___ now with rapid progression of pancytopenia, \r\nparticularly anemia. Bone marrow biopsy with dysplasia of all \r\ncell lines with noted cytogenetic abnormalities concerning for \r\ntreatment related MDS. ___ Dacogen x4 cycles with persistent \r\nthrombocytopenia but recovered WBCs. Bone marrow biopsy on \r\n___ shows persistent trilineage\r\ndyspoitic maturation. She underwent MUD Allogeneic transplant \r\nwith Fludarabine/Busulfan/ATG conditioning per protocol. She was \r\ndischarged on acyclovir, fluconazole, and Bactrim as per \r\nprotocol. She was on cyclosporine for immunosuppression as per \r\nprotocol. Levels were checked and the patient was discharged on \r\n50 BID. Weekly CMVs were negative.  \r\n\r\n___: Cr up to 1.3 on ___, baseline 0.7-0.8. Likely from \r\noverdiuresis. Urine studies w/ FeUrea ~40% indicating intrinsic \r\ndisease. Possibly renal injury from elevated cyclosporine \r\nlevels. Cr on discharge was 1.1. \r\n\r\n#CVID: Per ID recommendations, given profession and history, \r\nafter\r\nthe initial conditioning regimen would treat with isoniazid and \r\nB6 for a projected 9-month course to prevent TB reactivation. \r\nThis will be guided by Dr. ___ primary oncologist. \r\nPatient to receive monthly IVIG outpatient. \r\n\r\n#Transaminitis: \r\nThe patient developed a transaminitis into the 300-400s from \r\nnormal after her first infusion of busulfan and ATG. This \r\nresolved without further intervention and remained stable during \r\nher subsequent infusions. RUQUS showed patent hepatic \r\nvasculature and an echogenic liver.\r\n\r\n#Right leg DVT.  Had been on Xarelto 20 mg daily but this has\r\nbeen on hold as platelet count < 75,000. This was resumed with \r\nuptrending ___ and PTT. Given ___ BMI and possibility of \r\ninteraction with cyclosporine/fluconazole, she was switched to \r\nLovenox on discharge. Xa level was ### still pending at \r\ndischarge. Has IVC filter in place.\r\n\r\n#Pulmonary hypertension.  Evaluated by Dr. ___ \r\ncontraindication of proceeding with transplant. She remained \r\nstable from a pulmonary perspective.\r\n\r\n#Low Back Pain: Tapered gabapentin 400 mg BID. Continued \r\nVenlafaxine.  \r\n\r\n#OSA: Continued CPAP\r\n\r\n#Asthma: Continued Albuterol PRN with Duoneb q6H PRN\r\n\r\nTRANSITIONAL ISSUES:\r\n- Patient requires monthly IVIG for her CVID\r\n- Discharged on acyclovir (treatment dose) as well as \r\nfluconazole ppx and Bactrim ppx \r\n- ___ benefit from Valacyclovir instead of acyclovir: unable to \r\nobtain prior auth/medication delivery prior to discharge \r\n- Discuss treatment of latent TB with isoniazid and B6. \r\n- Monitor patient on Lovenox, follow-up Xa levels and adjust as \r\nneeded.\r\n\r\n# CODE: Full (confirmed) \r\n# EMERGENCY CONTACT: ___ (Daughter) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list may be inaccurate and requires \r\nfuther investigation.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n3. Omeprazole 20 mg PO DAILY \r\n4. Venlafaxine 25 mg PO BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Ondansetron 4 mg PO Q8H:PRN nausea \r\n7. FoLIC Acid 3 mg PO DAILY \r\n8. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n9. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n10. Cephalexin 200 mg PO ONCE \r\n11. Gabapentin 600 mg PO BID \r\n12. Loratadine 10 mg PO DAILY cold \r\n13. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14. Senna 8.6 mg PO BID:PRN constipation  \r\n\r\n \r\nDischarge Medications:\r\n1.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\nRX *cyclosporine modified [Neoral] 25 mg 2 capsule(s) by mouth \r\nevery twelve (12) hours Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 50 mg 1 capsule(s) by mouth twice a \r\nday Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 25 mg 2 capsule(s) by mouth twice a \r\nday Disp #*120 Capsule Refills:*0 \r\n2.  Enoxaparin Sodium 90 mg SC Q12H \r\nRX *enoxaparin 100 mg/mL 100 mg SC every twelve (12) hours Disp \r\n#*30 Syringe Refills:*0 \r\n3.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\nRX *lorazepam 0.5 mg ___ TABLETS by mouth Q6H:PRN Disp #*30 \r\nTablet Refills:*0 \r\n4.  Multivitamins 1 TAB PO DAILY \r\nRX *multivitamin  1 tablet(s) by mouth DAILY Disp #*30 Tablet \r\nRefills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n6.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0 \r\n7.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0 \r\n8.  Acyclovir 200 mg PO 5X/D  \r\n9.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth Q24H Disp #*60 \r\nTablet Refills:*0 \r\n10.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth Daily Disp #*30 Tablet \r\nRefills:*0 \r\n11.  Gabapentin 400 mg PO BID \r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0\r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0 \r\n12.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n13.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheeze  \r\n14.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n15.  Loratadine 10 mg PO DAILY cold  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n19.  Senna 8.6 mg PO BID:PRN constipation   \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nSecondary MDS ___ MUD AlloSCT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you during your recent \r\nhospitalization. You were admitted to ___ for a stem cell \r\ntransplant. You underwent the bone marrow transplant and \r\nremained in the hospital while your counts improved. Your counts \r\nare now improved and it is safe for you to be discharged. \r\n\r\nWHEN YOU GO HOME:\r\n- Please continue to take all of your medications as directed\r\n- Please follow-up with the doctors listed below\r\n- ___ monitor for any of the alarm symptoms listed below, \r\ncall your doctor or report to the emergency department \r\nimmediately if you experience any of these\r\n\r\nWe wish you the best!\r\nYour ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-22:1",
      "text": "History of Present Illness:\n___ year old female with CVID, history of follicular lymphoma \ntransformed to DLBCL ___ autoSCT in ___ in remission from \nlymphoma, but noted for treatment-related MDS ___ 4 cycles of \nDecitabine(C4 D1 =\n___, now presents for MUD AlloSCT w/ \nFludarabine/Busulfan/ATG conditioning. Of note, the patient was discharged ___ after admission for \nRSV Bronchiolitis. She was treated with palvilizumab on ___ and \nribavirin 600 mg q8h (___). Patient also was treated \nwith 4 days of 10 g IVIg (___). She received a 5 day \ncourse of azithromycin for anti-inflammatory effect. She was \nalso continued on cefepime (___), that was transitioned \nto levaquin on ___ for bacterial prophylaxis. She also had a tooth extraction on the lower left side on \n___ due to persistent tooth pain and completed 1 week of \nAmoxicillin. On arrival to the floor the patient is feeling quite well. Minimal discomfort from her tooth extraction. Otherwise denying \ncomplete review of systems. She is ready to go through with \ntransplant and hoping to get it over with.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-22",
        "chart_time": "104681",
        "section": "General",
        "position": 1,
        "tokenCount": 267,
        "note_metadata": {
          "note_id": "18887130-DS-22",
          "subject_id": 18887130,
          "hadm_id": 20942569,
          "note_type": "DS",
          "note_seq": 22,
          "charttime": 104681,
          "storetime": 104682.30277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nAlloSCT Admission\r\n \r\nMajor Surgical or Invasive Procedure:\r\nTemporary CVL\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with CVID, history of follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ in remission from \r\nlymphoma, but noted for treatment-related MDS ___ 4 cycles of \r\nDecitabine(C4 D1 =\r\n___, now presents for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\nOf note, the patient was discharged ___ after admission for \r\nRSV Bronchiolitis. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis.\r\n\r\nShe also had a tooth extraction on the lower left side on \r\n___ due to persistent tooth pain and completed 1 week of \r\nAmoxicillin.\r\n\r\nOn arrival to the floor the patient is feeling quite well. \r\nMinimal discomfort from her tooth extraction. Otherwise denying \r\ncomplete review of systems. She is ready to go through with \r\ntransplant and hoping to get it over with.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n \r\nPhysical Exam:\r\nADMISSION: \r\nVitals: 98.3 142/77 89 16 99 RA\r\nGen: Pleasant, calm, A&Ox3\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.  \r\nNECK: Supple, No LAD\r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No pitting edema but changes consistent with venous \r\nstasis dermatitis and edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3. Known R CN6 palsy since aneurism repair and R \r\npupil with minimal response to light. Otherwise CN intact and \r\nstrength ___ all extremities.\r\nLINES: L port, R CVL\r\n \r\nPertinent Results:\r\nADMISSION: \r\n___ 11:15AM BLOOD WBC-5.0 RBC-2.49* Hgb-8.7* Hct-27.2* \r\nMCV-109* MCH-34.9* MCHC-32.0 RDW-UNABLE TO  RDWSD-UNABLE TO  Plt \r\nCt-67*\r\n___ 11:15AM BLOOD Neuts-74.9* Lymphs-16.9* Monos-6.2 \r\nEos-1.2 Baso-0.4 Im ___ AbsNeut-3.78 AbsLymp-0.85* \r\nAbsMono-0.31 AbsEos-0.06 AbsBaso-0.02\r\n___ 11:15AM BLOOD Hypochr-NORMAL Anisocy-3+ Poiklo-1+ \r\nMacrocy-3+ Microcy-NORMAL Polychr-1+ Ovalocy-1+ Tear \r\nDr-OCCASIONAL\r\n___ 11:15AM BLOOD ___ PTT-30.7 ___\r\n___ 05:15AM BLOOD ___\r\n___ 11:15AM BLOOD UreaN-15 Creat-0.9 Na-140 K-4.0 Cl-105 \r\nHCO3-22 AnGap-17\r\n___ 11:15AM BLOOD ALT-11 AST-16 LD(LDH)-260* AlkPhos-124* \r\nTotBili-0.2 DirBili-<0.2 IndBili-0.2\r\n___ 11:15AM BLOOD TotProt-6.7 Albumin-4.2 Globuln-2.5 \r\nCalcium-8.7 Phos-3.4 Mg-2.2 UricAcd-3.7\r\n\r\nIMAGING: \r\n\r\nCXR ___:\r\nIn comparison with the study of ___, the cardiac silhouette \r\nremains at the upper limits of normal or mildly enlarged.  Mild \r\nindistinctness of pulmonary vessels is consistent with mild \r\nelevation of pulmonary venous pressure.  However, no evidence of \r\nacute focal pneumonia or pleural effusion. There has been \r\ninterval placement of right IJ catheter that extends to the \r\nlower SVC. \r\n\r\nRUQUS ___:\r\n1. Patent hepatic vasculature. \r\n2. Echogenic liver consistent with steatosis. Other forms of \r\nliver disease \r\nincluding steatohepatitis, hepatic fibrosis, or cirrhosis cannot \r\nbe excluded on the basis of this examination. \r\n\r\n \r\nBrief Hospital Course:\r\n___ year old female with CVID, RLE DVT, OSA on CPAP, and hx \r\ncerebral aneurism ___ coil, who follows for follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ now with \r\ntreatment-related MDS ___ 4 cycles of Decitabine(C4 D1 \r\n___, admitted for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\n#Treatment-Related MDS:\r\nPatient with follicular lymphoma transformed to DLBCL ___ \r\nautoSCT in ___ now with rapid progression of pancytopenia, \r\nparticularly anemia. Bone marrow biopsy with dysplasia of all \r\ncell lines with noted cytogenetic abnormalities concerning for \r\ntreatment related MDS. ___ Dacogen x4 cycles with persistent \r\nthrombocytopenia but recovered WBCs. Bone marrow biopsy on \r\n___ shows persistent trilineage\r\ndyspoitic maturation. She underwent MUD Allogeneic transplant \r\nwith Fludarabine/Busulfan/ATG conditioning per protocol. She was \r\ndischarged on acyclovir, fluconazole, and Bactrim as per \r\nprotocol. She was on cyclosporine for immunosuppression as per \r\nprotocol. Levels were checked and the patient was discharged on \r\n50 BID. Weekly CMVs were negative.  \r\n\r\n___: Cr up to 1.3 on ___, baseline 0.7-0.8. Likely from \r\noverdiuresis. Urine studies w/ FeUrea ~40% indicating intrinsic \r\ndisease. Possibly renal injury from elevated cyclosporine \r\nlevels. Cr on discharge was 1.1. \r\n\r\n#CVID: Per ID recommendations, given profession and history, \r\nafter\r\nthe initial conditioning regimen would treat with isoniazid and \r\nB6 for a projected 9-month course to prevent TB reactivation. \r\nThis will be guided by Dr. ___ primary oncologist. \r\nPatient to receive monthly IVIG outpatient. \r\n\r\n#Transaminitis: \r\nThe patient developed a transaminitis into the 300-400s from \r\nnormal after her first infusion of busulfan and ATG. This \r\nresolved without further intervention and remained stable during \r\nher subsequent infusions. RUQUS showed patent hepatic \r\nvasculature and an echogenic liver.\r\n\r\n#Right leg DVT.  Had been on Xarelto 20 mg daily but this has\r\nbeen on hold as platelet count < 75,000. This was resumed with \r\nuptrending ___ and PTT. Given ___ BMI and possibility of \r\ninteraction with cyclosporine/fluconazole, she was switched to \r\nLovenox on discharge. Xa level was ### still pending at \r\ndischarge. Has IVC filter in place.\r\n\r\n#Pulmonary hypertension.  Evaluated by Dr. ___ \r\ncontraindication of proceeding with transplant. She remained \r\nstable from a pulmonary perspective.\r\n\r\n#Low Back Pain: Tapered gabapentin 400 mg BID. Continued \r\nVenlafaxine.  \r\n\r\n#OSA: Continued CPAP\r\n\r\n#Asthma: Continued Albuterol PRN with Duoneb q6H PRN\r\n\r\nTRANSITIONAL ISSUES:\r\n- Patient requires monthly IVIG for her CVID\r\n- Discharged on acyclovir (treatment dose) as well as \r\nfluconazole ppx and Bactrim ppx \r\n- ___ benefit from Valacyclovir instead of acyclovir: unable to \r\nobtain prior auth/medication delivery prior to discharge \r\n- Discuss treatment of latent TB with isoniazid and B6. \r\n- Monitor patient on Lovenox, follow-up Xa levels and adjust as \r\nneeded.\r\n\r\n# CODE: Full (confirmed) \r\n# EMERGENCY CONTACT: ___ (Daughter) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list may be inaccurate and requires \r\nfuther investigation.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n3. Omeprazole 20 mg PO DAILY \r\n4. Venlafaxine 25 mg PO BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Ondansetron 4 mg PO Q8H:PRN nausea \r\n7. FoLIC Acid 3 mg PO DAILY \r\n8. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n9. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n10. Cephalexin 200 mg PO ONCE \r\n11. Gabapentin 600 mg PO BID \r\n12. Loratadine 10 mg PO DAILY cold \r\n13. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14. Senna 8.6 mg PO BID:PRN constipation  \r\n\r\n \r\nDischarge Medications:\r\n1.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\nRX *cyclosporine modified [Neoral] 25 mg 2 capsule(s) by mouth \r\nevery twelve (12) hours Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 50 mg 1 capsule(s) by mouth twice a \r\nday Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 25 mg 2 capsule(s) by mouth twice a \r\nday Disp #*120 Capsule Refills:*0 \r\n2.  Enoxaparin Sodium 90 mg SC Q12H \r\nRX *enoxaparin 100 mg/mL 100 mg SC every twelve (12) hours Disp \r\n#*30 Syringe Refills:*0 \r\n3.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\nRX *lorazepam 0.5 mg ___ TABLETS by mouth Q6H:PRN Disp #*30 \r\nTablet Refills:*0 \r\n4.  Multivitamins 1 TAB PO DAILY \r\nRX *multivitamin  1 tablet(s) by mouth DAILY Disp #*30 Tablet \r\nRefills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n6.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0 \r\n7.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0 \r\n8.  Acyclovir 200 mg PO 5X/D  \r\n9.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth Q24H Disp #*60 \r\nTablet Refills:*0 \r\n10.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth Daily Disp #*30 Tablet \r\nRefills:*0 \r\n11.  Gabapentin 400 mg PO BID \r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0\r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0 \r\n12.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n13.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheeze  \r\n14.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n15.  Loratadine 10 mg PO DAILY cold  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n19.  Senna 8.6 mg PO BID:PRN constipation   \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nSecondary MDS ___ MUD AlloSCT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you during your recent \r\nhospitalization. You were admitted to ___ for a stem cell \r\ntransplant. You underwent the bone marrow transplant and \r\nremained in the hospital while your counts improved. Your counts \r\nare now improved and it is safe for you to be discharged. \r\n\r\nWHEN YOU GO HOME:\r\n- Please continue to take all of your medications as directed\r\n- Please follow-up with the doctors listed below\r\n- ___ monitor for any of the alarm symptoms listed below, \r\ncall your doctor or report to the emergency department \r\nimmediately if you experience any of these\r\n\r\nWe wish you the best!\r\nYour ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-22:2",
      "text": "Past Medical History:\n- Treatment-Related MDS after transformed follicular lymphoma\n- CVID, received IVIG monthly; last given ___\n- GERD                                          \n- Osteoarthritis                                         \n- DVT, right lower extremity, IVC filter in place\n- Cervical radiculopathy\n- Sciatica\n- Obstructive sleep apnea, wears CPAP\n- H/O cerebral aneurism, noted on MRA with small R internal\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\nthe right eye, mild proptosis of the right eye, and hyperthesia\nof the right V1 distribution\n- Asthma\n- Obesity\n- Hypertension\n- Migraines\n- + RSV, ___\n- History of osteomyelitis with IV antibioitcs for 6\nweeks. Social History:\n___ Family History:\nBrother with lymphoma, died at age ___. Father had CAD and DM. Mother had CHF.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-22",
        "chart_time": "104681",
        "section": "General",
        "position": 2,
        "tokenCount": 217,
        "note_metadata": {
          "note_id": "18887130-DS-22",
          "subject_id": 18887130,
          "hadm_id": 20942569,
          "note_type": "DS",
          "note_seq": 22,
          "charttime": 104681,
          "storetime": 104682.30277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nAlloSCT Admission\r\n \r\nMajor Surgical or Invasive Procedure:\r\nTemporary CVL\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with CVID, history of follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ in remission from \r\nlymphoma, but noted for treatment-related MDS ___ 4 cycles of \r\nDecitabine(C4 D1 =\r\n___, now presents for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\nOf note, the patient was discharged ___ after admission for \r\nRSV Bronchiolitis. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis.\r\n\r\nShe also had a tooth extraction on the lower left side on \r\n___ due to persistent tooth pain and completed 1 week of \r\nAmoxicillin.\r\n\r\nOn arrival to the floor the patient is feeling quite well. \r\nMinimal discomfort from her tooth extraction. Otherwise denying \r\ncomplete review of systems. She is ready to go through with \r\ntransplant and hoping to get it over with.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n \r\nPhysical Exam:\r\nADMISSION: \r\nVitals: 98.3 142/77 89 16 99 RA\r\nGen: Pleasant, calm, A&Ox3\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.  \r\nNECK: Supple, No LAD\r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No pitting edema but changes consistent with venous \r\nstasis dermatitis and edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3. Known R CN6 palsy since aneurism repair and R \r\npupil with minimal response to light. Otherwise CN intact and \r\nstrength ___ all extremities.\r\nLINES: L port, R CVL\r\n \r\nPertinent Results:\r\nADMISSION: \r\n___ 11:15AM BLOOD WBC-5.0 RBC-2.49* Hgb-8.7* Hct-27.2* \r\nMCV-109* MCH-34.9* MCHC-32.0 RDW-UNABLE TO  RDWSD-UNABLE TO  Plt \r\nCt-67*\r\n___ 11:15AM BLOOD Neuts-74.9* Lymphs-16.9* Monos-6.2 \r\nEos-1.2 Baso-0.4 Im ___ AbsNeut-3.78 AbsLymp-0.85* \r\nAbsMono-0.31 AbsEos-0.06 AbsBaso-0.02\r\n___ 11:15AM BLOOD Hypochr-NORMAL Anisocy-3+ Poiklo-1+ \r\nMacrocy-3+ Microcy-NORMAL Polychr-1+ Ovalocy-1+ Tear \r\nDr-OCCASIONAL\r\n___ 11:15AM BLOOD ___ PTT-30.7 ___\r\n___ 05:15AM BLOOD ___\r\n___ 11:15AM BLOOD UreaN-15 Creat-0.9 Na-140 K-4.0 Cl-105 \r\nHCO3-22 AnGap-17\r\n___ 11:15AM BLOOD ALT-11 AST-16 LD(LDH)-260* AlkPhos-124* \r\nTotBili-0.2 DirBili-<0.2 IndBili-0.2\r\n___ 11:15AM BLOOD TotProt-6.7 Albumin-4.2 Globuln-2.5 \r\nCalcium-8.7 Phos-3.4 Mg-2.2 UricAcd-3.7\r\n\r\nIMAGING: \r\n\r\nCXR ___:\r\nIn comparison with the study of ___, the cardiac silhouette \r\nremains at the upper limits of normal or mildly enlarged.  Mild \r\nindistinctness of pulmonary vessels is consistent with mild \r\nelevation of pulmonary venous pressure.  However, no evidence of \r\nacute focal pneumonia or pleural effusion. There has been \r\ninterval placement of right IJ catheter that extends to the \r\nlower SVC. \r\n\r\nRUQUS ___:\r\n1. Patent hepatic vasculature. \r\n2. Echogenic liver consistent with steatosis. Other forms of \r\nliver disease \r\nincluding steatohepatitis, hepatic fibrosis, or cirrhosis cannot \r\nbe excluded on the basis of this examination. \r\n\r\n \r\nBrief Hospital Course:\r\n___ year old female with CVID, RLE DVT, OSA on CPAP, and hx \r\ncerebral aneurism ___ coil, who follows for follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ now with \r\ntreatment-related MDS ___ 4 cycles of Decitabine(C4 D1 \r\n___, admitted for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\n#Treatment-Related MDS:\r\nPatient with follicular lymphoma transformed to DLBCL ___ \r\nautoSCT in ___ now with rapid progression of pancytopenia, \r\nparticularly anemia. Bone marrow biopsy with dysplasia of all \r\ncell lines with noted cytogenetic abnormalities concerning for \r\ntreatment related MDS. ___ Dacogen x4 cycles with persistent \r\nthrombocytopenia but recovered WBCs. Bone marrow biopsy on \r\n___ shows persistent trilineage\r\ndyspoitic maturation. She underwent MUD Allogeneic transplant \r\nwith Fludarabine/Busulfan/ATG conditioning per protocol. She was \r\ndischarged on acyclovir, fluconazole, and Bactrim as per \r\nprotocol. She was on cyclosporine for immunosuppression as per \r\nprotocol. Levels were checked and the patient was discharged on \r\n50 BID. Weekly CMVs were negative.  \r\n\r\n___: Cr up to 1.3 on ___, baseline 0.7-0.8. Likely from \r\noverdiuresis. Urine studies w/ FeUrea ~40% indicating intrinsic \r\ndisease. Possibly renal injury from elevated cyclosporine \r\nlevels. Cr on discharge was 1.1. \r\n\r\n#CVID: Per ID recommendations, given profession and history, \r\nafter\r\nthe initial conditioning regimen would treat with isoniazid and \r\nB6 for a projected 9-month course to prevent TB reactivation. \r\nThis will be guided by Dr. ___ primary oncologist. \r\nPatient to receive monthly IVIG outpatient. \r\n\r\n#Transaminitis: \r\nThe patient developed a transaminitis into the 300-400s from \r\nnormal after her first infusion of busulfan and ATG. This \r\nresolved without further intervention and remained stable during \r\nher subsequent infusions. RUQUS showed patent hepatic \r\nvasculature and an echogenic liver.\r\n\r\n#Right leg DVT.  Had been on Xarelto 20 mg daily but this has\r\nbeen on hold as platelet count < 75,000. This was resumed with \r\nuptrending ___ and PTT. Given ___ BMI and possibility of \r\ninteraction with cyclosporine/fluconazole, she was switched to \r\nLovenox on discharge. Xa level was ### still pending at \r\ndischarge. Has IVC filter in place.\r\n\r\n#Pulmonary hypertension.  Evaluated by Dr. ___ \r\ncontraindication of proceeding with transplant. She remained \r\nstable from a pulmonary perspective.\r\n\r\n#Low Back Pain: Tapered gabapentin 400 mg BID. Continued \r\nVenlafaxine.  \r\n\r\n#OSA: Continued CPAP\r\n\r\n#Asthma: Continued Albuterol PRN with Duoneb q6H PRN\r\n\r\nTRANSITIONAL ISSUES:\r\n- Patient requires monthly IVIG for her CVID\r\n- Discharged on acyclovir (treatment dose) as well as \r\nfluconazole ppx and Bactrim ppx \r\n- ___ benefit from Valacyclovir instead of acyclovir: unable to \r\nobtain prior auth/medication delivery prior to discharge \r\n- Discuss treatment of latent TB with isoniazid and B6. \r\n- Monitor patient on Lovenox, follow-up Xa levels and adjust as \r\nneeded.\r\n\r\n# CODE: Full (confirmed) \r\n# EMERGENCY CONTACT: ___ (Daughter) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list may be inaccurate and requires \r\nfuther investigation.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n3. Omeprazole 20 mg PO DAILY \r\n4. Venlafaxine 25 mg PO BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Ondansetron 4 mg PO Q8H:PRN nausea \r\n7. FoLIC Acid 3 mg PO DAILY \r\n8. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n9. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n10. Cephalexin 200 mg PO ONCE \r\n11. Gabapentin 600 mg PO BID \r\n12. Loratadine 10 mg PO DAILY cold \r\n13. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14. Senna 8.6 mg PO BID:PRN constipation  \r\n\r\n \r\nDischarge Medications:\r\n1.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\nRX *cyclosporine modified [Neoral] 25 mg 2 capsule(s) by mouth \r\nevery twelve (12) hours Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 50 mg 1 capsule(s) by mouth twice a \r\nday Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 25 mg 2 capsule(s) by mouth twice a \r\nday Disp #*120 Capsule Refills:*0 \r\n2.  Enoxaparin Sodium 90 mg SC Q12H \r\nRX *enoxaparin 100 mg/mL 100 mg SC every twelve (12) hours Disp \r\n#*30 Syringe Refills:*0 \r\n3.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\nRX *lorazepam 0.5 mg ___ TABLETS by mouth Q6H:PRN Disp #*30 \r\nTablet Refills:*0 \r\n4.  Multivitamins 1 TAB PO DAILY \r\nRX *multivitamin  1 tablet(s) by mouth DAILY Disp #*30 Tablet \r\nRefills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n6.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0 \r\n7.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0 \r\n8.  Acyclovir 200 mg PO 5X/D  \r\n9.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth Q24H Disp #*60 \r\nTablet Refills:*0 \r\n10.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth Daily Disp #*30 Tablet \r\nRefills:*0 \r\n11.  Gabapentin 400 mg PO BID \r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0\r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0 \r\n12.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n13.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheeze  \r\n14.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n15.  Loratadine 10 mg PO DAILY cold  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n19.  Senna 8.6 mg PO BID:PRN constipation   \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nSecondary MDS ___ MUD AlloSCT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you during your recent \r\nhospitalization. You were admitted to ___ for a stem cell \r\ntransplant. You underwent the bone marrow transplant and \r\nremained in the hospital while your counts improved. Your counts \r\nare now improved and it is safe for you to be discharged. \r\n\r\nWHEN YOU GO HOME:\r\n- Please continue to take all of your medications as directed\r\n- Please follow-up with the doctors listed below\r\n- ___ monitor for any of the alarm symptoms listed below, \r\ncall your doctor or report to the emergency department \r\nimmediately if you experience any of these\r\n\r\nWe wish you the best!\r\nYour ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-22:3",
      "text": "Physical Exam:\nADMISSION: \nVitals: 98.3 142/77 89 16 99 RA\nGen: Pleasant, calm, A&Ox3\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear. NECK: Supple, No LAD\nCV: Normocardic, regular. Normal S1,S2. No MRG. LUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi. ABD: NABS. Soft, NT, ND. EXT: WWP. No pitting edema but changes consistent with venous \nstasis dermatitis and edema. SKIN: No rashes/lesions, petechiae/purpura ecchymoses. NEURO: A&Ox3. Known R CN6 palsy since aneurism repair and R \npupil with minimal response to light. Otherwise CN intact and \nstrength ___ all extremities. LINES: L port, R CVL\n \nPertinent Results:\nADMISSION: \n___ 11:15AM BLOOD WBC-5.0 RBC-2.49* Hgb-8.7* Hct-27.2* \nMCV-109* MCH-34.9* MCHC-32.0 RDW-UNABLE TO  RDWSD-UNABLE TO  Plt \nCt-67*\n___ 11:15AM BLOOD Neuts-74.9* Lymphs-16.9* Monos-6.2 \nEos-1.2 Baso-0.4 Im ___ AbsNeut-3.78 AbsLymp-0.85* \nAbsMono-0.31 AbsEos-0.06 AbsBaso-0.02\n___ 11:15AM BLOOD Hypochr-NORMAL Anisocy-3+ Poiklo-1+ \nMacrocy-3+ Microcy-NORMAL Polychr-1+ Ovalocy-1+ Tear \nDr-OCCASIONAL\n___ 11:15AM BLOOD ___ PTT-30.7 ___\n___ 05:15AM BLOOD ___\n___ 11:15AM BLOOD UreaN-15 Creat-0.9 Na-140 K-4.0 Cl-105 \nHCO3-22 AnGap-17\n___ 11:15AM BLOOD ALT-11 AST-16 LD(LDH)-260* AlkPhos-124* \nTotBili-0.2 DirBili-<0.2 IndBili-0.2\n___ 11:15AM BLOOD TotProt-6.7 Albumin-4.2 Globuln-2.5 \nCalcium-8.7 Phos-3.4 Mg-2.2 UricAcd-3.7",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-22",
        "chart_time": "104681",
        "section": "General",
        "position": 3,
        "tokenCount": 342,
        "note_metadata": {
          "note_id": "18887130-DS-22",
          "subject_id": 18887130,
          "hadm_id": 20942569,
          "note_type": "DS",
          "note_seq": 22,
          "charttime": 104681,
          "storetime": 104682.30277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nAlloSCT Admission\r\n \r\nMajor Surgical or Invasive Procedure:\r\nTemporary CVL\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with CVID, history of follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ in remission from \r\nlymphoma, but noted for treatment-related MDS ___ 4 cycles of \r\nDecitabine(C4 D1 =\r\n___, now presents for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\nOf note, the patient was discharged ___ after admission for \r\nRSV Bronchiolitis. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis.\r\n\r\nShe also had a tooth extraction on the lower left side on \r\n___ due to persistent tooth pain and completed 1 week of \r\nAmoxicillin.\r\n\r\nOn arrival to the floor the patient is feeling quite well. \r\nMinimal discomfort from her tooth extraction. Otherwise denying \r\ncomplete review of systems. She is ready to go through with \r\ntransplant and hoping to get it over with.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n \r\nPhysical Exam:\r\nADMISSION: \r\nVitals: 98.3 142/77 89 16 99 RA\r\nGen: Pleasant, calm, A&Ox3\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.  \r\nNECK: Supple, No LAD\r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No pitting edema but changes consistent with venous \r\nstasis dermatitis and edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3. Known R CN6 palsy since aneurism repair and R \r\npupil with minimal response to light. Otherwise CN intact and \r\nstrength ___ all extremities.\r\nLINES: L port, R CVL\r\n \r\nPertinent Results:\r\nADMISSION: \r\n___ 11:15AM BLOOD WBC-5.0 RBC-2.49* Hgb-8.7* Hct-27.2* \r\nMCV-109* MCH-34.9* MCHC-32.0 RDW-UNABLE TO  RDWSD-UNABLE TO  Plt \r\nCt-67*\r\n___ 11:15AM BLOOD Neuts-74.9* Lymphs-16.9* Monos-6.2 \r\nEos-1.2 Baso-0.4 Im ___ AbsNeut-3.78 AbsLymp-0.85* \r\nAbsMono-0.31 AbsEos-0.06 AbsBaso-0.02\r\n___ 11:15AM BLOOD Hypochr-NORMAL Anisocy-3+ Poiklo-1+ \r\nMacrocy-3+ Microcy-NORMAL Polychr-1+ Ovalocy-1+ Tear \r\nDr-OCCASIONAL\r\n___ 11:15AM BLOOD ___ PTT-30.7 ___\r\n___ 05:15AM BLOOD ___\r\n___ 11:15AM BLOOD UreaN-15 Creat-0.9 Na-140 K-4.0 Cl-105 \r\nHCO3-22 AnGap-17\r\n___ 11:15AM BLOOD ALT-11 AST-16 LD(LDH)-260* AlkPhos-124* \r\nTotBili-0.2 DirBili-<0.2 IndBili-0.2\r\n___ 11:15AM BLOOD TotProt-6.7 Albumin-4.2 Globuln-2.5 \r\nCalcium-8.7 Phos-3.4 Mg-2.2 UricAcd-3.7\r\n\r\nIMAGING: \r\n\r\nCXR ___:\r\nIn comparison with the study of ___, the cardiac silhouette \r\nremains at the upper limits of normal or mildly enlarged.  Mild \r\nindistinctness of pulmonary vessels is consistent with mild \r\nelevation of pulmonary venous pressure.  However, no evidence of \r\nacute focal pneumonia or pleural effusion. There has been \r\ninterval placement of right IJ catheter that extends to the \r\nlower SVC. \r\n\r\nRUQUS ___:\r\n1. Patent hepatic vasculature. \r\n2. Echogenic liver consistent with steatosis. Other forms of \r\nliver disease \r\nincluding steatohepatitis, hepatic fibrosis, or cirrhosis cannot \r\nbe excluded on the basis of this examination. \r\n\r\n \r\nBrief Hospital Course:\r\n___ year old female with CVID, RLE DVT, OSA on CPAP, and hx \r\ncerebral aneurism ___ coil, who follows for follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ now with \r\ntreatment-related MDS ___ 4 cycles of Decitabine(C4 D1 \r\n___, admitted for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\n#Treatment-Related MDS:\r\nPatient with follicular lymphoma transformed to DLBCL ___ \r\nautoSCT in ___ now with rapid progression of pancytopenia, \r\nparticularly anemia. Bone marrow biopsy with dysplasia of all \r\ncell lines with noted cytogenetic abnormalities concerning for \r\ntreatment related MDS. ___ Dacogen x4 cycles with persistent \r\nthrombocytopenia but recovered WBCs. Bone marrow biopsy on \r\n___ shows persistent trilineage\r\ndyspoitic maturation. She underwent MUD Allogeneic transplant \r\nwith Fludarabine/Busulfan/ATG conditioning per protocol. She was \r\ndischarged on acyclovir, fluconazole, and Bactrim as per \r\nprotocol. She was on cyclosporine for immunosuppression as per \r\nprotocol. Levels were checked and the patient was discharged on \r\n50 BID. Weekly CMVs were negative.  \r\n\r\n___: Cr up to 1.3 on ___, baseline 0.7-0.8. Likely from \r\noverdiuresis. Urine studies w/ FeUrea ~40% indicating intrinsic \r\ndisease. Possibly renal injury from elevated cyclosporine \r\nlevels. Cr on discharge was 1.1. \r\n\r\n#CVID: Per ID recommendations, given profession and history, \r\nafter\r\nthe initial conditioning regimen would treat with isoniazid and \r\nB6 for a projected 9-month course to prevent TB reactivation. \r\nThis will be guided by Dr. ___ primary oncologist. \r\nPatient to receive monthly IVIG outpatient. \r\n\r\n#Transaminitis: \r\nThe patient developed a transaminitis into the 300-400s from \r\nnormal after her first infusion of busulfan and ATG. This \r\nresolved without further intervention and remained stable during \r\nher subsequent infusions. RUQUS showed patent hepatic \r\nvasculature and an echogenic liver.\r\n\r\n#Right leg DVT.  Had been on Xarelto 20 mg daily but this has\r\nbeen on hold as platelet count < 75,000. This was resumed with \r\nuptrending ___ and PTT. Given ___ BMI and possibility of \r\ninteraction with cyclosporine/fluconazole, she was switched to \r\nLovenox on discharge. Xa level was ### still pending at \r\ndischarge. Has IVC filter in place.\r\n\r\n#Pulmonary hypertension.  Evaluated by Dr. ___ \r\ncontraindication of proceeding with transplant. She remained \r\nstable from a pulmonary perspective.\r\n\r\n#Low Back Pain: Tapered gabapentin 400 mg BID. Continued \r\nVenlafaxine.  \r\n\r\n#OSA: Continued CPAP\r\n\r\n#Asthma: Continued Albuterol PRN with Duoneb q6H PRN\r\n\r\nTRANSITIONAL ISSUES:\r\n- Patient requires monthly IVIG for her CVID\r\n- Discharged on acyclovir (treatment dose) as well as \r\nfluconazole ppx and Bactrim ppx \r\n- ___ benefit from Valacyclovir instead of acyclovir: unable to \r\nobtain prior auth/medication delivery prior to discharge \r\n- Discuss treatment of latent TB with isoniazid and B6. \r\n- Monitor patient on Lovenox, follow-up Xa levels and adjust as \r\nneeded.\r\n\r\n# CODE: Full (confirmed) \r\n# EMERGENCY CONTACT: ___ (Daughter) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list may be inaccurate and requires \r\nfuther investigation.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n3. Omeprazole 20 mg PO DAILY \r\n4. Venlafaxine 25 mg PO BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Ondansetron 4 mg PO Q8H:PRN nausea \r\n7. FoLIC Acid 3 mg PO DAILY \r\n8. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n9. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n10. Cephalexin 200 mg PO ONCE \r\n11. Gabapentin 600 mg PO BID \r\n12. Loratadine 10 mg PO DAILY cold \r\n13. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14. Senna 8.6 mg PO BID:PRN constipation  \r\n\r\n \r\nDischarge Medications:\r\n1.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\nRX *cyclosporine modified [Neoral] 25 mg 2 capsule(s) by mouth \r\nevery twelve (12) hours Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 50 mg 1 capsule(s) by mouth twice a \r\nday Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 25 mg 2 capsule(s) by mouth twice a \r\nday Disp #*120 Capsule Refills:*0 \r\n2.  Enoxaparin Sodium 90 mg SC Q12H \r\nRX *enoxaparin 100 mg/mL 100 mg SC every twelve (12) hours Disp \r\n#*30 Syringe Refills:*0 \r\n3.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\nRX *lorazepam 0.5 mg ___ TABLETS by mouth Q6H:PRN Disp #*30 \r\nTablet Refills:*0 \r\n4.  Multivitamins 1 TAB PO DAILY \r\nRX *multivitamin  1 tablet(s) by mouth DAILY Disp #*30 Tablet \r\nRefills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n6.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0 \r\n7.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0 \r\n8.  Acyclovir 200 mg PO 5X/D  \r\n9.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth Q24H Disp #*60 \r\nTablet Refills:*0 \r\n10.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth Daily Disp #*30 Tablet \r\nRefills:*0 \r\n11.  Gabapentin 400 mg PO BID \r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0\r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0 \r\n12.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n13.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheeze  \r\n14.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n15.  Loratadine 10 mg PO DAILY cold  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n19.  Senna 8.6 mg PO BID:PRN constipation   \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nSecondary MDS ___ MUD AlloSCT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you during your recent \r\nhospitalization. You were admitted to ___ for a stem cell \r\ntransplant. You underwent the bone marrow transplant and \r\nremained in the hospital while your counts improved. Your counts \r\nare now improved and it is safe for you to be discharged. \r\n\r\nWHEN YOU GO HOME:\r\n- Please continue to take all of your medications as directed\r\n- Please follow-up with the doctors listed below\r\n- ___ monitor for any of the alarm symptoms listed below, \r\ncall your doctor or report to the emergency department \r\nimmediately if you experience any of these\r\n\r\nWe wish you the best!\r\nYour ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-22:4",
      "text": "IMAGING: CXR ___:\nIn comparison with the study of ___, the cardiac silhouette \nremains at the upper limits of normal or mildly enlarged. Mild \nindistinctness of pulmonary vessels is consistent with mild \nelevation of pulmonary venous pressure. However, no evidence of \nacute focal pneumonia or pleural effusion. There has been \ninterval placement of right IJ catheter that extends to the \nlower SVC. RUQUS ___:\n1. Patent hepatic vasculature. 2. Echogenic liver consistent with steatosis. Other forms of \nliver disease \nincluding steatohepatitis, hepatic fibrosis, or cirrhosis cannot \nbe excluded on the basis of this examination.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-22",
        "chart_time": "104681",
        "section": "General",
        "position": 4,
        "tokenCount": 158,
        "note_metadata": {
          "note_id": "18887130-DS-22",
          "subject_id": 18887130,
          "hadm_id": 20942569,
          "note_type": "DS",
          "note_seq": 22,
          "charttime": 104681,
          "storetime": 104682.30277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nAlloSCT Admission\r\n \r\nMajor Surgical or Invasive Procedure:\r\nTemporary CVL\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with CVID, history of follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ in remission from \r\nlymphoma, but noted for treatment-related MDS ___ 4 cycles of \r\nDecitabine(C4 D1 =\r\n___, now presents for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\nOf note, the patient was discharged ___ after admission for \r\nRSV Bronchiolitis. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis.\r\n\r\nShe also had a tooth extraction on the lower left side on \r\n___ due to persistent tooth pain and completed 1 week of \r\nAmoxicillin.\r\n\r\nOn arrival to the floor the patient is feeling quite well. \r\nMinimal discomfort from her tooth extraction. Otherwise denying \r\ncomplete review of systems. She is ready to go through with \r\ntransplant and hoping to get it over with.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n \r\nPhysical Exam:\r\nADMISSION: \r\nVitals: 98.3 142/77 89 16 99 RA\r\nGen: Pleasant, calm, A&Ox3\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.  \r\nNECK: Supple, No LAD\r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No pitting edema but changes consistent with venous \r\nstasis dermatitis and edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3. Known R CN6 palsy since aneurism repair and R \r\npupil with minimal response to light. Otherwise CN intact and \r\nstrength ___ all extremities.\r\nLINES: L port, R CVL\r\n \r\nPertinent Results:\r\nADMISSION: \r\n___ 11:15AM BLOOD WBC-5.0 RBC-2.49* Hgb-8.7* Hct-27.2* \r\nMCV-109* MCH-34.9* MCHC-32.0 RDW-UNABLE TO  RDWSD-UNABLE TO  Plt \r\nCt-67*\r\n___ 11:15AM BLOOD Neuts-74.9* Lymphs-16.9* Monos-6.2 \r\nEos-1.2 Baso-0.4 Im ___ AbsNeut-3.78 AbsLymp-0.85* \r\nAbsMono-0.31 AbsEos-0.06 AbsBaso-0.02\r\n___ 11:15AM BLOOD Hypochr-NORMAL Anisocy-3+ Poiklo-1+ \r\nMacrocy-3+ Microcy-NORMAL Polychr-1+ Ovalocy-1+ Tear \r\nDr-OCCASIONAL\r\n___ 11:15AM BLOOD ___ PTT-30.7 ___\r\n___ 05:15AM BLOOD ___\r\n___ 11:15AM BLOOD UreaN-15 Creat-0.9 Na-140 K-4.0 Cl-105 \r\nHCO3-22 AnGap-17\r\n___ 11:15AM BLOOD ALT-11 AST-16 LD(LDH)-260* AlkPhos-124* \r\nTotBili-0.2 DirBili-<0.2 IndBili-0.2\r\n___ 11:15AM BLOOD TotProt-6.7 Albumin-4.2 Globuln-2.5 \r\nCalcium-8.7 Phos-3.4 Mg-2.2 UricAcd-3.7\r\n\r\nIMAGING: \r\n\r\nCXR ___:\r\nIn comparison with the study of ___, the cardiac silhouette \r\nremains at the upper limits of normal or mildly enlarged.  Mild \r\nindistinctness of pulmonary vessels is consistent with mild \r\nelevation of pulmonary venous pressure.  However, no evidence of \r\nacute focal pneumonia or pleural effusion. There has been \r\ninterval placement of right IJ catheter that extends to the \r\nlower SVC. \r\n\r\nRUQUS ___:\r\n1. Patent hepatic vasculature. \r\n2. Echogenic liver consistent with steatosis. Other forms of \r\nliver disease \r\nincluding steatohepatitis, hepatic fibrosis, or cirrhosis cannot \r\nbe excluded on the basis of this examination. \r\n\r\n \r\nBrief Hospital Course:\r\n___ year old female with CVID, RLE DVT, OSA on CPAP, and hx \r\ncerebral aneurism ___ coil, who follows for follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ now with \r\ntreatment-related MDS ___ 4 cycles of Decitabine(C4 D1 \r\n___, admitted for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\n#Treatment-Related MDS:\r\nPatient with follicular lymphoma transformed to DLBCL ___ \r\nautoSCT in ___ now with rapid progression of pancytopenia, \r\nparticularly anemia. Bone marrow biopsy with dysplasia of all \r\ncell lines with noted cytogenetic abnormalities concerning for \r\ntreatment related MDS. ___ Dacogen x4 cycles with persistent \r\nthrombocytopenia but recovered WBCs. Bone marrow biopsy on \r\n___ shows persistent trilineage\r\ndyspoitic maturation. She underwent MUD Allogeneic transplant \r\nwith Fludarabine/Busulfan/ATG conditioning per protocol. She was \r\ndischarged on acyclovir, fluconazole, and Bactrim as per \r\nprotocol. She was on cyclosporine for immunosuppression as per \r\nprotocol. Levels were checked and the patient was discharged on \r\n50 BID. Weekly CMVs were negative.  \r\n\r\n___: Cr up to 1.3 on ___, baseline 0.7-0.8. Likely from \r\noverdiuresis. Urine studies w/ FeUrea ~40% indicating intrinsic \r\ndisease. Possibly renal injury from elevated cyclosporine \r\nlevels. Cr on discharge was 1.1. \r\n\r\n#CVID: Per ID recommendations, given profession and history, \r\nafter\r\nthe initial conditioning regimen would treat with isoniazid and \r\nB6 for a projected 9-month course to prevent TB reactivation. \r\nThis will be guided by Dr. ___ primary oncologist. \r\nPatient to receive monthly IVIG outpatient. \r\n\r\n#Transaminitis: \r\nThe patient developed a transaminitis into the 300-400s from \r\nnormal after her first infusion of busulfan and ATG. This \r\nresolved without further intervention and remained stable during \r\nher subsequent infusions. RUQUS showed patent hepatic \r\nvasculature and an echogenic liver.\r\n\r\n#Right leg DVT.  Had been on Xarelto 20 mg daily but this has\r\nbeen on hold as platelet count < 75,000. This was resumed with \r\nuptrending ___ and PTT. Given ___ BMI and possibility of \r\ninteraction with cyclosporine/fluconazole, she was switched to \r\nLovenox on discharge. Xa level was ### still pending at \r\ndischarge. Has IVC filter in place.\r\n\r\n#Pulmonary hypertension.  Evaluated by Dr. ___ \r\ncontraindication of proceeding with transplant. She remained \r\nstable from a pulmonary perspective.\r\n\r\n#Low Back Pain: Tapered gabapentin 400 mg BID. Continued \r\nVenlafaxine.  \r\n\r\n#OSA: Continued CPAP\r\n\r\n#Asthma: Continued Albuterol PRN with Duoneb q6H PRN\r\n\r\nTRANSITIONAL ISSUES:\r\n- Patient requires monthly IVIG for her CVID\r\n- Discharged on acyclovir (treatment dose) as well as \r\nfluconazole ppx and Bactrim ppx \r\n- ___ benefit from Valacyclovir instead of acyclovir: unable to \r\nobtain prior auth/medication delivery prior to discharge \r\n- Discuss treatment of latent TB with isoniazid and B6. \r\n- Monitor patient on Lovenox, follow-up Xa levels and adjust as \r\nneeded.\r\n\r\n# CODE: Full (confirmed) \r\n# EMERGENCY CONTACT: ___ (Daughter) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list may be inaccurate and requires \r\nfuther investigation.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n3. Omeprazole 20 mg PO DAILY \r\n4. Venlafaxine 25 mg PO BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Ondansetron 4 mg PO Q8H:PRN nausea \r\n7. FoLIC Acid 3 mg PO DAILY \r\n8. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n9. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n10. Cephalexin 200 mg PO ONCE \r\n11. Gabapentin 600 mg PO BID \r\n12. Loratadine 10 mg PO DAILY cold \r\n13. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14. Senna 8.6 mg PO BID:PRN constipation  \r\n\r\n \r\nDischarge Medications:\r\n1.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\nRX *cyclosporine modified [Neoral] 25 mg 2 capsule(s) by mouth \r\nevery twelve (12) hours Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 50 mg 1 capsule(s) by mouth twice a \r\nday Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 25 mg 2 capsule(s) by mouth twice a \r\nday Disp #*120 Capsule Refills:*0 \r\n2.  Enoxaparin Sodium 90 mg SC Q12H \r\nRX *enoxaparin 100 mg/mL 100 mg SC every twelve (12) hours Disp \r\n#*30 Syringe Refills:*0 \r\n3.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\nRX *lorazepam 0.5 mg ___ TABLETS by mouth Q6H:PRN Disp #*30 \r\nTablet Refills:*0 \r\n4.  Multivitamins 1 TAB PO DAILY \r\nRX *multivitamin  1 tablet(s) by mouth DAILY Disp #*30 Tablet \r\nRefills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n6.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0 \r\n7.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0 \r\n8.  Acyclovir 200 mg PO 5X/D  \r\n9.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth Q24H Disp #*60 \r\nTablet Refills:*0 \r\n10.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth Daily Disp #*30 Tablet \r\nRefills:*0 \r\n11.  Gabapentin 400 mg PO BID \r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0\r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0 \r\n12.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n13.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheeze  \r\n14.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n15.  Loratadine 10 mg PO DAILY cold  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n19.  Senna 8.6 mg PO BID:PRN constipation   \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nSecondary MDS ___ MUD AlloSCT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you during your recent \r\nhospitalization. You were admitted to ___ for a stem cell \r\ntransplant. You underwent the bone marrow transplant and \r\nremained in the hospital while your counts improved. Your counts \r\nare now improved and it is safe for you to be discharged. \r\n\r\nWHEN YOU GO HOME:\r\n- Please continue to take all of your medications as directed\r\n- Please follow-up with the doctors listed below\r\n- ___ monitor for any of the alarm symptoms listed below, \r\ncall your doctor or report to the emergency department \r\nimmediately if you experience any of these\r\n\r\nWe wish you the best!\r\nYour ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-22:5",
      "text": "Brief Hospital Course:\n___ year old female with CVID, RLE DVT, OSA on CPAP, and hx \ncerebral aneurism ___ coil, who follows for follicular lymphoma \ntransformed to DLBCL ___ autoSCT in ___ now with \ntreatment-related MDS ___ 4 cycles of Decitabine(C4 D1 \n___, admitted for MUD AlloSCT w/ \nFludarabine/Busulfan/ATG conditioning. #Treatment-Related MDS:\nPatient with follicular lymphoma transformed to DLBCL ___ \nautoSCT in ___ now with rapid progression of pancytopenia, \nparticularly anemia. Bone marrow biopsy with dysplasia of all \ncell lines with noted cytogenetic abnormalities concerning for \ntreatment related MDS. ___ Dacogen x4 cycles with persistent \nthrombocytopenia but recovered WBCs. Bone marrow biopsy on \n___ shows persistent trilineage\ndyspoitic maturation. She underwent MUD Allogeneic transplant \nwith Fludarabine/Busulfan/ATG conditioning per protocol. She was \ndischarged on acyclovir, fluconazole, and Bactrim as per \nprotocol. She was on cyclosporine for immunosuppression as per \nprotocol. Levels were checked and the patient was discharged on \n50 BID. Weekly CMVs were negative. ___: Cr up to 1.3 on ___, baseline 0.7-0.8. Likely from \noverdiuresis. Urine studies w/ FeUrea ~40% indicating intrinsic \ndisease. Possibly renal injury from elevated cyclosporine \nlevels. Cr on discharge was 1.1. #CVID: Per ID recommendations, given profession and history, \nafter\nthe initial conditioning regimen would treat with isoniazid and \nB6 for a projected 9-month course to prevent TB reactivation. This will be guided by Dr. ___ primary oncologist. Patient to receive monthly IVIG outpatient. #Transaminitis: \nThe patient developed a transaminitis into the 300-400s from \nnormal after her first infusion of busulfan and ATG. This \nresolved without further intervention and remained stable during \nher subsequent infusions. RUQUS showed patent hepatic \nvasculature and an echogenic liver. #Right leg DVT. Had been on Xarelto 20 mg daily but this has\nbeen on hold as platelet count < 75,000. This was resumed with \nuptrending ___ and PTT. Given ___ BMI and possibility of \ninteraction with cyclosporine/fluconazole, she was switched to \nLovenox on discharge. Xa level was ### still pending at \ndischarge. Has IVC filter in place. #Pulmonary hypertension. Evaluated by Dr. ___ \ncontraindication of proceeding with transplant. She remained \nstable from a pulmonary perspective. #Low Back Pain: Tapered gabapentin 400 mg BID. Continued \nVenlafaxine. #OSA: Continued CPAP #Asthma: Continued Albuterol PRN with Duoneb q6H PRN",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-22",
        "chart_time": "104681",
        "section": "General",
        "position": 5,
        "tokenCount": 633,
        "note_metadata": {
          "note_id": "18887130-DS-22",
          "subject_id": 18887130,
          "hadm_id": 20942569,
          "note_type": "DS",
          "note_seq": 22,
          "charttime": 104681,
          "storetime": 104682.30277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nAlloSCT Admission\r\n \r\nMajor Surgical or Invasive Procedure:\r\nTemporary CVL\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with CVID, history of follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ in remission from \r\nlymphoma, but noted for treatment-related MDS ___ 4 cycles of \r\nDecitabine(C4 D1 =\r\n___, now presents for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\nOf note, the patient was discharged ___ after admission for \r\nRSV Bronchiolitis. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis.\r\n\r\nShe also had a tooth extraction on the lower left side on \r\n___ due to persistent tooth pain and completed 1 week of \r\nAmoxicillin.\r\n\r\nOn arrival to the floor the patient is feeling quite well. \r\nMinimal discomfort from her tooth extraction. Otherwise denying \r\ncomplete review of systems. She is ready to go through with \r\ntransplant and hoping to get it over with.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n \r\nPhysical Exam:\r\nADMISSION: \r\nVitals: 98.3 142/77 89 16 99 RA\r\nGen: Pleasant, calm, A&Ox3\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.  \r\nNECK: Supple, No LAD\r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No pitting edema but changes consistent with venous \r\nstasis dermatitis and edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3. Known R CN6 palsy since aneurism repair and R \r\npupil with minimal response to light. Otherwise CN intact and \r\nstrength ___ all extremities.\r\nLINES: L port, R CVL\r\n \r\nPertinent Results:\r\nADMISSION: \r\n___ 11:15AM BLOOD WBC-5.0 RBC-2.49* Hgb-8.7* Hct-27.2* \r\nMCV-109* MCH-34.9* MCHC-32.0 RDW-UNABLE TO  RDWSD-UNABLE TO  Plt \r\nCt-67*\r\n___ 11:15AM BLOOD Neuts-74.9* Lymphs-16.9* Monos-6.2 \r\nEos-1.2 Baso-0.4 Im ___ AbsNeut-3.78 AbsLymp-0.85* \r\nAbsMono-0.31 AbsEos-0.06 AbsBaso-0.02\r\n___ 11:15AM BLOOD Hypochr-NORMAL Anisocy-3+ Poiklo-1+ \r\nMacrocy-3+ Microcy-NORMAL Polychr-1+ Ovalocy-1+ Tear \r\nDr-OCCASIONAL\r\n___ 11:15AM BLOOD ___ PTT-30.7 ___\r\n___ 05:15AM BLOOD ___\r\n___ 11:15AM BLOOD UreaN-15 Creat-0.9 Na-140 K-4.0 Cl-105 \r\nHCO3-22 AnGap-17\r\n___ 11:15AM BLOOD ALT-11 AST-16 LD(LDH)-260* AlkPhos-124* \r\nTotBili-0.2 DirBili-<0.2 IndBili-0.2\r\n___ 11:15AM BLOOD TotProt-6.7 Albumin-4.2 Globuln-2.5 \r\nCalcium-8.7 Phos-3.4 Mg-2.2 UricAcd-3.7\r\n\r\nIMAGING: \r\n\r\nCXR ___:\r\nIn comparison with the study of ___, the cardiac silhouette \r\nremains at the upper limits of normal or mildly enlarged.  Mild \r\nindistinctness of pulmonary vessels is consistent with mild \r\nelevation of pulmonary venous pressure.  However, no evidence of \r\nacute focal pneumonia or pleural effusion. There has been \r\ninterval placement of right IJ catheter that extends to the \r\nlower SVC. \r\n\r\nRUQUS ___:\r\n1. Patent hepatic vasculature. \r\n2. Echogenic liver consistent with steatosis. Other forms of \r\nliver disease \r\nincluding steatohepatitis, hepatic fibrosis, or cirrhosis cannot \r\nbe excluded on the basis of this examination. \r\n\r\n \r\nBrief Hospital Course:\r\n___ year old female with CVID, RLE DVT, OSA on CPAP, and hx \r\ncerebral aneurism ___ coil, who follows for follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ now with \r\ntreatment-related MDS ___ 4 cycles of Decitabine(C4 D1 \r\n___, admitted for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\n#Treatment-Related MDS:\r\nPatient with follicular lymphoma transformed to DLBCL ___ \r\nautoSCT in ___ now with rapid progression of pancytopenia, \r\nparticularly anemia. Bone marrow biopsy with dysplasia of all \r\ncell lines with noted cytogenetic abnormalities concerning for \r\ntreatment related MDS. ___ Dacogen x4 cycles with persistent \r\nthrombocytopenia but recovered WBCs. Bone marrow biopsy on \r\n___ shows persistent trilineage\r\ndyspoitic maturation. She underwent MUD Allogeneic transplant \r\nwith Fludarabine/Busulfan/ATG conditioning per protocol. She was \r\ndischarged on acyclovir, fluconazole, and Bactrim as per \r\nprotocol. She was on cyclosporine for immunosuppression as per \r\nprotocol. Levels were checked and the patient was discharged on \r\n50 BID. Weekly CMVs were negative.  \r\n\r\n___: Cr up to 1.3 on ___, baseline 0.7-0.8. Likely from \r\noverdiuresis. Urine studies w/ FeUrea ~40% indicating intrinsic \r\ndisease. Possibly renal injury from elevated cyclosporine \r\nlevels. Cr on discharge was 1.1. \r\n\r\n#CVID: Per ID recommendations, given profession and history, \r\nafter\r\nthe initial conditioning regimen would treat with isoniazid and \r\nB6 for a projected 9-month course to prevent TB reactivation. \r\nThis will be guided by Dr. ___ primary oncologist. \r\nPatient to receive monthly IVIG outpatient. \r\n\r\n#Transaminitis: \r\nThe patient developed a transaminitis into the 300-400s from \r\nnormal after her first infusion of busulfan and ATG. This \r\nresolved without further intervention and remained stable during \r\nher subsequent infusions. RUQUS showed patent hepatic \r\nvasculature and an echogenic liver.\r\n\r\n#Right leg DVT.  Had been on Xarelto 20 mg daily but this has\r\nbeen on hold as platelet count < 75,000. This was resumed with \r\nuptrending ___ and PTT. Given ___ BMI and possibility of \r\ninteraction with cyclosporine/fluconazole, she was switched to \r\nLovenox on discharge. Xa level was ### still pending at \r\ndischarge. Has IVC filter in place.\r\n\r\n#Pulmonary hypertension.  Evaluated by Dr. ___ \r\ncontraindication of proceeding with transplant. She remained \r\nstable from a pulmonary perspective.\r\n\r\n#Low Back Pain: Tapered gabapentin 400 mg BID. Continued \r\nVenlafaxine.  \r\n\r\n#OSA: Continued CPAP\r\n\r\n#Asthma: Continued Albuterol PRN with Duoneb q6H PRN\r\n\r\nTRANSITIONAL ISSUES:\r\n- Patient requires monthly IVIG for her CVID\r\n- Discharged on acyclovir (treatment dose) as well as \r\nfluconazole ppx and Bactrim ppx \r\n- ___ benefit from Valacyclovir instead of acyclovir: unable to \r\nobtain prior auth/medication delivery prior to discharge \r\n- Discuss treatment of latent TB with isoniazid and B6. \r\n- Monitor patient on Lovenox, follow-up Xa levels and adjust as \r\nneeded.\r\n\r\n# CODE: Full (confirmed) \r\n# EMERGENCY CONTACT: ___ (Daughter) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list may be inaccurate and requires \r\nfuther investigation.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n3. Omeprazole 20 mg PO DAILY \r\n4. Venlafaxine 25 mg PO BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Ondansetron 4 mg PO Q8H:PRN nausea \r\n7. FoLIC Acid 3 mg PO DAILY \r\n8. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n9. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n10. Cephalexin 200 mg PO ONCE \r\n11. Gabapentin 600 mg PO BID \r\n12. Loratadine 10 mg PO DAILY cold \r\n13. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14. Senna 8.6 mg PO BID:PRN constipation  \r\n\r\n \r\nDischarge Medications:\r\n1.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\nRX *cyclosporine modified [Neoral] 25 mg 2 capsule(s) by mouth \r\nevery twelve (12) hours Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 50 mg 1 capsule(s) by mouth twice a \r\nday Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 25 mg 2 capsule(s) by mouth twice a \r\nday Disp #*120 Capsule Refills:*0 \r\n2.  Enoxaparin Sodium 90 mg SC Q12H \r\nRX *enoxaparin 100 mg/mL 100 mg SC every twelve (12) hours Disp \r\n#*30 Syringe Refills:*0 \r\n3.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\nRX *lorazepam 0.5 mg ___ TABLETS by mouth Q6H:PRN Disp #*30 \r\nTablet Refills:*0 \r\n4.  Multivitamins 1 TAB PO DAILY \r\nRX *multivitamin  1 tablet(s) by mouth DAILY Disp #*30 Tablet \r\nRefills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n6.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0 \r\n7.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0 \r\n8.  Acyclovir 200 mg PO 5X/D  \r\n9.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth Q24H Disp #*60 \r\nTablet Refills:*0 \r\n10.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth Daily Disp #*30 Tablet \r\nRefills:*0 \r\n11.  Gabapentin 400 mg PO BID \r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0\r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0 \r\n12.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n13.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheeze  \r\n14.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n15.  Loratadine 10 mg PO DAILY cold  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n19.  Senna 8.6 mg PO BID:PRN constipation   \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nSecondary MDS ___ MUD AlloSCT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you during your recent \r\nhospitalization. You were admitted to ___ for a stem cell \r\ntransplant. You underwent the bone marrow transplant and \r\nremained in the hospital while your counts improved. Your counts \r\nare now improved and it is safe for you to be discharged. \r\n\r\nWHEN YOU GO HOME:\r\n- Please continue to take all of your medications as directed\r\n- Please follow-up with the doctors listed below\r\n- ___ monitor for any of the alarm symptoms listed below, \r\ncall your doctor or report to the emergency department \r\nimmediately if you experience any of these\r\n\r\nWe wish you the best!\r\nYour ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-22:6",
      "text": "This was resumed with \nuptrending ___ and PTT. Given ___ BMI and possibility of \ninteraction with cyclosporine/fluconazole, she was switched to \nLovenox on discharge. Xa level was ### still pending at \ndischarge. Has IVC filter in place. #Pulmonary hypertension. Evaluated by Dr. ___ \ncontraindication of proceeding with transplant. She remained \nstable from a pulmonary perspective. #Low Back Pain: Tapered gabapentin 400 mg BID. Continued \nVenlafaxine. #OSA: Continued CPAP #Asthma: Continued Albuterol PRN with Duoneb q6H PRN TRANSITIONAL ISSUES:\n- Patient requires monthly IVIG for her CVID\n- Discharged on acyclovir (treatment dose) as well as \nfluconazole ppx and Bactrim ppx \n- ___ benefit from Valacyclovir instead of acyclovir: unable to \nobtain prior auth/medication delivery prior to discharge \n- Discuss treatment of latent TB with isoniazid and B6. - Monitor patient on Lovenox, follow-up Xa levels and adjust as \nneeded. # CODE: Full (confirmed) \n# EMERGENCY CONTACT: ___ (Daughter) ___\n \nMedications on Admission:\nThe Preadmission Medication list may be inaccurate and requires \nfuther investigation. 1. Acyclovir 400 mg PO Q8H \n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \n3. Omeprazole 20 mg PO DAILY \n4. Venlafaxine 25 mg PO BID \n5. Fluconazole 200 mg PO Q24H \n6. Ondansetron 4 mg PO Q8H:PRN nausea \n7. FoLIC Acid 3 mg PO DAILY \n8. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \n9. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \n10. Cephalexin 200 mg PO ONCE \n11. Gabapentin 600 mg PO BID \n12. Loratadine 10 mg PO DAILY cold \n13. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \n14. Senna 8.6 mg PO BID:PRN constipation",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-22",
        "chart_time": "104681",
        "section": "General",
        "position": 6,
        "tokenCount": 418,
        "note_metadata": {
          "note_id": "18887130-DS-22",
          "subject_id": 18887130,
          "hadm_id": 20942569,
          "note_type": "DS",
          "note_seq": 22,
          "charttime": 104681,
          "storetime": 104682.30277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nAlloSCT Admission\r\n \r\nMajor Surgical or Invasive Procedure:\r\nTemporary CVL\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with CVID, history of follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ in remission from \r\nlymphoma, but noted for treatment-related MDS ___ 4 cycles of \r\nDecitabine(C4 D1 =\r\n___, now presents for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\nOf note, the patient was discharged ___ after admission for \r\nRSV Bronchiolitis. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis.\r\n\r\nShe also had a tooth extraction on the lower left side on \r\n___ due to persistent tooth pain and completed 1 week of \r\nAmoxicillin.\r\n\r\nOn arrival to the floor the patient is feeling quite well. \r\nMinimal discomfort from her tooth extraction. Otherwise denying \r\ncomplete review of systems. She is ready to go through with \r\ntransplant and hoping to get it over with.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n \r\nPhysical Exam:\r\nADMISSION: \r\nVitals: 98.3 142/77 89 16 99 RA\r\nGen: Pleasant, calm, A&Ox3\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.  \r\nNECK: Supple, No LAD\r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No pitting edema but changes consistent with venous \r\nstasis dermatitis and edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3. Known R CN6 palsy since aneurism repair and R \r\npupil with minimal response to light. Otherwise CN intact and \r\nstrength ___ all extremities.\r\nLINES: L port, R CVL\r\n \r\nPertinent Results:\r\nADMISSION: \r\n___ 11:15AM BLOOD WBC-5.0 RBC-2.49* Hgb-8.7* Hct-27.2* \r\nMCV-109* MCH-34.9* MCHC-32.0 RDW-UNABLE TO  RDWSD-UNABLE TO  Plt \r\nCt-67*\r\n___ 11:15AM BLOOD Neuts-74.9* Lymphs-16.9* Monos-6.2 \r\nEos-1.2 Baso-0.4 Im ___ AbsNeut-3.78 AbsLymp-0.85* \r\nAbsMono-0.31 AbsEos-0.06 AbsBaso-0.02\r\n___ 11:15AM BLOOD Hypochr-NORMAL Anisocy-3+ Poiklo-1+ \r\nMacrocy-3+ Microcy-NORMAL Polychr-1+ Ovalocy-1+ Tear \r\nDr-OCCASIONAL\r\n___ 11:15AM BLOOD ___ PTT-30.7 ___\r\n___ 05:15AM BLOOD ___\r\n___ 11:15AM BLOOD UreaN-15 Creat-0.9 Na-140 K-4.0 Cl-105 \r\nHCO3-22 AnGap-17\r\n___ 11:15AM BLOOD ALT-11 AST-16 LD(LDH)-260* AlkPhos-124* \r\nTotBili-0.2 DirBili-<0.2 IndBili-0.2\r\n___ 11:15AM BLOOD TotProt-6.7 Albumin-4.2 Globuln-2.5 \r\nCalcium-8.7 Phos-3.4 Mg-2.2 UricAcd-3.7\r\n\r\nIMAGING: \r\n\r\nCXR ___:\r\nIn comparison with the study of ___, the cardiac silhouette \r\nremains at the upper limits of normal or mildly enlarged.  Mild \r\nindistinctness of pulmonary vessels is consistent with mild \r\nelevation of pulmonary venous pressure.  However, no evidence of \r\nacute focal pneumonia or pleural effusion. There has been \r\ninterval placement of right IJ catheter that extends to the \r\nlower SVC. \r\n\r\nRUQUS ___:\r\n1. Patent hepatic vasculature. \r\n2. Echogenic liver consistent with steatosis. Other forms of \r\nliver disease \r\nincluding steatohepatitis, hepatic fibrosis, or cirrhosis cannot \r\nbe excluded on the basis of this examination. \r\n\r\n \r\nBrief Hospital Course:\r\n___ year old female with CVID, RLE DVT, OSA on CPAP, and hx \r\ncerebral aneurism ___ coil, who follows for follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ now with \r\ntreatment-related MDS ___ 4 cycles of Decitabine(C4 D1 \r\n___, admitted for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\n#Treatment-Related MDS:\r\nPatient with follicular lymphoma transformed to DLBCL ___ \r\nautoSCT in ___ now with rapid progression of pancytopenia, \r\nparticularly anemia. Bone marrow biopsy with dysplasia of all \r\ncell lines with noted cytogenetic abnormalities concerning for \r\ntreatment related MDS. ___ Dacogen x4 cycles with persistent \r\nthrombocytopenia but recovered WBCs. Bone marrow biopsy on \r\n___ shows persistent trilineage\r\ndyspoitic maturation. She underwent MUD Allogeneic transplant \r\nwith Fludarabine/Busulfan/ATG conditioning per protocol. She was \r\ndischarged on acyclovir, fluconazole, and Bactrim as per \r\nprotocol. She was on cyclosporine for immunosuppression as per \r\nprotocol. Levels were checked and the patient was discharged on \r\n50 BID. Weekly CMVs were negative.  \r\n\r\n___: Cr up to 1.3 on ___, baseline 0.7-0.8. Likely from \r\noverdiuresis. Urine studies w/ FeUrea ~40% indicating intrinsic \r\ndisease. Possibly renal injury from elevated cyclosporine \r\nlevels. Cr on discharge was 1.1. \r\n\r\n#CVID: Per ID recommendations, given profession and history, \r\nafter\r\nthe initial conditioning regimen would treat with isoniazid and \r\nB6 for a projected 9-month course to prevent TB reactivation. \r\nThis will be guided by Dr. ___ primary oncologist. \r\nPatient to receive monthly IVIG outpatient. \r\n\r\n#Transaminitis: \r\nThe patient developed a transaminitis into the 300-400s from \r\nnormal after her first infusion of busulfan and ATG. This \r\nresolved without further intervention and remained stable during \r\nher subsequent infusions. RUQUS showed patent hepatic \r\nvasculature and an echogenic liver.\r\n\r\n#Right leg DVT.  Had been on Xarelto 20 mg daily but this has\r\nbeen on hold as platelet count < 75,000. This was resumed with \r\nuptrending ___ and PTT. Given ___ BMI and possibility of \r\ninteraction with cyclosporine/fluconazole, she was switched to \r\nLovenox on discharge. Xa level was ### still pending at \r\ndischarge. Has IVC filter in place.\r\n\r\n#Pulmonary hypertension.  Evaluated by Dr. ___ \r\ncontraindication of proceeding with transplant. She remained \r\nstable from a pulmonary perspective.\r\n\r\n#Low Back Pain: Tapered gabapentin 400 mg BID. Continued \r\nVenlafaxine.  \r\n\r\n#OSA: Continued CPAP\r\n\r\n#Asthma: Continued Albuterol PRN with Duoneb q6H PRN\r\n\r\nTRANSITIONAL ISSUES:\r\n- Patient requires monthly IVIG for her CVID\r\n- Discharged on acyclovir (treatment dose) as well as \r\nfluconazole ppx and Bactrim ppx \r\n- ___ benefit from Valacyclovir instead of acyclovir: unable to \r\nobtain prior auth/medication delivery prior to discharge \r\n- Discuss treatment of latent TB with isoniazid and B6. \r\n- Monitor patient on Lovenox, follow-up Xa levels and adjust as \r\nneeded.\r\n\r\n# CODE: Full (confirmed) \r\n# EMERGENCY CONTACT: ___ (Daughter) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list may be inaccurate and requires \r\nfuther investigation.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n3. Omeprazole 20 mg PO DAILY \r\n4. Venlafaxine 25 mg PO BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Ondansetron 4 mg PO Q8H:PRN nausea \r\n7. FoLIC Acid 3 mg PO DAILY \r\n8. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n9. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n10. Cephalexin 200 mg PO ONCE \r\n11. Gabapentin 600 mg PO BID \r\n12. Loratadine 10 mg PO DAILY cold \r\n13. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14. Senna 8.6 mg PO BID:PRN constipation  \r\n\r\n \r\nDischarge Medications:\r\n1.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\nRX *cyclosporine modified [Neoral] 25 mg 2 capsule(s) by mouth \r\nevery twelve (12) hours Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 50 mg 1 capsule(s) by mouth twice a \r\nday Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 25 mg 2 capsule(s) by mouth twice a \r\nday Disp #*120 Capsule Refills:*0 \r\n2.  Enoxaparin Sodium 90 mg SC Q12H \r\nRX *enoxaparin 100 mg/mL 100 mg SC every twelve (12) hours Disp \r\n#*30 Syringe Refills:*0 \r\n3.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\nRX *lorazepam 0.5 mg ___ TABLETS by mouth Q6H:PRN Disp #*30 \r\nTablet Refills:*0 \r\n4.  Multivitamins 1 TAB PO DAILY \r\nRX *multivitamin  1 tablet(s) by mouth DAILY Disp #*30 Tablet \r\nRefills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n6.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0 \r\n7.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0 \r\n8.  Acyclovir 200 mg PO 5X/D  \r\n9.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth Q24H Disp #*60 \r\nTablet Refills:*0 \r\n10.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth Daily Disp #*30 Tablet \r\nRefills:*0 \r\n11.  Gabapentin 400 mg PO BID \r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0\r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0 \r\n12.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n13.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheeze  \r\n14.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n15.  Loratadine 10 mg PO DAILY cold  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n19.  Senna 8.6 mg PO BID:PRN constipation   \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nSecondary MDS ___ MUD AlloSCT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you during your recent \r\nhospitalization. You were admitted to ___ for a stem cell \r\ntransplant. You underwent the bone marrow transplant and \r\nremained in the hospital while your counts improved. Your counts \r\nare now improved and it is safe for you to be discharged. \r\n\r\nWHEN YOU GO HOME:\r\n- Please continue to take all of your medications as directed\r\n- Please follow-up with the doctors listed below\r\n- ___ monitor for any of the alarm symptoms listed below, \r\ncall your doctor or report to the emergency department \r\nimmediately if you experience any of these\r\n\r\nWe wish you the best!\r\nYour ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-22:7",
      "text": "Discharge Medications:\n1. CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \nRX *cyclosporine modified [Neoral] 25 mg 2 capsule(s) by mouth \nevery twelve (12) hours Disp #*60 Capsule Refills:*0\nRX *cyclosporine modified 50 mg 1 capsule(s) by mouth twice a \nday Disp #*60 Capsule Refills:*0\nRX *cyclosporine modified 25 mg 2 capsule(s) by mouth twice a \nday Disp #*120 Capsule Refills:*0 \n2. Enoxaparin Sodium 90 mg SC Q12H \nRX *enoxaparin 100 mg/mL 100 mg SC every twelve (12) hours Disp \n#*30 Syringe Refills:*0 \n3. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \nnot relieved by ondansetron \nRX *lorazepam 0.5 mg ___ TABLETS by mouth Q6H:PRN Disp #*30 \nTablet Refills:*0 \n4. Multivitamins 1 TAB PO DAILY \nRX *multivitamin  1 tablet(s) by mouth DAILY Disp #*30 Tablet \nRefills:*0 \n5. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \n6. Ursodiol 300 mg PO QAM \nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \nRefills:*0\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \nRefills:*0 \n7. Ursodiol 600 mg PO QPM \nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \nRefills:*0\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \nRefills:*0 \n8. Acyclovir 200 mg PO 5X/D  \n9. Fluconazole 400 mg PO Q24H \nRX *fluconazole 200 mg 2 tablet(s) by mouth Q24H Disp #*60 \nTablet Refills:*0 \n10. FoLIC Acid 1 mg PO DAILY \nRX *folic acid 1 mg 1 tablet(s) by mouth Daily Disp #*30 Tablet \nRefills:*0 \n11. Gabapentin 400 mg PO BID \nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \n#*60 Capsule Refills:*0\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \n#*60 Capsule Refills:*0 \n12. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \n13. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \ncough/wheeze  \n14. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \n15. Loratadine 10 mg PO DAILY cold  \n16. Omeprazole 20 mg PO DAILY  \n17. Ondansetron 4 mg PO Q8H:PRN nausea  \n18. Polyethylene Glycol 17 g PO DAILY:PRN constipation   \n19. Senna 8.6 mg PO BID:PRN constipation   \n20. Venlafaxine 25 mg PO BID Discharge Disposition:\nHome Discharge Diagnosis:\nSecondary MDS ___ MUD AlloSCT Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-22",
        "chart_time": "104681",
        "section": "General",
        "position": 7,
        "tokenCount": 601,
        "note_metadata": {
          "note_id": "18887130-DS-22",
          "subject_id": 18887130,
          "hadm_id": 20942569,
          "note_type": "DS",
          "note_seq": 22,
          "charttime": 104681,
          "storetime": 104682.30277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nAlloSCT Admission\r\n \r\nMajor Surgical or Invasive Procedure:\r\nTemporary CVL\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with CVID, history of follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ in remission from \r\nlymphoma, but noted for treatment-related MDS ___ 4 cycles of \r\nDecitabine(C4 D1 =\r\n___, now presents for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\nOf note, the patient was discharged ___ after admission for \r\nRSV Bronchiolitis. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis.\r\n\r\nShe also had a tooth extraction on the lower left side on \r\n___ due to persistent tooth pain and completed 1 week of \r\nAmoxicillin.\r\n\r\nOn arrival to the floor the patient is feeling quite well. \r\nMinimal discomfort from her tooth extraction. Otherwise denying \r\ncomplete review of systems. She is ready to go through with \r\ntransplant and hoping to get it over with.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n \r\nPhysical Exam:\r\nADMISSION: \r\nVitals: 98.3 142/77 89 16 99 RA\r\nGen: Pleasant, calm, A&Ox3\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.  \r\nNECK: Supple, No LAD\r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No pitting edema but changes consistent with venous \r\nstasis dermatitis and edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3. Known R CN6 palsy since aneurism repair and R \r\npupil with minimal response to light. Otherwise CN intact and \r\nstrength ___ all extremities.\r\nLINES: L port, R CVL\r\n \r\nPertinent Results:\r\nADMISSION: \r\n___ 11:15AM BLOOD WBC-5.0 RBC-2.49* Hgb-8.7* Hct-27.2* \r\nMCV-109* MCH-34.9* MCHC-32.0 RDW-UNABLE TO  RDWSD-UNABLE TO  Plt \r\nCt-67*\r\n___ 11:15AM BLOOD Neuts-74.9* Lymphs-16.9* Monos-6.2 \r\nEos-1.2 Baso-0.4 Im ___ AbsNeut-3.78 AbsLymp-0.85* \r\nAbsMono-0.31 AbsEos-0.06 AbsBaso-0.02\r\n___ 11:15AM BLOOD Hypochr-NORMAL Anisocy-3+ Poiklo-1+ \r\nMacrocy-3+ Microcy-NORMAL Polychr-1+ Ovalocy-1+ Tear \r\nDr-OCCASIONAL\r\n___ 11:15AM BLOOD ___ PTT-30.7 ___\r\n___ 05:15AM BLOOD ___\r\n___ 11:15AM BLOOD UreaN-15 Creat-0.9 Na-140 K-4.0 Cl-105 \r\nHCO3-22 AnGap-17\r\n___ 11:15AM BLOOD ALT-11 AST-16 LD(LDH)-260* AlkPhos-124* \r\nTotBili-0.2 DirBili-<0.2 IndBili-0.2\r\n___ 11:15AM BLOOD TotProt-6.7 Albumin-4.2 Globuln-2.5 \r\nCalcium-8.7 Phos-3.4 Mg-2.2 UricAcd-3.7\r\n\r\nIMAGING: \r\n\r\nCXR ___:\r\nIn comparison with the study of ___, the cardiac silhouette \r\nremains at the upper limits of normal or mildly enlarged.  Mild \r\nindistinctness of pulmonary vessels is consistent with mild \r\nelevation of pulmonary venous pressure.  However, no evidence of \r\nacute focal pneumonia or pleural effusion. There has been \r\ninterval placement of right IJ catheter that extends to the \r\nlower SVC. \r\n\r\nRUQUS ___:\r\n1. Patent hepatic vasculature. \r\n2. Echogenic liver consistent with steatosis. Other forms of \r\nliver disease \r\nincluding steatohepatitis, hepatic fibrosis, or cirrhosis cannot \r\nbe excluded on the basis of this examination. \r\n\r\n \r\nBrief Hospital Course:\r\n___ year old female with CVID, RLE DVT, OSA on CPAP, and hx \r\ncerebral aneurism ___ coil, who follows for follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ now with \r\ntreatment-related MDS ___ 4 cycles of Decitabine(C4 D1 \r\n___, admitted for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\n#Treatment-Related MDS:\r\nPatient with follicular lymphoma transformed to DLBCL ___ \r\nautoSCT in ___ now with rapid progression of pancytopenia, \r\nparticularly anemia. Bone marrow biopsy with dysplasia of all \r\ncell lines with noted cytogenetic abnormalities concerning for \r\ntreatment related MDS. ___ Dacogen x4 cycles with persistent \r\nthrombocytopenia but recovered WBCs. Bone marrow biopsy on \r\n___ shows persistent trilineage\r\ndyspoitic maturation. She underwent MUD Allogeneic transplant \r\nwith Fludarabine/Busulfan/ATG conditioning per protocol. She was \r\ndischarged on acyclovir, fluconazole, and Bactrim as per \r\nprotocol. She was on cyclosporine for immunosuppression as per \r\nprotocol. Levels were checked and the patient was discharged on \r\n50 BID. Weekly CMVs were negative.  \r\n\r\n___: Cr up to 1.3 on ___, baseline 0.7-0.8. Likely from \r\noverdiuresis. Urine studies w/ FeUrea ~40% indicating intrinsic \r\ndisease. Possibly renal injury from elevated cyclosporine \r\nlevels. Cr on discharge was 1.1. \r\n\r\n#CVID: Per ID recommendations, given profession and history, \r\nafter\r\nthe initial conditioning regimen would treat with isoniazid and \r\nB6 for a projected 9-month course to prevent TB reactivation. \r\nThis will be guided by Dr. ___ primary oncologist. \r\nPatient to receive monthly IVIG outpatient. \r\n\r\n#Transaminitis: \r\nThe patient developed a transaminitis into the 300-400s from \r\nnormal after her first infusion of busulfan and ATG. This \r\nresolved without further intervention and remained stable during \r\nher subsequent infusions. RUQUS showed patent hepatic \r\nvasculature and an echogenic liver.\r\n\r\n#Right leg DVT.  Had been on Xarelto 20 mg daily but this has\r\nbeen on hold as platelet count < 75,000. This was resumed with \r\nuptrending ___ and PTT. Given ___ BMI and possibility of \r\ninteraction with cyclosporine/fluconazole, she was switched to \r\nLovenox on discharge. Xa level was ### still pending at \r\ndischarge. Has IVC filter in place.\r\n\r\n#Pulmonary hypertension.  Evaluated by Dr. ___ \r\ncontraindication of proceeding with transplant. She remained \r\nstable from a pulmonary perspective.\r\n\r\n#Low Back Pain: Tapered gabapentin 400 mg BID. Continued \r\nVenlafaxine.  \r\n\r\n#OSA: Continued CPAP\r\n\r\n#Asthma: Continued Albuterol PRN with Duoneb q6H PRN\r\n\r\nTRANSITIONAL ISSUES:\r\n- Patient requires monthly IVIG for her CVID\r\n- Discharged on acyclovir (treatment dose) as well as \r\nfluconazole ppx and Bactrim ppx \r\n- ___ benefit from Valacyclovir instead of acyclovir: unable to \r\nobtain prior auth/medication delivery prior to discharge \r\n- Discuss treatment of latent TB with isoniazid and B6. \r\n- Monitor patient on Lovenox, follow-up Xa levels and adjust as \r\nneeded.\r\n\r\n# CODE: Full (confirmed) \r\n# EMERGENCY CONTACT: ___ (Daughter) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list may be inaccurate and requires \r\nfuther investigation.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n3. Omeprazole 20 mg PO DAILY \r\n4. Venlafaxine 25 mg PO BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Ondansetron 4 mg PO Q8H:PRN nausea \r\n7. FoLIC Acid 3 mg PO DAILY \r\n8. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n9. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n10. Cephalexin 200 mg PO ONCE \r\n11. Gabapentin 600 mg PO BID \r\n12. Loratadine 10 mg PO DAILY cold \r\n13. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14. Senna 8.6 mg PO BID:PRN constipation  \r\n\r\n \r\nDischarge Medications:\r\n1.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\nRX *cyclosporine modified [Neoral] 25 mg 2 capsule(s) by mouth \r\nevery twelve (12) hours Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 50 mg 1 capsule(s) by mouth twice a \r\nday Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 25 mg 2 capsule(s) by mouth twice a \r\nday Disp #*120 Capsule Refills:*0 \r\n2.  Enoxaparin Sodium 90 mg SC Q12H \r\nRX *enoxaparin 100 mg/mL 100 mg SC every twelve (12) hours Disp \r\n#*30 Syringe Refills:*0 \r\n3.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\nRX *lorazepam 0.5 mg ___ TABLETS by mouth Q6H:PRN Disp #*30 \r\nTablet Refills:*0 \r\n4.  Multivitamins 1 TAB PO DAILY \r\nRX *multivitamin  1 tablet(s) by mouth DAILY Disp #*30 Tablet \r\nRefills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n6.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0 \r\n7.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0 \r\n8.  Acyclovir 200 mg PO 5X/D  \r\n9.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth Q24H Disp #*60 \r\nTablet Refills:*0 \r\n10.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth Daily Disp #*30 Tablet \r\nRefills:*0 \r\n11.  Gabapentin 400 mg PO BID \r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0\r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0 \r\n12.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n13.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheeze  \r\n14.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n15.  Loratadine 10 mg PO DAILY cold  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n19.  Senna 8.6 mg PO BID:PRN constipation   \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nSecondary MDS ___ MUD AlloSCT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you during your recent \r\nhospitalization. You were admitted to ___ for a stem cell \r\ntransplant. You underwent the bone marrow transplant and \r\nremained in the hospital while your counts improved. Your counts \r\nare now improved and it is safe for you to be discharged. \r\n\r\nWHEN YOU GO HOME:\r\n- Please continue to take all of your medications as directed\r\n- Please follow-up with the doctors listed below\r\n- ___ monitor for any of the alarm symptoms listed below, \r\ncall your doctor or report to the emergency department \r\nimmediately if you experience any of these\r\n\r\nWe wish you the best!\r\nYour ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-22:8",
      "text": "Discharge Instructions:\nDear Ms. ___, It was a pleasure caring for you during your recent \nhospitalization. You were admitted to ___ for a stem cell \ntransplant. You underwent the bone marrow transplant and \nremained in the hospital while your counts improved. Your counts \nare now improved and it is safe for you to be discharged. WHEN YOU GO HOME:\n- Please continue to take all of your medications as directed\n- Please follow-up with the doctors listed below\n- ___ monitor for any of the alarm symptoms listed below, \ncall your doctor or report to the emergency department \nimmediately if you experience any of these We wish you the best! Your ___ Care Team\n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-22",
        "chart_time": "104681",
        "section": "General",
        "position": 8,
        "tokenCount": 172,
        "note_metadata": {
          "note_id": "18887130-DS-22",
          "subject_id": 18887130,
          "hadm_id": 20942569,
          "note_type": "DS",
          "note_seq": 22,
          "charttime": 104681,
          "storetime": 104682.30277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___\r\n \r\nChief Complaint:\r\nAlloSCT Admission\r\n \r\nMajor Surgical or Invasive Procedure:\r\nTemporary CVL\r\n\r\n \r\nHistory of Present Illness:\r\n___ year old female with CVID, history of follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ in remission from \r\nlymphoma, but noted for treatment-related MDS ___ 4 cycles of \r\nDecitabine(C4 D1 =\r\n___, now presents for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\nOf note, the patient was discharged ___ after admission for \r\nRSV Bronchiolitis. She was treated with palvilizumab on ___ and \r\nribavirin 600 mg q8h (___). Patient also was treated \r\nwith 4 days of 10 g IVIg (___). She received a 5 day \r\ncourse of azithromycin for anti-inflammatory effect. She was \r\nalso continued on cefepime (___), that was transitioned \r\nto levaquin on ___ for bacterial prophylaxis.\r\n\r\nShe also had a tooth extraction on the lower left side on \r\n___ due to persistent tooth pain and completed 1 week of \r\nAmoxicillin.\r\n\r\nOn arrival to the floor the patient is feeling quite well. \r\nMinimal discomfort from her tooth extraction. Otherwise denying \r\ncomplete review of systems. She is ready to go through with \r\ntransplant and hoping to get it over with.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n \r\nPhysical Exam:\r\nADMISSION: \r\nVitals: 98.3 142/77 89 16 99 RA\r\nGen: Pleasant, calm, A&Ox3\r\nHEENT: No conjunctival pallor. No icterus. MMM. OP clear.  \r\nNECK: Supple, No LAD\r\nCV: Normocardic, regular. Normal S1,S2. No MRG.   \r\nLUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  \r\nABD: NABS. Soft, NT, ND.  \r\nEXT: WWP. No pitting edema but changes consistent with venous \r\nstasis dermatitis and edema. \r\nSKIN: No rashes/lesions, petechiae/purpura ecchymoses.  \r\nNEURO: A&Ox3. Known R CN6 palsy since aneurism repair and R \r\npupil with minimal response to light. Otherwise CN intact and \r\nstrength ___ all extremities.\r\nLINES: L port, R CVL\r\n \r\nPertinent Results:\r\nADMISSION: \r\n___ 11:15AM BLOOD WBC-5.0 RBC-2.49* Hgb-8.7* Hct-27.2* \r\nMCV-109* MCH-34.9* MCHC-32.0 RDW-UNABLE TO  RDWSD-UNABLE TO  Plt \r\nCt-67*\r\n___ 11:15AM BLOOD Neuts-74.9* Lymphs-16.9* Monos-6.2 \r\nEos-1.2 Baso-0.4 Im ___ AbsNeut-3.78 AbsLymp-0.85* \r\nAbsMono-0.31 AbsEos-0.06 AbsBaso-0.02\r\n___ 11:15AM BLOOD Hypochr-NORMAL Anisocy-3+ Poiklo-1+ \r\nMacrocy-3+ Microcy-NORMAL Polychr-1+ Ovalocy-1+ Tear \r\nDr-OCCASIONAL\r\n___ 11:15AM BLOOD ___ PTT-30.7 ___\r\n___ 05:15AM BLOOD ___\r\n___ 11:15AM BLOOD UreaN-15 Creat-0.9 Na-140 K-4.0 Cl-105 \r\nHCO3-22 AnGap-17\r\n___ 11:15AM BLOOD ALT-11 AST-16 LD(LDH)-260* AlkPhos-124* \r\nTotBili-0.2 DirBili-<0.2 IndBili-0.2\r\n___ 11:15AM BLOOD TotProt-6.7 Albumin-4.2 Globuln-2.5 \r\nCalcium-8.7 Phos-3.4 Mg-2.2 UricAcd-3.7\r\n\r\nIMAGING: \r\n\r\nCXR ___:\r\nIn comparison with the study of ___, the cardiac silhouette \r\nremains at the upper limits of normal or mildly enlarged.  Mild \r\nindistinctness of pulmonary vessels is consistent with mild \r\nelevation of pulmonary venous pressure.  However, no evidence of \r\nacute focal pneumonia or pleural effusion. There has been \r\ninterval placement of right IJ catheter that extends to the \r\nlower SVC. \r\n\r\nRUQUS ___:\r\n1. Patent hepatic vasculature. \r\n2. Echogenic liver consistent with steatosis. Other forms of \r\nliver disease \r\nincluding steatohepatitis, hepatic fibrosis, or cirrhosis cannot \r\nbe excluded on the basis of this examination. \r\n\r\n \r\nBrief Hospital Course:\r\n___ year old female with CVID, RLE DVT, OSA on CPAP, and hx \r\ncerebral aneurism ___ coil, who follows for follicular lymphoma \r\ntransformed to DLBCL ___ autoSCT in ___ now with \r\ntreatment-related MDS ___ 4 cycles of Decitabine(C4 D1 \r\n___, admitted for MUD AlloSCT w/ \r\nFludarabine/Busulfan/ATG conditioning.\r\n\r\n#Treatment-Related MDS:\r\nPatient with follicular lymphoma transformed to DLBCL ___ \r\nautoSCT in ___ now with rapid progression of pancytopenia, \r\nparticularly anemia. Bone marrow biopsy with dysplasia of all \r\ncell lines with noted cytogenetic abnormalities concerning for \r\ntreatment related MDS. ___ Dacogen x4 cycles with persistent \r\nthrombocytopenia but recovered WBCs. Bone marrow biopsy on \r\n___ shows persistent trilineage\r\ndyspoitic maturation. She underwent MUD Allogeneic transplant \r\nwith Fludarabine/Busulfan/ATG conditioning per protocol. She was \r\ndischarged on acyclovir, fluconazole, and Bactrim as per \r\nprotocol. She was on cyclosporine for immunosuppression as per \r\nprotocol. Levels were checked and the patient was discharged on \r\n50 BID. Weekly CMVs were negative.  \r\n\r\n___: Cr up to 1.3 on ___, baseline 0.7-0.8. Likely from \r\noverdiuresis. Urine studies w/ FeUrea ~40% indicating intrinsic \r\ndisease. Possibly renal injury from elevated cyclosporine \r\nlevels. Cr on discharge was 1.1. \r\n\r\n#CVID: Per ID recommendations, given profession and history, \r\nafter\r\nthe initial conditioning regimen would treat with isoniazid and \r\nB6 for a projected 9-month course to prevent TB reactivation. \r\nThis will be guided by Dr. ___ primary oncologist. \r\nPatient to receive monthly IVIG outpatient. \r\n\r\n#Transaminitis: \r\nThe patient developed a transaminitis into the 300-400s from \r\nnormal after her first infusion of busulfan and ATG. This \r\nresolved without further intervention and remained stable during \r\nher subsequent infusions. RUQUS showed patent hepatic \r\nvasculature and an echogenic liver.\r\n\r\n#Right leg DVT.  Had been on Xarelto 20 mg daily but this has\r\nbeen on hold as platelet count < 75,000. This was resumed with \r\nuptrending ___ and PTT. Given ___ BMI and possibility of \r\ninteraction with cyclosporine/fluconazole, she was switched to \r\nLovenox on discharge. Xa level was ### still pending at \r\ndischarge. Has IVC filter in place.\r\n\r\n#Pulmonary hypertension.  Evaluated by Dr. ___ \r\ncontraindication of proceeding with transplant. She remained \r\nstable from a pulmonary perspective.\r\n\r\n#Low Back Pain: Tapered gabapentin 400 mg BID. Continued \r\nVenlafaxine.  \r\n\r\n#OSA: Continued CPAP\r\n\r\n#Asthma: Continued Albuterol PRN with Duoneb q6H PRN\r\n\r\nTRANSITIONAL ISSUES:\r\n- Patient requires monthly IVIG for her CVID\r\n- Discharged on acyclovir (treatment dose) as well as \r\nfluconazole ppx and Bactrim ppx \r\n- ___ benefit from Valacyclovir instead of acyclovir: unable to \r\nobtain prior auth/medication delivery prior to discharge \r\n- Discuss treatment of latent TB with isoniazid and B6. \r\n- Monitor patient on Lovenox, follow-up Xa levels and adjust as \r\nneeded.\r\n\r\n# CODE: Full (confirmed) \r\n# EMERGENCY CONTACT: ___ (Daughter) ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list may be inaccurate and requires \r\nfuther investigation.\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n3. Omeprazole 20 mg PO DAILY \r\n4. Venlafaxine 25 mg PO BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Ondansetron 4 mg PO Q8H:PRN nausea \r\n7. FoLIC Acid 3 mg PO DAILY \r\n8. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n9. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n10. Cephalexin 200 mg PO ONCE \r\n11. Gabapentin 600 mg PO BID \r\n12. Loratadine 10 mg PO DAILY cold \r\n13. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n14. Senna 8.6 mg PO BID:PRN constipation  \r\n\r\n \r\nDischarge Medications:\r\n1.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\nRX *cyclosporine modified [Neoral] 25 mg 2 capsule(s) by mouth \r\nevery twelve (12) hours Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 50 mg 1 capsule(s) by mouth twice a \r\nday Disp #*60 Capsule Refills:*0\r\nRX *cyclosporine modified 25 mg 2 capsule(s) by mouth twice a \r\nday Disp #*120 Capsule Refills:*0 \r\n2.  Enoxaparin Sodium 90 mg SC Q12H \r\nRX *enoxaparin 100 mg/mL 100 mg SC every twelve (12) hours Disp \r\n#*30 Syringe Refills:*0 \r\n3.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\nRX *lorazepam 0.5 mg ___ TABLETS by mouth Q6H:PRN Disp #*30 \r\nTablet Refills:*0 \r\n4.  Multivitamins 1 TAB PO DAILY \r\nRX *multivitamin  1 tablet(s) by mouth DAILY Disp #*30 Tablet \r\nRefills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim [Bactrim] 400 mg-80 mg 1 \r\ntablet(s) by mouth daily Disp #*30 Tablet Refills:*0 \r\n6.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 1 capsule(s) by mouth QAM Disp #*30 Capsule \r\nRefills:*0 \r\n7.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0\r\nRX *ursodiol 300 mg 2 capsule(s) by mouth QPM Disp #*60 Capsule \r\nRefills:*0 \r\n8.  Acyclovir 200 mg PO 5X/D  \r\n9.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth Q24H Disp #*60 \r\nTablet Refills:*0 \r\n10.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth Daily Disp #*30 Tablet \r\nRefills:*0 \r\n11.  Gabapentin 400 mg PO BID \r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0\r\nRX *gabapentin 400 mg 1 capsule(s) by mouth twice a day Disp \r\n#*60 Capsule Refills:*0 \r\n12.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n13.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheeze  \r\n14.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n15.  Loratadine 10 mg PO DAILY cold  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n19.  Senna 8.6 mg PO BID:PRN constipation   \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nSecondary MDS ___ MUD AlloSCT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you during your recent \r\nhospitalization. You were admitted to ___ for a stem cell \r\ntransplant. You underwent the bone marrow transplant and \r\nremained in the hospital while your counts improved. Your counts \r\nare now improved and it is safe for you to be discharged. \r\n\r\nWHEN YOU GO HOME:\r\n- Please continue to take all of your medications as directed\r\n- Please follow-up with the doctors listed below\r\n- ___ monitor for any of the alarm symptoms listed below, \r\ncall your doctor or report to the emergency department \r\nimmediately if you experience any of these\r\n\r\nWe wish you the best!\r\nYour ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-23:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \ndapsone\n \nAttending: ___. Chief Complaint:\nFever, headaches, vomiting \n \nMajor Surgical or Invasive Procedure:\nLumbar puncture",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-23",
        "chart_time": "104710",
        "section": "General",
        "position": 0,
        "tokenCount": 76,
        "note_metadata": {
          "note_id": "18887130-DS-23",
          "subject_id": 18887130,
          "hadm_id": 26001675,
          "note_type": "DS",
          "note_seq": 23,
          "charttime": 104710,
          "storetime": 104711.45277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nFever, headaches, vomiting \r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture\r\n\r\n \r\nHistory of Present Illness:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT,\r\nsubsequent treatment related MDS now ___ URD allogeneic\r\ntransplant D+___, also h/o CVID (on IVIg), GERD, OA, h/o R DVT \r\n___\r\nIVC filter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b \r\nmild\r\nCN6 palsy, hypertensive, obesity presents with fever (T 100.5)\r\nand vomiting. \r\n\r\nToday, she had another episode of vomiting, without drinking any\r\ncoffee. She also noted frontal headache in band like \r\ndistribution\r\naround her head. She reports no neck stiffness (other than\r\nbaseline related to cervical radiculopathy with radiation down R\r\narm). Denies changes in vision, numbness, weakness. She has\r\ninfrequent, scattered abdominal pain. Denies further diarrhea.\r\nDenies rash. No chest pain, dyspnea, cough, dysuria. \r\n\r\nVS in ER T99.9 94 150/67 18 100% RA . Appears comfortable on the\r\nfloor. No other issues.\r\n\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM: \r\n\r\nGENERAL: No fever, chills, night sweats, recent weight changes. \r\nHEENT: No sores in the mouth, painful swallowing, intolerance to\r\nliquids or solids, sinus tenderness, rhinorrhea, or congestion. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough, shortness of breath, hemoptysis, or wheezing. \r\nGI: No nausea, vomiting, diarrhea, constipation or abdominal\r\npain.  \r\nGU: No dysuria or change in bladder habits. \r\nMSK: No arthritis, arthralgias, myalgias, or bone pain. \r\nDERM: Denies rashes, itching, or skin breakdown. \r\nNEURO: Mild ___ diffuse headache. No visual changes, +Chronic\r\nRUE tingling, No other focal neurologic symptoms. \r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nGen: NAD, sitting comfortably in a chair\r\nHEENT: MMM, oropharynx clear. No LAD.\r\nCV:  regular rhythm, no murmurs\r\nPULM:  CTAB, No crackles or wheezes.\r\nABD:  BS+, soft, NTND,\r\nExt: 1 ___ edema, no clubbing/tremors, venous stasis\r\ndermatitis bilaterally on ___\r\nSKIN:  No rashes\r\nNeuro: A&Ox3, prior R CN6 palsy and R pupil with minimal \r\nresponse\r\nto light, ___ strength throughout, sensation intact. No nuchal\r\nrigidity or photophobia.\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD CMV VL-3.4*\r\n___ 12:00AM BLOOD CMV VL-2.9*\r\n \r\nBrief Hospital Course:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT, \r\nsubsequent treatment related MDS now ___ URD allogeneic \r\ntransplant, also h/o CVID (on IVIg), GERD, OA, h/o R DVT ___ IVC \r\nfilter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b mild \r\nCN6 palsy, hypertensive, presented on ___ with fever (T 100.5),\r\nnausea/vomiting, headaches most concerning for meningitis.\r\n\r\n#Aseptic meningitis\r\nShe initially presented with headache fever, nausea and \r\nvomiting.  She was treated initially with cefepime and acyclovir \r\nto cover both bacterial meningitis and HSV meningitis.  These \r\nwere discontinued when an LP from ___ was  consistent with \r\naseptic meningitis and no HSV was found in the CSF.  Extensive \r\nworkup for VZV EBV HSV HHV6 adenovirus arbovirus TB\r\nAnaplasma and serum toxoplasmosis was negative.  She was noted \r\nto have CMV viremia and although this is an unlikely cause of \r\nmeningitis she was treated with ganciclovir.\r\n\r\n#CMV viremia\r\nFound to have CMV vl on ___, which persisted. She was treated \r\nwith IV ganciclovir and then transitioned to oral valganciclovir \r\nprior to discharge.\r\n\r\n#Diarrhea\r\nShe had mild diarrhea on and off throughout her admission that \r\nwas thought to be likely due to GVHD versus infection.  C. \r\ndifficile from ___ was negative.  Stool frequency slowly \r\nimproved over admission.\r\n\r\n#Anorexia \r\nWaxing and waning appetite that was concerning for acute GVHD.  \r\nA GI consult was considered for upper/lower endoscopy, but her \r\nappetite slowly improved over admission.  She never had \r\ndysphasia, odynophagia, or early satiety.\r\n\r\n#Dyspnea\r\nShe was noted to be short of breath on ___.  She had a drop in \r\nher oxygen saturation to the high ___ while ambulating this day. \r\n ECG was unchanged.  And a CTA was negative.  She had an echo \r\nperformed on ___ which is similar to a prior study on ___ with \r\nleft ventricular systolic dysfunction and hypokinesis of the \r\ninferior/inferior lateral walls.  Repeat ambulatory sat on the \r\nday of discharge was within normal limits.\r\n\r\n#MDS\r\n___ allogeneic transplant with URD with reduced intensity \r\nFlu/Bu/ATG conditioning. D0 = ___. Continued prophylaxis \r\nwith Bactrim and Fluconazole. Acyclovir on hold while on \r\ngancyclovir. Continued cyclosporine.\r\n\r\n#Lower extremity edema\r\nDiuresed as needed. \r\n\r\n#Right leg DVT\r\nContinued lovenox ___ mg once per day.She has IVC filter in \r\nplace.\r\n\r\n#Right lower back pain\r\nAggravated from moving. Persistent since past few months. \r\nContinued oxycodone.\r\nLumbar spine MRI with and without contrast to evaluate new \r\nright-sided sciatic pain with no significant changes.\r\n\r\n#Asthma\r\nInhalers were used as needed.\r\n\r\nTransitional Issues\r\n=======================\r\n\r\n[ ] Follow-up on cyclosporine levels \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Enoxaparin Sodium 100 mg SC Q24H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n3. Fluconazole 400 mg PO Q24H \r\n4. FoLIC Acid 1 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n7. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n8. Senna 8.6 mg PO BID:PRN constipation  \r\n9. Venlafaxine 25 mg PO BID \r\n10. CycloSPORINE (Neoral) MODIFIED 100 mg PO QAM \r\n11. Multivitamins 1 TAB PO DAILY \r\n12. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n\r\n13. Loratadine 10 mg PO DAILY cold \r\n14. Omeprazole 20 mg PO DAILY \r\n15. Ondansetron 4 mg PO Q8H:PRN nausea \r\n16. Ursodiol 300 mg PO QAM \r\n17. Ursodiol 600 mg PO QPM \r\n18. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n19. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n20. Acyclovir 200 mg PO 5X/D \r\n21. CycloSPORINE (Neoral) MODIFIED 125 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  ValGANCIclovir 900 mg PO Q12H \r\nRX *valganciclovir 450 mg 2 tablet(s) by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n2.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H \r\nRX *cyclosporine modified 25 mg 3 capsule(s) by mouth twice a \r\nday Disp #*180 Capsule Refills:*0 \r\n3.  Enoxaparin Sodium 100 mg SC DAILY \r\nStart: ___, First Dose: Next Routine Administration Time  \r\n4.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n5.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole [Diflucan] 200 mg 2 tablet(s) by mouth once a \r\nday Disp #*60 Tablet Refills:*0 \r\n6.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n \r\n7.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Gabapentin 400 mg PO BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n10.  Loratadine 10 mg PO DAILY cold  \r\n11.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n12.  Multivitamins 1 TAB PO DAILY  \r\n13.  Omeprazole 20 mg PO DAILY  \r\n14.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n15.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n16.  Senna 8.6 mg PO BID:PRN constipation   \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth qam Disp #*30 Capsule \r\nRefills:*0 \r\n19.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth qpm Disp #*60 Capsule \r\nRefills:*0 \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\nAseptic meningitis\r\nCMV Viremia\r\nMDS\r\n\r\n___:\r\nCVID\r\nRight leg DVT\r\nAsthma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nIt was a pleasure being involved in your care. \r\n\r\nWhy you were here: \r\n-You came in with a headaches, vomiting and a fever. \r\n\r\nWhat we did while you were here: \r\n-We tested you for an infection in the brain and treated you for \r\nwhat may have been a viral infection. \r\n\r\nWhat to do when you are discharged: \r\n-Continue taking your medications as prescribed \r\n-Attend your follow-up appointments \r\n\r\nIt was a pleasure taking care of you! We wish you the best!\r\n\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-23:1",
      "text": "History of Present Illness:\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT,\nsubsequent treatment related MDS now ___ URD allogeneic\ntransplant D+___, also h/o CVID (on IVIg), GERD, OA, h/o R DVT \n___\nIVC filter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b \nmild\nCN6 palsy, hypertensive, obesity presents with fever (T 100.5)\nand vomiting. Today, she had another episode of vomiting, without drinking any\ncoffee. She also noted frontal headache in band like \ndistribution\naround her head. She reports no neck stiffness (other than\nbaseline related to cervical radiculopathy with radiation down R\narm). Denies changes in vision, numbness, weakness. She has\ninfrequent, scattered abdominal pain. Denies further diarrhea. Denies rash. No chest pain, dyspnea, cough, dysuria. VS in ER T99.9 94 150/67 18 100% RA . Appears comfortable on the\nfloor. No other issues.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-23",
        "chart_time": "104710",
        "section": "General",
        "position": 1,
        "tokenCount": 219,
        "note_metadata": {
          "note_id": "18887130-DS-23",
          "subject_id": 18887130,
          "hadm_id": 26001675,
          "note_type": "DS",
          "note_seq": 23,
          "charttime": 104710,
          "storetime": 104711.45277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nFever, headaches, vomiting \r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture\r\n\r\n \r\nHistory of Present Illness:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT,\r\nsubsequent treatment related MDS now ___ URD allogeneic\r\ntransplant D+___, also h/o CVID (on IVIg), GERD, OA, h/o R DVT \r\n___\r\nIVC filter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b \r\nmild\r\nCN6 palsy, hypertensive, obesity presents with fever (T 100.5)\r\nand vomiting. \r\n\r\nToday, she had another episode of vomiting, without drinking any\r\ncoffee. She also noted frontal headache in band like \r\ndistribution\r\naround her head. She reports no neck stiffness (other than\r\nbaseline related to cervical radiculopathy with radiation down R\r\narm). Denies changes in vision, numbness, weakness. She has\r\ninfrequent, scattered abdominal pain. Denies further diarrhea.\r\nDenies rash. No chest pain, dyspnea, cough, dysuria. \r\n\r\nVS in ER T99.9 94 150/67 18 100% RA . Appears comfortable on the\r\nfloor. No other issues.\r\n\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM: \r\n\r\nGENERAL: No fever, chills, night sweats, recent weight changes. \r\nHEENT: No sores in the mouth, painful swallowing, intolerance to\r\nliquids or solids, sinus tenderness, rhinorrhea, or congestion. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough, shortness of breath, hemoptysis, or wheezing. \r\nGI: No nausea, vomiting, diarrhea, constipation or abdominal\r\npain.  \r\nGU: No dysuria or change in bladder habits. \r\nMSK: No arthritis, arthralgias, myalgias, or bone pain. \r\nDERM: Denies rashes, itching, or skin breakdown. \r\nNEURO: Mild ___ diffuse headache. No visual changes, +Chronic\r\nRUE tingling, No other focal neurologic symptoms. \r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nGen: NAD, sitting comfortably in a chair\r\nHEENT: MMM, oropharynx clear. No LAD.\r\nCV:  regular rhythm, no murmurs\r\nPULM:  CTAB, No crackles or wheezes.\r\nABD:  BS+, soft, NTND,\r\nExt: 1 ___ edema, no clubbing/tremors, venous stasis\r\ndermatitis bilaterally on ___\r\nSKIN:  No rashes\r\nNeuro: A&Ox3, prior R CN6 palsy and R pupil with minimal \r\nresponse\r\nto light, ___ strength throughout, sensation intact. No nuchal\r\nrigidity or photophobia.\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD CMV VL-3.4*\r\n___ 12:00AM BLOOD CMV VL-2.9*\r\n \r\nBrief Hospital Course:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT, \r\nsubsequent treatment related MDS now ___ URD allogeneic \r\ntransplant, also h/o CVID (on IVIg), GERD, OA, h/o R DVT ___ IVC \r\nfilter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b mild \r\nCN6 palsy, hypertensive, presented on ___ with fever (T 100.5),\r\nnausea/vomiting, headaches most concerning for meningitis.\r\n\r\n#Aseptic meningitis\r\nShe initially presented with headache fever, nausea and \r\nvomiting.  She was treated initially with cefepime and acyclovir \r\nto cover both bacterial meningitis and HSV meningitis.  These \r\nwere discontinued when an LP from ___ was  consistent with \r\naseptic meningitis and no HSV was found in the CSF.  Extensive \r\nworkup for VZV EBV HSV HHV6 adenovirus arbovirus TB\r\nAnaplasma and serum toxoplasmosis was negative.  She was noted \r\nto have CMV viremia and although this is an unlikely cause of \r\nmeningitis she was treated with ganciclovir.\r\n\r\n#CMV viremia\r\nFound to have CMV vl on ___, which persisted. She was treated \r\nwith IV ganciclovir and then transitioned to oral valganciclovir \r\nprior to discharge.\r\n\r\n#Diarrhea\r\nShe had mild diarrhea on and off throughout her admission that \r\nwas thought to be likely due to GVHD versus infection.  C. \r\ndifficile from ___ was negative.  Stool frequency slowly \r\nimproved over admission.\r\n\r\n#Anorexia \r\nWaxing and waning appetite that was concerning for acute GVHD.  \r\nA GI consult was considered for upper/lower endoscopy, but her \r\nappetite slowly improved over admission.  She never had \r\ndysphasia, odynophagia, or early satiety.\r\n\r\n#Dyspnea\r\nShe was noted to be short of breath on ___.  She had a drop in \r\nher oxygen saturation to the high ___ while ambulating this day. \r\n ECG was unchanged.  And a CTA was negative.  She had an echo \r\nperformed on ___ which is similar to a prior study on ___ with \r\nleft ventricular systolic dysfunction and hypokinesis of the \r\ninferior/inferior lateral walls.  Repeat ambulatory sat on the \r\nday of discharge was within normal limits.\r\n\r\n#MDS\r\n___ allogeneic transplant with URD with reduced intensity \r\nFlu/Bu/ATG conditioning. D0 = ___. Continued prophylaxis \r\nwith Bactrim and Fluconazole. Acyclovir on hold while on \r\ngancyclovir. Continued cyclosporine.\r\n\r\n#Lower extremity edema\r\nDiuresed as needed. \r\n\r\n#Right leg DVT\r\nContinued lovenox ___ mg once per day.She has IVC filter in \r\nplace.\r\n\r\n#Right lower back pain\r\nAggravated from moving. Persistent since past few months. \r\nContinued oxycodone.\r\nLumbar spine MRI with and without contrast to evaluate new \r\nright-sided sciatic pain with no significant changes.\r\n\r\n#Asthma\r\nInhalers were used as needed.\r\n\r\nTransitional Issues\r\n=======================\r\n\r\n[ ] Follow-up on cyclosporine levels \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Enoxaparin Sodium 100 mg SC Q24H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n3. Fluconazole 400 mg PO Q24H \r\n4. FoLIC Acid 1 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n7. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n8. Senna 8.6 mg PO BID:PRN constipation  \r\n9. Venlafaxine 25 mg PO BID \r\n10. CycloSPORINE (Neoral) MODIFIED 100 mg PO QAM \r\n11. Multivitamins 1 TAB PO DAILY \r\n12. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n\r\n13. Loratadine 10 mg PO DAILY cold \r\n14. Omeprazole 20 mg PO DAILY \r\n15. Ondansetron 4 mg PO Q8H:PRN nausea \r\n16. Ursodiol 300 mg PO QAM \r\n17. Ursodiol 600 mg PO QPM \r\n18. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n19. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n20. Acyclovir 200 mg PO 5X/D \r\n21. CycloSPORINE (Neoral) MODIFIED 125 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  ValGANCIclovir 900 mg PO Q12H \r\nRX *valganciclovir 450 mg 2 tablet(s) by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n2.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H \r\nRX *cyclosporine modified 25 mg 3 capsule(s) by mouth twice a \r\nday Disp #*180 Capsule Refills:*0 \r\n3.  Enoxaparin Sodium 100 mg SC DAILY \r\nStart: ___, First Dose: Next Routine Administration Time  \r\n4.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n5.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole [Diflucan] 200 mg 2 tablet(s) by mouth once a \r\nday Disp #*60 Tablet Refills:*0 \r\n6.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n \r\n7.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Gabapentin 400 mg PO BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n10.  Loratadine 10 mg PO DAILY cold  \r\n11.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n12.  Multivitamins 1 TAB PO DAILY  \r\n13.  Omeprazole 20 mg PO DAILY  \r\n14.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n15.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n16.  Senna 8.6 mg PO BID:PRN constipation   \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth qam Disp #*30 Capsule \r\nRefills:*0 \r\n19.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth qpm Disp #*60 Capsule \r\nRefills:*0 \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\nAseptic meningitis\r\nCMV Viremia\r\nMDS\r\n\r\n___:\r\nCVID\r\nRight leg DVT\r\nAsthma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nIt was a pleasure being involved in your care. \r\n\r\nWhy you were here: \r\n-You came in with a headaches, vomiting and a fever. \r\n\r\nWhat we did while you were here: \r\n-We tested you for an infection in the brain and treated you for \r\nwhat may have been a viral infection. \r\n\r\nWhat to do when you are discharged: \r\n-Continue taking your medications as prescribed \r\n-Attend your follow-up appointments \r\n\r\nIt was a pleasure taking care of you! We wish you the best!\r\n\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-23:2",
      "text": "Past Medical History:\n- Treatment-Related MDS after transformed follicular lymphoma\n- CVID, received IVIG monthly; last given ___\n- GERD                                          \n- Osteoarthritis                                         \n- DVT, right lower extremity, IVC filter in place\n- Cervical radiculopathy\n- Sciatica\n- Obstructive sleep apnea, wears CPAP\n- H/O cerebral aneurism, noted on MRA with small R internal\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\nthe right eye, mild proptosis of the right eye, and hyperthesia\nof the right V1 distribution\n- Asthma\n- Obesity\n- Hypertension\n- Migraines\n- + RSV, ___\n- History of osteomyelitis with IV antibioitcs for 6\nweeks. Social History:\n___ Family History:\nBrother with lymphoma, died at age ___. Father had CAD and DM. Mother had CHF.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-23",
        "chart_time": "104710",
        "section": "General",
        "position": 2,
        "tokenCount": 217,
        "note_metadata": {
          "note_id": "18887130-DS-23",
          "subject_id": 18887130,
          "hadm_id": 26001675,
          "note_type": "DS",
          "note_seq": 23,
          "charttime": 104710,
          "storetime": 104711.45277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nFever, headaches, vomiting \r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture\r\n\r\n \r\nHistory of Present Illness:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT,\r\nsubsequent treatment related MDS now ___ URD allogeneic\r\ntransplant D+___, also h/o CVID (on IVIg), GERD, OA, h/o R DVT \r\n___\r\nIVC filter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b \r\nmild\r\nCN6 palsy, hypertensive, obesity presents with fever (T 100.5)\r\nand vomiting. \r\n\r\nToday, she had another episode of vomiting, without drinking any\r\ncoffee. She also noted frontal headache in band like \r\ndistribution\r\naround her head. She reports no neck stiffness (other than\r\nbaseline related to cervical radiculopathy with radiation down R\r\narm). Denies changes in vision, numbness, weakness. She has\r\ninfrequent, scattered abdominal pain. Denies further diarrhea.\r\nDenies rash. No chest pain, dyspnea, cough, dysuria. \r\n\r\nVS in ER T99.9 94 150/67 18 100% RA . Appears comfortable on the\r\nfloor. No other issues.\r\n\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM: \r\n\r\nGENERAL: No fever, chills, night sweats, recent weight changes. \r\nHEENT: No sores in the mouth, painful swallowing, intolerance to\r\nliquids or solids, sinus tenderness, rhinorrhea, or congestion. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough, shortness of breath, hemoptysis, or wheezing. \r\nGI: No nausea, vomiting, diarrhea, constipation or abdominal\r\npain.  \r\nGU: No dysuria or change in bladder habits. \r\nMSK: No arthritis, arthralgias, myalgias, or bone pain. \r\nDERM: Denies rashes, itching, or skin breakdown. \r\nNEURO: Mild ___ diffuse headache. No visual changes, +Chronic\r\nRUE tingling, No other focal neurologic symptoms. \r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nGen: NAD, sitting comfortably in a chair\r\nHEENT: MMM, oropharynx clear. No LAD.\r\nCV:  regular rhythm, no murmurs\r\nPULM:  CTAB, No crackles or wheezes.\r\nABD:  BS+, soft, NTND,\r\nExt: 1 ___ edema, no clubbing/tremors, venous stasis\r\ndermatitis bilaterally on ___\r\nSKIN:  No rashes\r\nNeuro: A&Ox3, prior R CN6 palsy and R pupil with minimal \r\nresponse\r\nto light, ___ strength throughout, sensation intact. No nuchal\r\nrigidity or photophobia.\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD CMV VL-3.4*\r\n___ 12:00AM BLOOD CMV VL-2.9*\r\n \r\nBrief Hospital Course:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT, \r\nsubsequent treatment related MDS now ___ URD allogeneic \r\ntransplant, also h/o CVID (on IVIg), GERD, OA, h/o R DVT ___ IVC \r\nfilter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b mild \r\nCN6 palsy, hypertensive, presented on ___ with fever (T 100.5),\r\nnausea/vomiting, headaches most concerning for meningitis.\r\n\r\n#Aseptic meningitis\r\nShe initially presented with headache fever, nausea and \r\nvomiting.  She was treated initially with cefepime and acyclovir \r\nto cover both bacterial meningitis and HSV meningitis.  These \r\nwere discontinued when an LP from ___ was  consistent with \r\naseptic meningitis and no HSV was found in the CSF.  Extensive \r\nworkup for VZV EBV HSV HHV6 adenovirus arbovirus TB\r\nAnaplasma and serum toxoplasmosis was negative.  She was noted \r\nto have CMV viremia and although this is an unlikely cause of \r\nmeningitis she was treated with ganciclovir.\r\n\r\n#CMV viremia\r\nFound to have CMV vl on ___, which persisted. She was treated \r\nwith IV ganciclovir and then transitioned to oral valganciclovir \r\nprior to discharge.\r\n\r\n#Diarrhea\r\nShe had mild diarrhea on and off throughout her admission that \r\nwas thought to be likely due to GVHD versus infection.  C. \r\ndifficile from ___ was negative.  Stool frequency slowly \r\nimproved over admission.\r\n\r\n#Anorexia \r\nWaxing and waning appetite that was concerning for acute GVHD.  \r\nA GI consult was considered for upper/lower endoscopy, but her \r\nappetite slowly improved over admission.  She never had \r\ndysphasia, odynophagia, or early satiety.\r\n\r\n#Dyspnea\r\nShe was noted to be short of breath on ___.  She had a drop in \r\nher oxygen saturation to the high ___ while ambulating this day. \r\n ECG was unchanged.  And a CTA was negative.  She had an echo \r\nperformed on ___ which is similar to a prior study on ___ with \r\nleft ventricular systolic dysfunction and hypokinesis of the \r\ninferior/inferior lateral walls.  Repeat ambulatory sat on the \r\nday of discharge was within normal limits.\r\n\r\n#MDS\r\n___ allogeneic transplant with URD with reduced intensity \r\nFlu/Bu/ATG conditioning. D0 = ___. Continued prophylaxis \r\nwith Bactrim and Fluconazole. Acyclovir on hold while on \r\ngancyclovir. Continued cyclosporine.\r\n\r\n#Lower extremity edema\r\nDiuresed as needed. \r\n\r\n#Right leg DVT\r\nContinued lovenox ___ mg once per day.She has IVC filter in \r\nplace.\r\n\r\n#Right lower back pain\r\nAggravated from moving. Persistent since past few months. \r\nContinued oxycodone.\r\nLumbar spine MRI with and without contrast to evaluate new \r\nright-sided sciatic pain with no significant changes.\r\n\r\n#Asthma\r\nInhalers were used as needed.\r\n\r\nTransitional Issues\r\n=======================\r\n\r\n[ ] Follow-up on cyclosporine levels \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Enoxaparin Sodium 100 mg SC Q24H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n3. Fluconazole 400 mg PO Q24H \r\n4. FoLIC Acid 1 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n7. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n8. Senna 8.6 mg PO BID:PRN constipation  \r\n9. Venlafaxine 25 mg PO BID \r\n10. CycloSPORINE (Neoral) MODIFIED 100 mg PO QAM \r\n11. Multivitamins 1 TAB PO DAILY \r\n12. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n\r\n13. Loratadine 10 mg PO DAILY cold \r\n14. Omeprazole 20 mg PO DAILY \r\n15. Ondansetron 4 mg PO Q8H:PRN nausea \r\n16. Ursodiol 300 mg PO QAM \r\n17. Ursodiol 600 mg PO QPM \r\n18. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n19. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n20. Acyclovir 200 mg PO 5X/D \r\n21. CycloSPORINE (Neoral) MODIFIED 125 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  ValGANCIclovir 900 mg PO Q12H \r\nRX *valganciclovir 450 mg 2 tablet(s) by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n2.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H \r\nRX *cyclosporine modified 25 mg 3 capsule(s) by mouth twice a \r\nday Disp #*180 Capsule Refills:*0 \r\n3.  Enoxaparin Sodium 100 mg SC DAILY \r\nStart: ___, First Dose: Next Routine Administration Time  \r\n4.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n5.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole [Diflucan] 200 mg 2 tablet(s) by mouth once a \r\nday Disp #*60 Tablet Refills:*0 \r\n6.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n \r\n7.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Gabapentin 400 mg PO BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n10.  Loratadine 10 mg PO DAILY cold  \r\n11.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n12.  Multivitamins 1 TAB PO DAILY  \r\n13.  Omeprazole 20 mg PO DAILY  \r\n14.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n15.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n16.  Senna 8.6 mg PO BID:PRN constipation   \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth qam Disp #*30 Capsule \r\nRefills:*0 \r\n19.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth qpm Disp #*60 Capsule \r\nRefills:*0 \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\nAseptic meningitis\r\nCMV Viremia\r\nMDS\r\n\r\n___:\r\nCVID\r\nRight leg DVT\r\nAsthma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nIt was a pleasure being involved in your care. \r\n\r\nWhy you were here: \r\n-You came in with a headaches, vomiting and a fever. \r\n\r\nWhat we did while you were here: \r\n-We tested you for an infection in the brain and treated you for \r\nwhat may have been a viral infection. \r\n\r\nWhat to do when you are discharged: \r\n-Continue taking your medications as prescribed \r\n-Attend your follow-up appointments \r\n\r\nIt was a pleasure taking care of you! We wish you the best!\r\n\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-23:3",
      "text": "Physical Exam:\nADMISSION PHYSICAL EXAM: GENERAL: No fever, chills, night sweats, recent weight changes. HEENT: No sores in the mouth, painful swallowing, intolerance to\nliquids or solids, sinus tenderness, rhinorrhea, or congestion. CARDS: No chest pain, chest pressure, exertional symptoms, or\npalpitations. PULM: No cough, shortness of breath, hemoptysis, or wheezing. GI: No nausea, vomiting, diarrhea, constipation or abdominal\npain. GU: No dysuria or change in bladder habits. MSK: No arthritis, arthralgias, myalgias, or bone pain. DERM: Denies rashes, itching, or skin breakdown. NEURO: Mild ___ diffuse headache. No visual changes, +Chronic\nRUE tingling, No other focal neurologic symptoms. DISCHARGE PHYSICAL EXAM:\nGen: NAD, sitting comfortably in a chair\nHEENT: MMM, oropharynx clear. No LAD. CV:  regular rhythm, no murmurs\nPULM:  CTAB, No crackles or wheezes. ABD:  BS+, soft, NTND,\nExt: 1 ___ edema, no clubbing/tremors, venous stasis\ndermatitis bilaterally on ___\nSKIN:  No rashes\nNeuro: A&Ox3, prior R CN6 palsy and R pupil with minimal \nresponse\nto light, ___ strength throughout, sensation intact. No nuchal\nrigidity or photophobia. Pertinent Results:\n___ 12:00AM BLOOD CMV VL-3.4*\n___ 12:00AM BLOOD CMV VL-2.9*",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-23",
        "chart_time": "104710",
        "section": "General",
        "position": 3,
        "tokenCount": 307,
        "note_metadata": {
          "note_id": "18887130-DS-23",
          "subject_id": 18887130,
          "hadm_id": 26001675,
          "note_type": "DS",
          "note_seq": 23,
          "charttime": 104710,
          "storetime": 104711.45277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nFever, headaches, vomiting \r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture\r\n\r\n \r\nHistory of Present Illness:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT,\r\nsubsequent treatment related MDS now ___ URD allogeneic\r\ntransplant D+___, also h/o CVID (on IVIg), GERD, OA, h/o R DVT \r\n___\r\nIVC filter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b \r\nmild\r\nCN6 palsy, hypertensive, obesity presents with fever (T 100.5)\r\nand vomiting. \r\n\r\nToday, she had another episode of vomiting, without drinking any\r\ncoffee. She also noted frontal headache in band like \r\ndistribution\r\naround her head. She reports no neck stiffness (other than\r\nbaseline related to cervical radiculopathy with radiation down R\r\narm). Denies changes in vision, numbness, weakness. She has\r\ninfrequent, scattered abdominal pain. Denies further diarrhea.\r\nDenies rash. No chest pain, dyspnea, cough, dysuria. \r\n\r\nVS in ER T99.9 94 150/67 18 100% RA . Appears comfortable on the\r\nfloor. No other issues.\r\n\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM: \r\n\r\nGENERAL: No fever, chills, night sweats, recent weight changes. \r\nHEENT: No sores in the mouth, painful swallowing, intolerance to\r\nliquids or solids, sinus tenderness, rhinorrhea, or congestion. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough, shortness of breath, hemoptysis, or wheezing. \r\nGI: No nausea, vomiting, diarrhea, constipation or abdominal\r\npain.  \r\nGU: No dysuria or change in bladder habits. \r\nMSK: No arthritis, arthralgias, myalgias, or bone pain. \r\nDERM: Denies rashes, itching, or skin breakdown. \r\nNEURO: Mild ___ diffuse headache. No visual changes, +Chronic\r\nRUE tingling, No other focal neurologic symptoms. \r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nGen: NAD, sitting comfortably in a chair\r\nHEENT: MMM, oropharynx clear. No LAD.\r\nCV:  regular rhythm, no murmurs\r\nPULM:  CTAB, No crackles or wheezes.\r\nABD:  BS+, soft, NTND,\r\nExt: 1 ___ edema, no clubbing/tremors, venous stasis\r\ndermatitis bilaterally on ___\r\nSKIN:  No rashes\r\nNeuro: A&Ox3, prior R CN6 palsy and R pupil with minimal \r\nresponse\r\nto light, ___ strength throughout, sensation intact. No nuchal\r\nrigidity or photophobia.\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD CMV VL-3.4*\r\n___ 12:00AM BLOOD CMV VL-2.9*\r\n \r\nBrief Hospital Course:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT, \r\nsubsequent treatment related MDS now ___ URD allogeneic \r\ntransplant, also h/o CVID (on IVIg), GERD, OA, h/o R DVT ___ IVC \r\nfilter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b mild \r\nCN6 palsy, hypertensive, presented on ___ with fever (T 100.5),\r\nnausea/vomiting, headaches most concerning for meningitis.\r\n\r\n#Aseptic meningitis\r\nShe initially presented with headache fever, nausea and \r\nvomiting.  She was treated initially with cefepime and acyclovir \r\nto cover both bacterial meningitis and HSV meningitis.  These \r\nwere discontinued when an LP from ___ was  consistent with \r\naseptic meningitis and no HSV was found in the CSF.  Extensive \r\nworkup for VZV EBV HSV HHV6 adenovirus arbovirus TB\r\nAnaplasma and serum toxoplasmosis was negative.  She was noted \r\nto have CMV viremia and although this is an unlikely cause of \r\nmeningitis she was treated with ganciclovir.\r\n\r\n#CMV viremia\r\nFound to have CMV vl on ___, which persisted. She was treated \r\nwith IV ganciclovir and then transitioned to oral valganciclovir \r\nprior to discharge.\r\n\r\n#Diarrhea\r\nShe had mild diarrhea on and off throughout her admission that \r\nwas thought to be likely due to GVHD versus infection.  C. \r\ndifficile from ___ was negative.  Stool frequency slowly \r\nimproved over admission.\r\n\r\n#Anorexia \r\nWaxing and waning appetite that was concerning for acute GVHD.  \r\nA GI consult was considered for upper/lower endoscopy, but her \r\nappetite slowly improved over admission.  She never had \r\ndysphasia, odynophagia, or early satiety.\r\n\r\n#Dyspnea\r\nShe was noted to be short of breath on ___.  She had a drop in \r\nher oxygen saturation to the high ___ while ambulating this day. \r\n ECG was unchanged.  And a CTA was negative.  She had an echo \r\nperformed on ___ which is similar to a prior study on ___ with \r\nleft ventricular systolic dysfunction and hypokinesis of the \r\ninferior/inferior lateral walls.  Repeat ambulatory sat on the \r\nday of discharge was within normal limits.\r\n\r\n#MDS\r\n___ allogeneic transplant with URD with reduced intensity \r\nFlu/Bu/ATG conditioning. D0 = ___. Continued prophylaxis \r\nwith Bactrim and Fluconazole. Acyclovir on hold while on \r\ngancyclovir. Continued cyclosporine.\r\n\r\n#Lower extremity edema\r\nDiuresed as needed. \r\n\r\n#Right leg DVT\r\nContinued lovenox ___ mg once per day.She has IVC filter in \r\nplace.\r\n\r\n#Right lower back pain\r\nAggravated from moving. Persistent since past few months. \r\nContinued oxycodone.\r\nLumbar spine MRI with and without contrast to evaluate new \r\nright-sided sciatic pain with no significant changes.\r\n\r\n#Asthma\r\nInhalers were used as needed.\r\n\r\nTransitional Issues\r\n=======================\r\n\r\n[ ] Follow-up on cyclosporine levels \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Enoxaparin Sodium 100 mg SC Q24H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n3. Fluconazole 400 mg PO Q24H \r\n4. FoLIC Acid 1 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n7. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n8. Senna 8.6 mg PO BID:PRN constipation  \r\n9. Venlafaxine 25 mg PO BID \r\n10. CycloSPORINE (Neoral) MODIFIED 100 mg PO QAM \r\n11. Multivitamins 1 TAB PO DAILY \r\n12. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n\r\n13. Loratadine 10 mg PO DAILY cold \r\n14. Omeprazole 20 mg PO DAILY \r\n15. Ondansetron 4 mg PO Q8H:PRN nausea \r\n16. Ursodiol 300 mg PO QAM \r\n17. Ursodiol 600 mg PO QPM \r\n18. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n19. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n20. Acyclovir 200 mg PO 5X/D \r\n21. CycloSPORINE (Neoral) MODIFIED 125 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  ValGANCIclovir 900 mg PO Q12H \r\nRX *valganciclovir 450 mg 2 tablet(s) by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n2.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H \r\nRX *cyclosporine modified 25 mg 3 capsule(s) by mouth twice a \r\nday Disp #*180 Capsule Refills:*0 \r\n3.  Enoxaparin Sodium 100 mg SC DAILY \r\nStart: ___, First Dose: Next Routine Administration Time  \r\n4.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n5.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole [Diflucan] 200 mg 2 tablet(s) by mouth once a \r\nday Disp #*60 Tablet Refills:*0 \r\n6.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n \r\n7.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Gabapentin 400 mg PO BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n10.  Loratadine 10 mg PO DAILY cold  \r\n11.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n12.  Multivitamins 1 TAB PO DAILY  \r\n13.  Omeprazole 20 mg PO DAILY  \r\n14.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n15.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n16.  Senna 8.6 mg PO BID:PRN constipation   \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth qam Disp #*30 Capsule \r\nRefills:*0 \r\n19.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth qpm Disp #*60 Capsule \r\nRefills:*0 \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\nAseptic meningitis\r\nCMV Viremia\r\nMDS\r\n\r\n___:\r\nCVID\r\nRight leg DVT\r\nAsthma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nIt was a pleasure being involved in your care. \r\n\r\nWhy you were here: \r\n-You came in with a headaches, vomiting and a fever. \r\n\r\nWhat we did while you were here: \r\n-We tested you for an infection in the brain and treated you for \r\nwhat may have been a viral infection. \r\n\r\nWhat to do when you are discharged: \r\n-Continue taking your medications as prescribed \r\n-Attend your follow-up appointments \r\n\r\nIt was a pleasure taking care of you! We wish you the best!\r\n\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-23:4",
      "text": "Brief Hospital Course:\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT, \nsubsequent treatment related MDS now ___ URD allogeneic \ntransplant, also h/o CVID (on IVIg), GERD, OA, h/o R DVT ___ IVC \nfilter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b mild \nCN6 palsy, hypertensive, presented on ___ with fever (T 100.5),\nnausea/vomiting, headaches most concerning for meningitis. #Aseptic meningitis\nShe initially presented with headache fever, nausea and \nvomiting. She was treated initially with cefepime and acyclovir \nto cover both bacterial meningitis and HSV meningitis. These \nwere discontinued when an LP from ___ was  consistent with \naseptic meningitis and no HSV was found in the CSF. Extensive \nworkup for VZV EBV HSV HHV6 adenovirus arbovirus TB\nAnaplasma and serum toxoplasmosis was negative. She was noted \nto have CMV viremia and although this is an unlikely cause of \nmeningitis she was treated with ganciclovir. #CMV viremia\nFound to have CMV vl on ___, which persisted. She was treated \nwith IV ganciclovir and then transitioned to oral valganciclovir \nprior to discharge. #Diarrhea\nShe had mild diarrhea on and off throughout her admission that \nwas thought to be likely due to GVHD versus infection. C. difficile from ___ was negative. Stool frequency slowly \nimproved over admission. #Anorexia \nWaxing and waning appetite that was concerning for acute GVHD. A GI consult was considered for upper/lower endoscopy, but her \nappetite slowly improved over admission. She never had \ndysphasia, odynophagia, or early satiety. #Dyspnea\nShe was noted to be short of breath on ___. She had a drop in \nher oxygen saturation to the high ___ while ambulating this day. ECG was unchanged. And a CTA was negative. She had an echo \nperformed on ___ which is similar to a prior study on ___ with \nleft ventricular systolic dysfunction and hypokinesis of the \ninferior/inferior lateral walls. Repeat ambulatory sat on the \nday of discharge was within normal limits. #MDS\n___ allogeneic transplant with URD with reduced intensity \nFlu/Bu/ATG conditioning. D0 = ___. Continued prophylaxis \nwith Bactrim and Fluconazole. Acyclovir on hold while on \ngancyclovir. Continued cyclosporine. #Lower extremity edema\nDiuresed as needed. #Right leg DVT\nContinued lovenox ___ mg once per day.She has IVC filter in \nplace. #Right lower back pain\nAggravated from moving. Persistent since past few months. Continued oxycodone. Lumbar spine MRI with and without contrast to evaluate new \nright-sided sciatic pain with no significant changes. #Asthma\nInhalers were used as needed. Transitional Issues\n======================= [ ] Follow-up on cyclosporine levels \n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Enoxaparin Sodium 100 mg SC Q24H \n2.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-23",
        "chart_time": "104710",
        "section": "General",
        "position": 4,
        "tokenCount": 697,
        "note_metadata": {
          "note_id": "18887130-DS-23",
          "subject_id": 18887130,
          "hadm_id": 26001675,
          "note_type": "DS",
          "note_seq": 23,
          "charttime": 104710,
          "storetime": 104711.45277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nFever, headaches, vomiting \r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture\r\n\r\n \r\nHistory of Present Illness:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT,\r\nsubsequent treatment related MDS now ___ URD allogeneic\r\ntransplant D+___, also h/o CVID (on IVIg), GERD, OA, h/o R DVT \r\n___\r\nIVC filter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b \r\nmild\r\nCN6 palsy, hypertensive, obesity presents with fever (T 100.5)\r\nand vomiting. \r\n\r\nToday, she had another episode of vomiting, without drinking any\r\ncoffee. She also noted frontal headache in band like \r\ndistribution\r\naround her head. She reports no neck stiffness (other than\r\nbaseline related to cervical radiculopathy with radiation down R\r\narm). Denies changes in vision, numbness, weakness. She has\r\ninfrequent, scattered abdominal pain. Denies further diarrhea.\r\nDenies rash. No chest pain, dyspnea, cough, dysuria. \r\n\r\nVS in ER T99.9 94 150/67 18 100% RA . Appears comfortable on the\r\nfloor. No other issues.\r\n\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM: \r\n\r\nGENERAL: No fever, chills, night sweats, recent weight changes. \r\nHEENT: No sores in the mouth, painful swallowing, intolerance to\r\nliquids or solids, sinus tenderness, rhinorrhea, or congestion. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough, shortness of breath, hemoptysis, or wheezing. \r\nGI: No nausea, vomiting, diarrhea, constipation or abdominal\r\npain.  \r\nGU: No dysuria or change in bladder habits. \r\nMSK: No arthritis, arthralgias, myalgias, or bone pain. \r\nDERM: Denies rashes, itching, or skin breakdown. \r\nNEURO: Mild ___ diffuse headache. No visual changes, +Chronic\r\nRUE tingling, No other focal neurologic symptoms. \r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nGen: NAD, sitting comfortably in a chair\r\nHEENT: MMM, oropharynx clear. No LAD.\r\nCV:  regular rhythm, no murmurs\r\nPULM:  CTAB, No crackles or wheezes.\r\nABD:  BS+, soft, NTND,\r\nExt: 1 ___ edema, no clubbing/tremors, venous stasis\r\ndermatitis bilaterally on ___\r\nSKIN:  No rashes\r\nNeuro: A&Ox3, prior R CN6 palsy and R pupil with minimal \r\nresponse\r\nto light, ___ strength throughout, sensation intact. No nuchal\r\nrigidity or photophobia.\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD CMV VL-3.4*\r\n___ 12:00AM BLOOD CMV VL-2.9*\r\n \r\nBrief Hospital Course:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT, \r\nsubsequent treatment related MDS now ___ URD allogeneic \r\ntransplant, also h/o CVID (on IVIg), GERD, OA, h/o R DVT ___ IVC \r\nfilter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b mild \r\nCN6 palsy, hypertensive, presented on ___ with fever (T 100.5),\r\nnausea/vomiting, headaches most concerning for meningitis.\r\n\r\n#Aseptic meningitis\r\nShe initially presented with headache fever, nausea and \r\nvomiting.  She was treated initially with cefepime and acyclovir \r\nto cover both bacterial meningitis and HSV meningitis.  These \r\nwere discontinued when an LP from ___ was  consistent with \r\naseptic meningitis and no HSV was found in the CSF.  Extensive \r\nworkup for VZV EBV HSV HHV6 adenovirus arbovirus TB\r\nAnaplasma and serum toxoplasmosis was negative.  She was noted \r\nto have CMV viremia and although this is an unlikely cause of \r\nmeningitis she was treated with ganciclovir.\r\n\r\n#CMV viremia\r\nFound to have CMV vl on ___, which persisted. She was treated \r\nwith IV ganciclovir and then transitioned to oral valganciclovir \r\nprior to discharge.\r\n\r\n#Diarrhea\r\nShe had mild diarrhea on and off throughout her admission that \r\nwas thought to be likely due to GVHD versus infection.  C. \r\ndifficile from ___ was negative.  Stool frequency slowly \r\nimproved over admission.\r\n\r\n#Anorexia \r\nWaxing and waning appetite that was concerning for acute GVHD.  \r\nA GI consult was considered for upper/lower endoscopy, but her \r\nappetite slowly improved over admission.  She never had \r\ndysphasia, odynophagia, or early satiety.\r\n\r\n#Dyspnea\r\nShe was noted to be short of breath on ___.  She had a drop in \r\nher oxygen saturation to the high ___ while ambulating this day. \r\n ECG was unchanged.  And a CTA was negative.  She had an echo \r\nperformed on ___ which is similar to a prior study on ___ with \r\nleft ventricular systolic dysfunction and hypokinesis of the \r\ninferior/inferior lateral walls.  Repeat ambulatory sat on the \r\nday of discharge was within normal limits.\r\n\r\n#MDS\r\n___ allogeneic transplant with URD with reduced intensity \r\nFlu/Bu/ATG conditioning. D0 = ___. Continued prophylaxis \r\nwith Bactrim and Fluconazole. Acyclovir on hold while on \r\ngancyclovir. Continued cyclosporine.\r\n\r\n#Lower extremity edema\r\nDiuresed as needed. \r\n\r\n#Right leg DVT\r\nContinued lovenox ___ mg once per day.She has IVC filter in \r\nplace.\r\n\r\n#Right lower back pain\r\nAggravated from moving. Persistent since past few months. \r\nContinued oxycodone.\r\nLumbar spine MRI with and without contrast to evaluate new \r\nright-sided sciatic pain with no significant changes.\r\n\r\n#Asthma\r\nInhalers were used as needed.\r\n\r\nTransitional Issues\r\n=======================\r\n\r\n[ ] Follow-up on cyclosporine levels \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Enoxaparin Sodium 100 mg SC Q24H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n3. Fluconazole 400 mg PO Q24H \r\n4. FoLIC Acid 1 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n7. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n8. Senna 8.6 mg PO BID:PRN constipation  \r\n9. Venlafaxine 25 mg PO BID \r\n10. CycloSPORINE (Neoral) MODIFIED 100 mg PO QAM \r\n11. Multivitamins 1 TAB PO DAILY \r\n12. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n\r\n13. Loratadine 10 mg PO DAILY cold \r\n14. Omeprazole 20 mg PO DAILY \r\n15. Ondansetron 4 mg PO Q8H:PRN nausea \r\n16. Ursodiol 300 mg PO QAM \r\n17. Ursodiol 600 mg PO QPM \r\n18. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n19. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n20. Acyclovir 200 mg PO 5X/D \r\n21. CycloSPORINE (Neoral) MODIFIED 125 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  ValGANCIclovir 900 mg PO Q12H \r\nRX *valganciclovir 450 mg 2 tablet(s) by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n2.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H \r\nRX *cyclosporine modified 25 mg 3 capsule(s) by mouth twice a \r\nday Disp #*180 Capsule Refills:*0 \r\n3.  Enoxaparin Sodium 100 mg SC DAILY \r\nStart: ___, First Dose: Next Routine Administration Time  \r\n4.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n5.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole [Diflucan] 200 mg 2 tablet(s) by mouth once a \r\nday Disp #*60 Tablet Refills:*0 \r\n6.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n \r\n7.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Gabapentin 400 mg PO BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n10.  Loratadine 10 mg PO DAILY cold  \r\n11.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n12.  Multivitamins 1 TAB PO DAILY  \r\n13.  Omeprazole 20 mg PO DAILY  \r\n14.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n15.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n16.  Senna 8.6 mg PO BID:PRN constipation   \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth qam Disp #*30 Capsule \r\nRefills:*0 \r\n19.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth qpm Disp #*60 Capsule \r\nRefills:*0 \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\nAseptic meningitis\r\nCMV Viremia\r\nMDS\r\n\r\n___:\r\nCVID\r\nRight leg DVT\r\nAsthma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nIt was a pleasure being involved in your care. \r\n\r\nWhy you were here: \r\n-You came in with a headaches, vomiting and a fever. \r\n\r\nWhat we did while you were here: \r\n-We tested you for an infection in the brain and treated you for \r\nwhat may have been a viral infection. \r\n\r\nWhat to do when you are discharged: \r\n-Continue taking your medications as prescribed \r\n-Attend your follow-up appointments \r\n\r\nIt was a pleasure taking care of you! We wish you the best!\r\n\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-23:5",
      "text": "#Lower extremity edema\nDiuresed as needed. #Right leg DVT\nContinued lovenox ___ mg once per day.She has IVC filter in \nplace. #Right lower back pain\nAggravated from moving. Persistent since past few months. Continued oxycodone. Lumbar spine MRI with and without contrast to evaluate new \nright-sided sciatic pain with no significant changes. #Asthma\nInhalers were used as needed. Transitional Issues\n======================= [ ] Follow-up on cyclosporine levels \n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Enoxaparin Sodium 100 mg SC Q24H \n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \n3. Fluconazole 400 mg PO Q24H \n4. FoLIC Acid 1 mg PO DAILY \n5. Gabapentin 400 mg PO BID \n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \n7. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \n8. Senna 8.6 mg PO BID:PRN constipation  \n9. Venlafaxine 25 mg PO BID \n10. CycloSPORINE (Neoral) MODIFIED 100 mg PO QAM \n11. Multivitamins 1 TAB PO DAILY \n12. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze 13. Loratadine 10 mg PO DAILY cold \n14. Omeprazole 20 mg PO DAILY \n15. Ondansetron 4 mg PO Q8H:PRN nausea \n16. Ursodiol 300 mg PO QAM \n17. Ursodiol 600 mg PO QPM \n18. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \nnot relieved by ondansetron \n19. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \n20. Acyclovir 200 mg PO 5X/D \n21. CycloSPORINE (Neoral) MODIFIED 125 mg PO QPM",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-23",
        "chart_time": "104710",
        "section": "General",
        "position": 5,
        "tokenCount": 360,
        "note_metadata": {
          "note_id": "18887130-DS-23",
          "subject_id": 18887130,
          "hadm_id": 26001675,
          "note_type": "DS",
          "note_seq": 23,
          "charttime": 104710,
          "storetime": 104711.45277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nFever, headaches, vomiting \r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture\r\n\r\n \r\nHistory of Present Illness:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT,\r\nsubsequent treatment related MDS now ___ URD allogeneic\r\ntransplant D+___, also h/o CVID (on IVIg), GERD, OA, h/o R DVT \r\n___\r\nIVC filter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b \r\nmild\r\nCN6 palsy, hypertensive, obesity presents with fever (T 100.5)\r\nand vomiting. \r\n\r\nToday, she had another episode of vomiting, without drinking any\r\ncoffee. She also noted frontal headache in band like \r\ndistribution\r\naround her head. She reports no neck stiffness (other than\r\nbaseline related to cervical radiculopathy with radiation down R\r\narm). Denies changes in vision, numbness, weakness. She has\r\ninfrequent, scattered abdominal pain. Denies further diarrhea.\r\nDenies rash. No chest pain, dyspnea, cough, dysuria. \r\n\r\nVS in ER T99.9 94 150/67 18 100% RA . Appears comfortable on the\r\nfloor. No other issues.\r\n\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM: \r\n\r\nGENERAL: No fever, chills, night sweats, recent weight changes. \r\nHEENT: No sores in the mouth, painful swallowing, intolerance to\r\nliquids or solids, sinus tenderness, rhinorrhea, or congestion. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough, shortness of breath, hemoptysis, or wheezing. \r\nGI: No nausea, vomiting, diarrhea, constipation or abdominal\r\npain.  \r\nGU: No dysuria or change in bladder habits. \r\nMSK: No arthritis, arthralgias, myalgias, or bone pain. \r\nDERM: Denies rashes, itching, or skin breakdown. \r\nNEURO: Mild ___ diffuse headache. No visual changes, +Chronic\r\nRUE tingling, No other focal neurologic symptoms. \r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nGen: NAD, sitting comfortably in a chair\r\nHEENT: MMM, oropharynx clear. No LAD.\r\nCV:  regular rhythm, no murmurs\r\nPULM:  CTAB, No crackles or wheezes.\r\nABD:  BS+, soft, NTND,\r\nExt: 1 ___ edema, no clubbing/tremors, venous stasis\r\ndermatitis bilaterally on ___\r\nSKIN:  No rashes\r\nNeuro: A&Ox3, prior R CN6 palsy and R pupil with minimal \r\nresponse\r\nto light, ___ strength throughout, sensation intact. No nuchal\r\nrigidity or photophobia.\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD CMV VL-3.4*\r\n___ 12:00AM BLOOD CMV VL-2.9*\r\n \r\nBrief Hospital Course:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT, \r\nsubsequent treatment related MDS now ___ URD allogeneic \r\ntransplant, also h/o CVID (on IVIg), GERD, OA, h/o R DVT ___ IVC \r\nfilter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b mild \r\nCN6 palsy, hypertensive, presented on ___ with fever (T 100.5),\r\nnausea/vomiting, headaches most concerning for meningitis.\r\n\r\n#Aseptic meningitis\r\nShe initially presented with headache fever, nausea and \r\nvomiting.  She was treated initially with cefepime and acyclovir \r\nto cover both bacterial meningitis and HSV meningitis.  These \r\nwere discontinued when an LP from ___ was  consistent with \r\naseptic meningitis and no HSV was found in the CSF.  Extensive \r\nworkup for VZV EBV HSV HHV6 adenovirus arbovirus TB\r\nAnaplasma and serum toxoplasmosis was negative.  She was noted \r\nto have CMV viremia and although this is an unlikely cause of \r\nmeningitis she was treated with ganciclovir.\r\n\r\n#CMV viremia\r\nFound to have CMV vl on ___, which persisted. She was treated \r\nwith IV ganciclovir and then transitioned to oral valganciclovir \r\nprior to discharge.\r\n\r\n#Diarrhea\r\nShe had mild diarrhea on and off throughout her admission that \r\nwas thought to be likely due to GVHD versus infection.  C. \r\ndifficile from ___ was negative.  Stool frequency slowly \r\nimproved over admission.\r\n\r\n#Anorexia \r\nWaxing and waning appetite that was concerning for acute GVHD.  \r\nA GI consult was considered for upper/lower endoscopy, but her \r\nappetite slowly improved over admission.  She never had \r\ndysphasia, odynophagia, or early satiety.\r\n\r\n#Dyspnea\r\nShe was noted to be short of breath on ___.  She had a drop in \r\nher oxygen saturation to the high ___ while ambulating this day. \r\n ECG was unchanged.  And a CTA was negative.  She had an echo \r\nperformed on ___ which is similar to a prior study on ___ with \r\nleft ventricular systolic dysfunction and hypokinesis of the \r\ninferior/inferior lateral walls.  Repeat ambulatory sat on the \r\nday of discharge was within normal limits.\r\n\r\n#MDS\r\n___ allogeneic transplant with URD with reduced intensity \r\nFlu/Bu/ATG conditioning. D0 = ___. Continued prophylaxis \r\nwith Bactrim and Fluconazole. Acyclovir on hold while on \r\ngancyclovir. Continued cyclosporine.\r\n\r\n#Lower extremity edema\r\nDiuresed as needed. \r\n\r\n#Right leg DVT\r\nContinued lovenox ___ mg once per day.She has IVC filter in \r\nplace.\r\n\r\n#Right lower back pain\r\nAggravated from moving. Persistent since past few months. \r\nContinued oxycodone.\r\nLumbar spine MRI with and without contrast to evaluate new \r\nright-sided sciatic pain with no significant changes.\r\n\r\n#Asthma\r\nInhalers were used as needed.\r\n\r\nTransitional Issues\r\n=======================\r\n\r\n[ ] Follow-up on cyclosporine levels \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Enoxaparin Sodium 100 mg SC Q24H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n3. Fluconazole 400 mg PO Q24H \r\n4. FoLIC Acid 1 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n7. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n8. Senna 8.6 mg PO BID:PRN constipation  \r\n9. Venlafaxine 25 mg PO BID \r\n10. CycloSPORINE (Neoral) MODIFIED 100 mg PO QAM \r\n11. Multivitamins 1 TAB PO DAILY \r\n12. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n\r\n13. Loratadine 10 mg PO DAILY cold \r\n14. Omeprazole 20 mg PO DAILY \r\n15. Ondansetron 4 mg PO Q8H:PRN nausea \r\n16. Ursodiol 300 mg PO QAM \r\n17. Ursodiol 600 mg PO QPM \r\n18. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n19. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n20. Acyclovir 200 mg PO 5X/D \r\n21. CycloSPORINE (Neoral) MODIFIED 125 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  ValGANCIclovir 900 mg PO Q12H \r\nRX *valganciclovir 450 mg 2 tablet(s) by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n2.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H \r\nRX *cyclosporine modified 25 mg 3 capsule(s) by mouth twice a \r\nday Disp #*180 Capsule Refills:*0 \r\n3.  Enoxaparin Sodium 100 mg SC DAILY \r\nStart: ___, First Dose: Next Routine Administration Time  \r\n4.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n5.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole [Diflucan] 200 mg 2 tablet(s) by mouth once a \r\nday Disp #*60 Tablet Refills:*0 \r\n6.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n \r\n7.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Gabapentin 400 mg PO BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n10.  Loratadine 10 mg PO DAILY cold  \r\n11.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n12.  Multivitamins 1 TAB PO DAILY  \r\n13.  Omeprazole 20 mg PO DAILY  \r\n14.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n15.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n16.  Senna 8.6 mg PO BID:PRN constipation   \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth qam Disp #*30 Capsule \r\nRefills:*0 \r\n19.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth qpm Disp #*60 Capsule \r\nRefills:*0 \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\nAseptic meningitis\r\nCMV Viremia\r\nMDS\r\n\r\n___:\r\nCVID\r\nRight leg DVT\r\nAsthma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nIt was a pleasure being involved in your care. \r\n\r\nWhy you were here: \r\n-You came in with a headaches, vomiting and a fever. \r\n\r\nWhat we did while you were here: \r\n-We tested you for an infection in the brain and treated you for \r\nwhat may have been a viral infection. \r\n\r\nWhat to do when you are discharged: \r\n-Continue taking your medications as prescribed \r\n-Attend your follow-up appointments \r\n\r\nIt was a pleasure taking care of you! We wish you the best!\r\n\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-23:6",
      "text": "Discharge Medications:\n1. ValGANCIclovir 900 mg PO Q12H \nRX *valganciclovir 450 mg 2 tablet(s) by mouth twice a day Disp \n#*60 Tablet Refills:*0 \n2. CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H \nRX *cyclosporine modified 25 mg 3 capsule(s) by mouth twice a \nday Disp #*180 Capsule Refills:*0 \n3. Enoxaparin Sodium 100 mg SC DAILY \nStart: ___, First Dose: Next Routine Administration Time  \n4. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \n5. Fluconazole 400 mg PO Q24H \nRX *fluconazole [Diflucan] 200 mg 2 tablet(s) by mouth once a \nday Disp #*60 Tablet Refills:*0 \n6. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \n \n7. FoLIC Acid 1 mg PO DAILY \nRX *folic acid 1 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n8. Gabapentin 400 mg PO BID  \n9. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \n10. Loratadine 10 mg PO DAILY cold  \n11. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \nnot relieved by ondansetron  \n12. Multivitamins 1 TAB PO DAILY  \n13. Omeprazole 20 mg PO DAILY  \n14. Ondansetron 4 mg PO Q8H:PRN nausea  \n15. Polyethylene Glycol 17 g PO DAILY:PRN constipation   \n16. Senna 8.6 mg PO BID:PRN constipation   \n17. Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \n18. Ursodiol 300 mg PO QAM \nRX *ursodiol 300 mg 1 capsule(s) by mouth qam Disp #*30 Capsule \nRefills:*0 \n19. Ursodiol 600 mg PO QPM \nRX *ursodiol 300 mg 2 capsule(s) by mouth qpm Disp #*60 Capsule \nRefills:*0 \n20. Venlafaxine 25 mg PO BID Discharge Disposition:\nHome Discharge Diagnosis:\nPrimary Diagnoses:\nAseptic meningitis\nCMV Viremia\nMDS ___:\nCVID\nRight leg DVT\nAsthma Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-23",
        "chart_time": "104710",
        "section": "General",
        "position": 6,
        "tokenCount": 436,
        "note_metadata": {
          "note_id": "18887130-DS-23",
          "subject_id": 18887130,
          "hadm_id": 26001675,
          "note_type": "DS",
          "note_seq": 23,
          "charttime": 104710,
          "storetime": 104711.45277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nFever, headaches, vomiting \r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture\r\n\r\n \r\nHistory of Present Illness:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT,\r\nsubsequent treatment related MDS now ___ URD allogeneic\r\ntransplant D+___, also h/o CVID (on IVIg), GERD, OA, h/o R DVT \r\n___\r\nIVC filter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b \r\nmild\r\nCN6 palsy, hypertensive, obesity presents with fever (T 100.5)\r\nand vomiting. \r\n\r\nToday, she had another episode of vomiting, without drinking any\r\ncoffee. She also noted frontal headache in band like \r\ndistribution\r\naround her head. She reports no neck stiffness (other than\r\nbaseline related to cervical radiculopathy with radiation down R\r\narm). Denies changes in vision, numbness, weakness. She has\r\ninfrequent, scattered abdominal pain. Denies further diarrhea.\r\nDenies rash. No chest pain, dyspnea, cough, dysuria. \r\n\r\nVS in ER T99.9 94 150/67 18 100% RA . Appears comfortable on the\r\nfloor. No other issues.\r\n\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM: \r\n\r\nGENERAL: No fever, chills, night sweats, recent weight changes. \r\nHEENT: No sores in the mouth, painful swallowing, intolerance to\r\nliquids or solids, sinus tenderness, rhinorrhea, or congestion. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough, shortness of breath, hemoptysis, or wheezing. \r\nGI: No nausea, vomiting, diarrhea, constipation or abdominal\r\npain.  \r\nGU: No dysuria or change in bladder habits. \r\nMSK: No arthritis, arthralgias, myalgias, or bone pain. \r\nDERM: Denies rashes, itching, or skin breakdown. \r\nNEURO: Mild ___ diffuse headache. No visual changes, +Chronic\r\nRUE tingling, No other focal neurologic symptoms. \r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nGen: NAD, sitting comfortably in a chair\r\nHEENT: MMM, oropharynx clear. No LAD.\r\nCV:  regular rhythm, no murmurs\r\nPULM:  CTAB, No crackles or wheezes.\r\nABD:  BS+, soft, NTND,\r\nExt: 1 ___ edema, no clubbing/tremors, venous stasis\r\ndermatitis bilaterally on ___\r\nSKIN:  No rashes\r\nNeuro: A&Ox3, prior R CN6 palsy and R pupil with minimal \r\nresponse\r\nto light, ___ strength throughout, sensation intact. No nuchal\r\nrigidity or photophobia.\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD CMV VL-3.4*\r\n___ 12:00AM BLOOD CMV VL-2.9*\r\n \r\nBrief Hospital Course:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT, \r\nsubsequent treatment related MDS now ___ URD allogeneic \r\ntransplant, also h/o CVID (on IVIg), GERD, OA, h/o R DVT ___ IVC \r\nfilter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b mild \r\nCN6 palsy, hypertensive, presented on ___ with fever (T 100.5),\r\nnausea/vomiting, headaches most concerning for meningitis.\r\n\r\n#Aseptic meningitis\r\nShe initially presented with headache fever, nausea and \r\nvomiting.  She was treated initially with cefepime and acyclovir \r\nto cover both bacterial meningitis and HSV meningitis.  These \r\nwere discontinued when an LP from ___ was  consistent with \r\naseptic meningitis and no HSV was found in the CSF.  Extensive \r\nworkup for VZV EBV HSV HHV6 adenovirus arbovirus TB\r\nAnaplasma and serum toxoplasmosis was negative.  She was noted \r\nto have CMV viremia and although this is an unlikely cause of \r\nmeningitis she was treated with ganciclovir.\r\n\r\n#CMV viremia\r\nFound to have CMV vl on ___, which persisted. She was treated \r\nwith IV ganciclovir and then transitioned to oral valganciclovir \r\nprior to discharge.\r\n\r\n#Diarrhea\r\nShe had mild diarrhea on and off throughout her admission that \r\nwas thought to be likely due to GVHD versus infection.  C. \r\ndifficile from ___ was negative.  Stool frequency slowly \r\nimproved over admission.\r\n\r\n#Anorexia \r\nWaxing and waning appetite that was concerning for acute GVHD.  \r\nA GI consult was considered for upper/lower endoscopy, but her \r\nappetite slowly improved over admission.  She never had \r\ndysphasia, odynophagia, or early satiety.\r\n\r\n#Dyspnea\r\nShe was noted to be short of breath on ___.  She had a drop in \r\nher oxygen saturation to the high ___ while ambulating this day. \r\n ECG was unchanged.  And a CTA was negative.  She had an echo \r\nperformed on ___ which is similar to a prior study on ___ with \r\nleft ventricular systolic dysfunction and hypokinesis of the \r\ninferior/inferior lateral walls.  Repeat ambulatory sat on the \r\nday of discharge was within normal limits.\r\n\r\n#MDS\r\n___ allogeneic transplant with URD with reduced intensity \r\nFlu/Bu/ATG conditioning. D0 = ___. Continued prophylaxis \r\nwith Bactrim and Fluconazole. Acyclovir on hold while on \r\ngancyclovir. Continued cyclosporine.\r\n\r\n#Lower extremity edema\r\nDiuresed as needed. \r\n\r\n#Right leg DVT\r\nContinued lovenox ___ mg once per day.She has IVC filter in \r\nplace.\r\n\r\n#Right lower back pain\r\nAggravated from moving. Persistent since past few months. \r\nContinued oxycodone.\r\nLumbar spine MRI with and without contrast to evaluate new \r\nright-sided sciatic pain with no significant changes.\r\n\r\n#Asthma\r\nInhalers were used as needed.\r\n\r\nTransitional Issues\r\n=======================\r\n\r\n[ ] Follow-up on cyclosporine levels \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Enoxaparin Sodium 100 mg SC Q24H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n3. Fluconazole 400 mg PO Q24H \r\n4. FoLIC Acid 1 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n7. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n8. Senna 8.6 mg PO BID:PRN constipation  \r\n9. Venlafaxine 25 mg PO BID \r\n10. CycloSPORINE (Neoral) MODIFIED 100 mg PO QAM \r\n11. Multivitamins 1 TAB PO DAILY \r\n12. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n\r\n13. Loratadine 10 mg PO DAILY cold \r\n14. Omeprazole 20 mg PO DAILY \r\n15. Ondansetron 4 mg PO Q8H:PRN nausea \r\n16. Ursodiol 300 mg PO QAM \r\n17. Ursodiol 600 mg PO QPM \r\n18. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n19. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n20. Acyclovir 200 mg PO 5X/D \r\n21. CycloSPORINE (Neoral) MODIFIED 125 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  ValGANCIclovir 900 mg PO Q12H \r\nRX *valganciclovir 450 mg 2 tablet(s) by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n2.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H \r\nRX *cyclosporine modified 25 mg 3 capsule(s) by mouth twice a \r\nday Disp #*180 Capsule Refills:*0 \r\n3.  Enoxaparin Sodium 100 mg SC DAILY \r\nStart: ___, First Dose: Next Routine Administration Time  \r\n4.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n5.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole [Diflucan] 200 mg 2 tablet(s) by mouth once a \r\nday Disp #*60 Tablet Refills:*0 \r\n6.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n \r\n7.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Gabapentin 400 mg PO BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n10.  Loratadine 10 mg PO DAILY cold  \r\n11.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n12.  Multivitamins 1 TAB PO DAILY  \r\n13.  Omeprazole 20 mg PO DAILY  \r\n14.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n15.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n16.  Senna 8.6 mg PO BID:PRN constipation   \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth qam Disp #*30 Capsule \r\nRefills:*0 \r\n19.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth qpm Disp #*60 Capsule \r\nRefills:*0 \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\nAseptic meningitis\r\nCMV Viremia\r\nMDS\r\n\r\n___:\r\nCVID\r\nRight leg DVT\r\nAsthma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nIt was a pleasure being involved in your care. \r\n\r\nWhy you were here: \r\n-You came in with a headaches, vomiting and a fever. \r\n\r\nWhat we did while you were here: \r\n-We tested you for an infection in the brain and treated you for \r\nwhat may have been a viral infection. \r\n\r\nWhat to do when you are discharged: \r\n-Continue taking your medications as prescribed \r\n-Attend your follow-up appointments \r\n\r\nIt was a pleasure taking care of you! We wish you the best!\r\n\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-23:7",
      "text": "Discharge Instructions:\nDear Ms. ___, It was a pleasure being involved in your care. Why you were here: \n-You came in with a headaches, vomiting and a fever. What we did while you were here: \n-We tested you for an infection in the brain and treated you for \nwhat may have been a viral infection. What to do when you are discharged: \n-Continue taking your medications as prescribed \n-Attend your follow-up appointments It was a pleasure taking care of you! We wish you the best! Your ___ Team \n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-23",
        "chart_time": "104710",
        "section": "General",
        "position": 7,
        "tokenCount": 131,
        "note_metadata": {
          "note_id": "18887130-DS-23",
          "subject_id": 18887130,
          "hadm_id": 26001675,
          "note_type": "DS",
          "note_seq": 23,
          "charttime": 104710,
          "storetime": 104711.45277777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nFever, headaches, vomiting \r\n \r\nMajor Surgical or Invasive Procedure:\r\nLumbar puncture\r\n\r\n \r\nHistory of Present Illness:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT,\r\nsubsequent treatment related MDS now ___ URD allogeneic\r\ntransplant D+___, also h/o CVID (on IVIg), GERD, OA, h/o R DVT \r\n___\r\nIVC filter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b \r\nmild\r\nCN6 palsy, hypertensive, obesity presents with fever (T 100.5)\r\nand vomiting. \r\n\r\nToday, she had another episode of vomiting, without drinking any\r\ncoffee. She also noted frontal headache in band like \r\ndistribution\r\naround her head. She reports no neck stiffness (other than\r\nbaseline related to cervical radiculopathy with radiation down R\r\narm). Denies changes in vision, numbness, weakness. She has\r\ninfrequent, scattered abdominal pain. Denies further diarrhea.\r\nDenies rash. No chest pain, dyspnea, cough, dysuria. \r\n\r\nVS in ER T99.9 94 150/67 18 100% RA . Appears comfortable on the\r\nfloor. No other issues.\r\n\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM: \r\n\r\nGENERAL: No fever, chills, night sweats, recent weight changes. \r\nHEENT: No sores in the mouth, painful swallowing, intolerance to\r\nliquids or solids, sinus tenderness, rhinorrhea, or congestion. \r\nCARDS: No chest pain, chest pressure, exertional symptoms, or\r\npalpitations. \r\nPULM: No cough, shortness of breath, hemoptysis, or wheezing. \r\nGI: No nausea, vomiting, diarrhea, constipation or abdominal\r\npain.  \r\nGU: No dysuria or change in bladder habits. \r\nMSK: No arthritis, arthralgias, myalgias, or bone pain. \r\nDERM: Denies rashes, itching, or skin breakdown. \r\nNEURO: Mild ___ diffuse headache. No visual changes, +Chronic\r\nRUE tingling, No other focal neurologic symptoms. \r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nGen: NAD, sitting comfortably in a chair\r\nHEENT: MMM, oropharynx clear. No LAD.\r\nCV:  regular rhythm, no murmurs\r\nPULM:  CTAB, No crackles or wheezes.\r\nABD:  BS+, soft, NTND,\r\nExt: 1 ___ edema, no clubbing/tremors, venous stasis\r\ndermatitis bilaterally on ___\r\nSKIN:  No rashes\r\nNeuro: A&Ox3, prior R CN6 palsy and R pupil with minimal \r\nresponse\r\nto light, ___ strength throughout, sensation intact. No nuchal\r\nrigidity or photophobia.\r\n \r\nPertinent Results:\r\n___ 12:00AM BLOOD CMV VL-3.4*\r\n___ 12:00AM BLOOD CMV VL-2.9*\r\n \r\nBrief Hospital Course:\r\n___ yoF with transformed DLBCL ___ autoSCT ___ and IFRT, \r\nsubsequent treatment related MDS now ___ URD allogeneic \r\ntransplant, also h/o CVID (on IVIg), GERD, OA, h/o R DVT ___ IVC \r\nfilter, sciatica, OSA on CPAP, h/o cerebral aneurysm c/b mild \r\nCN6 palsy, hypertensive, presented on ___ with fever (T 100.5),\r\nnausea/vomiting, headaches most concerning for meningitis.\r\n\r\n#Aseptic meningitis\r\nShe initially presented with headache fever, nausea and \r\nvomiting.  She was treated initially with cefepime and acyclovir \r\nto cover both bacterial meningitis and HSV meningitis.  These \r\nwere discontinued when an LP from ___ was  consistent with \r\naseptic meningitis and no HSV was found in the CSF.  Extensive \r\nworkup for VZV EBV HSV HHV6 adenovirus arbovirus TB\r\nAnaplasma and serum toxoplasmosis was negative.  She was noted \r\nto have CMV viremia and although this is an unlikely cause of \r\nmeningitis she was treated with ganciclovir.\r\n\r\n#CMV viremia\r\nFound to have CMV vl on ___, which persisted. She was treated \r\nwith IV ganciclovir and then transitioned to oral valganciclovir \r\nprior to discharge.\r\n\r\n#Diarrhea\r\nShe had mild diarrhea on and off throughout her admission that \r\nwas thought to be likely due to GVHD versus infection.  C. \r\ndifficile from ___ was negative.  Stool frequency slowly \r\nimproved over admission.\r\n\r\n#Anorexia \r\nWaxing and waning appetite that was concerning for acute GVHD.  \r\nA GI consult was considered for upper/lower endoscopy, but her \r\nappetite slowly improved over admission.  She never had \r\ndysphasia, odynophagia, or early satiety.\r\n\r\n#Dyspnea\r\nShe was noted to be short of breath on ___.  She had a drop in \r\nher oxygen saturation to the high ___ while ambulating this day. \r\n ECG was unchanged.  And a CTA was negative.  She had an echo \r\nperformed on ___ which is similar to a prior study on ___ with \r\nleft ventricular systolic dysfunction and hypokinesis of the \r\ninferior/inferior lateral walls.  Repeat ambulatory sat on the \r\nday of discharge was within normal limits.\r\n\r\n#MDS\r\n___ allogeneic transplant with URD with reduced intensity \r\nFlu/Bu/ATG conditioning. D0 = ___. Continued prophylaxis \r\nwith Bactrim and Fluconazole. Acyclovir on hold while on \r\ngancyclovir. Continued cyclosporine.\r\n\r\n#Lower extremity edema\r\nDiuresed as needed. \r\n\r\n#Right leg DVT\r\nContinued lovenox ___ mg once per day.She has IVC filter in \r\nplace.\r\n\r\n#Right lower back pain\r\nAggravated from moving. Persistent since past few months. \r\nContinued oxycodone.\r\nLumbar spine MRI with and without contrast to evaluate new \r\nright-sided sciatic pain with no significant changes.\r\n\r\n#Asthma\r\nInhalers were used as needed.\r\n\r\nTransitional Issues\r\n=======================\r\n\r\n[ ] Follow-up on cyclosporine levels \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Enoxaparin Sodium 100 mg SC Q24H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n3. Fluconazole 400 mg PO Q24H \r\n4. FoLIC Acid 1 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n7. Polyethylene Glycol 17 g PO DAILY:PRN constipation  \r\n8. Senna 8.6 mg PO BID:PRN constipation  \r\n9. Venlafaxine 25 mg PO BID \r\n10. CycloSPORINE (Neoral) MODIFIED 100 mg PO QAM \r\n11. Multivitamins 1 TAB PO DAILY \r\n12. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n\r\n13. Loratadine 10 mg PO DAILY cold \r\n14. Omeprazole 20 mg PO DAILY \r\n15. Ondansetron 4 mg PO Q8H:PRN nausea \r\n16. Ursodiol 300 mg PO QAM \r\n17. Ursodiol 600 mg PO QPM \r\n18. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n19. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n20. Acyclovir 200 mg PO 5X/D \r\n21. CycloSPORINE (Neoral) MODIFIED 125 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  ValGANCIclovir 900 mg PO Q12H \r\nRX *valganciclovir 450 mg 2 tablet(s) by mouth twice a day Disp \r\n#*60 Tablet Refills:*0 \r\n2.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H \r\nRX *cyclosporine modified 25 mg 3 capsule(s) by mouth twice a \r\nday Disp #*180 Capsule Refills:*0 \r\n3.  Enoxaparin Sodium 100 mg SC DAILY \r\nStart: ___, First Dose: Next Routine Administration Time  \r\n4.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n5.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole [Diflucan] 200 mg 2 tablet(s) by mouth once a \r\nday Disp #*60 Tablet Refills:*0 \r\n6.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN cough/wheeze \r\n \r\n7.  FoLIC Acid 1 mg PO DAILY \r\nRX *folic acid 1 mg 1 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Gabapentin 400 mg PO BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n10.  Loratadine 10 mg PO DAILY cold  \r\n11.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n12.  Multivitamins 1 TAB PO DAILY  \r\n13.  Omeprazole 20 mg PO DAILY  \r\n14.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n15.  Polyethylene Glycol 17 g PO DAILY:PRN constipation   \r\n16.  Senna 8.6 mg PO BID:PRN constipation   \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Ursodiol 300 mg PO QAM \r\nRX *ursodiol 300 mg 1 capsule(s) by mouth qam Disp #*30 Capsule \r\nRefills:*0 \r\n19.  Ursodiol 600 mg PO QPM \r\nRX *ursodiol 300 mg 2 capsule(s) by mouth qpm Disp #*60 Capsule \r\nRefills:*0 \r\n20.  Venlafaxine 25 mg PO BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnoses:\r\nAseptic meningitis\r\nCMV Viremia\r\nMDS\r\n\r\n___:\r\nCVID\r\nRight leg DVT\r\nAsthma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___, \r\n\r\nIt was a pleasure being involved in your care. \r\n\r\nWhy you were here: \r\n-You came in with a headaches, vomiting and a fever. \r\n\r\nWhat we did while you were here: \r\n-We tested you for an infection in the brain and treated you for \r\nwhat may have been a viral infection. \r\n\r\nWhat to do when you are discharged: \r\n-Continue taking your medications as prescribed \r\n-Attend your follow-up appointments \r\n\r\nIt was a pleasure taking care of you! We wish you the best!\r\n\r\nYour ___ Team \r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-24:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \ndapsone\n \nAttending: ___. Chief Complaint:\nHeadache, Nausea, Vomiting\n \nMajor Surgical or Invasive Procedure:\nNone",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-24",
        "chart_time": "104763",
        "section": "General",
        "position": 0,
        "tokenCount": 73,
        "note_metadata": {
          "note_id": "18887130-DS-24",
          "subject_id": 18887130,
          "hadm_id": 23656314,
          "note_type": "DS",
          "note_seq": 24,
          "charttime": 104763,
          "storetime": 104766.75763888888,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nHeadache, Nausea, Vomiting\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\r\nTransplant who is admitted with a headache. The patient states\r\nher headache started yesterday morning. It was a right sided\r\nheadache which came down into her face. It intensified \r\nthroughout\r\nthe day and then in the afternoon she started vomiting numerous\r\ntimes. Which prompted her to go to the ED. She states the\r\nheadache was similar in location to when she gets migraines but\r\nthe duration was different and with migraines she usually gets\r\none episode of nausea in the morning and then it resolves. She\r\ndenies any neck stiffness, rashes, or fevers. She also denies \r\nany\r\nshortness of breath, diarrhea, or dysuria. \r\nShe went to the ED last night and had a head CT done which was \r\nunremarkable. She was then given Tylenol, dexamethasone,\r\nBenadryl, IV fluids, and Compazine. With improvement of her\r\nsymptoms. She then was discharged home early this morning. \r\nHer primary oncology team was concerned about the underlying\r\ncause of her headache given her history of a recent bone marrow\r\ntransplant and that she is on immunosuppression. So she was\r\ninstructed to return for admission for further workup. \r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL\r\n==================\r\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\r\nGeneral: No acute distress, sitting completely comfortably in a\r\nchair\r\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\r\nedema in right lower extremity, 2+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\nDISCHARGE PHYSICAL\r\n==================\r\nVS:  98.6 131 / 81 93 18 96 Ra \r\nGeneral: No acute distress, lying comfortably in bed\r\nHEENT: Hematoma and ecchymosis in occipital region of head,\r\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\r\nLAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: Edema over the radial aspect of the left wrist improving, \r\n1+\r\nperipheral edema in bilateral lower extremity, venous stasis\r\ndermatitis bilaterally on lower extremities, 1+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n==============\r\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \r\nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\r\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \r\nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \r\nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\r\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \r\nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\r\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\r\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \r\nK-4.2 Cl-104 HCO3-21* AnGap-14\r\n___ 11:17PM BLOOD Lipase-11\r\n___ 11:17PM BLOOD Albumin-3.6\r\n___ 11:22PM BLOOD Lactate-1.1\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \r\nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\r\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \r\nK-4.0 Cl-103 HCO3-24 AnGap-14\r\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \r\nAlkPhos-86 TotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\r\n___ 09:21AM BLOOD Cyclspr-184\r\n\r\nMICROBIOLOGY\r\n=============\r\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance Oxacillin RESISTANT Staphylococci MUST be \r\nreported as\r\n         also RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     2 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ ON \r\n___. \r\n\r\n___ 10:36 pm BLOOD CULTURE     Site: ARM\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \r\nresult\r\n         performed by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 10:08 pm BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------ <=0.5 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 12:40 pm BLOOD CULTURE\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\n___ 9:11 am BLOOD CULTURE      Source: Line-PORT. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\nIMAGING\r\n=========\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Evaluation limited by artifact from high-density metallic \r\nmaterial the area \r\nof the right carotid siphon. \r\n2. No acute intracranial abnormality. \r\n\r\nMR HEAD W/ & W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute intracranial process.  No abnormal enhancement after \r\ncontrast \r\nadministration. \r\n2. Susceptibility artifact from prior coiling in the region of \r\nthe right \r\ncavernous internal carotid artery limits evaluation in that \r\narea. \r\n\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Mildly limited study due to streak artifact from metallic \r\ndensity in the \r\nregion of the right carotid siphon. \r\n2. No acute intracranial abnormality or fracture. \r\n3. Soft tissue swelling and hematoma overlying the inferior left \r\nocciput, and \r\ncentrally near the vertex. \r\n\r\nCT C-SPINE W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute fracture or new alignment abnormality. \r\n2. Multilevel degenerative changes and levels of congenital \r\nfusion, grossly \r\nunchanged and better described on the prior MRI from ___. \r\n\r\nWRIST (3+ VIEWS) LEFT (___):\r\nIMPRESSION:  \r\nNo acute fracture or dislocation.  Mild widening of the distal \r\nradioulnar \r\njoint. \r\n\r\nCT ABD & PELVIS WITH CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No infectious source identified in the abdomen or pelvis. \r\n2.  Mild intrahepatic and extrahepatic biliary dilatation, \r\nlikely post \r\ncholecystectomy. \r\n3.  Tiny nonocclusive thrombus in the IVC, above the IVC filter. \r\n Some of the \r\nfilter struts have penetrated the vessel wall, not uncommonly \r\nseen.  Given \r\nthat this is a retrievable filter, interventional radiology \r\nconsultation could \r\nbe considered for filter removal if it is no longer needed. \r\n4.  Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \r\nwhich dates \r\nback to at least ___.  Consider periodic follow-up with pelvic \r\nultrasound to \r\ndocument expected continued stability. \r\n\r\nCT CHEST W/ CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No evidence of pneumonia. \r\n2.  Enlarged pulmonary artery may be seen in pulmonary arterial \r\nhypertension. \r\n\r\nUNILAT UP EXT VEINS US LEFT (___):\r\nIMPRESSION:  \r\nNo evidence of deep vein thrombosis in the left upper extremity. \r\n\r\n\r\nTTE (___):\r\nConclusions   \r\n The left atrium is normal in size. No atrial septal defect is \r\nseen by 2D or color Doppler. Left ventricular wall thicknesses \r\nand cavity size are normal. There is mild global left \r\nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. \r\nRight ventricular chamber size and free wall motion are normal. \r\nThe aortic valve leaflets (3) appear structurally normal with \r\ngood leaflet excursion. No masses or vegetations are seen on the \r\naortic valve. Trace aortic regurgitation is seen. The mitral \r\nvalve leaflets are structurally normal. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. The pulmonary artery \r\nsystolic pressure could not be determined. There is no \r\npericardial effusion. \r\n\r\n IMPRESSION: Normal biventricular cavity sizes with mild global \r\nleft ventricular hypokinesis. Mild mitral regurgitation with \r\nnormal valve morphology. Trace aortic regurgitation with normal \r\nvalve morphology. \r\n\r\n Compared with the prior report (images not available for \r\nreview) of ___, trace aortic regurgitation is now present \r\nwith similar valve morphology.   \r\n\r\nBILAT LOWER EXT VEINS (___):\r\nIMPRESSION: \r\n1. New deep venous thrombosis involving the left posterior \r\ntibial and right \r\npopliteal veins. \r\n2. No fluid collection in the area of pain in the left lateral \r\ncalf. \r\n\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ immunocompromised female ___ \r\nalloSCT for secondary MDS admitted for acute change in headaches \r\nwith new, severe symptoms such as nausea and vomiting now with \r\nfevers to 103 and coagulase-negative gram-positive cocci in \r\nclusters in blood cultures being treated for S. epidermidis \r\nbacteremia.\r\n\r\n#Headache\r\nCT head performed in the ED ___ was unremarkable but infectious \r\netiology remained very high on the\r\ndifferential given the patient's immunosuppression regimen and \r\nhistory of aseptic meningitis during her last admission. She \r\nalso had history of R internal carotid cavernous sinus aneurysm \r\nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \r\nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \r\ncrypotococcus, and fungal markers were tested and all were \r\nnegative. The patient's headache resolved and she was symptom \r\nfree at time of discharge. \r\n\r\n#S. epidermidis Bacteremia\r\nShe had fevers up to 103 on ___ and was started on vancomycin \r\nand cefepime. The vancomycin was DC'd ___ overnight and she was \r\nstarted on linezolid per ID recommendations as she had a history \r\nof VRE bacteremia in the past and was continued on cefepime. ___ \r\nblood culture bottles grew S. epidermidis and she was narrowed \r\nto vancomycin only. A chest x-ray was unremarkable for \r\npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \r\nCT abdomen pelvis ___ did not show any evidence of infection. An \r\nultrasound of her port site was without evidence of infection. \r\nAn ultrasound of her LLE ordered for concern of an abscess \r\nrevealed a distal DVT but no fluid collections. A TTE revealed \r\nnormal biventricular cavity sizes with mild global left \r\nventricular hypokinesis, mild mitral regurgitation with normal \r\nvalve morphology and trace aortic regurgitation with normal \r\nvalve morphology. A TEE was scheduled but was cancelled as \r\npatient will need 6 weeks of therapy for treatment of possible \r\nseptic thrombophlebitis. She was continued on Vancomycin until \r\n___ and was transitioned to Daptomycin on ___ as her \r\nVancomycin level fluctuated frequently throughout her \r\nhospitalization, making dosing of the medication challenging. \r\nShe will need to remain on Daptomycin until ___ to complete 6 \r\nweeks of antibiotic therapy.\r\n\r\n#Mechanical Fall\r\nPatient had a mechanical fall during the evening of ___. She \r\nbecame incontinent of urine and slipped and fell while trying to \r\nmake it to the bathroom. CT head and C spine were unremarkable. \r\nX rays of her left wrist revealed no fractures. She was given a \r\nhard brace based on an OT evaluation. Ecchymosis on head was \r\nimproving at discharge. She will continue to wear the brace \r\nuntil symptoms improve.\r\n\r\n#MDS ___ Allo MUD SCT\r\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \r\nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \r\nand 50mg QPM. Initial cyclosporine levels were low and her \r\ndosage was increased to 100mg BID. Her creatinine increased on \r\nthis dose and she was discharged on dosage of 75mg BID. Her home \r\nprophylaxis with fluconazole, Bactrim, and valganciclovir was \r\ninitially continued. However, given worsening neutropenia, her \r\nBactrim was transitioned to atovaquone and her valganciclovir \r\nwas transitioned to acyclovir. She was scheduled to have a bone \r\nmarrow biopsy with ___ as an outpatient on ___ but this was \r\ncancelled due to patient's new DVT. She will need to have a bone \r\nmarrow biopsy done as an outpatient.\r\n\r\n#DVT\r\nEnoxaparin was held ___ for possible LP but a US LLE \r\nperformed due to the concern of an abscess revealed a new distal \r\nDVT on ___ in LLE. LP was deferred due to resolution of her \r\nheadache and lack of neurologic symptoms and she was put on a \r\ntherapeutic dose of Enoxaparin. Her lower extremity swelling \r\nimproved and she was discharged on Enoxaparin 80mg BID.\r\n\r\n___\r\nShe presented with Cr above baseline at 1.7 No casts were \r\nvisualized on UA and she had a FENa of 1.7% on ___, indicating \r\nprerenal etiology. She was given fluids and her creatinine \r\nreturned to baseline. Her Cr increased again on ___ to 1.4. She \r\nwas again given IVF and her cyclosporine was decreased from \r\n100mg BID to 75mg BID. Cr at discharge improved to 1.2.\r\n\r\n#Asthma\r\nAlbuterol and duonebs were given as needed\r\n\r\nTRANSITIONAL ISSUES\r\n===================\r\n[] Follow up with Dr. ___ on ___\r\n[] Continue daptomycin and Vancomycin/heparin locks until ___.\r\n[] Will need to get weekly CK levels while on daptomycin.\r\n[] Repeat bone marrow biopsy scheduled for ___ was cancelled \r\ngiven new DVT and infection. Will need repeat bone marrow biopsy \r\nscheduled.\r\n\r\nCODE STATUS: FULL CODE\r\nHCP: ___ (Husband) ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n2. Fluconazole 400 mg PO Q24H \r\n3. FoLIC Acid 1 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n7. Multivitamins 1 TAB PO DAILY \r\n8. Omeprazole 20 mg PO DAILY \r\n9. Ondansetron 4 mg PO Q8H:PRN nausea \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. ValGANCIclovir 450 mg PO Q24H \r\n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \r\n14. Enoxaparin Sodium 100 mg SC DAILY \r\n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  Atovaquone Suspension 1500 mg PO DAILY \r\nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \r\nMilliliter Refills:*0 \r\n3.  Daptomycin 500 mg IV Q24H \r\nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \r\n4.  Nystatin Cream 1 Appl TP BID  \r\n5.  Vancomycin-Heparin Lock ___AILY  \r\n6.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \r\n7.  Enoxaparin Sodium 80 mg SC Q12H \r\nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \r\nRefills:*0 \r\n8.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n9.  Fluconazole 400 mg PO Q24H  \r\n10.  FoLIC Acid 1 mg PO DAILY  \r\n11.  Gabapentin 400 mg PO BID  \r\n12.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n13.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n14.  Multivitamins 1 TAB PO DAILY  \r\n15.  Omeprazole 20 mg PO DAILY  \r\n16.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n17.  Venlafaxine 25 mg PO DAILY  \r\n18.vancomycin lock\r\nVancomycin-Heparin Lock ___AILY \r\nVancomycin 2 mg/mL + Heparin 100 units/mL\r\n5mL solution daily\r\nDispense 170mL solution\r\nContinue until ___ \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSES\r\n=================\r\nHeadache\r\nS. epidermidis Bacteremia\r\nMechanical Fall\r\nSecondary MDS ___ AlloSCT\r\nGERD\r\nOSA\r\nSciatica\r\n\r\nSECONDARY DIAGNOSES\r\n===================\r\nCVID\r\nDVT\r\nAsthma\r\nPre-HTN\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure taking care of you in the hospital!\r\n\r\nWhy was I admitted to the hospital?\r\nYou were admitted to the hospital because you were experiencing \r\nheadaches, concerning for possible infection in or around your \r\nbrain.\r\n\r\nWhat happened while I was admitted in the hospital?\r\n-Your headache resolved on its own\r\n-Imaging studies were done to evaluate your headache and did not \r\ndemonstrate any clear cause\r\n-Numerous tests were conducted on your blood and you were found \r\nto have a bacterial infection of your blood\r\n-Imaging studies were performed to find the source of the \r\nbacteria and no clear source was found\r\n-You were started on antibiotics to treat your bacterial \r\ninfection\r\n-Imaging of your leg showed you had a clot in your leg\r\n-Your home Bactrim and Valganciclovir were discontinued and you \r\nwere started on Atovaquone and Acyclovir.\r\n\r\nWhat should I do after I get discharged from the hospital?\r\n-Take all of your medications as prescribed, details below\r\n-Keep all of your scheduled appointments \r\n\r\nWe wish you the very best!\r\n\r\nYour ___ Oncology Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-24:1",
      "text": "History of Present Illness:\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\nTransplant who is admitted with a headache. The patient states\nher headache started yesterday morning. It was a right sided\nheadache which came down into her face. It intensified \nthroughout\nthe day and then in the afternoon she started vomiting numerous\ntimes. Which prompted her to go to the ED. She states the\nheadache was similar in location to when she gets migraines but\nthe duration was different and with migraines she usually gets\none episode of nausea in the morning and then it resolves. She\ndenies any neck stiffness, rashes, or fevers. She also denies \nany\nshortness of breath, diarrhea, or dysuria. She went to the ED last night and had a head CT done which was \nunremarkable. She was then given Tylenol, dexamethasone,\nBenadryl, IV fluids, and Compazine. With improvement of her\nsymptoms. She then was discharged home early this morning. Her primary oncology team was concerned about the underlying\ncause of her headache given her history of a recent bone marrow\ntransplant and that she is on immunosuppression. So she was\ninstructed to return for admission for further workup.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-24",
        "chart_time": "104763",
        "section": "General",
        "position": 1,
        "tokenCount": 296,
        "note_metadata": {
          "note_id": "18887130-DS-24",
          "subject_id": 18887130,
          "hadm_id": 23656314,
          "note_type": "DS",
          "note_seq": 24,
          "charttime": 104763,
          "storetime": 104766.75763888888,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nHeadache, Nausea, Vomiting\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\r\nTransplant who is admitted with a headache. The patient states\r\nher headache started yesterday morning. It was a right sided\r\nheadache which came down into her face. It intensified \r\nthroughout\r\nthe day and then in the afternoon she started vomiting numerous\r\ntimes. Which prompted her to go to the ED. She states the\r\nheadache was similar in location to when she gets migraines but\r\nthe duration was different and with migraines she usually gets\r\none episode of nausea in the morning and then it resolves. She\r\ndenies any neck stiffness, rashes, or fevers. She also denies \r\nany\r\nshortness of breath, diarrhea, or dysuria. \r\nShe went to the ED last night and had a head CT done which was \r\nunremarkable. She was then given Tylenol, dexamethasone,\r\nBenadryl, IV fluids, and Compazine. With improvement of her\r\nsymptoms. She then was discharged home early this morning. \r\nHer primary oncology team was concerned about the underlying\r\ncause of her headache given her history of a recent bone marrow\r\ntransplant and that she is on immunosuppression. So she was\r\ninstructed to return for admission for further workup. \r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL\r\n==================\r\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\r\nGeneral: No acute distress, sitting completely comfortably in a\r\nchair\r\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\r\nedema in right lower extremity, 2+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\nDISCHARGE PHYSICAL\r\n==================\r\nVS:  98.6 131 / 81 93 18 96 Ra \r\nGeneral: No acute distress, lying comfortably in bed\r\nHEENT: Hematoma and ecchymosis in occipital region of head,\r\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\r\nLAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: Edema over the radial aspect of the left wrist improving, \r\n1+\r\nperipheral edema in bilateral lower extremity, venous stasis\r\ndermatitis bilaterally on lower extremities, 1+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n==============\r\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \r\nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\r\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \r\nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \r\nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\r\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \r\nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\r\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\r\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \r\nK-4.2 Cl-104 HCO3-21* AnGap-14\r\n___ 11:17PM BLOOD Lipase-11\r\n___ 11:17PM BLOOD Albumin-3.6\r\n___ 11:22PM BLOOD Lactate-1.1\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \r\nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\r\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \r\nK-4.0 Cl-103 HCO3-24 AnGap-14\r\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \r\nAlkPhos-86 TotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\r\n___ 09:21AM BLOOD Cyclspr-184\r\n\r\nMICROBIOLOGY\r\n=============\r\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance Oxacillin RESISTANT Staphylococci MUST be \r\nreported as\r\n         also RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     2 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ ON \r\n___. \r\n\r\n___ 10:36 pm BLOOD CULTURE     Site: ARM\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \r\nresult\r\n         performed by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 10:08 pm BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------ <=0.5 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 12:40 pm BLOOD CULTURE\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\n___ 9:11 am BLOOD CULTURE      Source: Line-PORT. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\nIMAGING\r\n=========\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Evaluation limited by artifact from high-density metallic \r\nmaterial the area \r\nof the right carotid siphon. \r\n2. No acute intracranial abnormality. \r\n\r\nMR HEAD W/ & W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute intracranial process.  No abnormal enhancement after \r\ncontrast \r\nadministration. \r\n2. Susceptibility artifact from prior coiling in the region of \r\nthe right \r\ncavernous internal carotid artery limits evaluation in that \r\narea. \r\n\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Mildly limited study due to streak artifact from metallic \r\ndensity in the \r\nregion of the right carotid siphon. \r\n2. No acute intracranial abnormality or fracture. \r\n3. Soft tissue swelling and hematoma overlying the inferior left \r\nocciput, and \r\ncentrally near the vertex. \r\n\r\nCT C-SPINE W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute fracture or new alignment abnormality. \r\n2. Multilevel degenerative changes and levels of congenital \r\nfusion, grossly \r\nunchanged and better described on the prior MRI from ___. \r\n\r\nWRIST (3+ VIEWS) LEFT (___):\r\nIMPRESSION:  \r\nNo acute fracture or dislocation.  Mild widening of the distal \r\nradioulnar \r\njoint. \r\n\r\nCT ABD & PELVIS WITH CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No infectious source identified in the abdomen or pelvis. \r\n2.  Mild intrahepatic and extrahepatic biliary dilatation, \r\nlikely post \r\ncholecystectomy. \r\n3.  Tiny nonocclusive thrombus in the IVC, above the IVC filter. \r\n Some of the \r\nfilter struts have penetrated the vessel wall, not uncommonly \r\nseen.  Given \r\nthat this is a retrievable filter, interventional radiology \r\nconsultation could \r\nbe considered for filter removal if it is no longer needed. \r\n4.  Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \r\nwhich dates \r\nback to at least ___.  Consider periodic follow-up with pelvic \r\nultrasound to \r\ndocument expected continued stability. \r\n\r\nCT CHEST W/ CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No evidence of pneumonia. \r\n2.  Enlarged pulmonary artery may be seen in pulmonary arterial \r\nhypertension. \r\n\r\nUNILAT UP EXT VEINS US LEFT (___):\r\nIMPRESSION:  \r\nNo evidence of deep vein thrombosis in the left upper extremity. \r\n\r\n\r\nTTE (___):\r\nConclusions   \r\n The left atrium is normal in size. No atrial septal defect is \r\nseen by 2D or color Doppler. Left ventricular wall thicknesses \r\nand cavity size are normal. There is mild global left \r\nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. \r\nRight ventricular chamber size and free wall motion are normal. \r\nThe aortic valve leaflets (3) appear structurally normal with \r\ngood leaflet excursion. No masses or vegetations are seen on the \r\naortic valve. Trace aortic regurgitation is seen. The mitral \r\nvalve leaflets are structurally normal. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. The pulmonary artery \r\nsystolic pressure could not be determined. There is no \r\npericardial effusion. \r\n\r\n IMPRESSION: Normal biventricular cavity sizes with mild global \r\nleft ventricular hypokinesis. Mild mitral regurgitation with \r\nnormal valve morphology. Trace aortic regurgitation with normal \r\nvalve morphology. \r\n\r\n Compared with the prior report (images not available for \r\nreview) of ___, trace aortic regurgitation is now present \r\nwith similar valve morphology.   \r\n\r\nBILAT LOWER EXT VEINS (___):\r\nIMPRESSION: \r\n1. New deep venous thrombosis involving the left posterior \r\ntibial and right \r\npopliteal veins. \r\n2. No fluid collection in the area of pain in the left lateral \r\ncalf. \r\n\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ immunocompromised female ___ \r\nalloSCT for secondary MDS admitted for acute change in headaches \r\nwith new, severe symptoms such as nausea and vomiting now with \r\nfevers to 103 and coagulase-negative gram-positive cocci in \r\nclusters in blood cultures being treated for S. epidermidis \r\nbacteremia.\r\n\r\n#Headache\r\nCT head performed in the ED ___ was unremarkable but infectious \r\netiology remained very high on the\r\ndifferential given the patient's immunosuppression regimen and \r\nhistory of aseptic meningitis during her last admission. She \r\nalso had history of R internal carotid cavernous sinus aneurysm \r\nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \r\nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \r\ncrypotococcus, and fungal markers were tested and all were \r\nnegative. The patient's headache resolved and she was symptom \r\nfree at time of discharge. \r\n\r\n#S. epidermidis Bacteremia\r\nShe had fevers up to 103 on ___ and was started on vancomycin \r\nand cefepime. The vancomycin was DC'd ___ overnight and she was \r\nstarted on linezolid per ID recommendations as she had a history \r\nof VRE bacteremia in the past and was continued on cefepime. ___ \r\nblood culture bottles grew S. epidermidis and she was narrowed \r\nto vancomycin only. A chest x-ray was unremarkable for \r\npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \r\nCT abdomen pelvis ___ did not show any evidence of infection. An \r\nultrasound of her port site was without evidence of infection. \r\nAn ultrasound of her LLE ordered for concern of an abscess \r\nrevealed a distal DVT but no fluid collections. A TTE revealed \r\nnormal biventricular cavity sizes with mild global left \r\nventricular hypokinesis, mild mitral regurgitation with normal \r\nvalve morphology and trace aortic regurgitation with normal \r\nvalve morphology. A TEE was scheduled but was cancelled as \r\npatient will need 6 weeks of therapy for treatment of possible \r\nseptic thrombophlebitis. She was continued on Vancomycin until \r\n___ and was transitioned to Daptomycin on ___ as her \r\nVancomycin level fluctuated frequently throughout her \r\nhospitalization, making dosing of the medication challenging. \r\nShe will need to remain on Daptomycin until ___ to complete 6 \r\nweeks of antibiotic therapy.\r\n\r\n#Mechanical Fall\r\nPatient had a mechanical fall during the evening of ___. She \r\nbecame incontinent of urine and slipped and fell while trying to \r\nmake it to the bathroom. CT head and C spine were unremarkable. \r\nX rays of her left wrist revealed no fractures. She was given a \r\nhard brace based on an OT evaluation. Ecchymosis on head was \r\nimproving at discharge. She will continue to wear the brace \r\nuntil symptoms improve.\r\n\r\n#MDS ___ Allo MUD SCT\r\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \r\nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \r\nand 50mg QPM. Initial cyclosporine levels were low and her \r\ndosage was increased to 100mg BID. Her creatinine increased on \r\nthis dose and she was discharged on dosage of 75mg BID. Her home \r\nprophylaxis with fluconazole, Bactrim, and valganciclovir was \r\ninitially continued. However, given worsening neutropenia, her \r\nBactrim was transitioned to atovaquone and her valganciclovir \r\nwas transitioned to acyclovir. She was scheduled to have a bone \r\nmarrow biopsy with ___ as an outpatient on ___ but this was \r\ncancelled due to patient's new DVT. She will need to have a bone \r\nmarrow biopsy done as an outpatient.\r\n\r\n#DVT\r\nEnoxaparin was held ___ for possible LP but a US LLE \r\nperformed due to the concern of an abscess revealed a new distal \r\nDVT on ___ in LLE. LP was deferred due to resolution of her \r\nheadache and lack of neurologic symptoms and she was put on a \r\ntherapeutic dose of Enoxaparin. Her lower extremity swelling \r\nimproved and she was discharged on Enoxaparin 80mg BID.\r\n\r\n___\r\nShe presented with Cr above baseline at 1.7 No casts were \r\nvisualized on UA and she had a FENa of 1.7% on ___, indicating \r\nprerenal etiology. She was given fluids and her creatinine \r\nreturned to baseline. Her Cr increased again on ___ to 1.4. She \r\nwas again given IVF and her cyclosporine was decreased from \r\n100mg BID to 75mg BID. Cr at discharge improved to 1.2.\r\n\r\n#Asthma\r\nAlbuterol and duonebs were given as needed\r\n\r\nTRANSITIONAL ISSUES\r\n===================\r\n[] Follow up with Dr. ___ on ___\r\n[] Continue daptomycin and Vancomycin/heparin locks until ___.\r\n[] Will need to get weekly CK levels while on daptomycin.\r\n[] Repeat bone marrow biopsy scheduled for ___ was cancelled \r\ngiven new DVT and infection. Will need repeat bone marrow biopsy \r\nscheduled.\r\n\r\nCODE STATUS: FULL CODE\r\nHCP: ___ (Husband) ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n2. Fluconazole 400 mg PO Q24H \r\n3. FoLIC Acid 1 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n7. Multivitamins 1 TAB PO DAILY \r\n8. Omeprazole 20 mg PO DAILY \r\n9. Ondansetron 4 mg PO Q8H:PRN nausea \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. ValGANCIclovir 450 mg PO Q24H \r\n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \r\n14. Enoxaparin Sodium 100 mg SC DAILY \r\n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  Atovaquone Suspension 1500 mg PO DAILY \r\nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \r\nMilliliter Refills:*0 \r\n3.  Daptomycin 500 mg IV Q24H \r\nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \r\n4.  Nystatin Cream 1 Appl TP BID  \r\n5.  Vancomycin-Heparin Lock ___AILY  \r\n6.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \r\n7.  Enoxaparin Sodium 80 mg SC Q12H \r\nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \r\nRefills:*0 \r\n8.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n9.  Fluconazole 400 mg PO Q24H  \r\n10.  FoLIC Acid 1 mg PO DAILY  \r\n11.  Gabapentin 400 mg PO BID  \r\n12.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n13.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n14.  Multivitamins 1 TAB PO DAILY  \r\n15.  Omeprazole 20 mg PO DAILY  \r\n16.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n17.  Venlafaxine 25 mg PO DAILY  \r\n18.vancomycin lock\r\nVancomycin-Heparin Lock ___AILY \r\nVancomycin 2 mg/mL + Heparin 100 units/mL\r\n5mL solution daily\r\nDispense 170mL solution\r\nContinue until ___ \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSES\r\n=================\r\nHeadache\r\nS. epidermidis Bacteremia\r\nMechanical Fall\r\nSecondary MDS ___ AlloSCT\r\nGERD\r\nOSA\r\nSciatica\r\n\r\nSECONDARY DIAGNOSES\r\n===================\r\nCVID\r\nDVT\r\nAsthma\r\nPre-HTN\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure taking care of you in the hospital!\r\n\r\nWhy was I admitted to the hospital?\r\nYou were admitted to the hospital because you were experiencing \r\nheadaches, concerning for possible infection in or around your \r\nbrain.\r\n\r\nWhat happened while I was admitted in the hospital?\r\n-Your headache resolved on its own\r\n-Imaging studies were done to evaluate your headache and did not \r\ndemonstrate any clear cause\r\n-Numerous tests were conducted on your blood and you were found \r\nto have a bacterial infection of your blood\r\n-Imaging studies were performed to find the source of the \r\nbacteria and no clear source was found\r\n-You were started on antibiotics to treat your bacterial \r\ninfection\r\n-Imaging of your leg showed you had a clot in your leg\r\n-Your home Bactrim and Valganciclovir were discontinued and you \r\nwere started on Atovaquone and Acyclovir.\r\n\r\nWhat should I do after I get discharged from the hospital?\r\n-Take all of your medications as prescribed, details below\r\n-Keep all of your scheduled appointments \r\n\r\nWe wish you the very best!\r\n\r\nYour ___ Oncology Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-24:2",
      "text": "Past Medical History:\n- Treatment-Related MDS after transformed follicular lymphoma\n- CVID, received IVIG monthly; last given ___\n- GERD                                          \n- Osteoarthritis                                         \n- DVT, right lower extremity, IVC filter in place\n- Cervical radiculopathy\n- Sciatica\n- Obstructive sleep apnea, wears CPAP\n- H/O cerebral aneurism, noted on MRA with small R internal\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\nthe right eye, mild proptosis of the right eye, and hyperthesia\nof the right V1 distribution\n- Asthma\n- Obesity\n- Hypertension\n- Migraines\n- + RSV, ___\n- History of osteomyelitis with IV antibioitcs for 6\nweeks. Social History:\n___ Family History:\nBrother with lymphoma, died at age ___. Father had CAD and DM. Mother had CHF.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-24",
        "chart_time": "104763",
        "section": "General",
        "position": 2,
        "tokenCount": 217,
        "note_metadata": {
          "note_id": "18887130-DS-24",
          "subject_id": 18887130,
          "hadm_id": 23656314,
          "note_type": "DS",
          "note_seq": 24,
          "charttime": 104763,
          "storetime": 104766.75763888888,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nHeadache, Nausea, Vomiting\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\r\nTransplant who is admitted with a headache. The patient states\r\nher headache started yesterday morning. It was a right sided\r\nheadache which came down into her face. It intensified \r\nthroughout\r\nthe day and then in the afternoon she started vomiting numerous\r\ntimes. Which prompted her to go to the ED. She states the\r\nheadache was similar in location to when she gets migraines but\r\nthe duration was different and with migraines she usually gets\r\none episode of nausea in the morning and then it resolves. She\r\ndenies any neck stiffness, rashes, or fevers. She also denies \r\nany\r\nshortness of breath, diarrhea, or dysuria. \r\nShe went to the ED last night and had a head CT done which was \r\nunremarkable. She was then given Tylenol, dexamethasone,\r\nBenadryl, IV fluids, and Compazine. With improvement of her\r\nsymptoms. She then was discharged home early this morning. \r\nHer primary oncology team was concerned about the underlying\r\ncause of her headache given her history of a recent bone marrow\r\ntransplant and that she is on immunosuppression. So she was\r\ninstructed to return for admission for further workup. \r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL\r\n==================\r\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\r\nGeneral: No acute distress, sitting completely comfortably in a\r\nchair\r\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\r\nedema in right lower extremity, 2+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\nDISCHARGE PHYSICAL\r\n==================\r\nVS:  98.6 131 / 81 93 18 96 Ra \r\nGeneral: No acute distress, lying comfortably in bed\r\nHEENT: Hematoma and ecchymosis in occipital region of head,\r\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\r\nLAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: Edema over the radial aspect of the left wrist improving, \r\n1+\r\nperipheral edema in bilateral lower extremity, venous stasis\r\ndermatitis bilaterally on lower extremities, 1+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n==============\r\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \r\nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\r\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \r\nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \r\nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\r\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \r\nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\r\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\r\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \r\nK-4.2 Cl-104 HCO3-21* AnGap-14\r\n___ 11:17PM BLOOD Lipase-11\r\n___ 11:17PM BLOOD Albumin-3.6\r\n___ 11:22PM BLOOD Lactate-1.1\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \r\nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\r\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \r\nK-4.0 Cl-103 HCO3-24 AnGap-14\r\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \r\nAlkPhos-86 TotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\r\n___ 09:21AM BLOOD Cyclspr-184\r\n\r\nMICROBIOLOGY\r\n=============\r\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance Oxacillin RESISTANT Staphylococci MUST be \r\nreported as\r\n         also RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     2 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ ON \r\n___. \r\n\r\n___ 10:36 pm BLOOD CULTURE     Site: ARM\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \r\nresult\r\n         performed by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 10:08 pm BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------ <=0.5 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 12:40 pm BLOOD CULTURE\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\n___ 9:11 am BLOOD CULTURE      Source: Line-PORT. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\nIMAGING\r\n=========\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Evaluation limited by artifact from high-density metallic \r\nmaterial the area \r\nof the right carotid siphon. \r\n2. No acute intracranial abnormality. \r\n\r\nMR HEAD W/ & W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute intracranial process.  No abnormal enhancement after \r\ncontrast \r\nadministration. \r\n2. Susceptibility artifact from prior coiling in the region of \r\nthe right \r\ncavernous internal carotid artery limits evaluation in that \r\narea. \r\n\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Mildly limited study due to streak artifact from metallic \r\ndensity in the \r\nregion of the right carotid siphon. \r\n2. No acute intracranial abnormality or fracture. \r\n3. Soft tissue swelling and hematoma overlying the inferior left \r\nocciput, and \r\ncentrally near the vertex. \r\n\r\nCT C-SPINE W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute fracture or new alignment abnormality. \r\n2. Multilevel degenerative changes and levels of congenital \r\nfusion, grossly \r\nunchanged and better described on the prior MRI from ___. \r\n\r\nWRIST (3+ VIEWS) LEFT (___):\r\nIMPRESSION:  \r\nNo acute fracture or dislocation.  Mild widening of the distal \r\nradioulnar \r\njoint. \r\n\r\nCT ABD & PELVIS WITH CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No infectious source identified in the abdomen or pelvis. \r\n2.  Mild intrahepatic and extrahepatic biliary dilatation, \r\nlikely post \r\ncholecystectomy. \r\n3.  Tiny nonocclusive thrombus in the IVC, above the IVC filter. \r\n Some of the \r\nfilter struts have penetrated the vessel wall, not uncommonly \r\nseen.  Given \r\nthat this is a retrievable filter, interventional radiology \r\nconsultation could \r\nbe considered for filter removal if it is no longer needed. \r\n4.  Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \r\nwhich dates \r\nback to at least ___.  Consider periodic follow-up with pelvic \r\nultrasound to \r\ndocument expected continued stability. \r\n\r\nCT CHEST W/ CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No evidence of pneumonia. \r\n2.  Enlarged pulmonary artery may be seen in pulmonary arterial \r\nhypertension. \r\n\r\nUNILAT UP EXT VEINS US LEFT (___):\r\nIMPRESSION:  \r\nNo evidence of deep vein thrombosis in the left upper extremity. \r\n\r\n\r\nTTE (___):\r\nConclusions   \r\n The left atrium is normal in size. No atrial septal defect is \r\nseen by 2D or color Doppler. Left ventricular wall thicknesses \r\nand cavity size are normal. There is mild global left \r\nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. \r\nRight ventricular chamber size and free wall motion are normal. \r\nThe aortic valve leaflets (3) appear structurally normal with \r\ngood leaflet excursion. No masses or vegetations are seen on the \r\naortic valve. Trace aortic regurgitation is seen. The mitral \r\nvalve leaflets are structurally normal. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. The pulmonary artery \r\nsystolic pressure could not be determined. There is no \r\npericardial effusion. \r\n\r\n IMPRESSION: Normal biventricular cavity sizes with mild global \r\nleft ventricular hypokinesis. Mild mitral regurgitation with \r\nnormal valve morphology. Trace aortic regurgitation with normal \r\nvalve morphology. \r\n\r\n Compared with the prior report (images not available for \r\nreview) of ___, trace aortic regurgitation is now present \r\nwith similar valve morphology.   \r\n\r\nBILAT LOWER EXT VEINS (___):\r\nIMPRESSION: \r\n1. New deep venous thrombosis involving the left posterior \r\ntibial and right \r\npopliteal veins. \r\n2. No fluid collection in the area of pain in the left lateral \r\ncalf. \r\n\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ immunocompromised female ___ \r\nalloSCT for secondary MDS admitted for acute change in headaches \r\nwith new, severe symptoms such as nausea and vomiting now with \r\nfevers to 103 and coagulase-negative gram-positive cocci in \r\nclusters in blood cultures being treated for S. epidermidis \r\nbacteremia.\r\n\r\n#Headache\r\nCT head performed in the ED ___ was unremarkable but infectious \r\netiology remained very high on the\r\ndifferential given the patient's immunosuppression regimen and \r\nhistory of aseptic meningitis during her last admission. She \r\nalso had history of R internal carotid cavernous sinus aneurysm \r\nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \r\nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \r\ncrypotococcus, and fungal markers were tested and all were \r\nnegative. The patient's headache resolved and she was symptom \r\nfree at time of discharge. \r\n\r\n#S. epidermidis Bacteremia\r\nShe had fevers up to 103 on ___ and was started on vancomycin \r\nand cefepime. The vancomycin was DC'd ___ overnight and she was \r\nstarted on linezolid per ID recommendations as she had a history \r\nof VRE bacteremia in the past and was continued on cefepime. ___ \r\nblood culture bottles grew S. epidermidis and she was narrowed \r\nto vancomycin only. A chest x-ray was unremarkable for \r\npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \r\nCT abdomen pelvis ___ did not show any evidence of infection. An \r\nultrasound of her port site was without evidence of infection. \r\nAn ultrasound of her LLE ordered for concern of an abscess \r\nrevealed a distal DVT but no fluid collections. A TTE revealed \r\nnormal biventricular cavity sizes with mild global left \r\nventricular hypokinesis, mild mitral regurgitation with normal \r\nvalve morphology and trace aortic regurgitation with normal \r\nvalve morphology. A TEE was scheduled but was cancelled as \r\npatient will need 6 weeks of therapy for treatment of possible \r\nseptic thrombophlebitis. She was continued on Vancomycin until \r\n___ and was transitioned to Daptomycin on ___ as her \r\nVancomycin level fluctuated frequently throughout her \r\nhospitalization, making dosing of the medication challenging. \r\nShe will need to remain on Daptomycin until ___ to complete 6 \r\nweeks of antibiotic therapy.\r\n\r\n#Mechanical Fall\r\nPatient had a mechanical fall during the evening of ___. She \r\nbecame incontinent of urine and slipped and fell while trying to \r\nmake it to the bathroom. CT head and C spine were unremarkable. \r\nX rays of her left wrist revealed no fractures. She was given a \r\nhard brace based on an OT evaluation. Ecchymosis on head was \r\nimproving at discharge. She will continue to wear the brace \r\nuntil symptoms improve.\r\n\r\n#MDS ___ Allo MUD SCT\r\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \r\nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \r\nand 50mg QPM. Initial cyclosporine levels were low and her \r\ndosage was increased to 100mg BID. Her creatinine increased on \r\nthis dose and she was discharged on dosage of 75mg BID. Her home \r\nprophylaxis with fluconazole, Bactrim, and valganciclovir was \r\ninitially continued. However, given worsening neutropenia, her \r\nBactrim was transitioned to atovaquone and her valganciclovir \r\nwas transitioned to acyclovir. She was scheduled to have a bone \r\nmarrow biopsy with ___ as an outpatient on ___ but this was \r\ncancelled due to patient's new DVT. She will need to have a bone \r\nmarrow biopsy done as an outpatient.\r\n\r\n#DVT\r\nEnoxaparin was held ___ for possible LP but a US LLE \r\nperformed due to the concern of an abscess revealed a new distal \r\nDVT on ___ in LLE. LP was deferred due to resolution of her \r\nheadache and lack of neurologic symptoms and she was put on a \r\ntherapeutic dose of Enoxaparin. Her lower extremity swelling \r\nimproved and she was discharged on Enoxaparin 80mg BID.\r\n\r\n___\r\nShe presented with Cr above baseline at 1.7 No casts were \r\nvisualized on UA and she had a FENa of 1.7% on ___, indicating \r\nprerenal etiology. She was given fluids and her creatinine \r\nreturned to baseline. Her Cr increased again on ___ to 1.4. She \r\nwas again given IVF and her cyclosporine was decreased from \r\n100mg BID to 75mg BID. Cr at discharge improved to 1.2.\r\n\r\n#Asthma\r\nAlbuterol and duonebs were given as needed\r\n\r\nTRANSITIONAL ISSUES\r\n===================\r\n[] Follow up with Dr. ___ on ___\r\n[] Continue daptomycin and Vancomycin/heparin locks until ___.\r\n[] Will need to get weekly CK levels while on daptomycin.\r\n[] Repeat bone marrow biopsy scheduled for ___ was cancelled \r\ngiven new DVT and infection. Will need repeat bone marrow biopsy \r\nscheduled.\r\n\r\nCODE STATUS: FULL CODE\r\nHCP: ___ (Husband) ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n2. Fluconazole 400 mg PO Q24H \r\n3. FoLIC Acid 1 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n7. Multivitamins 1 TAB PO DAILY \r\n8. Omeprazole 20 mg PO DAILY \r\n9. Ondansetron 4 mg PO Q8H:PRN nausea \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. ValGANCIclovir 450 mg PO Q24H \r\n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \r\n14. Enoxaparin Sodium 100 mg SC DAILY \r\n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  Atovaquone Suspension 1500 mg PO DAILY \r\nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \r\nMilliliter Refills:*0 \r\n3.  Daptomycin 500 mg IV Q24H \r\nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \r\n4.  Nystatin Cream 1 Appl TP BID  \r\n5.  Vancomycin-Heparin Lock ___AILY  \r\n6.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \r\n7.  Enoxaparin Sodium 80 mg SC Q12H \r\nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \r\nRefills:*0 \r\n8.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n9.  Fluconazole 400 mg PO Q24H  \r\n10.  FoLIC Acid 1 mg PO DAILY  \r\n11.  Gabapentin 400 mg PO BID  \r\n12.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n13.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n14.  Multivitamins 1 TAB PO DAILY  \r\n15.  Omeprazole 20 mg PO DAILY  \r\n16.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n17.  Venlafaxine 25 mg PO DAILY  \r\n18.vancomycin lock\r\nVancomycin-Heparin Lock ___AILY \r\nVancomycin 2 mg/mL + Heparin 100 units/mL\r\n5mL solution daily\r\nDispense 170mL solution\r\nContinue until ___ \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSES\r\n=================\r\nHeadache\r\nS. epidermidis Bacteremia\r\nMechanical Fall\r\nSecondary MDS ___ AlloSCT\r\nGERD\r\nOSA\r\nSciatica\r\n\r\nSECONDARY DIAGNOSES\r\n===================\r\nCVID\r\nDVT\r\nAsthma\r\nPre-HTN\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure taking care of you in the hospital!\r\n\r\nWhy was I admitted to the hospital?\r\nYou were admitted to the hospital because you were experiencing \r\nheadaches, concerning for possible infection in or around your \r\nbrain.\r\n\r\nWhat happened while I was admitted in the hospital?\r\n-Your headache resolved on its own\r\n-Imaging studies were done to evaluate your headache and did not \r\ndemonstrate any clear cause\r\n-Numerous tests were conducted on your blood and you were found \r\nto have a bacterial infection of your blood\r\n-Imaging studies were performed to find the source of the \r\nbacteria and no clear source was found\r\n-You were started on antibiotics to treat your bacterial \r\ninfection\r\n-Imaging of your leg showed you had a clot in your leg\r\n-Your home Bactrim and Valganciclovir were discontinued and you \r\nwere started on Atovaquone and Acyclovir.\r\n\r\nWhat should I do after I get discharged from the hospital?\r\n-Take all of your medications as prescribed, details below\r\n-Keep all of your scheduled appointments \r\n\r\nWe wish you the very best!\r\n\r\nYour ___ Oncology Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-24:3",
      "text": "Physical Exam:\nADMISSION PHYSICAL\n==================\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\nGeneral: No acute distress, sitting completely comfortably in a\nchair\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\nCV: RRR, +S1/S2 present\nLungs: CTAB, no W/R/R\nAbdomen: Soft, nontender, nondistended, +BS\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\nedema in right lower extremity, 2+ DPs\nNeuro: A&O3, grossly symmetric upper and lower extremity\nstrength and sensation\nSkin: No obvious rashes DISCHARGE PHYSICAL\n==================\nVS:  98.6 131 / 81 93 18 96 Ra \nGeneral: No acute distress, lying comfortably in bed\nHEENT: Hematoma and ecchymosis in occipital region of head,\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\nLAD\nCV: RRR, +S1/S2 present\nLungs: CTAB, no W/R/R\nAbdomen: Soft, nontender, nondistended, +BS\nExt: Edema over the radial aspect of the left wrist improving, \n1+\nperipheral edema in bilateral lower extremity, venous stasis\ndermatitis bilaterally on lower extremities, 1+ DPs\nNeuro: A&O3, grossly symmetric upper and lower extremity\nstrength and sensation\nSkin: No obvious rashes Pertinent Results:\nADMISSION LABS\n==============\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \nK-4.2 Cl-104 HCO3-21* AnGap-14\n___ 11:17PM BLOOD Lipase-11\n___ 11:17PM BLOOD Albumin-3.6\n___ 11:22PM BLOOD Lactate-1.1 DISCHARGE LABS\n==============\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \nK-4.0 Cl-103 HCO3-24 AnGap-14\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \nAlkPhos-86 TotBili-0.2\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\n___ 09:21AM BLOOD Cyclspr-184 MICROBIOLOGY\n=============\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. **FINAL REPORT ___ Blood Culture, Routine (Final ___: \n      STAPHYLOCOCCUS EPIDERMIDIS. FINAL SENSITIVITIES. COAG NEG STAPH does NOT require contact precautions, \nregardless of\n         resistance Oxacillin RESISTANT Staphylococci MUST be \nreported as\n         also RESISTANT to other penicillins, cephalosporins, \ncarbacephems,\n         carbapenems, and beta-lactamase inhibitor combinations.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-24",
        "chart_time": "104763",
        "section": "General",
        "position": 3,
        "tokenCount": 693,
        "note_metadata": {
          "note_id": "18887130-DS-24",
          "subject_id": 18887130,
          "hadm_id": 23656314,
          "note_type": "DS",
          "note_seq": 24,
          "charttime": 104763,
          "storetime": 104766.75763888888,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nHeadache, Nausea, Vomiting\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\r\nTransplant who is admitted with a headache. The patient states\r\nher headache started yesterday morning. It was a right sided\r\nheadache which came down into her face. It intensified \r\nthroughout\r\nthe day and then in the afternoon she started vomiting numerous\r\ntimes. Which prompted her to go to the ED. She states the\r\nheadache was similar in location to when she gets migraines but\r\nthe duration was different and with migraines she usually gets\r\none episode of nausea in the morning and then it resolves. She\r\ndenies any neck stiffness, rashes, or fevers. She also denies \r\nany\r\nshortness of breath, diarrhea, or dysuria. \r\nShe went to the ED last night and had a head CT done which was \r\nunremarkable. She was then given Tylenol, dexamethasone,\r\nBenadryl, IV fluids, and Compazine. With improvement of her\r\nsymptoms. She then was discharged home early this morning. \r\nHer primary oncology team was concerned about the underlying\r\ncause of her headache given her history of a recent bone marrow\r\ntransplant and that she is on immunosuppression. So she was\r\ninstructed to return for admission for further workup. \r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL\r\n==================\r\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\r\nGeneral: No acute distress, sitting completely comfortably in a\r\nchair\r\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\r\nedema in right lower extremity, 2+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\nDISCHARGE PHYSICAL\r\n==================\r\nVS:  98.6 131 / 81 93 18 96 Ra \r\nGeneral: No acute distress, lying comfortably in bed\r\nHEENT: Hematoma and ecchymosis in occipital region of head,\r\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\r\nLAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: Edema over the radial aspect of the left wrist improving, \r\n1+\r\nperipheral edema in bilateral lower extremity, venous stasis\r\ndermatitis bilaterally on lower extremities, 1+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n==============\r\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \r\nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\r\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \r\nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \r\nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\r\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \r\nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\r\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\r\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \r\nK-4.2 Cl-104 HCO3-21* AnGap-14\r\n___ 11:17PM BLOOD Lipase-11\r\n___ 11:17PM BLOOD Albumin-3.6\r\n___ 11:22PM BLOOD Lactate-1.1\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \r\nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\r\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \r\nK-4.0 Cl-103 HCO3-24 AnGap-14\r\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \r\nAlkPhos-86 TotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\r\n___ 09:21AM BLOOD Cyclspr-184\r\n\r\nMICROBIOLOGY\r\n=============\r\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance Oxacillin RESISTANT Staphylococci MUST be \r\nreported as\r\n         also RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     2 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ ON \r\n___. \r\n\r\n___ 10:36 pm BLOOD CULTURE     Site: ARM\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \r\nresult\r\n         performed by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 10:08 pm BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------ <=0.5 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 12:40 pm BLOOD CULTURE\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\n___ 9:11 am BLOOD CULTURE      Source: Line-PORT. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\nIMAGING\r\n=========\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Evaluation limited by artifact from high-density metallic \r\nmaterial the area \r\nof the right carotid siphon. \r\n2. No acute intracranial abnormality. \r\n\r\nMR HEAD W/ & W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute intracranial process.  No abnormal enhancement after \r\ncontrast \r\nadministration. \r\n2. Susceptibility artifact from prior coiling in the region of \r\nthe right \r\ncavernous internal carotid artery limits evaluation in that \r\narea. \r\n\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Mildly limited study due to streak artifact from metallic \r\ndensity in the \r\nregion of the right carotid siphon. \r\n2. No acute intracranial abnormality or fracture. \r\n3. Soft tissue swelling and hematoma overlying the inferior left \r\nocciput, and \r\ncentrally near the vertex. \r\n\r\nCT C-SPINE W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute fracture or new alignment abnormality. \r\n2. Multilevel degenerative changes and levels of congenital \r\nfusion, grossly \r\nunchanged and better described on the prior MRI from ___. \r\n\r\nWRIST (3+ VIEWS) LEFT (___):\r\nIMPRESSION:  \r\nNo acute fracture or dislocation.  Mild widening of the distal \r\nradioulnar \r\njoint. \r\n\r\nCT ABD & PELVIS WITH CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No infectious source identified in the abdomen or pelvis. \r\n2.  Mild intrahepatic and extrahepatic biliary dilatation, \r\nlikely post \r\ncholecystectomy. \r\n3.  Tiny nonocclusive thrombus in the IVC, above the IVC filter. \r\n Some of the \r\nfilter struts have penetrated the vessel wall, not uncommonly \r\nseen.  Given \r\nthat this is a retrievable filter, interventional radiology \r\nconsultation could \r\nbe considered for filter removal if it is no longer needed. \r\n4.  Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \r\nwhich dates \r\nback to at least ___.  Consider periodic follow-up with pelvic \r\nultrasound to \r\ndocument expected continued stability. \r\n\r\nCT CHEST W/ CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No evidence of pneumonia. \r\n2.  Enlarged pulmonary artery may be seen in pulmonary arterial \r\nhypertension. \r\n\r\nUNILAT UP EXT VEINS US LEFT (___):\r\nIMPRESSION:  \r\nNo evidence of deep vein thrombosis in the left upper extremity. \r\n\r\n\r\nTTE (___):\r\nConclusions   \r\n The left atrium is normal in size. No atrial septal defect is \r\nseen by 2D or color Doppler. Left ventricular wall thicknesses \r\nand cavity size are normal. There is mild global left \r\nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. \r\nRight ventricular chamber size and free wall motion are normal. \r\nThe aortic valve leaflets (3) appear structurally normal with \r\ngood leaflet excursion. No masses or vegetations are seen on the \r\naortic valve. Trace aortic regurgitation is seen. The mitral \r\nvalve leaflets are structurally normal. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. The pulmonary artery \r\nsystolic pressure could not be determined. There is no \r\npericardial effusion. \r\n\r\n IMPRESSION: Normal biventricular cavity sizes with mild global \r\nleft ventricular hypokinesis. Mild mitral regurgitation with \r\nnormal valve morphology. Trace aortic regurgitation with normal \r\nvalve morphology. \r\n\r\n Compared with the prior report (images not available for \r\nreview) of ___, trace aortic regurgitation is now present \r\nwith similar valve morphology.   \r\n\r\nBILAT LOWER EXT VEINS (___):\r\nIMPRESSION: \r\n1. New deep venous thrombosis involving the left posterior \r\ntibial and right \r\npopliteal veins. \r\n2. No fluid collection in the area of pain in the left lateral \r\ncalf. \r\n\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ immunocompromised female ___ \r\nalloSCT for secondary MDS admitted for acute change in headaches \r\nwith new, severe symptoms such as nausea and vomiting now with \r\nfevers to 103 and coagulase-negative gram-positive cocci in \r\nclusters in blood cultures being treated for S. epidermidis \r\nbacteremia.\r\n\r\n#Headache\r\nCT head performed in the ED ___ was unremarkable but infectious \r\netiology remained very high on the\r\ndifferential given the patient's immunosuppression regimen and \r\nhistory of aseptic meningitis during her last admission. She \r\nalso had history of R internal carotid cavernous sinus aneurysm \r\nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \r\nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \r\ncrypotococcus, and fungal markers were tested and all were \r\nnegative. The patient's headache resolved and she was symptom \r\nfree at time of discharge. \r\n\r\n#S. epidermidis Bacteremia\r\nShe had fevers up to 103 on ___ and was started on vancomycin \r\nand cefepime. The vancomycin was DC'd ___ overnight and she was \r\nstarted on linezolid per ID recommendations as she had a history \r\nof VRE bacteremia in the past and was continued on cefepime. ___ \r\nblood culture bottles grew S. epidermidis and she was narrowed \r\nto vancomycin only. A chest x-ray was unremarkable for \r\npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \r\nCT abdomen pelvis ___ did not show any evidence of infection. An \r\nultrasound of her port site was without evidence of infection. \r\nAn ultrasound of her LLE ordered for concern of an abscess \r\nrevealed a distal DVT but no fluid collections. A TTE revealed \r\nnormal biventricular cavity sizes with mild global left \r\nventricular hypokinesis, mild mitral regurgitation with normal \r\nvalve morphology and trace aortic regurgitation with normal \r\nvalve morphology. A TEE was scheduled but was cancelled as \r\npatient will need 6 weeks of therapy for treatment of possible \r\nseptic thrombophlebitis. She was continued on Vancomycin until \r\n___ and was transitioned to Daptomycin on ___ as her \r\nVancomycin level fluctuated frequently throughout her \r\nhospitalization, making dosing of the medication challenging. \r\nShe will need to remain on Daptomycin until ___ to complete 6 \r\nweeks of antibiotic therapy.\r\n\r\n#Mechanical Fall\r\nPatient had a mechanical fall during the evening of ___. She \r\nbecame incontinent of urine and slipped and fell while trying to \r\nmake it to the bathroom. CT head and C spine were unremarkable. \r\nX rays of her left wrist revealed no fractures. She was given a \r\nhard brace based on an OT evaluation. Ecchymosis on head was \r\nimproving at discharge. She will continue to wear the brace \r\nuntil symptoms improve.\r\n\r\n#MDS ___ Allo MUD SCT\r\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \r\nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \r\nand 50mg QPM. Initial cyclosporine levels were low and her \r\ndosage was increased to 100mg BID. Her creatinine increased on \r\nthis dose and she was discharged on dosage of 75mg BID. Her home \r\nprophylaxis with fluconazole, Bactrim, and valganciclovir was \r\ninitially continued. However, given worsening neutropenia, her \r\nBactrim was transitioned to atovaquone and her valganciclovir \r\nwas transitioned to acyclovir. She was scheduled to have a bone \r\nmarrow biopsy with ___ as an outpatient on ___ but this was \r\ncancelled due to patient's new DVT. She will need to have a bone \r\nmarrow biopsy done as an outpatient.\r\n\r\n#DVT\r\nEnoxaparin was held ___ for possible LP but a US LLE \r\nperformed due to the concern of an abscess revealed a new distal \r\nDVT on ___ in LLE. LP was deferred due to resolution of her \r\nheadache and lack of neurologic symptoms and she was put on a \r\ntherapeutic dose of Enoxaparin. Her lower extremity swelling \r\nimproved and she was discharged on Enoxaparin 80mg BID.\r\n\r\n___\r\nShe presented with Cr above baseline at 1.7 No casts were \r\nvisualized on UA and she had a FENa of 1.7% on ___, indicating \r\nprerenal etiology. She was given fluids and her creatinine \r\nreturned to baseline. Her Cr increased again on ___ to 1.4. She \r\nwas again given IVF and her cyclosporine was decreased from \r\n100mg BID to 75mg BID. Cr at discharge improved to 1.2.\r\n\r\n#Asthma\r\nAlbuterol and duonebs were given as needed\r\n\r\nTRANSITIONAL ISSUES\r\n===================\r\n[] Follow up with Dr. ___ on ___\r\n[] Continue daptomycin and Vancomycin/heparin locks until ___.\r\n[] Will need to get weekly CK levels while on daptomycin.\r\n[] Repeat bone marrow biopsy scheduled for ___ was cancelled \r\ngiven new DVT and infection. Will need repeat bone marrow biopsy \r\nscheduled.\r\n\r\nCODE STATUS: FULL CODE\r\nHCP: ___ (Husband) ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n2. Fluconazole 400 mg PO Q24H \r\n3. FoLIC Acid 1 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n7. Multivitamins 1 TAB PO DAILY \r\n8. Omeprazole 20 mg PO DAILY \r\n9. Ondansetron 4 mg PO Q8H:PRN nausea \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. ValGANCIclovir 450 mg PO Q24H \r\n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \r\n14. Enoxaparin Sodium 100 mg SC DAILY \r\n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  Atovaquone Suspension 1500 mg PO DAILY \r\nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \r\nMilliliter Refills:*0 \r\n3.  Daptomycin 500 mg IV Q24H \r\nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \r\n4.  Nystatin Cream 1 Appl TP BID  \r\n5.  Vancomycin-Heparin Lock ___AILY  \r\n6.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \r\n7.  Enoxaparin Sodium 80 mg SC Q12H \r\nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \r\nRefills:*0 \r\n8.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n9.  Fluconazole 400 mg PO Q24H  \r\n10.  FoLIC Acid 1 mg PO DAILY  \r\n11.  Gabapentin 400 mg PO BID  \r\n12.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n13.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n14.  Multivitamins 1 TAB PO DAILY  \r\n15.  Omeprazole 20 mg PO DAILY  \r\n16.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n17.  Venlafaxine 25 mg PO DAILY  \r\n18.vancomycin lock\r\nVancomycin-Heparin Lock ___AILY \r\nVancomycin 2 mg/mL + Heparin 100 units/mL\r\n5mL solution daily\r\nDispense 170mL solution\r\nContinue until ___ \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSES\r\n=================\r\nHeadache\r\nS. epidermidis Bacteremia\r\nMechanical Fall\r\nSecondary MDS ___ AlloSCT\r\nGERD\r\nOSA\r\nSciatica\r\n\r\nSECONDARY DIAGNOSES\r\n===================\r\nCVID\r\nDVT\r\nAsthma\r\nPre-HTN\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure taking care of you in the hospital!\r\n\r\nWhy was I admitted to the hospital?\r\nYou were admitted to the hospital because you were experiencing \r\nheadaches, concerning for possible infection in or around your \r\nbrain.\r\n\r\nWhat happened while I was admitted in the hospital?\r\n-Your headache resolved on its own\r\n-Imaging studies were done to evaluate your headache and did not \r\ndemonstrate any clear cause\r\n-Numerous tests were conducted on your blood and you were found \r\nto have a bacterial infection of your blood\r\n-Imaging studies were performed to find the source of the \r\nbacteria and no clear source was found\r\n-You were started on antibiotics to treat your bacterial \r\ninfection\r\n-Imaging of your leg showed you had a clot in your leg\r\n-Your home Bactrim and Valganciclovir were discontinued and you \r\nwere started on Atovaquone and Acyclovir.\r\n\r\nWhat should I do after I get discharged from the hospital?\r\n-Take all of your medications as prescribed, details below\r\n-Keep all of your scheduled appointments \r\n\r\nWe wish you the very best!\r\n\r\nYour ___ Oncology Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-24:4",
      "text": "MICROBIOLOGY\n=============\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. **FINAL REPORT ___ Blood Culture, Routine (Final ___: \n      STAPHYLOCOCCUS EPIDERMIDIS. FINAL SENSITIVITIES. COAG NEG STAPH does NOT require contact precautions, \nregardless of\n         resistance Oxacillin RESISTANT Staphylococci MUST be \nreported as\n         also RESISTANT to other penicillins, cephalosporins, \ncarbacephems,\n         carbapenems, and beta-lactamase inhibitor combinations. RIFAMPIN should not be used alone for therapy. Daptomycin AND LINEZOLID Susceptibility testing \nrequested by ___. ___ (___) ON ___. Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \nresult performed\n         by Etest. SENSITIVITIES: MIC expressed in \nMCG/ML\n                      \n_________________________________________________________\n                             STAPHYLOCOCCUS EPIDERMIDIS\n                             |   \nCLINDAMYCIN-----------   =>8 R\nDAPTOMYCIN------------       S\nERYTHROMYCIN----------   =>8 R\nGENTAMICIN------------ <=0.5 S\nLEVOFLOXACIN----------   =>8 R\nLINEZOLID-------------     2 S\nOXACILLIN-------------   =>4 R\nRIFAMPIN-------------- <=0.5 S\nVANCOMYCIN------------     1 S Aerobic Bottle Gram Stain (Final ___: \n      GRAM POSITIVE COCCI IN CLUSTERS. Reported to and read back by ___ (___) @ ___ ON \n___. ___ 10:36 pm BLOOD CULTURE     Site: ARM **FINAL REPORT ___ Blood Culture, Routine (Final ___: \n      STAPHYLOCOCCUS EPIDERMIDIS. FINAL SENSITIVITIES. COAG NEG STAPH does NOT require contact precautions, \nregardless of\n         resistance. Oxacillin RESISTANT Staphylococci MUST be reported as \nalso\n         RESISTANT to other penicillins, cephalosporins, \ncarbacephems,\n         carbapenems, and beta-lactamase inhibitor combinations. RIFAMPIN should not be used alone for therapy. Daptomycin AND LINEZOLID Susceptibility testing \nrequested by ___. ___ (___) ON ___. Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \nresult\n         performed by Etest. SENSITIVITIES: MIC expressed in \nMCG/ML\n                      \n_________________________________________________________\n                             STAPHYLOCOCCUS EPIDERMIDIS\n                             |   \nCLINDAMYCIN-----------   =>8 R\nDAPTOMYCIN------------       S\nERYTHROMYCIN----------   =>8 R\nGENTAMICIN------------ <=0.5 S\nLEVOFLOXACIN----------   =>8 R\nLINEZOLID-------------     1 S\nOXACILLIN-------------   =>4 R\nRIFAMPIN-------------- <=0.5 S\nVANCOMYCIN------------     1 S Anaerobic Bottle Gram Stain (Final ___: \n      GRAM POSITIVE COCCI IN CLUSTERS. Reported to and read back by ___ (___) @ ___ \nON ___. Aerobic Bottle Gram Stain (Final ___: \n      GRAM POSITIVE COCCI IN CLUSTERS. ___ 10:08 pm BLOOD CULTURE      Source: Line-poc. **FINAL REPORT ___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-24",
        "chart_time": "104763",
        "section": "General",
        "position": 4,
        "tokenCount": 685,
        "note_metadata": {
          "note_id": "18887130-DS-24",
          "subject_id": 18887130,
          "hadm_id": 23656314,
          "note_type": "DS",
          "note_seq": 24,
          "charttime": 104763,
          "storetime": 104766.75763888888,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nHeadache, Nausea, Vomiting\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\r\nTransplant who is admitted with a headache. The patient states\r\nher headache started yesterday morning. It was a right sided\r\nheadache which came down into her face. It intensified \r\nthroughout\r\nthe day and then in the afternoon she started vomiting numerous\r\ntimes. Which prompted her to go to the ED. She states the\r\nheadache was similar in location to when she gets migraines but\r\nthe duration was different and with migraines she usually gets\r\none episode of nausea in the morning and then it resolves. She\r\ndenies any neck stiffness, rashes, or fevers. She also denies \r\nany\r\nshortness of breath, diarrhea, or dysuria. \r\nShe went to the ED last night and had a head CT done which was \r\nunremarkable. She was then given Tylenol, dexamethasone,\r\nBenadryl, IV fluids, and Compazine. With improvement of her\r\nsymptoms. She then was discharged home early this morning. \r\nHer primary oncology team was concerned about the underlying\r\ncause of her headache given her history of a recent bone marrow\r\ntransplant and that she is on immunosuppression. So she was\r\ninstructed to return for admission for further workup. \r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL\r\n==================\r\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\r\nGeneral: No acute distress, sitting completely comfortably in a\r\nchair\r\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\r\nedema in right lower extremity, 2+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\nDISCHARGE PHYSICAL\r\n==================\r\nVS:  98.6 131 / 81 93 18 96 Ra \r\nGeneral: No acute distress, lying comfortably in bed\r\nHEENT: Hematoma and ecchymosis in occipital region of head,\r\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\r\nLAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: Edema over the radial aspect of the left wrist improving, \r\n1+\r\nperipheral edema in bilateral lower extremity, venous stasis\r\ndermatitis bilaterally on lower extremities, 1+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n==============\r\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \r\nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\r\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \r\nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \r\nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\r\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \r\nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\r\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\r\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \r\nK-4.2 Cl-104 HCO3-21* AnGap-14\r\n___ 11:17PM BLOOD Lipase-11\r\n___ 11:17PM BLOOD Albumin-3.6\r\n___ 11:22PM BLOOD Lactate-1.1\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \r\nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\r\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \r\nK-4.0 Cl-103 HCO3-24 AnGap-14\r\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \r\nAlkPhos-86 TotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\r\n___ 09:21AM BLOOD Cyclspr-184\r\n\r\nMICROBIOLOGY\r\n=============\r\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance Oxacillin RESISTANT Staphylococci MUST be \r\nreported as\r\n         also RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     2 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ ON \r\n___. \r\n\r\n___ 10:36 pm BLOOD CULTURE     Site: ARM\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \r\nresult\r\n         performed by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 10:08 pm BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------ <=0.5 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 12:40 pm BLOOD CULTURE\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\n___ 9:11 am BLOOD CULTURE      Source: Line-PORT. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\nIMAGING\r\n=========\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Evaluation limited by artifact from high-density metallic \r\nmaterial the area \r\nof the right carotid siphon. \r\n2. No acute intracranial abnormality. \r\n\r\nMR HEAD W/ & W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute intracranial process.  No abnormal enhancement after \r\ncontrast \r\nadministration. \r\n2. Susceptibility artifact from prior coiling in the region of \r\nthe right \r\ncavernous internal carotid artery limits evaluation in that \r\narea. \r\n\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Mildly limited study due to streak artifact from metallic \r\ndensity in the \r\nregion of the right carotid siphon. \r\n2. No acute intracranial abnormality or fracture. \r\n3. Soft tissue swelling and hematoma overlying the inferior left \r\nocciput, and \r\ncentrally near the vertex. \r\n\r\nCT C-SPINE W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute fracture or new alignment abnormality. \r\n2. Multilevel degenerative changes and levels of congenital \r\nfusion, grossly \r\nunchanged and better described on the prior MRI from ___. \r\n\r\nWRIST (3+ VIEWS) LEFT (___):\r\nIMPRESSION:  \r\nNo acute fracture or dislocation.  Mild widening of the distal \r\nradioulnar \r\njoint. \r\n\r\nCT ABD & PELVIS WITH CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No infectious source identified in the abdomen or pelvis. \r\n2.  Mild intrahepatic and extrahepatic biliary dilatation, \r\nlikely post \r\ncholecystectomy. \r\n3.  Tiny nonocclusive thrombus in the IVC, above the IVC filter. \r\n Some of the \r\nfilter struts have penetrated the vessel wall, not uncommonly \r\nseen.  Given \r\nthat this is a retrievable filter, interventional radiology \r\nconsultation could \r\nbe considered for filter removal if it is no longer needed. \r\n4.  Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \r\nwhich dates \r\nback to at least ___.  Consider periodic follow-up with pelvic \r\nultrasound to \r\ndocument expected continued stability. \r\n\r\nCT CHEST W/ CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No evidence of pneumonia. \r\n2.  Enlarged pulmonary artery may be seen in pulmonary arterial \r\nhypertension. \r\n\r\nUNILAT UP EXT VEINS US LEFT (___):\r\nIMPRESSION:  \r\nNo evidence of deep vein thrombosis in the left upper extremity. \r\n\r\n\r\nTTE (___):\r\nConclusions   \r\n The left atrium is normal in size. No atrial septal defect is \r\nseen by 2D or color Doppler. Left ventricular wall thicknesses \r\nand cavity size are normal. There is mild global left \r\nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. \r\nRight ventricular chamber size and free wall motion are normal. \r\nThe aortic valve leaflets (3) appear structurally normal with \r\ngood leaflet excursion. No masses or vegetations are seen on the \r\naortic valve. Trace aortic regurgitation is seen. The mitral \r\nvalve leaflets are structurally normal. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. The pulmonary artery \r\nsystolic pressure could not be determined. There is no \r\npericardial effusion. \r\n\r\n IMPRESSION: Normal biventricular cavity sizes with mild global \r\nleft ventricular hypokinesis. Mild mitral regurgitation with \r\nnormal valve morphology. Trace aortic regurgitation with normal \r\nvalve morphology. \r\n\r\n Compared with the prior report (images not available for \r\nreview) of ___, trace aortic regurgitation is now present \r\nwith similar valve morphology.   \r\n\r\nBILAT LOWER EXT VEINS (___):\r\nIMPRESSION: \r\n1. New deep venous thrombosis involving the left posterior \r\ntibial and right \r\npopliteal veins. \r\n2. No fluid collection in the area of pain in the left lateral \r\ncalf. \r\n\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ immunocompromised female ___ \r\nalloSCT for secondary MDS admitted for acute change in headaches \r\nwith new, severe symptoms such as nausea and vomiting now with \r\nfevers to 103 and coagulase-negative gram-positive cocci in \r\nclusters in blood cultures being treated for S. epidermidis \r\nbacteremia.\r\n\r\n#Headache\r\nCT head performed in the ED ___ was unremarkable but infectious \r\netiology remained very high on the\r\ndifferential given the patient's immunosuppression regimen and \r\nhistory of aseptic meningitis during her last admission. She \r\nalso had history of R internal carotid cavernous sinus aneurysm \r\nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \r\nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \r\ncrypotococcus, and fungal markers were tested and all were \r\nnegative. The patient's headache resolved and she was symptom \r\nfree at time of discharge. \r\n\r\n#S. epidermidis Bacteremia\r\nShe had fevers up to 103 on ___ and was started on vancomycin \r\nand cefepime. The vancomycin was DC'd ___ overnight and she was \r\nstarted on linezolid per ID recommendations as she had a history \r\nof VRE bacteremia in the past and was continued on cefepime. ___ \r\nblood culture bottles grew S. epidermidis and she was narrowed \r\nto vancomycin only. A chest x-ray was unremarkable for \r\npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \r\nCT abdomen pelvis ___ did not show any evidence of infection. An \r\nultrasound of her port site was without evidence of infection. \r\nAn ultrasound of her LLE ordered for concern of an abscess \r\nrevealed a distal DVT but no fluid collections. A TTE revealed \r\nnormal biventricular cavity sizes with mild global left \r\nventricular hypokinesis, mild mitral regurgitation with normal \r\nvalve morphology and trace aortic regurgitation with normal \r\nvalve morphology. A TEE was scheduled but was cancelled as \r\npatient will need 6 weeks of therapy for treatment of possible \r\nseptic thrombophlebitis. She was continued on Vancomycin until \r\n___ and was transitioned to Daptomycin on ___ as her \r\nVancomycin level fluctuated frequently throughout her \r\nhospitalization, making dosing of the medication challenging. \r\nShe will need to remain on Daptomycin until ___ to complete 6 \r\nweeks of antibiotic therapy.\r\n\r\n#Mechanical Fall\r\nPatient had a mechanical fall during the evening of ___. She \r\nbecame incontinent of urine and slipped and fell while trying to \r\nmake it to the bathroom. CT head and C spine were unremarkable. \r\nX rays of her left wrist revealed no fractures. She was given a \r\nhard brace based on an OT evaluation. Ecchymosis on head was \r\nimproving at discharge. She will continue to wear the brace \r\nuntil symptoms improve.\r\n\r\n#MDS ___ Allo MUD SCT\r\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \r\nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \r\nand 50mg QPM. Initial cyclosporine levels were low and her \r\ndosage was increased to 100mg BID. Her creatinine increased on \r\nthis dose and she was discharged on dosage of 75mg BID. Her home \r\nprophylaxis with fluconazole, Bactrim, and valganciclovir was \r\ninitially continued. However, given worsening neutropenia, her \r\nBactrim was transitioned to atovaquone and her valganciclovir \r\nwas transitioned to acyclovir. She was scheduled to have a bone \r\nmarrow biopsy with ___ as an outpatient on ___ but this was \r\ncancelled due to patient's new DVT. She will need to have a bone \r\nmarrow biopsy done as an outpatient.\r\n\r\n#DVT\r\nEnoxaparin was held ___ for possible LP but a US LLE \r\nperformed due to the concern of an abscess revealed a new distal \r\nDVT on ___ in LLE. LP was deferred due to resolution of her \r\nheadache and lack of neurologic symptoms and she was put on a \r\ntherapeutic dose of Enoxaparin. Her lower extremity swelling \r\nimproved and she was discharged on Enoxaparin 80mg BID.\r\n\r\n___\r\nShe presented with Cr above baseline at 1.7 No casts were \r\nvisualized on UA and she had a FENa of 1.7% on ___, indicating \r\nprerenal etiology. She was given fluids and her creatinine \r\nreturned to baseline. Her Cr increased again on ___ to 1.4. She \r\nwas again given IVF and her cyclosporine was decreased from \r\n100mg BID to 75mg BID. Cr at discharge improved to 1.2.\r\n\r\n#Asthma\r\nAlbuterol and duonebs were given as needed\r\n\r\nTRANSITIONAL ISSUES\r\n===================\r\n[] Follow up with Dr. ___ on ___\r\n[] Continue daptomycin and Vancomycin/heparin locks until ___.\r\n[] Will need to get weekly CK levels while on daptomycin.\r\n[] Repeat bone marrow biopsy scheduled for ___ was cancelled \r\ngiven new DVT and infection. Will need repeat bone marrow biopsy \r\nscheduled.\r\n\r\nCODE STATUS: FULL CODE\r\nHCP: ___ (Husband) ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n2. Fluconazole 400 mg PO Q24H \r\n3. FoLIC Acid 1 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n7. Multivitamins 1 TAB PO DAILY \r\n8. Omeprazole 20 mg PO DAILY \r\n9. Ondansetron 4 mg PO Q8H:PRN nausea \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. ValGANCIclovir 450 mg PO Q24H \r\n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \r\n14. Enoxaparin Sodium 100 mg SC DAILY \r\n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  Atovaquone Suspension 1500 mg PO DAILY \r\nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \r\nMilliliter Refills:*0 \r\n3.  Daptomycin 500 mg IV Q24H \r\nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \r\n4.  Nystatin Cream 1 Appl TP BID  \r\n5.  Vancomycin-Heparin Lock ___AILY  \r\n6.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \r\n7.  Enoxaparin Sodium 80 mg SC Q12H \r\nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \r\nRefills:*0 \r\n8.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n9.  Fluconazole 400 mg PO Q24H  \r\n10.  FoLIC Acid 1 mg PO DAILY  \r\n11.  Gabapentin 400 mg PO BID  \r\n12.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n13.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n14.  Multivitamins 1 TAB PO DAILY  \r\n15.  Omeprazole 20 mg PO DAILY  \r\n16.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n17.  Venlafaxine 25 mg PO DAILY  \r\n18.vancomycin lock\r\nVancomycin-Heparin Lock ___AILY \r\nVancomycin 2 mg/mL + Heparin 100 units/mL\r\n5mL solution daily\r\nDispense 170mL solution\r\nContinue until ___ \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSES\r\n=================\r\nHeadache\r\nS. epidermidis Bacteremia\r\nMechanical Fall\r\nSecondary MDS ___ AlloSCT\r\nGERD\r\nOSA\r\nSciatica\r\n\r\nSECONDARY DIAGNOSES\r\n===================\r\nCVID\r\nDVT\r\nAsthma\r\nPre-HTN\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure taking care of you in the hospital!\r\n\r\nWhy was I admitted to the hospital?\r\nYou were admitted to the hospital because you were experiencing \r\nheadaches, concerning for possible infection in or around your \r\nbrain.\r\n\r\nWhat happened while I was admitted in the hospital?\r\n-Your headache resolved on its own\r\n-Imaging studies were done to evaluate your headache and did not \r\ndemonstrate any clear cause\r\n-Numerous tests were conducted on your blood and you were found \r\nto have a bacterial infection of your blood\r\n-Imaging studies were performed to find the source of the \r\nbacteria and no clear source was found\r\n-You were started on antibiotics to treat your bacterial \r\ninfection\r\n-Imaging of your leg showed you had a clot in your leg\r\n-Your home Bactrim and Valganciclovir were discontinued and you \r\nwere started on Atovaquone and Acyclovir.\r\n\r\nWhat should I do after I get discharged from the hospital?\r\n-Take all of your medications as prescribed, details below\r\n-Keep all of your scheduled appointments \r\n\r\nWe wish you the very best!\r\n\r\nYour ___ Oncology Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-24:5",
      "text": "Anaerobic Bottle Gram Stain (Final ___: \n      GRAM POSITIVE COCCI IN CLUSTERS. Reported to and read back by ___ (___) @ ___ \nON ___. Aerobic Bottle Gram Stain (Final ___: \n      GRAM POSITIVE COCCI IN CLUSTERS. ___ 10:08 pm BLOOD CULTURE      Source: Line-poc. **FINAL REPORT ___ Blood Culture, Routine (Final ___: \n      STAPHYLOCOCCUS EPIDERMIDIS. FINAL SENSITIVITIES. COAG NEG STAPH does NOT require contact precautions, \nregardless of\n         resistance. Oxacillin RESISTANT Staphylococci MUST be reported as \nalso\n         RESISTANT to other penicillins, cephalosporins, \ncarbacephems,\n         carbapenems, and beta-lactamase inhibitor combinations. RIFAMPIN should not be used alone for therapy. Daptomycin AND LINEZOLID Susceptibility testing \nrequested by ___. ___ (___) ON ___. Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \nresult performed\n         by Etest. SENSITIVITIES: MIC expressed in \nMCG/ML\n                      \n_________________________________________________________\n                             STAPHYLOCOCCUS EPIDERMIDIS\n                             |   \nCLINDAMYCIN-----------   =>8 R\nDAPTOMYCIN------------       S\nERYTHROMYCIN----------   =>8 R\nGENTAMICIN------------ <=0.5 S\nLEVOFLOXACIN----------   =>8 R\nLINEZOLID-------------     1 S\nOXACILLIN-------------   =>4 R\nRIFAMPIN-------------- <=0.5 S\nVANCOMYCIN------------ <=0.5 S Aerobic Bottle Gram Stain (Final ___: \n      GRAM POSITIVE COCCI IN CLUSTERS. Reported to and read back by ___ (___) @ ___ \nON ___. Anaerobic Bottle Gram Stain (Final ___: \n      GRAM POSITIVE COCCI IN CLUSTERS. ___ 12:40 pm BLOOD CULTURE **FINAL REPORT ___ Blood Culture, Routine (Final ___:    NO GROWTH. ___ 9:11 am BLOOD CULTURE      Source: Line-PORT. **FINAL REPORT ___ Blood Culture, Routine (Final ___:    NO GROWTH. IMAGING\n=========\nCT HEAD W/O CONTRAST (___): IMPRESSION: \n1. Evaluation limited by artifact from high-density metallic \nmaterial the area \nof the right carotid siphon. 2. No acute intracranial abnormality. MR HEAD W/ & W/O CONTRAST (___): IMPRESSION: \n1. No acute intracranial process. No abnormal enhancement after \ncontrast \nadministration. 2. Susceptibility artifact from prior coiling in the region of \nthe right \ncavernous internal carotid artery limits evaluation in that \narea. CT HEAD W/O CONTRAST (___): IMPRESSION: \n1. Mildly limited study due to streak artifact from metallic \ndensity in the \nregion of the right carotid siphon. 2. No acute intracranial abnormality or fracture. 3. Soft tissue swelling and hematoma overlying the inferior left \nocciput, and \ncentrally near the vertex. CT C-SPINE W/O CONTRAST (___): IMPRESSION: \n1. No acute fracture or new alignment abnormality. 2. Multilevel degenerative changes and levels of congenital \nfusion, grossly \nunchanged and better described on the prior MRI from ___. WRIST (3+ VIEWS) LEFT (___): IMPRESSION:  \nNo acute fracture or dislocation. Mild widening of the distal \nradioulnar \njoint. CT ABD & PELVIS WITH CONTRAST (___):",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-24",
        "chart_time": "104763",
        "section": "General",
        "position": 5,
        "tokenCount": 746,
        "note_metadata": {
          "note_id": "18887130-DS-24",
          "subject_id": 18887130,
          "hadm_id": 23656314,
          "note_type": "DS",
          "note_seq": 24,
          "charttime": 104763,
          "storetime": 104766.75763888888,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nHeadache, Nausea, Vomiting\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\r\nTransplant who is admitted with a headache. The patient states\r\nher headache started yesterday morning. It was a right sided\r\nheadache which came down into her face. It intensified \r\nthroughout\r\nthe day and then in the afternoon she started vomiting numerous\r\ntimes. Which prompted her to go to the ED. She states the\r\nheadache was similar in location to when she gets migraines but\r\nthe duration was different and with migraines she usually gets\r\none episode of nausea in the morning and then it resolves. She\r\ndenies any neck stiffness, rashes, or fevers. She also denies \r\nany\r\nshortness of breath, diarrhea, or dysuria. \r\nShe went to the ED last night and had a head CT done which was \r\nunremarkable. She was then given Tylenol, dexamethasone,\r\nBenadryl, IV fluids, and Compazine. With improvement of her\r\nsymptoms. She then was discharged home early this morning. \r\nHer primary oncology team was concerned about the underlying\r\ncause of her headache given her history of a recent bone marrow\r\ntransplant and that she is on immunosuppression. So she was\r\ninstructed to return for admission for further workup. \r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL\r\n==================\r\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\r\nGeneral: No acute distress, sitting completely comfortably in a\r\nchair\r\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\r\nedema in right lower extremity, 2+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\nDISCHARGE PHYSICAL\r\n==================\r\nVS:  98.6 131 / 81 93 18 96 Ra \r\nGeneral: No acute distress, lying comfortably in bed\r\nHEENT: Hematoma and ecchymosis in occipital region of head,\r\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\r\nLAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: Edema over the radial aspect of the left wrist improving, \r\n1+\r\nperipheral edema in bilateral lower extremity, venous stasis\r\ndermatitis bilaterally on lower extremities, 1+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n==============\r\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \r\nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\r\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \r\nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \r\nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\r\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \r\nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\r\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\r\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \r\nK-4.2 Cl-104 HCO3-21* AnGap-14\r\n___ 11:17PM BLOOD Lipase-11\r\n___ 11:17PM BLOOD Albumin-3.6\r\n___ 11:22PM BLOOD Lactate-1.1\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \r\nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\r\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \r\nK-4.0 Cl-103 HCO3-24 AnGap-14\r\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \r\nAlkPhos-86 TotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\r\n___ 09:21AM BLOOD Cyclspr-184\r\n\r\nMICROBIOLOGY\r\n=============\r\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance Oxacillin RESISTANT Staphylococci MUST be \r\nreported as\r\n         also RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     2 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ ON \r\n___. \r\n\r\n___ 10:36 pm BLOOD CULTURE     Site: ARM\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \r\nresult\r\n         performed by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 10:08 pm BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------ <=0.5 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 12:40 pm BLOOD CULTURE\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\n___ 9:11 am BLOOD CULTURE      Source: Line-PORT. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\nIMAGING\r\n=========\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Evaluation limited by artifact from high-density metallic \r\nmaterial the area \r\nof the right carotid siphon. \r\n2. No acute intracranial abnormality. \r\n\r\nMR HEAD W/ & W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute intracranial process.  No abnormal enhancement after \r\ncontrast \r\nadministration. \r\n2. Susceptibility artifact from prior coiling in the region of \r\nthe right \r\ncavernous internal carotid artery limits evaluation in that \r\narea. \r\n\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Mildly limited study due to streak artifact from metallic \r\ndensity in the \r\nregion of the right carotid siphon. \r\n2. No acute intracranial abnormality or fracture. \r\n3. Soft tissue swelling and hematoma overlying the inferior left \r\nocciput, and \r\ncentrally near the vertex. \r\n\r\nCT C-SPINE W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute fracture or new alignment abnormality. \r\n2. Multilevel degenerative changes and levels of congenital \r\nfusion, grossly \r\nunchanged and better described on the prior MRI from ___. \r\n\r\nWRIST (3+ VIEWS) LEFT (___):\r\nIMPRESSION:  \r\nNo acute fracture or dislocation.  Mild widening of the distal \r\nradioulnar \r\njoint. \r\n\r\nCT ABD & PELVIS WITH CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No infectious source identified in the abdomen or pelvis. \r\n2.  Mild intrahepatic and extrahepatic biliary dilatation, \r\nlikely post \r\ncholecystectomy. \r\n3.  Tiny nonocclusive thrombus in the IVC, above the IVC filter. \r\n Some of the \r\nfilter struts have penetrated the vessel wall, not uncommonly \r\nseen.  Given \r\nthat this is a retrievable filter, interventional radiology \r\nconsultation could \r\nbe considered for filter removal if it is no longer needed. \r\n4.  Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \r\nwhich dates \r\nback to at least ___.  Consider periodic follow-up with pelvic \r\nultrasound to \r\ndocument expected continued stability. \r\n\r\nCT CHEST W/ CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No evidence of pneumonia. \r\n2.  Enlarged pulmonary artery may be seen in pulmonary arterial \r\nhypertension. \r\n\r\nUNILAT UP EXT VEINS US LEFT (___):\r\nIMPRESSION:  \r\nNo evidence of deep vein thrombosis in the left upper extremity. \r\n\r\n\r\nTTE (___):\r\nConclusions   \r\n The left atrium is normal in size. No atrial septal defect is \r\nseen by 2D or color Doppler. Left ventricular wall thicknesses \r\nand cavity size are normal. There is mild global left \r\nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. \r\nRight ventricular chamber size and free wall motion are normal. \r\nThe aortic valve leaflets (3) appear structurally normal with \r\ngood leaflet excursion. No masses or vegetations are seen on the \r\naortic valve. Trace aortic regurgitation is seen. The mitral \r\nvalve leaflets are structurally normal. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. The pulmonary artery \r\nsystolic pressure could not be determined. There is no \r\npericardial effusion. \r\n\r\n IMPRESSION: Normal biventricular cavity sizes with mild global \r\nleft ventricular hypokinesis. Mild mitral regurgitation with \r\nnormal valve morphology. Trace aortic regurgitation with normal \r\nvalve morphology. \r\n\r\n Compared with the prior report (images not available for \r\nreview) of ___, trace aortic regurgitation is now present \r\nwith similar valve morphology.   \r\n\r\nBILAT LOWER EXT VEINS (___):\r\nIMPRESSION: \r\n1. New deep venous thrombosis involving the left posterior \r\ntibial and right \r\npopliteal veins. \r\n2. No fluid collection in the area of pain in the left lateral \r\ncalf. \r\n\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ immunocompromised female ___ \r\nalloSCT for secondary MDS admitted for acute change in headaches \r\nwith new, severe symptoms such as nausea and vomiting now with \r\nfevers to 103 and coagulase-negative gram-positive cocci in \r\nclusters in blood cultures being treated for S. epidermidis \r\nbacteremia.\r\n\r\n#Headache\r\nCT head performed in the ED ___ was unremarkable but infectious \r\netiology remained very high on the\r\ndifferential given the patient's immunosuppression regimen and \r\nhistory of aseptic meningitis during her last admission. She \r\nalso had history of R internal carotid cavernous sinus aneurysm \r\nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \r\nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \r\ncrypotococcus, and fungal markers were tested and all were \r\nnegative. The patient's headache resolved and she was symptom \r\nfree at time of discharge. \r\n\r\n#S. epidermidis Bacteremia\r\nShe had fevers up to 103 on ___ and was started on vancomycin \r\nand cefepime. The vancomycin was DC'd ___ overnight and she was \r\nstarted on linezolid per ID recommendations as she had a history \r\nof VRE bacteremia in the past and was continued on cefepime. ___ \r\nblood culture bottles grew S. epidermidis and she was narrowed \r\nto vancomycin only. A chest x-ray was unremarkable for \r\npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \r\nCT abdomen pelvis ___ did not show any evidence of infection. An \r\nultrasound of her port site was without evidence of infection. \r\nAn ultrasound of her LLE ordered for concern of an abscess \r\nrevealed a distal DVT but no fluid collections. A TTE revealed \r\nnormal biventricular cavity sizes with mild global left \r\nventricular hypokinesis, mild mitral regurgitation with normal \r\nvalve morphology and trace aortic regurgitation with normal \r\nvalve morphology. A TEE was scheduled but was cancelled as \r\npatient will need 6 weeks of therapy for treatment of possible \r\nseptic thrombophlebitis. She was continued on Vancomycin until \r\n___ and was transitioned to Daptomycin on ___ as her \r\nVancomycin level fluctuated frequently throughout her \r\nhospitalization, making dosing of the medication challenging. \r\nShe will need to remain on Daptomycin until ___ to complete 6 \r\nweeks of antibiotic therapy.\r\n\r\n#Mechanical Fall\r\nPatient had a mechanical fall during the evening of ___. She \r\nbecame incontinent of urine and slipped and fell while trying to \r\nmake it to the bathroom. CT head and C spine were unremarkable. \r\nX rays of her left wrist revealed no fractures. She was given a \r\nhard brace based on an OT evaluation. Ecchymosis on head was \r\nimproving at discharge. She will continue to wear the brace \r\nuntil symptoms improve.\r\n\r\n#MDS ___ Allo MUD SCT\r\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \r\nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \r\nand 50mg QPM. Initial cyclosporine levels were low and her \r\ndosage was increased to 100mg BID. Her creatinine increased on \r\nthis dose and she was discharged on dosage of 75mg BID. Her home \r\nprophylaxis with fluconazole, Bactrim, and valganciclovir was \r\ninitially continued. However, given worsening neutropenia, her \r\nBactrim was transitioned to atovaquone and her valganciclovir \r\nwas transitioned to acyclovir. She was scheduled to have a bone \r\nmarrow biopsy with ___ as an outpatient on ___ but this was \r\ncancelled due to patient's new DVT. She will need to have a bone \r\nmarrow biopsy done as an outpatient.\r\n\r\n#DVT\r\nEnoxaparin was held ___ for possible LP but a US LLE \r\nperformed due to the concern of an abscess revealed a new distal \r\nDVT on ___ in LLE. LP was deferred due to resolution of her \r\nheadache and lack of neurologic symptoms and she was put on a \r\ntherapeutic dose of Enoxaparin. Her lower extremity swelling \r\nimproved and she was discharged on Enoxaparin 80mg BID.\r\n\r\n___\r\nShe presented with Cr above baseline at 1.7 No casts were \r\nvisualized on UA and she had a FENa of 1.7% on ___, indicating \r\nprerenal etiology. She was given fluids and her creatinine \r\nreturned to baseline. Her Cr increased again on ___ to 1.4. She \r\nwas again given IVF and her cyclosporine was decreased from \r\n100mg BID to 75mg BID. Cr at discharge improved to 1.2.\r\n\r\n#Asthma\r\nAlbuterol and duonebs were given as needed\r\n\r\nTRANSITIONAL ISSUES\r\n===================\r\n[] Follow up with Dr. ___ on ___\r\n[] Continue daptomycin and Vancomycin/heparin locks until ___.\r\n[] Will need to get weekly CK levels while on daptomycin.\r\n[] Repeat bone marrow biopsy scheduled for ___ was cancelled \r\ngiven new DVT and infection. Will need repeat bone marrow biopsy \r\nscheduled.\r\n\r\nCODE STATUS: FULL CODE\r\nHCP: ___ (Husband) ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n2. Fluconazole 400 mg PO Q24H \r\n3. FoLIC Acid 1 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n7. Multivitamins 1 TAB PO DAILY \r\n8. Omeprazole 20 mg PO DAILY \r\n9. Ondansetron 4 mg PO Q8H:PRN nausea \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. ValGANCIclovir 450 mg PO Q24H \r\n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \r\n14. Enoxaparin Sodium 100 mg SC DAILY \r\n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  Atovaquone Suspension 1500 mg PO DAILY \r\nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \r\nMilliliter Refills:*0 \r\n3.  Daptomycin 500 mg IV Q24H \r\nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \r\n4.  Nystatin Cream 1 Appl TP BID  \r\n5.  Vancomycin-Heparin Lock ___AILY  \r\n6.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \r\n7.  Enoxaparin Sodium 80 mg SC Q12H \r\nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \r\nRefills:*0 \r\n8.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n9.  Fluconazole 400 mg PO Q24H  \r\n10.  FoLIC Acid 1 mg PO DAILY  \r\n11.  Gabapentin 400 mg PO BID  \r\n12.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n13.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n14.  Multivitamins 1 TAB PO DAILY  \r\n15.  Omeprazole 20 mg PO DAILY  \r\n16.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n17.  Venlafaxine 25 mg PO DAILY  \r\n18.vancomycin lock\r\nVancomycin-Heparin Lock ___AILY \r\nVancomycin 2 mg/mL + Heparin 100 units/mL\r\n5mL solution daily\r\nDispense 170mL solution\r\nContinue until ___ \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSES\r\n=================\r\nHeadache\r\nS. epidermidis Bacteremia\r\nMechanical Fall\r\nSecondary MDS ___ AlloSCT\r\nGERD\r\nOSA\r\nSciatica\r\n\r\nSECONDARY DIAGNOSES\r\n===================\r\nCVID\r\nDVT\r\nAsthma\r\nPre-HTN\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure taking care of you in the hospital!\r\n\r\nWhy was I admitted to the hospital?\r\nYou were admitted to the hospital because you were experiencing \r\nheadaches, concerning for possible infection in or around your \r\nbrain.\r\n\r\nWhat happened while I was admitted in the hospital?\r\n-Your headache resolved on its own\r\n-Imaging studies were done to evaluate your headache and did not \r\ndemonstrate any clear cause\r\n-Numerous tests were conducted on your blood and you were found \r\nto have a bacterial infection of your blood\r\n-Imaging studies were performed to find the source of the \r\nbacteria and no clear source was found\r\n-You were started on antibiotics to treat your bacterial \r\ninfection\r\n-Imaging of your leg showed you had a clot in your leg\r\n-Your home Bactrim and Valganciclovir were discontinued and you \r\nwere started on Atovaquone and Acyclovir.\r\n\r\nWhat should I do after I get discharged from the hospital?\r\n-Take all of your medications as prescribed, details below\r\n-Keep all of your scheduled appointments \r\n\r\nWe wish you the very best!\r\n\r\nYour ___ Oncology Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-24:6",
      "text": "IMPRESSION:  \n1. No infectious source identified in the abdomen or pelvis. 2. Mild intrahepatic and extrahepatic biliary dilatation, \nlikely post \ncholecystectomy. 3. Tiny nonocclusive thrombus in the IVC, above the IVC filter. Some of the \nfilter struts have penetrated the vessel wall, not uncommonly \nseen. Given \nthat this is a retrievable filter, interventional radiology \nconsultation could \nbe considered for filter removal if it is no longer needed. 4. Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \nwhich dates \nback to at least ___. Consider periodic follow-up with pelvic \nultrasound to \ndocument expected continued stability. CT CHEST W/ CONTRAST (___): IMPRESSION:  \n1. No evidence of pneumonia. 2. Enlarged pulmonary artery may be seen in pulmonary arterial \nhypertension. UNILAT UP EXT VEINS US LEFT (___):",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-24",
        "chart_time": "104763",
        "section": "General",
        "position": 6,
        "tokenCount": 209,
        "note_metadata": {
          "note_id": "18887130-DS-24",
          "subject_id": 18887130,
          "hadm_id": 23656314,
          "note_type": "DS",
          "note_seq": 24,
          "charttime": 104763,
          "storetime": 104766.75763888888,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nHeadache, Nausea, Vomiting\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\r\nTransplant who is admitted with a headache. The patient states\r\nher headache started yesterday morning. It was a right sided\r\nheadache which came down into her face. It intensified \r\nthroughout\r\nthe day and then in the afternoon she started vomiting numerous\r\ntimes. Which prompted her to go to the ED. She states the\r\nheadache was similar in location to when she gets migraines but\r\nthe duration was different and with migraines she usually gets\r\none episode of nausea in the morning and then it resolves. She\r\ndenies any neck stiffness, rashes, or fevers. She also denies \r\nany\r\nshortness of breath, diarrhea, or dysuria. \r\nShe went to the ED last night and had a head CT done which was \r\nunremarkable. She was then given Tylenol, dexamethasone,\r\nBenadryl, IV fluids, and Compazine. With improvement of her\r\nsymptoms. She then was discharged home early this morning. \r\nHer primary oncology team was concerned about the underlying\r\ncause of her headache given her history of a recent bone marrow\r\ntransplant and that she is on immunosuppression. So she was\r\ninstructed to return for admission for further workup. \r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL\r\n==================\r\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\r\nGeneral: No acute distress, sitting completely comfortably in a\r\nchair\r\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\r\nedema in right lower extremity, 2+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\nDISCHARGE PHYSICAL\r\n==================\r\nVS:  98.6 131 / 81 93 18 96 Ra \r\nGeneral: No acute distress, lying comfortably in bed\r\nHEENT: Hematoma and ecchymosis in occipital region of head,\r\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\r\nLAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: Edema over the radial aspect of the left wrist improving, \r\n1+\r\nperipheral edema in bilateral lower extremity, venous stasis\r\ndermatitis bilaterally on lower extremities, 1+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n==============\r\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \r\nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\r\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \r\nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \r\nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\r\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \r\nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\r\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\r\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \r\nK-4.2 Cl-104 HCO3-21* AnGap-14\r\n___ 11:17PM BLOOD Lipase-11\r\n___ 11:17PM BLOOD Albumin-3.6\r\n___ 11:22PM BLOOD Lactate-1.1\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \r\nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\r\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \r\nK-4.0 Cl-103 HCO3-24 AnGap-14\r\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \r\nAlkPhos-86 TotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\r\n___ 09:21AM BLOOD Cyclspr-184\r\n\r\nMICROBIOLOGY\r\n=============\r\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance Oxacillin RESISTANT Staphylococci MUST be \r\nreported as\r\n         also RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     2 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ ON \r\n___. \r\n\r\n___ 10:36 pm BLOOD CULTURE     Site: ARM\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \r\nresult\r\n         performed by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 10:08 pm BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------ <=0.5 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 12:40 pm BLOOD CULTURE\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\n___ 9:11 am BLOOD CULTURE      Source: Line-PORT. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\nIMAGING\r\n=========\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Evaluation limited by artifact from high-density metallic \r\nmaterial the area \r\nof the right carotid siphon. \r\n2. No acute intracranial abnormality. \r\n\r\nMR HEAD W/ & W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute intracranial process.  No abnormal enhancement after \r\ncontrast \r\nadministration. \r\n2. Susceptibility artifact from prior coiling in the region of \r\nthe right \r\ncavernous internal carotid artery limits evaluation in that \r\narea. \r\n\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Mildly limited study due to streak artifact from metallic \r\ndensity in the \r\nregion of the right carotid siphon. \r\n2. No acute intracranial abnormality or fracture. \r\n3. Soft tissue swelling and hematoma overlying the inferior left \r\nocciput, and \r\ncentrally near the vertex. \r\n\r\nCT C-SPINE W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute fracture or new alignment abnormality. \r\n2. Multilevel degenerative changes and levels of congenital \r\nfusion, grossly \r\nunchanged and better described on the prior MRI from ___. \r\n\r\nWRIST (3+ VIEWS) LEFT (___):\r\nIMPRESSION:  \r\nNo acute fracture or dislocation.  Mild widening of the distal \r\nradioulnar \r\njoint. \r\n\r\nCT ABD & PELVIS WITH CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No infectious source identified in the abdomen or pelvis. \r\n2.  Mild intrahepatic and extrahepatic biliary dilatation, \r\nlikely post \r\ncholecystectomy. \r\n3.  Tiny nonocclusive thrombus in the IVC, above the IVC filter. \r\n Some of the \r\nfilter struts have penetrated the vessel wall, not uncommonly \r\nseen.  Given \r\nthat this is a retrievable filter, interventional radiology \r\nconsultation could \r\nbe considered for filter removal if it is no longer needed. \r\n4.  Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \r\nwhich dates \r\nback to at least ___.  Consider periodic follow-up with pelvic \r\nultrasound to \r\ndocument expected continued stability. \r\n\r\nCT CHEST W/ CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No evidence of pneumonia. \r\n2.  Enlarged pulmonary artery may be seen in pulmonary arterial \r\nhypertension. \r\n\r\nUNILAT UP EXT VEINS US LEFT (___):\r\nIMPRESSION:  \r\nNo evidence of deep vein thrombosis in the left upper extremity. \r\n\r\n\r\nTTE (___):\r\nConclusions   \r\n The left atrium is normal in size. No atrial septal defect is \r\nseen by 2D or color Doppler. Left ventricular wall thicknesses \r\nand cavity size are normal. There is mild global left \r\nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. \r\nRight ventricular chamber size and free wall motion are normal. \r\nThe aortic valve leaflets (3) appear structurally normal with \r\ngood leaflet excursion. No masses or vegetations are seen on the \r\naortic valve. Trace aortic regurgitation is seen. The mitral \r\nvalve leaflets are structurally normal. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. The pulmonary artery \r\nsystolic pressure could not be determined. There is no \r\npericardial effusion. \r\n\r\n IMPRESSION: Normal biventricular cavity sizes with mild global \r\nleft ventricular hypokinesis. Mild mitral regurgitation with \r\nnormal valve morphology. Trace aortic regurgitation with normal \r\nvalve morphology. \r\n\r\n Compared with the prior report (images not available for \r\nreview) of ___, trace aortic regurgitation is now present \r\nwith similar valve morphology.   \r\n\r\nBILAT LOWER EXT VEINS (___):\r\nIMPRESSION: \r\n1. New deep venous thrombosis involving the left posterior \r\ntibial and right \r\npopliteal veins. \r\n2. No fluid collection in the area of pain in the left lateral \r\ncalf. \r\n\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ immunocompromised female ___ \r\nalloSCT for secondary MDS admitted for acute change in headaches \r\nwith new, severe symptoms such as nausea and vomiting now with \r\nfevers to 103 and coagulase-negative gram-positive cocci in \r\nclusters in blood cultures being treated for S. epidermidis \r\nbacteremia.\r\n\r\n#Headache\r\nCT head performed in the ED ___ was unremarkable but infectious \r\netiology remained very high on the\r\ndifferential given the patient's immunosuppression regimen and \r\nhistory of aseptic meningitis during her last admission. She \r\nalso had history of R internal carotid cavernous sinus aneurysm \r\nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \r\nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \r\ncrypotococcus, and fungal markers were tested and all were \r\nnegative. The patient's headache resolved and she was symptom \r\nfree at time of discharge. \r\n\r\n#S. epidermidis Bacteremia\r\nShe had fevers up to 103 on ___ and was started on vancomycin \r\nand cefepime. The vancomycin was DC'd ___ overnight and she was \r\nstarted on linezolid per ID recommendations as she had a history \r\nof VRE bacteremia in the past and was continued on cefepime. ___ \r\nblood culture bottles grew S. epidermidis and she was narrowed \r\nto vancomycin only. A chest x-ray was unremarkable for \r\npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \r\nCT abdomen pelvis ___ did not show any evidence of infection. An \r\nultrasound of her port site was without evidence of infection. \r\nAn ultrasound of her LLE ordered for concern of an abscess \r\nrevealed a distal DVT but no fluid collections. A TTE revealed \r\nnormal biventricular cavity sizes with mild global left \r\nventricular hypokinesis, mild mitral regurgitation with normal \r\nvalve morphology and trace aortic regurgitation with normal \r\nvalve morphology. A TEE was scheduled but was cancelled as \r\npatient will need 6 weeks of therapy for treatment of possible \r\nseptic thrombophlebitis. She was continued on Vancomycin until \r\n___ and was transitioned to Daptomycin on ___ as her \r\nVancomycin level fluctuated frequently throughout her \r\nhospitalization, making dosing of the medication challenging. \r\nShe will need to remain on Daptomycin until ___ to complete 6 \r\nweeks of antibiotic therapy.\r\n\r\n#Mechanical Fall\r\nPatient had a mechanical fall during the evening of ___. She \r\nbecame incontinent of urine and slipped and fell while trying to \r\nmake it to the bathroom. CT head and C spine were unremarkable. \r\nX rays of her left wrist revealed no fractures. She was given a \r\nhard brace based on an OT evaluation. Ecchymosis on head was \r\nimproving at discharge. She will continue to wear the brace \r\nuntil symptoms improve.\r\n\r\n#MDS ___ Allo MUD SCT\r\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \r\nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \r\nand 50mg QPM. Initial cyclosporine levels were low and her \r\ndosage was increased to 100mg BID. Her creatinine increased on \r\nthis dose and she was discharged on dosage of 75mg BID. Her home \r\nprophylaxis with fluconazole, Bactrim, and valganciclovir was \r\ninitially continued. However, given worsening neutropenia, her \r\nBactrim was transitioned to atovaquone and her valganciclovir \r\nwas transitioned to acyclovir. She was scheduled to have a bone \r\nmarrow biopsy with ___ as an outpatient on ___ but this was \r\ncancelled due to patient's new DVT. She will need to have a bone \r\nmarrow biopsy done as an outpatient.\r\n\r\n#DVT\r\nEnoxaparin was held ___ for possible LP but a US LLE \r\nperformed due to the concern of an abscess revealed a new distal \r\nDVT on ___ in LLE. LP was deferred due to resolution of her \r\nheadache and lack of neurologic symptoms and she was put on a \r\ntherapeutic dose of Enoxaparin. Her lower extremity swelling \r\nimproved and she was discharged on Enoxaparin 80mg BID.\r\n\r\n___\r\nShe presented with Cr above baseline at 1.7 No casts were \r\nvisualized on UA and she had a FENa of 1.7% on ___, indicating \r\nprerenal etiology. She was given fluids and her creatinine \r\nreturned to baseline. Her Cr increased again on ___ to 1.4. She \r\nwas again given IVF and her cyclosporine was decreased from \r\n100mg BID to 75mg BID. Cr at discharge improved to 1.2.\r\n\r\n#Asthma\r\nAlbuterol and duonebs were given as needed\r\n\r\nTRANSITIONAL ISSUES\r\n===================\r\n[] Follow up with Dr. ___ on ___\r\n[] Continue daptomycin and Vancomycin/heparin locks until ___.\r\n[] Will need to get weekly CK levels while on daptomycin.\r\n[] Repeat bone marrow biopsy scheduled for ___ was cancelled \r\ngiven new DVT and infection. Will need repeat bone marrow biopsy \r\nscheduled.\r\n\r\nCODE STATUS: FULL CODE\r\nHCP: ___ (Husband) ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n2. Fluconazole 400 mg PO Q24H \r\n3. FoLIC Acid 1 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n7. Multivitamins 1 TAB PO DAILY \r\n8. Omeprazole 20 mg PO DAILY \r\n9. Ondansetron 4 mg PO Q8H:PRN nausea \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. ValGANCIclovir 450 mg PO Q24H \r\n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \r\n14. Enoxaparin Sodium 100 mg SC DAILY \r\n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  Atovaquone Suspension 1500 mg PO DAILY \r\nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \r\nMilliliter Refills:*0 \r\n3.  Daptomycin 500 mg IV Q24H \r\nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \r\n4.  Nystatin Cream 1 Appl TP BID  \r\n5.  Vancomycin-Heparin Lock ___AILY  \r\n6.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \r\n7.  Enoxaparin Sodium 80 mg SC Q12H \r\nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \r\nRefills:*0 \r\n8.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n9.  Fluconazole 400 mg PO Q24H  \r\n10.  FoLIC Acid 1 mg PO DAILY  \r\n11.  Gabapentin 400 mg PO BID  \r\n12.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n13.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n14.  Multivitamins 1 TAB PO DAILY  \r\n15.  Omeprazole 20 mg PO DAILY  \r\n16.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n17.  Venlafaxine 25 mg PO DAILY  \r\n18.vancomycin lock\r\nVancomycin-Heparin Lock ___AILY \r\nVancomycin 2 mg/mL + Heparin 100 units/mL\r\n5mL solution daily\r\nDispense 170mL solution\r\nContinue until ___ \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSES\r\n=================\r\nHeadache\r\nS. epidermidis Bacteremia\r\nMechanical Fall\r\nSecondary MDS ___ AlloSCT\r\nGERD\r\nOSA\r\nSciatica\r\n\r\nSECONDARY DIAGNOSES\r\n===================\r\nCVID\r\nDVT\r\nAsthma\r\nPre-HTN\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure taking care of you in the hospital!\r\n\r\nWhy was I admitted to the hospital?\r\nYou were admitted to the hospital because you were experiencing \r\nheadaches, concerning for possible infection in or around your \r\nbrain.\r\n\r\nWhat happened while I was admitted in the hospital?\r\n-Your headache resolved on its own\r\n-Imaging studies were done to evaluate your headache and did not \r\ndemonstrate any clear cause\r\n-Numerous tests were conducted on your blood and you were found \r\nto have a bacterial infection of your blood\r\n-Imaging studies were performed to find the source of the \r\nbacteria and no clear source was found\r\n-You were started on antibiotics to treat your bacterial \r\ninfection\r\n-Imaging of your leg showed you had a clot in your leg\r\n-Your home Bactrim and Valganciclovir were discontinued and you \r\nwere started on Atovaquone and Acyclovir.\r\n\r\nWhat should I do after I get discharged from the hospital?\r\n-Take all of your medications as prescribed, details below\r\n-Keep all of your scheduled appointments \r\n\r\nWe wish you the very best!\r\n\r\nYour ___ Oncology Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-24:7",
      "text": "IMPRESSION:  \nNo evidence of deep vein thrombosis in the left upper extremity. TTE (___):\nConclusions   \n The left atrium is normal in size. No atrial septal defect is \nseen by 2D or color Doppler. Left ventricular wall thicknesses \nand cavity size are normal. There is mild global left \nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. Right ventricular chamber size and free wall motion are normal. The aortic valve leaflets (3) appear structurally normal with \ngood leaflet excursion. No masses or vegetations are seen on the \naortic valve. Trace aortic regurgitation is seen. The mitral \nvalve leaflets are structurally normal. There is no mitral valve \nprolapse. No mass or vegetation is seen on the mitral valve. Mild (1+) mitral regurgitation is seen. The pulmonary artery \nsystolic pressure could not be determined. There is no \npericardial effusion. IMPRESSION: Normal biventricular cavity sizes with mild global \nleft ventricular hypokinesis. Mild mitral regurgitation with \nnormal valve morphology. Trace aortic regurgitation with normal \nvalve morphology. Compared with the prior report (images not available for \nreview) of ___, trace aortic regurgitation is now present \nwith similar valve morphology. BILAT LOWER EXT VEINS (___): IMPRESSION: \n1. New deep venous thrombosis involving the left posterior \ntibial and right \npopliteal veins. 2. No fluid collection in the area of pain in the left lateral \ncalf.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-24",
        "chart_time": "104763",
        "section": "General",
        "position": 7,
        "tokenCount": 359,
        "note_metadata": {
          "note_id": "18887130-DS-24",
          "subject_id": 18887130,
          "hadm_id": 23656314,
          "note_type": "DS",
          "note_seq": 24,
          "charttime": 104763,
          "storetime": 104766.75763888888,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nHeadache, Nausea, Vomiting\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\r\nTransplant who is admitted with a headache. The patient states\r\nher headache started yesterday morning. It was a right sided\r\nheadache which came down into her face. It intensified \r\nthroughout\r\nthe day and then in the afternoon she started vomiting numerous\r\ntimes. Which prompted her to go to the ED. She states the\r\nheadache was similar in location to when she gets migraines but\r\nthe duration was different and with migraines she usually gets\r\none episode of nausea in the morning and then it resolves. She\r\ndenies any neck stiffness, rashes, or fevers. She also denies \r\nany\r\nshortness of breath, diarrhea, or dysuria. \r\nShe went to the ED last night and had a head CT done which was \r\nunremarkable. She was then given Tylenol, dexamethasone,\r\nBenadryl, IV fluids, and Compazine. With improvement of her\r\nsymptoms. She then was discharged home early this morning. \r\nHer primary oncology team was concerned about the underlying\r\ncause of her headache given her history of a recent bone marrow\r\ntransplant and that she is on immunosuppression. So she was\r\ninstructed to return for admission for further workup. \r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL\r\n==================\r\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\r\nGeneral: No acute distress, sitting completely comfortably in a\r\nchair\r\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\r\nedema in right lower extremity, 2+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\nDISCHARGE PHYSICAL\r\n==================\r\nVS:  98.6 131 / 81 93 18 96 Ra \r\nGeneral: No acute distress, lying comfortably in bed\r\nHEENT: Hematoma and ecchymosis in occipital region of head,\r\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\r\nLAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: Edema over the radial aspect of the left wrist improving, \r\n1+\r\nperipheral edema in bilateral lower extremity, venous stasis\r\ndermatitis bilaterally on lower extremities, 1+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n==============\r\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \r\nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\r\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \r\nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \r\nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\r\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \r\nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\r\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\r\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \r\nK-4.2 Cl-104 HCO3-21* AnGap-14\r\n___ 11:17PM BLOOD Lipase-11\r\n___ 11:17PM BLOOD Albumin-3.6\r\n___ 11:22PM BLOOD Lactate-1.1\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \r\nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\r\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \r\nK-4.0 Cl-103 HCO3-24 AnGap-14\r\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \r\nAlkPhos-86 TotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\r\n___ 09:21AM BLOOD Cyclspr-184\r\n\r\nMICROBIOLOGY\r\n=============\r\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance Oxacillin RESISTANT Staphylococci MUST be \r\nreported as\r\n         also RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     2 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ ON \r\n___. \r\n\r\n___ 10:36 pm BLOOD CULTURE     Site: ARM\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \r\nresult\r\n         performed by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 10:08 pm BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------ <=0.5 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 12:40 pm BLOOD CULTURE\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\n___ 9:11 am BLOOD CULTURE      Source: Line-PORT. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\nIMAGING\r\n=========\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Evaluation limited by artifact from high-density metallic \r\nmaterial the area \r\nof the right carotid siphon. \r\n2. No acute intracranial abnormality. \r\n\r\nMR HEAD W/ & W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute intracranial process.  No abnormal enhancement after \r\ncontrast \r\nadministration. \r\n2. Susceptibility artifact from prior coiling in the region of \r\nthe right \r\ncavernous internal carotid artery limits evaluation in that \r\narea. \r\n\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Mildly limited study due to streak artifact from metallic \r\ndensity in the \r\nregion of the right carotid siphon. \r\n2. No acute intracranial abnormality or fracture. \r\n3. Soft tissue swelling and hematoma overlying the inferior left \r\nocciput, and \r\ncentrally near the vertex. \r\n\r\nCT C-SPINE W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute fracture or new alignment abnormality. \r\n2. Multilevel degenerative changes and levels of congenital \r\nfusion, grossly \r\nunchanged and better described on the prior MRI from ___. \r\n\r\nWRIST (3+ VIEWS) LEFT (___):\r\nIMPRESSION:  \r\nNo acute fracture or dislocation.  Mild widening of the distal \r\nradioulnar \r\njoint. \r\n\r\nCT ABD & PELVIS WITH CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No infectious source identified in the abdomen or pelvis. \r\n2.  Mild intrahepatic and extrahepatic biliary dilatation, \r\nlikely post \r\ncholecystectomy. \r\n3.  Tiny nonocclusive thrombus in the IVC, above the IVC filter. \r\n Some of the \r\nfilter struts have penetrated the vessel wall, not uncommonly \r\nseen.  Given \r\nthat this is a retrievable filter, interventional radiology \r\nconsultation could \r\nbe considered for filter removal if it is no longer needed. \r\n4.  Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \r\nwhich dates \r\nback to at least ___.  Consider periodic follow-up with pelvic \r\nultrasound to \r\ndocument expected continued stability. \r\n\r\nCT CHEST W/ CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No evidence of pneumonia. \r\n2.  Enlarged pulmonary artery may be seen in pulmonary arterial \r\nhypertension. \r\n\r\nUNILAT UP EXT VEINS US LEFT (___):\r\nIMPRESSION:  \r\nNo evidence of deep vein thrombosis in the left upper extremity. \r\n\r\n\r\nTTE (___):\r\nConclusions   \r\n The left atrium is normal in size. No atrial septal defect is \r\nseen by 2D or color Doppler. Left ventricular wall thicknesses \r\nand cavity size are normal. There is mild global left \r\nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. \r\nRight ventricular chamber size and free wall motion are normal. \r\nThe aortic valve leaflets (3) appear structurally normal with \r\ngood leaflet excursion. No masses or vegetations are seen on the \r\naortic valve. Trace aortic regurgitation is seen. The mitral \r\nvalve leaflets are structurally normal. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. The pulmonary artery \r\nsystolic pressure could not be determined. There is no \r\npericardial effusion. \r\n\r\n IMPRESSION: Normal biventricular cavity sizes with mild global \r\nleft ventricular hypokinesis. Mild mitral regurgitation with \r\nnormal valve morphology. Trace aortic regurgitation with normal \r\nvalve morphology. \r\n\r\n Compared with the prior report (images not available for \r\nreview) of ___, trace aortic regurgitation is now present \r\nwith similar valve morphology.   \r\n\r\nBILAT LOWER EXT VEINS (___):\r\nIMPRESSION: \r\n1. New deep venous thrombosis involving the left posterior \r\ntibial and right \r\npopliteal veins. \r\n2. No fluid collection in the area of pain in the left lateral \r\ncalf. \r\n\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ immunocompromised female ___ \r\nalloSCT for secondary MDS admitted for acute change in headaches \r\nwith new, severe symptoms such as nausea and vomiting now with \r\nfevers to 103 and coagulase-negative gram-positive cocci in \r\nclusters in blood cultures being treated for S. epidermidis \r\nbacteremia.\r\n\r\n#Headache\r\nCT head performed in the ED ___ was unremarkable but infectious \r\netiology remained very high on the\r\ndifferential given the patient's immunosuppression regimen and \r\nhistory of aseptic meningitis during her last admission. She \r\nalso had history of R internal carotid cavernous sinus aneurysm \r\nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \r\nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \r\ncrypotococcus, and fungal markers were tested and all were \r\nnegative. The patient's headache resolved and she was symptom \r\nfree at time of discharge. \r\n\r\n#S. epidermidis Bacteremia\r\nShe had fevers up to 103 on ___ and was started on vancomycin \r\nand cefepime. The vancomycin was DC'd ___ overnight and she was \r\nstarted on linezolid per ID recommendations as she had a history \r\nof VRE bacteremia in the past and was continued on cefepime. ___ \r\nblood culture bottles grew S. epidermidis and she was narrowed \r\nto vancomycin only. A chest x-ray was unremarkable for \r\npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \r\nCT abdomen pelvis ___ did not show any evidence of infection. An \r\nultrasound of her port site was without evidence of infection. \r\nAn ultrasound of her LLE ordered for concern of an abscess \r\nrevealed a distal DVT but no fluid collections. A TTE revealed \r\nnormal biventricular cavity sizes with mild global left \r\nventricular hypokinesis, mild mitral regurgitation with normal \r\nvalve morphology and trace aortic regurgitation with normal \r\nvalve morphology. A TEE was scheduled but was cancelled as \r\npatient will need 6 weeks of therapy for treatment of possible \r\nseptic thrombophlebitis. She was continued on Vancomycin until \r\n___ and was transitioned to Daptomycin on ___ as her \r\nVancomycin level fluctuated frequently throughout her \r\nhospitalization, making dosing of the medication challenging. \r\nShe will need to remain on Daptomycin until ___ to complete 6 \r\nweeks of antibiotic therapy.\r\n\r\n#Mechanical Fall\r\nPatient had a mechanical fall during the evening of ___. She \r\nbecame incontinent of urine and slipped and fell while trying to \r\nmake it to the bathroom. CT head and C spine were unremarkable. \r\nX rays of her left wrist revealed no fractures. She was given a \r\nhard brace based on an OT evaluation. Ecchymosis on head was \r\nimproving at discharge. She will continue to wear the brace \r\nuntil symptoms improve.\r\n\r\n#MDS ___ Allo MUD SCT\r\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \r\nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \r\nand 50mg QPM. Initial cyclosporine levels were low and her \r\ndosage was increased to 100mg BID. Her creatinine increased on \r\nthis dose and she was discharged on dosage of 75mg BID. Her home \r\nprophylaxis with fluconazole, Bactrim, and valganciclovir was \r\ninitially continued. However, given worsening neutropenia, her \r\nBactrim was transitioned to atovaquone and her valganciclovir \r\nwas transitioned to acyclovir. She was scheduled to have a bone \r\nmarrow biopsy with ___ as an outpatient on ___ but this was \r\ncancelled due to patient's new DVT. She will need to have a bone \r\nmarrow biopsy done as an outpatient.\r\n\r\n#DVT\r\nEnoxaparin was held ___ for possible LP but a US LLE \r\nperformed due to the concern of an abscess revealed a new distal \r\nDVT on ___ in LLE. LP was deferred due to resolution of her \r\nheadache and lack of neurologic symptoms and she was put on a \r\ntherapeutic dose of Enoxaparin. Her lower extremity swelling \r\nimproved and she was discharged on Enoxaparin 80mg BID.\r\n\r\n___\r\nShe presented with Cr above baseline at 1.7 No casts were \r\nvisualized on UA and she had a FENa of 1.7% on ___, indicating \r\nprerenal etiology. She was given fluids and her creatinine \r\nreturned to baseline. Her Cr increased again on ___ to 1.4. She \r\nwas again given IVF and her cyclosporine was decreased from \r\n100mg BID to 75mg BID. Cr at discharge improved to 1.2.\r\n\r\n#Asthma\r\nAlbuterol and duonebs were given as needed\r\n\r\nTRANSITIONAL ISSUES\r\n===================\r\n[] Follow up with Dr. ___ on ___\r\n[] Continue daptomycin and Vancomycin/heparin locks until ___.\r\n[] Will need to get weekly CK levels while on daptomycin.\r\n[] Repeat bone marrow biopsy scheduled for ___ was cancelled \r\ngiven new DVT and infection. Will need repeat bone marrow biopsy \r\nscheduled.\r\n\r\nCODE STATUS: FULL CODE\r\nHCP: ___ (Husband) ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n2. Fluconazole 400 mg PO Q24H \r\n3. FoLIC Acid 1 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n7. Multivitamins 1 TAB PO DAILY \r\n8. Omeprazole 20 mg PO DAILY \r\n9. Ondansetron 4 mg PO Q8H:PRN nausea \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. ValGANCIclovir 450 mg PO Q24H \r\n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \r\n14. Enoxaparin Sodium 100 mg SC DAILY \r\n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  Atovaquone Suspension 1500 mg PO DAILY \r\nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \r\nMilliliter Refills:*0 \r\n3.  Daptomycin 500 mg IV Q24H \r\nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \r\n4.  Nystatin Cream 1 Appl TP BID  \r\n5.  Vancomycin-Heparin Lock ___AILY  \r\n6.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \r\n7.  Enoxaparin Sodium 80 mg SC Q12H \r\nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \r\nRefills:*0 \r\n8.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n9.  Fluconazole 400 mg PO Q24H  \r\n10.  FoLIC Acid 1 mg PO DAILY  \r\n11.  Gabapentin 400 mg PO BID  \r\n12.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n13.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n14.  Multivitamins 1 TAB PO DAILY  \r\n15.  Omeprazole 20 mg PO DAILY  \r\n16.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n17.  Venlafaxine 25 mg PO DAILY  \r\n18.vancomycin lock\r\nVancomycin-Heparin Lock ___AILY \r\nVancomycin 2 mg/mL + Heparin 100 units/mL\r\n5mL solution daily\r\nDispense 170mL solution\r\nContinue until ___ \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSES\r\n=================\r\nHeadache\r\nS. epidermidis Bacteremia\r\nMechanical Fall\r\nSecondary MDS ___ AlloSCT\r\nGERD\r\nOSA\r\nSciatica\r\n\r\nSECONDARY DIAGNOSES\r\n===================\r\nCVID\r\nDVT\r\nAsthma\r\nPre-HTN\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure taking care of you in the hospital!\r\n\r\nWhy was I admitted to the hospital?\r\nYou were admitted to the hospital because you were experiencing \r\nheadaches, concerning for possible infection in or around your \r\nbrain.\r\n\r\nWhat happened while I was admitted in the hospital?\r\n-Your headache resolved on its own\r\n-Imaging studies were done to evaluate your headache and did not \r\ndemonstrate any clear cause\r\n-Numerous tests were conducted on your blood and you were found \r\nto have a bacterial infection of your blood\r\n-Imaging studies were performed to find the source of the \r\nbacteria and no clear source was found\r\n-You were started on antibiotics to treat your bacterial \r\ninfection\r\n-Imaging of your leg showed you had a clot in your leg\r\n-Your home Bactrim and Valganciclovir were discontinued and you \r\nwere started on Atovaquone and Acyclovir.\r\n\r\nWhat should I do after I get discharged from the hospital?\r\n-Take all of your medications as prescribed, details below\r\n-Keep all of your scheduled appointments \r\n\r\nWe wish you the very best!\r\n\r\nYour ___ Oncology Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-24:8",
      "text": "Brief Hospital Course:\nMs. ___ is a ___ immunocompromised female ___ \nalloSCT for secondary MDS admitted for acute change in headaches \nwith new, severe symptoms such as nausea and vomiting now with \nfevers to 103 and coagulase-negative gram-positive cocci in \nclusters in blood cultures being treated for S. epidermidis \nbacteremia. #Headache\nCT head performed in the ED ___ was unremarkable but infectious \netiology remained very high on the\ndifferential given the patient's immunosuppression regimen and \nhistory of aseptic meningitis during her last admission. She \nalso had history of R internal carotid cavernous sinus aneurysm \nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \ncrypotococcus, and fungal markers were tested and all were \nnegative. The patient's headache resolved and she was symptom \nfree at time of discharge. #S. epidermidis Bacteremia\nShe had fevers up to 103 on ___ and was started on vancomycin \nand cefepime. The vancomycin was DC'd ___ overnight and she was \nstarted on linezolid per ID recommendations as she had a history \nof VRE bacteremia in the past and was continued on cefepime. ___ \nblood culture bottles grew S. epidermidis and she was narrowed \nto vancomycin only. A chest x-ray was unremarkable for \npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \nCT abdomen pelvis ___ did not show any evidence of infection. An \nultrasound of her port site was without evidence of infection. An ultrasound of her LLE ordered for concern of an abscess \nrevealed a distal DVT but no fluid collections. A TTE revealed \nnormal biventricular cavity sizes with mild global left \nventricular hypokinesis, mild mitral regurgitation with normal \nvalve morphology and trace aortic regurgitation with normal \nvalve morphology. A TEE was scheduled but was cancelled as \npatient will need 6 weeks of therapy for treatment of possible \nseptic thrombophlebitis. She was continued on Vancomycin until \n___ and was transitioned to Daptomycin on ___ as her \nVancomycin level fluctuated frequently throughout her \nhospitalization, making dosing of the medication challenging. She will need to remain on Daptomycin until ___ to complete 6 \nweeks of antibiotic therapy. #Mechanical Fall\nPatient had a mechanical fall during the evening of ___. She \nbecame incontinent of urine and slipped and fell while trying to \nmake it to the bathroom. CT head and C spine were unremarkable. X rays of her left wrist revealed no fractures. She was given a \nhard brace based on an OT evaluation. Ecchymosis on head was \nimproving at discharge. She will continue to wear the brace \nuntil symptoms improve.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-24",
        "chart_time": "104763",
        "section": "General",
        "position": 8,
        "tokenCount": 669,
        "note_metadata": {
          "note_id": "18887130-DS-24",
          "subject_id": 18887130,
          "hadm_id": 23656314,
          "note_type": "DS",
          "note_seq": 24,
          "charttime": 104763,
          "storetime": 104766.75763888888,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nHeadache, Nausea, Vomiting\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\r\nTransplant who is admitted with a headache. The patient states\r\nher headache started yesterday morning. It was a right sided\r\nheadache which came down into her face. It intensified \r\nthroughout\r\nthe day and then in the afternoon she started vomiting numerous\r\ntimes. Which prompted her to go to the ED. She states the\r\nheadache was similar in location to when she gets migraines but\r\nthe duration was different and with migraines she usually gets\r\none episode of nausea in the morning and then it resolves. She\r\ndenies any neck stiffness, rashes, or fevers. She also denies \r\nany\r\nshortness of breath, diarrhea, or dysuria. \r\nShe went to the ED last night and had a head CT done which was \r\nunremarkable. She was then given Tylenol, dexamethasone,\r\nBenadryl, IV fluids, and Compazine. With improvement of her\r\nsymptoms. She then was discharged home early this morning. \r\nHer primary oncology team was concerned about the underlying\r\ncause of her headache given her history of a recent bone marrow\r\ntransplant and that she is on immunosuppression. So she was\r\ninstructed to return for admission for further workup. \r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL\r\n==================\r\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\r\nGeneral: No acute distress, sitting completely comfortably in a\r\nchair\r\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\r\nedema in right lower extremity, 2+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\nDISCHARGE PHYSICAL\r\n==================\r\nVS:  98.6 131 / 81 93 18 96 Ra \r\nGeneral: No acute distress, lying comfortably in bed\r\nHEENT: Hematoma and ecchymosis in occipital region of head,\r\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\r\nLAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: Edema over the radial aspect of the left wrist improving, \r\n1+\r\nperipheral edema in bilateral lower extremity, venous stasis\r\ndermatitis bilaterally on lower extremities, 1+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n==============\r\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \r\nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\r\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \r\nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \r\nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\r\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \r\nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\r\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\r\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \r\nK-4.2 Cl-104 HCO3-21* AnGap-14\r\n___ 11:17PM BLOOD Lipase-11\r\n___ 11:17PM BLOOD Albumin-3.6\r\n___ 11:22PM BLOOD Lactate-1.1\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \r\nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\r\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \r\nK-4.0 Cl-103 HCO3-24 AnGap-14\r\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \r\nAlkPhos-86 TotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\r\n___ 09:21AM BLOOD Cyclspr-184\r\n\r\nMICROBIOLOGY\r\n=============\r\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance Oxacillin RESISTANT Staphylococci MUST be \r\nreported as\r\n         also RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     2 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ ON \r\n___. \r\n\r\n___ 10:36 pm BLOOD CULTURE     Site: ARM\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \r\nresult\r\n         performed by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 10:08 pm BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------ <=0.5 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 12:40 pm BLOOD CULTURE\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\n___ 9:11 am BLOOD CULTURE      Source: Line-PORT. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\nIMAGING\r\n=========\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Evaluation limited by artifact from high-density metallic \r\nmaterial the area \r\nof the right carotid siphon. \r\n2. No acute intracranial abnormality. \r\n\r\nMR HEAD W/ & W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute intracranial process.  No abnormal enhancement after \r\ncontrast \r\nadministration. \r\n2. Susceptibility artifact from prior coiling in the region of \r\nthe right \r\ncavernous internal carotid artery limits evaluation in that \r\narea. \r\n\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Mildly limited study due to streak artifact from metallic \r\ndensity in the \r\nregion of the right carotid siphon. \r\n2. No acute intracranial abnormality or fracture. \r\n3. Soft tissue swelling and hematoma overlying the inferior left \r\nocciput, and \r\ncentrally near the vertex. \r\n\r\nCT C-SPINE W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute fracture or new alignment abnormality. \r\n2. Multilevel degenerative changes and levels of congenital \r\nfusion, grossly \r\nunchanged and better described on the prior MRI from ___. \r\n\r\nWRIST (3+ VIEWS) LEFT (___):\r\nIMPRESSION:  \r\nNo acute fracture or dislocation.  Mild widening of the distal \r\nradioulnar \r\njoint. \r\n\r\nCT ABD & PELVIS WITH CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No infectious source identified in the abdomen or pelvis. \r\n2.  Mild intrahepatic and extrahepatic biliary dilatation, \r\nlikely post \r\ncholecystectomy. \r\n3.  Tiny nonocclusive thrombus in the IVC, above the IVC filter. \r\n Some of the \r\nfilter struts have penetrated the vessel wall, not uncommonly \r\nseen.  Given \r\nthat this is a retrievable filter, interventional radiology \r\nconsultation could \r\nbe considered for filter removal if it is no longer needed. \r\n4.  Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \r\nwhich dates \r\nback to at least ___.  Consider periodic follow-up with pelvic \r\nultrasound to \r\ndocument expected continued stability. \r\n\r\nCT CHEST W/ CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No evidence of pneumonia. \r\n2.  Enlarged pulmonary artery may be seen in pulmonary arterial \r\nhypertension. \r\n\r\nUNILAT UP EXT VEINS US LEFT (___):\r\nIMPRESSION:  \r\nNo evidence of deep vein thrombosis in the left upper extremity. \r\n\r\n\r\nTTE (___):\r\nConclusions   \r\n The left atrium is normal in size. No atrial septal defect is \r\nseen by 2D or color Doppler. Left ventricular wall thicknesses \r\nand cavity size are normal. There is mild global left \r\nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. \r\nRight ventricular chamber size and free wall motion are normal. \r\nThe aortic valve leaflets (3) appear structurally normal with \r\ngood leaflet excursion. No masses or vegetations are seen on the \r\naortic valve. Trace aortic regurgitation is seen. The mitral \r\nvalve leaflets are structurally normal. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. The pulmonary artery \r\nsystolic pressure could not be determined. There is no \r\npericardial effusion. \r\n\r\n IMPRESSION: Normal biventricular cavity sizes with mild global \r\nleft ventricular hypokinesis. Mild mitral regurgitation with \r\nnormal valve morphology. Trace aortic regurgitation with normal \r\nvalve morphology. \r\n\r\n Compared with the prior report (images not available for \r\nreview) of ___, trace aortic regurgitation is now present \r\nwith similar valve morphology.   \r\n\r\nBILAT LOWER EXT VEINS (___):\r\nIMPRESSION: \r\n1. New deep venous thrombosis involving the left posterior \r\ntibial and right \r\npopliteal veins. \r\n2. No fluid collection in the area of pain in the left lateral \r\ncalf. \r\n\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ immunocompromised female ___ \r\nalloSCT for secondary MDS admitted for acute change in headaches \r\nwith new, severe symptoms such as nausea and vomiting now with \r\nfevers to 103 and coagulase-negative gram-positive cocci in \r\nclusters in blood cultures being treated for S. epidermidis \r\nbacteremia.\r\n\r\n#Headache\r\nCT head performed in the ED ___ was unremarkable but infectious \r\netiology remained very high on the\r\ndifferential given the patient's immunosuppression regimen and \r\nhistory of aseptic meningitis during her last admission. She \r\nalso had history of R internal carotid cavernous sinus aneurysm \r\nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \r\nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \r\ncrypotococcus, and fungal markers were tested and all were \r\nnegative. The patient's headache resolved and she was symptom \r\nfree at time of discharge. \r\n\r\n#S. epidermidis Bacteremia\r\nShe had fevers up to 103 on ___ and was started on vancomycin \r\nand cefepime. The vancomycin was DC'd ___ overnight and she was \r\nstarted on linezolid per ID recommendations as she had a history \r\nof VRE bacteremia in the past and was continued on cefepime. ___ \r\nblood culture bottles grew S. epidermidis and she was narrowed \r\nto vancomycin only. A chest x-ray was unremarkable for \r\npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \r\nCT abdomen pelvis ___ did not show any evidence of infection. An \r\nultrasound of her port site was without evidence of infection. \r\nAn ultrasound of her LLE ordered for concern of an abscess \r\nrevealed a distal DVT but no fluid collections. A TTE revealed \r\nnormal biventricular cavity sizes with mild global left \r\nventricular hypokinesis, mild mitral regurgitation with normal \r\nvalve morphology and trace aortic regurgitation with normal \r\nvalve morphology. A TEE was scheduled but was cancelled as \r\npatient will need 6 weeks of therapy for treatment of possible \r\nseptic thrombophlebitis. She was continued on Vancomycin until \r\n___ and was transitioned to Daptomycin on ___ as her \r\nVancomycin level fluctuated frequently throughout her \r\nhospitalization, making dosing of the medication challenging. \r\nShe will need to remain on Daptomycin until ___ to complete 6 \r\nweeks of antibiotic therapy.\r\n\r\n#Mechanical Fall\r\nPatient had a mechanical fall during the evening of ___. She \r\nbecame incontinent of urine and slipped and fell while trying to \r\nmake it to the bathroom. CT head and C spine were unremarkable. \r\nX rays of her left wrist revealed no fractures. She was given a \r\nhard brace based on an OT evaluation. Ecchymosis on head was \r\nimproving at discharge. She will continue to wear the brace \r\nuntil symptoms improve.\r\n\r\n#MDS ___ Allo MUD SCT\r\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \r\nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \r\nand 50mg QPM. Initial cyclosporine levels were low and her \r\ndosage was increased to 100mg BID. Her creatinine increased on \r\nthis dose and she was discharged on dosage of 75mg BID. Her home \r\nprophylaxis with fluconazole, Bactrim, and valganciclovir was \r\ninitially continued. However, given worsening neutropenia, her \r\nBactrim was transitioned to atovaquone and her valganciclovir \r\nwas transitioned to acyclovir. She was scheduled to have a bone \r\nmarrow biopsy with ___ as an outpatient on ___ but this was \r\ncancelled due to patient's new DVT. She will need to have a bone \r\nmarrow biopsy done as an outpatient.\r\n\r\n#DVT\r\nEnoxaparin was held ___ for possible LP but a US LLE \r\nperformed due to the concern of an abscess revealed a new distal \r\nDVT on ___ in LLE. LP was deferred due to resolution of her \r\nheadache and lack of neurologic symptoms and she was put on a \r\ntherapeutic dose of Enoxaparin. Her lower extremity swelling \r\nimproved and she was discharged on Enoxaparin 80mg BID.\r\n\r\n___\r\nShe presented with Cr above baseline at 1.7 No casts were \r\nvisualized on UA and she had a FENa of 1.7% on ___, indicating \r\nprerenal etiology. She was given fluids and her creatinine \r\nreturned to baseline. Her Cr increased again on ___ to 1.4. She \r\nwas again given IVF and her cyclosporine was decreased from \r\n100mg BID to 75mg BID. Cr at discharge improved to 1.2.\r\n\r\n#Asthma\r\nAlbuterol and duonebs were given as needed\r\n\r\nTRANSITIONAL ISSUES\r\n===================\r\n[] Follow up with Dr. ___ on ___\r\n[] Continue daptomycin and Vancomycin/heparin locks until ___.\r\n[] Will need to get weekly CK levels while on daptomycin.\r\n[] Repeat bone marrow biopsy scheduled for ___ was cancelled \r\ngiven new DVT and infection. Will need repeat bone marrow biopsy \r\nscheduled.\r\n\r\nCODE STATUS: FULL CODE\r\nHCP: ___ (Husband) ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n2. Fluconazole 400 mg PO Q24H \r\n3. FoLIC Acid 1 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n7. Multivitamins 1 TAB PO DAILY \r\n8. Omeprazole 20 mg PO DAILY \r\n9. Ondansetron 4 mg PO Q8H:PRN nausea \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. ValGANCIclovir 450 mg PO Q24H \r\n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \r\n14. Enoxaparin Sodium 100 mg SC DAILY \r\n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  Atovaquone Suspension 1500 mg PO DAILY \r\nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \r\nMilliliter Refills:*0 \r\n3.  Daptomycin 500 mg IV Q24H \r\nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \r\n4.  Nystatin Cream 1 Appl TP BID  \r\n5.  Vancomycin-Heparin Lock ___AILY  \r\n6.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \r\n7.  Enoxaparin Sodium 80 mg SC Q12H \r\nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \r\nRefills:*0 \r\n8.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n9.  Fluconazole 400 mg PO Q24H  \r\n10.  FoLIC Acid 1 mg PO DAILY  \r\n11.  Gabapentin 400 mg PO BID  \r\n12.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n13.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n14.  Multivitamins 1 TAB PO DAILY  \r\n15.  Omeprazole 20 mg PO DAILY  \r\n16.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n17.  Venlafaxine 25 mg PO DAILY  \r\n18.vancomycin lock\r\nVancomycin-Heparin Lock ___AILY \r\nVancomycin 2 mg/mL + Heparin 100 units/mL\r\n5mL solution daily\r\nDispense 170mL solution\r\nContinue until ___ \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSES\r\n=================\r\nHeadache\r\nS. epidermidis Bacteremia\r\nMechanical Fall\r\nSecondary MDS ___ AlloSCT\r\nGERD\r\nOSA\r\nSciatica\r\n\r\nSECONDARY DIAGNOSES\r\n===================\r\nCVID\r\nDVT\r\nAsthma\r\nPre-HTN\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure taking care of you in the hospital!\r\n\r\nWhy was I admitted to the hospital?\r\nYou were admitted to the hospital because you were experiencing \r\nheadaches, concerning for possible infection in or around your \r\nbrain.\r\n\r\nWhat happened while I was admitted in the hospital?\r\n-Your headache resolved on its own\r\n-Imaging studies were done to evaluate your headache and did not \r\ndemonstrate any clear cause\r\n-Numerous tests were conducted on your blood and you were found \r\nto have a bacterial infection of your blood\r\n-Imaging studies were performed to find the source of the \r\nbacteria and no clear source was found\r\n-You were started on antibiotics to treat your bacterial \r\ninfection\r\n-Imaging of your leg showed you had a clot in your leg\r\n-Your home Bactrim and Valganciclovir were discontinued and you \r\nwere started on Atovaquone and Acyclovir.\r\n\r\nWhat should I do after I get discharged from the hospital?\r\n-Take all of your medications as prescribed, details below\r\n-Keep all of your scheduled appointments \r\n\r\nWe wish you the very best!\r\n\r\nYour ___ Oncology Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-24:9",
      "text": "She will need to remain on Daptomycin until ___ to complete 6 \nweeks of antibiotic therapy. #Mechanical Fall\nPatient had a mechanical fall during the evening of ___. She \nbecame incontinent of urine and slipped and fell while trying to \nmake it to the bathroom. CT head and C spine were unremarkable. X rays of her left wrist revealed no fractures. She was given a \nhard brace based on an OT evaluation. Ecchymosis on head was \nimproving at discharge. She will continue to wear the brace \nuntil symptoms improve. #MDS ___ Allo MUD SCT\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \nand 50mg QPM. Initial cyclosporine levels were low and her \ndosage was increased to 100mg BID. Her creatinine increased on \nthis dose and she was discharged on dosage of 75mg BID. Her home \nprophylaxis with fluconazole, Bactrim, and valganciclovir was \ninitially continued. However, given worsening neutropenia, her \nBactrim was transitioned to atovaquone and her valganciclovir \nwas transitioned to acyclovir. She was scheduled to have a bone \nmarrow biopsy with ___ as an outpatient on ___ but this was \ncancelled due to patient's new DVT. She will need to have a bone \nmarrow biopsy done as an outpatient. #DVT\nEnoxaparin was held ___ for possible LP but a US LLE \nperformed due to the concern of an abscess revealed a new distal \nDVT on ___ in LLE. LP was deferred due to resolution of her \nheadache and lack of neurologic symptoms and she was put on a \ntherapeutic dose of Enoxaparin. Her lower extremity swelling \nimproved and she was discharged on Enoxaparin 80mg BID. ___\nShe presented with Cr above baseline at 1.7 No casts were \nvisualized on UA and she had a FENa of 1.7% on ___, indicating \nprerenal etiology. She was given fluids and her creatinine \nreturned to baseline. Her Cr increased again on ___ to 1.4. She \nwas again given IVF and her cyclosporine was decreased from \n100mg BID to 75mg BID. Cr at discharge improved to 1.2. #Asthma\nAlbuterol and duonebs were given as needed TRANSITIONAL ISSUES\n===================\n[] Follow up with Dr. ___ on ___\n[] Continue daptomycin and Vancomycin/heparin locks until ___. [] Will need to get weekly CK levels while on daptomycin. [] Repeat bone marrow biopsy scheduled for ___ was cancelled \ngiven new DVT and infection. Will need repeat bone marrow biopsy \nscheduled. CODE STATUS: FULL CODE\nHCP: ___ (Husband) ___ \n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \n2. Fluconazole 400 mg PO Q24H \n3. FoLIC Acid 1 mg PO DAILY \n4. Gabapentin 400 mg PO BID \n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \n6.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-24",
        "chart_time": "104763",
        "section": "General",
        "position": 9,
        "tokenCount": 682,
        "note_metadata": {
          "note_id": "18887130-DS-24",
          "subject_id": 18887130,
          "hadm_id": 23656314,
          "note_type": "DS",
          "note_seq": 24,
          "charttime": 104763,
          "storetime": 104766.75763888888,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nHeadache, Nausea, Vomiting\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\r\nTransplant who is admitted with a headache. The patient states\r\nher headache started yesterday morning. It was a right sided\r\nheadache which came down into her face. It intensified \r\nthroughout\r\nthe day and then in the afternoon she started vomiting numerous\r\ntimes. Which prompted her to go to the ED. She states the\r\nheadache was similar in location to when she gets migraines but\r\nthe duration was different and with migraines she usually gets\r\none episode of nausea in the morning and then it resolves. She\r\ndenies any neck stiffness, rashes, or fevers. She also denies \r\nany\r\nshortness of breath, diarrhea, or dysuria. \r\nShe went to the ED last night and had a head CT done which was \r\nunremarkable. She was then given Tylenol, dexamethasone,\r\nBenadryl, IV fluids, and Compazine. With improvement of her\r\nsymptoms. She then was discharged home early this morning. \r\nHer primary oncology team was concerned about the underlying\r\ncause of her headache given her history of a recent bone marrow\r\ntransplant and that she is on immunosuppression. So she was\r\ninstructed to return for admission for further workup. \r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL\r\n==================\r\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\r\nGeneral: No acute distress, sitting completely comfortably in a\r\nchair\r\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\r\nedema in right lower extremity, 2+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\nDISCHARGE PHYSICAL\r\n==================\r\nVS:  98.6 131 / 81 93 18 96 Ra \r\nGeneral: No acute distress, lying comfortably in bed\r\nHEENT: Hematoma and ecchymosis in occipital region of head,\r\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\r\nLAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: Edema over the radial aspect of the left wrist improving, \r\n1+\r\nperipheral edema in bilateral lower extremity, venous stasis\r\ndermatitis bilaterally on lower extremities, 1+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n==============\r\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \r\nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\r\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \r\nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \r\nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\r\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \r\nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\r\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\r\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \r\nK-4.2 Cl-104 HCO3-21* AnGap-14\r\n___ 11:17PM BLOOD Lipase-11\r\n___ 11:17PM BLOOD Albumin-3.6\r\n___ 11:22PM BLOOD Lactate-1.1\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \r\nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\r\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \r\nK-4.0 Cl-103 HCO3-24 AnGap-14\r\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \r\nAlkPhos-86 TotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\r\n___ 09:21AM BLOOD Cyclspr-184\r\n\r\nMICROBIOLOGY\r\n=============\r\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance Oxacillin RESISTANT Staphylococci MUST be \r\nreported as\r\n         also RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     2 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ ON \r\n___. \r\n\r\n___ 10:36 pm BLOOD CULTURE     Site: ARM\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \r\nresult\r\n         performed by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 10:08 pm BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------ <=0.5 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 12:40 pm BLOOD CULTURE\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\n___ 9:11 am BLOOD CULTURE      Source: Line-PORT. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\nIMAGING\r\n=========\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Evaluation limited by artifact from high-density metallic \r\nmaterial the area \r\nof the right carotid siphon. \r\n2. No acute intracranial abnormality. \r\n\r\nMR HEAD W/ & W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute intracranial process.  No abnormal enhancement after \r\ncontrast \r\nadministration. \r\n2. Susceptibility artifact from prior coiling in the region of \r\nthe right \r\ncavernous internal carotid artery limits evaluation in that \r\narea. \r\n\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Mildly limited study due to streak artifact from metallic \r\ndensity in the \r\nregion of the right carotid siphon. \r\n2. No acute intracranial abnormality or fracture. \r\n3. Soft tissue swelling and hematoma overlying the inferior left \r\nocciput, and \r\ncentrally near the vertex. \r\n\r\nCT C-SPINE W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute fracture or new alignment abnormality. \r\n2. Multilevel degenerative changes and levels of congenital \r\nfusion, grossly \r\nunchanged and better described on the prior MRI from ___. \r\n\r\nWRIST (3+ VIEWS) LEFT (___):\r\nIMPRESSION:  \r\nNo acute fracture or dislocation.  Mild widening of the distal \r\nradioulnar \r\njoint. \r\n\r\nCT ABD & PELVIS WITH CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No infectious source identified in the abdomen or pelvis. \r\n2.  Mild intrahepatic and extrahepatic biliary dilatation, \r\nlikely post \r\ncholecystectomy. \r\n3.  Tiny nonocclusive thrombus in the IVC, above the IVC filter. \r\n Some of the \r\nfilter struts have penetrated the vessel wall, not uncommonly \r\nseen.  Given \r\nthat this is a retrievable filter, interventional radiology \r\nconsultation could \r\nbe considered for filter removal if it is no longer needed. \r\n4.  Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \r\nwhich dates \r\nback to at least ___.  Consider periodic follow-up with pelvic \r\nultrasound to \r\ndocument expected continued stability. \r\n\r\nCT CHEST W/ CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No evidence of pneumonia. \r\n2.  Enlarged pulmonary artery may be seen in pulmonary arterial \r\nhypertension. \r\n\r\nUNILAT UP EXT VEINS US LEFT (___):\r\nIMPRESSION:  \r\nNo evidence of deep vein thrombosis in the left upper extremity. \r\n\r\n\r\nTTE (___):\r\nConclusions   \r\n The left atrium is normal in size. No atrial septal defect is \r\nseen by 2D or color Doppler. Left ventricular wall thicknesses \r\nand cavity size are normal. There is mild global left \r\nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. \r\nRight ventricular chamber size and free wall motion are normal. \r\nThe aortic valve leaflets (3) appear structurally normal with \r\ngood leaflet excursion. No masses or vegetations are seen on the \r\naortic valve. Trace aortic regurgitation is seen. The mitral \r\nvalve leaflets are structurally normal. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. The pulmonary artery \r\nsystolic pressure could not be determined. There is no \r\npericardial effusion. \r\n\r\n IMPRESSION: Normal biventricular cavity sizes with mild global \r\nleft ventricular hypokinesis. Mild mitral regurgitation with \r\nnormal valve morphology. Trace aortic regurgitation with normal \r\nvalve morphology. \r\n\r\n Compared with the prior report (images not available for \r\nreview) of ___, trace aortic regurgitation is now present \r\nwith similar valve morphology.   \r\n\r\nBILAT LOWER EXT VEINS (___):\r\nIMPRESSION: \r\n1. New deep venous thrombosis involving the left posterior \r\ntibial and right \r\npopliteal veins. \r\n2. No fluid collection in the area of pain in the left lateral \r\ncalf. \r\n\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ immunocompromised female ___ \r\nalloSCT for secondary MDS admitted for acute change in headaches \r\nwith new, severe symptoms such as nausea and vomiting now with \r\nfevers to 103 and coagulase-negative gram-positive cocci in \r\nclusters in blood cultures being treated for S. epidermidis \r\nbacteremia.\r\n\r\n#Headache\r\nCT head performed in the ED ___ was unremarkable but infectious \r\netiology remained very high on the\r\ndifferential given the patient's immunosuppression regimen and \r\nhistory of aseptic meningitis during her last admission. She \r\nalso had history of R internal carotid cavernous sinus aneurysm \r\nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \r\nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \r\ncrypotococcus, and fungal markers were tested and all were \r\nnegative. The patient's headache resolved and she was symptom \r\nfree at time of discharge. \r\n\r\n#S. epidermidis Bacteremia\r\nShe had fevers up to 103 on ___ and was started on vancomycin \r\nand cefepime. The vancomycin was DC'd ___ overnight and she was \r\nstarted on linezolid per ID recommendations as she had a history \r\nof VRE bacteremia in the past and was continued on cefepime. ___ \r\nblood culture bottles grew S. epidermidis and she was narrowed \r\nto vancomycin only. A chest x-ray was unremarkable for \r\npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \r\nCT abdomen pelvis ___ did not show any evidence of infection. An \r\nultrasound of her port site was without evidence of infection. \r\nAn ultrasound of her LLE ordered for concern of an abscess \r\nrevealed a distal DVT but no fluid collections. A TTE revealed \r\nnormal biventricular cavity sizes with mild global left \r\nventricular hypokinesis, mild mitral regurgitation with normal \r\nvalve morphology and trace aortic regurgitation with normal \r\nvalve morphology. A TEE was scheduled but was cancelled as \r\npatient will need 6 weeks of therapy for treatment of possible \r\nseptic thrombophlebitis. She was continued on Vancomycin until \r\n___ and was transitioned to Daptomycin on ___ as her \r\nVancomycin level fluctuated frequently throughout her \r\nhospitalization, making dosing of the medication challenging. \r\nShe will need to remain on Daptomycin until ___ to complete 6 \r\nweeks of antibiotic therapy.\r\n\r\n#Mechanical Fall\r\nPatient had a mechanical fall during the evening of ___. She \r\nbecame incontinent of urine and slipped and fell while trying to \r\nmake it to the bathroom. CT head and C spine were unremarkable. \r\nX rays of her left wrist revealed no fractures. She was given a \r\nhard brace based on an OT evaluation. Ecchymosis on head was \r\nimproving at discharge. She will continue to wear the brace \r\nuntil symptoms improve.\r\n\r\n#MDS ___ Allo MUD SCT\r\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \r\nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \r\nand 50mg QPM. Initial cyclosporine levels were low and her \r\ndosage was increased to 100mg BID. Her creatinine increased on \r\nthis dose and she was discharged on dosage of 75mg BID. Her home \r\nprophylaxis with fluconazole, Bactrim, and valganciclovir was \r\ninitially continued. However, given worsening neutropenia, her \r\nBactrim was transitioned to atovaquone and her valganciclovir \r\nwas transitioned to acyclovir. She was scheduled to have a bone \r\nmarrow biopsy with ___ as an outpatient on ___ but this was \r\ncancelled due to patient's new DVT. She will need to have a bone \r\nmarrow biopsy done as an outpatient.\r\n\r\n#DVT\r\nEnoxaparin was held ___ for possible LP but a US LLE \r\nperformed due to the concern of an abscess revealed a new distal \r\nDVT on ___ in LLE. LP was deferred due to resolution of her \r\nheadache and lack of neurologic symptoms and she was put on a \r\ntherapeutic dose of Enoxaparin. Her lower extremity swelling \r\nimproved and she was discharged on Enoxaparin 80mg BID.\r\n\r\n___\r\nShe presented with Cr above baseline at 1.7 No casts were \r\nvisualized on UA and she had a FENa of 1.7% on ___, indicating \r\nprerenal etiology. She was given fluids and her creatinine \r\nreturned to baseline. Her Cr increased again on ___ to 1.4. She \r\nwas again given IVF and her cyclosporine was decreased from \r\n100mg BID to 75mg BID. Cr at discharge improved to 1.2.\r\n\r\n#Asthma\r\nAlbuterol and duonebs were given as needed\r\n\r\nTRANSITIONAL ISSUES\r\n===================\r\n[] Follow up with Dr. ___ on ___\r\n[] Continue daptomycin and Vancomycin/heparin locks until ___.\r\n[] Will need to get weekly CK levels while on daptomycin.\r\n[] Repeat bone marrow biopsy scheduled for ___ was cancelled \r\ngiven new DVT and infection. Will need repeat bone marrow biopsy \r\nscheduled.\r\n\r\nCODE STATUS: FULL CODE\r\nHCP: ___ (Husband) ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n2. Fluconazole 400 mg PO Q24H \r\n3. FoLIC Acid 1 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n7. Multivitamins 1 TAB PO DAILY \r\n8. Omeprazole 20 mg PO DAILY \r\n9. Ondansetron 4 mg PO Q8H:PRN nausea \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. ValGANCIclovir 450 mg PO Q24H \r\n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \r\n14. Enoxaparin Sodium 100 mg SC DAILY \r\n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  Atovaquone Suspension 1500 mg PO DAILY \r\nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \r\nMilliliter Refills:*0 \r\n3.  Daptomycin 500 mg IV Q24H \r\nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \r\n4.  Nystatin Cream 1 Appl TP BID  \r\n5.  Vancomycin-Heparin Lock ___AILY  \r\n6.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \r\n7.  Enoxaparin Sodium 80 mg SC Q12H \r\nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \r\nRefills:*0 \r\n8.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n9.  Fluconazole 400 mg PO Q24H  \r\n10.  FoLIC Acid 1 mg PO DAILY  \r\n11.  Gabapentin 400 mg PO BID  \r\n12.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n13.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n14.  Multivitamins 1 TAB PO DAILY  \r\n15.  Omeprazole 20 mg PO DAILY  \r\n16.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n17.  Venlafaxine 25 mg PO DAILY  \r\n18.vancomycin lock\r\nVancomycin-Heparin Lock ___AILY \r\nVancomycin 2 mg/mL + Heparin 100 units/mL\r\n5mL solution daily\r\nDispense 170mL solution\r\nContinue until ___ \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSES\r\n=================\r\nHeadache\r\nS. epidermidis Bacteremia\r\nMechanical Fall\r\nSecondary MDS ___ AlloSCT\r\nGERD\r\nOSA\r\nSciatica\r\n\r\nSECONDARY DIAGNOSES\r\n===================\r\nCVID\r\nDVT\r\nAsthma\r\nPre-HTN\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure taking care of you in the hospital!\r\n\r\nWhy was I admitted to the hospital?\r\nYou were admitted to the hospital because you were experiencing \r\nheadaches, concerning for possible infection in or around your \r\nbrain.\r\n\r\nWhat happened while I was admitted in the hospital?\r\n-Your headache resolved on its own\r\n-Imaging studies were done to evaluate your headache and did not \r\ndemonstrate any clear cause\r\n-Numerous tests were conducted on your blood and you were found \r\nto have a bacterial infection of your blood\r\n-Imaging studies were performed to find the source of the \r\nbacteria and no clear source was found\r\n-You were started on antibiotics to treat your bacterial \r\ninfection\r\n-Imaging of your leg showed you had a clot in your leg\r\n-Your home Bactrim and Valganciclovir were discontinued and you \r\nwere started on Atovaquone and Acyclovir.\r\n\r\nWhat should I do after I get discharged from the hospital?\r\n-Take all of your medications as prescribed, details below\r\n-Keep all of your scheduled appointments \r\n\r\nWe wish you the very best!\r\n\r\nYour ___ Oncology Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-24:10",
      "text": "[] Will need to get weekly CK levels while on daptomycin. [] Repeat bone marrow biopsy scheduled for ___ was cancelled \ngiven new DVT and infection. Will need repeat bone marrow biopsy \nscheduled. CODE STATUS: FULL CODE\nHCP: ___ (Husband) ___ \n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \n2. Fluconazole 400 mg PO Q24H \n3. FoLIC Acid 1 mg PO DAILY \n4. Gabapentin 400 mg PO BID \n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \nnot relieved by ondansetron \n7. Multivitamins 1 TAB PO DAILY \n8. Omeprazole 20 mg PO DAILY \n9. Ondansetron 4 mg PO Q8H:PRN nausea \n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \n11. Venlafaxine 25 mg PO DAILY \n12. ValGANCIclovir 450 mg PO Q24H \n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \n14. Enoxaparin Sodium 100 mg SC DAILY \n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-24",
        "chart_time": "104763",
        "section": "General",
        "position": 10,
        "tokenCount": 243,
        "note_metadata": {
          "note_id": "18887130-DS-24",
          "subject_id": 18887130,
          "hadm_id": 23656314,
          "note_type": "DS",
          "note_seq": 24,
          "charttime": 104763,
          "storetime": 104766.75763888888,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nHeadache, Nausea, Vomiting\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\r\nTransplant who is admitted with a headache. The patient states\r\nher headache started yesterday morning. It was a right sided\r\nheadache which came down into her face. It intensified \r\nthroughout\r\nthe day and then in the afternoon she started vomiting numerous\r\ntimes. Which prompted her to go to the ED. She states the\r\nheadache was similar in location to when she gets migraines but\r\nthe duration was different and with migraines she usually gets\r\none episode of nausea in the morning and then it resolves. She\r\ndenies any neck stiffness, rashes, or fevers. She also denies \r\nany\r\nshortness of breath, diarrhea, or dysuria. \r\nShe went to the ED last night and had a head CT done which was \r\nunremarkable. She was then given Tylenol, dexamethasone,\r\nBenadryl, IV fluids, and Compazine. With improvement of her\r\nsymptoms. She then was discharged home early this morning. \r\nHer primary oncology team was concerned about the underlying\r\ncause of her headache given her history of a recent bone marrow\r\ntransplant and that she is on immunosuppression. So she was\r\ninstructed to return for admission for further workup. \r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL\r\n==================\r\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\r\nGeneral: No acute distress, sitting completely comfortably in a\r\nchair\r\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\r\nedema in right lower extremity, 2+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\nDISCHARGE PHYSICAL\r\n==================\r\nVS:  98.6 131 / 81 93 18 96 Ra \r\nGeneral: No acute distress, lying comfortably in bed\r\nHEENT: Hematoma and ecchymosis in occipital region of head,\r\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\r\nLAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: Edema over the radial aspect of the left wrist improving, \r\n1+\r\nperipheral edema in bilateral lower extremity, venous stasis\r\ndermatitis bilaterally on lower extremities, 1+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n==============\r\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \r\nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\r\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \r\nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \r\nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\r\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \r\nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\r\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\r\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \r\nK-4.2 Cl-104 HCO3-21* AnGap-14\r\n___ 11:17PM BLOOD Lipase-11\r\n___ 11:17PM BLOOD Albumin-3.6\r\n___ 11:22PM BLOOD Lactate-1.1\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \r\nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\r\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \r\nK-4.0 Cl-103 HCO3-24 AnGap-14\r\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \r\nAlkPhos-86 TotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\r\n___ 09:21AM BLOOD Cyclspr-184\r\n\r\nMICROBIOLOGY\r\n=============\r\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance Oxacillin RESISTANT Staphylococci MUST be \r\nreported as\r\n         also RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     2 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ ON \r\n___. \r\n\r\n___ 10:36 pm BLOOD CULTURE     Site: ARM\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \r\nresult\r\n         performed by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 10:08 pm BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------ <=0.5 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 12:40 pm BLOOD CULTURE\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\n___ 9:11 am BLOOD CULTURE      Source: Line-PORT. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\nIMAGING\r\n=========\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Evaluation limited by artifact from high-density metallic \r\nmaterial the area \r\nof the right carotid siphon. \r\n2. No acute intracranial abnormality. \r\n\r\nMR HEAD W/ & W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute intracranial process.  No abnormal enhancement after \r\ncontrast \r\nadministration. \r\n2. Susceptibility artifact from prior coiling in the region of \r\nthe right \r\ncavernous internal carotid artery limits evaluation in that \r\narea. \r\n\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Mildly limited study due to streak artifact from metallic \r\ndensity in the \r\nregion of the right carotid siphon. \r\n2. No acute intracranial abnormality or fracture. \r\n3. Soft tissue swelling and hematoma overlying the inferior left \r\nocciput, and \r\ncentrally near the vertex. \r\n\r\nCT C-SPINE W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute fracture or new alignment abnormality. \r\n2. Multilevel degenerative changes and levels of congenital \r\nfusion, grossly \r\nunchanged and better described on the prior MRI from ___. \r\n\r\nWRIST (3+ VIEWS) LEFT (___):\r\nIMPRESSION:  \r\nNo acute fracture or dislocation.  Mild widening of the distal \r\nradioulnar \r\njoint. \r\n\r\nCT ABD & PELVIS WITH CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No infectious source identified in the abdomen or pelvis. \r\n2.  Mild intrahepatic and extrahepatic biliary dilatation, \r\nlikely post \r\ncholecystectomy. \r\n3.  Tiny nonocclusive thrombus in the IVC, above the IVC filter. \r\n Some of the \r\nfilter struts have penetrated the vessel wall, not uncommonly \r\nseen.  Given \r\nthat this is a retrievable filter, interventional radiology \r\nconsultation could \r\nbe considered for filter removal if it is no longer needed. \r\n4.  Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \r\nwhich dates \r\nback to at least ___.  Consider periodic follow-up with pelvic \r\nultrasound to \r\ndocument expected continued stability. \r\n\r\nCT CHEST W/ CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No evidence of pneumonia. \r\n2.  Enlarged pulmonary artery may be seen in pulmonary arterial \r\nhypertension. \r\n\r\nUNILAT UP EXT VEINS US LEFT (___):\r\nIMPRESSION:  \r\nNo evidence of deep vein thrombosis in the left upper extremity. \r\n\r\n\r\nTTE (___):\r\nConclusions   \r\n The left atrium is normal in size. No atrial septal defect is \r\nseen by 2D or color Doppler. Left ventricular wall thicknesses \r\nand cavity size are normal. There is mild global left \r\nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. \r\nRight ventricular chamber size and free wall motion are normal. \r\nThe aortic valve leaflets (3) appear structurally normal with \r\ngood leaflet excursion. No masses or vegetations are seen on the \r\naortic valve. Trace aortic regurgitation is seen. The mitral \r\nvalve leaflets are structurally normal. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. The pulmonary artery \r\nsystolic pressure could not be determined. There is no \r\npericardial effusion. \r\n\r\n IMPRESSION: Normal biventricular cavity sizes with mild global \r\nleft ventricular hypokinesis. Mild mitral regurgitation with \r\nnormal valve morphology. Trace aortic regurgitation with normal \r\nvalve morphology. \r\n\r\n Compared with the prior report (images not available for \r\nreview) of ___, trace aortic regurgitation is now present \r\nwith similar valve morphology.   \r\n\r\nBILAT LOWER EXT VEINS (___):\r\nIMPRESSION: \r\n1. New deep venous thrombosis involving the left posterior \r\ntibial and right \r\npopliteal veins. \r\n2. No fluid collection in the area of pain in the left lateral \r\ncalf. \r\n\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ immunocompromised female ___ \r\nalloSCT for secondary MDS admitted for acute change in headaches \r\nwith new, severe symptoms such as nausea and vomiting now with \r\nfevers to 103 and coagulase-negative gram-positive cocci in \r\nclusters in blood cultures being treated for S. epidermidis \r\nbacteremia.\r\n\r\n#Headache\r\nCT head performed in the ED ___ was unremarkable but infectious \r\netiology remained very high on the\r\ndifferential given the patient's immunosuppression regimen and \r\nhistory of aseptic meningitis during her last admission. She \r\nalso had history of R internal carotid cavernous sinus aneurysm \r\nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \r\nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \r\ncrypotococcus, and fungal markers were tested and all were \r\nnegative. The patient's headache resolved and she was symptom \r\nfree at time of discharge. \r\n\r\n#S. epidermidis Bacteremia\r\nShe had fevers up to 103 on ___ and was started on vancomycin \r\nand cefepime. The vancomycin was DC'd ___ overnight and she was \r\nstarted on linezolid per ID recommendations as she had a history \r\nof VRE bacteremia in the past and was continued on cefepime. ___ \r\nblood culture bottles grew S. epidermidis and she was narrowed \r\nto vancomycin only. A chest x-ray was unremarkable for \r\npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \r\nCT abdomen pelvis ___ did not show any evidence of infection. An \r\nultrasound of her port site was without evidence of infection. \r\nAn ultrasound of her LLE ordered for concern of an abscess \r\nrevealed a distal DVT but no fluid collections. A TTE revealed \r\nnormal biventricular cavity sizes with mild global left \r\nventricular hypokinesis, mild mitral regurgitation with normal \r\nvalve morphology and trace aortic regurgitation with normal \r\nvalve morphology. A TEE was scheduled but was cancelled as \r\npatient will need 6 weeks of therapy for treatment of possible \r\nseptic thrombophlebitis. She was continued on Vancomycin until \r\n___ and was transitioned to Daptomycin on ___ as her \r\nVancomycin level fluctuated frequently throughout her \r\nhospitalization, making dosing of the medication challenging. \r\nShe will need to remain on Daptomycin until ___ to complete 6 \r\nweeks of antibiotic therapy.\r\n\r\n#Mechanical Fall\r\nPatient had a mechanical fall during the evening of ___. She \r\nbecame incontinent of urine and slipped and fell while trying to \r\nmake it to the bathroom. CT head and C spine were unremarkable. \r\nX rays of her left wrist revealed no fractures. She was given a \r\nhard brace based on an OT evaluation. Ecchymosis on head was \r\nimproving at discharge. She will continue to wear the brace \r\nuntil symptoms improve.\r\n\r\n#MDS ___ Allo MUD SCT\r\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \r\nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \r\nand 50mg QPM. Initial cyclosporine levels were low and her \r\ndosage was increased to 100mg BID. Her creatinine increased on \r\nthis dose and she was discharged on dosage of 75mg BID. Her home \r\nprophylaxis with fluconazole, Bactrim, and valganciclovir was \r\ninitially continued. However, given worsening neutropenia, her \r\nBactrim was transitioned to atovaquone and her valganciclovir \r\nwas transitioned to acyclovir. She was scheduled to have a bone \r\nmarrow biopsy with ___ as an outpatient on ___ but this was \r\ncancelled due to patient's new DVT. She will need to have a bone \r\nmarrow biopsy done as an outpatient.\r\n\r\n#DVT\r\nEnoxaparin was held ___ for possible LP but a US LLE \r\nperformed due to the concern of an abscess revealed a new distal \r\nDVT on ___ in LLE. LP was deferred due to resolution of her \r\nheadache and lack of neurologic symptoms and she was put on a \r\ntherapeutic dose of Enoxaparin. Her lower extremity swelling \r\nimproved and she was discharged on Enoxaparin 80mg BID.\r\n\r\n___\r\nShe presented with Cr above baseline at 1.7 No casts were \r\nvisualized on UA and she had a FENa of 1.7% on ___, indicating \r\nprerenal etiology. She was given fluids and her creatinine \r\nreturned to baseline. Her Cr increased again on ___ to 1.4. She \r\nwas again given IVF and her cyclosporine was decreased from \r\n100mg BID to 75mg BID. Cr at discharge improved to 1.2.\r\n\r\n#Asthma\r\nAlbuterol and duonebs were given as needed\r\n\r\nTRANSITIONAL ISSUES\r\n===================\r\n[] Follow up with Dr. ___ on ___\r\n[] Continue daptomycin and Vancomycin/heparin locks until ___.\r\n[] Will need to get weekly CK levels while on daptomycin.\r\n[] Repeat bone marrow biopsy scheduled for ___ was cancelled \r\ngiven new DVT and infection. Will need repeat bone marrow biopsy \r\nscheduled.\r\n\r\nCODE STATUS: FULL CODE\r\nHCP: ___ (Husband) ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n2. Fluconazole 400 mg PO Q24H \r\n3. FoLIC Acid 1 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n7. Multivitamins 1 TAB PO DAILY \r\n8. Omeprazole 20 mg PO DAILY \r\n9. Ondansetron 4 mg PO Q8H:PRN nausea \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. ValGANCIclovir 450 mg PO Q24H \r\n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \r\n14. Enoxaparin Sodium 100 mg SC DAILY \r\n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  Atovaquone Suspension 1500 mg PO DAILY \r\nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \r\nMilliliter Refills:*0 \r\n3.  Daptomycin 500 mg IV Q24H \r\nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \r\n4.  Nystatin Cream 1 Appl TP BID  \r\n5.  Vancomycin-Heparin Lock ___AILY  \r\n6.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \r\n7.  Enoxaparin Sodium 80 mg SC Q12H \r\nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \r\nRefills:*0 \r\n8.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n9.  Fluconazole 400 mg PO Q24H  \r\n10.  FoLIC Acid 1 mg PO DAILY  \r\n11.  Gabapentin 400 mg PO BID  \r\n12.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n13.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n14.  Multivitamins 1 TAB PO DAILY  \r\n15.  Omeprazole 20 mg PO DAILY  \r\n16.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n17.  Venlafaxine 25 mg PO DAILY  \r\n18.vancomycin lock\r\nVancomycin-Heparin Lock ___AILY \r\nVancomycin 2 mg/mL + Heparin 100 units/mL\r\n5mL solution daily\r\nDispense 170mL solution\r\nContinue until ___ \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSES\r\n=================\r\nHeadache\r\nS. epidermidis Bacteremia\r\nMechanical Fall\r\nSecondary MDS ___ AlloSCT\r\nGERD\r\nOSA\r\nSciatica\r\n\r\nSECONDARY DIAGNOSES\r\n===================\r\nCVID\r\nDVT\r\nAsthma\r\nPre-HTN\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure taking care of you in the hospital!\r\n\r\nWhy was I admitted to the hospital?\r\nYou were admitted to the hospital because you were experiencing \r\nheadaches, concerning for possible infection in or around your \r\nbrain.\r\n\r\nWhat happened while I was admitted in the hospital?\r\n-Your headache resolved on its own\r\n-Imaging studies were done to evaluate your headache and did not \r\ndemonstrate any clear cause\r\n-Numerous tests were conducted on your blood and you were found \r\nto have a bacterial infection of your blood\r\n-Imaging studies were performed to find the source of the \r\nbacteria and no clear source was found\r\n-You were started on antibiotics to treat your bacterial \r\ninfection\r\n-Imaging of your leg showed you had a clot in your leg\r\n-Your home Bactrim and Valganciclovir were discontinued and you \r\nwere started on Atovaquone and Acyclovir.\r\n\r\nWhat should I do after I get discharged from the hospital?\r\n-Take all of your medications as prescribed, details below\r\n-Keep all of your scheduled appointments \r\n\r\nWe wish you the very best!\r\n\r\nYour ___ Oncology Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-24:11",
      "text": "Discharge Medications:\n1. Acyclovir 400 mg PO Q8H  \n2. Atovaquone Suspension 1500 mg PO DAILY \nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \nMilliliter Refills:*0 \n3. Daptomycin 500 mg IV Q24H \nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \n4. Nystatin Cream 1 Appl TP BID  \n5. Vancomycin-Heparin Lock ___AILY  \n6. CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \n7. Enoxaparin Sodium 80 mg SC Q12H \nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \nRefills:*0 \n8. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \n9. Fluconazole 400 mg PO Q24H  \n10. FoLIC Acid 1 mg PO DAILY  \n11. Gabapentin 400 mg PO BID  \n12. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \n13. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \nnot relieved by ondansetron  \n14. Multivitamins 1 TAB PO DAILY  \n15. Omeprazole 20 mg PO DAILY  \n16. Ondansetron 4 mg PO Q8H:PRN nausea  \n17. Venlafaxine 25 mg PO DAILY  \n18.vancomycin lock\nVancomycin-Heparin Lock ___AILY \nVancomycin 2 mg/mL + Heparin 100 units/mL\n5mL solution daily\nDispense 170mL solution\nContinue until ___ Discharge Disposition:\nHome With Service\n \nFacility:\n___ Discharge Diagnosis:\nPRIMARY DIAGNOSES\n=================\nHeadache\nS. epidermidis Bacteremia\nMechanical Fall\nSecondary MDS ___ AlloSCT\nGERD\nOSA\nSciatica SECONDARY DIAGNOSES\n===================\nCVID\nDVT\nAsthma\nPre-HTN Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-24",
        "chart_time": "104763",
        "section": "General",
        "position": 11,
        "tokenCount": 380,
        "note_metadata": {
          "note_id": "18887130-DS-24",
          "subject_id": 18887130,
          "hadm_id": 23656314,
          "note_type": "DS",
          "note_seq": 24,
          "charttime": 104763,
          "storetime": 104766.75763888888,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nHeadache, Nausea, Vomiting\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\r\nTransplant who is admitted with a headache. The patient states\r\nher headache started yesterday morning. It was a right sided\r\nheadache which came down into her face. It intensified \r\nthroughout\r\nthe day and then in the afternoon she started vomiting numerous\r\ntimes. Which prompted her to go to the ED. She states the\r\nheadache was similar in location to when she gets migraines but\r\nthe duration was different and with migraines she usually gets\r\none episode of nausea in the morning and then it resolves. She\r\ndenies any neck stiffness, rashes, or fevers. She also denies \r\nany\r\nshortness of breath, diarrhea, or dysuria. \r\nShe went to the ED last night and had a head CT done which was \r\nunremarkable. She was then given Tylenol, dexamethasone,\r\nBenadryl, IV fluids, and Compazine. With improvement of her\r\nsymptoms. She then was discharged home early this morning. \r\nHer primary oncology team was concerned about the underlying\r\ncause of her headache given her history of a recent bone marrow\r\ntransplant and that she is on immunosuppression. So she was\r\ninstructed to return for admission for further workup. \r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL\r\n==================\r\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\r\nGeneral: No acute distress, sitting completely comfortably in a\r\nchair\r\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\r\nedema in right lower extremity, 2+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\nDISCHARGE PHYSICAL\r\n==================\r\nVS:  98.6 131 / 81 93 18 96 Ra \r\nGeneral: No acute distress, lying comfortably in bed\r\nHEENT: Hematoma and ecchymosis in occipital region of head,\r\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\r\nLAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: Edema over the radial aspect of the left wrist improving, \r\n1+\r\nperipheral edema in bilateral lower extremity, venous stasis\r\ndermatitis bilaterally on lower extremities, 1+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n==============\r\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \r\nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\r\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \r\nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \r\nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\r\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \r\nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\r\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\r\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \r\nK-4.2 Cl-104 HCO3-21* AnGap-14\r\n___ 11:17PM BLOOD Lipase-11\r\n___ 11:17PM BLOOD Albumin-3.6\r\n___ 11:22PM BLOOD Lactate-1.1\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \r\nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\r\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \r\nK-4.0 Cl-103 HCO3-24 AnGap-14\r\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \r\nAlkPhos-86 TotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\r\n___ 09:21AM BLOOD Cyclspr-184\r\n\r\nMICROBIOLOGY\r\n=============\r\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance Oxacillin RESISTANT Staphylococci MUST be \r\nreported as\r\n         also RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     2 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ ON \r\n___. \r\n\r\n___ 10:36 pm BLOOD CULTURE     Site: ARM\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \r\nresult\r\n         performed by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 10:08 pm BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------ <=0.5 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 12:40 pm BLOOD CULTURE\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\n___ 9:11 am BLOOD CULTURE      Source: Line-PORT. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\nIMAGING\r\n=========\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Evaluation limited by artifact from high-density metallic \r\nmaterial the area \r\nof the right carotid siphon. \r\n2. No acute intracranial abnormality. \r\n\r\nMR HEAD W/ & W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute intracranial process.  No abnormal enhancement after \r\ncontrast \r\nadministration. \r\n2. Susceptibility artifact from prior coiling in the region of \r\nthe right \r\ncavernous internal carotid artery limits evaluation in that \r\narea. \r\n\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Mildly limited study due to streak artifact from metallic \r\ndensity in the \r\nregion of the right carotid siphon. \r\n2. No acute intracranial abnormality or fracture. \r\n3. Soft tissue swelling and hematoma overlying the inferior left \r\nocciput, and \r\ncentrally near the vertex. \r\n\r\nCT C-SPINE W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute fracture or new alignment abnormality. \r\n2. Multilevel degenerative changes and levels of congenital \r\nfusion, grossly \r\nunchanged and better described on the prior MRI from ___. \r\n\r\nWRIST (3+ VIEWS) LEFT (___):\r\nIMPRESSION:  \r\nNo acute fracture or dislocation.  Mild widening of the distal \r\nradioulnar \r\njoint. \r\n\r\nCT ABD & PELVIS WITH CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No infectious source identified in the abdomen or pelvis. \r\n2.  Mild intrahepatic and extrahepatic biliary dilatation, \r\nlikely post \r\ncholecystectomy. \r\n3.  Tiny nonocclusive thrombus in the IVC, above the IVC filter. \r\n Some of the \r\nfilter struts have penetrated the vessel wall, not uncommonly \r\nseen.  Given \r\nthat this is a retrievable filter, interventional radiology \r\nconsultation could \r\nbe considered for filter removal if it is no longer needed. \r\n4.  Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \r\nwhich dates \r\nback to at least ___.  Consider periodic follow-up with pelvic \r\nultrasound to \r\ndocument expected continued stability. \r\n\r\nCT CHEST W/ CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No evidence of pneumonia. \r\n2.  Enlarged pulmonary artery may be seen in pulmonary arterial \r\nhypertension. \r\n\r\nUNILAT UP EXT VEINS US LEFT (___):\r\nIMPRESSION:  \r\nNo evidence of deep vein thrombosis in the left upper extremity. \r\n\r\n\r\nTTE (___):\r\nConclusions   \r\n The left atrium is normal in size. No atrial septal defect is \r\nseen by 2D or color Doppler. Left ventricular wall thicknesses \r\nand cavity size are normal. There is mild global left \r\nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. \r\nRight ventricular chamber size and free wall motion are normal. \r\nThe aortic valve leaflets (3) appear structurally normal with \r\ngood leaflet excursion. No masses or vegetations are seen on the \r\naortic valve. Trace aortic regurgitation is seen. The mitral \r\nvalve leaflets are structurally normal. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. The pulmonary artery \r\nsystolic pressure could not be determined. There is no \r\npericardial effusion. \r\n\r\n IMPRESSION: Normal biventricular cavity sizes with mild global \r\nleft ventricular hypokinesis. Mild mitral regurgitation with \r\nnormal valve morphology. Trace aortic regurgitation with normal \r\nvalve morphology. \r\n\r\n Compared with the prior report (images not available for \r\nreview) of ___, trace aortic regurgitation is now present \r\nwith similar valve morphology.   \r\n\r\nBILAT LOWER EXT VEINS (___):\r\nIMPRESSION: \r\n1. New deep venous thrombosis involving the left posterior \r\ntibial and right \r\npopliteal veins. \r\n2. No fluid collection in the area of pain in the left lateral \r\ncalf. \r\n\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ immunocompromised female ___ \r\nalloSCT for secondary MDS admitted for acute change in headaches \r\nwith new, severe symptoms such as nausea and vomiting now with \r\nfevers to 103 and coagulase-negative gram-positive cocci in \r\nclusters in blood cultures being treated for S. epidermidis \r\nbacteremia.\r\n\r\n#Headache\r\nCT head performed in the ED ___ was unremarkable but infectious \r\netiology remained very high on the\r\ndifferential given the patient's immunosuppression regimen and \r\nhistory of aseptic meningitis during her last admission. She \r\nalso had history of R internal carotid cavernous sinus aneurysm \r\nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \r\nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \r\ncrypotococcus, and fungal markers were tested and all were \r\nnegative. The patient's headache resolved and she was symptom \r\nfree at time of discharge. \r\n\r\n#S. epidermidis Bacteremia\r\nShe had fevers up to 103 on ___ and was started on vancomycin \r\nand cefepime. The vancomycin was DC'd ___ overnight and she was \r\nstarted on linezolid per ID recommendations as she had a history \r\nof VRE bacteremia in the past and was continued on cefepime. ___ \r\nblood culture bottles grew S. epidermidis and she was narrowed \r\nto vancomycin only. A chest x-ray was unremarkable for \r\npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \r\nCT abdomen pelvis ___ did not show any evidence of infection. An \r\nultrasound of her port site was without evidence of infection. \r\nAn ultrasound of her LLE ordered for concern of an abscess \r\nrevealed a distal DVT but no fluid collections. A TTE revealed \r\nnormal biventricular cavity sizes with mild global left \r\nventricular hypokinesis, mild mitral regurgitation with normal \r\nvalve morphology and trace aortic regurgitation with normal \r\nvalve morphology. A TEE was scheduled but was cancelled as \r\npatient will need 6 weeks of therapy for treatment of possible \r\nseptic thrombophlebitis. She was continued on Vancomycin until \r\n___ and was transitioned to Daptomycin on ___ as her \r\nVancomycin level fluctuated frequently throughout her \r\nhospitalization, making dosing of the medication challenging. \r\nShe will need to remain on Daptomycin until ___ to complete 6 \r\nweeks of antibiotic therapy.\r\n\r\n#Mechanical Fall\r\nPatient had a mechanical fall during the evening of ___. She \r\nbecame incontinent of urine and slipped and fell while trying to \r\nmake it to the bathroom. CT head and C spine were unremarkable. \r\nX rays of her left wrist revealed no fractures. She was given a \r\nhard brace based on an OT evaluation. Ecchymosis on head was \r\nimproving at discharge. She will continue to wear the brace \r\nuntil symptoms improve.\r\n\r\n#MDS ___ Allo MUD SCT\r\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \r\nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \r\nand 50mg QPM. Initial cyclosporine levels were low and her \r\ndosage was increased to 100mg BID. Her creatinine increased on \r\nthis dose and she was discharged on dosage of 75mg BID. Her home \r\nprophylaxis with fluconazole, Bactrim, and valganciclovir was \r\ninitially continued. However, given worsening neutropenia, her \r\nBactrim was transitioned to atovaquone and her valganciclovir \r\nwas transitioned to acyclovir. She was scheduled to have a bone \r\nmarrow biopsy with ___ as an outpatient on ___ but this was \r\ncancelled due to patient's new DVT. She will need to have a bone \r\nmarrow biopsy done as an outpatient.\r\n\r\n#DVT\r\nEnoxaparin was held ___ for possible LP but a US LLE \r\nperformed due to the concern of an abscess revealed a new distal \r\nDVT on ___ in LLE. LP was deferred due to resolution of her \r\nheadache and lack of neurologic symptoms and she was put on a \r\ntherapeutic dose of Enoxaparin. Her lower extremity swelling \r\nimproved and she was discharged on Enoxaparin 80mg BID.\r\n\r\n___\r\nShe presented with Cr above baseline at 1.7 No casts were \r\nvisualized on UA and she had a FENa of 1.7% on ___, indicating \r\nprerenal etiology. She was given fluids and her creatinine \r\nreturned to baseline. Her Cr increased again on ___ to 1.4. She \r\nwas again given IVF and her cyclosporine was decreased from \r\n100mg BID to 75mg BID. Cr at discharge improved to 1.2.\r\n\r\n#Asthma\r\nAlbuterol and duonebs were given as needed\r\n\r\nTRANSITIONAL ISSUES\r\n===================\r\n[] Follow up with Dr. ___ on ___\r\n[] Continue daptomycin and Vancomycin/heparin locks until ___.\r\n[] Will need to get weekly CK levels while on daptomycin.\r\n[] Repeat bone marrow biopsy scheduled for ___ was cancelled \r\ngiven new DVT and infection. Will need repeat bone marrow biopsy \r\nscheduled.\r\n\r\nCODE STATUS: FULL CODE\r\nHCP: ___ (Husband) ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n2. Fluconazole 400 mg PO Q24H \r\n3. FoLIC Acid 1 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n7. Multivitamins 1 TAB PO DAILY \r\n8. Omeprazole 20 mg PO DAILY \r\n9. Ondansetron 4 mg PO Q8H:PRN nausea \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. ValGANCIclovir 450 mg PO Q24H \r\n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \r\n14. Enoxaparin Sodium 100 mg SC DAILY \r\n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  Atovaquone Suspension 1500 mg PO DAILY \r\nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \r\nMilliliter Refills:*0 \r\n3.  Daptomycin 500 mg IV Q24H \r\nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \r\n4.  Nystatin Cream 1 Appl TP BID  \r\n5.  Vancomycin-Heparin Lock ___AILY  \r\n6.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \r\n7.  Enoxaparin Sodium 80 mg SC Q12H \r\nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \r\nRefills:*0 \r\n8.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n9.  Fluconazole 400 mg PO Q24H  \r\n10.  FoLIC Acid 1 mg PO DAILY  \r\n11.  Gabapentin 400 mg PO BID  \r\n12.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n13.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n14.  Multivitamins 1 TAB PO DAILY  \r\n15.  Omeprazole 20 mg PO DAILY  \r\n16.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n17.  Venlafaxine 25 mg PO DAILY  \r\n18.vancomycin lock\r\nVancomycin-Heparin Lock ___AILY \r\nVancomycin 2 mg/mL + Heparin 100 units/mL\r\n5mL solution daily\r\nDispense 170mL solution\r\nContinue until ___ \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSES\r\n=================\r\nHeadache\r\nS. epidermidis Bacteremia\r\nMechanical Fall\r\nSecondary MDS ___ AlloSCT\r\nGERD\r\nOSA\r\nSciatica\r\n\r\nSECONDARY DIAGNOSES\r\n===================\r\nCVID\r\nDVT\r\nAsthma\r\nPre-HTN\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure taking care of you in the hospital!\r\n\r\nWhy was I admitted to the hospital?\r\nYou were admitted to the hospital because you were experiencing \r\nheadaches, concerning for possible infection in or around your \r\nbrain.\r\n\r\nWhat happened while I was admitted in the hospital?\r\n-Your headache resolved on its own\r\n-Imaging studies were done to evaluate your headache and did not \r\ndemonstrate any clear cause\r\n-Numerous tests were conducted on your blood and you were found \r\nto have a bacterial infection of your blood\r\n-Imaging studies were performed to find the source of the \r\nbacteria and no clear source was found\r\n-You were started on antibiotics to treat your bacterial \r\ninfection\r\n-Imaging of your leg showed you had a clot in your leg\r\n-Your home Bactrim and Valganciclovir were discontinued and you \r\nwere started on Atovaquone and Acyclovir.\r\n\r\nWhat should I do after I get discharged from the hospital?\r\n-Take all of your medications as prescribed, details below\r\n-Keep all of your scheduled appointments \r\n\r\nWe wish you the very best!\r\n\r\nYour ___ Oncology Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-24:12",
      "text": "Discharge Instructions:\nDear Ms. ___, It was a pleasure taking care of you in the hospital! Why was I admitted to the hospital? You were admitted to the hospital because you were experiencing \nheadaches, concerning for possible infection in or around your \nbrain. What happened while I was admitted in the hospital? -Your headache resolved on its own\n-Imaging studies were done to evaluate your headache and did not \ndemonstrate any clear cause\n-Numerous tests were conducted on your blood and you were found \nto have a bacterial infection of your blood\n-Imaging studies were performed to find the source of the \nbacteria and no clear source was found\n-You were started on antibiotics to treat your bacterial \ninfection\n-Imaging of your leg showed you had a clot in your leg\n-Your home Bactrim and Valganciclovir were discontinued and you \nwere started on Atovaquone and Acyclovir. What should I do after I get discharged from the hospital? -Take all of your medications as prescribed, details below\n-Keep all of your scheduled appointments We wish you the very best! Your ___ Oncology Team\n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-24",
        "chart_time": "104763",
        "section": "General",
        "position": 12,
        "tokenCount": 280,
        "note_metadata": {
          "note_id": "18887130-DS-24",
          "subject_id": 18887130,
          "hadm_id": 23656314,
          "note_type": "DS",
          "note_seq": 24,
          "charttime": 104763,
          "storetime": 104766.75763888888,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nHeadache, Nausea, Vomiting\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\n___ yo female with a history of MDS ___ Allogenic MUD Stem Cell\r\nTransplant who is admitted with a headache. The patient states\r\nher headache started yesterday morning. It was a right sided\r\nheadache which came down into her face. It intensified \r\nthroughout\r\nthe day and then in the afternoon she started vomiting numerous\r\ntimes. Which prompted her to go to the ED. She states the\r\nheadache was similar in location to when she gets migraines but\r\nthe duration was different and with migraines she usually gets\r\none episode of nausea in the morning and then it resolves. She\r\ndenies any neck stiffness, rashes, or fevers. She also denies \r\nany\r\nshortness of breath, diarrhea, or dysuria. \r\nShe went to the ED last night and had a head CT done which was \r\nunremarkable. She was then given Tylenol, dexamethasone,\r\nBenadryl, IV fluids, and Compazine. With improvement of her\r\nsymptoms. She then was discharged home early this morning. \r\nHer primary oncology team was concerned about the underlying\r\ncause of her headache given her history of a recent bone marrow\r\ntransplant and that she is on immunosuppression. So she was\r\ninstructed to return for admission for further workup. \r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL\r\n==================\r\nVS -T 98.1, BP 122/77, P 86, RR 18, O2 sat 98% RA\r\nGeneral: No acute distress, sitting completely comfortably in a\r\nchair\r\nHEENT: MMM, no scleral icterus, no OP lesions, no cervical LAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: 2+ peripheral edema in left lower extremity, 1+ peripheral\r\nedema in right lower extremity, 2+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\nDISCHARGE PHYSICAL\r\n==================\r\nVS:  98.6 131 / 81 93 18 96 Ra \r\nGeneral: No acute distress, lying comfortably in bed\r\nHEENT: Hematoma and ecchymosis in occipital region of head,\r\nimproving; MMM, no scleral icterus, no OP lesions, no cervical\r\nLAD\r\nCV: RRR, +S1/S2 present\r\nLungs: CTAB, no W/R/R\r\nAbdomen: Soft, nontender, nondistended, +BS\r\nExt: Edema over the radial aspect of the left wrist improving, \r\n1+\r\nperipheral edema in bilateral lower extremity, venous stasis\r\ndermatitis bilaterally on lower extremities, 1+ DPs\r\nNeuro: A&O3, grossly symmetric upper and lower extremity\r\nstrength and sensation\r\nSkin: No obvious rashes\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n==============\r\n___ 11:17PM BLOOD WBC-2.8* RBC-3.37* Hgb-11.7 Hct-35.3 \r\nMCV-105* MCH-34.7* MCHC-33.1 RDW-15.6* RDWSD-60.3* Plt ___\r\n___ 11:17PM BLOOD Neuts-87* Bands-2 Lymphs-9* Monos-1* \r\nEos-1 Baso-0 ___ Myelos-0 AbsNeut-2.49 AbsLymp-0.25* \r\nAbsMono-0.03* AbsEos-0.03* AbsBaso-0.00*\r\n___ 11:17PM BLOOD Hypochr-NORMAL Anisocy-NORMAL \r\nPoiklo-OCCASIONAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL \r\nOvalocy-OCCASIONAL Tear Dr-OCCASIONAL\r\n___ 11:17PM BLOOD Plt Smr-LOW* Plt ___\r\n___ 11:17PM BLOOD ALT-25 AST-26 AlkPhos-82 TotBili-0.3\r\n___ 11:17PM BLOOD Glucose-112* UreaN-16 Creat-1.1 Na-139 \r\nK-4.2 Cl-104 HCO3-21* AnGap-14\r\n___ 11:17PM BLOOD Lipase-11\r\n___ 11:17PM BLOOD Albumin-3.6\r\n___ 11:22PM BLOOD Lactate-1.1\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 12:00AM BLOOD WBC-2.0* RBC-3.11* Hgb-10.5* Hct-32.2* \r\nMCV-104* MCH-33.8* MCHC-32.6 RDW-15.5 RDWSD-58.2* Plt ___\r\n___ 12:00AM BLOOD Glucose-96 UreaN-16 Creat-1.2* Na-141 \r\nK-4.0 Cl-103 HCO3-24 AnGap-14\r\n___ 12:00AM BLOOD ALT-16 AST-23 LD(LDH)-369* CK(CPK)-24* \r\nAlkPhos-86 TotBili-0.2\r\n___ 12:00AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.5 Mg-2.2\r\n___ 09:21AM BLOOD Cyclspr-184\r\n\r\nMICROBIOLOGY\r\n=============\r\n___ 12:00 am BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance Oxacillin RESISTANT Staphylococci MUST be \r\nreported as\r\n         also RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     2 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ ON \r\n___. \r\n\r\n___ 10:36 pm BLOOD CULTURE     Site: ARM\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.50 MCG/ML = SUSCEPTIBLE , test \r\nresult\r\n         performed by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------     1 S\r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 10:08 pm BLOOD CULTURE      Source: Line-poc. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___: \r\n      STAPHYLOCOCCUS EPIDERMIDIS.    FINAL SENSITIVITIES. \r\n         COAG NEG STAPH does NOT require contact precautions, \r\nregardless of\r\n         resistance. \r\n         Oxacillin RESISTANT Staphylococci MUST be reported as \r\nalso\r\n         RESISTANT to other penicillins, cephalosporins, \r\ncarbacephems,\r\n         carbapenems, and beta-lactamase inhibitor combinations. \r\n\r\n         RIFAMPIN should not be used alone for therapy. \r\n         Daptomycin AND LINEZOLID Susceptibility testing \r\nrequested by ___.\r\n         ___ (___) ON ___. \r\n         Daptomycin MIC OF 0.5 MCG/ML = SUSCEPTIBLE , test \r\nresult performed\r\n         by Etest. \r\n\r\n                              SENSITIVITIES: MIC expressed in \r\nMCG/ML\r\n                      \r\n_________________________________________________________\r\n                             STAPHYLOCOCCUS EPIDERMIDIS\r\n                             |   \r\nCLINDAMYCIN-----------   =>8 R\r\nDAPTOMYCIN------------       S\r\nERYTHROMYCIN----------   =>8 R\r\nGENTAMICIN------------ <=0.5 S\r\nLEVOFLOXACIN----------   =>8 R\r\nLINEZOLID-------------     1 S\r\nOXACILLIN-------------   =>4 R\r\nRIFAMPIN-------------- <=0.5 S\r\nVANCOMYCIN------------ <=0.5 S\r\n\r\n   Aerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n      Reported to and read back by ___ (___) @ ___ \r\nON ___. \r\n\r\n   Anaerobic Bottle Gram Stain (Final ___: \r\n      GRAM POSITIVE COCCI IN CLUSTERS. \r\n\r\n___ 12:40 pm BLOOD CULTURE\r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\n___ 9:11 am BLOOD CULTURE      Source: Line-PORT. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   Blood Culture, Routine (Final ___:    NO GROWTH. \r\n\r\nIMAGING\r\n=========\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Evaluation limited by artifact from high-density metallic \r\nmaterial the area \r\nof the right carotid siphon. \r\n2. No acute intracranial abnormality. \r\n\r\nMR HEAD W/ & W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute intracranial process.  No abnormal enhancement after \r\ncontrast \r\nadministration. \r\n2. Susceptibility artifact from prior coiling in the region of \r\nthe right \r\ncavernous internal carotid artery limits evaluation in that \r\narea. \r\n\r\nCT HEAD W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. Mildly limited study due to streak artifact from metallic \r\ndensity in the \r\nregion of the right carotid siphon. \r\n2. No acute intracranial abnormality or fracture. \r\n3. Soft tissue swelling and hematoma overlying the inferior left \r\nocciput, and \r\ncentrally near the vertex. \r\n\r\nCT C-SPINE W/O CONTRAST (___):\r\nIMPRESSION: \r\n1. No acute fracture or new alignment abnormality. \r\n2. Multilevel degenerative changes and levels of congenital \r\nfusion, grossly \r\nunchanged and better described on the prior MRI from ___. \r\n\r\nWRIST (3+ VIEWS) LEFT (___):\r\nIMPRESSION:  \r\nNo acute fracture or dislocation.  Mild widening of the distal \r\nradioulnar \r\njoint. \r\n\r\nCT ABD & PELVIS WITH CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No infectious source identified in the abdomen or pelvis. \r\n2.  Mild intrahepatic and extrahepatic biliary dilatation, \r\nlikely post \r\ncholecystectomy. \r\n3.  Tiny nonocclusive thrombus in the IVC, above the IVC filter. \r\n Some of the \r\nfilter struts have penetrated the vessel wall, not uncommonly \r\nseen.  Given \r\nthat this is a retrievable filter, interventional radiology \r\nconsultation could \r\nbe considered for filter removal if it is no longer needed. \r\n4.  Decrease in size of a now 2.8 x 2.2 cm right adnexal cyst, \r\nwhich dates \r\nback to at least ___.  Consider periodic follow-up with pelvic \r\nultrasound to \r\ndocument expected continued stability. \r\n\r\nCT CHEST W/ CONTRAST (___):\r\nIMPRESSION:  \r\n1.  No evidence of pneumonia. \r\n2.  Enlarged pulmonary artery may be seen in pulmonary arterial \r\nhypertension. \r\n\r\nUNILAT UP EXT VEINS US LEFT (___):\r\nIMPRESSION:  \r\nNo evidence of deep vein thrombosis in the left upper extremity. \r\n\r\n\r\nTTE (___):\r\nConclusions   \r\n The left atrium is normal in size. No atrial septal defect is \r\nseen by 2D or color Doppler. Left ventricular wall thicknesses \r\nand cavity size are normal. There is mild global left \r\nventricular hypokinesis. Quantitative (biplane) LVEF = 39 %. \r\nRight ventricular chamber size and free wall motion are normal. \r\nThe aortic valve leaflets (3) appear structurally normal with \r\ngood leaflet excursion. No masses or vegetations are seen on the \r\naortic valve. Trace aortic regurgitation is seen. The mitral \r\nvalve leaflets are structurally normal. There is no mitral valve \r\nprolapse. No mass or vegetation is seen on the mitral valve. \r\nMild (1+) mitral regurgitation is seen. The pulmonary artery \r\nsystolic pressure could not be determined. There is no \r\npericardial effusion. \r\n\r\n IMPRESSION: Normal biventricular cavity sizes with mild global \r\nleft ventricular hypokinesis. Mild mitral regurgitation with \r\nnormal valve morphology. Trace aortic regurgitation with normal \r\nvalve morphology. \r\n\r\n Compared with the prior report (images not available for \r\nreview) of ___, trace aortic regurgitation is now present \r\nwith similar valve morphology.   \r\n\r\nBILAT LOWER EXT VEINS (___):\r\nIMPRESSION: \r\n1. New deep venous thrombosis involving the left posterior \r\ntibial and right \r\npopliteal veins. \r\n2. No fluid collection in the area of pain in the left lateral \r\ncalf. \r\n\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ immunocompromised female ___ \r\nalloSCT for secondary MDS admitted for acute change in headaches \r\nwith new, severe symptoms such as nausea and vomiting now with \r\nfevers to 103 and coagulase-negative gram-positive cocci in \r\nclusters in blood cultures being treated for S. epidermidis \r\nbacteremia.\r\n\r\n#Headache\r\nCT head performed in the ED ___ was unremarkable but infectious \r\netiology remained very high on the\r\ndifferential given the patient's immunosuppression regimen and \r\nhistory of aseptic meningitis during her last admission. She \r\nalso had history of R internal carotid cavernous sinus aneurysm \r\nwith coiling in the past. An MRI head ___ was unremarkable. CMV, \r\nEBV, HSV, HHV6, adeno, ___, arboviruses, Lyme, \r\ncrypotococcus, and fungal markers were tested and all were \r\nnegative. The patient's headache resolved and she was symptom \r\nfree at time of discharge. \r\n\r\n#S. epidermidis Bacteremia\r\nShe had fevers up to 103 on ___ and was started on vancomycin \r\nand cefepime. The vancomycin was DC'd ___ overnight and she was \r\nstarted on linezolid per ID recommendations as she had a history \r\nof VRE bacteremia in the past and was continued on cefepime. ___ \r\nblood culture bottles grew S. epidermidis and she was narrowed \r\nto vancomycin only. A chest x-ray was unremarkable for \r\npneumonia. A CT chest ___ revealed no evidence of pneumonia. A \r\nCT abdomen pelvis ___ did not show any evidence of infection. An \r\nultrasound of her port site was without evidence of infection. \r\nAn ultrasound of her LLE ordered for concern of an abscess \r\nrevealed a distal DVT but no fluid collections. A TTE revealed \r\nnormal biventricular cavity sizes with mild global left \r\nventricular hypokinesis, mild mitral regurgitation with normal \r\nvalve morphology and trace aortic regurgitation with normal \r\nvalve morphology. A TEE was scheduled but was cancelled as \r\npatient will need 6 weeks of therapy for treatment of possible \r\nseptic thrombophlebitis. She was continued on Vancomycin until \r\n___ and was transitioned to Daptomycin on ___ as her \r\nVancomycin level fluctuated frequently throughout her \r\nhospitalization, making dosing of the medication challenging. \r\nShe will need to remain on Daptomycin until ___ to complete 6 \r\nweeks of antibiotic therapy.\r\n\r\n#Mechanical Fall\r\nPatient had a mechanical fall during the evening of ___. She \r\nbecame incontinent of urine and slipped and fell while trying to \r\nmake it to the bathroom. CT head and C spine were unremarkable. \r\nX rays of her left wrist revealed no fractures. She was given a \r\nhard brace based on an OT evaluation. Ecchymosis on head was \r\nimproving at discharge. She will continue to wear the brace \r\nuntil symptoms improve.\r\n\r\n#MDS ___ Allo MUD SCT\r\nShe was conditioned with Flu/Bu/ATG RI and was on cyclosporine \r\nfor immunosuppression. Her home cyclosporine dosage was 75mg QAM \r\nand 50mg QPM. Initial cyclosporine levels were low and her \r\ndosage was increased to 100mg BID. Her creatinine increased on \r\nthis dose and she was discharged on dosage of 75mg BID. Her home \r\nprophylaxis with fluconazole, Bactrim, and valganciclovir was \r\ninitially continued. However, given worsening neutropenia, her \r\nBactrim was transitioned to atovaquone and her valganciclovir \r\nwas transitioned to acyclovir. She was scheduled to have a bone \r\nmarrow biopsy with ___ as an outpatient on ___ but this was \r\ncancelled due to patient's new DVT. She will need to have a bone \r\nmarrow biopsy done as an outpatient.\r\n\r\n#DVT\r\nEnoxaparin was held ___ for possible LP but a US LLE \r\nperformed due to the concern of an abscess revealed a new distal \r\nDVT on ___ in LLE. LP was deferred due to resolution of her \r\nheadache and lack of neurologic symptoms and she was put on a \r\ntherapeutic dose of Enoxaparin. Her lower extremity swelling \r\nimproved and she was discharged on Enoxaparin 80mg BID.\r\n\r\n___\r\nShe presented with Cr above baseline at 1.7 No casts were \r\nvisualized on UA and she had a FENa of 1.7% on ___, indicating \r\nprerenal etiology. She was given fluids and her creatinine \r\nreturned to baseline. Her Cr increased again on ___ to 1.4. She \r\nwas again given IVF and her cyclosporine was decreased from \r\n100mg BID to 75mg BID. Cr at discharge improved to 1.2.\r\n\r\n#Asthma\r\nAlbuterol and duonebs were given as needed\r\n\r\nTRANSITIONAL ISSUES\r\n===================\r\n[] Follow up with Dr. ___ on ___\r\n[] Continue daptomycin and Vancomycin/heparin locks until ___.\r\n[] Will need to get weekly CK levels while on daptomycin.\r\n[] Repeat bone marrow biopsy scheduled for ___ was cancelled \r\ngiven new DVT and infection. Will need repeat bone marrow biopsy \r\nscheduled.\r\n\r\nCODE STATUS: FULL CODE\r\nHCP: ___ (Husband) ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough \r\n2. Fluconazole 400 mg PO Q24H \r\n3. FoLIC Acid 1 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze \r\n6. LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron \r\n7. Multivitamins 1 TAB PO DAILY \r\n8. Omeprazole 20 mg PO DAILY \r\n9. Ondansetron 4 mg PO Q8H:PRN nausea \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. ValGANCIclovir 450 mg PO Q24H \r\n13. CycloSPORINE (Neoral) MODIFIED 75 mg PO QAM \r\n14. Enoxaparin Sodium 100 mg SC DAILY \r\n15. CycloSPORINE (Neoral) MODIFIED 50 mg PO QPM \r\n\r\n \r\nDischarge Medications:\r\n1.  Acyclovir 400 mg PO Q8H  \r\n2.  Atovaquone Suspension 1500 mg PO DAILY \r\nRX *atovaquone 750 mg/5 mL 10 ml by mouth daily Disp #*300 \r\nMilliliter Refills:*0 \r\n3.  Daptomycin 500 mg IV Q24H \r\nRX *daptomycin 500 mg 1 vial daily Disp #*34 Vial Refills:*0 \r\n4.  Nystatin Cream 1 Appl TP BID  \r\n5.  Vancomycin-Heparin Lock ___AILY  \r\n6.  CycloSPORINE (Neoral) MODIFIED 75 mg PO Q12H  \r\n7.  Enoxaparin Sodium 80 mg SC Q12H \r\nRX *enoxaparin 80 mg/0.8 mL 80 mg twice a day Disp #*60 Syringe \r\nRefills:*0 \r\n8.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough  \r\n9.  Fluconazole 400 mg PO Q24H  \r\n10.  FoLIC Acid 1 mg PO DAILY  \r\n11.  Gabapentin 400 mg PO BID  \r\n12.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN SOB, wheeze  \r\n13.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if \r\nnot relieved by ondansetron  \r\n14.  Multivitamins 1 TAB PO DAILY  \r\n15.  Omeprazole 20 mg PO DAILY  \r\n16.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n17.  Venlafaxine 25 mg PO DAILY  \r\n18.vancomycin lock\r\nVancomycin-Heparin Lock ___AILY \r\nVancomycin 2 mg/mL + Heparin 100 units/mL\r\n5mL solution daily\r\nDispense 170mL solution\r\nContinue until ___ \r\n\r\n \r\nDischarge Disposition:\r\nHome With Service\r\n \r\nFacility:\r\n___\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSES\r\n=================\r\nHeadache\r\nS. epidermidis Bacteremia\r\nMechanical Fall\r\nSecondary MDS ___ AlloSCT\r\nGERD\r\nOSA\r\nSciatica\r\n\r\nSECONDARY DIAGNOSES\r\n===================\r\nCVID\r\nDVT\r\nAsthma\r\nPre-HTN\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure taking care of you in the hospital!\r\n\r\nWhy was I admitted to the hospital?\r\nYou were admitted to the hospital because you were experiencing \r\nheadaches, concerning for possible infection in or around your \r\nbrain.\r\n\r\nWhat happened while I was admitted in the hospital?\r\n-Your headache resolved on its own\r\n-Imaging studies were done to evaluate your headache and did not \r\ndemonstrate any clear cause\r\n-Numerous tests were conducted on your blood and you were found \r\nto have a bacterial infection of your blood\r\n-Imaging studies were performed to find the source of the \r\nbacteria and no clear source was found\r\n-You were started on antibiotics to treat your bacterial \r\ninfection\r\n-Imaging of your leg showed you had a clot in your leg\r\n-Your home Bactrim and Valganciclovir were discontinued and you \r\nwere started on Atovaquone and Acyclovir.\r\n\r\nWhat should I do after I get discharged from the hospital?\r\n-Take all of your medications as prescribed, details below\r\n-Keep all of your scheduled appointments \r\n\r\nWe wish you the very best!\r\n\r\nYour ___ Oncology Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-25:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \ndapsone\n \nAttending: ___. Chief Complaint:\nrash, diarrhea\n \nMajor Surgical or Invasive Procedure:\nNone",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-25",
        "chart_time": "104834",
        "section": "General",
        "position": 0,
        "tokenCount": 70,
        "note_metadata": {
          "note_id": "18887130-DS-25",
          "subject_id": 18887130,
          "hadm_id": 24673826,
          "note_type": "DS",
          "note_seq": 25,
          "charttime": 104834,
          "storetime": 104834.66319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nrash, diarrhea\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nMrs. ___ is a ___ year-old lady with a history of DLBCL\r\n(tr.follicular) ___ alloSCT c/b MDS who presents with worsening\r\nerythrodermic rash and diarrhea. \r\n\r\nOver the past 3 weeks she has developed a new erythematous rash\r\nthat has been extending throughout her body and is new\r\neythrodermic. She has a biopsy on ___ favoring GVHD vs. drug\r\neruption prompting course of prednisone 20mg without \r\nimprovement.\r\nYesterday she had 4 episodes of non-bloody non-mucoid diarrhea\r\nprompting call to her oncologist's office who referred her to \r\nED.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n==========================\r\nVS: 98.4 PO 134 / 69 L Sitting 90 18 98 RA \r\nGENERAL: Well- appearing lady, in no distress lying in bed\r\ncomfortably.\r\nHEENT: Anicteric, PERLL, Mucous membranes moist, oropharynx\r\nclear.\r\nCARDIAC: Regular rate and rhythm, no murmurs, rubs or gallops.\r\nLUNG: Appears in no respiratory distress, clear to auscultation\r\nbilaterally, no crackles, wheezes, or rhonchi.\r\nABD: Non-distended, normal bowel sounds, soft, non-tender, no\r\nguarding, no palpable masses, no organomegaly.\r\nEXT: Warm, well perfused. No lower extremity edema. No\r\ntenderness.\r\nNEURO: Alert and oriented, good attention,  linear thought\r\nprocess. CN II-XII intact. Strength full throughout. Sensation \r\nto\r\nlight touch intact.\r\nSKIN: Patchy erythrodermic erythematous rash. \r\n \r\nDISCHARGE EXAM\r\n==========================\r\nVITALS: 98.6 128/72 93 20 97 Ra \r\nGENERAL: NAD, sitting comfortably in chair \r\nHEENT: strabismus, right ptosis, anicteric, oropharynx clear\r\nCV: RRR, S1/S2, no m/r/g\r\nPULM: unlabored, CTAB\r\nGI: obese, soft, normoactive, nondistended, nontender, no\r\nrebound/guarding\r\nEXT: WWP, trace distal leg edema\r\nSKIN: erythema and scaling nearly resolved\r\n \r\nPertinent Results:\r\nPERTIENT STUDIES\r\n=============================\r\n___ Pathology Tissue: SKIN, LEVELS X4 ON 2 SLIDES:\r\n \r\nPATHOLOGIC DIAGNOSIS:\r\nSkin, right abdomen (1A):\r\nFocal vacuolar interface dermatitis with superficial \r\nperivascular lymphocytic inflammation, apoptotic\r\nkeratinocytes and lymphocyte exocytosis (see note).\r\nNote: The histopathologic findings are favored to represent \r\ngraft-versus-host disease. Less likely,\r\nthe differential diagnosis includes a drug eruption. Sections \r\nshow superficial perivascular\r\nlymphocytic inflammation with exocytosis of lymphocytes into the \r\nepidermis. There are scattered\r\napoptotic keratinocytes, some with satellite cell necrosis. \r\nFocal parakeratosis is present. Epidermal\r\ndysmaturation is seen which may be related to prior \r\nchemotherapeutic agents. No fungi are seen on\r\nPAS stain. Initial and multiple additional levels were examined.\r\n \r\nADMISSION LABS\r\n=============================\r\n___ 04:00PM BLOOD WBC-6.0 RBC-3.49* Hgb-12.3 Hct-37.5 \r\nMCV-107* MCH-35.2* MCHC-32.8 RDW-15.3 RDWSD-61.2* Plt ___\r\n___ 04:00PM BLOOD Neuts-85.0* Lymphs-10.4* Monos-3.2* \r\nEos-0.3* Baso-0.3 Im ___ AbsNeut-5.12# AbsLymp-0.63* \r\nAbsMono-0.19* AbsEos-0.02* AbsBaso-0.02\r\n___ 04:00PM BLOOD ___ PTT-33.4 ___\r\n___ 04:00PM BLOOD Glucose-103* UreaN-23* Creat-1.2* Na-140 \r\nK-4.6 Cl-104 HCO3-23 AnGap-13\r\n___ 04:00PM BLOOD ALT-32 AST-25 AlkPhos-124* TotBili-0.3\r\n___ 04:00PM BLOOD Albumin-3.9 Calcium-8.6 Phos-3.0 Mg-2.0\r\n___ 04:17PM BLOOD Lactate-1.8\r\n___ 06:35PM URINE Color-Straw Appear-Clear Sp ___\r\n___ 06:35PM URINE Blood-NEG Nitrite-NEG Protein-30* \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 06:35PM URINE RBC-<1 WBC-4 Bacteri-FEW* Yeast-NONE \r\nEpi-<1\r\n___ 06:35PM URINE\r\n___ 06:35PM URINE Hours-RANDOM\r\n \r\nPERTINENT LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 03:20PM BLOOD Glucose-175* UreaN-33* Creat-1.4* Na-139 \r\nK-5.7* Cl-105 HCO3-24 AnGap-10\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 09:20AM BLOOD Cyclspr-58*\r\n___ 09:40AM BLOOD Cyclspr-51*\r\n___ 07:00AM BLOOD CMV VL-NOT DETECT\r\n \r\nDISCHARGE LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 01:45AM BLOOD Neuts-78.2* Lymphs-12.5* Monos-7.4 \r\nEos-0.0* Baso-0.1 NRBC-0.2* Im ___ AbsNeut-7.22* \r\nAbsLymp-1.15* AbsMono-0.68 AbsEos-0.00* AbsBaso-0.01\r\n___ 01:45AM BLOOD Plt ___\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 01:45AM BLOOD ALT-30 AST-23 LD(LDH)-205 AlkPhos-112* \r\nTotBili-0.2\r\n___ 01:45AM BLOOD Calcium-8.3* Phos-3.9 Mg-2.0\r\n \r\nPERTINENT MICRO\r\n=============================\r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n \r\n\r\n \r\n \r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Final ___:    NO CYCLOSPORA SEEN. \r\n\r\n   FECAL CULTURE (Final ___:    NO SALMONELLA OR SHIGELLA \r\nFOUND. \r\n\r\n   CAMPYLOBACTER CULTURE (Final ___:    NO CAMPYLOBACTER \r\nFOUND. \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   FECAL CULTURE - R/O VIBRIO (Final ___:    NO VIBRIO \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O YERSINIA (Final ___:    NO YERSINIA \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O E.COLI 0157:H7 (Final ___: \r\n      No E. coli O157:H7 found. \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n \r\nBrief Hospital Course:\r\n___ female with history of diffuse large B-cell lymphoma \r\ncomplicated by secondary myelodysplastic syndrome status-post \r\nallogeneic stem cell transplant complicated by combined variable \r\nimmunodeficiency status-post IVIG, CMV viremia status-post \r\nganciclovir/valganciclovir and S. epidermidis bactermia \r\nstatus-post daptomycin, new deep venous thrombosis, on Lovenox, \r\nand recent biopsy-proven acute skin graft-versus-host disease, \r\non triamcinolone / prednisone, admitted for (1) worsening skin \r\nerythema, which resolved with high-dose corticosteroids and (2) \r\ndiarrhea, which spontaneously resolved upon admission.\r\n\r\n#) Skin graft-versus-host disease, acute, grade III: punch \r\nbiopsy (___) favoring GvHD versus drug eruption. Acute \r\nworsening of generalized eryhtroderma with xerosis/desquamation \r\nin days preceding admission despite use of \r\ntriamcinolone/prednisone. No cellulitic changes. Erythema \r\nregressed with five-day course of methylprednisolone 1 mg/kg in \r\ncombination with topical triamcinolone 0.1%/hydrocortisone 1% \r\n(face), which was converted to prednisone 100 -> 80 mg daily \r\nthereafter. Further taper plan to be determined as outpatient. \r\nHydroxyzine, Sarna, and emollients added for symptomatic care.\r\n\r\n#) Diarrhea, non-bloody: concern for acute gut GvHD, though \r\nspontaneously resolved prior to start of high-dose \r\ncorticosteroids. Of note, recent protracted antibiotic course, \r\nthough C. difficile negative. CMV viral load and stool studies \r\nlikewise negative. Stool volume normal throughout duration of \r\nhospital course. Flexible sigmoidoscopy not pursued in that \r\nregard.\r\n\r\n#) ___: Cr bumped to 1.4 shortly prior to discharge. Unclear \r\netiology though most suspicious for cyclosporine effect vs. \r\nhypovolemia. Non-fluid responsive to 1L bolus; urine studies \r\nwith intrinsic renal picture. Spontaneously resolved within 24 \r\nh. Of note, given fluid bolus in setting of HFrEF and concurrent \r\nsteroids patient was mildly volume overloaded at time of \r\ndischarge. No shortness of breath; O2 saturation normal. \r\nDischarged with 20 mg PO Lasix.\r\n\r\n#) DLBCL c/b secondary MDS ___ MUD allogeneic SCT, in remission: \r\n100% chimerism ___ surveillance bone marrow biopsy with \r\nnormal trilineage maturation. DLBCL also in remission by \r\nsurveillance CT. Complications, as delineated above. \r\nCyclosporine as well as acyclovir, fluconazole, and TMP/SMX all \r\ncontinued. \r\n\r\n#) Hyperkalemia, mild: suspect iatrogenic secondary to \r\ncyclosporine and TMP/SMX. \r\n\r\nCHRONIC/STABLE ISSUES\r\n==============================\r\n\r\n#) DVT, bilateral lower extremity: on therapeutic Lovenox, as of \r\n___. Of note, ___ IVC filter (___) for prior DVT. Lovenox 80 \r\nmg SC Q12H continued. \r\n\r\n#) ICA cavernous sinus aneurysm, right: ___ coil embolization \r\nc/b CN VI palsy, ptosis, V1 hyperesthesia. Home gabapentin \r\ncontinued. \r\n\r\n#) GERD: home omeprazole continued.\r\n\r\n#) OSA: nocturnal CPAP\r\n\r\nTRANSITIONAL ISSUES\r\n===============================\r\n [ ] Discharged on prednisone 80 mg daily. Please arrange for \r\ntaper as outpatient.\r\n\r\n [ ] Mildly volume overloaded at time of discharge due to \r\nconcurrent steroids and fluids with history of CHF. No shortness \r\nof breath; O2 saturation normal. Discharged with 20 mg PO Lasix. \r\nPlease increase or discontinue as needed.\r\n\r\n [ ] Monitor ongoing use of topical steroids and ensure \r\ndiscontinued after appropriate treatment course completed.\r\n\r\n [ ] Discharged on cyclosporine 50 mg q12 hours. Please monitor \r\nlevels and dose-adjust as needed.\r\n\r\n [ ] Prophylactic fluconazole increased to 400 mg daily.\r\n\r\n [ ] Vitamin D added for skeletal protection.\r\n\r\n#CODE: full (presumed)\r\n#CONTACT: ___ (daughter: ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 4 mg PO Q8H:PRN nausea \r\n2. PredniSONE 20 mg PO DAILY \r\n3. Magnesium Oxide 400 mg PO DAILY \r\n4. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Senna 8.6 mg PO BID:PRN constipation \r\n7. Cephalexin ___ mg PO PRN dental procedure \r\n8. Enoxaparin Sodium 80 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\n9. CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\n10. Acyclovir 400 mg PO Q8H \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. FoLIC Acid 1.6 mg PO DAILY \r\n14. Gabapentin 400 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Furosemide 20 mg PO DAILY \r\nRX *furosemide 20 mg 1 tablet(s) by mouth daily Disp #*14 Tablet \r\nRefills:*0 \r\n2.  Hydrocortisone Cream 1% 1 Appl TP BID \r\nRX *hydrocortisone 1 % apply as directed twice daily Refills:*0 \r\n3.  HydrOXYzine 25 mg PO QHS:PRN Itching \r\nRX *hydroxyzine HCl 25 mg 1 tablet by mouth at night Disp #*30 \r\nTablet Refills:*0 \r\n4.  Ketoconazole Shampoo 1 Appl TP BID \r\nRX *ketoconazole 2 % apply as directed twice daily Refills:*0 \r\n5.  Sarna Lotion 1 Appl TP QID:PRN Itching \r\nRX *camphor-menthol [Sarna Anti-Itch] 0.5 %-0.5 % apply as \r\ndirected four times daily Refills:*0 \r\n6.  Vitamin D 1000 UNIT PO DAILY \r\nRX *ergocalciferol (vitamin D2) 2,000 unit 1 tablet(s) by mouth \r\ndaily Disp #*30 Tablet Refills:*0 \r\n7.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n8.  PredniSONE 80 mg PO DAILY \r\nRX *prednisone 20 mg 4 tablet(s) by mouth daily Disp #*28 Tablet \r\nRefills:*0 \r\n9.  Acyclovir 400 mg PO Q8H  \r\n10.  Cephalexin ___ mg PO PRN dental procedure  \r\n11.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H  \r\n12.  Enoxaparin Sodium 80 mg SC Q12H  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  Magnesium Oxide 400 mg PO DAILY  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Senna 8.6 mg PO BID:PRN constipation  \r\n19.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n20.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY\r\n-Skin graft-versus-host-disease, acute \r\n\r\nSECONDARY\r\n-MDS, secondary \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___!\r\n\r\nWHY WERE YOU ADMITTED?\r\n-You had worsening graft-versus-host-disease of your skin.\r\n-You had diarrhea.\r\n\r\nWHAT HAPPENED IN THE HOSPITAL?\r\n-You received steroids and your rash improved.\r\n\r\nWHAT SHOULD YOU DO AT HOME?\r\n-Please take your steroids as directed\r\n-Continue to use triamcinolone (steroid) cream on your BODY only\r\n-Continue to use hydrocortisone (steroid) cream on your FACE\r\n-Take your cyclosporine and prophylactic medications as directed\r\n-Follow-up with your primary oncologist and dermatologist\r\n\r\nThank you for allowing us be involved in your care, we wish you \r\nall the best!\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-25:1",
      "text": "History of Present Illness:\nMrs. ___ is a ___ year-old lady with a history of DLBCL\n(tr.follicular) ___ alloSCT c/b MDS who presents with worsening\nerythrodermic rash and diarrhea. Over the past 3 weeks she has developed a new erythematous rash\nthat has been extending throughout her body and is new\neythrodermic. She has a biopsy on ___ favoring GVHD vs. drug\neruption prompting course of prednisone 20mg without \nimprovement. Yesterday she had 4 episodes of non-bloody non-mucoid diarrhea\nprompting call to her oncologist's office who referred her to \nED.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-25",
        "chart_time": "104834",
        "section": "General",
        "position": 1,
        "tokenCount": 140,
        "note_metadata": {
          "note_id": "18887130-DS-25",
          "subject_id": 18887130,
          "hadm_id": 24673826,
          "note_type": "DS",
          "note_seq": 25,
          "charttime": 104834,
          "storetime": 104834.66319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nrash, diarrhea\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nMrs. ___ is a ___ year-old lady with a history of DLBCL\r\n(tr.follicular) ___ alloSCT c/b MDS who presents with worsening\r\nerythrodermic rash and diarrhea. \r\n\r\nOver the past 3 weeks she has developed a new erythematous rash\r\nthat has been extending throughout her body and is new\r\neythrodermic. She has a biopsy on ___ favoring GVHD vs. drug\r\neruption prompting course of prednisone 20mg without \r\nimprovement.\r\nYesterday she had 4 episodes of non-bloody non-mucoid diarrhea\r\nprompting call to her oncologist's office who referred her to \r\nED.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n==========================\r\nVS: 98.4 PO 134 / 69 L Sitting 90 18 98 RA \r\nGENERAL: Well- appearing lady, in no distress lying in bed\r\ncomfortably.\r\nHEENT: Anicteric, PERLL, Mucous membranes moist, oropharynx\r\nclear.\r\nCARDIAC: Regular rate and rhythm, no murmurs, rubs or gallops.\r\nLUNG: Appears in no respiratory distress, clear to auscultation\r\nbilaterally, no crackles, wheezes, or rhonchi.\r\nABD: Non-distended, normal bowel sounds, soft, non-tender, no\r\nguarding, no palpable masses, no organomegaly.\r\nEXT: Warm, well perfused. No lower extremity edema. No\r\ntenderness.\r\nNEURO: Alert and oriented, good attention,  linear thought\r\nprocess. CN II-XII intact. Strength full throughout. Sensation \r\nto\r\nlight touch intact.\r\nSKIN: Patchy erythrodermic erythematous rash. \r\n \r\nDISCHARGE EXAM\r\n==========================\r\nVITALS: 98.6 128/72 93 20 97 Ra \r\nGENERAL: NAD, sitting comfortably in chair \r\nHEENT: strabismus, right ptosis, anicteric, oropharynx clear\r\nCV: RRR, S1/S2, no m/r/g\r\nPULM: unlabored, CTAB\r\nGI: obese, soft, normoactive, nondistended, nontender, no\r\nrebound/guarding\r\nEXT: WWP, trace distal leg edema\r\nSKIN: erythema and scaling nearly resolved\r\n \r\nPertinent Results:\r\nPERTIENT STUDIES\r\n=============================\r\n___ Pathology Tissue: SKIN, LEVELS X4 ON 2 SLIDES:\r\n \r\nPATHOLOGIC DIAGNOSIS:\r\nSkin, right abdomen (1A):\r\nFocal vacuolar interface dermatitis with superficial \r\nperivascular lymphocytic inflammation, apoptotic\r\nkeratinocytes and lymphocyte exocytosis (see note).\r\nNote: The histopathologic findings are favored to represent \r\ngraft-versus-host disease. Less likely,\r\nthe differential diagnosis includes a drug eruption. Sections \r\nshow superficial perivascular\r\nlymphocytic inflammation with exocytosis of lymphocytes into the \r\nepidermis. There are scattered\r\napoptotic keratinocytes, some with satellite cell necrosis. \r\nFocal parakeratosis is present. Epidermal\r\ndysmaturation is seen which may be related to prior \r\nchemotherapeutic agents. No fungi are seen on\r\nPAS stain. Initial and multiple additional levels were examined.\r\n \r\nADMISSION LABS\r\n=============================\r\n___ 04:00PM BLOOD WBC-6.0 RBC-3.49* Hgb-12.3 Hct-37.5 \r\nMCV-107* MCH-35.2* MCHC-32.8 RDW-15.3 RDWSD-61.2* Plt ___\r\n___ 04:00PM BLOOD Neuts-85.0* Lymphs-10.4* Monos-3.2* \r\nEos-0.3* Baso-0.3 Im ___ AbsNeut-5.12# AbsLymp-0.63* \r\nAbsMono-0.19* AbsEos-0.02* AbsBaso-0.02\r\n___ 04:00PM BLOOD ___ PTT-33.4 ___\r\n___ 04:00PM BLOOD Glucose-103* UreaN-23* Creat-1.2* Na-140 \r\nK-4.6 Cl-104 HCO3-23 AnGap-13\r\n___ 04:00PM BLOOD ALT-32 AST-25 AlkPhos-124* TotBili-0.3\r\n___ 04:00PM BLOOD Albumin-3.9 Calcium-8.6 Phos-3.0 Mg-2.0\r\n___ 04:17PM BLOOD Lactate-1.8\r\n___ 06:35PM URINE Color-Straw Appear-Clear Sp ___\r\n___ 06:35PM URINE Blood-NEG Nitrite-NEG Protein-30* \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 06:35PM URINE RBC-<1 WBC-4 Bacteri-FEW* Yeast-NONE \r\nEpi-<1\r\n___ 06:35PM URINE\r\n___ 06:35PM URINE Hours-RANDOM\r\n \r\nPERTINENT LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 03:20PM BLOOD Glucose-175* UreaN-33* Creat-1.4* Na-139 \r\nK-5.7* Cl-105 HCO3-24 AnGap-10\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 09:20AM BLOOD Cyclspr-58*\r\n___ 09:40AM BLOOD Cyclspr-51*\r\n___ 07:00AM BLOOD CMV VL-NOT DETECT\r\n \r\nDISCHARGE LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 01:45AM BLOOD Neuts-78.2* Lymphs-12.5* Monos-7.4 \r\nEos-0.0* Baso-0.1 NRBC-0.2* Im ___ AbsNeut-7.22* \r\nAbsLymp-1.15* AbsMono-0.68 AbsEos-0.00* AbsBaso-0.01\r\n___ 01:45AM BLOOD Plt ___\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 01:45AM BLOOD ALT-30 AST-23 LD(LDH)-205 AlkPhos-112* \r\nTotBili-0.2\r\n___ 01:45AM BLOOD Calcium-8.3* Phos-3.9 Mg-2.0\r\n \r\nPERTINENT MICRO\r\n=============================\r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n \r\n\r\n \r\n \r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Final ___:    NO CYCLOSPORA SEEN. \r\n\r\n   FECAL CULTURE (Final ___:    NO SALMONELLA OR SHIGELLA \r\nFOUND. \r\n\r\n   CAMPYLOBACTER CULTURE (Final ___:    NO CAMPYLOBACTER \r\nFOUND. \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   FECAL CULTURE - R/O VIBRIO (Final ___:    NO VIBRIO \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O YERSINIA (Final ___:    NO YERSINIA \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O E.COLI 0157:H7 (Final ___: \r\n      No E. coli O157:H7 found. \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n \r\nBrief Hospital Course:\r\n___ female with history of diffuse large B-cell lymphoma \r\ncomplicated by secondary myelodysplastic syndrome status-post \r\nallogeneic stem cell transplant complicated by combined variable \r\nimmunodeficiency status-post IVIG, CMV viremia status-post \r\nganciclovir/valganciclovir and S. epidermidis bactermia \r\nstatus-post daptomycin, new deep venous thrombosis, on Lovenox, \r\nand recent biopsy-proven acute skin graft-versus-host disease, \r\non triamcinolone / prednisone, admitted for (1) worsening skin \r\nerythema, which resolved with high-dose corticosteroids and (2) \r\ndiarrhea, which spontaneously resolved upon admission.\r\n\r\n#) Skin graft-versus-host disease, acute, grade III: punch \r\nbiopsy (___) favoring GvHD versus drug eruption. Acute \r\nworsening of generalized eryhtroderma with xerosis/desquamation \r\nin days preceding admission despite use of \r\ntriamcinolone/prednisone. No cellulitic changes. Erythema \r\nregressed with five-day course of methylprednisolone 1 mg/kg in \r\ncombination with topical triamcinolone 0.1%/hydrocortisone 1% \r\n(face), which was converted to prednisone 100 -> 80 mg daily \r\nthereafter. Further taper plan to be determined as outpatient. \r\nHydroxyzine, Sarna, and emollients added for symptomatic care.\r\n\r\n#) Diarrhea, non-bloody: concern for acute gut GvHD, though \r\nspontaneously resolved prior to start of high-dose \r\ncorticosteroids. Of note, recent protracted antibiotic course, \r\nthough C. difficile negative. CMV viral load and stool studies \r\nlikewise negative. Stool volume normal throughout duration of \r\nhospital course. Flexible sigmoidoscopy not pursued in that \r\nregard.\r\n\r\n#) ___: Cr bumped to 1.4 shortly prior to discharge. Unclear \r\netiology though most suspicious for cyclosporine effect vs. \r\nhypovolemia. Non-fluid responsive to 1L bolus; urine studies \r\nwith intrinsic renal picture. Spontaneously resolved within 24 \r\nh. Of note, given fluid bolus in setting of HFrEF and concurrent \r\nsteroids patient was mildly volume overloaded at time of \r\ndischarge. No shortness of breath; O2 saturation normal. \r\nDischarged with 20 mg PO Lasix.\r\n\r\n#) DLBCL c/b secondary MDS ___ MUD allogeneic SCT, in remission: \r\n100% chimerism ___ surveillance bone marrow biopsy with \r\nnormal trilineage maturation. DLBCL also in remission by \r\nsurveillance CT. Complications, as delineated above. \r\nCyclosporine as well as acyclovir, fluconazole, and TMP/SMX all \r\ncontinued. \r\n\r\n#) Hyperkalemia, mild: suspect iatrogenic secondary to \r\ncyclosporine and TMP/SMX. \r\n\r\nCHRONIC/STABLE ISSUES\r\n==============================\r\n\r\n#) DVT, bilateral lower extremity: on therapeutic Lovenox, as of \r\n___. Of note, ___ IVC filter (___) for prior DVT. Lovenox 80 \r\nmg SC Q12H continued. \r\n\r\n#) ICA cavernous sinus aneurysm, right: ___ coil embolization \r\nc/b CN VI palsy, ptosis, V1 hyperesthesia. Home gabapentin \r\ncontinued. \r\n\r\n#) GERD: home omeprazole continued.\r\n\r\n#) OSA: nocturnal CPAP\r\n\r\nTRANSITIONAL ISSUES\r\n===============================\r\n [ ] Discharged on prednisone 80 mg daily. Please arrange for \r\ntaper as outpatient.\r\n\r\n [ ] Mildly volume overloaded at time of discharge due to \r\nconcurrent steroids and fluids with history of CHF. No shortness \r\nof breath; O2 saturation normal. Discharged with 20 mg PO Lasix. \r\nPlease increase or discontinue as needed.\r\n\r\n [ ] Monitor ongoing use of topical steroids and ensure \r\ndiscontinued after appropriate treatment course completed.\r\n\r\n [ ] Discharged on cyclosporine 50 mg q12 hours. Please monitor \r\nlevels and dose-adjust as needed.\r\n\r\n [ ] Prophylactic fluconazole increased to 400 mg daily.\r\n\r\n [ ] Vitamin D added for skeletal protection.\r\n\r\n#CODE: full (presumed)\r\n#CONTACT: ___ (daughter: ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 4 mg PO Q8H:PRN nausea \r\n2. PredniSONE 20 mg PO DAILY \r\n3. Magnesium Oxide 400 mg PO DAILY \r\n4. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Senna 8.6 mg PO BID:PRN constipation \r\n7. Cephalexin ___ mg PO PRN dental procedure \r\n8. Enoxaparin Sodium 80 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\n9. CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\n10. Acyclovir 400 mg PO Q8H \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. FoLIC Acid 1.6 mg PO DAILY \r\n14. Gabapentin 400 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Furosemide 20 mg PO DAILY \r\nRX *furosemide 20 mg 1 tablet(s) by mouth daily Disp #*14 Tablet \r\nRefills:*0 \r\n2.  Hydrocortisone Cream 1% 1 Appl TP BID \r\nRX *hydrocortisone 1 % apply as directed twice daily Refills:*0 \r\n3.  HydrOXYzine 25 mg PO QHS:PRN Itching \r\nRX *hydroxyzine HCl 25 mg 1 tablet by mouth at night Disp #*30 \r\nTablet Refills:*0 \r\n4.  Ketoconazole Shampoo 1 Appl TP BID \r\nRX *ketoconazole 2 % apply as directed twice daily Refills:*0 \r\n5.  Sarna Lotion 1 Appl TP QID:PRN Itching \r\nRX *camphor-menthol [Sarna Anti-Itch] 0.5 %-0.5 % apply as \r\ndirected four times daily Refills:*0 \r\n6.  Vitamin D 1000 UNIT PO DAILY \r\nRX *ergocalciferol (vitamin D2) 2,000 unit 1 tablet(s) by mouth \r\ndaily Disp #*30 Tablet Refills:*0 \r\n7.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n8.  PredniSONE 80 mg PO DAILY \r\nRX *prednisone 20 mg 4 tablet(s) by mouth daily Disp #*28 Tablet \r\nRefills:*0 \r\n9.  Acyclovir 400 mg PO Q8H  \r\n10.  Cephalexin ___ mg PO PRN dental procedure  \r\n11.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H  \r\n12.  Enoxaparin Sodium 80 mg SC Q12H  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  Magnesium Oxide 400 mg PO DAILY  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Senna 8.6 mg PO BID:PRN constipation  \r\n19.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n20.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY\r\n-Skin graft-versus-host-disease, acute \r\n\r\nSECONDARY\r\n-MDS, secondary \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___!\r\n\r\nWHY WERE YOU ADMITTED?\r\n-You had worsening graft-versus-host-disease of your skin.\r\n-You had diarrhea.\r\n\r\nWHAT HAPPENED IN THE HOSPITAL?\r\n-You received steroids and your rash improved.\r\n\r\nWHAT SHOULD YOU DO AT HOME?\r\n-Please take your steroids as directed\r\n-Continue to use triamcinolone (steroid) cream on your BODY only\r\n-Continue to use hydrocortisone (steroid) cream on your FACE\r\n-Take your cyclosporine and prophylactic medications as directed\r\n-Follow-up with your primary oncologist and dermatologist\r\n\r\nThank you for allowing us be involved in your care, we wish you \r\nall the best!\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-25:2",
      "text": "Past Medical History:\n- Treatment-Related MDS after transformed follicular lymphoma\n- CVID, received IVIG monthly; last given ___\n- GERD                                          \n- Osteoarthritis                                         \n- DVT, right lower extremity, IVC filter in place\n- Cervical radiculopathy\n- Sciatica\n- Obstructive sleep apnea, wears CPAP\n- H/O cerebral aneurism, noted on MRA with small R internal\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\nthe right eye, mild proptosis of the right eye, and hyperthesia\nof the right V1 distribution\n- Asthma\n- Obesity\n- Hypertension\n- Migraines\n- + RSV, ___\n- History of osteomyelitis with IV antibioitcs for 6\nweeks. Social History:\n___ Family History:\nBrother with lymphoma, died at age ___. Father had CAD and DM. Mother had CHF.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-25",
        "chart_time": "104834",
        "section": "General",
        "position": 2,
        "tokenCount": 217,
        "note_metadata": {
          "note_id": "18887130-DS-25",
          "subject_id": 18887130,
          "hadm_id": 24673826,
          "note_type": "DS",
          "note_seq": 25,
          "charttime": 104834,
          "storetime": 104834.66319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nrash, diarrhea\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nMrs. ___ is a ___ year-old lady with a history of DLBCL\r\n(tr.follicular) ___ alloSCT c/b MDS who presents with worsening\r\nerythrodermic rash and diarrhea. \r\n\r\nOver the past 3 weeks she has developed a new erythematous rash\r\nthat has been extending throughout her body and is new\r\neythrodermic. She has a biopsy on ___ favoring GVHD vs. drug\r\neruption prompting course of prednisone 20mg without \r\nimprovement.\r\nYesterday she had 4 episodes of non-bloody non-mucoid diarrhea\r\nprompting call to her oncologist's office who referred her to \r\nED.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n==========================\r\nVS: 98.4 PO 134 / 69 L Sitting 90 18 98 RA \r\nGENERAL: Well- appearing lady, in no distress lying in bed\r\ncomfortably.\r\nHEENT: Anicteric, PERLL, Mucous membranes moist, oropharynx\r\nclear.\r\nCARDIAC: Regular rate and rhythm, no murmurs, rubs or gallops.\r\nLUNG: Appears in no respiratory distress, clear to auscultation\r\nbilaterally, no crackles, wheezes, or rhonchi.\r\nABD: Non-distended, normal bowel sounds, soft, non-tender, no\r\nguarding, no palpable masses, no organomegaly.\r\nEXT: Warm, well perfused. No lower extremity edema. No\r\ntenderness.\r\nNEURO: Alert and oriented, good attention,  linear thought\r\nprocess. CN II-XII intact. Strength full throughout. Sensation \r\nto\r\nlight touch intact.\r\nSKIN: Patchy erythrodermic erythematous rash. \r\n \r\nDISCHARGE EXAM\r\n==========================\r\nVITALS: 98.6 128/72 93 20 97 Ra \r\nGENERAL: NAD, sitting comfortably in chair \r\nHEENT: strabismus, right ptosis, anicteric, oropharynx clear\r\nCV: RRR, S1/S2, no m/r/g\r\nPULM: unlabored, CTAB\r\nGI: obese, soft, normoactive, nondistended, nontender, no\r\nrebound/guarding\r\nEXT: WWP, trace distal leg edema\r\nSKIN: erythema and scaling nearly resolved\r\n \r\nPertinent Results:\r\nPERTIENT STUDIES\r\n=============================\r\n___ Pathology Tissue: SKIN, LEVELS X4 ON 2 SLIDES:\r\n \r\nPATHOLOGIC DIAGNOSIS:\r\nSkin, right abdomen (1A):\r\nFocal vacuolar interface dermatitis with superficial \r\nperivascular lymphocytic inflammation, apoptotic\r\nkeratinocytes and lymphocyte exocytosis (see note).\r\nNote: The histopathologic findings are favored to represent \r\ngraft-versus-host disease. Less likely,\r\nthe differential diagnosis includes a drug eruption. Sections \r\nshow superficial perivascular\r\nlymphocytic inflammation with exocytosis of lymphocytes into the \r\nepidermis. There are scattered\r\napoptotic keratinocytes, some with satellite cell necrosis. \r\nFocal parakeratosis is present. Epidermal\r\ndysmaturation is seen which may be related to prior \r\nchemotherapeutic agents. No fungi are seen on\r\nPAS stain. Initial and multiple additional levels were examined.\r\n \r\nADMISSION LABS\r\n=============================\r\n___ 04:00PM BLOOD WBC-6.0 RBC-3.49* Hgb-12.3 Hct-37.5 \r\nMCV-107* MCH-35.2* MCHC-32.8 RDW-15.3 RDWSD-61.2* Plt ___\r\n___ 04:00PM BLOOD Neuts-85.0* Lymphs-10.4* Monos-3.2* \r\nEos-0.3* Baso-0.3 Im ___ AbsNeut-5.12# AbsLymp-0.63* \r\nAbsMono-0.19* AbsEos-0.02* AbsBaso-0.02\r\n___ 04:00PM BLOOD ___ PTT-33.4 ___\r\n___ 04:00PM BLOOD Glucose-103* UreaN-23* Creat-1.2* Na-140 \r\nK-4.6 Cl-104 HCO3-23 AnGap-13\r\n___ 04:00PM BLOOD ALT-32 AST-25 AlkPhos-124* TotBili-0.3\r\n___ 04:00PM BLOOD Albumin-3.9 Calcium-8.6 Phos-3.0 Mg-2.0\r\n___ 04:17PM BLOOD Lactate-1.8\r\n___ 06:35PM URINE Color-Straw Appear-Clear Sp ___\r\n___ 06:35PM URINE Blood-NEG Nitrite-NEG Protein-30* \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 06:35PM URINE RBC-<1 WBC-4 Bacteri-FEW* Yeast-NONE \r\nEpi-<1\r\n___ 06:35PM URINE\r\n___ 06:35PM URINE Hours-RANDOM\r\n \r\nPERTINENT LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 03:20PM BLOOD Glucose-175* UreaN-33* Creat-1.4* Na-139 \r\nK-5.7* Cl-105 HCO3-24 AnGap-10\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 09:20AM BLOOD Cyclspr-58*\r\n___ 09:40AM BLOOD Cyclspr-51*\r\n___ 07:00AM BLOOD CMV VL-NOT DETECT\r\n \r\nDISCHARGE LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 01:45AM BLOOD Neuts-78.2* Lymphs-12.5* Monos-7.4 \r\nEos-0.0* Baso-0.1 NRBC-0.2* Im ___ AbsNeut-7.22* \r\nAbsLymp-1.15* AbsMono-0.68 AbsEos-0.00* AbsBaso-0.01\r\n___ 01:45AM BLOOD Plt ___\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 01:45AM BLOOD ALT-30 AST-23 LD(LDH)-205 AlkPhos-112* \r\nTotBili-0.2\r\n___ 01:45AM BLOOD Calcium-8.3* Phos-3.9 Mg-2.0\r\n \r\nPERTINENT MICRO\r\n=============================\r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n \r\n\r\n \r\n \r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Final ___:    NO CYCLOSPORA SEEN. \r\n\r\n   FECAL CULTURE (Final ___:    NO SALMONELLA OR SHIGELLA \r\nFOUND. \r\n\r\n   CAMPYLOBACTER CULTURE (Final ___:    NO CAMPYLOBACTER \r\nFOUND. \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   FECAL CULTURE - R/O VIBRIO (Final ___:    NO VIBRIO \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O YERSINIA (Final ___:    NO YERSINIA \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O E.COLI 0157:H7 (Final ___: \r\n      No E. coli O157:H7 found. \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n \r\nBrief Hospital Course:\r\n___ female with history of diffuse large B-cell lymphoma \r\ncomplicated by secondary myelodysplastic syndrome status-post \r\nallogeneic stem cell transplant complicated by combined variable \r\nimmunodeficiency status-post IVIG, CMV viremia status-post \r\nganciclovir/valganciclovir and S. epidermidis bactermia \r\nstatus-post daptomycin, new deep venous thrombosis, on Lovenox, \r\nand recent biopsy-proven acute skin graft-versus-host disease, \r\non triamcinolone / prednisone, admitted for (1) worsening skin \r\nerythema, which resolved with high-dose corticosteroids and (2) \r\ndiarrhea, which spontaneously resolved upon admission.\r\n\r\n#) Skin graft-versus-host disease, acute, grade III: punch \r\nbiopsy (___) favoring GvHD versus drug eruption. Acute \r\nworsening of generalized eryhtroderma with xerosis/desquamation \r\nin days preceding admission despite use of \r\ntriamcinolone/prednisone. No cellulitic changes. Erythema \r\nregressed with five-day course of methylprednisolone 1 mg/kg in \r\ncombination with topical triamcinolone 0.1%/hydrocortisone 1% \r\n(face), which was converted to prednisone 100 -> 80 mg daily \r\nthereafter. Further taper plan to be determined as outpatient. \r\nHydroxyzine, Sarna, and emollients added for symptomatic care.\r\n\r\n#) Diarrhea, non-bloody: concern for acute gut GvHD, though \r\nspontaneously resolved prior to start of high-dose \r\ncorticosteroids. Of note, recent protracted antibiotic course, \r\nthough C. difficile negative. CMV viral load and stool studies \r\nlikewise negative. Stool volume normal throughout duration of \r\nhospital course. Flexible sigmoidoscopy not pursued in that \r\nregard.\r\n\r\n#) ___: Cr bumped to 1.4 shortly prior to discharge. Unclear \r\netiology though most suspicious for cyclosporine effect vs. \r\nhypovolemia. Non-fluid responsive to 1L bolus; urine studies \r\nwith intrinsic renal picture. Spontaneously resolved within 24 \r\nh. Of note, given fluid bolus in setting of HFrEF and concurrent \r\nsteroids patient was mildly volume overloaded at time of \r\ndischarge. No shortness of breath; O2 saturation normal. \r\nDischarged with 20 mg PO Lasix.\r\n\r\n#) DLBCL c/b secondary MDS ___ MUD allogeneic SCT, in remission: \r\n100% chimerism ___ surveillance bone marrow biopsy with \r\nnormal trilineage maturation. DLBCL also in remission by \r\nsurveillance CT. Complications, as delineated above. \r\nCyclosporine as well as acyclovir, fluconazole, and TMP/SMX all \r\ncontinued. \r\n\r\n#) Hyperkalemia, mild: suspect iatrogenic secondary to \r\ncyclosporine and TMP/SMX. \r\n\r\nCHRONIC/STABLE ISSUES\r\n==============================\r\n\r\n#) DVT, bilateral lower extremity: on therapeutic Lovenox, as of \r\n___. Of note, ___ IVC filter (___) for prior DVT. Lovenox 80 \r\nmg SC Q12H continued. \r\n\r\n#) ICA cavernous sinus aneurysm, right: ___ coil embolization \r\nc/b CN VI palsy, ptosis, V1 hyperesthesia. Home gabapentin \r\ncontinued. \r\n\r\n#) GERD: home omeprazole continued.\r\n\r\n#) OSA: nocturnal CPAP\r\n\r\nTRANSITIONAL ISSUES\r\n===============================\r\n [ ] Discharged on prednisone 80 mg daily. Please arrange for \r\ntaper as outpatient.\r\n\r\n [ ] Mildly volume overloaded at time of discharge due to \r\nconcurrent steroids and fluids with history of CHF. No shortness \r\nof breath; O2 saturation normal. Discharged with 20 mg PO Lasix. \r\nPlease increase or discontinue as needed.\r\n\r\n [ ] Monitor ongoing use of topical steroids and ensure \r\ndiscontinued after appropriate treatment course completed.\r\n\r\n [ ] Discharged on cyclosporine 50 mg q12 hours. Please monitor \r\nlevels and dose-adjust as needed.\r\n\r\n [ ] Prophylactic fluconazole increased to 400 mg daily.\r\n\r\n [ ] Vitamin D added for skeletal protection.\r\n\r\n#CODE: full (presumed)\r\n#CONTACT: ___ (daughter: ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 4 mg PO Q8H:PRN nausea \r\n2. PredniSONE 20 mg PO DAILY \r\n3. Magnesium Oxide 400 mg PO DAILY \r\n4. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Senna 8.6 mg PO BID:PRN constipation \r\n7. Cephalexin ___ mg PO PRN dental procedure \r\n8. Enoxaparin Sodium 80 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\n9. CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\n10. Acyclovir 400 mg PO Q8H \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. FoLIC Acid 1.6 mg PO DAILY \r\n14. Gabapentin 400 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Furosemide 20 mg PO DAILY \r\nRX *furosemide 20 mg 1 tablet(s) by mouth daily Disp #*14 Tablet \r\nRefills:*0 \r\n2.  Hydrocortisone Cream 1% 1 Appl TP BID \r\nRX *hydrocortisone 1 % apply as directed twice daily Refills:*0 \r\n3.  HydrOXYzine 25 mg PO QHS:PRN Itching \r\nRX *hydroxyzine HCl 25 mg 1 tablet by mouth at night Disp #*30 \r\nTablet Refills:*0 \r\n4.  Ketoconazole Shampoo 1 Appl TP BID \r\nRX *ketoconazole 2 % apply as directed twice daily Refills:*0 \r\n5.  Sarna Lotion 1 Appl TP QID:PRN Itching \r\nRX *camphor-menthol [Sarna Anti-Itch] 0.5 %-0.5 % apply as \r\ndirected four times daily Refills:*0 \r\n6.  Vitamin D 1000 UNIT PO DAILY \r\nRX *ergocalciferol (vitamin D2) 2,000 unit 1 tablet(s) by mouth \r\ndaily Disp #*30 Tablet Refills:*0 \r\n7.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n8.  PredniSONE 80 mg PO DAILY \r\nRX *prednisone 20 mg 4 tablet(s) by mouth daily Disp #*28 Tablet \r\nRefills:*0 \r\n9.  Acyclovir 400 mg PO Q8H  \r\n10.  Cephalexin ___ mg PO PRN dental procedure  \r\n11.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H  \r\n12.  Enoxaparin Sodium 80 mg SC Q12H  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  Magnesium Oxide 400 mg PO DAILY  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Senna 8.6 mg PO BID:PRN constipation  \r\n19.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n20.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY\r\n-Skin graft-versus-host-disease, acute \r\n\r\nSECONDARY\r\n-MDS, secondary \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___!\r\n\r\nWHY WERE YOU ADMITTED?\r\n-You had worsening graft-versus-host-disease of your skin.\r\n-You had diarrhea.\r\n\r\nWHAT HAPPENED IN THE HOSPITAL?\r\n-You received steroids and your rash improved.\r\n\r\nWHAT SHOULD YOU DO AT HOME?\r\n-Please take your steroids as directed\r\n-Continue to use triamcinolone (steroid) cream on your BODY only\r\n-Continue to use hydrocortisone (steroid) cream on your FACE\r\n-Take your cyclosporine and prophylactic medications as directed\r\n-Follow-up with your primary oncologist and dermatologist\r\n\r\nThank you for allowing us be involved in your care, we wish you \r\nall the best!\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-25:3",
      "text": "Physical Exam:\nADMISSION EXAM\n==========================\nVS: 98.4 PO 134 / 69 L Sitting 90 18 98 RA \nGENERAL: Well- appearing lady, in no distress lying in bed\ncomfortably. HEENT: Anicteric, PERLL, Mucous membranes moist, oropharynx\nclear. CARDIAC: Regular rate and rhythm, no murmurs, rubs or gallops. LUNG: Appears in no respiratory distress, clear to auscultation\nbilaterally, no crackles, wheezes, or rhonchi. ABD: Non-distended, normal bowel sounds, soft, non-tender, no\nguarding, no palpable masses, no organomegaly. EXT: Warm, well perfused. No lower extremity edema. No\ntenderness. NEURO: Alert and oriented, good attention,  linear thought\nprocess. CN II-XII intact. Strength full throughout. Sensation \nto\nlight touch intact. SKIN: Patchy erythrodermic erythematous rash. DISCHARGE EXAM\n==========================\nVITALS: 98.6 128/72 93 20 97 Ra \nGENERAL: NAD, sitting comfortably in chair \nHEENT: strabismus, right ptosis, anicteric, oropharynx clear\nCV: RRR, S1/S2, no m/r/g\nPULM: unlabored, CTAB\nGI: obese, soft, normoactive, nondistended, nontender, no\nrebound/guarding\nEXT: WWP, trace distal leg edema\nSKIN: erythema and scaling nearly resolved\n \nPertinent Results:\nPERTIENT STUDIES\n=============================\n___ Pathology Tissue: SKIN, LEVELS X4 ON 2 SLIDES:\n \nPATHOLOGIC DIAGNOSIS:\nSkin, right abdomen (1A):\nFocal vacuolar interface dermatitis with superficial \nperivascular lymphocytic inflammation, apoptotic\nkeratinocytes and lymphocyte exocytosis (see note). Note: The histopathologic findings are favored to represent \ngraft-versus-host disease. Less likely,\nthe differential diagnosis includes a drug eruption. Sections \nshow superficial perivascular\nlymphocytic inflammation with exocytosis of lymphocytes into the \nepidermis. There are scattered\napoptotic keratinocytes, some with satellite cell necrosis. Focal parakeratosis is present. Epidermal\ndysmaturation is seen which may be related to prior \nchemotherapeutic agents. No fungi are seen on\nPAS stain. Initial and multiple additional levels were examined.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-25",
        "chart_time": "104834",
        "section": "General",
        "position": 3,
        "tokenCount": 510,
        "note_metadata": {
          "note_id": "18887130-DS-25",
          "subject_id": 18887130,
          "hadm_id": 24673826,
          "note_type": "DS",
          "note_seq": 25,
          "charttime": 104834,
          "storetime": 104834.66319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nrash, diarrhea\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nMrs. ___ is a ___ year-old lady with a history of DLBCL\r\n(tr.follicular) ___ alloSCT c/b MDS who presents with worsening\r\nerythrodermic rash and diarrhea. \r\n\r\nOver the past 3 weeks she has developed a new erythematous rash\r\nthat has been extending throughout her body and is new\r\neythrodermic. She has a biopsy on ___ favoring GVHD vs. drug\r\neruption prompting course of prednisone 20mg without \r\nimprovement.\r\nYesterday she had 4 episodes of non-bloody non-mucoid diarrhea\r\nprompting call to her oncologist's office who referred her to \r\nED.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n==========================\r\nVS: 98.4 PO 134 / 69 L Sitting 90 18 98 RA \r\nGENERAL: Well- appearing lady, in no distress lying in bed\r\ncomfortably.\r\nHEENT: Anicteric, PERLL, Mucous membranes moist, oropharynx\r\nclear.\r\nCARDIAC: Regular rate and rhythm, no murmurs, rubs or gallops.\r\nLUNG: Appears in no respiratory distress, clear to auscultation\r\nbilaterally, no crackles, wheezes, or rhonchi.\r\nABD: Non-distended, normal bowel sounds, soft, non-tender, no\r\nguarding, no palpable masses, no organomegaly.\r\nEXT: Warm, well perfused. No lower extremity edema. No\r\ntenderness.\r\nNEURO: Alert and oriented, good attention,  linear thought\r\nprocess. CN II-XII intact. Strength full throughout. Sensation \r\nto\r\nlight touch intact.\r\nSKIN: Patchy erythrodermic erythematous rash. \r\n \r\nDISCHARGE EXAM\r\n==========================\r\nVITALS: 98.6 128/72 93 20 97 Ra \r\nGENERAL: NAD, sitting comfortably in chair \r\nHEENT: strabismus, right ptosis, anicteric, oropharynx clear\r\nCV: RRR, S1/S2, no m/r/g\r\nPULM: unlabored, CTAB\r\nGI: obese, soft, normoactive, nondistended, nontender, no\r\nrebound/guarding\r\nEXT: WWP, trace distal leg edema\r\nSKIN: erythema and scaling nearly resolved\r\n \r\nPertinent Results:\r\nPERTIENT STUDIES\r\n=============================\r\n___ Pathology Tissue: SKIN, LEVELS X4 ON 2 SLIDES:\r\n \r\nPATHOLOGIC DIAGNOSIS:\r\nSkin, right abdomen (1A):\r\nFocal vacuolar interface dermatitis with superficial \r\nperivascular lymphocytic inflammation, apoptotic\r\nkeratinocytes and lymphocyte exocytosis (see note).\r\nNote: The histopathologic findings are favored to represent \r\ngraft-versus-host disease. Less likely,\r\nthe differential diagnosis includes a drug eruption. Sections \r\nshow superficial perivascular\r\nlymphocytic inflammation with exocytosis of lymphocytes into the \r\nepidermis. There are scattered\r\napoptotic keratinocytes, some with satellite cell necrosis. \r\nFocal parakeratosis is present. Epidermal\r\ndysmaturation is seen which may be related to prior \r\nchemotherapeutic agents. No fungi are seen on\r\nPAS stain. Initial and multiple additional levels were examined.\r\n \r\nADMISSION LABS\r\n=============================\r\n___ 04:00PM BLOOD WBC-6.0 RBC-3.49* Hgb-12.3 Hct-37.5 \r\nMCV-107* MCH-35.2* MCHC-32.8 RDW-15.3 RDWSD-61.2* Plt ___\r\n___ 04:00PM BLOOD Neuts-85.0* Lymphs-10.4* Monos-3.2* \r\nEos-0.3* Baso-0.3 Im ___ AbsNeut-5.12# AbsLymp-0.63* \r\nAbsMono-0.19* AbsEos-0.02* AbsBaso-0.02\r\n___ 04:00PM BLOOD ___ PTT-33.4 ___\r\n___ 04:00PM BLOOD Glucose-103* UreaN-23* Creat-1.2* Na-140 \r\nK-4.6 Cl-104 HCO3-23 AnGap-13\r\n___ 04:00PM BLOOD ALT-32 AST-25 AlkPhos-124* TotBili-0.3\r\n___ 04:00PM BLOOD Albumin-3.9 Calcium-8.6 Phos-3.0 Mg-2.0\r\n___ 04:17PM BLOOD Lactate-1.8\r\n___ 06:35PM URINE Color-Straw Appear-Clear Sp ___\r\n___ 06:35PM URINE Blood-NEG Nitrite-NEG Protein-30* \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 06:35PM URINE RBC-<1 WBC-4 Bacteri-FEW* Yeast-NONE \r\nEpi-<1\r\n___ 06:35PM URINE\r\n___ 06:35PM URINE Hours-RANDOM\r\n \r\nPERTINENT LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 03:20PM BLOOD Glucose-175* UreaN-33* Creat-1.4* Na-139 \r\nK-5.7* Cl-105 HCO3-24 AnGap-10\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 09:20AM BLOOD Cyclspr-58*\r\n___ 09:40AM BLOOD Cyclspr-51*\r\n___ 07:00AM BLOOD CMV VL-NOT DETECT\r\n \r\nDISCHARGE LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 01:45AM BLOOD Neuts-78.2* Lymphs-12.5* Monos-7.4 \r\nEos-0.0* Baso-0.1 NRBC-0.2* Im ___ AbsNeut-7.22* \r\nAbsLymp-1.15* AbsMono-0.68 AbsEos-0.00* AbsBaso-0.01\r\n___ 01:45AM BLOOD Plt ___\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 01:45AM BLOOD ALT-30 AST-23 LD(LDH)-205 AlkPhos-112* \r\nTotBili-0.2\r\n___ 01:45AM BLOOD Calcium-8.3* Phos-3.9 Mg-2.0\r\n \r\nPERTINENT MICRO\r\n=============================\r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n \r\n\r\n \r\n \r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Final ___:    NO CYCLOSPORA SEEN. \r\n\r\n   FECAL CULTURE (Final ___:    NO SALMONELLA OR SHIGELLA \r\nFOUND. \r\n\r\n   CAMPYLOBACTER CULTURE (Final ___:    NO CAMPYLOBACTER \r\nFOUND. \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   FECAL CULTURE - R/O VIBRIO (Final ___:    NO VIBRIO \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O YERSINIA (Final ___:    NO YERSINIA \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O E.COLI 0157:H7 (Final ___: \r\n      No E. coli O157:H7 found. \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n \r\nBrief Hospital Course:\r\n___ female with history of diffuse large B-cell lymphoma \r\ncomplicated by secondary myelodysplastic syndrome status-post \r\nallogeneic stem cell transplant complicated by combined variable \r\nimmunodeficiency status-post IVIG, CMV viremia status-post \r\nganciclovir/valganciclovir and S. epidermidis bactermia \r\nstatus-post daptomycin, new deep venous thrombosis, on Lovenox, \r\nand recent biopsy-proven acute skin graft-versus-host disease, \r\non triamcinolone / prednisone, admitted for (1) worsening skin \r\nerythema, which resolved with high-dose corticosteroids and (2) \r\ndiarrhea, which spontaneously resolved upon admission.\r\n\r\n#) Skin graft-versus-host disease, acute, grade III: punch \r\nbiopsy (___) favoring GvHD versus drug eruption. Acute \r\nworsening of generalized eryhtroderma with xerosis/desquamation \r\nin days preceding admission despite use of \r\ntriamcinolone/prednisone. No cellulitic changes. Erythema \r\nregressed with five-day course of methylprednisolone 1 mg/kg in \r\ncombination with topical triamcinolone 0.1%/hydrocortisone 1% \r\n(face), which was converted to prednisone 100 -> 80 mg daily \r\nthereafter. Further taper plan to be determined as outpatient. \r\nHydroxyzine, Sarna, and emollients added for symptomatic care.\r\n\r\n#) Diarrhea, non-bloody: concern for acute gut GvHD, though \r\nspontaneously resolved prior to start of high-dose \r\ncorticosteroids. Of note, recent protracted antibiotic course, \r\nthough C. difficile negative. CMV viral load and stool studies \r\nlikewise negative. Stool volume normal throughout duration of \r\nhospital course. Flexible sigmoidoscopy not pursued in that \r\nregard.\r\n\r\n#) ___: Cr bumped to 1.4 shortly prior to discharge. Unclear \r\netiology though most suspicious for cyclosporine effect vs. \r\nhypovolemia. Non-fluid responsive to 1L bolus; urine studies \r\nwith intrinsic renal picture. Spontaneously resolved within 24 \r\nh. Of note, given fluid bolus in setting of HFrEF and concurrent \r\nsteroids patient was mildly volume overloaded at time of \r\ndischarge. No shortness of breath; O2 saturation normal. \r\nDischarged with 20 mg PO Lasix.\r\n\r\n#) DLBCL c/b secondary MDS ___ MUD allogeneic SCT, in remission: \r\n100% chimerism ___ surveillance bone marrow biopsy with \r\nnormal trilineage maturation. DLBCL also in remission by \r\nsurveillance CT. Complications, as delineated above. \r\nCyclosporine as well as acyclovir, fluconazole, and TMP/SMX all \r\ncontinued. \r\n\r\n#) Hyperkalemia, mild: suspect iatrogenic secondary to \r\ncyclosporine and TMP/SMX. \r\n\r\nCHRONIC/STABLE ISSUES\r\n==============================\r\n\r\n#) DVT, bilateral lower extremity: on therapeutic Lovenox, as of \r\n___. Of note, ___ IVC filter (___) for prior DVT. Lovenox 80 \r\nmg SC Q12H continued. \r\n\r\n#) ICA cavernous sinus aneurysm, right: ___ coil embolization \r\nc/b CN VI palsy, ptosis, V1 hyperesthesia. Home gabapentin \r\ncontinued. \r\n\r\n#) GERD: home omeprazole continued.\r\n\r\n#) OSA: nocturnal CPAP\r\n\r\nTRANSITIONAL ISSUES\r\n===============================\r\n [ ] Discharged on prednisone 80 mg daily. Please arrange for \r\ntaper as outpatient.\r\n\r\n [ ] Mildly volume overloaded at time of discharge due to \r\nconcurrent steroids and fluids with history of CHF. No shortness \r\nof breath; O2 saturation normal. Discharged with 20 mg PO Lasix. \r\nPlease increase or discontinue as needed.\r\n\r\n [ ] Monitor ongoing use of topical steroids and ensure \r\ndiscontinued after appropriate treatment course completed.\r\n\r\n [ ] Discharged on cyclosporine 50 mg q12 hours. Please monitor \r\nlevels and dose-adjust as needed.\r\n\r\n [ ] Prophylactic fluconazole increased to 400 mg daily.\r\n\r\n [ ] Vitamin D added for skeletal protection.\r\n\r\n#CODE: full (presumed)\r\n#CONTACT: ___ (daughter: ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 4 mg PO Q8H:PRN nausea \r\n2. PredniSONE 20 mg PO DAILY \r\n3. Magnesium Oxide 400 mg PO DAILY \r\n4. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Senna 8.6 mg PO BID:PRN constipation \r\n7. Cephalexin ___ mg PO PRN dental procedure \r\n8. Enoxaparin Sodium 80 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\n9. CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\n10. Acyclovir 400 mg PO Q8H \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. FoLIC Acid 1.6 mg PO DAILY \r\n14. Gabapentin 400 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Furosemide 20 mg PO DAILY \r\nRX *furosemide 20 mg 1 tablet(s) by mouth daily Disp #*14 Tablet \r\nRefills:*0 \r\n2.  Hydrocortisone Cream 1% 1 Appl TP BID \r\nRX *hydrocortisone 1 % apply as directed twice daily Refills:*0 \r\n3.  HydrOXYzine 25 mg PO QHS:PRN Itching \r\nRX *hydroxyzine HCl 25 mg 1 tablet by mouth at night Disp #*30 \r\nTablet Refills:*0 \r\n4.  Ketoconazole Shampoo 1 Appl TP BID \r\nRX *ketoconazole 2 % apply as directed twice daily Refills:*0 \r\n5.  Sarna Lotion 1 Appl TP QID:PRN Itching \r\nRX *camphor-menthol [Sarna Anti-Itch] 0.5 %-0.5 % apply as \r\ndirected four times daily Refills:*0 \r\n6.  Vitamin D 1000 UNIT PO DAILY \r\nRX *ergocalciferol (vitamin D2) 2,000 unit 1 tablet(s) by mouth \r\ndaily Disp #*30 Tablet Refills:*0 \r\n7.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n8.  PredniSONE 80 mg PO DAILY \r\nRX *prednisone 20 mg 4 tablet(s) by mouth daily Disp #*28 Tablet \r\nRefills:*0 \r\n9.  Acyclovir 400 mg PO Q8H  \r\n10.  Cephalexin ___ mg PO PRN dental procedure  \r\n11.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H  \r\n12.  Enoxaparin Sodium 80 mg SC Q12H  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  Magnesium Oxide 400 mg PO DAILY  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Senna 8.6 mg PO BID:PRN constipation  \r\n19.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n20.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY\r\n-Skin graft-versus-host-disease, acute \r\n\r\nSECONDARY\r\n-MDS, secondary \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___!\r\n\r\nWHY WERE YOU ADMITTED?\r\n-You had worsening graft-versus-host-disease of your skin.\r\n-You had diarrhea.\r\n\r\nWHAT HAPPENED IN THE HOSPITAL?\r\n-You received steroids and your rash improved.\r\n\r\nWHAT SHOULD YOU DO AT HOME?\r\n-Please take your steroids as directed\r\n-Continue to use triamcinolone (steroid) cream on your BODY only\r\n-Continue to use hydrocortisone (steroid) cream on your FACE\r\n-Take your cyclosporine and prophylactic medications as directed\r\n-Follow-up with your primary oncologist and dermatologist\r\n\r\nThank you for allowing us be involved in your care, we wish you \r\nall the best!\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-25:4",
      "text": "Note: The histopathologic findings are favored to represent \ngraft-versus-host disease. Less likely,\nthe differential diagnosis includes a drug eruption. Sections \nshow superficial perivascular\nlymphocytic inflammation with exocytosis of lymphocytes into the \nepidermis. There are scattered\napoptotic keratinocytes, some with satellite cell necrosis. Focal parakeratosis is present. Epidermal\ndysmaturation is seen which may be related to prior \nchemotherapeutic agents. No fungi are seen on\nPAS stain. Initial and multiple additional levels were examined. ADMISSION LABS\n=============================\n___ 04:00PM BLOOD WBC-6.0 RBC-3.49* Hgb-12.3 Hct-37.5 \nMCV-107* MCH-35.2* MCHC-32.8 RDW-15.3 RDWSD-61.2* Plt ___\n___ 04:00PM BLOOD Neuts-85.0* Lymphs-10.4* Monos-3.2* \nEos-0.3* Baso-0.3 Im ___ AbsNeut-5.12# AbsLymp-0.63* \nAbsMono-0.19* AbsEos-0.02* AbsBaso-0.02\n___ 04:00PM BLOOD ___ PTT-33.4 ___\n___ 04:00PM BLOOD Glucose-103* UreaN-23* Creat-1.2* Na-140 \nK-4.6 Cl-104 HCO3-23 AnGap-13\n___ 04:00PM BLOOD ALT-32 AST-25 AlkPhos-124* TotBili-0.3\n___ 04:00PM BLOOD Albumin-3.9 Calcium-8.6 Phos-3.0 Mg-2.0\n___ 04:17PM BLOOD Lactate-1.8\n___ 06:35PM URINE Color-Straw Appear-Clear Sp ___\n___ 06:35PM URINE Blood-NEG Nitrite-NEG Protein-30* \nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\n___ 06:35PM URINE RBC-<1 WBC-4 Bacteri-FEW* Yeast-NONE \nEpi-<1\n___ 06:35PM URINE\n___ 06:35PM URINE Hours-RANDOM\n \nPERTINENT LABS\n=============================\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\n___ 03:20PM BLOOD Glucose-175* UreaN-33* Creat-1.4* Na-139 \nK-5.7* Cl-105 HCO3-24 AnGap-10\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \nK-4.7 Cl-107 HCO3-24 AnGap-9*\n___ 09:20AM BLOOD Cyclspr-58*\n___ 09:40AM BLOOD Cyclspr-51*\n___ 07:00AM BLOOD CMV VL-NOT DETECT\n \nDISCHARGE LABS\n=============================\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\n___ 01:45AM BLOOD Neuts-78.2* Lymphs-12.5* Monos-7.4 \nEos-0.0* Baso-0.1 NRBC-0.2* Im ___ AbsNeut-7.22* \nAbsLymp-1.15* AbsMono-0.68 AbsEos-0.00* AbsBaso-0.01\n___ 01:45AM BLOOD Plt ___\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \nK-4.7 Cl-107 HCO3-24 AnGap-9*\n___ 01:45AM BLOOD ALT-30 AST-23 LD(LDH)-205 AlkPhos-112* \nTotBili-0.2\n___ 01:45AM BLOOD Calcium-8.3* Phos-3.9 Mg-2.0\n \nPERTINENT MICRO\n=============================\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\n      Source: Stool. **FINAL REPORT ___ C. difficile DNA amplification assay (Final ___: \n      Negative for toxigenic C. difficile by the Cepheid nucleic \nacid\n      amplification assay.. (Reference Range-Negative). ___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\n      Source: Stool.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-25",
        "chart_time": "104834",
        "section": "General",
        "position": 4,
        "tokenCount": 697,
        "note_metadata": {
          "note_id": "18887130-DS-25",
          "subject_id": 18887130,
          "hadm_id": 24673826,
          "note_type": "DS",
          "note_seq": 25,
          "charttime": 104834,
          "storetime": 104834.66319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nrash, diarrhea\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nMrs. ___ is a ___ year-old lady with a history of DLBCL\r\n(tr.follicular) ___ alloSCT c/b MDS who presents with worsening\r\nerythrodermic rash and diarrhea. \r\n\r\nOver the past 3 weeks she has developed a new erythematous rash\r\nthat has been extending throughout her body and is new\r\neythrodermic. She has a biopsy on ___ favoring GVHD vs. drug\r\neruption prompting course of prednisone 20mg without \r\nimprovement.\r\nYesterday she had 4 episodes of non-bloody non-mucoid diarrhea\r\nprompting call to her oncologist's office who referred her to \r\nED.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n==========================\r\nVS: 98.4 PO 134 / 69 L Sitting 90 18 98 RA \r\nGENERAL: Well- appearing lady, in no distress lying in bed\r\ncomfortably.\r\nHEENT: Anicteric, PERLL, Mucous membranes moist, oropharynx\r\nclear.\r\nCARDIAC: Regular rate and rhythm, no murmurs, rubs or gallops.\r\nLUNG: Appears in no respiratory distress, clear to auscultation\r\nbilaterally, no crackles, wheezes, or rhonchi.\r\nABD: Non-distended, normal bowel sounds, soft, non-tender, no\r\nguarding, no palpable masses, no organomegaly.\r\nEXT: Warm, well perfused. No lower extremity edema. No\r\ntenderness.\r\nNEURO: Alert and oriented, good attention,  linear thought\r\nprocess. CN II-XII intact. Strength full throughout. Sensation \r\nto\r\nlight touch intact.\r\nSKIN: Patchy erythrodermic erythematous rash. \r\n \r\nDISCHARGE EXAM\r\n==========================\r\nVITALS: 98.6 128/72 93 20 97 Ra \r\nGENERAL: NAD, sitting comfortably in chair \r\nHEENT: strabismus, right ptosis, anicteric, oropharynx clear\r\nCV: RRR, S1/S2, no m/r/g\r\nPULM: unlabored, CTAB\r\nGI: obese, soft, normoactive, nondistended, nontender, no\r\nrebound/guarding\r\nEXT: WWP, trace distal leg edema\r\nSKIN: erythema and scaling nearly resolved\r\n \r\nPertinent Results:\r\nPERTIENT STUDIES\r\n=============================\r\n___ Pathology Tissue: SKIN, LEVELS X4 ON 2 SLIDES:\r\n \r\nPATHOLOGIC DIAGNOSIS:\r\nSkin, right abdomen (1A):\r\nFocal vacuolar interface dermatitis with superficial \r\nperivascular lymphocytic inflammation, apoptotic\r\nkeratinocytes and lymphocyte exocytosis (see note).\r\nNote: The histopathologic findings are favored to represent \r\ngraft-versus-host disease. Less likely,\r\nthe differential diagnosis includes a drug eruption. Sections \r\nshow superficial perivascular\r\nlymphocytic inflammation with exocytosis of lymphocytes into the \r\nepidermis. There are scattered\r\napoptotic keratinocytes, some with satellite cell necrosis. \r\nFocal parakeratosis is present. Epidermal\r\ndysmaturation is seen which may be related to prior \r\nchemotherapeutic agents. No fungi are seen on\r\nPAS stain. Initial and multiple additional levels were examined.\r\n \r\nADMISSION LABS\r\n=============================\r\n___ 04:00PM BLOOD WBC-6.0 RBC-3.49* Hgb-12.3 Hct-37.5 \r\nMCV-107* MCH-35.2* MCHC-32.8 RDW-15.3 RDWSD-61.2* Plt ___\r\n___ 04:00PM BLOOD Neuts-85.0* Lymphs-10.4* Monos-3.2* \r\nEos-0.3* Baso-0.3 Im ___ AbsNeut-5.12# AbsLymp-0.63* \r\nAbsMono-0.19* AbsEos-0.02* AbsBaso-0.02\r\n___ 04:00PM BLOOD ___ PTT-33.4 ___\r\n___ 04:00PM BLOOD Glucose-103* UreaN-23* Creat-1.2* Na-140 \r\nK-4.6 Cl-104 HCO3-23 AnGap-13\r\n___ 04:00PM BLOOD ALT-32 AST-25 AlkPhos-124* TotBili-0.3\r\n___ 04:00PM BLOOD Albumin-3.9 Calcium-8.6 Phos-3.0 Mg-2.0\r\n___ 04:17PM BLOOD Lactate-1.8\r\n___ 06:35PM URINE Color-Straw Appear-Clear Sp ___\r\n___ 06:35PM URINE Blood-NEG Nitrite-NEG Protein-30* \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 06:35PM URINE RBC-<1 WBC-4 Bacteri-FEW* Yeast-NONE \r\nEpi-<1\r\n___ 06:35PM URINE\r\n___ 06:35PM URINE Hours-RANDOM\r\n \r\nPERTINENT LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 03:20PM BLOOD Glucose-175* UreaN-33* Creat-1.4* Na-139 \r\nK-5.7* Cl-105 HCO3-24 AnGap-10\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 09:20AM BLOOD Cyclspr-58*\r\n___ 09:40AM BLOOD Cyclspr-51*\r\n___ 07:00AM BLOOD CMV VL-NOT DETECT\r\n \r\nDISCHARGE LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 01:45AM BLOOD Neuts-78.2* Lymphs-12.5* Monos-7.4 \r\nEos-0.0* Baso-0.1 NRBC-0.2* Im ___ AbsNeut-7.22* \r\nAbsLymp-1.15* AbsMono-0.68 AbsEos-0.00* AbsBaso-0.01\r\n___ 01:45AM BLOOD Plt ___\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 01:45AM BLOOD ALT-30 AST-23 LD(LDH)-205 AlkPhos-112* \r\nTotBili-0.2\r\n___ 01:45AM BLOOD Calcium-8.3* Phos-3.9 Mg-2.0\r\n \r\nPERTINENT MICRO\r\n=============================\r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n \r\n\r\n \r\n \r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Final ___:    NO CYCLOSPORA SEEN. \r\n\r\n   FECAL CULTURE (Final ___:    NO SALMONELLA OR SHIGELLA \r\nFOUND. \r\n\r\n   CAMPYLOBACTER CULTURE (Final ___:    NO CAMPYLOBACTER \r\nFOUND. \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   FECAL CULTURE - R/O VIBRIO (Final ___:    NO VIBRIO \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O YERSINIA (Final ___:    NO YERSINIA \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O E.COLI 0157:H7 (Final ___: \r\n      No E. coli O157:H7 found. \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n \r\nBrief Hospital Course:\r\n___ female with history of diffuse large B-cell lymphoma \r\ncomplicated by secondary myelodysplastic syndrome status-post \r\nallogeneic stem cell transplant complicated by combined variable \r\nimmunodeficiency status-post IVIG, CMV viremia status-post \r\nganciclovir/valganciclovir and S. epidermidis bactermia \r\nstatus-post daptomycin, new deep venous thrombosis, on Lovenox, \r\nand recent biopsy-proven acute skin graft-versus-host disease, \r\non triamcinolone / prednisone, admitted for (1) worsening skin \r\nerythema, which resolved with high-dose corticosteroids and (2) \r\ndiarrhea, which spontaneously resolved upon admission.\r\n\r\n#) Skin graft-versus-host disease, acute, grade III: punch \r\nbiopsy (___) favoring GvHD versus drug eruption. Acute \r\nworsening of generalized eryhtroderma with xerosis/desquamation \r\nin days preceding admission despite use of \r\ntriamcinolone/prednisone. No cellulitic changes. Erythema \r\nregressed with five-day course of methylprednisolone 1 mg/kg in \r\ncombination with topical triamcinolone 0.1%/hydrocortisone 1% \r\n(face), which was converted to prednisone 100 -> 80 mg daily \r\nthereafter. Further taper plan to be determined as outpatient. \r\nHydroxyzine, Sarna, and emollients added for symptomatic care.\r\n\r\n#) Diarrhea, non-bloody: concern for acute gut GvHD, though \r\nspontaneously resolved prior to start of high-dose \r\ncorticosteroids. Of note, recent protracted antibiotic course, \r\nthough C. difficile negative. CMV viral load and stool studies \r\nlikewise negative. Stool volume normal throughout duration of \r\nhospital course. Flexible sigmoidoscopy not pursued in that \r\nregard.\r\n\r\n#) ___: Cr bumped to 1.4 shortly prior to discharge. Unclear \r\netiology though most suspicious for cyclosporine effect vs. \r\nhypovolemia. Non-fluid responsive to 1L bolus; urine studies \r\nwith intrinsic renal picture. Spontaneously resolved within 24 \r\nh. Of note, given fluid bolus in setting of HFrEF and concurrent \r\nsteroids patient was mildly volume overloaded at time of \r\ndischarge. No shortness of breath; O2 saturation normal. \r\nDischarged with 20 mg PO Lasix.\r\n\r\n#) DLBCL c/b secondary MDS ___ MUD allogeneic SCT, in remission: \r\n100% chimerism ___ surveillance bone marrow biopsy with \r\nnormal trilineage maturation. DLBCL also in remission by \r\nsurveillance CT. Complications, as delineated above. \r\nCyclosporine as well as acyclovir, fluconazole, and TMP/SMX all \r\ncontinued. \r\n\r\n#) Hyperkalemia, mild: suspect iatrogenic secondary to \r\ncyclosporine and TMP/SMX. \r\n\r\nCHRONIC/STABLE ISSUES\r\n==============================\r\n\r\n#) DVT, bilateral lower extremity: on therapeutic Lovenox, as of \r\n___. Of note, ___ IVC filter (___) for prior DVT. Lovenox 80 \r\nmg SC Q12H continued. \r\n\r\n#) ICA cavernous sinus aneurysm, right: ___ coil embolization \r\nc/b CN VI palsy, ptosis, V1 hyperesthesia. Home gabapentin \r\ncontinued. \r\n\r\n#) GERD: home omeprazole continued.\r\n\r\n#) OSA: nocturnal CPAP\r\n\r\nTRANSITIONAL ISSUES\r\n===============================\r\n [ ] Discharged on prednisone 80 mg daily. Please arrange for \r\ntaper as outpatient.\r\n\r\n [ ] Mildly volume overloaded at time of discharge due to \r\nconcurrent steroids and fluids with history of CHF. No shortness \r\nof breath; O2 saturation normal. Discharged with 20 mg PO Lasix. \r\nPlease increase or discontinue as needed.\r\n\r\n [ ] Monitor ongoing use of topical steroids and ensure \r\ndiscontinued after appropriate treatment course completed.\r\n\r\n [ ] Discharged on cyclosporine 50 mg q12 hours. Please monitor \r\nlevels and dose-adjust as needed.\r\n\r\n [ ] Prophylactic fluconazole increased to 400 mg daily.\r\n\r\n [ ] Vitamin D added for skeletal protection.\r\n\r\n#CODE: full (presumed)\r\n#CONTACT: ___ (daughter: ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 4 mg PO Q8H:PRN nausea \r\n2. PredniSONE 20 mg PO DAILY \r\n3. Magnesium Oxide 400 mg PO DAILY \r\n4. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Senna 8.6 mg PO BID:PRN constipation \r\n7. Cephalexin ___ mg PO PRN dental procedure \r\n8. Enoxaparin Sodium 80 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\n9. CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\n10. Acyclovir 400 mg PO Q8H \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. FoLIC Acid 1.6 mg PO DAILY \r\n14. Gabapentin 400 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Furosemide 20 mg PO DAILY \r\nRX *furosemide 20 mg 1 tablet(s) by mouth daily Disp #*14 Tablet \r\nRefills:*0 \r\n2.  Hydrocortisone Cream 1% 1 Appl TP BID \r\nRX *hydrocortisone 1 % apply as directed twice daily Refills:*0 \r\n3.  HydrOXYzine 25 mg PO QHS:PRN Itching \r\nRX *hydroxyzine HCl 25 mg 1 tablet by mouth at night Disp #*30 \r\nTablet Refills:*0 \r\n4.  Ketoconazole Shampoo 1 Appl TP BID \r\nRX *ketoconazole 2 % apply as directed twice daily Refills:*0 \r\n5.  Sarna Lotion 1 Appl TP QID:PRN Itching \r\nRX *camphor-menthol [Sarna Anti-Itch] 0.5 %-0.5 % apply as \r\ndirected four times daily Refills:*0 \r\n6.  Vitamin D 1000 UNIT PO DAILY \r\nRX *ergocalciferol (vitamin D2) 2,000 unit 1 tablet(s) by mouth \r\ndaily Disp #*30 Tablet Refills:*0 \r\n7.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n8.  PredniSONE 80 mg PO DAILY \r\nRX *prednisone 20 mg 4 tablet(s) by mouth daily Disp #*28 Tablet \r\nRefills:*0 \r\n9.  Acyclovir 400 mg PO Q8H  \r\n10.  Cephalexin ___ mg PO PRN dental procedure  \r\n11.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H  \r\n12.  Enoxaparin Sodium 80 mg SC Q12H  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  Magnesium Oxide 400 mg PO DAILY  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Senna 8.6 mg PO BID:PRN constipation  \r\n19.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n20.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY\r\n-Skin graft-versus-host-disease, acute \r\n\r\nSECONDARY\r\n-MDS, secondary \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___!\r\n\r\nWHY WERE YOU ADMITTED?\r\n-You had worsening graft-versus-host-disease of your skin.\r\n-You had diarrhea.\r\n\r\nWHAT HAPPENED IN THE HOSPITAL?\r\n-You received steroids and your rash improved.\r\n\r\nWHAT SHOULD YOU DO AT HOME?\r\n-Please take your steroids as directed\r\n-Continue to use triamcinolone (steroid) cream on your BODY only\r\n-Continue to use hydrocortisone (steroid) cream on your FACE\r\n-Take your cyclosporine and prophylactic medications as directed\r\n-Follow-up with your primary oncologist and dermatologist\r\n\r\nThank you for allowing us be involved in your care, we wish you \r\nall the best!\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-25:5",
      "text": "**FINAL REPORT ___ C. difficile DNA amplification assay (Final ___: \n      Negative for toxigenic C. difficile by the Cepheid nucleic \nacid\n      amplification assay.. (Reference Range-Negative). ___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\n      Source: Stool. **FINAL REPORT ___ MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \nSEEN. CYCLOSPORA STAIN (Final ___:    NO CYCLOSPORA SEEN. FECAL CULTURE (Final ___:    NO SALMONELLA OR SHIGELLA \nFOUND. CAMPYLOBACTER CULTURE (Final ___:    NO CAMPYLOBACTER \nFOUND. OVA + PARASITES (Final ___: \n      NO OVA AND PARASITES SEEN. This test does not reliably detect Cryptosporidium, \nCyclospora or\n      Microsporidium. While most cases of Giardia are detected \nby routine\n      O+P, the Giardia antigen test may enhance detection when \norganisms\n      are rare. FECAL CULTURE - R/O VIBRIO (Final ___:    NO VIBRIO \nFOUND. FECAL CULTURE - R/O YERSINIA (Final ___:    NO YERSINIA \nFOUND. FECAL CULTURE - R/O E.COLI 0157:H7 (Final ___: \n      No E. coli O157:H7 found. Cryptosporidium/Giardia (DFA) (Final ___: \n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-25",
        "chart_time": "104834",
        "section": "General",
        "position": 5,
        "tokenCount": 277,
        "note_metadata": {
          "note_id": "18887130-DS-25",
          "subject_id": 18887130,
          "hadm_id": 24673826,
          "note_type": "DS",
          "note_seq": 25,
          "charttime": 104834,
          "storetime": 104834.66319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nrash, diarrhea\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nMrs. ___ is a ___ year-old lady with a history of DLBCL\r\n(tr.follicular) ___ alloSCT c/b MDS who presents with worsening\r\nerythrodermic rash and diarrhea. \r\n\r\nOver the past 3 weeks she has developed a new erythematous rash\r\nthat has been extending throughout her body and is new\r\neythrodermic. She has a biopsy on ___ favoring GVHD vs. drug\r\neruption prompting course of prednisone 20mg without \r\nimprovement.\r\nYesterday she had 4 episodes of non-bloody non-mucoid diarrhea\r\nprompting call to her oncologist's office who referred her to \r\nED.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n==========================\r\nVS: 98.4 PO 134 / 69 L Sitting 90 18 98 RA \r\nGENERAL: Well- appearing lady, in no distress lying in bed\r\ncomfortably.\r\nHEENT: Anicteric, PERLL, Mucous membranes moist, oropharynx\r\nclear.\r\nCARDIAC: Regular rate and rhythm, no murmurs, rubs or gallops.\r\nLUNG: Appears in no respiratory distress, clear to auscultation\r\nbilaterally, no crackles, wheezes, or rhonchi.\r\nABD: Non-distended, normal bowel sounds, soft, non-tender, no\r\nguarding, no palpable masses, no organomegaly.\r\nEXT: Warm, well perfused. No lower extremity edema. No\r\ntenderness.\r\nNEURO: Alert and oriented, good attention,  linear thought\r\nprocess. CN II-XII intact. Strength full throughout. Sensation \r\nto\r\nlight touch intact.\r\nSKIN: Patchy erythrodermic erythematous rash. \r\n \r\nDISCHARGE EXAM\r\n==========================\r\nVITALS: 98.6 128/72 93 20 97 Ra \r\nGENERAL: NAD, sitting comfortably in chair \r\nHEENT: strabismus, right ptosis, anicteric, oropharynx clear\r\nCV: RRR, S1/S2, no m/r/g\r\nPULM: unlabored, CTAB\r\nGI: obese, soft, normoactive, nondistended, nontender, no\r\nrebound/guarding\r\nEXT: WWP, trace distal leg edema\r\nSKIN: erythema and scaling nearly resolved\r\n \r\nPertinent Results:\r\nPERTIENT STUDIES\r\n=============================\r\n___ Pathology Tissue: SKIN, LEVELS X4 ON 2 SLIDES:\r\n \r\nPATHOLOGIC DIAGNOSIS:\r\nSkin, right abdomen (1A):\r\nFocal vacuolar interface dermatitis with superficial \r\nperivascular lymphocytic inflammation, apoptotic\r\nkeratinocytes and lymphocyte exocytosis (see note).\r\nNote: The histopathologic findings are favored to represent \r\ngraft-versus-host disease. Less likely,\r\nthe differential diagnosis includes a drug eruption. Sections \r\nshow superficial perivascular\r\nlymphocytic inflammation with exocytosis of lymphocytes into the \r\nepidermis. There are scattered\r\napoptotic keratinocytes, some with satellite cell necrosis. \r\nFocal parakeratosis is present. Epidermal\r\ndysmaturation is seen which may be related to prior \r\nchemotherapeutic agents. No fungi are seen on\r\nPAS stain. Initial and multiple additional levels were examined.\r\n \r\nADMISSION LABS\r\n=============================\r\n___ 04:00PM BLOOD WBC-6.0 RBC-3.49* Hgb-12.3 Hct-37.5 \r\nMCV-107* MCH-35.2* MCHC-32.8 RDW-15.3 RDWSD-61.2* Plt ___\r\n___ 04:00PM BLOOD Neuts-85.0* Lymphs-10.4* Monos-3.2* \r\nEos-0.3* Baso-0.3 Im ___ AbsNeut-5.12# AbsLymp-0.63* \r\nAbsMono-0.19* AbsEos-0.02* AbsBaso-0.02\r\n___ 04:00PM BLOOD ___ PTT-33.4 ___\r\n___ 04:00PM BLOOD Glucose-103* UreaN-23* Creat-1.2* Na-140 \r\nK-4.6 Cl-104 HCO3-23 AnGap-13\r\n___ 04:00PM BLOOD ALT-32 AST-25 AlkPhos-124* TotBili-0.3\r\n___ 04:00PM BLOOD Albumin-3.9 Calcium-8.6 Phos-3.0 Mg-2.0\r\n___ 04:17PM BLOOD Lactate-1.8\r\n___ 06:35PM URINE Color-Straw Appear-Clear Sp ___\r\n___ 06:35PM URINE Blood-NEG Nitrite-NEG Protein-30* \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 06:35PM URINE RBC-<1 WBC-4 Bacteri-FEW* Yeast-NONE \r\nEpi-<1\r\n___ 06:35PM URINE\r\n___ 06:35PM URINE Hours-RANDOM\r\n \r\nPERTINENT LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 03:20PM BLOOD Glucose-175* UreaN-33* Creat-1.4* Na-139 \r\nK-5.7* Cl-105 HCO3-24 AnGap-10\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 09:20AM BLOOD Cyclspr-58*\r\n___ 09:40AM BLOOD Cyclspr-51*\r\n___ 07:00AM BLOOD CMV VL-NOT DETECT\r\n \r\nDISCHARGE LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 01:45AM BLOOD Neuts-78.2* Lymphs-12.5* Monos-7.4 \r\nEos-0.0* Baso-0.1 NRBC-0.2* Im ___ AbsNeut-7.22* \r\nAbsLymp-1.15* AbsMono-0.68 AbsEos-0.00* AbsBaso-0.01\r\n___ 01:45AM BLOOD Plt ___\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 01:45AM BLOOD ALT-30 AST-23 LD(LDH)-205 AlkPhos-112* \r\nTotBili-0.2\r\n___ 01:45AM BLOOD Calcium-8.3* Phos-3.9 Mg-2.0\r\n \r\nPERTINENT MICRO\r\n=============================\r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n \r\n\r\n \r\n \r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Final ___:    NO CYCLOSPORA SEEN. \r\n\r\n   FECAL CULTURE (Final ___:    NO SALMONELLA OR SHIGELLA \r\nFOUND. \r\n\r\n   CAMPYLOBACTER CULTURE (Final ___:    NO CAMPYLOBACTER \r\nFOUND. \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   FECAL CULTURE - R/O VIBRIO (Final ___:    NO VIBRIO \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O YERSINIA (Final ___:    NO YERSINIA \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O E.COLI 0157:H7 (Final ___: \r\n      No E. coli O157:H7 found. \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n \r\nBrief Hospital Course:\r\n___ female with history of diffuse large B-cell lymphoma \r\ncomplicated by secondary myelodysplastic syndrome status-post \r\nallogeneic stem cell transplant complicated by combined variable \r\nimmunodeficiency status-post IVIG, CMV viremia status-post \r\nganciclovir/valganciclovir and S. epidermidis bactermia \r\nstatus-post daptomycin, new deep venous thrombosis, on Lovenox, \r\nand recent biopsy-proven acute skin graft-versus-host disease, \r\non triamcinolone / prednisone, admitted for (1) worsening skin \r\nerythema, which resolved with high-dose corticosteroids and (2) \r\ndiarrhea, which spontaneously resolved upon admission.\r\n\r\n#) Skin graft-versus-host disease, acute, grade III: punch \r\nbiopsy (___) favoring GvHD versus drug eruption. Acute \r\nworsening of generalized eryhtroderma with xerosis/desquamation \r\nin days preceding admission despite use of \r\ntriamcinolone/prednisone. No cellulitic changes. Erythema \r\nregressed with five-day course of methylprednisolone 1 mg/kg in \r\ncombination with topical triamcinolone 0.1%/hydrocortisone 1% \r\n(face), which was converted to prednisone 100 -> 80 mg daily \r\nthereafter. Further taper plan to be determined as outpatient. \r\nHydroxyzine, Sarna, and emollients added for symptomatic care.\r\n\r\n#) Diarrhea, non-bloody: concern for acute gut GvHD, though \r\nspontaneously resolved prior to start of high-dose \r\ncorticosteroids. Of note, recent protracted antibiotic course, \r\nthough C. difficile negative. CMV viral load and stool studies \r\nlikewise negative. Stool volume normal throughout duration of \r\nhospital course. Flexible sigmoidoscopy not pursued in that \r\nregard.\r\n\r\n#) ___: Cr bumped to 1.4 shortly prior to discharge. Unclear \r\netiology though most suspicious for cyclosporine effect vs. \r\nhypovolemia. Non-fluid responsive to 1L bolus; urine studies \r\nwith intrinsic renal picture. Spontaneously resolved within 24 \r\nh. Of note, given fluid bolus in setting of HFrEF and concurrent \r\nsteroids patient was mildly volume overloaded at time of \r\ndischarge. No shortness of breath; O2 saturation normal. \r\nDischarged with 20 mg PO Lasix.\r\n\r\n#) DLBCL c/b secondary MDS ___ MUD allogeneic SCT, in remission: \r\n100% chimerism ___ surveillance bone marrow biopsy with \r\nnormal trilineage maturation. DLBCL also in remission by \r\nsurveillance CT. Complications, as delineated above. \r\nCyclosporine as well as acyclovir, fluconazole, and TMP/SMX all \r\ncontinued. \r\n\r\n#) Hyperkalemia, mild: suspect iatrogenic secondary to \r\ncyclosporine and TMP/SMX. \r\n\r\nCHRONIC/STABLE ISSUES\r\n==============================\r\n\r\n#) DVT, bilateral lower extremity: on therapeutic Lovenox, as of \r\n___. Of note, ___ IVC filter (___) for prior DVT. Lovenox 80 \r\nmg SC Q12H continued. \r\n\r\n#) ICA cavernous sinus aneurysm, right: ___ coil embolization \r\nc/b CN VI palsy, ptosis, V1 hyperesthesia. Home gabapentin \r\ncontinued. \r\n\r\n#) GERD: home omeprazole continued.\r\n\r\n#) OSA: nocturnal CPAP\r\n\r\nTRANSITIONAL ISSUES\r\n===============================\r\n [ ] Discharged on prednisone 80 mg daily. Please arrange for \r\ntaper as outpatient.\r\n\r\n [ ] Mildly volume overloaded at time of discharge due to \r\nconcurrent steroids and fluids with history of CHF. No shortness \r\nof breath; O2 saturation normal. Discharged with 20 mg PO Lasix. \r\nPlease increase or discontinue as needed.\r\n\r\n [ ] Monitor ongoing use of topical steroids and ensure \r\ndiscontinued after appropriate treatment course completed.\r\n\r\n [ ] Discharged on cyclosporine 50 mg q12 hours. Please monitor \r\nlevels and dose-adjust as needed.\r\n\r\n [ ] Prophylactic fluconazole increased to 400 mg daily.\r\n\r\n [ ] Vitamin D added for skeletal protection.\r\n\r\n#CODE: full (presumed)\r\n#CONTACT: ___ (daughter: ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 4 mg PO Q8H:PRN nausea \r\n2. PredniSONE 20 mg PO DAILY \r\n3. Magnesium Oxide 400 mg PO DAILY \r\n4. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Senna 8.6 mg PO BID:PRN constipation \r\n7. Cephalexin ___ mg PO PRN dental procedure \r\n8. Enoxaparin Sodium 80 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\n9. CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\n10. Acyclovir 400 mg PO Q8H \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. FoLIC Acid 1.6 mg PO DAILY \r\n14. Gabapentin 400 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Furosemide 20 mg PO DAILY \r\nRX *furosemide 20 mg 1 tablet(s) by mouth daily Disp #*14 Tablet \r\nRefills:*0 \r\n2.  Hydrocortisone Cream 1% 1 Appl TP BID \r\nRX *hydrocortisone 1 % apply as directed twice daily Refills:*0 \r\n3.  HydrOXYzine 25 mg PO QHS:PRN Itching \r\nRX *hydroxyzine HCl 25 mg 1 tablet by mouth at night Disp #*30 \r\nTablet Refills:*0 \r\n4.  Ketoconazole Shampoo 1 Appl TP BID \r\nRX *ketoconazole 2 % apply as directed twice daily Refills:*0 \r\n5.  Sarna Lotion 1 Appl TP QID:PRN Itching \r\nRX *camphor-menthol [Sarna Anti-Itch] 0.5 %-0.5 % apply as \r\ndirected four times daily Refills:*0 \r\n6.  Vitamin D 1000 UNIT PO DAILY \r\nRX *ergocalciferol (vitamin D2) 2,000 unit 1 tablet(s) by mouth \r\ndaily Disp #*30 Tablet Refills:*0 \r\n7.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n8.  PredniSONE 80 mg PO DAILY \r\nRX *prednisone 20 mg 4 tablet(s) by mouth daily Disp #*28 Tablet \r\nRefills:*0 \r\n9.  Acyclovir 400 mg PO Q8H  \r\n10.  Cephalexin ___ mg PO PRN dental procedure  \r\n11.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H  \r\n12.  Enoxaparin Sodium 80 mg SC Q12H  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  Magnesium Oxide 400 mg PO DAILY  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Senna 8.6 mg PO BID:PRN constipation  \r\n19.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n20.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY\r\n-Skin graft-versus-host-disease, acute \r\n\r\nSECONDARY\r\n-MDS, secondary \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___!\r\n\r\nWHY WERE YOU ADMITTED?\r\n-You had worsening graft-versus-host-disease of your skin.\r\n-You had diarrhea.\r\n\r\nWHAT HAPPENED IN THE HOSPITAL?\r\n-You received steroids and your rash improved.\r\n\r\nWHAT SHOULD YOU DO AT HOME?\r\n-Please take your steroids as directed\r\n-Continue to use triamcinolone (steroid) cream on your BODY only\r\n-Continue to use hydrocortisone (steroid) cream on your FACE\r\n-Take your cyclosporine and prophylactic medications as directed\r\n-Follow-up with your primary oncologist and dermatologist\r\n\r\nThank you for allowing us be involved in your care, we wish you \r\nall the best!\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-25:6",
      "text": "Brief Hospital Course:\n___ female with history of diffuse large B-cell lymphoma \ncomplicated by secondary myelodysplastic syndrome status-post \nallogeneic stem cell transplant complicated by combined variable \nimmunodeficiency status-post IVIG, CMV viremia status-post \nganciclovir/valganciclovir and S. epidermidis bactermia \nstatus-post daptomycin, new deep venous thrombosis, on Lovenox, \nand recent biopsy-proven acute skin graft-versus-host disease, \non triamcinolone / prednisone, admitted for (1) worsening skin \nerythema, which resolved with high-dose corticosteroids and (2) \ndiarrhea, which spontaneously resolved upon admission. #) Skin graft-versus-host disease, acute, grade III: punch \nbiopsy (___) favoring GvHD versus drug eruption. Acute \nworsening of generalized eryhtroderma with xerosis/desquamation \nin days preceding admission despite use of \ntriamcinolone/prednisone. No cellulitic changes. Erythema \nregressed with five-day course of methylprednisolone 1 mg/kg in \ncombination with topical triamcinolone 0.1%/hydrocortisone 1% \n(face), which was converted to prednisone 100 -> 80 mg daily \nthereafter. Further taper plan to be determined as outpatient. Hydroxyzine, Sarna, and emollients added for symptomatic care. #) Diarrhea, non-bloody: concern for acute gut GvHD, though \nspontaneously resolved prior to start of high-dose \ncorticosteroids. Of note, recent protracted antibiotic course, \nthough C. difficile negative. CMV viral load and stool studies \nlikewise negative. Stool volume normal throughout duration of \nhospital course. Flexible sigmoidoscopy not pursued in that \nregard. #) ___: Cr bumped to 1.4 shortly prior to discharge. Unclear \netiology though most suspicious for cyclosporine effect vs. hypovolemia. Non-fluid responsive to 1L bolus; urine studies \nwith intrinsic renal picture. Spontaneously resolved within 24 \nh. Of note, given fluid bolus in setting of HFrEF and concurrent \nsteroids patient was mildly volume overloaded at time of \ndischarge. No shortness of breath; O2 saturation normal. Discharged with 20 mg PO Lasix. #) DLBCL c/b secondary MDS ___ MUD allogeneic SCT, in remission: \n100% chimerism ___ surveillance bone marrow biopsy with \nnormal trilineage maturation. DLBCL also in remission by \nsurveillance CT. Complications, as delineated above. Cyclosporine as well as acyclovir, fluconazole, and TMP/SMX all \ncontinued. #) Hyperkalemia, mild: suspect iatrogenic secondary to \ncyclosporine and TMP/SMX. CHRONIC/STABLE ISSUES\n============================== #) DVT, bilateral lower extremity: on therapeutic Lovenox, as of \n___. Of note, ___ IVC filter (___) for prior DVT. Lovenox 80 \nmg SC Q12H continued. #) ICA cavernous sinus aneurysm, right: ___ coil embolization \nc/b CN VI palsy, ptosis, V1 hyperesthesia.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-25",
        "chart_time": "104834",
        "section": "General",
        "position": 6,
        "tokenCount": 694,
        "note_metadata": {
          "note_id": "18887130-DS-25",
          "subject_id": 18887130,
          "hadm_id": 24673826,
          "note_type": "DS",
          "note_seq": 25,
          "charttime": 104834,
          "storetime": 104834.66319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nrash, diarrhea\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nMrs. ___ is a ___ year-old lady with a history of DLBCL\r\n(tr.follicular) ___ alloSCT c/b MDS who presents with worsening\r\nerythrodermic rash and diarrhea. \r\n\r\nOver the past 3 weeks she has developed a new erythematous rash\r\nthat has been extending throughout her body and is new\r\neythrodermic. She has a biopsy on ___ favoring GVHD vs. drug\r\neruption prompting course of prednisone 20mg without \r\nimprovement.\r\nYesterday she had 4 episodes of non-bloody non-mucoid diarrhea\r\nprompting call to her oncologist's office who referred her to \r\nED.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n==========================\r\nVS: 98.4 PO 134 / 69 L Sitting 90 18 98 RA \r\nGENERAL: Well- appearing lady, in no distress lying in bed\r\ncomfortably.\r\nHEENT: Anicteric, PERLL, Mucous membranes moist, oropharynx\r\nclear.\r\nCARDIAC: Regular rate and rhythm, no murmurs, rubs or gallops.\r\nLUNG: Appears in no respiratory distress, clear to auscultation\r\nbilaterally, no crackles, wheezes, or rhonchi.\r\nABD: Non-distended, normal bowel sounds, soft, non-tender, no\r\nguarding, no palpable masses, no organomegaly.\r\nEXT: Warm, well perfused. No lower extremity edema. No\r\ntenderness.\r\nNEURO: Alert and oriented, good attention,  linear thought\r\nprocess. CN II-XII intact. Strength full throughout. Sensation \r\nto\r\nlight touch intact.\r\nSKIN: Patchy erythrodermic erythematous rash. \r\n \r\nDISCHARGE EXAM\r\n==========================\r\nVITALS: 98.6 128/72 93 20 97 Ra \r\nGENERAL: NAD, sitting comfortably in chair \r\nHEENT: strabismus, right ptosis, anicteric, oropharynx clear\r\nCV: RRR, S1/S2, no m/r/g\r\nPULM: unlabored, CTAB\r\nGI: obese, soft, normoactive, nondistended, nontender, no\r\nrebound/guarding\r\nEXT: WWP, trace distal leg edema\r\nSKIN: erythema and scaling nearly resolved\r\n \r\nPertinent Results:\r\nPERTIENT STUDIES\r\n=============================\r\n___ Pathology Tissue: SKIN, LEVELS X4 ON 2 SLIDES:\r\n \r\nPATHOLOGIC DIAGNOSIS:\r\nSkin, right abdomen (1A):\r\nFocal vacuolar interface dermatitis with superficial \r\nperivascular lymphocytic inflammation, apoptotic\r\nkeratinocytes and lymphocyte exocytosis (see note).\r\nNote: The histopathologic findings are favored to represent \r\ngraft-versus-host disease. Less likely,\r\nthe differential diagnosis includes a drug eruption. Sections \r\nshow superficial perivascular\r\nlymphocytic inflammation with exocytosis of lymphocytes into the \r\nepidermis. There are scattered\r\napoptotic keratinocytes, some with satellite cell necrosis. \r\nFocal parakeratosis is present. Epidermal\r\ndysmaturation is seen which may be related to prior \r\nchemotherapeutic agents. No fungi are seen on\r\nPAS stain. Initial and multiple additional levels were examined.\r\n \r\nADMISSION LABS\r\n=============================\r\n___ 04:00PM BLOOD WBC-6.0 RBC-3.49* Hgb-12.3 Hct-37.5 \r\nMCV-107* MCH-35.2* MCHC-32.8 RDW-15.3 RDWSD-61.2* Plt ___\r\n___ 04:00PM BLOOD Neuts-85.0* Lymphs-10.4* Monos-3.2* \r\nEos-0.3* Baso-0.3 Im ___ AbsNeut-5.12# AbsLymp-0.63* \r\nAbsMono-0.19* AbsEos-0.02* AbsBaso-0.02\r\n___ 04:00PM BLOOD ___ PTT-33.4 ___\r\n___ 04:00PM BLOOD Glucose-103* UreaN-23* Creat-1.2* Na-140 \r\nK-4.6 Cl-104 HCO3-23 AnGap-13\r\n___ 04:00PM BLOOD ALT-32 AST-25 AlkPhos-124* TotBili-0.3\r\n___ 04:00PM BLOOD Albumin-3.9 Calcium-8.6 Phos-3.0 Mg-2.0\r\n___ 04:17PM BLOOD Lactate-1.8\r\n___ 06:35PM URINE Color-Straw Appear-Clear Sp ___\r\n___ 06:35PM URINE Blood-NEG Nitrite-NEG Protein-30* \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 06:35PM URINE RBC-<1 WBC-4 Bacteri-FEW* Yeast-NONE \r\nEpi-<1\r\n___ 06:35PM URINE\r\n___ 06:35PM URINE Hours-RANDOM\r\n \r\nPERTINENT LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 03:20PM BLOOD Glucose-175* UreaN-33* Creat-1.4* Na-139 \r\nK-5.7* Cl-105 HCO3-24 AnGap-10\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 09:20AM BLOOD Cyclspr-58*\r\n___ 09:40AM BLOOD Cyclspr-51*\r\n___ 07:00AM BLOOD CMV VL-NOT DETECT\r\n \r\nDISCHARGE LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 01:45AM BLOOD Neuts-78.2* Lymphs-12.5* Monos-7.4 \r\nEos-0.0* Baso-0.1 NRBC-0.2* Im ___ AbsNeut-7.22* \r\nAbsLymp-1.15* AbsMono-0.68 AbsEos-0.00* AbsBaso-0.01\r\n___ 01:45AM BLOOD Plt ___\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 01:45AM BLOOD ALT-30 AST-23 LD(LDH)-205 AlkPhos-112* \r\nTotBili-0.2\r\n___ 01:45AM BLOOD Calcium-8.3* Phos-3.9 Mg-2.0\r\n \r\nPERTINENT MICRO\r\n=============================\r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n \r\n\r\n \r\n \r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Final ___:    NO CYCLOSPORA SEEN. \r\n\r\n   FECAL CULTURE (Final ___:    NO SALMONELLA OR SHIGELLA \r\nFOUND. \r\n\r\n   CAMPYLOBACTER CULTURE (Final ___:    NO CAMPYLOBACTER \r\nFOUND. \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   FECAL CULTURE - R/O VIBRIO (Final ___:    NO VIBRIO \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O YERSINIA (Final ___:    NO YERSINIA \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O E.COLI 0157:H7 (Final ___: \r\n      No E. coli O157:H7 found. \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n \r\nBrief Hospital Course:\r\n___ female with history of diffuse large B-cell lymphoma \r\ncomplicated by secondary myelodysplastic syndrome status-post \r\nallogeneic stem cell transplant complicated by combined variable \r\nimmunodeficiency status-post IVIG, CMV viremia status-post \r\nganciclovir/valganciclovir and S. epidermidis bactermia \r\nstatus-post daptomycin, new deep venous thrombosis, on Lovenox, \r\nand recent biopsy-proven acute skin graft-versus-host disease, \r\non triamcinolone / prednisone, admitted for (1) worsening skin \r\nerythema, which resolved with high-dose corticosteroids and (2) \r\ndiarrhea, which spontaneously resolved upon admission.\r\n\r\n#) Skin graft-versus-host disease, acute, grade III: punch \r\nbiopsy (___) favoring GvHD versus drug eruption. Acute \r\nworsening of generalized eryhtroderma with xerosis/desquamation \r\nin days preceding admission despite use of \r\ntriamcinolone/prednisone. No cellulitic changes. Erythema \r\nregressed with five-day course of methylprednisolone 1 mg/kg in \r\ncombination with topical triamcinolone 0.1%/hydrocortisone 1% \r\n(face), which was converted to prednisone 100 -> 80 mg daily \r\nthereafter. Further taper plan to be determined as outpatient. \r\nHydroxyzine, Sarna, and emollients added for symptomatic care.\r\n\r\n#) Diarrhea, non-bloody: concern for acute gut GvHD, though \r\nspontaneously resolved prior to start of high-dose \r\ncorticosteroids. Of note, recent protracted antibiotic course, \r\nthough C. difficile negative. CMV viral load and stool studies \r\nlikewise negative. Stool volume normal throughout duration of \r\nhospital course. Flexible sigmoidoscopy not pursued in that \r\nregard.\r\n\r\n#) ___: Cr bumped to 1.4 shortly prior to discharge. Unclear \r\netiology though most suspicious for cyclosporine effect vs. \r\nhypovolemia. Non-fluid responsive to 1L bolus; urine studies \r\nwith intrinsic renal picture. Spontaneously resolved within 24 \r\nh. Of note, given fluid bolus in setting of HFrEF and concurrent \r\nsteroids patient was mildly volume overloaded at time of \r\ndischarge. No shortness of breath; O2 saturation normal. \r\nDischarged with 20 mg PO Lasix.\r\n\r\n#) DLBCL c/b secondary MDS ___ MUD allogeneic SCT, in remission: \r\n100% chimerism ___ surveillance bone marrow biopsy with \r\nnormal trilineage maturation. DLBCL also in remission by \r\nsurveillance CT. Complications, as delineated above. \r\nCyclosporine as well as acyclovir, fluconazole, and TMP/SMX all \r\ncontinued. \r\n\r\n#) Hyperkalemia, mild: suspect iatrogenic secondary to \r\ncyclosporine and TMP/SMX. \r\n\r\nCHRONIC/STABLE ISSUES\r\n==============================\r\n\r\n#) DVT, bilateral lower extremity: on therapeutic Lovenox, as of \r\n___. Of note, ___ IVC filter (___) for prior DVT. Lovenox 80 \r\nmg SC Q12H continued. \r\n\r\n#) ICA cavernous sinus aneurysm, right: ___ coil embolization \r\nc/b CN VI palsy, ptosis, V1 hyperesthesia. Home gabapentin \r\ncontinued. \r\n\r\n#) GERD: home omeprazole continued.\r\n\r\n#) OSA: nocturnal CPAP\r\n\r\nTRANSITIONAL ISSUES\r\n===============================\r\n [ ] Discharged on prednisone 80 mg daily. Please arrange for \r\ntaper as outpatient.\r\n\r\n [ ] Mildly volume overloaded at time of discharge due to \r\nconcurrent steroids and fluids with history of CHF. No shortness \r\nof breath; O2 saturation normal. Discharged with 20 mg PO Lasix. \r\nPlease increase or discontinue as needed.\r\n\r\n [ ] Monitor ongoing use of topical steroids and ensure \r\ndiscontinued after appropriate treatment course completed.\r\n\r\n [ ] Discharged on cyclosporine 50 mg q12 hours. Please monitor \r\nlevels and dose-adjust as needed.\r\n\r\n [ ] Prophylactic fluconazole increased to 400 mg daily.\r\n\r\n [ ] Vitamin D added for skeletal protection.\r\n\r\n#CODE: full (presumed)\r\n#CONTACT: ___ (daughter: ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 4 mg PO Q8H:PRN nausea \r\n2. PredniSONE 20 mg PO DAILY \r\n3. Magnesium Oxide 400 mg PO DAILY \r\n4. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Senna 8.6 mg PO BID:PRN constipation \r\n7. Cephalexin ___ mg PO PRN dental procedure \r\n8. Enoxaparin Sodium 80 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\n9. CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\n10. Acyclovir 400 mg PO Q8H \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. FoLIC Acid 1.6 mg PO DAILY \r\n14. Gabapentin 400 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Furosemide 20 mg PO DAILY \r\nRX *furosemide 20 mg 1 tablet(s) by mouth daily Disp #*14 Tablet \r\nRefills:*0 \r\n2.  Hydrocortisone Cream 1% 1 Appl TP BID \r\nRX *hydrocortisone 1 % apply as directed twice daily Refills:*0 \r\n3.  HydrOXYzine 25 mg PO QHS:PRN Itching \r\nRX *hydroxyzine HCl 25 mg 1 tablet by mouth at night Disp #*30 \r\nTablet Refills:*0 \r\n4.  Ketoconazole Shampoo 1 Appl TP BID \r\nRX *ketoconazole 2 % apply as directed twice daily Refills:*0 \r\n5.  Sarna Lotion 1 Appl TP QID:PRN Itching \r\nRX *camphor-menthol [Sarna Anti-Itch] 0.5 %-0.5 % apply as \r\ndirected four times daily Refills:*0 \r\n6.  Vitamin D 1000 UNIT PO DAILY \r\nRX *ergocalciferol (vitamin D2) 2,000 unit 1 tablet(s) by mouth \r\ndaily Disp #*30 Tablet Refills:*0 \r\n7.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n8.  PredniSONE 80 mg PO DAILY \r\nRX *prednisone 20 mg 4 tablet(s) by mouth daily Disp #*28 Tablet \r\nRefills:*0 \r\n9.  Acyclovir 400 mg PO Q8H  \r\n10.  Cephalexin ___ mg PO PRN dental procedure  \r\n11.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H  \r\n12.  Enoxaparin Sodium 80 mg SC Q12H  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  Magnesium Oxide 400 mg PO DAILY  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Senna 8.6 mg PO BID:PRN constipation  \r\n19.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n20.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY\r\n-Skin graft-versus-host-disease, acute \r\n\r\nSECONDARY\r\n-MDS, secondary \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___!\r\n\r\nWHY WERE YOU ADMITTED?\r\n-You had worsening graft-versus-host-disease of your skin.\r\n-You had diarrhea.\r\n\r\nWHAT HAPPENED IN THE HOSPITAL?\r\n-You received steroids and your rash improved.\r\n\r\nWHAT SHOULD YOU DO AT HOME?\r\n-Please take your steroids as directed\r\n-Continue to use triamcinolone (steroid) cream on your BODY only\r\n-Continue to use hydrocortisone (steroid) cream on your FACE\r\n-Take your cyclosporine and prophylactic medications as directed\r\n-Follow-up with your primary oncologist and dermatologist\r\n\r\nThank you for allowing us be involved in your care, we wish you \r\nall the best!\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-25:7",
      "text": "DLBCL also in remission by \nsurveillance CT. Complications, as delineated above. Cyclosporine as well as acyclovir, fluconazole, and TMP/SMX all \ncontinued. #) Hyperkalemia, mild: suspect iatrogenic secondary to \ncyclosporine and TMP/SMX. CHRONIC/STABLE ISSUES\n============================== #) DVT, bilateral lower extremity: on therapeutic Lovenox, as of \n___. Of note, ___ IVC filter (___) for prior DVT. Lovenox 80 \nmg SC Q12H continued. #) ICA cavernous sinus aneurysm, right: ___ coil embolization \nc/b CN VI palsy, ptosis, V1 hyperesthesia. Home gabapentin \ncontinued. #) GERD: home omeprazole continued. #) OSA: nocturnal CPAP TRANSITIONAL ISSUES\n===============================\n [ ] Discharged on prednisone 80 mg daily. Please arrange for \ntaper as outpatient. [ ] Mildly volume overloaded at time of discharge due to \nconcurrent steroids and fluids with history of CHF. No shortness \nof breath; O2 saturation normal. Discharged with 20 mg PO Lasix. Please increase or discontinue as needed. [ ] Monitor ongoing use of topical steroids and ensure \ndiscontinued after appropriate treatment course completed. [ ] Discharged on cyclosporine 50 mg q12 hours. Please monitor \nlevels and dose-adjust as needed. [ ] Prophylactic fluconazole increased to 400 mg daily. [ ] Vitamin D added for skeletal protection. #CODE: full (presumed)\n#CONTACT: ___ (daughter: ___\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Ondansetron 4 mg PO Q8H:PRN nausea \n2. PredniSONE 20 mg PO DAILY \n3. Magnesium Oxide 400 mg PO DAILY \n4. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID \n5. Fluconazole 200 mg PO Q24H \n6. Senna 8.6 mg PO BID:PRN constipation \n7. Cephalexin ___ mg PO PRN dental procedure \n8. Enoxaparin Sodium 80 mg SC Q12H \nStart: ___, First Dose: Next Routine Administration Time \n9. CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \n10. Acyclovir 400 mg PO Q8H \n11. Omeprazole 20 mg PO DAILY \n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \n13. FoLIC Acid 1.6 mg PO DAILY \n14. Gabapentin 400 mg PO BID",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-25",
        "chart_time": "104834",
        "section": "General",
        "position": 7,
        "tokenCount": 510,
        "note_metadata": {
          "note_id": "18887130-DS-25",
          "subject_id": 18887130,
          "hadm_id": 24673826,
          "note_type": "DS",
          "note_seq": 25,
          "charttime": 104834,
          "storetime": 104834.66319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nrash, diarrhea\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nMrs. ___ is a ___ year-old lady with a history of DLBCL\r\n(tr.follicular) ___ alloSCT c/b MDS who presents with worsening\r\nerythrodermic rash and diarrhea. \r\n\r\nOver the past 3 weeks she has developed a new erythematous rash\r\nthat has been extending throughout her body and is new\r\neythrodermic. She has a biopsy on ___ favoring GVHD vs. drug\r\neruption prompting course of prednisone 20mg without \r\nimprovement.\r\nYesterday she had 4 episodes of non-bloody non-mucoid diarrhea\r\nprompting call to her oncologist's office who referred her to \r\nED.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n==========================\r\nVS: 98.4 PO 134 / 69 L Sitting 90 18 98 RA \r\nGENERAL: Well- appearing lady, in no distress lying in bed\r\ncomfortably.\r\nHEENT: Anicteric, PERLL, Mucous membranes moist, oropharynx\r\nclear.\r\nCARDIAC: Regular rate and rhythm, no murmurs, rubs or gallops.\r\nLUNG: Appears in no respiratory distress, clear to auscultation\r\nbilaterally, no crackles, wheezes, or rhonchi.\r\nABD: Non-distended, normal bowel sounds, soft, non-tender, no\r\nguarding, no palpable masses, no organomegaly.\r\nEXT: Warm, well perfused. No lower extremity edema. No\r\ntenderness.\r\nNEURO: Alert and oriented, good attention,  linear thought\r\nprocess. CN II-XII intact. Strength full throughout. Sensation \r\nto\r\nlight touch intact.\r\nSKIN: Patchy erythrodermic erythematous rash. \r\n \r\nDISCHARGE EXAM\r\n==========================\r\nVITALS: 98.6 128/72 93 20 97 Ra \r\nGENERAL: NAD, sitting comfortably in chair \r\nHEENT: strabismus, right ptosis, anicteric, oropharynx clear\r\nCV: RRR, S1/S2, no m/r/g\r\nPULM: unlabored, CTAB\r\nGI: obese, soft, normoactive, nondistended, nontender, no\r\nrebound/guarding\r\nEXT: WWP, trace distal leg edema\r\nSKIN: erythema and scaling nearly resolved\r\n \r\nPertinent Results:\r\nPERTIENT STUDIES\r\n=============================\r\n___ Pathology Tissue: SKIN, LEVELS X4 ON 2 SLIDES:\r\n \r\nPATHOLOGIC DIAGNOSIS:\r\nSkin, right abdomen (1A):\r\nFocal vacuolar interface dermatitis with superficial \r\nperivascular lymphocytic inflammation, apoptotic\r\nkeratinocytes and lymphocyte exocytosis (see note).\r\nNote: The histopathologic findings are favored to represent \r\ngraft-versus-host disease. Less likely,\r\nthe differential diagnosis includes a drug eruption. Sections \r\nshow superficial perivascular\r\nlymphocytic inflammation with exocytosis of lymphocytes into the \r\nepidermis. There are scattered\r\napoptotic keratinocytes, some with satellite cell necrosis. \r\nFocal parakeratosis is present. Epidermal\r\ndysmaturation is seen which may be related to prior \r\nchemotherapeutic agents. No fungi are seen on\r\nPAS stain. Initial and multiple additional levels were examined.\r\n \r\nADMISSION LABS\r\n=============================\r\n___ 04:00PM BLOOD WBC-6.0 RBC-3.49* Hgb-12.3 Hct-37.5 \r\nMCV-107* MCH-35.2* MCHC-32.8 RDW-15.3 RDWSD-61.2* Plt ___\r\n___ 04:00PM BLOOD Neuts-85.0* Lymphs-10.4* Monos-3.2* \r\nEos-0.3* Baso-0.3 Im ___ AbsNeut-5.12# AbsLymp-0.63* \r\nAbsMono-0.19* AbsEos-0.02* AbsBaso-0.02\r\n___ 04:00PM BLOOD ___ PTT-33.4 ___\r\n___ 04:00PM BLOOD Glucose-103* UreaN-23* Creat-1.2* Na-140 \r\nK-4.6 Cl-104 HCO3-23 AnGap-13\r\n___ 04:00PM BLOOD ALT-32 AST-25 AlkPhos-124* TotBili-0.3\r\n___ 04:00PM BLOOD Albumin-3.9 Calcium-8.6 Phos-3.0 Mg-2.0\r\n___ 04:17PM BLOOD Lactate-1.8\r\n___ 06:35PM URINE Color-Straw Appear-Clear Sp ___\r\n___ 06:35PM URINE Blood-NEG Nitrite-NEG Protein-30* \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 06:35PM URINE RBC-<1 WBC-4 Bacteri-FEW* Yeast-NONE \r\nEpi-<1\r\n___ 06:35PM URINE\r\n___ 06:35PM URINE Hours-RANDOM\r\n \r\nPERTINENT LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 03:20PM BLOOD Glucose-175* UreaN-33* Creat-1.4* Na-139 \r\nK-5.7* Cl-105 HCO3-24 AnGap-10\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 09:20AM BLOOD Cyclspr-58*\r\n___ 09:40AM BLOOD Cyclspr-51*\r\n___ 07:00AM BLOOD CMV VL-NOT DETECT\r\n \r\nDISCHARGE LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 01:45AM BLOOD Neuts-78.2* Lymphs-12.5* Monos-7.4 \r\nEos-0.0* Baso-0.1 NRBC-0.2* Im ___ AbsNeut-7.22* \r\nAbsLymp-1.15* AbsMono-0.68 AbsEos-0.00* AbsBaso-0.01\r\n___ 01:45AM BLOOD Plt ___\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 01:45AM BLOOD ALT-30 AST-23 LD(LDH)-205 AlkPhos-112* \r\nTotBili-0.2\r\n___ 01:45AM BLOOD Calcium-8.3* Phos-3.9 Mg-2.0\r\n \r\nPERTINENT MICRO\r\n=============================\r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n \r\n\r\n \r\n \r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Final ___:    NO CYCLOSPORA SEEN. \r\n\r\n   FECAL CULTURE (Final ___:    NO SALMONELLA OR SHIGELLA \r\nFOUND. \r\n\r\n   CAMPYLOBACTER CULTURE (Final ___:    NO CAMPYLOBACTER \r\nFOUND. \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   FECAL CULTURE - R/O VIBRIO (Final ___:    NO VIBRIO \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O YERSINIA (Final ___:    NO YERSINIA \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O E.COLI 0157:H7 (Final ___: \r\n      No E. coli O157:H7 found. \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n \r\nBrief Hospital Course:\r\n___ female with history of diffuse large B-cell lymphoma \r\ncomplicated by secondary myelodysplastic syndrome status-post \r\nallogeneic stem cell transplant complicated by combined variable \r\nimmunodeficiency status-post IVIG, CMV viremia status-post \r\nganciclovir/valganciclovir and S. epidermidis bactermia \r\nstatus-post daptomycin, new deep venous thrombosis, on Lovenox, \r\nand recent biopsy-proven acute skin graft-versus-host disease, \r\non triamcinolone / prednisone, admitted for (1) worsening skin \r\nerythema, which resolved with high-dose corticosteroids and (2) \r\ndiarrhea, which spontaneously resolved upon admission.\r\n\r\n#) Skin graft-versus-host disease, acute, grade III: punch \r\nbiopsy (___) favoring GvHD versus drug eruption. Acute \r\nworsening of generalized eryhtroderma with xerosis/desquamation \r\nin days preceding admission despite use of \r\ntriamcinolone/prednisone. No cellulitic changes. Erythema \r\nregressed with five-day course of methylprednisolone 1 mg/kg in \r\ncombination with topical triamcinolone 0.1%/hydrocortisone 1% \r\n(face), which was converted to prednisone 100 -> 80 mg daily \r\nthereafter. Further taper plan to be determined as outpatient. \r\nHydroxyzine, Sarna, and emollients added for symptomatic care.\r\n\r\n#) Diarrhea, non-bloody: concern for acute gut GvHD, though \r\nspontaneously resolved prior to start of high-dose \r\ncorticosteroids. Of note, recent protracted antibiotic course, \r\nthough C. difficile negative. CMV viral load and stool studies \r\nlikewise negative. Stool volume normal throughout duration of \r\nhospital course. Flexible sigmoidoscopy not pursued in that \r\nregard.\r\n\r\n#) ___: Cr bumped to 1.4 shortly prior to discharge. Unclear \r\netiology though most suspicious for cyclosporine effect vs. \r\nhypovolemia. Non-fluid responsive to 1L bolus; urine studies \r\nwith intrinsic renal picture. Spontaneously resolved within 24 \r\nh. Of note, given fluid bolus in setting of HFrEF and concurrent \r\nsteroids patient was mildly volume overloaded at time of \r\ndischarge. No shortness of breath; O2 saturation normal. \r\nDischarged with 20 mg PO Lasix.\r\n\r\n#) DLBCL c/b secondary MDS ___ MUD allogeneic SCT, in remission: \r\n100% chimerism ___ surveillance bone marrow biopsy with \r\nnormal trilineage maturation. DLBCL also in remission by \r\nsurveillance CT. Complications, as delineated above. \r\nCyclosporine as well as acyclovir, fluconazole, and TMP/SMX all \r\ncontinued. \r\n\r\n#) Hyperkalemia, mild: suspect iatrogenic secondary to \r\ncyclosporine and TMP/SMX. \r\n\r\nCHRONIC/STABLE ISSUES\r\n==============================\r\n\r\n#) DVT, bilateral lower extremity: on therapeutic Lovenox, as of \r\n___. Of note, ___ IVC filter (___) for prior DVT. Lovenox 80 \r\nmg SC Q12H continued. \r\n\r\n#) ICA cavernous sinus aneurysm, right: ___ coil embolization \r\nc/b CN VI palsy, ptosis, V1 hyperesthesia. Home gabapentin \r\ncontinued. \r\n\r\n#) GERD: home omeprazole continued.\r\n\r\n#) OSA: nocturnal CPAP\r\n\r\nTRANSITIONAL ISSUES\r\n===============================\r\n [ ] Discharged on prednisone 80 mg daily. Please arrange for \r\ntaper as outpatient.\r\n\r\n [ ] Mildly volume overloaded at time of discharge due to \r\nconcurrent steroids and fluids with history of CHF. No shortness \r\nof breath; O2 saturation normal. Discharged with 20 mg PO Lasix. \r\nPlease increase or discontinue as needed.\r\n\r\n [ ] Monitor ongoing use of topical steroids and ensure \r\ndiscontinued after appropriate treatment course completed.\r\n\r\n [ ] Discharged on cyclosporine 50 mg q12 hours. Please monitor \r\nlevels and dose-adjust as needed.\r\n\r\n [ ] Prophylactic fluconazole increased to 400 mg daily.\r\n\r\n [ ] Vitamin D added for skeletal protection.\r\n\r\n#CODE: full (presumed)\r\n#CONTACT: ___ (daughter: ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 4 mg PO Q8H:PRN nausea \r\n2. PredniSONE 20 mg PO DAILY \r\n3. Magnesium Oxide 400 mg PO DAILY \r\n4. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Senna 8.6 mg PO BID:PRN constipation \r\n7. Cephalexin ___ mg PO PRN dental procedure \r\n8. Enoxaparin Sodium 80 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\n9. CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\n10. Acyclovir 400 mg PO Q8H \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. FoLIC Acid 1.6 mg PO DAILY \r\n14. Gabapentin 400 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Furosemide 20 mg PO DAILY \r\nRX *furosemide 20 mg 1 tablet(s) by mouth daily Disp #*14 Tablet \r\nRefills:*0 \r\n2.  Hydrocortisone Cream 1% 1 Appl TP BID \r\nRX *hydrocortisone 1 % apply as directed twice daily Refills:*0 \r\n3.  HydrOXYzine 25 mg PO QHS:PRN Itching \r\nRX *hydroxyzine HCl 25 mg 1 tablet by mouth at night Disp #*30 \r\nTablet Refills:*0 \r\n4.  Ketoconazole Shampoo 1 Appl TP BID \r\nRX *ketoconazole 2 % apply as directed twice daily Refills:*0 \r\n5.  Sarna Lotion 1 Appl TP QID:PRN Itching \r\nRX *camphor-menthol [Sarna Anti-Itch] 0.5 %-0.5 % apply as \r\ndirected four times daily Refills:*0 \r\n6.  Vitamin D 1000 UNIT PO DAILY \r\nRX *ergocalciferol (vitamin D2) 2,000 unit 1 tablet(s) by mouth \r\ndaily Disp #*30 Tablet Refills:*0 \r\n7.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n8.  PredniSONE 80 mg PO DAILY \r\nRX *prednisone 20 mg 4 tablet(s) by mouth daily Disp #*28 Tablet \r\nRefills:*0 \r\n9.  Acyclovir 400 mg PO Q8H  \r\n10.  Cephalexin ___ mg PO PRN dental procedure  \r\n11.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H  \r\n12.  Enoxaparin Sodium 80 mg SC Q12H  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  Magnesium Oxide 400 mg PO DAILY  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Senna 8.6 mg PO BID:PRN constipation  \r\n19.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n20.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY\r\n-Skin graft-versus-host-disease, acute \r\n\r\nSECONDARY\r\n-MDS, secondary \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___!\r\n\r\nWHY WERE YOU ADMITTED?\r\n-You had worsening graft-versus-host-disease of your skin.\r\n-You had diarrhea.\r\n\r\nWHAT HAPPENED IN THE HOSPITAL?\r\n-You received steroids and your rash improved.\r\n\r\nWHAT SHOULD YOU DO AT HOME?\r\n-Please take your steroids as directed\r\n-Continue to use triamcinolone (steroid) cream on your BODY only\r\n-Continue to use hydrocortisone (steroid) cream on your FACE\r\n-Take your cyclosporine and prophylactic medications as directed\r\n-Follow-up with your primary oncologist and dermatologist\r\n\r\nThank you for allowing us be involved in your care, we wish you \r\nall the best!\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-25:8",
      "text": "Discharge Medications:\n1. Furosemide 20 mg PO DAILY \nRX *furosemide 20 mg 1 tablet(s) by mouth daily Disp #*14 Tablet \nRefills:*0 \n2. Hydrocortisone Cream 1% 1 Appl TP BID \nRX *hydrocortisone 1 % apply as directed twice daily Refills:*0 \n3. HydrOXYzine 25 mg PO QHS:PRN Itching \nRX *hydroxyzine HCl 25 mg 1 tablet by mouth at night Disp #*30 \nTablet Refills:*0 \n4. Ketoconazole Shampoo 1 Appl TP BID \nRX *ketoconazole 2 % apply as directed twice daily Refills:*0 \n5. Sarna Lotion 1 Appl TP QID:PRN Itching \nRX *camphor-menthol [Sarna Anti-Itch] 0.5 %-0.5 % apply as \ndirected four times daily Refills:*0 \n6. Vitamin D 1000 UNIT PO DAILY \nRX *ergocalciferol (vitamin D2) 2,000 unit 1 tablet(s) by mouth \ndaily Disp #*30 Tablet Refills:*0 \n7. Fluconazole 400 mg PO Q24H \nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \nTablet Refills:*0 \n8. PredniSONE 80 mg PO DAILY \nRX *prednisone 20 mg 4 tablet(s) by mouth daily Disp #*28 Tablet \nRefills:*0 \n9. Acyclovir 400 mg PO Q8H  \n10. Cephalexin ___ mg PO PRN dental procedure  \n11. CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H  \n12. Enoxaparin Sodium 80 mg SC Q12H  \n13. FoLIC Acid 1.6 mg PO DAILY  \n14. Gabapentin 400 mg PO BID  \n15. Magnesium Oxide 400 mg PO DAILY  \n16. Omeprazole 20 mg PO DAILY  \n17. Ondansetron 4 mg PO Q8H:PRN nausea  \n18. Senna 8.6 mg PO BID:PRN constipation  \n19. Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \n20. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID Discharge Disposition:\nHome Discharge Diagnosis:\nPRIMARY\n-Skin graft-versus-host-disease, acute SECONDARY\n-MDS, secondary Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-25",
        "chart_time": "104834",
        "section": "General",
        "position": 8,
        "tokenCount": 427,
        "note_metadata": {
          "note_id": "18887130-DS-25",
          "subject_id": 18887130,
          "hadm_id": 24673826,
          "note_type": "DS",
          "note_seq": 25,
          "charttime": 104834,
          "storetime": 104834.66319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nrash, diarrhea\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nMrs. ___ is a ___ year-old lady with a history of DLBCL\r\n(tr.follicular) ___ alloSCT c/b MDS who presents with worsening\r\nerythrodermic rash and diarrhea. \r\n\r\nOver the past 3 weeks she has developed a new erythematous rash\r\nthat has been extending throughout her body and is new\r\neythrodermic. She has a biopsy on ___ favoring GVHD vs. drug\r\neruption prompting course of prednisone 20mg without \r\nimprovement.\r\nYesterday she had 4 episodes of non-bloody non-mucoid diarrhea\r\nprompting call to her oncologist's office who referred her to \r\nED.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n==========================\r\nVS: 98.4 PO 134 / 69 L Sitting 90 18 98 RA \r\nGENERAL: Well- appearing lady, in no distress lying in bed\r\ncomfortably.\r\nHEENT: Anicteric, PERLL, Mucous membranes moist, oropharynx\r\nclear.\r\nCARDIAC: Regular rate and rhythm, no murmurs, rubs or gallops.\r\nLUNG: Appears in no respiratory distress, clear to auscultation\r\nbilaterally, no crackles, wheezes, or rhonchi.\r\nABD: Non-distended, normal bowel sounds, soft, non-tender, no\r\nguarding, no palpable masses, no organomegaly.\r\nEXT: Warm, well perfused. No lower extremity edema. No\r\ntenderness.\r\nNEURO: Alert and oriented, good attention,  linear thought\r\nprocess. CN II-XII intact. Strength full throughout. Sensation \r\nto\r\nlight touch intact.\r\nSKIN: Patchy erythrodermic erythematous rash. \r\n \r\nDISCHARGE EXAM\r\n==========================\r\nVITALS: 98.6 128/72 93 20 97 Ra \r\nGENERAL: NAD, sitting comfortably in chair \r\nHEENT: strabismus, right ptosis, anicteric, oropharynx clear\r\nCV: RRR, S1/S2, no m/r/g\r\nPULM: unlabored, CTAB\r\nGI: obese, soft, normoactive, nondistended, nontender, no\r\nrebound/guarding\r\nEXT: WWP, trace distal leg edema\r\nSKIN: erythema and scaling nearly resolved\r\n \r\nPertinent Results:\r\nPERTIENT STUDIES\r\n=============================\r\n___ Pathology Tissue: SKIN, LEVELS X4 ON 2 SLIDES:\r\n \r\nPATHOLOGIC DIAGNOSIS:\r\nSkin, right abdomen (1A):\r\nFocal vacuolar interface dermatitis with superficial \r\nperivascular lymphocytic inflammation, apoptotic\r\nkeratinocytes and lymphocyte exocytosis (see note).\r\nNote: The histopathologic findings are favored to represent \r\ngraft-versus-host disease. Less likely,\r\nthe differential diagnosis includes a drug eruption. Sections \r\nshow superficial perivascular\r\nlymphocytic inflammation with exocytosis of lymphocytes into the \r\nepidermis. There are scattered\r\napoptotic keratinocytes, some with satellite cell necrosis. \r\nFocal parakeratosis is present. Epidermal\r\ndysmaturation is seen which may be related to prior \r\nchemotherapeutic agents. No fungi are seen on\r\nPAS stain. Initial and multiple additional levels were examined.\r\n \r\nADMISSION LABS\r\n=============================\r\n___ 04:00PM BLOOD WBC-6.0 RBC-3.49* Hgb-12.3 Hct-37.5 \r\nMCV-107* MCH-35.2* MCHC-32.8 RDW-15.3 RDWSD-61.2* Plt ___\r\n___ 04:00PM BLOOD Neuts-85.0* Lymphs-10.4* Monos-3.2* \r\nEos-0.3* Baso-0.3 Im ___ AbsNeut-5.12# AbsLymp-0.63* \r\nAbsMono-0.19* AbsEos-0.02* AbsBaso-0.02\r\n___ 04:00PM BLOOD ___ PTT-33.4 ___\r\n___ 04:00PM BLOOD Glucose-103* UreaN-23* Creat-1.2* Na-140 \r\nK-4.6 Cl-104 HCO3-23 AnGap-13\r\n___ 04:00PM BLOOD ALT-32 AST-25 AlkPhos-124* TotBili-0.3\r\n___ 04:00PM BLOOD Albumin-3.9 Calcium-8.6 Phos-3.0 Mg-2.0\r\n___ 04:17PM BLOOD Lactate-1.8\r\n___ 06:35PM URINE Color-Straw Appear-Clear Sp ___\r\n___ 06:35PM URINE Blood-NEG Nitrite-NEG Protein-30* \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 06:35PM URINE RBC-<1 WBC-4 Bacteri-FEW* Yeast-NONE \r\nEpi-<1\r\n___ 06:35PM URINE\r\n___ 06:35PM URINE Hours-RANDOM\r\n \r\nPERTINENT LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 03:20PM BLOOD Glucose-175* UreaN-33* Creat-1.4* Na-139 \r\nK-5.7* Cl-105 HCO3-24 AnGap-10\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 09:20AM BLOOD Cyclspr-58*\r\n___ 09:40AM BLOOD Cyclspr-51*\r\n___ 07:00AM BLOOD CMV VL-NOT DETECT\r\n \r\nDISCHARGE LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 01:45AM BLOOD Neuts-78.2* Lymphs-12.5* Monos-7.4 \r\nEos-0.0* Baso-0.1 NRBC-0.2* Im ___ AbsNeut-7.22* \r\nAbsLymp-1.15* AbsMono-0.68 AbsEos-0.00* AbsBaso-0.01\r\n___ 01:45AM BLOOD Plt ___\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 01:45AM BLOOD ALT-30 AST-23 LD(LDH)-205 AlkPhos-112* \r\nTotBili-0.2\r\n___ 01:45AM BLOOD Calcium-8.3* Phos-3.9 Mg-2.0\r\n \r\nPERTINENT MICRO\r\n=============================\r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n \r\n\r\n \r\n \r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Final ___:    NO CYCLOSPORA SEEN. \r\n\r\n   FECAL CULTURE (Final ___:    NO SALMONELLA OR SHIGELLA \r\nFOUND. \r\n\r\n   CAMPYLOBACTER CULTURE (Final ___:    NO CAMPYLOBACTER \r\nFOUND. \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   FECAL CULTURE - R/O VIBRIO (Final ___:    NO VIBRIO \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O YERSINIA (Final ___:    NO YERSINIA \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O E.COLI 0157:H7 (Final ___: \r\n      No E. coli O157:H7 found. \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n \r\nBrief Hospital Course:\r\n___ female with history of diffuse large B-cell lymphoma \r\ncomplicated by secondary myelodysplastic syndrome status-post \r\nallogeneic stem cell transplant complicated by combined variable \r\nimmunodeficiency status-post IVIG, CMV viremia status-post \r\nganciclovir/valganciclovir and S. epidermidis bactermia \r\nstatus-post daptomycin, new deep venous thrombosis, on Lovenox, \r\nand recent biopsy-proven acute skin graft-versus-host disease, \r\non triamcinolone / prednisone, admitted for (1) worsening skin \r\nerythema, which resolved with high-dose corticosteroids and (2) \r\ndiarrhea, which spontaneously resolved upon admission.\r\n\r\n#) Skin graft-versus-host disease, acute, grade III: punch \r\nbiopsy (___) favoring GvHD versus drug eruption. Acute \r\nworsening of generalized eryhtroderma with xerosis/desquamation \r\nin days preceding admission despite use of \r\ntriamcinolone/prednisone. No cellulitic changes. Erythema \r\nregressed with five-day course of methylprednisolone 1 mg/kg in \r\ncombination with topical triamcinolone 0.1%/hydrocortisone 1% \r\n(face), which was converted to prednisone 100 -> 80 mg daily \r\nthereafter. Further taper plan to be determined as outpatient. \r\nHydroxyzine, Sarna, and emollients added for symptomatic care.\r\n\r\n#) Diarrhea, non-bloody: concern for acute gut GvHD, though \r\nspontaneously resolved prior to start of high-dose \r\ncorticosteroids. Of note, recent protracted antibiotic course, \r\nthough C. difficile negative. CMV viral load and stool studies \r\nlikewise negative. Stool volume normal throughout duration of \r\nhospital course. Flexible sigmoidoscopy not pursued in that \r\nregard.\r\n\r\n#) ___: Cr bumped to 1.4 shortly prior to discharge. Unclear \r\netiology though most suspicious for cyclosporine effect vs. \r\nhypovolemia. Non-fluid responsive to 1L bolus; urine studies \r\nwith intrinsic renal picture. Spontaneously resolved within 24 \r\nh. Of note, given fluid bolus in setting of HFrEF and concurrent \r\nsteroids patient was mildly volume overloaded at time of \r\ndischarge. No shortness of breath; O2 saturation normal. \r\nDischarged with 20 mg PO Lasix.\r\n\r\n#) DLBCL c/b secondary MDS ___ MUD allogeneic SCT, in remission: \r\n100% chimerism ___ surveillance bone marrow biopsy with \r\nnormal trilineage maturation. DLBCL also in remission by \r\nsurveillance CT. Complications, as delineated above. \r\nCyclosporine as well as acyclovir, fluconazole, and TMP/SMX all \r\ncontinued. \r\n\r\n#) Hyperkalemia, mild: suspect iatrogenic secondary to \r\ncyclosporine and TMP/SMX. \r\n\r\nCHRONIC/STABLE ISSUES\r\n==============================\r\n\r\n#) DVT, bilateral lower extremity: on therapeutic Lovenox, as of \r\n___. Of note, ___ IVC filter (___) for prior DVT. Lovenox 80 \r\nmg SC Q12H continued. \r\n\r\n#) ICA cavernous sinus aneurysm, right: ___ coil embolization \r\nc/b CN VI palsy, ptosis, V1 hyperesthesia. Home gabapentin \r\ncontinued. \r\n\r\n#) GERD: home omeprazole continued.\r\n\r\n#) OSA: nocturnal CPAP\r\n\r\nTRANSITIONAL ISSUES\r\n===============================\r\n [ ] Discharged on prednisone 80 mg daily. Please arrange for \r\ntaper as outpatient.\r\n\r\n [ ] Mildly volume overloaded at time of discharge due to \r\nconcurrent steroids and fluids with history of CHF. No shortness \r\nof breath; O2 saturation normal. Discharged with 20 mg PO Lasix. \r\nPlease increase or discontinue as needed.\r\n\r\n [ ] Monitor ongoing use of topical steroids and ensure \r\ndiscontinued after appropriate treatment course completed.\r\n\r\n [ ] Discharged on cyclosporine 50 mg q12 hours. Please monitor \r\nlevels and dose-adjust as needed.\r\n\r\n [ ] Prophylactic fluconazole increased to 400 mg daily.\r\n\r\n [ ] Vitamin D added for skeletal protection.\r\n\r\n#CODE: full (presumed)\r\n#CONTACT: ___ (daughter: ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 4 mg PO Q8H:PRN nausea \r\n2. PredniSONE 20 mg PO DAILY \r\n3. Magnesium Oxide 400 mg PO DAILY \r\n4. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Senna 8.6 mg PO BID:PRN constipation \r\n7. Cephalexin ___ mg PO PRN dental procedure \r\n8. Enoxaparin Sodium 80 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\n9. CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\n10. Acyclovir 400 mg PO Q8H \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. FoLIC Acid 1.6 mg PO DAILY \r\n14. Gabapentin 400 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Furosemide 20 mg PO DAILY \r\nRX *furosemide 20 mg 1 tablet(s) by mouth daily Disp #*14 Tablet \r\nRefills:*0 \r\n2.  Hydrocortisone Cream 1% 1 Appl TP BID \r\nRX *hydrocortisone 1 % apply as directed twice daily Refills:*0 \r\n3.  HydrOXYzine 25 mg PO QHS:PRN Itching \r\nRX *hydroxyzine HCl 25 mg 1 tablet by mouth at night Disp #*30 \r\nTablet Refills:*0 \r\n4.  Ketoconazole Shampoo 1 Appl TP BID \r\nRX *ketoconazole 2 % apply as directed twice daily Refills:*0 \r\n5.  Sarna Lotion 1 Appl TP QID:PRN Itching \r\nRX *camphor-menthol [Sarna Anti-Itch] 0.5 %-0.5 % apply as \r\ndirected four times daily Refills:*0 \r\n6.  Vitamin D 1000 UNIT PO DAILY \r\nRX *ergocalciferol (vitamin D2) 2,000 unit 1 tablet(s) by mouth \r\ndaily Disp #*30 Tablet Refills:*0 \r\n7.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n8.  PredniSONE 80 mg PO DAILY \r\nRX *prednisone 20 mg 4 tablet(s) by mouth daily Disp #*28 Tablet \r\nRefills:*0 \r\n9.  Acyclovir 400 mg PO Q8H  \r\n10.  Cephalexin ___ mg PO PRN dental procedure  \r\n11.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H  \r\n12.  Enoxaparin Sodium 80 mg SC Q12H  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  Magnesium Oxide 400 mg PO DAILY  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Senna 8.6 mg PO BID:PRN constipation  \r\n19.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n20.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY\r\n-Skin graft-versus-host-disease, acute \r\n\r\nSECONDARY\r\n-MDS, secondary \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___!\r\n\r\nWHY WERE YOU ADMITTED?\r\n-You had worsening graft-versus-host-disease of your skin.\r\n-You had diarrhea.\r\n\r\nWHAT HAPPENED IN THE HOSPITAL?\r\n-You received steroids and your rash improved.\r\n\r\nWHAT SHOULD YOU DO AT HOME?\r\n-Please take your steroids as directed\r\n-Continue to use triamcinolone (steroid) cream on your BODY only\r\n-Continue to use hydrocortisone (steroid) cream on your FACE\r\n-Take your cyclosporine and prophylactic medications as directed\r\n-Follow-up with your primary oncologist and dermatologist\r\n\r\nThank you for allowing us be involved in your care, we wish you \r\nall the best!\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-25:9",
      "text": "Discharge Instructions:\nDear Ms. ___, It was a pleasure caring for you at ___ \n___! WHY WERE YOU ADMITTED? -You had worsening graft-versus-host-disease of your skin. -You had diarrhea. WHAT HAPPENED IN THE HOSPITAL? -You received steroids and your rash improved. WHAT SHOULD YOU DO AT HOME? -Please take your steroids as directed\n-Continue to use triamcinolone (steroid) cream on your BODY only\n-Continue to use hydrocortisone (steroid) cream on your FACE\n-Take your cyclosporine and prophylactic medications as directed\n-Follow-up with your primary oncologist and dermatologist Thank you for allowing us be involved in your care, we wish you \nall the best! Your ___ Team\n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-25",
        "chart_time": "104834",
        "section": "General",
        "position": 9,
        "tokenCount": 175,
        "note_metadata": {
          "note_id": "18887130-DS-25",
          "subject_id": 18887130,
          "hadm_id": 24673826,
          "note_type": "DS",
          "note_seq": 25,
          "charttime": 104834,
          "storetime": 104834.66319444444,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nrash, diarrhea\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nMrs. ___ is a ___ year-old lady with a history of DLBCL\r\n(tr.follicular) ___ alloSCT c/b MDS who presents with worsening\r\nerythrodermic rash and diarrhea. \r\n\r\nOver the past 3 weeks she has developed a new erythematous rash\r\nthat has been extending throughout her body and is new\r\neythrodermic. She has a biopsy on ___ favoring GVHD vs. drug\r\neruption prompting course of prednisone 20mg without \r\nimprovement.\r\nYesterday she had 4 episodes of non-bloody non-mucoid diarrhea\r\nprompting call to her oncologist's office who referred her to \r\nED.\r\n \r\nPast Medical History:\r\n- Treatment-Related MDS after transformed follicular lymphoma\r\n- CVID, received IVIG monthly; last given ___\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___).  On Neurontin.  Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- History of osteomyelitis with IV antibioitcs for 6\r\nweeks. \r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother with lymphoma, died at age ___. Father had CAD and DM. \r\nMother had CHF.\r\n\r\n \r\nPhysical Exam:\r\nADMISSION EXAM\r\n==========================\r\nVS: 98.4 PO 134 / 69 L Sitting 90 18 98 RA \r\nGENERAL: Well- appearing lady, in no distress lying in bed\r\ncomfortably.\r\nHEENT: Anicteric, PERLL, Mucous membranes moist, oropharynx\r\nclear.\r\nCARDIAC: Regular rate and rhythm, no murmurs, rubs or gallops.\r\nLUNG: Appears in no respiratory distress, clear to auscultation\r\nbilaterally, no crackles, wheezes, or rhonchi.\r\nABD: Non-distended, normal bowel sounds, soft, non-tender, no\r\nguarding, no palpable masses, no organomegaly.\r\nEXT: Warm, well perfused. No lower extremity edema. No\r\ntenderness.\r\nNEURO: Alert and oriented, good attention,  linear thought\r\nprocess. CN II-XII intact. Strength full throughout. Sensation \r\nto\r\nlight touch intact.\r\nSKIN: Patchy erythrodermic erythematous rash. \r\n \r\nDISCHARGE EXAM\r\n==========================\r\nVITALS: 98.6 128/72 93 20 97 Ra \r\nGENERAL: NAD, sitting comfortably in chair \r\nHEENT: strabismus, right ptosis, anicteric, oropharynx clear\r\nCV: RRR, S1/S2, no m/r/g\r\nPULM: unlabored, CTAB\r\nGI: obese, soft, normoactive, nondistended, nontender, no\r\nrebound/guarding\r\nEXT: WWP, trace distal leg edema\r\nSKIN: erythema and scaling nearly resolved\r\n \r\nPertinent Results:\r\nPERTIENT STUDIES\r\n=============================\r\n___ Pathology Tissue: SKIN, LEVELS X4 ON 2 SLIDES:\r\n \r\nPATHOLOGIC DIAGNOSIS:\r\nSkin, right abdomen (1A):\r\nFocal vacuolar interface dermatitis with superficial \r\nperivascular lymphocytic inflammation, apoptotic\r\nkeratinocytes and lymphocyte exocytosis (see note).\r\nNote: The histopathologic findings are favored to represent \r\ngraft-versus-host disease. Less likely,\r\nthe differential diagnosis includes a drug eruption. Sections \r\nshow superficial perivascular\r\nlymphocytic inflammation with exocytosis of lymphocytes into the \r\nepidermis. There are scattered\r\napoptotic keratinocytes, some with satellite cell necrosis. \r\nFocal parakeratosis is present. Epidermal\r\ndysmaturation is seen which may be related to prior \r\nchemotherapeutic agents. No fungi are seen on\r\nPAS stain. Initial and multiple additional levels were examined.\r\n \r\nADMISSION LABS\r\n=============================\r\n___ 04:00PM BLOOD WBC-6.0 RBC-3.49* Hgb-12.3 Hct-37.5 \r\nMCV-107* MCH-35.2* MCHC-32.8 RDW-15.3 RDWSD-61.2* Plt ___\r\n___ 04:00PM BLOOD Neuts-85.0* Lymphs-10.4* Monos-3.2* \r\nEos-0.3* Baso-0.3 Im ___ AbsNeut-5.12# AbsLymp-0.63* \r\nAbsMono-0.19* AbsEos-0.02* AbsBaso-0.02\r\n___ 04:00PM BLOOD ___ PTT-33.4 ___\r\n___ 04:00PM BLOOD Glucose-103* UreaN-23* Creat-1.2* Na-140 \r\nK-4.6 Cl-104 HCO3-23 AnGap-13\r\n___ 04:00PM BLOOD ALT-32 AST-25 AlkPhos-124* TotBili-0.3\r\n___ 04:00PM BLOOD Albumin-3.9 Calcium-8.6 Phos-3.0 Mg-2.0\r\n___ 04:17PM BLOOD Lactate-1.8\r\n___ 06:35PM URINE Color-Straw Appear-Clear Sp ___\r\n___ 06:35PM URINE Blood-NEG Nitrite-NEG Protein-30* \r\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG\r\n___ 06:35PM URINE RBC-<1 WBC-4 Bacteri-FEW* Yeast-NONE \r\nEpi-<1\r\n___ 06:35PM URINE\r\n___ 06:35PM URINE Hours-RANDOM\r\n \r\nPERTINENT LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 03:20PM BLOOD Glucose-175* UreaN-33* Creat-1.4* Na-139 \r\nK-5.7* Cl-105 HCO3-24 AnGap-10\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 09:20AM BLOOD Cyclspr-58*\r\n___ 09:40AM BLOOD Cyclspr-51*\r\n___ 07:00AM BLOOD CMV VL-NOT DETECT\r\n \r\nDISCHARGE LABS\r\n=============================\r\n___ 01:45AM BLOOD WBC-9.2 RBC-3.13* Hgb-10.9* Hct-33.1* \r\nMCV-106* MCH-34.8* MCHC-32.9 RDW-14.9 RDWSD-58.2* Plt ___\r\n___ 01:45AM BLOOD Neuts-78.2* Lymphs-12.5* Monos-7.4 \r\nEos-0.0* Baso-0.1 NRBC-0.2* Im ___ AbsNeut-7.22* \r\nAbsLymp-1.15* AbsMono-0.68 AbsEos-0.00* AbsBaso-0.01\r\n___ 01:45AM BLOOD Plt ___\r\n___ 01:45AM BLOOD Glucose-122* UreaN-32* Creat-1.1 Na-140 \r\nK-4.7 Cl-107 HCO3-24 AnGap-9*\r\n___ 01:45AM BLOOD ALT-30 AST-23 LD(LDH)-205 AlkPhos-112* \r\nTotBili-0.2\r\n___ 01:45AM BLOOD Calcium-8.3* Phos-3.9 Mg-2.0\r\n \r\nPERTINENT MICRO\r\n=============================\r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   C. difficile DNA amplification assay (Final ___: \r\n      Negative for toxigenic C. difficile by the Cepheid nucleic \r\nacid\r\n      amplification assay.. \r\n           (Reference Range-Negative). \r\n \r\n\r\n \r\n \r\n___ 9:54 am STOOL     CONSISTENCY: NOT APPLICABLE\r\n      Source: Stool. \r\n\r\n                            **FINAL REPORT ___\r\n\r\n   MICROSPORIDIA STAIN (Final ___:    NO MICROSPORIDIUM \r\nSEEN. \r\n\r\n   CYCLOSPORA STAIN (Final ___:    NO CYCLOSPORA SEEN. \r\n\r\n   FECAL CULTURE (Final ___:    NO SALMONELLA OR SHIGELLA \r\nFOUND. \r\n\r\n   CAMPYLOBACTER CULTURE (Final ___:    NO CAMPYLOBACTER \r\nFOUND. \r\n\r\n   OVA + PARASITES (Final ___: \r\n      NO OVA AND PARASITES SEEN. \r\n      This test does not reliably detect Cryptosporidium, \r\nCyclospora or\r\n      Microsporidium. While most cases of Giardia are detected \r\nby routine\r\n      O+P, the Giardia antigen test may enhance detection when \r\norganisms\r\n      are rare. \r\n\r\n   FECAL CULTURE - R/O VIBRIO (Final ___:    NO VIBRIO \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O YERSINIA (Final ___:    NO YERSINIA \r\nFOUND. \r\n\r\n   FECAL CULTURE - R/O E.COLI 0157:H7 (Final ___: \r\n      No E. coli O157:H7 found. \r\n\r\n   Cryptosporidium/Giardia (DFA) (Final ___: \r\n      NO CRYPTOSPORIDIUM OR GIARDIA SEEN. \r\n \r\nBrief Hospital Course:\r\n___ female with history of diffuse large B-cell lymphoma \r\ncomplicated by secondary myelodysplastic syndrome status-post \r\nallogeneic stem cell transplant complicated by combined variable \r\nimmunodeficiency status-post IVIG, CMV viremia status-post \r\nganciclovir/valganciclovir and S. epidermidis bactermia \r\nstatus-post daptomycin, new deep venous thrombosis, on Lovenox, \r\nand recent biopsy-proven acute skin graft-versus-host disease, \r\non triamcinolone / prednisone, admitted for (1) worsening skin \r\nerythema, which resolved with high-dose corticosteroids and (2) \r\ndiarrhea, which spontaneously resolved upon admission.\r\n\r\n#) Skin graft-versus-host disease, acute, grade III: punch \r\nbiopsy (___) favoring GvHD versus drug eruption. Acute \r\nworsening of generalized eryhtroderma with xerosis/desquamation \r\nin days preceding admission despite use of \r\ntriamcinolone/prednisone. No cellulitic changes. Erythema \r\nregressed with five-day course of methylprednisolone 1 mg/kg in \r\ncombination with topical triamcinolone 0.1%/hydrocortisone 1% \r\n(face), which was converted to prednisone 100 -> 80 mg daily \r\nthereafter. Further taper plan to be determined as outpatient. \r\nHydroxyzine, Sarna, and emollients added for symptomatic care.\r\n\r\n#) Diarrhea, non-bloody: concern for acute gut GvHD, though \r\nspontaneously resolved prior to start of high-dose \r\ncorticosteroids. Of note, recent protracted antibiotic course, \r\nthough C. difficile negative. CMV viral load and stool studies \r\nlikewise negative. Stool volume normal throughout duration of \r\nhospital course. Flexible sigmoidoscopy not pursued in that \r\nregard.\r\n\r\n#) ___: Cr bumped to 1.4 shortly prior to discharge. Unclear \r\netiology though most suspicious for cyclosporine effect vs. \r\nhypovolemia. Non-fluid responsive to 1L bolus; urine studies \r\nwith intrinsic renal picture. Spontaneously resolved within 24 \r\nh. Of note, given fluid bolus in setting of HFrEF and concurrent \r\nsteroids patient was mildly volume overloaded at time of \r\ndischarge. No shortness of breath; O2 saturation normal. \r\nDischarged with 20 mg PO Lasix.\r\n\r\n#) DLBCL c/b secondary MDS ___ MUD allogeneic SCT, in remission: \r\n100% chimerism ___ surveillance bone marrow biopsy with \r\nnormal trilineage maturation. DLBCL also in remission by \r\nsurveillance CT. Complications, as delineated above. \r\nCyclosporine as well as acyclovir, fluconazole, and TMP/SMX all \r\ncontinued. \r\n\r\n#) Hyperkalemia, mild: suspect iatrogenic secondary to \r\ncyclosporine and TMP/SMX. \r\n\r\nCHRONIC/STABLE ISSUES\r\n==============================\r\n\r\n#) DVT, bilateral lower extremity: on therapeutic Lovenox, as of \r\n___. Of note, ___ IVC filter (___) for prior DVT. Lovenox 80 \r\nmg SC Q12H continued. \r\n\r\n#) ICA cavernous sinus aneurysm, right: ___ coil embolization \r\nc/b CN VI palsy, ptosis, V1 hyperesthesia. Home gabapentin \r\ncontinued. \r\n\r\n#) GERD: home omeprazole continued.\r\n\r\n#) OSA: nocturnal CPAP\r\n\r\nTRANSITIONAL ISSUES\r\n===============================\r\n [ ] Discharged on prednisone 80 mg daily. Please arrange for \r\ntaper as outpatient.\r\n\r\n [ ] Mildly volume overloaded at time of discharge due to \r\nconcurrent steroids and fluids with history of CHF. No shortness \r\nof breath; O2 saturation normal. Discharged with 20 mg PO Lasix. \r\nPlease increase or discontinue as needed.\r\n\r\n [ ] Monitor ongoing use of topical steroids and ensure \r\ndiscontinued after appropriate treatment course completed.\r\n\r\n [ ] Discharged on cyclosporine 50 mg q12 hours. Please monitor \r\nlevels and dose-adjust as needed.\r\n\r\n [ ] Prophylactic fluconazole increased to 400 mg daily.\r\n\r\n [ ] Vitamin D added for skeletal protection.\r\n\r\n#CODE: full (presumed)\r\n#CONTACT: ___ (daughter: ___\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 4 mg PO Q8H:PRN nausea \r\n2. PredniSONE 20 mg PO DAILY \r\n3. Magnesium Oxide 400 mg PO DAILY \r\n4. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID \r\n5. Fluconazole 200 mg PO Q24H \r\n6. Senna 8.6 mg PO BID:PRN constipation \r\n7. Cephalexin ___ mg PO PRN dental procedure \r\n8. Enoxaparin Sodium 80 mg SC Q12H \r\nStart: ___, First Dose: Next Routine Administration Time \r\n9. CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H \r\n10. Acyclovir 400 mg PO Q8H \r\n11. Omeprazole 20 mg PO DAILY \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. FoLIC Acid 1.6 mg PO DAILY \r\n14. Gabapentin 400 mg PO BID \r\n\r\n \r\nDischarge Medications:\r\n1.  Furosemide 20 mg PO DAILY \r\nRX *furosemide 20 mg 1 tablet(s) by mouth daily Disp #*14 Tablet \r\nRefills:*0 \r\n2.  Hydrocortisone Cream 1% 1 Appl TP BID \r\nRX *hydrocortisone 1 % apply as directed twice daily Refills:*0 \r\n3.  HydrOXYzine 25 mg PO QHS:PRN Itching \r\nRX *hydroxyzine HCl 25 mg 1 tablet by mouth at night Disp #*30 \r\nTablet Refills:*0 \r\n4.  Ketoconazole Shampoo 1 Appl TP BID \r\nRX *ketoconazole 2 % apply as directed twice daily Refills:*0 \r\n5.  Sarna Lotion 1 Appl TP QID:PRN Itching \r\nRX *camphor-menthol [Sarna Anti-Itch] 0.5 %-0.5 % apply as \r\ndirected four times daily Refills:*0 \r\n6.  Vitamin D 1000 UNIT PO DAILY \r\nRX *ergocalciferol (vitamin D2) 2,000 unit 1 tablet(s) by mouth \r\ndaily Disp #*30 Tablet Refills:*0 \r\n7.  Fluconazole 400 mg PO Q24H \r\nRX *fluconazole 200 mg 2 tablet(s) by mouth daily Disp #*60 \r\nTablet Refills:*0 \r\n8.  PredniSONE 80 mg PO DAILY \r\nRX *prednisone 20 mg 4 tablet(s) by mouth daily Disp #*28 Tablet \r\nRefills:*0 \r\n9.  Acyclovir 400 mg PO Q8H  \r\n10.  Cephalexin ___ mg PO PRN dental procedure  \r\n11.  CycloSPORINE (Neoral) MODIFIED 50 mg PO Q12H  \r\n12.  Enoxaparin Sodium 80 mg SC Q12H  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  Magnesium Oxide 400 mg PO DAILY  \r\n16.  Omeprazole 20 mg PO DAILY  \r\n17.  Ondansetron 4 mg PO Q8H:PRN nausea  \r\n18.  Senna 8.6 mg PO BID:PRN constipation  \r\n19.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n20.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY\r\n-Skin graft-versus-host-disease, acute \r\n\r\nSECONDARY\r\n-MDS, secondary \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___!\r\n\r\nWHY WERE YOU ADMITTED?\r\n-You had worsening graft-versus-host-disease of your skin.\r\n-You had diarrhea.\r\n\r\nWHAT HAPPENED IN THE HOSPITAL?\r\n-You received steroids and your rash improved.\r\n\r\nWHAT SHOULD YOU DO AT HOME?\r\n-Please take your steroids as directed\r\n-Continue to use triamcinolone (steroid) cream on your BODY only\r\n-Continue to use hydrocortisone (steroid) cream on your FACE\r\n-Take your cyclosporine and prophylactic medications as directed\r\n-Follow-up with your primary oncologist and dermatologist\r\n\r\nThank you for allowing us be involved in your care, we wish you \r\nall the best!\r\n\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-26:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \ndapsone\n \nAttending: ___. Chief Complaint:\nfever, chills, cough\n \nMajor Surgical or Invasive Procedure:\nnone",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-26",
        "chart_time": "105179",
        "section": "General",
        "position": 0,
        "tokenCount": 72,
        "note_metadata": {
          "note_id": "18887130-DS-26",
          "subject_id": 18887130,
          "hadm_id": 29331505,
          "note_type": "DS",
          "note_seq": 26,
          "charttime": 105179,
          "storetime": 105179.69236111111,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, chills, cough\r\n \r\nMajor Surgical or Invasive Procedure:\r\nnone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na\r\nhistory of stage IIA follicular lymphoma with treatment\r\nrelated MDS ___ allogeneic stem cell transplant on ___ who\r\npresents with four days of productive cough, fevers and chills.\r\n\r\nShe called her ___ clinic on ___ and reported fever,\r\nchills, and productive cough. She had been seen at urgent care\r\nearlier on ___ and received CXR which was consistent with\r\npneumonia, and she was treated with ceftriaxone 1g, steroids and\r\nDuoNebs. She called ___ clinic due to lack of improvement.\r\nShe was referred to ED for admission and IV antibiotics, given\r\nher pneumonia and history of allogenic transplant.\r\n\r\nIn the ED, her vitals were: T 98.8, HR 96, BP 129/65, RR 18, \r\nSPO2\r\n97% RA. Lung exam was significant for diffuse expiratory \r\nwheezing\r\nand rhonchi. Labs were remarkable for WBC 13, HGB 13, plt 256, K\r\n4.6, Cr 1.2. She was given azithromycin, albuterol nebs, DuoNeb,\r\nIVF.\r\n\r\nOn arrival to OMED, she reports she has laryngitis and continued\r\ncough. She has multiple sick contacts (grandchildren at home who\r\nhave colds). She denies current fever, chills, abdominal pain,\r\nnausea, diarrhea, dysuria, leg swelling.\r\n\r\nREVIEW OF SYSTEMS:  \r\nA complete 10-point review of systems was performed and was\r\nnegative unless otherwise noted in the HPI.  \r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY: \r\n Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO.  Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h).  Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging.  MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact.  Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning.  D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n\r\nTRANSPLANT DATA:\r\n  Transplant Date: ___\r\n  Graft: URD\r\n  Conditioning Intensity: Reduced-Intensity\r\n  Conditioning Regimen: Flu/Bu/ATG\r\n\r\n  Donor Info: ___ CMV(+), ABO: Opos\r\n  Recipient Info: CMV(+), ABO: Opos  \r\n \r\n\r\nPAST MEDICAL HISTORY:  \r\n- CVID\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- RLE DVT, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- R internal carotid cavernous sinus aneurism ___ coiling \r\n___\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- + Parainfluenza, ___\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:  \r\n___ ___ Temp: 98.3 PO BP: 110/42 HR: 91 RR: 20 O2 sat: 97%\r\nO2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nGU: Cutaneous candiasis in groin, R worse than L\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye, and hyperthesia of the right V1 distribution. CN II-XII\r\notherwise intact. Strength ___ in all extremities. Sensation\r\nintact in all extremities.\r\n\r\nDischarge Physical Exam:\r\nVS: ___ ___ Temp: 98.1 PO BP: 124/51 Sitting HR: 95 RR: 18\r\nO2 sat: 97% O2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n==============\r\n___ 11:00PM BLOOD WBC-13.0* RBC-4.07 Hgb-13.0 Hct-40.9 \r\nMCV-101* MCH-31.9 MCHC-31.8* RDW-14.1 RDWSD-51.1* Plt ___\r\n___ 11:00PM BLOOD Neuts-93.1* Lymphs-4.5* Monos-1.8* \r\nEos-0.1* Baso-0.1 Im ___ AbsNeut-12.08* AbsLymp-0.59* \r\nAbsMono-0.24 AbsEos-0.01* AbsBaso-0.01\r\n___ 11:00PM BLOOD Glucose-234* UreaN-14 Creat-1.2* Na-142 \r\nK-4.6 Cl-105 HCO3-21* AnGap-16\r\n___ 11:00PM BLOOD ALT-14 AST-19 AlkPhos-151* TotBili-0.2\r\n___ 11:00PM BLOOD Albumin-4.2\r\n___ 11:00PM BLOOD IgG-713\r\n___ 01:51AM BLOOD Lactate-1.3\r\n\r\nMICRO:\r\n======\r\n___ urine culture: negative\r\n___ fluA&B PCR: negative\r\n___ blood cultures: pending ***\r\n___ urine legionella antigen: negative\r\n___ urine strep pneumo Ag: pending ***\r\n___ respiratory viral screen and culture: pending ***\r\n\r\nIMAGING AND STUDIES:\r\n===================\r\n___ CXR:\r\nNo acute intrathoracic process.\r\n\r\n___ ECG: QTc 487\r\n\r\nDISCHARGE LABS:\r\n===============\r\n\r\n___ 07:00AM BLOOD WBC-5.6 RBC-3.91 Hgb-12.6 Hct-39.7 \r\nMCV-102* MCH-32.2* MCHC-31.7* RDW-14.4 RDWSD-53.7* Plt ___\r\n___ 07:00AM BLOOD Plt ___\r\n \r\nBrief Hospital Course:\r\nSUMMARY:\r\n========= \r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na history of stage IIA follicular lymphoma with treatment \r\nrelated MDS ___ allogeneic stem cell transplant on ___ who \r\npresents with four days of productive cough, fevers and chills \r\nconsistent with community acquired pneumonia \r\n\r\nACTIVE ISSUES:\r\n=============\r\n#community acquired pneumonia \r\nMost likely etiology is community acquired pneumonia, given \r\nabsence of consolidation on CXR, her sick contacts (grandkids \r\nwith colds), and lung exam with bronchial breath sounds and \r\nwheezing. Flu swab negative. Preliminary results from the viral \r\nrespiratory screen was negative. Given her immunocompromised \r\nstate, will treat for CAP. D1 CTX ___, D1 azithromycin ___. \r\nHer symptoms were treated with DuonNebs, Flovent, albuterol, and \r\nguafenisen. We discharged her home with lovenox to complete a 5 \r\nday course of antibiotics ending on ___\r\n\r\n#CVID\r\nReceives IVIG every 1 - 2 months to keep IGG > 500. Her last \r\ninfusion was ~1 month ago. IGG 715 this admission, so IVIG was \r\nnot given this admission. She was monitored for signs of \r\ninfection and treated as above.\r\n\r\n#MDS ___ allogeneic stem cell transplant on ___\r\nHer outpatient oncology team was notified of her admission. Her \r\nhome prednisone and MMF were continued, as well as her home \r\nacyclovir and Bactrim.\r\n\r\n#Cutaneous candidiasis of groin\r\nHas required 5-day course of fluconazole in past to resolve. She \r\nwas treated with nystatin cream only, due to hesitancy to \r\nprescribe a systemic antifungal with other QTc prolonging meds \r\n(azithro).\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Right lower extremity DVT: IVC filter in place. Continued home \r\nrivaroxaban.\r\n\r\n#GERD: continued home omeprazole.\r\n\r\n#Osteoarthritis \r\n#Cervical radiculopathy\r\n#Sciatica\r\n#Migraines\r\nContinued home gabapentin. Tylenol PRN.\r\n\r\n#Obstructive sleep apnea: she used her home CPAP while \r\ninpatient.\r\n\r\n#H/O cerebral aneurism: Noted on MRA with small R internal \r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm \r\n(___). Her home Neurontin was continued.\r\n\r\n#Asthma: continued home Flovent and DuoNebs, with albuterol PRN.\r\n\r\n#Hypertension: she was noted to not be on antihypertensives at \r\nhome. Her BP was monitored while inpatient.\r\n\r\n#Mood disorder: her home venlafaxine was continued.\r\n\r\nTRANSITIONAL ISSUES:\r\n===================\r\n[]Levofloxacin course ending ___\r\n[]Follow up with oncology ___\r\n[]Viral culture pending on discharge \r\n[]Glucose on admission was 234, consider screening for DM2 as \r\noutpatient \r\n\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: full code (confirmed)\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Rivaroxaban 20 mg PO DAILY \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Gabapentin 400 mg PO BID \r\n4. PredniSONE 5 mg PO DAILY \r\n5. Zofran (ondansetron HCl) 4 mg oral Q8H \r\n6. Mycophenolate Mofetil 500 mg PO BID \r\n7. Venlafaxine 25 mg PO DAILY \r\n8. Acyclovir 400 mg PO TID \r\n9. Cephalexin ___ mg PO ONCE \r\n10. Restasis 0.05 % ophthalmic (eye) BID \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n12. Hydrocortisone Cream 1% 1 Appl TP BID \r\n13. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n14. Nystatin Cream 1 Appl TP BID:PRN fungal rash \r\n15. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n16. Vitamin D ___ UNIT PO DAILY \r\n17. FoLIC Acid 1.6 mg PO DAILY \r\n18. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1.  GuaiFENesin ER 600 mg PO Q12H \r\nRX *guaifenesin 600 mg 1 tablet(s) by mouth q12hrs prn Disp #*10 \r\nTablet Refills:*0 \r\n2.  Levofloxacin 500 mg PO Q24H Duration: 2 Days \r\nRX *levofloxacin [Levaquin] 500 mg 1 tablet(s) by mouth daily \r\nDisp #*2 Tablet Refills:*0 \r\n3.  Acyclovir 400 mg PO TID  \r\n4.  Cephalexin ___ mg PO ONCE  \r\n5.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n6.  FoLIC Acid 1.6 mg PO DAILY  \r\n7.  Gabapentin 400 mg PO BID  \r\n8.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n10.  Mycophenolate Mofetil 500 mg PO BID  \r\n11.  Nystatin Cream 1 Appl TP BID:PRN fungal rash  \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n14.  PredniSONE 5 mg PO DAILY  \r\n15.  Restasis 0.05 % ophthalmic (eye) BID  \r\n16.  Rivaroxaban 20 mg PO DAILY  \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n19.  Venlafaxine 25 mg PO DAILY  \r\n20.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n4) Cutaneous candidiasis of groin \r\n5) RLE DVT\r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___.\r\n\r\nWHY WAS I IN THE HOSPITAL?\r\n- You had symptoms of a respiratory infection.\r\n\r\nWHAT HAPPENED TO ME IN THE HOSPITAL?\r\n- You were started on antibiotics to treat a possible bacterial \r\nlung infection, and were treated symptomatically with inhalers, \r\npain medicine and fluids.\r\n- Many tests were done to look for causes of infection.\r\n- We feel you most likely had a bacterial infection of your \r\nlungs and gave you medicine to treat it \r\n\r\nWHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?\r\n- Continue to take all your medicines and keep your \r\nappointments.\r\n\r\nWe wish you the best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-26:1",
      "text": "History of Present Illness:\nMs. ___ is a ___ year old female with transformed DLBCL with \na\nhistory of stage IIA follicular lymphoma with treatment\nrelated MDS ___ allogeneic stem cell transplant on ___ who\npresents with four days of productive cough, fevers and chills. She called her ___ clinic on ___ and reported fever,\nchills, and productive cough. She had been seen at urgent care\nearlier on ___ and received CXR which was consistent with\npneumonia, and she was treated with ceftriaxone 1g, steroids and\nDuoNebs. She called ___ clinic due to lack of improvement. She was referred to ED for admission and IV antibiotics, given\nher pneumonia and history of allogenic transplant. In the ED, her vitals were: T 98.8, HR 96, BP 129/65, RR 18, \nSPO2\n97% RA. Lung exam was significant for diffuse expiratory \nwheezing\nand rhonchi. Labs were remarkable for WBC 13, HGB 13, plt 256, K\n4.6, Cr 1.2. She was given azithromycin, albuterol nebs, DuoNeb,\nIVF. On arrival to OMED, she reports she has laryngitis and continued\ncough. She has multiple sick contacts (grandchildren at home who\nhave colds). She denies current fever, chills, abdominal pain,\nnausea, diarrhea, dysuria, leg swelling. REVIEW OF SYSTEMS:  \nA complete 10-point review of systems was performed and was\nnegative unless otherwise noted in the HPI.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-26",
        "chart_time": "105179",
        "section": "General",
        "position": 1,
        "tokenCount": 328,
        "note_metadata": {
          "note_id": "18887130-DS-26",
          "subject_id": 18887130,
          "hadm_id": 29331505,
          "note_type": "DS",
          "note_seq": 26,
          "charttime": 105179,
          "storetime": 105179.69236111111,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, chills, cough\r\n \r\nMajor Surgical or Invasive Procedure:\r\nnone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na\r\nhistory of stage IIA follicular lymphoma with treatment\r\nrelated MDS ___ allogeneic stem cell transplant on ___ who\r\npresents with four days of productive cough, fevers and chills.\r\n\r\nShe called her ___ clinic on ___ and reported fever,\r\nchills, and productive cough. She had been seen at urgent care\r\nearlier on ___ and received CXR which was consistent with\r\npneumonia, and she was treated with ceftriaxone 1g, steroids and\r\nDuoNebs. She called ___ clinic due to lack of improvement.\r\nShe was referred to ED for admission and IV antibiotics, given\r\nher pneumonia and history of allogenic transplant.\r\n\r\nIn the ED, her vitals were: T 98.8, HR 96, BP 129/65, RR 18, \r\nSPO2\r\n97% RA. Lung exam was significant for diffuse expiratory \r\nwheezing\r\nand rhonchi. Labs were remarkable for WBC 13, HGB 13, plt 256, K\r\n4.6, Cr 1.2. She was given azithromycin, albuterol nebs, DuoNeb,\r\nIVF.\r\n\r\nOn arrival to OMED, she reports she has laryngitis and continued\r\ncough. She has multiple sick contacts (grandchildren at home who\r\nhave colds). She denies current fever, chills, abdominal pain,\r\nnausea, diarrhea, dysuria, leg swelling.\r\n\r\nREVIEW OF SYSTEMS:  \r\nA complete 10-point review of systems was performed and was\r\nnegative unless otherwise noted in the HPI.  \r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY: \r\n Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO.  Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h).  Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging.  MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact.  Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning.  D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n\r\nTRANSPLANT DATA:\r\n  Transplant Date: ___\r\n  Graft: URD\r\n  Conditioning Intensity: Reduced-Intensity\r\n  Conditioning Regimen: Flu/Bu/ATG\r\n\r\n  Donor Info: ___ CMV(+), ABO: Opos\r\n  Recipient Info: CMV(+), ABO: Opos  \r\n \r\n\r\nPAST MEDICAL HISTORY:  \r\n- CVID\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- RLE DVT, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- R internal carotid cavernous sinus aneurism ___ coiling \r\n___\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- + Parainfluenza, ___\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:  \r\n___ ___ Temp: 98.3 PO BP: 110/42 HR: 91 RR: 20 O2 sat: 97%\r\nO2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nGU: Cutaneous candiasis in groin, R worse than L\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye, and hyperthesia of the right V1 distribution. CN II-XII\r\notherwise intact. Strength ___ in all extremities. Sensation\r\nintact in all extremities.\r\n\r\nDischarge Physical Exam:\r\nVS: ___ ___ Temp: 98.1 PO BP: 124/51 Sitting HR: 95 RR: 18\r\nO2 sat: 97% O2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n==============\r\n___ 11:00PM BLOOD WBC-13.0* RBC-4.07 Hgb-13.0 Hct-40.9 \r\nMCV-101* MCH-31.9 MCHC-31.8* RDW-14.1 RDWSD-51.1* Plt ___\r\n___ 11:00PM BLOOD Neuts-93.1* Lymphs-4.5* Monos-1.8* \r\nEos-0.1* Baso-0.1 Im ___ AbsNeut-12.08* AbsLymp-0.59* \r\nAbsMono-0.24 AbsEos-0.01* AbsBaso-0.01\r\n___ 11:00PM BLOOD Glucose-234* UreaN-14 Creat-1.2* Na-142 \r\nK-4.6 Cl-105 HCO3-21* AnGap-16\r\n___ 11:00PM BLOOD ALT-14 AST-19 AlkPhos-151* TotBili-0.2\r\n___ 11:00PM BLOOD Albumin-4.2\r\n___ 11:00PM BLOOD IgG-713\r\n___ 01:51AM BLOOD Lactate-1.3\r\n\r\nMICRO:\r\n======\r\n___ urine culture: negative\r\n___ fluA&B PCR: negative\r\n___ blood cultures: pending ***\r\n___ urine legionella antigen: negative\r\n___ urine strep pneumo Ag: pending ***\r\n___ respiratory viral screen and culture: pending ***\r\n\r\nIMAGING AND STUDIES:\r\n===================\r\n___ CXR:\r\nNo acute intrathoracic process.\r\n\r\n___ ECG: QTc 487\r\n\r\nDISCHARGE LABS:\r\n===============\r\n\r\n___ 07:00AM BLOOD WBC-5.6 RBC-3.91 Hgb-12.6 Hct-39.7 \r\nMCV-102* MCH-32.2* MCHC-31.7* RDW-14.4 RDWSD-53.7* Plt ___\r\n___ 07:00AM BLOOD Plt ___\r\n \r\nBrief Hospital Course:\r\nSUMMARY:\r\n========= \r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na history of stage IIA follicular lymphoma with treatment \r\nrelated MDS ___ allogeneic stem cell transplant on ___ who \r\npresents with four days of productive cough, fevers and chills \r\nconsistent with community acquired pneumonia \r\n\r\nACTIVE ISSUES:\r\n=============\r\n#community acquired pneumonia \r\nMost likely etiology is community acquired pneumonia, given \r\nabsence of consolidation on CXR, her sick contacts (grandkids \r\nwith colds), and lung exam with bronchial breath sounds and \r\nwheezing. Flu swab negative. Preliminary results from the viral \r\nrespiratory screen was negative. Given her immunocompromised \r\nstate, will treat for CAP. D1 CTX ___, D1 azithromycin ___. \r\nHer symptoms were treated with DuonNebs, Flovent, albuterol, and \r\nguafenisen. We discharged her home with lovenox to complete a 5 \r\nday course of antibiotics ending on ___\r\n\r\n#CVID\r\nReceives IVIG every 1 - 2 months to keep IGG > 500. Her last \r\ninfusion was ~1 month ago. IGG 715 this admission, so IVIG was \r\nnot given this admission. She was monitored for signs of \r\ninfection and treated as above.\r\n\r\n#MDS ___ allogeneic stem cell transplant on ___\r\nHer outpatient oncology team was notified of her admission. Her \r\nhome prednisone and MMF were continued, as well as her home \r\nacyclovir and Bactrim.\r\n\r\n#Cutaneous candidiasis of groin\r\nHas required 5-day course of fluconazole in past to resolve. She \r\nwas treated with nystatin cream only, due to hesitancy to \r\nprescribe a systemic antifungal with other QTc prolonging meds \r\n(azithro).\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Right lower extremity DVT: IVC filter in place. Continued home \r\nrivaroxaban.\r\n\r\n#GERD: continued home omeprazole.\r\n\r\n#Osteoarthritis \r\n#Cervical radiculopathy\r\n#Sciatica\r\n#Migraines\r\nContinued home gabapentin. Tylenol PRN.\r\n\r\n#Obstructive sleep apnea: she used her home CPAP while \r\ninpatient.\r\n\r\n#H/O cerebral aneurism: Noted on MRA with small R internal \r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm \r\n(___). Her home Neurontin was continued.\r\n\r\n#Asthma: continued home Flovent and DuoNebs, with albuterol PRN.\r\n\r\n#Hypertension: she was noted to not be on antihypertensives at \r\nhome. Her BP was monitored while inpatient.\r\n\r\n#Mood disorder: her home venlafaxine was continued.\r\n\r\nTRANSITIONAL ISSUES:\r\n===================\r\n[]Levofloxacin course ending ___\r\n[]Follow up with oncology ___\r\n[]Viral culture pending on discharge \r\n[]Glucose on admission was 234, consider screening for DM2 as \r\noutpatient \r\n\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: full code (confirmed)\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Rivaroxaban 20 mg PO DAILY \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Gabapentin 400 mg PO BID \r\n4. PredniSONE 5 mg PO DAILY \r\n5. Zofran (ondansetron HCl) 4 mg oral Q8H \r\n6. Mycophenolate Mofetil 500 mg PO BID \r\n7. Venlafaxine 25 mg PO DAILY \r\n8. Acyclovir 400 mg PO TID \r\n9. Cephalexin ___ mg PO ONCE \r\n10. Restasis 0.05 % ophthalmic (eye) BID \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n12. Hydrocortisone Cream 1% 1 Appl TP BID \r\n13. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n14. Nystatin Cream 1 Appl TP BID:PRN fungal rash \r\n15. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n16. Vitamin D ___ UNIT PO DAILY \r\n17. FoLIC Acid 1.6 mg PO DAILY \r\n18. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1.  GuaiFENesin ER 600 mg PO Q12H \r\nRX *guaifenesin 600 mg 1 tablet(s) by mouth q12hrs prn Disp #*10 \r\nTablet Refills:*0 \r\n2.  Levofloxacin 500 mg PO Q24H Duration: 2 Days \r\nRX *levofloxacin [Levaquin] 500 mg 1 tablet(s) by mouth daily \r\nDisp #*2 Tablet Refills:*0 \r\n3.  Acyclovir 400 mg PO TID  \r\n4.  Cephalexin ___ mg PO ONCE  \r\n5.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n6.  FoLIC Acid 1.6 mg PO DAILY  \r\n7.  Gabapentin 400 mg PO BID  \r\n8.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n10.  Mycophenolate Mofetil 500 mg PO BID  \r\n11.  Nystatin Cream 1 Appl TP BID:PRN fungal rash  \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n14.  PredniSONE 5 mg PO DAILY  \r\n15.  Restasis 0.05 % ophthalmic (eye) BID  \r\n16.  Rivaroxaban 20 mg PO DAILY  \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n19.  Venlafaxine 25 mg PO DAILY  \r\n20.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n4) Cutaneous candidiasis of groin \r\n5) RLE DVT\r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___.\r\n\r\nWHY WAS I IN THE HOSPITAL?\r\n- You had symptoms of a respiratory infection.\r\n\r\nWHAT HAPPENED TO ME IN THE HOSPITAL?\r\n- You were started on antibiotics to treat a possible bacterial \r\nlung infection, and were treated symptomatically with inhalers, \r\npain medicine and fluids.\r\n- Many tests were done to look for causes of infection.\r\n- We feel you most likely had a bacterial infection of your \r\nlungs and gave you medicine to treat it \r\n\r\nWHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?\r\n- Continue to take all your medicines and keep your \r\nappointments.\r\n\r\nWe wish you the best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-26:2",
      "text": "Past Medical History:\nPAST ONCOLOGIC HISTORY: \n Transformed DLBCL with a history of follicular lymphoma stage\nIIA\n- ___ developed worsening musculoskeletal back pain, early\nsatiety, hypoalbuminemia and found to have mesenteric mass\n- ?___ ex lap with 15 cm lobulated mass involving the\nduodenum, retroperitoneum and celiac access. Biopsies showed\nFollicular lymphomas grade II/III. Reportedly negative staging\nGallium scan. CD10+ BCL2+\n- ___ completed 6 cycles CHOP, complications included\nSVC/innominate thrombus (tPA)\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\nmarrow at completion was negative for lymphomatous involvement. - ___ PET-CT with very slight amount of increased tracer\nactivity within the posterior left supraclavicular region. No\nother areas of FDG avid disease were noted \n- ___ through ___ per records she was treated with CVP\nfollowed by course of single agent Rituxan\n- ___ through ___ surveillance imaging with no evidence of\nrecurrent disease, stable mesenteric mass. - ___ abdominal pain led to CT with no change in mass size,\nincreased conspicuity of nodular borders\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\nstable mesenteric mass with low level SUV 2.2 stable since \nprior. - ___ CT torso showed persistent mesenteric and left hilar\nlymphadenopathy. Stable right middle lobe small focus of ground\nglass opacity and adjacent subpleural fat hypertrophy, \nsuggestive\nof inflammatory process. Stable right adnexal cyst. - ___ Presented to PCP ___ ___iscomfort. Exam\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\nnormal differential, PLT 452. - ___ PET CT revealed, \"Large left cervical,\nsupraclavicular, mediastinal lymphadenopathy, and \nretroperitoneal\nlymphadenopathy, and small mesenteric\nlymphadenopathy, all markedly FDG-avid and concerning for\nlymphoma.\" SUVmax 35.5. - ___iopsy revealed diffuse large B cell\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \nare\npending\n- ___ C1D1 ICE\n- ___ C1 Rituximab, clinically improved adenopathy\n- ___ C2 Rituximab, WBC 6.5, PLT 43\n- ___ Admit for C2D1 ICE\n- ___ C3 Rituximab\n- ___ PET CT showed almost complete resolution of FDG avid\ndisease with a residual focus of avidity in the bed of the \nformer\nabdominal mass, SUV 3\n- ___ C4 Rituximab\n- ___ C4 ICE followed by stem cell mobilization and\ncollection, BMBx showed a nest of CLL unrelated to her \naggressive\nlymphoma\n- ___ Presented with large DVTs, SVC filter placed\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\n- ___ Switched to Rivaroxiban for AC\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\ncytopenias\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-26",
        "chart_time": "105179",
        "section": "General",
        "position": 2,
        "tokenCount": 681,
        "note_metadata": {
          "note_id": "18887130-DS-26",
          "subject_id": 18887130,
          "hadm_id": 29331505,
          "note_type": "DS",
          "note_seq": 26,
          "charttime": 105179,
          "storetime": 105179.69236111111,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, chills, cough\r\n \r\nMajor Surgical or Invasive Procedure:\r\nnone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na\r\nhistory of stage IIA follicular lymphoma with treatment\r\nrelated MDS ___ allogeneic stem cell transplant on ___ who\r\npresents with four days of productive cough, fevers and chills.\r\n\r\nShe called her ___ clinic on ___ and reported fever,\r\nchills, and productive cough. She had been seen at urgent care\r\nearlier on ___ and received CXR which was consistent with\r\npneumonia, and she was treated with ceftriaxone 1g, steroids and\r\nDuoNebs. She called ___ clinic due to lack of improvement.\r\nShe was referred to ED for admission and IV antibiotics, given\r\nher pneumonia and history of allogenic transplant.\r\n\r\nIn the ED, her vitals were: T 98.8, HR 96, BP 129/65, RR 18, \r\nSPO2\r\n97% RA. Lung exam was significant for diffuse expiratory \r\nwheezing\r\nand rhonchi. Labs were remarkable for WBC 13, HGB 13, plt 256, K\r\n4.6, Cr 1.2. She was given azithromycin, albuterol nebs, DuoNeb,\r\nIVF.\r\n\r\nOn arrival to OMED, she reports she has laryngitis and continued\r\ncough. She has multiple sick contacts (grandchildren at home who\r\nhave colds). She denies current fever, chills, abdominal pain,\r\nnausea, diarrhea, dysuria, leg swelling.\r\n\r\nREVIEW OF SYSTEMS:  \r\nA complete 10-point review of systems was performed and was\r\nnegative unless otherwise noted in the HPI.  \r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY: \r\n Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO.  Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h).  Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging.  MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact.  Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning.  D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n\r\nTRANSPLANT DATA:\r\n  Transplant Date: ___\r\n  Graft: URD\r\n  Conditioning Intensity: Reduced-Intensity\r\n  Conditioning Regimen: Flu/Bu/ATG\r\n\r\n  Donor Info: ___ CMV(+), ABO: Opos\r\n  Recipient Info: CMV(+), ABO: Opos  \r\n \r\n\r\nPAST MEDICAL HISTORY:  \r\n- CVID\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- RLE DVT, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- R internal carotid cavernous sinus aneurism ___ coiling \r\n___\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- + Parainfluenza, ___\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:  \r\n___ ___ Temp: 98.3 PO BP: 110/42 HR: 91 RR: 20 O2 sat: 97%\r\nO2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nGU: Cutaneous candiasis in groin, R worse than L\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye, and hyperthesia of the right V1 distribution. CN II-XII\r\notherwise intact. Strength ___ in all extremities. Sensation\r\nintact in all extremities.\r\n\r\nDischarge Physical Exam:\r\nVS: ___ ___ Temp: 98.1 PO BP: 124/51 Sitting HR: 95 RR: 18\r\nO2 sat: 97% O2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n==============\r\n___ 11:00PM BLOOD WBC-13.0* RBC-4.07 Hgb-13.0 Hct-40.9 \r\nMCV-101* MCH-31.9 MCHC-31.8* RDW-14.1 RDWSD-51.1* Plt ___\r\n___ 11:00PM BLOOD Neuts-93.1* Lymphs-4.5* Monos-1.8* \r\nEos-0.1* Baso-0.1 Im ___ AbsNeut-12.08* AbsLymp-0.59* \r\nAbsMono-0.24 AbsEos-0.01* AbsBaso-0.01\r\n___ 11:00PM BLOOD Glucose-234* UreaN-14 Creat-1.2* Na-142 \r\nK-4.6 Cl-105 HCO3-21* AnGap-16\r\n___ 11:00PM BLOOD ALT-14 AST-19 AlkPhos-151* TotBili-0.2\r\n___ 11:00PM BLOOD Albumin-4.2\r\n___ 11:00PM BLOOD IgG-713\r\n___ 01:51AM BLOOD Lactate-1.3\r\n\r\nMICRO:\r\n======\r\n___ urine culture: negative\r\n___ fluA&B PCR: negative\r\n___ blood cultures: pending ***\r\n___ urine legionella antigen: negative\r\n___ urine strep pneumo Ag: pending ***\r\n___ respiratory viral screen and culture: pending ***\r\n\r\nIMAGING AND STUDIES:\r\n===================\r\n___ CXR:\r\nNo acute intrathoracic process.\r\n\r\n___ ECG: QTc 487\r\n\r\nDISCHARGE LABS:\r\n===============\r\n\r\n___ 07:00AM BLOOD WBC-5.6 RBC-3.91 Hgb-12.6 Hct-39.7 \r\nMCV-102* MCH-32.2* MCHC-31.7* RDW-14.4 RDWSD-53.7* Plt ___\r\n___ 07:00AM BLOOD Plt ___\r\n \r\nBrief Hospital Course:\r\nSUMMARY:\r\n========= \r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na history of stage IIA follicular lymphoma with treatment \r\nrelated MDS ___ allogeneic stem cell transplant on ___ who \r\npresents with four days of productive cough, fevers and chills \r\nconsistent with community acquired pneumonia \r\n\r\nACTIVE ISSUES:\r\n=============\r\n#community acquired pneumonia \r\nMost likely etiology is community acquired pneumonia, given \r\nabsence of consolidation on CXR, her sick contacts (grandkids \r\nwith colds), and lung exam with bronchial breath sounds and \r\nwheezing. Flu swab negative. Preliminary results from the viral \r\nrespiratory screen was negative. Given her immunocompromised \r\nstate, will treat for CAP. D1 CTX ___, D1 azithromycin ___. \r\nHer symptoms were treated with DuonNebs, Flovent, albuterol, and \r\nguafenisen. We discharged her home with lovenox to complete a 5 \r\nday course of antibiotics ending on ___\r\n\r\n#CVID\r\nReceives IVIG every 1 - 2 months to keep IGG > 500. Her last \r\ninfusion was ~1 month ago. IGG 715 this admission, so IVIG was \r\nnot given this admission. She was monitored for signs of \r\ninfection and treated as above.\r\n\r\n#MDS ___ allogeneic stem cell transplant on ___\r\nHer outpatient oncology team was notified of her admission. Her \r\nhome prednisone and MMF were continued, as well as her home \r\nacyclovir and Bactrim.\r\n\r\n#Cutaneous candidiasis of groin\r\nHas required 5-day course of fluconazole in past to resolve. She \r\nwas treated with nystatin cream only, due to hesitancy to \r\nprescribe a systemic antifungal with other QTc prolonging meds \r\n(azithro).\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Right lower extremity DVT: IVC filter in place. Continued home \r\nrivaroxaban.\r\n\r\n#GERD: continued home omeprazole.\r\n\r\n#Osteoarthritis \r\n#Cervical radiculopathy\r\n#Sciatica\r\n#Migraines\r\nContinued home gabapentin. Tylenol PRN.\r\n\r\n#Obstructive sleep apnea: she used her home CPAP while \r\ninpatient.\r\n\r\n#H/O cerebral aneurism: Noted on MRA with small R internal \r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm \r\n(___). Her home Neurontin was continued.\r\n\r\n#Asthma: continued home Flovent and DuoNebs, with albuterol PRN.\r\n\r\n#Hypertension: she was noted to not be on antihypertensives at \r\nhome. Her BP was monitored while inpatient.\r\n\r\n#Mood disorder: her home venlafaxine was continued.\r\n\r\nTRANSITIONAL ISSUES:\r\n===================\r\n[]Levofloxacin course ending ___\r\n[]Follow up with oncology ___\r\n[]Viral culture pending on discharge \r\n[]Glucose on admission was 234, consider screening for DM2 as \r\noutpatient \r\n\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: full code (confirmed)\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Rivaroxaban 20 mg PO DAILY \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Gabapentin 400 mg PO BID \r\n4. PredniSONE 5 mg PO DAILY \r\n5. Zofran (ondansetron HCl) 4 mg oral Q8H \r\n6. Mycophenolate Mofetil 500 mg PO BID \r\n7. Venlafaxine 25 mg PO DAILY \r\n8. Acyclovir 400 mg PO TID \r\n9. Cephalexin ___ mg PO ONCE \r\n10. Restasis 0.05 % ophthalmic (eye) BID \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n12. Hydrocortisone Cream 1% 1 Appl TP BID \r\n13. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n14. Nystatin Cream 1 Appl TP BID:PRN fungal rash \r\n15. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n16. Vitamin D ___ UNIT PO DAILY \r\n17. FoLIC Acid 1.6 mg PO DAILY \r\n18. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1.  GuaiFENesin ER 600 mg PO Q12H \r\nRX *guaifenesin 600 mg 1 tablet(s) by mouth q12hrs prn Disp #*10 \r\nTablet Refills:*0 \r\n2.  Levofloxacin 500 mg PO Q24H Duration: 2 Days \r\nRX *levofloxacin [Levaquin] 500 mg 1 tablet(s) by mouth daily \r\nDisp #*2 Tablet Refills:*0 \r\n3.  Acyclovir 400 mg PO TID  \r\n4.  Cephalexin ___ mg PO ONCE  \r\n5.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n6.  FoLIC Acid 1.6 mg PO DAILY  \r\n7.  Gabapentin 400 mg PO BID  \r\n8.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n10.  Mycophenolate Mofetil 500 mg PO BID  \r\n11.  Nystatin Cream 1 Appl TP BID:PRN fungal rash  \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n14.  PredniSONE 5 mg PO DAILY  \r\n15.  Restasis 0.05 % ophthalmic (eye) BID  \r\n16.  Rivaroxaban 20 mg PO DAILY  \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n19.  Venlafaxine 25 mg PO DAILY  \r\n20.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n4) Cutaneous candidiasis of groin \r\n5) RLE DVT\r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___.\r\n\r\nWHY WAS I IN THE HOSPITAL?\r\n- You had symptoms of a respiratory infection.\r\n\r\nWHAT HAPPENED TO ME IN THE HOSPITAL?\r\n- You were started on antibiotics to treat a possible bacterial \r\nlung infection, and were treated symptomatically with inhalers, \r\npain medicine and fluids.\r\n- Many tests were done to look for causes of infection.\r\n- We feel you most likely had a bacterial infection of your \r\nlungs and gave you medicine to treat it \r\n\r\nWHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?\r\n- Continue to take all your medicines and keep your \r\nappointments.\r\n\r\nWe wish you the best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-26:3",
      "text": "MIB and cytogenetics \nare\npending\n- ___ C1D1 ICE\n- ___ C1 Rituximab, clinically improved adenopathy\n- ___ C2 Rituximab, WBC 6.5, PLT 43\n- ___ Admit for C2D1 ICE\n- ___ C3 Rituximab\n- ___ PET CT showed almost complete resolution of FDG avid\ndisease with a residual focus of avidity in the bed of the \nformer\nabdominal mass, SUV 3\n- ___ C4 Rituximab\n- ___ C4 ICE followed by stem cell mobilization and\ncollection, BMBx showed a nest of CLL unrelated to her \naggressive\nlymphoma\n- ___ Presented with large DVTs, SVC filter placed\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\n- ___ Switched to Rivaroxiban for AC\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\ncytopenias\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose. - ___, Norovirus\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\nDLCO. Finally d/ced ___. - IVIg 400 mg/kg, continues monthly for\nHypogammaglobuonemia/CVID. - ___, CT torso with no evidence of active disease. Stable\nappearance of a conglomeration of mesenteric lymph nodes. - ___, Right total knee replacement, complicated by foot\ndrop likely due to irritation of peroneal nerve from the CPM\nmachine, as well as a cellulitis of the right leg; same leg as\nher previous DVT and her circulation is poor. - ___, CT Torso with no evidence of active disease. Stable appearance of conglomerate of mesenteric LN's. Increased\ndilatation of the main pulmonary artery suggests worsening\npulmonary arterial hypertension of indeterminate etiology. - ___, CT torso with no evidence of active disease. Increased\ndilation of pulmonary artery. Evaluated by Dr. ___\n- ___, Increasing right leg swelling and shortness of breath\nwith noted DVT; no DVT. Xarelto increased back to 20 mg\ndaily(had been decreased given age and prior chronic DVT). No\nevidence for lymphoma on CT imaging. - ___, noted drop in blood counts. Bone marrow biopsy showed\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. Cytogenetics showing multiple abnormalities. - ___, C1 Dacogen\n- ___, admitted with fever in setting of neutropenia, and\nincreasing right sided back pain. No infectious source found;\nafter consultation with ID, it was decided to treat empirically\nfor presumptive osteomyelitis/discitis with 6 weeks of \nvancomycin\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\nq24h). Required short time of pain medicines for back pain. - ___, C2 Dacogen\n- ___, admitted with increased confusion and issues of\nword finding. Head CT and MRI of the head did not show any\nabnormality. Treated with concern for meningitis and remained \non\nher other antibiotics for treatment of presumed osteomyelitis.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-26",
        "chart_time": "105179",
        "section": "General",
        "position": 3,
        "tokenCount": 688,
        "note_metadata": {
          "note_id": "18887130-DS-26",
          "subject_id": 18887130,
          "hadm_id": 29331505,
          "note_type": "DS",
          "note_seq": 26,
          "charttime": 105179,
          "storetime": 105179.69236111111,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, chills, cough\r\n \r\nMajor Surgical or Invasive Procedure:\r\nnone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na\r\nhistory of stage IIA follicular lymphoma with treatment\r\nrelated MDS ___ allogeneic stem cell transplant on ___ who\r\npresents with four days of productive cough, fevers and chills.\r\n\r\nShe called her ___ clinic on ___ and reported fever,\r\nchills, and productive cough. She had been seen at urgent care\r\nearlier on ___ and received CXR which was consistent with\r\npneumonia, and she was treated with ceftriaxone 1g, steroids and\r\nDuoNebs. She called ___ clinic due to lack of improvement.\r\nShe was referred to ED for admission and IV antibiotics, given\r\nher pneumonia and history of allogenic transplant.\r\n\r\nIn the ED, her vitals were: T 98.8, HR 96, BP 129/65, RR 18, \r\nSPO2\r\n97% RA. Lung exam was significant for diffuse expiratory \r\nwheezing\r\nand rhonchi. Labs were remarkable for WBC 13, HGB 13, plt 256, K\r\n4.6, Cr 1.2. She was given azithromycin, albuterol nebs, DuoNeb,\r\nIVF.\r\n\r\nOn arrival to OMED, she reports she has laryngitis and continued\r\ncough. She has multiple sick contacts (grandchildren at home who\r\nhave colds). She denies current fever, chills, abdominal pain,\r\nnausea, diarrhea, dysuria, leg swelling.\r\n\r\nREVIEW OF SYSTEMS:  \r\nA complete 10-point review of systems was performed and was\r\nnegative unless otherwise noted in the HPI.  \r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY: \r\n Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO.  Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h).  Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging.  MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact.  Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning.  D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n\r\nTRANSPLANT DATA:\r\n  Transplant Date: ___\r\n  Graft: URD\r\n  Conditioning Intensity: Reduced-Intensity\r\n  Conditioning Regimen: Flu/Bu/ATG\r\n\r\n  Donor Info: ___ CMV(+), ABO: Opos\r\n  Recipient Info: CMV(+), ABO: Opos  \r\n \r\n\r\nPAST MEDICAL HISTORY:  \r\n- CVID\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- RLE DVT, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- R internal carotid cavernous sinus aneurism ___ coiling \r\n___\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- + Parainfluenza, ___\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:  \r\n___ ___ Temp: 98.3 PO BP: 110/42 HR: 91 RR: 20 O2 sat: 97%\r\nO2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nGU: Cutaneous candiasis in groin, R worse than L\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye, and hyperthesia of the right V1 distribution. CN II-XII\r\notherwise intact. Strength ___ in all extremities. Sensation\r\nintact in all extremities.\r\n\r\nDischarge Physical Exam:\r\nVS: ___ ___ Temp: 98.1 PO BP: 124/51 Sitting HR: 95 RR: 18\r\nO2 sat: 97% O2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n==============\r\n___ 11:00PM BLOOD WBC-13.0* RBC-4.07 Hgb-13.0 Hct-40.9 \r\nMCV-101* MCH-31.9 MCHC-31.8* RDW-14.1 RDWSD-51.1* Plt ___\r\n___ 11:00PM BLOOD Neuts-93.1* Lymphs-4.5* Monos-1.8* \r\nEos-0.1* Baso-0.1 Im ___ AbsNeut-12.08* AbsLymp-0.59* \r\nAbsMono-0.24 AbsEos-0.01* AbsBaso-0.01\r\n___ 11:00PM BLOOD Glucose-234* UreaN-14 Creat-1.2* Na-142 \r\nK-4.6 Cl-105 HCO3-21* AnGap-16\r\n___ 11:00PM BLOOD ALT-14 AST-19 AlkPhos-151* TotBili-0.2\r\n___ 11:00PM BLOOD Albumin-4.2\r\n___ 11:00PM BLOOD IgG-713\r\n___ 01:51AM BLOOD Lactate-1.3\r\n\r\nMICRO:\r\n======\r\n___ urine culture: negative\r\n___ fluA&B PCR: negative\r\n___ blood cultures: pending ***\r\n___ urine legionella antigen: negative\r\n___ urine strep pneumo Ag: pending ***\r\n___ respiratory viral screen and culture: pending ***\r\n\r\nIMAGING AND STUDIES:\r\n===================\r\n___ CXR:\r\nNo acute intrathoracic process.\r\n\r\n___ ECG: QTc 487\r\n\r\nDISCHARGE LABS:\r\n===============\r\n\r\n___ 07:00AM BLOOD WBC-5.6 RBC-3.91 Hgb-12.6 Hct-39.7 \r\nMCV-102* MCH-32.2* MCHC-31.7* RDW-14.4 RDWSD-53.7* Plt ___\r\n___ 07:00AM BLOOD Plt ___\r\n \r\nBrief Hospital Course:\r\nSUMMARY:\r\n========= \r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na history of stage IIA follicular lymphoma with treatment \r\nrelated MDS ___ allogeneic stem cell transplant on ___ who \r\npresents with four days of productive cough, fevers and chills \r\nconsistent with community acquired pneumonia \r\n\r\nACTIVE ISSUES:\r\n=============\r\n#community acquired pneumonia \r\nMost likely etiology is community acquired pneumonia, given \r\nabsence of consolidation on CXR, her sick contacts (grandkids \r\nwith colds), and lung exam with bronchial breath sounds and \r\nwheezing. Flu swab negative. Preliminary results from the viral \r\nrespiratory screen was negative. Given her immunocompromised \r\nstate, will treat for CAP. D1 CTX ___, D1 azithromycin ___. \r\nHer symptoms were treated with DuonNebs, Flovent, albuterol, and \r\nguafenisen. We discharged her home with lovenox to complete a 5 \r\nday course of antibiotics ending on ___\r\n\r\n#CVID\r\nReceives IVIG every 1 - 2 months to keep IGG > 500. Her last \r\ninfusion was ~1 month ago. IGG 715 this admission, so IVIG was \r\nnot given this admission. She was monitored for signs of \r\ninfection and treated as above.\r\n\r\n#MDS ___ allogeneic stem cell transplant on ___\r\nHer outpatient oncology team was notified of her admission. Her \r\nhome prednisone and MMF were continued, as well as her home \r\nacyclovir and Bactrim.\r\n\r\n#Cutaneous candidiasis of groin\r\nHas required 5-day course of fluconazole in past to resolve. She \r\nwas treated with nystatin cream only, due to hesitancy to \r\nprescribe a systemic antifungal with other QTc prolonging meds \r\n(azithro).\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Right lower extremity DVT: IVC filter in place. Continued home \r\nrivaroxaban.\r\n\r\n#GERD: continued home omeprazole.\r\n\r\n#Osteoarthritis \r\n#Cervical radiculopathy\r\n#Sciatica\r\n#Migraines\r\nContinued home gabapentin. Tylenol PRN.\r\n\r\n#Obstructive sleep apnea: she used her home CPAP while \r\ninpatient.\r\n\r\n#H/O cerebral aneurism: Noted on MRA with small R internal \r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm \r\n(___). Her home Neurontin was continued.\r\n\r\n#Asthma: continued home Flovent and DuoNebs, with albuterol PRN.\r\n\r\n#Hypertension: she was noted to not be on antihypertensives at \r\nhome. Her BP was monitored while inpatient.\r\n\r\n#Mood disorder: her home venlafaxine was continued.\r\n\r\nTRANSITIONAL ISSUES:\r\n===================\r\n[]Levofloxacin course ending ___\r\n[]Follow up with oncology ___\r\n[]Viral culture pending on discharge \r\n[]Glucose on admission was 234, consider screening for DM2 as \r\noutpatient \r\n\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: full code (confirmed)\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Rivaroxaban 20 mg PO DAILY \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Gabapentin 400 mg PO BID \r\n4. PredniSONE 5 mg PO DAILY \r\n5. Zofran (ondansetron HCl) 4 mg oral Q8H \r\n6. Mycophenolate Mofetil 500 mg PO BID \r\n7. Venlafaxine 25 mg PO DAILY \r\n8. Acyclovir 400 mg PO TID \r\n9. Cephalexin ___ mg PO ONCE \r\n10. Restasis 0.05 % ophthalmic (eye) BID \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n12. Hydrocortisone Cream 1% 1 Appl TP BID \r\n13. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n14. Nystatin Cream 1 Appl TP BID:PRN fungal rash \r\n15. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n16. Vitamin D ___ UNIT PO DAILY \r\n17. FoLIC Acid 1.6 mg PO DAILY \r\n18. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1.  GuaiFENesin ER 600 mg PO Q12H \r\nRX *guaifenesin 600 mg 1 tablet(s) by mouth q12hrs prn Disp #*10 \r\nTablet Refills:*0 \r\n2.  Levofloxacin 500 mg PO Q24H Duration: 2 Days \r\nRX *levofloxacin [Levaquin] 500 mg 1 tablet(s) by mouth daily \r\nDisp #*2 Tablet Refills:*0 \r\n3.  Acyclovir 400 mg PO TID  \r\n4.  Cephalexin ___ mg PO ONCE  \r\n5.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n6.  FoLIC Acid 1.6 mg PO DAILY  \r\n7.  Gabapentin 400 mg PO BID  \r\n8.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n10.  Mycophenolate Mofetil 500 mg PO BID  \r\n11.  Nystatin Cream 1 Appl TP BID:PRN fungal rash  \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n14.  PredniSONE 5 mg PO DAILY  \r\n15.  Restasis 0.05 % ophthalmic (eye) BID  \r\n16.  Rivaroxaban 20 mg PO DAILY  \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n19.  Venlafaxine 25 mg PO DAILY  \r\n20.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n4) Cutaneous candidiasis of groin \r\n5) RLE DVT\r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___.\r\n\r\nWHY WAS I IN THE HOSPITAL?\r\n- You had symptoms of a respiratory infection.\r\n\r\nWHAT HAPPENED TO ME IN THE HOSPITAL?\r\n- You were started on antibiotics to treat a possible bacterial \r\nlung infection, and were treated symptomatically with inhalers, \r\npain medicine and fluids.\r\n- Many tests were done to look for causes of infection.\r\n- We feel you most likely had a bacterial infection of your \r\nlungs and gave you medicine to treat it \r\n\r\nWHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?\r\n- Continue to take all your medicines and keep your \r\nappointments.\r\n\r\nWe wish you the best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-26:4",
      "text": "No infectious source found;\nafter consultation with ID, it was decided to treat empirically\nfor presumptive osteomyelitis/discitis with 6 weeks of \nvancomycin\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\nq24h). Required short time of pain medicines for back pain. - ___, C2 Dacogen\n- ___, admitted with increased confusion and issues of\nword finding. Head CT and MRI of the head did not show any\nabnormality. Treated with concern for meningitis and remained \non\nher other antibiotics for treatment of presumed osteomyelitis. Confusion resolved and no infectious etiology was noted except\nfor possible UTI. - ___, Admitted with 2 days of nausea, vomiting, fever,\nconfusion, and urinary incontinence, with infectious workup,\noverall negative, except for positive coronavirus. CTA negative\nfor PE and there was no evidence of pulmonary or abdominal\ninfection on imaging. MRI of brain was negative for an\nintracranial process; MRI spine was negative for abscess or\nosteomyelitis. - ___, C3 Dacogen and discharged to home on ___. - ___, Admitted with diarrhea, decreased appetite. Received IVF support, transfusions and potassium replacement;\ndischarged on ___. - ___, C4 Dacogen\n- ___, Admitted with cough and wheezing. + RSV, treated\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG. - ___, Bone marrow aspirate and biopsy showed a cellular\nmarrow by aspirate with trilineage dyspoitic maturation. By\nimmunohistochemistry CD34 highlights blast cells comprising less\nthan 5% of the overall cellularity. Cellularity in the core\nbiopsy is low, which may be a sampling artifact. Cytogenetics\nrevealed no cells noted with the previously observed complex\nabnormal karyotype with monosomy 7, deletion of 5q and other\nchromosome aberrations associated with myelodysplasia with an\nunfavorable prognosis. - ___, Admitted for MUD allogeneic transplant with Flu/Bu\nand ATG conditioning. D0 = ___. - ___ - ___, admission for aseptic meningitis; noted CMV\nviremia, on Valganciclovir. - ___ - ___, admission for headache, nausea and vomiting\nand development of fevers to 103 with coagulase-negative\ngram-positive cocci noted as S. epidermidis bacteremia;\nDaptomycin for total 6 week course of antibiotics(completed\n___. Also noted for new DVT's of lower legs, on Lovenox\nBID. - ___, admission for increased rash and diarrhea. Started increased systemic steroids and now tapered. TRANSPLANT DATA:\n  Transplant Date: ___\n  Graft: URD\n  Conditioning Intensity: Reduced-Intensity\n  Conditioning Regimen: Flu/Bu/ATG Donor Info: ___ CMV(+), ABO: Opos\n  Recipient Info: CMV(+), ABO: Opos PAST MEDICAL HISTORY:  \n- CVID\n- GERD                                          \n- Osteoarthritis                                         \n- RLE DVT, IVC filter in place\n- Cervical radiculopathy\n- Sciatica\n- Obstructive sleep apnea, wears CPAP\n- R internal carotid cavernous sinus aneurism ___ coiling \n___\n- Asthma\n- Obesity\n- Hypertension\n- Migraines\n- + RSV, ___\n- S. epidermidis bacteremia, POC removed; completed course of\nDaptomycin\n- + Parainfluenza, ___ Social History:\n___ Family History:\nBrother died at ___ from lymphoma. No other family history of\ncancer",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-26",
        "chart_time": "105179",
        "section": "General",
        "position": 4,
        "tokenCount": 789,
        "note_metadata": {
          "note_id": "18887130-DS-26",
          "subject_id": 18887130,
          "hadm_id": 29331505,
          "note_type": "DS",
          "note_seq": 26,
          "charttime": 105179,
          "storetime": 105179.69236111111,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, chills, cough\r\n \r\nMajor Surgical or Invasive Procedure:\r\nnone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na\r\nhistory of stage IIA follicular lymphoma with treatment\r\nrelated MDS ___ allogeneic stem cell transplant on ___ who\r\npresents with four days of productive cough, fevers and chills.\r\n\r\nShe called her ___ clinic on ___ and reported fever,\r\nchills, and productive cough. She had been seen at urgent care\r\nearlier on ___ and received CXR which was consistent with\r\npneumonia, and she was treated with ceftriaxone 1g, steroids and\r\nDuoNebs. She called ___ clinic due to lack of improvement.\r\nShe was referred to ED for admission and IV antibiotics, given\r\nher pneumonia and history of allogenic transplant.\r\n\r\nIn the ED, her vitals were: T 98.8, HR 96, BP 129/65, RR 18, \r\nSPO2\r\n97% RA. Lung exam was significant for diffuse expiratory \r\nwheezing\r\nand rhonchi. Labs were remarkable for WBC 13, HGB 13, plt 256, K\r\n4.6, Cr 1.2. She was given azithromycin, albuterol nebs, DuoNeb,\r\nIVF.\r\n\r\nOn arrival to OMED, she reports she has laryngitis and continued\r\ncough. She has multiple sick contacts (grandchildren at home who\r\nhave colds). She denies current fever, chills, abdominal pain,\r\nnausea, diarrhea, dysuria, leg swelling.\r\n\r\nREVIEW OF SYSTEMS:  \r\nA complete 10-point review of systems was performed and was\r\nnegative unless otherwise noted in the HPI.  \r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY: \r\n Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO.  Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h).  Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging.  MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact.  Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning.  D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n\r\nTRANSPLANT DATA:\r\n  Transplant Date: ___\r\n  Graft: URD\r\n  Conditioning Intensity: Reduced-Intensity\r\n  Conditioning Regimen: Flu/Bu/ATG\r\n\r\n  Donor Info: ___ CMV(+), ABO: Opos\r\n  Recipient Info: CMV(+), ABO: Opos  \r\n \r\n\r\nPAST MEDICAL HISTORY:  \r\n- CVID\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- RLE DVT, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- R internal carotid cavernous sinus aneurism ___ coiling \r\n___\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- + Parainfluenza, ___\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:  \r\n___ ___ Temp: 98.3 PO BP: 110/42 HR: 91 RR: 20 O2 sat: 97%\r\nO2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nGU: Cutaneous candiasis in groin, R worse than L\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye, and hyperthesia of the right V1 distribution. CN II-XII\r\notherwise intact. Strength ___ in all extremities. Sensation\r\nintact in all extremities.\r\n\r\nDischarge Physical Exam:\r\nVS: ___ ___ Temp: 98.1 PO BP: 124/51 Sitting HR: 95 RR: 18\r\nO2 sat: 97% O2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n==============\r\n___ 11:00PM BLOOD WBC-13.0* RBC-4.07 Hgb-13.0 Hct-40.9 \r\nMCV-101* MCH-31.9 MCHC-31.8* RDW-14.1 RDWSD-51.1* Plt ___\r\n___ 11:00PM BLOOD Neuts-93.1* Lymphs-4.5* Monos-1.8* \r\nEos-0.1* Baso-0.1 Im ___ AbsNeut-12.08* AbsLymp-0.59* \r\nAbsMono-0.24 AbsEos-0.01* AbsBaso-0.01\r\n___ 11:00PM BLOOD Glucose-234* UreaN-14 Creat-1.2* Na-142 \r\nK-4.6 Cl-105 HCO3-21* AnGap-16\r\n___ 11:00PM BLOOD ALT-14 AST-19 AlkPhos-151* TotBili-0.2\r\n___ 11:00PM BLOOD Albumin-4.2\r\n___ 11:00PM BLOOD IgG-713\r\n___ 01:51AM BLOOD Lactate-1.3\r\n\r\nMICRO:\r\n======\r\n___ urine culture: negative\r\n___ fluA&B PCR: negative\r\n___ blood cultures: pending ***\r\n___ urine legionella antigen: negative\r\n___ urine strep pneumo Ag: pending ***\r\n___ respiratory viral screen and culture: pending ***\r\n\r\nIMAGING AND STUDIES:\r\n===================\r\n___ CXR:\r\nNo acute intrathoracic process.\r\n\r\n___ ECG: QTc 487\r\n\r\nDISCHARGE LABS:\r\n===============\r\n\r\n___ 07:00AM BLOOD WBC-5.6 RBC-3.91 Hgb-12.6 Hct-39.7 \r\nMCV-102* MCH-32.2* MCHC-31.7* RDW-14.4 RDWSD-53.7* Plt ___\r\n___ 07:00AM BLOOD Plt ___\r\n \r\nBrief Hospital Course:\r\nSUMMARY:\r\n========= \r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na history of stage IIA follicular lymphoma with treatment \r\nrelated MDS ___ allogeneic stem cell transplant on ___ who \r\npresents with four days of productive cough, fevers and chills \r\nconsistent with community acquired pneumonia \r\n\r\nACTIVE ISSUES:\r\n=============\r\n#community acquired pneumonia \r\nMost likely etiology is community acquired pneumonia, given \r\nabsence of consolidation on CXR, her sick contacts (grandkids \r\nwith colds), and lung exam with bronchial breath sounds and \r\nwheezing. Flu swab negative. Preliminary results from the viral \r\nrespiratory screen was negative. Given her immunocompromised \r\nstate, will treat for CAP. D1 CTX ___, D1 azithromycin ___. \r\nHer symptoms were treated with DuonNebs, Flovent, albuterol, and \r\nguafenisen. We discharged her home with lovenox to complete a 5 \r\nday course of antibiotics ending on ___\r\n\r\n#CVID\r\nReceives IVIG every 1 - 2 months to keep IGG > 500. Her last \r\ninfusion was ~1 month ago. IGG 715 this admission, so IVIG was \r\nnot given this admission. She was monitored for signs of \r\ninfection and treated as above.\r\n\r\n#MDS ___ allogeneic stem cell transplant on ___\r\nHer outpatient oncology team was notified of her admission. Her \r\nhome prednisone and MMF were continued, as well as her home \r\nacyclovir and Bactrim.\r\n\r\n#Cutaneous candidiasis of groin\r\nHas required 5-day course of fluconazole in past to resolve. She \r\nwas treated with nystatin cream only, due to hesitancy to \r\nprescribe a systemic antifungal with other QTc prolonging meds \r\n(azithro).\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Right lower extremity DVT: IVC filter in place. Continued home \r\nrivaroxaban.\r\n\r\n#GERD: continued home omeprazole.\r\n\r\n#Osteoarthritis \r\n#Cervical radiculopathy\r\n#Sciatica\r\n#Migraines\r\nContinued home gabapentin. Tylenol PRN.\r\n\r\n#Obstructive sleep apnea: she used her home CPAP while \r\ninpatient.\r\n\r\n#H/O cerebral aneurism: Noted on MRA with small R internal \r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm \r\n(___). Her home Neurontin was continued.\r\n\r\n#Asthma: continued home Flovent and DuoNebs, with albuterol PRN.\r\n\r\n#Hypertension: she was noted to not be on antihypertensives at \r\nhome. Her BP was monitored while inpatient.\r\n\r\n#Mood disorder: her home venlafaxine was continued.\r\n\r\nTRANSITIONAL ISSUES:\r\n===================\r\n[]Levofloxacin course ending ___\r\n[]Follow up with oncology ___\r\n[]Viral culture pending on discharge \r\n[]Glucose on admission was 234, consider screening for DM2 as \r\noutpatient \r\n\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: full code (confirmed)\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Rivaroxaban 20 mg PO DAILY \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Gabapentin 400 mg PO BID \r\n4. PredniSONE 5 mg PO DAILY \r\n5. Zofran (ondansetron HCl) 4 mg oral Q8H \r\n6. Mycophenolate Mofetil 500 mg PO BID \r\n7. Venlafaxine 25 mg PO DAILY \r\n8. Acyclovir 400 mg PO TID \r\n9. Cephalexin ___ mg PO ONCE \r\n10. Restasis 0.05 % ophthalmic (eye) BID \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n12. Hydrocortisone Cream 1% 1 Appl TP BID \r\n13. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n14. Nystatin Cream 1 Appl TP BID:PRN fungal rash \r\n15. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n16. Vitamin D ___ UNIT PO DAILY \r\n17. FoLIC Acid 1.6 mg PO DAILY \r\n18. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1.  GuaiFENesin ER 600 mg PO Q12H \r\nRX *guaifenesin 600 mg 1 tablet(s) by mouth q12hrs prn Disp #*10 \r\nTablet Refills:*0 \r\n2.  Levofloxacin 500 mg PO Q24H Duration: 2 Days \r\nRX *levofloxacin [Levaquin] 500 mg 1 tablet(s) by mouth daily \r\nDisp #*2 Tablet Refills:*0 \r\n3.  Acyclovir 400 mg PO TID  \r\n4.  Cephalexin ___ mg PO ONCE  \r\n5.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n6.  FoLIC Acid 1.6 mg PO DAILY  \r\n7.  Gabapentin 400 mg PO BID  \r\n8.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n10.  Mycophenolate Mofetil 500 mg PO BID  \r\n11.  Nystatin Cream 1 Appl TP BID:PRN fungal rash  \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n14.  PredniSONE 5 mg PO DAILY  \r\n15.  Restasis 0.05 % ophthalmic (eye) BID  \r\n16.  Rivaroxaban 20 mg PO DAILY  \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n19.  Venlafaxine 25 mg PO DAILY  \r\n20.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n4) Cutaneous candidiasis of groin \r\n5) RLE DVT\r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___.\r\n\r\nWHY WAS I IN THE HOSPITAL?\r\n- You had symptoms of a respiratory infection.\r\n\r\nWHAT HAPPENED TO ME IN THE HOSPITAL?\r\n- You were started on antibiotics to treat a possible bacterial \r\nlung infection, and were treated symptomatically with inhalers, \r\npain medicine and fluids.\r\n- Many tests were done to look for causes of infection.\r\n- We feel you most likely had a bacterial infection of your \r\nlungs and gave you medicine to treat it \r\n\r\nWHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?\r\n- Continue to take all your medicines and keep your \r\nappointments.\r\n\r\nWe wish you the best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-26:5",
      "text": "Physical Exam:\nADMISSION PHYSICAL EXAM:  \n___ ___ Temp: 98.3 PO BP: 110/42 HR: 91 RR: 20 O2 sat: 97%\nO2 delivery: Ra \nGeneral:  Well appearing in NAD, sitting comfortably. HEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\nlesions. No oropharyngeal erythema or thrush \nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\nCV:  RRR, NL S1S2 no MRG\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\nperitoneal signs. GU: Cutaneous candiasis in groin, R worse than L\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace. Calves and feet are cool to the touch. SKIN: venous stasis changes to bilateral calves\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\neye, and hyperthesia of the right V1 distribution. CN II-XII\notherwise intact. Strength ___ in all extremities. Sensation\nintact in all extremities. Discharge Physical Exam:\nVS: ___ ___ Temp: 98.1 PO BP: 124/51 Sitting HR: 95 RR: 18\nO2 sat: 97% O2 delivery: Ra \nGeneral:  Well appearing in NAD, sitting comfortably. HEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\nlesions. No oropharyngeal erythema or thrush \nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\nCV:  RRR, NL S1S2 no MRG\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\nperitoneal signs. EXT:  Legs with nonpitting edema bilaterally. R wrist brace. Calves and feet are cool to the touch. SKIN: venous stasis changes to bilateral calves\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\neye DISCHARGE PHYSICAL EXAM:\n \nPertinent Results:\nADMISSION LABS:\n==============\n___ 11:00PM BLOOD WBC-13.0* RBC-4.07 Hgb-13.0 Hct-40.9 \nMCV-101* MCH-31.9 MCHC-31.8* RDW-14.1 RDWSD-51.1* Plt ___\n___ 11:00PM BLOOD Neuts-93.1* Lymphs-4.5* Monos-1.8* \nEos-0.1* Baso-0.1 Im ___ AbsNeut-12.08* AbsLymp-0.59* \nAbsMono-0.24 AbsEos-0.01* AbsBaso-0.01\n___ 11:00PM BLOOD Glucose-234* UreaN-14 Creat-1.2* Na-142 \nK-4.6 Cl-105 HCO3-21* AnGap-16\n___ 11:00PM BLOOD ALT-14 AST-19 AlkPhos-151* TotBili-0.2\n___ 11:00PM BLOOD Albumin-4.2\n___ 11:00PM BLOOD IgG-713\n___ 01:51AM BLOOD Lactate-1.3 MICRO:\n======\n___ urine culture: negative\n___ fluA&B PCR: negative\n___ blood cultures: pending ***\n___ urine legionella antigen: negative\n___ urine strep pneumo Ag: pending ***\n___ respiratory viral screen and culture: pending *** IMAGING AND STUDIES:\n===================\n___ CXR:\nNo acute intrathoracic process. ___ ECG: QTc 487 DISCHARGE LABS:\n=============== ___ 07:00AM BLOOD WBC-5.6 RBC-3.91 Hgb-12.6 Hct-39.7 \nMCV-102* MCH-32.2* MCHC-31.7* RDW-14.4 RDWSD-53.7* Plt ___\n___ 07:00AM BLOOD Plt ___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-26",
        "chart_time": "105179",
        "section": "General",
        "position": 5,
        "tokenCount": 675,
        "note_metadata": {
          "note_id": "18887130-DS-26",
          "subject_id": 18887130,
          "hadm_id": 29331505,
          "note_type": "DS",
          "note_seq": 26,
          "charttime": 105179,
          "storetime": 105179.69236111111,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, chills, cough\r\n \r\nMajor Surgical or Invasive Procedure:\r\nnone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na\r\nhistory of stage IIA follicular lymphoma with treatment\r\nrelated MDS ___ allogeneic stem cell transplant on ___ who\r\npresents with four days of productive cough, fevers and chills.\r\n\r\nShe called her ___ clinic on ___ and reported fever,\r\nchills, and productive cough. She had been seen at urgent care\r\nearlier on ___ and received CXR which was consistent with\r\npneumonia, and she was treated with ceftriaxone 1g, steroids and\r\nDuoNebs. She called ___ clinic due to lack of improvement.\r\nShe was referred to ED for admission and IV antibiotics, given\r\nher pneumonia and history of allogenic transplant.\r\n\r\nIn the ED, her vitals were: T 98.8, HR 96, BP 129/65, RR 18, \r\nSPO2\r\n97% RA. Lung exam was significant for diffuse expiratory \r\nwheezing\r\nand rhonchi. Labs were remarkable for WBC 13, HGB 13, plt 256, K\r\n4.6, Cr 1.2. She was given azithromycin, albuterol nebs, DuoNeb,\r\nIVF.\r\n\r\nOn arrival to OMED, she reports she has laryngitis and continued\r\ncough. She has multiple sick contacts (grandchildren at home who\r\nhave colds). She denies current fever, chills, abdominal pain,\r\nnausea, diarrhea, dysuria, leg swelling.\r\n\r\nREVIEW OF SYSTEMS:  \r\nA complete 10-point review of systems was performed and was\r\nnegative unless otherwise noted in the HPI.  \r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY: \r\n Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO.  Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h).  Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging.  MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact.  Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning.  D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n\r\nTRANSPLANT DATA:\r\n  Transplant Date: ___\r\n  Graft: URD\r\n  Conditioning Intensity: Reduced-Intensity\r\n  Conditioning Regimen: Flu/Bu/ATG\r\n\r\n  Donor Info: ___ CMV(+), ABO: Opos\r\n  Recipient Info: CMV(+), ABO: Opos  \r\n \r\n\r\nPAST MEDICAL HISTORY:  \r\n- CVID\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- RLE DVT, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- R internal carotid cavernous sinus aneurism ___ coiling \r\n___\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- + Parainfluenza, ___\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:  \r\n___ ___ Temp: 98.3 PO BP: 110/42 HR: 91 RR: 20 O2 sat: 97%\r\nO2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nGU: Cutaneous candiasis in groin, R worse than L\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye, and hyperthesia of the right V1 distribution. CN II-XII\r\notherwise intact. Strength ___ in all extremities. Sensation\r\nintact in all extremities.\r\n\r\nDischarge Physical Exam:\r\nVS: ___ ___ Temp: 98.1 PO BP: 124/51 Sitting HR: 95 RR: 18\r\nO2 sat: 97% O2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n==============\r\n___ 11:00PM BLOOD WBC-13.0* RBC-4.07 Hgb-13.0 Hct-40.9 \r\nMCV-101* MCH-31.9 MCHC-31.8* RDW-14.1 RDWSD-51.1* Plt ___\r\n___ 11:00PM BLOOD Neuts-93.1* Lymphs-4.5* Monos-1.8* \r\nEos-0.1* Baso-0.1 Im ___ AbsNeut-12.08* AbsLymp-0.59* \r\nAbsMono-0.24 AbsEos-0.01* AbsBaso-0.01\r\n___ 11:00PM BLOOD Glucose-234* UreaN-14 Creat-1.2* Na-142 \r\nK-4.6 Cl-105 HCO3-21* AnGap-16\r\n___ 11:00PM BLOOD ALT-14 AST-19 AlkPhos-151* TotBili-0.2\r\n___ 11:00PM BLOOD Albumin-4.2\r\n___ 11:00PM BLOOD IgG-713\r\n___ 01:51AM BLOOD Lactate-1.3\r\n\r\nMICRO:\r\n======\r\n___ urine culture: negative\r\n___ fluA&B PCR: negative\r\n___ blood cultures: pending ***\r\n___ urine legionella antigen: negative\r\n___ urine strep pneumo Ag: pending ***\r\n___ respiratory viral screen and culture: pending ***\r\n\r\nIMAGING AND STUDIES:\r\n===================\r\n___ CXR:\r\nNo acute intrathoracic process.\r\n\r\n___ ECG: QTc 487\r\n\r\nDISCHARGE LABS:\r\n===============\r\n\r\n___ 07:00AM BLOOD WBC-5.6 RBC-3.91 Hgb-12.6 Hct-39.7 \r\nMCV-102* MCH-32.2* MCHC-31.7* RDW-14.4 RDWSD-53.7* Plt ___\r\n___ 07:00AM BLOOD Plt ___\r\n \r\nBrief Hospital Course:\r\nSUMMARY:\r\n========= \r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na history of stage IIA follicular lymphoma with treatment \r\nrelated MDS ___ allogeneic stem cell transplant on ___ who \r\npresents with four days of productive cough, fevers and chills \r\nconsistent with community acquired pneumonia \r\n\r\nACTIVE ISSUES:\r\n=============\r\n#community acquired pneumonia \r\nMost likely etiology is community acquired pneumonia, given \r\nabsence of consolidation on CXR, her sick contacts (grandkids \r\nwith colds), and lung exam with bronchial breath sounds and \r\nwheezing. Flu swab negative. Preliminary results from the viral \r\nrespiratory screen was negative. Given her immunocompromised \r\nstate, will treat for CAP. D1 CTX ___, D1 azithromycin ___. \r\nHer symptoms were treated with DuonNebs, Flovent, albuterol, and \r\nguafenisen. We discharged her home with lovenox to complete a 5 \r\nday course of antibiotics ending on ___\r\n\r\n#CVID\r\nReceives IVIG every 1 - 2 months to keep IGG > 500. Her last \r\ninfusion was ~1 month ago. IGG 715 this admission, so IVIG was \r\nnot given this admission. She was monitored for signs of \r\ninfection and treated as above.\r\n\r\n#MDS ___ allogeneic stem cell transplant on ___\r\nHer outpatient oncology team was notified of her admission. Her \r\nhome prednisone and MMF were continued, as well as her home \r\nacyclovir and Bactrim.\r\n\r\n#Cutaneous candidiasis of groin\r\nHas required 5-day course of fluconazole in past to resolve. She \r\nwas treated with nystatin cream only, due to hesitancy to \r\nprescribe a systemic antifungal with other QTc prolonging meds \r\n(azithro).\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Right lower extremity DVT: IVC filter in place. Continued home \r\nrivaroxaban.\r\n\r\n#GERD: continued home omeprazole.\r\n\r\n#Osteoarthritis \r\n#Cervical radiculopathy\r\n#Sciatica\r\n#Migraines\r\nContinued home gabapentin. Tylenol PRN.\r\n\r\n#Obstructive sleep apnea: she used her home CPAP while \r\ninpatient.\r\n\r\n#H/O cerebral aneurism: Noted on MRA with small R internal \r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm \r\n(___). Her home Neurontin was continued.\r\n\r\n#Asthma: continued home Flovent and DuoNebs, with albuterol PRN.\r\n\r\n#Hypertension: she was noted to not be on antihypertensives at \r\nhome. Her BP was monitored while inpatient.\r\n\r\n#Mood disorder: her home venlafaxine was continued.\r\n\r\nTRANSITIONAL ISSUES:\r\n===================\r\n[]Levofloxacin course ending ___\r\n[]Follow up with oncology ___\r\n[]Viral culture pending on discharge \r\n[]Glucose on admission was 234, consider screening for DM2 as \r\noutpatient \r\n\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: full code (confirmed)\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Rivaroxaban 20 mg PO DAILY \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Gabapentin 400 mg PO BID \r\n4. PredniSONE 5 mg PO DAILY \r\n5. Zofran (ondansetron HCl) 4 mg oral Q8H \r\n6. Mycophenolate Mofetil 500 mg PO BID \r\n7. Venlafaxine 25 mg PO DAILY \r\n8. Acyclovir 400 mg PO TID \r\n9. Cephalexin ___ mg PO ONCE \r\n10. Restasis 0.05 % ophthalmic (eye) BID \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n12. Hydrocortisone Cream 1% 1 Appl TP BID \r\n13. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n14. Nystatin Cream 1 Appl TP BID:PRN fungal rash \r\n15. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n16. Vitamin D ___ UNIT PO DAILY \r\n17. FoLIC Acid 1.6 mg PO DAILY \r\n18. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1.  GuaiFENesin ER 600 mg PO Q12H \r\nRX *guaifenesin 600 mg 1 tablet(s) by mouth q12hrs prn Disp #*10 \r\nTablet Refills:*0 \r\n2.  Levofloxacin 500 mg PO Q24H Duration: 2 Days \r\nRX *levofloxacin [Levaquin] 500 mg 1 tablet(s) by mouth daily \r\nDisp #*2 Tablet Refills:*0 \r\n3.  Acyclovir 400 mg PO TID  \r\n4.  Cephalexin ___ mg PO ONCE  \r\n5.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n6.  FoLIC Acid 1.6 mg PO DAILY  \r\n7.  Gabapentin 400 mg PO BID  \r\n8.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n10.  Mycophenolate Mofetil 500 mg PO BID  \r\n11.  Nystatin Cream 1 Appl TP BID:PRN fungal rash  \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n14.  PredniSONE 5 mg PO DAILY  \r\n15.  Restasis 0.05 % ophthalmic (eye) BID  \r\n16.  Rivaroxaban 20 mg PO DAILY  \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n19.  Venlafaxine 25 mg PO DAILY  \r\n20.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n4) Cutaneous candidiasis of groin \r\n5) RLE DVT\r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___.\r\n\r\nWHY WAS I IN THE HOSPITAL?\r\n- You had symptoms of a respiratory infection.\r\n\r\nWHAT HAPPENED TO ME IN THE HOSPITAL?\r\n- You were started on antibiotics to treat a possible bacterial \r\nlung infection, and were treated symptomatically with inhalers, \r\npain medicine and fluids.\r\n- Many tests were done to look for causes of infection.\r\n- We feel you most likely had a bacterial infection of your \r\nlungs and gave you medicine to treat it \r\n\r\nWHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?\r\n- Continue to take all your medicines and keep your \r\nappointments.\r\n\r\nWe wish you the best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-26:6",
      "text": "Brief Hospital Course:\nSUMMARY:\n========= \nMs. ___ is a ___ year old female with transformed DLBCL with \na history of stage IIA follicular lymphoma with treatment \nrelated MDS ___ allogeneic stem cell transplant on ___ who \npresents with four days of productive cough, fevers and chills \nconsistent with community acquired pneumonia ACTIVE ISSUES:\n=============\n#community acquired pneumonia \nMost likely etiology is community acquired pneumonia, given \nabsence of consolidation on CXR, her sick contacts (grandkids \nwith colds), and lung exam with bronchial breath sounds and \nwheezing. Flu swab negative. Preliminary results from the viral \nrespiratory screen was negative. Given her immunocompromised \nstate, will treat for CAP. D1 CTX ___, D1 azithromycin ___. Her symptoms were treated with DuonNebs, Flovent, albuterol, and \nguafenisen. We discharged her home with lovenox to complete a 5 \nday course of antibiotics ending on ___ #CVID\nReceives IVIG every 1 - 2 months to keep IGG > 500. Her last \ninfusion was ~1 month ago. IGG 715 this admission, so IVIG was \nnot given this admission. She was monitored for signs of \ninfection and treated as above. #MDS ___ allogeneic stem cell transplant on ___\nHer outpatient oncology team was notified of her admission. Her \nhome prednisone and MMF were continued, as well as her home \nacyclovir and Bactrim. #Cutaneous candidiasis of groin\nHas required 5-day course of fluconazole in past to resolve. She \nwas treated with nystatin cream only, due to hesitancy to \nprescribe a systemic antifungal with other QTc prolonging meds \n(azithro).",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-26",
        "chart_time": "105179",
        "section": "General",
        "position": 6,
        "tokenCount": 397,
        "note_metadata": {
          "note_id": "18887130-DS-26",
          "subject_id": 18887130,
          "hadm_id": 29331505,
          "note_type": "DS",
          "note_seq": 26,
          "charttime": 105179,
          "storetime": 105179.69236111111,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, chills, cough\r\n \r\nMajor Surgical or Invasive Procedure:\r\nnone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na\r\nhistory of stage IIA follicular lymphoma with treatment\r\nrelated MDS ___ allogeneic stem cell transplant on ___ who\r\npresents with four days of productive cough, fevers and chills.\r\n\r\nShe called her ___ clinic on ___ and reported fever,\r\nchills, and productive cough. She had been seen at urgent care\r\nearlier on ___ and received CXR which was consistent with\r\npneumonia, and she was treated with ceftriaxone 1g, steroids and\r\nDuoNebs. She called ___ clinic due to lack of improvement.\r\nShe was referred to ED for admission and IV antibiotics, given\r\nher pneumonia and history of allogenic transplant.\r\n\r\nIn the ED, her vitals were: T 98.8, HR 96, BP 129/65, RR 18, \r\nSPO2\r\n97% RA. Lung exam was significant for diffuse expiratory \r\nwheezing\r\nand rhonchi. Labs were remarkable for WBC 13, HGB 13, plt 256, K\r\n4.6, Cr 1.2. She was given azithromycin, albuterol nebs, DuoNeb,\r\nIVF.\r\n\r\nOn arrival to OMED, she reports she has laryngitis and continued\r\ncough. She has multiple sick contacts (grandchildren at home who\r\nhave colds). She denies current fever, chills, abdominal pain,\r\nnausea, diarrhea, dysuria, leg swelling.\r\n\r\nREVIEW OF SYSTEMS:  \r\nA complete 10-point review of systems was performed and was\r\nnegative unless otherwise noted in the HPI.  \r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY: \r\n Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO.  Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h).  Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging.  MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact.  Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning.  D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n\r\nTRANSPLANT DATA:\r\n  Transplant Date: ___\r\n  Graft: URD\r\n  Conditioning Intensity: Reduced-Intensity\r\n  Conditioning Regimen: Flu/Bu/ATG\r\n\r\n  Donor Info: ___ CMV(+), ABO: Opos\r\n  Recipient Info: CMV(+), ABO: Opos  \r\n \r\n\r\nPAST MEDICAL HISTORY:  \r\n- CVID\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- RLE DVT, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- R internal carotid cavernous sinus aneurism ___ coiling \r\n___\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- + Parainfluenza, ___\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:  \r\n___ ___ Temp: 98.3 PO BP: 110/42 HR: 91 RR: 20 O2 sat: 97%\r\nO2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nGU: Cutaneous candiasis in groin, R worse than L\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye, and hyperthesia of the right V1 distribution. CN II-XII\r\notherwise intact. Strength ___ in all extremities. Sensation\r\nintact in all extremities.\r\n\r\nDischarge Physical Exam:\r\nVS: ___ ___ Temp: 98.1 PO BP: 124/51 Sitting HR: 95 RR: 18\r\nO2 sat: 97% O2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n==============\r\n___ 11:00PM BLOOD WBC-13.0* RBC-4.07 Hgb-13.0 Hct-40.9 \r\nMCV-101* MCH-31.9 MCHC-31.8* RDW-14.1 RDWSD-51.1* Plt ___\r\n___ 11:00PM BLOOD Neuts-93.1* Lymphs-4.5* Monos-1.8* \r\nEos-0.1* Baso-0.1 Im ___ AbsNeut-12.08* AbsLymp-0.59* \r\nAbsMono-0.24 AbsEos-0.01* AbsBaso-0.01\r\n___ 11:00PM BLOOD Glucose-234* UreaN-14 Creat-1.2* Na-142 \r\nK-4.6 Cl-105 HCO3-21* AnGap-16\r\n___ 11:00PM BLOOD ALT-14 AST-19 AlkPhos-151* TotBili-0.2\r\n___ 11:00PM BLOOD Albumin-4.2\r\n___ 11:00PM BLOOD IgG-713\r\n___ 01:51AM BLOOD Lactate-1.3\r\n\r\nMICRO:\r\n======\r\n___ urine culture: negative\r\n___ fluA&B PCR: negative\r\n___ blood cultures: pending ***\r\n___ urine legionella antigen: negative\r\n___ urine strep pneumo Ag: pending ***\r\n___ respiratory viral screen and culture: pending ***\r\n\r\nIMAGING AND STUDIES:\r\n===================\r\n___ CXR:\r\nNo acute intrathoracic process.\r\n\r\n___ ECG: QTc 487\r\n\r\nDISCHARGE LABS:\r\n===============\r\n\r\n___ 07:00AM BLOOD WBC-5.6 RBC-3.91 Hgb-12.6 Hct-39.7 \r\nMCV-102* MCH-32.2* MCHC-31.7* RDW-14.4 RDWSD-53.7* Plt ___\r\n___ 07:00AM BLOOD Plt ___\r\n \r\nBrief Hospital Course:\r\nSUMMARY:\r\n========= \r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na history of stage IIA follicular lymphoma with treatment \r\nrelated MDS ___ allogeneic stem cell transplant on ___ who \r\npresents with four days of productive cough, fevers and chills \r\nconsistent with community acquired pneumonia \r\n\r\nACTIVE ISSUES:\r\n=============\r\n#community acquired pneumonia \r\nMost likely etiology is community acquired pneumonia, given \r\nabsence of consolidation on CXR, her sick contacts (grandkids \r\nwith colds), and lung exam with bronchial breath sounds and \r\nwheezing. Flu swab negative. Preliminary results from the viral \r\nrespiratory screen was negative. Given her immunocompromised \r\nstate, will treat for CAP. D1 CTX ___, D1 azithromycin ___. \r\nHer symptoms were treated with DuonNebs, Flovent, albuterol, and \r\nguafenisen. We discharged her home with lovenox to complete a 5 \r\nday course of antibiotics ending on ___\r\n\r\n#CVID\r\nReceives IVIG every 1 - 2 months to keep IGG > 500. Her last \r\ninfusion was ~1 month ago. IGG 715 this admission, so IVIG was \r\nnot given this admission. She was monitored for signs of \r\ninfection and treated as above.\r\n\r\n#MDS ___ allogeneic stem cell transplant on ___\r\nHer outpatient oncology team was notified of her admission. Her \r\nhome prednisone and MMF were continued, as well as her home \r\nacyclovir and Bactrim.\r\n\r\n#Cutaneous candidiasis of groin\r\nHas required 5-day course of fluconazole in past to resolve. She \r\nwas treated with nystatin cream only, due to hesitancy to \r\nprescribe a systemic antifungal with other QTc prolonging meds \r\n(azithro).\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Right lower extremity DVT: IVC filter in place. Continued home \r\nrivaroxaban.\r\n\r\n#GERD: continued home omeprazole.\r\n\r\n#Osteoarthritis \r\n#Cervical radiculopathy\r\n#Sciatica\r\n#Migraines\r\nContinued home gabapentin. Tylenol PRN.\r\n\r\n#Obstructive sleep apnea: she used her home CPAP while \r\ninpatient.\r\n\r\n#H/O cerebral aneurism: Noted on MRA with small R internal \r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm \r\n(___). Her home Neurontin was continued.\r\n\r\n#Asthma: continued home Flovent and DuoNebs, with albuterol PRN.\r\n\r\n#Hypertension: she was noted to not be on antihypertensives at \r\nhome. Her BP was monitored while inpatient.\r\n\r\n#Mood disorder: her home venlafaxine was continued.\r\n\r\nTRANSITIONAL ISSUES:\r\n===================\r\n[]Levofloxacin course ending ___\r\n[]Follow up with oncology ___\r\n[]Viral culture pending on discharge \r\n[]Glucose on admission was 234, consider screening for DM2 as \r\noutpatient \r\n\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: full code (confirmed)\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Rivaroxaban 20 mg PO DAILY \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Gabapentin 400 mg PO BID \r\n4. PredniSONE 5 mg PO DAILY \r\n5. Zofran (ondansetron HCl) 4 mg oral Q8H \r\n6. Mycophenolate Mofetil 500 mg PO BID \r\n7. Venlafaxine 25 mg PO DAILY \r\n8. Acyclovir 400 mg PO TID \r\n9. Cephalexin ___ mg PO ONCE \r\n10. Restasis 0.05 % ophthalmic (eye) BID \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n12. Hydrocortisone Cream 1% 1 Appl TP BID \r\n13. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n14. Nystatin Cream 1 Appl TP BID:PRN fungal rash \r\n15. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n16. Vitamin D ___ UNIT PO DAILY \r\n17. FoLIC Acid 1.6 mg PO DAILY \r\n18. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1.  GuaiFENesin ER 600 mg PO Q12H \r\nRX *guaifenesin 600 mg 1 tablet(s) by mouth q12hrs prn Disp #*10 \r\nTablet Refills:*0 \r\n2.  Levofloxacin 500 mg PO Q24H Duration: 2 Days \r\nRX *levofloxacin [Levaquin] 500 mg 1 tablet(s) by mouth daily \r\nDisp #*2 Tablet Refills:*0 \r\n3.  Acyclovir 400 mg PO TID  \r\n4.  Cephalexin ___ mg PO ONCE  \r\n5.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n6.  FoLIC Acid 1.6 mg PO DAILY  \r\n7.  Gabapentin 400 mg PO BID  \r\n8.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n10.  Mycophenolate Mofetil 500 mg PO BID  \r\n11.  Nystatin Cream 1 Appl TP BID:PRN fungal rash  \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n14.  PredniSONE 5 mg PO DAILY  \r\n15.  Restasis 0.05 % ophthalmic (eye) BID  \r\n16.  Rivaroxaban 20 mg PO DAILY  \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n19.  Venlafaxine 25 mg PO DAILY  \r\n20.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n4) Cutaneous candidiasis of groin \r\n5) RLE DVT\r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___.\r\n\r\nWHY WAS I IN THE HOSPITAL?\r\n- You had symptoms of a respiratory infection.\r\n\r\nWHAT HAPPENED TO ME IN THE HOSPITAL?\r\n- You were started on antibiotics to treat a possible bacterial \r\nlung infection, and were treated symptomatically with inhalers, \r\npain medicine and fluids.\r\n- Many tests were done to look for causes of infection.\r\n- We feel you most likely had a bacterial infection of your \r\nlungs and gave you medicine to treat it \r\n\r\nWHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?\r\n- Continue to take all your medicines and keep your \r\nappointments.\r\n\r\nWe wish you the best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-26:7",
      "text": "CHRONIC ISSUES:\n===============\n#Right lower extremity DVT: IVC filter in place. Continued home \nrivaroxaban. #GERD: continued home omeprazole. #Osteoarthritis \n#Cervical radiculopathy\n#Sciatica\n#Migraines\nContinued home gabapentin. Tylenol PRN. #Obstructive sleep apnea: she used her home CPAP while \ninpatient. #H/O cerebral aneurism: Noted on MRA with small R internal \ncarotid cavernous sinus aneurysm; coil placed in the aneurysm \n(___). Her home Neurontin was continued. #Asthma: continued home Flovent and DuoNebs, with albuterol PRN. #Hypertension: she was noted to not be on antihypertensives at \nhome. Her BP was monitored while inpatient. #Mood disorder: her home venlafaxine was continued. TRANSITIONAL ISSUES:\n===================\n[]Levofloxacin course ending ___\n[]Follow up with oncology ___\n[]Viral culture pending on discharge \n[]Glucose on admission was 234, consider screening for DM2 as \noutpatient #HCP/CONTACT: ___ (daughter) ___\n#CODE STATUS: full code (confirmed)\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Rivaroxaban 20 mg PO DAILY \n2. Omeprazole 20 mg PO DAILY \n3. Gabapentin 400 mg PO BID \n4. PredniSONE 5 mg PO DAILY \n5. Zofran (ondansetron HCl) 4 mg oral Q8H \n6. Mycophenolate Mofetil 500 mg PO BID \n7. Venlafaxine 25 mg PO DAILY \n8. Acyclovir 400 mg PO TID \n9. Cephalexin ___ mg PO ONCE \n10. Restasis 0.05 % ophthalmic (eye) BID \n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \ncough/wheezing \n12. Hydrocortisone Cream 1% 1 Appl TP BID \n13. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \nwheezing/shortness of breath \n14. Nystatin Cream 1 Appl TP BID:PRN fungal rash \n15. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \nunspecified \n16. Vitamin D ___ UNIT PO DAILY \n17. FoLIC Acid 1.6 mg PO DAILY \n18. Sulfameth/Trimethoprim SS 1 TAB PO DAILY",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-26",
        "chart_time": "105179",
        "section": "General",
        "position": 7,
        "tokenCount": 457,
        "note_metadata": {
          "note_id": "18887130-DS-26",
          "subject_id": 18887130,
          "hadm_id": 29331505,
          "note_type": "DS",
          "note_seq": 26,
          "charttime": 105179,
          "storetime": 105179.69236111111,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, chills, cough\r\n \r\nMajor Surgical or Invasive Procedure:\r\nnone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na\r\nhistory of stage IIA follicular lymphoma with treatment\r\nrelated MDS ___ allogeneic stem cell transplant on ___ who\r\npresents with four days of productive cough, fevers and chills.\r\n\r\nShe called her ___ clinic on ___ and reported fever,\r\nchills, and productive cough. She had been seen at urgent care\r\nearlier on ___ and received CXR which was consistent with\r\npneumonia, and she was treated with ceftriaxone 1g, steroids and\r\nDuoNebs. She called ___ clinic due to lack of improvement.\r\nShe was referred to ED for admission and IV antibiotics, given\r\nher pneumonia and history of allogenic transplant.\r\n\r\nIn the ED, her vitals were: T 98.8, HR 96, BP 129/65, RR 18, \r\nSPO2\r\n97% RA. Lung exam was significant for diffuse expiratory \r\nwheezing\r\nand rhonchi. Labs were remarkable for WBC 13, HGB 13, plt 256, K\r\n4.6, Cr 1.2. She was given azithromycin, albuterol nebs, DuoNeb,\r\nIVF.\r\n\r\nOn arrival to OMED, she reports she has laryngitis and continued\r\ncough. She has multiple sick contacts (grandchildren at home who\r\nhave colds). She denies current fever, chills, abdominal pain,\r\nnausea, diarrhea, dysuria, leg swelling.\r\n\r\nREVIEW OF SYSTEMS:  \r\nA complete 10-point review of systems was performed and was\r\nnegative unless otherwise noted in the HPI.  \r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY: \r\n Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO.  Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h).  Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging.  MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact.  Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning.  D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n\r\nTRANSPLANT DATA:\r\n  Transplant Date: ___\r\n  Graft: URD\r\n  Conditioning Intensity: Reduced-Intensity\r\n  Conditioning Regimen: Flu/Bu/ATG\r\n\r\n  Donor Info: ___ CMV(+), ABO: Opos\r\n  Recipient Info: CMV(+), ABO: Opos  \r\n \r\n\r\nPAST MEDICAL HISTORY:  \r\n- CVID\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- RLE DVT, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- R internal carotid cavernous sinus aneurism ___ coiling \r\n___\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- + Parainfluenza, ___\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:  \r\n___ ___ Temp: 98.3 PO BP: 110/42 HR: 91 RR: 20 O2 sat: 97%\r\nO2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nGU: Cutaneous candiasis in groin, R worse than L\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye, and hyperthesia of the right V1 distribution. CN II-XII\r\notherwise intact. Strength ___ in all extremities. Sensation\r\nintact in all extremities.\r\n\r\nDischarge Physical Exam:\r\nVS: ___ ___ Temp: 98.1 PO BP: 124/51 Sitting HR: 95 RR: 18\r\nO2 sat: 97% O2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n==============\r\n___ 11:00PM BLOOD WBC-13.0* RBC-4.07 Hgb-13.0 Hct-40.9 \r\nMCV-101* MCH-31.9 MCHC-31.8* RDW-14.1 RDWSD-51.1* Plt ___\r\n___ 11:00PM BLOOD Neuts-93.1* Lymphs-4.5* Monos-1.8* \r\nEos-0.1* Baso-0.1 Im ___ AbsNeut-12.08* AbsLymp-0.59* \r\nAbsMono-0.24 AbsEos-0.01* AbsBaso-0.01\r\n___ 11:00PM BLOOD Glucose-234* UreaN-14 Creat-1.2* Na-142 \r\nK-4.6 Cl-105 HCO3-21* AnGap-16\r\n___ 11:00PM BLOOD ALT-14 AST-19 AlkPhos-151* TotBili-0.2\r\n___ 11:00PM BLOOD Albumin-4.2\r\n___ 11:00PM BLOOD IgG-713\r\n___ 01:51AM BLOOD Lactate-1.3\r\n\r\nMICRO:\r\n======\r\n___ urine culture: negative\r\n___ fluA&B PCR: negative\r\n___ blood cultures: pending ***\r\n___ urine legionella antigen: negative\r\n___ urine strep pneumo Ag: pending ***\r\n___ respiratory viral screen and culture: pending ***\r\n\r\nIMAGING AND STUDIES:\r\n===================\r\n___ CXR:\r\nNo acute intrathoracic process.\r\n\r\n___ ECG: QTc 487\r\n\r\nDISCHARGE LABS:\r\n===============\r\n\r\n___ 07:00AM BLOOD WBC-5.6 RBC-3.91 Hgb-12.6 Hct-39.7 \r\nMCV-102* MCH-32.2* MCHC-31.7* RDW-14.4 RDWSD-53.7* Plt ___\r\n___ 07:00AM BLOOD Plt ___\r\n \r\nBrief Hospital Course:\r\nSUMMARY:\r\n========= \r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na history of stage IIA follicular lymphoma with treatment \r\nrelated MDS ___ allogeneic stem cell transplant on ___ who \r\npresents with four days of productive cough, fevers and chills \r\nconsistent with community acquired pneumonia \r\n\r\nACTIVE ISSUES:\r\n=============\r\n#community acquired pneumonia \r\nMost likely etiology is community acquired pneumonia, given \r\nabsence of consolidation on CXR, her sick contacts (grandkids \r\nwith colds), and lung exam with bronchial breath sounds and \r\nwheezing. Flu swab negative. Preliminary results from the viral \r\nrespiratory screen was negative. Given her immunocompromised \r\nstate, will treat for CAP. D1 CTX ___, D1 azithromycin ___. \r\nHer symptoms were treated with DuonNebs, Flovent, albuterol, and \r\nguafenisen. We discharged her home with lovenox to complete a 5 \r\nday course of antibiotics ending on ___\r\n\r\n#CVID\r\nReceives IVIG every 1 - 2 months to keep IGG > 500. Her last \r\ninfusion was ~1 month ago. IGG 715 this admission, so IVIG was \r\nnot given this admission. She was monitored for signs of \r\ninfection and treated as above.\r\n\r\n#MDS ___ allogeneic stem cell transplant on ___\r\nHer outpatient oncology team was notified of her admission. Her \r\nhome prednisone and MMF were continued, as well as her home \r\nacyclovir and Bactrim.\r\n\r\n#Cutaneous candidiasis of groin\r\nHas required 5-day course of fluconazole in past to resolve. She \r\nwas treated with nystatin cream only, due to hesitancy to \r\nprescribe a systemic antifungal with other QTc prolonging meds \r\n(azithro).\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Right lower extremity DVT: IVC filter in place. Continued home \r\nrivaroxaban.\r\n\r\n#GERD: continued home omeprazole.\r\n\r\n#Osteoarthritis \r\n#Cervical radiculopathy\r\n#Sciatica\r\n#Migraines\r\nContinued home gabapentin. Tylenol PRN.\r\n\r\n#Obstructive sleep apnea: she used her home CPAP while \r\ninpatient.\r\n\r\n#H/O cerebral aneurism: Noted on MRA with small R internal \r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm \r\n(___). Her home Neurontin was continued.\r\n\r\n#Asthma: continued home Flovent and DuoNebs, with albuterol PRN.\r\n\r\n#Hypertension: she was noted to not be on antihypertensives at \r\nhome. Her BP was monitored while inpatient.\r\n\r\n#Mood disorder: her home venlafaxine was continued.\r\n\r\nTRANSITIONAL ISSUES:\r\n===================\r\n[]Levofloxacin course ending ___\r\n[]Follow up with oncology ___\r\n[]Viral culture pending on discharge \r\n[]Glucose on admission was 234, consider screening for DM2 as \r\noutpatient \r\n\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: full code (confirmed)\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Rivaroxaban 20 mg PO DAILY \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Gabapentin 400 mg PO BID \r\n4. PredniSONE 5 mg PO DAILY \r\n5. Zofran (ondansetron HCl) 4 mg oral Q8H \r\n6. Mycophenolate Mofetil 500 mg PO BID \r\n7. Venlafaxine 25 mg PO DAILY \r\n8. Acyclovir 400 mg PO TID \r\n9. Cephalexin ___ mg PO ONCE \r\n10. Restasis 0.05 % ophthalmic (eye) BID \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n12. Hydrocortisone Cream 1% 1 Appl TP BID \r\n13. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n14. Nystatin Cream 1 Appl TP BID:PRN fungal rash \r\n15. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n16. Vitamin D ___ UNIT PO DAILY \r\n17. FoLIC Acid 1.6 mg PO DAILY \r\n18. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1.  GuaiFENesin ER 600 mg PO Q12H \r\nRX *guaifenesin 600 mg 1 tablet(s) by mouth q12hrs prn Disp #*10 \r\nTablet Refills:*0 \r\n2.  Levofloxacin 500 mg PO Q24H Duration: 2 Days \r\nRX *levofloxacin [Levaquin] 500 mg 1 tablet(s) by mouth daily \r\nDisp #*2 Tablet Refills:*0 \r\n3.  Acyclovir 400 mg PO TID  \r\n4.  Cephalexin ___ mg PO ONCE  \r\n5.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n6.  FoLIC Acid 1.6 mg PO DAILY  \r\n7.  Gabapentin 400 mg PO BID  \r\n8.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n10.  Mycophenolate Mofetil 500 mg PO BID  \r\n11.  Nystatin Cream 1 Appl TP BID:PRN fungal rash  \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n14.  PredniSONE 5 mg PO DAILY  \r\n15.  Restasis 0.05 % ophthalmic (eye) BID  \r\n16.  Rivaroxaban 20 mg PO DAILY  \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n19.  Venlafaxine 25 mg PO DAILY  \r\n20.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n4) Cutaneous candidiasis of groin \r\n5) RLE DVT\r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___.\r\n\r\nWHY WAS I IN THE HOSPITAL?\r\n- You had symptoms of a respiratory infection.\r\n\r\nWHAT HAPPENED TO ME IN THE HOSPITAL?\r\n- You were started on antibiotics to treat a possible bacterial \r\nlung infection, and were treated symptomatically with inhalers, \r\npain medicine and fluids.\r\n- Many tests were done to look for causes of infection.\r\n- We feel you most likely had a bacterial infection of your \r\nlungs and gave you medicine to treat it \r\n\r\nWHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?\r\n- Continue to take all your medicines and keep your \r\nappointments.\r\n\r\nWe wish you the best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-26:8",
      "text": "Discharge Medications:\n1. GuaiFENesin ER 600 mg PO Q12H \nRX *guaifenesin 600 mg 1 tablet(s) by mouth q12hrs prn Disp #*10 \nTablet Refills:*0 \n2. Levofloxacin 500 mg PO Q24H Duration: 2 Days \nRX *levofloxacin [Levaquin] 500 mg 1 tablet(s) by mouth daily \nDisp #*2 Tablet Refills:*0 \n3. Acyclovir 400 mg PO TID  \n4. Cephalexin ___ mg PO ONCE  \n5. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \ncough/wheezing  \n6. FoLIC Acid 1.6 mg PO DAILY  \n7. Gabapentin 400 mg PO BID  \n8. Hydrocortisone Cream 1% 1 Appl TP BID  \n9. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \nwheezing/shortness of breath  \n10. Mycophenolate Mofetil 500 mg PO BID  \n11. Nystatin Cream 1 Appl TP BID:PRN fungal rash  \n12. Omeprazole 20 mg PO DAILY  \n13. Ondansetron (ondansetron HCl) 4 mg oral Q8H  \n14. PredniSONE 5 mg PO DAILY  \n15. Restasis 0.05 % ophthalmic (eye) BID  \n16. Rivaroxaban 20 mg PO DAILY  \n17. Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \n18. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \nunspecified  \n19. Venlafaxine 25 mg PO DAILY  \n20. Vitamin D ___ UNIT PO DAILY Discharge Disposition:\nHome Discharge Diagnosis:\nPrimary Diagnosis\n=================\n1) Community Acquired Pneumonia \n2) CVID \n3) MDS ___ allogenic stem cell transplant \n4) Cutaneous candidiasis of groin \n5) RLE DVT Secondary Diagnosis\n===================\n1) GERD \n2) OSA \n3) OA \n4) Asthma \n5) HTN\n6) Mood disorder Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-26",
        "chart_time": "105179",
        "section": "General",
        "position": 8,
        "tokenCount": 381,
        "note_metadata": {
          "note_id": "18887130-DS-26",
          "subject_id": 18887130,
          "hadm_id": 29331505,
          "note_type": "DS",
          "note_seq": 26,
          "charttime": 105179,
          "storetime": 105179.69236111111,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, chills, cough\r\n \r\nMajor Surgical or Invasive Procedure:\r\nnone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na\r\nhistory of stage IIA follicular lymphoma with treatment\r\nrelated MDS ___ allogeneic stem cell transplant on ___ who\r\npresents with four days of productive cough, fevers and chills.\r\n\r\nShe called her ___ clinic on ___ and reported fever,\r\nchills, and productive cough. She had been seen at urgent care\r\nearlier on ___ and received CXR which was consistent with\r\npneumonia, and she was treated with ceftriaxone 1g, steroids and\r\nDuoNebs. She called ___ clinic due to lack of improvement.\r\nShe was referred to ED for admission and IV antibiotics, given\r\nher pneumonia and history of allogenic transplant.\r\n\r\nIn the ED, her vitals were: T 98.8, HR 96, BP 129/65, RR 18, \r\nSPO2\r\n97% RA. Lung exam was significant for diffuse expiratory \r\nwheezing\r\nand rhonchi. Labs were remarkable for WBC 13, HGB 13, plt 256, K\r\n4.6, Cr 1.2. She was given azithromycin, albuterol nebs, DuoNeb,\r\nIVF.\r\n\r\nOn arrival to OMED, she reports she has laryngitis and continued\r\ncough. She has multiple sick contacts (grandchildren at home who\r\nhave colds). She denies current fever, chills, abdominal pain,\r\nnausea, diarrhea, dysuria, leg swelling.\r\n\r\nREVIEW OF SYSTEMS:  \r\nA complete 10-point review of systems was performed and was\r\nnegative unless otherwise noted in the HPI.  \r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY: \r\n Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO.  Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h).  Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging.  MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact.  Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning.  D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n\r\nTRANSPLANT DATA:\r\n  Transplant Date: ___\r\n  Graft: URD\r\n  Conditioning Intensity: Reduced-Intensity\r\n  Conditioning Regimen: Flu/Bu/ATG\r\n\r\n  Donor Info: ___ CMV(+), ABO: Opos\r\n  Recipient Info: CMV(+), ABO: Opos  \r\n \r\n\r\nPAST MEDICAL HISTORY:  \r\n- CVID\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- RLE DVT, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- R internal carotid cavernous sinus aneurism ___ coiling \r\n___\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- + Parainfluenza, ___\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:  \r\n___ ___ Temp: 98.3 PO BP: 110/42 HR: 91 RR: 20 O2 sat: 97%\r\nO2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nGU: Cutaneous candiasis in groin, R worse than L\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye, and hyperthesia of the right V1 distribution. CN II-XII\r\notherwise intact. Strength ___ in all extremities. Sensation\r\nintact in all extremities.\r\n\r\nDischarge Physical Exam:\r\nVS: ___ ___ Temp: 98.1 PO BP: 124/51 Sitting HR: 95 RR: 18\r\nO2 sat: 97% O2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n==============\r\n___ 11:00PM BLOOD WBC-13.0* RBC-4.07 Hgb-13.0 Hct-40.9 \r\nMCV-101* MCH-31.9 MCHC-31.8* RDW-14.1 RDWSD-51.1* Plt ___\r\n___ 11:00PM BLOOD Neuts-93.1* Lymphs-4.5* Monos-1.8* \r\nEos-0.1* Baso-0.1 Im ___ AbsNeut-12.08* AbsLymp-0.59* \r\nAbsMono-0.24 AbsEos-0.01* AbsBaso-0.01\r\n___ 11:00PM BLOOD Glucose-234* UreaN-14 Creat-1.2* Na-142 \r\nK-4.6 Cl-105 HCO3-21* AnGap-16\r\n___ 11:00PM BLOOD ALT-14 AST-19 AlkPhos-151* TotBili-0.2\r\n___ 11:00PM BLOOD Albumin-4.2\r\n___ 11:00PM BLOOD IgG-713\r\n___ 01:51AM BLOOD Lactate-1.3\r\n\r\nMICRO:\r\n======\r\n___ urine culture: negative\r\n___ fluA&B PCR: negative\r\n___ blood cultures: pending ***\r\n___ urine legionella antigen: negative\r\n___ urine strep pneumo Ag: pending ***\r\n___ respiratory viral screen and culture: pending ***\r\n\r\nIMAGING AND STUDIES:\r\n===================\r\n___ CXR:\r\nNo acute intrathoracic process.\r\n\r\n___ ECG: QTc 487\r\n\r\nDISCHARGE LABS:\r\n===============\r\n\r\n___ 07:00AM BLOOD WBC-5.6 RBC-3.91 Hgb-12.6 Hct-39.7 \r\nMCV-102* MCH-32.2* MCHC-31.7* RDW-14.4 RDWSD-53.7* Plt ___\r\n___ 07:00AM BLOOD Plt ___\r\n \r\nBrief Hospital Course:\r\nSUMMARY:\r\n========= \r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na history of stage IIA follicular lymphoma with treatment \r\nrelated MDS ___ allogeneic stem cell transplant on ___ who \r\npresents with four days of productive cough, fevers and chills \r\nconsistent with community acquired pneumonia \r\n\r\nACTIVE ISSUES:\r\n=============\r\n#community acquired pneumonia \r\nMost likely etiology is community acquired pneumonia, given \r\nabsence of consolidation on CXR, her sick contacts (grandkids \r\nwith colds), and lung exam with bronchial breath sounds and \r\nwheezing. Flu swab negative. Preliminary results from the viral \r\nrespiratory screen was negative. Given her immunocompromised \r\nstate, will treat for CAP. D1 CTX ___, D1 azithromycin ___. \r\nHer symptoms were treated with DuonNebs, Flovent, albuterol, and \r\nguafenisen. We discharged her home with lovenox to complete a 5 \r\nday course of antibiotics ending on ___\r\n\r\n#CVID\r\nReceives IVIG every 1 - 2 months to keep IGG > 500. Her last \r\ninfusion was ~1 month ago. IGG 715 this admission, so IVIG was \r\nnot given this admission. She was monitored for signs of \r\ninfection and treated as above.\r\n\r\n#MDS ___ allogeneic stem cell transplant on ___\r\nHer outpatient oncology team was notified of her admission. Her \r\nhome prednisone and MMF were continued, as well as her home \r\nacyclovir and Bactrim.\r\n\r\n#Cutaneous candidiasis of groin\r\nHas required 5-day course of fluconazole in past to resolve. She \r\nwas treated with nystatin cream only, due to hesitancy to \r\nprescribe a systemic antifungal with other QTc prolonging meds \r\n(azithro).\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Right lower extremity DVT: IVC filter in place. Continued home \r\nrivaroxaban.\r\n\r\n#GERD: continued home omeprazole.\r\n\r\n#Osteoarthritis \r\n#Cervical radiculopathy\r\n#Sciatica\r\n#Migraines\r\nContinued home gabapentin. Tylenol PRN.\r\n\r\n#Obstructive sleep apnea: she used her home CPAP while \r\ninpatient.\r\n\r\n#H/O cerebral aneurism: Noted on MRA with small R internal \r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm \r\n(___). Her home Neurontin was continued.\r\n\r\n#Asthma: continued home Flovent and DuoNebs, with albuterol PRN.\r\n\r\n#Hypertension: she was noted to not be on antihypertensives at \r\nhome. Her BP was monitored while inpatient.\r\n\r\n#Mood disorder: her home venlafaxine was continued.\r\n\r\nTRANSITIONAL ISSUES:\r\n===================\r\n[]Levofloxacin course ending ___\r\n[]Follow up with oncology ___\r\n[]Viral culture pending on discharge \r\n[]Glucose on admission was 234, consider screening for DM2 as \r\noutpatient \r\n\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: full code (confirmed)\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Rivaroxaban 20 mg PO DAILY \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Gabapentin 400 mg PO BID \r\n4. PredniSONE 5 mg PO DAILY \r\n5. Zofran (ondansetron HCl) 4 mg oral Q8H \r\n6. Mycophenolate Mofetil 500 mg PO BID \r\n7. Venlafaxine 25 mg PO DAILY \r\n8. Acyclovir 400 mg PO TID \r\n9. Cephalexin ___ mg PO ONCE \r\n10. Restasis 0.05 % ophthalmic (eye) BID \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n12. Hydrocortisone Cream 1% 1 Appl TP BID \r\n13. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n14. Nystatin Cream 1 Appl TP BID:PRN fungal rash \r\n15. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n16. Vitamin D ___ UNIT PO DAILY \r\n17. FoLIC Acid 1.6 mg PO DAILY \r\n18. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1.  GuaiFENesin ER 600 mg PO Q12H \r\nRX *guaifenesin 600 mg 1 tablet(s) by mouth q12hrs prn Disp #*10 \r\nTablet Refills:*0 \r\n2.  Levofloxacin 500 mg PO Q24H Duration: 2 Days \r\nRX *levofloxacin [Levaquin] 500 mg 1 tablet(s) by mouth daily \r\nDisp #*2 Tablet Refills:*0 \r\n3.  Acyclovir 400 mg PO TID  \r\n4.  Cephalexin ___ mg PO ONCE  \r\n5.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n6.  FoLIC Acid 1.6 mg PO DAILY  \r\n7.  Gabapentin 400 mg PO BID  \r\n8.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n10.  Mycophenolate Mofetil 500 mg PO BID  \r\n11.  Nystatin Cream 1 Appl TP BID:PRN fungal rash  \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n14.  PredniSONE 5 mg PO DAILY  \r\n15.  Restasis 0.05 % ophthalmic (eye) BID  \r\n16.  Rivaroxaban 20 mg PO DAILY  \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n19.  Venlafaxine 25 mg PO DAILY  \r\n20.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n4) Cutaneous candidiasis of groin \r\n5) RLE DVT\r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___.\r\n\r\nWHY WAS I IN THE HOSPITAL?\r\n- You had symptoms of a respiratory infection.\r\n\r\nWHAT HAPPENED TO ME IN THE HOSPITAL?\r\n- You were started on antibiotics to treat a possible bacterial \r\nlung infection, and were treated symptomatically with inhalers, \r\npain medicine and fluids.\r\n- Many tests were done to look for causes of infection.\r\n- We feel you most likely had a bacterial infection of your \r\nlungs and gave you medicine to treat it \r\n\r\nWHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?\r\n- Continue to take all your medicines and keep your \r\nappointments.\r\n\r\nWe wish you the best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-26:9",
      "text": "Discharge Instructions:\nDear Ms. ___, It was a pleasure caring for you at ___ \n___. WHY WAS I IN THE HOSPITAL? - You had symptoms of a respiratory infection. WHAT HAPPENED TO ME IN THE HOSPITAL? - You were started on antibiotics to treat a possible bacterial \nlung infection, and were treated symptomatically with inhalers, \npain medicine and fluids. - Many tests were done to look for causes of infection. - We feel you most likely had a bacterial infection of your \nlungs and gave you medicine to treat it WHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL? - Continue to take all your medicines and keep your \nappointments. We wish you the best! Sincerely,\nYour ___ Team\n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-26",
        "chart_time": "105179",
        "section": "General",
        "position": 9,
        "tokenCount": 174,
        "note_metadata": {
          "note_id": "18887130-DS-26",
          "subject_id": 18887130,
          "hadm_id": 29331505,
          "note_type": "DS",
          "note_seq": 26,
          "charttime": 105179,
          "storetime": 105179.69236111111,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, chills, cough\r\n \r\nMajor Surgical or Invasive Procedure:\r\nnone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na\r\nhistory of stage IIA follicular lymphoma with treatment\r\nrelated MDS ___ allogeneic stem cell transplant on ___ who\r\npresents with four days of productive cough, fevers and chills.\r\n\r\nShe called her ___ clinic on ___ and reported fever,\r\nchills, and productive cough. She had been seen at urgent care\r\nearlier on ___ and received CXR which was consistent with\r\npneumonia, and she was treated with ceftriaxone 1g, steroids and\r\nDuoNebs. She called ___ clinic due to lack of improvement.\r\nShe was referred to ED for admission and IV antibiotics, given\r\nher pneumonia and history of allogenic transplant.\r\n\r\nIn the ED, her vitals were: T 98.8, HR 96, BP 129/65, RR 18, \r\nSPO2\r\n97% RA. Lung exam was significant for diffuse expiratory \r\nwheezing\r\nand rhonchi. Labs were remarkable for WBC 13, HGB 13, plt 256, K\r\n4.6, Cr 1.2. She was given azithromycin, albuterol nebs, DuoNeb,\r\nIVF.\r\n\r\nOn arrival to OMED, she reports she has laryngitis and continued\r\ncough. She has multiple sick contacts (grandchildren at home who\r\nhave colds). She denies current fever, chills, abdominal pain,\r\nnausea, diarrhea, dysuria, leg swelling.\r\n\r\nREVIEW OF SYSTEMS:  \r\nA complete 10-point review of systems was performed and was\r\nnegative unless otherwise noted in the HPI.  \r\n \r\nPast Medical History:\r\nPAST ONCOLOGIC HISTORY: \r\n Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA\r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV 3\r\n- ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO.  Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h).  Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging.  MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact.  Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning.  D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n\r\nTRANSPLANT DATA:\r\n  Transplant Date: ___\r\n  Graft: URD\r\n  Conditioning Intensity: Reduced-Intensity\r\n  Conditioning Regimen: Flu/Bu/ATG\r\n\r\n  Donor Info: ___ CMV(+), ABO: Opos\r\n  Recipient Info: CMV(+), ABO: Opos  \r\n \r\n\r\nPAST MEDICAL HISTORY:  \r\n- CVID\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- RLE DVT, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- R internal carotid cavernous sinus aneurism ___ coiling \r\n___\r\n- Asthma\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- + Parainfluenza, ___\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:  \r\n___ ___ Temp: 98.3 PO BP: 110/42 HR: 91 RR: 20 O2 sat: 97%\r\nO2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nGU: Cutaneous candiasis in groin, R worse than L\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye, and hyperthesia of the right V1 distribution. CN II-XII\r\notherwise intact. Strength ___ in all extremities. Sensation\r\nintact in all extremities.\r\n\r\nDischarge Physical Exam:\r\nVS: ___ ___ Temp: 98.1 PO BP: 124/51 Sitting HR: 95 RR: 18\r\nO2 sat: 97% O2 delivery: Ra \r\nGeneral:  Well appearing in NAD, sitting comfortably.\r\nHEENT:  slight ptosis of right eye, Sclerae anicteric. MMM. No\r\nlesions. No oropharyngeal erythema or thrush \r\nNECK:  Supple. No cervical or supraclavicular lymphadenopathy\r\nCV:  RRR, NL S1S2 no MRG\r\nPULM:  Bronchial breath sounds, diffuse expiratory wheezes\r\nABD:  BS normoactive, soft, NTND. No HSM appreciated. No\r\nperitoneal signs.\r\nEXT:  Legs with nonpitting edema bilaterally. R wrist brace.\r\nCalves and feet are cool to the touch.\r\nSKIN: venous stasis changes to bilateral calves\r\nNEURO:  CN 6 palsy of the right eye, mild proptosis of the right\r\neye\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n==============\r\n___ 11:00PM BLOOD WBC-13.0* RBC-4.07 Hgb-13.0 Hct-40.9 \r\nMCV-101* MCH-31.9 MCHC-31.8* RDW-14.1 RDWSD-51.1* Plt ___\r\n___ 11:00PM BLOOD Neuts-93.1* Lymphs-4.5* Monos-1.8* \r\nEos-0.1* Baso-0.1 Im ___ AbsNeut-12.08* AbsLymp-0.59* \r\nAbsMono-0.24 AbsEos-0.01* AbsBaso-0.01\r\n___ 11:00PM BLOOD Glucose-234* UreaN-14 Creat-1.2* Na-142 \r\nK-4.6 Cl-105 HCO3-21* AnGap-16\r\n___ 11:00PM BLOOD ALT-14 AST-19 AlkPhos-151* TotBili-0.2\r\n___ 11:00PM BLOOD Albumin-4.2\r\n___ 11:00PM BLOOD IgG-713\r\n___ 01:51AM BLOOD Lactate-1.3\r\n\r\nMICRO:\r\n======\r\n___ urine culture: negative\r\n___ fluA&B PCR: negative\r\n___ blood cultures: pending ***\r\n___ urine legionella antigen: negative\r\n___ urine strep pneumo Ag: pending ***\r\n___ respiratory viral screen and culture: pending ***\r\n\r\nIMAGING AND STUDIES:\r\n===================\r\n___ CXR:\r\nNo acute intrathoracic process.\r\n\r\n___ ECG: QTc 487\r\n\r\nDISCHARGE LABS:\r\n===============\r\n\r\n___ 07:00AM BLOOD WBC-5.6 RBC-3.91 Hgb-12.6 Hct-39.7 \r\nMCV-102* MCH-32.2* MCHC-31.7* RDW-14.4 RDWSD-53.7* Plt ___\r\n___ 07:00AM BLOOD Plt ___\r\n \r\nBrief Hospital Course:\r\nSUMMARY:\r\n========= \r\nMs. ___ is a ___ year old female with transformed DLBCL with \r\na history of stage IIA follicular lymphoma with treatment \r\nrelated MDS ___ allogeneic stem cell transplant on ___ who \r\npresents with four days of productive cough, fevers and chills \r\nconsistent with community acquired pneumonia \r\n\r\nACTIVE ISSUES:\r\n=============\r\n#community acquired pneumonia \r\nMost likely etiology is community acquired pneumonia, given \r\nabsence of consolidation on CXR, her sick contacts (grandkids \r\nwith colds), and lung exam with bronchial breath sounds and \r\nwheezing. Flu swab negative. Preliminary results from the viral \r\nrespiratory screen was negative. Given her immunocompromised \r\nstate, will treat for CAP. D1 CTX ___, D1 azithromycin ___. \r\nHer symptoms were treated with DuonNebs, Flovent, albuterol, and \r\nguafenisen. We discharged her home with lovenox to complete a 5 \r\nday course of antibiotics ending on ___\r\n\r\n#CVID\r\nReceives IVIG every 1 - 2 months to keep IGG > 500. Her last \r\ninfusion was ~1 month ago. IGG 715 this admission, so IVIG was \r\nnot given this admission. She was monitored for signs of \r\ninfection and treated as above.\r\n\r\n#MDS ___ allogeneic stem cell transplant on ___\r\nHer outpatient oncology team was notified of her admission. Her \r\nhome prednisone and MMF were continued, as well as her home \r\nacyclovir and Bactrim.\r\n\r\n#Cutaneous candidiasis of groin\r\nHas required 5-day course of fluconazole in past to resolve. She \r\nwas treated with nystatin cream only, due to hesitancy to \r\nprescribe a systemic antifungal with other QTc prolonging meds \r\n(azithro).\r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#Right lower extremity DVT: IVC filter in place. Continued home \r\nrivaroxaban.\r\n\r\n#GERD: continued home omeprazole.\r\n\r\n#Osteoarthritis \r\n#Cervical radiculopathy\r\n#Sciatica\r\n#Migraines\r\nContinued home gabapentin. Tylenol PRN.\r\n\r\n#Obstructive sleep apnea: she used her home CPAP while \r\ninpatient.\r\n\r\n#H/O cerebral aneurism: Noted on MRA with small R internal \r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm \r\n(___). Her home Neurontin was continued.\r\n\r\n#Asthma: continued home Flovent and DuoNebs, with albuterol PRN.\r\n\r\n#Hypertension: she was noted to not be on antihypertensives at \r\nhome. Her BP was monitored while inpatient.\r\n\r\n#Mood disorder: her home venlafaxine was continued.\r\n\r\nTRANSITIONAL ISSUES:\r\n===================\r\n[]Levofloxacin course ending ___\r\n[]Follow up with oncology ___\r\n[]Viral culture pending on discharge \r\n[]Glucose on admission was 234, consider screening for DM2 as \r\noutpatient \r\n\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: full code (confirmed)\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Rivaroxaban 20 mg PO DAILY \r\n2. Omeprazole 20 mg PO DAILY \r\n3. Gabapentin 400 mg PO BID \r\n4. PredniSONE 5 mg PO DAILY \r\n5. Zofran (ondansetron HCl) 4 mg oral Q8H \r\n6. Mycophenolate Mofetil 500 mg PO BID \r\n7. Venlafaxine 25 mg PO DAILY \r\n8. Acyclovir 400 mg PO TID \r\n9. Cephalexin ___ mg PO ONCE \r\n10. Restasis 0.05 % ophthalmic (eye) BID \r\n11. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n12. Hydrocortisone Cream 1% 1 Appl TP BID \r\n13. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n14. Nystatin Cream 1 Appl TP BID:PRN fungal rash \r\n15. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n16. Vitamin D ___ UNIT PO DAILY \r\n17. FoLIC Acid 1.6 mg PO DAILY \r\n18. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1.  GuaiFENesin ER 600 mg PO Q12H \r\nRX *guaifenesin 600 mg 1 tablet(s) by mouth q12hrs prn Disp #*10 \r\nTablet Refills:*0 \r\n2.  Levofloxacin 500 mg PO Q24H Duration: 2 Days \r\nRX *levofloxacin [Levaquin] 500 mg 1 tablet(s) by mouth daily \r\nDisp #*2 Tablet Refills:*0 \r\n3.  Acyclovir 400 mg PO TID  \r\n4.  Cephalexin ___ mg PO ONCE  \r\n5.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n6.  FoLIC Acid 1.6 mg PO DAILY  \r\n7.  Gabapentin 400 mg PO BID  \r\n8.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n9.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n10.  Mycophenolate Mofetil 500 mg PO BID  \r\n11.  Nystatin Cream 1 Appl TP BID:PRN fungal rash  \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n14.  PredniSONE 5 mg PO DAILY  \r\n15.  Restasis 0.05 % ophthalmic (eye) BID  \r\n16.  Rivaroxaban 20 mg PO DAILY  \r\n17.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n18.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n19.  Venlafaxine 25 mg PO DAILY  \r\n20.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n4) Cutaneous candidiasis of groin \r\n5) RLE DVT\r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nIt was a pleasure caring for you at ___ \r\n___.\r\n\r\nWHY WAS I IN THE HOSPITAL?\r\n- You had symptoms of a respiratory infection.\r\n\r\nWHAT HAPPENED TO ME IN THE HOSPITAL?\r\n- You were started on antibiotics to treat a possible bacterial \r\nlung infection, and were treated symptomatically with inhalers, \r\npain medicine and fluids.\r\n- Many tests were done to look for causes of infection.\r\n- We feel you most likely had a bacterial infection of your \r\nlungs and gave you medicine to treat it \r\n\r\nWHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?\r\n- Continue to take all your medicines and keep your \r\nappointments.\r\n\r\nWe wish you the best!\r\n\r\nSincerely,\r\nYour ___ Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \ndapsone\n \nAttending: ___. Chief Complaint:\nfever, cough, headache\n \nMajor Surgical or Invasive Procedure:\nNone",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 0,
        "tokenCount": 72,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:1",
      "text": "History of Present Illness:\nA ___ year old female with CVID,\nhistory of follicular lymphoma transformed to DLBCL status post\nautolgous SCT in ___ (in remission from lymphoma) but noted for\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \n=\n___ with plans to move toward allogeneic transplant but\ndeveloped productive cough of clear sputum and wheezing for 2\ndays in ___ and was found to have RSV. She was then\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\nfrom ___. She received IVIG 10 grams daily for 4\ndays from ___. She required a tooth extraction on\nthe lower left side on ___ due to persistent tooth pain. Following recovery of her respiratory symptoms and dental \nissues,\nMs. ___ was admitted on ___ for her MUD allogeneic\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\nallogeneic transplantation course was complicated by aseptic\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \nlower\nlegs, and GVDH. She was last seen outpatient on ___. During this visit, \nshe did not have any URI symptoms. She reported using her\ninhalers as needed only. She noted some diarrhea and vomiting\nwhich persisted for several days and then stopped. Overall, she\nreported feeling well without sick contacts. Since the visit on ___, she reported that the several days \n(4\ndays ago), she was more fatigue, had mild sore throat, and had\nexposure to sick contacts with URI symptoms. She noted increased\ncough and wheezing but this improved somewhat with inhaler and \nso\nshe felt she was improving. However, on ___, she\nstarted feeling unwell again. On ___, she visited a\nlocal urgent care and was found to have a fever of 100.7. At \nthis\npoint, she was coughing more with increased wheezing and \nfatigue. In addition, she noticed a headache (somewhat typical of her\nmigraines) that wrapped around her head like a \"C\". The headache\nstarted from the back of the head and progressed into the \nfrontal\npart of her head. She did not notice any visual disturbances,\nlightheadedness, or dizziness. The headache appeared to be worse\nwith increased cough but was not associated with visual\ndisturbances, nausea, or vomiting. Her appetite has diminished\nsignificantly - she did eat or drink adequately for almost the\npast 48 hours. The provider at the urgent care advised her to\ncome to the ED and so she called the ___ fellow who directed her\nto the ___ ED. In the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\nsignificant for loud audible cough, diffuse wheezing, and\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 1,
        "tokenCount": 690,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:2",
      "text": "The provider at the urgent care advised her to\ncome to the ED and so she called the ___ fellow who directed her\nto the ___ ED. In the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\nsignificant for loud audible cough, diffuse wheezing, and\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. Given CXR findings, she was given cefepime IV and vancomycin IV. She was also noted to have increased 02 requirement (RA on\ninitial ED visit then became hypoxic, ___ via NC). This \nprompted\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\nevidence of pulmonary embolism or aortic abnormality but did\nreveal consolidation in nodular opacities with perihilar and\nperipheral consolidation and surrounding ground glass which are\nmost severe in the right lower and upper lobe with additional\nfindings in the left lower lobe. On arrival to ___ unit, she reported that her cough and wheezing\nis still profound. No sore throat, headache or night sweats. She\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \ndysuria,\nhematuria, leg swelling. No rash in her groin area but does have\nmultiple creams prescribed by dermatology due to various skin\nrashes and GVHD. Erythema of right shin improved per patient\nreport - reported injury to RLE ~ 6 weeks ago that appears to\nhave no healed completely - no worsening erythema or\npain/discharge. Usual numbness of right toes following prior\nsurgery; has noted some increased sensations on the bottom of \nhis\nfeet.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 2,
        "tokenCount": 417,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:3",
      "text": "Past Medical History:\nTRANSPLANT DATA (PER OMR)\n===================================\nTransplant Date: ___\nGraft: URD\nConditioning Intensity: Reduced-Intensity\nConditioning Regimen: Flu/Bu/ATG\nDonor Info: ___ CMV(+), ABO: Opos\nRecipient Info: CMV(+), ABO: Opos POST TRANSPLANT COURSE (PER OMR)\n==================================== \n*D0 = ___. Had expected reactions to ATG with some fluid\noverload issues and given diuresis with Lasix. Creatinine\nincreased slightly in this setting. No ongoing fevers. Required \n1\nred cell transfusion and 2 platelet transfusions during her\nadmission. Has history of prior DVT's(has filter in place) and\nanticoagulation was switched to Lovenox. Discharged on \n___. *Doing well and was transitioned to home. She had periodic loose\nstools, felt more related to medications and not GVHD. ___, presented to the emergency room with headache, \nfevers,\nand vomiting and was admitted with concern for meningitis. Treated initially with cefepime and acyclovir to cover both\nbacterial meningitis and HSV meningitis. LP on ___ was\nconsistent with aseptic meningitis and no HSV was found in the\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\ntoxoplasmosis was negative. Symptoms improved over time. *Noted for CMV viremia and started IV ganciclovir on ___\nwhich was transitioned to oral valganciclovir prior to \ndischarge. CMV VL has been negative since ___ and her Valganciclovir\nwas switched to maintenance dosing, and then discontinued\n(switched back to Acyclovir). ___ - ___, Admission with headache, nausea and vomiting\nand development of fevers to 103 with coagulase-negative\ngram-positive cocci in blood cultures noted as S. epidermidis\nbacteremia. Headache resolved on own with MRI of head from ___\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \narboviruses,\nLyme, crypotococcus, and fungal markers were all negative. Treated with antibiotics which were narrowed to vancomycin with\nnoted S. epidermidis bacteremia. No other sources of infection\nwere noted. A TTE revealed normal biventricular cavity sizes \nwith\nmild global left ventricular hypokinesis, mild mitral\nregurgitation with normal valve morphology and trace aortic\nregurgitation with normal valve morphology. No TEE as it would\nnot change the course of therapy. Continued on Vancomycin until\n___ and was transitioned to Daptomycin as Vancomycin \nlevels\nfluctuated frequently throughout her hospitalization. Complete 6\nweeks of antibiotics therapy with Daptomycin until ___\nwith vanco locks in attempt to save her port. POC pulled on\n___ and continued Daptomycin peripherally until PICC \nplaced\non ___. Daptomycin course completed on ___\nas planned; PICC line removed. *URI with prolonged cough in ___.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 3,
        "tokenCount": 692,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:4",
      "text": "No TEE as it would\nnot change the course of therapy. Continued on Vancomycin until\n___ and was transitioned to Daptomycin as Vancomycin \nlevels\nfluctuated frequently throughout her hospitalization. Complete 6\nweeks of antibiotics therapy with Daptomycin until ___\nwith vanco locks in attempt to save her port. POC pulled on\n___ and continued Daptomycin peripherally until PICC \nplaced\non ___. Daptomycin course completed on ___\nas planned; PICC line removed. *URI with prolonged cough in ___. + Enterovirus noted on\nviral PCR testing. Symptoms slowly improved. *Increased rash on face and torso; tried steroid creams. ___ - ___, admitted with diarrhea and worsening rash. Diarrhea resolved without intervention. Started on increased\nsteroids with improvement in rash. Discharged on Prednisone 80 \nmg\ndaily which is now being tapered, currently on 7.5 mg daily. ___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\nin CellCept to try and taper other medications. ___ - ___, Admitted with four days of productive cough,\nfevers and chills consistent with community acquired pneumonia;\ntreated with antibiotics. PAST ONCOLOGIC HISTORY (PER OMR)\n==========================================\n-Transformed DLBCL with a history of follicular lymphoma stage\nIIA \n- ___ developed worsening musculoskeletal back pain, early\nsatiety, hypoalbuminemia and found to have mesenteric mass\n- ?___ ex lap with 15 cm lobulated mass involving the\nduodenum, retroperitoneum and celiac access. Biopsies showed\nFollicular lymphomas grade II/III. Reportedly negative staging\nGallium scan. CD10+ BCL2+\n- ___ completed 6 cycles CHOP, complications included\nSVC/innominate thrombus (tPA)\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\nmarrow at completion was negative for lymphomatous involvement. - ___ PET-CT with very slight amount of increased tracer\nactivity within the posterior left supraclavicular region. No\nother areas of FDG avid disease were noted \n- ___ through ___ per records she was treated with CVP\nfollowed by course of single agent Rituxan\n- ___ through ___ surveillance imaging with no evidence of\nrecurrent disease, stable mesenteric mass. - ___ abdominal pain led to CT with no change in mass size,\nincreased conspicuity of nodular borders\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\nstable mesenteric mass with low level SUV 2.2 stable since \nprior. - ___ CT torso showed persistent mesenteric and left hilar\nlymphadenopathy. Stable right middle lobe small focus of ground\nglass opacity and adjacent subpleural fat hypertrophy, \nsuggestive\nof inflammatory process. Stable right adnexal cyst. - ___ Presented to PCP ___ ___iscomfort. Exam\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\nnormal differential, PLT 452.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 4,
        "tokenCount": 689,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:5",
      "text": "hilar LN PET-avid to SUV 7.9, otherwise\nstable mesenteric mass with low level SUV 2.2 stable since \nprior. - ___ CT torso showed persistent mesenteric and left hilar\nlymphadenopathy. Stable right middle lobe small focus of ground\nglass opacity and adjacent subpleural fat hypertrophy, \nsuggestive\nof inflammatory process. Stable right adnexal cyst. - ___ Presented to PCP ___ ___iscomfort. Exam\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\nnormal differential, PLT 452. - ___ PET CT revealed, \"Large left cervical,\nsupraclavicular, mediastinal lymphadenopathy, and \nretroperitoneal\nlymphadenopathy, and small mesenteric\nlymphadenopathy, all markedly FDG-avid and concerning for\nlymphoma.\" SUVmax 35.5. - ___iopsy revealed diffuse large B cell\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \nare\npending\n- ___ C1D1 ICE\n- ___ C1 Rituximab, clinically improved adenopathy\n- ___ C2 Rituximab, WBC 6.5, PLT 43\n- ___ Admit for C2D1 ICE\n- ___ C3 Rituximab\n- ___ PET CT showed almost complete resolution of FDG avid\ndisease with a residual focus of avidity in the bed of the \nformer\nabdominal mass, SUV ___ C4 Rituximab\n- ___ C4 ICE followed by stem cell mobilization and\ncollection, BMBx showed a nest of CLL unrelated to her \naggressive\nlymphoma\n- ___ Presented with large DVTs, SVC filter placed\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\n- ___ Switched to Rivaroxiban for AC\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\ncytopenias\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose. - ___, Norovirus\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\nDLCO. Finally d/ced ___. - IVIg 400 mg/kg, continues monthly for\nHypogammaglobuonemia/CVID. - ___, CT torso with no evidence of active disease. Stable\nappearance of a conglomeration of mesenteric lymph nodes. - ___, Right total knee replacement, complicated by foot\ndrop likely due to irritation of peroneal nerve from the CPM\nmachine, as well as a cellulitis of the right leg; same leg as\nher previous DVT and her circulation is poor. - ___, CT Torso with no evidence of active disease. Stable appearance of conglomerate of mesenteric LN's. Increased\ndilatation of the main pulmonary artery suggests worsening\npulmonary arterial hypertension of indeterminate etiology. - ___, CT torso with no evidence of active disease. Increased\ndilation of pulmonary artery. Evaluated by Dr. ___\n- ___, Increasing right leg swelling and shortness of breath\nwith noted DVT; no DVT. Xarelto increased back to 20 mg\ndaily(had been decreased given age and prior chronic DVT). No\nevidence for lymphoma on CT imaging. - ___, noted drop in blood counts.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 5,
        "tokenCount": 690,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:6",
      "text": "- ___, CT Torso with no evidence of active disease. Stable appearance of conglomerate of mesenteric LN's. Increased\ndilatation of the main pulmonary artery suggests worsening\npulmonary arterial hypertension of indeterminate etiology. - ___, CT torso with no evidence of active disease. Increased\ndilation of pulmonary artery. Evaluated by Dr. ___\n- ___, Increasing right leg swelling and shortness of breath\nwith noted DVT; no DVT. Xarelto increased back to 20 mg\ndaily(had been decreased given age and prior chronic DVT). No\nevidence for lymphoma on CT imaging. - ___, noted drop in blood counts. Bone marrow biopsy showed\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. Cytogenetics showing multiple abnormalities. - ___, C1 Dacogen\n- ___, admitted with fever in setting of neutropenia, and\nincreasing right sided back pain. No infectious source found;\nafter consultation with ID, it was decided to treat empirically\nfor presumptive osteomyelitis/discitis with 6 weeks of \nvancomycin\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\nq24h). Required short time of pain medicines for back pain. - ___, C2 Dacogen\n- ___, admitted with increased confusion and issues of\nword finding. Head CT and MRI of the head did not show any\nabnormality. Treated with concern for meningitis and remained \non\nher other antibiotics for treatment of presumed osteomyelitis. Confusion resolved and no infectious etiology was noted except\nfor possible UTI. - ___, Admitted with 2 days of nausea, vomiting, fever,\nconfusion, and urinary incontinence, with infectious workup,\noverall negative, except for positive coronavirus. CTA negative\nfor PE and there was no evidence of pulmonary or abdominal\ninfection on imaging. MRI of brain was negative for an\nintracranial process; MRI spine was negative for abscess or\nosteomyelitis. - ___, C3 Dacogen and discharged to home on ___. - ___, Admitted with diarrhea, decreased appetite. Received IVF support, transfusions and potassium replacement;\ndischarged on ___. - ___, C4 Dacogen\n- ___, Admitted with cough and wheezing. + RSV, treated\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG. - ___, Bone marrow aspirate and biopsy showed a cellular\nmarrow by aspirate with trilineage dyspoitic maturation. By\nimmunohistochemistry CD34 highlights blast cells comprising less\nthan 5% of the overall cellularity. Cellularity in the core\nbiopsy is low, which may be a sampling artifact. Cytogenetics\nrevealed no cells noted with the previously observed complex\nabnormal karyotype with monosomy 7, deletion of 5q and other\nchromosome aberrations associated with myelodysplasia with an\nunfavorable prognosis. - ___, Admitted for MUD allogeneic transplant with Flu/Bu\nand ATG conditioning. D0 = ___.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 6,
        "tokenCount": 688,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:7",
      "text": "By\nimmunohistochemistry CD34 highlights blast cells comprising less\nthan 5% of the overall cellularity. Cellularity in the core\nbiopsy is low, which may be a sampling artifact. Cytogenetics\nrevealed no cells noted with the previously observed complex\nabnormal karyotype with monosomy 7, deletion of 5q and other\nchromosome aberrations associated with myelodysplasia with an\nunfavorable prognosis. - ___, Admitted for MUD allogeneic transplant with Flu/Bu\nand ATG conditioning. D0 = ___. - ___ - ___, admission for aseptic meningitis; noted CMV\nviremia, on Valganciclovir. - ___ - ___, admission for headache, nausea and vomiting\nand development of fevers to 103 with coagulase-negative\ngram-positive cocci noted as S. epidermidis bacteremia;\nDaptomycin for total 6 week course of antibiotics(completed\n___. Also noted for new DVT's of lower legs, on Lovenox\nBID. - ___, admission for increased rash and diarrhea. Started increased systemic steroids and now tapered. - ___ - ___, Admitted with four days of productive cough,\nfevers and chills consistent with community acquired pneumonia;\ntreated with antibiotics OTHER PAST MEDICAL HISTORY (PER OMR)\n===============================================\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\n- GERD                                          \n- Osteoarthritis                                         \n- DVT, right lower extremity, IVC filter in place\n- Cervical radiculopathy\n- Sciatica\n- Obstructive sleep apnea, wears CPAP\n- H/O cerebral aneurism, noted on MRA with small R internal\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\nthe right eye, mild proptosis of the right eye, and hyperthesia\nof the right V1 distribution\n- Asthma, with episodic bronchitis/exacerbations\n- Obesity\n- Hypertension\n- Migraines\n- + RSV, ___\n- S. epidermidis bacteremia, POC removed; completed course of\nDaptomycin\n- +Parainfluenza, ___ PAST SURGICAL HISTORY (PER OMR)\n========================================\n-aneurysm coil in ___ of Right ICA\n-C5 fusion ___\n-Cholecystectomy ___\n-anterior scalenotomy\n-Surgery for ruptured Meckels\n-___ Excisional Bx L Cervical Lymph Node\n-___ L total knee replacement ___, walks with cane\n-___ R total Knee replacement \n-___ I&D Labial Abscess\n-___ Excision Cyst R ___ Digit of Hand\n-numerous laparoscopies. Social History:\n___ Family History:\nBrother died at ___ from lymphoma. No other family history of\ncancer",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 7,
        "tokenCount": 617,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:8",
      "text": "Physical Exam:\nADMISSION PHYSICAL EXAM\n=============================\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\nO2 delivery: 3L NC \nGENERAL: Fatigue and chronically ill appearing. Moderate\nrespiratory distress, siting in bed. HEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\nplace. NECK: Supple. No cervical or supraclavicular lymphadenopathy\nCV: RRR, NL S1/S2. No M/R/G\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\ninspiratory wheezes and crackles with occasional rhonchi. Poor \nto\nfair aeration. ABD: Soft, protuberant with several well healed scars. NT. No \nHSM\nappreciated. No peritoneal signs. GU: No foley\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \nare\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\nadmission - secondary to traumatic injury per patient report\nSKIN: Venous stasis changes to bilateral calves \nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\nproptosis of the right eye and hyperthesia of the right V1\ndistribution. CN II-XII otherwise intact. Strength ___ in all\nextremities. Sensation intact in all extremities. ACCESS: PIV DISCHARGE PHYSICAL EXAM:\nVSS\nGENERAL: No distress, sitting up in chair. HEENT: Deviation of right eye which is baseline, Sclerae\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\nthrush. NECK: Supple. No cervical or supraclavicular lymphadenopathy\nCV: RRR, NL S1/S2. No M/R/G\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\nABD: Soft, protuberant with several well healed scars. NT. No \nHSM\nappreciated. EXT: Legs with non-pitting edema and chronic venous stasis\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \nnoted\non admission - secondary to traumatic injury per patient report\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\nproptosis of the right eye and hyperthesia of the right V1\ndistribution. CN II-XII otherwise intact. Strength ___ in all\nextremities. Sensation intact in all extremities. Skin: back with confluent erythema from neck to lower rib area\nupper chest with large macular and excoriations. ACCESS: PIV Pertinent Results:\nADMISSION LABS\n=============================\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \n___ 01:52AM BLOOD Lactate: 1.1",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 8,
        "tokenCount": 685,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:9",
      "text": "ACCESS: PIV Pertinent Results:\nADMISSION LABS\n=============================\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \n___ 01:52AM BLOOD Lactate: 1.1 IMAGING/STUDIES\n================================\n___ CXR: Increased opacity in the right lower lobe is\nconcerning for developing pneumonia. ___ CTA CHEST: No evidence of pulmonary embolism or aortic\nabnormality. Dilatation of the main pulmonary artery is similar\nto the prior study, concerning for pulmonary hypertension. Consolidative in nodular opacities with perihilar and peripheral consolidation and surrounding ground-glass are most severe in \nthe\nright lower and upper lobe, with additional findings in the left\nlower lobe. Findings are in close proximity to multiple mucus\nimpacted bronchi, and likely reflect a multifocal infectious\nprocess. However, given the patient's history of \nmalignancy in the appearance of the findings, recommend close\ninterval follow-up with repeat imaging after treatment to\ndocument resolution. Moderate-severe central and peripheral\nbilateral airway thickening. MICROBIOLOGY\n=================================\n___ Blood cultures - pending\n___ Flu swab - negative for flu A and flu B\n___ RVP\n___ Urine culture\n___ MRSA Screen\n___ Legionella Urinary Antigen\n___ Fungal markers DISCHARGE LABS: ___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \nK-3.8 Cl-107 HCO3-22 AnGap-13\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \nTotBili-0.2\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\ntransformed diffuse large B cell lymphoma status post curative\nintent with an autologous SCT with BEAM conditioning in ___\n___s IFRT with noted treatment related MDS and status post\nURD allogeneic transplant in ___ presenting with fevers,\nheadache and worsening URI symptoms, found to have radiographic\nevidence of multifocal pneumonia. ACUTE CONDITIONS\n===========================",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 9,
        "tokenCount": 647,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:10",
      "text": "ACUTE CONDITIONS\n=========================== #MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\nhypoxia showed consolidative in nodular opacities with perihilar\nand peripheral consolidation and surrounding ground-glass most\nsevere in the right lower and upper lobe, with additional\nfindings in the left lower lobe. Findings were felt likely\nmultifocal PNA. Given her underlying\nhypogammaglobulinemia and overall impaired immunity from prior\nchemotherapies, we pursed CAP treatment with cefepime and\nvancomycin plus levofloxacin for atypical coverage. - Hypoxia resolved as of ___. - bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \ncomplete 7d course of ABX total ___\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\nsputum culture, MRSA screen--NTD\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \ncan\nconsider PFTs as outpatient once recovered from acute illness\n \n#Rash: given timing most likely antibiotic-induced. Back could \nbe\nc/w Redman's but chest area has raised appearance that is\natypical. d/c vanco/cefepime as above and monitor. She does\nhave hx GVHD so if persists may need to pursue biopsy, f/u \noutpatient ___: stable. Cr 1.1-1.3 baseline. She is\nlikely dehydrated in the setting of poor PO intake. Of\nnote, she has had elevated Cr attributed to medication effect. -IVF PRN (received 1L ___\n-encourage po intake on own #Asthma: Stable, now on RA since ___. Exacerbated in the\nsetting of multifocal pneumonia. She continues on inhalers and\nnebulizers. Monitor for respiratory decompensation. CHRONIC/STABLE CONDITIONS\n=================================== #RLE Wound: Secondary to a traumatic skin injury from a stick ~ \n6\nweeks ago. Consulted wound nursing for evaluation and \nmanagement,\nsee progress note ___. No apparent infection concerns on\nadmission. #MDS: Noted for rapid progression of pancytopenia particularly\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\nnoted cytogenetic abnormalities concerning for treatment related\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\nconditioning. D0 = ___. ABO compatible with donor. Had BM\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\ndonor. Now, patient is exactly ___ years from her allogeneic\ntransplant on ___. Peripheral chimerism from ___ shows\n100% donor by FISH. Remains in remission. Infection Prophylaxis\n    PCP: ___ \n    VZV/HSV: Acyclovir\n    Fungal: Off fluconazole\n    CMV: Off Valganciclovir #GVHD: Waxing and waning rashes followed closely by Dermatology. Fungal rash in groin area now resolved. Lipodermatosclerosis on\nlower legs. No other skin thickening. No other evidence of GVHD\nwith prior skin and ? eye involvement. Steroids tapered.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 10,
        "tokenCount": 679,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:11",
      "text": "Had BM\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\ndonor. Now, patient is exactly ___ years from her allogeneic\ntransplant on ___. Peripheral chimerism from ___ shows\n100% donor by FISH. Remains in remission. Infection Prophylaxis\n    PCP: ___ \n    VZV/HSV: Acyclovir\n    Fungal: Off fluconazole\n    CMV: Off Valganciclovir #GVHD: Waxing and waning rashes followed closely by Dermatology. Fungal rash in groin area now resolved. Lipodermatosclerosis on\nlower legs. No other skin thickening. No other evidence of GVHD\nwith prior skin and ? eye involvement. Steroids tapered. Had\nEndoscopy and colonoscopy which did not show evidence of GVHD. Also, with increased dryness of scalp and flaking of scalp. Had\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept. GVHD Treatment\n-Continue Prednisone 5 mg daily \n-Continue triamcinolone cream BID PRN\n-Continue hydrocortisone/nystatin TP to groin area PRN        \n-Restasis for dry eyes\n    \n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\ntransplant for previous DVTs. This was switched to Lovenox with\nconcern for drug interactions. Has filter in place now with new\ndeep venous thrombosis involving the left posterior tibial and\nright popliteal veins. Continues on Xarelto as above. #CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\nin past and was previously on IV ganciclovir and then\nValganciclovir. CMV VL negative ___, repeat ___ negative. #Arthritis of thumbs/Probable tendon tear of left thumb: Has had\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\nfor complicated recovery and also able to do any activities she\ndesires. #Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\ncontraindication of proceeding with transplant. TTE ___ \nshowed\nnormal biventricular cavity sizes with mild global left\nventricular hypokinesis. Mild mitral regurgitation with normal\nvalve morphology. Trace aortic regurgitation with normal valve\nmorphology. #Lymphoma/CLL/Disease Status: Been in remission with last CT\nscans without evidence of lymphoma/adenopathy. Has history of \nCLL\nas well. She had no evidence of this on prior BM biopsy. #Osteoarthritis:                                         \n#Cervical radiculopathy:\n#Sciatica:\nChronic left lower back pain with sciatica. Lumbar spine MRI \nwith\nand without contrast with no significant changes but noted\nsignificant disc disease and degenerative changes. Monitor for\nexacerbation while inpatient. #History of Cerebral Aneurysm: Noted on MRA with small R \ninternal\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\n(___). She continues on home Neurontin 400mg BID.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 11,
        "tokenCount": 686,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:12",
      "text": "Has history of \nCLL\nas well. She had no evidence of this on prior BM biopsy. #Osteoarthritis:                                         \n#Cervical radiculopathy:\n#Sciatica:\nChronic left lower back pain with sciatica. Lumbar spine MRI \nwith\nand without contrast with no significant changes but noted\nsignificant disc disease and degenerative changes. Monitor for\nexacerbation while inpatient. #History of Cerebral Aneurysm: Noted on MRA with small R \ninternal\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\n(___). She continues on home Neurontin 400mg BID. #CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\nlast infusion was ___, added on IgG level and consider giving\nIVIG if level <600 in the setting of active infection. #GERD: No acute exacerbation. Continues Omeprazole 20mg daily. #Obstructive Sleep Apnea: Using CPAP machine more regularly and\nsleeping better. RT consulted on admission. #Early Macular Degeneration: On Preservision but not available\nin-house so did not order on admission. #Mood Disorder: Continues on Effexor 25mg daily. Living with\ndaughter in her new home which is less stressful and has better\nsupports. Followed by SW. CORE MEASURES\n=========================\n#FEN: Regular diet, replete electrolytes PRN per oncology \nsliding\nscales\n#PPX: Xarelto as above\n#ACCESS: PIV\n#HCP/CONTACT: ___ (daughter) ___\n#CODE STATUS: Full code (confirmed) DISPOSITION: home f/u ___ \n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Acyclovir 400 mg PO Q12H \n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \ncough/wheezing \n3. FoLIC Acid 1.6 mg PO DAILY \n4. Gabapentin 400 mg PO BID \n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \nwheezing/shortness of breath \n6. Nystatin Cream 1 Appl TP BID fungal rash \n7. Omeprazole 20 mg PO DAILY \n8. PredniSONE 5 mg PO DAILY \n9. Rivaroxaban 20 mg PO DAILY \n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \n11. Venlafaxine 25 mg PO DAILY \n12. Vitamin D ___ UNIT PO DAILY \n13. Cephalexin ___ mg PO ONCE \n14. Hydrocortisone Cream 1% 1 Appl TP BID \n15. Restasis 0.05 % ophthalmic (eye) BID \n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \nunspecified \n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \n20. econazole 1 % topical BID groin, thighs \n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \n___ unit-mg-unit oral BID \n23. nystatin 100,000 unit/gram topical BID rash \n24. fluocinonide 1 Appl TP 2X/WEEK \n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \nPain - Moderate",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 12,
        "tokenCount": 675,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-27:13",
      "text": "Discharge Medications:\n1. Benzonatate 100 mg PO TID:PRN Cough   \n2. GuaiFENesin ER 600 mg PO Q12H:PRN cough  \n3. LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \nContinue until ___  \n4. Sarna Lotion 1 Appl TP QID:PRN itch  \n5. ___ ___ unit/gram topical BID:PRN rash  \n6. Acyclovir 400 mg PO Q12H  \n7. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \n8. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \n9. Cephalexin ___ mg PO ONCE  \n10. econazole 1 % topical BID groin, thighs  \n11. fluocinonide 1 Appl TP 2X/WEEK  \n12. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \ncough/wheezing  \n13. FoLIC Acid 1.6 mg PO DAILY  \n14. Gabapentin 400 mg PO BID  \n15. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \nPain - Moderate  \n16. Hydrocortisone Cream 1% 1 Appl TP BID  \n17. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \nwheezing/shortness of breath  \n18. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \n \n19. Nystatin Cream 1 Appl TP BID fungal rash  \n20. Omeprazole 20 mg PO DAILY  \n21. Ondansetron (ondansetron HCl) 4 mg oral Q8H  \n22. PredniSONE 5 mg PO DAILY  \n23. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \n___ unit-mg-unit oral BID  \n24. Restasis 0.05 % ophthalmic (eye) BID  \n25. Rivaroxaban 20 mg PO DAILY  \n26. Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \n27. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \nunspecified  \n28. Venlafaxine 25 mg PO DAILY  \n29. Vitamin D ___ UNIT PO DAILY Discharge Disposition:\nHome with Service Discharge Diagnosis:\nPrimary Diagnosis\n=================\n1) Community Acquired Pneumonia \n2) CVID \n3) MDS ___ allogenic stem cell transplant Secondary Diagnosis\n===================\n1) GERD \n2) OSA \n3) OA \n4) Asthma \n5) HTN\n6) Mood disorder \n7) RLE DVT Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent. Discharge Instructions:\nDear Ms. ___, You were admitted with upper respiratory symptoms, found to have \npnueumonia. We treated you with intravenous antibiotics and your \nsymptoms improved. You are now safe to be discharged home. Please continue your medications as prescribed. It was a \npleasure taking care of you. Followup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-27",
        "chart_time": "105391",
        "section": "General",
        "position": 13,
        "tokenCount": 555,
        "note_metadata": {
          "note_id": "18887130-DS-27",
          "subject_id": 18887130,
          "hadm_id": 26703193,
          "note_type": "DS",
          "note_seq": 27,
          "charttime": 105391,
          "storetime": 105391.47847222222,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nfever, cough, headache\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n\r\n \r\nHistory of Present Illness:\r\nA ___ year old female with CVID,\r\nhistory of follicular lymphoma transformed to DLBCL status post\r\nautolgous SCT in ___ (in remission from lymphoma) but noted for\r\ntreatment related MDS status post 4 cycles of Decitabine (C4 D1 \r\n=\r\n___ with plans to move toward allogeneic transplant but\r\ndeveloped productive cough of clear sputum and wheezing for 2\r\ndays in ___ and was found to have RSV. She was then\r\ntreated with palvilizumab on ___ and ribavirin 600mg q 8h\r\nfrom ___. She received IVIG 10 grams daily for 4\r\ndays from ___. She required a tooth extraction on\r\nthe lower left side on ___ due to persistent tooth pain.\r\n\r\nFollowing recovery of her respiratory symptoms and dental \r\nissues,\r\nMs. ___ was admitted on ___ for her MUD allogeneic\r\ntransplant with Fludarabine, Busulfan and ATG conditioning. Her\r\nallogeneic transplantation course was complicated by aseptic\r\nmenigitis, CMV viremia, S. epidermidis bacteremia, DVT's of \r\nlower\r\nlegs, and GVDH. \r\n\r\nShe was last seen outpatient on ___. During this visit, \r\nshe did not have any URI symptoms. She reported using her\r\ninhalers as needed only. She noted some diarrhea and vomiting\r\nwhich persisted for several days and then stopped. Overall, she\r\nreported feeling well without sick contacts. \r\n\r\nSince the visit on ___, she reported that the several days \r\n(4\r\ndays ago), she was more fatigue, had mild sore throat, and had\r\nexposure to sick contacts with URI symptoms. She noted increased\r\ncough and wheezing but this improved somewhat with inhaler and \r\nso\r\nshe felt she was improving. However, on ___, she\r\nstarted feeling unwell again. On ___, she visited a\r\nlocal urgent care and was found to have a fever of 100.7. At \r\nthis\r\npoint, she was coughing more with increased wheezing and \r\nfatigue.\r\n\r\nIn addition, she noticed a headache (somewhat typical of her\r\nmigraines) that wrapped around her head like a \"C\". The headache\r\nstarted from the back of the head and progressed into the \r\nfrontal\r\npart of her head. She did not notice any visual disturbances,\r\nlightheadedness, or dizziness. The headache appeared to be worse\r\nwith increased cough but was not associated with visual\r\ndisturbances, nausea, or vomiting. Her appetite has diminished\r\nsignificantly - she did eat or drink adequately for almost the\r\npast 48 hours. The provider at the urgent care advised her to\r\ncome to the ED and so she called the ___ fellow who directed her\r\nto the ___ ED. \r\n\r\nIn the ED, her initial vitals were: T 99-100.2, HR 104-103, BP\r\n114-134/52-66, RR ___, SPO2 95-97% RA. Lung examination was\r\nsignificant for loud audible cough, diffuse wheezing, and\r\ncrackles. Labs were remarkable for WBC 13.4, HGB 12.9, plt 229, \r\nCr 1.3 and lactate 1.1. Flu negative. She was given albuterol\r\nnebs, DuoNeb, and IVF. CXR showed RLL opacity c/f pneumonia. \r\nGiven CXR findings, she was given cefepime IV and vancomycin IV. \r\n\r\nShe was also noted to have increased 02 requirement (RA on\r\ninitial ED visit then became hypoxic, ___ via NC). This \r\nprompted\r\nCTA CHEST  (given DVT hx) but fortunately, CT chest did not show\r\nevidence of pulmonary embolism or aortic abnormality but did\r\nreveal consolidation in nodular opacities with perihilar and\r\nperipheral consolidation and surrounding ground glass which are\r\nmost severe in the right lower and upper lobe with additional\r\nfindings in the left lower lobe. \r\n \r\nOn arrival to ___ unit, she reported that her cough and wheezing\r\nis still profound. No sore throat, headache or night sweats. She\r\ndenies chills, rigors, abdominal pain, nausea, diarrhea, \r\ndysuria,\r\nhematuria, leg swelling. No rash in her groin area but does have\r\nmultiple creams prescribed by dermatology due to various skin\r\nrashes and GVHD. Erythema of right shin improved per patient\r\nreport - reported injury to RLE ~ 6 weeks ago that appears to\r\nhave no healed completely - no worsening erythema or\r\npain/discharge. Usual numbness of right toes following prior\r\nsurgery; has noted some increased sensations on the bottom of \r\nhis\r\nfeet.  \r\n\r\n \r\nPast Medical History:\r\nTRANSPLANT DATA (PER OMR)\r\n===================================\r\nTransplant Date: ___\r\nGraft: URD\r\nConditioning Intensity: Reduced-Intensity\r\nConditioning Regimen: Flu/Bu/ATG\r\nDonor Info: ___ CMV(+), ABO: Opos\r\nRecipient Info: CMV(+), ABO: Opos    \r\n\r\nPOST TRANSPLANT COURSE (PER OMR)\r\n==================================== \r\n*D0 = ___. Had expected reactions to ATG with some fluid\r\noverload issues and given diuresis with Lasix. Creatinine\r\nincreased slightly in this setting. No ongoing fevers. Required \r\n1\r\nred cell transfusion and 2 platelet transfusions during her\r\nadmission. Has history of prior DVT's(has filter in place) and\r\nanticoagulation was switched to Lovenox. Discharged on \r\n___.\r\n\r\n*Doing well and was transitioned to home. She had periodic loose\r\nstools, felt more related to medications and not GVHD.\r\n \r\n___, presented to the emergency room with headache, \r\nfevers,\r\nand vomiting and was admitted with concern for meningitis.\r\nTreated initially with cefepime and acyclovir to cover both\r\nbacterial meningitis and HSV meningitis. LP on ___ was\r\nconsistent with aseptic meningitis and no HSV was found in the\r\nCSF; IV antibiotics discontinued. Extensive workup for VZV, EBV,\r\nHSV, HHV6, adenovirus, arbovirus, TB, Anaplasma and serum\r\ntoxoplasmosis was negative. Symptoms improved over time. \r\n\r\n*Noted for CMV viremia and started IV ganciclovir on ___\r\nwhich was transitioned to oral valganciclovir prior to \r\ndischarge.\r\nCMV VL has been negative since ___ and her Valganciclovir\r\nwas switched to maintenance dosing, and then discontinued\r\n(switched back to Acyclovir).  \r\n\r\n___ - ___, Admission with headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci in blood cultures noted as S. epidermidis\r\nbacteremia. Headache resolved on own with MRI of head from ___\r\nunremarkable. CMV, EBV, HSV, HHV6, adeno, ___, \r\narboviruses,\r\nLyme, crypotococcus, and fungal markers were all negative. \r\nTreated with antibiotics which were narrowed to vancomycin with\r\nnoted S. epidermidis bacteremia. No other sources of infection\r\nwere noted. A TTE revealed normal biventricular cavity sizes \r\nwith\r\nmild global left ventricular hypokinesis, mild mitral\r\nregurgitation with normal valve morphology and trace aortic\r\nregurgitation with normal valve morphology. No TEE as it would\r\nnot change the course of therapy. Continued on Vancomycin until\r\n___ and was transitioned to Daptomycin as Vancomycin \r\nlevels\r\nfluctuated frequently throughout her hospitalization. Complete 6\r\nweeks of antibiotics therapy with Daptomycin until ___\r\nwith vanco locks in attempt to save her port. POC pulled on\r\n___ and continued Daptomycin peripherally until PICC \r\nplaced\r\non ___.  Daptomycin course completed on ___\r\nas planned; PICC line removed.\r\n  \r\n*URI with prolonged cough in ___. + Enterovirus noted on\r\nviral PCR testing. Symptoms slowly improved.\r\n \r\n*Increased rash on face and torso; tried steroid creams.\r\n\r\n___ - ___, admitted with diarrhea and worsening rash.\r\nDiarrhea resolved without intervention. Started on increased\r\nsteroids with improvement in rash. Discharged on Prednisone 80 \r\nmg\r\ndaily which is now being tapered, currently on 7.5 mg daily.\r\n\r\n___, Rituxan for GVHD (muscle cramping) x 1 dose. Added\r\nin CellCept to try and taper other medications.\r\n\r\n___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics.\r\n\r\nPAST ONCOLOGIC HISTORY (PER OMR)\r\n==========================================\r\n-Transformed DLBCL with a history of follicular lymphoma stage\r\nIIA \r\n- ___ developed worsening musculoskeletal back pain, early\r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the\r\nduodenum, retroperitoneum and celiac access.  Biopsies showed\r\nFollicular lymphomas grade II/III.  Reportedly negative staging\r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included\r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal\r\nlymphadenopathy, and small mesenteric\r\nlymphadenopathy, all markedly FDG-avid and concerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare\r\npending\r\n- ___ C1D1 ICE\r\n- ___ C1 Rituximab, clinically improved adenopathy\r\n- ___ C2 Rituximab, WBC 6.5, PLT 43\r\n- ___ Admit for C2D1 ICE\r\n- ___ C3 Rituximab\r\n- ___ PET CT showed almost complete resolution of FDG avid\r\ndisease with a residual focus of avidity in the bed of the \r\nformer\r\nabdominal mass, SUV ___ C4 Rituximab\r\n- ___ C4 ICE followed by stem cell mobilization and\r\ncollection, BMBx showed a nest of CLL unrelated to her \r\naggressive\r\nlymphoma\r\n- ___ Presented with large DVTs, SVC filter placed\r\n- ___ D0 of a BEAM autoSCT, course notable for mucositis\r\n- ___ Switched to Rivaroxiban for AC\r\n- ___ PET CT ___, PFTs with normal Hb adjusted DLCO\r\n- ___ IVIg 400 mg/kg c/b fever, aseptic meningitis,\r\ncytopenias\r\n- ___ Started IFRT to paraaortic LNs, 3600 cGy total dose.\r\n- ___, Norovirus\r\n- ___ Presented with dyspnea, DLCO 79% predicted (adjusted\r\nfor Hb). Started prednisone 80 mg PO daily and adjusted with\r\nDLCO. Finally d/ced ___. \r\n- IVIg 400 mg/kg, continues monthly for\r\nHypogammaglobuonemia/CVID.\r\n- ___, CT torso with no evidence of active disease. Stable\r\nappearance of a conglomeration of mesenteric lymph nodes. \r\n- ___, Right total knee replacement, complicated by foot\r\ndrop likely due to irritation of peroneal nerve from the CPM\r\nmachine, as well as a cellulitis of the right leg; same leg as\r\nher previous DVT and her circulation is poor. \r\n- ___, CT Torso with no evidence of active disease. \r\nStable appearance of conglomerate of mesenteric LN's. Increased\r\ndilatation of the main pulmonary artery suggests worsening\r\npulmonary arterial hypertension of indeterminate etiology.\r\n- ___, CT torso with no evidence of active disease. Increased\r\ndilation of pulmonary artery.  Evaluated by Dr. ___\r\n- ___, Increasing right leg swelling and shortness of breath\r\nwith noted DVT; no DVT.  Xarelto increased back to 20 mg\r\ndaily(had been decreased given age and prior chronic DVT).  No\r\nevidence for lymphoma on CT imaging.\r\n- ___, noted drop in blood counts. Bone marrow biopsy showed\r\ndysplasia in all cell lines with ~ 6% blasts noted in aspirate. \r\nCytogenetics showing multiple abnormalities. \r\n- ___, C1 Dacogen\r\n- ___, admitted with fever in setting of neutropenia, and\r\nincreasing right sided back pain.  No infectious source found;\r\nafter consultation with ID, it was decided to treat empirically\r\nfor presumptive osteomyelitis/discitis with 6 weeks of \r\nvancomycin\r\n(750mg IV q12h), cefepime (2g IV q12h), micafungin (100 mg PO\r\nq24h). Required short time of pain medicines for back pain. \r\n- ___, C2 Dacogen\r\n- ___, admitted with increased confusion and issues of\r\nword finding.  Head CT and MRI of the head did not show any\r\nabnormality.  Treated with concern for meningitis and remained \r\non\r\nher other antibiotics for treatment of presumed osteomyelitis. \r\nConfusion resolved and no infectious etiology was noted except\r\nfor possible UTI. \r\n- ___, Admitted with 2 days of nausea, vomiting, fever,\r\nconfusion, and urinary incontinence, with infectious workup,\r\noverall negative, except for positive coronavirus.  CTA negative\r\nfor PE and there was no evidence of pulmonary or abdominal\r\ninfection on imaging. MRI of brain was negative for an\r\nintracranial process; MRI spine was negative for abscess or\r\nosteomyelitis. \r\n- ___, C3 Dacogen and discharged to home on ___.\r\n- ___, Admitted with diarrhea, decreased appetite. \r\nReceived IVF support, transfusions and potassium replacement;\r\ndischarged on ___. \r\n- ___, C4 Dacogen\r\n- ___, Admitted with cough and wheezing.  + RSV, treated\r\nwith empiric antibiotics, palvilizumab, ribavirin and IVIG.\r\n- ___, Bone marrow aspirate and biopsy showed a cellular\r\nmarrow by aspirate with trilineage dyspoitic maturation. By\r\nimmunohistochemistry CD34 highlights blast cells comprising less\r\nthan 5% of the overall cellularity. Cellularity in the core\r\nbiopsy is low, which may be a sampling artifact. Cytogenetics\r\nrevealed no cells noted with the previously observed complex\r\nabnormal karyotype with monosomy 7, deletion of 5q and other\r\nchromosome aberrations associated with myelodysplasia with an\r\nunfavorable prognosis.\r\n- ___, Admitted for MUD allogeneic transplant with Flu/Bu\r\nand ATG conditioning. D0 = ___. \r\n- ___ - ___, admission for aseptic meningitis; noted CMV\r\nviremia, on Valganciclovir.\r\n- ___ - ___, admission for headache, nausea and vomiting\r\nand development of fevers to 103 with coagulase-negative\r\ngram-positive cocci noted as S. epidermidis bacteremia;\r\nDaptomycin for total 6 week course of antibiotics(completed\r\n___.  Also noted for new DVT's of lower legs, on Lovenox\r\nBID. \r\n- ___, admission for increased rash and diarrhea. \r\nStarted increased systemic steroids and now tapered.\r\n- ___ - ___, Admitted with four days of productive cough,\r\nfevers and chills consistent with community acquired pneumonia;\r\ntreated with antibiotics\r\n\r\nOTHER PAST MEDICAL HISTORY (PER OMR)\r\n===============================================\r\n- CVID, receives IVIG every 1 - 2 months to keep IGG > 500\r\n- GERD                                          \r\n- Osteoarthritis                                         \r\n- DVT, right lower extremity, IVC filter in place\r\n- Cervical radiculopathy\r\n- Sciatica\r\n- Obstructive sleep apnea, wears CPAP\r\n- H/O cerebral aneurism, noted on MRA with small R internal\r\ncarotid cavernous sinus aneurysm; coil placed in the aneurysm\r\n(___). On Neurontin. Exam notable for slight CN 6 palsy of\r\nthe right eye, mild proptosis of the right eye, and hyperthesia\r\nof the right V1 distribution\r\n- Asthma, with episodic bronchitis/exacerbations\r\n- Obesity\r\n- Hypertension\r\n- Migraines\r\n- + RSV, ___\r\n- S. epidermidis bacteremia, POC removed; completed course of\r\nDaptomycin\r\n- +Parainfluenza, ___\r\n\r\nPAST SURGICAL HISTORY (PER OMR)\r\n========================================\r\n-aneurysm coil in ___ of Right ICA\r\n-C5 fusion ___\r\n-Cholecystectomy ___\r\n-anterior scalenotomy\r\n-Surgery for ruptured Meckels\r\n-___ Excisional Bx L Cervical Lymph Node\r\n-___ L total knee replacement ___, walks with cane\r\n-___ R total Knee replacement \r\n-___ I&D Labial Abscess\r\n-___ Excision Cyst R ___ Digit of Hand\r\n-numerous laparoscopies.\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nBrother died at ___ from lymphoma. No other family history of\r\ncancer\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM\r\n=============================\r\n___ 1328 Temp: 98.4 PO BP: 115/77 HR: 91 RR: 16 O2 sat: 99%\r\nO2 delivery: 3L NC \r\nGENERAL: Fatigue and chronically ill appearing. Moderate\r\nrespiratory distress, siting in bed. \r\nHEENT: Ptosis of right eye, Sclerae anicteric. Dry MM. No\r\nlesions. No oropharyngeal erythema or thrush. Nasal cannula in\r\nplace.  \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Labored. Bronchial breath sounds. Diffuse expiratory and\r\ninspiratory wheezes and crackles with occasional rhonchi. Poor \r\nto\r\nfair aeration.\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. No peritoneal signs.\r\nGU: No foley\r\nEXT: Legs with non-pitting edema bilaterally. Calves and feet \r\nare\r\ncool to the touch. RLE w/ 2.0cm (L) x 1.0 cm (W) wound noted on\r\nadmission - secondary to traumatic injury per patient report\r\nSKIN: Venous stasis changes to bilateral calves \r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nACCESS: PIV\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVSS\r\nGENERAL: No distress, sitting up in chair.\r\nHEENT: Deviation of right eye which is baseline, Sclerae\r\nanicteric. Dry MM. No lesions. No oropharyngeal erythema or\r\nthrush. \r\nNECK: Supple. No cervical or supraclavicular lymphadenopathy\r\nCV: RRR, NL S1/S2. No M/R/G\r\nPULM: Bilateral coarse rhonchi, and exp wheeze. nonlabored\r\nABD: Soft, protuberant with several well healed scars. NT. No \r\nHSM\r\nappreciated. \r\nEXT: Legs with non-pitting edema and chronic venous stasis\r\nchanges bilaterally. RLE with 2.0cm (L) x 1.0 cm (W) stable \r\nnoted\r\non admission - secondary to traumatic injury per patient report\r\nNEURO: CN 6 palsy of the right eye since aneurism repair w/ mild\r\nproptosis of the right eye and hyperthesia of the right V1\r\ndistribution. CN II-XII otherwise intact. Strength ___ in all\r\nextremities. Sensation intact in all extremities.\r\nSkin: back with confluent erythema from neck to lower rib area\r\nupper chest with large macular and excoriations.\r\nACCESS: PIV\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS\r\n=============================\r\n___ WBC: 13.4* RBC: 4.08 Hgb: 12.9 Hct: 40.5 MCV: 99* MCH:\r\n31.6 MCHC: 31.9* RDW: 14.6 RDWSD: 54.4* Plt Ct: 229 \r\n___ 01:44AM BLOOD Neuts: 67.5 Lymphs: ___ Monos: 5.9 Eos:\r\n1.4 Baso: 0.2 Im ___: 0.4 AbsNeut: 9.06* AbsLymp: 3.30 AbsMono:\r\n0.79 AbsEos: 0.19 AbsBaso: 0.03 \r\n___ 01:44AM BLOOD Glucose: 81 UreaN: 12 Creat: 1.3* Na: 138\r\nK: 4.8 Cl: 103 HCO3: 18* AnGap: 17 \r\n___ 01:52AM BLOOD Type: ___ pO2: 87 pCO2: 32* pH: 7.43\r\ncalTCO2: 22 Base XS: -1 Comment: GREEN TOP \r\n___ 01:52AM BLOOD Lactate: 1.1 \r\n\r\nIMAGING/STUDIES\r\n================================\r\n___ CXR: Increased opacity in the right lower lobe is\r\nconcerning for developing pneumonia. \r\n\r\n___ CTA CHEST: No evidence of pulmonary embolism or aortic\r\nabnormality. Dilatation of the main pulmonary artery is similar\r\nto the prior study, concerning for pulmonary hypertension. \r\nConsolidative in nodular opacities with perihilar and peripheral \r\n\r\nconsolidation and surrounding ground-glass are most severe in \r\nthe\r\nright lower and upper lobe, with additional findings in the left\r\nlower lobe. Findings are in close proximity to multiple mucus\r\nimpacted bronchi, and likely reflect a multifocal infectious\r\nprocess. However, given the patient's history of \r\nmalignancy in the appearance of the findings, recommend close\r\ninterval follow-up with repeat imaging after treatment to\r\ndocument resolution. Moderate-severe central and peripheral\r\nbilateral airway thickening.\r\n\r\nMICROBIOLOGY\r\n=================================\r\n___ Blood cultures - pending\r\n___ Flu swab - negative for flu A and flu B\r\n___ RVP\r\n___ Urine culture\r\n___ MRSA Screen\r\n___ Legionella Urinary Antigen\r\n___ Fungal markers \r\n\r\nDISCHARGE LABS:\r\n\r\n___ 05:30AM BLOOD WBC-6.5 RBC-4.00 Hgb-12.3 Hct-38.6 MCV-97 \r\nMCH-30.8 MCHC-31.9* RDW-14.3 RDWSD-50.6* Plt ___\r\n___ 05:30AM BLOOD Neuts-62.8 Lymphs-16.5* Monos-10.0 \r\nEos-9.7* Baso-0.2 Im ___ AbsNeut-4.08 AbsLymp-1.07* \r\nAbsMono-0.65 AbsEos-0.63* AbsBaso-0.01\r\n___ 05:30AM BLOOD Glucose-89 UreaN-18 Creat-1.3* Na-142 \r\nK-3.8 Cl-107 HCO3-22 AnGap-13\r\n___ 05:30AM BLOOD ALT-10 AST-13 LD(LDH)-192 AlkPhos-92 \r\nTotBili-0.2\r\n___ 05:30AM BLOOD Albumin-3.4* Calcium-8.3* Phos-3.0 Mg-2.___ ___ year old female with history of\r\ntransformed diffuse large B cell lymphoma status post curative\r\nintent with an autologous SCT with BEAM conditioning in ___\r\n___s IFRT with noted treatment related MDS and status post\r\nURD allogeneic transplant in ___ presenting with fevers,\r\nheadache and worsening URI symptoms, found to have radiographic\r\nevidence of multifocal pneumonia.\r\n\r\nACUTE CONDITIONS\r\n===========================\r\n\r\n#MULTIFOCAL PNEUMONIA: CTA Chest obtained in the setting of\r\nhypoxia showed consolidative in nodular opacities with perihilar\r\nand peripheral consolidation and surrounding ground-glass most\r\nsevere in the right lower and upper lobe, with additional\r\nfindings in the left lower lobe. Findings were felt likely\r\nmultifocal PNA. Given her underlying\r\nhypogammaglobulinemia and overall impaired immunity from prior\r\nchemotherapies, we pursed CAP treatment with cefepime and\r\nvancomycin plus levofloxacin for atypical coverage. \r\n- Hypoxia resolved as of ___. \r\n- bcx remain negative x 72 hrs, de-escalated to Levaquin ___, to \r\ncomplete 7d course of ABX total ___\r\n-F/U RVP, urine Legionella, Strep pneumo Ag, fungal markers,\r\nsputum culture, MRSA screen--NTD\r\n- cont supportive DuonNebs, Flovent, Tessarlon & Guaifenisin, \r\ncan\r\nconsider PFTs as outpatient once recovered from acute illness\r\n \r\n#Rash: given timing most likely antibiotic-induced. Back could \r\nbe\r\nc/w Redman's but chest area has raised appearance that is\r\natypical. d/c vanco/cefepime as above and monitor. She does\r\nhave hx GVHD so if persists may need to pursue biopsy, f/u \r\noutpatient\r\n\r\n___: stable. Cr 1.1-1.3 baseline. She is\r\nlikely dehydrated in the setting of poor PO intake. Of\r\nnote, she has had elevated Cr attributed to medication effect. \r\n-IVF PRN (received 1L ___\r\n-encourage po intake on own\r\n\r\n#Asthma: Stable, now on RA since ___. Exacerbated in the\r\nsetting of multifocal pneumonia. She continues on inhalers and\r\nnebulizers. Monitor for respiratory decompensation.\r\n\r\nCHRONIC/STABLE CONDITIONS\r\n===================================\r\n\r\n#RLE Wound: Secondary to a traumatic skin injury from a stick ~ \r\n6\r\nweeks ago. Consulted wound nursing for evaluation and \r\nmanagement,\r\nsee progress note ___. No apparent infection concerns on\r\nadmission. \r\n              \r\n#MDS: Noted for rapid progression of pancytopenia particularly\r\nanemia. Bone marrow biopsy with dysplasia of all cell lines with\r\nnoted cytogenetic abnormalities concerning for treatment related\r\nMDS. ___ allogeneic transplant with URD with Flu/Bu/ATG\r\nconditioning. D0 = ___. ABO compatible with donor. Had BM\r\nbiopsy at ~ D100 which showed no evidence for MDS and noted 100%\r\ndonor. Now, patient is exactly ___ years from her allogeneic\r\ntransplant on ___. Peripheral chimerism from ___ shows\r\n100% donor by FISH. Remains in remission. \r\n\r\nInfection Prophylaxis\r\n    PCP: ___ \r\n    VZV/HSV: Acyclovir\r\n    Fungal: Off fluconazole\r\n    CMV: Off Valganciclovir\r\n\r\n#GVHD: Waxing and waning rashes followed closely by Dermatology.\r\nFungal rash in groin area now resolved. Lipodermatosclerosis on\r\nlower legs. No other skin thickening. No other evidence of GVHD\r\nwith prior skin and ? eye involvement. Steroids tapered. Had\r\nEndoscopy and colonoscopy which did not show evidence of GVHD.\r\nAlso, with increased dryness of scalp and flaking of scalp. Had\r\nPFTs on ___ which are stable to improved (FVC 86%; FEV1\r\n87%; DLCO 105%). Tapered off Cyclosporine and CellCept.\r\n\r\nGVHD Treatment\r\n-Continue Prednisone 5 mg daily \r\n-Continue triamcinolone cream BID PRN\r\n-Continue hydrocortisone/nystatin TP to groin area PRN        \r\n-Restasis for dry eyes\r\n    \r\n#Lower Extremity DVTs: Had been on Xarelto 20mg daily prior to\r\ntransplant for previous DVTs. This was switched to Lovenox with\r\nconcern for drug interactions. Has filter in place now with new\r\ndeep venous thrombosis involving the left posterior tibial and\r\nright popliteal veins. Continues on Xarelto as above.\r\n\r\n#CMV Viremia: Noted for low level CMV VL (<2.1). Had CMV viremia\r\nin past and was previously on IV ganciclovir and then\r\nValganciclovir. CMV VL negative ___, repeat ___ negative.  \r\n\r\n\r\n#Arthritis of thumbs/Probable tendon tear of left thumb: Has had\r\nsteroid injections to thumbs in past. ___ MD at ___ is following. Plan is to hold on surgery due to concern\r\nfor complicated recovery and also able to do any activities she\r\ndesires.\r\n\r\n#Pulmonary Hypertension: Evaluated by Dr. ___ in past and no\r\ncontraindication of proceeding with transplant. TTE ___ \r\nshowed\r\nnormal biventricular cavity sizes with mild global left\r\nventricular hypokinesis. Mild mitral regurgitation with normal\r\nvalve morphology. Trace aortic regurgitation with normal valve\r\nmorphology. \r\n\r\n#Lymphoma/CLL/Disease Status: Been in remission with last CT\r\nscans without evidence of lymphoma/adenopathy. Has history of \r\nCLL\r\nas well. She had no evidence of this on prior BM biopsy.\r\n\r\n#Osteoarthritis:                                         \r\n#Cervical radiculopathy:\r\n#Sciatica:\r\nChronic left lower back pain with sciatica. Lumbar spine MRI \r\nwith\r\nand without contrast with no significant changes but noted\r\nsignificant disc disease and degenerative changes. Monitor for\r\nexacerbation while inpatient. \r\n\r\n#History of Cerebral Aneurysm: Noted on MRA with small R \r\ninternal\r\ncarotid cavernous sinus aneurysm. Coil placed in the aneurysm\r\n(___). She continues on home Neurontin 400mg BID.\r\n\r\n#CVID: Receives IVIG every 1 - 2 months to keep IGG > 500. Her\r\nlast infusion was ___, added on IgG level and consider giving\r\nIVIG if level <600 in the setting of active infection. \r\n\r\n#GERD: No acute exacerbation. Continues Omeprazole 20mg daily.\r\n                                       \r\n#Obstructive Sleep Apnea: Using CPAP machine more regularly and\r\nsleeping better. RT consulted on admission. \r\n\r\n#Early Macular Degeneration: On Preservision but not available\r\nin-house so did not order on admission.  \r\n\r\n#Mood Disorder: Continues on Effexor 25mg daily. Living with\r\ndaughter in her new home which is less stressful and has better\r\nsupports. Followed by SW. \r\n\r\nCORE MEASURES\r\n=========================\r\n#FEN: Regular diet, replete electrolytes PRN per oncology \r\nsliding\r\nscales\r\n#PPX: Xarelto as above\r\n#ACCESS: PIV\r\n#HCP/CONTACT: ___ (daughter) ___\r\n#CODE STATUS: Full code (confirmed)\r\n\r\nDISPOSITION: home f/u ___ \r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n3. FoLIC Acid 1.6 mg PO DAILY \r\n4. Gabapentin 400 mg PO BID \r\n5. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n6. Nystatin Cream 1 Appl TP BID fungal rash \r\n7. Omeprazole 20 mg PO DAILY \r\n8. PredniSONE 5 mg PO DAILY \r\n9. Rivaroxaban 20 mg PO DAILY \r\n10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Cephalexin ___ mg PO ONCE \r\n14. Hydrocortisone Cream 1% 1 Appl TP BID \r\n15. Restasis 0.05 % ophthalmic (eye) BID \r\n16. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified \r\n17. Ondansetron (ondansetron HCl) 4 mg oral Q8H \r\n18. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n19. Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash \r\n20. econazole 1 % topical BID groin, thighs \r\n21. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n22. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n23. nystatin 100,000 unit/gram topical BID rash \r\n24. fluocinonide 1 Appl TP 2X/WEEK \r\n25. HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate \r\n\r\n \r\nDischarge Medications:\r\n1.  Benzonatate 100 mg PO TID:PRN Cough   \r\n2.  GuaiFENesin ER 600 mg PO Q12H:PRN cough  \r\n3.  LevoFLOXacin 750 mg PO ONCE Duration: 1 Dose \r\nContinue until ___  \r\n4.  Sarna Lotion 1 Appl TP QID:PRN itch  \r\n5.  ___ ___ unit/gram topical BID:PRN rash  \r\n6.  Acyclovir 400 mg PO Q12H  \r\n7.  Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB  \r\n8.  Betamethasone Dipro 0.05% Oint 1 Appl TP BID:PRN rash  \r\n9.  Cephalexin ___ mg PO ONCE  \r\n10.  econazole 1 % topical BID groin, thighs  \r\n11.  fluocinonide 1 Appl TP 2X/WEEK  \r\n12.  Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing  \r\n13.  FoLIC Acid 1.6 mg PO DAILY  \r\n14.  Gabapentin 400 mg PO BID  \r\n15.  HYDROcodone-Acetaminophen (5mg-325mg) ___ TAB PO Q4H:PRN \r\nPain - Moderate  \r\n16.  Hydrocortisone Cream 1% 1 Appl TP BID  \r\n17.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath  \r\n18.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n19.  Nystatin Cream 1 Appl TP BID fungal rash  \r\n20.  Omeprazole 20 mg PO DAILY  \r\n21.  Ondansetron (ondansetron HCl) 4 mg oral Q8H  \r\n22.  PredniSONE 5 mg PO DAILY  \r\n23.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n24.  Restasis 0.05 % ophthalmic (eye) BID  \r\n25.  Rivaroxaban 20 mg PO DAILY  \r\n26.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  \r\n27.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID:PRN \r\nunspecified  \r\n28.  Venlafaxine 25 mg PO DAILY  \r\n29.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome with Service\r\n \r\nDischarge Diagnosis:\r\nPrimary Diagnosis\r\n=================\r\n1) Community Acquired Pneumonia \r\n2) CVID \r\n3) MDS ___ allogenic stem cell transplant \r\n\r\nSecondary Diagnosis\r\n===================\r\n1) GERD \r\n2) OSA \r\n3) OA \r\n4) Asthma \r\n5) HTN\r\n6) Mood disorder \r\n7) RLE DVT\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,\r\n\r\nYou were admitted with upper respiratory symptoms, found to have \r\npnueumonia. We treated you with intravenous antibiotics and your \r\nsymptoms improved. You are now safe to be discharged home. \r\nPlease continue your medications as prescribed. It was a \r\npleasure taking care of you.\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-28:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-28",
        "chart_time": "105580",
        "section": "General",
        "position": 0,
        "tokenCount": 41,
        "note_metadata": {
          "note_id": "18887130-DS-28",
          "subject_id": 18887130,
          "hadm_id": 26914904,
          "note_type": "DS",
          "note_seq": 28,
          "charttime": 105580,
          "storetime": 105580.72777777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy (___)\r\nPICC placed (___)\r\n\r\nattach\r\n \r\nPertinent Results:\r\nINITIAL LABS\r\n============\r\n___ 02:30PM BLOOD WBC-9.8 RBC-3.43* Hgb-11.1* Hct-33.6* \r\nMCV-98 MCH-32.4* MCHC-33.0 RDW-17.4* RDWSD-62.2* Plt Ct-24*\r\n___ 02:30PM BLOOD Neuts-6* ___ Monos-1* Eos-0* Baso-0 \r\nAtyps-2* Blasts-65* AbsNeut-0.59* AbsLymp-2.74 AbsMono-0.10* \r\nAbsEos-0.00* AbsBaso-0.00*\r\n___ 02:30PM BLOOD ___ PTT-27.7 ___\r\n___ 05:40AM BLOOD ___ D-Dimer-<215\r\n___ 05:40AM BLOOD Ret Aut-0.8 Abs Ret-0.02\r\n___ 02:30PM BLOOD UreaN-14 Creat-1.0 Na-136 K-3.8 Cl-100 \r\nHCO3-20* AnGap-16\r\n___ 02:30PM BLOOD ALT-8 AST-17 LD(LDH)-1709* AlkPhos-93 \r\nTotBili-0.2\r\n___ 04:26PM BLOOD Lipase-11\r\n___ 04:26PM BLOOD CK-MB-2 cTropnT-<0.01\r\n___ 02:30PM BLOOD Albumin-3.6 Calcium-9.0 Mg-1.9 \r\nUricAcd-3.6\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 05:40AM BLOOD CRP-153.6*\r\n___ 02:30PM BLOOD IgG-621* \r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n___ 04:18PM BLOOD Lactate-1.3 K-4.2\r\n\r\nMICROBIOLOGY\r\n============\r\nAll blood cultures drawn during admission where negative ___, \r\n___\r\nMRSA screen negative\r\nRapid resp viral screen and culture negative (___)\r\nUrine culture ___ negative\r\n\r\nIMAGING\r\n=======\r\n___ CT SINUS:\r\n1. New bilateral maxillary sinus disease with hyperdense \r\nmaterial suggesting fungal colonization or inspissated \r\nsecretions.  However, there is also fat stranding in the retro \r\nmaxillary fat pads, which raises the possibility of invasive \r\nfungal sinusitis in the context of immune suppression. \r\n2. Please see separate head CT for intracranial findings.\r\n\r\n___ CT HEAD:\r\nNo acute intracranial abnormalities are identified or change \r\nseen compared with ___.\r\n\r\n___ TTE:\r\nThe left atrium is mildly dilated. The right atrium is mildly \r\nenlarged. There is no evidence for an atrial septal defect by \r\n2D/color Doppler. The estimated right atrial pressure is ___ \r\nmmHg. There is mild symmetric left ventricular hypertrophy with \r\na normal cavity size. There is normal regional and global left \r\nventricular systolic function. Quantitative biplane left \r\nventricular ejection fraction is 56 % (normal 54-73%). Left \r\nventricular cardiac index is normal (>2.5 L/min/m2). There is no \r\nresting left ventricular outflow tract gradient. No ventricular \r\nseptal defect is seen. Normal right ventricular cavity size with \r\nnormal free wall motion. Tricuspid annular plane systolic \r\nexcursion (TAPSE) is normal. The aortic sinus diameter is normal \r\nfor gender with a mildly dilated ascending aorta. The aortic \r\narch diameter is normal with a normal descending aorta diameter. \r\nThe aortic valve leaflets (3) appear structurally normal. There \r\nis no aortic valve stenosis. There is no aortic regurgitation. \r\nThe mitral valve leaflets are mildly thickened with no mitral \r\nvalve prolapse. There is mild [1+] mitral regurgitation. The \r\npulmonic valve leaflets are normal. The tricuspid valve leaflets \r\nappear structurally normal. There is mild [1+] tricuspid \r\nregurgitation. The estimated pulmonary artery systolic pressure \r\nis normal. There is a trivial pericardial effusion. IMPRESSION: \r\nMild symmetric left ventricular hypertrophy with normal cavity \r\nsize and regional/ global biventricular systolic function. Mild \r\nmitral regurgitation. Mildly dilated ascending aorta.\r\n\r\n___ CT chest without contrast\r\nNo evidence of recurrent lymphoma in the chest. Stable small \r\nmediastinal lymph nodes. Complete resolution of the parenchymal \r\nopacity in the right lower lobe which most likely represented \r\npneumonia.  Patchy opacity in the left lung base is new and \r\ncould represent atelectasis. \r\n\r\n___ MRI skull base with and without contrast\r\n1. Limited study as described.\r\n2. Interval progression of opacification and enhancement within \r\nthe left mastoid air cells and middle ear cavity concerning for \r\notomastoiditis, with no definite evidence of intracranial \r\nextension.\r\n3. Adjacent heterogeneity of the petrous temporal bone versus \r\nartifact.  If not artifactual, differential considerations \r\ninclude infectious and inflammatory etiologies.\r\n4. Bilateral maxillary sinus disease is redemonstrated, \r\naerosolized secretions are better demonstrated on the CT from ___, with no definite extension into the adjacent soft \r\ntissue.\r\n5. Question mild enhancement of the left retro maxillary fat \r\nversus volume averaging of adjacent vessels.  Recommend \r\nattention on follow-up imaging.\r\n6. Nonspecific new clivus and medial temporal bone marrow \r\nheterogeneity compared to ___ prior exam with question \r\nenhancement.  While finding may represent marrow expansion, \r\ninfectious, inflammatory, and neoplastic etiologies are not \r\nexcluded on the basis of this examination.  Recommend attention \r\non follow-up imaging.\r\n\r\n___ MR head with and without contrast\r\n1. Unchanged persistent extensive fluid opacification and \r\nenhancement within the left middle ear cavity and mastoid air \r\ncells concerning for \r\notomastoiditis.  No evidence of intracranial extension. \r\n2. Persistent heterogenous signal intensity within the adjacent \r\npetrous \r\ntemporal bone.  Inflammatory, infectious or neoplastic \r\netiologies are not \r\nexcluded. \r\n3. Mild mucosal thickening in the frontal sinus, multiple \r\nethmoid air cells and predominately in the bilateral maxillary \r\nsinuses, improved since the prior study.  Enhancement in the \r\nretromaxillary fat is difficult to evaluate due to lack of T1 \r\npost-contrast fat saturated images. \r\n4. Persistent heterogenous signal intensity within the clivus, \r\nnonspecific. Differential considerations include marrow \r\nexpansion, infectious, inflammatory or neoplastic etiologies. \r\n5. No evidence of hemorrhage, infarction, mass or other abnormal \r\nenhancement. \r\n\r\n___ bilateral lower extremity venous ultrasound\r\n1. Nonocclusive deep vein thrombosis in the mid right femoral \r\nvein, new \r\ncompared to ___. \r\n2. Deep vein thrombosis in the right popliteal vein.  Of note, \r\nthe right \r\npopliteal vein contained a DVT on ultrasound ___, \r\nhowever the \r\nchronicity of the DVT seen today is uncertain. \r\n3. No evidence of DVT in the left lower extremity. \r\n\r\n___ MR head with and without contrast\r\n1. Ongoing opacification and enhancement of the left mastoid air \r\ncells and \r\nmiddle ear cavity, concerning for otomastoiditis. \r\n2. There is no evidence of intracranial extension. \r\n3. No acute intracranial abnormality is identified. \r\n4. Persistent, unchanged heterogenous signal intensity within \r\nthe clivus. This is nonspecific in nature. \r\n\r\n___ chest x-ray AP\r\nChronic deformity of the right rib cage.  Cardiomediastinal \r\nsilhouette is \r\nwithin normal limits.  There are no focal consolidations, \r\npleural effusion. Right basilar atelectasis.  Tortuous aorta.  \r\nThere are no pneumothoraces. \r\n\r\nOTHER RESULTS\r\n=============\r\n___ 05:40AM BLOOD G6PD-NORMAL\r\n___ 12:00AM BLOOD  WBC-0.7*# Lymph-98* Abs ___ CD3%-88 \r\nAbs CD3-604 CD4%-32 Abs CD4-217* CD8%-55 Abs CD8-380 \r\nCD4/CD8-0.57*\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 12:00AM BLOOD IgG-593* IgA-24* IgM-136\r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 06:05AM BLOOD WBC-4.4 RBC-2.59* Hgb-8.1* Hct-26.1* \r\nMCV-101* MCH-31.3 MCHC-31.0* RDW-18.4* RDWSD-65.2* Plt ___\r\n___ 06:05AM BLOOD Neuts-58 Bands-1 Lymphs-13* Monos-20* \r\nEos-0* ___ Myelos-7* NRBC-0.5* AbsNeut-2.60 AbsLymp-0.57* \r\nAbsMono-0.88* AbsEos-0.00* AbsBaso-0.04\r\n___ 06:05AM BLOOD Anisocy-1+* Poiklo-1+* Macrocy-1+* \r\nMicrocy-1+* Polychr-1+* Ovalocy-1+* RBC Mor-SLIDE REVI\r\n___ 06:05AM BLOOD ___ PTT-31.8 ___\r\n___ 06:05AM BLOOD ___ 06:05AM BLOOD Glucose-83 UreaN-15 Creat-1.1 Na-143 \r\nK-4.7 Cl-105 HCO3-23 AnGap-15\r\n___ 06:05AM BLOOD ALT-14 AST-16 LD(LDH)-209 AlkPhos-153* \r\nTotBili-<0.2\r\n___ 06:05AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.2 Mg-2.0\r\n \r\nBrief Hospital Course:\r\nTRANSITIONAL ISSUES\r\n===================\r\n[ ] f/u with ID regarding fungal/bacterial sinusitis and therapy \r\nduration\r\n[ ] f/u with ENT regarding chronic sinusitis\r\n\r\nSUMMARY STATMENT\r\n================\r\nMs. ___ is a ___ year old woman with history of follicular \r\nlymphoma to DLBCL treated with multiple rounds chemotherapy \r\ncomplicated by therapy-related myelodysplasia treated with \r\nalloHSCT with Flu/Bu/ATG RIC (D0 ___ complicated by \r\ngraft-versus-host disease, multiple deep vein thromboses with \r\nIVC filter in place, cavernous sinus aneurysm with coiling \r\n(___) complicated by residual cranial nerve palsy who \r\npresented to ___ with sinusitis and new acute myelogenous \r\nleukemia. Her course was notable for initiation of \r\nvenetoclax/decitabine.\r\n\r\nACTIVE ISSUES\r\n=============\r\n# AML\r\n# t-MDS ___ alloHSCT\r\nt-MDS transformed to AML with up to 83% blasts (___) in elderly\r\nhost with significant co-morbidities. G6PD normal. Patient\r\ncytogenetics show multiple complex mutations from bone marrow\r\nbiopsy. Chimerism from cytogenetics shows a greater percentage\r\nof XX chromosomal cells versus donor XY (~88 vs ~12%). \r\nDecitabine/venetoclax induction (___) every four \r\nweeks. Doses of chemotherapy were adjusted as the patient was \r\nput on different antifungals. BMB ___ with reassuring \r\nfindings, no signs of disease. Neupogen given briefly with \r\nappropriate marrow response. Patient kept on acyclovir and \r\natovaquone for prophylaxis. Bactrim chose over atovaquone at \r\ndischarge.\r\n\r\n# Maxillary sinusitis\r\nPresented with one week of progressive sinus pressure, headache,\r\nfacial warmth. CT SINUS (___) demonstrated pan-opacification of\r\nbilateral maxillary sinuses with circumferential mucosal\r\nthickening, with fat stranding in the retro maxillary fat pads\r\nconcerning for invasive fungal vs bacterial sinusitis yet\r\nfiberoptic exam (___) not consistent with fungal sinusitis.\r\nAspergillius negative, but Beta glucan positive initially in\r\nsetting of neutropenia, Zosyn, ___, and continued sinus\r\nsymptoms. ENT saw pt multiple times and noted no c/f invasive\r\nfungal sinusitis, MRI w&w/out contrast of sinus/skull base ___\r\nwith heterogeneity in left maxilla/middle ear c/f infectious\r\nprocess and pt was placed on AmBisome (___). MRI results \r\n___ were reassuring, and switch to Cresemba from AmBisome was \r\nmade. Due to likely drug rash vs viral exanthem described below, \r\nZosyn was switched for meropenem ___. Reimaging of sinuses \r\n___,\r\nlooked stable from prior and ID recommended ongoing therapy with\r\nIsavunconazole 372mg PO QD and Levofloxacin 750mg PO QD for\r\nprolonged duration of ___ weeks pending reassessment in\r\noutpatient ___ clinic.\r\n- ABx: Cresemba ___- ) + levofloxacin ___- ) ___ meropenem\r\n(___), Zosyn (___) AmBisome (___),\r\nposaconazole (___), meropenem (___) + vancomycin (___)\r\n+ levofloxacin (___) + flagyl (___) + augmentin\r\n(-___)\r\n\r\n# Nonocclusive right femoral vein DVT\r\nOn ___ patient complained of unilateral right lower leg\r\nswelling, right lower extremity noninvasives showed new right\r\nfemoral vein nonocclusive clot compared to ___ bilateral lower\r\nextremity ultrasound. Patient has an extensive history of DVTs, \r\nincluding a DVT developing while on 10mg of Xarelto. Patient was \r\ngiven platelets and started on Lovenox half dose every 12 hours \r\nonce plts > 30. She was discharged on Xarelto 20mg daily, which \r\nwas her home medication before admission.\r\n\r\n# Morbilliform rash\r\nOn ___ presented with suspected drug rash with Zosyn being\r\nlikely aggravating factor. ___ spreading to arms and chest.\r\nWithout involvement of mucosa or face. Decreasing in intensity\r\nand itching daily until ___ when patient woke up with xerotic,\r\nblanching, non-raised rash over chest, legs, arms, and back.\r\nDermatology consulted and recommended steroids topically, \r\nsuggested drug rash. Meropenem switched to levofloxacin. \r\nResolution of rash within the following days. Steroid creams \r\nprescribed per dermatology service.\r\n\r\nCHRONIC/RESOLVED:\r\n=================\r\n# Asthma\r\n- inhalers: duonebs q6hrs PRN + albuterol q4hrs PRN\r\n\r\n# OSA\r\n- continue home CPAP\r\n\r\n# Depression\r\n- continue home venlafaxine 25\r\n\r\n# Neuropathic pain\r\n- continue home gabapentin 400 bid\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n4. FoLIC Acid 1.6 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron (ondansetron HCl) 4 mg oral Q8H:PRN nausea \r\n9. Restasis 0.05 % ophthalmic (eye) BID \r\n10. Rivaroxaban 20 mg PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n14. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n15. Benzonatate 100 mg PO TID:PRN Cough  \r\n16. Ketoconazole Shampoo 1 Appl TP TWO TO THREE TIMES WEEKLY AS \r\nNEEDED FOR DRY SCALP \r\n\r\n \r\nDischarge Medications:\r\n1.  Betamethasone Dipro 0.05% Cream 1 Appl TP BID  \r\n2.  Cetirizine 20 mg PO BID \r\nRX *cetirizine 10 mg 2 tablet(s) by mouth once a day Disp #*60 \r\nTablet Refills:*0 \r\n3.  Isavuconazonium Sulfate 372 mg PO DAILY \r\nRX *isavuconazonium sulfate [Cresemba] 186 mg 2 capsule(s) by \r\nmouth once a day Disp #*60 Capsule Refills:*0 \r\n4.  LevoFLOXacin 750 mg PO Q24H \r\nRX *levofloxacin 750 mg 1 tablet(s) by mouth once a day Disp \r\n#*42 Tablet Refills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim 400 mg-80 mg 1 tablet(s) by \r\nmouth once a day Disp #*30 Tablet Refills:*0 \r\n6.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n7.  FoLIC Acid 2 mg PO DAILY \r\nRX *folic acid 1 mg 2 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Acyclovir 400 mg PO Q12H  \r\n9.  Gabapentin 400 mg PO BID  \r\n10.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nneb every six (6) hours Disp #*30 Ampule Refills:*0 \r\n11.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n14.  Restasis 0.05 % ophthalmic (eye) BID  \r\n15.  Rivaroxaban 20 mg PO DAILY  \r\n16.  Venlafaxine 25 mg PO DAILY  \r\n17.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS\r\n==================\r\n- Acute myelogenous leukemia\r\n\r\nSECONDARY DIAGNOSIS\r\n===================\r\n- Bacterial vs Fungal sinusitis\r\n- Right femoral vein thrombosis \r\n- Obstructive sleep apnea\r\n- Asthma\r\n- Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,  \r\n\r\nWHY WERE YOU ADMITTED TO THE HOSPITAL?  \r\n- You had a sinus infection and were found to have acute \r\nmyelogenous leukemia\r\n\r\nWHAT WAS DONE WHILE YOU WERE IN THE HOSPITAL?  \r\n- You were given chemotherapy to treat your cancer\r\n- You received antibiotics and antifungals to treat your sinus \r\ninfection\r\n \r\nWHAT DO YOU NEED TO DO WHEN YOU LEAVE THE HOSPITAL?  \r\n- Take all of your medications as prescribed (listed below)  \r\n- Follow up with your doctors as listed below  \r\n\r\nPlease see below for more information on your hospitalization. \r\nIt was a pleasure taking part in your care here at ___. We \r\nwish you all the best,\r\n\r\n- Your ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-28:1",
      "text": "Allergies: \ndapsone\n \nAttending: ___. Major Surgical or Invasive Procedure:\nBone marrow biopsy (___)\nPICC placed (___) attach\n \nPertinent Results:\nINITIAL LABS\n============\n___ 02:30PM BLOOD WBC-9.8 RBC-3.43* Hgb-11.1* Hct-33.6* \nMCV-98 MCH-32.4* MCHC-33.0 RDW-17.4* RDWSD-62.2* Plt Ct-24*\n___ 02:30PM BLOOD Neuts-6* ___ Monos-1* Eos-0* Baso-0 \nAtyps-2* Blasts-65* AbsNeut-0.59* AbsLymp-2.74 AbsMono-0.10* \nAbsEos-0.00* AbsBaso-0.00*\n___ 02:30PM BLOOD ___ PTT-27.7 ___\n___ 05:40AM BLOOD ___ D-Dimer-<215\n___ 05:40AM BLOOD Ret Aut-0.8 Abs Ret-0.02\n___ 02:30PM BLOOD UreaN-14 Creat-1.0 Na-136 K-3.8 Cl-100 \nHCO3-20* AnGap-16\n___ 02:30PM BLOOD ALT-8 AST-17 LD(LDH)-1709* AlkPhos-93 \nTotBili-0.2\n___ 04:26PM BLOOD Lipase-11\n___ 04:26PM BLOOD CK-MB-2 cTropnT-<0.01\n___ 02:30PM BLOOD Albumin-3.6 Calcium-9.0 Mg-1.9 \nUricAcd-3.6\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\n___ 05:40AM BLOOD CRP-153.6*\n___ 02:30PM BLOOD IgG-621* \n___ 02:30PM BLOOD CMV VL-NOT DETECT\n___ 04:18PM BLOOD Lactate-1.3 K-4.2 MICROBIOLOGY\n============\nAll blood cultures drawn during admission where negative ___, \n___\nMRSA screen negative\nRapid resp viral screen and culture negative (___)\nUrine culture ___ negative IMAGING\n=======\n___ CT SINUS:\n1. New bilateral maxillary sinus disease with hyperdense \nmaterial suggesting fungal colonization or inspissated \nsecretions. However, there is also fat stranding in the retro \nmaxillary fat pads, which raises the possibility of invasive \nfungal sinusitis in the context of immune suppression. 2. Please see separate head CT for intracranial findings. ___ CT HEAD:\nNo acute intracranial abnormalities are identified or change \nseen compared with ___. ___ TTE:\nThe left atrium is mildly dilated. The right atrium is mildly \nenlarged. There is no evidence for an atrial septal defect by \n2D/color Doppler. The estimated right atrial pressure is ___ \nmmHg. There is mild symmetric left ventricular hypertrophy with \na normal cavity size. There is normal regional and global left \nventricular systolic function. Quantitative biplane left \nventricular ejection fraction is 56 % (normal 54-73%). Left \nventricular cardiac index is normal (>2.5 L/min/m2). There is no \nresting left ventricular outflow tract gradient. No ventricular \nseptal defect is seen. Normal right ventricular cavity size with \nnormal free wall motion. Tricuspid annular plane systolic \nexcursion (TAPSE) is normal. The aortic sinus diameter is normal \nfor gender with a mildly dilated ascending aorta. The aortic \narch diameter is normal with a normal descending aorta diameter. The aortic valve leaflets (3) appear structurally normal. There \nis no aortic valve stenosis. There is no aortic regurgitation.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-28",
        "chart_time": "105580",
        "section": "General",
        "position": 1,
        "tokenCount": 686,
        "note_metadata": {
          "note_id": "18887130-DS-28",
          "subject_id": 18887130,
          "hadm_id": 26914904,
          "note_type": "DS",
          "note_seq": 28,
          "charttime": 105580,
          "storetime": 105580.72777777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy (___)\r\nPICC placed (___)\r\n\r\nattach\r\n \r\nPertinent Results:\r\nINITIAL LABS\r\n============\r\n___ 02:30PM BLOOD WBC-9.8 RBC-3.43* Hgb-11.1* Hct-33.6* \r\nMCV-98 MCH-32.4* MCHC-33.0 RDW-17.4* RDWSD-62.2* Plt Ct-24*\r\n___ 02:30PM BLOOD Neuts-6* ___ Monos-1* Eos-0* Baso-0 \r\nAtyps-2* Blasts-65* AbsNeut-0.59* AbsLymp-2.74 AbsMono-0.10* \r\nAbsEos-0.00* AbsBaso-0.00*\r\n___ 02:30PM BLOOD ___ PTT-27.7 ___\r\n___ 05:40AM BLOOD ___ D-Dimer-<215\r\n___ 05:40AM BLOOD Ret Aut-0.8 Abs Ret-0.02\r\n___ 02:30PM BLOOD UreaN-14 Creat-1.0 Na-136 K-3.8 Cl-100 \r\nHCO3-20* AnGap-16\r\n___ 02:30PM BLOOD ALT-8 AST-17 LD(LDH)-1709* AlkPhos-93 \r\nTotBili-0.2\r\n___ 04:26PM BLOOD Lipase-11\r\n___ 04:26PM BLOOD CK-MB-2 cTropnT-<0.01\r\n___ 02:30PM BLOOD Albumin-3.6 Calcium-9.0 Mg-1.9 \r\nUricAcd-3.6\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 05:40AM BLOOD CRP-153.6*\r\n___ 02:30PM BLOOD IgG-621* \r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n___ 04:18PM BLOOD Lactate-1.3 K-4.2\r\n\r\nMICROBIOLOGY\r\n============\r\nAll blood cultures drawn during admission where negative ___, \r\n___\r\nMRSA screen negative\r\nRapid resp viral screen and culture negative (___)\r\nUrine culture ___ negative\r\n\r\nIMAGING\r\n=======\r\n___ CT SINUS:\r\n1. New bilateral maxillary sinus disease with hyperdense \r\nmaterial suggesting fungal colonization or inspissated \r\nsecretions.  However, there is also fat stranding in the retro \r\nmaxillary fat pads, which raises the possibility of invasive \r\nfungal sinusitis in the context of immune suppression. \r\n2. Please see separate head CT for intracranial findings.\r\n\r\n___ CT HEAD:\r\nNo acute intracranial abnormalities are identified or change \r\nseen compared with ___.\r\n\r\n___ TTE:\r\nThe left atrium is mildly dilated. The right atrium is mildly \r\nenlarged. There is no evidence for an atrial septal defect by \r\n2D/color Doppler. The estimated right atrial pressure is ___ \r\nmmHg. There is mild symmetric left ventricular hypertrophy with \r\na normal cavity size. There is normal regional and global left \r\nventricular systolic function. Quantitative biplane left \r\nventricular ejection fraction is 56 % (normal 54-73%). Left \r\nventricular cardiac index is normal (>2.5 L/min/m2). There is no \r\nresting left ventricular outflow tract gradient. No ventricular \r\nseptal defect is seen. Normal right ventricular cavity size with \r\nnormal free wall motion. Tricuspid annular plane systolic \r\nexcursion (TAPSE) is normal. The aortic sinus diameter is normal \r\nfor gender with a mildly dilated ascending aorta. The aortic \r\narch diameter is normal with a normal descending aorta diameter. \r\nThe aortic valve leaflets (3) appear structurally normal. There \r\nis no aortic valve stenosis. There is no aortic regurgitation. \r\nThe mitral valve leaflets are mildly thickened with no mitral \r\nvalve prolapse. There is mild [1+] mitral regurgitation. The \r\npulmonic valve leaflets are normal. The tricuspid valve leaflets \r\nappear structurally normal. There is mild [1+] tricuspid \r\nregurgitation. The estimated pulmonary artery systolic pressure \r\nis normal. There is a trivial pericardial effusion. IMPRESSION: \r\nMild symmetric left ventricular hypertrophy with normal cavity \r\nsize and regional/ global biventricular systolic function. Mild \r\nmitral regurgitation. Mildly dilated ascending aorta.\r\n\r\n___ CT chest without contrast\r\nNo evidence of recurrent lymphoma in the chest. Stable small \r\nmediastinal lymph nodes. Complete resolution of the parenchymal \r\nopacity in the right lower lobe which most likely represented \r\npneumonia.  Patchy opacity in the left lung base is new and \r\ncould represent atelectasis. \r\n\r\n___ MRI skull base with and without contrast\r\n1. Limited study as described.\r\n2. Interval progression of opacification and enhancement within \r\nthe left mastoid air cells and middle ear cavity concerning for \r\notomastoiditis, with no definite evidence of intracranial \r\nextension.\r\n3. Adjacent heterogeneity of the petrous temporal bone versus \r\nartifact.  If not artifactual, differential considerations \r\ninclude infectious and inflammatory etiologies.\r\n4. Bilateral maxillary sinus disease is redemonstrated, \r\naerosolized secretions are better demonstrated on the CT from ___, with no definite extension into the adjacent soft \r\ntissue.\r\n5. Question mild enhancement of the left retro maxillary fat \r\nversus volume averaging of adjacent vessels.  Recommend \r\nattention on follow-up imaging.\r\n6. Nonspecific new clivus and medial temporal bone marrow \r\nheterogeneity compared to ___ prior exam with question \r\nenhancement.  While finding may represent marrow expansion, \r\ninfectious, inflammatory, and neoplastic etiologies are not \r\nexcluded on the basis of this examination.  Recommend attention \r\non follow-up imaging.\r\n\r\n___ MR head with and without contrast\r\n1. Unchanged persistent extensive fluid opacification and \r\nenhancement within the left middle ear cavity and mastoid air \r\ncells concerning for \r\notomastoiditis.  No evidence of intracranial extension. \r\n2. Persistent heterogenous signal intensity within the adjacent \r\npetrous \r\ntemporal bone.  Inflammatory, infectious or neoplastic \r\netiologies are not \r\nexcluded. \r\n3. Mild mucosal thickening in the frontal sinus, multiple \r\nethmoid air cells and predominately in the bilateral maxillary \r\nsinuses, improved since the prior study.  Enhancement in the \r\nretromaxillary fat is difficult to evaluate due to lack of T1 \r\npost-contrast fat saturated images. \r\n4. Persistent heterogenous signal intensity within the clivus, \r\nnonspecific. Differential considerations include marrow \r\nexpansion, infectious, inflammatory or neoplastic etiologies. \r\n5. No evidence of hemorrhage, infarction, mass or other abnormal \r\nenhancement. \r\n\r\n___ bilateral lower extremity venous ultrasound\r\n1. Nonocclusive deep vein thrombosis in the mid right femoral \r\nvein, new \r\ncompared to ___. \r\n2. Deep vein thrombosis in the right popliteal vein.  Of note, \r\nthe right \r\npopliteal vein contained a DVT on ultrasound ___, \r\nhowever the \r\nchronicity of the DVT seen today is uncertain. \r\n3. No evidence of DVT in the left lower extremity. \r\n\r\n___ MR head with and without contrast\r\n1. Ongoing opacification and enhancement of the left mastoid air \r\ncells and \r\nmiddle ear cavity, concerning for otomastoiditis. \r\n2. There is no evidence of intracranial extension. \r\n3. No acute intracranial abnormality is identified. \r\n4. Persistent, unchanged heterogenous signal intensity within \r\nthe clivus. This is nonspecific in nature. \r\n\r\n___ chest x-ray AP\r\nChronic deformity of the right rib cage.  Cardiomediastinal \r\nsilhouette is \r\nwithin normal limits.  There are no focal consolidations, \r\npleural effusion. Right basilar atelectasis.  Tortuous aorta.  \r\nThere are no pneumothoraces. \r\n\r\nOTHER RESULTS\r\n=============\r\n___ 05:40AM BLOOD G6PD-NORMAL\r\n___ 12:00AM BLOOD  WBC-0.7*# Lymph-98* Abs ___ CD3%-88 \r\nAbs CD3-604 CD4%-32 Abs CD4-217* CD8%-55 Abs CD8-380 \r\nCD4/CD8-0.57*\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 12:00AM BLOOD IgG-593* IgA-24* IgM-136\r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 06:05AM BLOOD WBC-4.4 RBC-2.59* Hgb-8.1* Hct-26.1* \r\nMCV-101* MCH-31.3 MCHC-31.0* RDW-18.4* RDWSD-65.2* Plt ___\r\n___ 06:05AM BLOOD Neuts-58 Bands-1 Lymphs-13* Monos-20* \r\nEos-0* ___ Myelos-7* NRBC-0.5* AbsNeut-2.60 AbsLymp-0.57* \r\nAbsMono-0.88* AbsEos-0.00* AbsBaso-0.04\r\n___ 06:05AM BLOOD Anisocy-1+* Poiklo-1+* Macrocy-1+* \r\nMicrocy-1+* Polychr-1+* Ovalocy-1+* RBC Mor-SLIDE REVI\r\n___ 06:05AM BLOOD ___ PTT-31.8 ___\r\n___ 06:05AM BLOOD ___ 06:05AM BLOOD Glucose-83 UreaN-15 Creat-1.1 Na-143 \r\nK-4.7 Cl-105 HCO3-23 AnGap-15\r\n___ 06:05AM BLOOD ALT-14 AST-16 LD(LDH)-209 AlkPhos-153* \r\nTotBili-<0.2\r\n___ 06:05AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.2 Mg-2.0\r\n \r\nBrief Hospital Course:\r\nTRANSITIONAL ISSUES\r\n===================\r\n[ ] f/u with ID regarding fungal/bacterial sinusitis and therapy \r\nduration\r\n[ ] f/u with ENT regarding chronic sinusitis\r\n\r\nSUMMARY STATMENT\r\n================\r\nMs. ___ is a ___ year old woman with history of follicular \r\nlymphoma to DLBCL treated with multiple rounds chemotherapy \r\ncomplicated by therapy-related myelodysplasia treated with \r\nalloHSCT with Flu/Bu/ATG RIC (D0 ___ complicated by \r\ngraft-versus-host disease, multiple deep vein thromboses with \r\nIVC filter in place, cavernous sinus aneurysm with coiling \r\n(___) complicated by residual cranial nerve palsy who \r\npresented to ___ with sinusitis and new acute myelogenous \r\nleukemia. Her course was notable for initiation of \r\nvenetoclax/decitabine.\r\n\r\nACTIVE ISSUES\r\n=============\r\n# AML\r\n# t-MDS ___ alloHSCT\r\nt-MDS transformed to AML with up to 83% blasts (___) in elderly\r\nhost with significant co-morbidities. G6PD normal. Patient\r\ncytogenetics show multiple complex mutations from bone marrow\r\nbiopsy. Chimerism from cytogenetics shows a greater percentage\r\nof XX chromosomal cells versus donor XY (~88 vs ~12%). \r\nDecitabine/venetoclax induction (___) every four \r\nweeks. Doses of chemotherapy were adjusted as the patient was \r\nput on different antifungals. BMB ___ with reassuring \r\nfindings, no signs of disease. Neupogen given briefly with \r\nappropriate marrow response. Patient kept on acyclovir and \r\natovaquone for prophylaxis. Bactrim chose over atovaquone at \r\ndischarge.\r\n\r\n# Maxillary sinusitis\r\nPresented with one week of progressive sinus pressure, headache,\r\nfacial warmth. CT SINUS (___) demonstrated pan-opacification of\r\nbilateral maxillary sinuses with circumferential mucosal\r\nthickening, with fat stranding in the retro maxillary fat pads\r\nconcerning for invasive fungal vs bacterial sinusitis yet\r\nfiberoptic exam (___) not consistent with fungal sinusitis.\r\nAspergillius negative, but Beta glucan positive initially in\r\nsetting of neutropenia, Zosyn, ___, and continued sinus\r\nsymptoms. ENT saw pt multiple times and noted no c/f invasive\r\nfungal sinusitis, MRI w&w/out contrast of sinus/skull base ___\r\nwith heterogeneity in left maxilla/middle ear c/f infectious\r\nprocess and pt was placed on AmBisome (___). MRI results \r\n___ were reassuring, and switch to Cresemba from AmBisome was \r\nmade. Due to likely drug rash vs viral exanthem described below, \r\nZosyn was switched for meropenem ___. Reimaging of sinuses \r\n___,\r\nlooked stable from prior and ID recommended ongoing therapy with\r\nIsavunconazole 372mg PO QD and Levofloxacin 750mg PO QD for\r\nprolonged duration of ___ weeks pending reassessment in\r\noutpatient ___ clinic.\r\n- ABx: Cresemba ___- ) + levofloxacin ___- ) ___ meropenem\r\n(___), Zosyn (___) AmBisome (___),\r\nposaconazole (___), meropenem (___) + vancomycin (___)\r\n+ levofloxacin (___) + flagyl (___) + augmentin\r\n(-___)\r\n\r\n# Nonocclusive right femoral vein DVT\r\nOn ___ patient complained of unilateral right lower leg\r\nswelling, right lower extremity noninvasives showed new right\r\nfemoral vein nonocclusive clot compared to ___ bilateral lower\r\nextremity ultrasound. Patient has an extensive history of DVTs, \r\nincluding a DVT developing while on 10mg of Xarelto. Patient was \r\ngiven platelets and started on Lovenox half dose every 12 hours \r\nonce plts > 30. She was discharged on Xarelto 20mg daily, which \r\nwas her home medication before admission.\r\n\r\n# Morbilliform rash\r\nOn ___ presented with suspected drug rash with Zosyn being\r\nlikely aggravating factor. ___ spreading to arms and chest.\r\nWithout involvement of mucosa or face. Decreasing in intensity\r\nand itching daily until ___ when patient woke up with xerotic,\r\nblanching, non-raised rash over chest, legs, arms, and back.\r\nDermatology consulted and recommended steroids topically, \r\nsuggested drug rash. Meropenem switched to levofloxacin. \r\nResolution of rash within the following days. Steroid creams \r\nprescribed per dermatology service.\r\n\r\nCHRONIC/RESOLVED:\r\n=================\r\n# Asthma\r\n- inhalers: duonebs q6hrs PRN + albuterol q4hrs PRN\r\n\r\n# OSA\r\n- continue home CPAP\r\n\r\n# Depression\r\n- continue home venlafaxine 25\r\n\r\n# Neuropathic pain\r\n- continue home gabapentin 400 bid\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n4. FoLIC Acid 1.6 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron (ondansetron HCl) 4 mg oral Q8H:PRN nausea \r\n9. Restasis 0.05 % ophthalmic (eye) BID \r\n10. Rivaroxaban 20 mg PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n14. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n15. Benzonatate 100 mg PO TID:PRN Cough  \r\n16. Ketoconazole Shampoo 1 Appl TP TWO TO THREE TIMES WEEKLY AS \r\nNEEDED FOR DRY SCALP \r\n\r\n \r\nDischarge Medications:\r\n1.  Betamethasone Dipro 0.05% Cream 1 Appl TP BID  \r\n2.  Cetirizine 20 mg PO BID \r\nRX *cetirizine 10 mg 2 tablet(s) by mouth once a day Disp #*60 \r\nTablet Refills:*0 \r\n3.  Isavuconazonium Sulfate 372 mg PO DAILY \r\nRX *isavuconazonium sulfate [Cresemba] 186 mg 2 capsule(s) by \r\nmouth once a day Disp #*60 Capsule Refills:*0 \r\n4.  LevoFLOXacin 750 mg PO Q24H \r\nRX *levofloxacin 750 mg 1 tablet(s) by mouth once a day Disp \r\n#*42 Tablet Refills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim 400 mg-80 mg 1 tablet(s) by \r\nmouth once a day Disp #*30 Tablet Refills:*0 \r\n6.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n7.  FoLIC Acid 2 mg PO DAILY \r\nRX *folic acid 1 mg 2 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Acyclovir 400 mg PO Q12H  \r\n9.  Gabapentin 400 mg PO BID  \r\n10.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nneb every six (6) hours Disp #*30 Ampule Refills:*0 \r\n11.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n14.  Restasis 0.05 % ophthalmic (eye) BID  \r\n15.  Rivaroxaban 20 mg PO DAILY  \r\n16.  Venlafaxine 25 mg PO DAILY  \r\n17.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS\r\n==================\r\n- Acute myelogenous leukemia\r\n\r\nSECONDARY DIAGNOSIS\r\n===================\r\n- Bacterial vs Fungal sinusitis\r\n- Right femoral vein thrombosis \r\n- Obstructive sleep apnea\r\n- Asthma\r\n- Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,  \r\n\r\nWHY WERE YOU ADMITTED TO THE HOSPITAL?  \r\n- You had a sinus infection and were found to have acute \r\nmyelogenous leukemia\r\n\r\nWHAT WAS DONE WHILE YOU WERE IN THE HOSPITAL?  \r\n- You were given chemotherapy to treat your cancer\r\n- You received antibiotics and antifungals to treat your sinus \r\ninfection\r\n \r\nWHAT DO YOU NEED TO DO WHEN YOU LEAVE THE HOSPITAL?  \r\n- Take all of your medications as prescribed (listed below)  \r\n- Follow up with your doctors as listed below  \r\n\r\nPlease see below for more information on your hospitalization. \r\nIt was a pleasure taking part in your care here at ___. We \r\nwish you all the best,\r\n\r\n- Your ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-28:2",
      "text": "Left \nventricular cardiac index is normal (>2.5 L/min/m2). There is no \nresting left ventricular outflow tract gradient. No ventricular \nseptal defect is seen. Normal right ventricular cavity size with \nnormal free wall motion. Tricuspid annular plane systolic \nexcursion (TAPSE) is normal. The aortic sinus diameter is normal \nfor gender with a mildly dilated ascending aorta. The aortic \narch diameter is normal with a normal descending aorta diameter. The aortic valve leaflets (3) appear structurally normal. There \nis no aortic valve stenosis. There is no aortic regurgitation. The mitral valve leaflets are mildly thickened with no mitral \nvalve prolapse. There is mild [1+] mitral regurgitation. The \npulmonic valve leaflets are normal. The tricuspid valve leaflets \nappear structurally normal. There is mild [1+] tricuspid \nregurgitation. The estimated pulmonary artery systolic pressure \nis normal. There is a trivial pericardial effusion. IMPRESSION: \nMild symmetric left ventricular hypertrophy with normal cavity \nsize and regional/ global biventricular systolic function. Mild \nmitral regurgitation. Mildly dilated ascending aorta. ___ CT chest without contrast\nNo evidence of recurrent lymphoma in the chest. Stable small \nmediastinal lymph nodes. Complete resolution of the parenchymal \nopacity in the right lower lobe which most likely represented \npneumonia. Patchy opacity in the left lung base is new and \ncould represent atelectasis. ___ MRI skull base with and without contrast\n1. Limited study as described. 2. Interval progression of opacification and enhancement within \nthe left mastoid air cells and middle ear cavity concerning for \notomastoiditis, with no definite evidence of intracranial \nextension. 3. Adjacent heterogeneity of the petrous temporal bone versus \nartifact. If not artifactual, differential considerations \ninclude infectious and inflammatory etiologies. 4. Bilateral maxillary sinus disease is redemonstrated, \naerosolized secretions are better demonstrated on the CT from ___, with no definite extension into the adjacent soft \ntissue. 5. Question mild enhancement of the left retro maxillary fat \nversus volume averaging of adjacent vessels. Recommend \nattention on follow-up imaging. 6. Nonspecific new clivus and medial temporal bone marrow \nheterogeneity compared to ___ prior exam with question \nenhancement. While finding may represent marrow expansion, \ninfectious, inflammatory, and neoplastic etiologies are not \nexcluded on the basis of this examination. Recommend attention \non follow-up imaging. ___ MR head with and without contrast\n1. Unchanged persistent extensive fluid opacification and \nenhancement within the left middle ear cavity and mastoid air \ncells concerning for \notomastoiditis.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-28",
        "chart_time": "105580",
        "section": "General",
        "position": 2,
        "tokenCount": 688,
        "note_metadata": {
          "note_id": "18887130-DS-28",
          "subject_id": 18887130,
          "hadm_id": 26914904,
          "note_type": "DS",
          "note_seq": 28,
          "charttime": 105580,
          "storetime": 105580.72777777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy (___)\r\nPICC placed (___)\r\n\r\nattach\r\n \r\nPertinent Results:\r\nINITIAL LABS\r\n============\r\n___ 02:30PM BLOOD WBC-9.8 RBC-3.43* Hgb-11.1* Hct-33.6* \r\nMCV-98 MCH-32.4* MCHC-33.0 RDW-17.4* RDWSD-62.2* Plt Ct-24*\r\n___ 02:30PM BLOOD Neuts-6* ___ Monos-1* Eos-0* Baso-0 \r\nAtyps-2* Blasts-65* AbsNeut-0.59* AbsLymp-2.74 AbsMono-0.10* \r\nAbsEos-0.00* AbsBaso-0.00*\r\n___ 02:30PM BLOOD ___ PTT-27.7 ___\r\n___ 05:40AM BLOOD ___ D-Dimer-<215\r\n___ 05:40AM BLOOD Ret Aut-0.8 Abs Ret-0.02\r\n___ 02:30PM BLOOD UreaN-14 Creat-1.0 Na-136 K-3.8 Cl-100 \r\nHCO3-20* AnGap-16\r\n___ 02:30PM BLOOD ALT-8 AST-17 LD(LDH)-1709* AlkPhos-93 \r\nTotBili-0.2\r\n___ 04:26PM BLOOD Lipase-11\r\n___ 04:26PM BLOOD CK-MB-2 cTropnT-<0.01\r\n___ 02:30PM BLOOD Albumin-3.6 Calcium-9.0 Mg-1.9 \r\nUricAcd-3.6\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 05:40AM BLOOD CRP-153.6*\r\n___ 02:30PM BLOOD IgG-621* \r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n___ 04:18PM BLOOD Lactate-1.3 K-4.2\r\n\r\nMICROBIOLOGY\r\n============\r\nAll blood cultures drawn during admission where negative ___, \r\n___\r\nMRSA screen negative\r\nRapid resp viral screen and culture negative (___)\r\nUrine culture ___ negative\r\n\r\nIMAGING\r\n=======\r\n___ CT SINUS:\r\n1. New bilateral maxillary sinus disease with hyperdense \r\nmaterial suggesting fungal colonization or inspissated \r\nsecretions.  However, there is also fat stranding in the retro \r\nmaxillary fat pads, which raises the possibility of invasive \r\nfungal sinusitis in the context of immune suppression. \r\n2. Please see separate head CT for intracranial findings.\r\n\r\n___ CT HEAD:\r\nNo acute intracranial abnormalities are identified or change \r\nseen compared with ___.\r\n\r\n___ TTE:\r\nThe left atrium is mildly dilated. The right atrium is mildly \r\nenlarged. There is no evidence for an atrial septal defect by \r\n2D/color Doppler. The estimated right atrial pressure is ___ \r\nmmHg. There is mild symmetric left ventricular hypertrophy with \r\na normal cavity size. There is normal regional and global left \r\nventricular systolic function. Quantitative biplane left \r\nventricular ejection fraction is 56 % (normal 54-73%). Left \r\nventricular cardiac index is normal (>2.5 L/min/m2). There is no \r\nresting left ventricular outflow tract gradient. No ventricular \r\nseptal defect is seen. Normal right ventricular cavity size with \r\nnormal free wall motion. Tricuspid annular plane systolic \r\nexcursion (TAPSE) is normal. The aortic sinus diameter is normal \r\nfor gender with a mildly dilated ascending aorta. The aortic \r\narch diameter is normal with a normal descending aorta diameter. \r\nThe aortic valve leaflets (3) appear structurally normal. There \r\nis no aortic valve stenosis. There is no aortic regurgitation. \r\nThe mitral valve leaflets are mildly thickened with no mitral \r\nvalve prolapse. There is mild [1+] mitral regurgitation. The \r\npulmonic valve leaflets are normal. The tricuspid valve leaflets \r\nappear structurally normal. There is mild [1+] tricuspid \r\nregurgitation. The estimated pulmonary artery systolic pressure \r\nis normal. There is a trivial pericardial effusion. IMPRESSION: \r\nMild symmetric left ventricular hypertrophy with normal cavity \r\nsize and regional/ global biventricular systolic function. Mild \r\nmitral regurgitation. Mildly dilated ascending aorta.\r\n\r\n___ CT chest without contrast\r\nNo evidence of recurrent lymphoma in the chest. Stable small \r\nmediastinal lymph nodes. Complete resolution of the parenchymal \r\nopacity in the right lower lobe which most likely represented \r\npneumonia.  Patchy opacity in the left lung base is new and \r\ncould represent atelectasis. \r\n\r\n___ MRI skull base with and without contrast\r\n1. Limited study as described.\r\n2. Interval progression of opacification and enhancement within \r\nthe left mastoid air cells and middle ear cavity concerning for \r\notomastoiditis, with no definite evidence of intracranial \r\nextension.\r\n3. Adjacent heterogeneity of the petrous temporal bone versus \r\nartifact.  If not artifactual, differential considerations \r\ninclude infectious and inflammatory etiologies.\r\n4. Bilateral maxillary sinus disease is redemonstrated, \r\naerosolized secretions are better demonstrated on the CT from ___, with no definite extension into the adjacent soft \r\ntissue.\r\n5. Question mild enhancement of the left retro maxillary fat \r\nversus volume averaging of adjacent vessels.  Recommend \r\nattention on follow-up imaging.\r\n6. Nonspecific new clivus and medial temporal bone marrow \r\nheterogeneity compared to ___ prior exam with question \r\nenhancement.  While finding may represent marrow expansion, \r\ninfectious, inflammatory, and neoplastic etiologies are not \r\nexcluded on the basis of this examination.  Recommend attention \r\non follow-up imaging.\r\n\r\n___ MR head with and without contrast\r\n1. Unchanged persistent extensive fluid opacification and \r\nenhancement within the left middle ear cavity and mastoid air \r\ncells concerning for \r\notomastoiditis.  No evidence of intracranial extension. \r\n2. Persistent heterogenous signal intensity within the adjacent \r\npetrous \r\ntemporal bone.  Inflammatory, infectious or neoplastic \r\netiologies are not \r\nexcluded. \r\n3. Mild mucosal thickening in the frontal sinus, multiple \r\nethmoid air cells and predominately in the bilateral maxillary \r\nsinuses, improved since the prior study.  Enhancement in the \r\nretromaxillary fat is difficult to evaluate due to lack of T1 \r\npost-contrast fat saturated images. \r\n4. Persistent heterogenous signal intensity within the clivus, \r\nnonspecific. Differential considerations include marrow \r\nexpansion, infectious, inflammatory or neoplastic etiologies. \r\n5. No evidence of hemorrhage, infarction, mass or other abnormal \r\nenhancement. \r\n\r\n___ bilateral lower extremity venous ultrasound\r\n1. Nonocclusive deep vein thrombosis in the mid right femoral \r\nvein, new \r\ncompared to ___. \r\n2. Deep vein thrombosis in the right popliteal vein.  Of note, \r\nthe right \r\npopliteal vein contained a DVT on ultrasound ___, \r\nhowever the \r\nchronicity of the DVT seen today is uncertain. \r\n3. No evidence of DVT in the left lower extremity. \r\n\r\n___ MR head with and without contrast\r\n1. Ongoing opacification and enhancement of the left mastoid air \r\ncells and \r\nmiddle ear cavity, concerning for otomastoiditis. \r\n2. There is no evidence of intracranial extension. \r\n3. No acute intracranial abnormality is identified. \r\n4. Persistent, unchanged heterogenous signal intensity within \r\nthe clivus. This is nonspecific in nature. \r\n\r\n___ chest x-ray AP\r\nChronic deformity of the right rib cage.  Cardiomediastinal \r\nsilhouette is \r\nwithin normal limits.  There are no focal consolidations, \r\npleural effusion. Right basilar atelectasis.  Tortuous aorta.  \r\nThere are no pneumothoraces. \r\n\r\nOTHER RESULTS\r\n=============\r\n___ 05:40AM BLOOD G6PD-NORMAL\r\n___ 12:00AM BLOOD  WBC-0.7*# Lymph-98* Abs ___ CD3%-88 \r\nAbs CD3-604 CD4%-32 Abs CD4-217* CD8%-55 Abs CD8-380 \r\nCD4/CD8-0.57*\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 12:00AM BLOOD IgG-593* IgA-24* IgM-136\r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 06:05AM BLOOD WBC-4.4 RBC-2.59* Hgb-8.1* Hct-26.1* \r\nMCV-101* MCH-31.3 MCHC-31.0* RDW-18.4* RDWSD-65.2* Plt ___\r\n___ 06:05AM BLOOD Neuts-58 Bands-1 Lymphs-13* Monos-20* \r\nEos-0* ___ Myelos-7* NRBC-0.5* AbsNeut-2.60 AbsLymp-0.57* \r\nAbsMono-0.88* AbsEos-0.00* AbsBaso-0.04\r\n___ 06:05AM BLOOD Anisocy-1+* Poiklo-1+* Macrocy-1+* \r\nMicrocy-1+* Polychr-1+* Ovalocy-1+* RBC Mor-SLIDE REVI\r\n___ 06:05AM BLOOD ___ PTT-31.8 ___\r\n___ 06:05AM BLOOD ___ 06:05AM BLOOD Glucose-83 UreaN-15 Creat-1.1 Na-143 \r\nK-4.7 Cl-105 HCO3-23 AnGap-15\r\n___ 06:05AM BLOOD ALT-14 AST-16 LD(LDH)-209 AlkPhos-153* \r\nTotBili-<0.2\r\n___ 06:05AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.2 Mg-2.0\r\n \r\nBrief Hospital Course:\r\nTRANSITIONAL ISSUES\r\n===================\r\n[ ] f/u with ID regarding fungal/bacterial sinusitis and therapy \r\nduration\r\n[ ] f/u with ENT regarding chronic sinusitis\r\n\r\nSUMMARY STATMENT\r\n================\r\nMs. ___ is a ___ year old woman with history of follicular \r\nlymphoma to DLBCL treated with multiple rounds chemotherapy \r\ncomplicated by therapy-related myelodysplasia treated with \r\nalloHSCT with Flu/Bu/ATG RIC (D0 ___ complicated by \r\ngraft-versus-host disease, multiple deep vein thromboses with \r\nIVC filter in place, cavernous sinus aneurysm with coiling \r\n(___) complicated by residual cranial nerve palsy who \r\npresented to ___ with sinusitis and new acute myelogenous \r\nleukemia. Her course was notable for initiation of \r\nvenetoclax/decitabine.\r\n\r\nACTIVE ISSUES\r\n=============\r\n# AML\r\n# t-MDS ___ alloHSCT\r\nt-MDS transformed to AML with up to 83% blasts (___) in elderly\r\nhost with significant co-morbidities. G6PD normal. Patient\r\ncytogenetics show multiple complex mutations from bone marrow\r\nbiopsy. Chimerism from cytogenetics shows a greater percentage\r\nof XX chromosomal cells versus donor XY (~88 vs ~12%). \r\nDecitabine/venetoclax induction (___) every four \r\nweeks. Doses of chemotherapy were adjusted as the patient was \r\nput on different antifungals. BMB ___ with reassuring \r\nfindings, no signs of disease. Neupogen given briefly with \r\nappropriate marrow response. Patient kept on acyclovir and \r\natovaquone for prophylaxis. Bactrim chose over atovaquone at \r\ndischarge.\r\n\r\n# Maxillary sinusitis\r\nPresented with one week of progressive sinus pressure, headache,\r\nfacial warmth. CT SINUS (___) demonstrated pan-opacification of\r\nbilateral maxillary sinuses with circumferential mucosal\r\nthickening, with fat stranding in the retro maxillary fat pads\r\nconcerning for invasive fungal vs bacterial sinusitis yet\r\nfiberoptic exam (___) not consistent with fungal sinusitis.\r\nAspergillius negative, but Beta glucan positive initially in\r\nsetting of neutropenia, Zosyn, ___, and continued sinus\r\nsymptoms. ENT saw pt multiple times and noted no c/f invasive\r\nfungal sinusitis, MRI w&w/out contrast of sinus/skull base ___\r\nwith heterogeneity in left maxilla/middle ear c/f infectious\r\nprocess and pt was placed on AmBisome (___). MRI results \r\n___ were reassuring, and switch to Cresemba from AmBisome was \r\nmade. Due to likely drug rash vs viral exanthem described below, \r\nZosyn was switched for meropenem ___. Reimaging of sinuses \r\n___,\r\nlooked stable from prior and ID recommended ongoing therapy with\r\nIsavunconazole 372mg PO QD and Levofloxacin 750mg PO QD for\r\nprolonged duration of ___ weeks pending reassessment in\r\noutpatient ___ clinic.\r\n- ABx: Cresemba ___- ) + levofloxacin ___- ) ___ meropenem\r\n(___), Zosyn (___) AmBisome (___),\r\nposaconazole (___), meropenem (___) + vancomycin (___)\r\n+ levofloxacin (___) + flagyl (___) + augmentin\r\n(-___)\r\n\r\n# Nonocclusive right femoral vein DVT\r\nOn ___ patient complained of unilateral right lower leg\r\nswelling, right lower extremity noninvasives showed new right\r\nfemoral vein nonocclusive clot compared to ___ bilateral lower\r\nextremity ultrasound. Patient has an extensive history of DVTs, \r\nincluding a DVT developing while on 10mg of Xarelto. Patient was \r\ngiven platelets and started on Lovenox half dose every 12 hours \r\nonce plts > 30. She was discharged on Xarelto 20mg daily, which \r\nwas her home medication before admission.\r\n\r\n# Morbilliform rash\r\nOn ___ presented with suspected drug rash with Zosyn being\r\nlikely aggravating factor. ___ spreading to arms and chest.\r\nWithout involvement of mucosa or face. Decreasing in intensity\r\nand itching daily until ___ when patient woke up with xerotic,\r\nblanching, non-raised rash over chest, legs, arms, and back.\r\nDermatology consulted and recommended steroids topically, \r\nsuggested drug rash. Meropenem switched to levofloxacin. \r\nResolution of rash within the following days. Steroid creams \r\nprescribed per dermatology service.\r\n\r\nCHRONIC/RESOLVED:\r\n=================\r\n# Asthma\r\n- inhalers: duonebs q6hrs PRN + albuterol q4hrs PRN\r\n\r\n# OSA\r\n- continue home CPAP\r\n\r\n# Depression\r\n- continue home venlafaxine 25\r\n\r\n# Neuropathic pain\r\n- continue home gabapentin 400 bid\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n4. FoLIC Acid 1.6 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron (ondansetron HCl) 4 mg oral Q8H:PRN nausea \r\n9. Restasis 0.05 % ophthalmic (eye) BID \r\n10. Rivaroxaban 20 mg PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n14. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n15. Benzonatate 100 mg PO TID:PRN Cough  \r\n16. Ketoconazole Shampoo 1 Appl TP TWO TO THREE TIMES WEEKLY AS \r\nNEEDED FOR DRY SCALP \r\n\r\n \r\nDischarge Medications:\r\n1.  Betamethasone Dipro 0.05% Cream 1 Appl TP BID  \r\n2.  Cetirizine 20 mg PO BID \r\nRX *cetirizine 10 mg 2 tablet(s) by mouth once a day Disp #*60 \r\nTablet Refills:*0 \r\n3.  Isavuconazonium Sulfate 372 mg PO DAILY \r\nRX *isavuconazonium sulfate [Cresemba] 186 mg 2 capsule(s) by \r\nmouth once a day Disp #*60 Capsule Refills:*0 \r\n4.  LevoFLOXacin 750 mg PO Q24H \r\nRX *levofloxacin 750 mg 1 tablet(s) by mouth once a day Disp \r\n#*42 Tablet Refills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim 400 mg-80 mg 1 tablet(s) by \r\nmouth once a day Disp #*30 Tablet Refills:*0 \r\n6.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n7.  FoLIC Acid 2 mg PO DAILY \r\nRX *folic acid 1 mg 2 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Acyclovir 400 mg PO Q12H  \r\n9.  Gabapentin 400 mg PO BID  \r\n10.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nneb every six (6) hours Disp #*30 Ampule Refills:*0 \r\n11.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n14.  Restasis 0.05 % ophthalmic (eye) BID  \r\n15.  Rivaroxaban 20 mg PO DAILY  \r\n16.  Venlafaxine 25 mg PO DAILY  \r\n17.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS\r\n==================\r\n- Acute myelogenous leukemia\r\n\r\nSECONDARY DIAGNOSIS\r\n===================\r\n- Bacterial vs Fungal sinusitis\r\n- Right femoral vein thrombosis \r\n- Obstructive sleep apnea\r\n- Asthma\r\n- Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,  \r\n\r\nWHY WERE YOU ADMITTED TO THE HOSPITAL?  \r\n- You had a sinus infection and were found to have acute \r\nmyelogenous leukemia\r\n\r\nWHAT WAS DONE WHILE YOU WERE IN THE HOSPITAL?  \r\n- You were given chemotherapy to treat your cancer\r\n- You received antibiotics and antifungals to treat your sinus \r\ninfection\r\n \r\nWHAT DO YOU NEED TO DO WHEN YOU LEAVE THE HOSPITAL?  \r\n- Take all of your medications as prescribed (listed below)  \r\n- Follow up with your doctors as listed below  \r\n\r\nPlease see below for more information on your hospitalization. \r\nIt was a pleasure taking part in your care here at ___. We \r\nwish you all the best,\r\n\r\n- Your ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-28:3",
      "text": "Recommend \nattention on follow-up imaging. 6. Nonspecific new clivus and medial temporal bone marrow \nheterogeneity compared to ___ prior exam with question \nenhancement. While finding may represent marrow expansion, \ninfectious, inflammatory, and neoplastic etiologies are not \nexcluded on the basis of this examination. Recommend attention \non follow-up imaging. ___ MR head with and without contrast\n1. Unchanged persistent extensive fluid opacification and \nenhancement within the left middle ear cavity and mastoid air \ncells concerning for \notomastoiditis. No evidence of intracranial extension. 2. Persistent heterogenous signal intensity within the adjacent \npetrous \ntemporal bone. Inflammatory, infectious or neoplastic \netiologies are not \nexcluded. 3. Mild mucosal thickening in the frontal sinus, multiple \nethmoid air cells and predominately in the bilateral maxillary \nsinuses, improved since the prior study. Enhancement in the \nretromaxillary fat is difficult to evaluate due to lack of T1 \npost-contrast fat saturated images. 4. Persistent heterogenous signal intensity within the clivus, \nnonspecific. Differential considerations include marrow \nexpansion, infectious, inflammatory or neoplastic etiologies. 5. No evidence of hemorrhage, infarction, mass or other abnormal \nenhancement. ___ bilateral lower extremity venous ultrasound\n1. Nonocclusive deep vein thrombosis in the mid right femoral \nvein, new \ncompared to ___. 2. Deep vein thrombosis in the right popliteal vein. Of note, \nthe right \npopliteal vein contained a DVT on ultrasound ___, \nhowever the \nchronicity of the DVT seen today is uncertain. 3. No evidence of DVT in the left lower extremity. ___ MR head with and without contrast\n1. Ongoing opacification and enhancement of the left mastoid air \ncells and \nmiddle ear cavity, concerning for otomastoiditis. 2. There is no evidence of intracranial extension. 3. No acute intracranial abnormality is identified. 4. Persistent, unchanged heterogenous signal intensity within \nthe clivus. This is nonspecific in nature. ___ chest x-ray AP\nChronic deformity of the right rib cage. Cardiomediastinal \nsilhouette is \nwithin normal limits. There are no focal consolidations, \npleural effusion. Right basilar atelectasis. Tortuous aorta. There are no pneumothoraces. OTHER RESULTS\n=============\n___ 05:40AM BLOOD G6PD-NORMAL\n___ 12:00AM BLOOD  WBC-0.7*# Lymph-98* Abs ___ CD3%-88 \nAbs CD3-604 CD4%-32 Abs CD4-217* CD8%-55 Abs CD8-380 \nCD4/CD8-0.57*\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\n___ 12:00AM BLOOD IgG-593* IgA-24* IgM-136\n___ 02:30PM BLOOD CMV VL-NOT DETECT",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-28",
        "chart_time": "105580",
        "section": "General",
        "position": 3,
        "tokenCount": 664,
        "note_metadata": {
          "note_id": "18887130-DS-28",
          "subject_id": 18887130,
          "hadm_id": 26914904,
          "note_type": "DS",
          "note_seq": 28,
          "charttime": 105580,
          "storetime": 105580.72777777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy (___)\r\nPICC placed (___)\r\n\r\nattach\r\n \r\nPertinent Results:\r\nINITIAL LABS\r\n============\r\n___ 02:30PM BLOOD WBC-9.8 RBC-3.43* Hgb-11.1* Hct-33.6* \r\nMCV-98 MCH-32.4* MCHC-33.0 RDW-17.4* RDWSD-62.2* Plt Ct-24*\r\n___ 02:30PM BLOOD Neuts-6* ___ Monos-1* Eos-0* Baso-0 \r\nAtyps-2* Blasts-65* AbsNeut-0.59* AbsLymp-2.74 AbsMono-0.10* \r\nAbsEos-0.00* AbsBaso-0.00*\r\n___ 02:30PM BLOOD ___ PTT-27.7 ___\r\n___ 05:40AM BLOOD ___ D-Dimer-<215\r\n___ 05:40AM BLOOD Ret Aut-0.8 Abs Ret-0.02\r\n___ 02:30PM BLOOD UreaN-14 Creat-1.0 Na-136 K-3.8 Cl-100 \r\nHCO3-20* AnGap-16\r\n___ 02:30PM BLOOD ALT-8 AST-17 LD(LDH)-1709* AlkPhos-93 \r\nTotBili-0.2\r\n___ 04:26PM BLOOD Lipase-11\r\n___ 04:26PM BLOOD CK-MB-2 cTropnT-<0.01\r\n___ 02:30PM BLOOD Albumin-3.6 Calcium-9.0 Mg-1.9 \r\nUricAcd-3.6\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 05:40AM BLOOD CRP-153.6*\r\n___ 02:30PM BLOOD IgG-621* \r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n___ 04:18PM BLOOD Lactate-1.3 K-4.2\r\n\r\nMICROBIOLOGY\r\n============\r\nAll blood cultures drawn during admission where negative ___, \r\n___\r\nMRSA screen negative\r\nRapid resp viral screen and culture negative (___)\r\nUrine culture ___ negative\r\n\r\nIMAGING\r\n=======\r\n___ CT SINUS:\r\n1. New bilateral maxillary sinus disease with hyperdense \r\nmaterial suggesting fungal colonization or inspissated \r\nsecretions.  However, there is also fat stranding in the retro \r\nmaxillary fat pads, which raises the possibility of invasive \r\nfungal sinusitis in the context of immune suppression. \r\n2. Please see separate head CT for intracranial findings.\r\n\r\n___ CT HEAD:\r\nNo acute intracranial abnormalities are identified or change \r\nseen compared with ___.\r\n\r\n___ TTE:\r\nThe left atrium is mildly dilated. The right atrium is mildly \r\nenlarged. There is no evidence for an atrial septal defect by \r\n2D/color Doppler. The estimated right atrial pressure is ___ \r\nmmHg. There is mild symmetric left ventricular hypertrophy with \r\na normal cavity size. There is normal regional and global left \r\nventricular systolic function. Quantitative biplane left \r\nventricular ejection fraction is 56 % (normal 54-73%). Left \r\nventricular cardiac index is normal (>2.5 L/min/m2). There is no \r\nresting left ventricular outflow tract gradient. No ventricular \r\nseptal defect is seen. Normal right ventricular cavity size with \r\nnormal free wall motion. Tricuspid annular plane systolic \r\nexcursion (TAPSE) is normal. The aortic sinus diameter is normal \r\nfor gender with a mildly dilated ascending aorta. The aortic \r\narch diameter is normal with a normal descending aorta diameter. \r\nThe aortic valve leaflets (3) appear structurally normal. There \r\nis no aortic valve stenosis. There is no aortic regurgitation. \r\nThe mitral valve leaflets are mildly thickened with no mitral \r\nvalve prolapse. There is mild [1+] mitral regurgitation. The \r\npulmonic valve leaflets are normal. The tricuspid valve leaflets \r\nappear structurally normal. There is mild [1+] tricuspid \r\nregurgitation. The estimated pulmonary artery systolic pressure \r\nis normal. There is a trivial pericardial effusion. IMPRESSION: \r\nMild symmetric left ventricular hypertrophy with normal cavity \r\nsize and regional/ global biventricular systolic function. Mild \r\nmitral regurgitation. Mildly dilated ascending aorta.\r\n\r\n___ CT chest without contrast\r\nNo evidence of recurrent lymphoma in the chest. Stable small \r\nmediastinal lymph nodes. Complete resolution of the parenchymal \r\nopacity in the right lower lobe which most likely represented \r\npneumonia.  Patchy opacity in the left lung base is new and \r\ncould represent atelectasis. \r\n\r\n___ MRI skull base with and without contrast\r\n1. Limited study as described.\r\n2. Interval progression of opacification and enhancement within \r\nthe left mastoid air cells and middle ear cavity concerning for \r\notomastoiditis, with no definite evidence of intracranial \r\nextension.\r\n3. Adjacent heterogeneity of the petrous temporal bone versus \r\nartifact.  If not artifactual, differential considerations \r\ninclude infectious and inflammatory etiologies.\r\n4. Bilateral maxillary sinus disease is redemonstrated, \r\naerosolized secretions are better demonstrated on the CT from ___, with no definite extension into the adjacent soft \r\ntissue.\r\n5. Question mild enhancement of the left retro maxillary fat \r\nversus volume averaging of adjacent vessels.  Recommend \r\nattention on follow-up imaging.\r\n6. Nonspecific new clivus and medial temporal bone marrow \r\nheterogeneity compared to ___ prior exam with question \r\nenhancement.  While finding may represent marrow expansion, \r\ninfectious, inflammatory, and neoplastic etiologies are not \r\nexcluded on the basis of this examination.  Recommend attention \r\non follow-up imaging.\r\n\r\n___ MR head with and without contrast\r\n1. Unchanged persistent extensive fluid opacification and \r\nenhancement within the left middle ear cavity and mastoid air \r\ncells concerning for \r\notomastoiditis.  No evidence of intracranial extension. \r\n2. Persistent heterogenous signal intensity within the adjacent \r\npetrous \r\ntemporal bone.  Inflammatory, infectious or neoplastic \r\netiologies are not \r\nexcluded. \r\n3. Mild mucosal thickening in the frontal sinus, multiple \r\nethmoid air cells and predominately in the bilateral maxillary \r\nsinuses, improved since the prior study.  Enhancement in the \r\nretromaxillary fat is difficult to evaluate due to lack of T1 \r\npost-contrast fat saturated images. \r\n4. Persistent heterogenous signal intensity within the clivus, \r\nnonspecific. Differential considerations include marrow \r\nexpansion, infectious, inflammatory or neoplastic etiologies. \r\n5. No evidence of hemorrhage, infarction, mass or other abnormal \r\nenhancement. \r\n\r\n___ bilateral lower extremity venous ultrasound\r\n1. Nonocclusive deep vein thrombosis in the mid right femoral \r\nvein, new \r\ncompared to ___. \r\n2. Deep vein thrombosis in the right popliteal vein.  Of note, \r\nthe right \r\npopliteal vein contained a DVT on ultrasound ___, \r\nhowever the \r\nchronicity of the DVT seen today is uncertain. \r\n3. No evidence of DVT in the left lower extremity. \r\n\r\n___ MR head with and without contrast\r\n1. Ongoing opacification and enhancement of the left mastoid air \r\ncells and \r\nmiddle ear cavity, concerning for otomastoiditis. \r\n2. There is no evidence of intracranial extension. \r\n3. No acute intracranial abnormality is identified. \r\n4. Persistent, unchanged heterogenous signal intensity within \r\nthe clivus. This is nonspecific in nature. \r\n\r\n___ chest x-ray AP\r\nChronic deformity of the right rib cage.  Cardiomediastinal \r\nsilhouette is \r\nwithin normal limits.  There are no focal consolidations, \r\npleural effusion. Right basilar atelectasis.  Tortuous aorta.  \r\nThere are no pneumothoraces. \r\n\r\nOTHER RESULTS\r\n=============\r\n___ 05:40AM BLOOD G6PD-NORMAL\r\n___ 12:00AM BLOOD  WBC-0.7*# Lymph-98* Abs ___ CD3%-88 \r\nAbs CD3-604 CD4%-32 Abs CD4-217* CD8%-55 Abs CD8-380 \r\nCD4/CD8-0.57*\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 12:00AM BLOOD IgG-593* IgA-24* IgM-136\r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 06:05AM BLOOD WBC-4.4 RBC-2.59* Hgb-8.1* Hct-26.1* \r\nMCV-101* MCH-31.3 MCHC-31.0* RDW-18.4* RDWSD-65.2* Plt ___\r\n___ 06:05AM BLOOD Neuts-58 Bands-1 Lymphs-13* Monos-20* \r\nEos-0* ___ Myelos-7* NRBC-0.5* AbsNeut-2.60 AbsLymp-0.57* \r\nAbsMono-0.88* AbsEos-0.00* AbsBaso-0.04\r\n___ 06:05AM BLOOD Anisocy-1+* Poiklo-1+* Macrocy-1+* \r\nMicrocy-1+* Polychr-1+* Ovalocy-1+* RBC Mor-SLIDE REVI\r\n___ 06:05AM BLOOD ___ PTT-31.8 ___\r\n___ 06:05AM BLOOD ___ 06:05AM BLOOD Glucose-83 UreaN-15 Creat-1.1 Na-143 \r\nK-4.7 Cl-105 HCO3-23 AnGap-15\r\n___ 06:05AM BLOOD ALT-14 AST-16 LD(LDH)-209 AlkPhos-153* \r\nTotBili-<0.2\r\n___ 06:05AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.2 Mg-2.0\r\n \r\nBrief Hospital Course:\r\nTRANSITIONAL ISSUES\r\n===================\r\n[ ] f/u with ID regarding fungal/bacterial sinusitis and therapy \r\nduration\r\n[ ] f/u with ENT regarding chronic sinusitis\r\n\r\nSUMMARY STATMENT\r\n================\r\nMs. ___ is a ___ year old woman with history of follicular \r\nlymphoma to DLBCL treated with multiple rounds chemotherapy \r\ncomplicated by therapy-related myelodysplasia treated with \r\nalloHSCT with Flu/Bu/ATG RIC (D0 ___ complicated by \r\ngraft-versus-host disease, multiple deep vein thromboses with \r\nIVC filter in place, cavernous sinus aneurysm with coiling \r\n(___) complicated by residual cranial nerve palsy who \r\npresented to ___ with sinusitis and new acute myelogenous \r\nleukemia. Her course was notable for initiation of \r\nvenetoclax/decitabine.\r\n\r\nACTIVE ISSUES\r\n=============\r\n# AML\r\n# t-MDS ___ alloHSCT\r\nt-MDS transformed to AML with up to 83% blasts (___) in elderly\r\nhost with significant co-morbidities. G6PD normal. Patient\r\ncytogenetics show multiple complex mutations from bone marrow\r\nbiopsy. Chimerism from cytogenetics shows a greater percentage\r\nof XX chromosomal cells versus donor XY (~88 vs ~12%). \r\nDecitabine/venetoclax induction (___) every four \r\nweeks. Doses of chemotherapy were adjusted as the patient was \r\nput on different antifungals. BMB ___ with reassuring \r\nfindings, no signs of disease. Neupogen given briefly with \r\nappropriate marrow response. Patient kept on acyclovir and \r\natovaquone for prophylaxis. Bactrim chose over atovaquone at \r\ndischarge.\r\n\r\n# Maxillary sinusitis\r\nPresented with one week of progressive sinus pressure, headache,\r\nfacial warmth. CT SINUS (___) demonstrated pan-opacification of\r\nbilateral maxillary sinuses with circumferential mucosal\r\nthickening, with fat stranding in the retro maxillary fat pads\r\nconcerning for invasive fungal vs bacterial sinusitis yet\r\nfiberoptic exam (___) not consistent with fungal sinusitis.\r\nAspergillius negative, but Beta glucan positive initially in\r\nsetting of neutropenia, Zosyn, ___, and continued sinus\r\nsymptoms. ENT saw pt multiple times and noted no c/f invasive\r\nfungal sinusitis, MRI w&w/out contrast of sinus/skull base ___\r\nwith heterogeneity in left maxilla/middle ear c/f infectious\r\nprocess and pt was placed on AmBisome (___). MRI results \r\n___ were reassuring, and switch to Cresemba from AmBisome was \r\nmade. Due to likely drug rash vs viral exanthem described below, \r\nZosyn was switched for meropenem ___. Reimaging of sinuses \r\n___,\r\nlooked stable from prior and ID recommended ongoing therapy with\r\nIsavunconazole 372mg PO QD and Levofloxacin 750mg PO QD for\r\nprolonged duration of ___ weeks pending reassessment in\r\noutpatient ___ clinic.\r\n- ABx: Cresemba ___- ) + levofloxacin ___- ) ___ meropenem\r\n(___), Zosyn (___) AmBisome (___),\r\nposaconazole (___), meropenem (___) + vancomycin (___)\r\n+ levofloxacin (___) + flagyl (___) + augmentin\r\n(-___)\r\n\r\n# Nonocclusive right femoral vein DVT\r\nOn ___ patient complained of unilateral right lower leg\r\nswelling, right lower extremity noninvasives showed new right\r\nfemoral vein nonocclusive clot compared to ___ bilateral lower\r\nextremity ultrasound. Patient has an extensive history of DVTs, \r\nincluding a DVT developing while on 10mg of Xarelto. Patient was \r\ngiven platelets and started on Lovenox half dose every 12 hours \r\nonce plts > 30. She was discharged on Xarelto 20mg daily, which \r\nwas her home medication before admission.\r\n\r\n# Morbilliform rash\r\nOn ___ presented with suspected drug rash with Zosyn being\r\nlikely aggravating factor. ___ spreading to arms and chest.\r\nWithout involvement of mucosa or face. Decreasing in intensity\r\nand itching daily until ___ when patient woke up with xerotic,\r\nblanching, non-raised rash over chest, legs, arms, and back.\r\nDermatology consulted and recommended steroids topically, \r\nsuggested drug rash. Meropenem switched to levofloxacin. \r\nResolution of rash within the following days. Steroid creams \r\nprescribed per dermatology service.\r\n\r\nCHRONIC/RESOLVED:\r\n=================\r\n# Asthma\r\n- inhalers: duonebs q6hrs PRN + albuterol q4hrs PRN\r\n\r\n# OSA\r\n- continue home CPAP\r\n\r\n# Depression\r\n- continue home venlafaxine 25\r\n\r\n# Neuropathic pain\r\n- continue home gabapentin 400 bid\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n4. FoLIC Acid 1.6 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron (ondansetron HCl) 4 mg oral Q8H:PRN nausea \r\n9. Restasis 0.05 % ophthalmic (eye) BID \r\n10. Rivaroxaban 20 mg PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n14. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n15. Benzonatate 100 mg PO TID:PRN Cough  \r\n16. Ketoconazole Shampoo 1 Appl TP TWO TO THREE TIMES WEEKLY AS \r\nNEEDED FOR DRY SCALP \r\n\r\n \r\nDischarge Medications:\r\n1.  Betamethasone Dipro 0.05% Cream 1 Appl TP BID  \r\n2.  Cetirizine 20 mg PO BID \r\nRX *cetirizine 10 mg 2 tablet(s) by mouth once a day Disp #*60 \r\nTablet Refills:*0 \r\n3.  Isavuconazonium Sulfate 372 mg PO DAILY \r\nRX *isavuconazonium sulfate [Cresemba] 186 mg 2 capsule(s) by \r\nmouth once a day Disp #*60 Capsule Refills:*0 \r\n4.  LevoFLOXacin 750 mg PO Q24H \r\nRX *levofloxacin 750 mg 1 tablet(s) by mouth once a day Disp \r\n#*42 Tablet Refills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim 400 mg-80 mg 1 tablet(s) by \r\nmouth once a day Disp #*30 Tablet Refills:*0 \r\n6.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n7.  FoLIC Acid 2 mg PO DAILY \r\nRX *folic acid 1 mg 2 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Acyclovir 400 mg PO Q12H  \r\n9.  Gabapentin 400 mg PO BID  \r\n10.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nneb every six (6) hours Disp #*30 Ampule Refills:*0 \r\n11.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n14.  Restasis 0.05 % ophthalmic (eye) BID  \r\n15.  Rivaroxaban 20 mg PO DAILY  \r\n16.  Venlafaxine 25 mg PO DAILY  \r\n17.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS\r\n==================\r\n- Acute myelogenous leukemia\r\n\r\nSECONDARY DIAGNOSIS\r\n===================\r\n- Bacterial vs Fungal sinusitis\r\n- Right femoral vein thrombosis \r\n- Obstructive sleep apnea\r\n- Asthma\r\n- Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,  \r\n\r\nWHY WERE YOU ADMITTED TO THE HOSPITAL?  \r\n- You had a sinus infection and were found to have acute \r\nmyelogenous leukemia\r\n\r\nWHAT WAS DONE WHILE YOU WERE IN THE HOSPITAL?  \r\n- You were given chemotherapy to treat your cancer\r\n- You received antibiotics and antifungals to treat your sinus \r\ninfection\r\n \r\nWHAT DO YOU NEED TO DO WHEN YOU LEAVE THE HOSPITAL?  \r\n- Take all of your medications as prescribed (listed below)  \r\n- Follow up with your doctors as listed below  \r\n\r\nPlease see below for more information on your hospitalization. \r\nIt was a pleasure taking part in your care here at ___. We \r\nwish you all the best,\r\n\r\n- Your ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-28:4",
      "text": "Cardiomediastinal \nsilhouette is \nwithin normal limits. There are no focal consolidations, \npleural effusion. Right basilar atelectasis. Tortuous aorta. There are no pneumothoraces. OTHER RESULTS\n=============\n___ 05:40AM BLOOD G6PD-NORMAL\n___ 12:00AM BLOOD  WBC-0.7*# Lymph-98* Abs ___ CD3%-88 \nAbs CD3-604 CD4%-32 Abs CD4-217* CD8%-55 Abs CD8-380 \nCD4/CD8-0.57*\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\n___ 12:00AM BLOOD IgG-593* IgA-24* IgM-136\n___ 02:30PM BLOOD CMV VL-NOT DETECT DISCHARGE LABS\n==============\n___ 06:05AM BLOOD WBC-4.4 RBC-2.59* Hgb-8.1* Hct-26.1* \nMCV-101* MCH-31.3 MCHC-31.0* RDW-18.4* RDWSD-65.2* Plt ___\n___ 06:05AM BLOOD Neuts-58 Bands-1 Lymphs-13* Monos-20* \nEos-0* ___ Myelos-7* NRBC-0.5* AbsNeut-2.60 AbsLymp-0.57* \nAbsMono-0.88* AbsEos-0.00* AbsBaso-0.04\n___ 06:05AM BLOOD Anisocy-1+* Poiklo-1+* Macrocy-1+* \nMicrocy-1+* Polychr-1+* Ovalocy-1+* RBC Mor-SLIDE REVI\n___ 06:05AM BLOOD ___ PTT-31.8 ___\n___ 06:05AM BLOOD ___ 06:05AM BLOOD Glucose-83 UreaN-15 Creat-1.1 Na-143 \nK-4.7 Cl-105 HCO3-23 AnGap-15\n___ 06:05AM BLOOD ALT-14 AST-16 LD(LDH)-209 AlkPhos-153* \nTotBili-<0.2\n___ 06:05AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.2 Mg-2.0",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-28",
        "chart_time": "105580",
        "section": "General",
        "position": 4,
        "tokenCount": 305,
        "note_metadata": {
          "note_id": "18887130-DS-28",
          "subject_id": 18887130,
          "hadm_id": 26914904,
          "note_type": "DS",
          "note_seq": 28,
          "charttime": 105580,
          "storetime": 105580.72777777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy (___)\r\nPICC placed (___)\r\n\r\nattach\r\n \r\nPertinent Results:\r\nINITIAL LABS\r\n============\r\n___ 02:30PM BLOOD WBC-9.8 RBC-3.43* Hgb-11.1* Hct-33.6* \r\nMCV-98 MCH-32.4* MCHC-33.0 RDW-17.4* RDWSD-62.2* Plt Ct-24*\r\n___ 02:30PM BLOOD Neuts-6* ___ Monos-1* Eos-0* Baso-0 \r\nAtyps-2* Blasts-65* AbsNeut-0.59* AbsLymp-2.74 AbsMono-0.10* \r\nAbsEos-0.00* AbsBaso-0.00*\r\n___ 02:30PM BLOOD ___ PTT-27.7 ___\r\n___ 05:40AM BLOOD ___ D-Dimer-<215\r\n___ 05:40AM BLOOD Ret Aut-0.8 Abs Ret-0.02\r\n___ 02:30PM BLOOD UreaN-14 Creat-1.0 Na-136 K-3.8 Cl-100 \r\nHCO3-20* AnGap-16\r\n___ 02:30PM BLOOD ALT-8 AST-17 LD(LDH)-1709* AlkPhos-93 \r\nTotBili-0.2\r\n___ 04:26PM BLOOD Lipase-11\r\n___ 04:26PM BLOOD CK-MB-2 cTropnT-<0.01\r\n___ 02:30PM BLOOD Albumin-3.6 Calcium-9.0 Mg-1.9 \r\nUricAcd-3.6\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 05:40AM BLOOD CRP-153.6*\r\n___ 02:30PM BLOOD IgG-621* \r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n___ 04:18PM BLOOD Lactate-1.3 K-4.2\r\n\r\nMICROBIOLOGY\r\n============\r\nAll blood cultures drawn during admission where negative ___, \r\n___\r\nMRSA screen negative\r\nRapid resp viral screen and culture negative (___)\r\nUrine culture ___ negative\r\n\r\nIMAGING\r\n=======\r\n___ CT SINUS:\r\n1. New bilateral maxillary sinus disease with hyperdense \r\nmaterial suggesting fungal colonization or inspissated \r\nsecretions.  However, there is also fat stranding in the retro \r\nmaxillary fat pads, which raises the possibility of invasive \r\nfungal sinusitis in the context of immune suppression. \r\n2. Please see separate head CT for intracranial findings.\r\n\r\n___ CT HEAD:\r\nNo acute intracranial abnormalities are identified or change \r\nseen compared with ___.\r\n\r\n___ TTE:\r\nThe left atrium is mildly dilated. The right atrium is mildly \r\nenlarged. There is no evidence for an atrial septal defect by \r\n2D/color Doppler. The estimated right atrial pressure is ___ \r\nmmHg. There is mild symmetric left ventricular hypertrophy with \r\na normal cavity size. There is normal regional and global left \r\nventricular systolic function. Quantitative biplane left \r\nventricular ejection fraction is 56 % (normal 54-73%). Left \r\nventricular cardiac index is normal (>2.5 L/min/m2). There is no \r\nresting left ventricular outflow tract gradient. No ventricular \r\nseptal defect is seen. Normal right ventricular cavity size with \r\nnormal free wall motion. Tricuspid annular plane systolic \r\nexcursion (TAPSE) is normal. The aortic sinus diameter is normal \r\nfor gender with a mildly dilated ascending aorta. The aortic \r\narch diameter is normal with a normal descending aorta diameter. \r\nThe aortic valve leaflets (3) appear structurally normal. There \r\nis no aortic valve stenosis. There is no aortic regurgitation. \r\nThe mitral valve leaflets are mildly thickened with no mitral \r\nvalve prolapse. There is mild [1+] mitral regurgitation. The \r\npulmonic valve leaflets are normal. The tricuspid valve leaflets \r\nappear structurally normal. There is mild [1+] tricuspid \r\nregurgitation. The estimated pulmonary artery systolic pressure \r\nis normal. There is a trivial pericardial effusion. IMPRESSION: \r\nMild symmetric left ventricular hypertrophy with normal cavity \r\nsize and regional/ global biventricular systolic function. Mild \r\nmitral regurgitation. Mildly dilated ascending aorta.\r\n\r\n___ CT chest without contrast\r\nNo evidence of recurrent lymphoma in the chest. Stable small \r\nmediastinal lymph nodes. Complete resolution of the parenchymal \r\nopacity in the right lower lobe which most likely represented \r\npneumonia.  Patchy opacity in the left lung base is new and \r\ncould represent atelectasis. \r\n\r\n___ MRI skull base with and without contrast\r\n1. Limited study as described.\r\n2. Interval progression of opacification and enhancement within \r\nthe left mastoid air cells and middle ear cavity concerning for \r\notomastoiditis, with no definite evidence of intracranial \r\nextension.\r\n3. Adjacent heterogeneity of the petrous temporal bone versus \r\nartifact.  If not artifactual, differential considerations \r\ninclude infectious and inflammatory etiologies.\r\n4. Bilateral maxillary sinus disease is redemonstrated, \r\naerosolized secretions are better demonstrated on the CT from ___, with no definite extension into the adjacent soft \r\ntissue.\r\n5. Question mild enhancement of the left retro maxillary fat \r\nversus volume averaging of adjacent vessels.  Recommend \r\nattention on follow-up imaging.\r\n6. Nonspecific new clivus and medial temporal bone marrow \r\nheterogeneity compared to ___ prior exam with question \r\nenhancement.  While finding may represent marrow expansion, \r\ninfectious, inflammatory, and neoplastic etiologies are not \r\nexcluded on the basis of this examination.  Recommend attention \r\non follow-up imaging.\r\n\r\n___ MR head with and without contrast\r\n1. Unchanged persistent extensive fluid opacification and \r\nenhancement within the left middle ear cavity and mastoid air \r\ncells concerning for \r\notomastoiditis.  No evidence of intracranial extension. \r\n2. Persistent heterogenous signal intensity within the adjacent \r\npetrous \r\ntemporal bone.  Inflammatory, infectious or neoplastic \r\netiologies are not \r\nexcluded. \r\n3. Mild mucosal thickening in the frontal sinus, multiple \r\nethmoid air cells and predominately in the bilateral maxillary \r\nsinuses, improved since the prior study.  Enhancement in the \r\nretromaxillary fat is difficult to evaluate due to lack of T1 \r\npost-contrast fat saturated images. \r\n4. Persistent heterogenous signal intensity within the clivus, \r\nnonspecific. Differential considerations include marrow \r\nexpansion, infectious, inflammatory or neoplastic etiologies. \r\n5. No evidence of hemorrhage, infarction, mass or other abnormal \r\nenhancement. \r\n\r\n___ bilateral lower extremity venous ultrasound\r\n1. Nonocclusive deep vein thrombosis in the mid right femoral \r\nvein, new \r\ncompared to ___. \r\n2. Deep vein thrombosis in the right popliteal vein.  Of note, \r\nthe right \r\npopliteal vein contained a DVT on ultrasound ___, \r\nhowever the \r\nchronicity of the DVT seen today is uncertain. \r\n3. No evidence of DVT in the left lower extremity. \r\n\r\n___ MR head with and without contrast\r\n1. Ongoing opacification and enhancement of the left mastoid air \r\ncells and \r\nmiddle ear cavity, concerning for otomastoiditis. \r\n2. There is no evidence of intracranial extension. \r\n3. No acute intracranial abnormality is identified. \r\n4. Persistent, unchanged heterogenous signal intensity within \r\nthe clivus. This is nonspecific in nature. \r\n\r\n___ chest x-ray AP\r\nChronic deformity of the right rib cage.  Cardiomediastinal \r\nsilhouette is \r\nwithin normal limits.  There are no focal consolidations, \r\npleural effusion. Right basilar atelectasis.  Tortuous aorta.  \r\nThere are no pneumothoraces. \r\n\r\nOTHER RESULTS\r\n=============\r\n___ 05:40AM BLOOD G6PD-NORMAL\r\n___ 12:00AM BLOOD  WBC-0.7*# Lymph-98* Abs ___ CD3%-88 \r\nAbs CD3-604 CD4%-32 Abs CD4-217* CD8%-55 Abs CD8-380 \r\nCD4/CD8-0.57*\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 12:00AM BLOOD IgG-593* IgA-24* IgM-136\r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 06:05AM BLOOD WBC-4.4 RBC-2.59* Hgb-8.1* Hct-26.1* \r\nMCV-101* MCH-31.3 MCHC-31.0* RDW-18.4* RDWSD-65.2* Plt ___\r\n___ 06:05AM BLOOD Neuts-58 Bands-1 Lymphs-13* Monos-20* \r\nEos-0* ___ Myelos-7* NRBC-0.5* AbsNeut-2.60 AbsLymp-0.57* \r\nAbsMono-0.88* AbsEos-0.00* AbsBaso-0.04\r\n___ 06:05AM BLOOD Anisocy-1+* Poiklo-1+* Macrocy-1+* \r\nMicrocy-1+* Polychr-1+* Ovalocy-1+* RBC Mor-SLIDE REVI\r\n___ 06:05AM BLOOD ___ PTT-31.8 ___\r\n___ 06:05AM BLOOD ___ 06:05AM BLOOD Glucose-83 UreaN-15 Creat-1.1 Na-143 \r\nK-4.7 Cl-105 HCO3-23 AnGap-15\r\n___ 06:05AM BLOOD ALT-14 AST-16 LD(LDH)-209 AlkPhos-153* \r\nTotBili-<0.2\r\n___ 06:05AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.2 Mg-2.0\r\n \r\nBrief Hospital Course:\r\nTRANSITIONAL ISSUES\r\n===================\r\n[ ] f/u with ID regarding fungal/bacterial sinusitis and therapy \r\nduration\r\n[ ] f/u with ENT regarding chronic sinusitis\r\n\r\nSUMMARY STATMENT\r\n================\r\nMs. ___ is a ___ year old woman with history of follicular \r\nlymphoma to DLBCL treated with multiple rounds chemotherapy \r\ncomplicated by therapy-related myelodysplasia treated with \r\nalloHSCT with Flu/Bu/ATG RIC (D0 ___ complicated by \r\ngraft-versus-host disease, multiple deep vein thromboses with \r\nIVC filter in place, cavernous sinus aneurysm with coiling \r\n(___) complicated by residual cranial nerve palsy who \r\npresented to ___ with sinusitis and new acute myelogenous \r\nleukemia. Her course was notable for initiation of \r\nvenetoclax/decitabine.\r\n\r\nACTIVE ISSUES\r\n=============\r\n# AML\r\n# t-MDS ___ alloHSCT\r\nt-MDS transformed to AML with up to 83% blasts (___) in elderly\r\nhost with significant co-morbidities. G6PD normal. Patient\r\ncytogenetics show multiple complex mutations from bone marrow\r\nbiopsy. Chimerism from cytogenetics shows a greater percentage\r\nof XX chromosomal cells versus donor XY (~88 vs ~12%). \r\nDecitabine/venetoclax induction (___) every four \r\nweeks. Doses of chemotherapy were adjusted as the patient was \r\nput on different antifungals. BMB ___ with reassuring \r\nfindings, no signs of disease. Neupogen given briefly with \r\nappropriate marrow response. Patient kept on acyclovir and \r\natovaquone for prophylaxis. Bactrim chose over atovaquone at \r\ndischarge.\r\n\r\n# Maxillary sinusitis\r\nPresented with one week of progressive sinus pressure, headache,\r\nfacial warmth. CT SINUS (___) demonstrated pan-opacification of\r\nbilateral maxillary sinuses with circumferential mucosal\r\nthickening, with fat stranding in the retro maxillary fat pads\r\nconcerning for invasive fungal vs bacterial sinusitis yet\r\nfiberoptic exam (___) not consistent with fungal sinusitis.\r\nAspergillius negative, but Beta glucan positive initially in\r\nsetting of neutropenia, Zosyn, ___, and continued sinus\r\nsymptoms. ENT saw pt multiple times and noted no c/f invasive\r\nfungal sinusitis, MRI w&w/out contrast of sinus/skull base ___\r\nwith heterogeneity in left maxilla/middle ear c/f infectious\r\nprocess and pt was placed on AmBisome (___). MRI results \r\n___ were reassuring, and switch to Cresemba from AmBisome was \r\nmade. Due to likely drug rash vs viral exanthem described below, \r\nZosyn was switched for meropenem ___. Reimaging of sinuses \r\n___,\r\nlooked stable from prior and ID recommended ongoing therapy with\r\nIsavunconazole 372mg PO QD and Levofloxacin 750mg PO QD for\r\nprolonged duration of ___ weeks pending reassessment in\r\noutpatient ___ clinic.\r\n- ABx: Cresemba ___- ) + levofloxacin ___- ) ___ meropenem\r\n(___), Zosyn (___) AmBisome (___),\r\nposaconazole (___), meropenem (___) + vancomycin (___)\r\n+ levofloxacin (___) + flagyl (___) + augmentin\r\n(-___)\r\n\r\n# Nonocclusive right femoral vein DVT\r\nOn ___ patient complained of unilateral right lower leg\r\nswelling, right lower extremity noninvasives showed new right\r\nfemoral vein nonocclusive clot compared to ___ bilateral lower\r\nextremity ultrasound. Patient has an extensive history of DVTs, \r\nincluding a DVT developing while on 10mg of Xarelto. Patient was \r\ngiven platelets and started on Lovenox half dose every 12 hours \r\nonce plts > 30. She was discharged on Xarelto 20mg daily, which \r\nwas her home medication before admission.\r\n\r\n# Morbilliform rash\r\nOn ___ presented with suspected drug rash with Zosyn being\r\nlikely aggravating factor. ___ spreading to arms and chest.\r\nWithout involvement of mucosa or face. Decreasing in intensity\r\nand itching daily until ___ when patient woke up with xerotic,\r\nblanching, non-raised rash over chest, legs, arms, and back.\r\nDermatology consulted and recommended steroids topically, \r\nsuggested drug rash. Meropenem switched to levofloxacin. \r\nResolution of rash within the following days. Steroid creams \r\nprescribed per dermatology service.\r\n\r\nCHRONIC/RESOLVED:\r\n=================\r\n# Asthma\r\n- inhalers: duonebs q6hrs PRN + albuterol q4hrs PRN\r\n\r\n# OSA\r\n- continue home CPAP\r\n\r\n# Depression\r\n- continue home venlafaxine 25\r\n\r\n# Neuropathic pain\r\n- continue home gabapentin 400 bid\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n4. FoLIC Acid 1.6 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron (ondansetron HCl) 4 mg oral Q8H:PRN nausea \r\n9. Restasis 0.05 % ophthalmic (eye) BID \r\n10. Rivaroxaban 20 mg PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n14. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n15. Benzonatate 100 mg PO TID:PRN Cough  \r\n16. Ketoconazole Shampoo 1 Appl TP TWO TO THREE TIMES WEEKLY AS \r\nNEEDED FOR DRY SCALP \r\n\r\n \r\nDischarge Medications:\r\n1.  Betamethasone Dipro 0.05% Cream 1 Appl TP BID  \r\n2.  Cetirizine 20 mg PO BID \r\nRX *cetirizine 10 mg 2 tablet(s) by mouth once a day Disp #*60 \r\nTablet Refills:*0 \r\n3.  Isavuconazonium Sulfate 372 mg PO DAILY \r\nRX *isavuconazonium sulfate [Cresemba] 186 mg 2 capsule(s) by \r\nmouth once a day Disp #*60 Capsule Refills:*0 \r\n4.  LevoFLOXacin 750 mg PO Q24H \r\nRX *levofloxacin 750 mg 1 tablet(s) by mouth once a day Disp \r\n#*42 Tablet Refills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim 400 mg-80 mg 1 tablet(s) by \r\nmouth once a day Disp #*30 Tablet Refills:*0 \r\n6.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n7.  FoLIC Acid 2 mg PO DAILY \r\nRX *folic acid 1 mg 2 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Acyclovir 400 mg PO Q12H  \r\n9.  Gabapentin 400 mg PO BID  \r\n10.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nneb every six (6) hours Disp #*30 Ampule Refills:*0 \r\n11.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n14.  Restasis 0.05 % ophthalmic (eye) BID  \r\n15.  Rivaroxaban 20 mg PO DAILY  \r\n16.  Venlafaxine 25 mg PO DAILY  \r\n17.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS\r\n==================\r\n- Acute myelogenous leukemia\r\n\r\nSECONDARY DIAGNOSIS\r\n===================\r\n- Bacterial vs Fungal sinusitis\r\n- Right femoral vein thrombosis \r\n- Obstructive sleep apnea\r\n- Asthma\r\n- Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,  \r\n\r\nWHY WERE YOU ADMITTED TO THE HOSPITAL?  \r\n- You had a sinus infection and were found to have acute \r\nmyelogenous leukemia\r\n\r\nWHAT WAS DONE WHILE YOU WERE IN THE HOSPITAL?  \r\n- You were given chemotherapy to treat your cancer\r\n- You received antibiotics and antifungals to treat your sinus \r\ninfection\r\n \r\nWHAT DO YOU NEED TO DO WHEN YOU LEAVE THE HOSPITAL?  \r\n- Take all of your medications as prescribed (listed below)  \r\n- Follow up with your doctors as listed below  \r\n\r\nPlease see below for more information on your hospitalization. \r\nIt was a pleasure taking part in your care here at ___. We \r\nwish you all the best,\r\n\r\n- Your ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-28:5",
      "text": "Brief Hospital Course:\nTRANSITIONAL ISSUES\n===================\n[ ] f/u with ID regarding fungal/bacterial sinusitis and therapy \nduration\n[ ] f/u with ENT regarding chronic sinusitis SUMMARY STATMENT\n================\nMs. ___ is a ___ year old woman with history of follicular \nlymphoma to DLBCL treated with multiple rounds chemotherapy \ncomplicated by therapy-related myelodysplasia treated with \nalloHSCT with Flu/Bu/ATG RIC (D0 ___ complicated by \ngraft-versus-host disease, multiple deep vein thromboses with \nIVC filter in place, cavernous sinus aneurysm with coiling \n(___) complicated by residual cranial nerve palsy who \npresented to ___ with sinusitis and new acute myelogenous \nleukemia. Her course was notable for initiation of \nvenetoclax/decitabine. ACTIVE ISSUES\n=============\n# AML\n# t-MDS ___ alloHSCT\nt-MDS transformed to AML with up to 83% blasts (___) in elderly\nhost with significant co-morbidities. G6PD normal. Patient\ncytogenetics show multiple complex mutations from bone marrow\nbiopsy. Chimerism from cytogenetics shows a greater percentage\nof XX chromosomal cells versus donor XY (~88 vs ~12%). Decitabine/venetoclax induction (___) every four \nweeks. Doses of chemotherapy were adjusted as the patient was \nput on different antifungals. BMB ___ with reassuring \nfindings, no signs of disease. Neupogen given briefly with \nappropriate marrow response. Patient kept on acyclovir and \natovaquone for prophylaxis. Bactrim chose over atovaquone at \ndischarge. # Maxillary sinusitis\nPresented with one week of progressive sinus pressure, headache,\nfacial warmth. CT SINUS (___) demonstrated pan-opacification of\nbilateral maxillary sinuses with circumferential mucosal\nthickening, with fat stranding in the retro maxillary fat pads\nconcerning for invasive fungal vs bacterial sinusitis yet\nfiberoptic exam (___) not consistent with fungal sinusitis. Aspergillius negative, but Beta glucan positive initially in\nsetting of neutropenia, Zosyn, ___, and continued sinus\nsymptoms. ENT saw pt multiple times and noted no c/f invasive\nfungal sinusitis, MRI w&w/out contrast of sinus/skull base ___\nwith heterogeneity in left maxilla/middle ear c/f infectious\nprocess and pt was placed on AmBisome (___). MRI results \n___ were reassuring, and switch to Cresemba from AmBisome was \nmade. Due to likely drug rash vs viral exanthem described below, \nZosyn was switched for meropenem ___. Reimaging of sinuses \n___,\nlooked stable from prior and ID recommended ongoing therapy with\nIsavunconazole 372mg PO QD and Levofloxacin 750mg PO QD for\nprolonged duration of ___ weeks pending reassessment in\noutpatient ___ clinic.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-28",
        "chart_time": "105580",
        "section": "General",
        "position": 5,
        "tokenCount": 658,
        "note_metadata": {
          "note_id": "18887130-DS-28",
          "subject_id": 18887130,
          "hadm_id": 26914904,
          "note_type": "DS",
          "note_seq": 28,
          "charttime": 105580,
          "storetime": 105580.72777777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy (___)\r\nPICC placed (___)\r\n\r\nattach\r\n \r\nPertinent Results:\r\nINITIAL LABS\r\n============\r\n___ 02:30PM BLOOD WBC-9.8 RBC-3.43* Hgb-11.1* Hct-33.6* \r\nMCV-98 MCH-32.4* MCHC-33.0 RDW-17.4* RDWSD-62.2* Plt Ct-24*\r\n___ 02:30PM BLOOD Neuts-6* ___ Monos-1* Eos-0* Baso-0 \r\nAtyps-2* Blasts-65* AbsNeut-0.59* AbsLymp-2.74 AbsMono-0.10* \r\nAbsEos-0.00* AbsBaso-0.00*\r\n___ 02:30PM BLOOD ___ PTT-27.7 ___\r\n___ 05:40AM BLOOD ___ D-Dimer-<215\r\n___ 05:40AM BLOOD Ret Aut-0.8 Abs Ret-0.02\r\n___ 02:30PM BLOOD UreaN-14 Creat-1.0 Na-136 K-3.8 Cl-100 \r\nHCO3-20* AnGap-16\r\n___ 02:30PM BLOOD ALT-8 AST-17 LD(LDH)-1709* AlkPhos-93 \r\nTotBili-0.2\r\n___ 04:26PM BLOOD Lipase-11\r\n___ 04:26PM BLOOD CK-MB-2 cTropnT-<0.01\r\n___ 02:30PM BLOOD Albumin-3.6 Calcium-9.0 Mg-1.9 \r\nUricAcd-3.6\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 05:40AM BLOOD CRP-153.6*\r\n___ 02:30PM BLOOD IgG-621* \r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n___ 04:18PM BLOOD Lactate-1.3 K-4.2\r\n\r\nMICROBIOLOGY\r\n============\r\nAll blood cultures drawn during admission where negative ___, \r\n___\r\nMRSA screen negative\r\nRapid resp viral screen and culture negative (___)\r\nUrine culture ___ negative\r\n\r\nIMAGING\r\n=======\r\n___ CT SINUS:\r\n1. New bilateral maxillary sinus disease with hyperdense \r\nmaterial suggesting fungal colonization or inspissated \r\nsecretions.  However, there is also fat stranding in the retro \r\nmaxillary fat pads, which raises the possibility of invasive \r\nfungal sinusitis in the context of immune suppression. \r\n2. Please see separate head CT for intracranial findings.\r\n\r\n___ CT HEAD:\r\nNo acute intracranial abnormalities are identified or change \r\nseen compared with ___.\r\n\r\n___ TTE:\r\nThe left atrium is mildly dilated. The right atrium is mildly \r\nenlarged. There is no evidence for an atrial septal defect by \r\n2D/color Doppler. The estimated right atrial pressure is ___ \r\nmmHg. There is mild symmetric left ventricular hypertrophy with \r\na normal cavity size. There is normal regional and global left \r\nventricular systolic function. Quantitative biplane left \r\nventricular ejection fraction is 56 % (normal 54-73%). Left \r\nventricular cardiac index is normal (>2.5 L/min/m2). There is no \r\nresting left ventricular outflow tract gradient. No ventricular \r\nseptal defect is seen. Normal right ventricular cavity size with \r\nnormal free wall motion. Tricuspid annular plane systolic \r\nexcursion (TAPSE) is normal. The aortic sinus diameter is normal \r\nfor gender with a mildly dilated ascending aorta. The aortic \r\narch diameter is normal with a normal descending aorta diameter. \r\nThe aortic valve leaflets (3) appear structurally normal. There \r\nis no aortic valve stenosis. There is no aortic regurgitation. \r\nThe mitral valve leaflets are mildly thickened with no mitral \r\nvalve prolapse. There is mild [1+] mitral regurgitation. The \r\npulmonic valve leaflets are normal. The tricuspid valve leaflets \r\nappear structurally normal. There is mild [1+] tricuspid \r\nregurgitation. The estimated pulmonary artery systolic pressure \r\nis normal. There is a trivial pericardial effusion. IMPRESSION: \r\nMild symmetric left ventricular hypertrophy with normal cavity \r\nsize and regional/ global biventricular systolic function. Mild \r\nmitral regurgitation. Mildly dilated ascending aorta.\r\n\r\n___ CT chest without contrast\r\nNo evidence of recurrent lymphoma in the chest. Stable small \r\nmediastinal lymph nodes. Complete resolution of the parenchymal \r\nopacity in the right lower lobe which most likely represented \r\npneumonia.  Patchy opacity in the left lung base is new and \r\ncould represent atelectasis. \r\n\r\n___ MRI skull base with and without contrast\r\n1. Limited study as described.\r\n2. Interval progression of opacification and enhancement within \r\nthe left mastoid air cells and middle ear cavity concerning for \r\notomastoiditis, with no definite evidence of intracranial \r\nextension.\r\n3. Adjacent heterogeneity of the petrous temporal bone versus \r\nartifact.  If not artifactual, differential considerations \r\ninclude infectious and inflammatory etiologies.\r\n4. Bilateral maxillary sinus disease is redemonstrated, \r\naerosolized secretions are better demonstrated on the CT from ___, with no definite extension into the adjacent soft \r\ntissue.\r\n5. Question mild enhancement of the left retro maxillary fat \r\nversus volume averaging of adjacent vessels.  Recommend \r\nattention on follow-up imaging.\r\n6. Nonspecific new clivus and medial temporal bone marrow \r\nheterogeneity compared to ___ prior exam with question \r\nenhancement.  While finding may represent marrow expansion, \r\ninfectious, inflammatory, and neoplastic etiologies are not \r\nexcluded on the basis of this examination.  Recommend attention \r\non follow-up imaging.\r\n\r\n___ MR head with and without contrast\r\n1. Unchanged persistent extensive fluid opacification and \r\nenhancement within the left middle ear cavity and mastoid air \r\ncells concerning for \r\notomastoiditis.  No evidence of intracranial extension. \r\n2. Persistent heterogenous signal intensity within the adjacent \r\npetrous \r\ntemporal bone.  Inflammatory, infectious or neoplastic \r\netiologies are not \r\nexcluded. \r\n3. Mild mucosal thickening in the frontal sinus, multiple \r\nethmoid air cells and predominately in the bilateral maxillary \r\nsinuses, improved since the prior study.  Enhancement in the \r\nretromaxillary fat is difficult to evaluate due to lack of T1 \r\npost-contrast fat saturated images. \r\n4. Persistent heterogenous signal intensity within the clivus, \r\nnonspecific. Differential considerations include marrow \r\nexpansion, infectious, inflammatory or neoplastic etiologies. \r\n5. No evidence of hemorrhage, infarction, mass or other abnormal \r\nenhancement. \r\n\r\n___ bilateral lower extremity venous ultrasound\r\n1. Nonocclusive deep vein thrombosis in the mid right femoral \r\nvein, new \r\ncompared to ___. \r\n2. Deep vein thrombosis in the right popliteal vein.  Of note, \r\nthe right \r\npopliteal vein contained a DVT on ultrasound ___, \r\nhowever the \r\nchronicity of the DVT seen today is uncertain. \r\n3. No evidence of DVT in the left lower extremity. \r\n\r\n___ MR head with and without contrast\r\n1. Ongoing opacification and enhancement of the left mastoid air \r\ncells and \r\nmiddle ear cavity, concerning for otomastoiditis. \r\n2. There is no evidence of intracranial extension. \r\n3. No acute intracranial abnormality is identified. \r\n4. Persistent, unchanged heterogenous signal intensity within \r\nthe clivus. This is nonspecific in nature. \r\n\r\n___ chest x-ray AP\r\nChronic deformity of the right rib cage.  Cardiomediastinal \r\nsilhouette is \r\nwithin normal limits.  There are no focal consolidations, \r\npleural effusion. Right basilar atelectasis.  Tortuous aorta.  \r\nThere are no pneumothoraces. \r\n\r\nOTHER RESULTS\r\n=============\r\n___ 05:40AM BLOOD G6PD-NORMAL\r\n___ 12:00AM BLOOD  WBC-0.7*# Lymph-98* Abs ___ CD3%-88 \r\nAbs CD3-604 CD4%-32 Abs CD4-217* CD8%-55 Abs CD8-380 \r\nCD4/CD8-0.57*\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 12:00AM BLOOD IgG-593* IgA-24* IgM-136\r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 06:05AM BLOOD WBC-4.4 RBC-2.59* Hgb-8.1* Hct-26.1* \r\nMCV-101* MCH-31.3 MCHC-31.0* RDW-18.4* RDWSD-65.2* Plt ___\r\n___ 06:05AM BLOOD Neuts-58 Bands-1 Lymphs-13* Monos-20* \r\nEos-0* ___ Myelos-7* NRBC-0.5* AbsNeut-2.60 AbsLymp-0.57* \r\nAbsMono-0.88* AbsEos-0.00* AbsBaso-0.04\r\n___ 06:05AM BLOOD Anisocy-1+* Poiklo-1+* Macrocy-1+* \r\nMicrocy-1+* Polychr-1+* Ovalocy-1+* RBC Mor-SLIDE REVI\r\n___ 06:05AM BLOOD ___ PTT-31.8 ___\r\n___ 06:05AM BLOOD ___ 06:05AM BLOOD Glucose-83 UreaN-15 Creat-1.1 Na-143 \r\nK-4.7 Cl-105 HCO3-23 AnGap-15\r\n___ 06:05AM BLOOD ALT-14 AST-16 LD(LDH)-209 AlkPhos-153* \r\nTotBili-<0.2\r\n___ 06:05AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.2 Mg-2.0\r\n \r\nBrief Hospital Course:\r\nTRANSITIONAL ISSUES\r\n===================\r\n[ ] f/u with ID regarding fungal/bacterial sinusitis and therapy \r\nduration\r\n[ ] f/u with ENT regarding chronic sinusitis\r\n\r\nSUMMARY STATMENT\r\n================\r\nMs. ___ is a ___ year old woman with history of follicular \r\nlymphoma to DLBCL treated with multiple rounds chemotherapy \r\ncomplicated by therapy-related myelodysplasia treated with \r\nalloHSCT with Flu/Bu/ATG RIC (D0 ___ complicated by \r\ngraft-versus-host disease, multiple deep vein thromboses with \r\nIVC filter in place, cavernous sinus aneurysm with coiling \r\n(___) complicated by residual cranial nerve palsy who \r\npresented to ___ with sinusitis and new acute myelogenous \r\nleukemia. Her course was notable for initiation of \r\nvenetoclax/decitabine.\r\n\r\nACTIVE ISSUES\r\n=============\r\n# AML\r\n# t-MDS ___ alloHSCT\r\nt-MDS transformed to AML with up to 83% blasts (___) in elderly\r\nhost with significant co-morbidities. G6PD normal. Patient\r\ncytogenetics show multiple complex mutations from bone marrow\r\nbiopsy. Chimerism from cytogenetics shows a greater percentage\r\nof XX chromosomal cells versus donor XY (~88 vs ~12%). \r\nDecitabine/venetoclax induction (___) every four \r\nweeks. Doses of chemotherapy were adjusted as the patient was \r\nput on different antifungals. BMB ___ with reassuring \r\nfindings, no signs of disease. Neupogen given briefly with \r\nappropriate marrow response. Patient kept on acyclovir and \r\natovaquone for prophylaxis. Bactrim chose over atovaquone at \r\ndischarge.\r\n\r\n# Maxillary sinusitis\r\nPresented with one week of progressive sinus pressure, headache,\r\nfacial warmth. CT SINUS (___) demonstrated pan-opacification of\r\nbilateral maxillary sinuses with circumferential mucosal\r\nthickening, with fat stranding in the retro maxillary fat pads\r\nconcerning for invasive fungal vs bacterial sinusitis yet\r\nfiberoptic exam (___) not consistent with fungal sinusitis.\r\nAspergillius negative, but Beta glucan positive initially in\r\nsetting of neutropenia, Zosyn, ___, and continued sinus\r\nsymptoms. ENT saw pt multiple times and noted no c/f invasive\r\nfungal sinusitis, MRI w&w/out contrast of sinus/skull base ___\r\nwith heterogeneity in left maxilla/middle ear c/f infectious\r\nprocess and pt was placed on AmBisome (___). MRI results \r\n___ were reassuring, and switch to Cresemba from AmBisome was \r\nmade. Due to likely drug rash vs viral exanthem described below, \r\nZosyn was switched for meropenem ___. Reimaging of sinuses \r\n___,\r\nlooked stable from prior and ID recommended ongoing therapy with\r\nIsavunconazole 372mg PO QD and Levofloxacin 750mg PO QD for\r\nprolonged duration of ___ weeks pending reassessment in\r\noutpatient ___ clinic.\r\n- ABx: Cresemba ___- ) + levofloxacin ___- ) ___ meropenem\r\n(___), Zosyn (___) AmBisome (___),\r\nposaconazole (___), meropenem (___) + vancomycin (___)\r\n+ levofloxacin (___) + flagyl (___) + augmentin\r\n(-___)\r\n\r\n# Nonocclusive right femoral vein DVT\r\nOn ___ patient complained of unilateral right lower leg\r\nswelling, right lower extremity noninvasives showed new right\r\nfemoral vein nonocclusive clot compared to ___ bilateral lower\r\nextremity ultrasound. Patient has an extensive history of DVTs, \r\nincluding a DVT developing while on 10mg of Xarelto. Patient was \r\ngiven platelets and started on Lovenox half dose every 12 hours \r\nonce plts > 30. She was discharged on Xarelto 20mg daily, which \r\nwas her home medication before admission.\r\n\r\n# Morbilliform rash\r\nOn ___ presented with suspected drug rash with Zosyn being\r\nlikely aggravating factor. ___ spreading to arms and chest.\r\nWithout involvement of mucosa or face. Decreasing in intensity\r\nand itching daily until ___ when patient woke up with xerotic,\r\nblanching, non-raised rash over chest, legs, arms, and back.\r\nDermatology consulted and recommended steroids topically, \r\nsuggested drug rash. Meropenem switched to levofloxacin. \r\nResolution of rash within the following days. Steroid creams \r\nprescribed per dermatology service.\r\n\r\nCHRONIC/RESOLVED:\r\n=================\r\n# Asthma\r\n- inhalers: duonebs q6hrs PRN + albuterol q4hrs PRN\r\n\r\n# OSA\r\n- continue home CPAP\r\n\r\n# Depression\r\n- continue home venlafaxine 25\r\n\r\n# Neuropathic pain\r\n- continue home gabapentin 400 bid\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n4. FoLIC Acid 1.6 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron (ondansetron HCl) 4 mg oral Q8H:PRN nausea \r\n9. Restasis 0.05 % ophthalmic (eye) BID \r\n10. Rivaroxaban 20 mg PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n14. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n15. Benzonatate 100 mg PO TID:PRN Cough  \r\n16. Ketoconazole Shampoo 1 Appl TP TWO TO THREE TIMES WEEKLY AS \r\nNEEDED FOR DRY SCALP \r\n\r\n \r\nDischarge Medications:\r\n1.  Betamethasone Dipro 0.05% Cream 1 Appl TP BID  \r\n2.  Cetirizine 20 mg PO BID \r\nRX *cetirizine 10 mg 2 tablet(s) by mouth once a day Disp #*60 \r\nTablet Refills:*0 \r\n3.  Isavuconazonium Sulfate 372 mg PO DAILY \r\nRX *isavuconazonium sulfate [Cresemba] 186 mg 2 capsule(s) by \r\nmouth once a day Disp #*60 Capsule Refills:*0 \r\n4.  LevoFLOXacin 750 mg PO Q24H \r\nRX *levofloxacin 750 mg 1 tablet(s) by mouth once a day Disp \r\n#*42 Tablet Refills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim 400 mg-80 mg 1 tablet(s) by \r\nmouth once a day Disp #*30 Tablet Refills:*0 \r\n6.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n7.  FoLIC Acid 2 mg PO DAILY \r\nRX *folic acid 1 mg 2 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Acyclovir 400 mg PO Q12H  \r\n9.  Gabapentin 400 mg PO BID  \r\n10.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nneb every six (6) hours Disp #*30 Ampule Refills:*0 \r\n11.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n14.  Restasis 0.05 % ophthalmic (eye) BID  \r\n15.  Rivaroxaban 20 mg PO DAILY  \r\n16.  Venlafaxine 25 mg PO DAILY  \r\n17.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS\r\n==================\r\n- Acute myelogenous leukemia\r\n\r\nSECONDARY DIAGNOSIS\r\n===================\r\n- Bacterial vs Fungal sinusitis\r\n- Right femoral vein thrombosis \r\n- Obstructive sleep apnea\r\n- Asthma\r\n- Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,  \r\n\r\nWHY WERE YOU ADMITTED TO THE HOSPITAL?  \r\n- You had a sinus infection and were found to have acute \r\nmyelogenous leukemia\r\n\r\nWHAT WAS DONE WHILE YOU WERE IN THE HOSPITAL?  \r\n- You were given chemotherapy to treat your cancer\r\n- You received antibiotics and antifungals to treat your sinus \r\ninfection\r\n \r\nWHAT DO YOU NEED TO DO WHEN YOU LEAVE THE HOSPITAL?  \r\n- Take all of your medications as prescribed (listed below)  \r\n- Follow up with your doctors as listed below  \r\n\r\nPlease see below for more information on your hospitalization. \r\nIt was a pleasure taking part in your care here at ___. We \r\nwish you all the best,\r\n\r\n- Your ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-28:6",
      "text": "MRI results \n___ were reassuring, and switch to Cresemba from AmBisome was \nmade. Due to likely drug rash vs viral exanthem described below, \nZosyn was switched for meropenem ___. Reimaging of sinuses \n___,\nlooked stable from prior and ID recommended ongoing therapy with\nIsavunconazole 372mg PO QD and Levofloxacin 750mg PO QD for\nprolonged duration of ___ weeks pending reassessment in\noutpatient ___ clinic. - ABx: Cresemba ___- ) + levofloxacin ___- ) ___ meropenem\n(___), Zosyn (___) AmBisome (___),\nposaconazole (___), meropenem (___) + vancomycin (___)\n+ levofloxacin (___) + flagyl (___) + augmentin\n(-___) # Nonocclusive right femoral vein DVT\nOn ___ patient complained of unilateral right lower leg\nswelling, right lower extremity noninvasives showed new right\nfemoral vein nonocclusive clot compared to ___ bilateral lower\nextremity ultrasound. Patient has an extensive history of DVTs, \nincluding a DVT developing while on 10mg of Xarelto. Patient was \ngiven platelets and started on Lovenox half dose every 12 hours \nonce plts > 30. She was discharged on Xarelto 20mg daily, which \nwas her home medication before admission. # Morbilliform rash\nOn ___ presented with suspected drug rash with Zosyn being\nlikely aggravating factor. ___ spreading to arms and chest. Without involvement of mucosa or face. Decreasing in intensity\nand itching daily until ___ when patient woke up with xerotic,\nblanching, non-raised rash over chest, legs, arms, and back. Dermatology consulted and recommended steroids topically, \nsuggested drug rash. Meropenem switched to levofloxacin. Resolution of rash within the following days. Steroid creams \nprescribed per dermatology service. CHRONIC/RESOLVED:\n=================\n# Asthma\n- inhalers: duonebs q6hrs PRN + albuterol q4hrs PRN # OSA\n- continue home CPAP # Depression\n- continue home venlafaxine 25 # Neuropathic pain\n- continue home gabapentin 400 bid Medications on Admission:\nThe Preadmission Medication list is accurate and complete. 1. Acyclovir 400 mg PO Q12H \n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \ncough/wheezing \n4. FoLIC Acid 1.6 mg PO DAILY \n5. Gabapentin 400 mg PO BID \n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \nwheezing/shortness of breath \n7. Omeprazole 20 mg PO DAILY \n8. Ondansetron (ondansetron HCl) 4 mg oral Q8H:PRN nausea \n9. Restasis 0.05 % ophthalmic (eye) BID \n10. Rivaroxaban 20 mg PO DAILY \n11. Venlafaxine 25 mg PO DAILY \n12. Vitamin D ___ UNIT PO DAILY \n13. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \n14. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \n___ unit-mg-unit oral BID \n15. Benzonatate 100 mg PO TID:PRN Cough  \n16. Ketoconazole Shampoo 1 Appl TP TWO TO THREE TIMES WEEKLY AS \nNEEDED FOR DRY SCALP",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-28",
        "chart_time": "105580",
        "section": "General",
        "position": 6,
        "tokenCount": 696,
        "note_metadata": {
          "note_id": "18887130-DS-28",
          "subject_id": 18887130,
          "hadm_id": 26914904,
          "note_type": "DS",
          "note_seq": 28,
          "charttime": 105580,
          "storetime": 105580.72777777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy (___)\r\nPICC placed (___)\r\n\r\nattach\r\n \r\nPertinent Results:\r\nINITIAL LABS\r\n============\r\n___ 02:30PM BLOOD WBC-9.8 RBC-3.43* Hgb-11.1* Hct-33.6* \r\nMCV-98 MCH-32.4* MCHC-33.0 RDW-17.4* RDWSD-62.2* Plt Ct-24*\r\n___ 02:30PM BLOOD Neuts-6* ___ Monos-1* Eos-0* Baso-0 \r\nAtyps-2* Blasts-65* AbsNeut-0.59* AbsLymp-2.74 AbsMono-0.10* \r\nAbsEos-0.00* AbsBaso-0.00*\r\n___ 02:30PM BLOOD ___ PTT-27.7 ___\r\n___ 05:40AM BLOOD ___ D-Dimer-<215\r\n___ 05:40AM BLOOD Ret Aut-0.8 Abs Ret-0.02\r\n___ 02:30PM BLOOD UreaN-14 Creat-1.0 Na-136 K-3.8 Cl-100 \r\nHCO3-20* AnGap-16\r\n___ 02:30PM BLOOD ALT-8 AST-17 LD(LDH)-1709* AlkPhos-93 \r\nTotBili-0.2\r\n___ 04:26PM BLOOD Lipase-11\r\n___ 04:26PM BLOOD CK-MB-2 cTropnT-<0.01\r\n___ 02:30PM BLOOD Albumin-3.6 Calcium-9.0 Mg-1.9 \r\nUricAcd-3.6\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 05:40AM BLOOD CRP-153.6*\r\n___ 02:30PM BLOOD IgG-621* \r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n___ 04:18PM BLOOD Lactate-1.3 K-4.2\r\n\r\nMICROBIOLOGY\r\n============\r\nAll blood cultures drawn during admission where negative ___, \r\n___\r\nMRSA screen negative\r\nRapid resp viral screen and culture negative (___)\r\nUrine culture ___ negative\r\n\r\nIMAGING\r\n=======\r\n___ CT SINUS:\r\n1. New bilateral maxillary sinus disease with hyperdense \r\nmaterial suggesting fungal colonization or inspissated \r\nsecretions.  However, there is also fat stranding in the retro \r\nmaxillary fat pads, which raises the possibility of invasive \r\nfungal sinusitis in the context of immune suppression. \r\n2. Please see separate head CT for intracranial findings.\r\n\r\n___ CT HEAD:\r\nNo acute intracranial abnormalities are identified or change \r\nseen compared with ___.\r\n\r\n___ TTE:\r\nThe left atrium is mildly dilated. The right atrium is mildly \r\nenlarged. There is no evidence for an atrial septal defect by \r\n2D/color Doppler. The estimated right atrial pressure is ___ \r\nmmHg. There is mild symmetric left ventricular hypertrophy with \r\na normal cavity size. There is normal regional and global left \r\nventricular systolic function. Quantitative biplane left \r\nventricular ejection fraction is 56 % (normal 54-73%). Left \r\nventricular cardiac index is normal (>2.5 L/min/m2). There is no \r\nresting left ventricular outflow tract gradient. No ventricular \r\nseptal defect is seen. Normal right ventricular cavity size with \r\nnormal free wall motion. Tricuspid annular plane systolic \r\nexcursion (TAPSE) is normal. The aortic sinus diameter is normal \r\nfor gender with a mildly dilated ascending aorta. The aortic \r\narch diameter is normal with a normal descending aorta diameter. \r\nThe aortic valve leaflets (3) appear structurally normal. There \r\nis no aortic valve stenosis. There is no aortic regurgitation. \r\nThe mitral valve leaflets are mildly thickened with no mitral \r\nvalve prolapse. There is mild [1+] mitral regurgitation. The \r\npulmonic valve leaflets are normal. The tricuspid valve leaflets \r\nappear structurally normal. There is mild [1+] tricuspid \r\nregurgitation. The estimated pulmonary artery systolic pressure \r\nis normal. There is a trivial pericardial effusion. IMPRESSION: \r\nMild symmetric left ventricular hypertrophy with normal cavity \r\nsize and regional/ global biventricular systolic function. Mild \r\nmitral regurgitation. Mildly dilated ascending aorta.\r\n\r\n___ CT chest without contrast\r\nNo evidence of recurrent lymphoma in the chest. Stable small \r\nmediastinal lymph nodes. Complete resolution of the parenchymal \r\nopacity in the right lower lobe which most likely represented \r\npneumonia.  Patchy opacity in the left lung base is new and \r\ncould represent atelectasis. \r\n\r\n___ MRI skull base with and without contrast\r\n1. Limited study as described.\r\n2. Interval progression of opacification and enhancement within \r\nthe left mastoid air cells and middle ear cavity concerning for \r\notomastoiditis, with no definite evidence of intracranial \r\nextension.\r\n3. Adjacent heterogeneity of the petrous temporal bone versus \r\nartifact.  If not artifactual, differential considerations \r\ninclude infectious and inflammatory etiologies.\r\n4. Bilateral maxillary sinus disease is redemonstrated, \r\naerosolized secretions are better demonstrated on the CT from ___, with no definite extension into the adjacent soft \r\ntissue.\r\n5. Question mild enhancement of the left retro maxillary fat \r\nversus volume averaging of adjacent vessels.  Recommend \r\nattention on follow-up imaging.\r\n6. Nonspecific new clivus and medial temporal bone marrow \r\nheterogeneity compared to ___ prior exam with question \r\nenhancement.  While finding may represent marrow expansion, \r\ninfectious, inflammatory, and neoplastic etiologies are not \r\nexcluded on the basis of this examination.  Recommend attention \r\non follow-up imaging.\r\n\r\n___ MR head with and without contrast\r\n1. Unchanged persistent extensive fluid opacification and \r\nenhancement within the left middle ear cavity and mastoid air \r\ncells concerning for \r\notomastoiditis.  No evidence of intracranial extension. \r\n2. Persistent heterogenous signal intensity within the adjacent \r\npetrous \r\ntemporal bone.  Inflammatory, infectious or neoplastic \r\netiologies are not \r\nexcluded. \r\n3. Mild mucosal thickening in the frontal sinus, multiple \r\nethmoid air cells and predominately in the bilateral maxillary \r\nsinuses, improved since the prior study.  Enhancement in the \r\nretromaxillary fat is difficult to evaluate due to lack of T1 \r\npost-contrast fat saturated images. \r\n4. Persistent heterogenous signal intensity within the clivus, \r\nnonspecific. Differential considerations include marrow \r\nexpansion, infectious, inflammatory or neoplastic etiologies. \r\n5. No evidence of hemorrhage, infarction, mass or other abnormal \r\nenhancement. \r\n\r\n___ bilateral lower extremity venous ultrasound\r\n1. Nonocclusive deep vein thrombosis in the mid right femoral \r\nvein, new \r\ncompared to ___. \r\n2. Deep vein thrombosis in the right popliteal vein.  Of note, \r\nthe right \r\npopliteal vein contained a DVT on ultrasound ___, \r\nhowever the \r\nchronicity of the DVT seen today is uncertain. \r\n3. No evidence of DVT in the left lower extremity. \r\n\r\n___ MR head with and without contrast\r\n1. Ongoing opacification and enhancement of the left mastoid air \r\ncells and \r\nmiddle ear cavity, concerning for otomastoiditis. \r\n2. There is no evidence of intracranial extension. \r\n3. No acute intracranial abnormality is identified. \r\n4. Persistent, unchanged heterogenous signal intensity within \r\nthe clivus. This is nonspecific in nature. \r\n\r\n___ chest x-ray AP\r\nChronic deformity of the right rib cage.  Cardiomediastinal \r\nsilhouette is \r\nwithin normal limits.  There are no focal consolidations, \r\npleural effusion. Right basilar atelectasis.  Tortuous aorta.  \r\nThere are no pneumothoraces. \r\n\r\nOTHER RESULTS\r\n=============\r\n___ 05:40AM BLOOD G6PD-NORMAL\r\n___ 12:00AM BLOOD  WBC-0.7*# Lymph-98* Abs ___ CD3%-88 \r\nAbs CD3-604 CD4%-32 Abs CD4-217* CD8%-55 Abs CD8-380 \r\nCD4/CD8-0.57*\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 12:00AM BLOOD IgG-593* IgA-24* IgM-136\r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 06:05AM BLOOD WBC-4.4 RBC-2.59* Hgb-8.1* Hct-26.1* \r\nMCV-101* MCH-31.3 MCHC-31.0* RDW-18.4* RDWSD-65.2* Plt ___\r\n___ 06:05AM BLOOD Neuts-58 Bands-1 Lymphs-13* Monos-20* \r\nEos-0* ___ Myelos-7* NRBC-0.5* AbsNeut-2.60 AbsLymp-0.57* \r\nAbsMono-0.88* AbsEos-0.00* AbsBaso-0.04\r\n___ 06:05AM BLOOD Anisocy-1+* Poiklo-1+* Macrocy-1+* \r\nMicrocy-1+* Polychr-1+* Ovalocy-1+* RBC Mor-SLIDE REVI\r\n___ 06:05AM BLOOD ___ PTT-31.8 ___\r\n___ 06:05AM BLOOD ___ 06:05AM BLOOD Glucose-83 UreaN-15 Creat-1.1 Na-143 \r\nK-4.7 Cl-105 HCO3-23 AnGap-15\r\n___ 06:05AM BLOOD ALT-14 AST-16 LD(LDH)-209 AlkPhos-153* \r\nTotBili-<0.2\r\n___ 06:05AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.2 Mg-2.0\r\n \r\nBrief Hospital Course:\r\nTRANSITIONAL ISSUES\r\n===================\r\n[ ] f/u with ID regarding fungal/bacterial sinusitis and therapy \r\nduration\r\n[ ] f/u with ENT regarding chronic sinusitis\r\n\r\nSUMMARY STATMENT\r\n================\r\nMs. ___ is a ___ year old woman with history of follicular \r\nlymphoma to DLBCL treated with multiple rounds chemotherapy \r\ncomplicated by therapy-related myelodysplasia treated with \r\nalloHSCT with Flu/Bu/ATG RIC (D0 ___ complicated by \r\ngraft-versus-host disease, multiple deep vein thromboses with \r\nIVC filter in place, cavernous sinus aneurysm with coiling \r\n(___) complicated by residual cranial nerve palsy who \r\npresented to ___ with sinusitis and new acute myelogenous \r\nleukemia. Her course was notable for initiation of \r\nvenetoclax/decitabine.\r\n\r\nACTIVE ISSUES\r\n=============\r\n# AML\r\n# t-MDS ___ alloHSCT\r\nt-MDS transformed to AML with up to 83% blasts (___) in elderly\r\nhost with significant co-morbidities. G6PD normal. Patient\r\ncytogenetics show multiple complex mutations from bone marrow\r\nbiopsy. Chimerism from cytogenetics shows a greater percentage\r\nof XX chromosomal cells versus donor XY (~88 vs ~12%). \r\nDecitabine/venetoclax induction (___) every four \r\nweeks. Doses of chemotherapy were adjusted as the patient was \r\nput on different antifungals. BMB ___ with reassuring \r\nfindings, no signs of disease. Neupogen given briefly with \r\nappropriate marrow response. Patient kept on acyclovir and \r\natovaquone for prophylaxis. Bactrim chose over atovaquone at \r\ndischarge.\r\n\r\n# Maxillary sinusitis\r\nPresented with one week of progressive sinus pressure, headache,\r\nfacial warmth. CT SINUS (___) demonstrated pan-opacification of\r\nbilateral maxillary sinuses with circumferential mucosal\r\nthickening, with fat stranding in the retro maxillary fat pads\r\nconcerning for invasive fungal vs bacterial sinusitis yet\r\nfiberoptic exam (___) not consistent with fungal sinusitis.\r\nAspergillius negative, but Beta glucan positive initially in\r\nsetting of neutropenia, Zosyn, ___, and continued sinus\r\nsymptoms. ENT saw pt multiple times and noted no c/f invasive\r\nfungal sinusitis, MRI w&w/out contrast of sinus/skull base ___\r\nwith heterogeneity in left maxilla/middle ear c/f infectious\r\nprocess and pt was placed on AmBisome (___). MRI results \r\n___ were reassuring, and switch to Cresemba from AmBisome was \r\nmade. Due to likely drug rash vs viral exanthem described below, \r\nZosyn was switched for meropenem ___. Reimaging of sinuses \r\n___,\r\nlooked stable from prior and ID recommended ongoing therapy with\r\nIsavunconazole 372mg PO QD and Levofloxacin 750mg PO QD for\r\nprolonged duration of ___ weeks pending reassessment in\r\noutpatient ___ clinic.\r\n- ABx: Cresemba ___- ) + levofloxacin ___- ) ___ meropenem\r\n(___), Zosyn (___) AmBisome (___),\r\nposaconazole (___), meropenem (___) + vancomycin (___)\r\n+ levofloxacin (___) + flagyl (___) + augmentin\r\n(-___)\r\n\r\n# Nonocclusive right femoral vein DVT\r\nOn ___ patient complained of unilateral right lower leg\r\nswelling, right lower extremity noninvasives showed new right\r\nfemoral vein nonocclusive clot compared to ___ bilateral lower\r\nextremity ultrasound. Patient has an extensive history of DVTs, \r\nincluding a DVT developing while on 10mg of Xarelto. Patient was \r\ngiven platelets and started on Lovenox half dose every 12 hours \r\nonce plts > 30. She was discharged on Xarelto 20mg daily, which \r\nwas her home medication before admission.\r\n\r\n# Morbilliform rash\r\nOn ___ presented with suspected drug rash with Zosyn being\r\nlikely aggravating factor. ___ spreading to arms and chest.\r\nWithout involvement of mucosa or face. Decreasing in intensity\r\nand itching daily until ___ when patient woke up with xerotic,\r\nblanching, non-raised rash over chest, legs, arms, and back.\r\nDermatology consulted and recommended steroids topically, \r\nsuggested drug rash. Meropenem switched to levofloxacin. \r\nResolution of rash within the following days. Steroid creams \r\nprescribed per dermatology service.\r\n\r\nCHRONIC/RESOLVED:\r\n=================\r\n# Asthma\r\n- inhalers: duonebs q6hrs PRN + albuterol q4hrs PRN\r\n\r\n# OSA\r\n- continue home CPAP\r\n\r\n# Depression\r\n- continue home venlafaxine 25\r\n\r\n# Neuropathic pain\r\n- continue home gabapentin 400 bid\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n4. FoLIC Acid 1.6 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron (ondansetron HCl) 4 mg oral Q8H:PRN nausea \r\n9. Restasis 0.05 % ophthalmic (eye) BID \r\n10. Rivaroxaban 20 mg PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n14. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n15. Benzonatate 100 mg PO TID:PRN Cough  \r\n16. Ketoconazole Shampoo 1 Appl TP TWO TO THREE TIMES WEEKLY AS \r\nNEEDED FOR DRY SCALP \r\n\r\n \r\nDischarge Medications:\r\n1.  Betamethasone Dipro 0.05% Cream 1 Appl TP BID  \r\n2.  Cetirizine 20 mg PO BID \r\nRX *cetirizine 10 mg 2 tablet(s) by mouth once a day Disp #*60 \r\nTablet Refills:*0 \r\n3.  Isavuconazonium Sulfate 372 mg PO DAILY \r\nRX *isavuconazonium sulfate [Cresemba] 186 mg 2 capsule(s) by \r\nmouth once a day Disp #*60 Capsule Refills:*0 \r\n4.  LevoFLOXacin 750 mg PO Q24H \r\nRX *levofloxacin 750 mg 1 tablet(s) by mouth once a day Disp \r\n#*42 Tablet Refills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim 400 mg-80 mg 1 tablet(s) by \r\nmouth once a day Disp #*30 Tablet Refills:*0 \r\n6.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n7.  FoLIC Acid 2 mg PO DAILY \r\nRX *folic acid 1 mg 2 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Acyclovir 400 mg PO Q12H  \r\n9.  Gabapentin 400 mg PO BID  \r\n10.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nneb every six (6) hours Disp #*30 Ampule Refills:*0 \r\n11.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n14.  Restasis 0.05 % ophthalmic (eye) BID  \r\n15.  Rivaroxaban 20 mg PO DAILY  \r\n16.  Venlafaxine 25 mg PO DAILY  \r\n17.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS\r\n==================\r\n- Acute myelogenous leukemia\r\n\r\nSECONDARY DIAGNOSIS\r\n===================\r\n- Bacterial vs Fungal sinusitis\r\n- Right femoral vein thrombosis \r\n- Obstructive sleep apnea\r\n- Asthma\r\n- Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,  \r\n\r\nWHY WERE YOU ADMITTED TO THE HOSPITAL?  \r\n- You had a sinus infection and were found to have acute \r\nmyelogenous leukemia\r\n\r\nWHAT WAS DONE WHILE YOU WERE IN THE HOSPITAL?  \r\n- You were given chemotherapy to treat your cancer\r\n- You received antibiotics and antifungals to treat your sinus \r\ninfection\r\n \r\nWHAT DO YOU NEED TO DO WHEN YOU LEAVE THE HOSPITAL?  \r\n- Take all of your medications as prescribed (listed below)  \r\n- Follow up with your doctors as listed below  \r\n\r\nPlease see below for more information on your hospitalization. \r\nIt was a pleasure taking part in your care here at ___. We \r\nwish you all the best,\r\n\r\n- Your ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-28:7",
      "text": "Discharge Medications:\n1. Betamethasone Dipro 0.05% Cream 1 Appl TP BID  \n2. Cetirizine 20 mg PO BID \nRX *cetirizine 10 mg 2 tablet(s) by mouth once a day Disp #*60 \nTablet Refills:*0 \n3. Isavuconazonium Sulfate 372 mg PO DAILY \nRX *isavuconazonium sulfate [Cresemba] 186 mg 2 capsule(s) by \nmouth once a day Disp #*60 Capsule Refills:*0 \n4. LevoFLOXacin 750 mg PO Q24H \nRX *levofloxacin 750 mg 1 tablet(s) by mouth once a day Disp \n#*42 Tablet Refills:*0 \n5. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \nRX *sulfamethoxazole-trimethoprim 400 mg-80 mg 1 tablet(s) by \nmouth once a day Disp #*30 Tablet Refills:*0 \n6. Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \n7. FoLIC Acid 2 mg PO DAILY \nRX *folic acid 1 mg 2 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n8. Acyclovir 400 mg PO Q12H  \n9. Gabapentin 400 mg PO BID  \n10. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \nwheezing/shortness of breath \nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \nneb every six (6) hours Disp #*30 Ampule Refills:*0 \n11. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \n \n12. Omeprazole 20 mg PO DAILY  \n13. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \n___ unit-mg-unit oral BID  \n14. Restasis 0.05 % ophthalmic (eye) BID  \n15. Rivaroxaban 20 mg PO DAILY  \n16. Venlafaxine 25 mg PO DAILY  \n17. Vitamin D ___ UNIT PO DAILY Discharge Disposition:\nHome Discharge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\n- Acute myelogenous leukemia SECONDARY DIAGNOSIS\n===================\n- Bacterial vs Fungal sinusitis\n- Right femoral vein thrombosis \n- Obstructive sleep apnea\n- Asthma\n- Depression Discharge Condition:\nMental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-28",
        "chart_time": "105580",
        "section": "General",
        "position": 7,
        "tokenCount": 442,
        "note_metadata": {
          "note_id": "18887130-DS-28",
          "subject_id": 18887130,
          "hadm_id": 26914904,
          "note_type": "DS",
          "note_seq": 28,
          "charttime": 105580,
          "storetime": 105580.72777777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy (___)\r\nPICC placed (___)\r\n\r\nattach\r\n \r\nPertinent Results:\r\nINITIAL LABS\r\n============\r\n___ 02:30PM BLOOD WBC-9.8 RBC-3.43* Hgb-11.1* Hct-33.6* \r\nMCV-98 MCH-32.4* MCHC-33.0 RDW-17.4* RDWSD-62.2* Plt Ct-24*\r\n___ 02:30PM BLOOD Neuts-6* ___ Monos-1* Eos-0* Baso-0 \r\nAtyps-2* Blasts-65* AbsNeut-0.59* AbsLymp-2.74 AbsMono-0.10* \r\nAbsEos-0.00* AbsBaso-0.00*\r\n___ 02:30PM BLOOD ___ PTT-27.7 ___\r\n___ 05:40AM BLOOD ___ D-Dimer-<215\r\n___ 05:40AM BLOOD Ret Aut-0.8 Abs Ret-0.02\r\n___ 02:30PM BLOOD UreaN-14 Creat-1.0 Na-136 K-3.8 Cl-100 \r\nHCO3-20* AnGap-16\r\n___ 02:30PM BLOOD ALT-8 AST-17 LD(LDH)-1709* AlkPhos-93 \r\nTotBili-0.2\r\n___ 04:26PM BLOOD Lipase-11\r\n___ 04:26PM BLOOD CK-MB-2 cTropnT-<0.01\r\n___ 02:30PM BLOOD Albumin-3.6 Calcium-9.0 Mg-1.9 \r\nUricAcd-3.6\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 05:40AM BLOOD CRP-153.6*\r\n___ 02:30PM BLOOD IgG-621* \r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n___ 04:18PM BLOOD Lactate-1.3 K-4.2\r\n\r\nMICROBIOLOGY\r\n============\r\nAll blood cultures drawn during admission where negative ___, \r\n___\r\nMRSA screen negative\r\nRapid resp viral screen and culture negative (___)\r\nUrine culture ___ negative\r\n\r\nIMAGING\r\n=======\r\n___ CT SINUS:\r\n1. New bilateral maxillary sinus disease with hyperdense \r\nmaterial suggesting fungal colonization or inspissated \r\nsecretions.  However, there is also fat stranding in the retro \r\nmaxillary fat pads, which raises the possibility of invasive \r\nfungal sinusitis in the context of immune suppression. \r\n2. Please see separate head CT for intracranial findings.\r\n\r\n___ CT HEAD:\r\nNo acute intracranial abnormalities are identified or change \r\nseen compared with ___.\r\n\r\n___ TTE:\r\nThe left atrium is mildly dilated. The right atrium is mildly \r\nenlarged. There is no evidence for an atrial septal defect by \r\n2D/color Doppler. The estimated right atrial pressure is ___ \r\nmmHg. There is mild symmetric left ventricular hypertrophy with \r\na normal cavity size. There is normal regional and global left \r\nventricular systolic function. Quantitative biplane left \r\nventricular ejection fraction is 56 % (normal 54-73%). Left \r\nventricular cardiac index is normal (>2.5 L/min/m2). There is no \r\nresting left ventricular outflow tract gradient. No ventricular \r\nseptal defect is seen. Normal right ventricular cavity size with \r\nnormal free wall motion. Tricuspid annular plane systolic \r\nexcursion (TAPSE) is normal. The aortic sinus diameter is normal \r\nfor gender with a mildly dilated ascending aorta. The aortic \r\narch diameter is normal with a normal descending aorta diameter. \r\nThe aortic valve leaflets (3) appear structurally normal. There \r\nis no aortic valve stenosis. There is no aortic regurgitation. \r\nThe mitral valve leaflets are mildly thickened with no mitral \r\nvalve prolapse. There is mild [1+] mitral regurgitation. The \r\npulmonic valve leaflets are normal. The tricuspid valve leaflets \r\nappear structurally normal. There is mild [1+] tricuspid \r\nregurgitation. The estimated pulmonary artery systolic pressure \r\nis normal. There is a trivial pericardial effusion. IMPRESSION: \r\nMild symmetric left ventricular hypertrophy with normal cavity \r\nsize and regional/ global biventricular systolic function. Mild \r\nmitral regurgitation. Mildly dilated ascending aorta.\r\n\r\n___ CT chest without contrast\r\nNo evidence of recurrent lymphoma in the chest. Stable small \r\nmediastinal lymph nodes. Complete resolution of the parenchymal \r\nopacity in the right lower lobe which most likely represented \r\npneumonia.  Patchy opacity in the left lung base is new and \r\ncould represent atelectasis. \r\n\r\n___ MRI skull base with and without contrast\r\n1. Limited study as described.\r\n2. Interval progression of opacification and enhancement within \r\nthe left mastoid air cells and middle ear cavity concerning for \r\notomastoiditis, with no definite evidence of intracranial \r\nextension.\r\n3. Adjacent heterogeneity of the petrous temporal bone versus \r\nartifact.  If not artifactual, differential considerations \r\ninclude infectious and inflammatory etiologies.\r\n4. Bilateral maxillary sinus disease is redemonstrated, \r\naerosolized secretions are better demonstrated on the CT from ___, with no definite extension into the adjacent soft \r\ntissue.\r\n5. Question mild enhancement of the left retro maxillary fat \r\nversus volume averaging of adjacent vessels.  Recommend \r\nattention on follow-up imaging.\r\n6. Nonspecific new clivus and medial temporal bone marrow \r\nheterogeneity compared to ___ prior exam with question \r\nenhancement.  While finding may represent marrow expansion, \r\ninfectious, inflammatory, and neoplastic etiologies are not \r\nexcluded on the basis of this examination.  Recommend attention \r\non follow-up imaging.\r\n\r\n___ MR head with and without contrast\r\n1. Unchanged persistent extensive fluid opacification and \r\nenhancement within the left middle ear cavity and mastoid air \r\ncells concerning for \r\notomastoiditis.  No evidence of intracranial extension. \r\n2. Persistent heterogenous signal intensity within the adjacent \r\npetrous \r\ntemporal bone.  Inflammatory, infectious or neoplastic \r\netiologies are not \r\nexcluded. \r\n3. Mild mucosal thickening in the frontal sinus, multiple \r\nethmoid air cells and predominately in the bilateral maxillary \r\nsinuses, improved since the prior study.  Enhancement in the \r\nretromaxillary fat is difficult to evaluate due to lack of T1 \r\npost-contrast fat saturated images. \r\n4. Persistent heterogenous signal intensity within the clivus, \r\nnonspecific. Differential considerations include marrow \r\nexpansion, infectious, inflammatory or neoplastic etiologies. \r\n5. No evidence of hemorrhage, infarction, mass or other abnormal \r\nenhancement. \r\n\r\n___ bilateral lower extremity venous ultrasound\r\n1. Nonocclusive deep vein thrombosis in the mid right femoral \r\nvein, new \r\ncompared to ___. \r\n2. Deep vein thrombosis in the right popliteal vein.  Of note, \r\nthe right \r\npopliteal vein contained a DVT on ultrasound ___, \r\nhowever the \r\nchronicity of the DVT seen today is uncertain. \r\n3. No evidence of DVT in the left lower extremity. \r\n\r\n___ MR head with and without contrast\r\n1. Ongoing opacification and enhancement of the left mastoid air \r\ncells and \r\nmiddle ear cavity, concerning for otomastoiditis. \r\n2. There is no evidence of intracranial extension. \r\n3. No acute intracranial abnormality is identified. \r\n4. Persistent, unchanged heterogenous signal intensity within \r\nthe clivus. This is nonspecific in nature. \r\n\r\n___ chest x-ray AP\r\nChronic deformity of the right rib cage.  Cardiomediastinal \r\nsilhouette is \r\nwithin normal limits.  There are no focal consolidations, \r\npleural effusion. Right basilar atelectasis.  Tortuous aorta.  \r\nThere are no pneumothoraces. \r\n\r\nOTHER RESULTS\r\n=============\r\n___ 05:40AM BLOOD G6PD-NORMAL\r\n___ 12:00AM BLOOD  WBC-0.7*# Lymph-98* Abs ___ CD3%-88 \r\nAbs CD3-604 CD4%-32 Abs CD4-217* CD8%-55 Abs CD8-380 \r\nCD4/CD8-0.57*\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 12:00AM BLOOD IgG-593* IgA-24* IgM-136\r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 06:05AM BLOOD WBC-4.4 RBC-2.59* Hgb-8.1* Hct-26.1* \r\nMCV-101* MCH-31.3 MCHC-31.0* RDW-18.4* RDWSD-65.2* Plt ___\r\n___ 06:05AM BLOOD Neuts-58 Bands-1 Lymphs-13* Monos-20* \r\nEos-0* ___ Myelos-7* NRBC-0.5* AbsNeut-2.60 AbsLymp-0.57* \r\nAbsMono-0.88* AbsEos-0.00* AbsBaso-0.04\r\n___ 06:05AM BLOOD Anisocy-1+* Poiklo-1+* Macrocy-1+* \r\nMicrocy-1+* Polychr-1+* Ovalocy-1+* RBC Mor-SLIDE REVI\r\n___ 06:05AM BLOOD ___ PTT-31.8 ___\r\n___ 06:05AM BLOOD ___ 06:05AM BLOOD Glucose-83 UreaN-15 Creat-1.1 Na-143 \r\nK-4.7 Cl-105 HCO3-23 AnGap-15\r\n___ 06:05AM BLOOD ALT-14 AST-16 LD(LDH)-209 AlkPhos-153* \r\nTotBili-<0.2\r\n___ 06:05AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.2 Mg-2.0\r\n \r\nBrief Hospital Course:\r\nTRANSITIONAL ISSUES\r\n===================\r\n[ ] f/u with ID regarding fungal/bacterial sinusitis and therapy \r\nduration\r\n[ ] f/u with ENT regarding chronic sinusitis\r\n\r\nSUMMARY STATMENT\r\n================\r\nMs. ___ is a ___ year old woman with history of follicular \r\nlymphoma to DLBCL treated with multiple rounds chemotherapy \r\ncomplicated by therapy-related myelodysplasia treated with \r\nalloHSCT with Flu/Bu/ATG RIC (D0 ___ complicated by \r\ngraft-versus-host disease, multiple deep vein thromboses with \r\nIVC filter in place, cavernous sinus aneurysm with coiling \r\n(___) complicated by residual cranial nerve palsy who \r\npresented to ___ with sinusitis and new acute myelogenous \r\nleukemia. Her course was notable for initiation of \r\nvenetoclax/decitabine.\r\n\r\nACTIVE ISSUES\r\n=============\r\n# AML\r\n# t-MDS ___ alloHSCT\r\nt-MDS transformed to AML with up to 83% blasts (___) in elderly\r\nhost with significant co-morbidities. G6PD normal. Patient\r\ncytogenetics show multiple complex mutations from bone marrow\r\nbiopsy. Chimerism from cytogenetics shows a greater percentage\r\nof XX chromosomal cells versus donor XY (~88 vs ~12%). \r\nDecitabine/venetoclax induction (___) every four \r\nweeks. Doses of chemotherapy were adjusted as the patient was \r\nput on different antifungals. BMB ___ with reassuring \r\nfindings, no signs of disease. Neupogen given briefly with \r\nappropriate marrow response. Patient kept on acyclovir and \r\natovaquone for prophylaxis. Bactrim chose over atovaquone at \r\ndischarge.\r\n\r\n# Maxillary sinusitis\r\nPresented with one week of progressive sinus pressure, headache,\r\nfacial warmth. CT SINUS (___) demonstrated pan-opacification of\r\nbilateral maxillary sinuses with circumferential mucosal\r\nthickening, with fat stranding in the retro maxillary fat pads\r\nconcerning for invasive fungal vs bacterial sinusitis yet\r\nfiberoptic exam (___) not consistent with fungal sinusitis.\r\nAspergillius negative, but Beta glucan positive initially in\r\nsetting of neutropenia, Zosyn, ___, and continued sinus\r\nsymptoms. ENT saw pt multiple times and noted no c/f invasive\r\nfungal sinusitis, MRI w&w/out contrast of sinus/skull base ___\r\nwith heterogeneity in left maxilla/middle ear c/f infectious\r\nprocess and pt was placed on AmBisome (___). MRI results \r\n___ were reassuring, and switch to Cresemba from AmBisome was \r\nmade. Due to likely drug rash vs viral exanthem described below, \r\nZosyn was switched for meropenem ___. Reimaging of sinuses \r\n___,\r\nlooked stable from prior and ID recommended ongoing therapy with\r\nIsavunconazole 372mg PO QD and Levofloxacin 750mg PO QD for\r\nprolonged duration of ___ weeks pending reassessment in\r\noutpatient ___ clinic.\r\n- ABx: Cresemba ___- ) + levofloxacin ___- ) ___ meropenem\r\n(___), Zosyn (___) AmBisome (___),\r\nposaconazole (___), meropenem (___) + vancomycin (___)\r\n+ levofloxacin (___) + flagyl (___) + augmentin\r\n(-___)\r\n\r\n# Nonocclusive right femoral vein DVT\r\nOn ___ patient complained of unilateral right lower leg\r\nswelling, right lower extremity noninvasives showed new right\r\nfemoral vein nonocclusive clot compared to ___ bilateral lower\r\nextremity ultrasound. Patient has an extensive history of DVTs, \r\nincluding a DVT developing while on 10mg of Xarelto. Patient was \r\ngiven platelets and started on Lovenox half dose every 12 hours \r\nonce plts > 30. She was discharged on Xarelto 20mg daily, which \r\nwas her home medication before admission.\r\n\r\n# Morbilliform rash\r\nOn ___ presented with suspected drug rash with Zosyn being\r\nlikely aggravating factor. ___ spreading to arms and chest.\r\nWithout involvement of mucosa or face. Decreasing in intensity\r\nand itching daily until ___ when patient woke up with xerotic,\r\nblanching, non-raised rash over chest, legs, arms, and back.\r\nDermatology consulted and recommended steroids topically, \r\nsuggested drug rash. Meropenem switched to levofloxacin. \r\nResolution of rash within the following days. Steroid creams \r\nprescribed per dermatology service.\r\n\r\nCHRONIC/RESOLVED:\r\n=================\r\n# Asthma\r\n- inhalers: duonebs q6hrs PRN + albuterol q4hrs PRN\r\n\r\n# OSA\r\n- continue home CPAP\r\n\r\n# Depression\r\n- continue home venlafaxine 25\r\n\r\n# Neuropathic pain\r\n- continue home gabapentin 400 bid\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n4. FoLIC Acid 1.6 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron (ondansetron HCl) 4 mg oral Q8H:PRN nausea \r\n9. Restasis 0.05 % ophthalmic (eye) BID \r\n10. Rivaroxaban 20 mg PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n14. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n15. Benzonatate 100 mg PO TID:PRN Cough  \r\n16. Ketoconazole Shampoo 1 Appl TP TWO TO THREE TIMES WEEKLY AS \r\nNEEDED FOR DRY SCALP \r\n\r\n \r\nDischarge Medications:\r\n1.  Betamethasone Dipro 0.05% Cream 1 Appl TP BID  \r\n2.  Cetirizine 20 mg PO BID \r\nRX *cetirizine 10 mg 2 tablet(s) by mouth once a day Disp #*60 \r\nTablet Refills:*0 \r\n3.  Isavuconazonium Sulfate 372 mg PO DAILY \r\nRX *isavuconazonium sulfate [Cresemba] 186 mg 2 capsule(s) by \r\nmouth once a day Disp #*60 Capsule Refills:*0 \r\n4.  LevoFLOXacin 750 mg PO Q24H \r\nRX *levofloxacin 750 mg 1 tablet(s) by mouth once a day Disp \r\n#*42 Tablet Refills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim 400 mg-80 mg 1 tablet(s) by \r\nmouth once a day Disp #*30 Tablet Refills:*0 \r\n6.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n7.  FoLIC Acid 2 mg PO DAILY \r\nRX *folic acid 1 mg 2 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Acyclovir 400 mg PO Q12H  \r\n9.  Gabapentin 400 mg PO BID  \r\n10.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nneb every six (6) hours Disp #*30 Ampule Refills:*0 \r\n11.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n14.  Restasis 0.05 % ophthalmic (eye) BID  \r\n15.  Rivaroxaban 20 mg PO DAILY  \r\n16.  Venlafaxine 25 mg PO DAILY  \r\n17.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS\r\n==================\r\n- Acute myelogenous leukemia\r\n\r\nSECONDARY DIAGNOSIS\r\n===================\r\n- Bacterial vs Fungal sinusitis\r\n- Right femoral vein thrombosis \r\n- Obstructive sleep apnea\r\n- Asthma\r\n- Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,  \r\n\r\nWHY WERE YOU ADMITTED TO THE HOSPITAL?  \r\n- You had a sinus infection and were found to have acute \r\nmyelogenous leukemia\r\n\r\nWHAT WAS DONE WHILE YOU WERE IN THE HOSPITAL?  \r\n- You were given chemotherapy to treat your cancer\r\n- You received antibiotics and antifungals to treat your sinus \r\ninfection\r\n \r\nWHAT DO YOU NEED TO DO WHEN YOU LEAVE THE HOSPITAL?  \r\n- Take all of your medications as prescribed (listed below)  \r\n- Follow up with your doctors as listed below  \r\n\r\nPlease see below for more information on your hospitalization. \r\nIt was a pleasure taking part in your care here at ___. We \r\nwish you all the best,\r\n\r\n- Your ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-28:8",
      "text": "Discharge Instructions:\nDear Ms. ___, WHY WERE YOU ADMITTED TO THE HOSPITAL? - You had a sinus infection and were found to have acute \nmyelogenous leukemia WHAT WAS DONE WHILE YOU WERE IN THE HOSPITAL? - You were given chemotherapy to treat your cancer\n- You received antibiotics and antifungals to treat your sinus \ninfection\n \nWHAT DO YOU NEED TO DO WHEN YOU LEAVE THE HOSPITAL? - Take all of your medications as prescribed (listed below)  \n- Follow up with your doctors as listed below Please see below for more information on your hospitalization. It was a pleasure taking part in your care here at ___. We \nwish you all the best, - Your ___ Care Team\n \nFollowup Instructions:\n___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-28",
        "chart_time": "105580",
        "section": "General",
        "position": 8,
        "tokenCount": 171,
        "note_metadata": {
          "note_id": "18887130-DS-28",
          "subject_id": 18887130,
          "hadm_id": 26914904,
          "note_type": "DS",
          "note_seq": 28,
          "charttime": 105580,
          "storetime": 105580.72777777778,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\ndapsone\r\n \r\nAttending: ___.\r\n \r\nMajor Surgical or Invasive Procedure:\r\nBone marrow biopsy (___)\r\nPICC placed (___)\r\n\r\nattach\r\n \r\nPertinent Results:\r\nINITIAL LABS\r\n============\r\n___ 02:30PM BLOOD WBC-9.8 RBC-3.43* Hgb-11.1* Hct-33.6* \r\nMCV-98 MCH-32.4* MCHC-33.0 RDW-17.4* RDWSD-62.2* Plt Ct-24*\r\n___ 02:30PM BLOOD Neuts-6* ___ Monos-1* Eos-0* Baso-0 \r\nAtyps-2* Blasts-65* AbsNeut-0.59* AbsLymp-2.74 AbsMono-0.10* \r\nAbsEos-0.00* AbsBaso-0.00*\r\n___ 02:30PM BLOOD ___ PTT-27.7 ___\r\n___ 05:40AM BLOOD ___ D-Dimer-<215\r\n___ 05:40AM BLOOD Ret Aut-0.8 Abs Ret-0.02\r\n___ 02:30PM BLOOD UreaN-14 Creat-1.0 Na-136 K-3.8 Cl-100 \r\nHCO3-20* AnGap-16\r\n___ 02:30PM BLOOD ALT-8 AST-17 LD(LDH)-1709* AlkPhos-93 \r\nTotBili-0.2\r\n___ 04:26PM BLOOD Lipase-11\r\n___ 04:26PM BLOOD CK-MB-2 cTropnT-<0.01\r\n___ 02:30PM BLOOD Albumin-3.6 Calcium-9.0 Mg-1.9 \r\nUricAcd-3.6\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 05:40AM BLOOD CRP-153.6*\r\n___ 02:30PM BLOOD IgG-621* \r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n___ 04:18PM BLOOD Lactate-1.3 K-4.2\r\n\r\nMICROBIOLOGY\r\n============\r\nAll blood cultures drawn during admission where negative ___, \r\n___\r\nMRSA screen negative\r\nRapid resp viral screen and culture negative (___)\r\nUrine culture ___ negative\r\n\r\nIMAGING\r\n=======\r\n___ CT SINUS:\r\n1. New bilateral maxillary sinus disease with hyperdense \r\nmaterial suggesting fungal colonization or inspissated \r\nsecretions.  However, there is also fat stranding in the retro \r\nmaxillary fat pads, which raises the possibility of invasive \r\nfungal sinusitis in the context of immune suppression. \r\n2. Please see separate head CT for intracranial findings.\r\n\r\n___ CT HEAD:\r\nNo acute intracranial abnormalities are identified or change \r\nseen compared with ___.\r\n\r\n___ TTE:\r\nThe left atrium is mildly dilated. The right atrium is mildly \r\nenlarged. There is no evidence for an atrial septal defect by \r\n2D/color Doppler. The estimated right atrial pressure is ___ \r\nmmHg. There is mild symmetric left ventricular hypertrophy with \r\na normal cavity size. There is normal regional and global left \r\nventricular systolic function. Quantitative biplane left \r\nventricular ejection fraction is 56 % (normal 54-73%). Left \r\nventricular cardiac index is normal (>2.5 L/min/m2). There is no \r\nresting left ventricular outflow tract gradient. No ventricular \r\nseptal defect is seen. Normal right ventricular cavity size with \r\nnormal free wall motion. Tricuspid annular plane systolic \r\nexcursion (TAPSE) is normal. The aortic sinus diameter is normal \r\nfor gender with a mildly dilated ascending aorta. The aortic \r\narch diameter is normal with a normal descending aorta diameter. \r\nThe aortic valve leaflets (3) appear structurally normal. There \r\nis no aortic valve stenosis. There is no aortic regurgitation. \r\nThe mitral valve leaflets are mildly thickened with no mitral \r\nvalve prolapse. There is mild [1+] mitral regurgitation. The \r\npulmonic valve leaflets are normal. The tricuspid valve leaflets \r\nappear structurally normal. There is mild [1+] tricuspid \r\nregurgitation. The estimated pulmonary artery systolic pressure \r\nis normal. There is a trivial pericardial effusion. IMPRESSION: \r\nMild symmetric left ventricular hypertrophy with normal cavity \r\nsize and regional/ global biventricular systolic function. Mild \r\nmitral regurgitation. Mildly dilated ascending aorta.\r\n\r\n___ CT chest without contrast\r\nNo evidence of recurrent lymphoma in the chest. Stable small \r\nmediastinal lymph nodes. Complete resolution of the parenchymal \r\nopacity in the right lower lobe which most likely represented \r\npneumonia.  Patchy opacity in the left lung base is new and \r\ncould represent atelectasis. \r\n\r\n___ MRI skull base with and without contrast\r\n1. Limited study as described.\r\n2. Interval progression of opacification and enhancement within \r\nthe left mastoid air cells and middle ear cavity concerning for \r\notomastoiditis, with no definite evidence of intracranial \r\nextension.\r\n3. Adjacent heterogeneity of the petrous temporal bone versus \r\nartifact.  If not artifactual, differential considerations \r\ninclude infectious and inflammatory etiologies.\r\n4. Bilateral maxillary sinus disease is redemonstrated, \r\naerosolized secretions are better demonstrated on the CT from ___, with no definite extension into the adjacent soft \r\ntissue.\r\n5. Question mild enhancement of the left retro maxillary fat \r\nversus volume averaging of adjacent vessels.  Recommend \r\nattention on follow-up imaging.\r\n6. Nonspecific new clivus and medial temporal bone marrow \r\nheterogeneity compared to ___ prior exam with question \r\nenhancement.  While finding may represent marrow expansion, \r\ninfectious, inflammatory, and neoplastic etiologies are not \r\nexcluded on the basis of this examination.  Recommend attention \r\non follow-up imaging.\r\n\r\n___ MR head with and without contrast\r\n1. Unchanged persistent extensive fluid opacification and \r\nenhancement within the left middle ear cavity and mastoid air \r\ncells concerning for \r\notomastoiditis.  No evidence of intracranial extension. \r\n2. Persistent heterogenous signal intensity within the adjacent \r\npetrous \r\ntemporal bone.  Inflammatory, infectious or neoplastic \r\netiologies are not \r\nexcluded. \r\n3. Mild mucosal thickening in the frontal sinus, multiple \r\nethmoid air cells and predominately in the bilateral maxillary \r\nsinuses, improved since the prior study.  Enhancement in the \r\nretromaxillary fat is difficult to evaluate due to lack of T1 \r\npost-contrast fat saturated images. \r\n4. Persistent heterogenous signal intensity within the clivus, \r\nnonspecific. Differential considerations include marrow \r\nexpansion, infectious, inflammatory or neoplastic etiologies. \r\n5. No evidence of hemorrhage, infarction, mass or other abnormal \r\nenhancement. \r\n\r\n___ bilateral lower extremity venous ultrasound\r\n1. Nonocclusive deep vein thrombosis in the mid right femoral \r\nvein, new \r\ncompared to ___. \r\n2. Deep vein thrombosis in the right popliteal vein.  Of note, \r\nthe right \r\npopliteal vein contained a DVT on ultrasound ___, \r\nhowever the \r\nchronicity of the DVT seen today is uncertain. \r\n3. No evidence of DVT in the left lower extremity. \r\n\r\n___ MR head with and without contrast\r\n1. Ongoing opacification and enhancement of the left mastoid air \r\ncells and \r\nmiddle ear cavity, concerning for otomastoiditis. \r\n2. There is no evidence of intracranial extension. \r\n3. No acute intracranial abnormality is identified. \r\n4. Persistent, unchanged heterogenous signal intensity within \r\nthe clivus. This is nonspecific in nature. \r\n\r\n___ chest x-ray AP\r\nChronic deformity of the right rib cage.  Cardiomediastinal \r\nsilhouette is \r\nwithin normal limits.  There are no focal consolidations, \r\npleural effusion. Right basilar atelectasis.  Tortuous aorta.  \r\nThere are no pneumothoraces. \r\n\r\nOTHER RESULTS\r\n=============\r\n___ 05:40AM BLOOD G6PD-NORMAL\r\n___ 12:00AM BLOOD  WBC-0.7*# Lymph-98* Abs ___ CD3%-88 \r\nAbs CD3-604 CD4%-32 Abs CD4-217* CD8%-55 Abs CD8-380 \r\nCD4/CD8-0.57*\r\n___ 04:26PM BLOOD %HbA1c-5.6 eAG-114\r\n___ 04:26PM BLOOD Triglyc-149 HDL-48 CHOL/HD-3.5 LDLcalc-89\r\n___ 12:00AM BLOOD IgG-593* IgA-24* IgM-136\r\n___ 02:30PM BLOOD CMV VL-NOT DETECT\r\n\r\nDISCHARGE LABS\r\n==============\r\n___ 06:05AM BLOOD WBC-4.4 RBC-2.59* Hgb-8.1* Hct-26.1* \r\nMCV-101* MCH-31.3 MCHC-31.0* RDW-18.4* RDWSD-65.2* Plt ___\r\n___ 06:05AM BLOOD Neuts-58 Bands-1 Lymphs-13* Monos-20* \r\nEos-0* ___ Myelos-7* NRBC-0.5* AbsNeut-2.60 AbsLymp-0.57* \r\nAbsMono-0.88* AbsEos-0.00* AbsBaso-0.04\r\n___ 06:05AM BLOOD Anisocy-1+* Poiklo-1+* Macrocy-1+* \r\nMicrocy-1+* Polychr-1+* Ovalocy-1+* RBC Mor-SLIDE REVI\r\n___ 06:05AM BLOOD ___ PTT-31.8 ___\r\n___ 06:05AM BLOOD ___ 06:05AM BLOOD Glucose-83 UreaN-15 Creat-1.1 Na-143 \r\nK-4.7 Cl-105 HCO3-23 AnGap-15\r\n___ 06:05AM BLOOD ALT-14 AST-16 LD(LDH)-209 AlkPhos-153* \r\nTotBili-<0.2\r\n___ 06:05AM BLOOD Albumin-3.4* Calcium-8.1* Phos-3.2 Mg-2.0\r\n \r\nBrief Hospital Course:\r\nTRANSITIONAL ISSUES\r\n===================\r\n[ ] f/u with ID regarding fungal/bacterial sinusitis and therapy \r\nduration\r\n[ ] f/u with ENT regarding chronic sinusitis\r\n\r\nSUMMARY STATMENT\r\n================\r\nMs. ___ is a ___ year old woman with history of follicular \r\nlymphoma to DLBCL treated with multiple rounds chemotherapy \r\ncomplicated by therapy-related myelodysplasia treated with \r\nalloHSCT with Flu/Bu/ATG RIC (D0 ___ complicated by \r\ngraft-versus-host disease, multiple deep vein thromboses with \r\nIVC filter in place, cavernous sinus aneurysm with coiling \r\n(___) complicated by residual cranial nerve palsy who \r\npresented to ___ with sinusitis and new acute myelogenous \r\nleukemia. Her course was notable for initiation of \r\nvenetoclax/decitabine.\r\n\r\nACTIVE ISSUES\r\n=============\r\n# AML\r\n# t-MDS ___ alloHSCT\r\nt-MDS transformed to AML with up to 83% blasts (___) in elderly\r\nhost with significant co-morbidities. G6PD normal. Patient\r\ncytogenetics show multiple complex mutations from bone marrow\r\nbiopsy. Chimerism from cytogenetics shows a greater percentage\r\nof XX chromosomal cells versus donor XY (~88 vs ~12%). \r\nDecitabine/venetoclax induction (___) every four \r\nweeks. Doses of chemotherapy were adjusted as the patient was \r\nput on different antifungals. BMB ___ with reassuring \r\nfindings, no signs of disease. Neupogen given briefly with \r\nappropriate marrow response. Patient kept on acyclovir and \r\natovaquone for prophylaxis. Bactrim chose over atovaquone at \r\ndischarge.\r\n\r\n# Maxillary sinusitis\r\nPresented with one week of progressive sinus pressure, headache,\r\nfacial warmth. CT SINUS (___) demonstrated pan-opacification of\r\nbilateral maxillary sinuses with circumferential mucosal\r\nthickening, with fat stranding in the retro maxillary fat pads\r\nconcerning for invasive fungal vs bacterial sinusitis yet\r\nfiberoptic exam (___) not consistent with fungal sinusitis.\r\nAspergillius negative, but Beta glucan positive initially in\r\nsetting of neutropenia, Zosyn, ___, and continued sinus\r\nsymptoms. ENT saw pt multiple times and noted no c/f invasive\r\nfungal sinusitis, MRI w&w/out contrast of sinus/skull base ___\r\nwith heterogeneity in left maxilla/middle ear c/f infectious\r\nprocess and pt was placed on AmBisome (___). MRI results \r\n___ were reassuring, and switch to Cresemba from AmBisome was \r\nmade. Due to likely drug rash vs viral exanthem described below, \r\nZosyn was switched for meropenem ___. Reimaging of sinuses \r\n___,\r\nlooked stable from prior and ID recommended ongoing therapy with\r\nIsavunconazole 372mg PO QD and Levofloxacin 750mg PO QD for\r\nprolonged duration of ___ weeks pending reassessment in\r\noutpatient ___ clinic.\r\n- ABx: Cresemba ___- ) + levofloxacin ___- ) ___ meropenem\r\n(___), Zosyn (___) AmBisome (___),\r\nposaconazole (___), meropenem (___) + vancomycin (___)\r\n+ levofloxacin (___) + flagyl (___) + augmentin\r\n(-___)\r\n\r\n# Nonocclusive right femoral vein DVT\r\nOn ___ patient complained of unilateral right lower leg\r\nswelling, right lower extremity noninvasives showed new right\r\nfemoral vein nonocclusive clot compared to ___ bilateral lower\r\nextremity ultrasound. Patient has an extensive history of DVTs, \r\nincluding a DVT developing while on 10mg of Xarelto. Patient was \r\ngiven platelets and started on Lovenox half dose every 12 hours \r\nonce plts > 30. She was discharged on Xarelto 20mg daily, which \r\nwas her home medication before admission.\r\n\r\n# Morbilliform rash\r\nOn ___ presented with suspected drug rash with Zosyn being\r\nlikely aggravating factor. ___ spreading to arms and chest.\r\nWithout involvement of mucosa or face. Decreasing in intensity\r\nand itching daily until ___ when patient woke up with xerotic,\r\nblanching, non-raised rash over chest, legs, arms, and back.\r\nDermatology consulted and recommended steroids topically, \r\nsuggested drug rash. Meropenem switched to levofloxacin. \r\nResolution of rash within the following days. Steroid creams \r\nprescribed per dermatology service.\r\n\r\nCHRONIC/RESOLVED:\r\n=================\r\n# Asthma\r\n- inhalers: duonebs q6hrs PRN + albuterol q4hrs PRN\r\n\r\n# OSA\r\n- continue home CPAP\r\n\r\n# Depression\r\n- continue home venlafaxine 25\r\n\r\n# Neuropathic pain\r\n- continue home gabapentin 400 bid\r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Acyclovir 400 mg PO Q12H \r\n2. Albuterol Inhaler ___ PUFF IH Q4H:PRN cough, wheezing, SOB \r\n3. Fluticasone Propionate 110mcg 2 PUFF IH BID:PRN \r\ncough/wheezing \r\n4. FoLIC Acid 1.6 mg PO DAILY \r\n5. Gabapentin 400 mg PO BID \r\n6. Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron (ondansetron HCl) 4 mg oral Q8H:PRN nausea \r\n9. Restasis 0.05 % ophthalmic (eye) BID \r\n10. Rivaroxaban 20 mg PO DAILY \r\n11. Venlafaxine 25 mg PO DAILY \r\n12. Vitamin D ___ UNIT PO DAILY \r\n13. Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n14. PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID \r\n15. Benzonatate 100 mg PO TID:PRN Cough  \r\n16. Ketoconazole Shampoo 1 Appl TP TWO TO THREE TIMES WEEKLY AS \r\nNEEDED FOR DRY SCALP \r\n\r\n \r\nDischarge Medications:\r\n1.  Betamethasone Dipro 0.05% Cream 1 Appl TP BID  \r\n2.  Cetirizine 20 mg PO BID \r\nRX *cetirizine 10 mg 2 tablet(s) by mouth once a day Disp #*60 \r\nTablet Refills:*0 \r\n3.  Isavuconazonium Sulfate 372 mg PO DAILY \r\nRX *isavuconazonium sulfate [Cresemba] 186 mg 2 capsule(s) by \r\nmouth once a day Disp #*60 Capsule Refills:*0 \r\n4.  LevoFLOXacin 750 mg PO Q24H \r\nRX *levofloxacin 750 mg 1 tablet(s) by mouth once a day Disp \r\n#*42 Tablet Refills:*0 \r\n5.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\nRX *sulfamethoxazole-trimethoprim 400 mg-80 mg 1 tablet(s) by \r\nmouth once a day Disp #*30 Tablet Refills:*0 \r\n6.  Triamcinolone Acetonide 0.1% Cream 1 Appl TP BID  \r\n7.  FoLIC Acid 2 mg PO DAILY \r\nRX *folic acid 1 mg 2 tablet(s) by mouth once a day Disp #*30 \r\nTablet Refills:*0 \r\n8.  Acyclovir 400 mg PO Q12H  \r\n9.  Gabapentin 400 mg PO BID  \r\n10.  Ipratropium-Albuterol Neb 1 NEB NEB Q6H:PRN \r\nwheezing/shortness of breath \r\nRX *ipratropium-albuterol 0.5 mg-3 mg (2.5 mg base)/3 mL 1 neb \r\nneb every six (6) hours Disp #*30 Ampule Refills:*0 \r\n11.  Ketoconazole Shampoo 1 Appl TP ___ TIMES PER WEEK AS NEEDED \r\n \r\n12.  Omeprazole 20 mg PO DAILY  \r\n13.  PreserVision AREDS (vitamins  A,C,E-zinc-copper) \r\n___ unit-mg-unit oral BID  \r\n14.  Restasis 0.05 % ophthalmic (eye) BID  \r\n15.  Rivaroxaban 20 mg PO DAILY  \r\n16.  Venlafaxine 25 mg PO DAILY  \r\n17.  Vitamin D ___ UNIT PO DAILY  \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nPRIMARY DIAGNOSIS\r\n==================\r\n- Acute myelogenous leukemia\r\n\r\nSECONDARY DIAGNOSIS\r\n===================\r\n- Bacterial vs Fungal sinusitis\r\n- Right femoral vein thrombosis \r\n- Obstructive sleep apnea\r\n- Asthma\r\n- Depression\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\nDischarge Instructions:\r\nDear Ms. ___,  \r\n\r\nWHY WERE YOU ADMITTED TO THE HOSPITAL?  \r\n- You had a sinus infection and were found to have acute \r\nmyelogenous leukemia\r\n\r\nWHAT WAS DONE WHILE YOU WERE IN THE HOSPITAL?  \r\n- You were given chemotherapy to treat your cancer\r\n- You received antibiotics and antifungals to treat your sinus \r\ninfection\r\n \r\nWHAT DO YOU NEED TO DO WHEN YOU LEAVE THE HOSPITAL?  \r\n- Take all of your medications as prescribed (listed below)  \r\n- Follow up with your doctors as listed below  \r\n\r\nPlease see below for more information on your hospitalization. \r\nIt was a pleasure taking part in your care here at ___. We \r\nwish you all the best,\r\n\r\n- Your ___ Care Team\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-7:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: OBSTETRICS/GYNECOLOGY Allergies: \nPatient recorded as having No Known Allergies to Drugs\n \nAttending: ___. Chief Complaint:\nright labial abscess\n \nMajor Surgical or Invasive Procedure:\nIV antibiotics\nIncision and Drainage of labial abscess",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-7",
        "chart_time": "101820",
        "section": "General",
        "position": 0,
        "tokenCount": 99,
        "note_metadata": {
          "note_id": "18887130-DS-7",
          "subject_id": 18887130,
          "hadm_id": 29694217,
          "note_type": "DS",
          "note_seq": 7,
          "charttime": 101820,
          "storetime": 101820.42708333333,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: OBSTETRICS/GYNECOLOGY\r\n \r\nAllergies: \r\nPatient recorded as having No Known Allergies to Drugs\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nright labial abscess\r\n \r\nMajor Surgical or Invasive Procedure:\r\nIV antibiotics\r\nIncision and Drainage of labial abscess\r\n\r\n \r\nHistory of Present Illness:\r\n___ P3 female with h/o non-Hodgkins lymphoma presents to\r\nthe ___ ED with a right labial abscess.  Patient initially\r\nnoticed a pimple on her right labium one week ago, with \r\nassociated\r\nlabial itching.  Over the last three days it has been enlarging. \r\n\r\nShe tried placing warm compresses over the area, with no\r\nimprovement.  \r\n\r\nIn the last day, the area has become increasing swollen,\r\nerythematous, and painful.  It is now difficult to walk.  She\r\ndenies drainage from the area.  Denies fever or chills.  Denies\r\nabdominal pain.  Denies excessive vaginal discharge.  \r\n\r\nPatient has a history of a MRSA infection of an abdominal boil\r\n___ years ago.  She denies h/o diabetes and states that recent\r\nfasting blood sugar was 89.  Denies current immunosuppression,\r\nher non-Hogkin's lymphoma has been in remission since ___\r\n \r\nPast Medical History:\r\nObHx:\r\nSVD x 3, no complications\r\n\r\nGynHx:\r\nPostmenopausal since age ___\r\ns/p tubal ligation\r\ndenies h/o abnl paps\r\ndenies h/o STIs\r\n\r\nPMH:\r\nCerebral aneurysm s/p multiple coil and stent procedures\r\nh/o Non Hodgkins Lymphoma, remission since ___.\r\nMigraines\r\nTrigeminal neuralgia\r\nAnterior outlet syndrome, s/p anterior scalenotomy\r\nGERD \r\nOA\r\nCarpal tunnel\r\nMRSA positive boil on abdomen\r\n\r\nPSH:\r\nEx-lap for right-sided pain, tubal ligation\r\nEx-lap for lymphoma\r\nEx-lap for ruptured Meckel's diverticulum\r\nAnterior fusion C5-6\r\nAnterior scalenotomy\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nPE: VS: T 99.4  BP 132/69  HR 100  RR 18  O2Sat 98% RA\r\nNAD\r\nAbd soft, obese, NT, cutaneous candidiasis in bilateral groin\r\nfolds\r\nRight labium majorus 8cm x 5cm area of significant induration,\r\nwarm, extensive erythema (across entire right labium, mons, and\r\nlower abdomen; from 4cm above pubic symphysis to buttocks), no\r\nobvious area of fluctance, no drainage, no ulceration; no\r\nBartholin's cyst; moderately tender to palpation; no crepitus\r\nLeft labium normal appearing, soft, no erythema, no induration, \r\nno\r\ndrainage\r\n\r\n \r\nPertinent Results:\r\n___ 02:10PM   WBC-14.6*# RBC-4.08* HGB-12.8 HCT-37.9 MCV-93 \r\nMCH-31.2 MCHC-33.6 RDW-13.1\r\nHA1C: 6.0\r\n \r\nBrief Hospital Course:\r\nPatient was admitted to the surgical floor for IV antibiotics \r\n(Vancomycin/Unasyn) and pain control for treatment of labial \r\ncellulitis. There was concern for abscess despite ultrasound \r\nshowing labial edema, without evidence of drainable fluid \r\ncollection. She was afebrile for 24 hours but her pain and exam \r\ndid not improve after 24 hours of IV antibiotics so a bedside \r\nincision and drainage was attempted. A fluid collection was \r\nidentified and exlpored. It was found to have significant depth \r\nwhich was not ammendable to bedside drainage.  the patient was \r\nthen taken to the OR for a complete incision and drainage. A \r\nlarge pocket of purulent fluid was drained, oculations were \r\nbroken up, and a  Foley left in wound to drain the cavity. The \r\ndrainage was sent for culture.\r\nA blood culture that was drawn in the emergency room returned \r\npositive ___ bottles) for Coag negative Staph which was \r\npresumed to be a Staph epi contaminant. All further blood \r\ncultures were negative.\r\nShe was kept in the hospital for 48 hours more until the \r\nsensitivities returned from her would culture. She remained \r\nafebrile and her pain was significantly decreased after the \r\nprocedure. \r\nThe wound was found to be caused by MRSA but was sensitive to \r\nBactrim. She was sent home on a 2 week course of Bactrim and \r\nwill follow-up in 2 weeks in ___ clinic.\r\n \r\nMedications on Admission:\r\nNeurotin 300mg qam, 600mg qpm\r\nOmeprazole 20mg qdaily\r\nASA 325mg qdaily\r\nHCTZ 25mg BID\r\nEtodolac 500mg BID\r\nMVI\r\n\r\n \r\nDischarge Medications:\r\n1. Acetaminophen 500 mg Tablet Sig: One (1) Tablet PO Q6H (every \r\n6 hours) as needed for pain, fever.  \r\n2. Ibuprofen 400 mg Tablet Sig: One (1) Tablet PO Q6H (every 6 \r\nhours) as needed for pain, fever.\r\nDisp:*35 Tablet(s)* Refills:*1*\r\n3. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM ().  \r\n4. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \r\nbedtime).  \r\n5. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid ().  \r\n6. Hydrocodone-Acetaminophen ___ mg Tablet Sig: ___ Tablets PO \r\nQ4H (every 4 hours) as needed for pain.\r\nDisp:*30 Tablet(s)* Refills:*0*\r\n7. Venlafaxine 25 mg Tablet Sig: One (1) Tablet PO DAILY \r\n(Daily).  \r\n8. Hydrochlorothiazide 12.5 mg Capsule Sig: One (1) Capsule PO \r\nBID (2 times a day).  \r\n9. Aspirin 325 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).  \r\n10. Omeprazole 20 mg Capsule, Delayed Release(E.C.) Sig: One (1) \r\nCapsule, Delayed Release(E.C.) PO DAILY (Daily).  \r\n11. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM ().  \r\n12. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \r\nbedtime).  \r\n13. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid ().  \r\n14. Trimethoprim-Sulfamethoxazole 160-800 mg Tablet Sig: One (1) \r\nTablet PO BID (2 times a day) for 14 days.\r\nDisp:*28 Tablet(s)* Refills:*0*\r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nLabial cellulitis/abscess\r\n\r\n \r\nDischarge Condition:\r\nStable, afebrile\r\n\r\n \r\nDischarge Instructions:\r\nCall your doctor for:\r\n* fever > 100.4\r\n* severe abdominal pain\r\n* difficulty urinating\r\n* vaginal bleeding requiring >1 pad/hr\r\n* abnormal vaginal discharge\r\n* nausea/vomiting where you are unable to keep down fluids/food \r\nor your medication\r\n\r\nGeneral instructions:\r\n* Take your medications as prescribed.\r\n* Do not drive while taking narcotics.\r\n* No strenuous activity, nothing in the vagina (no tampons, no \r\ndouching, no sex), no heavy lifting of objects >10lbs for 6 \r\nweeks. \r\n* You may eat a regular diet.\r\n\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-7:1",
      "text": "History of Present Illness:\n___ P3 female with h/o non-Hodgkins lymphoma presents to\nthe ___ ED with a right labial abscess. Patient initially\nnoticed a pimple on her right labium one week ago, with \nassociated\nlabial itching. Over the last three days it has been enlarging. She tried placing warm compresses over the area, with no\nimprovement. In the last day, the area has become increasing swollen,\nerythematous, and painful. It is now difficult to walk. She\ndenies drainage from the area. Denies fever or chills. Denies\nabdominal pain. Denies excessive vaginal discharge. Patient has a history of a MRSA infection of an abdominal boil\n___ years ago. She denies h/o diabetes and states that recent\nfasting blood sugar was 89. Denies current immunosuppression,\nher non-Hogkin's lymphoma has been in remission since ___",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-7",
        "chart_time": "101820",
        "section": "General",
        "position": 1,
        "tokenCount": 205,
        "note_metadata": {
          "note_id": "18887130-DS-7",
          "subject_id": 18887130,
          "hadm_id": 29694217,
          "note_type": "DS",
          "note_seq": 7,
          "charttime": 101820,
          "storetime": 101820.42708333333,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: OBSTETRICS/GYNECOLOGY\r\n \r\nAllergies: \r\nPatient recorded as having No Known Allergies to Drugs\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nright labial abscess\r\n \r\nMajor Surgical or Invasive Procedure:\r\nIV antibiotics\r\nIncision and Drainage of labial abscess\r\n\r\n \r\nHistory of Present Illness:\r\n___ P3 female with h/o non-Hodgkins lymphoma presents to\r\nthe ___ ED with a right labial abscess.  Patient initially\r\nnoticed a pimple on her right labium one week ago, with \r\nassociated\r\nlabial itching.  Over the last three days it has been enlarging. \r\n\r\nShe tried placing warm compresses over the area, with no\r\nimprovement.  \r\n\r\nIn the last day, the area has become increasing swollen,\r\nerythematous, and painful.  It is now difficult to walk.  She\r\ndenies drainage from the area.  Denies fever or chills.  Denies\r\nabdominal pain.  Denies excessive vaginal discharge.  \r\n\r\nPatient has a history of a MRSA infection of an abdominal boil\r\n___ years ago.  She denies h/o diabetes and states that recent\r\nfasting blood sugar was 89.  Denies current immunosuppression,\r\nher non-Hogkin's lymphoma has been in remission since ___\r\n \r\nPast Medical History:\r\nObHx:\r\nSVD x 3, no complications\r\n\r\nGynHx:\r\nPostmenopausal since age ___\r\ns/p tubal ligation\r\ndenies h/o abnl paps\r\ndenies h/o STIs\r\n\r\nPMH:\r\nCerebral aneurysm s/p multiple coil and stent procedures\r\nh/o Non Hodgkins Lymphoma, remission since ___.\r\nMigraines\r\nTrigeminal neuralgia\r\nAnterior outlet syndrome, s/p anterior scalenotomy\r\nGERD \r\nOA\r\nCarpal tunnel\r\nMRSA positive boil on abdomen\r\n\r\nPSH:\r\nEx-lap for right-sided pain, tubal ligation\r\nEx-lap for lymphoma\r\nEx-lap for ruptured Meckel's diverticulum\r\nAnterior fusion C5-6\r\nAnterior scalenotomy\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nPE: VS: T 99.4  BP 132/69  HR 100  RR 18  O2Sat 98% RA\r\nNAD\r\nAbd soft, obese, NT, cutaneous candidiasis in bilateral groin\r\nfolds\r\nRight labium majorus 8cm x 5cm area of significant induration,\r\nwarm, extensive erythema (across entire right labium, mons, and\r\nlower abdomen; from 4cm above pubic symphysis to buttocks), no\r\nobvious area of fluctance, no drainage, no ulceration; no\r\nBartholin's cyst; moderately tender to palpation; no crepitus\r\nLeft labium normal appearing, soft, no erythema, no induration, \r\nno\r\ndrainage\r\n\r\n \r\nPertinent Results:\r\n___ 02:10PM   WBC-14.6*# RBC-4.08* HGB-12.8 HCT-37.9 MCV-93 \r\nMCH-31.2 MCHC-33.6 RDW-13.1\r\nHA1C: 6.0\r\n \r\nBrief Hospital Course:\r\nPatient was admitted to the surgical floor for IV antibiotics \r\n(Vancomycin/Unasyn) and pain control for treatment of labial \r\ncellulitis. There was concern for abscess despite ultrasound \r\nshowing labial edema, without evidence of drainable fluid \r\ncollection. She was afebrile for 24 hours but her pain and exam \r\ndid not improve after 24 hours of IV antibiotics so a bedside \r\nincision and drainage was attempted. A fluid collection was \r\nidentified and exlpored. It was found to have significant depth \r\nwhich was not ammendable to bedside drainage.  the patient was \r\nthen taken to the OR for a complete incision and drainage. A \r\nlarge pocket of purulent fluid was drained, oculations were \r\nbroken up, and a  Foley left in wound to drain the cavity. The \r\ndrainage was sent for culture.\r\nA blood culture that was drawn in the emergency room returned \r\npositive ___ bottles) for Coag negative Staph which was \r\npresumed to be a Staph epi contaminant. All further blood \r\ncultures were negative.\r\nShe was kept in the hospital for 48 hours more until the \r\nsensitivities returned from her would culture. She remained \r\nafebrile and her pain was significantly decreased after the \r\nprocedure. \r\nThe wound was found to be caused by MRSA but was sensitive to \r\nBactrim. She was sent home on a 2 week course of Bactrim and \r\nwill follow-up in 2 weeks in ___ clinic.\r\n \r\nMedications on Admission:\r\nNeurotin 300mg qam, 600mg qpm\r\nOmeprazole 20mg qdaily\r\nASA 325mg qdaily\r\nHCTZ 25mg BID\r\nEtodolac 500mg BID\r\nMVI\r\n\r\n \r\nDischarge Medications:\r\n1. Acetaminophen 500 mg Tablet Sig: One (1) Tablet PO Q6H (every \r\n6 hours) as needed for pain, fever.  \r\n2. Ibuprofen 400 mg Tablet Sig: One (1) Tablet PO Q6H (every 6 \r\nhours) as needed for pain, fever.\r\nDisp:*35 Tablet(s)* Refills:*1*\r\n3. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM ().  \r\n4. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \r\nbedtime).  \r\n5. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid ().  \r\n6. Hydrocodone-Acetaminophen ___ mg Tablet Sig: ___ Tablets PO \r\nQ4H (every 4 hours) as needed for pain.\r\nDisp:*30 Tablet(s)* Refills:*0*\r\n7. Venlafaxine 25 mg Tablet Sig: One (1) Tablet PO DAILY \r\n(Daily).  \r\n8. Hydrochlorothiazide 12.5 mg Capsule Sig: One (1) Capsule PO \r\nBID (2 times a day).  \r\n9. Aspirin 325 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).  \r\n10. Omeprazole 20 mg Capsule, Delayed Release(E.C.) Sig: One (1) \r\nCapsule, Delayed Release(E.C.) PO DAILY (Daily).  \r\n11. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM ().  \r\n12. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \r\nbedtime).  \r\n13. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid ().  \r\n14. Trimethoprim-Sulfamethoxazole 160-800 mg Tablet Sig: One (1) \r\nTablet PO BID (2 times a day) for 14 days.\r\nDisp:*28 Tablet(s)* Refills:*0*\r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nLabial cellulitis/abscess\r\n\r\n \r\nDischarge Condition:\r\nStable, afebrile\r\n\r\n \r\nDischarge Instructions:\r\nCall your doctor for:\r\n* fever > 100.4\r\n* severe abdominal pain\r\n* difficulty urinating\r\n* vaginal bleeding requiring >1 pad/hr\r\n* abnormal vaginal discharge\r\n* nausea/vomiting where you are unable to keep down fluids/food \r\nor your medication\r\n\r\nGeneral instructions:\r\n* Take your medications as prescribed.\r\n* Do not drive while taking narcotics.\r\n* No strenuous activity, nothing in the vagina (no tampons, no \r\ndouching, no sex), no heavy lifting of objects >10lbs for 6 \r\nweeks. \r\n* You may eat a regular diet.\r\n\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-7:2",
      "text": "Past Medical History:\nObHx:\nSVD x 3, no complications GynHx:\nPostmenopausal since age ___\ns/p tubal ligation\ndenies h/o abnl paps\ndenies h/o STIs PMH:\nCerebral aneurysm s/p multiple coil and stent procedures\nh/o Non Hodgkins Lymphoma, remission since ___. Migraines\nTrigeminal neuralgia\nAnterior outlet syndrome, s/p anterior scalenotomy\nGERD \nOA\nCarpal tunnel\nMRSA positive boil on abdomen PSH:\nEx-lap for right-sided pain, tubal ligation\nEx-lap for lymphoma\nEx-lap for ruptured Meckel's diverticulum\nAnterior fusion C5-6\nAnterior scalenotomy Social History:\n___ Family History:\nNC",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-7",
        "chart_time": "101820",
        "section": "General",
        "position": 2,
        "tokenCount": 146,
        "note_metadata": {
          "note_id": "18887130-DS-7",
          "subject_id": 18887130,
          "hadm_id": 29694217,
          "note_type": "DS",
          "note_seq": 7,
          "charttime": 101820,
          "storetime": 101820.42708333333,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: OBSTETRICS/GYNECOLOGY\r\n \r\nAllergies: \r\nPatient recorded as having No Known Allergies to Drugs\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nright labial abscess\r\n \r\nMajor Surgical or Invasive Procedure:\r\nIV antibiotics\r\nIncision and Drainage of labial abscess\r\n\r\n \r\nHistory of Present Illness:\r\n___ P3 female with h/o non-Hodgkins lymphoma presents to\r\nthe ___ ED with a right labial abscess.  Patient initially\r\nnoticed a pimple on her right labium one week ago, with \r\nassociated\r\nlabial itching.  Over the last three days it has been enlarging. \r\n\r\nShe tried placing warm compresses over the area, with no\r\nimprovement.  \r\n\r\nIn the last day, the area has become increasing swollen,\r\nerythematous, and painful.  It is now difficult to walk.  She\r\ndenies drainage from the area.  Denies fever or chills.  Denies\r\nabdominal pain.  Denies excessive vaginal discharge.  \r\n\r\nPatient has a history of a MRSA infection of an abdominal boil\r\n___ years ago.  She denies h/o diabetes and states that recent\r\nfasting blood sugar was 89.  Denies current immunosuppression,\r\nher non-Hogkin's lymphoma has been in remission since ___\r\n \r\nPast Medical History:\r\nObHx:\r\nSVD x 3, no complications\r\n\r\nGynHx:\r\nPostmenopausal since age ___\r\ns/p tubal ligation\r\ndenies h/o abnl paps\r\ndenies h/o STIs\r\n\r\nPMH:\r\nCerebral aneurysm s/p multiple coil and stent procedures\r\nh/o Non Hodgkins Lymphoma, remission since ___.\r\nMigraines\r\nTrigeminal neuralgia\r\nAnterior outlet syndrome, s/p anterior scalenotomy\r\nGERD \r\nOA\r\nCarpal tunnel\r\nMRSA positive boil on abdomen\r\n\r\nPSH:\r\nEx-lap for right-sided pain, tubal ligation\r\nEx-lap for lymphoma\r\nEx-lap for ruptured Meckel's diverticulum\r\nAnterior fusion C5-6\r\nAnterior scalenotomy\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nPE: VS: T 99.4  BP 132/69  HR 100  RR 18  O2Sat 98% RA\r\nNAD\r\nAbd soft, obese, NT, cutaneous candidiasis in bilateral groin\r\nfolds\r\nRight labium majorus 8cm x 5cm area of significant induration,\r\nwarm, extensive erythema (across entire right labium, mons, and\r\nlower abdomen; from 4cm above pubic symphysis to buttocks), no\r\nobvious area of fluctance, no drainage, no ulceration; no\r\nBartholin's cyst; moderately tender to palpation; no crepitus\r\nLeft labium normal appearing, soft, no erythema, no induration, \r\nno\r\ndrainage\r\n\r\n \r\nPertinent Results:\r\n___ 02:10PM   WBC-14.6*# RBC-4.08* HGB-12.8 HCT-37.9 MCV-93 \r\nMCH-31.2 MCHC-33.6 RDW-13.1\r\nHA1C: 6.0\r\n \r\nBrief Hospital Course:\r\nPatient was admitted to the surgical floor for IV antibiotics \r\n(Vancomycin/Unasyn) and pain control for treatment of labial \r\ncellulitis. There was concern for abscess despite ultrasound \r\nshowing labial edema, without evidence of drainable fluid \r\ncollection. She was afebrile for 24 hours but her pain and exam \r\ndid not improve after 24 hours of IV antibiotics so a bedside \r\nincision and drainage was attempted. A fluid collection was \r\nidentified and exlpored. It was found to have significant depth \r\nwhich was not ammendable to bedside drainage.  the patient was \r\nthen taken to the OR for a complete incision and drainage. A \r\nlarge pocket of purulent fluid was drained, oculations were \r\nbroken up, and a  Foley left in wound to drain the cavity. The \r\ndrainage was sent for culture.\r\nA blood culture that was drawn in the emergency room returned \r\npositive ___ bottles) for Coag negative Staph which was \r\npresumed to be a Staph epi contaminant. All further blood \r\ncultures were negative.\r\nShe was kept in the hospital for 48 hours more until the \r\nsensitivities returned from her would culture. She remained \r\nafebrile and her pain was significantly decreased after the \r\nprocedure. \r\nThe wound was found to be caused by MRSA but was sensitive to \r\nBactrim. She was sent home on a 2 week course of Bactrim and \r\nwill follow-up in 2 weeks in ___ clinic.\r\n \r\nMedications on Admission:\r\nNeurotin 300mg qam, 600mg qpm\r\nOmeprazole 20mg qdaily\r\nASA 325mg qdaily\r\nHCTZ 25mg BID\r\nEtodolac 500mg BID\r\nMVI\r\n\r\n \r\nDischarge Medications:\r\n1. Acetaminophen 500 mg Tablet Sig: One (1) Tablet PO Q6H (every \r\n6 hours) as needed for pain, fever.  \r\n2. Ibuprofen 400 mg Tablet Sig: One (1) Tablet PO Q6H (every 6 \r\nhours) as needed for pain, fever.\r\nDisp:*35 Tablet(s)* Refills:*1*\r\n3. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM ().  \r\n4. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \r\nbedtime).  \r\n5. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid ().  \r\n6. Hydrocodone-Acetaminophen ___ mg Tablet Sig: ___ Tablets PO \r\nQ4H (every 4 hours) as needed for pain.\r\nDisp:*30 Tablet(s)* Refills:*0*\r\n7. Venlafaxine 25 mg Tablet Sig: One (1) Tablet PO DAILY \r\n(Daily).  \r\n8. Hydrochlorothiazide 12.5 mg Capsule Sig: One (1) Capsule PO \r\nBID (2 times a day).  \r\n9. Aspirin 325 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).  \r\n10. Omeprazole 20 mg Capsule, Delayed Release(E.C.) Sig: One (1) \r\nCapsule, Delayed Release(E.C.) PO DAILY (Daily).  \r\n11. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM ().  \r\n12. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \r\nbedtime).  \r\n13. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid ().  \r\n14. Trimethoprim-Sulfamethoxazole 160-800 mg Tablet Sig: One (1) \r\nTablet PO BID (2 times a day) for 14 days.\r\nDisp:*28 Tablet(s)* Refills:*0*\r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nLabial cellulitis/abscess\r\n\r\n \r\nDischarge Condition:\r\nStable, afebrile\r\n\r\n \r\nDischarge Instructions:\r\nCall your doctor for:\r\n* fever > 100.4\r\n* severe abdominal pain\r\n* difficulty urinating\r\n* vaginal bleeding requiring >1 pad/hr\r\n* abnormal vaginal discharge\r\n* nausea/vomiting where you are unable to keep down fluids/food \r\nor your medication\r\n\r\nGeneral instructions:\r\n* Take your medications as prescribed.\r\n* Do not drive while taking narcotics.\r\n* No strenuous activity, nothing in the vagina (no tampons, no \r\ndouching, no sex), no heavy lifting of objects >10lbs for 6 \r\nweeks. \r\n* You may eat a regular diet.\r\n\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-7:3",
      "text": "Physical Exam:\nPE: VS: T 99.4  BP 132/69  HR 100  RR 18  O2Sat 98% RA\nNAD\nAbd soft, obese, NT, cutaneous candidiasis in bilateral groin\nfolds\nRight labium majorus 8cm x 5cm area of significant induration,\nwarm, extensive erythema (across entire right labium, mons, and\nlower abdomen; from 4cm above pubic symphysis to buttocks), no\nobvious area of fluctance, no drainage, no ulceration; no\nBartholin's cyst; moderately tender to palpation; no crepitus\nLeft labium normal appearing, soft, no erythema, no induration, \nno\ndrainage Pertinent Results:\n___ 02:10PM   WBC-14.6*# RBC-4.08* HGB-12.8 HCT-37.9 MCV-93 \nMCH-31.2 MCHC-33.6 RDW-13.1\nHA1C: 6.0",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-7",
        "chart_time": "101820",
        "section": "General",
        "position": 3,
        "tokenCount": 162,
        "note_metadata": {
          "note_id": "18887130-DS-7",
          "subject_id": 18887130,
          "hadm_id": 29694217,
          "note_type": "DS",
          "note_seq": 7,
          "charttime": 101820,
          "storetime": 101820.42708333333,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: OBSTETRICS/GYNECOLOGY\r\n \r\nAllergies: \r\nPatient recorded as having No Known Allergies to Drugs\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nright labial abscess\r\n \r\nMajor Surgical or Invasive Procedure:\r\nIV antibiotics\r\nIncision and Drainage of labial abscess\r\n\r\n \r\nHistory of Present Illness:\r\n___ P3 female with h/o non-Hodgkins lymphoma presents to\r\nthe ___ ED with a right labial abscess.  Patient initially\r\nnoticed a pimple on her right labium one week ago, with \r\nassociated\r\nlabial itching.  Over the last three days it has been enlarging. \r\n\r\nShe tried placing warm compresses over the area, with no\r\nimprovement.  \r\n\r\nIn the last day, the area has become increasing swollen,\r\nerythematous, and painful.  It is now difficult to walk.  She\r\ndenies drainage from the area.  Denies fever or chills.  Denies\r\nabdominal pain.  Denies excessive vaginal discharge.  \r\n\r\nPatient has a history of a MRSA infection of an abdominal boil\r\n___ years ago.  She denies h/o diabetes and states that recent\r\nfasting blood sugar was 89.  Denies current immunosuppression,\r\nher non-Hogkin's lymphoma has been in remission since ___\r\n \r\nPast Medical History:\r\nObHx:\r\nSVD x 3, no complications\r\n\r\nGynHx:\r\nPostmenopausal since age ___\r\ns/p tubal ligation\r\ndenies h/o abnl paps\r\ndenies h/o STIs\r\n\r\nPMH:\r\nCerebral aneurysm s/p multiple coil and stent procedures\r\nh/o Non Hodgkins Lymphoma, remission since ___.\r\nMigraines\r\nTrigeminal neuralgia\r\nAnterior outlet syndrome, s/p anterior scalenotomy\r\nGERD \r\nOA\r\nCarpal tunnel\r\nMRSA positive boil on abdomen\r\n\r\nPSH:\r\nEx-lap for right-sided pain, tubal ligation\r\nEx-lap for lymphoma\r\nEx-lap for ruptured Meckel's diverticulum\r\nAnterior fusion C5-6\r\nAnterior scalenotomy\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nPE: VS: T 99.4  BP 132/69  HR 100  RR 18  O2Sat 98% RA\r\nNAD\r\nAbd soft, obese, NT, cutaneous candidiasis in bilateral groin\r\nfolds\r\nRight labium majorus 8cm x 5cm area of significant induration,\r\nwarm, extensive erythema (across entire right labium, mons, and\r\nlower abdomen; from 4cm above pubic symphysis to buttocks), no\r\nobvious area of fluctance, no drainage, no ulceration; no\r\nBartholin's cyst; moderately tender to palpation; no crepitus\r\nLeft labium normal appearing, soft, no erythema, no induration, \r\nno\r\ndrainage\r\n\r\n \r\nPertinent Results:\r\n___ 02:10PM   WBC-14.6*# RBC-4.08* HGB-12.8 HCT-37.9 MCV-93 \r\nMCH-31.2 MCHC-33.6 RDW-13.1\r\nHA1C: 6.0\r\n \r\nBrief Hospital Course:\r\nPatient was admitted to the surgical floor for IV antibiotics \r\n(Vancomycin/Unasyn) and pain control for treatment of labial \r\ncellulitis. There was concern for abscess despite ultrasound \r\nshowing labial edema, without evidence of drainable fluid \r\ncollection. She was afebrile for 24 hours but her pain and exam \r\ndid not improve after 24 hours of IV antibiotics so a bedside \r\nincision and drainage was attempted. A fluid collection was \r\nidentified and exlpored. It was found to have significant depth \r\nwhich was not ammendable to bedside drainage.  the patient was \r\nthen taken to the OR for a complete incision and drainage. A \r\nlarge pocket of purulent fluid was drained, oculations were \r\nbroken up, and a  Foley left in wound to drain the cavity. The \r\ndrainage was sent for culture.\r\nA blood culture that was drawn in the emergency room returned \r\npositive ___ bottles) for Coag negative Staph which was \r\npresumed to be a Staph epi contaminant. All further blood \r\ncultures were negative.\r\nShe was kept in the hospital for 48 hours more until the \r\nsensitivities returned from her would culture. She remained \r\nafebrile and her pain was significantly decreased after the \r\nprocedure. \r\nThe wound was found to be caused by MRSA but was sensitive to \r\nBactrim. She was sent home on a 2 week course of Bactrim and \r\nwill follow-up in 2 weeks in ___ clinic.\r\n \r\nMedications on Admission:\r\nNeurotin 300mg qam, 600mg qpm\r\nOmeprazole 20mg qdaily\r\nASA 325mg qdaily\r\nHCTZ 25mg BID\r\nEtodolac 500mg BID\r\nMVI\r\n\r\n \r\nDischarge Medications:\r\n1. Acetaminophen 500 mg Tablet Sig: One (1) Tablet PO Q6H (every \r\n6 hours) as needed for pain, fever.  \r\n2. Ibuprofen 400 mg Tablet Sig: One (1) Tablet PO Q6H (every 6 \r\nhours) as needed for pain, fever.\r\nDisp:*35 Tablet(s)* Refills:*1*\r\n3. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM ().  \r\n4. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \r\nbedtime).  \r\n5. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid ().  \r\n6. Hydrocodone-Acetaminophen ___ mg Tablet Sig: ___ Tablets PO \r\nQ4H (every 4 hours) as needed for pain.\r\nDisp:*30 Tablet(s)* Refills:*0*\r\n7. Venlafaxine 25 mg Tablet Sig: One (1) Tablet PO DAILY \r\n(Daily).  \r\n8. Hydrochlorothiazide 12.5 mg Capsule Sig: One (1) Capsule PO \r\nBID (2 times a day).  \r\n9. Aspirin 325 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).  \r\n10. Omeprazole 20 mg Capsule, Delayed Release(E.C.) Sig: One (1) \r\nCapsule, Delayed Release(E.C.) PO DAILY (Daily).  \r\n11. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM ().  \r\n12. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \r\nbedtime).  \r\n13. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid ().  \r\n14. Trimethoprim-Sulfamethoxazole 160-800 mg Tablet Sig: One (1) \r\nTablet PO BID (2 times a day) for 14 days.\r\nDisp:*28 Tablet(s)* Refills:*0*\r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nLabial cellulitis/abscess\r\n\r\n \r\nDischarge Condition:\r\nStable, afebrile\r\n\r\n \r\nDischarge Instructions:\r\nCall your doctor for:\r\n* fever > 100.4\r\n* severe abdominal pain\r\n* difficulty urinating\r\n* vaginal bleeding requiring >1 pad/hr\r\n* abnormal vaginal discharge\r\n* nausea/vomiting where you are unable to keep down fluids/food \r\nor your medication\r\n\r\nGeneral instructions:\r\n* Take your medications as prescribed.\r\n* Do not drive while taking narcotics.\r\n* No strenuous activity, nothing in the vagina (no tampons, no \r\ndouching, no sex), no heavy lifting of objects >10lbs for 6 \r\nweeks. \r\n* You may eat a regular diet.\r\n\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-7:4",
      "text": "Brief Hospital Course:\nPatient was admitted to the surgical floor for IV antibiotics \n(Vancomycin/Unasyn) and pain control for treatment of labial \ncellulitis. There was concern for abscess despite ultrasound \nshowing labial edema, without evidence of drainable fluid \ncollection. She was afebrile for 24 hours but her pain and exam \ndid not improve after 24 hours of IV antibiotics so a bedside \nincision and drainage was attempted. A fluid collection was \nidentified and exlpored. It was found to have significant depth \nwhich was not ammendable to bedside drainage. the patient was \nthen taken to the OR for a complete incision and drainage. A \nlarge pocket of purulent fluid was drained, oculations were \nbroken up, and a  Foley left in wound to drain the cavity. The \ndrainage was sent for culture. A blood culture that was drawn in the emergency room returned \npositive ___ bottles) for Coag negative Staph which was \npresumed to be a Staph epi contaminant. All further blood \ncultures were negative. She was kept in the hospital for 48 hours more until the \nsensitivities returned from her would culture. She remained \nafebrile and her pain was significantly decreased after the \nprocedure. The wound was found to be caused by MRSA but was sensitive to \nBactrim. She was sent home on a 2 week course of Bactrim and \nwill follow-up in 2 weeks in ___ clinic. Medications on Admission:\nNeurotin 300mg qam, 600mg qpm\nOmeprazole 20mg qdaily\nASA 325mg qdaily\nHCTZ 25mg BID\nEtodolac 500mg BID\nMVI",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-7",
        "chart_time": "101820",
        "section": "General",
        "position": 4,
        "tokenCount": 374,
        "note_metadata": {
          "note_id": "18887130-DS-7",
          "subject_id": 18887130,
          "hadm_id": 29694217,
          "note_type": "DS",
          "note_seq": 7,
          "charttime": 101820,
          "storetime": 101820.42708333333,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: OBSTETRICS/GYNECOLOGY\r\n \r\nAllergies: \r\nPatient recorded as having No Known Allergies to Drugs\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nright labial abscess\r\n \r\nMajor Surgical or Invasive Procedure:\r\nIV antibiotics\r\nIncision and Drainage of labial abscess\r\n\r\n \r\nHistory of Present Illness:\r\n___ P3 female with h/o non-Hodgkins lymphoma presents to\r\nthe ___ ED with a right labial abscess.  Patient initially\r\nnoticed a pimple on her right labium one week ago, with \r\nassociated\r\nlabial itching.  Over the last three days it has been enlarging. \r\n\r\nShe tried placing warm compresses over the area, with no\r\nimprovement.  \r\n\r\nIn the last day, the area has become increasing swollen,\r\nerythematous, and painful.  It is now difficult to walk.  She\r\ndenies drainage from the area.  Denies fever or chills.  Denies\r\nabdominal pain.  Denies excessive vaginal discharge.  \r\n\r\nPatient has a history of a MRSA infection of an abdominal boil\r\n___ years ago.  She denies h/o diabetes and states that recent\r\nfasting blood sugar was 89.  Denies current immunosuppression,\r\nher non-Hogkin's lymphoma has been in remission since ___\r\n \r\nPast Medical History:\r\nObHx:\r\nSVD x 3, no complications\r\n\r\nGynHx:\r\nPostmenopausal since age ___\r\ns/p tubal ligation\r\ndenies h/o abnl paps\r\ndenies h/o STIs\r\n\r\nPMH:\r\nCerebral aneurysm s/p multiple coil and stent procedures\r\nh/o Non Hodgkins Lymphoma, remission since ___.\r\nMigraines\r\nTrigeminal neuralgia\r\nAnterior outlet syndrome, s/p anterior scalenotomy\r\nGERD \r\nOA\r\nCarpal tunnel\r\nMRSA positive boil on abdomen\r\n\r\nPSH:\r\nEx-lap for right-sided pain, tubal ligation\r\nEx-lap for lymphoma\r\nEx-lap for ruptured Meckel's diverticulum\r\nAnterior fusion C5-6\r\nAnterior scalenotomy\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nPE: VS: T 99.4  BP 132/69  HR 100  RR 18  O2Sat 98% RA\r\nNAD\r\nAbd soft, obese, NT, cutaneous candidiasis in bilateral groin\r\nfolds\r\nRight labium majorus 8cm x 5cm area of significant induration,\r\nwarm, extensive erythema (across entire right labium, mons, and\r\nlower abdomen; from 4cm above pubic symphysis to buttocks), no\r\nobvious area of fluctance, no drainage, no ulceration; no\r\nBartholin's cyst; moderately tender to palpation; no crepitus\r\nLeft labium normal appearing, soft, no erythema, no induration, \r\nno\r\ndrainage\r\n\r\n \r\nPertinent Results:\r\n___ 02:10PM   WBC-14.6*# RBC-4.08* HGB-12.8 HCT-37.9 MCV-93 \r\nMCH-31.2 MCHC-33.6 RDW-13.1\r\nHA1C: 6.0\r\n \r\nBrief Hospital Course:\r\nPatient was admitted to the surgical floor for IV antibiotics \r\n(Vancomycin/Unasyn) and pain control for treatment of labial \r\ncellulitis. There was concern for abscess despite ultrasound \r\nshowing labial edema, without evidence of drainable fluid \r\ncollection. She was afebrile for 24 hours but her pain and exam \r\ndid not improve after 24 hours of IV antibiotics so a bedside \r\nincision and drainage was attempted. A fluid collection was \r\nidentified and exlpored. It was found to have significant depth \r\nwhich was not ammendable to bedside drainage.  the patient was \r\nthen taken to the OR for a complete incision and drainage. A \r\nlarge pocket of purulent fluid was drained, oculations were \r\nbroken up, and a  Foley left in wound to drain the cavity. The \r\ndrainage was sent for culture.\r\nA blood culture that was drawn in the emergency room returned \r\npositive ___ bottles) for Coag negative Staph which was \r\npresumed to be a Staph epi contaminant. All further blood \r\ncultures were negative.\r\nShe was kept in the hospital for 48 hours more until the \r\nsensitivities returned from her would culture. She remained \r\nafebrile and her pain was significantly decreased after the \r\nprocedure. \r\nThe wound was found to be caused by MRSA but was sensitive to \r\nBactrim. She was sent home on a 2 week course of Bactrim and \r\nwill follow-up in 2 weeks in ___ clinic.\r\n \r\nMedications on Admission:\r\nNeurotin 300mg qam, 600mg qpm\r\nOmeprazole 20mg qdaily\r\nASA 325mg qdaily\r\nHCTZ 25mg BID\r\nEtodolac 500mg BID\r\nMVI\r\n\r\n \r\nDischarge Medications:\r\n1. Acetaminophen 500 mg Tablet Sig: One (1) Tablet PO Q6H (every \r\n6 hours) as needed for pain, fever.  \r\n2. Ibuprofen 400 mg Tablet Sig: One (1) Tablet PO Q6H (every 6 \r\nhours) as needed for pain, fever.\r\nDisp:*35 Tablet(s)* Refills:*1*\r\n3. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM ().  \r\n4. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \r\nbedtime).  \r\n5. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid ().  \r\n6. Hydrocodone-Acetaminophen ___ mg Tablet Sig: ___ Tablets PO \r\nQ4H (every 4 hours) as needed for pain.\r\nDisp:*30 Tablet(s)* Refills:*0*\r\n7. Venlafaxine 25 mg Tablet Sig: One (1) Tablet PO DAILY \r\n(Daily).  \r\n8. Hydrochlorothiazide 12.5 mg Capsule Sig: One (1) Capsule PO \r\nBID (2 times a day).  \r\n9. Aspirin 325 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).  \r\n10. Omeprazole 20 mg Capsule, Delayed Release(E.C.) Sig: One (1) \r\nCapsule, Delayed Release(E.C.) PO DAILY (Daily).  \r\n11. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM ().  \r\n12. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \r\nbedtime).  \r\n13. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid ().  \r\n14. Trimethoprim-Sulfamethoxazole 160-800 mg Tablet Sig: One (1) \r\nTablet PO BID (2 times a day) for 14 days.\r\nDisp:*28 Tablet(s)* Refills:*0*\r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nLabial cellulitis/abscess\r\n\r\n \r\nDischarge Condition:\r\nStable, afebrile\r\n\r\n \r\nDischarge Instructions:\r\nCall your doctor for:\r\n* fever > 100.4\r\n* severe abdominal pain\r\n* difficulty urinating\r\n* vaginal bleeding requiring >1 pad/hr\r\n* abnormal vaginal discharge\r\n* nausea/vomiting where you are unable to keep down fluids/food \r\nor your medication\r\n\r\nGeneral instructions:\r\n* Take your medications as prescribed.\r\n* Do not drive while taking narcotics.\r\n* No strenuous activity, nothing in the vagina (no tampons, no \r\ndouching, no sex), no heavy lifting of objects >10lbs for 6 \r\nweeks. \r\n* You may eat a regular diet.\r\n\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-7:5",
      "text": "Discharge Medications:\n1. Acetaminophen 500 mg Tablet Sig: One (1) Tablet PO Q6H (every \n6 hours) as needed for pain, fever. 2. Ibuprofen 400 mg Tablet Sig: One (1) Tablet PO Q6H (every 6 \nhours) as needed for pain, fever. Disp:*35 Tablet(s)* Refills:*1*\n3. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM (). 4. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \nbedtime). 5. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid (). 6. Hydrocodone-Acetaminophen ___ mg Tablet Sig: ___ Tablets PO \nQ4H (every 4 hours) as needed for pain. Disp:*30 Tablet(s)* Refills:*0*\n7. Venlafaxine 25 mg Tablet Sig: One (1) Tablet PO DAILY \n(Daily). 8. Hydrochlorothiazide 12.5 mg Capsule Sig: One (1) Capsule PO \nBID (2 times a day). 9. Aspirin 325 mg Tablet Sig: One (1) Tablet PO DAILY (Daily). 10. Omeprazole 20 mg Capsule, Delayed Release(E.C.) Sig: One (1) \nCapsule, Delayed Release(E.C.) PO DAILY (Daily). 11. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM (). 12. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \nbedtime). 13. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid (). 14. Trimethoprim-Sulfamethoxazole 160-800 mg Tablet Sig: One (1) \nTablet PO BID (2 times a day) for 14 days. Disp:*28 Tablet(s)* Refills:*0* Discharge Disposition:\nHome Discharge Diagnosis:\nLabial cellulitis/abscess Discharge Condition:\nStable, afebrile",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-7",
        "chart_time": "101820",
        "section": "General",
        "position": 5,
        "tokenCount": 341,
        "note_metadata": {
          "note_id": "18887130-DS-7",
          "subject_id": 18887130,
          "hadm_id": 29694217,
          "note_type": "DS",
          "note_seq": 7,
          "charttime": 101820,
          "storetime": 101820.42708333333,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: OBSTETRICS/GYNECOLOGY\r\n \r\nAllergies: \r\nPatient recorded as having No Known Allergies to Drugs\r\n \r\nAttending: ___.\r\n \r\nChief Complaint:\r\nright labial abscess\r\n \r\nMajor Surgical or Invasive Procedure:\r\nIV antibiotics\r\nIncision and Drainage of labial abscess\r\n\r\n \r\nHistory of Present Illness:\r\n___ P3 female with h/o non-Hodgkins lymphoma presents to\r\nthe ___ ED with a right labial abscess.  Patient initially\r\nnoticed a pimple on her right labium one week ago, with \r\nassociated\r\nlabial itching.  Over the last three days it has been enlarging. \r\n\r\nShe tried placing warm compresses over the area, with no\r\nimprovement.  \r\n\r\nIn the last day, the area has become increasing swollen,\r\nerythematous, and painful.  It is now difficult to walk.  She\r\ndenies drainage from the area.  Denies fever or chills.  Denies\r\nabdominal pain.  Denies excessive vaginal discharge.  \r\n\r\nPatient has a history of a MRSA infection of an abdominal boil\r\n___ years ago.  She denies h/o diabetes and states that recent\r\nfasting blood sugar was 89.  Denies current immunosuppression,\r\nher non-Hogkin's lymphoma has been in remission since ___\r\n \r\nPast Medical History:\r\nObHx:\r\nSVD x 3, no complications\r\n\r\nGynHx:\r\nPostmenopausal since age ___\r\ns/p tubal ligation\r\ndenies h/o abnl paps\r\ndenies h/o STIs\r\n\r\nPMH:\r\nCerebral aneurysm s/p multiple coil and stent procedures\r\nh/o Non Hodgkins Lymphoma, remission since ___.\r\nMigraines\r\nTrigeminal neuralgia\r\nAnterior outlet syndrome, s/p anterior scalenotomy\r\nGERD \r\nOA\r\nCarpal tunnel\r\nMRSA positive boil on abdomen\r\n\r\nPSH:\r\nEx-lap for right-sided pain, tubal ligation\r\nEx-lap for lymphoma\r\nEx-lap for ruptured Meckel's diverticulum\r\nAnterior fusion C5-6\r\nAnterior scalenotomy\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nPE: VS: T 99.4  BP 132/69  HR 100  RR 18  O2Sat 98% RA\r\nNAD\r\nAbd soft, obese, NT, cutaneous candidiasis in bilateral groin\r\nfolds\r\nRight labium majorus 8cm x 5cm area of significant induration,\r\nwarm, extensive erythema (across entire right labium, mons, and\r\nlower abdomen; from 4cm above pubic symphysis to buttocks), no\r\nobvious area of fluctance, no drainage, no ulceration; no\r\nBartholin's cyst; moderately tender to palpation; no crepitus\r\nLeft labium normal appearing, soft, no erythema, no induration, \r\nno\r\ndrainage\r\n\r\n \r\nPertinent Results:\r\n___ 02:10PM   WBC-14.6*# RBC-4.08* HGB-12.8 HCT-37.9 MCV-93 \r\nMCH-31.2 MCHC-33.6 RDW-13.1\r\nHA1C: 6.0\r\n \r\nBrief Hospital Course:\r\nPatient was admitted to the surgical floor for IV antibiotics \r\n(Vancomycin/Unasyn) and pain control for treatment of labial \r\ncellulitis. There was concern for abscess despite ultrasound \r\nshowing labial edema, without evidence of drainable fluid \r\ncollection. She was afebrile for 24 hours but her pain and exam \r\ndid not improve after 24 hours of IV antibiotics so a bedside \r\nincision and drainage was attempted. A fluid collection was \r\nidentified and exlpored. It was found to have significant depth \r\nwhich was not ammendable to bedside drainage.  the patient was \r\nthen taken to the OR for a complete incision and drainage. A \r\nlarge pocket of purulent fluid was drained, oculations were \r\nbroken up, and a  Foley left in wound to drain the cavity. The \r\ndrainage was sent for culture.\r\nA blood culture that was drawn in the emergency room returned \r\npositive ___ bottles) for Coag negative Staph which was \r\npresumed to be a Staph epi contaminant. All further blood \r\ncultures were negative.\r\nShe was kept in the hospital for 48 hours more until the \r\nsensitivities returned from her would culture. She remained \r\nafebrile and her pain was significantly decreased after the \r\nprocedure. \r\nThe wound was found to be caused by MRSA but was sensitive to \r\nBactrim. She was sent home on a 2 week course of Bactrim and \r\nwill follow-up in 2 weeks in ___ clinic.\r\n \r\nMedications on Admission:\r\nNeurotin 300mg qam, 600mg qpm\r\nOmeprazole 20mg qdaily\r\nASA 325mg qdaily\r\nHCTZ 25mg BID\r\nEtodolac 500mg BID\r\nMVI\r\n\r\n \r\nDischarge Medications:\r\n1. Acetaminophen 500 mg Tablet Sig: One (1) Tablet PO Q6H (every \r\n6 hours) as needed for pain, fever.  \r\n2. Ibuprofen 400 mg Tablet Sig: One (1) Tablet PO Q6H (every 6 \r\nhours) as needed for pain, fever.\r\nDisp:*35 Tablet(s)* Refills:*1*\r\n3. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM ().  \r\n4. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \r\nbedtime).  \r\n5. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid ().  \r\n6. Hydrocodone-Acetaminophen ___ mg Tablet Sig: ___ Tablets PO \r\nQ4H (every 4 hours) as needed for pain.\r\nDisp:*30 Tablet(s)* Refills:*0*\r\n7. Venlafaxine 25 mg Tablet Sig: One (1) Tablet PO DAILY \r\n(Daily).  \r\n8. Hydrochlorothiazide 12.5 mg Capsule Sig: One (1) Capsule PO \r\nBID (2 times a day).  \r\n9. Aspirin 325 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).  \r\n10. Omeprazole 20 mg Capsule, Delayed Release(E.C.) Sig: One (1) \r\nCapsule, Delayed Release(E.C.) PO DAILY (Daily).  \r\n11. Gabapentin 300 mg Capsule Sig: One (1) Capsule PO Q AM ().  \r\n12. Gabapentin 300 mg Capsule Sig: Three (3) Capsule PO HS (at \r\nbedtime).  \r\n13. Etodolac 500 mg Tablet Sig: One (1) Tablet PO bid ().  \r\n14. Trimethoprim-Sulfamethoxazole 160-800 mg Tablet Sig: One (1) \r\nTablet PO BID (2 times a day) for 14 days.\r\nDisp:*28 Tablet(s)* Refills:*0*\r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nLabial cellulitis/abscess\r\n\r\n \r\nDischarge Condition:\r\nStable, afebrile\r\n\r\n \r\nDischarge Instructions:\r\nCall your doctor for:\r\n* fever > 100.4\r\n* severe abdominal pain\r\n* difficulty urinating\r\n* vaginal bleeding requiring >1 pad/hr\r\n* abnormal vaginal discharge\r\n* nausea/vomiting where you are unable to keep down fluids/food \r\nor your medication\r\n\r\nGeneral instructions:\r\n* Take your medications as prescribed.\r\n* Do not drive while taking narcotics.\r\n* No strenuous activity, nothing in the vagina (no tampons, no \r\ndouching, no sex), no heavy lifting of objects >10lbs for 6 \r\nweeks. \r\n* You may eat a regular diet.\r\n\r\n \r\nFollowup Instructions:\r\n___\r\n"
        }
      }
    }
  ],
  "collection": "patient"
}
